{"meta":{"query_hash":"a8073ea30bc6","filters":{"venue":"Molecular Cancer Therapeutics"},"cohort_total":759,"direct_labels_cover":2,"predictions_cover":759,"exported":759,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/a8073ea30bc6","api":"https://metacan.xera.ac/api/v1/cohort?venue=Molecular+Cancer+Therapeutics"},"results":[{"id":"W1638855221","doi":"10.1158/1535-7163.mct-06-0562","title":"Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; Leukemia and Lymphoma Society; V Foundation for Cancer Research; U.S. Department of Defense","keywords":"XIAP; Vorinostat; Clonogenic assay; Cancer research; Chemistry; Apoptosis; Biology; Cell biology; Histone deacetylase; Histone; Programmed cell death; Caspase; Biochemistry","score_opus":0.012058875052699262,"score_gpt":0.263187212290849,"score_spread":0.25112833723814976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1638855221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821215,0.0031792335,0.014034331,0.00012232542,0.00014178328,0.0001564954,0.000011284834,0.000006813195,0.00022617851],"genre_scores_gemma":[0.9984869,0.00042574984,0.0004899252,0.0003613184,0.00006437936,0.000011898297,0.000038612667,0.000014930226,0.00010632733],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993176,0.000028927616,0.00019486078,0.00021026815,0.00010775501,0.00014060109],"domain_scores_gemma":[0.9996755,0.000008992307,0.00007515091,0.00013470711,0.000063737374,0.000041881183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001274328,0.00010942959,0.000097645985,0.0000881287,0.00003696938,0.0000116736055,0.000041101455,0.00008975065,0.00001567756],"category_scores_gemma":[0.0000070919914,0.00011322001,0.000031684907,0.000091568494,0.00006176651,0.00000859418,0.00004127448,0.0000815203,5.717623e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008563026,0.000024429579,0.0026071335,0.000010195365,0.000035871548,4.452081e-7,0.00006878214,0.00003472102,0.98121494,0.0018762555,0.0000141531555,0.014027463],"study_design_scores_gemma":[0.00051776925,0.00007403982,0.009920766,0.000020766469,0.000018151151,0.000008898467,0.00009440269,0.00043777443,0.97928786,0.001544993,0.007952961,0.00012163427],"about_ca_topic_score_codex":0.000054019587,"about_ca_topic_score_gemma":0.00010963972,"teacher_disagreement_score":0.016365305,"about_ca_system_score_codex":0.000023592538,"about_ca_system_score_gemma":0.000045113433,"threshold_uncertainty_score":0.46169782},"labels":[],"label_agreement":null},{"id":"W1864382350","doi":"10.1158/1535-7163.641.3.5","title":"Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Pancreatic cancer; Identification (biology); Cancer; Polo-like kinase; Kinase; Biology; Cancer research; Computational biology; Genetics; Cell cycle","score_opus":0.010385604758839588,"score_gpt":0.2819086709854192,"score_spread":0.2715230662265796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1864382350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97482926,0.015696863,0.008386225,0.00034347014,0.00021802897,0.00038667326,0.00005247791,0.000014094835,0.000072884126],"genre_scores_gemma":[0.995283,0.0024044423,0.00015808389,0.00157561,0.00008163769,0.00014734559,0.00008777984,0.000059891612,0.00020219416],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99848515,0.000081678634,0.0004443886,0.00042735878,0.00021615184,0.00034525662],"domain_scores_gemma":[0.9991063,0.000002997213,0.00021087602,0.0004994039,0.000120138015,0.00006032317],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001384295,0.0002510234,0.00025736538,0.00010599829,0.00006885179,0.000025708187,0.0003102642,0.00021923418,0.000037397473],"category_scores_gemma":[0.0000042615457,0.00026145435,0.00015744148,0.00021423273,0.0001290793,0.0000072620237,0.00006511845,0.00014536089,0.000004471316],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008779143,0.0001858659,0.002246373,0.000044316752,0.00022059373,0.00001209727,0.00017686875,0.00439094,0.9904155,0.00051988114,0.000007272977,0.0016924973],"study_design_scores_gemma":[0.0014025845,0.00021064209,0.0027466116,0.000052483698,0.00015562557,0.0000075911785,0.00009463171,0.00016202214,0.99124265,0.0020211055,0.0015823905,0.00032167736],"about_ca_topic_score_codex":0.00093191373,"about_ca_topic_score_gemma":0.00038940675,"teacher_disagreement_score":0.020453732,"about_ca_system_score_codex":0.00010526689,"about_ca_system_score_gemma":0.00026368184,"threshold_uncertainty_score":0.9999838},"labels":[],"label_agreement":null},{"id":"W1924355940","doi":"10.1158/1535-7163.149.3.2","title":"Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy <i>in vitro</i>","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Wnt/β-catenin signaling in development and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Natural Sciences and Engineering Research Council of Canada; Government of Ontario","keywords":"Cancer research; Cancer cell; Biology; Cisplatin; Immunology; Chemistry; Cancer; Chemotherapy","score_opus":0.011094331950695117,"score_gpt":0.25953332959864456,"score_spread":0.24843899764794944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1924355940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822889,0.006762278,0.008711991,0.001059921,0.00034651213,0.0004656955,0.00001937619,0.00004492302,0.00030043625],"genre_scores_gemma":[0.9775828,0.0006693801,0.011592574,0.009458242,0.00023463751,0.00008696568,0.00006106948,0.00011527473,0.00019906515],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979337,0.00007077168,0.00038825275,0.0006656384,0.00030602445,0.00063564046],"domain_scores_gemma":[0.999219,0.00000895263,0.000117479656,0.00037798195,0.00015121225,0.00012535989],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022256996,0.00040502756,0.00034877355,0.00007994162,0.000101566315,0.000057517133,0.0003313712,0.0001716616,0.000029507353],"category_scores_gemma":[0.000015474174,0.000421488,0.00015824914,0.000312156,0.00009744712,0.000008169935,0.00010600518,0.00019219045,0.000023934423],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039941768,0.00008041072,0.00080937915,0.000026927692,0.00017441658,0.00008247249,0.00047495042,0.003228415,0.9922821,0.000021191094,0.00011306431,0.0023072865],"study_design_scores_gemma":[0.0018430668,0.00011006533,0.00036239313,0.00006544067,0.000035511563,0.000008867154,0.00019857583,0.00005904613,0.97370607,0.00013680951,0.022894263,0.00057991035],"about_ca_topic_score_codex":0.00011327945,"about_ca_topic_score_gemma":0.000029458079,"teacher_disagreement_score":0.022781199,"about_ca_system_score_codex":0.00013239369,"about_ca_system_score_gemma":0.00023629112,"threshold_uncertainty_score":0.9998237},"labels":[],"label_agreement":null},{"id":"W1964263225","doi":"10.1158/1535-7163.targ-13-a299","title":"Abstract A299: Select microtubule inhibitors increase lysosome acidity and promote lysosomal disruption in acute myeloid leukemia (AML) cells.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Biological Stains and Phytochemicals","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Ontario Institute for Cancer Research; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Vinca; Cytotoxic T cell; Microtubule polymerization; Tubulin; Microtubule; Cancer research; Epothilone; Mitosis; Cell culture; Biology; Haematopoiesis; Chemistry; In vitro; Pharmacology; Cell biology; Stem cell; Biochemistry; Genetics","score_opus":0.01379377703811732,"score_gpt":0.267030862395834,"score_spread":0.2532370853577167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964263225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99487144,0.0025695062,0.000081321836,0.0011890908,0.00007222807,0.0009186836,0.000033840388,0.00005561609,0.00020824715],"genre_scores_gemma":[0.99518,0.0013831626,0.0004966825,0.0025182895,0.00012097829,0.00015349431,0.000049194907,0.000036523288,0.000061670165],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984668,0.000059281123,0.00034861022,0.0004442221,0.00021814098,0.00046294933],"domain_scores_gemma":[0.9992807,0.000027393658,0.000108081964,0.000267863,0.00009604649,0.00021991186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013380512,0.00029569495,0.00039423932,0.00006940663,0.00006403289,0.00005122794,0.00011066523,0.00031443365,0.00017965307],"category_scores_gemma":[0.000009557185,0.00023071829,0.00011401966,0.00026456214,0.00014212665,0.00008560708,0.00007180892,0.00046134638,0.000020265306],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015770052,0.00012314388,0.0062320656,0.00008284429,0.00013502658,0.000060216484,0.00011520412,0.0000052962478,0.9685488,0.000010385887,0.00007358025,0.02445578],"study_design_scores_gemma":[0.001542969,0.00025534173,0.062355164,0.00012431803,0.00015311304,0.000027741198,0.00002418987,0.00027460608,0.93013865,0.00060595723,0.0041519077,0.00034607077],"about_ca_topic_score_codex":0.0006559338,"about_ca_topic_score_gemma":0.000026434413,"teacher_disagreement_score":0.056123096,"about_ca_system_score_codex":0.0003286887,"about_ca_system_score_gemma":0.00013639209,"threshold_uncertainty_score":0.94084185},"labels":[],"label_agreement":null},{"id":"W1965097080","doi":"10.1158/1535-7163.mct-04-0297","title":"Raf kinase as a target for anticancer therapeutics","year":2005,"lang":"en","type":"review","venue":"Molecular Cancer Therapeutics","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":247,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"MAPK/ERK pathway; Receptor tyrosine kinase; Kinase; Tyrosine kinase; Cancer research; Signal transduction; Biology; Medicine; Cell biology","score_opus":0.055910670510332154,"score_gpt":0.36204434229330806,"score_spread":0.3061336717829759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965097080","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000076929144,0.9884716,0.007155266,0.00015733363,0.00079952896,0.0018425082,0.000568069,0.00005086054,0.0008778781],"genre_scores_gemma":[0.00014002879,0.9881042,0.0023508412,0.003487072,0.0014584902,0.0012973984,0.00088237686,0.00035413128,0.0019254441],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99683756,0.00019663367,0.00070670247,0.0010684488,0.00034830763,0.0008423753],"domain_scores_gemma":[0.99794006,0.00004011383,0.0004366282,0.0011885237,0.0002103047,0.00018437114],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024385637,0.0009561764,0.0013557515,0.00013163885,0.00015773228,0.000089607274,0.00080624525,0.0009875401,0.00009547202],"category_scores_gemma":[0.000016096425,0.0008477849,0.001179758,0.000233423,0.00015269016,0.0000051411002,0.00016913695,0.00037431152,0.000048134083],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008206576,0.00012495687,0.0000020601337,0.0020141527,0.0016221008,0.0000197067,0.000032811746,0.000015649919,0.009118518,0.00044828435,0.00058537564,0.9859343],"study_design_scores_gemma":[0.000737434,0.0004952103,2.8128548e-7,0.0008215375,0.0019750998,0.000035737812,0.000008819394,0.000025612117,0.011273344,0.00017714557,0.98342925,0.0010205407],"about_ca_topic_score_codex":0.0000145297445,"about_ca_topic_score_gemma":0.000016664751,"teacher_disagreement_score":0.98491377,"about_ca_system_score_codex":0.00013341014,"about_ca_system_score_gemma":0.0012174333,"threshold_uncertainty_score":0.9993973},"labels":[],"label_agreement":null},{"id":"W1966863570","doi":"10.1158/1535-7163.targ-09-b242","title":"Abstract B242: A phase I/II study of oncolytic reovirus plus chemotherapy (carboplatin/paclitaxel) in patients with advanced solid tumors (with emphasis on patients with squamous cell carcinoma of the head and neck (SCCHN)","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Oncolytic virus; Carboplatin; Neutropenia; Internal medicine; Chemotherapy; Paclitaxel; Oncology; Head and neck cancer; Cancer; Gastroenterology; Leukopenia; Cisplatin","score_opus":0.012069501451377059,"score_gpt":0.29479091423690734,"score_spread":0.28272141278553026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966863570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972299,0.0005838244,0.000014635212,0.000064613894,0.000020630498,0.0019320077,0.000070645845,0.000007993604,0.000075786455],"genre_scores_gemma":[0.9990611,0.00003735988,0.000081083206,0.00059152156,0.0000142323825,0.00009092529,0.000025712116,0.00008137336,0.000016699507],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976786,0.0001275778,0.00042942437,0.0005910756,0.00072015676,0.00045317342],"domain_scores_gemma":[0.99836475,0.000017621907,0.0003709481,0.00086122256,0.0002841898,0.000101279096],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011948173,0.0004243114,0.00048700022,0.000120035686,0.000106412364,0.000016912802,0.00036704514,0.00012072744,0.000008529022],"category_scores_gemma":[0.00000609047,0.00028090386,0.00007038025,0.00041237846,0.00017797243,0.000012144784,0.00005241772,0.00025244776,1.8897859e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1435629,0.020288434,0.36080465,0.00015443724,0.0005481238,0.00003629178,0.0037560721,0.01117258,0.3632916,0.0000026241544,0.000008326772,0.09637397],"study_design_scores_gemma":[0.047948275,0.12121245,0.3415022,0.00012177072,0.00008756956,7.596688e-7,0.00022253838,0.00005964387,0.4883443,0.000006073999,0.000050786628,0.00044363437],"about_ca_topic_score_codex":0.00012754387,"about_ca_topic_score_gemma":0.0005659622,"teacher_disagreement_score":0.12505272,"about_ca_system_score_codex":0.00012742655,"about_ca_system_score_gemma":0.00033086562,"threshold_uncertainty_score":0.9999643},"labels":[],"label_agreement":null},{"id":"W1968812521","doi":"10.1158/1535-7163.targ-09-c155","title":"Abstract C155: External Qi of Yan Xin Qigong induces apoptosis and inhibits migration and invasion of estrogen-independent breast cancer cells by down-regulating Akt/NF-κB signaling","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Biofield Effects and Biophysics","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Clonogenic assay; Apoptosis; Protein kinase B; Viability assay; Cancer research; Flow cytometry; Cancer cell; Trypan blue; Matrigel; Medicine; Biology; Molecular biology; Cancer; Chemistry; Angiogenesis; Internal medicine; Biochemistry","score_opus":0.014483333280025,"score_gpt":0.26233191273311546,"score_spread":0.24784857945309047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968812521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99242145,0.0060832007,0.00031425586,0.00078592624,0.000067411645,0.000258245,0.000041693973,0.000011379157,0.000016415055],"genre_scores_gemma":[0.99782604,0.0010177173,0.00040251517,0.00063662,0.00008059506,0.0000062921727,0.000007950783,0.000016746268,0.0000055518467],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99895996,0.00002999992,0.00030184057,0.0002390541,0.00029652438,0.00017259804],"domain_scores_gemma":[0.99942625,0.000022138534,0.00023248726,0.00013726485,0.00010326342,0.000078629615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001123654,0.00018672922,0.0002980619,0.00005397501,0.00004699361,0.000023290368,0.000053990956,0.00015547231,0.000015131614],"category_scores_gemma":[0.0000016259402,0.00015518925,0.00006582785,0.00011825781,0.00006696722,0.00006832371,0.000022128734,0.0001768045,1.2983776e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012303234,0.00008338511,0.003704542,0.00015520467,0.00009152414,0.000002009182,0.00026204655,0.00009301444,0.9103419,0.000020696516,0.000005761939,0.085116886],"study_design_scores_gemma":[0.0008451152,0.0002152029,0.010771519,0.0005681259,0.00020123935,0.0000074276722,0.00006895425,0.00039060504,0.98669183,0.00007249359,0.000018875562,0.00014861142],"about_ca_topic_score_codex":0.0011870906,"about_ca_topic_score_gemma":0.000037884423,"teacher_disagreement_score":0.08496828,"about_ca_system_score_codex":0.00003635185,"about_ca_system_score_gemma":0.00005742118,"threshold_uncertainty_score":0.6328434},"labels":[],"label_agreement":null},{"id":"W1970298367","doi":"10.1158/1535-7163.pms-ia7","title":"Abstract IA7: Chromosome instability and synthetic lethality in yeast and cancer","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Fungal and yeast genetics research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Synthetic lethality; Biology; Cohesin; Gene; Mutant; Genetics; DNA replication; DNA repair; Mutation; Molecular biology; Chromosome","score_opus":0.02327029834187335,"score_gpt":0.30067677469375226,"score_spread":0.27740647635187893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970298367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797939,0.018529959,0.00004908868,0.0008491695,0.0000666984,0.00033537578,0.000045843804,0.0000073567935,0.00032259105],"genre_scores_gemma":[0.9939423,0.0049983608,0.00009887918,0.0006137498,0.000056544526,0.0001702876,0.000009813567,0.000028424942,0.000081646045],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987711,0.00007482571,0.0001913772,0.00044585482,0.00017933726,0.00033752123],"domain_scores_gemma":[0.9994233,0.000010081334,0.00004234059,0.00031287703,0.00008807834,0.00012329071],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015347233,0.00018738389,0.00017053851,0.000041883282,0.000052134725,0.000055676443,0.00014144814,0.0001569052,0.00011309014],"category_scores_gemma":[0.000013148183,0.00017254475,0.000040874336,0.00010050304,0.00023134971,0.0000066674856,0.00014992373,0.00018139601,0.0000048495776],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031741838,0.000054763183,0.027696153,0.00007270824,0.000051422037,0.0000038645467,0.0000762494,0.00004787063,0.9297636,0.000021094625,0.000013706031,0.042166807],"study_design_scores_gemma":[0.0009372631,0.0001475893,0.3121554,0.00006845108,0.00002924229,0.00001057272,0.00009599574,0.00041845167,0.6748505,0.0005713068,0.010254669,0.00046053415],"about_ca_topic_score_codex":0.001209998,"about_ca_topic_score_gemma":0.0003969763,"teacher_disagreement_score":0.28445926,"about_ca_system_score_codex":0.000036239533,"about_ca_system_score_gemma":0.0001087814,"threshold_uncertainty_score":0.70361704},"labels":[],"label_agreement":null},{"id":"W1970969296","doi":"10.1158/1535-7163.mct-07-2444","title":"Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Bortezomib; Head and neck squamous-cell carcinoma; Cisplatin; Proteasome inhibitor; Cancer research; Apoptosis; Programmed cell death; Cancer cell; Small interfering RNA; Cancer; Chemistry; Chemotherapy; Head and neck cancer; Medicine; Biology; Cell culture; Internal medicine; Transfection; Multiple myeloma","score_opus":0.014035730986765017,"score_gpt":0.23229907220717882,"score_spread":0.2182633412204138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970969296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873195,0.008967256,0.0033064238,0.00009975724,0.000042717817,0.00022743172,0.0000061725873,0.000003498269,0.00002720135],"genre_scores_gemma":[0.9968815,0.0020952306,0.00072369806,0.00018699086,0.000029298022,0.000017018487,0.00001743635,0.000021803788,0.00002705478],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99922293,0.000058856585,0.00017082962,0.00026150735,0.00013557967,0.00015031252],"domain_scores_gemma":[0.9996293,0.000014158543,0.00010000747,0.00017687007,0.000045590896,0.000034037195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008954982,0.00015897282,0.00015119695,0.00005347447,0.00008995936,0.000016521342,0.00006281382,0.00012734506,0.0000013774833],"category_scores_gemma":[0.0000011196813,0.000115695526,0.000025493322,0.000107097,0.00012438647,0.0000064345904,0.000032937158,0.00007233548,5.6193894e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009693207,0.00006080772,0.004286245,0.000045627767,0.000019890156,0.000002647467,0.0006019963,0.00034889067,0.9893673,0.000046621506,0.000002374408,0.0051206704],"study_design_scores_gemma":[0.0019682099,0.0003891835,0.0162967,0.00001901455,0.00006917967,0.000023663228,0.00016860438,0.0019584515,0.9783483,0.00011489677,0.0004503046,0.0001934859],"about_ca_topic_score_codex":0.00018487115,"about_ca_topic_score_gemma":0.00006408006,"teacher_disagreement_score":0.012010455,"about_ca_system_score_codex":0.000007833711,"about_ca_system_score_gemma":0.000033152683,"threshold_uncertainty_score":0.47179267},"labels":[],"label_agreement":null},{"id":"W1971180088","doi":"10.1158/1535-7163.pms-a10","title":"Abstract A10: MLL2 interactions in follicular and diffuse large B-cell lymphoma","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"","keywords":"Biology; Epigenetics; Gene; Genetics; Diffuse large B-cell lymphoma; Cancer research; Follicular lymphoma; Lymphoma","score_opus":0.011402309642660745,"score_gpt":0.260975255464491,"score_spread":0.24957294582183026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971180088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98695374,0.009848559,0.0011011944,0.00051128113,0.00022665568,0.0003352654,0.000050808627,0.000012933556,0.000959556],"genre_scores_gemma":[0.99213254,0.003901054,0.00030410086,0.0030630552,0.00011164855,0.0001659981,0.000054002987,0.000053974687,0.00021361848],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99882907,0.000030113017,0.00024693966,0.00039384686,0.00011990012,0.00038010417],"domain_scores_gemma":[0.9993202,0.0000192506,0.00008410381,0.00038799745,0.0000770892,0.0001113335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000072386596,0.00023090884,0.00017879602,0.000071041206,0.00006760244,0.00008454811,0.00017177967,0.000116259806,0.000060705373],"category_scores_gemma":[0.000010964237,0.00023893711,0.00009532386,0.00010939718,0.000055124725,0.0000090940175,0.00012264033,0.00010822453,0.000020412155],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048154438,0.000985268,0.0065611084,0.00003800621,0.0001246345,0.00002408148,0.00016737223,0.00011644894,0.97163236,0.00019178842,0.0006323586,0.019478427],"study_design_scores_gemma":[0.013096596,0.00022895247,0.056758307,0.00008188813,0.00014088607,0.000025554265,0.0003664145,0.0013794972,0.5472273,0.0010100463,0.37850282,0.00118173],"about_ca_topic_score_codex":0.0005406606,"about_ca_topic_score_gemma":0.00059499685,"teacher_disagreement_score":0.42440504,"about_ca_system_score_codex":0.0000642201,"about_ca_system_score_gemma":0.00009937165,"threshold_uncertainty_score":0.97435725},"labels":[],"label_agreement":null},{"id":"W1972475443","doi":"10.1158/1535-7163.targ-11-c17","title":"Abstract C17: A phase I study of the combination of RO4929097 (RO) and cediranib (Cd) in patients with advanced solid tumors (PJC-004/NCI 8503).","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Medicine; Pharmacodynamics; Pharmacology; Pharmacokinetics; Notch signaling pathway; Internal medicine; Gastroenterology; Toxicity; Response Evaluation Criteria in Solid Tumors; Maximum tolerated dose; Adverse effect; Oncology; Phases of clinical research; Receptor","score_opus":0.018376902107883335,"score_gpt":0.27997071752476477,"score_spread":0.2615938154168814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972475443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99771154,0.0013849426,0.00010334838,0.00001463372,0.00007275991,0.0005505803,0.000030168181,0.0000035747184,0.0001284651],"genre_scores_gemma":[0.9995093,0.00014655957,0.00006903955,0.00015865767,0.000011598501,0.000048524063,0.000011612856,0.000031359596,0.00001334844],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989774,0.00005459103,0.00030120896,0.00026503895,0.00022533056,0.00017638251],"domain_scores_gemma":[0.9991683,0.0000047329413,0.00025444973,0.0003591243,0.00017959562,0.000033815773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009505099,0.00017515768,0.00022669185,0.00004331685,0.00003741696,0.0000048437005,0.00019612153,0.000081081045,0.00001378503],"category_scores_gemma":[0.0000052812334,0.00012881582,0.000060996997,0.00015694305,0.00011207011,0.0000064527458,0.00006515292,0.00007496469,1.2808707e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002225185,0.0043167854,0.41892672,0.000104098646,0.0005435233,0.0000052203986,0.0025208464,0.0003241403,0.53958076,0.00008155093,0.000011070266,0.03136009],"study_design_scores_gemma":[0.0077035283,0.002381737,0.54426396,0.00007752598,0.00011438422,6.2417627e-7,0.00045004187,0.000027890308,0.4445131,0.000047205747,0.00018555249,0.00023446495],"about_ca_topic_score_codex":0.00016074887,"about_ca_topic_score_gemma":0.00020483031,"teacher_disagreement_score":0.12533721,"about_ca_system_score_codex":0.000022819493,"about_ca_system_score_gemma":0.000079987556,"threshold_uncertainty_score":0.5252957},"labels":[],"label_agreement":null},{"id":"W1973760749","doi":"10.1158/1535-7163.targ-13-b129","title":"Abstract B129: Clinical implications of inter- and intra- prostatic heterogeneity.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; BC Cancer Agency; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Prostate cancer; Prostate; Genetic heterogeneity; Genome instability; Biology; SNP; Single-nucleotide polymorphism; Biochemical recurrence; Oncology; Medicine; Internal medicine; Cancer; Gene; Genetics; Prostatectomy; Genotype; DNA; Phenotype","score_opus":0.0746681729146952,"score_gpt":0.4133804645949236,"score_spread":0.33871229168022843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973760749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843853,0.0055565783,0.00062136125,0.008046162,0.000064297616,0.00083405233,0.000022301298,0.000023303872,0.00044666036],"genre_scores_gemma":[0.9949734,0.0026636396,0.000560555,0.0014185318,0.000035090983,0.00018724958,0.0000169008,0.000025405428,0.00011922127],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99906635,0.00003589896,0.0003211333,0.0002231425,0.00013797428,0.0002154937],"domain_scores_gemma":[0.99924403,0.00004594334,0.000085385036,0.00030263443,0.00018655512,0.00013547335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010600701,0.00012339614,0.0002515295,0.00005732684,0.00003508697,0.000021401627,0.00007914894,0.0000805591,0.00010847324],"category_scores_gemma":[0.000009753643,0.00009333188,0.00009039451,0.00011989222,0.00022910537,0.00004538189,0.000039453098,0.00017843381,0.000012689576],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019001232,0.00047376382,0.26847753,0.0003138559,0.0010000234,0.00001724429,0.00029865702,0.0000028402544,0.34874007,0.00026312866,0.0002892136,0.37993369],"study_design_scores_gemma":[0.003895365,0.0009102526,0.78476846,0.00025286785,0.00042720998,0.00002795113,0.00011171093,0.0002538075,0.20102873,0.0025557193,0.005485399,0.00028249092],"about_ca_topic_score_codex":0.00010329408,"about_ca_topic_score_gemma":0.0000138396545,"teacher_disagreement_score":0.51629096,"about_ca_system_score_codex":0.00005379549,"about_ca_system_score_gemma":0.00015046235,"threshold_uncertainty_score":0.38059637},"labels":[],"label_agreement":null},{"id":"W1975292630","doi":"10.1158/1535-7163.mct-13-1066","title":"Preferential Estrogen Receptor β Ligands Reduce Bcl-2 Expression in Hormone-Resistant Breast Cancer Cells to Increase Autophagy","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carleton University; University of Manitoba; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Estrogen receptor; Cancer research; Selective estrogen receptor modulator; Estrogen receptor alpha; Autophagy; Cyclin D1; Chemistry; Estrogen receptor beta; Estrogen; Agonist; Biology; Breast cancer; Endocrinology; Internal medicine; Receptor; Cancer; Apoptosis; Cell cycle; Medicine; Biochemistry","score_opus":0.007841281655722841,"score_gpt":0.25968884507432854,"score_spread":0.2518475634186057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975292630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880699,0.009367031,0.00091214816,0.00042373792,0.00038391975,0.00047486462,0.000118542084,0.00003657975,0.00021329634],"genre_scores_gemma":[0.995374,0.0020875577,0.00047228084,0.0010443047,0.00033369317,0.00023739162,0.00007954093,0.00009444634,0.00027677827],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979599,0.00018373343,0.00034461153,0.00066033093,0.00029102102,0.0005603814],"domain_scores_gemma":[0.9989307,0.000011411943,0.00012197037,0.00056742155,0.00010011662,0.00026837402],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001970804,0.00037991258,0.00030706043,0.00010544315,0.00009607296,0.000052105912,0.00037953164,0.00038898148,0.000040267976],"category_scores_gemma":[0.000008908612,0.00034416432,0.0001599202,0.00024959547,0.00006539618,0.000008185939,0.00017054152,0.00026721403,0.000020330237],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011178303,0.00014482933,0.0001979388,0.000023656527,0.00014472567,0.0000069614507,0.00010032778,0.0009136843,0.9869293,0.000028942151,0.00079721736,0.009594573],"study_design_scores_gemma":[0.0014004732,0.0003544293,0.0008307653,0.00009979882,0.000083458806,0.0000063029074,0.00001816612,0.00021351765,0.97627485,0.000020502112,0.02025603,0.00044170136],"about_ca_topic_score_codex":0.0002744408,"about_ca_topic_score_gemma":0.00003457986,"teacher_disagreement_score":0.019458814,"about_ca_system_score_codex":0.00010262717,"about_ca_system_score_gemma":0.00019347815,"threshold_uncertainty_score":0.99990106},"labels":[],"label_agreement":null},{"id":"W1975783060","doi":"10.1158/1535-7163.targ-13-b282","title":"Abstract B282: The PLK-4 inhibitor CFI-400945 reduces tumor growth in patient-derived pancreatic xenografts.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Gemcitabine; Pancreatic cancer; Medicine; Internal medicine; Cancer research; Metastasis; Oncology; Cancer; Biology","score_opus":0.009383804395736776,"score_gpt":0.23557580562191097,"score_spread":0.2261920012261742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975783060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912008,0.0063424595,0.00017929093,0.00083877303,0.00030360618,0.0007042122,0.00003206725,0.000022250713,0.0003765644],"genre_scores_gemma":[0.99311906,0.0014428432,0.00024742412,0.004434428,0.00019904539,0.00035333165,0.00007407385,0.000071552815,0.000058215388],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99830866,0.000102059494,0.00039246306,0.00046074038,0.00022632688,0.00050975906],"domain_scores_gemma":[0.9990833,0.000017661905,0.0001656981,0.00048563108,0.0001571651,0.00009057796],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010612756,0.0003321576,0.00024565062,0.00006453206,0.00011044715,0.00009492822,0.00040262245,0.00017544994,0.000067754576],"category_scores_gemma":[0.000019867342,0.00025760778,0.00014895223,0.00021627035,0.00015908798,0.000012101625,0.00012635515,0.00025148335,0.000025096375],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042586536,0.00010331897,0.0011033157,0.000024182205,0.00014842198,0.000012924331,0.0002481955,0.00006925366,0.9906801,0.000027958347,0.00061001617,0.006929713],"study_design_scores_gemma":[0.00061216514,0.00016750637,0.0049266615,0.000057865924,0.000060871975,0.000013019825,0.00031646958,0.00008575207,0.9833144,0.00017626063,0.009871556,0.00039750527],"about_ca_topic_score_codex":0.00043923952,"about_ca_topic_score_gemma":0.000120917866,"teacher_disagreement_score":0.00926154,"about_ca_system_score_codex":0.000054994933,"about_ca_system_score_gemma":0.00014379073,"threshold_uncertainty_score":0.9999876},"labels":[],"label_agreement":null},{"id":"W1976746884","doi":"10.1158/1535-7163.targ-09-a146","title":"Abstract A146: The role of cystine transport in darinaparsin-induced cell death","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Glutathione; Intracellular; Cystine; Extracellular; Propidium iodide; Buthionine sulfoximine; Cysteine; Chemistry; Apoptosis; Oxidative stress; Flow cytometry; Biochemistry; Programmed cell death; Molecular biology; Biology; Enzyme","score_opus":0.013043837165822353,"score_gpt":0.26035562462680084,"score_spread":0.24731178746097848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976746884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805417,0.013697995,0.00040354542,0.0002370149,0.00006288015,0.00020203293,0.000008901915,0.000009184596,0.004836754],"genre_scores_gemma":[0.9976448,0.0011679718,0.00020444751,0.0007674422,0.00006658317,0.000019077743,0.000028105685,0.000025885258,0.00007572913],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988727,0.00004219051,0.0002968771,0.0002986262,0.00020488162,0.00028469804],"domain_scores_gemma":[0.99931324,0.0000063787925,0.0001206649,0.0004384297,0.00007888502,0.000042417356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016585809,0.00020278743,0.00018719953,0.000036981943,0.000044678054,0.000011125784,0.00037575053,0.00017546015,0.000013670086],"category_scores_gemma":[0.0000045061324,0.00016226259,0.00011817881,0.00015587735,0.000046669295,0.0000037882069,0.000019904614,0.00018737908,0.0000014858578],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000096292606,0.00011495473,0.0033635458,0.000022406237,0.000033486816,0.00001133905,0.000116068404,0.00035220565,0.98280275,0.00016124868,0.0000043582177,0.012921372],"study_design_scores_gemma":[0.0005197558,0.00019894393,0.010294844,0.000024365077,0.000045318568,0.0000052362407,0.00009774327,0.000060011327,0.97905535,0.0007838694,0.008718458,0.00019610499],"about_ca_topic_score_codex":0.00008218294,"about_ca_topic_score_gemma":0.000024398774,"teacher_disagreement_score":0.017103067,"about_ca_system_score_codex":0.000028026561,"about_ca_system_score_gemma":0.00019681774,"threshold_uncertainty_score":0.6616876},"labels":[],"label_agreement":null},{"id":"W1977237795","doi":"10.1158/1535-7163.targ-09-a55","title":"Abstract A55: A first-in-human, phase I study of an oral hedgehog pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Pharmacodynamics; Pharmacokinetics; Dosing; Cohort; Internal medicine; Pharmacology; Oncology; Gastroenterology; Adverse effect","score_opus":0.03588005930201919,"score_gpt":0.34989656382648365,"score_spread":0.31401650452446445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977237795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964419,0.0019750197,0.00026919576,0.000071815986,0.000054414588,0.0010329629,0.000047998292,0.00002538108,0.000081304424],"genre_scores_gemma":[0.99848574,0.00015685093,0.00050597504,0.0005108206,0.00003848525,0.00014340007,0.000053807533,0.00007295357,0.000031986918],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974663,0.00017011412,0.00066977425,0.00072772475,0.00036613888,0.00059989747],"domain_scores_gemma":[0.9987693,0.00002033067,0.00027186758,0.00067462487,0.00015022377,0.000113676455],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032017127,0.00047294513,0.0006868543,0.0001857028,0.000107754255,0.000033541517,0.00039042672,0.00011255914,0.000013479577],"category_scores_gemma":[0.000021991349,0.00039564082,0.00009134716,0.00045854496,0.0001306856,0.00001752205,0.00005619564,0.00025090625,8.772537e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002185201,0.0040229624,0.0018610659,0.00008691169,0.00029696786,0.0008744901,0.0022205599,0.008103137,0.9669759,0.000011129283,0.000003130759,0.013358515],"study_design_scores_gemma":[0.015419555,0.015326236,0.013005222,0.00024297644,0.00015401335,0.000024672887,0.002844964,0.00033046774,0.9509756,0.000089708585,0.0006928972,0.0008936755],"about_ca_topic_score_codex":0.00024550557,"about_ca_topic_score_gemma":0.005483405,"teacher_disagreement_score":0.01600032,"about_ca_system_score_codex":0.0000963942,"about_ca_system_score_gemma":0.00029837084,"threshold_uncertainty_score":0.99984956},"labels":[],"label_agreement":null},{"id":"W1978648859","doi":"10.1158/1535-7163.targ-11-b147","title":"Abstract B147: P-Rex1 is required for efficient melanoma metastasis.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Metastasis; Melanoma; Cancer research; Biology; Cancer; Medicine; Internal medicine","score_opus":0.07008065111251921,"score_gpt":0.3093644996851106,"score_spread":0.23928384857259138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978648859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8374862,0.044334974,0.08925167,0.0038597907,0.0023499883,0.0050108526,0.00061673333,0.0005791989,0.01651061],"genre_scores_gemma":[0.9851622,0.0004241742,0.005827767,0.0075759967,0.00013180345,0.00036911707,0.00004644899,0.00018727424,0.00027522308],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976401,0.000039753297,0.0005015819,0.00064164924,0.0005103162,0.00066660205],"domain_scores_gemma":[0.998322,0.000028120627,0.00021687962,0.00089436624,0.00029931136,0.00023933261],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002446579,0.0004129958,0.00053762214,0.00017584983,0.00011393818,0.000027144366,0.0002553026,0.00026468304,0.00056020264],"category_scores_gemma":[0.000019260531,0.00039030105,0.00050675037,0.00034565793,0.00013871545,0.000038889004,0.000055422097,0.0003016564,0.000060107322],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017653565,0.0007646234,0.00025236545,0.00034124203,0.0030746092,0.00031220602,0.0028569624,0.00022721865,0.9086324,0.0016556274,0.0014952394,0.07862218],"study_design_scores_gemma":[0.0042152717,0.00061970524,0.0017723019,0.00018394073,0.0016536083,0.00005874648,0.00011077373,0.0012157564,0.8881205,0.00047972827,0.10098315,0.0005865521],"about_ca_topic_score_codex":0.00016021254,"about_ca_topic_score_gemma":0.000018325698,"teacher_disagreement_score":0.147676,"about_ca_system_score_codex":0.00031288798,"about_ca_system_score_gemma":0.00038856867,"threshold_uncertainty_score":0.99985486},"labels":[],"label_agreement":null},{"id":"W1979154472","doi":"10.1158/1535-7163.targ-09-c92","title":"Abstract C92: DNA methylating combi-molecule ZRS1 induces p53 and blocks the epidermal growth factor (EGFR)-activated pathways in EGFR-expressing human tumor cells: Relationship to O6-methylguanine DNA methyltransferase (MGMT) status","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Methyltransferase; Cancer research; Biology; DNA methyltransferase; DNA damage; Molecular biology; Chemistry; Biochemistry; DNA; Methylation","score_opus":0.03847306299729982,"score_gpt":0.30269716673723207,"score_spread":0.26422410373993227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979154472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877313,0.0063799093,0.00390731,0.0007210246,0.00012742735,0.0006834515,0.00009587884,0.000040559727,0.00031317916],"genre_scores_gemma":[0.99608135,0.0004368172,0.0011993593,0.0018820661,0.000119880024,0.00006148043,0.000114688744,0.000086101005,0.000018243818],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969149,0.00043898675,0.00070635485,0.00078555214,0.0004066893,0.00074747374],"domain_scores_gemma":[0.9985836,0.00014169142,0.00026082882,0.00057315733,0.0001958311,0.00024490495],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005604795,0.00052057585,0.0004249633,0.00019526946,0.00039457312,0.00017508543,0.00034973273,0.0003033226,0.0000218562],"category_scores_gemma":[0.00011762439,0.00046609863,0.00015418974,0.00046106547,0.0001260036,0.000027403701,0.00009480074,0.00054865255,0.0000017209737],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000089471,0.00012217353,0.0029569801,0.000023819915,0.00011132114,0.000019501711,0.00085949624,0.0008579127,0.9888667,0.0001250726,0.0000068637914,0.005960675],"study_design_scores_gemma":[0.0010120895,0.00035138655,0.04617084,0.00007096132,0.000084934036,0.0000019817353,0.0001980554,0.000113507944,0.9497188,0.0009531289,0.0007691418,0.00055517897],"about_ca_topic_score_codex":0.00028131533,"about_ca_topic_score_gemma":0.00013456053,"teacher_disagreement_score":0.04321386,"about_ca_system_score_codex":0.000114674964,"about_ca_system_score_gemma":0.00017272978,"threshold_uncertainty_score":0.99977905},"labels":[],"label_agreement":null},{"id":"W1979880713","doi":"10.1158/1535-7163.targ-11-a125","title":"Abstract A125: Silencing Stat3 signaling in human cancers: Identifying potent small molecule inhibitors of Stat3 function.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"STAT3; Survivin; Cancer research; Cancer; Angiogenesis; Biology; Medicine; Signal transduction; Cell biology; Internal medicine","score_opus":0.0905372937456725,"score_gpt":0.31531432319890795,"score_spread":0.22477702945323547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979880713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99022263,0.0028542124,0.0047618733,0.00006280237,0.00040465983,0.000402033,0.000026037174,0.000057933692,0.0012078057],"genre_scores_gemma":[0.9983062,0.00016826109,0.00058957824,0.0006430634,0.00010126351,0.000058752874,0.00002133605,0.00007380054,0.000037722133],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981155,0.000049319708,0.0006822807,0.00038655102,0.00035932736,0.00040701978],"domain_scores_gemma":[0.99896806,0.000021461226,0.0002998316,0.00035074048,0.00024131287,0.00011856099],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022203442,0.00027044833,0.00039376397,0.0003201944,0.000095352785,0.000025219884,0.0001334584,0.00011989103,0.00048867945],"category_scores_gemma":[0.000007890772,0.00027267003,0.0002228729,0.00036934728,0.00007775571,0.00010341212,0.000043001837,0.00044608832,0.0000046212285],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001689992,0.00017962557,0.0030911334,0.00015926403,0.0003056404,0.00010362491,0.002456134,0.0013628781,0.9864672,0.00013014216,0.00001681482,0.0055585355],"study_design_scores_gemma":[0.0012351688,0.00036249965,0.006348757,0.000732229,0.00028477915,0.0000071044237,0.0020665051,0.00022992802,0.98791564,0.00021681139,0.00032456976,0.00027598895],"about_ca_topic_score_codex":0.00708923,"about_ca_topic_score_gemma":0.0006840145,"teacher_disagreement_score":0.008083579,"about_ca_system_score_codex":0.00045420634,"about_ca_system_score_gemma":0.0003455244,"threshold_uncertainty_score":0.9999725},"labels":[],"label_agreement":null},{"id":"W1980976141","doi":"10.1158/1535-7163.mct-08-0762","title":"Crocetin inhibits pancreatic cancer cell proliferation and tumor progression in a xenograft mouse model","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Saffron Plant Research Studies","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Public Health Agency of Canada","keywords":"Crocetin; In vivo; Pancreatic cancer; Cell growth; In vitro; Apoptosis; Cancer research; Cancer; Proliferating cell nuclear antigen; Nude mouse; Cell cycle; Chemistry; Molecular biology; Biology; Pharmacology; Biochemistry; Internal medicine; Medicine; Carotenoid","score_opus":0.029456163390863842,"score_gpt":0.34228013323689965,"score_spread":0.31282396984603583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980976141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9691906,0.02509294,0.0005010228,0.00370583,0.000018022041,0.0010322008,0.000020862799,0.000058634687,0.00037989154],"genre_scores_gemma":[0.9880314,0.0062378985,0.0012701026,0.0035924953,0.00003968803,0.00027419682,0.000012621093,0.000028676497,0.0005129048],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985536,0.00005663047,0.00024060831,0.00033011477,0.00042522073,0.00039385218],"domain_scores_gemma":[0.9994834,0.00001591128,0.000072179995,0.00019373497,0.00012520723,0.000109537934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001458644,0.0002180779,0.00031610558,0.0001093443,0.00007220154,0.00003569452,0.0000672845,0.00007623991,0.000017469169],"category_scores_gemma":[0.000012433136,0.00017666872,0.00004221487,0.0002055157,0.000062564766,0.000076337456,0.00003499233,0.00024176478,0.0000018388863],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080136646,0.0004246416,0.025703289,0.00030585067,0.00009221524,0.00008810911,0.0018228107,0.00047772375,0.9462451,0.000053769374,0.0001465382,0.023838624],"study_design_scores_gemma":[0.0040266984,0.00067204266,0.0084467055,0.00072074326,0.00022668944,0.000020776039,0.00018406117,0.05140177,0.9329048,0.00034111092,0.0006417893,0.00041282453],"about_ca_topic_score_codex":0.00013953228,"about_ca_topic_score_gemma":0.00023387313,"teacher_disagreement_score":0.050924048,"about_ca_system_score_codex":0.00021845318,"about_ca_system_score_gemma":0.00024146083,"threshold_uncertainty_score":0.7204341},"labels":[],"label_agreement":null},{"id":"W1982868690","doi":"10.1158/1535-7163.targ-11-b55","title":"Abstract B55: A study of REOLYSIN in combination with gemcitabine in patients with advanced pancreatic adenocarcinoma.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Gemcitabine; Tolerability; Medicine; Internal medicine; Pancreatic cancer; Oncology; Chemotherapy; Cancer; Gastroenterology; Pharmacology; Adverse effect","score_opus":0.020648776372777462,"score_gpt":0.27699074372922605,"score_spread":0.2563419673564486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982868690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976401,0.0011171935,0.000078918434,0.000018293824,0.000017002909,0.0009872218,0.000008049836,0.000006586398,0.00012663829],"genre_scores_gemma":[0.99933577,0.00008773182,0.00020235153,0.00010600299,0.0000063282837,0.0001607917,0.000033822704,0.000053866457,0.000013342119],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985303,0.00012506508,0.00028979426,0.00039218535,0.0003546371,0.0003079689],"domain_scores_gemma":[0.9991269,0.000007161917,0.00013788338,0.00050122343,0.00017930185,0.000047493035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016723391,0.00021862841,0.00026377974,0.0001664356,0.000023158904,0.000007769287,0.0002408347,0.00008673672,0.00002095637],"category_scores_gemma":[0.000004916734,0.00018285398,0.00003038365,0.0003986428,0.00008057332,0.000009163933,0.00004091593,0.00016259735,8.193145e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014534059,0.0025499475,0.85557365,0.000037688034,0.0002625095,0.00002599044,0.0009869253,0.0006908413,0.11830878,0.000007062523,7.278751e-7,0.007021818],"study_design_scores_gemma":[0.010091323,0.013265167,0.81752586,0.00006304338,0.000046177345,4.963392e-7,0.00030338648,0.00002896042,0.15838473,0.000025864536,0.000014426983,0.00025054964],"about_ca_topic_score_codex":0.00032976756,"about_ca_topic_score_gemma":0.0029191365,"teacher_disagreement_score":0.04007594,"about_ca_system_score_codex":0.00006628009,"about_ca_system_score_gemma":0.00015110093,"threshold_uncertainty_score":0.7456569},"labels":[],"label_agreement":null},{"id":"W1983005412","doi":"10.1158/1535-7163.mct-07-0179","title":"Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Health Canada; Royal Victoria Hospital","funders":"","keywords":"Imatinib; Chronic myelogenous leukemia; Cancer research; ABL; Imatinib mesylate; breakpoint cluster region; Apoptosis; Tyrosine kinase; Leukemia; Tyrosine-kinase inhibitor; Chemistry; Pharmacology; Biology; Immunology; Cancer; Cell biology; Signal transduction; Receptor; Biochemistry","score_opus":0.05143331692213097,"score_gpt":0.3044808825892281,"score_spread":0.25304756566709713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983005412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8361911,0.07361062,0.08546695,0.0007228864,0.00033768278,0.0031660686,0.00014058505,0.0001710931,0.00019296442],"genre_scores_gemma":[0.9801382,0.006114308,0.01127658,0.0008787488,0.0002946756,0.0004836889,0.00022053675,0.00016805824,0.00042520114],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9975414,0.00009928524,0.0006238526,0.00056476274,0.00045586523,0.00071479235],"domain_scores_gemma":[0.9982865,0.00016220193,0.00033003013,0.0007706899,0.00028135153,0.00016925164],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014067978,0.000491558,0.0007476545,0.00007487124,0.00037540597,0.000019428084,0.00021846415,0.00020203758,0.000055648663],"category_scores_gemma":[0.000018771476,0.00036349235,0.00042433137,0.00021469107,0.00033455563,0.00006449804,0.00003430948,0.00017417567,0.0000029648274],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013168335,0.0021155295,0.00027203446,0.00014518667,0.0030673246,0.0002380062,0.010703099,0.2760259,0.6714983,0.000114532726,0.00020688868,0.03429636],"study_design_scores_gemma":[0.013907948,0.0029240234,0.000042437234,0.00006923681,0.0013515188,0.00007185775,0.0002037118,0.5973822,0.37917647,0.000045474826,0.004447342,0.00037781996],"about_ca_topic_score_codex":0.00029447733,"about_ca_topic_score_gemma":0.000026234053,"teacher_disagreement_score":0.32135627,"about_ca_system_score_codex":0.004279111,"about_ca_system_score_gemma":0.001941521,"threshold_uncertainty_score":0.9998817},"labels":[],"label_agreement":null},{"id":"W1985530449","doi":"10.1158/1535-7163.mct-15-0039","title":"Enhanced <i>GAB2</i> Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Ovarian cancer; Serous fluid; Serous carcinoma; Ovarian carcinoma; Cancer research; Cancer; Oncology; PI3K/AKT/mTOR pathway; Biology; Comparative genomic hybridization; Internal medicine; Medicine; Gene; Genetics; Signal transduction; Genome","score_opus":0.02712509881237877,"score_gpt":0.2853249266071337,"score_spread":0.2581998277947549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985530449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98670584,0.0013200878,0.0024606478,0.00812201,0.00023132197,0.00087857334,0.000113791844,0.00005988056,0.000107840984],"genre_scores_gemma":[0.99135387,0.00039368,0.0005646879,0.0070785154,0.000089236935,0.00032523062,0.000041026567,0.00006657546,0.00008720532],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99826026,0.00013730633,0.00024503347,0.00054239697,0.000410543,0.00040447843],"domain_scores_gemma":[0.9990271,0.000041422023,0.00012012671,0.00031634528,0.00021488695,0.00028016733],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002363332,0.00031046593,0.0004930757,0.000102791426,0.000055776578,0.000043138556,0.00003365541,0.00016452093,0.000017484257],"category_scores_gemma":[0.000014290109,0.00025639747,0.000050356226,0.00040930457,0.000053461466,0.00007847051,0.000047312365,0.00021801193,0.000002315375],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001928392,0.0010839851,0.032916903,0.00007427225,0.0008701835,0.0007676613,0.0038581642,0.0005616177,0.9335906,0.00009265233,0.00020683503,0.024048733],"study_design_scores_gemma":[0.014008837,0.00096711365,0.061852455,0.0009314456,0.0004989204,0.000017532699,0.00020377497,0.00051051093,0.91940516,0.0001390891,0.00095673907,0.0005084132],"about_ca_topic_score_codex":0.003190171,"about_ca_topic_score_gemma":0.003340912,"teacher_disagreement_score":0.028935552,"about_ca_system_score_codex":0.0007598416,"about_ca_system_score_gemma":0.00035081292,"threshold_uncertainty_score":0.99998885},"labels":[],"label_agreement":null},{"id":"W1986700293","doi":"10.1158/1535-7163.targ-11-c69","title":"Abstract C69: Preliminary activity of temsirolimus, an mTOR inhibitor, in patients with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix: An NCIC-CTG phase II clinical trial.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Temsirolimus; Medicine; Response Evaluation Criteria in Solid Tumors; Internal medicine; Clinical endpoint; Progressive disease; Phases of clinical research; Oncology; Adenosquamous carcinoma; Cancer; Chemotherapy; Cervix; Adenocarcinoma; Surgery; Clinical trial; PI3K/AKT/mTOR pathway; Discovery and development of mTOR inhibitors","score_opus":0.09987743406618643,"score_gpt":0.3790143645730128,"score_spread":0.27913693050682636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986700293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957217,0.0011266249,0.000045696317,0.00008205378,0.00032634733,0.0024954998,0.00011853103,0.00001469718,0.00006882389],"genre_scores_gemma":[0.9986214,0.00028033904,0.0004377664,0.00025375676,0.000050333903,0.00025355062,0.000026466143,0.00006028736,0.000016124226],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.997641,0.00026243753,0.0007405075,0.0004799438,0.00054748135,0.00032859587],"domain_scores_gemma":[0.99801445,0.00007728383,0.00056261074,0.0009003372,0.00027133207,0.00017396711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029653354,0.00031516276,0.00075759616,0.00010098609,0.00005721497,0.0000071570103,0.00023878034,0.00011393521,0.00009165879],"category_scores_gemma":[0.000026895194,0.0001936991,0.00019396204,0.0003761946,0.00020382272,0.00015566022,0.00007076773,0.00030650722,3.5421496e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41295055,0.05280259,0.17606862,0.00043187488,0.0011121159,0.0000918775,0.0018365709,0.000075829215,0.004759612,0.00002666067,0.000014641142,0.34982905],"study_design_scores_gemma":[0.13340814,0.06828085,0.7217058,0.0005672675,0.0011737954,0.0000024498304,0.00010931062,0.00018349248,0.07396556,0.000033200697,0.00027086269,0.00029925545],"about_ca_topic_score_codex":0.0010484549,"about_ca_topic_score_gemma":0.0009985499,"teacher_disagreement_score":0.5456372,"about_ca_system_score_codex":0.0001967189,"about_ca_system_score_gemma":0.00079746504,"threshold_uncertainty_score":0.78988206},"labels":[],"label_agreement":null},{"id":"W1986763134","doi":"10.1158/1535-7163.targ-09-a185","title":"Abstract A185: Phase I clinical, pharmacokinetic, and pharmacodynamic study of SB939, an oral histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nausea; Vomiting; Pharmacokinetics; Pharmacodynamics; Adverse effect; Gastroenterology; Internal medicine; Peripheral blood mononuclear cell; Pharmacology; Colorectal cancer; Cmax; Cancer; Biology; In vitro","score_opus":0.023379375978761066,"score_gpt":0.4074113515472472,"score_spread":0.3840319755684862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986763134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99695337,0.0014466547,0.000087394474,0.00006411245,0.00010999739,0.0011922661,0.00006342236,0.00002133208,0.00006142875],"genre_scores_gemma":[0.9985421,0.00034763303,0.000250171,0.00050721655,0.000077824734,0.00006312258,0.00010534689,0.00007325104,0.000033360197],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99717927,0.00026383708,0.0007577099,0.00077305804,0.00051795266,0.0005081611],"domain_scores_gemma":[0.99862,0.000014844841,0.00028190447,0.0005619027,0.00027252294,0.0002488242],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035128888,0.0003948679,0.0005226063,0.00017317868,0.00008094095,0.000024434861,0.00030691098,0.0001569793,0.00002348988],"category_scores_gemma":[0.00001799928,0.00037690985,0.00008675212,0.00028677075,0.00023916215,0.000025096435,0.00007352646,0.00040907212,0.0000015194574],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003628162,0.0071068536,0.004324987,0.000030389687,0.00017948849,0.00006270675,0.00031000585,0.0008672216,0.8574439,0.0000013350069,0.00003165828,0.12601323],"study_design_scores_gemma":[0.04455444,0.01861514,0.04969781,0.00011760995,0.00023942054,0.000005616921,0.0003150516,0.0009765674,0.88236654,0.000008485497,0.0021018356,0.001001475],"about_ca_topic_score_codex":0.000071297734,"about_ca_topic_score_gemma":0.00014287586,"teacher_disagreement_score":0.12501176,"about_ca_system_score_codex":0.00008727919,"about_ca_system_score_gemma":0.00020781287,"threshold_uncertainty_score":0.9998683},"labels":[],"label_agreement":null},{"id":"W1989623500","doi":"10.1158/1535-7163.pms-b16","title":"Abstract B16: Cells containing mutations in the cohesin component, STAG2, are sensitive to PARP inhibition","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Cohesin; Synthetic lethality; Olaparib; Establishment of sister chromatid cohesion; Biology; Cancer cell; Chromosome instability; Cancer research; Molecular biology; PARP1; Genome instability; Genetics; Cancer; DNA repair; DNA damage; Poly ADP ribose polymerase; Chromosome; DNA; Polymerase; Gene","score_opus":0.016924990088164046,"score_gpt":0.2661388540910567,"score_spread":0.24921386400289264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989623500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99159664,0.00038274867,0.005579041,0.0013140993,0.0000939051,0.0006698583,0.000067206616,0.000010878193,0.0002856081],"genre_scores_gemma":[0.9893382,0.00016625196,0.00033246004,0.00971451,0.00007040774,0.0001702766,0.00013618062,0.00003189733,0.000039797767],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99891806,0.00010992889,0.0002276669,0.0002964899,0.00015409684,0.00029379054],"domain_scores_gemma":[0.99938464,0.000021681713,0.00010227406,0.00030239872,0.00013171375,0.000057283327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013733444,0.000187947,0.00014820637,0.0000548062,0.000085363914,0.00007004759,0.00014486503,0.00012506501,0.00001886297],"category_scores_gemma":[0.0000066383127,0.00016374081,0.000079595826,0.00014026611,0.00005675052,0.0000066234566,0.000045081404,0.00015764701,0.000027810824],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031792137,0.00007287622,0.0005768353,0.000010411574,0.00006162322,0.00001752178,0.0005755514,0.001450068,0.9948275,0.000049477367,0.0002607266,0.0020656264],"study_design_scores_gemma":[0.00065871584,0.00013824063,0.016147662,0.000061559615,0.000046372388,0.00000808848,0.0018439267,0.0003085747,0.9705088,0.000099953526,0.009842186,0.0003359277],"about_ca_topic_score_codex":0.00035847674,"about_ca_topic_score_gemma":0.0004423853,"teacher_disagreement_score":0.024318697,"about_ca_system_score_codex":0.000049687333,"about_ca_system_score_gemma":0.00006150546,"threshold_uncertainty_score":0.66771567},"labels":[],"label_agreement":null},{"id":"W1989966460","doi":"10.1158/1535-7163.mct-07-0515","title":"UBE1L represses PML/RARα by targeting the PML domain for ISG15ylation","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"Cleveland Clinic Foundation; National Institutes of Health; Cleveland Clinic; National Cancer Institute; Samuel Waxman Cancer Research Foundation","keywords":"Promyelocytic leukemia protein; Acute promyelocytic leukemia; Ubiquitin; Biology; Retinoic acid; Cancer research; ISG15; Psychological repression; HEK 293 cells; Tretinoin; Cell biology; Gene expression; Receptor; Gene; Biochemistry","score_opus":0.016154917774387618,"score_gpt":0.27062417790616555,"score_spread":0.25446926013177795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989966460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8153543,0.054383647,0.12701958,0.0011765164,0.00033043354,0.0006013516,0.00006294654,0.00004095069,0.0010303067],"genre_scores_gemma":[0.9891221,0.0037241827,0.0020338197,0.0028988232,0.00037047482,0.00027800185,0.00024919133,0.00007569232,0.0012477089],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986072,0.00009447827,0.0002695112,0.0004461449,0.0002263159,0.00035635591],"domain_scores_gemma":[0.9991259,0.000028649514,0.00015074824,0.00046932918,0.00017309395,0.000052306084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021528546,0.00023732633,0.00016381452,0.000020397514,0.00035981712,0.000038109152,0.00037273703,0.0001985852,0.000020010088],"category_scores_gemma":[0.000038180508,0.00018737486,0.0001588338,0.0001265281,0.00018828947,0.000006787558,0.000066050656,0.00013368407,0.0000031403754],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009351806,0.000036573016,0.00077685976,0.000036041296,0.00015015491,0.000004051986,0.00021309555,0.0003397768,0.98748106,0.00012307907,0.008201684,0.002544081],"study_design_scores_gemma":[0.00042504846,0.00009055434,0.00003102131,0.000008402594,0.000041437823,0.000011146637,0.00007693315,0.00012768261,0.6636491,0.00046226187,0.33487287,0.00020359056],"about_ca_topic_score_codex":0.000020676705,"about_ca_topic_score_gemma":0.0000035720639,"teacher_disagreement_score":0.32667118,"about_ca_system_score_codex":0.000035475372,"about_ca_system_score_gemma":0.00016804403,"threshold_uncertainty_score":0.7640925},"labels":[],"label_agreement":null},{"id":"W1990418094","doi":"10.1158/1535-7163.mct-08-0198","title":"Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":238,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Hypoxia (environmental); Senescence; Biology; Population; Small interfering RNA; Apoptosis; Etoposide; Pharmacology; Daunorubicin; Mitoxantrone; Clonogenic assay; Drug resistance; Hypoxia-inducible factors; Cancer research; Immunology; Cell biology; Chemistry; Cell culture; Medicine; Transfection; Biochemistry; Chemotherapy; Leukemia; Oxygen","score_opus":0.02930541796033482,"score_gpt":0.2765230141652082,"score_spread":0.24721759620487338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990418094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98733073,0.007951772,0.0022042019,0.00086479995,0.00042693556,0.0005627726,0.00015365118,0.000057741978,0.00044738295],"genre_scores_gemma":[0.98934656,0.0033052554,0.0005315081,0.005110193,0.0003821603,0.00012927958,0.000021791257,0.000113748196,0.0010594918],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99719447,0.00015679357,0.00029139122,0.0010365408,0.0005852659,0.0007355494],"domain_scores_gemma":[0.99824417,0.000033178883,0.00020676422,0.00085342687,0.00030964107,0.00035279285],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016609089,0.0005159693,0.0005084994,0.00010391396,0.00030990838,0.0000605007,0.00034667124,0.00030722175,0.000023898916],"category_scores_gemma":[0.000054112163,0.00048876274,0.00014141302,0.00047041866,0.000240192,0.000023605979,0.00012821009,0.00024986852,0.000004164912],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005930483,0.000116318144,0.0014520539,0.000023512015,0.00039082652,0.000018067809,0.00056742446,0.000016501004,0.98699915,0.00002001286,0.0005357116,0.0092673395],"study_design_scores_gemma":[0.0017433639,0.00027135407,0.0254715,0.00010407733,0.00015765871,0.000019915607,0.000057044886,0.00002890453,0.9135337,0.00003657093,0.057787318,0.0007886255],"about_ca_topic_score_codex":0.00025591796,"about_ca_topic_score_gemma":0.00042967006,"teacher_disagreement_score":0.07346552,"about_ca_system_score_codex":0.000118835844,"about_ca_system_score_gemma":0.00060767547,"threshold_uncertainty_score":0.9997564},"labels":[],"label_agreement":null},{"id":"W1991500129","doi":"10.1158/1535-7163.targ-13-b133","title":"Abstract B133: Regulation of the androgen receptor function by a metabolic kinase in prostate cancer.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Androgen receptor; Kinase; Cancer research; Androgen; Cancer; LNCaP; Kinome; Biology; Medicine; Internal medicine; Endocrinology; Cell biology; Hormone","score_opus":0.022211170552774218,"score_gpt":0.29957309379486463,"score_spread":0.2773619232420904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991500129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9569024,0.037148826,0.000026302008,0.004122276,0.00018234567,0.0013261391,0.000057276626,0.000019746532,0.00021472546],"genre_scores_gemma":[0.9926498,0.004918727,0.000037592552,0.0007225282,0.00004076879,0.00051411387,0.00003901195,0.000035049008,0.0010424118],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879795,0.000059436017,0.0002577291,0.00023149104,0.00037061208,0.00028280047],"domain_scores_gemma":[0.99930656,0.000012770137,0.00012258446,0.00030987101,0.00017973337,0.00006847678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010617449,0.00016029259,0.0002381827,0.00007622989,0.000051460018,0.000019683175,0.00010070116,0.00007925958,0.00045858792],"category_scores_gemma":[0.0000050150384,0.00010531769,0.00009991677,0.00043862747,0.000106829306,0.00008574663,0.000028289913,0.00019567253,0.000009973735],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003640952,0.00014822483,0.035205886,0.00009006733,0.00026380256,0.0000021560159,0.00031864824,0.00009435899,0.88705266,0.000037117643,0.000639048,0.07578392],"study_design_scores_gemma":[0.002757498,0.00013036361,0.17204094,0.00020055812,0.00019558042,0.0000014823472,0.00009290833,0.00030468294,0.79484886,0.00032587108,0.02894542,0.00015583262],"about_ca_topic_score_codex":0.0017322137,"about_ca_topic_score_gemma":0.00007089346,"teacher_disagreement_score":0.13683505,"about_ca_system_score_codex":0.00019529526,"about_ca_system_score_gemma":0.0002567097,"threshold_uncertainty_score":0.5021216},"labels":[],"label_agreement":null},{"id":"W1992078544","doi":"10.1158/1535-7163.targ-13-c246","title":"Abstract C246: SH-4-54, a novel small-molecule inhibitor of STAT3, demonstrates significant anti-tumor activity against multiple myeloma.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Annexin; STAT3; Viability assay; Angiogenesis; Cancer research; Molecular biology; Cell culture; Annexin A5; Multiple myeloma; Cancer cell; Chemistry; Apoptosis; Flow cytometry; Biology; Medicine; Cancer; Immunology; Biochemistry; Internal medicine","score_opus":0.04529557599727723,"score_gpt":0.3077879985497879,"score_spread":0.26249242255251065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992078544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918934,0.0027193055,0.001401568,0.001515542,0.00013638381,0.001001029,0.00017491817,0.000058186106,0.0010996377],"genre_scores_gemma":[0.99592525,0.00082975836,0.0011528832,0.0014969377,0.00013845517,0.00012919196,0.00003898343,0.00007804123,0.00021049017],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975753,0.00006387545,0.00048517418,0.00050169654,0.0006751918,0.00069876853],"domain_scores_gemma":[0.99843127,0.00013614893,0.00022809052,0.0004729281,0.0004282036,0.0003033593],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017381397,0.0003992024,0.00061070145,0.00015947578,0.00011486651,0.000055822176,0.00026972085,0.00015645761,0.00021206323],"category_scores_gemma":[0.000034578195,0.00032972844,0.000294776,0.0003458448,0.00035695964,0.00011161449,0.00010478281,0.0005232677,0.000045515204],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033591088,0.000667173,0.01401415,0.00036613407,0.00043138862,0.000117797674,0.00013876798,0.0000698631,0.95817065,0.00005011582,0.00007293516,0.0255651],"study_design_scores_gemma":[0.0016894845,0.00032977568,0.08628672,0.00020470683,0.000100816294,0.000016003612,0.00009265537,0.0031090395,0.9048679,0.000035883444,0.0028928036,0.00037420596],"about_ca_topic_score_codex":0.0013469844,"about_ca_topic_score_gemma":0.00007358528,"teacher_disagreement_score":0.07227258,"about_ca_system_score_codex":0.000108103144,"about_ca_system_score_gemma":0.00048395264,"threshold_uncertainty_score":0.9999155},"labels":[],"label_agreement":null},{"id":"W1995058453","doi":"10.1158/1535-7163.targ-09-a189","title":"Abstract A189: Expression of fusion proteins in acute myeloid leukemia cells increases sensitivity to histone deacetylase inhibitors","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Biology; DNA damage; DNA repair; Vorinostat; Cancer research; Cell biology; Fusion protein; Histone; Gene silencing; Myeloid leukemia; Histone deacetylase; Molecular biology; Genetics; Gene; DNA","score_opus":0.010349741509557865,"score_gpt":0.27076716155885505,"score_spread":0.2604174200492972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995058453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956188,0.0012100431,0.0018325989,0.00035533056,0.00011592722,0.0006225503,0.00004431534,0.000020489686,0.00017989501],"genre_scores_gemma":[0.9961432,0.000425821,0.0014487664,0.0016645994,0.000094651885,0.00004355013,0.00005538496,0.0000307482,0.000093257804],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99850833,0.000115863695,0.00036611265,0.00042320217,0.0002866862,0.00029978156],"domain_scores_gemma":[0.9991466,0.000008212197,0.00016791794,0.00043652317,0.00011116062,0.00012962909],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002206622,0.00025618836,0.00025013316,0.00012574616,0.00005560031,0.000017282762,0.00015298002,0.00022446353,0.000016499012],"category_scores_gemma":[0.000021175278,0.00025096885,0.00012324635,0.00022992777,0.00005675624,0.000011046435,0.000081613915,0.00016608315,0.000005701571],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030465698,0.00016408661,0.000114304945,0.000017287628,0.000023917115,0.000026789856,0.00007620915,0.00059785997,0.9854079,0.000009670284,0.0002662053,0.012991148],"study_design_scores_gemma":[0.00071670895,0.00029479622,0.0027307984,0.00012523399,0.000024938476,0.0000040152463,0.000024579922,0.000047224596,0.99113035,0.000029876961,0.0045834756,0.00028799582],"about_ca_topic_score_codex":0.0003094864,"about_ca_topic_score_gemma":0.00011532587,"teacher_disagreement_score":0.012703151,"about_ca_system_score_codex":0.00015777147,"about_ca_system_score_gemma":0.00022275603,"threshold_uncertainty_score":0.9999943},"labels":[],"label_agreement":null},{"id":"W1997050616","doi":"10.1158/1535-7163.targ-11-a201","title":"Abstract A201: The potent STAT3/5 inhibitor, BP-1–102, demonstrates significant antitumor activity against Waldenstrom macroglobulinemia.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"STAT3; Cancer research; Macroglobulinemia; Waldenstrom macroglobulinemia; Biology; Cell growth; Transcription factor; Carcinogenesis; STAT5; Lymphoma; Signal transduction; Gene; Immunology; Multiple myeloma; Cell biology; Genetics","score_opus":0.05389147754549747,"score_gpt":0.3120570654793618,"score_spread":0.25816558793386435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997050616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876723,0.0039003773,0.00074765325,0.0012218531,0.0004181141,0.001076131,0.000068766734,0.00013223419,0.0047625266],"genre_scores_gemma":[0.9948938,0.0013748995,0.00054107606,0.002345846,0.00023191462,0.0001283411,0.000018499682,0.000108260814,0.0003573593],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99676216,0.0001327412,0.00045081953,0.0006345018,0.0009770689,0.0010426965],"domain_scores_gemma":[0.9980356,0.00008860032,0.00020244239,0.0010696993,0.0002607628,0.00034287863],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045316367,0.00045359103,0.00047497658,0.00010524266,0.00021679843,0.000083497776,0.00046871265,0.00022389136,0.00030190646],"category_scores_gemma":[0.000024003068,0.00031856424,0.00029023812,0.00038273822,0.00056490535,0.000087261426,0.00014839345,0.0007785916,0.000092093265],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001580913,0.0010334995,0.0023977484,0.00029730695,0.0015424563,0.0035664628,0.0016054104,0.00013499867,0.8534573,0.00031385853,0.0008048003,0.13326526],"study_design_scores_gemma":[0.010398047,0.0004949025,0.016753258,0.00031141925,0.00053117506,0.00022259053,0.0007680926,0.0036839726,0.955817,0.0002303281,0.0100288205,0.0007603787],"about_ca_topic_score_codex":0.0017698448,"about_ca_topic_score_gemma":0.00006584786,"teacher_disagreement_score":0.13250488,"about_ca_system_score_codex":0.0038569851,"about_ca_system_score_gemma":0.0051140925,"threshold_uncertainty_score":0.99996704},"labels":[],"label_agreement":null},{"id":"W1997663619","doi":"10.1158/1535-7163.targ-13-a236","title":"Abstract A236: The orphan G-protein coupled receptor GPR161 is an oncogene in triple negative breast cancer.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Receptor Mechanisms and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Triple-negative breast cancer; Cancer research; Cancer; Biology; Breast cancer; mTORC1; Carcinogenesis; Gene knockdown; PI3K/AKT/mTOR pathway; Cell growth; Oncogene; Signal transduction; Cell biology; Cell culture; Genetics; Cell cycle","score_opus":0.019466022167806518,"score_gpt":0.27534674363905204,"score_spread":0.2558807214712455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997663619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916983,0.0037111216,0.0011352942,0.0019731289,0.0003050995,0.0009349972,0.00012350999,0.000020853613,0.000097650605],"genre_scores_gemma":[0.9929117,0.0012374757,0.00052121293,0.0039056907,0.00030814772,0.0006132414,0.00005405539,0.00008500572,0.00036349354],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99813914,0.00013346305,0.0003626043,0.0005588215,0.00030139976,0.00050458673],"domain_scores_gemma":[0.99888945,0.000010171023,0.0001818409,0.0005673179,0.00021815652,0.00013305507],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023463865,0.00034371568,0.00026867774,0.000052384057,0.00015046216,0.000108583205,0.00048578138,0.00025718933,0.002250631],"category_scores_gemma":[0.000007158223,0.00026731176,0.00015062571,0.00024168486,0.000105730585,0.000018337125,0.000077378616,0.00025648385,0.000028195587],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011931191,0.0000884843,0.00021404357,0.000012744997,0.00016566574,0.0000029243843,0.00032560286,0.00029444232,0.97810626,0.000039098486,0.00017940458,0.020452028],"study_design_scores_gemma":[0.0011304852,0.00016586565,0.0013928652,0.000054811226,0.00003677218,0.000004026687,0.00035150524,0.0013031305,0.9893768,0.00038369998,0.0053732563,0.00042681408],"about_ca_topic_score_codex":0.003923396,"about_ca_topic_score_gemma":0.000605913,"teacher_disagreement_score":0.020025214,"about_ca_system_score_codex":0.00010353493,"about_ca_system_score_gemma":0.00024825445,"threshold_uncertainty_score":0.9999779},"labels":[],"label_agreement":null},{"id":"W2000068551","doi":"10.1158/1535-7163.targ-09-b154","title":"Abstract B154: Thymoquinone causes mitochondrial membrane disruption and potentiates chemotherapeutic drug- and radiation-induced cytotoxicity in breast cancer cells","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Nigella sativa pharmacological applications","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Thymoquinone; Propidium iodide; Pharmacology; Apoptosis; Cytotoxicity; Cancer cell; Cancer research; Chemistry; Programmed cell death; Medicine; Cancer; Biochemistry; Internal medicine; In vitro; Antioxidant","score_opus":0.01958534159994146,"score_gpt":0.3112050312178061,"score_spread":0.29161968961786466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000068551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829828,0.004282602,0.00013146573,0.011337546,0.00010948322,0.0009669782,0.000054445405,0.00006270651,0.00007195013],"genre_scores_gemma":[0.9870129,0.0066043683,0.0002641287,0.0057398714,0.00017021457,0.00012542485,0.000014145973,0.000033469918,0.000035426503],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985492,0.000058769343,0.00033313766,0.00045494203,0.0002656829,0.00033822097],"domain_scores_gemma":[0.99935013,0.00005409303,0.00013241974,0.00022322616,0.000079428784,0.00016067774],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009026666,0.00027909293,0.00036976064,0.00011279982,0.00009552646,0.00004662567,0.000090954236,0.00014937329,0.00014315237],"category_scores_gemma":[0.0000024514063,0.000247087,0.00006664999,0.00029489858,0.00010192893,0.000092684684,0.000022439615,0.0003082257,0.0000037669945],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028349683,0.00025756864,0.0029660447,0.000047917205,0.00012867087,0.00001579263,0.0003426573,0.000055370856,0.9717426,0.000041889078,0.000013902611,0.024104124],"study_design_scores_gemma":[0.002711028,0.00006884879,0.25588208,0.00007109147,0.00025515843,0.000021974714,0.000051162537,0.00045686605,0.7396545,0.0003197945,0.00024515507,0.00026237074],"about_ca_topic_score_codex":0.00029447113,"about_ca_topic_score_gemma":0.00005225269,"teacher_disagreement_score":0.25291604,"about_ca_system_score_codex":0.00019118647,"about_ca_system_score_gemma":0.000101359794,"threshold_uncertainty_score":0.99999815},"labels":[],"label_agreement":null},{"id":"W2000610923","doi":"10.1158/1535-7163.targ-09-a106","title":"Abstract A106: A phase 1 study of ENMD-2076 in patients with relapsed or refractory acute myeloid leukemia (AML)","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nausea; Adverse effect; Refractory (planetary science); Internal medicine; Gastroenterology; Dosing; Surgery","score_opus":0.025273758897927222,"score_gpt":0.3350625837744868,"score_spread":0.30978882487655957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000610923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996591,0.00047367217,0.00009792052,0.00032808297,0.0000615981,0.0018581839,0.000032975742,0.000054056803,0.0005025288],"genre_scores_gemma":[0.9971268,0.00024914314,0.00036742789,0.0017234186,0.000046659778,0.00007913848,0.000045160374,0.000082870494,0.00027938845],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99711406,0.000112216105,0.0005956228,0.0005405187,0.0010523949,0.0005851559],"domain_scores_gemma":[0.9982941,0.00005392379,0.00024752948,0.0008742602,0.00033609863,0.00019408822],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002393531,0.00038027717,0.000678027,0.00034733675,0.00005775337,0.00002044928,0.00032483521,0.00020415321,0.00015142237],"category_scores_gemma":[0.000023680834,0.00027926944,0.0000944671,0.0007966622,0.00010775485,0.0001224604,0.000047249552,0.0007402964,0.000007427388],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09031575,0.02374537,0.09395196,0.00031091072,0.0044321013,0.004423531,0.010013574,0.00048440133,0.45786795,0.000034353416,0.0005291935,0.3138909],"study_design_scores_gemma":[0.16901757,0.050456263,0.67915493,0.0007881676,0.0018703865,0.000031941978,0.0015663619,0.0005157638,0.08715248,0.00007378692,0.008007533,0.0013648275],"about_ca_topic_score_codex":0.00025902505,"about_ca_topic_score_gemma":0.0000983079,"teacher_disagreement_score":0.58520293,"about_ca_system_score_codex":0.0014701192,"about_ca_system_score_gemma":0.0013231484,"threshold_uncertainty_score":0.99996597},"labels":[],"label_agreement":null},{"id":"W2001379228","doi":"10.1158/1535-7163.targ-13-a247","title":"Abstract A247: BT2111, a new anticancer agent composed of trastuzumab and transcend a vector for brain delivery for the treatment of metastatic Her2+ breast cancer.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Institute for Biological Sciences","funders":"","keywords":"Trastuzumab; Medicine; Parenchyma; Monoclonal antibody; Breast cancer; Antibody; Confocal microscopy; Blood–brain barrier; Intracardiac injection; Pathology; Metastatic breast cancer; Cancer research; Pharmacology; Cancer; Internal medicine; Immunology; Central nervous system; Biology; Cell biology","score_opus":0.05868971413243731,"score_gpt":0.3592567249271313,"score_spread":0.300567010794694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001379228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9382994,0.02137282,0.014330809,0.021288449,0.00007089578,0.0036527026,0.0009352056,0.000020795505,0.000028894665],"genre_scores_gemma":[0.9930863,0.0034266682,0.0012664427,0.000965482,0.00008464166,0.0010145722,0.00001978537,0.00003474949,0.00010136699],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990551,0.000013849759,0.00031628986,0.0002266332,0.00015791651,0.00023024401],"domain_scores_gemma":[0.99910533,0.00026275867,0.00012314178,0.00023600599,0.00014395204,0.00012880944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000052692347,0.00019495531,0.00039050294,0.000022507316,0.0000673563,0.000012649963,0.00009461905,0.000050430306,0.00014292986],"category_scores_gemma":[0.000002855468,0.00013449765,0.00021913691,0.00011157919,0.00016473203,0.000025957865,0.0000037648977,0.000059297145,3.4293015e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064913934,0.00053369417,0.00014159136,0.0004921878,0.001456005,0.0000012693916,0.0005624787,0.0001729241,0.8612769,0.000098281314,0.00016420928,0.13445129],"study_design_scores_gemma":[0.0093981065,0.0007959239,0.013294425,0.00018853095,0.0032917054,0.000019603716,0.00027081248,0.007816912,0.9376363,0.00030733392,0.026705328,0.0002750032],"about_ca_topic_score_codex":0.0005209703,"about_ca_topic_score_gemma":0.00002512627,"teacher_disagreement_score":0.13417628,"about_ca_system_score_codex":0.00011677547,"about_ca_system_score_gemma":0.00024677333,"threshold_uncertainty_score":0.5484655},"labels":[],"label_agreement":null},{"id":"W2002734325","doi":"10.1158/1535-7163.targ-13-c205","title":"Abstract C205: Cytotoxicity and target modulation in pediatric solid tumors by the proteasome inhibitor carfilzomib.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"","keywords":"Carfilzomib; Tolerability; Proteasome inhibitor; Cancer research; Proteasome; Cytotoxicity; Apoptosis; Pharmacology; Cell cycle; Cell culture; Chemistry; Medicine; In vitro; Biology; Adverse effect; Biochemistry","score_opus":0.01292518297111887,"score_gpt":0.25261422608241035,"score_spread":0.2396890431112915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002734325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916686,0.005583843,0.0007074153,0.00065730436,0.000072232906,0.0010059811,0.000045610643,0.000016770453,0.00024227831],"genre_scores_gemma":[0.9970445,0.00060159573,0.00020232133,0.0012754919,0.00021644348,0.0004708491,0.000051631807,0.000042678934,0.00009449031],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987156,0.00009554066,0.00026988247,0.0003746744,0.00019547464,0.00034885926],"domain_scores_gemma":[0.9993977,0.000010350277,0.00012205998,0.00030906446,0.00007897022,0.00008185211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018879316,0.00023294934,0.00017269191,0.000044769084,0.000095648415,0.00006871186,0.00019803968,0.00018127693,0.000043749737],"category_scores_gemma":[0.00001527715,0.00018682197,0.000065444634,0.00014409218,0.00008344938,0.000011937594,0.00008615502,0.00021699142,0.0000087160315],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029495846,0.00005149139,0.009857445,0.00003770041,0.000031757136,0.0000025389631,0.000118562595,0.00021032218,0.98651445,0.00001890011,0.00024100902,0.002886312],"study_design_scores_gemma":[0.00071714516,0.0001320153,0.04377376,0.000018064542,0.000021678487,0.0000065686204,0.00004979957,0.000805928,0.95094246,0.0007057535,0.0024613023,0.00036550013],"about_ca_topic_score_codex":0.00020053261,"about_ca_topic_score_gemma":0.000030483792,"teacher_disagreement_score":0.03557198,"about_ca_system_score_codex":0.0000360596,"about_ca_system_score_gemma":0.00009036111,"threshold_uncertainty_score":0.7618379},"labels":[],"label_agreement":null},{"id":"W2003518997","doi":"10.1158/1535-7163.targ-09-a170","title":"Abstract A170: High-content screening for inhibitors of oncogenic transcription by c-Myc","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Molecular Biology Techniques and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; McMaster University","funders":"","keywords":"Förster resonance energy transfer; Fluorescence; Bimolecular fluorescence complementation; Protein-fragment complementation assay; Protein–protein interaction; Computational biology; Transcription factor; Fluorescence microscope; Small molecule; Biology; Chemistry; Biochemistry; Cancer research; Cell biology; Gene; Complementation","score_opus":0.03336528089470042,"score_gpt":0.3012368638498766,"score_spread":0.26787158295517616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003518997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7282302,0.00477755,0.2648073,0.0011724685,0.000072706964,0.00062898255,0.00019168224,0.00003117525,0.000087954],"genre_scores_gemma":[0.9899999,0.00081522984,0.006049518,0.0023687189,0.00008276468,0.00016669004,0.00040931322,0.000033863347,0.00007401043],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988957,0.000026224923,0.00032432444,0.00036525738,0.00012391809,0.00026459363],"domain_scores_gemma":[0.99927616,0.0000048407533,0.00016062289,0.00036180267,0.00013650094,0.000060058195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012686098,0.00020659808,0.00020018044,0.000039380015,0.000070534465,0.000012667839,0.00022625261,0.000251543,0.000009395339],"category_scores_gemma":[0.00000498204,0.0002052795,0.00023766379,0.000092277,0.00007338378,0.0000036916022,0.000016597369,0.000096733114,5.1086784e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000106241634,0.0000990067,0.00005389559,0.000012363956,0.000120693105,5.2691854e-7,0.000017973127,0.000053598043,0.9534329,0.00046803104,0.0004829156,0.045151852],"study_design_scores_gemma":[0.0006526862,0.0004122514,0.0004949258,0.000021134321,0.0000842432,0.0000021108672,0.000016940794,0.000037631347,0.9422108,0.0004283428,0.055418625,0.0002203175],"about_ca_topic_score_codex":0.000046347384,"about_ca_topic_score_gemma":0.0000071121535,"teacher_disagreement_score":0.2617697,"about_ca_system_score_codex":0.000020489071,"about_ca_system_score_gemma":0.000047992184,"threshold_uncertainty_score":0.8371055},"labels":[],"label_agreement":null},{"id":"W2004062881","doi":"10.1158/1535-7163.targ-11-a121","title":"Abstract A121: Direct SH2 domain-targeting inhibitors of Stat3: Potent anticancer agents and mitigators of drug resistance.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Synthesis and biological activity","field":"Chemistry","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"SH2 domain; STAT3; Cancer research; STAT protein; Cancer cell; Cancer; Biology; Chemistry; Signal transduction; Cell biology; Tyrosine phosphorylation","score_opus":0.02840876955575181,"score_gpt":0.25265526855958653,"score_spread":0.22424649900383473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004062881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98761773,0.004477518,0.000032267624,0.00010074499,0.0000793758,0.000084625106,0.00008322165,0.000025229263,0.0074992785],"genre_scores_gemma":[0.9977932,0.0011138634,0.00080796477,0.00014030503,0.00003789677,0.000014476129,0.000004145074,0.000027565751,0.000060563496],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986454,0.000045913104,0.00040828422,0.00032746882,0.0002899528,0.00028297098],"domain_scores_gemma":[0.99916047,0.000072317984,0.00033671557,0.00025789908,0.00008847586,0.00008410152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020828246,0.00022070539,0.00038959185,0.00003395873,0.00005299604,0.000009322374,0.00017983849,0.00012425425,0.00035717772],"category_scores_gemma":[0.000018990648,0.00017444727,0.00015078369,0.0001089836,0.0002684564,0.00004206912,0.00006373238,0.00014815538,6.487337e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019929744,0.0002286141,0.037650213,0.0002936972,0.00032150757,0.00001687975,0.0008169661,0.0000026589728,0.9501849,0.00009672225,0.00006146621,0.010127098],"study_design_scores_gemma":[0.0003114561,0.000016176318,0.014910171,0.0001867315,0.00008304716,3.806966e-7,0.0002878055,0.0000060748453,0.979531,0.0006795873,0.0037698771,0.0002177119],"about_ca_topic_score_codex":0.00024481417,"about_ca_topic_score_gemma":0.00003142201,"teacher_disagreement_score":0.029346101,"about_ca_system_score_codex":0.000056626126,"about_ca_system_score_gemma":0.000049224593,"threshold_uncertainty_score":0.7113753},"labels":[],"label_agreement":null},{"id":"W2005166484","doi":"10.1158/1535-7163.mct-04-0214","title":"Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Oncosuisse; Terry Fox Foundation; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Cancer Institute; National Science Foundation","keywords":"Cancer research; Biology; MSH2; DNA repair; DNA mismatch repair; Cancer; Cancer cell; DNA; Genetics","score_opus":0.03412404557386352,"score_gpt":0.32579379448660695,"score_spread":0.29166974891274344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005166484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883044,0.00215359,0.004651697,0.002371362,0.00003988652,0.0021839365,0.000029067842,0.000044804507,0.00022129212],"genre_scores_gemma":[0.9619378,0.000022884715,0.036066763,0.0010074576,0.000065369946,0.0005640357,0.000014422502,0.000048641654,0.00027265173],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987402,0.000031577583,0.00042186968,0.00035742924,0.00019303011,0.0002558814],"domain_scores_gemma":[0.99915844,0.00003195568,0.00014340338,0.00040245042,0.00017553051,0.00008824573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016658947,0.00017457314,0.00027844438,0.00009201534,0.00006452286,0.00001017361,0.00009402349,0.000072940726,0.00003091565],"category_scores_gemma":[0.00003231747,0.00018044212,0.000082375,0.00025849172,0.000058196307,0.000031538908,0.000037205344,0.000099338235,7.1000215e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018553145,0.00010901731,0.011052993,0.00023018832,0.00007691823,0.0000014695979,0.0006960568,0.0007896491,0.9814763,0.00015519951,0.000048304373,0.005178372],"study_design_scores_gemma":[0.0023112043,0.00028642293,0.12848724,0.00033765877,0.0001657369,0.0000033716833,0.00007746554,0.0020621608,0.85277754,0.0006570601,0.012572597,0.00026151192],"about_ca_topic_score_codex":0.000060046103,"about_ca_topic_score_gemma":0.00055852084,"teacher_disagreement_score":0.12869874,"about_ca_system_score_codex":0.00025631223,"about_ca_system_score_gemma":0.00008436781,"threshold_uncertainty_score":0.7358216},"labels":[],"label_agreement":null},{"id":"W2005910933","doi":"10.1158/1535-7163.targ-11-b63","title":"Abstract B63: Targeting cancer cells with a glucose-conjugated DNA repair inhibitor.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"","keywords":"Temozolomide; Cancer research; O-6-methylguanine-DNA methyltransferase; Methyltransferase; DNA repair; Guanine; DNA damage; Cancer cell; DNA; Lomustine; DNA methyltransferase; Cancer; Cisplatin; Chemistry; Pharmacology; Chemotherapy; Biology; Biochemistry; Vincristine; Methylation; Glioma; Nucleotide; Genetics","score_opus":0.02793375412653739,"score_gpt":0.26911507958806247,"score_spread":0.24118132546152507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005910933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98395795,0.012911125,0.000055134697,0.0004828586,0.0002604671,0.0006159504,0.000030804917,0.00021039913,0.0014753295],"genre_scores_gemma":[0.9938981,0.001356716,0.0015234101,0.0026416194,0.00012340592,0.00028254802,0.000019016585,0.00009819141,0.000056999823],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99839395,0.00003288975,0.00030467502,0.00044789864,0.00036233477,0.00045825593],"domain_scores_gemma":[0.9990315,0.00001800334,0.00015262487,0.0004207755,0.00019392243,0.00018319502],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009416842,0.00033314544,0.00037036734,0.000087439556,0.00009445985,0.000021807877,0.000097366355,0.00013361298,0.0005474062],"category_scores_gemma":[0.0000031434176,0.00024866068,0.00019406271,0.0002669816,0.00009085046,0.000057643352,0.000028765366,0.0002144389,0.00003173232],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006268923,0.000885791,0.03139058,0.00013078585,0.0019578994,0.001407918,0.0013155778,0.00007765842,0.9528385,0.00006841339,0.00052878365,0.008771245],"study_design_scores_gemma":[0.002553336,0.00036378027,0.015700476,0.00028820214,0.00080103654,0.000014483742,0.00011487925,0.000117798525,0.9693818,0.000031726344,0.010315567,0.00031693353],"about_ca_topic_score_codex":0.0013159402,"about_ca_topic_score_gemma":0.00015681544,"teacher_disagreement_score":0.016543327,"about_ca_system_score_codex":0.00022534512,"about_ca_system_score_gemma":0.00022629567,"threshold_uncertainty_score":0.99999654},"labels":[],"label_agreement":null},{"id":"W2006293080","doi":"10.1158/1535-7163.targ-13-a110","title":"Abstract A110: EGFRvIII expression is associated with shorter progression-free and overall survival in glioblastoma patients treated with standard-of-care temozolomide and radiation: A report from the RTOG-0525 trial.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; McGill University","funders":"","keywords":"Temozolomide; Medicine; Oncology; Internal medicine; Progression-free survival; Univariate analysis; Glioblastoma; Radiation therapy; Epidermal growth factor receptor; Multivariate analysis; Hazard ratio; Population; Dacarbazine; Cancer; Overall survival; Cancer research; Confidence interval; Chemotherapy","score_opus":0.01286034333198139,"score_gpt":0.2714484211420608,"score_spread":0.2585880778100794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006293080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99338377,0.0037977316,0.000007007854,0.00083850365,0.000041145122,0.0017241467,0.00012202171,0.000021470156,0.000064185995],"genre_scores_gemma":[0.99880034,0.00029891217,0.00011391454,0.0003532718,0.00002459528,0.0002750107,0.00008654992,0.000039687224,0.000007704948],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984688,0.0000780348,0.00033560387,0.0003633643,0.0005413612,0.00021282793],"domain_scores_gemma":[0.99883634,0.000109491244,0.00027896193,0.00042936305,0.00025674663,0.00008907426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008916165,0.00025219898,0.00045196523,0.000057713452,0.000068122514,0.000051597446,0.00007609999,0.00012237648,0.0000505504],"category_scores_gemma":[0.000024555158,0.00013600849,0.000048291837,0.00015918151,0.00009723695,0.00008030843,0.000039977625,0.00012003199,3.3082864e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013823894,0.0004981585,0.9544983,0.000031649637,0.00074862613,0.00033164638,0.0016998709,0.000007750042,0.0035898315,0.0000021490405,0.00018137616,0.024586754],"study_design_scores_gemma":[0.060502302,0.003120754,0.878867,0.001108058,0.0005175412,0.000007770401,0.00028305443,0.000045937162,0.054802768,0.000043436554,0.00045948697,0.00024192555],"about_ca_topic_score_codex":0.0005706768,"about_ca_topic_score_gemma":0.00031222714,"teacher_disagreement_score":0.07563133,"about_ca_system_score_codex":0.0001630918,"about_ca_system_score_gemma":0.00010740947,"threshold_uncertainty_score":0.5546265},"labels":[],"label_agreement":null},{"id":"W2006884048","doi":"10.1158/1535-7163.targ-11-a194","title":"Abstract A194: A QT/QTc and multi-dose pharmacokinetic (PK) study of abiraterone acetate (AA) plus prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Abiraterone acetate; Medicine; Prostate cancer; QT interval; Docetaxel; Pharmacokinetics; Internal medicine; Prednisone; Pharmacology; Cancer; Androgen deprivation therapy; Urology","score_opus":0.07343865574434846,"score_gpt":0.3474244786887221,"score_spread":0.2739858229443737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006884048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99025345,0.0061293026,0.00002753729,0.00013199849,0.000072844145,0.0031727222,0.00011679161,0.000028288287,0.00006709271],"genre_scores_gemma":[0.9967192,0.0014914842,0.00061376207,0.0001625501,0.000012657639,0.0006741753,0.00003042078,0.00008159084,0.00021417675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773526,0.000113244336,0.0005173914,0.0005201264,0.0006034521,0.00051054475],"domain_scores_gemma":[0.9989037,0.000019195539,0.00023605948,0.0003530726,0.00030924365,0.00017871494],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015031788,0.00038184048,0.0005790023,0.00021546967,0.00007091816,0.000029338547,0.00013445412,0.000058854526,0.000107926535],"category_scores_gemma":[0.0000038588682,0.00028118392,0.00005240619,0.0004002581,0.00019705962,0.00012673122,0.00005212803,0.00028872714,0.0000023062817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042930536,0.013531492,0.49904212,0.0020493567,0.0061782636,0.0018730075,0.0558523,0.0014778088,0.30459172,0.000008828624,0.000017924853,0.07244662],"study_design_scores_gemma":[0.06933326,0.005684502,0.8431763,0.0005677264,0.0015451745,0.000008231325,0.0024661548,0.0013356435,0.07522531,0.000020849593,0.000085419,0.0005514185],"about_ca_topic_score_codex":0.0024686852,"about_ca_topic_score_gemma":0.0021459572,"teacher_disagreement_score":0.34413418,"about_ca_system_score_codex":0.0003201618,"about_ca_system_score_gemma":0.00041884268,"threshold_uncertainty_score":0.99996406},"labels":[],"label_agreement":null},{"id":"W2007517393","doi":"10.1158/1535-7163.mct-09-0148","title":"Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Hsp27; Bladder cancer; Protein kinase B; PI3K/AKT/mTOR pathway; Cancer research; Cytotoxicity; In vivo; Medicine; Heat shock protein; Cancer; Pharmacology; Apoptosis; Chemistry; Internal medicine; Biology; In vitro; Hsp70; Biochemistry","score_opus":0.02672840169013674,"score_gpt":0.3180621902871511,"score_spread":0.29133378859701436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007517393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97823614,0.004802877,0.012719623,0.002170131,0.000039388546,0.0018585565,0.00007573743,0.000028648596,0.0000689054],"genre_scores_gemma":[0.9936212,0.0013601019,0.0031416202,0.0008579781,0.00015592577,0.00044491352,0.000093249975,0.00007107316,0.00025397242],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99819857,0.00007941628,0.00025317768,0.00061220344,0.00029003568,0.0005665686],"domain_scores_gemma":[0.999227,0.000013107069,0.0000614031,0.0003191014,0.00021507488,0.00016430057],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012493307,0.00035497863,0.00028815994,0.00006776187,0.00017040956,0.00010028813,0.0001553318,0.00021263234,0.000015634949],"category_scores_gemma":[0.000010152971,0.0002944322,0.000078610414,0.00014743718,0.00013553166,0.000013791887,0.00003661541,0.00014682484,0.0000012257592],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044653218,0.00031851933,0.000104302475,0.000034110744,0.00034044724,0.000016420308,0.00008348946,0.00045943123,0.95707166,0.0007300962,0.000021261798,0.040373705],"study_design_scores_gemma":[0.0032272027,0.0051919282,0.00041727585,0.000053433054,0.000110124354,0.00001781278,0.000070584116,0.0012307892,0.9840206,0.00041540398,0.004836622,0.00040824225],"about_ca_topic_score_codex":0.0005100211,"about_ca_topic_score_gemma":0.00015270486,"teacher_disagreement_score":0.039965462,"about_ca_system_score_codex":0.00013605984,"about_ca_system_score_gemma":0.00037748454,"threshold_uncertainty_score":0.99995077},"labels":[],"label_agreement":null},{"id":"W2008744352","doi":"10.1158/1535-7163.targ-11-c22","title":"Abstract C22: A phase II study of intravenous wild-type reovirus (Reolysin®) in combination with paclitaxel plus carboplatin in patients with platinum refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Carboplatin; Regimen; Tolerability; Chemotherapy; Phases of clinical research; Oncology; Population; Surgery; Adverse effect; Cisplatin","score_opus":0.03269678786943771,"score_gpt":0.2977749498705359,"score_spread":0.2650781620010982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008744352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99634665,0.0024419392,0.000013422676,0.000013550441,0.000028974831,0.0011008701,0.000026686153,0.0000028637228,0.000025059153],"genre_scores_gemma":[0.9996066,0.00011423636,0.00009894638,0.000059796253,0.0000048999696,0.000049175,0.00001707257,0.000040771512,0.0000084936155],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99847066,0.00021230652,0.00036533902,0.00035692626,0.00034051566,0.00025425284],"domain_scores_gemma":[0.9990706,0.000020236217,0.0002588657,0.00043347423,0.00016322486,0.00005364138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020234461,0.00023429486,0.000320444,0.00011718065,0.000051052688,0.0000075503576,0.0001800132,0.00007997498,0.000007291317],"category_scores_gemma":[0.000010823853,0.00016076445,0.000026952986,0.00031391397,0.00015816957,0.000009319542,0.00008283385,0.0002206418,6.370325e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09384774,0.018492654,0.30085367,0.000501318,0.00054012967,0.00008387958,0.0237535,0.0007122812,0.51045316,0.0000072560265,0.0000033588292,0.050751027],"study_design_scores_gemma":[0.04710853,0.12885737,0.36134583,0.00016969233,0.00024512399,0.000004186803,0.0015885733,0.0002654158,0.4597737,0.00004067304,0.00003639674,0.0005645116],"about_ca_topic_score_codex":0.00091716176,"about_ca_topic_score_gemma":0.0052050655,"teacher_disagreement_score":0.11036473,"about_ca_system_score_codex":0.00006673016,"about_ca_system_score_gemma":0.00027719152,"threshold_uncertainty_score":0.65557843},"labels":[],"label_agreement":null},{"id":"W2008775683","doi":"10.1158/1535-7163.targ-13-a203","title":"Abstract A203: An in vitro tumor model to characterize tumor cell metabolism in heterogeneous complex microenvironments.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Tumor microenvironment; In vivo; Cell culture; Biology; Context (archaeology); Cancer cell; Cell biology; Cell; Cell type; In vitro; Cancer research; Chemistry; Cancer; Tumor cells; Biochemistry; Genetics","score_opus":0.0242807989622685,"score_gpt":0.25734573396754634,"score_spread":0.23306493500527783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008775683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925377,0.005110015,0.0006597211,0.00022587499,0.00035290842,0.00080968544,0.00017171743,0.00001704453,0.000115328425],"genre_scores_gemma":[0.9846551,0.0008071061,0.0019255563,0.011502442,0.00030032755,0.0004296956,0.0001691253,0.00011277517,0.00009786692],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99769646,0.0000897456,0.00047864925,0.00075297436,0.0002537654,0.0007284321],"domain_scores_gemma":[0.998857,0.0000042870474,0.00013916561,0.00070532184,0.00005181209,0.00024239527],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013011612,0.00042995936,0.00044857655,0.00014935373,0.00004935255,0.0000694198,0.00047661978,0.00013843398,0.000107425134],"category_scores_gemma":[0.0000038197068,0.00045991954,0.00015414543,0.00016455232,0.000073666975,0.000019092202,0.00014415312,0.00022869714,0.000032973625],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020242634,0.00026590997,0.00012841163,0.000021269117,0.000042943037,0.00001464326,0.00017284148,0.005757917,0.9862901,0.0000026045193,0.000065838816,0.0070350943],"study_design_scores_gemma":[0.001544383,0.00006823996,0.01722955,0.000012904629,0.000041336254,0.000012036695,0.000041093903,0.002305528,0.93128836,0.000060406794,0.04680218,0.0005939712],"about_ca_topic_score_codex":0.0006575694,"about_ca_topic_score_gemma":0.00017902892,"teacher_disagreement_score":0.055001732,"about_ca_system_score_codex":0.00009152274,"about_ca_system_score_gemma":0.00012975864,"threshold_uncertainty_score":0.99978524},"labels":[],"label_agreement":null},{"id":"W2014051778","doi":"10.1158/1535-7163.targ-11-b126","title":"Abstract B126: Optimization of culture conditions for the establishment of de novo renal cell carcinoma cell lines.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Clear cell renal cell carcinoma; Cancer research; Cell culture; Cancer; Biology; Gene knockdown; Malignancy; Cancer cell; Fetal bovine serum; Cell growth; Renal cell carcinoma; Medicine; Pathology; Genetics","score_opus":0.01720443224136935,"score_gpt":0.2534081869839953,"score_spread":0.23620375474262595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014051778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89389443,0.019088471,0.08291307,0.00016443034,0.00026778044,0.0006508415,0.0003003334,0.000009353362,0.0027112975],"genre_scores_gemma":[0.995271,0.0021085215,0.0018255473,0.00034987228,0.000058471473,0.0000640638,0.000085794185,0.000024165174,0.00021252851],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99931675,0.000020799474,0.00021692303,0.000167226,0.0001069114,0.00017140931],"domain_scores_gemma":[0.999325,0.000008124667,0.00018619708,0.0002440719,0.00019826219,0.000038342067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000748798,0.00012904662,0.00011978985,0.000024117737,0.00005445235,0.0000062297136,0.00020045628,0.00016612059,0.000030492723],"category_scores_gemma":[0.0000029063303,0.00009211654,0.00014908468,0.00008885639,0.000107439104,0.0000033248193,0.000025164774,0.0000854245,2.4037377e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014258153,0.00009891961,0.0002348928,0.000081286715,0.00013184207,0.0000015444543,0.00042198406,0.048152596,0.95003694,0.000029824772,0.00022601555,0.00044159195],"study_design_scores_gemma":[0.0007336655,0.00022273982,0.00034953104,0.000018333072,0.00016707694,0.0000023194316,0.00014668875,0.00079201866,0.9935267,0.000057260277,0.0038643721,0.00011931327],"about_ca_topic_score_codex":0.000088320536,"about_ca_topic_score_gemma":0.000009754827,"teacher_disagreement_score":0.10137661,"about_ca_system_score_codex":0.000023294702,"about_ca_system_score_gemma":0.0001733144,"threshold_uncertainty_score":0.37564033},"labels":[],"label_agreement":null},{"id":"W2014093910","doi":"10.1158/1535-7163.targ-13-b267","title":"Abstract B267: Inhibition of PLK4 as a therapeutic strategy for genomically unstable cancers deficient for PTEN.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"PTEN; Cancer; Cancer research; Biology; Centrosome; Kinase; Mitosis; Cancer cell; Cell cycle; Apoptosis; PI3K/AKT/mTOR pathway; Cell biology; Genetics","score_opus":0.049749592852205884,"score_gpt":0.34668496005035554,"score_spread":0.29693536719814967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014093910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745078,0.009949582,0.0076539773,0.002116011,0.00033239802,0.003865168,0.0001823919,0.000052354997,0.0013402831],"genre_scores_gemma":[0.9920253,0.00063375937,0.00075095147,0.0040777517,0.00012131354,0.0017694545,0.00009836171,0.00007106328,0.00045205187],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986041,0.000021326847,0.00037875533,0.00034373507,0.00019792978,0.00045415328],"domain_scores_gemma":[0.99900585,0.000084345425,0.00019164996,0.0002447009,0.0003553525,0.000118080665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010550331,0.00025500517,0.00041080007,0.00009586586,0.00007917195,0.000026167203,0.00009249919,0.0001494641,0.0004975241],"category_scores_gemma":[0.0000038805506,0.0002260777,0.00026794907,0.00014376992,0.00010864184,0.000060233997,0.000014156704,0.000119272976,0.000010426732],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011701429,0.00035561374,0.0003153873,0.00031699095,0.0009447203,0.0000048024667,0.00028316013,0.0016088448,0.9397054,0.0013975363,0.0005196998,0.053377748],"study_design_scores_gemma":[0.012751413,0.0031890515,0.00338574,0.00017568361,0.0020748682,0.000013707088,0.00035572713,0.004554354,0.9112566,0.007882364,0.053779185,0.0005813149],"about_ca_topic_score_codex":0.0009552116,"about_ca_topic_score_gemma":0.000095046424,"teacher_disagreement_score":0.053259484,"about_ca_system_score_codex":0.00049480185,"about_ca_system_score_gemma":0.00074617966,"threshold_uncertainty_score":0.9219181},"labels":[],"label_agreement":null},{"id":"W2016041796","doi":"10.1158/1535-7163.targ-09-c29","title":"Abstract C29: Bladder cancer-associated single nucleotide polymorphisms of vascular endothelial growth factor in 12 human cell lines","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Single-nucleotide polymorphism; dbSNP; Genotype; Bladder cancer; SNP; Vascular endothelial growth factor; Angiogenesis; Biology; Cancer; Cancer research; Cell culture; Metastasis; SNP genotyping; Oncology; Molecular biology; Immunology; Genetics; Gene; Medicine; VEGF receptors","score_opus":0.019033190470462008,"score_gpt":0.2629453667457473,"score_spread":0.2439121762752853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016041796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9730537,0.024508055,0.00013269854,0.00023232966,0.0008075142,0.00035550044,0.00024511522,0.000029491797,0.000635623],"genre_scores_gemma":[0.99131644,0.0057089436,0.00009477798,0.0016148575,0.0008190483,0.000038568935,0.000082114035,0.000081601356,0.00024364122],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978044,0.00009018882,0.0005273027,0.0005521347,0.00037194052,0.0006540255],"domain_scores_gemma":[0.9988667,0.000012467462,0.00030619165,0.000486124,0.00018924961,0.00013930612],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014603561,0.0004095282,0.00048511414,0.00013211436,0.000078662815,0.00003437261,0.00039530624,0.0003351021,0.00009196844],"category_scores_gemma":[0.000020003328,0.00042359665,0.00034170912,0.00022372944,0.000115056166,0.000012195594,0.0000536314,0.00023729923,0.0000021140638],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008335687,0.00047639734,0.0019345932,0.000025677511,0.00024212508,0.000005641934,0.00021094328,0.00018805795,0.98948085,0.000024482966,0.00013812052,0.0071897767],"study_design_scores_gemma":[0.002113227,0.00028043392,0.026983857,0.000055208468,0.00015230743,0.0000010776596,0.000031822336,0.000015816255,0.9458905,0.00015718021,0.023828281,0.00049028464],"about_ca_topic_score_codex":0.0012122749,"about_ca_topic_score_gemma":0.0010241184,"teacher_disagreement_score":0.043590322,"about_ca_system_score_codex":0.0001129338,"about_ca_system_score_gemma":0.000252493,"threshold_uncertainty_score":0.9998216},"labels":[],"label_agreement":null},{"id":"W2018891796","doi":"10.1158/1535-7163.targ-09-c161","title":"Abstract C161: Modulation of thymidine phosphorylase (TP) expression in breast cancer cell lines exposed to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Thymidine phosphorylase; SKBR3; Pharmacology; Cytidine deaminase; Cell growth; Cancer research; Capecitabine; Epidermal growth factor receptor; Cancer; Growth inhibition; Chemistry; Biology; Cancer cell; Internal medicine; Biochemistry; Medicine; Colorectal cancer; Enzyme","score_opus":0.025792739691510157,"score_gpt":0.3074214845298739,"score_spread":0.28162874483836375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018891796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9734811,0.011678882,0.00015324312,0.012793476,0.00051192945,0.0009831069,0.00027202745,0.00004294572,0.00008329477],"genre_scores_gemma":[0.9906705,0.003280861,0.00029255298,0.0049134144,0.00044626865,0.00014438381,0.000063655105,0.000050422717,0.00013794465],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982368,0.000079470534,0.0005031836,0.00040848771,0.0003721931,0.00039989286],"domain_scores_gemma":[0.9989915,0.000048090762,0.00021465422,0.00035054504,0.00023018777,0.00016505456],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011346665,0.0003482932,0.00045701716,0.000116939555,0.0000708004,0.000018027373,0.00017089453,0.00016570078,0.0006484416],"category_scores_gemma":[0.0000067793158,0.0002540123,0.00016334596,0.00038339052,0.00005290404,0.00010626083,0.000034318044,0.000252285,0.000007652436],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020993014,0.0007578163,0.0060150875,0.00007728436,0.00007881406,0.000026518379,0.00089938636,0.000995639,0.96369535,0.0000059470012,0.00084648887,0.024502369],"study_design_scores_gemma":[0.0034513108,0.00035390558,0.08985836,0.00024258823,0.00015146402,0.0000035076298,0.00007014547,0.00038583126,0.90228677,0.000021560223,0.0029319925,0.0002425754],"about_ca_topic_score_codex":0.0007114108,"about_ca_topic_score_gemma":0.0001716033,"teacher_disagreement_score":0.08384327,"about_ca_system_score_codex":0.00046585206,"about_ca_system_score_gemma":0.00020793463,"threshold_uncertainty_score":0.99999124},"labels":[],"label_agreement":null},{"id":"W2020280952","doi":"10.1158/1535-7163.mct-08-0864","title":"ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"National Heart, Lung, and Blood Institute","keywords":"Ovarian cancer; Cancer research; Vascular endothelial growth factor; Apoptosis; Angiogenesis; Ovarian tumor; Cell growth; Cancer; Biology; Thrombospondin 1; Medicine; Internal medicine; VEGF receptors","score_opus":0.021197709795987216,"score_gpt":0.2728384742654683,"score_spread":0.2516407644694811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020280952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896861,0.007708922,0.0013475119,0.00036841453,0.00015045745,0.00033551714,0.00013469213,0.000014265178,0.00025416317],"genre_scores_gemma":[0.99281704,0.0019890207,0.0010741254,0.003666818,0.00021308908,0.000097304124,0.000028318018,0.00005670846,0.00005755388],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981913,0.000100799014,0.00041407254,0.00061805046,0.00023864613,0.0004371293],"domain_scores_gemma":[0.9990857,0.0000057503357,0.00020364065,0.0004005665,0.00016752638,0.00013681276],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001653169,0.00034948174,0.0003723119,0.000112831076,0.00007499082,0.00003665124,0.0002972029,0.0002009327,0.00001843278],"category_scores_gemma":[0.0000050686285,0.00033989782,0.00013543594,0.00021891392,0.000107006344,0.000016674561,0.00007313261,0.00015548475,5.709101e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022334691,0.00016615815,0.0034037246,0.000046655936,0.00007699705,0.000005404187,0.00020453306,0.0013142911,0.98874587,0.00023179993,0.000012816643,0.0055683786],"study_design_scores_gemma":[0.0011828864,0.00032575944,0.0041069207,0.00005457074,0.00011094048,0.000003619704,0.00005125998,0.0012872659,0.99150896,0.00047597423,0.0004525758,0.00043925433],"about_ca_topic_score_codex":0.00038755275,"about_ca_topic_score_gemma":0.00021108866,"teacher_disagreement_score":0.005719901,"about_ca_system_score_codex":0.000054605447,"about_ca_system_score_gemma":0.00033102868,"threshold_uncertainty_score":0.9999053},"labels":[],"label_agreement":null},{"id":"W2021144570","doi":"10.1158/1535-7163.targ-13-c77","title":"Abstract C77: A novel BRCA2 targeting antisense oligonucleotide sensitizes human tumor cells to chemotherapy and radiotherapy - the induction of ‘complementary lethality’ by targeting DNA repair.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Cisplatin; RAD51; Carboplatin; Cancer research; Synthetic lethality; DNA repair; Cancer; Biology; Cancer cell; Homologous recombination; DNA damage; Population; Molecular biology; Medicine; Chemotherapy; DNA; Genetics","score_opus":0.013807759295505187,"score_gpt":0.26765255118332104,"score_spread":0.25384479188781583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021144570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920266,0.0029884756,0.0024933163,0.0012532651,0.00019471905,0.0008511696,0.00008941195,0.000053944266,0.00004906772],"genre_scores_gemma":[0.98338753,0.000455749,0.0087640975,0.006856015,0.00021131214,0.00006776721,0.000083148676,0.00011258219,0.0000618149],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99801165,0.00012641774,0.00050503615,0.000598158,0.00029723323,0.00046153567],"domain_scores_gemma":[0.9988917,0.000021851685,0.00027696826,0.00052583,0.00016616503,0.00011745337],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044964594,0.00035908676,0.00032141153,0.000056010827,0.0002025967,0.00006266688,0.00025714329,0.0001301625,0.00008216135],"category_scores_gemma":[0.000010698622,0.00031515612,0.00018232742,0.00015173327,0.00015549676,0.000015015965,0.00010541912,0.0001854667,0.000002253432],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005575489,0.000092975184,0.00021214457,0.000045080134,0.00038962575,0.0000037956609,0.0003770663,0.00011677757,0.99353766,0.000031441272,0.002589437,0.0025482636],"study_design_scores_gemma":[0.0008488798,0.00022213937,0.0007437185,0.000033230957,0.000050653198,0.000011000217,0.00040856845,0.00022688188,0.9760251,0.00006596353,0.020996507,0.00036734392],"about_ca_topic_score_codex":0.00088164007,"about_ca_topic_score_gemma":0.000021643673,"teacher_disagreement_score":0.018407071,"about_ca_system_score_codex":0.000056240187,"about_ca_system_score_gemma":0.00005094999,"threshold_uncertainty_score":0.99993},"labels":[],"label_agreement":null},{"id":"W2021253518","doi":"10.1158/1535-7163.targ-09-a115","title":"Abstract A115: Contextual synthetic lethality: Repair-deficient hypoxic tumor cells are sensitized to poly(ADP-ribose) polymerase (PARP) inhibition","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"PARP1; Poly ADP ribose polymerase; Synthetic lethality; PARP inhibitor; RAD51; Cancer research; Cancer cell; Hypoxia (environmental); Biology; DNA repair; Clonogenic assay; Homologous recombination; Molecular biology; Programmed cell death; DNA damage; Polymerase; Cell culture; Chemistry; Cancer; Apoptosis; DNA; Genetics","score_opus":0.031868384040929426,"score_gpt":0.30876111917182025,"score_spread":0.27689273513089085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021253518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9646206,0.008536669,0.003585476,0.018217618,0.0008212927,0.0016837005,0.00040088574,0.0006559149,0.0014778265],"genre_scores_gemma":[0.93038225,0.0002374247,0.0010624191,0.06726926,0.00047933235,0.00012770592,0.00005574039,0.00012659574,0.00025926766],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958241,0.00021301008,0.0008871914,0.0010360052,0.0010896464,0.00095003104],"domain_scores_gemma":[0.9973989,0.00008893897,0.00039292307,0.0011987424,0.00037850114,0.00054199377],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044508628,0.0006665506,0.0008924375,0.0003454599,0.00022267908,0.000087511144,0.00017924767,0.00025218487,0.00037796923],"category_scores_gemma":[0.000033172564,0.00067277305,0.0005560719,0.000671489,0.00020213444,0.000107022825,0.000045082306,0.0005795353,0.0001693181],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001438131,0.0006970439,0.000080285194,0.0000859706,0.00029554314,0.0010641199,0.0006131374,0.00018921665,0.98130536,0.00024334964,0.0011164409,0.012871378],"study_design_scores_gemma":[0.004526033,0.0008234211,0.002144115,0.00083202554,0.00043295496,0.00022292766,0.00040162186,0.0002339252,0.9641599,0.00026807887,0.02512488,0.00083013164],"about_ca_topic_score_codex":0.00018457565,"about_ca_topic_score_gemma":0.000023302016,"teacher_disagreement_score":0.049051642,"about_ca_system_score_codex":0.0008257849,"about_ca_system_score_gemma":0.00039500452,"threshold_uncertainty_score":0.99957234},"labels":[],"label_agreement":null},{"id":"W2022249592","doi":"10.1158/1535-7163.targ-09-b32","title":"Abstract B32: Retrospective correlative study between EGFRvIII, HPV, p16, c-MET and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Erlotinib; Internal medicine; Oncology; Immunohistochemistry; Cancer; Univariate analysis; Head and neck squamous-cell carcinoma; Head and neck cancer; Epidermal growth factor receptor; Multivariate analysis","score_opus":0.018213220886722625,"score_gpt":0.31584793952418144,"score_spread":0.29763471863745883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022249592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99596447,0.0010159507,0.00002442821,0.0004911858,0.000067896755,0.0022188604,0.00010396435,0.000010438262,0.000102836624],"genre_scores_gemma":[0.99915093,0.000013424118,0.00021660217,0.00043324803,0.000014442873,0.00008112625,0.0000082509105,0.000027869593,0.00005408765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99860793,0.0001268985,0.0003062039,0.0003513372,0.00038057138,0.00022706424],"domain_scores_gemma":[0.99919015,0.00007766714,0.00015925655,0.0002972546,0.00016309165,0.00011258565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013792567,0.00024044098,0.00040261337,0.00013482208,0.00008550428,0.000018704022,0.00007289833,0.000047198875,0.000012276581],"category_scores_gemma":[0.000023435308,0.00014714364,0.000043225555,0.0004671513,0.00008273278,0.000054281474,0.000033103428,0.00021535442,4.814367e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043474003,0.0010321283,0.9702943,0.000030024925,0.0002031714,0.000033589033,0.009902725,0.000040953077,0.0006379239,0.000004756544,0.000009897817,0.013463122],"study_design_scores_gemma":[0.00902409,0.008625773,0.97764355,0.000130164,0.0007708121,0.0000014050502,0.0010813136,0.0000069752195,0.0024505113,0.00003373519,0.00007043288,0.000161268],"about_ca_topic_score_codex":0.0003019631,"about_ca_topic_score_gemma":0.00023254949,"teacher_disagreement_score":0.013301854,"about_ca_system_score_codex":0.00041046223,"about_ca_system_score_gemma":0.00025363828,"threshold_uncertainty_score":0.60003436},"labels":[],"label_agreement":null},{"id":"W2022590973","doi":"10.1158/1535-7163.targ-13-c184","title":"Abstract C184: Thyroid hormone receptors: Future targets for breast cancer therapy?.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Thyroid Disorders and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto","funders":"","keywords":"Breast cancer; Medicine; Lymphovascular invasion; Internal medicine; Lymph node; Oncology; Cancer; Hormone receptor; Immunohistochemistry; Pathological; Thyroid; Tissue microarray; Thyroid cancer; Pathology; Metastasis","score_opus":0.015472260958944847,"score_gpt":0.2815190106673419,"score_spread":0.2660467497083971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022590973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6946928,0.27039,0.00076836813,0.027778633,0.0011983522,0.0034620557,0.00046228274,0.00022373292,0.0010237945],"genre_scores_gemma":[0.9559568,0.031640902,0.00077043887,0.008444692,0.00069542334,0.0013904138,0.000093218965,0.00014842866,0.000859638],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983788,0.000022681974,0.00028521332,0.00044228163,0.00032419956,0.00054680806],"domain_scores_gemma":[0.9989237,0.000018096125,0.00013594414,0.00044228078,0.00028627206,0.00019366498],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000055851746,0.00039018845,0.00040683406,0.00007798482,0.00013479442,0.000059097816,0.00016175324,0.00021373328,0.0008670505],"category_scores_gemma":[0.0000017435005,0.00029935813,0.00027774222,0.00019002598,0.00007093179,0.000116913194,0.000021976613,0.00021109851,0.000052222815],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010572078,0.00089203403,0.0055691744,0.00006533928,0.0022926566,0.00002462129,0.0006516741,0.000035038203,0.39763728,0.00012493611,0.015698994,0.57595104],"study_design_scores_gemma":[0.025676265,0.0016279586,0.35365307,0.0001796756,0.0010930616,0.000062486644,0.00087635417,0.00032985423,0.076102786,0.0022724858,0.5364889,0.0016371191],"about_ca_topic_score_codex":0.0006204549,"about_ca_topic_score_gemma":0.00003673675,"teacher_disagreement_score":0.57431394,"about_ca_system_score_codex":0.00018746272,"about_ca_system_score_gemma":0.00018811549,"threshold_uncertainty_score":0.9999459},"labels":[],"label_agreement":null},{"id":"W2022649408","doi":"10.1158/1535-7163.targ-13-b256","title":"Abstract B256: Ring-DIMs induce mitochondrial dysfunction and ER stress in human prostate cancer cells.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Redox biology and oxidative stress","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; Armand Frappier Museum; Institut National de la Recherche Scientifique","funders":"","keywords":"LNCaP; Unfolded protein response; Programmed cell death; Apoptosis; Mitochondrion; Chemistry; Cancer research; Endoplasmic reticulum; Prostate cancer; Biology; Endocrinology; Cell biology; Internal medicine; Medicine; Cancer; Biochemistry","score_opus":0.013490378062112498,"score_gpt":0.2759282278425214,"score_spread":0.2624378497804089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022649408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992977,0.0052356916,0.00012406151,0.0003613467,0.000443763,0.00049273175,0.00005759798,0.0000142513745,0.00029354187],"genre_scores_gemma":[0.99650586,0.0015533266,0.00008523971,0.00085736293,0.00023445812,0.00029218895,0.000081540755,0.00003894909,0.0003510616],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986914,0.00007959633,0.00024627228,0.0004972515,0.00012203849,0.00036343676],"domain_scores_gemma":[0.9994162,0.0000074164273,0.00011816555,0.00028067257,0.000100437195,0.000077135104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005894857,0.00026026092,0.00019451536,0.0000611683,0.000098103104,0.000050258484,0.00016826755,0.00029829404,0.00012361143],"category_scores_gemma":[0.0000041141357,0.00023855377,0.000061208535,0.00009911163,0.00017291475,0.000016656797,0.000084130326,0.00024569852,0.0000058458018],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008310676,0.00006293942,0.014327153,0.000027261416,0.00012766835,0.0000061255028,0.000121256424,0.0003829948,0.97651744,0.00003861659,0.00011989363,0.008185523],"study_design_scores_gemma":[0.0011286258,0.00013715518,0.038573805,0.00005114381,0.000032101394,0.0000014801166,0.00007847132,0.000039770035,0.95479226,0.00018946477,0.0046594357,0.00031630532],"about_ca_topic_score_codex":0.000907293,"about_ca_topic_score_gemma":0.0005251191,"teacher_disagreement_score":0.024246654,"about_ca_system_score_codex":0.000038692295,"about_ca_system_score_gemma":0.00006745909,"threshold_uncertainty_score":0.97279406},"labels":[],"label_agreement":null},{"id":"W2022706281","doi":"10.1158/1535-7163.targ-11-a143","title":"Abstract A143: ARRY-380, a selective HER2 inhibitor: From drug design to clinical evaluation.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Kingston General Hospital","funders":"","keywords":"Pharmacokinetics; Pharmacology; Kinase; Drug; Potency; Metastatic breast cancer; Tyrosine-kinase inhibitor; Medicine; Cancer; Chemistry; Breast cancer; Cancer research; Internal medicine; In vitro; Biochemistry","score_opus":0.23610018967859558,"score_gpt":0.45589901344279576,"score_spread":0.21979882376420018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022706281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9269699,0.01376309,0.03446997,0.0054656877,0.0023208691,0.006510867,0.0001268966,0.00036220296,0.0100105135],"genre_scores_gemma":[0.9804429,0.00050311117,0.009402084,0.007985017,0.0006816472,0.0005936514,0.000018665942,0.00014308089,0.00022985344],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99593353,0.0005552204,0.0006625554,0.0007945616,0.0014102539,0.0006438591],"domain_scores_gemma":[0.997477,0.00020709737,0.00014659809,0.00086664583,0.0008270036,0.0004756417],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017454254,0.0003425168,0.0005359605,0.00016252628,0.00009963118,0.00004593922,0.00036412387,0.00025724797,0.0016459061],"category_scores_gemma":[0.000161191,0.00031931725,0.00024151144,0.0005406017,0.00016089038,0.00007285552,0.00009124363,0.0008342298,0.00033887604],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005455342,0.0020256182,0.04434065,0.00012494139,0.003891628,0.0005576905,0.014998071,0.00042051726,0.16024844,0.00008306697,0.022282746,0.7455713],"study_design_scores_gemma":[0.0077626584,0.0018191879,0.11648499,0.00072300516,0.0015749884,0.00001754244,0.0006224409,0.0032338465,0.80272645,0.004270824,0.059536006,0.00122804],"about_ca_topic_score_codex":0.0016724201,"about_ca_topic_score_gemma":0.00023684792,"teacher_disagreement_score":0.7443433,"about_ca_system_score_codex":0.0007652486,"about_ca_system_score_gemma":0.0020656704,"threshold_uncertainty_score":0.9999259},"labels":[],"label_agreement":null},{"id":"W2023431277","doi":"10.1158/1535-7163.mct-15-0067","title":"AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Antibody-drug conjugate; Pharmacology; Medicine; Drug; Conjugate; Antibody; Immunology; Monoclonal antibody","score_opus":0.05551429481243274,"score_gpt":0.3826702077750343,"score_spread":0.32715591296260155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023431277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92036736,0.043054942,0.024462776,0.0069615915,0.00038785356,0.0040639723,0.00020711217,0.00011569559,0.00037867387],"genre_scores_gemma":[0.98246336,0.0019013813,0.0059444597,0.006702167,0.0003176448,0.00062888255,0.0001320088,0.00022911819,0.001680999],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968098,0.00018801475,0.0005676459,0.00081256015,0.00064097764,0.0009810089],"domain_scores_gemma":[0.99806863,0.00010121067,0.00018482209,0.0006410477,0.00042882166,0.00057546375],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008142739,0.00046412257,0.0007404587,0.00030589022,0.00011607911,0.0001603316,0.00035516487,0.00021897128,0.000043989905],"category_scores_gemma":[0.00004410677,0.00044538683,0.00020366111,0.0004214701,0.00022269641,0.00015710032,0.00008551475,0.00036528055,0.000008812786],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004629747,0.00074699544,0.006248447,0.0007706166,0.0005782331,0.00017477103,0.006226867,0.00065701525,0.9119869,0.00072637247,0.0010621701,0.0661919],"study_design_scores_gemma":[0.03794439,0.00737045,0.004762929,0.00063242466,0.0014183837,0.00014566378,0.0045124227,0.03868015,0.61364263,0.022992816,0.2658356,0.0020620858],"about_ca_topic_score_codex":0.0015387563,"about_ca_topic_score_gemma":0.00030422088,"teacher_disagreement_score":0.29834422,"about_ca_system_score_codex":0.00031707707,"about_ca_system_score_gemma":0.0017823704,"threshold_uncertainty_score":0.9997998},"labels":[],"label_agreement":null},{"id":"W2023617697","doi":"10.1158/1535-7163.targ-11-b25","title":"Abstract B25: Emerging role of heterogeneous ribonucleoproteins (hnRNPs) as early predictive marker and prognosticator for head and neck oral squamous cell carcinoma.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Biomarker; Immunohistochemistry; Heterogeneous ribonucleoprotein particle; Ribonucleoprotein; Malignancy; Biology; Pathology; Cancer research; Head and neck squamous-cell carcinoma; Tissue microarray; Cancer; Medicine; RNA; Head and neck cancer; Biochemistry","score_opus":0.017955821812976655,"score_gpt":0.258876544099643,"score_spread":0.24092072228666633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023617697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98172164,0.015725302,0.0012404678,0.000038216152,0.000048289756,0.0006558592,0.00012160361,0.000010819579,0.00043779955],"genre_scores_gemma":[0.9978663,0.00042121098,0.0010849816,0.00020055697,0.00004325751,0.00025293266,0.000021054093,0.000053559914,0.000056182187],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989656,0.000023531768,0.00022356623,0.0004012713,0.000116942334,0.00026905112],"domain_scores_gemma":[0.9993095,0.000007938036,0.00013121233,0.00031125007,0.00014102436,0.00009909953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000077750396,0.0002064305,0.00018095487,0.00004027402,0.000084208434,0.000021175614,0.0001354525,0.00014994657,0.000018575713],"category_scores_gemma":[0.000007584634,0.00020388921,0.000081451886,0.000057772446,0.00013890443,0.000007370076,0.000060454753,0.00007781615,6.9589663e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063435256,0.0001676462,0.023562359,0.000090356734,0.00014786771,0.000004527778,0.0006668875,0.000028756584,0.95389754,0.00011284303,0.0000098669,0.020677015],"study_design_scores_gemma":[0.0012590241,0.0011087281,0.068521686,0.00001804854,0.00017831745,0.000009260295,0.00014978286,0.00037706786,0.9228401,0.0004240711,0.0048041544,0.00030971222],"about_ca_topic_score_codex":0.00034098202,"about_ca_topic_score_gemma":0.00004026477,"teacher_disagreement_score":0.04495933,"about_ca_system_score_codex":0.000016613481,"about_ca_system_score_gemma":0.000090701295,"threshold_uncertainty_score":0.8314361},"labels":[],"label_agreement":null},{"id":"W2024119342","doi":"10.1158/1535-7163.targ-11-c225","title":"Abstract C225: Differential regulation of simultaneous antitumor and alloreactive CD8+ T cell responses in the same host by rapamycin.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Epitope; Immunogenicity; Vaccinia; Biology; CD8; T cell; Cytotoxic T cell; Immune system; Cancer; Adjuvant; Virus; Antigen; Immunology; Cancer research; Virology; In vitro; Recombinant DNA; Genetics; Gene","score_opus":0.03717051993193556,"score_gpt":0.30991346684701493,"score_spread":0.2727429469150794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024119342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950419,0.0025227505,0.00019258517,0.0003130975,0.00005480974,0.0006392532,0.00004106286,0.000015676518,0.0011788777],"genre_scores_gemma":[0.99752605,0.0011622176,0.000102023165,0.0005665537,0.000034951907,0.000029904046,0.000016780981,0.000041366267,0.00052013196],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985653,0.00016376108,0.00026761816,0.00027183397,0.00045557608,0.00027591988],"domain_scores_gemma":[0.99910927,0.00020905749,0.00011897127,0.00038742088,0.00011486435,0.00006041737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000233774,0.0001909333,0.00028874082,0.0001251127,0.000042210744,0.000018993904,0.000162019,0.00011554651,0.0005219866],"category_scores_gemma":[0.000018361572,0.0001423142,0.000084756706,0.00021178763,0.0002217886,0.000041850457,0.000030669155,0.0003118475,0.000002353262],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028509016,0.00032067156,0.0024923522,0.00006475568,0.000121068064,0.00008486626,0.0034301537,0.000005419309,0.9796812,0.000028638233,0.000018421928,0.010901531],"study_design_scores_gemma":[0.0022246852,0.0004817332,0.06291502,0.000070591625,0.00014074081,0.000022320159,0.0005694895,0.00045301617,0.9307709,0.0001373354,0.0020341338,0.00018007965],"about_ca_topic_score_codex":0.00064416666,"about_ca_topic_score_gemma":0.00006204781,"teacher_disagreement_score":0.06042267,"about_ca_system_score_codex":0.00007738357,"about_ca_system_score_gemma":0.00010362449,"threshold_uncertainty_score":0.58034045},"labels":[],"label_agreement":null},{"id":"W2025569005","doi":"10.1158/1535-7163.targ-11-a22","title":"Abstract A22: A genome-wide shRNA screen identifies α/β hydrolase domain containing 4 (ABHD4) as a novel regulator of anoikis resistance.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Anoikis; Small hairpin RNA; Gene knockdown; Biology; Population; Molecular biology; Programmed cell death; Cell culture; Cell biology; Cancer research; Genetics; Apoptosis; Medicine","score_opus":0.03650405908379534,"score_gpt":0.30219000174368676,"score_spread":0.2656859426598914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025569005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97696674,0.008679366,0.0010605972,0.002186462,0.00012280574,0.0007456975,0.00010232319,0.000060360017,0.010075647],"genre_scores_gemma":[0.9918181,0.00034846287,0.0009963859,0.0021320214,0.000091972055,0.00011220725,0.00002461955,0.000100219855,0.0043760315],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99739844,0.000054306784,0.0005788208,0.00049567514,0.00085934723,0.00061341],"domain_scores_gemma":[0.9982336,0.000017407312,0.00025552316,0.0008082429,0.00040666334,0.00027857523],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048502468,0.0003198713,0.0005647727,0.00024382009,0.00012152711,0.00004295238,0.00032945207,0.00019337087,0.000833166],"category_scores_gemma":[0.000040898885,0.00029704603,0.00031191795,0.00041868875,0.00035419656,0.00009317327,0.00010139414,0.0003796447,0.000015515814],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029131477,0.00038403852,0.0041866014,0.0003358026,0.0009526468,0.0003896957,0.0028435383,0.000012741884,0.9839936,0.0012527702,0.00061451073,0.0021209202],"study_design_scores_gemma":[0.00693873,0.0009326043,0.15950437,0.00068528054,0.0006351902,0.00005834534,0.0017715555,0.00006274425,0.71541303,0.002806846,0.11033481,0.0008564923],"about_ca_topic_score_codex":0.0009769021,"about_ca_topic_score_gemma":0.00028510243,"teacher_disagreement_score":0.26858056,"about_ca_system_score_codex":0.00022870705,"about_ca_system_score_gemma":0.0006191998,"threshold_uncertainty_score":0.99994814},"labels":[],"label_agreement":null},{"id":"W2026071766","doi":"10.1158/1535-7163.pms-pr12","title":"Abstract PR12: A genome-wide shRNA screen reveals that inhibiting kinases potentiates the anti-breast cancer activity of fluvastatin","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Sunnybrook Hospital; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Fluvastatin; Small hairpin RNA; Kinase; Cancer research; RNA interference; Gene knockdown; Pharmacology; Small interfering RNA; Biology; Medicine; Simvastatin; Transfection; Cell culture; Cell biology; Gene; Genetics; RNA","score_opus":0.0189061889641678,"score_gpt":0.2651292238012099,"score_spread":0.2462230348370421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026071766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97904575,0.016305212,0.0010930357,0.0013969808,0.0009426105,0.00064372603,0.00033676435,0.000022206128,0.00021369178],"genre_scores_gemma":[0.990363,0.0052653425,0.00015402444,0.002084457,0.0016431393,0.00019687148,0.000047450212,0.000076430624,0.00016927626],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99813765,0.00013103994,0.00034615092,0.0004892139,0.00036207095,0.00053384824],"domain_scores_gemma":[0.9986056,0.000035201294,0.00038489135,0.00057765417,0.00028650978,0.000110105924],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023552457,0.00035999002,0.00038804993,0.00006016306,0.00016765538,0.000081657934,0.00041597744,0.00017628096,0.00017983867],"category_scores_gemma":[0.000018024419,0.00028085918,0.00026661626,0.0001854886,0.00023715242,0.00002229788,0.00016460163,0.00022652725,0.000005534265],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006774064,0.00007738325,0.011413309,0.000067944165,0.00039557574,4.934019e-7,0.00012852292,0.0004924793,0.9623603,0.000012658202,0.0008497682,0.024133813],"study_design_scores_gemma":[0.0007531312,0.000053724787,0.32299173,0.00010605372,0.00021100741,0.000010330928,0.00017948446,0.00006129329,0.653407,0.00010320219,0.021674588,0.00044847964],"about_ca_topic_score_codex":0.0028185197,"about_ca_topic_score_gemma":0.0002349701,"teacher_disagreement_score":0.31157842,"about_ca_system_score_codex":0.00004669135,"about_ca_system_score_gemma":0.00022995724,"threshold_uncertainty_score":0.99996436},"labels":[],"label_agreement":null},{"id":"W2026797869","doi":"10.1158/1535-7163.targ-13-a248","title":"Abstract A248: Integrated therapeutic antibody development at the National Research Council of Canada.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"National Research Council Canada","funders":"","keywords":"Antibody; Monoclonal antibody; Computational biology; Immunization; Panning (audio); clone (Java method); Biology; Immunology; Gene; Genetics","score_opus":0.15013527047675648,"score_gpt":0.38545341106528863,"score_spread":0.23531814058853215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026797869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9490009,0.00997201,0.000071078066,0.016498044,0.00014794793,0.0009128594,0.000052848583,0.000019885927,0.023324415],"genre_scores_gemma":[0.9846896,0.00043289096,0.00015497902,0.0042096814,0.00007153949,0.00012699218,0.000034634042,0.00003540424,0.0102442615],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99370015,0.0001200862,0.00037239143,0.00027550137,0.004968021,0.00056383194],"domain_scores_gemma":[0.9937707,0.00020879426,0.000083491854,0.00025398625,0.005536732,0.0001462762],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001443729,0.00019791875,0.0002583565,0.00007491687,0.0003059327,0.0000323557,0.00030263406,0.00009316396,0.0018815852],"category_scores_gemma":[0.00008524806,0.00012101208,0.00008088856,0.00043817033,0.00033968853,0.0000356749,0.00011317759,0.000521097,0.00005758136],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048631785,0.00024185641,0.004912909,0.00021506946,0.0012326676,0.00004471002,0.001025831,0.000111841044,0.93968433,0.00067889586,0.016265027,0.035100516],"study_design_scores_gemma":[0.0006402065,0.00009167102,0.077973105,0.00011946229,0.000033528137,0.000023064687,0.00020784765,0.0004667097,0.1979417,0.00036166658,0.7219419,0.00019913974],"about_ca_topic_score_codex":0.12860645,"about_ca_topic_score_gemma":0.0721109,"teacher_disagreement_score":0.7417427,"about_ca_system_score_codex":0.003801845,"about_ca_system_score_gemma":0.019734012,"threshold_uncertainty_score":0.9990308},"labels":[],"label_agreement":null},{"id":"W2027281639","doi":"10.1158/1535-7163.mct-06-0073","title":"Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre; Lawson Health Research Institute","funders":"","keywords":"Mesothelioma; Cancer research; Pemetrexed; Thymidylate synthase; HeLa; Apoptosis; Antisense therapy; Cell culture; Cancer; Growth inhibition; Medicine; Biology; Chemotherapy; Pathology; Internal medicine; Cisplatin; Oligonucleotide; Gene; Fluorouracil","score_opus":0.010329654757341293,"score_gpt":0.2676101548514891,"score_spread":0.2572805000941478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027281639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99238175,0.0047824117,0.0006598476,0.001155533,0.00009107722,0.00041235605,0.00007681323,0.000033437194,0.00040676488],"genre_scores_gemma":[0.9968258,0.00023611076,0.00046429274,0.0021237014,0.00006058525,0.00003095141,0.00002819467,0.000048065158,0.000182303],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986495,0.00004957809,0.00034009764,0.00028628652,0.00038239837,0.0002921372],"domain_scores_gemma":[0.9994666,0.000016009106,0.000081256665,0.00030190393,0.000039644776,0.00009459844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007165606,0.00021255533,0.00030970457,0.00018073313,0.000034795296,0.00001316439,0.00010171675,0.00007637085,0.00015513001],"category_scores_gemma":[0.0000024274902,0.00018848144,0.00015735405,0.00029918013,0.000108771965,0.00004287363,0.00003835884,0.00008977765,0.00002466403],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007952506,0.00050473266,0.046341006,0.000075506745,0.00017514844,0.00018947393,0.00005845558,0.0064371023,0.93439627,0.00046672535,0.000027263102,0.010533041],"study_design_scores_gemma":[0.0016583026,0.0002356323,0.6576881,0.00017310603,0.0003665569,0.0000239479,0.000032274787,0.0012104078,0.33546343,0.0012621164,0.0016069517,0.00027920163],"about_ca_topic_score_codex":0.00044615314,"about_ca_topic_score_gemma":0.000038589085,"teacher_disagreement_score":0.6113471,"about_ca_system_score_codex":0.00010702627,"about_ca_system_score_gemma":0.00006007904,"threshold_uncertainty_score":0.768605},"labels":[],"label_agreement":null},{"id":"W2027782825","doi":"10.1158/1535-7163.targ-11-b48","title":"Abstract B48: Feasibility study of molecular profiling (MP) in patients (Pts) with advanced solid cancers using targeted mutation analysis and targeted exome sequencing.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Exome sequencing; Sanger sequencing; Exome; Medicine; COLD-PCR; Germline mutation; DNA sequencing; Oncology; Ion semiconductor sequencing; Liquid biopsy; Mutation; Targeted therapy; Internal medicine; Computational biology; Cancer; Genetics; Gene; Biology; Point mutation","score_opus":0.02792714412372515,"score_gpt":0.2875685918545766,"score_spread":0.25964144773085146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027782825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993925,0.0018364654,0.0030950764,0.000005062462,0.00007247129,0.00093637686,0.00008438382,0.000010430899,0.000034781773],"genre_scores_gemma":[0.9965243,0.00018208628,0.0028886367,0.00016078638,0.0000137609295,0.000066531305,0.00010784313,0.00005412004,0.0000019697566],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99813116,0.00008826366,0.00048627105,0.0006510334,0.00028320873,0.00036009212],"domain_scores_gemma":[0.99872106,0.000010770093,0.00034234428,0.00050726515,0.0003214686,0.00009707291],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017210387,0.0003146949,0.00042722365,0.00020913499,0.00006166666,0.00002059496,0.0001837055,0.00014379459,0.000010694356],"category_scores_gemma":[0.000023143715,0.00031489687,0.00009884413,0.0006079581,0.000106475476,0.0000140960965,0.00007618164,0.00014831361,1.4424865e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007844559,0.00041735306,0.2725036,0.00005752915,0.001101125,0.000030075664,0.00093583023,0.037052654,0.68533474,0.0000064513824,2.5311655e-7,0.0017758923],"study_design_scores_gemma":[0.003657491,0.0014784005,0.19719411,0.00003835294,0.00084931793,0.0000013410273,0.0009208376,0.0017308454,0.793557,0.00005268605,0.000009085272,0.0005105484],"about_ca_topic_score_codex":0.0020623284,"about_ca_topic_score_gemma":0.0018116935,"teacher_disagreement_score":0.10822221,"about_ca_system_score_codex":0.0003155106,"about_ca_system_score_gemma":0.00036265934,"threshold_uncertainty_score":0.9999303},"labels":[],"label_agreement":null},{"id":"W2029933153","doi":"10.1158/1535-7163.targ-11-c1","title":"Abstract C1: BRCA1 protein levels and PI3KA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Breast cancer; Medicine; Oncology; Internal medicine; Chemotherapy; Logistic regression; Exact test; Cancer; Neoadjuvant therapy; Immunohistochemistry; Pathology","score_opus":0.024380037405454764,"score_gpt":0.3019271508783546,"score_spread":0.27754711347289984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029933153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98532075,0.003432612,0.0076292176,0.0012761002,0.00007465351,0.0013549492,0.0008383626,0.0000331576,0.00004020037],"genre_scores_gemma":[0.99354994,0.00028620983,0.002107847,0.0016872224,0.000049604856,0.0021450678,0.00006440202,0.00007972601,0.00003000449],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99812424,0.00013142817,0.00033398965,0.000766543,0.00019852082,0.00044526992],"domain_scores_gemma":[0.9989258,0.000017752547,0.00014997057,0.00047408883,0.0002547334,0.00017766505],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002504393,0.00038104082,0.00037380678,0.0002204923,0.00012249318,0.00002883987,0.00022916717,0.00016618954,0.000033720135],"category_scores_gemma":[0.0000146635875,0.00037875978,0.00014455854,0.0004724102,0.00016758734,0.000024181196,0.00006183486,0.0000969255,0.0000013282753],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018298848,0.00037508132,0.0085241245,0.000032960135,0.003121809,0.00002237105,0.0034844968,0.0012587175,0.91100657,0.000022088196,0.000010917639,0.053842034],"study_design_scores_gemma":[0.0062208003,0.0013207006,0.5156761,0.00012920547,0.0007576768,0.000009708151,0.0017075809,0.00025077985,0.4709352,0.00035624616,0.0017623769,0.000873629],"about_ca_topic_score_codex":0.0005160912,"about_ca_topic_score_gemma":0.0017056196,"teacher_disagreement_score":0.50715196,"about_ca_system_score_codex":0.00018873191,"about_ca_system_score_gemma":0.00038440543,"threshold_uncertainty_score":0.9998664},"labels":[],"label_agreement":null},{"id":"W2030324514","doi":"10.1158/1535-7163.mct-08-0499","title":"A peptide inhibitor derived from p55PIK phosphatidylinositol 3-kinase regulatory subunit: a novel cancer therapy","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Cell growth; Cell cycle; Cancer cell; Cancer research; Protein subunit; Cell cycle checkpoint; Retinoblastoma protein; Cancer; Kinase; PI3K/AKT/mTOR pathway; Biology; Cell; Chemistry; Molecular biology; Cell biology; Signal transduction; Biochemistry","score_opus":0.03244883850122982,"score_gpt":0.27934309793475687,"score_spread":0.24689425943352705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030324514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93279284,0.060760643,0.0038735096,0.00051863433,0.0009496725,0.00053564424,0.00029352985,0.000087112276,0.00018842258],"genre_scores_gemma":[0.9797874,0.008119144,0.001805594,0.0077486928,0.0011273813,0.00045355115,0.00017166272,0.00021645705,0.0005700882],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99705416,0.00013372902,0.0005027066,0.0009942265,0.00059330295,0.00072186015],"domain_scores_gemma":[0.9979912,0.000029970468,0.0002927545,0.0011075531,0.0003409171,0.0002376231],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001329373,0.00062676094,0.00046332722,0.00008725629,0.00029363832,0.000052834006,0.000650737,0.00045978115,0.00020445882],"category_scores_gemma":[0.000015055416,0.0006388257,0.0003389048,0.00029520888,0.000376273,0.000016530004,0.00015173532,0.000338671,0.000014018025],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005289279,0.00021579697,0.009209964,0.000015113222,0.0007656139,0.000039928,0.00046036506,0.001020596,0.9805769,0.00001173762,0.0010267101,0.006128396],"study_design_scores_gemma":[0.0027374416,0.00024281966,0.0054180454,0.0000802341,0.00011115859,0.000015316165,0.000042402386,0.00017290606,0.91052204,0.000038821247,0.07984625,0.0007725546],"about_ca_topic_score_codex":0.0009770676,"about_ca_topic_score_gemma":0.00019203642,"teacher_disagreement_score":0.078819536,"about_ca_system_score_codex":0.00021775934,"about_ca_system_score_gemma":0.00082230807,"threshold_uncertainty_score":0.9996063},"labels":[],"label_agreement":null},{"id":"W2031077597","doi":"10.1158/1535-7163.targ-13-c265","title":"Abstract C265: Significant <i>in vivo</i> activity of ENMD-2076, a novel multi-targeted kinase inhibitor, towards xenograft models of human hepatocellular carcinomas .","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Sorafenib; Medicine; Hepatocellular carcinoma; Doxorubicin; Tolerability; In vivo; Cancer; Liver cancer; Pharmacology; Cancer research; Chemotherapy; Oncology; Internal medicine; Adverse effect; Biology","score_opus":0.029832691583120387,"score_gpt":0.2663489538847015,"score_spread":0.2365162623015811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031077597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98361355,0.0035787737,0.011534202,0.000057284684,0.00009713742,0.0007589687,0.00020170692,0.000013364577,0.00014502397],"genre_scores_gemma":[0.99779254,0.00048732484,0.0010788777,0.00025576967,0.000046212182,0.00013728232,0.000054315627,0.000077566285,0.00007011373],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981138,0.00006984539,0.0005465387,0.0005300017,0.00028325492,0.00045656104],"domain_scores_gemma":[0.99861324,0.000007999902,0.00031732293,0.0006815512,0.00026845644,0.000111460926],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016248746,0.00037675057,0.00047074576,0.00012352827,0.00004805182,0.00001848289,0.00037448166,0.00034627822,0.000038916452],"category_scores_gemma":[0.000006208483,0.0003842666,0.00028197837,0.00021226892,0.00018900933,0.000016543449,0.00013499567,0.00022383887,0.0000010695808],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007414899,0.00070103625,0.0026726078,0.00013438376,0.00020123797,0.0000070567453,0.00020808663,0.0012268077,0.99262965,0.0000439768,0.000020480975,0.0020805267],"study_design_scores_gemma":[0.0015323611,0.00025831608,0.0022353036,0.00006154284,0.00007364185,0.0000015614269,0.000063173014,0.005895978,0.98891354,0.000063774765,0.0005044875,0.0003963469],"about_ca_topic_score_codex":0.0033360778,"about_ca_topic_score_gemma":0.0002655424,"teacher_disagreement_score":0.014178999,"about_ca_system_score_codex":0.00006179149,"about_ca_system_score_gemma":0.00022856407,"threshold_uncertainty_score":0.99986094},"labels":[],"label_agreement":null},{"id":"W2032186020","doi":"10.1158/1535-7163.targ-13-c51","title":"Abstract C51: eIF2alpha phosphorylation determines cell susceptibility to oxidative stress via Akt activation.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University","funders":"","keywords":"Protein kinase B; Oxidative stress; Biology; Reactive oxygen species; Phosphorylation; Cell biology; PI3K/AKT/mTOR pathway; Kinase; Molecular biology; Cancer research; Chemistry; Signal transduction; Biochemistry","score_opus":0.014399531608537927,"score_gpt":0.2682460381234599,"score_spread":0.25384650651492197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032186020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97834694,0.003756998,0.015447141,0.00039644097,0.0007133984,0.0007942929,0.000060595397,0.000032129174,0.000452055],"genre_scores_gemma":[0.99457234,0.0006029552,0.00093264156,0.0023380786,0.00070374354,0.0002590638,0.00012100605,0.00005512004,0.0004150649],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983454,0.000061722494,0.00031212225,0.0005870295,0.00027113617,0.00042258817],"domain_scores_gemma":[0.9986939,0.000014718074,0.00015723528,0.0006181897,0.0003433627,0.00017259168],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010766181,0.0003196676,0.00023697244,0.00006367928,0.00010965226,0.00007361687,0.00028994546,0.00021441623,0.00022719527],"category_scores_gemma":[0.000016218955,0.0003179344,0.00015096186,0.00018850226,0.00007585604,0.000020982186,0.000091557034,0.0001461613,0.000042465206],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000073746975,0.00010889234,0.0008651185,0.000029869676,0.00008912854,4.9853526e-7,0.00016809508,0.0005690153,0.93629533,0.000005185726,0.0006741416,0.061120976],"study_design_scores_gemma":[0.0005322584,0.000115741845,0.01211001,0.0000177399,0.000050763396,9.156664e-7,0.000073998686,0.00008642414,0.9203284,0.00011708576,0.06619015,0.00037651134],"about_ca_topic_score_codex":0.00066423067,"about_ca_topic_score_gemma":0.00024453647,"teacher_disagreement_score":0.06551601,"about_ca_system_score_codex":0.000073313866,"about_ca_system_score_gemma":0.00014441213,"threshold_uncertainty_score":0.9999273},"labels":[],"label_agreement":null},{"id":"W2032990424","doi":"10.1158/1535-7163.targ-13-a186","title":"Abstract A186: Novel target to control lung tumor growth: Disruption of cell membrane remodeling by modulating myoferlin expression.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Muscle Physiology and Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Cell biology; Biology; Cancer; Cancer cell; Gene silencing; Cancer research; Cell growth; Cell; Endocytosis; Genetics","score_opus":0.009870320619063575,"score_gpt":0.25294147505257303,"score_spread":0.24307115443350946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032990424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8854757,0.0020623556,0.11137931,0.00024837122,0.000110549685,0.0004291164,0.000064568,0.000015483214,0.0002145296],"genre_scores_gemma":[0.99396414,0.0001090305,0.0029540514,0.0026054615,0.000068393005,0.00011501278,0.00009441372,0.000049443344,0.000040050898],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986908,0.000049703845,0.00034076892,0.00041080694,0.00017303698,0.00033489475],"domain_scores_gemma":[0.99917966,0.000016237565,0.00017050467,0.00034520292,0.00018451629,0.00010388103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001049036,0.00023780657,0.00024088794,0.000041399937,0.000081521954,0.000017932562,0.00023379421,0.00016384621,0.00007594634],"category_scores_gemma":[0.000018633269,0.00022865135,0.00012822782,0.00008879561,0.000053962747,0.000010918743,0.000060111735,0.00013618627,0.0000050069193],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012875156,0.000121475205,0.00036788228,0.000068151494,0.00006763343,3.8880947e-7,0.00007768312,0.01654883,0.9819874,0.000014195664,0.00020875355,0.0004088355],"study_design_scores_gemma":[0.001135481,0.000094912546,0.00074693974,0.000037457277,0.000036469915,6.783066e-7,0.000073741394,0.009990247,0.9871051,0.0001221954,0.00037432322,0.00028248644],"about_ca_topic_score_codex":0.00016138292,"about_ca_topic_score_gemma":0.0000036165468,"teacher_disagreement_score":0.108488426,"about_ca_system_score_codex":0.00001972308,"about_ca_system_score_gemma":0.000056738332,"threshold_uncertainty_score":0.9324131},"labels":[],"label_agreement":null},{"id":"W2034458673","doi":"10.1158/1535-7163.targ-11-b50","title":"Abstract B50: A phase I study of various administration schedules for RO4929097 (R) with multi-parameter assessment (pharmacokinetics [PK] and primary tumor xenograft [XG]) in patients (pts) with advanced solid cancers.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pharmacokinetics; Nausea; Vomiting; Dosing; Hypophosphatemia; Pharmacology; Cancer; Adverse effect; Internal medicine; Oncology; Gastroenterology","score_opus":0.02431198423476477,"score_gpt":0.32397939890351174,"score_spread":0.29966741466874697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034458673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882416,0.0023081454,0.007337726,0.000015058705,0.00018390224,0.0017235429,0.00013996859,0.000012082378,0.000037957132],"genre_scores_gemma":[0.9826268,0.00062088686,0.015558532,0.00041845915,0.000069808964,0.0005204973,0.00010117862,0.00007237834,0.000011469195],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983559,0.000056034318,0.00039963718,0.00055342726,0.00026938424,0.00036560587],"domain_scores_gemma":[0.9989255,0.00001168995,0.00031303355,0.00038270658,0.00026180313,0.00010527822],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000120106386,0.00035018285,0.00040266282,0.000090341884,0.000065125336,0.00002502683,0.00018090925,0.00009903431,0.0000063237667],"category_scores_gemma":[0.0000052997298,0.00030030223,0.0000617634,0.0001431621,0.00012892886,0.000017339307,0.000045165823,0.0001723744,1.0373112e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019800115,0.0126330815,0.0620884,0.0005744983,0.0024120375,0.00003699387,0.0031055056,0.0024044598,0.7900903,0.00003972122,0.000023098097,0.10679179],"study_design_scores_gemma":[0.073782414,0.026210941,0.21475004,0.00023414192,0.0014246589,0.000013292743,0.0011603341,0.0010128263,0.6723125,0.000040439154,0.0074432567,0.0016151748],"about_ca_topic_score_codex":0.0002018932,"about_ca_topic_score_gemma":0.0009981523,"teacher_disagreement_score":0.15266164,"about_ca_system_score_codex":0.0000821487,"about_ca_system_score_gemma":0.00048406902,"threshold_uncertainty_score":0.9999449},"labels":[],"label_agreement":null},{"id":"W2034981234","doi":"10.1158/1535-7163.targ-09-a135","title":"Abstract A135: Evaluation of CPX-351 (cytarabine:daunorubicin) liposome injection efficacy in acute lymphoblastic leukemia (ALL) xenograft models","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Celator Pharmaceuticals (Canada)","funders":"","keywords":"Medicine; Cytarabine; Daunorubicin; Leukemia; Pharmacology; Bone marrow; Immunology","score_opus":0.03370912947750481,"score_gpt":0.3120673052806275,"score_spread":0.27835817580312266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034981234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99157053,0.0047529372,0.002408375,0.00015507547,0.00023603147,0.0004017714,0.00002176851,0.000016065713,0.00043742443],"genre_scores_gemma":[0.9967767,0.0016268528,0.00012489002,0.0011472903,0.00010384783,0.000040684525,0.00010466907,0.000032455577,0.000042597185],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982022,0.00010575218,0.00044328562,0.00045297598,0.000445717,0.00035003605],"domain_scores_gemma":[0.9989413,0.000009888503,0.00019074771,0.00046729975,0.00032691073,0.00006385564],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003088947,0.00028060345,0.00026856462,0.0001551867,0.00003831849,0.000027174814,0.00027948833,0.00026308166,0.000024665924],"category_scores_gemma":[0.000013067088,0.0002842953,0.0001676465,0.0002421312,0.000059202946,0.000019632715,0.000038476737,0.0001549479,0.0000058552682],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029583296,0.00015586804,0.00013715065,0.000011651653,0.0002415076,0.0000058870637,0.0001739186,0.122681245,0.84338313,0.00003102631,0.000039200924,0.032843564],"study_design_scores_gemma":[0.0033110871,0.0012009138,0.014576904,0.0001319521,0.0005307805,0.00001768606,0.00007233678,0.029433621,0.9482505,0.0013039737,0.0006122503,0.00055803446],"about_ca_topic_score_codex":0.0001714343,"about_ca_topic_score_gemma":0.00010245906,"teacher_disagreement_score":0.10486732,"about_ca_system_score_codex":0.00024120539,"about_ca_system_score_gemma":0.0003985224,"threshold_uncertainty_score":0.9999609},"labels":[],"label_agreement":null},{"id":"W2035386385","doi":"10.1158/1535-7163.mct-05-0128","title":"Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair–deficient malignant glioma xenograft","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Neurological Disorders and Stroke","keywords":"Temozolomide; Poly ADP ribose polymerase; Glioma; DNA repair; Pharmacology; O-6-methylguanine-DNA methyltransferase; Cancer research; PARP inhibitor; Growth inhibition; Medicine; Chemistry; Polymerase; DNA; Methyltransferase; Cell growth; Biochemistry; Methylation","score_opus":0.024224175741875877,"score_gpt":0.3031121217187833,"score_spread":0.27888794597690747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035386385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9050052,0.06859414,0.0014418982,0.020442534,0.00044346665,0.0011328303,0.00012943121,0.00042672592,0.0023837355],"genre_scores_gemma":[0.9725727,0.0014193272,0.004645849,0.019134976,0.00049680326,0.00037274466,0.000061286024,0.00015221535,0.0011441399],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99624413,0.00021569966,0.0009088927,0.0008930043,0.00087022944,0.0008680292],"domain_scores_gemma":[0.9982079,0.000056259876,0.00029982376,0.0010080083,0.00018792518,0.00024005907],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041990916,0.0005253796,0.0006621109,0.0004667103,0.00018740298,0.00006777253,0.00019009112,0.0002979311,0.00032840003],"category_scores_gemma":[0.000019221045,0.0005284621,0.00039004895,0.0011504221,0.00029879794,0.00016728969,0.00005671057,0.00046466838,0.00006240904],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018104549,0.0007319838,0.002122229,0.00022755342,0.00035755502,0.0008847129,0.0019519157,0.00010735516,0.9797226,0.0010588587,0.0026790106,0.008345731],"study_design_scores_gemma":[0.0053750835,0.00022578427,0.0015344372,0.001086765,0.00023055999,0.00013328054,0.00025760394,0.00028098773,0.8047727,0.00041003746,0.18503372,0.0006590856],"about_ca_topic_score_codex":0.00024272443,"about_ca_topic_score_gemma":0.00049266836,"teacher_disagreement_score":0.18235472,"about_ca_system_score_codex":0.0012116394,"about_ca_system_score_gemma":0.00046247776,"threshold_uncertainty_score":0.9997167},"labels":[],"label_agreement":null},{"id":"W2036143910","doi":"10.1158/1535-7163.targ-13-pr09","title":"Abstract PR09: Synergistic activity of CRLX101, a nanopharmaceutical in Phase II clinical trials, with antiangiogenic therapies mediated through HIF-1alpha inhibition: A translational research program.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Cancer research; Bevacizumab; Camptothecin; Angiogenesis; Metastasis; Cancer; Ovarian cancer; Tumor hypoxia; Gemcitabine; Oncology; Pharmacology; Internal medicine; Chemotherapy; Biology; Radiation therapy","score_opus":0.1639044074039281,"score_gpt":0.47201744317284133,"score_spread":0.30811303576891325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036143910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96951896,0.024970584,0.0014915037,0.0015694861,0.00034828254,0.0017674824,0.00011884646,0.00002794606,0.00018692855],"genre_scores_gemma":[0.9908477,0.0062733274,0.000928601,0.00048038404,0.000616651,0.00061635836,0.00012331973,0.00006488708,0.00004877142],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99633014,0.00094805344,0.0008569499,0.0006320823,0.00064502575,0.0005877699],"domain_scores_gemma":[0.99846554,0.00019763605,0.0002825834,0.0004591288,0.0004410497,0.00015404308],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017909562,0.0003268541,0.0006889319,0.00012929966,0.00013564496,0.000047771646,0.0002500316,0.00037979055,0.00021525526],"category_scores_gemma":[0.00011275,0.0002701917,0.00034507355,0.0005674948,0.0006490751,0.00002734415,0.00006820748,0.00050174136,0.0000050745844],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017013084,0.0018454796,0.00022819174,0.00006464585,0.0006896145,0.00001030264,0.00027979683,0.00006188828,0.9011588,0.00011397719,0.00019624503,0.09364974],"study_design_scores_gemma":[0.018526062,0.002858706,0.0061057685,0.00019362988,0.00040911417,0.000015216791,0.00014439327,0.00067264144,0.83428186,0.00085596304,0.13514127,0.00079538743],"about_ca_topic_score_codex":0.00024288123,"about_ca_topic_score_gemma":0.00018160268,"teacher_disagreement_score":0.13494503,"about_ca_system_score_codex":0.000036501082,"about_ca_system_score_gemma":0.0007115905,"threshold_uncertainty_score":0.999975},"labels":[],"label_agreement":null},{"id":"W2036366645","doi":"10.1158/1535-7163.mct-08-0743","title":"Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Agencia Estatal de Investigación","keywords":"Cytidine; Biology; Methyltransferase; DNA demethylation; Biochemistry; Molecular biology; Nucleoside; Uridine; DNA; Methylation; DNA methylation; RNA; Enzyme; Gene","score_opus":0.019738416773341136,"score_gpt":0.29972183852093753,"score_spread":0.2799834217475964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036366645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783841,0.006900782,0.013303708,0.00026319473,0.000091251226,0.00025839932,0.000038367176,0.000015650561,0.00074457325],"genre_scores_gemma":[0.99695057,0.0012324449,0.0007558992,0.0006918884,0.00009375494,0.000014090385,0.00018057335,0.00002577011,0.00005499777],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99876493,0.00006810457,0.00039438502,0.00031252776,0.00022069123,0.00023938004],"domain_scores_gemma":[0.9992543,0.0000066787115,0.00020624245,0.0002904004,0.00017764764,0.00006475504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014440538,0.00020236135,0.0002132672,0.00004617216,0.00006656297,0.0000148257,0.00016285459,0.00017478375,0.000037083762],"category_scores_gemma":[0.000008727418,0.0002004294,0.00012594453,0.00015080097,0.00008477431,0.0000062274244,0.000010730309,0.000089467605,0.0000015336911],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045173158,0.0000725993,0.0010100884,0.000008972755,0.00011515901,0.0000020883383,0.00016914608,0.0002879805,0.9854752,0.000311315,0.000008135363,0.012494144],"study_design_scores_gemma":[0.00065614074,0.00045679926,0.022641592,0.00001952561,0.0000822635,3.3187504e-7,0.000033320834,0.0001038259,0.9673176,0.0007854023,0.007689058,0.0002141395],"about_ca_topic_score_codex":0.000014409887,"about_ca_topic_score_gemma":0.000038582573,"teacher_disagreement_score":0.021631502,"about_ca_system_score_codex":0.000021522294,"about_ca_system_score_gemma":0.000076594915,"threshold_uncertainty_score":0.8173273},"labels":[],"label_agreement":null},{"id":"W2036796362","doi":"10.1158/1535-7163.targ-09-c88","title":"Abstract C88: Imiquimod induces reactive oxygen species- and caspase-independent cell cycle arrest and apoptosis in MDA-MB-468 breast cancer cells","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Imiquimod; Propidium iodide; Apoptosis; Cancer research; Reactive oxygen species; Annexin; Biology; Molecular biology; Chemistry; Programmed cell death; Immunology; Cell biology; Biochemistry","score_opus":0.019305760937364216,"score_gpt":0.277632966839723,"score_spread":0.2583272059023588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036796362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97768176,0.014687518,0.00002847099,0.004184113,0.00029267475,0.0006380978,0.00013997014,0.000036954694,0.0023104362],"genre_scores_gemma":[0.9870402,0.00965026,0.0001699061,0.0026453293,0.00023159126,0.00009184782,0.0000082224815,0.00006234543,0.000100270605],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9978711,0.000053070682,0.0003734098,0.00068342616,0.00045013317,0.0005688564],"domain_scores_gemma":[0.99906695,0.000050056777,0.00018653765,0.00038642753,0.0001091767,0.00020086391],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014584146,0.00044602042,0.0005991389,0.00017654593,0.00012523674,0.00006300482,0.00014509364,0.0002066599,0.00006978211],"category_scores_gemma":[0.0000030052975,0.00041647148,0.00009122586,0.00028067926,0.00017575437,0.0001204252,0.000079701495,0.0005063971,0.0000038000996],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060149084,0.00039275314,0.020875989,0.0001691214,0.00045950248,0.00026275302,0.0023730623,0.00011747973,0.943831,0.000037570917,0.00015675597,0.030722514],"study_design_scores_gemma":[0.0023097075,0.00017394399,0.55673796,0.00023691593,0.00028344255,0.000031141142,0.00059165683,0.000044480377,0.43797496,0.00017620606,0.0009924811,0.00044709723],"about_ca_topic_score_codex":0.0016462903,"about_ca_topic_score_gemma":0.0005062407,"teacher_disagreement_score":0.53586197,"about_ca_system_score_codex":0.0005230796,"about_ca_system_score_gemma":0.00021439831,"threshold_uncertainty_score":0.9998287},"labels":[],"label_agreement":null},{"id":"W2039457659","doi":"10.1158/1535-7163.targ-11-a221","title":"Abstract A221: A phase II study of SB939 in patients with recurrent or metastatic castration resistant prostate cancer (CRPC).","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; Ontario Institute for Cancer Research; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Clinical endpoint; Oncology; Cancer; Adverse effect; Androgen deprivation therapy; Lymph node; Prostate; Clinical trial","score_opus":0.08893729981605718,"score_gpt":0.3766998605302653,"score_spread":0.2877625607142081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039457659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994489,0.0022946852,0.000011869431,0.00012140764,0.00008301422,0.0027265497,0.00011334562,0.00002008185,0.00014000501],"genre_scores_gemma":[0.9983226,0.0005713903,0.00020940637,0.00010526672,0.000012968088,0.0005342406,0.00004289259,0.000049866685,0.00015138552],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980899,0.00008112015,0.0004454519,0.00037376254,0.00062787876,0.00038188728],"domain_scores_gemma":[0.99898916,0.00001410534,0.00020735156,0.00035631936,0.00031814384,0.00011493127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015072631,0.00026215578,0.00042180848,0.00019606702,0.00007241324,0.000012650237,0.00011092238,0.00004687198,0.00022569367],"category_scores_gemma":[0.000005467427,0.0001681427,0.000053670636,0.0004827848,0.000092156464,0.00008969966,0.000033846005,0.00023846753,0.0000012333271],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18861938,0.05796636,0.2949269,0.0013664485,0.0053646546,0.0016511453,0.058283124,0.00015425711,0.069628425,0.000034354398,0.00006309482,0.32194185],"study_design_scores_gemma":[0.12920475,0.081293084,0.68999064,0.0017301765,0.0024712903,0.000005212153,0.004566714,0.00019239214,0.08847806,0.000101588405,0.0010187924,0.0009473238],"about_ca_topic_score_codex":0.0013620267,"about_ca_topic_score_gemma":0.0019785766,"teacher_disagreement_score":0.3950637,"about_ca_system_score_codex":0.0003166862,"about_ca_system_score_gemma":0.00058162963,"threshold_uncertainty_score":0.685666},"labels":[],"label_agreement":null},{"id":"W2040706169","doi":"10.1158/1535-7163.targ-11-c170","title":"Abstract C170: The combination of statins and dipyridamole is effective preclinically in AML, MM, and breast cancer.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Statin; Medicine; Cancer; Pharmacology; Atorvastatin; Cancer research; Combination therapy; Apoptosis; Breast cancer; Cancer cell; Internal medicine; Chemistry; Biochemistry","score_opus":0.017725676646052145,"score_gpt":0.2920528456197336,"score_spread":0.2743271689736815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040706169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848817,0.012848671,0.00025141364,0.0004040198,0.00065359497,0.0004500739,0.00015234674,0.000005816453,0.0003523793],"genre_scores_gemma":[0.98801273,0.010144415,0.00008675653,0.0012614558,0.0002943857,0.00011985872,0.000009107929,0.000026602174,0.000044679564],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99904877,0.000080556936,0.0002461803,0.0003005173,0.00012922811,0.00019476975],"domain_scores_gemma":[0.99941665,0.000024628422,0.00014657088,0.00024827474,0.00011135867,0.000052509717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019652167,0.00016789761,0.00020822437,0.000035655947,0.000047264733,0.0000150027845,0.00013458749,0.00012318228,0.000033165514],"category_scores_gemma":[0.000008557721,0.00013560573,0.000058330745,0.00008478876,0.00023287856,0.000007262083,0.00006933684,0.00013385067,4.421141e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000772741,0.0003013918,0.04868198,0.00014460625,0.00046208533,7.2603234e-7,0.0033292675,0.00003204979,0.7625551,0.00039333038,0.0004142263,0.18291248],"study_design_scores_gemma":[0.0024217574,0.0002717958,0.76025,0.00008438389,0.00017931036,0.000009015968,0.0002616278,0.000107072905,0.21121423,0.0007024997,0.024156736,0.00034160598],"about_ca_topic_score_codex":0.0011644101,"about_ca_topic_score_gemma":0.0006813462,"teacher_disagreement_score":0.711568,"about_ca_system_score_codex":0.000019295348,"about_ca_system_score_gemma":0.00010388138,"threshold_uncertainty_score":0.5529841},"labels":[],"label_agreement":null},{"id":"W2041065385","doi":"10.1158/1535-7163.targ-13-c2","title":"Abstract C2: Cross-talk between the O(6)-Methylguanine-DNA methyltransferase (MGMT) and p53 in glioblastoma multiforme.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Temozolomide; Sunitinib; Methyltransferase; Cancer research; Angiogenesis; DNA repair; Biology; Glioma; Medicine; Cancer; Internal medicine; DNA; Methylation","score_opus":0.022498644374585212,"score_gpt":0.31439804526733445,"score_spread":0.29189940089274924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041065385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877216,0.006599583,0.000092706716,0.004222739,0.00008222972,0.0010029132,0.000034468623,0.00004355384,0.00020020404],"genre_scores_gemma":[0.99626166,0.0008743922,0.00021018216,0.002129104,0.00007926843,0.00034944178,0.0000109347375,0.000060055467,0.000024974683],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984203,0.00005582489,0.00037063082,0.00037517885,0.00033296985,0.00044512193],"domain_scores_gemma":[0.999075,0.00014269802,0.00007198193,0.00043324078,0.0001118974,0.00016516002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017536402,0.00031343338,0.00039266414,0.00012806847,0.00010583416,0.000109427536,0.00014482674,0.00015267992,0.00022026595],"category_scores_gemma":[0.00001413076,0.00020826458,0.00014557566,0.00029914835,0.00017577918,0.000102399,0.00003657901,0.0003059455,0.000038092567],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001794365,0.00049401383,0.3736426,0.00011595335,0.001206799,0.0004166345,0.00090558303,0.00010327962,0.42812714,0.00009894835,0.000059060814,0.19465055],"study_design_scores_gemma":[0.0033092757,0.000256992,0.62079376,0.00009797442,0.00033541623,0.00002270727,0.00010292974,0.00017421815,0.37121558,0.0002891519,0.003161382,0.00024060442],"about_ca_topic_score_codex":0.0013233707,"about_ca_topic_score_gemma":0.00025329582,"teacher_disagreement_score":0.24715118,"about_ca_system_score_codex":0.00012981296,"about_ca_system_score_gemma":0.0000748595,"threshold_uncertainty_score":0.84927833},"labels":[],"label_agreement":null},{"id":"W2041687360","doi":"10.1158/1535-7163.targ-13-a192","title":"Abstract A192: Role of O(6)-Methylguanine-DNA Methyltransferase in the Proliferation/Invasion Dichotomy and Differential Effect of FAK inhibitor Y11 based on expression of MGMT in Glioblastoma.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Cancer research; U87; Cell growth; Focal adhesion; Gene knockdown; Methyltransferase; Regulator; DNA methyltransferase; Blot; Biology; Small hairpin RNA; Western blot; Glioblastoma; Cell culture; Phosphorylation; Molecular biology; Cell biology; DNA; Biochemistry; Methylation; Genetics","score_opus":0.009265723989132292,"score_gpt":0.26543543821942756,"score_spread":0.2561697142302953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041687360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99674904,0.0013944829,0.00006787193,0.00027831973,0.00003325861,0.0014083865,0.00001826668,0.000006134069,0.00004420932],"genre_scores_gemma":[0.99920607,0.000162998,0.000086254964,0.00015829064,0.000017779534,0.00033475316,0.000010134776,0.0000231108,6.314776e-7],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859047,0.0002096022,0.00041282864,0.00022182301,0.00040024283,0.00016503678],"domain_scores_gemma":[0.99923223,0.00022176791,0.00013033659,0.0002950743,0.000073780895,0.000046809444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001900846,0.00020642811,0.00044549734,0.00022764699,0.000018431207,0.000009628732,0.000084435036,0.00011195167,0.000049015718],"category_scores_gemma":[0.000019346324,0.00012669379,0.000111012014,0.00024676413,0.000070937334,0.000040271298,0.000012953599,0.00015818323,5.8377174e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008480587,0.0008226434,0.056020476,0.00022816707,0.000057585643,0.000014960167,0.00047926776,0.00016338682,0.93065447,0.000012209402,0.0000032481041,0.010695509],"study_design_scores_gemma":[0.004777954,0.0013760291,0.09825408,0.0006329491,0.00014424247,0.0000011830487,0.000057692803,0.0008215906,0.89379454,0.000038246722,0.000018157907,0.00008335753],"about_ca_topic_score_codex":0.0002812445,"about_ca_topic_score_gemma":0.000055340148,"teacher_disagreement_score":0.042233605,"about_ca_system_score_codex":0.000040355542,"about_ca_system_score_gemma":0.000049008646,"threshold_uncertainty_score":0.5166423},"labels":[],"label_agreement":null},{"id":"W2042130205","doi":"10.1158/1535-7163.targ-13-c175","title":"Abstract C175: Effective targeting of PI3K/mTOR pathways with GDC-0980 in FLT-3 mutant pediatric leukemia.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"","keywords":"PI3K/AKT/mTOR pathway; Protein kinase B; Apoptosis; Caspase; Caspase 3; Kinase; Growth inhibition; Pharmacology; Cancer research; Caspase 8; Chemistry; Cell growth; Biology; Cell biology; Programmed cell death; Biochemistry","score_opus":0.01573195703276472,"score_gpt":0.27608041828657137,"score_spread":0.2603484612538067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042130205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99192256,0.0039716773,0.00061459886,0.00044579088,0.00008492665,0.0017150611,0.00002572005,0.000058047008,0.0011616141],"genre_scores_gemma":[0.99659467,0.0009113911,0.0009483469,0.00080754474,0.00019086499,0.00035757545,0.000016356815,0.00011086941,0.000062391475],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99758005,0.00011270985,0.00046714707,0.00046852534,0.0006996343,0.00067193614],"domain_scores_gemma":[0.9985829,0.00015304054,0.00020664479,0.00048868224,0.00038244156,0.00018629673],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034601323,0.00033810158,0.0005608121,0.0003009018,0.000053384018,0.000028228837,0.0002522348,0.00021629725,0.0002735267],"category_scores_gemma":[0.00005007163,0.00026477003,0.00012910548,0.000765282,0.00014064094,0.00011169864,0.00007904452,0.00068476447,0.000040720315],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005705677,0.00022771372,0.034590326,0.0005555072,0.00037854252,0.00045180155,0.0011866374,0.000598586,0.9234874,0.000065132415,0.00015968228,0.037728097],"study_design_scores_gemma":[0.010785085,0.0016597701,0.2399401,0.0005053541,0.00058147527,0.000048579994,0.000968119,0.004780367,0.73749965,0.00046996004,0.0017891214,0.0009724053],"about_ca_topic_score_codex":0.00089826505,"about_ca_topic_score_gemma":0.000039495808,"teacher_disagreement_score":0.20534977,"about_ca_system_score_codex":0.001316813,"about_ca_system_score_gemma":0.0011101384,"threshold_uncertainty_score":0.99998045},"labels":[],"label_agreement":null},{"id":"W2044602856","doi":"10.1158/1535-7163.targ-13-c232","title":"Abstract C232: B-raf/Mek/Erk Pathway inhibition induces GPNMB expression and sensitizes melanoma cells to the antibody-drug conjugate glembatumumab vedotin.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Vemurafenib; Trametinib; Dabrafenib; Melanoma; Medicine; Cancer research; Selumetinib; Antibody-drug conjugate; MAPK/ERK pathway; Targeted therapy; MEK inhibitor; Cancer; Kinase; Antibody; Immunology; Internal medicine; Monoclonal antibody; Biology; KRAS; Metastatic melanoma","score_opus":0.014183342169906209,"score_gpt":0.27512767143708655,"score_spread":0.26094432926718036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044602856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98159945,0.0073465896,0.0012173381,0.007618462,0.00041329162,0.0013002575,0.00006327642,0.00013635457,0.0003049724],"genre_scores_gemma":[0.9875133,0.0005709292,0.0011642381,0.009893807,0.00030467391,0.00019466277,0.00003884936,0.00011319187,0.0002063312],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977912,0.0000927783,0.00042115513,0.0005901267,0.0005303192,0.00057442195],"domain_scores_gemma":[0.9985475,0.00008325983,0.00021370541,0.00063615886,0.00027286133,0.00024654932],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001903578,0.00045390456,0.00046652,0.000120318095,0.00024223141,0.00013211824,0.00016438923,0.0001614926,0.00017336616],"category_scores_gemma":[0.000011028894,0.0003262165,0.00012431543,0.00027167427,0.00020138112,0.00021292275,0.00011787222,0.00045125114,0.00008942506],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022982324,0.00007046556,0.00018471098,0.00008197627,0.00016336582,0.00006402659,0.0016657838,0.00012154382,0.9495526,0.00005478407,0.00017524733,0.047635697],"study_design_scores_gemma":[0.0018051427,0.00015804403,0.0077951928,0.0005097687,0.00011920649,0.00006122769,0.0007280115,0.00011445908,0.9654017,0.00048208714,0.022401834,0.00042329676],"about_ca_topic_score_codex":0.00032781193,"about_ca_topic_score_gemma":0.0000433341,"teacher_disagreement_score":0.0472124,"about_ca_system_score_codex":0.00015013154,"about_ca_system_score_gemma":0.00015712202,"threshold_uncertainty_score":0.999919},"labels":[],"label_agreement":null},{"id":"W2046235081","doi":"10.1158/1535-7163.targ-09-a104","title":"Abstract A104: Safety and effectiveness of phase I solid tumor trial designs of molecularly targeted combination therapies","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Clinical trial; Cancer; Pharmacology; Oncology; Population; Internal medicine; Pharmacokinetics","score_opus":0.034705481045193866,"score_gpt":0.3695591450582382,"score_spread":0.33485366401304434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046235081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98620063,0.009144721,0.0026608498,0.00043493073,0.00014888983,0.001148922,0.000037620437,0.000023386732,0.0002000686],"genre_scores_gemma":[0.99826896,0.000787129,0.00015400008,0.00065275637,0.000031553554,0.00003669411,0.00003604294,0.000021835202,0.000011017496],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99889946,0.0001546087,0.0003330057,0.00021013846,0.00022146926,0.00018132446],"domain_scores_gemma":[0.9992883,0.000090128335,0.00020314562,0.00018280247,0.00017386166,0.00006172192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002410417,0.00019020317,0.0005082524,0.000107497086,0.000036682843,0.0000070533233,0.00006756124,0.0000844864,0.00006065137],"category_scores_gemma":[0.000007860622,0.00016830224,0.0001338104,0.00018156512,0.00011616379,0.00004370074,0.000009024772,0.0001233342,3.9252262e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058496058,0.0015080487,0.00020287573,0.00014638084,0.0007258428,0.00003856134,0.0003199779,0.000035091372,0.9186678,0.00039077728,0.0000031366296,0.019465439],"study_design_scores_gemma":[0.09343525,0.0060789497,0.018947568,0.00013940723,0.0007631749,0.000008035012,0.000026220052,0.0002033899,0.8789375,0.00096982333,0.00032979823,0.00016090134],"about_ca_topic_score_codex":0.000046467852,"about_ca_topic_score_gemma":0.0000022914787,"teacher_disagreement_score":0.039730325,"about_ca_system_score_codex":0.0000870313,"about_ca_system_score_gemma":0.0001638105,"threshold_uncertainty_score":0.6863166},"labels":[],"label_agreement":null},{"id":"W2049741091","doi":"10.1158/1535-7163.targ-13-b20","title":"Abstract B20: Defining the minimal ING1b-derived peptide that is pro-apoptotic.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Apoptosis; Biology; Cancer research; Cancer cell; Carcinogenesis; Cancer; Cell biology; Molecular biology; Genetics","score_opus":0.02411590153455583,"score_gpt":0.27174845487526633,"score_spread":0.2476325533407105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049741091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982752,0.0073260185,0.0016459103,0.004334102,0.00027360304,0.000639006,0.000020933712,0.000038676662,0.0029697479],"genre_scores_gemma":[0.9866932,0.00047992912,0.000886596,0.010877664,0.00014214768,0.00021846601,0.00004313582,0.00005675481,0.00060208444],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99867576,0.00006185808,0.00023491273,0.0003794074,0.00027107625,0.00037699685],"domain_scores_gemma":[0.99910307,0.000012380411,0.0001471668,0.0005285356,0.00012597807,0.00008284521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012666763,0.0002561995,0.00015107109,0.000033463577,0.00016958026,0.00012576344,0.00037143286,0.00017528613,0.0002943642],"category_scores_gemma":[0.000017218199,0.00019478085,0.00015369091,0.00010432705,0.00014340841,0.000012026386,0.00011114325,0.00020065828,0.000095926334],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027181675,0.000036440324,0.0012624082,0.000015503396,0.00018764465,0.000002253722,0.00019619455,0.000026573794,0.98103195,0.00011613764,0.0023903148,0.014707371],"study_design_scores_gemma":[0.00038190765,0.0000861945,0.0045873057,0.000025551442,0.00004617147,0.0000055349165,0.00020458507,0.00011214223,0.91205084,0.00015108443,0.08206624,0.0002824585],"about_ca_topic_score_codex":0.00012535305,"about_ca_topic_score_gemma":0.00001729957,"teacher_disagreement_score":0.07967592,"about_ca_system_score_codex":0.000030703388,"about_ca_system_score_gemma":0.00011978829,"threshold_uncertainty_score":0.7942932},"labels":[],"label_agreement":null},{"id":"W2049880080","doi":"10.1158/1535-7163.targ-13-b81","title":"Abstract B81: Phase I/II trial of vorinostat in combination with etoposide in pediatric patients with relapsed/refractory solid tumors.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"","keywords":"Medicine; Vorinostat; Etoposide; Pharmacology; Internal medicine; Oncology; Regimen; Toxicity; Chemotherapy; Histone deacetylase; Biology; Histone","score_opus":0.016198980365157555,"score_gpt":0.30262396926699425,"score_spread":0.2864249889018367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049880080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975905,0.00020007629,0.000021887987,0.00019593748,0.00004543944,0.0017032052,0.000013633206,0.000014450723,0.00021488154],"genre_scores_gemma":[0.99922794,0.00016066499,0.00010589371,0.00017385192,0.000020911475,0.00018970238,0.000039521776,0.000041748746,0.00003975194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846447,0.00006113287,0.00032687894,0.00026023033,0.0005589638,0.00032834854],"domain_scores_gemma":[0.99924237,0.000037986898,0.0001620996,0.00026085658,0.00018718682,0.00010947664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000070583716,0.00019192041,0.00032448513,0.00029103502,0.000028269302,0.000012676255,0.00008526677,0.00006525983,0.000043212887],"category_scores_gemma":[0.00001125462,0.0001408626,0.00004198766,0.00040290874,0.000060707534,0.00012504292,0.000023066445,0.00029806446,0.0000048806965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13799779,0.045035433,0.6918305,0.00053724134,0.0006199204,0.0012800433,0.0014399076,0.00026601623,0.03214355,0.000054405034,0.000054374534,0.088740796],"study_design_scores_gemma":[0.29004386,0.025365887,0.6573125,0.00021889216,0.00015553158,0.000002863263,0.000036997917,0.00011771238,0.026328132,0.00008192061,0.00008385585,0.00025184278],"about_ca_topic_score_codex":0.00027098315,"about_ca_topic_score_gemma":0.000113528564,"teacher_disagreement_score":0.15204607,"about_ca_system_score_codex":0.00016032033,"about_ca_system_score_gemma":0.0002928636,"threshold_uncertainty_score":0.574421},"labels":[],"label_agreement":null},{"id":"W2051367856","doi":"10.1158/1535-7163.targ-13-b59","title":"Abstract B59: Zhangfei/CREBZF arrests the growth of osteosarcoma cells by displacing Mdm2 and stabilizing p53.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Osteosarcoma; Leucine zipper; Cancer research; Transcription factor; Suppressor; Cell growth; Biology; Mdm2; Cell culture; Cell; Cancer cell; Cancer; Cell biology; Gene; Genetics","score_opus":0.013964043401972806,"score_gpt":0.2555600314737198,"score_spread":0.241595988071747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051367856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96721226,0.026676912,0.0014591105,0.002338245,0.00029721338,0.0010988481,0.00004969562,0.00006415049,0.00080354244],"genre_scores_gemma":[0.99588525,0.0013946213,0.0003441998,0.0019932766,0.00006655283,0.0001131498,0.000018415893,0.00010270609,0.00008180284],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980423,0.000084003404,0.00044979362,0.00042984475,0.0005024542,0.0004916331],"domain_scores_gemma":[0.99865395,0.000095579926,0.00022993947,0.00061969634,0.00022296039,0.00017785301],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001986131,0.00034026033,0.00042655136,0.00007214484,0.00011383981,0.000059717215,0.00021968524,0.00019070691,0.00012518185],"category_scores_gemma":[0.000020706166,0.00026156075,0.0001680685,0.00030805427,0.00028191163,0.00009403584,0.0000917326,0.00046493954,0.000015252232],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007220658,0.00008596169,0.0015807411,0.00020232855,0.00032590158,0.000025446181,0.00065671105,0.00003196516,0.98413426,0.00009527068,0.0004552505,0.012333973],"study_design_scores_gemma":[0.0017611281,0.00021464862,0.006655252,0.00034132294,0.00043103157,0.000033934855,0.00030603967,0.0005743673,0.98336226,0.00028849836,0.005670139,0.0003613948],"about_ca_topic_score_codex":0.0010684247,"about_ca_topic_score_gemma":0.000046172518,"teacher_disagreement_score":0.028672991,"about_ca_system_score_codex":0.00014893168,"about_ca_system_score_gemma":0.00019107267,"threshold_uncertainty_score":0.99998367},"labels":[],"label_agreement":null},{"id":"W2051884443","doi":"10.1158/1535-7163.targ-09-b91","title":"Abstract B91: RNAi knockdown of Mek2, but not Mek1, increases proliferation of malignant and non-malignant human breast cells","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Trois-Rivières","funders":"","keywords":"Gene knockdown; Kinase; Cell growth; Cancer research; MAPK/ERK pathway; Phosphorylation; Small hairpin RNA; Cell culture; Biology; Cell biology; Downregulation and upregulation; Biochemistry; Gene","score_opus":0.014301344045576989,"score_gpt":0.2705639052180859,"score_spread":0.2562625611725089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051884443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943368,0.0030899413,0.0015401605,0.0002625686,0.000048755035,0.0003050437,0.00018424672,0.000007639006,0.00022484074],"genre_scores_gemma":[0.99707425,0.0018084237,0.00026464343,0.0005569735,0.00008061955,0.00003455208,0.000059760994,0.000026345184,0.0000944465],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987655,0.000043012245,0.00040280208,0.00034465874,0.00022180675,0.00022220865],"domain_scores_gemma":[0.998974,0.0000057609773,0.00026899853,0.0004496426,0.00022804731,0.00007354145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014154996,0.00021554646,0.00026091604,0.000060869967,0.00007711835,0.000022873595,0.00018941422,0.00015407232,0.000023814646],"category_scores_gemma":[0.0000032576538,0.00019526925,0.00011140043,0.00009876519,0.00014647412,0.000008383982,0.00003562125,0.0000769398,7.259933e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000120309225,0.00019170204,0.0005317031,0.000051287076,0.00012876328,0.0000029927246,0.000062446066,0.0002045269,0.9882034,0.00022472814,0.000053417,0.010224732],"study_design_scores_gemma":[0.00058432494,0.00028543515,0.022524823,0.00007017259,0.00010463573,0.000009950174,0.00004297937,0.00008512973,0.97504634,0.00011116262,0.00091320043,0.00022185268],"about_ca_topic_score_codex":0.00022834392,"about_ca_topic_score_gemma":0.00003603551,"teacher_disagreement_score":0.021993121,"about_ca_system_score_codex":0.000022632428,"about_ca_system_score_gemma":0.00014119247,"threshold_uncertainty_score":0.7962849},"labels":[],"label_agreement":null},{"id":"W2052027458","doi":"10.1158/1535-7163.targ-11-b220","title":"Abstract B220: Artificially inducing protein-membrane anchorage: Introducing a new therapeutic modality.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Click Chemistry and Applications","field":"Chemistry","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Cell biology; Cancer cell; STAT3; Prenylation; STAT protein; Membrane protein; Gene knockdown; Target protein; Chemistry; Biology; Biochemistry; Cancer; Membrane; Signal transduction; Gene; Enzyme","score_opus":0.055904775003702833,"score_gpt":0.2895475400700889,"score_spread":0.2336427650663861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052027458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9735644,0.0020708716,0.005969355,0.001622435,0.00010570311,0.0003360575,0.000036962974,0.00030185547,0.015992401],"genre_scores_gemma":[0.99553454,0.000102871745,0.0013380889,0.0009422352,0.00048612492,0.00019459706,0.00003052898,0.00010102866,0.0012700052],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997848,0.00002181783,0.0005070282,0.00070797757,0.000353594,0.0005616056],"domain_scores_gemma":[0.998313,0.000028898097,0.0002531867,0.001088069,0.000111993504,0.00020482884],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016172242,0.00039780344,0.00032281043,0.000047229772,0.00020241574,0.00009262567,0.0005495447,0.00027870634,0.0028173681],"category_scores_gemma":[0.00001530376,0.00041673475,0.00018427997,0.000313678,0.00010945036,0.000111939225,0.00007757757,0.0006205393,0.00004776407],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008510303,0.00017973683,0.00014600332,0.00012758138,0.00023216299,0.000018981378,0.0009148388,0.0001507039,0.94416463,0.0009869504,0.000019204555,0.052974083],"study_design_scores_gemma":[0.0004475866,0.000012760594,0.00023276065,0.00012499045,0.00013910202,0.000007651877,0.00013814332,0.00020029231,0.9842562,0.0055415127,0.008418215,0.0004807545],"about_ca_topic_score_codex":0.0006649925,"about_ca_topic_score_gemma":0.000049784936,"teacher_disagreement_score":0.052493326,"about_ca_system_score_codex":0.00015628559,"about_ca_system_score_gemma":0.00034743303,"threshold_uncertainty_score":0.99982846},"labels":[],"label_agreement":null},{"id":"W2053354626","doi":"10.1158/1535-7163.mct-08-0885","title":"WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; University of California, Irvine","keywords":"Wnt signaling pathway; Cancer research; Biology; Ectopic expression; Gene silencing; Cell biology; Signal transduction; Cell culture; Gene","score_opus":0.01596058149435428,"score_gpt":0.2749779907451785,"score_spread":0.25901740925082417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053354626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98472565,0.0135936495,0.00076473085,0.00037221776,0.00010114678,0.00030355272,0.000026846039,0.0000104943465,0.00010168189],"genre_scores_gemma":[0.99526125,0.0032461185,0.00045442127,0.00070347387,0.00016937594,0.000035053825,0.00003467114,0.000033073262,0.00006257398],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988165,0.00007670397,0.0002645566,0.0004282045,0.0001763253,0.00023770946],"domain_scores_gemma":[0.9993722,0.000011194303,0.00014057543,0.00022428173,0.0001392767,0.00011249037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001122056,0.0002288517,0.00021266364,0.00008110355,0.000110062334,0.000034370936,0.000078064935,0.00018763504,0.0000062643003],"category_scores_gemma":[0.000007756783,0.00022525746,0.000055971712,0.00011438769,0.0000860734,0.000009640203,0.00008488076,0.00009616943,4.4897925e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065658765,0.000067728484,0.0011035554,0.000044853576,0.000047560236,0.0000062715767,0.0003846856,0.00015985686,0.9936131,0.00008108368,0.000033260665,0.004392382],"study_design_scores_gemma":[0.000519867,0.00072956475,0.0034108353,0.00016564284,0.00004987942,0.0000015037605,0.000051299325,0.000015998301,0.9929997,0.0011175537,0.00066400046,0.0002742091],"about_ca_topic_score_codex":0.000052400585,"about_ca_topic_score_gemma":0.00003530061,"teacher_disagreement_score":0.010535559,"about_ca_system_score_codex":0.000027846078,"about_ca_system_score_gemma":0.00006458234,"threshold_uncertainty_score":0.91857326},"labels":[],"label_agreement":null},{"id":"W2053411198","doi":"10.1158/1535-7163.targ-11-c165","title":"Abstract C165: Breast cancer, statins, and 3-D cell culture.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Fluvastatin; Cell culture; Cancer; Breast cancer; Cancer research; Cell growth; Cell cycle; Apoptosis; Cell; Statin; Cancer cell; Medicine; Pharmacology; Chemistry; Biology; Internal medicine; Biochemistry; Genetics","score_opus":0.017975087999392958,"score_gpt":0.26066453214097673,"score_spread":0.24268944414158378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053411198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8352381,0.14417328,0.002315142,0.00047160624,0.008072041,0.0007166148,0.0009526518,0.000086393666,0.007974193],"genre_scores_gemma":[0.94188315,0.047955915,0.0010075604,0.0039843055,0.0036330337,0.00014395827,0.00006412196,0.00010574132,0.0012221951],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99863464,0.000041462565,0.00023556373,0.00048871967,0.00018942868,0.00041016794],"domain_scores_gemma":[0.9991741,0.0000030800525,0.00012961234,0.00040087552,0.00013346413,0.00015884064],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009054335,0.00030572302,0.00023152783,0.000040348215,0.00009888139,0.00003544947,0.00023171578,0.00020465012,0.00018854297],"category_scores_gemma":[0.0000021839453,0.00028389043,0.00011650497,0.00010978305,0.0001403177,0.000008370804,0.000083619096,0.00016957143,0.0000068514087],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020481729,0.00011668332,0.0022382333,0.000067999754,0.00022019795,0.0000012046888,0.0007189802,0.000019231966,0.9549886,0.0001139755,0.0053081736,0.0360019],"study_design_scores_gemma":[0.001254215,0.0001081468,0.01977648,0.000030470708,0.00017776732,0.00001918854,0.00019285754,0.000014493268,0.3253071,0.0001562111,0.6524218,0.0005413202],"about_ca_topic_score_codex":0.000800367,"about_ca_topic_score_gemma":0.00030748098,"teacher_disagreement_score":0.64711356,"about_ca_system_score_codex":0.000030344572,"about_ca_system_score_gemma":0.00019067294,"threshold_uncertainty_score":0.9999613},"labels":[],"label_agreement":null},{"id":"W2053902344","doi":"10.1158/1535-7163.targ-13-c70","title":"Abstract C70: A phase 2 study of intravenous administration of REOLYSIN® (reovirus type 3 dearing) in combination with paclitaxel (P) and carboplatin (C) in patients with squamous cell carcinoma of the lung.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Carboplatin; Oncolytic virus; Internal medicine; Chemotherapy; Regimen; Clinical endpoint; Oncology; Gastroenterology; Phases of clinical research; Rash; Paclitaxel; Clinical trial; Cancer; Cisplatin","score_opus":0.010920829223191287,"score_gpt":0.2704467142879798,"score_spread":0.2595258850647885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053902344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983518,0.000690957,0.00001181635,0.000013417258,0.000011045279,0.00085559546,0.00001900705,9.491574e-7,0.000045414134],"genre_scores_gemma":[0.99984485,0.000023127797,0.00002880702,0.000014778951,0.0000027385654,0.000046050485,0.000019531712,0.000015018038,0.000005100611],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992141,0.00005761916,0.00021185634,0.00017416241,0.0002122885,0.00012998377],"domain_scores_gemma":[0.99940646,0.000007907894,0.00016380427,0.00023485924,0.00015985414,0.000027111251],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000052408224,0.0001111462,0.000157233,0.00005481943,0.0000150369415,0.0000064953765,0.00008246677,0.000051413717,0.0000041945227],"category_scores_gemma":[0.0000045627694,0.0000792902,0.000017908418,0.0001825797,0.00007111575,0.000006151539,0.000028542787,0.000075950724,5.700454e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002543524,0.0037858898,0.833036,0.000113163245,0.0001076845,0.0000072727607,0.0009225773,0.0002444723,0.15480508,0.0000038693347,0.0000016400467,0.00442881],"study_design_scores_gemma":[0.008711948,0.0059796446,0.74770594,0.000025896425,0.000047060057,5.4866325e-7,0.00019393046,0.000082635794,0.23715125,0.000010987863,0.0000034966006,0.000086684],"about_ca_topic_score_codex":0.004048909,"about_ca_topic_score_gemma":0.002449379,"teacher_disagreement_score":0.0853301,"about_ca_system_score_codex":0.00003855055,"about_ca_system_score_gemma":0.00016124408,"threshold_uncertainty_score":0.61207664},"labels":[],"label_agreement":null},{"id":"W2053960137","doi":"10.1158/1535-7163.targ-11-a50","title":"Abstract A50: Biomarker analysis of PTEN, targeted oncogenic mutations, and HPV in a phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor dacomitinib (D) (PF-299804) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Pfizer (Canada); London Health Sciences Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; Ontario Clinical Oncology Group; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"PTEN; Neuroblastoma RAS viral oncogene homolog; Medicine; Biomarker; Cancer; Genotyping; Exact test; Mutation; Internal medicine; Oncology; Genotype; Cancer research; KRAS; Gene; Biology; Genetics; Apoptosis; PI3K/AKT/mTOR pathway","score_opus":0.06901843089128866,"score_gpt":0.3468851743945893,"score_spread":0.27786674350330065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053960137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857694,0.011903194,0.0000033313936,0.00037469863,0.00009946441,0.0015787404,0.00023676138,0.0000041661137,0.000030254692],"genre_scores_gemma":[0.99788237,0.0015494617,0.00013364773,0.00010071416,0.000011150177,0.00023405513,0.00003721537,0.000023541956,0.000027851913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983832,0.0001503224,0.00067628454,0.00032719952,0.000259882,0.00020311555],"domain_scores_gemma":[0.9989722,0.00009900432,0.00039740436,0.00037858458,0.00008290241,0.00006990839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018489095,0.00025768226,0.0007393706,0.0002467365,0.000068394205,0.0000072145335,0.000089407906,0.00007807721,0.00014887725],"category_scores_gemma":[0.000018254243,0.00015464817,0.00023839498,0.00073921756,0.00020040624,0.000034059347,0.0000616263,0.00011352919,1.3489729e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.072446555,0.05654855,0.44062963,0.0014420219,0.010339509,0.00018819036,0.033282764,0.00019309775,0.14318778,0.00007523176,0.00009443446,0.24157223],"study_design_scores_gemma":[0.16008168,0.015301155,0.4354942,0.00042234678,0.01215089,0.00000787403,0.0011496684,0.0009765623,0.3732013,0.00011600553,0.0006910394,0.00040724754],"about_ca_topic_score_codex":0.0071513783,"about_ca_topic_score_gemma":0.008230504,"teacher_disagreement_score":0.24116498,"about_ca_system_score_codex":0.00022836914,"about_ca_system_score_gemma":0.00025256976,"threshold_uncertainty_score":0.9994601},"labels":[],"label_agreement":null},{"id":"W2054755055","doi":"10.1158/1535-7163.targ-11-ed01-01","title":"Abstract ED01-01: Preventing multiple types of cancer through HPV vaccination.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cervical cancer; Genital warts; HPV vaccines; Medicine; Vaccination; Recurrent Respiratory Papillomatosis; Virology; Cancer; Antibody; Cervix; Penile cancer; Immunology; Human papillomavirus; HPV infection; Internal medicine","score_opus":0.09091567059140804,"score_gpt":0.378963751330603,"score_spread":0.28804808073919497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054755055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6979657,0.10636132,0.0051896432,0.0019964883,0.0009117657,0.0020402442,0.00014077403,0.0002029761,0.18519108],"genre_scores_gemma":[0.99456984,0.0027617994,0.00094171846,0.0010961394,0.00012897598,0.00009596335,0.000009706335,0.000048391666,0.00034746618],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99863064,0.000031871394,0.00030605803,0.00026602903,0.00043334518,0.00033207002],"domain_scores_gemma":[0.99908906,0.00003576318,0.00011779928,0.0003349591,0.00033746875,0.000084926236],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012920047,0.00016650226,0.0002977208,0.00006587539,0.000057493242,0.000011029927,0.00017109557,0.000113731425,0.015736964],"category_scores_gemma":[0.000020444171,0.0001447519,0.0001578277,0.00027282353,0.00005803785,0.000074411226,0.00005617583,0.00025944848,0.000013869257],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011427767,0.00066401146,0.07412843,0.0011280442,0.0013499984,0.000054242195,0.0030507746,0.00012920928,0.08808882,0.00073458586,0.00023106049,0.829298],"study_design_scores_gemma":[0.002103452,0.00016493072,0.5424943,0.000059415794,0.00033681677,0.0000026261482,0.00012494522,0.0004014882,0.43966687,0.00094990275,0.013463823,0.00023142052],"about_ca_topic_score_codex":0.0022114655,"about_ca_topic_score_gemma":0.00048008157,"teacher_disagreement_score":0.82906663,"about_ca_system_score_codex":0.00012964617,"about_ca_system_score_gemma":0.00025673563,"threshold_uncertainty_score":0.9851628},"labels":[],"label_agreement":null},{"id":"W2057360831","doi":"10.1158/1535-7163.targ-11-c25","title":"Abstract C25: A phase I study evaluating the proton pump inhibitor pantoprazole (PTP) in combination with doxorubicin (DOX) for advanced cancer patients (pts).","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"ATP Synthase and ATPases Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Neutropenia; Mucositis; Febrile neutropenia; Epirubicin; Cancer; Pharmacology; Doxorubicin; Cardiotoxicity; Pharmacokinetics; Anthracycline; Toxicity; Internal medicine; Chemotherapy; Gastroenterology; Breast cancer","score_opus":0.0660289416052039,"score_gpt":0.39767779684636717,"score_spread":0.3316488552411633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057360831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99376625,0.00093114167,0.000615095,0.00013155816,0.000115968665,0.004259698,0.000061094455,0.000013674634,0.000105527484],"genre_scores_gemma":[0.99522144,0.00020453552,0.00018508344,0.00038986577,0.00007615788,0.0037249257,0.00006850855,0.000066781344,0.00006269031],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99818176,0.00013934202,0.00032528993,0.0004887142,0.0004204211,0.0004444858],"domain_scores_gemma":[0.99899113,0.000024789664,0.00018172046,0.00041420452,0.00032349885,0.00006463594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040474746,0.0002638513,0.00021031576,0.000062929445,0.00015777165,0.000036772028,0.00030057438,0.00010773158,0.00003549124],"category_scores_gemma":[0.00002904164,0.0001890955,0.000079988546,0.00020526249,0.000092750764,0.000015547103,0.00007656602,0.00019436739,0.0000017279195],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029862483,0.002682982,0.016779507,0.000074954514,0.00027972079,0.00000888673,0.00124902,0.00022682891,0.86528236,0.000011833817,0.000010484073,0.11040715],"study_design_scores_gemma":[0.012888993,0.007850353,0.0053935884,0.000096074284,0.000118534575,4.811958e-7,0.00091691734,0.000796737,0.96952116,0.00006009028,0.0019622243,0.00039486558],"about_ca_topic_score_codex":0.00031351758,"about_ca_topic_score_gemma":0.00035019236,"teacher_disagreement_score":0.110012285,"about_ca_system_score_codex":0.00008502174,"about_ca_system_score_gemma":0.00023418569,"threshold_uncertainty_score":0.77110904},"labels":[],"label_agreement":null},{"id":"W2057494314","doi":"10.1158/1535-7163.targ-11-a19","title":"Abstract A19: Establishment of patient primary tumor-derived xenograft models for testing anticancer agents.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Medicine; Irinotecan; Gemcitabine; Docetaxel; In vivo; Paclitaxel; Cancer; Cisplatin; Doxorubicin; Erlotinib; Cancer research; Primary tumor; Pharmacology; Colorectal cancer; Chemotherapy; Internal medicine; Metastasis; Biology","score_opus":0.06952482561264713,"score_gpt":0.3080648751406081,"score_spread":0.23854004952796098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057494314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98454094,0.006193907,0.005971801,0.00004518649,0.0001365556,0.00089198817,0.00021830518,0.000019602696,0.0019817362],"genre_scores_gemma":[0.99308246,0.0005696395,0.0048763314,0.00088777085,0.000047596044,0.00035339827,0.00009094511,0.00006134467,0.0000304917],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984815,0.000031989075,0.00031453464,0.00041963148,0.00029587786,0.00045644311],"domain_scores_gemma":[0.9989703,0.0000135246855,0.00018580614,0.00043545707,0.00027198432,0.00012291205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009588239,0.00024246392,0.00023934782,0.000058659785,0.00007489566,0.00002042741,0.00024240866,0.000085042266,0.00003340947],"category_scores_gemma":[0.000012646685,0.00022934859,0.00016873235,0.00013596044,0.000119114935,0.000011085946,0.00010758046,0.00008515895,0.0000011203027],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006888706,0.0004600195,0.0026046124,0.00015266781,0.0007484652,0.000022013468,0.00033356965,0.0007005242,0.9545044,0.000055485707,0.00014982348,0.039579585],"study_design_scores_gemma":[0.0015273949,0.000834521,0.0032428764,0.00006704275,0.00012181931,0.0000039828687,0.000067765955,0.00029988447,0.9876541,0.0007289794,0.0051428084,0.00030882884],"about_ca_topic_score_codex":0.0005575956,"about_ca_topic_score_gemma":0.00006130185,"teacher_disagreement_score":0.039270755,"about_ca_system_score_codex":0.00008830773,"about_ca_system_score_gemma":0.00030274712,"threshold_uncertainty_score":0.9352564},"labels":[],"label_agreement":null},{"id":"W2058563691","doi":"10.1158/1535-7163.targ-13-b235","title":"Abstract B235: The role of eIF4E in promoting melanoma cell proliferation and maintaining acquired resistance to vemurafenib in melanoma.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Autophagy in Disease and Therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Montreal General Hospital; McGill University","funders":"","keywords":"Vemurafenib; Melanoma; Cancer research; Cell growth; Gene silencing; Cell culture; EIF4E; Biology; Autophagy; Carcinogenesis; Cancer; Apoptosis; Translation (biology); Messenger RNA; Genetics; Gene","score_opus":0.011321510108316304,"score_gpt":0.2647805564617168,"score_spread":0.2534590463534005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058563691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98818994,0.008153167,0.00005383619,0.0015621672,0.000029070907,0.001051673,0.000004254391,0.000015941445,0.0009399514],"genre_scores_gemma":[0.99765325,0.00018190597,0.00027642524,0.0015101566,0.000035795434,0.00023790142,0.0000053195135,0.000031893385,0.00006737105],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99887425,0.000067412766,0.00033402257,0.00023817063,0.00022001757,0.00026614984],"domain_scores_gemma":[0.9994426,0.00003739049,0.00010938282,0.00026943348,0.000070776805,0.00007046662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021177078,0.00015738126,0.0002420296,0.00010729813,0.00003961124,0.000026599831,0.000113926166,0.000083331775,0.000050190756],"category_scores_gemma":[0.000009546921,0.00012270319,0.000042744545,0.0002659478,0.000050514183,0.00006912549,0.000027854841,0.0001333296,0.0000042361894],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004608709,0.0002251057,0.0801363,0.00013848126,0.00010544819,0.000055804863,0.0099134445,0.00014219264,0.86932063,0.00037311626,0.000007282997,0.039121293],"study_design_scores_gemma":[0.0022140313,0.00020635029,0.31966645,0.00040297132,0.000066544955,0.000004208267,0.0013150035,0.0017281466,0.6701272,0.0026762187,0.0013466269,0.00024621878],"about_ca_topic_score_codex":0.00019320812,"about_ca_topic_score_gemma":0.00017147852,"teacher_disagreement_score":0.23953015,"about_ca_system_score_codex":0.00009247483,"about_ca_system_score_gemma":0.00011485327,"threshold_uncertainty_score":0.50036913},"labels":[],"label_agreement":null},{"id":"W2060486960","doi":"10.1158/1535-7163.targ-09-b223","title":"Abstract B223: Protein kinase C iota as a target for glioblastoma therapy","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Lamellipodium; Motility; Cancer research; MARCKS; Mitosis; Protein kinase C; Biology; Cell growth; Cell biology; Small hairpin RNA; Cell; Cancer; Cancer cell; Filopodia; Pseudopodia; Kinase; Cell migration; Actin; Cell culture; Genetics","score_opus":0.020119616501461834,"score_gpt":0.29111817036076626,"score_spread":0.27099855385930444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060486960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792101,0.012713936,0.0026063637,0.001491582,0.00014837112,0.0015495989,0.00010049891,0.000047538648,0.0021320302],"genre_scores_gemma":[0.98968107,0.0004896965,0.0021783123,0.0063642547,0.0003245862,0.0003921866,0.000057685167,0.000069485635,0.00044274225],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99846715,0.00005297029,0.00025390042,0.0005089449,0.00022059567,0.00049642887],"domain_scores_gemma":[0.999062,0.0000070853616,0.00012634939,0.0005253134,0.00015264178,0.0001266023],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017540774,0.0003312203,0.00022118751,0.00005235288,0.0001294748,0.00006171283,0.00034433792,0.0002596806,0.000078044664],"category_scores_gemma":[0.000016614013,0.00031492088,0.00024257525,0.00012372514,0.000063768675,0.000003857181,0.000030602278,0.00014998371,0.00001465504],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008051148,0.00015165139,0.000019439954,0.000019174628,0.00012788744,0.000013471622,0.00005991141,0.00003857294,0.9459229,0.0007833673,0.00015225605,0.051906247],"study_design_scores_gemma":[0.0012545523,0.0017381833,0.00009972382,0.000028107821,0.000016939386,0.000006305154,0.000018188157,0.00003406985,0.81324613,0.0031286895,0.18007678,0.00035232442],"about_ca_topic_score_codex":0.000014093826,"about_ca_topic_score_gemma":0.0000074811414,"teacher_disagreement_score":0.17992452,"about_ca_system_score_codex":0.00003222529,"about_ca_system_score_gemma":0.00020791197,"threshold_uncertainty_score":0.99993026},"labels":[],"label_agreement":null},{"id":"W2060631498","doi":"10.1158/1535-7163.mct-05-0167","title":"Transcriptional targeting modalities in breast cancer gene therapy using adenovirus vectors controlled by α-lactalbumin promoter","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Lactalbumin; Cancer research; Breast cancer; Biology; Promoter; Molecular biology; Genetic enhancement; Gene; Cell culture; Cancer; Gene expression; Genetics; Biochemistry","score_opus":0.027214311535851344,"score_gpt":0.3120649585151987,"score_spread":0.28485064697934737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060631498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93944436,0.05631472,0.0008987317,0.0021110144,0.00014031351,0.0007298493,0.0002995141,0.000024489118,0.000036983834],"genre_scores_gemma":[0.9885521,0.0063852463,0.0003244899,0.0034717398,0.00044926818,0.00033593466,0.000107895656,0.00013069689,0.00024262542],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99737746,0.00031417634,0.0004741766,0.00061288767,0.0004917669,0.00072951],"domain_scores_gemma":[0.9991882,0.000013232249,0.00013394291,0.0003676255,0.00017252745,0.00012448759],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037025954,0.00042594795,0.00042415914,0.00013062036,0.00012807031,0.0000724994,0.00038340536,0.00027119927,0.0002931942],"category_scores_gemma":[0.000004051694,0.00040345534,0.000239467,0.00023566467,0.00016417858,0.000018485127,0.000044175304,0.00029461694,0.0000038577555],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060017533,0.00022300892,0.0011889153,0.000013291775,0.00047732185,0.0000066396647,0.00027924732,0.0050542727,0.9762881,0.0000068478885,0.00009336061,0.0103672715],"study_design_scores_gemma":[0.007453005,0.0003485031,0.00027206316,0.000028594119,0.000046014226,0.00001126661,0.00005768522,0.0036800625,0.97736263,0.00003144767,0.010176668,0.0005320687],"about_ca_topic_score_codex":0.00034175417,"about_ca_topic_score_gemma":0.00026264106,"teacher_disagreement_score":0.049929474,"about_ca_system_score_codex":0.00025745435,"about_ca_system_score_gemma":0.0004315576,"threshold_uncertainty_score":0.99984175},"labels":[],"label_agreement":null},{"id":"W2061181299","doi":"10.1158/1535-7163.mct-07-2166","title":"Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Endoplasmic Reticulum Stress and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Neurological Disorders and Stroke; National Institute of General Medical Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Cell biology; Biology; Endoplasmic reticulum; Gene knockdown; Unfolded protein response; Apoptosis; Molecular biology; Protein kinase A; Cathepsin; Kinase; Cancer research; Biochemistry","score_opus":0.01816623585862282,"score_gpt":0.25395953258808807,"score_spread":0.23579329672946525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061181299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99423796,0.004334682,0.0004313055,0.000054428783,0.000104768485,0.00023078933,0.000037907375,0.000009003956,0.0005591381],"genre_scores_gemma":[0.9979486,0.0012245311,0.00028402562,0.00026037416,0.000050745562,0.000028503482,0.000056759618,0.000040623556,0.00010583967],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99876815,0.000076515586,0.00029788737,0.00038107097,0.00022225648,0.00025413252],"domain_scores_gemma":[0.99932474,0.000008105748,0.00014051225,0.00036044337,0.00007736823,0.00008885091],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007869899,0.00021139403,0.00022046502,0.00007971764,0.00008188467,0.000012329914,0.00013844403,0.00016081243,0.000011181558],"category_scores_gemma":[0.0000026424066,0.00021498093,0.00009068989,0.000106093124,0.00010295237,0.0000046868995,0.00007385516,0.000105845655,8.9551713e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007643259,0.00011405352,0.0047389553,0.000069339396,0.000041876992,0.00005886575,0.00020986592,0.00061896996,0.99341726,0.000031487572,0.000014137064,0.000608751],"study_design_scores_gemma":[0.0011667783,0.00016153682,0.005936598,0.00003152452,0.0000561879,0.00001925777,0.00006608834,0.00019852056,0.99178493,0.00007201218,0.00025804882,0.00024853763],"about_ca_topic_score_codex":0.00020891982,"about_ca_topic_score_gemma":0.000049305847,"teacher_disagreement_score":0.0037106208,"about_ca_system_score_codex":0.000044248198,"about_ca_system_score_gemma":0.00012017504,"threshold_uncertainty_score":0.8766668},"labels":[],"label_agreement":null},{"id":"W2063170049","doi":"10.1158/1535-7163.mct-06-0043","title":"Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an<i>in vitro</i>bladder cancer carcinogenesis model","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Erlotinib; Epidermal growth factor receptor; Cancer research; Tyrosine-kinase inhibitor; Epidermal growth factor; MAPK/ERK pathway; Tyrosine kinase; Biology; Chemistry; Kinase; Cell biology; Molecular biology; Signal transduction; Receptor; Cancer; Biochemistry","score_opus":0.024786608915299935,"score_gpt":0.31071206138325674,"score_spread":0.2859254524679568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063170049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940492,0.0035428994,0.00033678644,0.000507407,0.0002063187,0.0009309664,0.0002664129,0.000050266357,0.0001097631],"genre_scores_gemma":[0.9967137,0.0003333079,0.0006314811,0.0015261999,0.00023178845,0.00027978115,0.00009297709,0.00013819778,0.000052571475],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974445,0.0002829196,0.0005452631,0.00065104186,0.00051326334,0.0005629897],"domain_scores_gemma":[0.99899185,0.000049572533,0.00015085003,0.0005061072,0.00014523012,0.00015641899],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019425702,0.000475893,0.0007367837,0.00029093816,0.000050650506,0.00002155765,0.00016743549,0.00024306861,0.000055083834],"category_scores_gemma":[0.000009004732,0.00041428243,0.00017738577,0.00041591006,0.0000713344,0.00015592595,0.00002776625,0.0003301417,0.0000024466556],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053031817,0.0006365445,0.013084754,0.00016061123,0.00010272799,0.00006036001,0.00029057125,0.018151212,0.9349087,0.000011614311,0.000009401761,0.027280359],"study_design_scores_gemma":[0.0061210543,0.0011365155,0.0036849938,0.00021878065,0.0002775681,0.0000033360313,0.00001889001,0.026713038,0.9613395,0.000066391556,0.000064631284,0.00035529767],"about_ca_topic_score_codex":0.005883958,"about_ca_topic_score_gemma":0.00069115404,"teacher_disagreement_score":0.02692506,"about_ca_system_score_codex":0.00061590516,"about_ca_system_score_gemma":0.00033432632,"threshold_uncertainty_score":0.9998309},"labels":[],"label_agreement":null},{"id":"W2063990365","doi":"10.1158/1535-7163.mct-08-0309","title":"A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institute of General Medical Sciences; University of Alberta","keywords":"STAT3; stat; Signal transduction; Cancer research; Tyrosine phosphorylation; Cancer cell; Cell signaling; JAK-STAT signaling pathway; Phosphorylation; Biology; PIM1; Cell culture; Cancer; Tyrosine kinase; Cell biology; Genetics","score_opus":0.08874461016305578,"score_gpt":0.3205069088335087,"score_spread":0.2317622986704529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063990365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9668382,0.004260179,0.026077196,0.00046748915,0.00035179005,0.00067938474,0.00005825058,0.000115062845,0.0011524878],"genre_scores_gemma":[0.9920814,0.00017028837,0.0016749431,0.005088381,0.00015826988,0.00022186463,0.000064264896,0.00012900856,0.00041160473],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99752265,0.00012544054,0.0006242322,0.00061240315,0.0004882046,0.0006270745],"domain_scores_gemma":[0.9988232,0.000059376387,0.00024164809,0.00048154301,0.00024452916,0.00014967569],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015006422,0.00041841934,0.0005387057,0.00023590548,0.00031165365,0.00006284117,0.00019899753,0.0001785168,0.0003826453],"category_scores_gemma":[0.000005267987,0.00042725183,0.00030639934,0.0005801996,0.00014572503,0.00009787524,0.00005408678,0.00063090055,0.000012239084],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018782626,0.00039936148,0.0012469073,0.00009808804,0.00018396422,0.00071926275,0.0018121805,0.0077236383,0.9870224,0.0000476322,0.00008279106,0.00047597697],"study_design_scores_gemma":[0.0033041986,0.00023194062,0.0002824896,0.00059946,0.00019841024,0.0000320026,0.00024329136,0.0021057802,0.9885557,0.000036737998,0.00395323,0.00045672146],"about_ca_topic_score_codex":0.0026020578,"about_ca_topic_score_gemma":0.00032969474,"teacher_disagreement_score":0.025243215,"about_ca_system_score_codex":0.00030741017,"about_ca_system_score_gemma":0.00044499958,"threshold_uncertainty_score":0.9998179},"labels":[],"label_agreement":null},{"id":"W2065683374","doi":"10.1158/1535-7163.mct-06-0389","title":"C35 (<i>C17orf37</i>) is a novel tumor biomarker abundantly expressed in breast cancer","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"Cancer Institute, University of Pittsburgh; Tufts University School of Medicine; National Cancer Institute; Ludwig Institute for Cancer Research","keywords":"Biology; Biomarker; Breast cancer; Gene; Immunohistochemistry; Cancer; Oncogene; Cancer research; Complementary DNA; Open reading frame; Pathology; Gene expression; Medicine; Immunology; Genetics; Cell cycle; Peptide sequence","score_opus":0.04298584457033967,"score_gpt":0.3514532504766201,"score_spread":0.30846740590628047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065683374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9397132,0.01919918,0.0026927087,0.030690001,0.0006258231,0.0017528719,0.0009716275,0.00020774246,0.0041468926],"genre_scores_gemma":[0.9786737,0.0012843519,0.0007330253,0.016795535,0.00032962282,0.0006254093,0.000027423464,0.00020469965,0.0013262195],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99649096,0.0000897865,0.0005775153,0.0007753567,0.001052904,0.0010134904],"domain_scores_gemma":[0.99846494,0.00004325218,0.00013979367,0.0008273729,0.00030870238,0.0002159584],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029867908,0.00044764503,0.00058479526,0.00032390075,0.000090189,0.000083897445,0.00038055098,0.0002016373,0.0010331725],"category_scores_gemma":[0.000006621681,0.0004208793,0.00022341518,0.0010255931,0.000250634,0.000090301124,0.000108494154,0.00057673786,0.00003598792],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006940464,0.00059729785,0.060779694,0.00026351705,0.00027055026,0.00036449276,0.00030456716,0.00014960303,0.9179223,0.00015667504,0.003202247,0.015295012],"study_design_scores_gemma":[0.011589588,0.00019907324,0.25927845,0.0014396427,0.0004374269,0.00025503457,0.00015433626,0.006167866,0.34783038,0.0006361777,0.37065586,0.0013561717],"about_ca_topic_score_codex":0.008307308,"about_ca_topic_score_gemma":0.00065720495,"teacher_disagreement_score":0.5700919,"about_ca_system_score_codex":0.000903073,"about_ca_system_score_gemma":0.0010892663,"threshold_uncertainty_score":0.99988},"labels":[],"label_agreement":null},{"id":"W2065864502","doi":"10.1158/1535-7163.mct-08-0930","title":"<i>Connexin43</i> pseudogene in breast cancer cells offers a novel therapeutic target","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Connexins and lens biology","field":"Biochemistry, Genetics and Molecular Biology","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Pseudogene; Gene knockdown; Cancer; Cancer research; Biology; Cancer cell; Breast cancer; Cytotoxic T cell; Gene; Carcinogenesis; In vitro; Molecular biology; Genetics","score_opus":0.014954157037738666,"score_gpt":0.2660059375885211,"score_spread":0.2510517805507824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065864502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9697228,0.015636487,0.00636914,0.006411703,0.0005111235,0.0005057952,0.00028022178,0.00004382435,0.00051888236],"genre_scores_gemma":[0.97205704,0.0031261588,0.00039696472,0.023817083,0.00023522385,0.00008234968,0.00004966256,0.0000597828,0.00017572417],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99796546,0.00010270441,0.0003665707,0.000694178,0.00019266122,0.0006784068],"domain_scores_gemma":[0.99903804,0.0000103311395,0.00012761648,0.0005854044,0.000118816824,0.00011980495],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016971507,0.00041469105,0.00035709175,0.00011098235,0.000075618256,0.0000357406,0.00042628846,0.00034859098,0.00013284659],"category_scores_gemma":[0.000002377264,0.00039233992,0.00020493673,0.00029112605,0.0001215241,0.000006671307,0.00006644997,0.0002466171,0.000007173413],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030947628,0.0002232742,0.0024850953,0.000010181693,0.00017989014,0.00001548097,0.00008953147,0.0010318588,0.9780486,0.00027387426,0.000097907505,0.017234834],"study_design_scores_gemma":[0.0023961947,0.00036316935,0.012523094,0.00004211996,0.000101908634,0.000046916783,0.00006791512,0.0006604035,0.92090064,0.00040461132,0.06166189,0.00083113735],"about_ca_topic_score_codex":0.00018227185,"about_ca_topic_score_gemma":0.00013809989,"teacher_disagreement_score":0.061563984,"about_ca_system_score_codex":0.000087770684,"about_ca_system_score_gemma":0.0002436748,"threshold_uncertainty_score":0.99985284},"labels":[],"label_agreement":null},{"id":"W2066040725","doi":"10.1158/1535-7163.mct-05-0495","title":"β-Escin inhibits colonic aberrant crypt foci formation in rats and regulates the cell cycle growth by inducing p21waf1/cip1 in colon cancer cells","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Natural product bioactivities and synthesis","field":"Biochemistry, Genetics and Molecular Biology","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"National Cancer Institute; U.S. Public Health Service","keywords":"Azoxymethane; Aberrant crypt foci; Apoptosis; Grape seed extract; Colorectal cancer; Medicine; Flow cytometry; Cell; Cell growth; Cancer; Pharmacology; Internal medicine; Cancer research; Pathology; Chemistry; Immunology; Biochemistry","score_opus":0.007171750770668461,"score_gpt":0.22606718763604047,"score_spread":0.21889543686537202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066040725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97232926,0.024965243,0.000056759858,0.0019555406,0.000119251665,0.0004136849,0.000038390575,0.0000084805115,0.00011336553],"genre_scores_gemma":[0.99504983,0.0035005067,0.000059356462,0.0009899663,0.00007641413,0.00009347799,0.000031300984,0.00003327034,0.00016586504],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99867785,0.00012174392,0.00029364604,0.00037272347,0.00016386199,0.00037020294],"domain_scores_gemma":[0.9995186,0.000022662296,0.00013607302,0.00023615835,0.000054317272,0.000032188258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020812219,0.00022819813,0.0002037601,0.00006162937,0.00010137105,0.00005476673,0.0001650027,0.00021433739,0.0000084047315],"category_scores_gemma":[0.0000052114983,0.00018650104,0.000056617195,0.00022144178,0.00010445042,0.000018916897,0.00007357866,0.00021810117,7.217426e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000091877366,0.00006345177,0.00056682766,0.000039362916,0.000021815576,0.0000037257128,0.00023707694,0.0005952145,0.99508655,0.000020239548,0.0004217882,0.002852043],"study_design_scores_gemma":[0.0006305815,0.00007434497,0.0009949064,0.00004324371,0.000029060517,0.0000028438903,0.0001172168,0.0005979319,0.9938737,0.0002866453,0.0030957395,0.00025374375],"about_ca_topic_score_codex":0.0021882425,"about_ca_topic_score_gemma":0.0026818495,"teacher_disagreement_score":0.022720559,"about_ca_system_score_codex":0.00011500281,"about_ca_system_score_gemma":0.00006611223,"threshold_uncertainty_score":0.76052916},"labels":[],"label_agreement":null},{"id":"W2066244997","doi":"10.1158/1535-7163.pms-b17","title":"Abstract B17: Dexamethasone synthetic lethal screens uncover two potential combination therapies for the treatment of multiple myeloma","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University","funders":"","keywords":"Dexamethasone; Cancer research; Multiple myeloma; Programmed cell death; Apoptosis; Glucocorticoid receptor; Medicine; Pharmacology; Biology; Glucocorticoid; Immunology; Internal medicine","score_opus":0.041579972672195674,"score_gpt":0.33072438364142387,"score_spread":0.2891444109692282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066244997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96953064,0.016717607,0.007871999,0.0024391871,0.0001737311,0.0029759419,0.00009712744,0.00004045984,0.0001533066],"genre_scores_gemma":[0.99495256,0.002269949,0.0012328079,0.00028151486,0.00008823051,0.0008466424,0.000054529006,0.000059137623,0.00021462936],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984817,0.000068775385,0.00028473433,0.00029271806,0.00046267395,0.0004093961],"domain_scores_gemma":[0.9986232,0.000315075,0.00013400814,0.00049118657,0.00032461633,0.0001119379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011043337,0.00026628803,0.00034996396,0.00008756753,0.00014314223,0.000042223186,0.00013974986,0.00009014196,0.000248763],"category_scores_gemma":[0.000021599253,0.000165776,0.00030512523,0.00014011974,0.00019082864,0.00007354774,0.00001669313,0.00009887583,0.000018536988],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010842449,0.0017407747,0.011887716,0.00009692834,0.0030295441,0.000037677266,0.000619245,0.0003660686,0.3453623,0.00015045817,0.00003043721,0.6355946],"study_design_scores_gemma":[0.031270277,0.00407956,0.2984568,0.00016338426,0.0017135524,0.000039002138,0.0005773832,0.029830301,0.6166107,0.0011847066,0.015538816,0.0005355355],"about_ca_topic_score_codex":0.001456512,"about_ca_topic_score_gemma":0.000090155314,"teacher_disagreement_score":0.63505906,"about_ca_system_score_codex":0.00021510648,"about_ca_system_score_gemma":0.00012699467,"threshold_uncertainty_score":0.6760149},"labels":[],"label_agreement":null},{"id":"W2068506100","doi":"10.1158/1535-7163.targ-11-a10","title":"Abstract A10: Combined blockade of VEGF and Ang2 promotes dramatic tumor necrosis and growth inhibition of colorectal cancer xenografts.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Aflibercept; Angiogenesis; Tumor hypoxia; Colorectal cancer; Cancer research; Medicine; HIF1A; Pharmacology; Oxaliplatin; Bevacizumab; Combination therapy; Cancer; Blockade; Tumor progression; CD31; Internal medicine; Chemotherapy; Receptor; Radiation therapy","score_opus":0.015542342030486595,"score_gpt":0.24402229729944142,"score_spread":0.22847995526895482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068506100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98281616,0.016154738,0.00012465572,0.000080636404,0.00023903415,0.00034303966,0.00010173828,0.000010383334,0.0001296103],"genre_scores_gemma":[0.99437547,0.004528288,0.00059686997,0.00023878698,0.00010113579,0.00008170392,0.000021740463,0.00003920812,0.000016779431],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99894947,0.000041140123,0.00031146666,0.00030457013,0.00015859997,0.00023476341],"domain_scores_gemma":[0.9993089,0.000008292669,0.0002383365,0.00019203262,0.00017039318,0.000082072824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010587687,0.00021931983,0.0003226674,0.00006526316,0.000047162783,0.000013484496,0.00010000605,0.00013450706,0.000023515284],"category_scores_gemma":[0.000010796947,0.00021178089,0.000090146976,0.00012835115,0.00030291625,0.000008496393,0.000071868504,0.00009642484,1.9852111e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002673843,0.0001266129,0.004248591,0.00024391805,0.0002484066,0.000001719018,0.0007374573,0.0000028238494,0.99004346,0.000101801044,0.000023372246,0.0039544357],"study_design_scores_gemma":[0.0012671329,0.00034785445,0.030351495,0.00009741504,0.00022757082,0.0000068072513,0.000069169466,0.00003806182,0.966371,0.00038446623,0.0006084134,0.00023062978],"about_ca_topic_score_codex":0.0008389284,"about_ca_topic_score_gemma":0.0001548962,"teacher_disagreement_score":0.026102904,"about_ca_system_score_codex":0.000013544446,"about_ca_system_score_gemma":0.00011942496,"threshold_uncertainty_score":0.86361736},"labels":[],"label_agreement":null},{"id":"W2068863254","doi":"10.1158/1535-7163.targ-09-c182","title":"Abstract C182: Use of an oncolytic adenovirus (ONYX-015) <i>in vitro</i> to enhance chemotherapy","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Oncolytic virus; Oncolytic adenovirus; Cancer research; Cell culture; Cisplatin; Virus; Carboplatin; Cytotoxicity; In vitro; Genetic enhancement; Melphalan; Biology; Viability assay; Virology; Chemotherapy; Gene","score_opus":0.028011019677393806,"score_gpt":0.34984623422599664,"score_spread":0.32183521454860287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068863254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942413,0.0028795358,0.00087167614,0.0010459585,0.00008362845,0.0006282811,0.000059389684,0.000023842496,0.0001663618],"genre_scores_gemma":[0.98425144,0.001031642,0.0013899595,0.01283523,0.00013285548,0.000062472944,0.000048173293,0.000083100625,0.00016510193],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976418,0.00013603567,0.00045219148,0.0006709011,0.00046209936,0.0006369683],"domain_scores_gemma":[0.9984499,0.00001827488,0.00013797494,0.0010098121,0.00017266542,0.00021132833],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030897427,0.00035550675,0.00037183618,0.00016293037,0.000050901777,0.00005408006,0.0005710934,0.00021237993,0.000050918006],"category_scores_gemma":[0.000017537493,0.00037417,0.00015982238,0.00043009283,0.000092843424,0.00001752463,0.000048004204,0.00025339084,0.000011236866],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045721955,0.0003318582,0.00006361346,0.000012745667,0.00008941854,0.00001996577,0.00011920695,0.0015767856,0.8512785,0.0000058999854,0.00005425232,0.14187558],"study_design_scores_gemma":[0.00088881585,0.0021836967,0.0014251494,0.000032892345,0.00001945918,0.0000033563626,0.00001852339,0.000144245,0.9802006,0.00008160974,0.014596553,0.00040509537],"about_ca_topic_score_codex":0.00013457303,"about_ca_topic_score_gemma":0.0003027688,"teacher_disagreement_score":0.14147048,"about_ca_system_score_codex":0.00011645527,"about_ca_system_score_gemma":0.0003073898,"threshold_uncertainty_score":0.999871},"labels":[],"label_agreement":null},{"id":"W2070026312","doi":"10.1158/1535-7163.targ-13-b181","title":"Abstract B181: TP53 mutation screening in patients with recurrent platinum-sensitive ovarian cancer.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Ovarian cancer; Missense mutation; Exon; Nonsense mutation; Mutation; Medicine; Cancer; Population; Genetics; Olaparib; Gene mutation; Cancer research; Molecular biology; Oncology; Biology; Internal medicine; Gene","score_opus":0.020973451297443265,"score_gpt":0.2818688197757348,"score_spread":0.26089536847829153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070026312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99255204,0.0013800322,0.00081928965,0.0027608408,0.00020211164,0.0014416781,0.000057278645,0.000044621032,0.00074210175],"genre_scores_gemma":[0.9955165,0.0002316411,0.0014110914,0.0020930555,0.00007598045,0.00048803995,0.00009568068,0.000059935584,0.000028113076],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984602,0.00003955052,0.0003008143,0.00040559005,0.00042392744,0.00036993466],"domain_scores_gemma":[0.9991558,0.000032080232,0.00016307572,0.00027925498,0.0002463239,0.00012342882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000060957278,0.00027651814,0.0003331539,0.00011821251,0.00006249242,0.00004872312,0.00006534075,0.00010293041,0.00031294706],"category_scores_gemma":[0.000004447709,0.00022352696,0.000075712145,0.0002887422,0.00005320251,0.00010148918,0.000019076215,0.00024806,0.000018179147],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077224924,0.00080724666,0.48946592,0.000086488915,0.0010854682,0.00016550143,0.0011049025,0.0014814788,0.0011710057,0.00012607097,0.00010801157,0.5036257],"study_design_scores_gemma":[0.0063517103,0.0004368039,0.98515266,0.0006161177,0.00028122417,0.0000026244022,0.00009732508,0.000635739,0.0052475864,0.00005505711,0.00084803934,0.0002751097],"about_ca_topic_score_codex":0.0025434382,"about_ca_topic_score_gemma":0.00035289626,"teacher_disagreement_score":0.50335056,"about_ca_system_score_codex":0.00039211407,"about_ca_system_score_gemma":0.00018416067,"threshold_uncertainty_score":0.91151655},"labels":[],"label_agreement":null},{"id":"W2072454789","doi":"10.1158/1535-7163.mct-08-0192","title":"Anticancer drugs affect the alternative splicing of <i>Bcl-x</i> and other human apoptotic genes","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Alternative splicing; RNA splicing; Biology; HeLa; Cell culture; Gene; Cancer cell; Apoptosis; Cell biology; Cancer research; Cancer; Gene isoform; Genetics","score_opus":0.022857436595253623,"score_gpt":0.2884122166424213,"score_spread":0.26555478004716765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072454789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827459,0.010844028,0.005473269,0.00018118288,0.00011089524,0.00023597389,0.000010754727,0.000007588834,0.00039041508],"genre_scores_gemma":[0.9950191,0.0031088998,0.00019816295,0.00118456,0.00013499196,0.000022879427,0.000007009089,0.000035221874,0.00028919958],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99918866,0.000065526605,0.00015674665,0.00024435847,0.0001710585,0.00017363459],"domain_scores_gemma":[0.9995028,0.000009410322,0.00010846824,0.0002859331,0.000060779606,0.00003260412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010841291,0.00015418905,0.00014629564,0.000026496165,0.00014492354,0.00001019078,0.00013754149,0.00008552726,0.0000120063105],"category_scores_gemma":[0.0000016780292,0.00011165078,0.00008230544,0.000075677126,0.00019860255,0.0000025953768,0.000059243062,0.000066968285,6.006662e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026782072,0.000024165292,0.00092154124,0.000017543258,0.00016134958,0.0000019393738,0.00045772488,0.0005080656,0.99153894,0.0005908257,0.000019336394,0.005731764],"study_design_scores_gemma":[0.00051174965,0.00014505198,0.0008605392,0.000024307019,0.000083987914,0.000014553328,0.00007610051,0.00047300608,0.98276925,0.00028548235,0.014582563,0.00017343389],"about_ca_topic_score_codex":0.0001558203,"about_ca_topic_score_gemma":0.000025014118,"teacher_disagreement_score":0.014563227,"about_ca_system_score_codex":0.000012809687,"about_ca_system_score_gemma":0.000035130186,"threshold_uncertainty_score":0.45529866},"labels":[],"label_agreement":null},{"id":"W2072767047","doi":"10.1158/1535-7163.targ-11-b49","title":"Abstract B49: GRN1005 phase I studies: Final results.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Angiochem (Canada)","funders":"","keywords":"Tolerability; Pharmacokinetics; Immunogenicity; Medicine; Glioma; Brain tumor; Pharmacology; Transcytosis; Paclitaxel; Cancer; Internal medicine; Cancer research; Oncology; Receptor; Antibody; Immunology; Adverse effect; Pathology; Endocytosis","score_opus":0.09631823802331448,"score_gpt":0.35380369026139524,"score_spread":0.2574854522380808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072767047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86579615,0.119509764,0.0020640418,0.00047273858,0.0037361574,0.0005620268,0.00030604601,0.00007871877,0.007474377],"genre_scores_gemma":[0.96803594,0.023717275,0.0011013001,0.0040296726,0.0015961177,0.0001302084,0.000098005774,0.00009377653,0.0011976875],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982359,0.000056159042,0.00039683914,0.00057861884,0.00024916613,0.00048334114],"domain_scores_gemma":[0.9987676,0.000009000914,0.00017958519,0.00069842365,0.00021173652,0.00013366842],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022875749,0.00033284858,0.00030460427,0.000060904007,0.000111323265,0.00002294454,0.00035230332,0.00020454482,0.00007252082],"category_scores_gemma":[0.000029407576,0.0003153681,0.00022280659,0.00014867295,0.00019064704,0.0000073161714,0.00010364579,0.00019072268,0.000020472977],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011626203,0.00033471244,0.000048996062,0.000044565917,0.0009192501,0.000016400758,0.0009994246,0.00003497661,0.90769756,0.0001752993,0.0043486618,0.08421755],"study_design_scores_gemma":[0.0029724673,0.00027246325,0.00037988668,0.000025910544,0.00016472147,0.0000079557885,0.00018542545,0.000009065628,0.4510123,0.00021391203,0.5443858,0.00037009537],"about_ca_topic_score_codex":0.00009190313,"about_ca_topic_score_gemma":0.000089313166,"teacher_disagreement_score":0.5400371,"about_ca_system_score_codex":0.000042256805,"about_ca_system_score_gemma":0.0002120893,"threshold_uncertainty_score":0.99992985},"labels":[],"label_agreement":null},{"id":"W2072861311","doi":"10.1158/1535-7163.targ-09-a122","title":"Abstract A122: The tyrosine kinase inhibitor MP470 inhibits RAD51-mediated homologous recombination and increases tumor cell radio- and chemosensitivity","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"RAD51; Clonogenic assay; Molecular biology; Cell cycle; Flow cytometry; DNA repair; Biology; Cancer research; Cell; DNA; Biochemistry","score_opus":0.008518994146340443,"score_gpt":0.23325091246906274,"score_spread":0.2247319183227223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072861311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987325,0.010818928,0.00023385952,0.00086262124,0.00011018945,0.0003921975,0.000042289645,0.00004032469,0.0001745677],"genre_scores_gemma":[0.9944033,0.0016014283,0.00029631803,0.0033823973,0.00010841697,0.000025265805,0.00007985877,0.00003938471,0.00006362839],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99867696,0.00012046166,0.0002246071,0.00047256265,0.00019126019,0.00031413973],"domain_scores_gemma":[0.99923915,0.000032052678,0.00014283022,0.0003708486,0.00010467293,0.00011044509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002598004,0.00028705373,0.0002246045,0.00004661386,0.000147699,0.00006662271,0.0001269355,0.00017875664,0.000006880784],"category_scores_gemma":[0.000041122337,0.00024225531,0.00006980618,0.00013134426,0.000153288,0.000010594926,0.000079773,0.00019093328,0.000001998156],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012716245,0.00014914342,0.00018274134,0.00002194388,0.000047237816,0.00004236468,0.000058562688,0.000009898793,0.9850029,0.000055329645,0.00007909665,0.014223667],"study_design_scores_gemma":[0.0012634032,0.00037149704,0.0072228154,0.00003209438,0.00008031177,0.000069689246,0.0000394354,0.00018815177,0.988097,0.00037256643,0.0019507627,0.00031228003],"about_ca_topic_score_codex":0.00006249131,"about_ca_topic_score_gemma":0.000024050574,"teacher_disagreement_score":0.013911386,"about_ca_system_score_codex":0.000039579994,"about_ca_system_score_gemma":0.000086692286,"threshold_uncertainty_score":0.98788846},"labels":[],"label_agreement":null},{"id":"W2073326558","doi":"10.1158/1535-7163.targ-11-b224","title":"Abstract B224: Structure-based drug design of signal transducers and activator of transcription 5 inhibitors.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada); University of Toronto","funders":"","keywords":"STAT5; STAT protein; Biology; SH2 domain; STAT3; Cancer research; Transcription factor; Chemistry; Cell biology; Signal transduction; Tyrosine kinase; Biochemistry; Gene","score_opus":0.048708493380333104,"score_gpt":0.2768567224036029,"score_spread":0.22814822902326976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073326558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752252,0.0011797999,0.02274475,0.00016373576,0.00012936186,0.00033692745,0.000066301254,0.000021150396,0.00013278222],"genre_scores_gemma":[0.9974246,0.00007906913,0.0021207626,0.00028809046,0.00003200379,0.000010728872,0.000008362903,0.000030832325,0.000005521601],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991434,0.00003895579,0.00029941203,0.00017262048,0.00020861354,0.00013698249],"domain_scores_gemma":[0.99948406,0.000025716561,0.00013966975,0.00016000344,0.0001255027,0.000065016655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000081072576,0.00015193278,0.0002692549,0.00011004412,0.000027490156,0.0000045787892,0.000055318804,0.00008007742,0.00040660257],"category_scores_gemma":[0.0000025642173,0.00013354153,0.00012336945,0.00012462898,0.00011367107,0.00005026329,0.000003029005,0.00016945413,3.2629458e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074811326,0.00014785887,0.0003640293,0.00016036247,0.0002191126,0.000005890688,0.0015340388,0.00030295874,0.9903248,0.00004571388,0.0000117315,0.006135411],"study_design_scores_gemma":[0.0011983879,0.000314685,0.00265314,0.0002036809,0.00031784555,0.0000045785737,0.00011439583,0.00054895,0.99410087,0.00012885015,0.00029789825,0.000116727424],"about_ca_topic_score_codex":0.0002358513,"about_ca_topic_score_gemma":0.000008453901,"teacher_disagreement_score":0.022199437,"about_ca_system_score_codex":0.000039761424,"about_ca_system_score_gemma":0.00017503247,"threshold_uncertainty_score":0.5445666},"labels":[],"label_agreement":null},{"id":"W2075821315","doi":"10.1158/1535-7163.targ-13-c284","title":"Abstract C284: IRE1 and PERK as targets of cellular adaptation and survival to hypoxia.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Social Innovation; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Unfolded protein response; ATF6; Hypoxia (environmental); Integrated stress response; XBP1; Gene knockdown; Endoplasmic reticulum; Cancer research; Biology; Cell biology; Signal transduction; Chemistry; Apoptosis; Translation (biology); Biochemistry; Gene; RNA splicing; Messenger RNA","score_opus":0.0179218119996761,"score_gpt":0.2571078537452758,"score_spread":0.23918604174559968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075821315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9613273,0.03344571,0.0035755304,0.0004848723,0.00044131055,0.00035227413,0.000018527911,0.000010025886,0.0003444414],"genre_scores_gemma":[0.99245656,0.0045866594,0.0011897478,0.0011464874,0.0002808874,0.00006463319,0.000023192186,0.000041514308,0.0002103379],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99894506,0.000043657168,0.00021467454,0.0003616747,0.0001903741,0.00024455652],"domain_scores_gemma":[0.9993282,0.000009552044,0.000088247005,0.00027908932,0.00015241312,0.00014250603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000111103356,0.00020369563,0.00022076226,0.00005116538,0.000062016756,0.000034982535,0.00011779277,0.00014370933,0.0000421318],"category_scores_gemma":[0.000014292693,0.0002024112,0.00006490819,0.00008430964,0.00010052046,0.000008207668,0.00007546131,0.00008238431,0.000006057952],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050690913,0.0000247037,0.00022821616,0.000038185066,0.00011310949,0.0000011741031,0.00034997507,0.00009295521,0.9516371,0.000107905966,0.00010345191,0.047252536],"study_design_scores_gemma":[0.00096553605,0.000257356,0.015344218,0.000028011777,0.00012151149,0.0000070218584,0.00033161984,0.0001700531,0.8365976,0.0006566805,0.14507729,0.0004430807],"about_ca_topic_score_codex":0.00073087396,"about_ca_topic_score_gemma":0.00009951836,"teacher_disagreement_score":0.14497383,"about_ca_system_score_codex":0.00001248697,"about_ca_system_score_gemma":0.00009335632,"threshold_uncertainty_score":0.82540894},"labels":[],"label_agreement":null},{"id":"W2077011774","doi":"10.1158/1535-7163.targ-11-a186","title":"Abstract A186: KIF14 is a novel therapeutic target for ovarian cancer.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research","funders":"","keywords":"Serous fluid; Carcinogenesis; Ovarian cancer; Cancer; Retinoblastoma; Oncogene; Tumor progression; Oncology; Biology; Cancer research; Internal medicine; Medicine; Cell cycle; Gene; Genetics","score_opus":0.05762617491862869,"score_gpt":0.2977113244404225,"score_spread":0.24008514952179377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077011774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66620195,0.06313247,0.2480861,0.003297319,0.0022872738,0.0040035993,0.002424232,0.0002286719,0.010338362],"genre_scores_gemma":[0.97966063,0.001127086,0.00667439,0.010570307,0.00039123851,0.00080661377,0.00008580353,0.00014170929,0.00054220995],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99820864,0.00003546347,0.0003201273,0.00061903836,0.00021583111,0.00060087483],"domain_scores_gemma":[0.99885964,0.000010410444,0.00017575105,0.00061367574,0.00019921346,0.00014130052],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000196446,0.00038410036,0.00027368375,0.000057346115,0.00015322355,0.000041675426,0.00045741227,0.00032098123,0.00044961626],"category_scores_gemma":[0.0000074252503,0.00037343532,0.00028747055,0.00013839657,0.00011450671,0.000007552324,0.00007660347,0.0001765102,0.000010838056],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003455298,0.00017470232,0.00080863765,0.000075080425,0.0006171937,0.0000032776877,0.00054605893,0.000026224543,0.97600436,0.0008215594,0.0002893624,0.020287996],"study_design_scores_gemma":[0.0012498751,0.0002873294,0.0012601729,0.000031440588,0.000120455865,0.0000046597934,0.000052548887,0.00013887673,0.8161307,0.0011669849,0.17908451,0.0004724386],"about_ca_topic_score_codex":0.0002361196,"about_ca_topic_score_gemma":0.000049786653,"teacher_disagreement_score":0.31345865,"about_ca_system_score_codex":0.000046735502,"about_ca_system_score_gemma":0.00029908755,"threshold_uncertainty_score":0.99987173},"labels":[],"label_agreement":null},{"id":"W2078578614","doi":"10.1158/1535-7163.targ-09-b168","title":"Abstract B168: ANG1005: Results of a phase I study in patients with advanced solid tumors and metastatic brain cancer","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Angiochem (Canada)","funders":"","keywords":"Medicine; Tolerability; Neutropenia; Cancer; Internal medicine; Adverse effect; Mucositis; Oncology; Brain metastasis; Metastatic breast cancer; Taxane; Breast cancer; Metastasis; Chemotherapy","score_opus":0.02621273335514649,"score_gpt":0.38129536866898156,"score_spread":0.35508263531383505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078578614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99423814,0.0030475387,0.000014932593,0.0011236534,0.000058783735,0.0012825913,0.00010284206,0.000018401584,0.00011314748],"genre_scores_gemma":[0.99721724,0.00025188216,0.00014455819,0.0021614302,0.000018727374,0.00009395704,0.00002977251,0.000026452024,0.000055987523],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99870867,0.000053188,0.00036899006,0.00032361152,0.00027252044,0.00027304844],"domain_scores_gemma":[0.99935776,0.000036761172,0.00018498657,0.00021989843,0.000108843094,0.00009175568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001048347,0.00022749456,0.00048568365,0.00013618711,0.000027791668,0.000008066865,0.00006684015,0.000036763864,0.000040265975],"category_scores_gemma":[0.0000058148667,0.00017980605,0.00004579001,0.0002868942,0.000065518034,0.000057406098,0.000011769617,0.00016269003,4.52703e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049404547,0.020215992,0.21346413,0.00023221869,0.0026416508,0.00076274684,0.008213085,0.001172461,0.13705987,0.000018371113,0.00016410284,0.5666508],"study_design_scores_gemma":[0.10695122,0.015039671,0.84472054,0.0003204831,0.001202067,0.000004288391,0.00033042702,0.00016004474,0.029549697,0.000066930115,0.001249994,0.00040463184],"about_ca_topic_score_codex":0.00025930384,"about_ca_topic_score_gemma":0.00025949438,"teacher_disagreement_score":0.6312564,"about_ca_system_score_codex":0.00014677935,"about_ca_system_score_gemma":0.00018613928,"threshold_uncertainty_score":0.7332278},"labels":[],"label_agreement":null},{"id":"W2079176280","doi":"10.1158/1535-7163.targ-11-a2","title":"Abstract A2: Development of a phenotypic profiling platform with high predictive value for the identification of novel antiangiogenic drugs.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Angiogenesis; High-content screening; Phenotypic screening; Drug discovery; In vivo; Drug development; Receptor tyrosine kinase; Pharmacology; Drug; Cancer research; Small molecule; Medicine; Computational biology; Chemistry; Biology; Receptor; Phenotype; Bioinformatics; Biochemistry; Cell; Genetics","score_opus":0.03656891870939759,"score_gpt":0.27520221290191177,"score_spread":0.23863329419251417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079176280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7633739,0.004683308,0.23109172,0.00001910008,0.00010702838,0.0005433843,0.00009716088,0.0000060093453,0.00007840107],"genre_scores_gemma":[0.9894521,0.00023023429,0.009860094,0.00010398642,0.00004996501,0.00019736671,0.000046579113,0.000035994974,0.000023651735],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990303,0.000008864376,0.00036389977,0.00024148496,0.00017668601,0.00017877831],"domain_scores_gemma":[0.99907076,0.00001217977,0.00033161935,0.00031742916,0.00024286819,0.000025154217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020973927,0.00015231344,0.00015278823,0.00003156624,0.00007653895,0.0000061685682,0.00023806006,0.000098525605,0.0000062415124],"category_scores_gemma":[0.000004008331,0.0001078959,0.00012098683,0.00010180754,0.00011353376,0.000005028845,0.00003695055,0.00004062595,2.4960133e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005556137,0.00012342527,0.0005891789,0.00007309059,0.00097455306,1.5244329e-7,0.00084028975,0.00082584145,0.9867254,0.00066668156,0.0000037993923,0.008621995],"study_design_scores_gemma":[0.00070987135,0.0001409967,0.006616142,0.00003571683,0.00021809933,7.9555923e-7,0.0002587267,0.00033793977,0.990718,0.00004811082,0.0007718319,0.00014376438],"about_ca_topic_score_codex":0.000042945,"about_ca_topic_score_gemma":0.000016693582,"teacher_disagreement_score":0.22607824,"about_ca_system_score_codex":0.000026713906,"about_ca_system_score_gemma":0.0002721472,"threshold_uncertainty_score":0.43998674},"labels":[],"label_agreement":null},{"id":"W2079525831","doi":"10.1158/1535-7163.targ-13-a260","title":"Abstract A260: BP-4-018, a novel inhibitor of STATs demonstrates anti-myeloma activity in preclinical models: Therapeutic implications of targeting aberrant STAT3 signaling in multiple myeloma.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Gene knockdown; STAT3; Cancer research; Small hairpin RNA; In vivo; Apoptosis; Cell culture; Biology; Molecular biology; Biochemistry; Genetics","score_opus":0.09090890726976292,"score_gpt":0.3443109252553725,"score_spread":0.2534020179856096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079525831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983576,0.0026432164,0.0117443,0.0007044844,0.00010442689,0.00094593863,0.00011314778,0.00003305914,0.00013539912],"genre_scores_gemma":[0.9966552,0.0003736496,0.0023377845,0.00033162092,0.000044703498,0.00016369807,0.000025371128,0.00006269886,0.0000052331475],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99764323,0.00008885099,0.0010513054,0.00044215468,0.000334428,0.00044002183],"domain_scores_gemma":[0.9983304,0.00033827542,0.00045646986,0.0004084835,0.0003589897,0.00010733892],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035029175,0.00029800727,0.0006737366,0.00028543695,0.000052828836,0.000024358465,0.00017908524,0.00019801292,0.00009549849],"category_scores_gemma":[0.00004839162,0.00027787036,0.00022432,0.0005155024,0.0001987567,0.00025538824,0.000045917754,0.00056799065,0.0000025702348],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019572981,0.0010431529,0.027166331,0.00017708515,0.00018946403,0.000005134352,0.0007345878,0.010525642,0.9406539,0.00010866123,0.0000043740747,0.019195892],"study_design_scores_gemma":[0.0024181495,0.00023399747,0.13151671,0.0006353929,0.00012556548,0.000006670847,0.00040356425,0.03953849,0.8238674,0.00082630577,0.00013100218,0.00029674245],"about_ca_topic_score_codex":0.0013743413,"about_ca_topic_score_gemma":0.00026986108,"teacher_disagreement_score":0.11678655,"about_ca_system_score_codex":0.00016131895,"about_ca_system_score_gemma":0.00038690507,"threshold_uncertainty_score":0.99996734},"labels":[],"label_agreement":null},{"id":"W2080020172","doi":"10.1158/1535-7163.targ-09-b236","title":"Abstract B236: A small molecule disrupts the BCL6 transcriptional repressor complex and kills lymphoma cells <i>in vitro</i> and <i>in vivo</i>","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"BCL6; Corepressor; Repressor; Chemistry; Small molecule; Cancer research; Psychological repression; Lymphoma; Biology; Cell biology; Germinal center; Stereochemistry; Biochemistry; Transcription factor; Genetics; B cell; Gene; Immunology; Antibody; Gene expression","score_opus":0.022255415707319235,"score_gpt":0.25882615254623875,"score_spread":0.23657073683891952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080020172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848687,0.011454296,0.0003867669,0.0014848177,0.000066495035,0.00048681887,0.00012987644,0.000013495729,0.0011087034],"genre_scores_gemma":[0.98935217,0.0021379928,0.00039218008,0.007849189,0.00006405922,0.000065238084,0.000030466188,0.00003198142,0.000076748984],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985276,0.000107470805,0.0002894661,0.0005099411,0.0001684605,0.00039705724],"domain_scores_gemma":[0.9994225,0.000019419786,0.000079887024,0.00035286127,0.0000375115,0.00008785334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002149601,0.00027644893,0.00022947884,0.000050984876,0.00008116418,0.000063454994,0.00021733344,0.00017474254,0.000018995865],"category_scores_gemma":[0.000005379398,0.00023685864,0.000086185886,0.00012398309,0.00014636425,0.000006528949,0.00004734373,0.00014420545,0.0000010366898],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003256038,0.00011721821,0.00015111404,0.000022225226,0.000037622096,0.000031844364,0.0001993892,0.00007912315,0.9853152,0.000085832435,0.000035494995,0.013599331],"study_design_scores_gemma":[0.0015951784,0.000108403045,0.008674565,0.00003527831,0.000029525789,0.00002334954,0.00004547523,0.00025839495,0.9698086,0.0003015719,0.01880478,0.00031489204],"about_ca_topic_score_codex":0.00007812415,"about_ca_topic_score_gemma":0.00009697928,"teacher_disagreement_score":0.018769285,"about_ca_system_score_codex":0.000027432117,"about_ca_system_score_gemma":0.00006816875,"threshold_uncertainty_score":0.96588147},"labels":[],"label_agreement":null},{"id":"W2080417833","doi":"10.1158/1535-7163.targ-11-c210","title":"Abstract C210: Microregional distribution and activity of camptothecins in tumor xenografts.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Photodynamic Therapy Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Spinal Cord Injury BC","funders":"","keywords":"Topotecan; Irinotecan; Camptothecin; Distribution (mathematics); Pharmacology; Topoisomerase; Medicine; Cancer research; Cancer; Chemistry; Pathology; Chemotherapy; Internal medicine; Enzyme; Biochemistry; Colorectal cancer","score_opus":0.04322675754856139,"score_gpt":0.32258226187078576,"score_spread":0.2793555043222244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080417833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99609834,0.0024185092,0.0003678088,0.0003565445,0.000044905453,0.0003276233,0.00008784855,0.000016090586,0.00028231984],"genre_scores_gemma":[0.99836403,0.0011181248,0.000085941705,0.00032656742,0.000018870005,0.000037295697,0.000010849268,0.00001989947,0.000018423341],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99911016,0.000036138492,0.00016805466,0.00020444789,0.00023009384,0.00025109877],"domain_scores_gemma":[0.99954635,0.000024981353,0.000079271456,0.00020260729,0.000082022285,0.00006475125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014480225,0.00014242188,0.00027993324,0.00007490983,0.000030034598,0.0000043484024,0.00007571017,0.0000598883,0.000048799466],"category_scores_gemma":[0.000008981673,0.00012285548,0.00006834042,0.00017765,0.0002510279,0.000037778675,0.00003900004,0.0002270761,9.090297e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012102484,0.00039786458,0.028409874,0.00013040904,0.00032765465,0.00009150487,0.0010056997,0.0000022005784,0.9512603,0.00012551805,0.000018101508,0.017020613],"study_design_scores_gemma":[0.0013391004,0.00018961183,0.57739794,0.00011153514,0.000046748642,0.00001649133,0.000059399994,0.00008082168,0.41936436,0.00025945684,0.0010145714,0.000119994],"about_ca_topic_score_codex":0.0009206991,"about_ca_topic_score_gemma":0.00021923575,"teacher_disagreement_score":0.54898804,"about_ca_system_score_codex":0.00010886473,"about_ca_system_score_gemma":0.00012117955,"threshold_uncertainty_score":0.5009901},"labels":[],"label_agreement":null},{"id":"W2080430705","doi":"10.1158/1535-7163.targ-11-b24","title":"Abstract B24: Detection of O6- and N7-methylguanine adducts by LC/MS in brain tumor tissues obtained from patients treated with temozolomide.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chemical Reactions and Isotopes","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; Université de Montréal; McGill University; Montreal Neurological Institute and Hospital","funders":"","keywords":"Temozolomide; O-6-methylguanine-DNA methyltransferase; Cancer; Medicine; Guanine; Cancer research; Regimen; Adduct; Radiation therapy; Methylation; DNA; Glioblastoma; Oncology; Chemistry; Internal medicine; Methyltransferase; Biochemistry; Gene","score_opus":0.051507694884336624,"score_gpt":0.35029806211871256,"score_spread":0.2987903672343759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080430705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99598724,0.0026920966,0.00007649689,0.00013555729,0.000096379415,0.000326555,0.00015314778,0.000033272416,0.0004992669],"genre_scores_gemma":[0.9981765,0.00047722211,0.00012178461,0.0010080526,0.000024390041,0.000045267047,0.000050398423,0.000033369466,0.000062979234],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989172,0.00011496137,0.00029251515,0.00029502262,0.00012274442,0.0002575371],"domain_scores_gemma":[0.9993649,0.00011580418,0.00016769521,0.0001565233,0.00009699045,0.00009809567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011338514,0.00021936622,0.0002824015,0.00007691457,0.000052698233,0.00000896593,0.00011524819,0.00018783846,0.00042249146],"category_scores_gemma":[0.000017877283,0.00018767036,0.000040342282,0.00020341839,0.00016099727,0.00007605057,0.000028037706,0.00036619412,0.0000043785426],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079663546,0.00040378555,0.047422927,0.000022732385,0.00026056173,0.000018030867,0.00051206985,0.000008252376,0.9154021,0.0000094247835,0.000063001055,0.03508045],"study_design_scores_gemma":[0.0022666568,0.0002805137,0.04417406,0.000028620465,0.00015370808,0.0000015261079,0.000061809136,0.00017251605,0.9367565,0.00013113089,0.015756024,0.00021696405],"about_ca_topic_score_codex":0.0016657854,"about_ca_topic_score_gemma":0.0002763493,"teacher_disagreement_score":0.034863487,"about_ca_system_score_codex":0.00007771242,"about_ca_system_score_gemma":0.000034711346,"threshold_uncertainty_score":0.76529753},"labels":[],"label_agreement":null},{"id":"W2082176717","doi":"10.1158/1535-7163.pms-pr01","title":"Abstract PR01: Functional characterization of breast cancer using pooled lentivirus shRNA screens","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced biosensing and bioanalysis techniques","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Small hairpin RNA; Synthetic lethality; Breast cancer; Cancer; Oncogene; Biology; Cancer research; Gene; Genetics; Computational biology; Cell cycle; Gene knockdown; DNA repair","score_opus":0.02258048701726297,"score_gpt":0.2837138328554489,"score_spread":0.2611333458381859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082176717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981473,0.0006293332,0.016945412,0.00034951893,0.000112052134,0.0002311146,0.00017162898,0.000028913451,0.00005899162],"genre_scores_gemma":[0.99687564,0.00077586155,0.000909745,0.0009270354,0.00018096222,0.00003138398,0.00015690547,0.00004107814,0.0001014048],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988676,0.000040541083,0.0002868073,0.00033500904,0.00022345419,0.0002465982],"domain_scores_gemma":[0.99903643,0.0000033124618,0.0002462979,0.00030396736,0.00035504423,0.000054931963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007008202,0.00021714182,0.00020736616,0.000070957685,0.00007438185,0.000030028368,0.00013061205,0.00017281987,0.00006592686],"category_scores_gemma":[0.0000028461322,0.000198191,0.00015319305,0.00017576398,0.000114077986,0.000013635923,0.00005533467,0.00009979811,0.0000020782663],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059005582,0.000066937304,0.0024421297,0.000017807644,0.00034203278,0.0000011150491,0.000008004808,0.000111747046,0.97774345,0.000010548486,0.000021167334,0.019176086],"study_design_scores_gemma":[0.00026047896,0.00003428532,0.04375993,0.00004850922,0.00016366235,0.000007388654,0.000012869519,0.0006466211,0.9537169,0.000041379004,0.0010621053,0.00024586983],"about_ca_topic_score_codex":0.0002608697,"about_ca_topic_score_gemma":0.000025137275,"teacher_disagreement_score":0.041317802,"about_ca_system_score_codex":0.000046048026,"about_ca_system_score_gemma":0.00010570572,"threshold_uncertainty_score":0.80819947},"labels":[],"label_agreement":null},{"id":"W2083169847","doi":"10.1158/1535-7163.targ-09-b98","title":"Abstract B98: Induction of metabolic and oxidative stresses by the novel inhibitor of NAD+ biosynthesis, GMX 1778, for specific killing of human glioblastomas","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Biochemical and Molecular Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Xenon Pharmaceuticals (Canada)","funders":"","keywords":"NAD+ kinase; Nicotinamide adenine dinucleotide; Biosynthesis; Cancer; Biochemistry; Nicotinamide; In vivo; Enzyme; Nicotinamide phosphoribosyltransferase; Cancer cell; Oxidative phosphorylation; In vitro; Biology; Cancer research; Chemistry; Genetics","score_opus":0.02997847592673606,"score_gpt":0.3086536899765374,"score_spread":0.27867521404980133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083169847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9703048,0.025636403,0.0032080507,0.00023994426,0.000037849422,0.00033445813,0.00017711059,0.00000352101,0.00005787499],"genre_scores_gemma":[0.99687195,0.002379479,0.0004571351,0.00011772906,0.000065555374,0.000021088583,0.000047075268,0.000022188675,0.000017794528],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99891055,0.00003712123,0.0003266969,0.00028422638,0.00023027767,0.00021111286],"domain_scores_gemma":[0.9991463,0.000023868977,0.00023421903,0.0003060308,0.00024194585,0.000047624046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015986738,0.00017742526,0.00025923637,0.000054329274,0.000056603232,0.000011171344,0.00022172286,0.0001695904,0.0000064856968],"category_scores_gemma":[0.000018645498,0.00013896154,0.00013762499,0.00014938576,0.00028678676,0.000005092824,0.00004894534,0.00011056177,8.4646956e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014467085,0.00018301453,0.00005743533,0.00006081978,0.00021337678,2.2961254e-7,0.00007013063,0.000012981822,0.9831756,0.0003796381,0.000056396653,0.015645746],"study_design_scores_gemma":[0.000549697,0.0003757977,0.00056876405,0.000053318083,0.00007255167,0.0000015459545,0.00010266667,0.000009434236,0.99037004,0.00016319258,0.007592769,0.00014025047],"about_ca_topic_score_codex":0.000051612187,"about_ca_topic_score_gemma":0.000008616342,"teacher_disagreement_score":0.026567167,"about_ca_system_score_codex":0.000007526855,"about_ca_system_score_gemma":0.000054334392,"threshold_uncertainty_score":0.5666687},"labels":[],"label_agreement":null},{"id":"W2086921761","doi":"10.1158/1535-7163.targ-11-a229","title":"Abstract A229: BRAF inhibitors upregulate EGFR ligands: A molecular link to RAF inhibitor-induced cutaneous squamous cell carcinomas.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Workplace Health, Safety and Compensation Commission","funders":"","keywords":"Vemurafenib; Cancer research; HRAS; Melanoma; Cancer; Downregulation and upregulation; Neuroblastoma RAS viral oncogene homolog; EGFR inhibitors; MAPK/ERK pathway; Skin cancer; Kinase; Cell growth; Medicine; Biology; KRAS; Epidermal growth factor receptor; Internal medicine; Colorectal cancer; Cell biology","score_opus":0.022563827664879663,"score_gpt":0.2431232919268744,"score_spread":0.22055946426199474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086921761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98827964,0.0040890216,0.001212588,0.00032806597,0.0011176076,0.00082730595,0.00006076605,0.00010106094,0.0039839153],"genre_scores_gemma":[0.9941236,0.00014144262,0.00076545286,0.0035524939,0.0006002013,0.00015497011,0.000076019314,0.00021794051,0.00036790082],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99672085,0.00008865357,0.0006328991,0.0011028461,0.00048820372,0.00096657337],"domain_scores_gemma":[0.99778175,0.000014368309,0.0002401902,0.001240522,0.00024391124,0.00047923482],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018285752,0.0007107483,0.000481238,0.00016798246,0.00016256764,0.00007830474,0.00067215814,0.00062304095,0.0000898922],"category_scores_gemma":[0.000020988675,0.0007312769,0.00039716056,0.00031925194,0.00009822765,0.000012230796,0.0002885122,0.00038554487,0.00007796019],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030835922,0.00018689568,0.0004599111,0.00007448352,0.00015330075,0.00052051165,0.00065948657,0.00015253409,0.9817195,0.000059352617,0.00028623422,0.015419422],"study_design_scores_gemma":[0.0012033675,0.0009484197,0.0009920975,0.000046164296,0.00016206331,0.00007356506,0.00007787283,0.000036748446,0.9779076,0.00012413076,0.017497353,0.00093060586],"about_ca_topic_score_codex":0.00031443,"about_ca_topic_score_gemma":0.00009012011,"teacher_disagreement_score":0.017211119,"about_ca_system_score_codex":0.00010775036,"about_ca_system_score_gemma":0.0003394953,"threshold_uncertainty_score":0.9995138},"labels":[],"label_agreement":null},{"id":"W2086966942","doi":"10.1158/1535-7163.mct-05-0339","title":"Combination therapy of androgen-independent prostate cancer using a prostate restricted replicative adenovirus and a replication-defective adenovirus encoding human endostatin-angiostatin fusion gene","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Prostate cancer; Angiostatin; Cancer research; Prostate; Adenoviridae; Genetic enhancement; Biology; Cancer; Medicine; Angiogenesis; Internal medicine; Gene","score_opus":0.03225362112432835,"score_gpt":0.3360878543704452,"score_spread":0.30383423324611686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086966942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791717,0.01763422,0.00075930596,0.00022919028,0.000050513117,0.0018014325,0.00023958497,0.00003608172,0.00007796563],"genre_scores_gemma":[0.9914428,0.0066170665,0.00049919734,0.00030780098,0.00007833677,0.0005327148,0.000262795,0.000117707044,0.00014160156],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99693537,0.00037950385,0.0006007717,0.0010207801,0.00054310734,0.00052047905],"domain_scores_gemma":[0.9977521,0.00003319993,0.00057982863,0.0008950542,0.00063658017,0.00010327371],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038276814,0.0004085317,0.0003660844,0.00021679698,0.00030328822,0.000065225875,0.00029855387,0.00021223622,0.000018922423],"category_scores_gemma":[0.000022912265,0.00041152874,0.00013332696,0.00055084843,0.00026555048,0.000020487398,0.00014466436,0.0002450037,8.842673e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002000272,0.00024108666,0.0075250803,0.000032147967,0.00034451945,0.000010883935,0.00060759694,0.00087837974,0.96845734,0.00009977037,0.000016927446,0.019786006],"study_design_scores_gemma":[0.0031185243,0.0019605074,0.0044987155,0.000054449945,0.00007460717,0.000013906515,0.00010311282,0.00065050105,0.98765385,0.00058899465,0.000852477,0.00043038014],"about_ca_topic_score_codex":0.001464451,"about_ca_topic_score_gemma":0.00032068213,"teacher_disagreement_score":0.019355625,"about_ca_system_score_codex":0.00020311387,"about_ca_system_score_gemma":0.00043028872,"threshold_uncertainty_score":0.99983364},"labels":[],"label_agreement":null},{"id":"W2087964934","doi":"10.1158/1535-7163.pms-b13","title":"Abstract B13: ATR and PARP inhibition enhances topoisomerase I-dependent DNA damage in colon cancer cell lines","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Cytotoxicity; RAD51; DNA damage; PARP inhibitor; Poly ADP ribose polymerase; DNA repair; Cancer cell; Topoisomerase; Cancer research; IC50; Chemistry; Cell culture; Synthetic lethality; Molecular biology; Cancer; DNA; Biology; Polymerase; Biochemistry; In vitro; Genetics","score_opus":0.022851423000106435,"score_gpt":0.3095930713613835,"score_spread":0.286741648361277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087964934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747129,0.01873179,0.00015968847,0.0037054385,0.00035342877,0.0010153641,0.000053518976,0.00007976305,0.0011880848],"genre_scores_gemma":[0.9796366,0.011718583,0.00023357105,0.0067318985,0.0002472821,0.00080492115,0.000032440075,0.00007493164,0.00051975204],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979614,0.000083113206,0.00050309324,0.00052919803,0.000445818,0.00047739546],"domain_scores_gemma":[0.99898875,0.000054486783,0.00020586759,0.00037641832,0.00019286027,0.00018164092],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016965832,0.00035853827,0.00043539668,0.0001311218,0.00008739048,0.000078474426,0.000106378866,0.00023901473,0.0019176579],"category_scores_gemma":[0.000005757569,0.00033936548,0.00010060038,0.0002553277,0.00015936527,0.00026382046,0.00004264676,0.0003910187,0.0000337587],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019177368,0.00022677821,0.0056471406,0.00019303373,0.000101639125,0.0000779435,0.0006742805,0.00011524987,0.97784555,0.000031154166,0.00032454336,0.0145709],"study_design_scores_gemma":[0.0038437133,0.00025023223,0.025624586,0.00041373217,0.00012127385,0.000012176724,0.00035938373,0.00025741657,0.9625249,0.00047703332,0.005665051,0.0004505364],"about_ca_topic_score_codex":0.002949623,"about_ca_topic_score_gemma":0.0017348609,"teacher_disagreement_score":0.019977445,"about_ca_system_score_codex":0.00047470792,"about_ca_system_score_gemma":0.00022066821,"threshold_uncertainty_score":0.9999058},"labels":[],"label_agreement":null},{"id":"W2088569000","doi":"10.1158/1535-7163.targ-11-b155","title":"Abstract B155: A phase I study of the MEK inhibitor GSK1120212 (GSK212) in combination with PI3K/mTOR inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Tolerability; Pharmacodynamics; Medicine; Pharmacokinetics; Dosing; Pharmacology; PI3K/AKT/mTOR pathway; Toxicity; Kinase; Adverse effect; Internal medicine; Oncology; Chemistry; Signal transduction","score_opus":0.012014701293701965,"score_gpt":0.25670900492023707,"score_spread":0.2446943036265351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088569000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99748194,0.0005844649,0.000117546,0.000055350087,0.00017781927,0.0013771408,0.00006088959,0.000008144707,0.00013668695],"genre_scores_gemma":[0.9990058,0.000080679754,0.00019163557,0.00034778644,0.000045056495,0.00019948692,0.000039784853,0.00007455562,0.00001519279],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99815464,0.000088436,0.00047087364,0.00051074335,0.00039651725,0.0003787872],"domain_scores_gemma":[0.99871606,0.000016859549,0.00033813197,0.00062033394,0.00023416559,0.0000744494],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015103101,0.0003377695,0.0003644794,0.00011422785,0.0000580285,0.000021719292,0.00033761183,0.00013017049,0.00001388969],"category_scores_gemma":[0.000019089688,0.00025536158,0.00007224771,0.00039205112,0.00013055891,0.000015218219,0.000115004856,0.0002359093,7.9697713e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012066277,0.01807668,0.5246233,0.00016671009,0.00069175794,0.0000891207,0.006169891,0.0027985175,0.41118646,0.00012468424,0.000057179703,0.023949433],"study_design_scores_gemma":[0.035698537,0.009427928,0.41251367,0.00034462358,0.00018089794,0.0000024034944,0.0012211422,0.000087927205,0.5387511,0.00008850446,0.00081167795,0.0008715488],"about_ca_topic_score_codex":0.0002782554,"about_ca_topic_score_gemma":0.0019820645,"teacher_disagreement_score":0.12756468,"about_ca_system_score_codex":0.00012356523,"about_ca_system_score_gemma":0.00028717465,"threshold_uncertainty_score":0.99998987},"labels":[],"label_agreement":null},{"id":"W2088621502","doi":"10.1158/1535-7163.targ-09-b204","title":"Abstract B204: Development of ALN-VSP: An RNAi therapeutic for liver malignancies","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arbutus Biopharma (Canada)","funders":"","keywords":"Cancer; Biology; Medicine; Cancer research; Virology; Genetics","score_opus":0.03685174826064542,"score_gpt":0.3027337702390711,"score_spread":0.2658820219784257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088621502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9609665,0.010248277,0.027815918,0.00016958216,0.00015027742,0.00034674528,0.000032209344,0.000017910937,0.00025254945],"genre_scores_gemma":[0.9925837,0.0007590232,0.0033102066,0.0029055618,0.00010330177,0.000053234067,0.00008072514,0.000032938202,0.00017130708],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987547,0.000028515877,0.00033146123,0.0003695727,0.0001826306,0.00033311063],"domain_scores_gemma":[0.9991383,0.0000067977803,0.00014456769,0.0004106596,0.0002288572,0.00007080827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001426382,0.00024475486,0.00021509672,0.000052972435,0.00008551993,0.000027341193,0.00034313122,0.00017640856,0.000028042325],"category_scores_gemma":[0.000003971052,0.00022982643,0.00015238157,0.00007480536,0.00006271265,0.000009202275,0.000028472052,0.000073973984,0.000003860306],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017308035,0.00012975838,0.00012254492,0.000024888293,0.00018023957,0.0000026301095,0.0002863287,0.00009184716,0.84974366,0.00011961311,0.00006238111,0.14906299],"study_design_scores_gemma":[0.0005136355,0.000567144,0.005622496,0.00003640857,0.0000651599,0.0000033464253,0.00008708891,0.00010086622,0.9534637,0.00031496608,0.038910795,0.0003144282],"about_ca_topic_score_codex":0.000012641283,"about_ca_topic_score_gemma":0.000041132414,"teacher_disagreement_score":0.14874856,"about_ca_system_score_codex":0.00002778728,"about_ca_system_score_gemma":0.00022692201,"threshold_uncertainty_score":0.93720496},"labels":[],"label_agreement":null},{"id":"W2088704835","doi":"10.1158/1535-7163.targ-13-a204","title":"Abstract A204: Flow cytometric assay of proteasome inhibition in whole blood.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Bortezomib; Proteasome; Whole blood; Proteasome inhibitor; Chemistry; Pharmacology; Molecular biology; Carfilzomib; Flow cytometry; Multiple myeloma; Biochemistry; Medicine; Biology; Immunology","score_opus":0.01841877815427692,"score_gpt":0.2624383344964026,"score_spread":0.24401955634212566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088704835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916584,0.0047327545,0.0013561016,0.00036342817,0.000085738306,0.0007588214,0.000055263168,0.000016324484,0.0009731634],"genre_scores_gemma":[0.9972665,0.0002931572,0.0010232184,0.0007023332,0.00008772101,0.00033686036,0.000079186306,0.000045593228,0.00016547856],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99862933,0.00009703335,0.00033781232,0.00034607592,0.00025087685,0.00033889784],"domain_scores_gemma":[0.9992204,0.00001202441,0.00015048866,0.00038551076,0.0001563773,0.00007524407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025262038,0.000215902,0.0002184845,0.00018164283,0.00003348068,0.000030355039,0.00015549075,0.0002355967,0.00014676352],"category_scores_gemma":[0.000029443123,0.00021375062,0.00012134052,0.00043140564,0.00007782995,0.000010119702,0.00007100769,0.00018306341,0.000027835105],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002834396,0.00016634914,0.001953198,0.00006931347,0.00008754503,0.000010304979,0.000059420585,0.00028201213,0.9798285,0.000026381775,0.0000678,0.017420882],"study_design_scores_gemma":[0.00089853717,0.00018888104,0.0062406575,0.00006418134,0.000031039872,0.000006809096,0.00002643229,0.00019201983,0.9862155,0.00037060547,0.0055056773,0.00025970896],"about_ca_topic_score_codex":0.0001453652,"about_ca_topic_score_gemma":0.000028051294,"teacher_disagreement_score":0.017161172,"about_ca_system_score_codex":0.000028740715,"about_ca_system_score_gemma":0.000113714115,"threshold_uncertainty_score":0.87164974},"labels":[],"label_agreement":null},{"id":"W2089316300","doi":"10.1158/1535-7163.mct-07-0568","title":"Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"National Cancer Institute; Howard Hughes Medical Institute","keywords":"Neuroblastoma; Cancer research; Erlotinib; Epidermal growth factor receptor; Tyrosine kinase; Vascular endothelial growth factor; Tumor progression; Vascular endothelial growth inhibitor; Receptor tyrosine kinase; Medicine; Biology; Receptor; Cancer; Vascular endothelial growth factor A; Internal medicine; Cell culture","score_opus":0.013555014707577764,"score_gpt":0.2639087834060725,"score_spread":0.25035376869849474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089316300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972077,0.0014668946,0.0001943609,0.0001507827,0.00014504585,0.0006292777,0.000036280417,0.000028781476,0.0001408475],"genre_scores_gemma":[0.99784034,0.00046384978,0.00045207035,0.001031177,0.000042915493,0.00003284437,0.000003697303,0.000060117465,0.00007298247],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983577,0.00010725957,0.00030315944,0.00032723352,0.00052945886,0.0003751612],"domain_scores_gemma":[0.99914,0.00009684494,0.00016842113,0.00030368983,0.00012017134,0.00017085568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006076567,0.00024668776,0.00044811412,0.00014997584,0.00006575277,0.0000054748193,0.00008590979,0.00003554286,0.000014667985],"category_scores_gemma":[0.000022067143,0.00020587546,0.00013632086,0.0001966157,0.00022979721,0.000030473333,0.00005707158,0.00020867334,0.0000066022626],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006957619,0.0005292929,0.0017742398,0.0004341671,0.00026437786,0.0036791952,0.00012157473,0.00004587994,0.9908089,0.000021844611,0.00003076298,0.0015940034],"study_design_scores_gemma":[0.002940987,0.002666842,0.008841672,0.00019799489,0.0001574078,0.00025669756,0.000010003851,0.0003072898,0.9840836,0.000021836882,0.00038232337,0.00013337149],"about_ca_topic_score_codex":0.00006151455,"about_ca_topic_score_gemma":0.0000013392973,"teacher_disagreement_score":0.0070674326,"about_ca_system_score_codex":0.000045719255,"about_ca_system_score_gemma":0.00013788982,"threshold_uncertainty_score":0.8395358},"labels":[],"label_agreement":null},{"id":"W2089842133","doi":"10.1158/1535-7163.targ-09-c49","title":"Abstract C49: Combination treatment with metronomic cyclophosphamide and the EGFR monoclonal antibody nimotuzumab is efficacious and non-toxic in a preclinical model of advanced triple negative breast cancer","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aptose Biosciences (Canada); Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Nimotuzumab; Medicine; Metastatic breast cancer; Panitumumab; Cetuximab; Triple-negative breast cancer; Cyclophosphamide; Breast cancer; Cancer; Bevacizumab; Docetaxel; Trastuzumab; Oncology; Combination therapy; Cancer research; Targeted therapy; Pharmacology; Monoclonal antibody; Chemotherapy; Epidermal growth factor receptor; Internal medicine; Immunology; Antibody; Colorectal cancer","score_opus":0.03126555443784302,"score_gpt":0.3740643119938047,"score_spread":0.3427987575559617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089842133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836489,0.008072258,0.0005971683,0.005842614,0.000036197187,0.0015383213,0.00010885808,0.000015535374,0.00014015903],"genre_scores_gemma":[0.9868608,0.011076447,0.00064711383,0.0010894393,0.0000246058,0.000190171,0.000008583743,0.000039176743,0.00006363666],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99827766,0.000080803744,0.00042788964,0.0004600347,0.00039555482,0.0003580541],"domain_scores_gemma":[0.99905515,0.00013275036,0.0001854758,0.0003530849,0.00014826017,0.00012529678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002331247,0.00028910162,0.0006336567,0.00012276255,0.000064876134,0.000025863294,0.00012320967,0.00012360259,0.000023089991],"category_scores_gemma":[0.000009602504,0.00019403102,0.00009206787,0.00027995513,0.00038930812,0.00006884074,0.000027755415,0.00032276622,6.0166815e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037246495,0.002333823,0.07436846,0.0003453919,0.00214738,0.00010093594,0.0088383565,0.016588291,0.13970788,0.00038319206,0.000021991538,0.7179178],"study_design_scores_gemma":[0.06135195,0.0031687936,0.7062993,0.00078626315,0.00076046266,0.000041083054,0.0003784693,0.13081264,0.09421481,0.0014696334,0.00014646791,0.0005701154],"about_ca_topic_score_codex":0.0009033838,"about_ca_topic_score_gemma":0.00022409909,"teacher_disagreement_score":0.7173477,"about_ca_system_score_codex":0.0006466905,"about_ca_system_score_gemma":0.00065123354,"threshold_uncertainty_score":0.7912355},"labels":[],"label_agreement":null},{"id":"W2090002637","doi":"10.1158/1535-7163.targ-09-b99","title":"Abstract B99: Dysregulation of HMGCR and the mevalonate pathway in human cancers","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Allergan (Canada); University Health Network; Ontario Institute for Cancer Research","funders":"","keywords":"Carcinogenesis; Biology; Mevalonate pathway; Cancer research; Ectopic expression; Cancer; Lovastatin; Statin; Cell biology; Genetics; Reductase; Gene; Enzyme; Endocrinology; Cholesterol; Biochemistry","score_opus":0.013108791716325365,"score_gpt":0.2746868128224779,"score_spread":0.2615780211061526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090002637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96898216,0.027276032,0.00044118194,0.00078789785,0.0009890345,0.00036430903,0.00002420298,0.00000919062,0.0011260055],"genre_scores_gemma":[0.99508756,0.0024104333,0.00006401667,0.00149846,0.0007470681,0.000028385757,0.000021838552,0.0000196613,0.00012258445],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999004,0.00006894489,0.00027064164,0.00026484323,0.0001733193,0.00021826605],"domain_scores_gemma":[0.9994283,0.000007371444,0.0001354207,0.000318634,0.00007026703,0.000040045736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025134606,0.0001672211,0.0002249047,0.000049132268,0.00005750954,0.000017534327,0.00016258184,0.00012145597,0.000011574654],"category_scores_gemma":[0.0000068513873,0.00013386033,0.00009440843,0.00011690926,0.00018627524,0.000004991747,0.000027488068,0.00011252047,2.5811408e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002477255,0.00002820299,0.0002981006,0.00001676255,0.00007428881,2.6707664e-7,0.00028960835,0.0009933413,0.95721716,0.002025198,0.00012865938,0.0386807],"study_design_scores_gemma":[0.0070216,0.00023340793,0.058440544,0.00008344438,0.00012247344,0.000006577942,0.00016198467,0.00033698892,0.69415647,0.0041273856,0.23476985,0.00053928845],"about_ca_topic_score_codex":0.00044049975,"about_ca_topic_score_gemma":0.00045427025,"teacher_disagreement_score":0.2630607,"about_ca_system_score_codex":0.00004059231,"about_ca_system_score_gemma":0.00013453845,"threshold_uncertainty_score":0.54586655},"labels":[],"label_agreement":null},{"id":"W2091036980","doi":"10.1158/1535-7163.targ-11-b72","title":"Abstract B72: Assessing specific biological mechanisms of drug resistance in adult and pediatric AML.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Clofarabine; Gemtuzumab ozogamicin; Azacitidine; Daunorubicin; Decitabine; DNA damage; Cancer research; Flow cytometry; Apoptosis; Cytarabine; Pharmacology; Myeloid leukemia; Medicine; Biology; Leukemia; Immunology; Stem cell; CD34; CD33; DNA; DNA methylation; Biochemistry; Cell biology","score_opus":0.05734255629292785,"score_gpt":0.3173960237299353,"score_spread":0.26005346743700747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091036980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98662263,0.0077389525,0.0025724526,0.00045035325,0.00007201601,0.00032137014,0.000007953669,0.000027328106,0.0021869144],"genre_scores_gemma":[0.9840544,0.0054759886,0.009688743,0.0005905656,0.000049802373,0.000025739586,0.0000046729688,0.00003338422,0.00007673915],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986414,0.000073124174,0.00032227207,0.0003303007,0.00030139525,0.000331512],"domain_scores_gemma":[0.99927783,0.0000503565,0.00011433192,0.0003075882,0.00015478156,0.00009509411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027713354,0.00017230988,0.00031981157,0.00017271435,0.000033171873,0.000014803864,0.00015022942,0.00014269682,0.000102672624],"category_scores_gemma":[0.000019785379,0.00014332232,0.00006437713,0.00036918014,0.00012917758,0.000054416916,0.000056217246,0.00038604124,0.0000042574256],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012560398,0.0005080802,0.06822191,0.00056553073,0.00021574825,0.0009827393,0.0028095914,0.0000035611483,0.8976497,0.010710649,0.0001721083,0.016904337],"study_design_scores_gemma":[0.0053449296,0.00023689975,0.50427556,0.00036365812,0.00020374669,0.000026535188,0.00094540865,0.00013684583,0.47212493,0.013969617,0.0017305284,0.00064132013],"about_ca_topic_score_codex":0.000107867934,"about_ca_topic_score_gemma":0.000044892335,"teacher_disagreement_score":0.43605366,"about_ca_system_score_codex":0.00017564256,"about_ca_system_score_gemma":0.00019498181,"threshold_uncertainty_score":0.58445144},"labels":[],"label_agreement":null},{"id":"W2091977946","doi":"10.1158/1535-7163.pms-a02","title":"Abstract A02: PARP inhibition selectively kills RNF20-depleted cells","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Homologous recombination; Biology; DNA repair; Genome instability; Cancer cell; Molecular biology; DNA damage; Chromosome instability; Cancer research; Chromosome; Cancer; Gene; Genetics; Cell biology; DNA","score_opus":0.02606190089490515,"score_gpt":0.2985627160633738,"score_spread":0.2725008151684687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091977946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9737964,0.0040146387,0.0054728333,0.0065159015,0.00066897005,0.0018540168,0.0000746418,0.00042275435,0.007179792],"genre_scores_gemma":[0.9766415,0.00097589946,0.0010570505,0.019937715,0.000299674,0.0005303785,0.000050809835,0.00014226709,0.00036470356],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976054,0.00008437966,0.0004965927,0.0005697859,0.00062073127,0.0006231189],"domain_scores_gemma":[0.9984323,0.00005423288,0.00022545626,0.00055702066,0.000484287,0.00024671433],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012579662,0.00041079553,0.00045182713,0.00018485225,0.00012792305,0.00008558648,0.00011269308,0.00027065678,0.0020906539],"category_scores_gemma":[0.000008421729,0.00039381417,0.00024348132,0.00052172,0.00016034255,0.00019129968,0.000031072574,0.00049637107,0.00046930453],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013863522,0.0002147307,0.0007096619,0.00007178476,0.00038962983,0.00006485296,0.00028071608,0.00008113712,0.97792,0.00014081378,0.0027020664,0.017285962],"study_design_scores_gemma":[0.003170112,0.00025444626,0.01097813,0.00024281435,0.00019328039,0.000044034554,0.000089138,0.0002504344,0.9515413,0.0020177606,0.030709343,0.00050918275],"about_ca_topic_score_codex":0.0003493073,"about_ca_topic_score_gemma":0.000017355545,"teacher_disagreement_score":0.028007276,"about_ca_system_score_codex":0.00052118197,"about_ca_system_score_gemma":0.00030294425,"threshold_uncertainty_score":0.99985135},"labels":[],"label_agreement":null},{"id":"W2094097070","doi":"10.1158/1535-7163.targ-13-b69","title":"Abstract B69: Dynamic reprogramming of signaling following Met inhibition reveals pathways for cell proliferation and negative feedback in gastric cancer.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Liver physiology and pathology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital; McGill University","funders":"","keywords":"PI3K/AKT/mTOR pathway; MAPK/ERK pathway; Receptor tyrosine kinase; Cancer; Protein kinase B; Cell growth; Reprogramming; Cancer research; Biology; Signal transduction; Cancer cell; Kinase; Cell biology; Cell; Genetics","score_opus":0.02710289600573308,"score_gpt":0.2968725744253503,"score_spread":0.26976967841961724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094097070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99434376,0.0026066601,0.0015207675,0.00020751634,0.00008048701,0.0011667822,0.000017067636,0.000016823959,0.000040143754],"genre_scores_gemma":[0.99501467,0.00022794414,0.0036314698,0.0005932945,0.000032198,0.00042336053,0.000034169556,0.00002422405,0.000018670986],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99903613,0.00006669841,0.000300459,0.00027161653,0.00009957022,0.00022554568],"domain_scores_gemma":[0.99945545,0.000075728836,0.00017159972,0.00013648377,0.00011913812,0.00004158774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019117966,0.00014232869,0.00030822647,0.00010348766,0.000048921727,0.000010630252,0.00003604433,0.00014022709,0.000015929209],"category_scores_gemma":[0.000015229359,0.00013260174,0.00008665355,0.00017789582,0.000055561253,0.00008279756,0.000015752368,0.00016529157,8.62058e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013476625,0.00007767441,0.011840079,0.00023122964,0.00009708313,0.000011695503,0.0011717782,0.00021742082,0.9613271,0.000023070364,0.000001830101,0.024866316],"study_design_scores_gemma":[0.004848035,0.0008864637,0.117559165,0.0006471335,0.00047496296,0.000010969502,0.0008389407,0.0028903987,0.86530495,0.006190973,0.000023067376,0.00032494793],"about_ca_topic_score_codex":0.00018322929,"about_ca_topic_score_gemma":0.000028302835,"teacher_disagreement_score":0.10571909,"about_ca_system_score_codex":0.000085581676,"about_ca_system_score_gemma":0.000095483665,"threshold_uncertainty_score":0.54073423},"labels":[],"label_agreement":null},{"id":"W2095005464","doi":"10.1158/1535-7163.targ-11-b83","title":"Abstract B83: Combination therapy with the histone deacetylase inhibitor panobinostat and the CD20-targeting antibody rituximab in diffuse large B-cell lymphoma.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Panobinostat; Cancer research; Diffuse large B-cell lymphoma; CD20; Rituximab; Lymphoma; Propidium iodide; Histone deacetylase inhibitor; Histone deacetylase; Medicine; Immunology; Chemistry; Programmed cell death; Histone; Apoptosis; Biochemistry","score_opus":0.012282811002304076,"score_gpt":0.25611898960161394,"score_spread":0.24383617859930987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095005464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982355,0.014086694,0.0014240049,0.0009504048,0.00011628175,0.0006392513,0.000016256272,0.00001784439,0.00039427128],"genre_scores_gemma":[0.99349666,0.0031858447,0.00013539514,0.0027719769,0.00006151329,0.00011559804,0.000066949666,0.000048485123,0.000117603486],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986365,0.00021366625,0.0002490852,0.00034896753,0.00022510214,0.00032670572],"domain_scores_gemma":[0.9992654,0.000024645222,0.00017796099,0.00038432173,0.00009619965,0.00005147887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045539113,0.00025724454,0.00019386687,0.000046534497,0.00020919305,0.000051926047,0.00024884607,0.00013244135,0.00001257446],"category_scores_gemma":[0.000011657919,0.00015258738,0.0000780706,0.00015520224,0.00030284323,0.000013973939,0.000071938644,0.00016153313,0.0000028237016],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017308072,0.003401934,0.0015577913,0.00003367459,0.00017694662,0.000021050066,0.0021508208,0.0000053371577,0.97839254,0.00090871233,0.0002559485,0.011364447],"study_design_scores_gemma":[0.03493358,0.00023683865,0.0028512147,0.000029325392,0.000044682485,0.0000063034154,0.00043209776,0.00017331472,0.9345767,0.00012723482,0.026233716,0.00035500457],"about_ca_topic_score_codex":0.00020968511,"about_ca_topic_score_gemma":0.00011183074,"teacher_disagreement_score":0.04381584,"about_ca_system_score_codex":0.000042423537,"about_ca_system_score_gemma":0.00009864916,"threshold_uncertainty_score":0.6222333},"labels":[],"label_agreement":null},{"id":"W2095303664","doi":"10.1158/1535-7163.targ-11-cn08-01","title":"Abstract CN08-01: Targeting the androgen receptor in castration-resistant prostate cancer.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Androgen receptor; Castration; Medicine; Androgen; Enzalutamide; Cancer; Internal medicine; Oncology; Biology; Hormone","score_opus":0.05933011130010995,"score_gpt":0.3317127302610393,"score_spread":0.27238261896092936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095303664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9618256,0.031418316,0.000016978833,0.003309989,0.0002345224,0.001161421,0.000073157935,0.000049376704,0.001910656],"genre_scores_gemma":[0.9912549,0.0063707484,0.0002726327,0.0009963149,0.00009651058,0.00042786932,0.000038594848,0.000055153952,0.00048722673],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983884,0.00006471144,0.000323234,0.0003310395,0.00038905954,0.0005035691],"domain_scores_gemma":[0.9993095,0.00002405446,0.000105691644,0.00031468316,0.00013490827,0.000111159505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025774902,0.00022800955,0.00024717487,0.00008244064,0.00013338117,0.000035329333,0.00016982754,0.00009714787,0.0005934683],"category_scores_gemma":[0.000007962445,0.00014980778,0.00010245212,0.0003563769,0.00014231281,0.000072185336,0.000034943605,0.00035417874,0.000018383615],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024591293,0.00035051804,0.049493566,0.00020194094,0.00069576025,0.00039545685,0.008086194,0.00010181569,0.9019586,0.00014307497,0.00038575663,0.035728198],"study_design_scores_gemma":[0.0052689207,0.00048763634,0.07056845,0.00047718213,0.00031649502,0.000011208471,0.0018257799,0.00023087717,0.8855568,0.00046568245,0.034240674,0.0005502677],"about_ca_topic_score_codex":0.0018861447,"about_ca_topic_score_gemma":0.00052374887,"teacher_disagreement_score":0.03517793,"about_ca_system_score_codex":0.00033927325,"about_ca_system_score_gemma":0.0005328075,"threshold_uncertainty_score":0.6498062},"labels":[],"label_agreement":null},{"id":"W2095681827","doi":"10.1158/1535-7163.mct-06-0745","title":"Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Lovastatin; Apoptosis; Multiple myeloma; Cancer research; Medicine; Pharmacology; Cancer; Biology; Immunology; Internal medicine; Genetics; Cholesterol","score_opus":0.024275630030600362,"score_gpt":0.3001197825491058,"score_spread":0.27584415251850547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095681827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887022,0.0015340352,0.007396423,0.00006796218,0.001807992,0.00030804408,0.00003717515,0.000009194826,0.00013697908],"genre_scores_gemma":[0.99629474,0.00032702443,0.0010348092,0.0012946912,0.00091445964,0.000024492243,0.000010592115,0.000043919255,0.000055299955],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985662,0.00007971798,0.0003455431,0.0003765316,0.00020949393,0.00042247976],"domain_scores_gemma":[0.99921846,0.000023344313,0.00011215242,0.00041213652,0.0001230912,0.00011082945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004074492,0.00021148732,0.0002919658,0.00011497273,0.00003385468,0.000010504394,0.00014262697,0.00016167447,0.0000061207147],"category_scores_gemma":[0.00003780472,0.00022508536,0.00012138884,0.00025791855,0.000052198924,0.000004847766,0.00008317344,0.000114023926,0.0000028758218],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024917754,0.00006735388,0.019826759,0.000025060723,0.000039323004,0.0000011742892,0.0002112193,0.00012682138,0.88010347,0.000008364976,0.00005884033,0.09928242],"study_design_scores_gemma":[0.0007990107,0.00012715923,0.035417512,0.000030331823,0.000031513362,0.000004424252,0.000089607,0.0000719357,0.91119653,0.000011910309,0.051967468,0.0002525723],"about_ca_topic_score_codex":0.00045682568,"about_ca_topic_score_gemma":0.004083985,"teacher_disagreement_score":0.09902985,"about_ca_system_score_codex":0.000043895707,"about_ca_system_score_gemma":0.00013158236,"threshold_uncertainty_score":0.9178715},"labels":[],"label_agreement":null},{"id":"W2096108152","doi":"10.1158/1535-7163.mct-06-0412","title":"Chemosensitization of carcinoma cells using epithelial cell adhesion molecule–targeted liposomal antisense against bcl-2/bcl-xL","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"University of Alberta","keywords":"Epithelial cell adhesion molecule; Liposome; Endocytosis; Cancer cell; Cancer research; Targeted drug delivery; Drug delivery; Apoptosis; Molecular biology; Targeted therapy; Chemistry; Cancer; Biology; Cell adhesion molecule; Cell; Cell biology; Biochemistry","score_opus":0.012632925320697617,"score_gpt":0.23953368345086448,"score_spread":0.22690075813016686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096108152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893616,0.004564103,0.005017754,0.000049770828,0.0003126373,0.00026342884,0.000095491036,0.000019469422,0.0003157417],"genre_scores_gemma":[0.99696714,0.0007383601,0.0007840929,0.0007443357,0.00025298732,0.0000087889775,0.00021448846,0.00007663365,0.0002131902],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99827236,0.00011866098,0.00043093314,0.0004930405,0.00028824175,0.0003967727],"domain_scores_gemma":[0.9988749,0.0000069281764,0.00025564973,0.000495473,0.00029956974,0.000067456254],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008439276,0.00033101565,0.00028873127,0.00009215535,0.000088807115,0.00003087674,0.00022550326,0.00028947843,0.000009324241],"category_scores_gemma":[0.0000036471558,0.00034675698,0.00022445677,0.00019997108,0.00011044289,0.000008661343,0.00009343718,0.00012372082,0.0000060886186],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015880146,0.0002747808,0.00072573515,0.00004846528,0.000073862255,0.000037263166,0.000052477484,0.0027453264,0.9946381,0.00000962537,0.00007372741,0.0011618461],"study_design_scores_gemma":[0.0015660692,0.00021981412,0.0004490162,0.000038394766,0.00012227856,0.000008043576,0.0000412817,0.0026556347,0.9931776,0.000026924901,0.0013023188,0.0003926278],"about_ca_topic_score_codex":0.00024392022,"about_ca_topic_score_gemma":0.000029573108,"teacher_disagreement_score":0.007605519,"about_ca_system_score_codex":0.000050022725,"about_ca_system_score_gemma":0.00015716227,"threshold_uncertainty_score":0.99989843},"labels":[],"label_agreement":null},{"id":"W2096687091","doi":"10.1158/1535-7163.mct-10-0550","title":"Inhibition of Constitutive Activation of STAT3 by Curcurbitacin-I (JSI-124) Sensitized Human B-Leukemia Cells to Apoptosis","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"University of Manitoba; McGill University","keywords":"XIAP; Apoptosis; Gene knockdown; STAT3; Leukemia; Cancer research; Phosphorylation; Chronic lymphocytic leukemia; Cell cycle; Inhibitor of apoptosis; Molecular biology; Chemistry; Programmed cell death; Biology; Cell biology; Immunology; Caspase; Biochemistry","score_opus":0.009510150858963132,"score_gpt":0.26234797743980504,"score_spread":0.2528378265808419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096687091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9674136,0.0001356787,0.031378772,0.000072110626,0.00018926502,0.00034054814,0.000103805316,0.000009206901,0.00035702923],"genre_scores_gemma":[0.9978842,0.000081618025,0.001221122,0.000409935,0.000046147718,0.00002179405,0.0001985648,0.000027703745,0.000108891036],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990259,0.00004609792,0.0002829907,0.00027394004,0.00019774906,0.00017334707],"domain_scores_gemma":[0.99917644,0.000007394987,0.00020129608,0.00030120107,0.0002513125,0.00006237754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011164618,0.0001682529,0.00019883533,0.00006561011,0.000057644873,0.000010230511,0.000083256564,0.00020725522,0.000025106536],"category_scores_gemma":[0.000006489343,0.00016970227,0.00008419221,0.00013846147,0.00011549765,0.0000058075934,0.00004573778,0.00011232273,0.0000011040087],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007277593,0.000055924145,0.00003595663,0.000029853307,0.00009950302,3.8483813e-7,0.0001351766,0.00043472167,0.995137,0.0007402771,0.00012968188,0.0031287821],"study_design_scores_gemma":[0.00067410123,0.00024301921,0.00006976937,0.000031285534,0.00006388255,7.1257824e-7,0.00005294651,0.000093608855,0.993485,0.00023101235,0.004867871,0.00018683508],"about_ca_topic_score_codex":0.00012126583,"about_ca_topic_score_gemma":0.000023210254,"teacher_disagreement_score":0.030470641,"about_ca_system_score_codex":0.00003626545,"about_ca_system_score_gemma":0.00011745007,"threshold_uncertainty_score":0.6920258},"labels":[],"label_agreement":null},{"id":"W2096717481","doi":"10.1158/1535-7163.targ-09-b174","title":"Abstract B174: The effect of histone deacetylase inhibition on BRCA1 expression: A potential novel mechanism for enhancing platinum sensitivity in breast and ovarian cancer","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Ovarian cancer; Cisplatin; Cancer research; Breast cancer; Histone deacetylase inhibitor; Histone deacetylase; MTT assay; Flow cytometry; Biology; Western blot; Viability assay; Molecular biology; Cell culture; Cancer; Histone; Chemotherapy; DNA; Biochemistry; Gene","score_opus":0.010002712533497824,"score_gpt":0.2929313654018364,"score_spread":0.28292865286833857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096717481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9609647,0.0010368585,0.035632305,0.0014187897,0.00018632029,0.0005621537,0.00015686352,0.000009391684,0.000032642176],"genre_scores_gemma":[0.9975747,0.00016206242,0.0005614957,0.0013060072,0.00015348656,0.00015693654,0.00003732391,0.000032235464,0.000015788497],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988654,0.00007459914,0.00025066658,0.00038007722,0.00018505471,0.0002441658],"domain_scores_gemma":[0.9993644,0.000034315002,0.00016376722,0.00029602073,0.00009978414,0.000041746356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030649503,0.00022355602,0.0002117771,0.00005560124,0.00010134797,0.000020727026,0.000080122336,0.00018177537,0.000006875302],"category_scores_gemma":[0.000013528671,0.00018417118,0.000099046025,0.000102419115,0.00007110824,0.0000069659377,0.000032797445,0.00015123925,2.2960958e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058093236,0.0000553948,0.00007132366,0.0000393928,0.00006595499,0.0000058384126,0.00012026274,0.0035258704,0.983217,0.0001327632,0.000021587362,0.012163655],"study_design_scores_gemma":[0.0020564378,0.00028070138,0.004839935,0.00013431483,0.00007894664,0.000024618237,0.000031409418,0.0008052782,0.99122286,0.0002117097,0.000110132634,0.00020364078],"about_ca_topic_score_codex":0.00012552508,"about_ca_topic_score_gemma":0.0002633499,"teacher_disagreement_score":0.03660999,"about_ca_system_score_codex":0.00013823377,"about_ca_system_score_gemma":0.00013486041,"threshold_uncertainty_score":0.7510283},"labels":[],"label_agreement":null},{"id":"W2097382536","doi":"10.1158/1535-7163.mct-10-0850","title":"Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression <i>In vivo</i>","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Deutsche Forschungsgemeinschaft","keywords":"Gene knockdown; LNCaP; Transactivation; Cancer research; Androgen receptor; Prostate cancer; STAT5; Androgen deprivation therapy; DU145; STAT protein; Biology; Transcription factor; Medicine; Apoptosis; Internal medicine; Cancer; Signal transduction; STAT3; Cell biology","score_opus":0.052477183403012474,"score_gpt":0.33209017566095417,"score_spread":0.2796129922579417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097382536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.975067,0.021864958,0.00021972557,0.0008205742,0.00016383342,0.0013218978,0.0002045295,0.00005104401,0.00028640535],"genre_scores_gemma":[0.98013747,0.017335014,0.0009266429,0.0003185533,0.000043888555,0.00056450034,0.00006192876,0.000048725033,0.000563273],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99837255,0.00008569308,0.00031455734,0.00042177047,0.00039405472,0.00041136568],"domain_scores_gemma":[0.9993767,0.000012064197,0.00010611892,0.0001963426,0.00016067427,0.00014810877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011202988,0.00025705202,0.00027684684,0.00013607065,0.00010746829,0.000041411902,0.000075353,0.00012436941,0.00033584566],"category_scores_gemma":[0.0000029920466,0.0002004268,0.00006619685,0.00028607534,0.00012932687,0.00017923431,0.00001610957,0.00020472228,0.0000029212279],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00178858,0.00015735606,0.014703043,0.00016002671,0.0001909399,0.00004763159,0.003854341,0.00000315999,0.91090673,0.00003970504,0.000029739707,0.06811874],"study_design_scores_gemma":[0.0028724582,0.0006519917,0.007127334,0.0003598887,0.0001616163,0.000006140493,0.00034637295,0.00016059662,0.98269963,0.00011022817,0.0052435347,0.00026020058],"about_ca_topic_score_codex":0.00062595383,"about_ca_topic_score_gemma":0.0006582588,"teacher_disagreement_score":0.0717929,"about_ca_system_score_codex":0.00028069608,"about_ca_system_score_gemma":0.00034653314,"threshold_uncertainty_score":0.8173168},"labels":[],"label_agreement":null},{"id":"W2098247131","doi":"10.1158/1535-7163.mct-06-0452","title":"The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression <i>in vitro</i> and <i>in vivo</i>","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Tamoxifen; Cancer research; Estrogen receptor; Pharmacology; Cell growth; Farnesyltransferase inhibitor; Farnesyltransferase; Cell cycle; Cell cycle checkpoint; Cancer; Biology; Breast cancer; Medicine; Internal medicine; Prenylation; Biochemistry","score_opus":0.0036046031280118794,"score_gpt":0.23732967330418847,"score_spread":0.23372507017617658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098247131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99028546,0.006945788,0.00079414697,0.00073848123,0.00007001324,0.0009070679,0.000020934045,0.000010807546,0.00022731345],"genre_scores_gemma":[0.9961475,0.002475773,0.00020641576,0.0008611756,0.000046584693,0.00015764762,0.000018204995,0.000046985548,0.000039695828],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984664,0.00011927432,0.00029914393,0.00045048934,0.00022431584,0.00044037987],"domain_scores_gemma":[0.9995002,0.000030042122,0.00007003637,0.0001940559,0.000076236865,0.00012939336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036201373,0.00026144684,0.00019103193,0.000076966455,0.00009575639,0.00006525389,0.0001072051,0.00024135748,0.000001511732],"category_scores_gemma":[0.000005296778,0.00019679593,0.000029613393,0.00026464526,0.000104294355,0.000015222343,0.00005058736,0.00025628935,4.0939224e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019577297,0.00023069889,0.0048488546,0.000050965802,0.000019087654,0.0000405484,0.00026408597,0.00045312976,0.979845,0.000023395181,0.000007223068,0.012259321],"study_design_scores_gemma":[0.00272816,0.00034617737,0.0027586217,0.0001227372,0.000029895264,0.000014819734,0.0000862448,0.00059098215,0.99192697,0.000026087175,0.0010751573,0.00029416804],"about_ca_topic_score_codex":0.00016633327,"about_ca_topic_score_gemma":0.0014063941,"teacher_disagreement_score":0.01208199,"about_ca_system_score_codex":0.00009632555,"about_ca_system_score_gemma":0.00011603957,"threshold_uncertainty_score":0.8025105},"labels":[],"label_agreement":null},{"id":"W2098409094","doi":"10.1158/1535-7163.mct-14-0771","title":"Targeting Integrin-Linked Kinase Suppresses Invasion and Metastasis through Downregulation of Epithelial-to-Mesenchymal Transition in Renal Cell Carcinoma","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"U.S. Public Health Service","keywords":"Integrin-linked kinase; Cancer research; Vimentin; Metastasis; Epithelial–mesenchymal transition; Gene knockdown; Cell migration; Tumor progression; Biology; Downregulation and upregulation; MMP2; Cancer; Kinase; Cell; Cell culture; Protein kinase A; Cell biology; Immunology; Immunohistochemistry; Cyclin-dependent kinase 2","score_opus":0.04722484246943109,"score_gpt":0.29763041294676496,"score_spread":0.25040557047733386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098409094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778915,0.0075222817,0.012372105,0.0012514319,0.00011566812,0.00054762233,0.00006715108,0.00001776511,0.0002144417],"genre_scores_gemma":[0.99108964,0.0006317696,0.0071550263,0.000887929,0.00007158156,0.00004297039,0.000053901054,0.000036740093,0.000030416471],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985256,0.00012284439,0.00039188642,0.00033340717,0.00036668679,0.0002595466],"domain_scores_gemma":[0.99926054,0.000027322845,0.00011549049,0.00024446912,0.00020967764,0.00014252128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029526808,0.00021067451,0.0004087436,0.00015696687,0.00002852998,0.000016368213,0.000072926705,0.00010243837,0.0000366953],"category_scores_gemma":[0.000017819804,0.0001880387,0.00009143115,0.0003821762,0.00007013344,0.00009774523,0.00003762681,0.0001799797,0.0000016155569],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007675641,0.00014615878,0.0008601931,0.00020096783,0.00006307643,0.00004666075,0.0047892905,0.0030498125,0.9745488,0.00006174575,0.000050556435,0.01541514],"study_design_scores_gemma":[0.0033258754,0.00048023646,0.0032419702,0.00016106057,0.0004256454,0.000011159645,0.00083484035,0.0009635509,0.9840634,0.00025450627,0.00600833,0.00022941302],"about_ca_topic_score_codex":0.0013444566,"about_ca_topic_score_gemma":0.00010316031,"teacher_disagreement_score":0.015185727,"about_ca_system_score_codex":0.00014252993,"about_ca_system_score_gemma":0.00021754148,"threshold_uncertainty_score":0.7667995},"labels":[],"label_agreement":null},{"id":"W2098853281","doi":"10.1158/1535-7163.mct-05-0200","title":"Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells <i>in vitro</i>","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute","keywords":"Cidofovir; In vitro; Cervical cancer; Cancer; Cancer research; Pharmacology; Chemistry; Medicine; Biology; Virology; Genetics; Virus","score_opus":0.008883492898231387,"score_gpt":0.2705525696305286,"score_spread":0.2616690767322972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098853281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98409486,0.00990477,0.0035130184,0.00026928162,0.00029162847,0.0012008202,0.00004831364,0.000031927306,0.00064538984],"genre_scores_gemma":[0.997488,0.00055516383,0.00042711172,0.001074344,0.000066759596,0.00021054655,0.0000268485,0.0000941613,0.000057040972],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997465,0.00016517473,0.00078433345,0.00051501975,0.00054054393,0.00052992045],"domain_scores_gemma":[0.9988602,0.00006133842,0.00030975832,0.00051277736,0.000170034,0.00008593054],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001449849,0.00037659638,0.0008979539,0.00034885673,0.000027034128,0.0000092202745,0.00020425323,0.00029111124,0.000029533183],"category_scores_gemma":[0.000007170819,0.0003845734,0.00024107768,0.00080288737,0.00022110548,0.00005157163,0.00005753014,0.00046727288,0.0000016233588],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006573494,0.0005233141,0.0016281889,0.0005935783,0.00019499294,0.00015204276,0.00054348406,0.002874009,0.98860925,0.00011594046,0.000015342512,0.0040924926],"study_design_scores_gemma":[0.0059344997,0.00032088955,0.004753174,0.0007779879,0.00025529024,0.0000037221448,0.000036448087,0.00049434317,0.9866675,0.00013726915,0.00030552008,0.0003133468],"about_ca_topic_score_codex":0.0026952415,"about_ca_topic_score_gemma":0.0007455992,"teacher_disagreement_score":0.013393173,"about_ca_system_score_codex":0.00042713856,"about_ca_system_score_gemma":0.00035653004,"threshold_uncertainty_score":0.99986064},"labels":[],"label_agreement":null},{"id":"W2098999466","doi":"10.1158/1535-7163.mct-05-0178","title":"Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both<i>in vitro</i>and<i>in vivo</i>","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Clusterin; Gene knockdown; Paclitaxel; Cancer research; In vivo; Biology; Apoptosis; SKBR3; Small interfering RNA; Breast cancer; Cell culture; Cancer; Transfection; Biochemistry","score_opus":0.013911167559450929,"score_gpt":0.2822270790386065,"score_spread":0.26831591147915557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098999466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98921007,0.0025911857,0.00010185224,0.0064160516,0.00014974017,0.00083381846,0.00018188442,0.000026096268,0.0004893138],"genre_scores_gemma":[0.99308586,0.0005139194,0.00018430925,0.0056222198,0.00012534678,0.00018685397,0.0000013715512,0.000060736915,0.00021940317],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99837446,0.00012758,0.00039278957,0.00041753013,0.00027490058,0.00041273152],"domain_scores_gemma":[0.99916226,0.000029619778,0.00014577963,0.00049917056,0.00008072916,0.000082459046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013559725,0.0002718603,0.00046269794,0.00011434071,0.0000505535,0.000009281356,0.00017683403,0.00015624274,0.00014006393],"category_scores_gemma":[0.000004115949,0.00020654302,0.00012914075,0.0002702452,0.00030621383,0.000041138843,0.00016865262,0.00028044177,0.000001999132],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071320613,0.0001439354,0.002678505,0.00010220533,0.000079612444,0.00004609713,0.0005874917,0.00019308655,0.983651,0.000017357728,0.0000138686755,0.011773651],"study_design_scores_gemma":[0.003119336,0.000047939215,0.035629515,0.00031837408,0.00013232444,0.00008589551,0.000065145454,0.0005220392,0.95818657,0.00007341757,0.0015805553,0.00023887199],"about_ca_topic_score_codex":0.000354,"about_ca_topic_score_gemma":0.00059223676,"teacher_disagreement_score":0.03295101,"about_ca_system_score_codex":0.00036717442,"about_ca_system_score_gemma":0.00013626575,"threshold_uncertainty_score":0.842258},"labels":[],"label_agreement":null},{"id":"W2099228074","doi":"10.1158/1535-7163.mct-06-0154","title":"Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Blood Coagulation and Thrombosis Mechanisms","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Immunovaccine (Canada); McMaster University Medical Centre","funders":"","keywords":"Thrombomodulin; Protein C; Endothelial protein C receptor; Doxorubicin; Endothelial stem cell; Pharmacology; Endothelium; Umbilical vein; Cancer research; Chemistry; Biology; Immunology; Medicine; Thrombin; Chemotherapy; Biochemistry; Endocrinology; Internal medicine; In vitro; Platelet","score_opus":0.02114866477243443,"score_gpt":0.26014676708645423,"score_spread":0.2389981023140198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099228074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98504627,0.0018500412,0.0017060757,0.008280574,0.00024870582,0.0018237699,0.000005043263,0.00005101489,0.0009885145],"genre_scores_gemma":[0.98923194,0.000041330128,0.000100830046,0.009847534,0.00007668957,0.00012183261,0.0000021606663,0.000050189778,0.00052747404],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985612,0.00015625075,0.00026659935,0.00023188247,0.00052355486,0.00026049165],"domain_scores_gemma":[0.99907684,0.000052829608,0.00016331716,0.0005866214,0.00008303751,0.000037364538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014913702,0.00022150946,0.00028454364,0.000044489967,0.00010923252,0.000018307655,0.00021716421,0.000103578015,0.000052072548],"category_scores_gemma":[0.000007350711,0.00011816097,0.00022366305,0.000301267,0.0001155475,0.000013208096,0.000037332207,0.00022448877,0.000009906064],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054552176,0.0003105075,0.00021605538,0.000097410055,0.0002050596,0.0000067079905,0.0001003806,0.000045970595,0.9708544,0.02427446,0.000024897028,0.0038096195],"study_design_scores_gemma":[0.0011767374,0.00018643313,0.008543003,0.000300234,0.00027806722,0.00000479935,0.000017963615,0.00037968828,0.98211896,0.0026196889,0.0042402856,0.00013415817],"about_ca_topic_score_codex":0.000080463346,"about_ca_topic_score_gemma":0.000009597299,"teacher_disagreement_score":0.021654772,"about_ca_system_score_codex":0.00007034567,"about_ca_system_score_gemma":0.00011256176,"threshold_uncertainty_score":0.48184645},"labels":[],"label_agreement":null},{"id":"W2099259281","doi":"10.1158/1535-7163.mct-11-0705","title":"Off-Target Function of the Sonic Hedgehog Inhibitor Cyclopamine in Mediating Apoptosis via Nitric Oxide–Dependent Neutral Sphingomyelinase 2/Ceramide Induction","year":2012,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Center for Research Resources; National Institute of Dental and Craniofacial Research; National Institutes of Health; National Cancer Institute; Rally Foundation","keywords":"Cyclopamine; Ceramide; Biology; Programmed cell death; Gene knockdown; Apoptosis; Cell biology; GLI1; Hedgehog signaling pathway; Smoothened; Cancer research; Signal transduction; Biochemistry","score_opus":0.017670717036158263,"score_gpt":0.256220465018098,"score_spread":0.2385497479819397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099259281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839376,0.011682887,0.0029678992,0.00020911543,0.0007577309,0.0003516722,0.000021600912,0.000017764272,0.000053724518],"genre_scores_gemma":[0.997854,0.00049452914,0.00028517834,0.00063604634,0.00050448556,0.0000929296,0.000031963096,0.000057483787,0.000043402033],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998194,0.00020846142,0.00045883685,0.00034031292,0.00030045965,0.00049793744],"domain_scores_gemma":[0.99907047,0.000019798137,0.0002654563,0.000433147,0.0001349231,0.0000762186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004183446,0.0002830148,0.00026634277,0.000102069025,0.00011781123,0.00001350133,0.0002357048,0.00023217239,0.000006113883],"category_scores_gemma":[0.00005180637,0.0002415781,0.00017221372,0.00039230302,0.00010850525,0.000014540994,0.00016700967,0.00028820874,0.0000022666209],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008428053,0.00012604715,0.025829753,0.000043987213,0.00016906296,6.8314347e-7,0.0002192835,0.0020212682,0.96320325,0.000019580008,0.00001309959,0.008269675],"study_design_scores_gemma":[0.0006785809,0.00008966917,0.02379259,0.000039897885,0.00011816857,0.0000039014712,0.00019916608,0.00016513167,0.9726594,0.00007885037,0.0019075683,0.0002670675],"about_ca_topic_score_codex":0.00013437653,"about_ca_topic_score_gemma":0.00006484567,"teacher_disagreement_score":0.013916376,"about_ca_system_score_codex":0.00013279995,"about_ca_system_score_gemma":0.00012179105,"threshold_uncertainty_score":0.9851269},"labels":[],"label_agreement":null},{"id":"W2099385922","doi":"10.1158/1535-7163.mct-06-0033","title":"Telomerase inhibition enhances the response to anticancer drug treatment in human breast cancer cells","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Telomeres, Telomerase, and Senescence","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Telomerase; Telomere; Cancer research; Cancer; Cancer cell; Telomerase reverse transcriptase; Breast cancer; Biology; DNA; Genetics","score_opus":0.014879848485194812,"score_gpt":0.30000692387022365,"score_spread":0.28512707538502885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099385922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802236,0.0037814477,0.00012539812,0.0142050255,0.0002587327,0.0010293173,0.00012776119,0.0000746538,0.00017406738],"genre_scores_gemma":[0.9905134,0.0010456359,0.00011000575,0.0061549298,0.00029707907,0.0004717948,0.000018242425,0.00007058669,0.0013183354],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99766725,0.0002341587,0.00045422424,0.00055120396,0.0004973713,0.000595782],"domain_scores_gemma":[0.9989478,0.00007413702,0.00011882166,0.0005740491,0.0001415431,0.00014364102],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002677261,0.00038959153,0.00044204568,0.00023195682,0.00019325642,0.000060188824,0.00016186103,0.00010375444,0.00023116311],"category_scores_gemma":[0.00000377192,0.0002795513,0.00015809806,0.0007451764,0.00018209363,0.000072317795,0.000036153113,0.00022856728,0.000023064105],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013582835,0.00039890155,0.0075622676,0.0000345464,0.0001003463,0.00020174285,0.0011549193,0.0005187169,0.9748353,0.000060276892,0.00028803624,0.013486668],"study_design_scores_gemma":[0.0021350023,0.00020989114,0.08130372,0.00026615837,0.00020649793,0.000025153531,0.00024249489,0.00010653694,0.89647484,0.00010971043,0.018529946,0.00039003484],"about_ca_topic_score_codex":0.008315507,"about_ca_topic_score_gemma":0.0039015464,"teacher_disagreement_score":0.078360446,"about_ca_system_score_codex":0.00081770227,"about_ca_system_score_gemma":0.00037966564,"threshold_uncertainty_score":0.99996567},"labels":[],"label_agreement":null},{"id":"W2099591397","doi":"10.1158/1535-7163.mct-08-0929","title":"Base excision repair of reactive oxygen species–initiated 7,8-dihydro-8-oxo-2′-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Environmental Health Sciences","keywords":"Oxaliplatin; Cisplatin; Reactive oxygen species; DNA damage; DNA glycosylase; DNA repair; Cytotoxicity; Chemistry; Base excision repair; Pharmacology; Cancer research; Biochemistry; Molecular biology; Biology; Cancer; DNA; Chemotherapy; In vitro; Colorectal cancer","score_opus":0.023975527633122645,"score_gpt":0.2807184961561233,"score_spread":0.25674296852300066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099591397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99164116,0.0024779353,0.0029889955,0.00050556177,0.00014345943,0.00057718833,0.00012007368,0.000046880956,0.0014987573],"genre_scores_gemma":[0.9957765,0.0006595336,0.00095077336,0.0021475495,0.00010956392,0.000026978036,0.00006896082,0.000053815787,0.00020635368],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99776894,0.00021096911,0.0005652196,0.0005275543,0.00054277765,0.00038453206],"domain_scores_gemma":[0.9981106,0.00003631172,0.0004247882,0.0009758914,0.00037152393,0.00008089452],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038010135,0.00034091235,0.00040906286,0.00008045775,0.000092013695,0.00001404871,0.00041328877,0.00026307395,0.000051127798],"category_scores_gemma":[0.000051561685,0.00027517736,0.00034410637,0.0003783095,0.00022656945,0.000010781012,0.00013065504,0.00021419792,0.0000019614981],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004301989,0.00020852676,0.00014908994,0.000026143089,0.0002910217,0.00000867952,0.00030769908,0.00024255193,0.9958554,0.0005091174,0.00013407465,0.0018375056],"study_design_scores_gemma":[0.000946418,0.00069281086,0.0019567085,0.000090723624,0.00015542177,0.0000071849195,0.00014700508,0.0005637199,0.9916355,0.0006594478,0.0028454284,0.00029960653],"about_ca_topic_score_codex":0.000046970483,"about_ca_topic_score_gemma":0.00001512608,"teacher_disagreement_score":0.004219867,"about_ca_system_score_codex":0.00006732883,"about_ca_system_score_gemma":0.00021192736,"threshold_uncertainty_score":0.99997},"labels":[],"label_agreement":null},{"id":"W2100604791","doi":"10.1158/1535-7163.mct-07-0449","title":"Effects of folate and folylpolyglutamyl synthase modulation on chemosensitivity of breast cancer cells","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Folate and B Vitamins Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Antifolate; Biology; Intracellular; Cancer cell; Antimetabolite; Cancer research; Methotrexate; Pharmacology; Cancer; Biochemistry; Immunology","score_opus":0.014923779629011456,"score_gpt":0.30925372379734284,"score_spread":0.29432994416833136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100604791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950953,0.0023244827,0.0016470018,0.0002725152,0.00008960438,0.0003881623,0.0000337891,0.000013399374,0.00013570556],"genre_scores_gemma":[0.99844044,0.00088857656,0.00010846637,0.00041433898,0.000042775853,0.000008171462,0.0000029628256,0.00003074361,0.000063539585],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99891555,0.000038071146,0.00021108535,0.0002109883,0.0003714025,0.00025290938],"domain_scores_gemma":[0.9993308,0.00009424985,0.00009896815,0.00021706254,0.00016297074,0.00009595135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020555778,0.00014883514,0.00030742696,0.00012816834,0.000027933173,0.000005027031,0.000047687125,0.00011572911,0.000014729505],"category_scores_gemma":[0.0000066253197,0.00012846533,0.00008563391,0.0002329691,0.000115737,0.000030381034,0.000026775167,0.00016071397,0.0000010740968],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007579513,0.00019520467,0.0019614594,0.0003937848,0.00026755515,0.00006336346,0.00015577143,0.00005361135,0.8759279,0.000042676118,0.00000440146,0.120176315],"study_design_scores_gemma":[0.0013535593,0.00032315415,0.09656267,0.00025838573,0.00020791957,0.000010187943,0.000013103483,0.0018541022,0.89919096,0.000037556805,0.00008573927,0.00010266518],"about_ca_topic_score_codex":0.00042261602,"about_ca_topic_score_gemma":0.000028770939,"teacher_disagreement_score":0.12007365,"about_ca_system_score_codex":0.00008253507,"about_ca_system_score_gemma":0.0000851024,"threshold_uncertainty_score":0.52386636},"labels":[],"label_agreement":null},{"id":"W2101599998","doi":"10.1158/1535-7163.mct-09-0243","title":"Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations <i>in vitro</i> and <i>in vivo</i>","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Celator Pharmaceuticals (Canada)","funders":"","keywords":"Irinotecan; Cisplatin; In vivo; Pharmacology; Drug; In vitro; Cytotoxicity; Chemistry; Medicine; Liposome; Chemotherapy; Cancer; Biology; Internal medicine; Biochemistry","score_opus":0.01875205029635636,"score_gpt":0.32668222912345213,"score_spread":0.3079301788270958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101599998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858716,0.0063883546,0.0002443351,0.0062010637,0.00003608386,0.000560583,0.00002769592,0.000014974226,0.0006553064],"genre_scores_gemma":[0.99626756,0.0022707738,0.00017503869,0.0010943186,0.000013213601,0.000035727608,0.0000018790715,0.000014673319,0.00012680035],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988867,0.000072806986,0.00020621136,0.00026153517,0.00031995683,0.0002528097],"domain_scores_gemma":[0.99954295,0.000046758385,0.0000680457,0.00020432186,0.00007173561,0.00006616513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019534142,0.0001508376,0.0003472312,0.00015895409,0.000041492465,0.000016261403,0.00006293927,0.000046826226,0.000006813242],"category_scores_gemma":[0.0000147732535,0.00014258026,0.000033937627,0.00026585435,0.00013469563,0.00006603387,0.000043978212,0.00023625923,2.2550739e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043873064,0.0003398665,0.0072522312,0.00011047504,0.00006645879,0.0000689388,0.00058561424,0.000038686772,0.97168046,0.00022379072,0.000022708833,0.019172018],"study_design_scores_gemma":[0.004234185,0.00024337108,0.0535774,0.00016061898,0.00008138512,0.000011986373,0.000087604945,0.0013166816,0.9391633,0.0004316868,0.0005179433,0.00017381427],"about_ca_topic_score_codex":0.00035456102,"about_ca_topic_score_gemma":0.00035714902,"teacher_disagreement_score":0.04632517,"about_ca_system_score_codex":0.00015247162,"about_ca_system_score_gemma":0.00012930244,"threshold_uncertainty_score":0.5814254},"labels":[],"label_agreement":null},{"id":"W2101657719","doi":"10.1158/1535-7163.mct-13-0401","title":"Microtubule Dynamics Control Tail Retraction in Migrating Vascular Endothelial Cells","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Canadian Institutes of Health Research; Alberta Innovates; National Institutes of Health; University of Calgary","keywords":"Microtubule; Cell biology; Nocodazole; Motility; Lamellipodium; Biology; Cytoskeleton; Microtubule polymerization; Paclitaxel; Angiogenesis; Colchicine; Cell migration; Biophysics; Cell; Chemistry; Tubulin; Biochemistry; Genetics","score_opus":0.006482326832698986,"score_gpt":0.2305935236054468,"score_spread":0.22411119677274782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101657719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746539,0.0029244998,0.02040641,0.00031510778,0.00043195504,0.0007684886,0.000090089845,0.000026818436,0.0003827219],"genre_scores_gemma":[0.99411577,0.0013202642,0.00092265324,0.0026673349,0.00018723278,0.00022408502,0.000105517865,0.00008184971,0.00037527963],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983188,0.00013387851,0.00036868383,0.00049028004,0.00020052487,0.00048786428],"domain_scores_gemma":[0.9991393,0.000015206054,0.00014101187,0.0004917994,0.000128287,0.00008435895],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016324196,0.00030575856,0.00025827112,0.00008548026,0.00007739447,0.00007568154,0.00027861085,0.00037021586,0.0000737033],"category_scores_gemma":[0.000012806203,0.00031847286,0.00020109049,0.00012957607,0.00007322155,0.000010655852,0.000055984954,0.00029755023,0.000029814588],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035934587,0.00009102461,0.0030160786,0.000023262543,0.0001634958,0.0000056848394,0.000070790484,0.0011724121,0.9879327,0.000048506736,0.0001828558,0.0072572506],"study_design_scores_gemma":[0.0021876208,0.00017496703,0.0016194474,0.00004392467,0.00010361084,0.000009844779,0.00016475038,0.011948974,0.9485646,0.00013254068,0.03445779,0.0005919528],"about_ca_topic_score_codex":0.0007421394,"about_ca_topic_score_gemma":0.001461568,"teacher_disagreement_score":0.03936813,"about_ca_system_score_codex":0.00013264266,"about_ca_system_score_gemma":0.000113084796,"threshold_uncertainty_score":0.99992675},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"bench_or_experimental","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2101891042","doi":"10.1158/1535-7163.mct-13-0748","title":"Enhancement of the Tumor Penetration of Monoclonal Antibody by Fusion of a Neuropilin-Targeting Peptide Improves the Antitumor Efficacy","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Biotechnology Research Institute","funders":"","keywords":"Monoclonal antibody; Antibody; Cancer research; Radioimmunotherapy; Cetuximab; Chemistry; Molecular biology; Receptor; Biology; Immunology; Biochemistry","score_opus":0.017743263608985843,"score_gpt":0.31687297863078867,"score_spread":0.29912971502180286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101891042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99347985,0.0029662831,0.0010675212,0.0015232216,0.00012423401,0.0004916355,0.000025372576,0.000005834869,0.00031602167],"genre_scores_gemma":[0.997919,0.0006399654,0.00028973605,0.00080258184,0.00006616498,0.000011748787,0.000019808189,0.000021812468,0.00022916419],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99826527,0.0001762977,0.00046997465,0.00020305562,0.00065591285,0.00022949665],"domain_scores_gemma":[0.99889123,0.00011493286,0.0003291168,0.00036944172,0.00024995007,0.00004534445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003223634,0.00016086052,0.00031663376,0.000041899788,0.00008729696,0.0000075428,0.0002842963,0.000040064628,0.00004713747],"category_scores_gemma":[0.00004650908,0.00009010034,0.00020257487,0.00023368138,0.0002989932,0.000022972077,0.000108295775,0.00021107365,0.0000011589383],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036780012,0.00021160787,0.008064573,0.00020743857,0.00012707493,0.0000015756053,0.00019744615,0.00004373703,0.986189,0.00028609656,0.000076500655,0.004227147],"study_design_scores_gemma":[0.00071913603,0.0004954877,0.030978268,0.00015908676,0.00012616145,0.0000045193087,0.00004188182,0.0027383948,0.95878774,0.000060409504,0.005801315,0.00008762572],"about_ca_topic_score_codex":0.0003758925,"about_ca_topic_score_gemma":0.000008436486,"teacher_disagreement_score":0.027401289,"about_ca_system_score_codex":0.000021188796,"about_ca_system_score_gemma":0.00015637776,"threshold_uncertainty_score":0.3674185},"labels":[],"label_agreement":null},{"id":"W2102442341","doi":"10.1158/1535-7163.mct-04-0048","title":"<i>In vitro</i> and <i>in vivo</i> irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Biology; Cell cycle; Myeloid leukemia; Flow cytometry; Molecular biology; Apoptosis; In vivo; Gene expression; Cancer research; Myeloid; Leukemia; Gene; Immunology; Genetics","score_opus":0.010233188221277525,"score_gpt":0.2466762618659913,"score_spread":0.23644307364471376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102442341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913804,0.007578125,0.00005505674,0.00033047568,0.00009323094,0.00042883487,0.000060923063,0.0000061087935,0.00006687032],"genre_scores_gemma":[0.98461413,0.0131679475,0.00046006977,0.0014650628,0.00003917327,0.00012638555,0.000014394323,0.00005019383,0.000062615094],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99845177,0.00011478626,0.0003481603,0.0004908584,0.000164923,0.00042947434],"domain_scores_gemma":[0.9994845,0.000013120729,0.0001434219,0.00026283305,0.000034716715,0.00006140393],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021107701,0.00028068433,0.00036422882,0.00018169933,0.00002420083,0.000018497743,0.0001696603,0.00030356864,0.00000619661],"category_scores_gemma":[0.000001857339,0.00029628628,0.00004742943,0.00024152696,0.000057074107,0.000011447891,0.00011924841,0.00019872034,2.4045676e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032313896,0.00015378419,0.00043492074,0.00004344139,0.000031355983,0.000008020283,0.0003589106,0.0003367006,0.99046046,0.0000053977287,0.000003905583,0.007839992],"study_design_scores_gemma":[0.0024858115,0.00016886779,0.00029982033,0.00008822748,0.00002907849,0.0000015840507,0.00010821266,0.0006078831,0.9940685,0.00006407391,0.001759535,0.0003184231],"about_ca_topic_score_codex":0.00041807257,"about_ca_topic_score_gemma":0.0028471143,"teacher_disagreement_score":0.0075215693,"about_ca_system_score_codex":0.00016119455,"about_ca_system_score_gemma":0.00012678605,"threshold_uncertainty_score":0.9999489},"labels":[],"label_agreement":null},{"id":"W2102474050","doi":"10.1158/1535-7163.mct-10-0909","title":"Caspase-3–Dependent Mitotic Checkpoint Inactivation by the Small-Molecule Inducers of Mitotic Slippage SU6656 and Geraldol","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Mitosis; Cell biology; Mitotic exit; Cyclin B1; Biology; Cyclin B; Cell cycle; Chemistry; Spindle apparatus; Cyclin-dependent kinase 1; Cell division; Cell; Cyclin; Genetics","score_opus":0.024925979636441938,"score_gpt":0.24567223632081003,"score_spread":0.2207462566843681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102474050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98274094,0.005464477,0.010409924,0.00030318002,0.00015934385,0.0004280393,0.000042271353,0.00001253471,0.00043928315],"genre_scores_gemma":[0.9964983,0.0012394391,0.00038121492,0.0014500878,0.000056192315,0.00006763726,0.000053799213,0.0000571348,0.00019619848],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986563,0.0001244071,0.00032458574,0.0003994962,0.00017603065,0.00031919774],"domain_scores_gemma":[0.99906135,0.000011847755,0.00019925775,0.0005304186,0.000119435215,0.00007766863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016294104,0.0002697486,0.00021568367,0.000048223435,0.00009526553,0.000025275212,0.00030219826,0.00021837791,0.000022130824],"category_scores_gemma":[0.000013851468,0.00022509588,0.00012108136,0.00012673548,0.00018139208,0.000006256475,0.00013175141,0.00019482583,0.0000015650055],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008474423,0.000111813686,0.00048785747,0.00003896743,0.00030244538,0.0000053908316,0.00041030353,0.000029232282,0.9951712,0.00013849066,0.00008875713,0.0031308103],"study_design_scores_gemma":[0.00051534834,0.00023566827,0.0006922877,0.000024592342,0.00017265057,0.000020006953,0.00025630358,0.00016797516,0.9962763,0.00013107092,0.0012283708,0.00027938045],"about_ca_topic_score_codex":0.00046959586,"about_ca_topic_score_gemma":0.00014660793,"teacher_disagreement_score":0.01375735,"about_ca_system_score_codex":0.000047125115,"about_ca_system_score_gemma":0.00010783342,"threshold_uncertainty_score":0.91791433},"labels":[],"label_agreement":null},{"id":"W2102672521","doi":"10.1158/1535-7163.mct-12-0753","title":"New Directions for Biologic Targets in Urothelial Carcinoma – Response","year":2012,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pazopanib; Sunitinib; Medicine; Cancer; Angiogenesis; Oncology; Kidney cancer; Bladder cancer; Renal cell carcinoma; Internal medicine; Cabozantinib; Disease; Urothelial cancer; Clinical trial; Metastatic Urothelial Carcinoma; Cancer research; Urothelial carcinoma","score_opus":0.042735871982933736,"score_gpt":0.33199900550733463,"score_spread":0.2892631335244009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102672521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9011327,0.064485535,0.019660173,0.008260029,0.0018315543,0.0026096036,0.00018426072,0.00017112432,0.0016650152],"genre_scores_gemma":[0.991244,0.0003525381,0.0023393866,0.0039988244,0.00035025578,0.0003174986,0.000015508884,0.0000523891,0.0013295749],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989076,0.000085784515,0.0001897574,0.0002229585,0.00013792062,0.00045592725],"domain_scores_gemma":[0.9994284,0.00005246939,0.00004482602,0.0002535289,0.000049728875,0.000171043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016374045,0.0001933798,0.00025483003,0.00011818055,0.000059272876,0.000010480847,0.00007568777,0.00012354268,0.00013995163],"category_scores_gemma":[0.000018084802,0.00016328802,0.00014430171,0.00021930496,0.000034170433,0.000048279817,0.000017187587,0.00012412302,0.0000142175],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014289079,0.0008948355,0.254121,0.000089069916,0.00076967553,0.000058125097,0.0026161135,0.000030747386,0.5810325,0.0006360911,0.0013759943,0.14408675],"study_design_scores_gemma":[0.008374556,0.0010808398,0.1888983,0.000056855446,0.0005565834,0.00004101232,0.000101193946,0.000074337084,0.30885255,0.0005695674,0.49097046,0.00042375043],"about_ca_topic_score_codex":0.000391425,"about_ca_topic_score_gemma":0.00004314218,"teacher_disagreement_score":0.48959446,"about_ca_system_score_codex":0.00027111458,"about_ca_system_score_gemma":0.00036037405,"threshold_uncertainty_score":0.66586924},"labels":[],"label_agreement":null},{"id":"W2103272465","doi":"10.1158/1535-7163.mct-09-0872","title":"ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Synthetic lethality; Olaparib; Poly ADP ribose polymerase; Cancer research; Mantle cell lymphoma; Biology; DNA damage; Cell culture; DNA repair; Cancer cell; Polymerase; Molecular biology; Cancer; Lymphoma; Gene; DNA; Genetics; Immunology","score_opus":0.014287442575405696,"score_gpt":0.2850526350548136,"score_spread":0.2707651924794079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103272465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97514725,0.0055354172,0.0023630175,0.006579779,0.0029168264,0.00089285517,0.00012630482,0.00027831085,0.0061602374],"genre_scores_gemma":[0.9703413,0.00032647725,0.0029705674,0.023753865,0.000910365,0.00012763524,0.000024372945,0.00017819875,0.0013671677],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970256,0.000083978404,0.0005202,0.0007445688,0.0007857566,0.00083986373],"domain_scores_gemma":[0.99803436,0.000055357956,0.00017313487,0.0010064837,0.00025010933,0.0004805737],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020800074,0.0005123859,0.00051117584,0.00026966986,0.00020511023,0.00007902715,0.00028249982,0.00031311868,0.0005085413],"category_scores_gemma":[0.000008024978,0.0005002079,0.0002979277,0.0006907653,0.00020930353,0.000082403465,0.00008493122,0.00042840632,0.00038190614],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002643262,0.00036804707,0.0004989692,0.00005910833,0.00009391705,0.00016175314,0.00060721627,0.000028304345,0.9717165,0.0001550385,0.0015446878,0.02450213],"study_design_scores_gemma":[0.0029682314,0.0002734608,0.0005041019,0.0000801022,0.00018804823,0.00007386675,0.000120649755,0.00011289755,0.88957053,0.0001166607,0.10546989,0.00052156014],"about_ca_topic_score_codex":0.0002866544,"about_ca_topic_score_gemma":0.000049766102,"teacher_disagreement_score":0.1039252,"about_ca_system_score_codex":0.00028342623,"about_ca_system_score_gemma":0.00052807067,"threshold_uncertainty_score":0.99974495},"labels":[],"label_agreement":null},{"id":"W2103596673","doi":"10.1158/1535-7163.mct-12-0967","title":"Use of Molecular Biomarkers to Quantify the Spatial Distribution of Effects of Anticancer Drugs in Solid Tumors","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Doxorubicin; Distribution (mathematics); Docetaxel; Pharmacology; Melphalan; Monoclonal antibody; Drug; Cancer; Cancer research; Chemistry; Medicine; Antibody; Chemotherapy; Internal medicine; Immunology","score_opus":0.011499604327096668,"score_gpt":0.2684066430607366,"score_spread":0.2569070387336399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103596673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833418,0.0030383694,0.012133448,0.00048725517,0.0001609209,0.00071929354,0.00010089634,0.0000033128356,0.000014717584],"genre_scores_gemma":[0.99792945,0.0008352417,0.00029995674,0.00071637455,0.000028522087,0.00010033469,0.0000483388,0.0000350146,0.0000067774095],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99858797,0.00009951234,0.00047734383,0.00028950436,0.0002630277,0.00028266836],"domain_scores_gemma":[0.9987897,0.00007778893,0.0002535932,0.00054879906,0.00026475245,0.00006535412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013285593,0.00020508587,0.0003346571,0.00006673233,0.000022217431,0.000015992444,0.00028626702,0.00012733114,0.000007736996],"category_scores_gemma":[0.00009362362,0.00017705123,0.00016242234,0.00029203272,0.00020516355,0.0000056521653,0.00013422874,0.0000864265,0.0000010694102],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001373389,0.00010722524,0.004096773,0.00012543019,0.0002301193,0.0000024821463,0.0001516662,0.002434552,0.9838865,0.00024095034,0.000084352236,0.008502602],"study_design_scores_gemma":[0.00053575926,0.00031082402,0.0317954,0.00013353629,0.00008934982,8.7179575e-7,0.000045799155,0.00050581206,0.96524066,0.00013199232,0.0010203151,0.00018970112],"about_ca_topic_score_codex":0.003548906,"about_ca_topic_score_gemma":0.0001739083,"teacher_disagreement_score":0.027698629,"about_ca_system_score_codex":0.000046091172,"about_ca_system_score_gemma":0.00018314685,"threshold_uncertainty_score":0.721994},"labels":[],"label_agreement":null},{"id":"W2104386241","doi":"10.1158/1535-7163.mct-06-0434","title":"Plasminogen Kringle 5 blocks tumor progression by antiangiogenic and proinflammatory pathways","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université de Montréal; McGill University","funders":"","keywords":"Angiostatin; Proinflammatory cytokine; Immune system; Immunology; Cancer research; Cancer; Biology; Angiogenesis; Population; Vasculogenic mimicry; Inflammation; Metastasis; Medicine","score_opus":0.013736588472239084,"score_gpt":0.2711282613187341,"score_spread":0.257391672846495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104386241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95031255,0.04515951,0.0034432507,0.00009721338,0.00015584796,0.00031397963,0.000056921977,0.000031607655,0.0004291202],"genre_scores_gemma":[0.99606395,0.0012726926,0.0007107695,0.001341138,0.00021350982,0.000059896458,0.00006109147,0.000071694514,0.00020523266],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985694,0.000033733624,0.0002516465,0.00046791453,0.00022627908,0.0004509765],"domain_scores_gemma":[0.9993144,0.0000068220043,0.00012217362,0.00033792935,0.000081090104,0.00013756672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023876438,0.00026070952,0.00017390186,0.000046211455,0.00012469369,0.00003296495,0.00018967832,0.00017313228,0.00002748082],"category_scores_gemma":[0.0000045323536,0.00024257261,0.00013242973,0.00010618868,0.00012563255,0.000004701503,0.00011739475,0.00008916733,0.0000025737586],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011878256,0.00005253659,0.008254525,0.000023061295,0.00017457799,0.000025619647,0.000053244526,0.000008866025,0.95647144,0.00003276729,0.0006835695,0.034101],"study_design_scores_gemma":[0.00042626265,0.00017770157,0.0009348501,0.000028532733,0.00006942683,0.00002646376,0.000043608386,0.000038739352,0.8657076,0.000027619662,0.13220946,0.00030972518],"about_ca_topic_score_codex":0.000013021633,"about_ca_topic_score_gemma":0.000021886153,"teacher_disagreement_score":0.1315259,"about_ca_system_score_codex":0.000036066947,"about_ca_system_score_gemma":0.000104701576,"threshold_uncertainty_score":0.9891824},"labels":[],"label_agreement":null},{"id":"W2105020329","doi":"10.1158/1535-7163.mct-12-1150","title":"Fibroblast Growth Factor Receptor 3 Is a Rational Therapeutic Target in Bladder Cancer","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Fibroblast growth factor receptor 3; Bladder cancer; Cancer research; Fibroblast growth factor receptor; Cancer; Urothelial Cell; Medicine; Fibroblast growth factor receptor 2; Targeted therapy; Monoclonal antibody; Fibroblast growth factor receptor 4; Fibroblast growth factor; Receptor; Antibody; Internal medicine; Immunology","score_opus":0.02118418005377775,"score_gpt":0.29294327350275723,"score_spread":0.27175909344897947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105020329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98517776,0.0054751146,0.0028820077,0.004494231,0.00021445993,0.0010459456,0.00027047447,0.000039877465,0.00040010992],"genre_scores_gemma":[0.9904511,0.00080836937,0.00079997943,0.00574032,0.00023537144,0.0007099166,0.000109054694,0.00012880137,0.0010170942],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974574,0.0001774125,0.00038323813,0.0007057245,0.00052475143,0.00075151626],"domain_scores_gemma":[0.9988502,0.000019669293,0.00011323373,0.0005022326,0.00034544885,0.00016917202],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009351924,0.00041414032,0.00027992192,0.00014806034,0.00009249847,0.000113196234,0.00049563765,0.00032427502,0.0033569278],"category_scores_gemma":[0.000015837653,0.00039309837,0.0001771394,0.00036552877,0.00017259885,0.000025493962,0.00015555011,0.00034642895,0.00013775914],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007773376,0.000100178026,0.013017715,0.00004310952,0.0003266336,0.0000025494421,0.00023486579,0.00014376813,0.98156315,0.000088972134,0.0019042988,0.0024970148],"study_design_scores_gemma":[0.0011955837,0.00025253257,0.021515222,0.00007803017,0.000019167133,0.0000031626905,0.00006176302,0.0006908687,0.9483557,0.00058403134,0.026603641,0.00064032205],"about_ca_topic_score_codex":0.00057292177,"about_ca_topic_score_gemma":0.00011870916,"teacher_disagreement_score":0.033207487,"about_ca_system_score_codex":0.00015062673,"about_ca_system_score_gemma":0.0004133506,"threshold_uncertainty_score":0.99985206},"labels":[],"label_agreement":null},{"id":"W2106131552","doi":"10.1158/1535-7163.mct-08-0335","title":"Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; University Health Network","funders":"University Health Network","keywords":"Fas ligand; Mitoxantrone; Apoptosis; Docetaxel; Prostate cancer; Cancer research; Fas receptor; Survivin; Cancer cell; Cytotoxic T cell; Biology; Cancer; Medicine; Chemistry; Programmed cell death; Internal medicine; In vitro; Chemotherapy; Biochemistry","score_opus":0.010026724583103308,"score_gpt":0.22776108589238314,"score_spread":0.21773436130927984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106131552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94008726,0.05581103,0.0032237035,0.00021162603,0.00012239031,0.00027736815,0.00019946297,0.000011724388,0.000055452536],"genre_scores_gemma":[0.9413296,0.05545834,0.0007538363,0.0016950695,0.000068212845,0.000043453798,0.00017927182,0.000047073183,0.00042516788],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989477,0.000044300992,0.00023456941,0.0003323131,0.0001989626,0.00024215931],"domain_scores_gemma":[0.9994238,0.0000070222113,0.00014669525,0.00023868622,0.00010560308,0.00007817982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006699404,0.00019986059,0.00022450682,0.000036755486,0.00008042,0.000009703095,0.00010268526,0.00016881323,0.000024430165],"category_scores_gemma":[0.0000016908651,0.00018532161,0.00007597768,0.00009453193,0.00012585738,0.000004615835,0.000052515956,0.000082394894,7.029431e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000107470136,0.00005686341,0.0011050139,0.00005161689,0.00018658291,0.0000045664915,0.00016287768,0.00011438964,0.99102354,0.0000046138816,0.00034882515,0.006833663],"study_design_scores_gemma":[0.0010216873,0.00012450304,0.0007258655,0.000025790792,0.000086140324,0.0000055970013,0.00001826178,0.0007344244,0.9572669,0.000019867493,0.039737076,0.00023387135],"about_ca_topic_score_codex":0.00024420652,"about_ca_topic_score_gemma":0.000010924382,"teacher_disagreement_score":0.03938825,"about_ca_system_score_codex":0.00003088937,"about_ca_system_score_gemma":0.00013111164,"threshold_uncertainty_score":0.7557196},"labels":[],"label_agreement":null},{"id":"W2106198555","doi":"10.1158/1535-7163.mct-05-0146","title":"Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Cancer research; Lymphoma; Biology; Diffuse large B-cell lymphoma; Immune system; Tumor microenvironment; Immunology","score_opus":0.015815451971037616,"score_gpt":0.2625357891127456,"score_spread":0.246720337141708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106198555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9659762,0.030084834,0.00015104002,0.000854395,0.00019102986,0.0010896645,0.0001363623,0.00008951342,0.0014269907],"genre_scores_gemma":[0.99240637,0.0011190877,0.000924581,0.0037576132,0.00018918588,0.00037756105,0.000054923454,0.00011628447,0.001054388],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975742,0.00010034494,0.00048048366,0.00068507803,0.00047507987,0.00068479683],"domain_scores_gemma":[0.99905795,0.000043715256,0.00013851137,0.0004777251,0.00008180657,0.00020027797],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014884496,0.0005050211,0.0005738303,0.00014617336,0.00013720721,0.00011367467,0.00017469011,0.00017475715,0.00013180175],"category_scores_gemma":[0.0000056299855,0.0004276122,0.0002189835,0.0002561058,0.00012129892,0.00011788212,0.000050961815,0.00013287168,0.000019362906],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003288844,0.030113796,0.06582866,0.0010080641,0.00071694236,0.0019556405,0.0060326084,0.00007949699,0.7967112,0.0005457713,0.00030586685,0.093413085],"study_design_scores_gemma":[0.051406264,0.00032694047,0.04787453,0.00019883618,0.00052713754,0.000044878616,0.0005332744,0.0025587773,0.869771,0.000047294612,0.02601769,0.00069335126],"about_ca_topic_score_codex":0.00021451933,"about_ca_topic_score_gemma":0.00041315766,"teacher_disagreement_score":0.09271973,"about_ca_system_score_codex":0.00062194525,"about_ca_system_score_gemma":0.0002467542,"threshold_uncertainty_score":0.99981755},"labels":[],"label_agreement":null},{"id":"W2106336697","doi":"10.1158/1535-7163.mct-05-0223","title":"Caspase-dependent apoptosis induction by guggulsterone, a constituent of Ayurvedic medicinal plant <i>Commiphora mukul</i>, in PC-3 human prostate cancer cells is mediated by Bax and Bak","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Pharmacological Effects of Medicinal Plants","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Apoptosis; Programmed cell death; Biology; Caspase; Caspase 3; Cell growth; Cancer research; Biochemistry","score_opus":0.022257129652861387,"score_gpt":0.3115336007673237,"score_spread":0.28927647111446236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106336697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9716437,0.020072091,0.000047266192,0.0057056947,0.00031717212,0.001134714,0.00087591365,0.00004667506,0.00015676678],"genre_scores_gemma":[0.9808424,0.007304317,0.000051027848,0.0112253055,0.00011007409,0.00015668411,0.00016750405,0.000049240833,0.000093431896],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971803,0.00019922144,0.00065749785,0.00053330575,0.0008832336,0.0005464393],"domain_scores_gemma":[0.9988913,0.0001060971,0.00029254064,0.0002504532,0.00011458344,0.00034502507],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045356387,0.00040738838,0.0007430786,0.00018807796,0.00006905916,0.000015910224,0.00018515924,0.0002600239,0.00037428952],"category_scores_gemma":[0.000016456324,0.00033834475,0.00007064083,0.00026414334,0.00040424633,0.00009176218,0.00006930501,0.00067749893,0.0000055163837],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069837476,0.0005070235,0.0028533118,0.00024951025,0.0003762101,0.000112097674,0.00064357853,0.000038345916,0.9744467,0.0000025663326,0.00870731,0.011364963],"study_design_scores_gemma":[0.007740912,0.00091082155,0.00067901844,0.0006592774,0.00066175667,0.00005647744,0.00019504564,0.0006538397,0.9773522,0.000012638122,0.010700584,0.0003773995],"about_ca_topic_score_codex":0.0021722044,"about_ca_topic_score_gemma":0.00026806732,"teacher_disagreement_score":0.012767775,"about_ca_system_score_codex":0.00041055417,"about_ca_system_score_gemma":0.00019257328,"threshold_uncertainty_score":0.99990684},"labels":[],"label_agreement":null},{"id":"W2106888030","doi":"10.1158/1535-7163.mct-11-0510","title":"A Systems Biology Approach Identifies SART1 as a Novel Determinant of Both 5-Fluorouracil and SN38 Drug Resistance in Colorectal Cancer","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Queen's University Belfast; Public Health Agency; National Institute for Health and Care Research; Cancer Research UK; Shijiazhuang Tiedao University","keywords":"Gene silencing; Irinotecan; Colorectal cancer; Cancer research; Biology; Drug resistance; Cancer; Gene; Genetics","score_opus":0.030433607074460474,"score_gpt":0.28134143341862733,"score_spread":0.25090782634416686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106888030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9481515,0.046068333,0.0040757507,0.000054858923,0.0001747977,0.0003591547,0.000078930054,0.000008638005,0.0010280043],"genre_scores_gemma":[0.9938042,0.004248619,0.0008220169,0.0001599632,0.000042056505,0.00039540717,0.000021042133,0.000035089903,0.000471574],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99872345,0.00008489524,0.0003332499,0.0004530447,0.000120334684,0.00028503654],"domain_scores_gemma":[0.99931175,0.000007550319,0.00019066132,0.00032117788,0.000113479,0.000055361204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001753701,0.00021063477,0.0002731336,0.0000733101,0.000053564112,0.000020851945,0.00023820001,0.00016059798,0.000009589212],"category_scores_gemma":[0.000007103841,0.00019643994,0.00007156547,0.00015679115,0.00022501037,0.000007635932,0.00007412482,0.000106424224,5.772079e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000235756,0.00012463196,0.0064232107,0.00009457883,0.00015476353,0.0000033221056,0.00089705293,0.0000448108,0.98898435,0.0012215284,0.000029072562,0.0017868982],"study_design_scores_gemma":[0.0016262004,0.00017095906,0.013888198,0.00014274738,0.00014755933,0.00001906978,0.0005090674,0.00053475355,0.97066534,0.00042426432,0.0112715755,0.0006002909],"about_ca_topic_score_codex":0.002071579,"about_ca_topic_score_gemma":0.0012719557,"teacher_disagreement_score":0.0456527,"about_ca_system_score_codex":0.00004747691,"about_ca_system_score_gemma":0.00018540137,"threshold_uncertainty_score":0.8010588},"labels":[],"label_agreement":null},{"id":"W2107790510","doi":"10.1158/1535-7163.mct-09-0193","title":"Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"U.S. National Library of Medicine; National Cancer Institute","keywords":"Imatinib mesylate; GiST; Imatinib; Stromal tumor; Medicine; Cancer research; PDGFRA; Oncology; Internal medicine; Stromal cell","score_opus":0.022835729548239446,"score_gpt":0.32724604666114254,"score_spread":0.3044103171129031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107790510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932727,0.0011511352,0.0010245452,0.0038645815,0.000012131218,0.00052885286,0.0000137367215,0.00003993053,0.000092359354],"genre_scores_gemma":[0.96559864,0.000016628328,0.03208207,0.002136174,0.000028403301,0.000042515374,0.0000062558347,0.000023873667,0.000065463864],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99852383,0.00012263839,0.00020921166,0.00033291298,0.00035156743,0.00045983295],"domain_scores_gemma":[0.99928015,0.000048199134,0.00004591381,0.00024864473,0.00008416584,0.00029290176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019831872,0.00021338188,0.00025197113,0.00017460967,0.00004661147,0.000032086366,0.00008814437,0.00002326676,0.000030938452],"category_scores_gemma":[0.00007336917,0.00017462425,0.000056872304,0.00020392932,0.0000454069,0.000033055276,0.000040202467,0.00027480567,0.0000060391153],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058005676,0.00019347935,0.012599261,0.000015235151,0.000016774513,0.0031676628,0.00011551831,0.000117516174,0.9731053,0.000017013343,0.000018348426,0.0048333067],"study_design_scores_gemma":[0.003933935,0.0063845017,0.3131777,0.0010486827,0.000060175378,0.0014560389,0.00009069905,0.0006313809,0.6724197,0.0003295139,0.0002234552,0.00024421126],"about_ca_topic_score_codex":0.000028189645,"about_ca_topic_score_gemma":0.0000065037634,"teacher_disagreement_score":0.3006856,"about_ca_system_score_codex":0.00016285155,"about_ca_system_score_gemma":0.0001584127,"threshold_uncertainty_score":0.712097},"labels":[],"label_agreement":null},{"id":"W2107867323","doi":"10.1158/1535-7163.mct-04-0077","title":"Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Antimicrobial Peptides and Activities","field":"Immunology and Microbiology","cited_by":260,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Jurkat cells; Apoptosis; Biology; Cancer cell; Programmed cell death; Cytotoxic T cell; Cell biology; Cell culture; Cytochrome c; Annexin; Caspase; Molecular biology; Biochemistry; In vitro; Immunology; T cell; Cancer; Immune system","score_opus":0.018128054094807257,"score_gpt":0.25673612980095234,"score_spread":0.2386080757061451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107867323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894129,0.008973505,0.000087777174,0.0005253848,0.00009447449,0.00014719395,0.00001747219,0.000033599317,0.00070771686],"genre_scores_gemma":[0.9967985,0.0004279396,0.00010371877,0.0014543162,0.0000506497,0.000018399149,0.000017867065,0.000029861158,0.001098743],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990818,0.00008823803,0.00019961648,0.0002738671,0.000029523077,0.00032697283],"domain_scores_gemma":[0.9997019,0.000024737725,0.00008074955,0.00013682096,0.000039278417,0.000016499012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006810992,0.00020715981,0.0002544208,0.00010979746,0.00012546401,0.000023423761,0.00012837659,0.00020181281,0.00008021012],"category_scores_gemma":[0.000001941239,0.00019447142,0.00005307731,0.00013531573,0.00014713714,0.00008300921,0.000056955152,0.00030998164,0.0000108467175],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057315614,0.0000646747,0.0049161077,0.000018276041,0.00006762394,0.000002183039,0.0006959045,0.000056995555,0.9873907,0.00015057063,0.00015278909,0.006426844],"study_design_scores_gemma":[0.0009827983,0.00012883238,0.0072250143,0.000025040523,0.000055059776,0.0000060647385,0.00020025395,0.000017974866,0.9845928,0.00007645801,0.0064457366,0.0002439892],"about_ca_topic_score_codex":0.0011478575,"about_ca_topic_score_gemma":0.00030909295,"teacher_disagreement_score":0.008545565,"about_ca_system_score_codex":0.00014517836,"about_ca_system_score_gemma":0.00008158974,"threshold_uncertainty_score":0.7930314},"labels":[],"label_agreement":null},{"id":"W2108052323","doi":"10.1158/1535-7163.mct-11-0058","title":"Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Ovarian Cancer Canada; Government of Ontario","keywords":"Docetaxel; Dosing; Chemotherapy; Pharmacology; Ovarian cancer; Drug resistance; Medicine; Cancer; Downregulation and upregulation; Efflux; Internal medicine; Oncology; Biology; Gene","score_opus":0.04093129730218682,"score_gpt":0.3039166700605155,"score_spread":0.2629853727583287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108052323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95783204,0.030843938,0.00065182085,0.0058479514,0.00036391662,0.0008272851,0.000010203886,0.00007616522,0.0035467055],"genre_scores_gemma":[0.97681415,0.0028677848,0.011956386,0.0070833284,0.00007145698,0.0005486366,0.0000062048457,0.00007014414,0.00058190373],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99823123,0.000051594187,0.00040067302,0.00049068587,0.0003612818,0.00046454085],"domain_scores_gemma":[0.9992052,0.000015566404,0.00013392024,0.00040392193,0.0001109472,0.00013049447],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016288926,0.00030834757,0.0003947207,0.00014390271,0.00009093173,0.00003030813,0.00016914101,0.0001085843,0.0004700107],"category_scores_gemma":[0.0000031636175,0.0002737361,0.00009728663,0.0004323103,0.00009044992,0.00007975882,0.000029668045,0.00021908655,0.000012794491],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016879303,0.0019225143,0.77485347,0.0003974726,0.0024572741,0.0006350594,0.02027937,0.00008548053,0.056464408,0.002954054,0.00028602255,0.13797696],"study_design_scores_gemma":[0.0053366697,0.00006414733,0.3208118,0.0010012973,0.00025515232,0.000005595003,0.00015486055,0.00003307893,0.5975176,0.0004921996,0.07379211,0.0005354738],"about_ca_topic_score_codex":0.00076170365,"about_ca_topic_score_gemma":0.0015534195,"teacher_disagreement_score":0.54105324,"about_ca_system_score_codex":0.0006485569,"about_ca_system_score_gemma":0.0006654721,"threshold_uncertainty_score":0.9999715},"labels":[],"label_agreement":null},{"id":"W2108585358","doi":"10.1158/1535-7163.mct-12-1012","title":"Single-Domain Antibody–Based and Linker-Free Bispecific Antibodies Targeting FcγRIII Induce Potent Antitumor Activity without Recruiting Regulatory T Cells","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nautical Research Society","funders":"","keywords":"Antibody; Antigen; Bispecific antibody; Fragment crystallizable region; Fc receptor; Monoclonal antibody; Cytotoxic T cell; Chemistry; Antibody-dependent cell-mediated cytotoxicity; Carcinoembryonic antigen; Receptor; Cytotoxicity; Peripheral blood mononuclear cell; Molecular biology; Cancer research; Biology; Immunology; In vitro; Biochemistry; Cancer","score_opus":0.0477747923252392,"score_gpt":0.32061872969535077,"score_spread":0.2728439373701116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108585358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828011,0.007367516,0.0014295602,0.0060147527,0.00026394852,0.00095416146,0.000042017044,0.000111701855,0.0010152824],"genre_scores_gemma":[0.9885279,0.000945545,0.0071094823,0.0022850747,0.00030440936,0.00005889428,0.000036472746,0.00010695854,0.0006252921],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970066,0.00022285165,0.00043688895,0.00068478903,0.0008211173,0.0008277725],"domain_scores_gemma":[0.9983546,0.00010500377,0.00021914329,0.00066016894,0.00034146875,0.0003196081],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037800867,0.00046327687,0.00063411647,0.00022233694,0.0003455316,0.00015616737,0.0002897273,0.00021507165,0.00014329635],"category_scores_gemma":[0.000034717705,0.00039455327,0.00020209483,0.0003288712,0.00046281607,0.00016092784,0.0002291516,0.00066977117,0.00002709912],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002551909,0.00022150956,0.018778421,0.00030107223,0.00027498364,0.00013319838,0.00024266774,0.000024478933,0.95159477,0.00008714243,0.00022946592,0.027857076],"study_design_scores_gemma":[0.0021460743,0.0004624732,0.038563926,0.00055788277,0.00019827302,0.00004723822,0.00027088536,0.0032583638,0.9354282,0.00042704315,0.017965136,0.0006745201],"about_ca_topic_score_codex":0.00044139792,"about_ca_topic_score_gemma":0.00001658429,"teacher_disagreement_score":0.027182557,"about_ca_system_score_codex":0.00014745475,"about_ca_system_score_gemma":0.00023712563,"threshold_uncertainty_score":0.99985063},"labels":[],"label_agreement":null},{"id":"W2110033484","doi":"10.1158/1535-7163.mct-07-0302","title":"Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-κB, p53, bax, and p27 levels","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Gene silencing; Cyclin D1; Biology; Small interfering RNA; Cancer research; Apoptosis; Molecular biology; Cell culture; Cell cycle; Biochemistry; Genetics; Transfection; Gene","score_opus":0.043564459720718846,"score_gpt":0.26053918392861986,"score_spread":0.216974724207901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110033484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98912364,0.00882554,0.00061190047,0.00016874449,0.00006551509,0.0005251516,0.00008175667,0.000045350127,0.0005523906],"genre_scores_gemma":[0.99552745,0.0023702264,0.00042812328,0.0014294203,0.00001557776,0.00002616366,0.000012926671,0.00011710248,0.00007302672],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979486,0.00010815044,0.00048532354,0.00048155623,0.00051061454,0.00046579773],"domain_scores_gemma":[0.999064,0.000054944918,0.0002116787,0.00039503438,0.00013032416,0.00014399909],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000117177224,0.00033634904,0.00063272193,0.00027886874,0.000054100045,0.000012534002,0.00014192892,0.0002756846,0.000060088187],"category_scores_gemma":[0.000017652123,0.00032370727,0.000109416666,0.0005658107,0.00017182676,0.00009065983,0.000058902384,0.00027814074,0.000002540346],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009946526,0.0014781562,0.021261394,0.00025814978,0.00066802,0.0020352309,0.0107553,0.0039662574,0.94859135,0.00006550545,0.000050758186,0.009875196],"study_design_scores_gemma":[0.025410753,0.0011677669,0.0634535,0.0024063054,0.0005867898,0.00023934714,0.0010224056,0.03474942,0.8686361,0.0004553146,0.00062204234,0.0012503056],"about_ca_topic_score_codex":0.0015288638,"about_ca_topic_score_gemma":0.00046264677,"teacher_disagreement_score":0.07995533,"about_ca_system_score_codex":0.00052018464,"about_ca_system_score_gemma":0.00047269807,"threshold_uncertainty_score":0.9999215},"labels":[],"label_agreement":null},{"id":"W2110468894","doi":"10.1158/1535-7163.mct-05-0244","title":"Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non–small cell lung cancer receiving paclitaxel","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":219,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Paclitaxel; Lung cancer; Internal medicine; Oncology; Chemotherapy; Tubulin; Survival analysis; Medicine; Cancer; Prognostic variable; Cancer research; Immunology; Biology; Microtubule","score_opus":0.00737668742288458,"score_gpt":0.24447623848799582,"score_spread":0.23709955106511124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110468894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99387646,0.004067147,0.0009969965,0.00018029258,0.00010028768,0.0006357384,0.00006612253,0.000013079442,0.000063881926],"genre_scores_gemma":[0.9956875,0.0009062394,0.0010737114,0.0018446973,0.000059189562,0.00014367428,0.000034204302,0.00006973065,0.00018105074],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982633,0.00015791417,0.0003869022,0.0005512382,0.00018369782,0.00045697097],"domain_scores_gemma":[0.999261,0.000018700566,0.00014985178,0.00039597927,0.000075989345,0.00009843107],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002372571,0.00031116832,0.0002814647,0.00011267325,0.000050764098,0.00003303943,0.00021154687,0.00020943256,0.000009690228],"category_scores_gemma":[0.0000069842213,0.00028438246,0.000055880242,0.00015911952,0.000060720355,0.000011018102,0.0001270236,0.00025958972,8.838913e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012690293,0.00016959457,0.26451546,0.00005425872,0.000033199438,0.000009845426,0.00039527053,0.0023994255,0.72967756,5.340869e-7,0.000045282235,0.0014305525],"study_design_scores_gemma":[0.0072379108,0.00035761323,0.12723093,0.00030053992,0.00008555203,0.0000015012341,0.00011198665,0.0032439004,0.85339993,0.0000027097915,0.0073627266,0.00066473347],"about_ca_topic_score_codex":0.00011764897,"about_ca_topic_score_gemma":0.0008007838,"teacher_disagreement_score":0.13728455,"about_ca_system_score_codex":0.00015069605,"about_ca_system_score_gemma":0.00016452385,"threshold_uncertainty_score":0.99996084},"labels":[],"label_agreement":null},{"id":"W2110804935","doi":"10.1158/1535-7163.mct-12-1039","title":"Expression of Leukemia-Associated Fusion Proteins Increases Sensitivity to Histone Deacetylase Inhibitor–Induced DNA Damage and Apoptosis","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Vorinostat; DNA damage; DNA repair; Biology; Cancer research; Histone deacetylase inhibitor; Apoptosis; Downregulation and upregulation; Histone deacetylase; Myeloid leukemia; Cell cycle; Molecular biology; Cell cycle checkpoint; Histone; DNA; Biochemistry; Gene","score_opus":0.016967447127626288,"score_gpt":0.2886146272937587,"score_spread":0.27164718016613243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110804935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99699956,0.0007182537,0.00068322965,0.00033922313,0.000082048886,0.0010050648,0.00006198293,0.000029746287,0.000080906655],"genre_scores_gemma":[0.9977782,0.00017654065,0.0006738263,0.00073971314,0.00008763525,0.00023239995,0.00007161046,0.000074474556,0.00016565078],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99779725,0.00038626487,0.00034417,0.00057065097,0.00045497585,0.00044669214],"domain_scores_gemma":[0.99859524,0.000030359037,0.00016682476,0.00057245453,0.00037652973,0.00025861105],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003090467,0.000312811,0.00033728217,0.00013462674,0.00014774936,0.000038281178,0.00017085458,0.0003136303,0.000031668827],"category_scores_gemma":[0.00013486785,0.00030983854,0.00011871448,0.00026649004,0.00014809816,0.000014335127,0.0003233451,0.00021728536,0.000010087843],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001296639,0.00017945949,0.00018057175,0.000043956756,0.000073089024,0.0000069801445,0.00016225537,0.00005669497,0.9943842,0.000003727217,0.0007638634,0.0040154816],"study_design_scores_gemma":[0.0008710638,0.0004233323,0.0012209511,0.0001275899,0.000043250715,0.0000040403033,0.000068345056,0.00014493646,0.99549365,0.000010091951,0.0012476313,0.0003450932],"about_ca_topic_score_codex":0.0018415134,"about_ca_topic_score_gemma":0.00021824297,"teacher_disagreement_score":0.0036703881,"about_ca_system_score_codex":0.0002614509,"about_ca_system_score_gemma":0.00028083927,"threshold_uncertainty_score":0.9999354},"labels":[],"label_agreement":null},{"id":"W2111521405","doi":"10.1158/1535-7163.mct-11-1014","title":"CTLA-4 Blockade Expands Infiltrating T Cells and Inhibits Cancer Cell Repopulation during the Intervals of Chemotherapy in Murine Mesothelioma","year":2012,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Mesothelioma Applied Research Foundation","keywords":"Blockade; Mesothelioma; Chemotherapy; Cancer research; Repopulation; Medicine; Cancer; Biology; Oncology; Immunology; Internal medicine; Pathology; Cell biology; Receptor; Stem cell","score_opus":0.018637470073894474,"score_gpt":0.2933234176663179,"score_spread":0.27468594759242343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111521405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9629168,0.03515303,0.00007464644,0.0008737163,0.00019328202,0.0005027948,0.000014044801,0.000024590658,0.0002471073],"genre_scores_gemma":[0.991501,0.0063893534,0.00019601449,0.0014328047,0.00014801933,0.00008872583,0.000003858562,0.000055461955,0.00018475897],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99851,0.000085588516,0.000516732,0.00023293465,0.00028778077,0.00036698073],"domain_scores_gemma":[0.9992192,0.000033518696,0.0002696179,0.00034104008,0.00006834477,0.00006827136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032404138,0.00023855275,0.00034352034,0.00009835441,0.00006606809,0.000019570061,0.0001047474,0.0001234825,0.00013861673],"category_scores_gemma":[0.00000389957,0.00017876062,0.000119615,0.00034578386,0.00011358079,0.00011178585,0.000036814785,0.0001897352,4.5779265e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006588066,0.00012623012,0.0618564,0.00020306779,0.00017932893,0.0000036859665,0.0032023024,0.00004340696,0.92056787,0.000006112498,0.0000067063356,0.013146064],"study_design_scores_gemma":[0.0029694058,0.00009639228,0.062240534,0.00029331044,0.000103082646,0.000019809737,0.00033256126,0.00018372638,0.93191785,0.00001231901,0.0016424966,0.00018852239],"about_ca_topic_score_codex":0.0012619646,"about_ca_topic_score_gemma":0.0001781213,"teacher_disagreement_score":0.028763676,"about_ca_system_score_codex":0.0002106945,"about_ca_system_score_gemma":0.0000739316,"threshold_uncertainty_score":0.7289647},"labels":[],"label_agreement":null},{"id":"W2111592390","doi":"10.1158/1535-7163.mct-09-0868","title":"Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic, and Pharmacodynamic Evaluation from an Expansion Cohort","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Sorafenib; Erlotinib; Medicine; Pharmacodynamics; Pharmacokinetics; Pharmacology; Dosing; Internal medicine; Oncology; Epidermal growth factor receptor; Cancer; Hepatocellular carcinoma","score_opus":0.023696432221420247,"score_gpt":0.4094501007553262,"score_spread":0.3857536685339059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111592390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938723,0.003312395,0.00036576958,0.00072385784,0.00017663374,0.0013153242,0.00008406061,0.000022759677,0.00012694095],"genre_scores_gemma":[0.9956509,0.0027382153,0.000322983,0.00077732414,0.0000447672,0.00013541135,0.00028375429,0.00003402894,0.000012607412],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988399,0.00009286441,0.00030426512,0.000297659,0.0003138139,0.00015145859],"domain_scores_gemma":[0.999363,0.00002815689,0.00013098486,0.0001949949,0.00019355144,0.00008929358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022673012,0.00017107998,0.00027959526,0.00011957276,0.00005023632,0.000016748585,0.000051506737,0.000074283176,0.000123454],"category_scores_gemma":[0.0000053945732,0.00015364989,0.000032605756,0.00014289153,0.00009724358,0.000108403125,0.000014817117,0.00017926832,4.3519202e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043183865,0.0007228833,0.013543039,0.000013500738,0.00021113583,0.000007552357,0.0009449175,0.00004542004,0.6785026,0.000040579405,0.0000016156049,0.3055349],"study_design_scores_gemma":[0.059182446,0.0017804956,0.22385775,0.00018110189,0.0018953059,0.00001981419,0.0002224738,0.114124246,0.59601355,0.0014840658,0.0008272413,0.00041154254],"about_ca_topic_score_codex":0.0005594201,"about_ca_topic_score_gemma":0.00013124006,"teacher_disagreement_score":0.30512336,"about_ca_system_score_codex":0.00007745311,"about_ca_system_score_gemma":0.00018913657,"threshold_uncertainty_score":0.62656605},"labels":[],"label_agreement":null},{"id":"W2111954625","doi":"10.1158/1535-7163.mct-10-0590","title":"Reovirus Virotherapy Overrides Tumor Antigen Presentation Evasion and Promotes Protective Antitumor Immunity","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Viral gastroenteritis research and epidemiology","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Canadian Institutes of Health Research","keywords":"Immune system; Oncolytic virus; Antigen; Cancer research; Tumor microenvironment; Virotherapy; Immunology; Biology; Immunotherapy; Dendritic cell; Antigen presentation; Tumor antigen; T cell","score_opus":0.03400446285726151,"score_gpt":0.3567167288196482,"score_spread":0.3227122659623867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111954625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99328613,0.0016009418,0.0017845478,0.0019084834,0.0001177278,0.0011177392,0.000020271707,0.000051327203,0.00011280529],"genre_scores_gemma":[0.99503404,0.0012749103,0.0013927353,0.0019267151,0.00010593663,0.00016209295,0.000014973916,0.00003800492,0.00005059281],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99869514,0.00018958886,0.00021609364,0.00029535822,0.00023784438,0.0003660025],"domain_scores_gemma":[0.9993183,0.000017132992,0.00008631669,0.000306203,0.00013324156,0.00013879147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029372814,0.00017681322,0.00028934362,0.000091624155,0.0001291958,0.000031196156,0.00010292504,0.0000857247,0.00008512344],"category_scores_gemma":[0.000088009336,0.00014790306,0.00007533545,0.0001263538,0.00025069155,0.00009148518,0.00005232284,0.00053121103,0.0000046105474],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006079115,0.00010022741,0.048373375,0.000058888516,0.00013880947,0.00006617976,0.00015380535,0.0000023910468,0.92878807,0.000053762888,0.00002002213,0.021636542],"study_design_scores_gemma":[0.0025951914,0.0014787589,0.31916758,0.00014507928,0.000071013244,0.00022562892,0.00008439298,0.0013457529,0.6671376,0.0013760102,0.00613697,0.00023600987],"about_ca_topic_score_codex":0.00075851777,"about_ca_topic_score_gemma":0.00018136445,"teacher_disagreement_score":0.27079418,"about_ca_system_score_codex":0.00004573198,"about_ca_system_score_gemma":0.00010990683,"threshold_uncertainty_score":0.60313123},"labels":[],"label_agreement":null},{"id":"W2112099873","doi":"10.1158/1535-7163.mct-06-0100","title":"A non–RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis <i>in vivo</i>","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":199,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Canadian Institutes of Health Research; McGill University Health Centre; McGill University","keywords":"Metastasis; Breast cancer; In vivo; Cancer; Cancer research; Medicine; Metastatic breast cancer; Pathology; Biology; Internal medicine","score_opus":0.019052252458583222,"score_gpt":0.2994801537536257,"score_spread":0.28042790129504247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112099873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98602355,0.0045455312,0.0011465488,0.005315424,0.00010703574,0.00080703053,0.00013724215,0.00007058801,0.0018470453],"genre_scores_gemma":[0.9938343,0.00089276186,0.0009986444,0.002945849,0.000115034134,0.00024084623,0.000021439186,0.00011977413,0.0008313191],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973179,0.00010503301,0.00044231513,0.00064846117,0.0007506924,0.0007355744],"domain_scores_gemma":[0.9989601,0.00006254665,0.000114571805,0.00045193065,0.00019568909,0.00021519262],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024761676,0.00040576278,0.0005417963,0.0004588447,0.000096693366,0.00007633673,0.00022006227,0.0001845238,0.00046153375],"category_scores_gemma":[0.000009398457,0.00036588626,0.00018830321,0.00085358333,0.00019872129,0.000057769783,0.000099776225,0.00059427763,0.000008965039],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004373722,0.00026048374,0.057536952,0.00019154124,0.00020742186,0.00046661845,0.00010820025,0.0002892865,0.93354887,0.000056885558,0.0003570194,0.006539357],"study_design_scores_gemma":[0.0048788358,0.00019607434,0.014158142,0.0004983629,0.00046242322,0.00009050061,0.00011044305,0.00418995,0.9644387,0.000092410606,0.010295093,0.0005891118],"about_ca_topic_score_codex":0.004917833,"about_ca_topic_score_gemma":0.0008001783,"teacher_disagreement_score":0.04337881,"about_ca_system_score_codex":0.00039551745,"about_ca_system_score_gemma":0.000474544,"threshold_uncertainty_score":0.9998793},"labels":[],"label_agreement":null},{"id":"W2112317932","doi":"10.1158/1535-7163.mct-08-0326","title":"Down-regulation of X-linked inhibitor of apoptosis synergistically enhanced peroxisome proliferator-activated receptor γ ligand-induced growth inhibition in colon cancer","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Peroxisome Proliferator-Activated Receptors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"XIAP; Troglitazone; Inhibitor of apoptosis; Apoptosis; Cancer research; Angiogenesis; Chemistry; Cancer cell; Peroxisome proliferator-activated receptor; Receptor; Biology; Cancer; Programmed cell death; Caspase; Biochemistry","score_opus":0.01924725001374443,"score_gpt":0.26673867782384786,"score_spread":0.24749142781010341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112317932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99663514,0.00083213474,0.0009285143,0.00030793608,0.0003257482,0.0007654171,0.00010321678,0.000035226258,0.00006668417],"genre_scores_gemma":[0.9966217,0.001676591,0.00056132727,0.00033408462,0.00017272032,0.00035430052,0.0001457297,0.00009872582,0.00003478389],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973055,0.00023397006,0.0008375926,0.00065469305,0.00049237453,0.0004758854],"domain_scores_gemma":[0.998131,0.000025927391,0.0004932167,0.0005466649,0.0006742876,0.00012889795],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018085827,0.00043921513,0.0006023795,0.00024225343,0.00008966388,0.0000137116,0.00025982747,0.0005875438,0.000059763664],"category_scores_gemma":[0.00010227916,0.00044682017,0.00019032629,0.0007235376,0.00025340362,0.000027846394,0.00012147766,0.0003009715,0.000002354609],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010731103,0.0003794263,0.0021928495,0.00012207762,0.00029091138,0.000001980545,0.0003693728,0.00047131992,0.99416035,0.000048565067,0.000048202575,0.0008418536],"study_design_scores_gemma":[0.0019998695,0.000554602,0.0011748846,0.00020219377,0.000064600106,0.0000033635959,0.000044335524,0.00009685015,0.9951412,0.000050366645,0.00020723694,0.0004605028],"about_ca_topic_score_codex":0.00019311576,"about_ca_topic_score_gemma":0.000039836723,"teacher_disagreement_score":0.0010179648,"about_ca_system_score_codex":0.00021905874,"about_ca_system_score_gemma":0.0005571937,"threshold_uncertainty_score":0.99979836},"labels":[],"label_agreement":null},{"id":"W2112332697","doi":"10.1158/1535-7163.mct-07-0172","title":"Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Selenium in Biological Systems","field":"Nursing","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Survivin; Chromatin immunoprecipitation; Promoter; Cancer research; Molecular biology; Biology; Small interfering RNA; Cancer cell; Sp1 transcription factor; Transcription factor; Gene expression; Transcription (linguistics); LNCaP; Chemistry; Cancer; Gene; Biochemistry; Transfection; Genetics","score_opus":0.0330193369078273,"score_gpt":0.30994565275181263,"score_spread":0.2769263158439853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112332697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885275,0.0013546868,0.0079062,0.00040400182,0.0007159526,0.0006803907,0.00002648579,0.00008559799,0.00029918458],"genre_scores_gemma":[0.9980139,0.000013459076,0.00087443576,0.0007565654,0.00012749339,0.0000343835,0.000019621664,0.00004980197,0.000110337016],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998087,0.00019412875,0.00047736306,0.00037558202,0.00038718415,0.00047874058],"domain_scores_gemma":[0.99921465,0.00007048866,0.00023123636,0.00025019998,0.00013421586,0.000099231314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072109484,0.00021435374,0.0002656613,0.00013190637,0.00008379953,0.00002903986,0.0001777809,0.00021780355,0.000050628452],"category_scores_gemma":[0.00002848033,0.00018824867,0.000097695636,0.00049209205,0.00003133862,0.00006985238,0.00006691729,0.00018879003,0.000016644593],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014549037,0.00008226291,0.0031923887,0.000076591736,0.000029852534,0.0000014695407,0.0004796996,0.0000250535,0.9895507,0.000012821847,0.000121045436,0.0062826257],"study_design_scores_gemma":[0.00034372837,0.00016451364,0.0006279869,0.0002992868,0.00003504635,0.0000026289904,0.00007743224,0.000058409732,0.99111056,0.000040958414,0.007003041,0.00023643188],"about_ca_topic_score_codex":0.00005157315,"about_ca_topic_score_gemma":0.0000146213015,"teacher_disagreement_score":0.009486402,"about_ca_system_score_codex":0.00018665724,"about_ca_system_score_gemma":0.000012717704,"threshold_uncertainty_score":0.7676558},"labels":[],"label_agreement":null},{"id":"W2113026440","doi":"10.1158/1535-7163.mct-08-0400","title":"Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells <i>in vitro</i> via suppression of c-FLIP-s levels and activation of CD95","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Mitochondrial Function and Pathology","field":"Biochemistry, Genetics and Molecular Biology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Neurological Disorders and Stroke; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Geldanamycin; MAPK/ERK pathway; Protein kinase B; Cancer research; Protein kinase A; Chemistry; p38 mitogen-activated protein kinases; Caspase 8; Kinase; Cell biology; Biology; Molecular biology; Programmed cell death; Apoptosis; Hsp90; Signal transduction; Caspase; Biochemistry; Heat shock protein","score_opus":0.02153823245135176,"score_gpt":0.2646778597574336,"score_spread":0.24313962730608182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113026440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905203,0.00045193743,0.008104091,0.00010640909,0.00011432483,0.00057060935,0.00007088042,0.000009899425,0.00005156851],"genre_scores_gemma":[0.9942884,0.000028253873,0.004814134,0.00044004098,0.0000700554,0.00006163163,0.00004786975,0.000039306586,0.00021029598],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99844265,0.00020595767,0.0004233378,0.00046949214,0.00018356983,0.00027501973],"domain_scores_gemma":[0.9991685,0.000020458474,0.0002246026,0.00031299985,0.00015758906,0.00011582835],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014397071,0.00026634525,0.00033465968,0.00013817598,0.0000730657,0.0000076272636,0.000119193515,0.00014544484,0.00001831378],"category_scores_gemma":[0.000034324585,0.00026451933,0.00007427311,0.00019816156,0.00016826445,0.000009769803,0.00010358157,0.0001632074,3.0618202e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008788149,0.00010845127,0.0005975266,0.000053697666,0.000036250098,0.00003082301,0.00018543201,0.00019045685,0.99658686,0.000009750454,0.000081186416,0.001240724],"study_design_scores_gemma":[0.0012591131,0.0006661743,0.00095836376,0.00012470344,0.00002795142,0.000044176766,0.000041288964,0.00006915438,0.9948759,0.000025556314,0.0016650556,0.0002425639],"about_ca_topic_score_codex":0.00017197005,"about_ca_topic_score_gemma":0.00002453162,"teacher_disagreement_score":0.0037681311,"about_ca_system_score_codex":0.00002996928,"about_ca_system_score_gemma":0.00008575871,"threshold_uncertainty_score":0.9999807},"labels":[],"label_agreement":null},{"id":"W2114383393","doi":"10.1158/1535-7163.mct-10-0735","title":"Pancratistatin Selectively Targets Cancer Cell Mitochondria and Reduces Growth of Human Colon Tumor Xenografts","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chemical synthesis and alkaloids","field":"Chemistry","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Windsor","funders":"National Research Council Canada","keywords":"Apoptosis; Programmed cell death; Cancer cell; Biology; Cancer research; Mitochondrion; Cell culture; Molecular biology; Terminal deoxynucleotidyl transferase; Cancer; Cell biology; TUNEL assay; Biochemistry; Genetics","score_opus":0.022704713456772243,"score_gpt":0.2597427636189568,"score_spread":0.23703805016218457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114383393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98318034,0.010487527,0.00006014667,0.000055375964,0.000070864546,0.00010698966,0.00010299793,0.00003882525,0.0058969134],"genre_scores_gemma":[0.99731845,0.0010610553,0.00092505256,0.00026858237,0.000081948245,0.00011117467,0.000008122312,0.000053429605,0.00017217897],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879247,0.00003031234,0.00029707456,0.00035923978,0.00021194025,0.00030896362],"domain_scores_gemma":[0.99933326,0.000029401723,0.00021603446,0.00019207,0.00013363312,0.0000955706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000046408793,0.00024739574,0.00032099368,0.000033083452,0.00008587628,0.000020078533,0.00021111386,0.00010785248,0.0008997045],"category_scores_gemma":[0.0000050382087,0.00023292816,0.00008945325,0.00015733023,0.00015794029,0.000052908417,0.00005089263,0.00016454334,0.000001051694],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006579766,0.00014616348,0.002292725,0.00015652244,0.00016099491,0.000009624639,0.0007919672,4.101022e-7,0.9943015,0.00013897712,0.00017227916,0.0017630351],"study_design_scores_gemma":[0.00048398267,0.000057120742,0.00069120177,0.00008283804,0.00015212016,0.0000016220714,0.00010945073,0.000023246397,0.99640656,0.00071051874,0.0009965214,0.00028483165],"about_ca_topic_score_codex":0.0018296571,"about_ca_topic_score_gemma":0.00013345867,"teacher_disagreement_score":0.014138096,"about_ca_system_score_codex":0.00007949081,"about_ca_system_score_gemma":0.00006340949,"threshold_uncertainty_score":0.9851134},"labels":[],"label_agreement":null},{"id":"W2114788766","doi":"10.1158/1535-7163.mct-06-0417","title":"Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":188,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital; Vancouver Hospital and Health Sciences Centre; University of British Columbia Hospital","funders":"","keywords":"Hsp27; Gene knockdown; Paclitaxel; Cancer research; Bladder cancer; Heat shock protein; Apoptosis; Cell growth; Cancer cell; In vivo; Biology; Cancer; Medicine; Hsp70; Internal medicine; Biochemistry","score_opus":0.020248630632105562,"score_gpt":0.32835803411700953,"score_spread":0.30810940348490395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114788766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801936,0.009625945,0.008610809,0.00056345353,0.00008879635,0.00067699637,0.00002431828,0.000025487772,0.00019057369],"genre_scores_gemma":[0.9928028,0.0010490194,0.0014583918,0.0041896966,0.0001688142,0.00009194981,0.000012457327,0.00012748424,0.00009940387],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975785,0.00014574872,0.00041217124,0.0006864401,0.00038993286,0.00078720105],"domain_scores_gemma":[0.99906784,0.00002096438,0.00011740047,0.0004826292,0.00015582921,0.00015530766],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004533808,0.00038880575,0.00031752198,0.0001862685,0.00016334491,0.00007152359,0.0003227885,0.00023800417,0.000095199466],"category_scores_gemma":[0.000010200564,0.00039085376,0.00011158009,0.00036142662,0.00027230452,0.000011093547,0.0001040163,0.0003309342,0.0000017735928],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019845666,0.00011873349,0.0051132925,0.000066624074,0.00015388918,0.00003587154,0.00019782569,0.00026849937,0.98588765,0.00003227172,0.00001487857,0.007911985],"study_design_scores_gemma":[0.0013533169,0.00019026684,0.0014616644,0.00008135153,0.00002721689,0.0000034454863,0.000065069864,0.0003515874,0.9910711,0.0000911842,0.004836763,0.00046700446],"about_ca_topic_score_codex":0.00086001604,"about_ca_topic_score_gemma":0.0006216656,"teacher_disagreement_score":0.012609163,"about_ca_system_score_codex":0.00013414402,"about_ca_system_score_gemma":0.00030312184,"threshold_uncertainty_score":0.9998543},"labels":[],"label_agreement":null},{"id":"W2114905010","doi":"10.1158/1535-7163.1127.3.9","title":"Brain tumor cell lines resistant to <i>O</i>6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have <i>O</i>6-alkylguanine-DNA alkyltransferase mutations","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Neurological Disorders and Stroke; National Cancer Institute","keywords":"Carmustine; Nitrosourea; Cell culture; Cancer research; Biology; Molecular biology; Chemotherapy; Etoposide; Genetics","score_opus":0.01190603776951182,"score_gpt":0.2658752838930298,"score_spread":0.25396924612351796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114905010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9414667,0.0037181408,0.043491874,0.008165933,0.00042693553,0.0012643419,0.00035476737,0.00018355867,0.0009277511],"genre_scores_gemma":[0.9492165,0.00038134799,0.0078305835,0.04012221,0.00039787695,0.00036541402,0.00027017563,0.000304166,0.0011117692],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965803,0.00013526971,0.00063388847,0.0011247902,0.00059372134,0.00093202974],"domain_scores_gemma":[0.9978538,0.00002734199,0.00018019193,0.001181726,0.00034955266,0.00040735988],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027622812,0.00073869544,0.00049220683,0.00017259855,0.00024732834,0.00013137984,0.0007169978,0.0003148611,0.000067994784],"category_scores_gemma":[0.000037746984,0.0007715501,0.00041152805,0.0004428688,0.00015186484,0.00001663847,0.00012405404,0.0003211727,0.000035292065],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053239655,0.00029944276,0.00006174889,0.000049492173,0.00025103436,0.00009537657,0.00046706418,0.0028527193,0.9932578,0.00036912947,0.0005436002,0.0012201824],"study_design_scores_gemma":[0.0030696357,0.0008815216,0.00006957812,0.00005543289,0.00013617925,0.000030345918,0.00022376944,0.000046294463,0.8969257,0.0006398516,0.09707688,0.00084483187],"about_ca_topic_score_codex":0.00021264465,"about_ca_topic_score_gemma":0.00045559596,"teacher_disagreement_score":0.09653328,"about_ca_system_score_codex":0.00016235947,"about_ca_system_score_gemma":0.000578372,"threshold_uncertainty_score":0.9994736},"labels":[],"label_agreement":null},{"id":"W2115427861","doi":"10.1158/1535-7163.mct-05-0302","title":"Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"STAT3; STAT protein; Paclitaxel; Cancer research; Head and neck squamous-cell carcinoma; Apoptosis; Activator (genetics); Chemistry; Cancer; Medicine; Biology; Head and neck cancer; Internal medicine; Receptor","score_opus":0.02353293548528013,"score_gpt":0.2876131956695739,"score_spread":0.26408026018429376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115427861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9408458,0.0052104793,0.052019626,0.0011054435,0.000073872514,0.0005682469,0.0001227246,0.000025899708,0.000027892023],"genre_scores_gemma":[0.99537796,0.00077218114,0.002763916,0.000713798,0.00015798579,0.00011011927,0.00002411712,0.000051108622,0.000028796348],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991237,0.000016171767,0.00023168499,0.00025374617,0.00016824152,0.00020647066],"domain_scores_gemma":[0.99958974,0.000017816265,0.00009252893,0.00009793667,0.0001485211,0.000053472213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006087622,0.00018596828,0.00027643493,0.00006829582,0.00008382358,0.000024158444,0.000034535635,0.00007249177,0.000049940838],"category_scores_gemma":[9.0075923e-7,0.00014867948,0.00008790642,0.0001014096,0.00009095657,0.00006995241,0.0000031377313,0.00012504905,7.0212785e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014745549,0.00020508892,0.00090951443,0.00011114916,0.0002935493,0.0000031811574,0.00047562073,0.0007909537,0.9849921,0.0000951723,0.0000213629,0.010627756],"study_design_scores_gemma":[0.0075132526,0.0013985075,0.0063953907,0.0003413482,0.00046768982,0.00003129956,0.00017610234,0.006029041,0.9675686,0.00009540069,0.009714341,0.0002690251],"about_ca_topic_score_codex":0.00085861376,"about_ca_topic_score_gemma":0.00006816162,"teacher_disagreement_score":0.054532163,"about_ca_system_score_codex":0.000035955174,"about_ca_system_score_gemma":0.000108373584,"threshold_uncertainty_score":0.6062973},"labels":[],"label_agreement":null},{"id":"W2117096084","doi":"10.1158/1535-7163.mct-08-0753","title":"UBE1L causes lung cancer growth suppression by targeting cyclin D1","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Cyclin D1; Cancer research; Cyclin B; Cyclin D; Cyclin; Biology; Cyclin A; Cyclin A2; Cyclin E; Cell cycle; Gene knockdown; Molecular biology; Cancer; Biochemistry; Apoptosis; Genetics","score_opus":0.01612231471546178,"score_gpt":0.2856829874855768,"score_spread":0.26956067277011503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117096084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81898147,0.17620784,0.0010040754,0.0010644519,0.0018994677,0.0002510171,0.00011260525,0.00012279539,0.00035629934],"genre_scores_gemma":[0.97902995,0.012277095,0.000045102115,0.0030970506,0.000046193487,0.00009923683,0.00008766015,0.0000634834,0.005254238],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99837494,0.00031164227,0.0003270918,0.00036163148,0.00007868449,0.0005459943],"domain_scores_gemma":[0.9993643,0.0000653418,0.00013167907,0.0002765818,0.00013170976,0.000030348316],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000101843165,0.0002959756,0.0003202031,0.00007973732,0.00034096118,0.000016879847,0.00030837688,0.00028966868,0.0011706457],"category_scores_gemma":[0.000020412985,0.00025711663,0.0001468267,0.00014227748,0.00023917983,0.000079051766,0.000090833346,0.00041172994,0.00006702877],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034178,0.00008424646,0.003996192,0.00002306838,0.00046538084,0.000022649656,0.0006957321,0.000015966783,0.9662161,0.00004570511,0.026765086,0.0013281209],"study_design_scores_gemma":[0.0009029026,0.00007417835,0.00061181607,0.0000667201,0.000099009565,0.000028625524,0.00006997917,0.00003099226,0.8474083,0.000013864265,0.15039693,0.00029671175],"about_ca_topic_score_codex":0.00069348497,"about_ca_topic_score_gemma":0.00001489121,"teacher_disagreement_score":0.16393074,"about_ca_system_score_codex":0.00012645105,"about_ca_system_score_gemma":0.00015836918,"threshold_uncertainty_score":0.9999881},"labels":[],"label_agreement":null},{"id":"W2117428432","doi":"10.1158/1535-7163.mct-13-0842","title":"The Tyrphostin NT157 Suppresses Insulin Receptor Substrates and Augments Therapeutic Response of Prostate Cancer","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"Canadian Institutes of Health Research","keywords":"LNCaP; Prostate cancer; IRS1; Cancer research; Insulin-like growth factor 1 receptor; Downregulation and upregulation; Protein kinase B; PI3K/AKT/mTOR pathway; Androgen receptor; MAPK/ERK pathway; Endocrinology; Insulin receptor; Cancer; Signal transduction; Internal medicine; Biology; Growth factor; Receptor; Medicine; Insulin; Insulin resistance; Cell biology; Biochemistry","score_opus":0.014327079659651961,"score_gpt":0.2817261972726698,"score_spread":0.2673991176130178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117428432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9339778,0.063365616,0.00048697533,0.0012061158,0.00040025005,0.00037810826,0.00010784405,0.000021669926,0.00005566648],"genre_scores_gemma":[0.9857455,0.01186716,0.00019991705,0.0013527692,0.00013142457,0.00021938916,0.000022700391,0.0000799952,0.0003811268],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99798423,0.00039612906,0.00038027752,0.0004847599,0.0003124035,0.00044218762],"domain_scores_gemma":[0.9986741,0.00013293988,0.00025285472,0.0005977895,0.00024943904,0.00009286239],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005947808,0.00031887073,0.00025664517,0.000043749456,0.00018819628,0.000068282134,0.00041798872,0.00018841574,0.000032500524],"category_scores_gemma":[0.000064110616,0.00024910766,0.0001015436,0.00017476261,0.00040515393,0.000007630136,0.000114453986,0.00017564489,0.0000027260442],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018077304,0.0000442971,0.0069881375,0.000043191634,0.00036833266,0.0000010693241,0.00022124506,0.00033448904,0.959467,0.000081651335,0.00018560664,0.03045724],"study_design_scores_gemma":[0.0009342451,0.00041419704,0.0033793713,0.00006681052,0.000101200225,0.000002822024,0.000065928936,0.0001675506,0.8805847,0.00021815355,0.11376682,0.00029820035],"about_ca_topic_score_codex":0.000121614285,"about_ca_topic_score_gemma":0.000070808586,"teacher_disagreement_score":0.11358121,"about_ca_system_score_codex":0.000050292158,"about_ca_system_score_gemma":0.00026325477,"threshold_uncertainty_score":0.9999961},"labels":[],"label_agreement":null},{"id":"W2117514750","doi":"10.1158/1535-7163.mct-07-2376","title":"Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death<i>in vitro</i>and<i>in vivo</i>","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"In vivo; In vitro; Programmed cell death; Cancer research; Chemistry; Transient (computer programming); Cell culture; Cell biology; Biology; Apoptosis; Pharmacology; Biochemistry; Genetics","score_opus":0.014835812172876427,"score_gpt":0.22654438564568544,"score_spread":0.211708573472809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117514750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98936194,0.00949884,0.00028663987,0.00009836577,0.00013291699,0.00033110465,0.00006761809,0.0000060714383,0.00021649318],"genre_scores_gemma":[0.9962505,0.002028603,0.00045251203,0.0010259917,0.0000472871,0.00004750503,0.000009545479,0.000038883318,0.00009917729],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987058,0.000077637764,0.00030363855,0.0004228493,0.00016273397,0.00032733273],"domain_scores_gemma":[0.9994811,0.000010607338,0.00006417245,0.00028640253,0.00004115001,0.00011657568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009443455,0.00023906145,0.00027946942,0.00009902658,0.000038153576,0.000008455974,0.00012273813,0.0001660073,0.000004015971],"category_scores_gemma":[0.0000026698383,0.00024108724,0.000069846785,0.00014082446,0.00008141535,0.000004210534,0.00006092913,0.00010858627,5.556765e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023244566,0.00017374541,0.008730759,0.000059226248,0.000022412756,0.00007387796,0.00065212254,0.0000992269,0.9893718,0.0000072891207,0.000039637835,0.00053750386],"study_design_scores_gemma":[0.0020487965,0.00029133412,0.0035115303,0.000025756615,0.0000288972,0.00001571629,0.00007320155,0.000025494237,0.98668903,0.000011017564,0.007016531,0.0002627171],"about_ca_topic_score_codex":0.00021635811,"about_ca_topic_score_gemma":0.00017988,"teacher_disagreement_score":0.0074702366,"about_ca_system_score_codex":0.000024295408,"about_ca_system_score_gemma":0.00010495378,"threshold_uncertainty_score":0.9831252},"labels":[],"label_agreement":null},{"id":"W2118283685","doi":"10.1158/1535-7163.mct-09-0478","title":"Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent <i>O</i> 6-methylguanine-DNA methyltransferase","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; McGill University; University of British Columbia; Montreal Children's Hospital; BC Cancer Agency","funders":"C17 Council; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Temozolomide; Methyltransferase; Cancer research; Medicine; Glioblastoma; O-6-methylguanine-DNA methyltransferase; Cancer; Brain tumor; Internal medicine; Oncology; Gene; Biology; Pathology; Methylation; Biochemistry","score_opus":0.013756989929822161,"score_gpt":0.27043612883997775,"score_spread":0.2566791389101556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118283685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931461,0.0011766073,0.00057694764,0.0037176467,0.00003786715,0.0012068242,0.000050378854,0.00002411403,0.000063507156],"genre_scores_gemma":[0.99698925,0.000229363,0.0010680412,0.0015672649,0.000025132977,0.00007579736,0.000006990666,0.000027415837,0.000010754931],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99865544,0.00006444565,0.00037619643,0.00026394226,0.00039624912,0.00024371606],"domain_scores_gemma":[0.99924165,0.00004752575,0.00012482521,0.00027912503,0.00019859953,0.00010830258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019998613,0.00022722923,0.00040105023,0.00017210368,0.00006146316,0.000014702097,0.000064356194,0.000097071694,0.000009526013],"category_scores_gemma":[0.000018614903,0.00015776439,0.0001402287,0.00036207662,0.0000797654,0.00003966704,0.000023023667,0.00013759876,0.0000017394038],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004635824,0.00027591223,0.0009212868,0.00006706805,0.0002928201,0.000084084495,0.0007464483,0.000025055675,0.985967,0.0003539539,0.000006396889,0.010796432],"study_design_scores_gemma":[0.0022559976,0.0012677391,0.0019140161,0.0002815722,0.00047644234,0.00003260849,0.00017707456,0.000041953543,0.99313813,0.00019461114,0.00007602521,0.00014381522],"about_ca_topic_score_codex":0.00010972935,"about_ca_topic_score_gemma":0.00003880553,"teacher_disagreement_score":0.010652618,"about_ca_system_score_codex":0.00007525383,"about_ca_system_score_gemma":0.00006743241,"threshold_uncertainty_score":0.64334446},"labels":[],"label_agreement":null},{"id":"W2118566193","doi":"10.1158/1535-7163.mct-05-0030","title":"The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Sesquiterpenes and Asteraceae Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":159,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Parthenolide; Docetaxel; In vivo; Medicine; Pharmacology; Cancer research; Sesquiterpene lactone; Metastasis; Apoptosis; In vitro; Cancer; Internal medicine; Chemistry; Biology; Sesquiterpene; Biochemistry; Stereochemistry","score_opus":0.017568944458584736,"score_gpt":0.2848227319139941,"score_spread":0.26725378745540934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118566193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811722,0.016019203,0.00035057124,0.0020740398,0.000038056303,0.00022957113,0.00005990728,0.0000041731746,0.000052286276],"genre_scores_gemma":[0.9917156,0.007377166,0.00029562422,0.000372595,0.000035653255,0.000105182946,0.0000086171285,0.000026790693,0.00006274282],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99896336,0.00007092251,0.00025305912,0.00027895524,0.00016130258,0.00027242603],"domain_scores_gemma":[0.99952614,0.00001582867,0.00012228113,0.00021116891,0.00009318346,0.00003142094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016973335,0.00019263026,0.00022554662,0.000055282428,0.000060736485,0.000033494576,0.00014982546,0.000061985425,0.000002195059],"category_scores_gemma":[0.0000029452344,0.00013510864,0.000045253124,0.00015772239,0.0001550075,0.000012633794,0.000086237036,0.00009150354,1.15124074e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005507633,0.00015848345,0.011412556,0.000031256288,0.0002994907,0.0000020523592,0.0006874618,0.0061989413,0.8716538,0.000121363875,0.000004524526,0.1088793],"study_design_scores_gemma":[0.0058387625,0.00050436455,0.03935158,0.00023844288,0.00027801227,0.000015784532,0.001459818,0.022619074,0.92354786,0.00032895184,0.0049820356,0.0008353117],"about_ca_topic_score_codex":0.00024646503,"about_ca_topic_score_gemma":0.0031244883,"teacher_disagreement_score":0.10804398,"about_ca_system_score_codex":0.000029838453,"about_ca_system_score_gemma":0.000082788945,"threshold_uncertainty_score":0.5509571},"labels":[],"label_agreement":null},{"id":"W2119142674","doi":"10.1158/1535-7163.mct-04-0107","title":"Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2–related protein Bad","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"Trichostatin A; Histone deacetylase; Histone deacetylase inhibitor; Apoptosis; Cancer research; Cell cycle checkpoint; Biology; Cell cycle; Viability assay; Cell biology; Molecular biology; Chemistry; Histone; Genetics; Gene","score_opus":0.011151770276515777,"score_gpt":0.27048365189860496,"score_spread":0.2593318816220892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119142674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99411005,0.003579732,0.000051004703,0.0009768215,0.00011433557,0.00088535115,0.00008996887,0.000016003187,0.00017671636],"genre_scores_gemma":[0.9983909,0.00022344114,0.00020795243,0.00026154958,0.00006958042,0.00021869325,0.00002636976,0.00008711992,0.0005143866],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99747425,0.00033758735,0.0005424288,0.0005867043,0.00056288124,0.0004961621],"domain_scores_gemma":[0.9987104,0.000021586373,0.00035733083,0.00059685693,0.00018698236,0.00012682978],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034435224,0.0003617471,0.00034552335,0.00011182183,0.00013763372,0.000029610139,0.00032433032,0.00039405044,0.00002900435],"category_scores_gemma":[0.00004810528,0.0002809537,0.00012325741,0.00048643703,0.00034156168,0.0000137209045,0.00019418857,0.00048685138,0.0000013784381],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033974598,0.0002160677,0.00040893938,0.00004214175,0.00018815426,0.00000478191,0.00037852157,0.0011769839,0.9948545,0.000023094964,0.00009227246,0.002274763],"study_design_scores_gemma":[0.0020583912,0.00018893887,0.0013309442,0.00066458277,0.0000625342,0.0000018841997,0.000055193723,0.00034322424,0.99212307,0.000014169373,0.0027966008,0.00036047725],"about_ca_topic_score_codex":0.00083213067,"about_ca_topic_score_gemma":0.0015237145,"teacher_disagreement_score":0.0042808405,"about_ca_system_score_codex":0.0003921695,"about_ca_system_score_gemma":0.0004640887,"threshold_uncertainty_score":0.99996424},"labels":[],"label_agreement":null},{"id":"W2119501278","doi":"10.1158/1535-7163.mct-07-0299","title":"TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Gemcitabine; Pancreatic cancer; Cytotoxicity; Combination therapy; Apoptosis; Cancer research; Medicine; Monoclonal antibody; Pancreatic tumor; Pharmacology; Growth inhibition; Cancer; Internal medicine; Oncology; In vitro; Antibody; Immunology; Chemistry; Biochemistry","score_opus":0.013922291159863435,"score_gpt":0.2705841328905045,"score_spread":0.25666184173064105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119501278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97460455,0.005824389,0.018811062,0.00019803476,0.00010231003,0.00030333316,0.000014602004,0.000022731627,0.00011901418],"genre_scores_gemma":[0.99293315,0.0034053253,0.0021543005,0.0011480361,0.00011145011,0.000015980362,0.00011328132,0.000036645888,0.000081839964],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987033,0.00006533005,0.00027070174,0.00046407324,0.0001567446,0.00033984034],"domain_scores_gemma":[0.99944854,0.000013912927,0.00010545075,0.00021737142,0.00009694507,0.00011777053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002531034,0.00025526187,0.00025316406,0.000064933134,0.000112989466,0.000043285545,0.00010125009,0.00021237438,0.000013624768],"category_scores_gemma":[0.000011118525,0.00022032057,0.0000684302,0.0001403543,0.00012464201,0.0000068643685,0.00007561785,0.00012810878,6.6000996e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000075542965,0.000042841057,0.0080224415,0.000033788514,0.00014334297,0.000016212405,0.000047139485,0.000012159505,0.9848915,0.0004847017,0.0000047571434,0.00622562],"study_design_scores_gemma":[0.0009671279,0.00030195233,0.03344266,0.000028311808,0.0001471528,0.000057127923,0.000036717614,0.0001879456,0.9615722,0.00041587398,0.002493364,0.00034957274],"about_ca_topic_score_codex":0.000039929007,"about_ca_topic_score_gemma":0.000008062624,"teacher_disagreement_score":0.02542022,"about_ca_system_score_codex":0.00001848798,"about_ca_system_score_gemma":0.000042915162,"threshold_uncertainty_score":0.8984412},"labels":[],"label_agreement":null},{"id":"W2119528020","doi":"10.1158/1535-7163.mct-12-0072","title":"Cotargeting Stress-Activated Hsp27 and Autophagy as a Combinatorial Strategy to Amplify Endoplasmic Reticular Stress in Prostate Cancer","year":2012,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Hsp27; Autophagy; Unfolded protein response; Gene silencing; Endoplasmic reticulum; Cell biology; Cancer research; Cancer cell; Programmed cell death; Biology; Heat shock protein; Apoptosis; Cancer; Hsp70; Biochemistry","score_opus":0.020288330371814704,"score_gpt":0.3277551220036669,"score_spread":0.3074667916318522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119528020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98735535,0.0103623755,0.00017630226,0.0003053594,0.00029773233,0.0010956356,0.00017749945,0.000026871736,0.00020288749],"genre_scores_gemma":[0.99679005,0.0013921779,0.0001679222,0.0005693786,0.00022638547,0.00055050675,0.00008911248,0.00009577784,0.00011869739],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99734825,0.0003081204,0.00035094915,0.0005761442,0.00042657604,0.0009899762],"domain_scores_gemma":[0.9989371,0.000021758055,0.00008872652,0.00045234736,0.00015854025,0.00034157952],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032736675,0.0003627915,0.00031894306,0.00012739313,0.000115240065,0.0000862164,0.0002806633,0.00027642283,0.00006470414],"category_scores_gemma":[0.000053810407,0.00036918354,0.00006456052,0.00033132677,0.00011339431,0.000020528993,0.0002468497,0.0004103858,0.0000084094],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035289666,0.00017192782,0.019461425,0.00008833121,0.00018093019,0.00003584549,0.00039097972,0.0011361099,0.9714681,0.00026938083,0.000019834128,0.0064242696],"study_design_scores_gemma":[0.0014294875,0.00040834516,0.0020474347,0.00010586003,0.00003389238,0.000009812943,0.00018876832,0.00013927228,0.9845067,0.00009973924,0.010589469,0.00044120496],"about_ca_topic_score_codex":0.0013311296,"about_ca_topic_score_gemma":0.0002002981,"teacher_disagreement_score":0.01741399,"about_ca_system_score_codex":0.00016391647,"about_ca_system_score_gemma":0.00035317175,"threshold_uncertainty_score":0.999876},"labels":[],"label_agreement":null},{"id":"W2119722464","doi":"10.1158/1535-7163.mct-04-0315","title":"Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of General Medical Sciences; National Cancer Institute","keywords":"Irinotecan; Chemistry; Camptothecin; Pharmacokinetics; Apoptosis; Pharmacology; Cancer research; Biochemistry; Cancer; Biology; Medicine; Internal medicine","score_opus":0.022519276494559825,"score_gpt":0.321063407416807,"score_spread":0.2985441309222472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119722464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97652584,0.020725857,0.001131206,0.0009316078,0.00007406688,0.00041160212,0.000053889788,0.00001941768,0.00012650367],"genre_scores_gemma":[0.9920356,0.0032248998,0.00043456032,0.003738772,0.00016434825,0.00012145475,0.00006659282,0.00007074,0.00014300772],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99853486,0.00008522103,0.00031654126,0.0005177122,0.00014674017,0.00039890397],"domain_scores_gemma":[0.99944603,0.000005535432,0.00009408788,0.00026126046,0.000050348244,0.00014271367],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013322508,0.00030845823,0.00024717068,0.00010092139,0.00012103459,0.000058172944,0.00016796429,0.00013114435,0.000027669348],"category_scores_gemma":[0.0000014689781,0.0003348166,0.000058769965,0.00014256044,0.00008077331,0.000009886282,0.000099311255,0.0002016558,0.0000011233988],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006426362,0.00009545337,0.00017645326,0.000018515217,0.00013540729,0.0000038176095,0.00018662114,0.00011279328,0.94550127,0.00010898909,0.00002683329,0.05356956],"study_design_scores_gemma":[0.0027913523,0.00040294166,0.0003179834,0.000027786573,0.00010012365,0.00001610003,0.000030811014,0.0006904173,0.9234707,0.00010734288,0.07163746,0.00040699003],"about_ca_topic_score_codex":0.00018718542,"about_ca_topic_score_gemma":0.00028606885,"teacher_disagreement_score":0.07161062,"about_ca_system_score_codex":0.0000633319,"about_ca_system_score_gemma":0.000070090886,"threshold_uncertainty_score":0.9999104},"labels":[],"label_agreement":null},{"id":"W2119871165","doi":"10.1158/1535-7163.mct-06-0159","title":"Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance","keywords":"Antibody; Liposome; Internalization; Trastuzumab; Cancer research; In vivo; Chemistry; Monoclonal antibody; Viability assay; Cancer; Cell; Biology; Immunology; Biochemistry; Breast cancer","score_opus":0.06995553550740947,"score_gpt":0.3823563580540386,"score_spread":0.31240082254662915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119871165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738517,0.017000154,0.0066370014,0.00021398917,0.00041868893,0.00046765615,0.00007111571,0.000033241584,0.0013064456],"genre_scores_gemma":[0.9954653,0.0021678333,0.0012873833,0.0005674557,0.00020070441,0.00000862414,0.000029761277,0.000057745954,0.00021521059],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99782115,0.000083054016,0.00045452453,0.00033644246,0.0007665733,0.0005382602],"domain_scores_gemma":[0.99888414,0.00007284939,0.0001859325,0.00031679583,0.00037150847,0.00016875056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002766299,0.00027156767,0.00042977446,0.00011083465,0.000100213816,0.000015236848,0.00015359516,0.0001615835,0.00021796215],"category_scores_gemma":[0.0000044343965,0.00023070621,0.00020637183,0.00029064502,0.00022966778,0.00006036886,0.000063390486,0.00026052698,0.0000032617738],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006194752,0.00019294542,0.0789505,0.00021622577,0.00036896556,0.000060733604,0.0003029387,0.00037670395,0.88310826,0.00050071196,9.606072e-7,0.035301585],"study_design_scores_gemma":[0.0019318255,0.00026438932,0.095119864,0.0001932977,0.0003422151,0.000022279426,0.00021746768,0.01290165,0.886409,0.00021080994,0.0020615677,0.00032562227],"about_ca_topic_score_codex":0.0018073855,"about_ca_topic_score_gemma":0.00016309536,"teacher_disagreement_score":0.03497596,"about_ca_system_score_codex":0.00022090429,"about_ca_system_score_gemma":0.00034730244,"threshold_uncertainty_score":0.9407926},"labels":[],"label_agreement":null},{"id":"W2119900319","doi":"10.1158/1535-7163.mct-07-0181","title":"Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Pharmacology; Pharmacokinetics; CYP3A4; Pharmacodynamics; Cyclophosphamide; Aldehyde dehydrogenase; Dosing; Chemotherapy; Drug; Doxorubicin; Medicine; Chemistry; Cytochrome P450; Enzyme; Internal medicine; Metabolism; Biochemistry","score_opus":0.018920540200897777,"score_gpt":0.3265055325236362,"score_spread":0.3075849923227384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119900319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98435825,0.012564009,0.0013427458,0.00009769913,0.00016470574,0.0012575424,0.0000053880117,0.000026777694,0.00018285088],"genre_scores_gemma":[0.99457896,0.0045844107,0.00015184421,0.00050861255,0.000040892213,0.000049124454,0.00000625971,0.000052761152,0.000027142845],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985563,0.00007081379,0.00047314295,0.00030976385,0.00026916683,0.00032082552],"domain_scores_gemma":[0.9994647,0.000067863104,0.00012044916,0.0002017459,0.00005689675,0.000088376706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003292638,0.0002195027,0.00036667887,0.00021780547,0.000023047562,0.000007021625,0.00010397473,0.000070034774,0.00005816285],"category_scores_gemma":[0.0000015698834,0.00021155109,0.000056550332,0.00034805672,0.000066206005,0.000035500623,0.000014951631,0.00021055646,0.0000025650127],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008804286,0.0008969253,0.03300766,0.00022270823,0.00038251988,0.0001573304,0.0020241933,0.0003800224,0.8964966,0.000010960967,9.038617e-7,0.06553976],"study_design_scores_gemma":[0.021517524,0.0011817162,0.14114088,0.00022665139,0.0005287007,0.000040257393,0.0006459571,0.0042079175,0.82983565,0.00002945944,0.00031605165,0.00032920553],"about_ca_topic_score_codex":0.00028102146,"about_ca_topic_score_gemma":0.00014265114,"teacher_disagreement_score":0.10813322,"about_ca_system_score_codex":0.00024508464,"about_ca_system_score_gemma":0.00012450325,"threshold_uncertainty_score":0.8626803},"labels":[],"label_agreement":null},{"id":"W2120070286","doi":"10.1158/1535-7163.mct-13-0598","title":"Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Università di Catania","keywords":"Pharmacology; In vitro; Signal transduction; Cancer; In vivo; Receptor; Monoclonal antibody; Cancer cell; Growth inhibition; Antibody; Cancer research; Biology; Medicine; Immunology; Cell biology; Internal medicine; Biochemistry","score_opus":0.021321436416336523,"score_gpt":0.3013254112828246,"score_spread":0.28000397486648804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120070286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809019,0.0009860827,0.016333727,0.00057603314,0.00005276085,0.0010440436,0.00002247706,0.000028571705,0.000054417367],"genre_scores_gemma":[0.99854726,0.00030646264,0.00047957816,0.00041388487,0.000025190679,0.00009770099,0.000041812604,0.00003934464,0.0000487757],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99908745,0.00003136922,0.00021008073,0.00025729954,0.00019936869,0.00021444708],"domain_scores_gemma":[0.9993554,0.00006385943,0.00013925435,0.00013096981,0.00022334151,0.0000872254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008418628,0.0001981509,0.00031509125,0.00012764956,0.000110670095,0.00003176092,0.00004862256,0.00007908943,0.000012497319],"category_scores_gemma":[0.000008502447,0.00016669263,0.000046761055,0.00015478351,0.00010740636,0.00011790002,0.00002090395,0.00012360181,5.0353333e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002025724,0.00013144272,0.005265985,0.00032514796,0.00023139929,0.000004253001,0.0002616249,0.000010680901,0.98993534,0.0011481867,0.000008609345,0.0024747816],"study_design_scores_gemma":[0.0073149805,0.0017583498,0.06617742,0.00023679397,0.00091489975,0.000041306677,0.00011454828,0.017774321,0.903704,0.001354299,0.0002376803,0.00037144456],"about_ca_topic_score_codex":0.00013438644,"about_ca_topic_score_gemma":0.000016508895,"teacher_disagreement_score":0.08623136,"about_ca_system_score_codex":0.000034257264,"about_ca_system_score_gemma":0.000086676424,"threshold_uncertainty_score":0.6797528},"labels":[],"label_agreement":null},{"id":"W2121030224","doi":"10.1158/1535-7163.mct-10-0413","title":"Modulation of 4E-BP1 Function as a Critical Determinant of Enzastaurin-Induced Apoptosis","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"PI3K/AKT/mTOR pathway; EIF4E; Cancer research; Protein kinase B; Biology; Kinase; Cell biology; Apoptosis; EIF4G; Signal transduction; Translation (biology); Biochemistry; Messenger RNA; Gene","score_opus":0.02080046411245612,"score_gpt":0.31405611619262674,"score_spread":0.2932556520801706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121030224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98577124,0.0006699051,0.012200787,0.00015665474,0.00073606765,0.00018411454,0.00002701757,0.000012708955,0.00024152256],"genre_scores_gemma":[0.99823016,0.00007867819,0.00091266324,0.00044836782,0.00017477576,0.000049490984,0.000020264963,0.000048942362,0.000036664624],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99866825,0.00006702691,0.00035610463,0.00035174028,0.00029905082,0.00025781273],"domain_scores_gemma":[0.9988706,0.000022967091,0.00017232989,0.00053639745,0.00032456164,0.00007311892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001610659,0.00020166999,0.00023202828,0.00006687599,0.000044472443,0.000012358466,0.000222954,0.00029333777,0.0000711427],"category_scores_gemma":[0.000056721616,0.00020444002,0.0001674277,0.00013994242,0.00015580961,0.000006612921,0.0000664165,0.000190431,0.0000024268384],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023086311,0.00009401228,0.0008076263,0.000055957436,0.00014065203,0.0000011391878,0.000056524157,0.0001605377,0.9801522,0.0004871425,0.00001268619,0.017800689],"study_design_scores_gemma":[0.00048992067,0.0005797881,0.0011929956,0.000032702534,0.00014148708,0.000005248352,0.000022048876,0.0004702491,0.9930115,0.0005415566,0.0032962244,0.00021633046],"about_ca_topic_score_codex":0.00009289722,"about_ca_topic_score_gemma":0.000036982547,"teacher_disagreement_score":0.01758436,"about_ca_system_score_codex":0.000023735061,"about_ca_system_score_gemma":0.00019882819,"threshold_uncertainty_score":0.8336822},"labels":[],"label_agreement":null},{"id":"W2121447040","doi":"10.1158/1535-7163.mct-06-0316","title":"Potentiation of radiation sensitivity in breast tumor cells by the vitamin D3 analogue, EB 1089, through promotion of autophagy and interference with proliferative recovery","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Telomeres, Telomerase, and Senescence","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"National Cancer Institute","keywords":"Programmed cell death; Apoptosis; Radiation sensitivity; Cancer research; Reactive oxygen species; Autophagy; Biology; Mitotic catastrophe; DNA damage; Radioresistance; Cell biology; Chemistry; Cell culture; Biochemistry; Irradiation; Genetics; DNA","score_opus":0.010005527643853632,"score_gpt":0.24187143673724246,"score_spread":0.23186590909338883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121447040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98268676,0.0011039336,0.014709005,0.0008039316,0.00004125221,0.0005002489,0.00008787541,0.0000117356785,0.000055255572],"genre_scores_gemma":[0.9988874,0.00032492785,0.00025730455,0.00038953783,0.000022360655,0.000020472358,0.00005480719,0.000016151118,0.000027035747],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99899,0.00014321884,0.00027268796,0.0002190182,0.00022612365,0.00014895182],"domain_scores_gemma":[0.9993939,0.00003130908,0.00022772644,0.00018398663,0.00014255884,0.000020559328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015992895,0.00014455669,0.00026138313,0.00006498739,0.000030848518,0.00001130195,0.000042633845,0.000057955087,0.000006024607],"category_scores_gemma":[0.0000040986206,0.00010418764,0.000036913105,0.00028652517,0.0001414411,0.00010413851,0.000013315232,0.00012805975,2.6022715e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046091384,0.00027781975,0.026520303,0.00012900353,0.00008829552,0.000019400708,0.0006615954,0.00030180623,0.9479546,0.00007483179,0.000023282259,0.023488132],"study_design_scores_gemma":[0.0010323174,0.0003435952,0.17791362,0.00018739939,0.000115672505,0.00004440362,0.000089595254,0.0022335942,0.81773955,0.00014848915,0.000040354294,0.0001113771],"about_ca_topic_score_codex":0.0010019238,"about_ca_topic_score_gemma":0.00033546463,"teacher_disagreement_score":0.15139332,"about_ca_system_score_codex":0.000076684715,"about_ca_system_score_gemma":0.000112499576,"threshold_uncertainty_score":0.42486486},"labels":[],"label_agreement":null},{"id":"W2123027432","doi":"10.1158/1535-7163.mct-07-0138","title":"Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":273,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; University of Pittsburgh; AstraZeneca","keywords":"Gefitinib; Erlotinib; Head and neck squamous-cell carcinoma; Cancer research; Epithelial–mesenchymal transition; Epidermal growth factor receptor; Biology; Vimentin; Squamous carcinoma; Medicine; Pathology; Oncology; Carcinoma; Internal medicine; Cancer; Head and neck cancer; Immunohistochemistry; Metastasis","score_opus":0.014017879677184339,"score_gpt":0.2841128916032479,"score_spread":0.27009501192606356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123027432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98039055,0.013831526,0.002188665,0.0006061532,0.000110721776,0.0009802534,0.000121321944,0.000018207475,0.0017525755],"genre_scores_gemma":[0.9954073,0.00021970473,0.0026416234,0.0011235046,0.000091184476,0.000055800887,0.000028721912,0.000049793463,0.00038240777],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99856806,0.000036570025,0.00038112904,0.00039848467,0.0002390729,0.0003766639],"domain_scores_gemma":[0.9992692,0.000046527406,0.00010135826,0.0002542706,0.00013440695,0.00019425254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013138904,0.00025344847,0.0003561654,0.00017683387,0.000062869636,0.000016463791,0.00006765174,0.0001355799,0.000009034587],"category_scores_gemma":[0.0000030128683,0.00023975805,0.00006840125,0.00026384392,0.00007099979,0.000043304743,0.000023176945,0.00016337547,7.3198845e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002098185,0.0008241453,0.20004654,0.002004507,0.00008689675,0.00058655895,0.021495353,0.00030903213,0.7690243,0.00004855417,0.00005405588,0.0034218382],"study_design_scores_gemma":[0.010090646,0.0009292426,0.33606493,0.00018503908,0.00079481205,0.0000124322505,0.0006166143,0.0005605457,0.64915377,0.000050037434,0.0011980627,0.00034388347],"about_ca_topic_score_codex":0.0008749553,"about_ca_topic_score_gemma":0.0012210009,"teacher_disagreement_score":0.1360184,"about_ca_system_score_codex":0.00015957668,"about_ca_system_score_gemma":0.00022244603,"threshold_uncertainty_score":0.977705},"labels":[],"label_agreement":null},{"id":"W2124328035","doi":"10.1158/1535-7163.mct-05-0157","title":"Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"XIAP; Histone deacetylase inhibitor; Apoptosis; Biology; Inhibitor of apoptosis; Free radical scavenger; Histone deacetylase; Cyclin-dependent kinase; Molecular biology; Chemistry; Cancer research; Programmed cell death; Biochemistry; Cell cycle; Caspase; Histone; Oxidative stress","score_opus":0.01260473809142781,"score_gpt":0.29945841185625754,"score_spread":0.28685367376482973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124328035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992574,0.0040858868,0.00021745746,0.0017599744,0.0003181623,0.0006993261,0.00016396701,0.000007844701,0.00017341597],"genre_scores_gemma":[0.9975425,0.00017352236,0.000045220433,0.0009485251,0.00021071947,0.000074978794,0.000029635667,0.000056915127,0.00091796205],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972285,0.00055458857,0.00064881047,0.00043784198,0.0007337322,0.0003965516],"domain_scores_gemma":[0.99816155,0.000026337966,0.00039900868,0.0011482077,0.00020325533,0.00006165349],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006084427,0.00028116742,0.0002723932,0.000052581636,0.00019134868,0.000021472606,0.0007985354,0.0002635574,0.00002281709],"category_scores_gemma":[0.000043447995,0.0001828249,0.00029405972,0.0003439169,0.0005278122,0.000009787191,0.00035303432,0.00046930087,0.0000020760376],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000072446775,0.00020630631,0.00049512554,0.00004365244,0.00007020678,0.0000015814029,0.00021097714,0.0019058865,0.9941448,0.000036497124,0.0009998019,0.0018127284],"study_design_scores_gemma":[0.0010713228,0.00008294545,0.0007963219,0.00006298466,0.00006194252,0.000003408914,0.000072432355,0.0001340551,0.9844714,0.000024554653,0.013022951,0.00019568343],"about_ca_topic_score_codex":0.00079287536,"about_ca_topic_score_gemma":0.0010932076,"teacher_disagreement_score":0.012023149,"about_ca_system_score_codex":0.0004511862,"about_ca_system_score_gemma":0.0004177761,"threshold_uncertainty_score":0.7455383},"labels":[],"label_agreement":null},{"id":"W2124337012","doi":"10.1158/1535-7163.mct-07-2050","title":"Mitochondrial regulation by c-Myc and hypoxia-inducible factor-1α controls sensitivity to econazole","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Endoplasmic Reticulum Stress and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Discovery Centre; University Health Network","funders":"University of Pennsylvania","keywords":"Econazole; Biology; Mitochondrion; Apoptosis; Cell biology; HL60; Molecular biology; Biochemistry","score_opus":0.015362245277534943,"score_gpt":0.25906216322243636,"score_spread":0.24369991794490142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124337012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98644465,0.0027005344,0.009199349,0.00057625666,0.00020903915,0.00034356816,0.00021827778,0.000020298106,0.00028805292],"genre_scores_gemma":[0.99593985,0.0005277366,0.00035817266,0.0024475753,0.00017631374,0.00005329668,0.00009323314,0.00003754698,0.00036626976],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987727,0.00009202337,0.00018160333,0.00046359995,0.00019061666,0.00029945094],"domain_scores_gemma":[0.99927235,0.000014641188,0.000069114525,0.00035760726,0.00008918789,0.00019708769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000042986987,0.00022403216,0.00019995323,0.000033373333,0.00013016432,0.000032276344,0.00008489302,0.00015434682,0.000023713848],"category_scores_gemma":[0.000019553958,0.00022299073,0.00009058694,0.00007221696,0.0000908702,0.000006685761,0.00006550564,0.00008426184,0.0000061082683],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017356098,0.000050923747,0.0020925193,0.000008556805,0.000102787635,0.000017060467,0.000062241896,0.0002616792,0.99333674,0.00003965573,0.0010827726,0.002771494],"study_design_scores_gemma":[0.0014342214,0.000163312,0.0058048987,0.000012173536,0.000056274002,0.000027225562,0.00001886944,0.0003332657,0.94142187,0.00005220282,0.050320257,0.00035545335],"about_ca_topic_score_codex":0.00009109697,"about_ca_topic_score_gemma":0.000038608563,"teacher_disagreement_score":0.0519149,"about_ca_system_score_codex":0.000027771444,"about_ca_system_score_gemma":0.000094770396,"threshold_uncertainty_score":0.9093298},"labels":[],"label_agreement":null},{"id":"W2125755807","doi":"10.1158/1535-7163.mct-14-0399","title":"ANG4043, a Novel Brain-Penetrant Peptide–mAb Conjugate, Is Efficacious against HER2-Positive Intracranial Tumors in Mice","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal; Angiochem (Canada)","funders":"","keywords":"Transcytosis; Monoclonal antibody; Cancer research; Conjugate; LRP1; In vivo; Blood–brain barrier; In vitro; Biology; Antibody; Receptor; Pharmacology; Immunology; Central nervous system; Biochemistry; Endocrinology; Endocytosis","score_opus":0.019523839949170698,"score_gpt":0.3064393769036586,"score_spread":0.2869155369544879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125755807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808091,0.0013075393,0.002338691,0.012019746,0.00014054436,0.0006641937,0.00012745758,0.00004760682,0.0025451586],"genre_scores_gemma":[0.96151143,0.0004364778,0.0010441057,0.035957746,0.0002974803,0.0000527742,0.00006172391,0.000074669515,0.00056357996],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99762326,0.00013193191,0.00041991522,0.0005261223,0.00061833067,0.0006804296],"domain_scores_gemma":[0.9990397,0.00013161887,0.00009329866,0.00031243992,0.00018996335,0.00023296944],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029563234,0.00035241366,0.0005302198,0.00017072428,0.00010545172,0.000044032,0.00024463295,0.00016593702,0.00016371577],"category_scores_gemma":[0.000025406804,0.0003088678,0.0002061719,0.00037904116,0.00024355712,0.000044102348,0.000074033356,0.000601556,0.000055129913],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020766822,0.00075456465,0.002933445,0.00022405846,0.00054979516,0.0008263565,0.0019179562,0.00030911452,0.93539864,0.0009743982,0.0002371509,0.05379784],"study_design_scores_gemma":[0.029363263,0.0052844435,0.18299666,0.0021634062,0.00065144885,0.00086149294,0.0005434167,0.072799735,0.5116425,0.00086453225,0.1897916,0.0030374706],"about_ca_topic_score_codex":0.0008392816,"about_ca_topic_score_gemma":0.00026112885,"teacher_disagreement_score":0.42375612,"about_ca_system_score_codex":0.0001784165,"about_ca_system_score_gemma":0.00023798186,"threshold_uncertainty_score":0.99993634},"labels":[],"label_agreement":null},{"id":"W2126092906","doi":"10.1158/1535-7163.mct-09-0583","title":"Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Cyclophosphamide; Medicine; Angiogenesis; Cancer research; Chemotherapy; Pharmacology; Apoptosis; Cancer; Internal medicine; Biology","score_opus":0.036662051581358324,"score_gpt":0.32175363718286976,"score_spread":0.28509158560151143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126092906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98531646,0.0101192985,0.003393138,0.0002879142,0.00010204951,0.000575611,0.00001640026,0.000032161264,0.00015697854],"genre_scores_gemma":[0.9944101,0.0024948684,0.00054066756,0.0021565042,0.00013716858,0.000113904505,0.000035953915,0.00007657883,0.000034279503],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977808,0.00016852265,0.00040196977,0.00076335313,0.00030565704,0.0005796985],"domain_scores_gemma":[0.9988726,0.000012436436,0.00022303601,0.0006678809,0.000098906974,0.00012514243],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031601338,0.00043924153,0.00046932293,0.00009173658,0.00014497785,0.000066251596,0.00040450695,0.00019299166,0.000012207768],"category_scores_gemma":[0.00000451789,0.00037721804,0.00029467832,0.00025691776,0.00013706078,0.000020834503,0.00007259559,0.00025567025,0.0000016275018],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010754825,0.0007031008,0.005365741,0.000019326919,0.0004497323,0.00003983435,0.00009976843,0.009641528,0.95079225,0.00012313841,0.000011325357,0.03167878],"study_design_scores_gemma":[0.0049708243,0.0021223694,0.047778614,0.000118800745,0.00012728336,0.0000072071184,0.000065052496,0.0013323906,0.9403655,0.00038978815,0.0017917142,0.0009304348],"about_ca_topic_score_codex":0.00014125032,"about_ca_topic_score_gemma":0.00010872619,"teacher_disagreement_score":0.042412873,"about_ca_system_score_codex":0.00010822629,"about_ca_system_score_gemma":0.00020953314,"threshold_uncertainty_score":0.999868},"labels":[],"label_agreement":null},{"id":"W2126163147","doi":"10.1158/1535-7163.mct-08-1186","title":"Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Genomics, phytochemicals, and oxidative stress","field":"Biochemistry, Genetics and Molecular Biology","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"University of Southern California","keywords":"Breast cancer; Cancer research; Cancer; Doxorubicin; Carcinogen; Paclitaxel; Oxidative stress; Cancer cell; Biology; Cytotoxicity; Molecular biology; Chemistry; Chemotherapy; Endocrinology; Biochemistry; In vitro; Genetics","score_opus":0.009806876768941873,"score_gpt":0.2616770354476037,"score_spread":0.2518701586786618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126163147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914817,0.001425725,0.00091394776,0.0050079916,0.000024470353,0.0005370867,0.0005670701,0.000011523601,0.000030443623],"genre_scores_gemma":[0.97915536,0.00066024624,0.0006507675,0.01930505,0.00006719915,0.0000553704,0.00003518418,0.00003575472,0.00003505962],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985178,0.00007734913,0.00017466374,0.0006523384,0.00017928735,0.00039853956],"domain_scores_gemma":[0.9992338,0.000013673012,0.000069825765,0.00029284818,0.00015751862,0.00023233904],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009280987,0.00031356848,0.00030233254,0.000072554416,0.00006695232,0.00004488293,0.000114855575,0.00014868838,0.000007478924],"category_scores_gemma":[0.000013062657,0.00028938855,0.00003915829,0.0002068923,0.000058156864,0.00000718314,0.00009172912,0.0001195742,7.2101847e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044404677,0.00007707467,0.044516545,0.000010976799,0.00012587722,0.000007926962,0.0007809042,0.0002550179,0.9449507,0.0000053916247,0.00015895342,0.00866658],"study_design_scores_gemma":[0.0008491686,0.00026651667,0.16132553,0.00022771211,0.000030513436,0.0000040157583,0.000101371435,0.00003692366,0.83590394,0.000042968888,0.0008283556,0.00038298848],"about_ca_topic_score_codex":0.00029171936,"about_ca_topic_score_gemma":0.0006157033,"teacher_disagreement_score":0.11680898,"about_ca_system_score_codex":0.0000885081,"about_ca_system_score_gemma":0.00007559162,"threshold_uncertainty_score":0.99995583},"labels":[],"label_agreement":null},{"id":"W2126724373","doi":"10.1158/1535-7163.mct-05-0064","title":"A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"","keywords":"Antisense therapy; Bcl-xL; Apoptosis; XIAP; Oligonucleotide; Biology; Cancer research; Inhibitor of apoptosis; LNCaP; Prostate cancer; Molecular biology; Caspase; Programmed cell death; Cancer; Biochemistry; Gene; Genetics; Locked nucleic acid","score_opus":0.015963691219313653,"score_gpt":0.26792920004160753,"score_spread":0.25196550882229385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126724373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99389774,0.0042705983,0.00075550284,0.00029467244,0.00016744049,0.0004407584,0.000043628515,0.000023242495,0.00010640657],"genre_scores_gemma":[0.99328405,0.004139479,0.00108264,0.0010266202,0.00016741348,0.00004678473,0.00003894861,0.00006402122,0.00015006475],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99816954,0.00007717325,0.00036221012,0.00063935475,0.00027270606,0.0004790235],"domain_scores_gemma":[0.99936223,0.000007900234,0.0001868915,0.0002466855,0.000093181385,0.000103136816],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022826772,0.0003468792,0.0003056511,0.00009613827,0.00015865562,0.00007874482,0.00011534033,0.00023644695,0.000010343487],"category_scores_gemma":[0.0000030606864,0.0003482998,0.0001022581,0.00017713758,0.000111636655,0.00002144223,0.000118449425,0.00019540639,0.0000011131506],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006216748,0.000108517146,0.0003188962,0.000047355286,0.00013155382,0.000008202387,0.00036989176,0.0039014772,0.976842,0.000028255614,0.000008477538,0.018173221],"study_design_scores_gemma":[0.0013070935,0.00009073271,0.0016327491,0.00009828544,0.000084712905,0.000013128826,0.0001633924,0.0016640546,0.99325615,0.000024741992,0.0012043602,0.00046061038],"about_ca_topic_score_codex":0.0005899026,"about_ca_topic_score_gemma":0.00071083766,"teacher_disagreement_score":0.01771261,"about_ca_system_score_codex":0.00008318597,"about_ca_system_score_gemma":0.00009920154,"threshold_uncertainty_score":0.9998969},"labels":[],"label_agreement":null},{"id":"W2127372364","doi":"10.1158/1535-7163.mct-07-0329","title":"Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of Integrin-linked kinase (ILK)","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; QLT (Canada); University of British Columbia","funders":"","keywords":"Integrin-linked kinase; Protein kinase B; Angiogenesis; Apoptosis; Cell growth; Cancer research; CD31; DAPI; In vivo; Chemistry; Cell cycle; Flow cytometry; Biology; Molecular biology; Biochemistry","score_opus":0.022975262270749388,"score_gpt":0.28694280679909334,"score_spread":0.263967544528344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127372364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942419,0.004108647,0.0004617632,0.0006197566,0.000027392145,0.0004603727,0.000028566565,0.000009391553,0.000042245523],"genre_scores_gemma":[0.9931852,0.0060473736,0.0002928134,0.000272411,0.000011646589,0.000039283714,0.000032607164,0.000029924293,0.00008872086],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987896,0.000079685335,0.00027821917,0.0002382898,0.0004037672,0.00021040326],"domain_scores_gemma":[0.9994791,0.000023513749,0.00011656526,0.00023285244,0.00006807668,0.00007989278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000106605796,0.00015046712,0.00028165657,0.00018708302,0.000025857536,0.0000031469274,0.000055066546,0.00012974348,0.00007583019],"category_scores_gemma":[0.000010577534,0.00013629512,0.000054111097,0.00019220776,0.00021900554,0.00002918986,0.00007145336,0.00021277762,0.0000015303334],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000680045,0.00025297707,0.004882578,0.00020502455,0.000036399804,0.00006945125,0.00075422134,0.00001787096,0.9850987,0.0000052166183,0.000035317422,0.007962166],"study_design_scores_gemma":[0.0021844206,0.0006598905,0.010467967,0.00033605561,0.00003937254,0.00002371823,0.00013088586,0.00087186956,0.98350996,0.000018746543,0.0016497344,0.00010737901],"about_ca_topic_score_codex":0.0001456719,"about_ca_topic_score_gemma":0.000046224224,"teacher_disagreement_score":0.007854788,"about_ca_system_score_codex":0.000136344,"about_ca_system_score_gemma":0.000052112173,"threshold_uncertainty_score":0.5557954},"labels":[],"label_agreement":null},{"id":"W2127580939","doi":"10.1158/1535-7163.mct-08-0200","title":"Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using β-human choriogonadotropin secreting tumor cell lines","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Toyota Research Institute, North America","keywords":"Metastasis; Medicine; Cancer research; Cancer; Trastuzumab; Antibody; Oncology; Internal medicine; Breast cancer; Immunology","score_opus":0.0419588195616885,"score_gpt":0.3378455719101534,"score_spread":0.2958867523484649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127580939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98297244,0.015273569,0.00022890634,0.00042478886,0.00007215563,0.00095691206,0.000038167604,0.000026448948,0.000006579164],"genre_scores_gemma":[0.9967495,0.0012521191,0.0011477435,0.0004848235,0.00007014944,0.00014147203,0.000018556853,0.00008235685,0.000053240823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815273,0.00019086886,0.00046242782,0.0004379438,0.00038677032,0.00036923971],"domain_scores_gemma":[0.99898773,0.00005786176,0.00024061462,0.00037604736,0.00013018817,0.00020757277],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014370609,0.00033789975,0.0005293048,0.00021770183,0.00012292789,0.000020875812,0.00010110068,0.000048280264,0.000018733077],"category_scores_gemma":[0.00000955113,0.00028662354,0.00013936449,0.00026468138,0.00018627114,0.00005168939,0.000054830107,0.00018899838,7.233389e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002701439,0.00087048433,0.5236641,0.0004543362,0.0003116406,0.0018192121,0.0006492779,0.00028767312,0.46720713,0.000006315167,0.000001205302,0.0020271835],"study_design_scores_gemma":[0.006114752,0.0006961624,0.6413365,0.0007741764,0.00066733814,0.000059644124,0.000045414028,0.0015824243,0.34835514,0.000022450702,0.00003092958,0.00031506922],"about_ca_topic_score_codex":0.00017201097,"about_ca_topic_score_gemma":0.000015393916,"teacher_disagreement_score":0.118851975,"about_ca_system_score_codex":0.0002701194,"about_ca_system_score_gemma":0.00042234545,"threshold_uncertainty_score":0.9999586},"labels":[],"label_agreement":null},{"id":"W2128317422","doi":"10.1158/1535-7163.mct-06-0532","title":"17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Protein kinase B; MAPK/ERK pathway; Protein kinase A; Chemistry; Kinase; p38 mitogen-activated protein kinases; Geldanamycin; Deoxycholic acid; Heat shock protein; Molecular biology; Apoptosis; Biochemistry; Biology; Hsp90; Bile acid","score_opus":0.02460500927441307,"score_gpt":0.3220273320435263,"score_spread":0.29742232276911323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128317422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9620591,0.026778644,0.008992742,0.00047467873,0.000063415566,0.00056457747,0.00001835699,0.000009476707,0.0010390524],"genre_scores_gemma":[0.99324256,0.003390018,0.0014717764,0.0013672317,0.00009815382,0.00007859848,0.000023733914,0.000039587776,0.00028833904],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979366,0.00026180336,0.00044381808,0.00046809198,0.00038493253,0.0005047256],"domain_scores_gemma":[0.99892515,0.00005870557,0.00012081453,0.0006280722,0.00017340924,0.00009382701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012924745,0.00024880678,0.00029119698,0.00009666788,0.00007563211,0.000037286565,0.00043957506,0.00024059216,0.000018708039],"category_scores_gemma":[0.000046601286,0.00019792873,0.00009843054,0.00028620704,0.0002577124,0.000009151316,0.00023525968,0.0003032487,8.442693e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001637187,0.000103315084,0.008140098,0.00008150888,0.00007514418,0.000013001812,0.00021774595,0.00006457968,0.9759087,0.000015825075,0.000034853027,0.0151815275],"study_design_scores_gemma":[0.0006148615,0.0001731335,0.020425446,0.000029866305,0.000029126368,0.000004935656,0.00009602493,0.000070966395,0.96782005,0.00008128975,0.010438456,0.00021584274],"about_ca_topic_score_codex":0.0004663634,"about_ca_topic_score_gemma":0.00091030716,"teacher_disagreement_score":0.031183505,"about_ca_system_score_codex":0.000067282985,"about_ca_system_score_gemma":0.00022711584,"threshold_uncertainty_score":0.80713},"labels":[],"label_agreement":null},{"id":"W2128591359","doi":"10.1158/1535-7163.mct-13-0731","title":"Hedgehog Pathway Inhibition in Chondrosarcoma Using the Smoothened Inhibitor IPI-926 Directly Inhibits Sarcoma Cell Growth","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; SickKids Foundation; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Smoothened; Hedgehog; Hedgehog signaling pathway; Cancer research; Biology; Cell growth; Chondrosarcoma; Vismodegib; Medicine; Cell biology; Signal transduction; Genetics; Pathology","score_opus":0.020560192702489367,"score_gpt":0.260187499756258,"score_spread":0.2396273070537686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128591359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843861,0.006148348,0.007264815,0.0005425692,0.00039986693,0.00053468684,0.00003586769,0.000046448033,0.0006413305],"genre_scores_gemma":[0.9949448,0.00035411646,0.00057436636,0.0033121493,0.0004232906,0.00012376516,0.00004385625,0.0001255767,0.0000980554],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99728143,0.0004634395,0.00049848325,0.0007056452,0.000383567,0.0006674487],"domain_scores_gemma":[0.99877626,0.0000445476,0.00021204981,0.0006626088,0.00020287432,0.000101671154],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049986463,0.00047425152,0.00037138126,0.0001289145,0.0002521251,0.00007853092,0.0003012322,0.00029455245,0.00000895336],"category_scores_gemma":[0.000046912573,0.00039933028,0.00021156845,0.0004301747,0.00024809144,0.000011691714,0.00023769468,0.00032891176,0.000007971533],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010866048,0.00013082991,0.0017904473,0.00005226987,0.00007557194,0.000015086896,0.0004203624,0.00042192132,0.99496377,0.00012448606,0.000037121452,0.0018594761],"study_design_scores_gemma":[0.0014114709,0.00026744496,0.00056733,0.00010002036,0.000056302597,0.000013525753,0.00009623296,0.0006155073,0.98526984,0.0003931781,0.010691687,0.0005174444],"about_ca_topic_score_codex":0.0001364383,"about_ca_topic_score_gemma":0.0001776454,"teacher_disagreement_score":0.010654566,"about_ca_system_score_codex":0.00012282706,"about_ca_system_score_gemma":0.00018220877,"threshold_uncertainty_score":0.99984586},"labels":[],"label_agreement":null},{"id":"W2128701004","doi":"10.1158/1535-7163.mct-08-0126","title":"SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Kinase Regulation and GTPase Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":166,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Natural Sciences and Engineering Research Council of Canada; National Institutes of Health","keywords":"Bosutinib; Proto-oncogene tyrosine-protein kinase Src; Focal adhesion; Cancer research; Src family kinase; Tyrosine kinase; Cancer cell; Kinase; Cancer; Cell biology; Biology; Chemistry; Signal transduction; Dasatinib","score_opus":0.023687532859094515,"score_gpt":0.27067359435683075,"score_spread":0.24698606149773622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128701004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98829585,0.008142825,0.0026591725,0.00031913747,0.000101795864,0.00026987784,0.00015081643,0.000015286945,0.000045262954],"genre_scores_gemma":[0.9966423,0.0019088772,0.00043510948,0.0006053394,0.00015412104,0.000054304666,0.00007396474,0.000038962236,0.000087012086],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998873,0.00005493434,0.0002764827,0.00035483477,0.0002220103,0.00021874563],"domain_scores_gemma":[0.9992746,0.0000058084347,0.0001633762,0.00029276067,0.00018172557,0.000081715756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008475583,0.00021512425,0.00019767624,0.00006367576,0.00014236962,0.000019877632,0.000118471835,0.00017528377,0.000032780677],"category_scores_gemma":[0.0000041449257,0.00021147112,0.00009399097,0.00012875312,0.00017663672,0.000008815268,0.00007657172,0.00009308533,5.957465e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008791071,0.00010646984,0.002339867,0.000058352747,0.00008546452,0.0000064506853,0.00014480011,0.0003490684,0.99460936,0.0000699061,0.00008146342,0.0020608671],"study_design_scores_gemma":[0.000947653,0.00011367726,0.002656054,0.000080666105,0.00006319198,0.000023755785,0.000026829379,0.00021676111,0.98953325,0.00003514754,0.006054539,0.0002484647],"about_ca_topic_score_codex":0.00036609385,"about_ca_topic_score_gemma":0.00015270486,"teacher_disagreement_score":0.008346484,"about_ca_system_score_codex":0.000025694844,"about_ca_system_score_gemma":0.00013469235,"threshold_uncertainty_score":0.8623542},"labels":[],"label_agreement":null},{"id":"W2129000610","doi":"10.1158/1535-7163.mct-12-0978","title":"Spongian Diterpenoids Inhibit Androgen Receptor Activity","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Androgen receptor; Antiandrogens; Androgen; Antiandrogen; Chemistry; Prostate cancer; Flutamide; In vivo; Biology; LNCaP; Internal medicine; Endocrinology; Biochemistry; Medicine; Cancer; Hormone; Genetics","score_opus":0.009160678739824301,"score_gpt":0.2520462786868974,"score_spread":0.2428855999470731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129000610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99057144,0.0057099597,0.0012133215,0.00066408556,0.00026324164,0.00043012318,0.00001787801,0.00003759788,0.0010923453],"genre_scores_gemma":[0.9960837,0.00093385804,0.00034525976,0.0014384849,0.00017838128,0.00013044034,0.000054820448,0.000067587054,0.000767485],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987729,0.00010788233,0.00015141227,0.00039664505,0.00018055797,0.0003905882],"domain_scores_gemma":[0.99924856,0.000006397127,0.00007684921,0.00043865637,0.00009060189,0.00013896024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008278529,0.0002572743,0.00017529643,0.000043924047,0.00009232259,0.000059295286,0.00022275418,0.00030885424,0.00016792104],"category_scores_gemma":[0.0000059832705,0.00023145844,0.0001586923,0.00014180517,0.00009433535,0.000008812899,0.00009687684,0.00020593191,0.00014223915],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000624315,0.00006899704,0.0009604974,0.000011727863,0.0002561547,0.0000058855035,0.000041737665,0.000040166935,0.96105397,0.000028340119,0.00075107504,0.036719035],"study_design_scores_gemma":[0.0005499497,0.00024920653,0.00060803746,0.000016775766,0.00005668768,0.000011310921,0.0000132404475,0.0001192094,0.94884497,0.0000629676,0.04914084,0.00032680717],"about_ca_topic_score_codex":0.00007580784,"about_ca_topic_score_gemma":0.0000046274176,"teacher_disagreement_score":0.048389766,"about_ca_system_score_codex":0.000038130962,"about_ca_system_score_gemma":0.00008548082,"threshold_uncertainty_score":0.9438601},"labels":[],"label_agreement":null},{"id":"W2129867347","doi":"10.1158/1535-7163.mct-12-1093","title":"Synthetic Lethal Targeting of PTEN-Deficient Cancer Cells Using Selective Disruption of Polynucleotide Kinase/Phosphatase","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Cancer Research UK; AstraZeneca","keywords":"PTEN; Tensin; Phosphatase; Biology; DNA repair; Cancer research; Synthetic lethality; DNA damage; Kinase; Molecular biology; DNA; Cell biology; Genetics; Phosphorylation; Apoptosis; PI3K/AKT/mTOR pathway","score_opus":0.017382240815631517,"score_gpt":0.2850966624290463,"score_spread":0.2677144216134148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129867347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9665931,0.02368679,0.0084620295,0.0000895464,0.00041737434,0.00045647958,0.00020235268,0.000014856144,0.0000774984],"genre_scores_gemma":[0.9971307,0.0006157894,0.0015182903,0.00038121198,0.0001143245,0.00009027206,0.00003446989,0.000084032996,0.000030920408],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980507,0.00013402036,0.0004889358,0.0005108548,0.0003642119,0.00045126677],"domain_scores_gemma":[0.9985431,0.000021354104,0.0004300677,0.00047875915,0.00043505378,0.00009170188],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019064867,0.0003108282,0.00035004082,0.0000796231,0.0000772047,0.00002148249,0.00031265555,0.00019859885,0.00012887243],"category_scores_gemma":[0.000019377701,0.00031120307,0.00021173985,0.0002657454,0.0002337336,0.000011202923,0.00011332016,0.0001654774,0.0000033066924],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000090386915,0.000112432645,0.00096724596,0.00009162602,0.00029966934,0.0000035179166,0.00016784233,0.015570036,0.9781812,0.00004046361,0.00009098034,0.004384628],"study_design_scores_gemma":[0.00048707446,0.00017857549,0.00027801405,0.00012173282,0.00020992107,0.0000032632993,0.00010517439,0.0030810435,0.9938892,0.000058781327,0.0012524112,0.0003347673],"about_ca_topic_score_codex":0.0017108694,"about_ca_topic_score_gemma":0.000027280234,"teacher_disagreement_score":0.030537616,"about_ca_system_score_codex":0.00014803439,"about_ca_system_score_gemma":0.00028181283,"threshold_uncertainty_score":0.999934},"labels":[],"label_agreement":null},{"id":"W2129944198","doi":"10.1158/1535-7163.mct-14-1078","title":"AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arbutus Biopharma (Canada)","funders":"","keywords":"Cancer research; Antibody-drug conjugate; Epidermal growth factor receptor; Antibody; Conjugate; Chemistry; Monoclonal antibody; Molecular biology; Medicine; Receptor; Biology; Immunology; Biochemistry","score_opus":0.040843058974255664,"score_gpt":0.33336690187824247,"score_spread":0.2925238429039868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129944198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901453,0.005319033,0.00028011392,0.0019299553,0.00054423907,0.0006914506,0.00005656218,0.00017888953,0.00085441547],"genre_scores_gemma":[0.99492806,0.0008099709,0.00050583767,0.003216288,0.00023170626,0.00007832728,0.00006312216,0.0001180495,0.000048626065],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99722016,0.00019791294,0.00038094816,0.00072174397,0.0007990762,0.00068018574],"domain_scores_gemma":[0.99798346,0.000028902572,0.00025142747,0.0008328203,0.0003625659,0.00054080226],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002568735,0.0005288502,0.0007196782,0.00022521926,0.0002004985,0.00016851192,0.0002576331,0.00017522539,0.000027018872],"category_scores_gemma":[0.000015654437,0.0004510945,0.00023264275,0.0004470174,0.00019150293,0.00028670192,0.00011054811,0.00036387084,0.00003388565],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040429807,0.0017422995,0.01885375,0.00007126494,0.0007152296,0.0014735265,0.0007354231,0.00043336066,0.9445757,0.0000697734,0.00012789066,0.030797463],"study_design_scores_gemma":[0.00527082,0.0007682018,0.025588235,0.00039383842,0.0006759553,0.00010239671,0.00034308963,0.0015383703,0.9565059,0.0000807444,0.008111664,0.00062079955],"about_ca_topic_score_codex":0.00040462724,"about_ca_topic_score_gemma":0.000068733534,"teacher_disagreement_score":0.030176662,"about_ca_system_score_codex":0.00032441627,"about_ca_system_score_gemma":0.00043801262,"threshold_uncertainty_score":0.99979407},"labels":[],"label_agreement":null},{"id":"W2130441903","doi":"10.1158/1535-7163.mct-08-0891","title":"The phytochemical piceatannol induces the loss of CBL and CBL-associated proteins","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Sirtuins and Resveratrol in Medicine","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Cancer Foundation","funders":"University of Calgary","keywords":"Piceatannol; Phytochemical; Chemistry; Biology; Biochemistry; Resveratrol","score_opus":0.0184652020286719,"score_gpt":0.3016650934681308,"score_spread":0.2831998914394589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130441903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95923674,0.01931472,0.00013406244,0.020140894,0.00010266931,0.00058206375,0.0000063243815,0.000024512161,0.000457989],"genre_scores_gemma":[0.9918376,0.0021911869,0.000055485692,0.0055458266,0.00013800924,0.00003301042,0.0000044732565,0.000017449054,0.00017694544],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988871,0.000065125845,0.0002370452,0.00017332686,0.00038721223,0.00025015004],"domain_scores_gemma":[0.9992521,0.00006279272,0.00011603984,0.00035771917,0.00014787934,0.00006349524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023041411,0.00015499386,0.00024800206,0.000025162512,0.00014522731,0.00002034015,0.00016583255,0.00011916634,0.000009369426],"category_scores_gemma":[0.0000411658,0.00007534784,0.00007942148,0.00021762909,0.00031941,0.000017202567,0.000025287309,0.00033947238,6.714149e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031595796,0.00019034988,0.0022360377,0.000030211739,0.00059291214,0.00004698054,0.0008436874,0.000007751185,0.9458827,0.0006376561,0.00021774444,0.04899802],"study_design_scores_gemma":[0.006707002,0.002180374,0.056286816,0.00065581047,0.0014266481,0.00010750892,0.0010660605,0.0008049719,0.89461994,0.0026994376,0.03297998,0.00046545817],"about_ca_topic_score_codex":0.000029661089,"about_ca_topic_score_gemma":0.0000067603096,"teacher_disagreement_score":0.054050777,"about_ca_system_score_codex":0.000047260255,"about_ca_system_score_gemma":0.00010607316,"threshold_uncertainty_score":0.30725956},"labels":[],"label_agreement":null},{"id":"W2131496779","doi":"10.1158/1535-7163.mct-07-0615","title":"Antitumor activity of an epithelial cell adhesion molecule–targeted nanovesicular drug delivery system","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"University of Alberta","keywords":"Doxorubicin; Biodistribution; Epithelial cell adhesion molecule; Liposome; Drug delivery; Pharmacology; Pharmacokinetics; Chemistry; Cancer research; Antibody; Internalization; Targeted drug delivery; In vitro; Cell; Medicine; Drug; Immunology; Chemotherapy; Biochemistry; Internal medicine","score_opus":0.020605470227439554,"score_gpt":0.3030636069733631,"score_spread":0.28245813674592357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131496779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920178,0.00438192,0.0014557203,0.0002351771,0.00020370296,0.00048153297,0.00007154755,0.00006587846,0.0010867119],"genre_scores_gemma":[0.9973067,0.00035165471,0.0010971711,0.00060767814,0.00015285634,0.000012494529,0.000029810915,0.00006025994,0.00038139228],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976632,0.0001426524,0.00036791418,0.00040297478,0.00082944357,0.00059378555],"domain_scores_gemma":[0.9987147,0.000048621427,0.00016484794,0.00047482026,0.0003139547,0.0002830755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044643242,0.00028353484,0.000470548,0.00017789252,0.000109302244,0.000017020695,0.00022898841,0.00014076261,0.000048693797],"category_scores_gemma":[0.000004881979,0.0002367202,0.00025349364,0.0003437244,0.00015427475,0.000078842306,0.00007688041,0.00032215475,0.000016258626],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001662841,0.0003756973,0.0012578294,0.0005026256,0.0001935543,0.0006541139,0.00018138347,0.000022897348,0.9802315,0.0001283974,0.00001317857,0.014775944],"study_design_scores_gemma":[0.0012364816,0.00041492033,0.008296238,0.00016948191,0.00019797325,0.000040855623,0.00012853813,0.0013432653,0.9853489,0.000017343318,0.0025592668,0.00024676466],"about_ca_topic_score_codex":0.0009969942,"about_ca_topic_score_gemma":0.000052933603,"teacher_disagreement_score":0.01452918,"about_ca_system_score_codex":0.00017810211,"about_ca_system_score_gemma":0.00023875976,"threshold_uncertainty_score":0.96531695},"labels":[],"label_agreement":null},{"id":"W2132090254","doi":"10.1158/1535-7163.mct-07-0560","title":"Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Romidepsin; Cancer research; Histone deacetylase; Histone deacetylase inhibitor; Biology; Cell growth; Cell cycle; Propidium iodide; Cell cycle checkpoint; Vorinostat; Apoptosis; Molecular biology; Programmed cell death; Histone; Biochemistry","score_opus":0.022626705361165556,"score_gpt":0.27782189018545866,"score_spread":0.2551951848242931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132090254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894666,0.0075991903,0.0016367171,0.00032450753,0.000188282,0.0003526273,0.000020271757,0.000023891178,0.00038788453],"genre_scores_gemma":[0.9946911,0.0037769128,0.000336489,0.0005710125,0.00013693105,0.00009168184,0.00006647243,0.000084396925,0.0002450458],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980126,0.00018934911,0.00033991912,0.00059396226,0.00038554272,0.00047861904],"domain_scores_gemma":[0.99918175,0.00001299571,0.000105798055,0.0004149368,0.00012845722,0.00015609],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014782354,0.0003041068,0.00025297797,0.00017333434,0.00015084808,0.000026011685,0.00022886174,0.00029450227,0.000008638477],"category_scores_gemma":[0.000014314882,0.00033031954,0.00010094278,0.00026180514,0.00022490561,0.000016306261,0.0001522416,0.00033805557,0.000005797321],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017148288,0.000203662,0.0008791287,0.000043531374,0.000047638685,0.00002369815,0.00039731374,0.0003646743,0.99641067,0.000057064608,0.00038658307,0.001014527],"study_design_scores_gemma":[0.00135757,0.00020891549,0.00064089836,0.00002965584,0.000025854642,0.0000127758,0.000045200988,0.0010067264,0.9944224,0.000114668976,0.0017510707,0.0003842793],"about_ca_topic_score_codex":0.00033253807,"about_ca_topic_score_gemma":0.000089935886,"teacher_disagreement_score":0.0052244295,"about_ca_system_score_codex":0.00016697713,"about_ca_system_score_gemma":0.00019936856,"threshold_uncertainty_score":0.9999149},"labels":[],"label_agreement":null},{"id":"W2132678065","doi":"10.1158/1535-7163.mct-07-0134","title":"The role of integrin-linked kinase in melanoma cell migration, invasion, and tumor growth","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Vancouver Coastal Health Research Institute; University of British Columbia; Vancouver Coastal Health","funders":"","keywords":"Integrin-linked kinase; Gene knockdown; Melanoma; Cancer research; Cell migration; Cell growth; Metastasis; Focal adhesion; Biology; Angiogenesis; Extracellular matrix; Small hairpin RNA; Cell; Small interfering RNA; Kinase; Chemistry; Protein kinase A; Cancer; Cell biology; Medicine; Signal transduction; Internal medicine; Cell culture; Transfection; Cyclin-dependent kinase 2; Biochemistry","score_opus":0.017484134794276626,"score_gpt":0.2895511336196776,"score_spread":0.272066998825401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132678065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809593,0.015393805,0.00044928098,0.0012277578,0.000042981865,0.00044931663,0.0000030082792,0.00001410151,0.001460455],"genre_scores_gemma":[0.9965988,0.0019533003,0.00038899577,0.00078448764,0.000027306563,0.00002495183,0.000005443022,0.00003335397,0.0001833698],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99857855,0.00008297308,0.000360875,0.00023632142,0.00041968195,0.00032159855],"domain_scores_gemma":[0.9990709,0.00013574887,0.0000929163,0.0003293422,0.0002548843,0.00011623423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005021483,0.0001511761,0.00021203097,0.00015493171,0.000060791073,0.000020033724,0.00015838013,0.00008129896,0.000023557956],"category_scores_gemma":[0.00004904198,0.000108555716,0.00006558218,0.0003946641,0.0001681433,0.000024355948,0.00007371841,0.00031693224,0.000004178342],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038155244,0.0001194266,0.042950276,0.000057094287,0.000039775718,0.000114733055,0.0005051484,0.0000032578992,0.9370437,0.0006432759,0.000020206453,0.0181215],"study_design_scores_gemma":[0.0011645806,0.00022834894,0.029741976,0.000064489475,0.000047171754,0.000015552574,0.0006105189,0.00044258923,0.9513471,0.0010574365,0.015161796,0.000118419266],"about_ca_topic_score_codex":0.0004889312,"about_ca_topic_score_gemma":0.0006596566,"teacher_disagreement_score":0.01800308,"about_ca_system_score_codex":0.000105785824,"about_ca_system_score_gemma":0.00018499886,"threshold_uncertainty_score":0.44267735},"labels":[],"label_agreement":null},{"id":"W2133519168","doi":"10.1158/1535-7163.mct-08-0769","title":"Potent induction of B- and T-cell immunity against human carcinoembryonic antigen-expressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Institutes of Health","keywords":"Carcinoembryonic antigen; Antigen; Biology; Immunity; Transgene; Genetically modified mouse; Immunology; Cancer research; Cancer; Immune system; Gene; Genetics","score_opus":0.017078938938005637,"score_gpt":0.2640789944945212,"score_spread":0.24700005555651558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133519168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9068142,0.09200505,0.00008908607,0.00007989565,0.0002504433,0.00045687062,0.00004465206,0.000060531806,0.00019925502],"genre_scores_gemma":[0.9930178,0.0061673173,0.0000103230905,0.00030300464,0.000017310678,0.000023033868,0.00019576821,0.00005188093,0.0002135841],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972811,0.0009110295,0.00066062825,0.00046842697,0.00011275241,0.0005660883],"domain_scores_gemma":[0.99905306,0.00004942759,0.00033687174,0.00042285476,0.00010895944,0.000028811102],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003881717,0.0004131182,0.0006051708,0.00035323415,0.0004146462,0.000031378826,0.00030366925,0.00039517484,0.000039522463],"category_scores_gemma":[0.000007396372,0.0004240314,0.00018545223,0.0004342273,0.0003124214,0.00015894302,0.000037254606,0.0006710924,0.000002903067],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041099935,0.00039231314,0.0056914994,0.00003653149,0.00028600503,0.000003965975,0.0020343806,0.000081154096,0.9849838,0.00001042811,0.000020927257,0.006047971],"study_design_scores_gemma":[0.0026155773,0.00059125904,0.13236575,0.0001454124,0.0000667042,0.00001018518,0.00040066493,0.000013073573,0.8622318,0.000026625397,0.001150666,0.00038228152],"about_ca_topic_score_codex":0.0015645146,"about_ca_topic_score_gemma":0.00008471304,"teacher_disagreement_score":0.12667425,"about_ca_system_score_codex":0.00021467796,"about_ca_system_score_gemma":0.00014985303,"threshold_uncertainty_score":0.9998211},"labels":[],"label_agreement":null},{"id":"W2133803355","doi":"10.1158/1535-7163.mct-08-1152","title":"Silibinin inhibits translation initiation: implications for anticancer therapy","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Silymarin and Mushroom Poisoning","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance; Faculty of Medicine, McGill University; McGill University","keywords":"Silibinin; Translation (biology); Medicine; Pharmacology; Cancer research; Oncology; Bioinformatics; Biology; Genetics; Messenger RNA","score_opus":0.08830345045470665,"score_gpt":0.3750177748265545,"score_spread":0.28671432437184785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133803355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79716444,0.02527912,0.0958073,0.07191183,0.0003691018,0.0026121617,0.00005640078,0.00032849208,0.0064711887],"genre_scores_gemma":[0.9738119,0.0014563069,0.0028313776,0.02139557,0.0001768072,0.00015301033,0.00005759111,0.00003320148,0.00008422393],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99912256,0.00002167009,0.00022572141,0.0002484627,0.00014037092,0.00024119191],"domain_scores_gemma":[0.99938965,0.000039984032,0.000070893264,0.0002645587,0.00016259261,0.00007232818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008762926,0.0001547163,0.00019863225,0.000075775526,0.0000981642,0.000026506063,0.00007090154,0.00010508162,0.000038015158],"category_scores_gemma":[0.0000069268935,0.00014466124,0.00013174511,0.00024754988,0.000033625314,0.00006594666,0.0000035569249,0.00010911204,0.0000026734533],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022270161,0.00011719124,0.0023390823,0.000014067071,0.00010766885,0.0000012411293,0.00045885873,0.00004664919,0.4919454,0.0028836448,0.00008942938,0.5017741],"study_design_scores_gemma":[0.009784082,0.0012521932,0.1365421,0.00018383528,0.00048610018,0.000032875887,0.000082558916,0.0018442915,0.71910936,0.008780175,0.12125784,0.00064457685],"about_ca_topic_score_codex":0.0000065461804,"about_ca_topic_score_gemma":0.0000050412928,"teacher_disagreement_score":0.5011295,"about_ca_system_score_codex":0.00007775148,"about_ca_system_score_gemma":0.00016884548,"threshold_uncertainty_score":0.58991146},"labels":[],"label_agreement":null},{"id":"W2135108162","doi":"10.1158/1535-7163.mct-14-0475","title":"Tissue Penetration and Activity of Camptothecins in Solid Tumor Xenografts","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canadian Centre for Applied Research in Cancer Control; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Irinotecan; Camptothecin; Topotecan; Topoisomerase; Active metabolite; Pharmacology; Cancer research; Pharmacokinetics; Distribution (mathematics); Chemistry; Metabolite; Cancer; Medicine; Colorectal cancer; Chemotherapy; Internal medicine; Biochemistry; Enzyme","score_opus":0.01367049090223115,"score_gpt":0.290800525270385,"score_spread":0.27713003436815387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135108162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9660242,0.0020159835,0.031029714,0.0001856327,0.00016858852,0.00022077074,0.00001595548,0.0000075906682,0.00033153497],"genre_scores_gemma":[0.99760413,0.0007748121,0.00041089705,0.0009685424,0.000093494375,0.00003649022,0.00001001765,0.000034183267,0.00006741087],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990951,0.0000766254,0.00017727664,0.00029392296,0.00013725457,0.00021985792],"domain_scores_gemma":[0.9994794,0.0000077039085,0.000106211926,0.00029465967,0.00006030774,0.000051692263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016394965,0.00016516117,0.00019724289,0.00006149137,0.00003248711,0.000016328355,0.00012298819,0.00010468753,0.000011625456],"category_scores_gemma":[0.0000056355434,0.00016905485,0.000047141635,0.000106500775,0.00006995229,0.00000423331,0.00004986918,0.00008704242,6.442498e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008753165,0.00005415449,0.0005444208,0.000025066553,0.000049710623,0.000001254581,0.00009050925,0.00019198425,0.94099754,0.00037609492,0.00000477883,0.057576973],"study_design_scores_gemma":[0.00072478305,0.00037475774,0.0020226077,0.000023130238,0.000034812692,0.0000049294654,0.000016977938,0.0005928047,0.97409123,0.00044742762,0.02147327,0.00019327602],"about_ca_topic_score_codex":0.00014286928,"about_ca_topic_score_gemma":0.00046725987,"teacher_disagreement_score":0.057383697,"about_ca_system_score_codex":0.00002271141,"about_ca_system_score_gemma":0.00006976072,"threshold_uncertainty_score":0.6893857},"labels":[],"label_agreement":null},{"id":"W2135227533","doi":"10.1158/1535-7163.mct-08-0385","title":"Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"DNA damage; Fludarabine; Chemistry; SOD2; Molecular biology; Reactive oxygen species; Cancer research; Superoxide dismutase; Biology; Biochemistry; DNA; Oxidative stress; Genetics","score_opus":0.02381161412216235,"score_gpt":0.31750936273773106,"score_spread":0.2936977486155687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135227533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99386114,0.004269654,0.000081647064,0.00020819051,0.00011749093,0.00033204892,0.00006219236,0.00001608125,0.0010515453],"genre_scores_gemma":[0.9976445,0.0009631556,0.00018957374,0.0002137432,0.00012710458,0.000064427455,0.00007202655,0.00006340861,0.00066209503],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982767,0.00015441245,0.00038237846,0.0004971203,0.0003085454,0.00038081233],"domain_scores_gemma":[0.9990207,0.000023584247,0.00015060983,0.0005005888,0.0001917263,0.000112823516],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014636245,0.00027452,0.0003269263,0.00021281665,0.00011451811,0.000013232506,0.00022104592,0.0001891962,0.000025934203],"category_scores_gemma":[0.0000393338,0.00029713562,0.0001154531,0.00030134426,0.00032010526,0.00001615048,0.00015176286,0.00033863154,0.0000044088947],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023706416,0.00016745656,0.0007117122,0.00002304272,0.000114345545,0.000045311474,0.000646362,0.00004382541,0.99656576,0.00003170808,0.00020554192,0.0012078636],"study_design_scores_gemma":[0.0010589641,0.000222014,0.00601725,0.00005117775,0.000030166722,0.000048870115,0.00024671087,0.00014533938,0.9751094,0.00002441341,0.016761122,0.00028455807],"about_ca_topic_score_codex":0.0003592871,"about_ca_topic_score_gemma":0.0005247163,"teacher_disagreement_score":0.021456353,"about_ca_system_score_codex":0.00023911733,"about_ca_system_score_gemma":0.00032719166,"threshold_uncertainty_score":0.9999481},"labels":[],"label_agreement":null},{"id":"W2135658143","doi":"10.1158/1535-7163.mct-07-0442","title":"Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; Fondation de France","keywords":"DU145; Radiosensitizer; Clonogenic assay; Cancer research; LNCaP; Apoptosis; Chemistry; Cell culture; Cancer cell; Cancer; Biology; Radiation therapy; Internal medicine; Medicine; Biochemistry; Genetics","score_opus":0.024323404240407236,"score_gpt":0.2706454463307952,"score_spread":0.24632204209038794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135658143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9627588,0.03171483,0.001356421,0.0011323272,0.00083671534,0.0011215028,0.0001230794,0.00013533424,0.0008210089],"genre_scores_gemma":[0.98113203,0.013746537,0.0009238945,0.0029941623,0.00015807133,0.00014125864,0.000022667457,0.00015896096,0.0007224114],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972935,0.00010216063,0.00058142905,0.0005676255,0.00086082425,0.00059446396],"domain_scores_gemma":[0.9982971,0.000028037612,0.00029140306,0.0007651574,0.00038757134,0.0002307584],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013801627,0.00042015154,0.0006943773,0.00021526184,0.000109447115,0.000013180132,0.00020573604,0.00027507296,0.0001679974],"category_scores_gemma":[0.000009360042,0.00040484598,0.00034794962,0.00053599814,0.00031723073,0.00005341876,0.000073478805,0.00050943036,0.00002224433],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005218791,0.00023557429,0.001420293,0.0001549575,0.00088835653,0.0007192899,0.0012985304,0.0017044204,0.98166823,0.00005708757,0.00034409424,0.010987306],"study_design_scores_gemma":[0.0036757432,0.00033253455,0.002108077,0.00026456,0.00063599943,0.00022982957,0.00007777667,0.0006102655,0.97466815,0.00007090652,0.016899835,0.0004263435],"about_ca_topic_score_codex":0.00045167215,"about_ca_topic_score_gemma":0.000056603672,"teacher_disagreement_score":0.018373255,"about_ca_system_score_codex":0.00044063263,"about_ca_system_score_gemma":0.00097558694,"threshold_uncertainty_score":0.9998403},"labels":[],"label_agreement":null},{"id":"W2136405771","doi":"10.1158/1535-7163.mct-05-0229","title":"Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CRISPR and Genetic Engineering","field":"Biochemistry, Genetics and Molecular Biology","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"AP site; Molecular biology; Melanoma; DNA-(apurinic or apyrimidinic site) lyase; Apoptosis; Transcription factor; Biology; DNA damage; Cancer research; Chemistry; Resveratrol; Base excision repair; DNA; Biochemistry; Gene","score_opus":0.012584265504455867,"score_gpt":0.30510517275107873,"score_spread":0.2925209072466229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136405771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99474907,0.00350178,0.00076956605,0.00036178634,0.000107256805,0.00043432563,0.000033246542,0.0000033741119,0.00003959061],"genre_scores_gemma":[0.9991776,0.0003121278,0.00005048893,0.0002829073,0.0000750609,0.00003934763,0.000010934828,0.00002543494,0.00002614301],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99855727,0.00025721808,0.000492692,0.00025960786,0.00025606685,0.00017713083],"domain_scores_gemma":[0.99899596,0.0000144318765,0.00022079394,0.0006749802,0.00006893263,0.00002487769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021900798,0.00016959298,0.00017603516,0.000057367735,0.000082049744,0.000020415288,0.00044227194,0.00013559006,0.000009725018],"category_scores_gemma":[0.000011102855,0.00011045434,0.0001238765,0.00017689756,0.00014438786,0.000011384902,0.0000939476,0.00016893918,1.8521307e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056629313,0.00012486358,0.0018871152,0.000027819327,0.00003911024,4.579193e-7,0.0009873816,0.0037314277,0.99075484,0.00015784742,0.0000037667162,0.0022287169],"study_design_scores_gemma":[0.00068947807,0.00012561526,0.02711344,0.00004631702,0.00005523325,0.000004962403,0.00032169698,0.0005918529,0.97030324,0.00015552535,0.00047502757,0.000117598545],"about_ca_topic_score_codex":0.00007164672,"about_ca_topic_score_gemma":0.00022765019,"teacher_disagreement_score":0.025226325,"about_ca_system_score_codex":0.000022224438,"about_ca_system_score_gemma":0.00007406,"threshold_uncertainty_score":0.45041975},"labels":[],"label_agreement":null},{"id":"W2136509222","doi":"10.1158/1535-7163.mct-06-0050","title":"Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"Apoptosis; Leukemia; Tumor necrosis factor alpha; Biology; Cancer cell; Programmed cell death; Receptor; Ligand (biochemistry); HL60; Recombinant DNA; Cancer research; Cell biology; Molecular biology; Cancer; Gene; Immunology; Genetics","score_opus":0.011518527909936972,"score_gpt":0.23907698181875311,"score_spread":0.22755845390881616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136509222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5975319,0.004736656,0.39520305,0.00034064843,0.00043793788,0.0005332932,0.00007346191,0.000032301577,0.0011107492],"genre_scores_gemma":[0.9880265,0.00029263753,0.007873215,0.0008067711,0.000115172596,0.00003944139,0.000064007494,0.000055471457,0.0027268133],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99877447,0.000039229144,0.0002795291,0.0003801901,0.00023972524,0.00028685684],"domain_scores_gemma":[0.9992509,0.000007547521,0.00011955428,0.00043204887,0.00012482189,0.000065111344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010598742,0.00021131696,0.00019342979,0.000054912154,0.00006735729,0.00002019393,0.0002071669,0.00019726412,0.000014301138],"category_scores_gemma":[0.0000032945736,0.00020868672,0.00013400683,0.00016013643,0.000044245673,0.0000030186507,0.00006122831,0.000069723195,0.000005067327],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000101619284,0.000041678923,0.00002537752,0.000029237624,0.00006289677,0.0000038021506,0.00003291478,0.005147822,0.98945916,0.0024066241,0.00028100907,0.0024078882],"study_design_scores_gemma":[0.00056135276,0.00011913768,0.0002076955,0.000026625074,0.0000515518,0.0000012615867,0.000026626261,0.0002574573,0.94550264,0.002626511,0.050370928,0.00024821254],"about_ca_topic_score_codex":0.00011687046,"about_ca_topic_score_gemma":0.00044521427,"teacher_disagreement_score":0.39049459,"about_ca_system_score_codex":0.000068444824,"about_ca_system_score_gemma":0.00012544268,"threshold_uncertainty_score":0.8509997},"labels":[],"label_agreement":null},{"id":"W2136671570","doi":"10.1158/1535-7163.mct-11-0756","title":"New Directions for Biologic Targets in Urothelial Carcinoma","year":2012,"lang":"en","type":"review","venue":"Molecular Cancer Therapeutics","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Context (archaeology); Metastatic Urothelial Carcinoma; Clinical trial; Urothelial carcinoma; Disease; Oncology; Cancer; Stage (stratigraphy); Urothelial cancer; Internal medicine; Bladder cancer; Intensive care medicine; Biology","score_opus":0.09693421337094198,"score_gpt":0.37602540015036656,"score_spread":0.27909118677942457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136671570","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00000767585,0.99310845,0.0017686351,0.0002164158,0.0010120504,0.0028174345,0.00028800542,0.000066400644,0.0007149589],"genre_scores_gemma":[0.00025415883,0.9934798,0.0011302397,0.0009680381,0.0008365679,0.0014473571,0.00018666223,0.0001712956,0.0015258912],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980975,0.000102546095,0.0004946183,0.0005071619,0.00019429471,0.00060388335],"domain_scores_gemma":[0.9990199,0.00005455195,0.00017948715,0.0004758614,0.00006195154,0.0002082233],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000100888064,0.00057298865,0.0015152956,0.00024425724,0.00006351875,0.000020512993,0.00018546132,0.0004770741,0.00020583994],"category_scores_gemma":[0.0000064547366,0.000439953,0.0007469528,0.00038170046,0.00004463888,0.000032403314,0.000037070076,0.00037063757,0.0000332114],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000779318,0.00014028403,0.00017346824,0.0025061995,0.0007354917,0.000024515351,0.00007686341,4.238298e-7,0.000048512025,0.00007646788,0.00013917532,0.99600065],"study_design_scores_gemma":[0.0015872983,0.00026709435,0.000061569335,0.0014174039,0.0051516527,0.000040423016,0.000004909605,0.0000025310171,0.00024408531,0.000117621115,0.99071074,0.0003946616],"about_ca_topic_score_codex":0.00045577335,"about_ca_topic_score_gemma":0.00008111739,"teacher_disagreement_score":0.995606,"about_ca_system_score_codex":0.00060108537,"about_ca_system_score_gemma":0.0013550763,"threshold_uncertainty_score":0.9998052},"labels":[],"label_agreement":null},{"id":"W2136923586","doi":"10.1158/1535-7163.mct-06-0118","title":"Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":326,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Celator Pharmaceuticals (Canada)","funders":"","keywords":"Drug; Pharmacology; In vivo; Daunorubicin; Irinotecan; Pharmacokinetics; Medicine; Therapeutic index; Drug interaction; Floxuridine; In vitro; Dosing; Chemotherapy; Chemistry; Cancer; Internal medicine; Fluorouracil; Biology; Colorectal cancer","score_opus":0.012454386906906128,"score_gpt":0.2571616014258772,"score_spread":0.24470721451897107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136923586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98508865,0.008748037,0.004590151,0.00039049223,0.0003093397,0.0007293936,0.0000285127,0.000072600196,0.000042830492],"genre_scores_gemma":[0.9988521,0.000069164904,0.00038617424,0.00033008552,0.000057706387,0.00020274486,0.000006169825,0.00005034761,0.000045550507],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973777,0.00040575388,0.00070133613,0.00046864673,0.00059854257,0.00044804608],"domain_scores_gemma":[0.99861735,0.0002435291,0.0004276254,0.00040643927,0.00025530785,0.000049724542],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000744642,0.00028872478,0.00045221145,0.0004056835,0.00011239964,0.00016082637,0.00026197825,0.00007303288,0.00004730424],"category_scores_gemma":[0.000018791612,0.00029537437,0.0001088291,0.0011235982,0.00015501672,0.0003955554,0.000041982785,0.00017844609,0.000009828717],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031048796,0.00028675408,0.007344945,0.00012044635,0.000033794793,0.000024983392,0.00030207378,0.0072364737,0.9830363,0.00045849942,0.0000026307966,0.0008426611],"study_design_scores_gemma":[0.0017860042,0.000045201185,0.005278211,0.00024011312,0.00012864938,0.0000074554723,0.000097544085,0.01725967,0.9741758,0.0006483343,0.000022207249,0.00031078898],"about_ca_topic_score_codex":0.0007789676,"about_ca_topic_score_gemma":0.0003713473,"teacher_disagreement_score":0.013763413,"about_ca_system_score_codex":0.00039643687,"about_ca_system_score_gemma":0.00030485025,"threshold_uncertainty_score":0.9999498},"labels":[],"label_agreement":null},{"id":"W2137268781","doi":"10.1158/1535-7163.mct-09-0960","title":"Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada); Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Canada Research Chairs; GlaxoSmithKline","keywords":"Topotecan; Medicine; Pazopanib; Ovarian cancer; Pharmacology; Paclitaxel; Irinotecan; Chemotherapy; Cyclophosphamide; Ovarian carcinoma; Cancer; Oncology; Internal medicine; Sunitinib; Colorectal cancer","score_opus":0.030211782874553963,"score_gpt":0.3444115221306979,"score_spread":0.314199739256144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137268781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794526,0.008053376,0.0005244734,0.009130679,0.00032098612,0.0022229059,0.0002467112,0.00001714293,0.000031105545],"genre_scores_gemma":[0.9956879,0.0022731365,0.00050049403,0.00048373395,0.00014189712,0.0007339494,0.000020060874,0.0000626979,0.0000961152],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986321,0.000064681124,0.00037501767,0.00032805695,0.00026085414,0.00033930677],"domain_scores_gemma":[0.9983798,0.00020868043,0.0002862392,0.0008256201,0.00019592092,0.00010368702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018475212,0.00030748322,0.0005926796,0.00005443079,0.00009901575,0.000020395959,0.00022237666,0.00009263603,0.00014753232],"category_scores_gemma":[0.0000044705703,0.00014440333,0.0006789199,0.00021611367,0.00027704047,0.00002450362,0.000019983603,0.00015004697,8.78189e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020756079,0.010055606,0.20576908,0.0002756833,0.050351683,0.000057176796,0.004490484,0.0060804924,0.13068089,0.0016737639,0.0006726686,0.5691364],"study_design_scores_gemma":[0.036685478,0.015777603,0.5422763,0.0002585466,0.016199414,0.00002424104,0.00031513124,0.004667925,0.364939,0.00023343385,0.017934881,0.00068800064],"about_ca_topic_score_codex":0.0035547945,"about_ca_topic_score_gemma":0.0022829748,"teacher_disagreement_score":0.56844836,"about_ca_system_score_codex":0.00034222662,"about_ca_system_score_gemma":0.0008044917,"threshold_uncertainty_score":0.5888597},"labels":[],"label_agreement":null},{"id":"W2137667786","doi":"10.1158/1535-7163.mct-05-0504","title":"Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Erlotinib; MAPK/ERK pathway; Ribosomal protein s6; Pharmacology; Epidermal growth factor receptor; Cancer research; Kinase; Epidermal growth factor; Phosphorylation; EGFR inhibitors; Medicine; Vascular endothelial growth factor; Erlotinib Hydrochloride; Chemistry; Biology; Protein kinase A; Internal medicine; Receptor; Biochemistry; Protein phosphorylation; VEGF receptors","score_opus":0.015827044223813883,"score_gpt":0.2724241610232969,"score_spread":0.25659711679948305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137667786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99119365,0.0029795247,0.004437942,0.0002544423,0.00021446311,0.00030059068,0.000031109783,0.000018680335,0.00056961784],"genre_scores_gemma":[0.9977612,0.000048831338,0.0010910947,0.0005770408,0.00017143105,0.000091463604,0.000069362846,0.000065875465,0.00012368313],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985207,0.00010435933,0.00037623718,0.00040007534,0.0002498013,0.0003488525],"domain_scores_gemma":[0.9991833,0.000021181897,0.00016789627,0.00041468657,0.00016052485,0.000052385352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001227361,0.00025311095,0.00027317659,0.000110278605,0.00004517111,0.000020742338,0.0002610112,0.0001421453,0.000045538047],"category_scores_gemma":[0.000004515664,0.00024070339,0.00011753044,0.00031313594,0.00013505142,0.000005977269,0.000055881977,0.00019980478,0.000001678671],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005717687,0.00017358566,0.042332847,0.00003739538,0.00012517061,0.000019168794,0.00008004998,0.006374164,0.9493828,0.00011811773,0.00005836117,0.00072657753],"study_design_scores_gemma":[0.0019325939,0.0005779266,0.008902966,0.00008426667,0.00008723215,0.000011001874,0.000061925304,0.00029148217,0.9801264,0.00013067736,0.0074525266,0.0003410285],"about_ca_topic_score_codex":0.0003944376,"about_ca_topic_score_gemma":0.00073716923,"teacher_disagreement_score":0.03342988,"about_ca_system_score_codex":0.00007292641,"about_ca_system_score_gemma":0.00019056647,"threshold_uncertainty_score":0.98155993},"labels":[],"label_agreement":null},{"id":"W2138124620","doi":"10.1158/1535-7163.mct-10-0249","title":"Continuous Docetaxel Chemotherapy Improves Therapeutic Efficacy in Murine Models of Ovarian Cancer","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Docetaxel; Ovarian cancer; Chemotherapy; Medicine; Debulking; Oncology; Internal medicine; Cancer; Angiogenesis; Tumor microenvironment; Cancer research; Pharmacology","score_opus":0.021881203073399767,"score_gpt":0.3033659557191305,"score_spread":0.28148475264573075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138124620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97630274,0.012392961,0.0006274383,0.007553885,0.0005658061,0.0012666004,0.000048714708,0.0000680279,0.0011738269],"genre_scores_gemma":[0.9890623,0.004178531,0.0010829305,0.004824184,0.00016680133,0.00035875497,0.000012441219,0.00010910336,0.00020493392],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979916,0.000048269052,0.00052370207,0.00052969053,0.00040598473,0.0005007079],"domain_scores_gemma":[0.99865276,0.00005159012,0.00022163604,0.0007402984,0.00018816833,0.00014553546],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016917985,0.000394303,0.0007414999,0.00018194306,0.00004364165,0.00002902821,0.00022765202,0.0002328191,0.00033647584],"category_scores_gemma":[0.000004782797,0.0003323233,0.00025545727,0.00041856852,0.00016762907,0.00008043429,0.00003578484,0.0004766212,0.0000035857897],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079171656,0.0023330068,0.023299228,0.0001548884,0.0015538625,0.00009268907,0.0010847985,0.000420657,0.65844333,0.0037523243,0.00003244845,0.30804107],"study_design_scores_gemma":[0.030035377,0.0010246743,0.2276109,0.00056181033,0.0014913074,0.00004464283,0.00012191048,0.0053404286,0.7068953,0.003620723,0.022221448,0.0010315119],"about_ca_topic_score_codex":0.0015094398,"about_ca_topic_score_gemma":0.00047920342,"teacher_disagreement_score":0.30700955,"about_ca_system_score_codex":0.00016902224,"about_ca_system_score_gemma":0.00042039537,"threshold_uncertainty_score":0.99991286},"labels":[],"label_agreement":null},{"id":"W2138465485","doi":"10.1158/1535-7163.mct-05-0361","title":"AGRO100 inhibits activation of nuclear factor-κB (NF-κB) by forming a complex with NF-κB essential modulator (NEMO) and nucleolin","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"NF-κB Signaling Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":234,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"Nucleolin; IκB kinase; IκBα; NF-κB; Biology; Phosphorylation; Cancer research; Kinase; Transcription factor; Cell biology; Molecular biology; Signal transduction; Biochemistry; Cytoplasm; Gene","score_opus":0.012420503632412521,"score_gpt":0.24124494833509222,"score_spread":0.2288244447026797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138465485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98684484,0.0010970789,0.011101748,0.00017121791,0.000058911304,0.00033326712,0.00012514828,0.00003410834,0.00023368737],"genre_scores_gemma":[0.99723953,0.00010109821,0.0013991187,0.0007601851,0.0001243388,0.000017924709,0.00017212513,0.00010981257,0.00007589256],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99838775,0.00006597814,0.0003368483,0.0004988241,0.00033204115,0.00037852957],"domain_scores_gemma":[0.9991,0.000010507085,0.0002467316,0.00039156494,0.00017212855,0.00007900963],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000079204685,0.0003319295,0.00029599905,0.00006569342,0.00012492121,0.00004950557,0.00020094155,0.0002405967,0.00003175395],"category_scores_gemma":[0.0000052274654,0.00032021233,0.00009771334,0.00015988885,0.00018803802,0.000015338252,0.00009731646,0.00015330668,0.0000016142387],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020914279,0.000101212,0.0007009825,0.000057234334,0.00018490528,0.0000036571432,0.00014413112,0.00041801206,0.9951585,0.00019784068,0.00016863128,0.0026557753],"study_design_scores_gemma":[0.0012715281,0.00025963856,0.00053737854,0.00006153301,0.00008026568,0.000009446037,0.000051705116,0.001163494,0.9816605,0.000104145394,0.01440269,0.00039768295],"about_ca_topic_score_codex":0.00026303486,"about_ca_topic_score_gemma":0.000048249327,"teacher_disagreement_score":0.014234059,"about_ca_system_score_codex":0.000049346178,"about_ca_system_score_gemma":0.00010144583,"threshold_uncertainty_score":0.999925},"labels":[],"label_agreement":null},{"id":"W2138590199","doi":"10.1158/1535-7163.mct-07-0482","title":"Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":435,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Center for Research Resources; National Cancer Institute","keywords":"Glycolysis; Chemistry; Intracellular; NAD+ kinase; Flux (metallurgy); Biochemistry; Cell culture; Enzyme; Cell growth; Transfection; Cancer cell; Growth inhibition; Kinase; Molecular biology; Biology; Cancer; Gene","score_opus":0.019702526442697908,"score_gpt":0.24644757474416887,"score_spread":0.22674504830147096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138590199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778957,0.018769415,0.0020804363,0.00014134176,0.0003938787,0.00031021284,0.00007909976,0.000021361642,0.0003085493],"genre_scores_gemma":[0.9932715,0.0047226287,0.00034330308,0.0009623677,0.00028770772,0.00007187724,0.000043342992,0.00006047352,0.00023677357],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986218,0.00008589008,0.00024378116,0.0004747541,0.00022481973,0.00034894503],"domain_scores_gemma":[0.9990821,0.000010196558,0.00016389014,0.00041892225,0.00020446104,0.00012044516],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008876949,0.00029012028,0.000318791,0.000068030815,0.00011817525,0.000018349792,0.00015527732,0.00015578493,0.00002781571],"category_scores_gemma":[0.000024640547,0.0003000599,0.00014970257,0.00018060887,0.00030127555,0.000009645661,0.0001199209,0.00014511212,0.0000017478102],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002642631,0.00011909817,0.0006945079,0.00007942668,0.00015765063,0.000018713366,0.00011654603,0.000020833508,0.9955891,0.000096738055,0.00026668122,0.0025764816],"study_design_scores_gemma":[0.001231883,0.00022190684,0.0026801378,0.000030372035,0.00013552385,0.00006143812,0.00002304738,0.000043759,0.9787447,0.00009625778,0.01639892,0.00033205902],"about_ca_topic_score_codex":0.00025271595,"about_ca_topic_score_gemma":0.00008161881,"teacher_disagreement_score":0.016844364,"about_ca_system_score_codex":0.000027755383,"about_ca_system_score_gemma":0.0002499361,"threshold_uncertainty_score":0.99994516},"labels":[],"label_agreement":null},{"id":"W2138642497","doi":"10.1158/1535-7163.mct-13-0420","title":"Novel Neutralizing Hedgehog Antibody MEDI-5304 Exhibits Antitumor Activity by Inhibiting Paracrine Hedgehog Signaling","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada)","funders":"","keywords":"Paracrine signalling; Hedgehog; Hedgehog signaling pathway; Cancer research; Stromal cell; Smoothened; Sonic hedgehog; Biology; GLI1; Autocrine signalling; Cell biology; Signal transduction; Cell culture; Receptor; Genetics","score_opus":0.02851572192640275,"score_gpt":0.30492392390308837,"score_spread":0.27640820197668564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138642497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9528498,0.009571349,0.035183795,0.0008379634,0.00038695754,0.0006433398,0.00008666277,0.00010412642,0.0003360024],"genre_scores_gemma":[0.9941836,0.00072261045,0.0013282794,0.0026037453,0.0004231542,0.00017576388,0.00015286927,0.00016813773,0.00024183738],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968512,0.00015403984,0.0005320954,0.0009901412,0.00046994217,0.0010025937],"domain_scores_gemma":[0.998478,0.000042374686,0.00030518812,0.0005909523,0.00035223534,0.00023124971],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032293613,0.0006442249,0.000542816,0.00009907239,0.00035322923,0.00016203169,0.00047385483,0.00030310548,0.00005402351],"category_scores_gemma":[0.000054536842,0.0006504657,0.0002693551,0.00034390294,0.00025657495,0.00003106443,0.00030864586,0.0004000525,0.00003342176],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043995853,0.00017267972,0.0016409667,0.00009109299,0.00037903964,0.000016191925,0.00017165144,0.0005059843,0.9894401,0.00002938108,0.0002771061,0.0072317985],"study_design_scores_gemma":[0.0011385259,0.00019170193,0.0006631583,0.00014169089,0.00011799358,0.000024730445,0.00013755802,0.0005595699,0.9854028,0.00003788463,0.010788468,0.0007958672],"about_ca_topic_score_codex":0.00033852528,"about_ca_topic_score_gemma":0.00002920344,"teacher_disagreement_score":0.0413338,"about_ca_system_score_codex":0.00008341688,"about_ca_system_score_gemma":0.00017133472,"threshold_uncertainty_score":0.9995947},"labels":[],"label_agreement":null},{"id":"W2138761399","doi":"10.1158/1535-7163.mct-06-0169","title":"Adenovirus-mediated small interfering RNA against matrix metalloproteinase-2 suppresses tumor growth and lung metastasis in mice","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"Metastasis; Angiogenesis; Cancer research; Matrix metalloproteinase; Small interfering RNA; Lung cancer; Matrix metalloproteinase inhibitor; Biology; Tumor progression; RNA interference; Extracellular matrix; Gene silencing; Cancer; Medicine; Pathology; RNA; Cell culture; Transfection; Cell biology; Gene; Biochemistry","score_opus":0.010935803983070654,"score_gpt":0.24499564020017997,"score_spread":0.23405983621710932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138761399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9626169,0.03195207,0.0042678886,0.00019311538,0.000118467586,0.0004500225,0.00007609411,0.000030080528,0.00029537053],"genre_scores_gemma":[0.99597114,0.0009803588,0.0014244217,0.0011175864,0.0001224085,0.0001632029,0.00010220425,0.000069139845,0.000049515198],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985041,0.000113017864,0.00032226395,0.0004899177,0.00016274012,0.00040793992],"domain_scores_gemma":[0.9994703,0.0000106056,0.00011505732,0.00026322657,0.00006685532,0.00007394367],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014297204,0.00030957873,0.00026558797,0.00011032179,0.000061477884,0.00006130286,0.00023033225,0.00014291622,0.000011007848],"category_scores_gemma":[0.00001792451,0.000309973,0.00010437164,0.00018486097,0.00006913054,0.000010872225,0.0001575164,0.0001770941,0.0000021386008],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011245054,0.00006691692,0.00025791844,0.00008160907,0.00016234856,0.00006929765,0.000024909603,0.0000758357,0.9982547,0.0001456334,0.000025815982,0.0007225216],"study_design_scores_gemma":[0.00085485086,0.000112725094,0.00008204775,0.000057856545,0.00010654339,0.000009957441,0.000031472835,0.0003395159,0.99528503,0.00024398888,0.0025080438,0.00036795594],"about_ca_topic_score_codex":0.00033372396,"about_ca_topic_score_gemma":0.00019769813,"teacher_disagreement_score":0.03335427,"about_ca_system_score_codex":0.000038158054,"about_ca_system_score_gemma":0.00008240543,"threshold_uncertainty_score":0.9999352},"labels":[],"label_agreement":null},{"id":"W2139514479","doi":"10.1158/1535-7163.1513.3.12","title":"The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical–dependent and Jun NH2-terminal kinase–dependent mechanism","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Apoptosis; Kinase; Chemistry; Caspase; Mitochondrion; Cell biology; Cancer research; Programmed cell death; Biology; Biochemistry","score_opus":0.011366418037141553,"score_gpt":0.25635340888952596,"score_spread":0.2449869908523844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139514479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96600324,0.0013026552,0.030169604,0.0011841578,0.00039564475,0.0008304593,0.000034053475,0.000018445664,0.0000617406],"genre_scores_gemma":[0.99417716,0.0007865205,0.0028345827,0.0015180121,0.00024630997,0.00017725393,0.00002499428,0.00007591888,0.0001592238],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978635,0.00012144268,0.0004030186,0.00074039836,0.00037591284,0.0004957379],"domain_scores_gemma":[0.9989596,0.000018106874,0.00013847709,0.0005991878,0.00010040052,0.00018421198],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001676532,0.00040180323,0.00029302776,0.000077703044,0.00026451182,0.00017262704,0.00034902553,0.00029669597,0.0000054366596],"category_scores_gemma":[0.000017316854,0.00031123628,0.000075189346,0.00014481806,0.00017811288,0.00001310045,0.00034086607,0.00028629412,0.0000013911081],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047122064,0.00011388756,0.000007660243,0.00003106926,0.00012995985,0.000056092504,0.00030454536,0.00021182896,0.99187404,0.0021228746,0.000017911938,0.0046588974],"study_design_scores_gemma":[0.0022451913,0.001093046,0.00008125924,0.00013718627,0.000119824486,0.000033557964,0.00012569608,0.00004296921,0.99122524,0.0020059375,0.0024365361,0.0004535588],"about_ca_topic_score_codex":0.00023174373,"about_ca_topic_score_gemma":0.0008664008,"teacher_disagreement_score":0.028173944,"about_ca_system_score_codex":0.00010900486,"about_ca_system_score_gemma":0.0001565841,"threshold_uncertainty_score":0.99993396},"labels":[],"label_agreement":null},{"id":"W2139966699","doi":"10.1158/1535-7163.mct-10-0677","title":"Notch Signaling Pathway as a Therapeutic Target in Breast Cancer","year":2010,"lang":"en","type":"review","venue":"Molecular Cancer Therapeutics","topic":"Developmental Biology and Gene Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":152,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Research Resources; University of California, Davis; Cancer Research Coordinating Committee; Office of Research and Development; Purdue University","keywords":"Notch signaling pathway; Cancer; Breast cancer; Signal transduction; Cancer research; Medicine; Disease; Biology; Bioinformatics; Pharmacology; Internal medicine; Genetics","score_opus":0.022170255742610258,"score_gpt":0.314756041743817,"score_spread":0.2925857860012067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139966699","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002502429,0.9951951,0.00023578171,0.00021549137,0.0006827615,0.00072682585,0.00021662457,0.000023656163,0.0002013133],"genre_scores_gemma":[0.0053703785,0.9906407,0.00024076464,0.0016274771,0.00033464518,0.00057919807,0.00060458464,0.0001473018,0.00045497614],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99748534,0.00026597505,0.00059751,0.00084646535,0.00023076439,0.0005739731],"domain_scores_gemma":[0.9989026,0.000018295517,0.000326938,0.00055330875,0.00009762744,0.00010119424],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00026129332,0.0006834406,0.00091933,0.00016320015,0.0000977979,0.000042477568,0.0005088499,0.0012987778,0.00016479188],"category_scores_gemma":[0.000004119412,0.000599096,0.0004320746,0.000345,0.00014481183,0.000005554582,0.00014080218,0.0006561848,0.0000316883],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051004718,0.00007562876,0.0001985269,0.0006338883,0.00053322926,0.000021052065,0.000040771476,0.00003969641,0.114231996,0.00005123229,0.000017576645,0.8841054],"study_design_scores_gemma":[0.00036846325,0.000052234373,0.000052765572,0.0010924416,0.00028093436,0.00007855297,0.000009132379,0.000007655085,0.030504731,0.00017603255,0.966599,0.0007780858],"about_ca_topic_score_codex":0.00006768169,"about_ca_topic_score_gemma":0.0001034945,"teacher_disagreement_score":0.9665814,"about_ca_system_score_codex":0.00013405166,"about_ca_system_score_gemma":0.0011854903,"threshold_uncertainty_score":0.99999774},"labels":[],"label_agreement":null},{"id":"W2139995836","doi":"10.1158/1535-7163.mct-07-2217","title":"Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor–induced angiogenesis","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"Pharmacology; RHOA; Angiogenesis; Vascular endothelial growth factor; Chemistry; Naltrexone; Protein kinase B; Cancer research; Medicine; Receptor; Opioid; Signal transduction; Biochemistry","score_opus":0.026847572037158148,"score_gpt":0.2854884292025764,"score_spread":0.25864085716541824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139995836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99278504,0.0057191327,0.0005785487,0.00015617299,0.000083449566,0.00049681053,0.00003957586,0.000021541504,0.000119760625],"genre_scores_gemma":[0.9970636,0.0021425465,0.00020360909,0.00038482554,0.00005154053,0.00006866127,0.000013834725,0.000039867657,0.000031524833],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99891615,0.00009256647,0.00021709937,0.00024782948,0.00033270678,0.00019366942],"domain_scores_gemma":[0.99928373,0.00012386189,0.0001478119,0.00020371588,0.0001585908,0.00008231206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000040724397,0.0002203654,0.0004745306,0.00013600662,0.000046758872,0.0000024566407,0.000042091506,0.000096046024,0.00003458422],"category_scores_gemma":[0.000011260143,0.00017333076,0.00013704482,0.00021789614,0.00013541331,0.000026760004,0.000014685784,0.00009819587,8.8226307e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012069161,0.00038470604,0.0047175996,0.0003568775,0.0014515483,0.00019580575,0.0005122257,0.000018350514,0.98526776,0.00010787045,0.0000045351126,0.0057757883],"study_design_scores_gemma":[0.0055548046,0.0025077814,0.017144145,0.00016799044,0.0013622928,0.000022371474,0.000011004688,0.000027679815,0.97289824,0.000037118785,0.00011500505,0.00015157068],"about_ca_topic_score_codex":0.0003028676,"about_ca_topic_score_gemma":0.000017569737,"teacher_disagreement_score":0.012426547,"about_ca_system_score_codex":0.00010293365,"about_ca_system_score_gemma":0.00015624227,"threshold_uncertainty_score":0.70682234},"labels":[],"label_agreement":null},{"id":"W2140081727","doi":"10.1158/1535-7163.mct-12-0060","title":"Engineering and Therapeutic Application of Single-Chain Bivalent TGF-β Family Traps","year":2012,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"TGF-β signaling in diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Biotechnology Research Institute","funders":"","keywords":"Bivalent (engine); Ectodomain; Antibody; Receptor; Potency; In vivo; Chemistry; Immunoglobulin light chain; In vitro; Linker; Transforming growth factor; Molecular biology; Biology; Biochemistry; Cell biology; Immunology; Genetics","score_opus":0.01984387045036865,"score_gpt":0.2575980395753182,"score_spread":0.23775416912494954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140081727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90359807,0.04896836,0.04695347,0.000052381336,0.000112369904,0.00021466307,0.000017034448,0.000023599603,0.00006003186],"genre_scores_gemma":[0.99805653,0.00028644808,0.00079526735,0.0005666689,0.00012708387,0.00006948826,0.000023974459,0.000052276115,0.00002227398],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990716,0.000042779273,0.00020898039,0.00023217508,0.00016358779,0.0002808951],"domain_scores_gemma":[0.9994048,0.000013149777,0.00009446086,0.00033635303,0.000058436668,0.00009280541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012045778,0.00018810625,0.00015182167,0.00005059114,0.00003490215,0.000011753912,0.00014733472,0.000121801546,0.000004480871],"category_scores_gemma":[0.000006592076,0.00019203522,0.00007758601,0.0000968235,0.00007066247,0.0000037596983,0.000048880735,0.00006563572,0.0000016408363],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037213416,0.000118163,0.0034458695,0.00005437278,0.00017434596,3.551092e-7,0.00013290162,0.00063472596,0.96671003,0.00016213558,0.000005605227,0.02852429],"study_design_scores_gemma":[0.00039336924,0.00009809213,0.005699075,0.000023620605,0.00012816665,0.0000037565776,0.000044310786,0.000667654,0.94518703,0.00003141495,0.047458686,0.00026483258],"about_ca_topic_score_codex":0.00001181537,"about_ca_topic_score_gemma":0.0000018412569,"teacher_disagreement_score":0.09445842,"about_ca_system_score_codex":0.000024299292,"about_ca_system_score_gemma":0.0000383788,"threshold_uncertainty_score":0.7830969},"labels":[],"label_agreement":null},{"id":"W2140280994","doi":"10.1158/1535-7163.mct-11-0402","title":"ABT-898 Induces Tumor Regression and Prolongs Survival in a Mouse Model of Epithelial Ovarian Cancer","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"Canadian Institutes of Health Research","keywords":"Ovarian cancer; Debulking; Medicine; Cancer; Stage (stratigraphy); Ovarian tumor; Internal medicine; Asymptomatic; Disease; Malignancy; Cancer research; Oncology; Pathology; Biology","score_opus":0.045531385289772235,"score_gpt":0.2908881867137836,"score_spread":0.24535680142401134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140280994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904309,0.0075897193,0.0010839647,0.0001047281,0.00015386048,0.00023223329,0.00011426573,0.000008747326,0.0002816096],"genre_scores_gemma":[0.99539196,0.0027097086,0.00077686296,0.00064388796,0.00009540622,0.00012828315,0.000009628652,0.00004994003,0.00019430707],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988079,0.000073456744,0.000269888,0.000391805,0.00017329906,0.00028361578],"domain_scores_gemma":[0.9993657,0.0000040079753,0.00015388362,0.00030983324,0.00009891718,0.00006769883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016164238,0.00022611041,0.00025648857,0.00006274163,0.000040991537,0.000010034379,0.00020634983,0.00017732513,0.000020993666],"category_scores_gemma":[0.000005337992,0.0001942478,0.00009304679,0.00010137587,0.00013715283,0.000006752679,0.000106370775,0.000107989144,4.3909546e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048682405,0.00008797322,0.008372355,0.00003809193,0.00012583881,0.0000042842917,0.0005040025,0.0002692911,0.98428714,0.0001564321,0.00001007105,0.0056576906],"study_design_scores_gemma":[0.0009162399,0.00014219504,0.002864702,0.00005480025,0.000057858655,0.0000018069546,0.0000768406,0.0008233985,0.99376434,0.00027689684,0.00074911135,0.00027181834],"about_ca_topic_score_codex":0.00072982255,"about_ca_topic_score_gemma":0.00038426914,"teacher_disagreement_score":0.009477186,"about_ca_system_score_codex":0.000029105813,"about_ca_system_score_gemma":0.00020562425,"threshold_uncertainty_score":0.79211956},"labels":[],"label_agreement":null},{"id":"W2140445067","doi":"10.1158/1535-7163.mct-06-0593","title":"A novel three-dimensional model to quantify metastatic melanoma invasion","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"3D Printing in Biomedical Research","field":"Engineering","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institutes of Health; National Heart, Lung, and Blood Institute; Achievement Rewards for College Scientists Foundation","keywords":"In vivo; Metastasis; Melanoma; Cancer research; Metastatic melanoma; Cell culture; In vitro; Biology; Cell; Cancer; Matrix (chemical analysis); Chemistry; Biotechnology; Genetics","score_opus":0.08281787466730878,"score_gpt":0.3430587174017718,"score_spread":0.260240842734463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140445067","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37484238,0.00087045645,0.6230854,0.00038199007,0.00017432484,0.00020106207,0.000012408919,0.00012613287,0.00030583932],"genre_scores_gemma":[0.9429629,0.000026223343,0.05527452,0.00153749,0.000040379862,0.000031763622,0.000005227894,0.00007901724,0.000042507963],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9982175,0.000014216873,0.000269665,0.00025405252,0.0006904862,0.0005540858],"domain_scores_gemma":[0.9992125,0.00009338493,0.00002205308,0.00034595485,0.00009339012,0.00023268713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005362192,0.00019743462,0.00018934367,0.00017767824,0.00005574508,0.000032898635,0.0003086739,0.00009382446,0.000048909507],"category_scores_gemma":[0.000028528428,0.00018668002,0.00007652799,0.00043503978,0.00005570116,0.00003716865,0.00010482225,0.00030598763,0.000062530344],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033183904,0.00004473503,0.00021545269,0.00004763036,0.00016305062,0.000032188193,0.00010119223,0.14967482,0.8167744,0.000980062,0.000057866317,0.031875376],"study_design_scores_gemma":[0.0004894796,0.000054192464,0.0012445222,0.00007203842,0.000047246987,0.000009343241,0.000008600499,0.7038525,0.28997654,0.0010359966,0.002890861,0.00031869297],"about_ca_topic_score_codex":0.00006822729,"about_ca_topic_score_gemma":0.000138127,"teacher_disagreement_score":0.5681205,"about_ca_system_score_codex":0.00017409667,"about_ca_system_score_gemma":0.000088070396,"threshold_uncertainty_score":0.761259},"labels":[],"label_agreement":null},{"id":"W2141129148","doi":"10.1158/1535-7163.mct-08-0569","title":"A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Kinase Regulation and GTPase Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":200,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"GLUT1; Programmed cell death; Apoptosis; Receptor; Glucose transporter; Cell biology; Fas ligand; Cancer cell; Intracellular; Glucose uptake; Biology; Mechanism of action; Tumor necrosis factor alpha; Chemistry; Biochemistry; Pharmacology; In vitro; Endocrinology; Cancer; Insulin; Genetics","score_opus":0.030223424061894526,"score_gpt":0.2658304461202831,"score_spread":0.2356070220583886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141129148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683478,0.0019194584,0.028786447,0.0001346737,0.00015344885,0.00033931568,0.000047939153,0.000018599803,0.00025231132],"genre_scores_gemma":[0.99164224,0.00024136175,0.0058534537,0.0018303843,0.00014377314,0.000032987227,0.000025249026,0.00005011545,0.00018041985],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879086,0.000043037122,0.00028123477,0.00035635234,0.0002454785,0.00028302087],"domain_scores_gemma":[0.999166,0.0000053168797,0.00011500372,0.00040456737,0.00018402637,0.0001250508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009193328,0.00022258198,0.00021345398,0.000068547175,0.00008064017,0.000010759362,0.00015662715,0.00016702745,0.00001528147],"category_scores_gemma":[0.000006512663,0.00022750415,0.0001530749,0.00016663433,0.000045412547,0.0000030587285,0.00007991981,0.000089813824,0.0000067585706],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010504693,0.00010321152,0.00005216098,0.00002277835,0.00006972576,0.000016177779,0.00014378809,0.0009613206,0.9964124,0.00003471484,0.00004167503,0.002036986],"study_design_scores_gemma":[0.0008096157,0.00020671218,0.00024608884,0.000026121961,0.000040742612,0.000014713121,0.000026875581,0.00020167453,0.9852336,0.000012651328,0.012915192,0.00026598445],"about_ca_topic_score_codex":0.000053441796,"about_ca_topic_score_gemma":0.000011329898,"teacher_disagreement_score":0.023294449,"about_ca_system_score_codex":0.00002996655,"about_ca_system_score_gemma":0.00018444924,"threshold_uncertainty_score":0.92773503},"labels":[],"label_agreement":null},{"id":"W2141293359","doi":"10.1158/1535-7163.mct-07-0471","title":"WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Biology; DNA damage; Cell cycle; Radioresistance; Apoptosis; Cancer research; DNA repair; Molecular biology; Transfection; Cancer cell; Programmed cell death; Cancer; Cell cycle checkpoint; Tumor suppressor gene; Carcinogenesis; Cell culture; DNA; Genetics","score_opus":0.01783123944710964,"score_gpt":0.26757718047156304,"score_spread":0.2497459410244534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141293359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9686809,0.017450105,0.010136544,0.0015074466,0.00084924913,0.0009770505,0.000060405975,0.000068180365,0.00027007321],"genre_scores_gemma":[0.99042773,0.004366059,0.001076694,0.003251976,0.00016275712,0.0002291863,0.000010391133,0.000101979414,0.00037322185],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99770296,0.00008138212,0.0005193465,0.00064944715,0.000572606,0.0004742694],"domain_scores_gemma":[0.9987879,0.00003201847,0.00021484154,0.0005625793,0.00021253245,0.0001901629],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016984674,0.00036434745,0.00060502347,0.00028007734,0.00009771258,0.000015717531,0.00013873327,0.00024746612,0.00005156217],"category_scores_gemma":[0.000021009126,0.00034081368,0.00013411506,0.0007338147,0.00018749844,0.00009125569,0.000050334354,0.00043463852,0.0000024067044],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014634004,0.00010729763,0.0031387948,0.00028501631,0.0002702046,0.00020260637,0.0009021953,0.001522929,0.98457956,0.00013051015,0.0002308714,0.0071665994],"study_design_scores_gemma":[0.0024567656,0.00017043742,0.02475357,0.0005608071,0.000356986,0.00004496164,0.00007410494,0.00084627164,0.9656219,0.00008213327,0.004595616,0.000436447],"about_ca_topic_score_codex":0.0007177278,"about_ca_topic_score_gemma":0.00065897545,"teacher_disagreement_score":0.02174679,"about_ca_system_score_codex":0.00073452946,"about_ca_system_score_gemma":0.00043471175,"threshold_uncertainty_score":0.9999044},"labels":[],"label_agreement":null},{"id":"W2141323228","doi":"10.1158/1535-7163.mct-11-0826","title":"Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenosine Phosphorylase, an Exploitable Tumor Target","year":2012,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Prostate cancer; Cancer; Prostate; Cancer research; Medicine; Gene; Chromoplexy; DNA sequencing; Internal medicine; Oncology; Biology; PCA3; Genetics","score_opus":0.08997307342824663,"score_gpt":0.33383762010003104,"score_spread":0.24386454667178442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141323228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8661769,0.13197401,0.00046416506,0.00021147655,0.00027673342,0.0006414225,0.00018173554,0.000023514795,0.000050036724],"genre_scores_gemma":[0.99324006,0.00375176,0.0018990688,0.00045191904,0.00009840715,0.0002806662,0.00012349448,0.000053210253,0.00010143337],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980808,0.00010758576,0.00044451328,0.00029529238,0.0006012526,0.00047054206],"domain_scores_gemma":[0.9987774,0.000022067163,0.00025319005,0.00038980198,0.00039466357,0.00016287445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019021695,0.00022714643,0.00041809358,0.00012720043,0.00007814067,0.000024539197,0.00011750681,0.000075051306,0.00022258393],"category_scores_gemma":[0.000012165024,0.00018493639,0.00011308762,0.00037668433,0.00014331934,0.0003007328,0.000048999034,0.00016733655,0.0000024271947],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031303026,0.00035601205,0.023734722,0.00016031493,0.00030890456,0.000016896885,0.007188913,0.00037696696,0.95966053,0.00003627055,0.000042586555,0.007804825],"study_design_scores_gemma":[0.0011630148,0.0004285079,0.0014205185,0.00017621221,0.00036503872,0.000003221291,0.0013661197,0.0012626494,0.9929251,0.00009746669,0.0006110305,0.00018109818],"about_ca_topic_score_codex":0.0029858984,"about_ca_topic_score_gemma":0.000067141955,"teacher_disagreement_score":0.12822226,"about_ca_system_score_codex":0.0003983259,"about_ca_system_score_gemma":0.000564516,"threshold_uncertainty_score":0.7541487},"labels":[],"label_agreement":null},{"id":"W2141787758","doi":"10.1158/1535-7163.targ-09-b54","title":"Abstract B54: A phase 1 study to assess the safety, tolerability and pharmacokinetics of the ErbB-family inhibitor ARRY-334543 in patients with advanced solid tumors","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Juravinski Cancer Centre","funders":"","keywords":"Pharmacokinetics; Medicine; Dosing; Tolerability; Cmax; Capsule; Adverse effect; Pharmacology; Internal medicine; Gastroenterology","score_opus":0.027314768822341542,"score_gpt":0.3634590329814251,"score_spread":0.3361442641590836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141787758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941633,0.00086759834,0.00003710168,0.0020620995,0.00017282928,0.002497714,0.00004893331,0.000016269481,0.00013420347],"genre_scores_gemma":[0.99471176,0.00010513921,0.00006459678,0.00495414,0.000054785985,0.000060231967,0.0000065446966,0.000026062278,0.000016746893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845207,0.00011645138,0.00041006328,0.00033018965,0.00040094386,0.00029027765],"domain_scores_gemma":[0.999123,0.000052133182,0.00015966079,0.00040741285,0.00016163383,0.00009616879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018138645,0.00025677966,0.00043018674,0.00006173608,0.000076909426,0.000014758483,0.00017840082,0.000042861844,0.000029439472],"category_scores_gemma":[0.000007346815,0.0001487014,0.00006973069,0.00038929353,0.00011282663,0.00004077798,0.0000476843,0.00029381533,5.765618e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018594166,0.017318523,0.42915103,0.0001224536,0.0010001841,0.00008885856,0.0071064085,0.0027557688,0.34954533,0.000018629964,0.00011715344,0.1741815],"study_design_scores_gemma":[0.017231183,0.004200878,0.93171334,0.00011735024,0.0005240201,0.0000019057807,0.00030716485,0.00007080685,0.044374093,0.000036222606,0.001219669,0.0002033589],"about_ca_topic_score_codex":0.000059348004,"about_ca_topic_score_gemma":0.000065307155,"teacher_disagreement_score":0.50256234,"about_ca_system_score_codex":0.00018573305,"about_ca_system_score_gemma":0.00018029788,"threshold_uncertainty_score":0.60638666},"labels":[],"label_agreement":null},{"id":"W2142067446","doi":"10.1158/1535-7163.mct-09-0495","title":"Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research","keywords":"Receptor; Histone deacetylase; Apoptosis; Programmed cell death; HDAC6; Histone; Histone deacetylase inhibitor; Biology; Chemistry; Cancer research; Cell biology; Pharmacology; Gene; Biochemistry","score_opus":0.014746398252306281,"score_gpt":0.31615507126264547,"score_spread":0.3014086730103392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142067446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99536145,0.0008308736,0.0019887073,0.00039353422,0.0004199054,0.00044424867,0.00013322681,0.000023703946,0.00040434106],"genre_scores_gemma":[0.9957377,0.0002408869,0.0020028672,0.00093824905,0.00023738189,0.000092396396,0.00007475631,0.000077330245,0.0005984438],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982337,0.00007626058,0.0003303372,0.00052858616,0.00038933774,0.00044181285],"domain_scores_gemma":[0.9986477,0.000018310951,0.00012623836,0.0005570855,0.00046508014,0.00018559911],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023081986,0.00027726687,0.0002784145,0.00014189887,0.00010061444,0.00002279571,0.00019779934,0.00027755563,0.000057781443],"category_scores_gemma":[0.00003975011,0.00028311528,0.00016598329,0.00029498446,0.00015411696,0.0000045592865,0.000121602505,0.0002922486,0.000024859592],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022942663,0.000103834675,0.0001357511,0.000028415994,0.00012638731,0.0000109001,0.000212655,0.00013198765,0.99572444,0.000082708524,0.0014888134,0.0017246602],"study_design_scores_gemma":[0.00052992895,0.00042348084,0.00009998115,0.000040776784,0.000043006447,0.000009771285,0.00003722658,0.000028051592,0.9764564,0.000029607925,0.021977928,0.00032382744],"about_ca_topic_score_codex":0.00016890111,"about_ca_topic_score_gemma":0.00023486589,"teacher_disagreement_score":0.020489115,"about_ca_system_score_codex":0.00008973488,"about_ca_system_score_gemma":0.0003107962,"threshold_uncertainty_score":0.9999621},"labels":[],"label_agreement":null},{"id":"W2143782801","doi":"10.1158/1535-7163.mct-06-0557","title":"Gene expression analysis of gallium-resistant and gallium-sensitive lymphoma cells reveals a role for metal-responsive transcription factor-1, metallothionein-2A, and zinc transporter-1 in modulating the antineoplastic activity of gallium nitrate","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Trace Elements in Health","field":"Nursing","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; BC Cancer Agency","keywords":"Metallothionein; Transcription factor; Gene; Biology; Gene expression; Gallium; Transporter; Molecular biology; Cancer research; Genetics; Chemistry","score_opus":0.02408011798436612,"score_gpt":0.2993019458024416,"score_spread":0.2752218278180755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143782801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95374364,0.002378428,0.042145055,0.00016142282,0.00015381545,0.0010669621,0.00032231212,0.000020379657,0.000007973823],"genre_scores_gemma":[0.99525493,0.00027417866,0.004104874,0.00021210907,0.000026396345,0.0000417992,0.000017987393,0.00006016829,0.000007537129],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971931,0.00041706042,0.00085085037,0.00054015423,0.00049016695,0.0005086468],"domain_scores_gemma":[0.99812585,0.0005601568,0.0006007155,0.0003688621,0.0002493819,0.000095025716],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009897798,0.0003633806,0.0008274691,0.00042476683,0.00014120064,0.000026248765,0.00015255272,0.00018779284,0.0000066726643],"category_scores_gemma":[0.000023716695,0.00030871184,0.00024689225,0.00069787615,0.00019692362,0.00014382697,0.000019443598,0.00018385338,6.564185e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003922517,0.00020379467,0.0034892717,0.00023439321,0.0009978114,0.000009192631,0.0050287466,0.0023906408,0.97617024,0.000034578963,2.5299656e-7,0.0075185336],"study_design_scores_gemma":[0.0013812515,0.00028669773,0.15534945,0.0001498138,0.0019519605,0.000001545432,0.00048266698,0.006743641,0.83326906,0.000118526,0.000023517072,0.00024188892],"about_ca_topic_score_codex":0.0006437691,"about_ca_topic_score_gemma":0.0016734435,"teacher_disagreement_score":0.15186018,"about_ca_system_score_codex":0.00016456377,"about_ca_system_score_gemma":0.000070997135,"threshold_uncertainty_score":0.9999365},"labels":[],"label_agreement":null},{"id":"W2143814205","doi":"10.1158/1535-7163.mct-13-0649","title":"KRAS Mutation Status Is Associated with Enhanced Dependency on Folate Metabolism Pathways in Non–Small Cell Lung Cancer Cells","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"London Health Sciences Centre","keywords":"KRAS; Pemetrexed; Antifolate; Cancer research; Gene knockdown; Biology; Mutant; Cancer; Cell culture; Antimetabolite; Gene; Genetics; Colorectal cancer; Chemotherapy","score_opus":0.012331464038611479,"score_gpt":0.2861007131037423,"score_spread":0.27376924906513084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143814205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828174,0.0040294137,0.008696242,0.00037867643,0.0003126558,0.0011050577,0.000115199175,0.000066871544,0.0024784438],"genre_scores_gemma":[0.99225813,0.0013552648,0.0004933738,0.004696837,0.00006360912,0.00045447593,0.0000755107,0.000098954646,0.000503836],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99810976,0.00009720494,0.00031511253,0.00049378653,0.00042637307,0.0005577706],"domain_scores_gemma":[0.99899304,0.00005151194,0.00021693291,0.00036275,0.00021799661,0.0001577594],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001079616,0.0003489985,0.00044496442,0.00016557734,0.000093465555,0.000039815703,0.00010279716,0.00016294833,0.00011108385],"category_scores_gemma":[0.000005319915,0.00028626245,0.00011101625,0.00041483753,0.000037921105,0.000067724104,0.000013618894,0.0002927811,0.000009819782],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000927508,0.0014995623,0.012811509,0.0003127901,0.003123268,0.00032201532,0.01814542,0.00977967,0.8639886,0.00043953126,0.000101836384,0.088548325],"study_design_scores_gemma":[0.011812667,0.0008030677,0.020037308,0.0005850672,0.002854038,0.0000027563212,0.00020358231,0.0077639385,0.9531239,0.0004992613,0.0016789929,0.0006353802],"about_ca_topic_score_codex":0.0011321292,"about_ca_topic_score_gemma":0.0011093523,"teacher_disagreement_score":0.08913538,"about_ca_system_score_codex":0.00063016504,"about_ca_system_score_gemma":0.00056183164,"threshold_uncertainty_score":0.99995893},"labels":[],"label_agreement":null},{"id":"W2143972162","doi":"10.1158/1535-7163.mct-06-0663","title":"Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Kruppel-like factors research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Lethbridge","funders":"","keywords":"Epigenetics; Biology; DNA methylation; Cancer epigenetics; Cancer research; Estrogen receptor; MCF-7; Cisplatin; Histone H3; Cancer cell; Histone; Vorinostat; Cancer; Histone methyltransferase; Gene expression; Genetics; Breast cancer; Histone deacetylase; Gene","score_opus":0.026268298539420306,"score_gpt":0.3103611688220568,"score_spread":0.28409287028263647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143972162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97871524,0.013390715,0.0068606595,0.000072868774,0.000107026,0.0005139015,0.00018995634,0.000017303713,0.00013234292],"genre_scores_gemma":[0.99605316,0.0004360797,0.0028128733,0.00022946196,0.000090653215,0.000022216775,0.00007653392,0.000093137256,0.00018590712],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99774057,0.00010000694,0.000496917,0.000592648,0.0004170569,0.000652778],"domain_scores_gemma":[0.99869317,0.000028051776,0.00019193356,0.0005941236,0.00029633273,0.00019641186],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004938078,0.0003301214,0.00034206852,0.00015228674,0.00011932707,0.000029100358,0.0003490934,0.0002940557,0.000016580565],"category_scores_gemma":[0.000017362561,0.00032607312,0.0001347575,0.00026195342,0.00026411912,0.0000053847934,0.00019733762,0.00023312388,0.0000020056764],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020595448,0.00013750081,0.013902967,0.00009241038,0.00024064994,0.000013869291,0.00010030414,0.00006934392,0.9822991,0.000037672715,0.0000069824027,0.0028932667],"study_design_scores_gemma":[0.0010161924,0.000290989,0.026579505,0.00003678284,0.0000745645,0.00001598836,0.0000883475,0.00008745134,0.9706555,0.000041177722,0.0007633797,0.00035010726],"about_ca_topic_score_codex":0.0002481167,"about_ca_topic_score_gemma":0.000065798806,"teacher_disagreement_score":0.01733791,"about_ca_system_score_codex":0.000066275985,"about_ca_system_score_gemma":0.00013163574,"threshold_uncertainty_score":0.9999191},"labels":[],"label_agreement":null},{"id":"W2144520265","doi":"10.1158/1535-7163.mct-05-0539","title":"Promise of vitamin D analogues in the treatment of hyperproliferative conditions","year":2006,"lang":"en","type":"review","venue":"Molecular Cancer Therapeutics","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Calcitriol; Vitamin D and neurology; Calcitriol receptor; Pharmacology; Cancer; Cancer research; Steroid hormone; Medicine; Calcipotriol; Angiogenesis; Endocrinology; Internal medicine; Biology; Psoriasis; Hormone; Immunology","score_opus":0.09284472894735561,"score_gpt":0.4210077713324955,"score_spread":0.3281630423851399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144520265","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016764512,0.9949892,0.000018828896,0.00017308304,0.000035776622,0.0022707111,0.00039559844,0.000007321319,0.0004329926],"genre_scores_gemma":[0.0059662974,0.9922712,0.00007928274,0.00007041359,0.000052630334,0.0011341956,0.00020877495,0.000038583617,0.00017863844],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982239,0.00032418195,0.00055131863,0.0002490636,0.00040899758,0.00024254453],"domain_scores_gemma":[0.9988898,0.00017504884,0.00025925203,0.00047902318,0.00016695338,0.000029917344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013405914,0.0003255973,0.0015820253,0.00024169276,0.000036266214,0.000006514983,0.00017639395,0.00015152423,0.000012520348],"category_scores_gemma":[0.0000130748795,0.00017892562,0.00047925796,0.00052152836,0.000336335,0.0000129532655,0.00001940231,0.00019528723,0.000001800926],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058218775,0.0034722704,0.00055557,0.019416582,0.005512121,0.0003606546,0.0035196703,0.000015449596,0.0007889424,0.00034160158,0.0002275989,0.9657313],"study_design_scores_gemma":[0.0021294043,0.0022347546,0.0009532064,0.009453551,0.006420694,0.00003749661,0.00036565168,0.00001542903,0.0017838012,0.00009541409,0.9761755,0.0003351331],"about_ca_topic_score_codex":0.0001486876,"about_ca_topic_score_gemma":0.00009486711,"teacher_disagreement_score":0.97594786,"about_ca_system_score_codex":0.00028847693,"about_ca_system_score_gemma":0.0005255144,"threshold_uncertainty_score":0.7296375},"labels":[],"label_agreement":null},{"id":"W2144900656","doi":"10.1158/1535-7163.mct-08-1068","title":"Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"U.S. Department of Veterans Affairs","keywords":"KRAS; Lung cancer; Medicine; Epidermal growth factor receptor; Immunohistochemistry; Paclitaxel; Internal medicine; Fluorescence in situ hybridization; Targeted therapy; Cancer; Oncology; Cancer research; Biology; Colorectal cancer; Gene","score_opus":0.008356432669197871,"score_gpt":0.31058050054610215,"score_spread":0.30222406787690426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144900656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98921764,0.0010981829,0.006106386,0.0007008767,0.00005494036,0.0026370396,0.000088432265,0.000018912582,0.00007761213],"genre_scores_gemma":[0.99209034,0.00006620821,0.0053367857,0.0017083053,0.0000073408655,0.0006097488,0.000031505744,0.000055043387,0.00009470681],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874115,0.000039050134,0.00027190536,0.00033564126,0.0002903619,0.0003218642],"domain_scores_gemma":[0.9990142,0.000030644795,0.00015686497,0.0003237467,0.00037073053,0.00010382431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007278349,0.0002411278,0.00036365146,0.00017579505,0.00004366055,0.00001309798,0.000095635136,0.00007448532,0.0000056475196],"category_scores_gemma":[0.000006482394,0.00018803928,0.000062951294,0.00037311733,0.000029526722,0.000056729725,0.000010297782,0.00008918548,3.9529093e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044247568,0.0043102847,0.5691112,0.0008213983,0.00090156414,0.00021035684,0.0061851502,0.011561044,0.22860456,0.00010284065,0.000038131624,0.13390589],"study_design_scores_gemma":[0.040696174,0.012636832,0.6149472,0.0016915702,0.0016888208,0.0000037939437,0.0002458454,0.0020208918,0.3241217,0.000100026635,0.0011496521,0.0006974728],"about_ca_topic_score_codex":0.00011582888,"about_ca_topic_score_gemma":0.000118013966,"teacher_disagreement_score":0.13320842,"about_ca_system_score_codex":0.00046462042,"about_ca_system_score_gemma":0.00047396417,"threshold_uncertainty_score":0.7668019},"labels":[],"label_agreement":null},{"id":"W2145353373","doi":"10.1158/1535-7163.mct-05-0033","title":"Identification of genes and molecular pathways involved in the progression of premalignant oral epithelia","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"National Cancer Institute","keywords":"Identification (biology); Gene; Biology; Cancer; Genetics; Computational biology; Cancer research","score_opus":0.01877441894176379,"score_gpt":0.2866875490502745,"score_spread":0.2679131301085107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145353373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9676856,0.02766006,0.0037264659,0.0004148262,0.000052513587,0.0004115407,0.000019615634,0.000005077961,0.000024289879],"genre_scores_gemma":[0.99714553,0.0019654483,0.0005126557,0.00020915565,0.00003827201,0.00006361203,0.00003220593,0.00002425028,0.000008860758],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99880284,0.00014786063,0.00038990242,0.00025810572,0.00024101202,0.00016025783],"domain_scores_gemma":[0.9992019,0.0000070694978,0.0002529463,0.00039440842,0.000120190096,0.000023495399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031615703,0.00014534705,0.00016153631,0.000063027015,0.000027289105,0.000011933179,0.00019347262,0.00014809483,0.0000027521892],"category_scores_gemma":[0.000008393645,0.00011671569,0.00007377838,0.0001841284,0.00012496505,0.0000064192936,0.0000493474,0.00006956657,3.485698e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000076095595,0.0000733918,0.0019051202,0.000045231736,0.00006700442,0.0000010574286,0.00028698816,0.0018385455,0.94191307,0.00024149615,0.000006551313,0.053545438],"study_design_scores_gemma":[0.0005265857,0.0001395406,0.0029481852,0.000056080884,0.00006938112,0.0000034149405,0.00008163892,0.0017805542,0.9916464,0.00017142933,0.002447587,0.00012919596],"about_ca_topic_score_codex":0.00003086033,"about_ca_topic_score_gemma":0.00009771365,"teacher_disagreement_score":0.05341624,"about_ca_system_score_codex":0.000019934789,"about_ca_system_score_gemma":0.000085052394,"threshold_uncertainty_score":0.47595274},"labels":[],"label_agreement":null},{"id":"W2146004287","doi":"10.1158/1535-7163.mct-10-0643","title":"Radiosensitization of Head and Neck Squamous Cell Carcinoma by a SMAC-Mimetic Compound, SM-164, Requires Activation of Caspases","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; La Trobe University; McGill University; University of Michigan","keywords":"Radiosensitizer; Apoptosis; Cancer research; Head and neck squamous-cell carcinoma; Gene knockdown; Caspase; Radioresistance; Cell culture; Caspase 3; Activator (genetics); Inhibitor of apoptosis; Caspase-9; Medicine; Cancer cell; Chemistry; Programmed cell death; Caspase 8; Cancer; Head and neck cancer; Biology; Radiation therapy; Internal medicine; Biochemistry","score_opus":0.02162316544434196,"score_gpt":0.24553467346716087,"score_spread":0.22391150802281892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146004287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787656,0.0053291316,0.015351478,0.000029871122,0.00006663456,0.00020905548,0.00002563446,0.0000059980357,0.00021660977],"genre_scores_gemma":[0.99831814,0.000447815,0.0008389936,0.00015662432,0.000026189284,0.000009278118,0.00010337292,0.000028937166,0.00007063379],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992143,0.00005932515,0.00023221412,0.00022523807,0.0001311035,0.00013785454],"domain_scores_gemma":[0.99941176,0.000007497203,0.00019020773,0.00023316237,0.000118119715,0.00003923935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000059632494,0.00014463364,0.0001688129,0.000047021258,0.000039430826,0.0000063726434,0.000073279465,0.00013689947,0.000010004952],"category_scores_gemma":[0.000004362839,0.00014223701,0.00006111109,0.00009056488,0.00008946034,0.0000054247944,0.000034084354,0.000043076274,1.7798982e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017357976,0.00009863549,0.0017794209,0.00007833116,0.000036909332,0.0000019098652,0.0002488063,0.00009159226,0.99175465,0.000120281475,0.00002296934,0.005592929],"study_design_scores_gemma":[0.0008150472,0.00053183746,0.0029342338,0.000017387169,0.00008755012,0.0000059820177,0.00006233393,0.00055411586,0.9939486,0.00015010902,0.0007420674,0.00015073406],"about_ca_topic_score_codex":0.00035026317,"about_ca_topic_score_gemma":0.000021832917,"teacher_disagreement_score":0.019552568,"about_ca_system_score_codex":0.00001588459,"about_ca_system_score_gemma":0.000047417667,"threshold_uncertainty_score":0.58002573},"labels":[],"label_agreement":null},{"id":"W2146553113","doi":"10.1158/1535-7163.mct-14-0547","title":"Contribution of Hepatic Organic Anion-Transporting Polypeptides to Docetaxel Uptake and Clearance","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Institute of General Medical Sciences; Canadian Institutes of Health Research","keywords":"Docetaxel; Pharmacology; Transporter; Chemistry; Organic anion transporter 1; Organic anion-transporting polypeptide; Pharmacokinetics; Transfection; In vivo; Biochemistry; Biology; Internal medicine; Medicine; Cancer; Gene","score_opus":0.021909245701659804,"score_gpt":0.2826174546863057,"score_spread":0.2607082089846459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146553113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9690365,0.006984461,0.022025706,0.0012497632,0.00014132587,0.00038077834,0.000014040403,0.00004392189,0.00012346017],"genre_scores_gemma":[0.99613446,0.00051874336,0.0016238608,0.0015248369,0.000043287764,0.000015748108,0.000012611515,0.00003503989,0.000091427064],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99888617,0.000019918598,0.00032043896,0.0002183864,0.00031019255,0.00024489212],"domain_scores_gemma":[0.99922526,0.000007118273,0.00010140378,0.00021183027,0.0002685021,0.0001858801],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000200394,0.00015429077,0.00033517074,0.00006302081,0.0000359076,0.000009551624,0.00006952627,0.000082915736,0.000020717222],"category_scores_gemma":[0.000010890314,0.00013505876,0.00006685421,0.00026276408,0.000056821515,0.000036313235,0.000006762785,0.00011295164,0.00000380403],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005984377,0.00009030685,0.020142758,0.00013069686,0.00019236251,0.000052280484,0.0011808584,0.00005068545,0.9683411,0.0010039385,0.0000084160665,0.008208128],"study_design_scores_gemma":[0.0037236325,0.000600557,0.06121123,0.0005995886,0.0007197086,0.000025543837,0.0004580012,0.00037547378,0.9198908,0.00096326746,0.011057071,0.00037512954],"about_ca_topic_score_codex":0.00005806686,"about_ca_topic_score_gemma":0.00011085922,"teacher_disagreement_score":0.048450336,"about_ca_system_score_codex":0.00006376235,"about_ca_system_score_gemma":0.00016173102,"threshold_uncertainty_score":0.5507536},"labels":[],"label_agreement":null},{"id":"W2146832982","doi":"10.1158/1535-7163.mct-08-1090","title":"Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Etoposide; DNA damage; Topoisomerase; Hypoxia (environmental); Biology; Cancer research; Cancer cell; DNA repair; Tumor hypoxia; Molecular biology; Pharmacology; DNA; Chemistry; Cancer; Medicine; Internal medicine; Chemotherapy; Biochemistry; Genetics; Oxygen; Radiation therapy","score_opus":0.0356408677871664,"score_gpt":0.30391991231239,"score_spread":0.2682790445252236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146832982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733853,0.020585507,0.0018035078,0.00059967197,0.0021098147,0.0008210084,0.00011520171,0.000055501223,0.00052450766],"genre_scores_gemma":[0.98058546,0.009385782,0.00088940345,0.007191492,0.00095014955,0.00019043835,0.000045953973,0.00012087279,0.00064045674],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99681187,0.00020041062,0.0005590496,0.0010208166,0.0004744191,0.00093345344],"domain_scores_gemma":[0.99845225,0.000013377372,0.00025147738,0.00095776806,0.00014277577,0.00018237195],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019677477,0.0006026804,0.00055261,0.0001357773,0.00014307947,0.0000908502,0.0006259092,0.00050913333,0.00010576713],"category_scores_gemma":[0.000015534457,0.00063057087,0.00029059668,0.00043167087,0.00006293975,0.00003384169,0.00014420292,0.0004270357,0.000009479698],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010749996,0.00021155155,0.000079602025,0.00003060372,0.0001843983,0.000013683638,0.0005383596,0.00018082716,0.98618835,0.000347548,0.0002772226,0.011840332],"study_design_scores_gemma":[0.0016811261,0.00027761798,0.0018216063,0.000098003155,0.00013043452,0.0000056079307,0.00009531789,0.00010404667,0.95031977,0.001967102,0.04275742,0.0007419528],"about_ca_topic_score_codex":0.0006654982,"about_ca_topic_score_gemma":0.0006785913,"teacher_disagreement_score":0.0424802,"about_ca_system_score_codex":0.00019499984,"about_ca_system_score_gemma":0.00051202584,"threshold_uncertainty_score":0.99961454},"labels":[],"label_agreement":null},{"id":"W2147186597","doi":"10.1158/1535-7163.mct-12-1166","title":"PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Mechanisms and Therapy","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Moffitt Cancer Center","keywords":"Multiple myeloma; Apoptosis; Dexamethasone; Cancer research; Gene knockdown; In vivo; Gene silencing; Cell culture; Doxorubicin; Chemistry; Medicine; Biology; Immunology; Internal medicine; Chemotherapy","score_opus":0.018219872193544838,"score_gpt":0.26820796506068445,"score_spread":0.2499880928671396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147186597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912427,0.0031900986,0.0032850008,0.0012967034,0.00021140833,0.0006478342,0.00003248397,0.000025034145,0.00006873988],"genre_scores_gemma":[0.9967654,0.0011931912,0.00064064225,0.0010521781,0.00005470031,0.000109182925,0.000012486328,0.000043787957,0.00012847631],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989215,0.000047550868,0.00022183511,0.00030302414,0.000247892,0.00025819548],"domain_scores_gemma":[0.9993819,0.00002079476,0.00012438574,0.00029111415,0.0000977747,0.00008403139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009473535,0.00019603179,0.00036944877,0.00010113767,0.00003989039,0.000020107951,0.00007385432,0.00012288884,0.00010965731],"category_scores_gemma":[0.000005844032,0.00017731148,0.00006475877,0.00023413982,0.00009236372,0.00010993878,0.00003116123,0.00021699611,0.0000031149011],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002014384,0.00017565479,0.004602395,0.000078096025,0.00011731496,0.000008052591,0.0001898354,0.000009763952,0.9161077,0.0001861072,0.000059570688,0.07826403],"study_design_scores_gemma":[0.003136856,0.00035004903,0.06784117,0.00011561582,0.00009430216,0.000011028055,0.00006212184,0.00090831233,0.9236659,0.0005779108,0.0030118364,0.00022491354],"about_ca_topic_score_codex":0.0026310678,"about_ca_topic_score_gemma":0.00012265783,"teacher_disagreement_score":0.07803912,"about_ca_system_score_codex":0.00013002426,"about_ca_system_score_gemma":0.00008663585,"threshold_uncertainty_score":0.7230552},"labels":[],"label_agreement":null},{"id":"W2147195140","doi":"10.1158/1535-7163.targ-09-a196","title":"Abstract A196: Characterization of stability and biological activity of the cancer gene therapy biologic SNS01 following storage at ambient and freezing temperatures","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Polyamine Metabolism and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Molecular biology; Agarose gel electrophoresis; Biology; In vivo; Apoptosis; Cancer cell; In vitro; Transfection; Polyethylenimine; Biochemistry; Cell biology; Cancer; Gene","score_opus":0.026881084944715982,"score_gpt":0.2819565397507381,"score_spread":0.2550754548060221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147195140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897648,0.009081379,0.00028236222,0.00035174278,0.000071392176,0.00029014164,0.00014388055,0.000006077107,0.000008232971],"genre_scores_gemma":[0.9928387,0.006439542,0.00006800081,0.00054121925,0.0000390571,0.000030408883,0.000027603155,0.00000926982,0.00000622608],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99920964,0.00007402502,0.00017342395,0.0002977203,0.00009530217,0.00014990085],"domain_scores_gemma":[0.9994345,0.000008998567,0.00015931213,0.00031500836,0.00004761301,0.00003460638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013897427,0.00015133842,0.00019467447,0.000017986184,0.000090374946,0.000010678261,0.0001456801,0.00012109307,0.0000057777524],"category_scores_gemma":[0.000008051132,0.000101888625,0.00008948187,0.00010005606,0.00014456252,0.000004940903,0.00007698518,0.000078639554,3.6472013e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006816728,0.00006869214,0.014956867,0.000006960926,0.000065312706,2.8607263e-7,0.000058573874,0.00000723343,0.9775035,0.000031647636,8.768398e-7,0.007231879],"study_design_scores_gemma":[0.00023662795,0.00005864796,0.30996022,0.000007526463,0.00001961241,7.495765e-7,0.000005174165,0.000014417752,0.689006,0.000032848457,0.00057756697,0.000080625614],"about_ca_topic_score_codex":0.000045505378,"about_ca_topic_score_gemma":0.000013153294,"teacher_disagreement_score":0.29500335,"about_ca_system_score_codex":0.00001580349,"about_ca_system_score_gemma":0.00004250521,"threshold_uncertainty_score":0.41548973},"labels":[],"label_agreement":null},{"id":"W2147471000","doi":"10.1158/1535-7163.mct-05-0082","title":"Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non–small cell lung cancer cells","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":152,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Neurological Disorders and Stroke; National Cancer Institute","keywords":"Urokinase receptor; Cancer research; Metastasis; Angiogenesis; Matrix metalloproteinase; Zymography; Lung cancer; Biology; Cancer cell; Cancer; Molecular biology; Pathology; Chemistry; Plasminogen activator; Medicine; Internal medicine; Endocrinology; Biochemistry","score_opus":0.008975766653876045,"score_gpt":0.22871856950205932,"score_spread":0.2197428028481833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147471000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9516422,0.04554943,0.0018794057,0.000113378905,0.000041897183,0.00040231785,0.00034339758,0.0000050892795,0.000022877653],"genre_scores_gemma":[0.9859743,0.012539937,0.00043891525,0.0008425547,0.00003834246,0.00006214116,0.00005311503,0.000040789604,0.0000098847195],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988159,0.00008627097,0.00034821327,0.00035713558,0.0001518574,0.0002406371],"domain_scores_gemma":[0.9995313,0.00000914954,0.00010166214,0.00019104185,0.00008813365,0.000078703604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012213284,0.00022516723,0.00028960672,0.00008992943,0.000029596491,0.000009635708,0.000083756175,0.00015640003,0.000012572627],"category_scores_gemma":[0.0000035172357,0.00022591228,0.00008178373,0.00016498165,0.00009285697,0.000009813573,0.000047320158,0.00008420394,2.404558e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012659952,0.00011263237,0.0009839995,0.00018834019,0.000109816305,0.000006500057,0.00016316462,0.000039511564,0.9970071,0.0000071265126,0.00006497874,0.0011902532],"study_design_scores_gemma":[0.0013727545,0.00016912425,0.00015009967,0.00007963459,0.00018495685,0.0000029431856,0.000040658324,0.00017130247,0.9970791,0.000014840531,0.00049488473,0.0002397211],"about_ca_topic_score_codex":0.00024516555,"about_ca_topic_score_gemma":0.00012747766,"teacher_disagreement_score":0.03433211,"about_ca_system_score_codex":0.000018439845,"about_ca_system_score_gemma":0.000092154056,"threshold_uncertainty_score":0.9212436},"labels":[],"label_agreement":null},{"id":"W2147582215","doi":"10.1158/1535-7163.mct-10-0312","title":"Small Interfering RNA Targeting 14-3-3ζ Increases Efficacy of Chemotherapeutic Agents in Head and Neck Cancer Cells","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"14-3-3 protein interactions","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Small interfering RNA; Propidium iodide; Transfection; Cancer research; Cisplatin; Cancer cell; Molecular biology; Doxorubicin; Apoptosis; Annexin; Cancer; Head and neck squamous-cell carcinoma; Paclitaxel; Biology; Flow cytometry; Cell culture; Programmed cell death; Head and neck cancer; Chemotherapy; Biochemistry","score_opus":0.027621851449162894,"score_gpt":0.3059244296367972,"score_spread":0.2783025781876343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147582215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935783,0.0045828447,0.00066451036,0.00018633973,0.00039739325,0.00037198534,0.000030883308,0.000017224364,0.00017049952],"genre_scores_gemma":[0.9959023,0.0012357894,0.001418904,0.0010003845,0.00014082005,0.0001043236,0.000018321261,0.000075490454,0.00010366314],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998591,0.00007466522,0.00037118662,0.0004521196,0.00014544907,0.0003655615],"domain_scores_gemma":[0.99918264,0.000025104728,0.00017833417,0.00040467337,0.000118326876,0.00009091147],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001416443,0.00027964768,0.0002667115,0.00009822646,0.000057643552,0.000035089317,0.00028029765,0.00021601697,0.00008428331],"category_scores_gemma":[0.000028799192,0.00029185342,0.00011214345,0.00015871445,0.0001339927,0.000008361203,0.00015005104,0.000353866,0.0000020315404],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016324814,0.00015841657,0.0079896655,0.00005531214,0.00018797824,0.0000046851637,0.00015507461,0.00028284133,0.97795576,0.0000127058975,0.0000213386,0.013012974],"study_design_scores_gemma":[0.0012820554,0.00012851243,0.0061392137,0.0001225219,0.00006611221,0.000005579131,0.000034916848,0.00033609656,0.981798,0.000031997217,0.0097494405,0.00030554357],"about_ca_topic_score_codex":0.001376897,"about_ca_topic_score_gemma":0.0014279356,"teacher_disagreement_score":0.012707431,"about_ca_system_score_codex":0.000043726395,"about_ca_system_score_gemma":0.00011995609,"threshold_uncertainty_score":0.9999534},"labels":[],"label_agreement":null},{"id":"W2148047944","doi":"10.1158/1535-7163.mct-14-0521","title":"Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Transactivation; Androgen receptor; CYP17A1; Enzalutamide; LNCaP; Prostate cancer; In vivo; Chemistry; Reporter gene; Luciferase; Androgen deprivation therapy; Cancer research; Internal medicine; Pharmacology; Biology; Cancer; Transfection; Medicine; Gene expression; Gene; Biochemistry","score_opus":0.07939099133391246,"score_gpt":0.38985684938807197,"score_spread":0.3104658580541595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148047944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911692,0.004325259,0.0015551525,0.0010328023,0.00011992887,0.0010426125,0.00016255828,0.000020783127,0.0005716621],"genre_scores_gemma":[0.99662775,0.0020731802,0.00053138455,0.00022975226,0.00006108553,0.00024513708,0.000007705064,0.0000544851,0.00016951717],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978766,0.00012362054,0.00049423357,0.00045307423,0.00058083714,0.00047167615],"domain_scores_gemma":[0.99872416,0.00009178549,0.00024450218,0.00038496722,0.00042730907,0.00012729861],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033132161,0.00026533214,0.00071205106,0.00017368994,0.000032923424,0.000010260065,0.0001404094,0.00017083794,0.00002527786],"category_scores_gemma":[0.000021393409,0.00021610089,0.00017132927,0.0005819955,0.0003217572,0.00009325331,0.00005676518,0.00038739134,5.241652e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061382023,0.0012667375,0.013182337,0.0005086454,0.0006427011,0.00001963991,0.0012168217,0.0028345683,0.95269144,0.0002643881,0.000013163462,0.021221347],"study_design_scores_gemma":[0.00888389,0.0013298885,0.01618453,0.0007895755,0.00035081038,0.0000035123958,0.00008071416,0.022339849,0.94894195,0.00045805363,0.0003540734,0.0002831616],"about_ca_topic_score_codex":0.0019454876,"about_ca_topic_score_gemma":0.0005454952,"teacher_disagreement_score":0.020938186,"about_ca_system_score_codex":0.00036021307,"about_ca_system_score_gemma":0.0011418626,"threshold_uncertainty_score":0.8812338},"labels":[],"label_agreement":null},{"id":"W2148098988","doi":"10.1158/1535-7163.mct-06-0230","title":"High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m–labeled anti-DR5 antibody in breast tumor xenografts","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Single-photon emission computed tomography; Biodistribution; Emission computed tomography; Nuclear medicine; Chemistry; Distribution (mathematics); Antibody; Monoclonal antibody; Molecular biology; Cancer research; Positron emission tomography; Medicine; Biology; In vitro; Immunology; Biochemistry","score_opus":0.015791139513509824,"score_gpt":0.30285195562941397,"score_spread":0.28706081611590417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148098988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97712535,0.0061318036,0.01493404,0.00091618253,0.00011542904,0.00055045536,0.000044853772,0.0001036391,0.000078274694],"genre_scores_gemma":[0.9955538,0.00015624204,0.0028551358,0.001156123,0.000094666946,0.000016059632,0.000118828124,0.00004511475,0.0000040283576],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99804574,0.000059093367,0.0005636892,0.0004760661,0.0003704187,0.0004849837],"domain_scores_gemma":[0.9989247,0.00006166614,0.0002005586,0.00036635663,0.00020278065,0.00024395979],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026459523,0.00031377625,0.00049822,0.0003326586,0.000099860226,0.000028157167,0.00015927246,0.00012589474,0.000016324047],"category_scores_gemma":[0.000004267592,0.00030721418,0.00015714265,0.0014275765,0.00029905353,0.00006295452,0.00005355295,0.00036903718,5.397435e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002843335,0.0005886715,0.079506196,0.00019600143,0.00016128128,0.000088660665,0.00009237692,0.00016206171,0.9136476,0.000063260995,0.000018321929,0.005191241],"study_design_scores_gemma":[0.0035004031,0.00009699654,0.17605476,0.0005401031,0.00031755472,0.00011934749,0.00006321802,0.0128877275,0.8045709,0.000084948246,0.0013996515,0.00036438947],"about_ca_topic_score_codex":0.00011039523,"about_ca_topic_score_gemma":0.0000036094723,"teacher_disagreement_score":0.10907669,"about_ca_system_score_codex":0.000084222775,"about_ca_system_score_gemma":0.0000598203,"threshold_uncertainty_score":0.999938},"labels":[],"label_agreement":null},{"id":"W2148135357","doi":"10.1158/1535-7163.mct-06-0134","title":"Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agent","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Ontario Genomics","funders":"National Institutes of Health","keywords":"Apoptosis; Pharmacology; Traditional medicine; Medicine; Biology; Genetics","score_opus":0.019980352863682875,"score_gpt":0.2784638712500205,"score_spread":0.2584835183863376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148135357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763089,0.0025604775,0.01978694,0.00025230914,0.0005003797,0.0003302592,0.00007285648,0.00003263288,0.0001552514],"genre_scores_gemma":[0.99446744,0.0012166437,0.001337496,0.001855946,0.00042780503,0.000063416606,0.00014900588,0.00010638078,0.00037586826],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99800736,0.000082371414,0.0004335234,0.0005881534,0.00039569166,0.000492911],"domain_scores_gemma":[0.9987419,0.000006647166,0.00023754583,0.00068776857,0.0002106914,0.000115401235],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014846734,0.00034386755,0.00030713604,0.00007822917,0.00010583706,0.000069135865,0.00031926474,0.00021513995,0.000060493825],"category_scores_gemma":[0.00000544406,0.0003524542,0.00023161943,0.00018661763,0.00012756784,0.000016103935,0.00011305636,0.000136745,0.0000037770865],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023407815,0.0002050773,0.00027920326,0.000028645985,0.00024755066,0.000008131316,0.000057841185,0.002257449,0.987549,0.0012047382,0.000037788937,0.007890477],"study_design_scores_gemma":[0.00081220677,0.0004999411,0.00024674615,0.000033248067,0.00021240767,0.00001216894,0.000027496635,0.0010644108,0.95633537,0.0011100502,0.03923491,0.00041104064],"about_ca_topic_score_codex":0.0008955222,"about_ca_topic_score_gemma":0.00011729774,"teacher_disagreement_score":0.03919712,"about_ca_system_score_codex":0.00005756401,"about_ca_system_score_gemma":0.00017354728,"threshold_uncertainty_score":0.9998928},"labels":[],"label_agreement":null},{"id":"W2148148974","doi":"10.1158/1535-7163.mct-14-0337","title":"Interactions of Multitargeted Kinase Inhibitors and Nucleoside Drugs: Achilles Heel of Combination Therapy?","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Alberta","funders":"","keywords":"Pharmacology; Gemcitabine; Sunitinib; Pazopanib; Cytotoxicity; Axitinib; Nucleoside; Medicine; Nucleoside analogue; Erlotinib; Tyrosine kinase; Cancer research; Chemistry; Cancer; Biochemistry; Internal medicine; In vitro; Receptor; Epidermal growth factor receptor","score_opus":0.026876852741158724,"score_gpt":0.34438449292463374,"score_spread":0.317507640183475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148148974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935845,0.0032297166,0.0010295107,0.00073943107,0.000081820006,0.00028554286,0.000008217986,0.000017246726,0.0010239729],"genre_scores_gemma":[0.9967495,0.0019486499,0.0007124346,0.00043773378,0.000023160415,0.00002534005,0.000008850745,0.000019288289,0.00007502984],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992195,0.00011265062,0.00023440833,0.000118454125,0.00018988423,0.0001251138],"domain_scores_gemma":[0.999388,0.000112411435,0.00008917058,0.00018247639,0.00017190774,0.000056077235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001820975,0.00009893857,0.00030407717,0.000109653876,0.000039945633,0.000003812343,0.00005204548,0.00006821515,0.00003793302],"category_scores_gemma":[0.00002638934,0.000083437386,0.000060285816,0.00012601833,0.00019384091,0.00002931421,0.00001917506,0.00015478469,8.772462e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003393315,0.00047749135,0.075502664,0.00017924578,0.0006369499,0.0000033056644,0.002164019,0.000020628071,0.8117282,0.00079271925,0.000066538065,0.10808892],"study_design_scores_gemma":[0.008540665,0.0016277508,0.12785153,0.0004362481,0.00058622385,0.000012898755,0.0010321051,0.029574376,0.8135588,0.0010355149,0.01545011,0.00029375547],"about_ca_topic_score_codex":0.00011213215,"about_ca_topic_score_gemma":0.000013604185,"teacher_disagreement_score":0.10779516,"about_ca_system_score_codex":0.00003686379,"about_ca_system_score_gemma":0.000064166605,"threshold_uncertainty_score":0.3402478},"labels":[],"label_agreement":null},{"id":"W2148192822","doi":"10.1158/1535-7163.mct-07-0155","title":"The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Neurological Disorders and Stroke; National Cancer Institute","keywords":"Glioma; Cancer research; PI3K/AKT/mTOR pathway; Protein kinase B; Cell growth; Kinase; Biology; Cell cycle; Cyclin-dependent kinase 6; Signal transduction; Cell; Protein kinase A; Cell biology; Cyclin-dependent kinase 2; Biochemistry","score_opus":0.01031715399708017,"score_gpt":0.254356103785512,"score_spread":0.24403894978843182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148192822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97259873,0.010260033,0.016359441,0.0002126837,0.00009232326,0.0003950305,0.000016256981,0.00000506642,0.00006043296],"genre_scores_gemma":[0.9975458,0.0010374655,0.0011286525,0.00016106745,0.000031438787,0.000016415268,0.000041726664,0.000022496564,0.00001494219],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988656,0.00007029189,0.0004226747,0.00022477358,0.0002572636,0.00015938128],"domain_scores_gemma":[0.9990774,0.000027867662,0.00031706603,0.00025563288,0.00026520426,0.000056827663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003915147,0.0001584063,0.00018568001,0.00008415682,0.00006583295,0.0000127672865,0.00011361773,0.00014822719,0.00000220395],"category_scores_gemma":[0.000055651934,0.00012941178,0.000068431524,0.00018060129,0.00025781445,0.000009912625,0.00006710379,0.00006804623,5.358957e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022464707,0.00013529287,0.0026795503,0.000069062015,0.0000981516,0.0000011159776,0.00007414596,0.000032256008,0.98993313,0.0009847877,0.000016998147,0.0057508345],"study_design_scores_gemma":[0.0013110995,0.00030194077,0.0014494621,0.0000662973,0.00004596314,0.0000060574953,0.000058446876,0.00032171115,0.99479836,0.00024805331,0.0012614297,0.00013116548],"about_ca_topic_score_codex":0.00002722276,"about_ca_topic_score_gemma":0.00001982826,"teacher_disagreement_score":0.024947062,"about_ca_system_score_codex":0.000013821188,"about_ca_system_score_gemma":0.00008873279,"threshold_uncertainty_score":0.52772593},"labels":[],"label_agreement":null},{"id":"W2149564446","doi":"10.1158/1535-7163.mct-06-0106","title":"Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Neurological Disorders and Stroke","keywords":"Immunohistochemistry; Biology; Glioma; Methylation; DNA methylation; O-6-methylguanine-DNA methyltransferase; Molecular biology; Methyltransferase; DNA; Cancer research; Pathology; Immunology; Biochemistry; Gene; Medicine; Gene expression","score_opus":0.01899061330498693,"score_gpt":0.3014807369575591,"score_spread":0.2824901236525722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149564446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9626777,0.013424479,0.023072163,0.00011839375,0.000064244356,0.00016454983,0.00007628081,0.000006694386,0.0003954849],"genre_scores_gemma":[0.9978183,0.00075919385,0.00091393664,0.00016244958,0.000029634004,0.000028986628,0.00020875751,0.000030144534,0.0000486318],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987038,0.00011067177,0.0003872927,0.0003476462,0.00020586266,0.00024476877],"domain_scores_gemma":[0.9993548,0.000015822341,0.00011559483,0.00034416871,0.00013390824,0.00003575263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018091273,0.00018654454,0.0002889842,0.00026921308,0.00002843663,0.000014241439,0.0001610268,0.00014588758,0.000024010793],"category_scores_gemma":[0.0000071996856,0.00018658639,0.00021089843,0.0008290837,0.00007845153,0.0000031862835,0.000028574252,0.000066676366,9.3890174e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010379255,0.000114940885,0.018677276,0.000011108257,0.0005523188,0.000013426445,0.0000662849,0.012235329,0.9660836,0.0009996645,0.0000044908097,0.0011377889],"study_design_scores_gemma":[0.00058032933,0.00021067416,0.01863595,0.000012668831,0.0004839698,4.392757e-7,0.000040040395,0.002312256,0.9753738,0.0004607379,0.0016585804,0.00023052935],"about_ca_topic_score_codex":0.00050555187,"about_ca_topic_score_gemma":0.0015315902,"teacher_disagreement_score":0.035140555,"about_ca_system_score_codex":0.00002744834,"about_ca_system_score_gemma":0.000072580784,"threshold_uncertainty_score":0.76087725},"labels":[],"label_agreement":null},{"id":"W2150186278","doi":"10.1158/1535-7163.271.4.2","title":"Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":174,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"AKT2; Protein kinase B; AKT1; AKT3; PI3K/AKT/mTOR pathway; Pleckstrin homology domain; Biology; Cancer research; Cell biology; Kinase; Phosphorylation; Signal transduction; Proto-Oncogene Proteins c-akt; Cell growth; Chemistry; Biochemistry","score_opus":0.014561717447437315,"score_gpt":0.26588085075826956,"score_spread":0.2513191333108322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150186278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9588639,0.0066411896,0.032004885,0.0005759213,0.00023797431,0.0004747225,0.00013334813,0.000028238988,0.0010397877],"genre_scores_gemma":[0.99223953,0.0003808432,0.0021822597,0.0043840962,0.00027173906,0.000054000902,0.00014035331,0.00008875171,0.000258423],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99829453,0.00010717198,0.00034956113,0.00053739466,0.00033424172,0.00037711734],"domain_scores_gemma":[0.99898046,0.000015726278,0.00018192173,0.00040649954,0.00029914468,0.00011623119],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013213317,0.00029559227,0.00024856796,0.000082900086,0.000069108624,0.000027873011,0.00017251442,0.0001705031,0.000045421744],"category_scores_gemma":[0.000009093852,0.00033148326,0.00012541615,0.00032317467,0.00008884099,0.000008832764,0.0000613366,0.00014797451,0.000015598567],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016313735,0.000097111086,0.00010140894,0.000028457769,0.000108257635,0.0000031274474,0.0001705448,0.01970606,0.97276,0.000020085507,0.0035668325,0.0032749688],"study_design_scores_gemma":[0.0007551392,0.0003282396,0.000089584,0.000039120514,0.00007350339,0.0000035584408,0.000046412963,0.0005278525,0.9456997,0.00003644927,0.052041322,0.00035910422],"about_ca_topic_score_codex":0.000049406324,"about_ca_topic_score_gemma":0.000025676065,"teacher_disagreement_score":0.04847449,"about_ca_system_score_codex":0.00019595631,"about_ca_system_score_gemma":0.00015681886,"threshold_uncertainty_score":0.9999137},"labels":[],"label_agreement":null},{"id":"W2150625778","doi":"10.1158/1535-7163.mct-06-0174","title":"Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Curcumin's Biomedical Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":243,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Curcumin; Cancer; Pharmacology; Chemistry; In vivo; Cancer cell; Oncogene; Cyclin D1; Phytochemical; In vitro; Cancer research; Biochemistry; Biology; Cell cycle; Apoptosis; Biotechnology","score_opus":0.028360169432652592,"score_gpt":0.32228043699161596,"score_spread":0.2939202675589634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150625778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8697414,0.014299974,0.11487364,0.0005535589,0.000037279387,0.00028079856,0.000195527,0.0000057504603,0.000012087076],"genre_scores_gemma":[0.99610376,0.0024185188,0.0008071604,0.00012629143,0.00015257185,0.00020197617,0.00012896926,0.000014329402,0.00004642266],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990904,0.00003573104,0.00026373594,0.00029813463,0.00013677403,0.00017524789],"domain_scores_gemma":[0.99934244,0.00004340811,0.00015158777,0.00031275657,0.00009228518,0.000057546917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007799758,0.00014998406,0.00028400196,0.00006660628,0.000058455338,0.000008246358,0.00016686974,0.0001235651,0.000023335024],"category_scores_gemma":[0.000008126208,0.00010068485,0.00018068426,0.00027062485,0.00026557298,0.000002160325,0.000029231922,0.000028488183,6.859917e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010708861,0.00012610546,0.002695963,0.000008433634,0.0015077008,3.3334334e-7,0.000069728616,0.0007583483,0.9276294,0.0001189379,0.000012490592,0.06696543],"study_design_scores_gemma":[0.00048442517,0.00034422998,0.021234367,0.000008001319,0.0024919694,6.6980033e-7,0.0000751072,0.0019115622,0.96672636,0.00015327572,0.0064387503,0.00013127133],"about_ca_topic_score_codex":0.0022007953,"about_ca_topic_score_gemma":0.00081832457,"teacher_disagreement_score":0.12636237,"about_ca_system_score_codex":0.000024650048,"about_ca_system_score_gemma":0.00009119176,"threshold_uncertainty_score":0.41058087},"labels":[],"label_agreement":null},{"id":"W2150670449","doi":"10.1158/1535-7163.mct-06-0468","title":"Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Myofibroblast; Cancer research; Docetaxel; Epithelial–mesenchymal transition; Medicine; Fibroblast; Stromal cell; Cancer; Pathology; Biology; Internal medicine; Cell culture; Metastasis; Fibrosis","score_opus":0.004249424430683317,"score_gpt":0.23868883065374175,"score_spread":0.23443940622305842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150670449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8940051,0.0026023607,0.09907434,0.0032581438,0.00014483645,0.00063922897,0.00012505744,0.000018854567,0.00013205995],"genre_scores_gemma":[0.9918493,0.00027204302,0.00012441864,0.0073275426,0.00009333254,0.000046072375,0.00016185976,0.000042979096,0.000082449464],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998728,0.00007349682,0.00028799585,0.00032046658,0.00022522856,0.00036481617],"domain_scores_gemma":[0.9993729,0.000019881852,0.000088250476,0.00028167706,0.00012906262,0.00010823412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027843783,0.00023235126,0.00022365245,0.000073594325,0.00008019372,0.000022299224,0.00017223455,0.00018992073,0.000010616647],"category_scores_gemma":[0.00000904713,0.00017291882,0.00013787945,0.00040871403,0.00009502411,0.0000042850693,0.000031841602,0.00012892482,0.000009303463],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008944268,0.000043117634,0.00010757402,0.00003286416,0.0002459634,0.000004048751,0.00016960826,0.0017496491,0.98772,0.000015060866,0.0014417917,0.0075758547],"study_design_scores_gemma":[0.0010971726,0.0008162965,0.000315218,0.0001260888,0.000056636658,0.0000044141,0.000038490653,0.00005854599,0.96208215,0.000014021832,0.035182476,0.00020849009],"about_ca_topic_score_codex":0.000085211956,"about_ca_topic_score_gemma":0.00006452117,"teacher_disagreement_score":0.098949924,"about_ca_system_score_codex":0.000057305206,"about_ca_system_score_gemma":0.000056324545,"threshold_uncertainty_score":0.70514244},"labels":[],"label_agreement":null},{"id":"W2150852167","doi":"10.1158/1535-7163.mct-08-0444","title":"Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Fibroblast growth factor receptor; Cancer research; Fibroblast growth factor receptor 1; Biology; Epidermal growth factor receptor; Fibroblast growth factor; Receptor; Cell growth; Growth factor receptor; Epidermal growth factor; Cancer cell; Lung cancer; Cancer; Signal transduction; Cell biology; Internal medicine; Medicine; Biochemistry; Genetics","score_opus":0.01746676278443335,"score_gpt":0.26264557398758875,"score_spread":0.2451788112031554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150852167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97255987,0.004185057,0.01779334,0.0020254406,0.000108185675,0.0015446007,0.0017031834,0.000035740686,0.000044570977],"genre_scores_gemma":[0.9935809,0.0031889908,0.000579179,0.0015684902,0.00015678954,0.00044989807,0.00020409827,0.00014381822,0.00012785137],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971028,0.0002856184,0.00052594714,0.00080451625,0.00048545355,0.0007956516],"domain_scores_gemma":[0.9978602,0.00009688084,0.00031540095,0.0006451622,0.0007905203,0.00029185505],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000155663,0.0005427664,0.00046598536,0.00014026334,0.0002962919,0.000055992317,0.00047632842,0.00031219798,0.0001131651],"category_scores_gemma":[0.000025513142,0.00040714428,0.00016375617,0.0005231779,0.00033199036,0.000022521852,0.00020484849,0.00034597155,0.000011916176],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035082066,0.00011497232,0.0056516407,0.00017439657,0.00043888376,0.0000043307823,0.00060487626,0.0002760258,0.99144304,0.000028136134,0.00050814135,0.00040472337],"study_design_scores_gemma":[0.001251434,0.0006591232,0.012508771,0.00017911401,0.00008168246,0.0000068718605,0.000059907892,0.0001695182,0.982198,0.000012481745,0.0023271365,0.0005459295],"about_ca_topic_score_codex":0.0004001388,"about_ca_topic_score_gemma":0.00011849578,"teacher_disagreement_score":0.021021003,"about_ca_system_score_codex":0.00013262819,"about_ca_system_score_gemma":0.0005185195,"threshold_uncertainty_score":0.99983805},"labels":[],"label_agreement":null},{"id":"W2151135547","doi":"10.1158/1535-7163.mct-08-0136","title":"Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-κB-dependent mechanism","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Pomegranate: compositions and health benefits","field":"Nursing","cited_by":135,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; University of California, Los Angeles; U.S. Department of Veterans Affairs; U.S. Department of Defense","keywords":"Prostate cancer; Androgen; Apoptosis; Cancer; Cancer research; Internal medicine; Prostate; Endocrinology; Viability assay; Medicine; Chemistry; Hormone; Biochemistry","score_opus":0.03845215773367282,"score_gpt":0.301945314570622,"score_spread":0.2634931568369492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151135547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757391,0.013878686,0.0009009964,0.0051070894,0.0016158816,0.0011882376,0.00045595987,0.0003601911,0.00075384486],"genre_scores_gemma":[0.9807213,0.008539085,0.0006678878,0.009290232,0.00016442026,0.00018135749,0.000023749139,0.00022128568,0.0001906889],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962161,0.00019440711,0.00065305986,0.0008332661,0.00097591884,0.0011272415],"domain_scores_gemma":[0.9984305,0.000032579537,0.00031521125,0.00058266055,0.00034746272,0.0002916106],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014850116,0.00060419866,0.0005817991,0.00021696328,0.0009579465,0.00011214336,0.00045587186,0.00032196232,0.00030807414],"category_scores_gemma":[0.000004713565,0.00058739976,0.00027734716,0.000520923,0.00013732357,0.0003357577,0.00009992891,0.0007200658,0.00006484757],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002635254,0.0016196506,0.0050316374,0.00062138244,0.0016731294,0.0012198008,0.027730636,0.000925729,0.8730058,0.01221079,0.000539873,0.07278629],"study_design_scores_gemma":[0.007839039,0.0011414587,0.0058438266,0.00059772405,0.00065506593,0.00046058622,0.00048606648,0.0025998005,0.9256072,0.0127121,0.039430477,0.0026266337],"about_ca_topic_score_codex":0.003008637,"about_ca_topic_score_gemma":0.0004028668,"teacher_disagreement_score":0.07015965,"about_ca_system_score_codex":0.0007441445,"about_ca_system_score_gemma":0.00023340397,"threshold_uncertainty_score":0.99965775},"labels":[],"label_agreement":null},{"id":"W2151701983","doi":"10.1158/1535-7163.mct-09-0962","title":"SKI-606 (Bosutinib) Blocks Prostate Cancer Invasion, Growth, and Metastasis <i>In vitro</i> and <i>In vivo</i> through Regulation of Genes Involved in Cancer Growth and Skeletal Metastasis","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Bosutinib; Cancer; Metastasis; Cancer research; Prostate cancer; Matrigel; Bone metastasis; Cancer cell; Medicine; Biology; Pathology; Internal medicine; Angiogenesis","score_opus":0.020053318019657988,"score_gpt":0.28311392525580115,"score_spread":0.26306060723614316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151701983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9548047,0.041975986,0.000026714559,0.0016640495,0.00014311551,0.0010977968,0.00019000935,0.000022188919,0.00007542975],"genre_scores_gemma":[0.96421725,0.03218697,0.0018271239,0.0011874748,0.000049233393,0.00039707072,0.000026927373,0.00007784969,0.000030078823],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975034,0.00014438013,0.00067025755,0.00073768175,0.0004201403,0.0005241115],"domain_scores_gemma":[0.99902964,0.00008842342,0.0002623673,0.00036100004,0.00012356053,0.00013498619],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026661315,0.00046080456,0.0008462255,0.0002825145,0.00005783378,0.000035331144,0.0001118171,0.0002356497,0.000046165893],"category_scores_gemma":[0.000027009852,0.00041842856,0.000083579165,0.00065810466,0.00034785527,0.00020220682,0.000113022405,0.00045700622,1.7380052e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060805766,0.00019228652,0.15603872,0.00045628834,0.00037352197,0.00005876426,0.0014939873,0.000042057443,0.8219601,0.000087142405,0.000009346357,0.018679725],"study_design_scores_gemma":[0.009359869,0.00014065391,0.030478928,0.0003556073,0.0007262586,0.000027005493,0.00020290246,0.00052942935,0.9560104,0.0006738735,0.0010678103,0.00042724193],"about_ca_topic_score_codex":0.012864472,"about_ca_topic_score_gemma":0.010318725,"teacher_disagreement_score":0.13405031,"about_ca_system_score_codex":0.00029568496,"about_ca_system_score_gemma":0.00050087756,"threshold_uncertainty_score":0.9998267},"labels":[],"label_agreement":null},{"id":"W2151876400","doi":"10.1158/1535-7163.mct-12-0950","title":"RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Université Laval","keywords":"Olaparib; PARP inhibitor; Cancer research; DNA damage; Cancer; DNA repair; Medicine; Biology; Poly ADP ribose polymerase; Internal medicine; DNA; Polymerase","score_opus":0.02604159606197083,"score_gpt":0.29894876053579533,"score_spread":0.2729071644738245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151876400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9028069,0.007635072,0.005643385,0.07641435,0.0025196138,0.003176952,0.00024440096,0.00024227216,0.0013170916],"genre_scores_gemma":[0.92011756,0.0011624588,0.0004995365,0.0749388,0.00075060123,0.0013284616,0.000014372684,0.00012966615,0.0010585645],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971171,0.00017176387,0.0004736556,0.0006610906,0.0008274348,0.000748941],"domain_scores_gemma":[0.99785835,0.0000709841,0.0002325825,0.0009088917,0.0006043159,0.00032485795],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019655508,0.00046279083,0.00052169245,0.0001420435,0.00023688433,0.000115026305,0.00028263396,0.00019374004,0.00047698105],"category_scores_gemma":[0.0000097434495,0.00034036217,0.00025309742,0.00067372434,0.00018887062,0.00008692147,0.00009358105,0.0004964804,0.00046477036],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030562314,0.00022091417,0.00093256106,0.00006937018,0.00064821803,0.00007019821,0.0021776815,0.0023984753,0.950589,0.00023599483,0.02361811,0.018733827],"study_design_scores_gemma":[0.001899186,0.00021467458,0.0031979382,0.00032635118,0.00028973565,0.000026212943,0.0005101639,0.0006642608,0.79414386,0.000101660116,0.19814195,0.00048404126],"about_ca_topic_score_codex":0.0010206276,"about_ca_topic_score_gemma":0.00014853722,"teacher_disagreement_score":0.17452383,"about_ca_system_score_codex":0.0007256095,"about_ca_system_score_gemma":0.0003425025,"threshold_uncertainty_score":0.9999048},"labels":[],"label_agreement":null},{"id":"W2151970029","doi":"10.1158/1535-7163.mct-12-0299","title":"A New Nonestrogenic Steroidal Inhibitor of 17β-Hydroxysteroid Dehydrogenase Type I Blocks the Estrogen-Dependent Breast Cancer Tumor Growth Induced by Estrone","year":2012,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval","funders":"Canadian Institutes of Health Research; Centre Hospitalier Universitaire de Québec","keywords":"Estrone; Estrogen; In vivo; Endocrinology; Internal medicine; Hydroxysteroid dehydrogenase; Breast cancer; Steroid; Chemistry; Cell growth; IC50; Estrogen receptor; Cancer; Pharmacology; Dehydrogenase; Hormone; Biology; Medicine; In vitro; Enzyme; Biochemistry","score_opus":0.008911511635038087,"score_gpt":0.25048146752405615,"score_spread":0.24156995588901806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151970029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9479518,0.049786936,0.00048755136,0.0004261897,0.00058060786,0.0005451699,0.00014171794,0.000028524732,0.000051505027],"genre_scores_gemma":[0.9969655,0.0009826064,0.00014383762,0.000923691,0.00053649757,0.00009735461,0.00006481084,0.00012147491,0.00016422679],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975962,0.00019609321,0.0004566774,0.00048335883,0.000461753,0.00080588786],"domain_scores_gemma":[0.99848443,0.000015642885,0.0003065739,0.0006727514,0.00017924579,0.00034132702],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021340996,0.0004951778,0.0003776025,0.000060088627,0.00013330916,0.000038978753,0.00051866216,0.00033477804,0.000051137806],"category_scores_gemma":[0.000007780304,0.00038510517,0.00026812975,0.00030164936,0.00012829113,0.000017272805,0.00019004734,0.00039728,0.000012318486],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038266054,0.00020394848,0.006676346,0.000028608732,0.0010073616,0.000007493774,0.0001362039,0.00007704114,0.98851323,0.000035557623,0.00040788006,0.0025236902],"study_design_scores_gemma":[0.0014712048,0.00040411443,0.0003497239,0.000045983437,0.00047486494,0.00014764267,0.000053752407,0.00005446609,0.99425507,0.000012485104,0.0022891413,0.00044155898],"about_ca_topic_score_codex":0.00045227556,"about_ca_topic_score_gemma":0.00002020966,"teacher_disagreement_score":0.049013704,"about_ca_system_score_codex":0.00009461008,"about_ca_system_score_gemma":0.00044418394,"threshold_uncertainty_score":0.9998601},"labels":[],"label_agreement":null},{"id":"W2152324247","doi":"10.1158/1535-7163.mct-09-0365","title":"Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; University of British Columbia","funders":"National Cancer Institute","keywords":"Rhabdomyosarcoma; PLK1; Polo-like kinase; Biology; Kinase; Cancer research; Small interfering RNA; Propidium iodide; Molecular biology; Sarcoma; Apoptosis; Cell cycle; Cell culture; Cell biology; Medicine; Pathology; Programmed cell death; Biochemistry; Genetics; Transfection","score_opus":0.049664839311527584,"score_gpt":0.31208443345900094,"score_spread":0.26241959414747335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152324247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83792096,0.15948984,0.00022948913,0.0012819149,0.0000717065,0.00087317877,0.00007054614,0.000025986064,0.00003639229],"genre_scores_gemma":[0.988027,0.009505486,0.0015265216,0.00054505875,0.00013125787,0.00008083394,0.000047940368,0.000036086596,0.00009985656],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99903005,0.000028568113,0.00031378385,0.00024789263,0.00015460464,0.00022512025],"domain_scores_gemma":[0.99921864,0.00013990256,0.00017032638,0.0003340172,0.000046723944,0.00009036594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000039448354,0.00023233518,0.00040708124,0.00010154259,0.00008653476,0.00003313613,0.00010751799,0.000056385255,0.000031290518],"category_scores_gemma":[0.000007226675,0.00015798396,0.00019871547,0.00015234064,0.00007411939,0.00005591362,0.00002496029,0.00004632264,3.360791e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002542356,0.004682092,0.098205775,0.00046926757,0.0036953648,0.00034071165,0.004732196,0.00008979058,0.17911202,0.0018768953,0.0004906508,0.7037629],"study_design_scores_gemma":[0.0043829624,0.004431796,0.023713484,0.00019726525,0.0023183343,0.000014318149,0.00026002832,0.00006921645,0.95810187,0.0013889944,0.0049116593,0.00021009447],"about_ca_topic_score_codex":0.0005260352,"about_ca_topic_score_gemma":0.000022437433,"teacher_disagreement_score":0.77898985,"about_ca_system_score_codex":0.000048532533,"about_ca_system_score_gemma":0.00014181806,"threshold_uncertainty_score":0.64423984},"labels":[],"label_agreement":null},{"id":"W2152445171","doi":"10.1158/1535-7163.1193.3.10","title":"Targeting heterogeneous nuclear ribonucleoparticule A1 and A2 proteins by RNA interference promotes cell death in transformed but not in normal mouse cell lines","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Telomeres, Telomerase, and Senescence","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Gene knockdown; RNA interference; Biology; HeLa; Telomere; Telomerase; Molecular biology; Cell biology; Cell culture; Small interfering RNA; RNA; Complementary DNA; Nuclear protein; Cell; Transfection; Gene; Genetics; Transcription factor","score_opus":0.017867742682679266,"score_gpt":0.25116947067901785,"score_spread":0.23330172799633858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152445171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939921,0.003319577,0.00072203536,0.00084057543,0.000053077154,0.0008987601,0.000034857956,0.00006420894,0.00007481873],"genre_scores_gemma":[0.9955083,0.0013540874,0.0013653906,0.0014995651,0.000034249744,0.000074136144,0.000015939535,0.0000778809,0.00007044683],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981401,0.000062918276,0.0004641215,0.0004677812,0.00027586587,0.00058921654],"domain_scores_gemma":[0.99940294,0.000016762917,0.00009426696,0.00025252445,0.00006732318,0.00016615825],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013111343,0.0003319618,0.00041107225,0.00013559639,0.00006747726,0.00004796382,0.00016884936,0.00016738682,0.000025151317],"category_scores_gemma":[0.00001060088,0.00030981243,0.000075087075,0.00023784596,0.00010745199,0.000099880745,0.000041971743,0.0004092696,0.0000065831896],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003710546,0.00047173628,0.0029855738,0.00025254366,0.000027582231,0.00021965212,0.0027552007,0.00051187316,0.9892104,0.000008086769,0.0000016891324,0.003184601],"study_design_scores_gemma":[0.003242542,0.00048476498,0.00080294436,0.0001904556,0.000058792823,0.000020020372,0.00021573216,0.0021353522,0.9920865,0.000025001425,0.0003786385,0.00035921443],"about_ca_topic_score_codex":0.0010375453,"about_ca_topic_score_gemma":0.00031590703,"teacher_disagreement_score":0.0028761346,"about_ca_system_score_codex":0.00018767167,"about_ca_system_score_gemma":0.00015234912,"threshold_uncertainty_score":0.9999354},"labels":[],"label_agreement":null},{"id":"W2152545151","doi":"10.1158/1535-7163.911.3.8","title":"The DNA double-stranded break repair protein endo-exonuclease as a therapeutic target for cancer","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Jewish General Hospital; Montreal General Hospital","funders":"","keywords":"Exonuclease; Cancer cell; DNA repair; DNA damage; Biology; Cisplatin; Cancer research; DNA; Molecular biology; Chemistry; Cancer; Biochemistry; Genetics; DNA polymerase; Chemotherapy","score_opus":0.01797271554480728,"score_gpt":0.28399503031428797,"score_spread":0.2660223147694807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152545151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9329959,0.028939078,0.025015457,0.0060053966,0.000896813,0.0047418852,0.00019547454,0.00030844068,0.0009015255],"genre_scores_gemma":[0.98675364,0.0011457065,0.002485839,0.0046022516,0.00033565427,0.0027918306,0.00006537664,0.0001969178,0.0016228001],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99760824,0.000096100186,0.0003952121,0.00074427796,0.00038343514,0.0007727222],"domain_scores_gemma":[0.99840105,0.00001634502,0.00019183445,0.000973991,0.00025115107,0.00016563489],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032051656,0.0004600594,0.00028882924,0.000044089702,0.00040299175,0.0001019248,0.00058290485,0.00030055962,0.000037730737],"category_scores_gemma":[0.000014722779,0.0003674529,0.000500084,0.00018432103,0.00019545424,0.000009643202,0.00010355905,0.00020788872,0.000011264635],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014882345,0.00012993469,0.0000265512,0.000046740253,0.0008669164,0.000014991022,0.00011582117,0.0008033937,0.9824084,0.0048103672,0.000071167895,0.009217504],"study_design_scores_gemma":[0.003496477,0.00054662564,0.000015100773,0.00003812993,0.00016383991,0.000014088044,0.00006401038,0.00011453567,0.7616668,0.006150304,0.22732353,0.0004065561],"about_ca_topic_score_codex":0.00024217961,"about_ca_topic_score_gemma":0.00033914408,"teacher_disagreement_score":0.22725236,"about_ca_system_score_codex":0.00015627958,"about_ca_system_score_gemma":0.0006914027,"threshold_uncertainty_score":0.99987775},"labels":[],"label_agreement":null},{"id":"W2153507021","doi":"10.1158/1535-7163.mct-08-0248","title":"Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; University of Chicago","keywords":"International HapMap Project; Carboplatin; Biology; Genetics; Single-nucleotide polymorphism; Gene; Genotype","score_opus":0.02559635144748617,"score_gpt":0.2469385469462732,"score_spread":0.22134219549878703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153507021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905543,0.0026894687,0.005672006,0.00011409517,0.0001725294,0.00037017168,0.00010434389,0.000029736924,0.00029340215],"genre_scores_gemma":[0.99562496,0.0010665766,0.00093059795,0.0018367857,0.00013324982,0.00011623423,0.00007929284,0.00010104169,0.00011124969],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99812335,0.00013293038,0.00031455627,0.00061531086,0.00030765674,0.0005062171],"domain_scores_gemma":[0.99902314,0.000018790563,0.0001755197,0.00052972214,0.00013408874,0.000118734766],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000079568395,0.0003713883,0.0003382646,0.00007372141,0.00011243753,0.000024769945,0.000314618,0.00028989578,0.00003158875],"category_scores_gemma":[0.000008030937,0.0003567664,0.000111357935,0.00029279198,0.000087043976,0.000005124078,0.00007530885,0.0002219371,0.0000028569477],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000181286,0.00017909802,0.0056287954,0.000005207178,0.00025962546,0.00010229558,0.00040738002,0.0007283238,0.9915607,0.000006479493,0.000005804971,0.00093501364],"study_design_scores_gemma":[0.002377576,0.00038385656,0.04016684,0.000038438422,0.00011497095,0.000009683771,0.000055206983,0.00070721627,0.9549395,0.0001452206,0.00051990745,0.0005415866],"about_ca_topic_score_codex":0.0007641925,"about_ca_topic_score_gemma":0.0014022494,"teacher_disagreement_score":0.036621194,"about_ca_system_score_codex":0.00011229905,"about_ca_system_score_gemma":0.00038264276,"threshold_uncertainty_score":0.9998884},"labels":[],"label_agreement":null},{"id":"W2154040159","doi":"10.1158/1535-7163.mct-08-0021","title":"Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":636,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Lethbridge","funders":"Oak Ridge Institute for Science and Education","keywords":"microRNA; Cancer research; Cancer cell; Doxorubicin; Breast cancer chemotherapy; Cancer; Transfection; Biology; Epigenetics; Breast cancer; MCF-7; Drug resistance; Gene silencing; Multiple drug resistance; Cell culture; Gene; Chemotherapy; Genetics","score_opus":0.012762503057607403,"score_gpt":0.25152260790769804,"score_spread":0.23876010485009064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154040159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893808,0.008169075,0.00036725914,0.0011477064,0.00016255205,0.0005451008,0.0001541827,0.0000056406607,0.00006769203],"genre_scores_gemma":[0.9962324,0.0009512859,0.00032087404,0.0019502215,0.000051628438,0.000073878284,0.000008983857,0.00004960885,0.00036113823],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99850273,0.00011398809,0.00042400882,0.0003663647,0.00030120515,0.0002916828],"domain_scores_gemma":[0.9988173,0.000007715645,0.00024012553,0.0006850901,0.00018843234,0.0000612994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013003616,0.00022738086,0.00025922668,0.000072923045,0.000049794126,0.000005413262,0.00044213916,0.000112901726,0.00003222573],"category_scores_gemma":[0.0000029146447,0.00019662247,0.00016436496,0.00039306702,0.00018455845,0.000004065671,0.00011750624,0.00010006781,0.0000011747254],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022782535,0.00012857528,0.007594722,0.00009273171,0.00014579645,0.0000016715509,0.00042845853,0.0015495622,0.98888236,0.000019244531,0.00027695566,0.00065207283],"study_design_scores_gemma":[0.00073447474,0.000023712768,0.028532272,0.0001468149,0.000054886365,0.0000024620058,0.000040797124,0.000027691667,0.96405935,0.0000392812,0.006134213,0.00020402117],"about_ca_topic_score_codex":0.0002987227,"about_ca_topic_score_gemma":0.000671403,"teacher_disagreement_score":0.024823012,"about_ca_system_score_codex":0.00012159747,"about_ca_system_score_gemma":0.00030892494,"threshold_uncertainty_score":0.8018032},"labels":[],"label_agreement":null},{"id":"W2154252904","doi":"10.1158/1535-7163.mct-07-2164","title":"Arsenic trioxide decreases AKT protein in a caspase-dependent manner","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Protein kinase B; Arsenic trioxide; Cancer research; Chemistry; Phosphorylation; Caspase; Cell biology; Apoptosis; Kinase; Acute promyelocytic leukemia; Biology; Biochemistry; Programmed cell death; Retinoic acid","score_opus":0.01950918625296531,"score_gpt":0.26461104711954453,"score_spread":0.24510186086657923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154252904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98300815,0.013855578,0.0015784111,0.00022552881,0.0001002128,0.000404018,0.000011518841,0.000028589739,0.0007880127],"genre_scores_gemma":[0.9942722,0.00177721,0.000570412,0.0012781813,0.00012961065,0.0002536684,0.00003877251,0.00007217197,0.0016077968],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99831796,0.000121158904,0.00030994788,0.00051885337,0.00029026964,0.0004418262],"domain_scores_gemma":[0.9991902,0.0000075866033,0.00010331714,0.00050395314,0.00009250964,0.00010241468],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012605458,0.00028992767,0.00023239321,0.00007994068,0.00009064016,0.000021488433,0.00032544896,0.00023662632,0.00004250809],"category_scores_gemma":[0.000025987061,0.000281545,0.00014158948,0.00020074383,0.00014484371,0.0000058922,0.00009136646,0.0002020765,0.000014200858],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001712884,0.00012882172,0.0022728485,0.000036144258,0.000103646824,0.00032497296,0.00009345694,0.00030128105,0.9942892,0.00006851139,0.0000992961,0.0021105376],"study_design_scores_gemma":[0.0011944989,0.00016425805,0.00037258124,0.00004215182,0.000037221875,0.00011782683,0.00005629004,0.000058150767,0.9781674,0.00017516577,0.019229665,0.0003847509],"about_ca_topic_score_codex":0.00016143495,"about_ca_topic_score_gemma":0.00013270824,"teacher_disagreement_score":0.01913037,"about_ca_system_score_codex":0.00008170896,"about_ca_system_score_gemma":0.00039841977,"threshold_uncertainty_score":0.9999637},"labels":[],"label_agreement":null},{"id":"W2154416389","doi":"10.1158/1535-7163.mct-11-0659","title":"Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health; Eli Lilly and Company","keywords":"Medicine; Gemcitabine; Pharmacology; Prodrug; Chemotherapy; Paclitaxel; Vinblastine; Topotecan; Cyclophosphamide; Bone marrow; Cancer research; Internal medicine","score_opus":0.022541055487687794,"score_gpt":0.2668235972590885,"score_spread":0.2442825417714007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154416389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97989064,0.01745002,0.0021121663,0.000009203461,0.000081463964,0.00038599977,0.000035014848,0.0000025365046,0.00003294631],"genre_scores_gemma":[0.99795586,0.0014035162,0.00045155713,0.000075710224,0.000022324626,0.000050850034,0.000010346191,0.00002577342,0.000004081021],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99875385,0.00017013833,0.00047500778,0.00023302843,0.0001895854,0.00017842201],"domain_scores_gemma":[0.9989469,0.00001956196,0.00041117016,0.0004322615,0.00017018784,0.000019908424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032830797,0.00016972769,0.0003729844,0.00009227816,0.000016751528,0.0000026343532,0.00023497659,0.00010403466,0.0000060589596],"category_scores_gemma":[0.000013440915,0.00013356142,0.0002102743,0.00024627952,0.00019748583,0.000005915342,0.000057438432,0.00004928778,1.9908612e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018682604,0.00018603948,0.019270644,0.00062590005,0.00024620464,0.000002832215,0.00055939733,0.00026742506,0.9766392,0.00012939276,0.0000031314726,0.0018829848],"study_design_scores_gemma":[0.0007348039,0.00028175302,0.019367302,0.00035697143,0.00014743194,0.0000043213663,0.00019321422,0.000045670058,0.97868276,0.000038853967,0.000019256793,0.00012766033],"about_ca_topic_score_codex":0.0004901878,"about_ca_topic_score_gemma":0.00007954085,"teacher_disagreement_score":0.018065194,"about_ca_system_score_codex":0.000024515368,"about_ca_system_score_gemma":0.00013816844,"threshold_uncertainty_score":0.54464763},"labels":[],"label_agreement":null},{"id":"W2155021489","doi":"10.1158/1535-7163.mct-07-2282","title":"Cyclooxygenase inhibitors block uterine tumorigenesis in <i>HMGA1a</i> transgenic mice and human xenografts","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; U.S. Public Health Service","keywords":"Sulindac; Celecoxib; Cyclooxygenase; Cancer; Cancer research; Carcinogenesis; Medicine; Pharmacology; Internal medicine; Biology; Enzyme; Biochemistry","score_opus":0.017437790963481456,"score_gpt":0.2817271344254578,"score_spread":0.26428934346197636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155021489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925037,0.0059694997,0.000041700478,0.0003921553,0.00036066066,0.0005013699,0.00001012184,0.00006394964,0.0001568108],"genre_scores_gemma":[0.99521136,0.0020303424,0.0001286574,0.0019636732,0.00035163946,0.00008430343,0.000010086427,0.00007022384,0.00014971365],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985143,0.00008140709,0.00033823392,0.0003563555,0.00029564401,0.00041405123],"domain_scores_gemma":[0.9993726,0.000022786586,0.000068623754,0.00029064642,0.000055564844,0.00018978039],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001387054,0.00028554205,0.00039727145,0.00017057415,0.000118607466,0.000010528391,0.00008757535,0.00013825134,0.000027824139],"category_scores_gemma":[0.0000044954986,0.00026776586,0.00012298013,0.00030636677,0.00014372791,0.000044889784,0.000025501562,0.00024502326,0.000006282562],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020681527,0.00018439104,0.042896554,0.00029641227,0.00016580541,0.0009947403,0.0012528405,0.000037674065,0.95154095,0.000029933646,0.000102784674,0.0022910729],"study_design_scores_gemma":[0.0053812163,0.0005428564,0.06873648,0.0002619751,0.00026902024,0.00032888656,0.000061011164,0.000105521714,0.88598454,0.00003638116,0.037685823,0.0006063065],"about_ca_topic_score_codex":0.00024216085,"about_ca_topic_score_gemma":0.00020020315,"teacher_disagreement_score":0.06555645,"about_ca_system_score_codex":0.00009788026,"about_ca_system_score_gemma":0.0001520196,"threshold_uncertainty_score":0.99997747},"labels":[],"label_agreement":null},{"id":"W2155136577","doi":"10.1158/1535-7163.mct-13-1053","title":"Akt-Activated Endothelium Constitutes the Niche for Residual Disease and Resistance to Bevacizumab in Ovarian Cancer","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"U.S. Food and Drug Administration","keywords":"Bevacizumab; Ovarian cancer; Medicine; Cancer research; Stromal cell; Minimal residual disease; Autocrine signalling; Cancer; Progenitor cell; Protein kinase B; Immunology; Oncology; Internal medicine; Biology; Stem cell; Bone marrow; Chemotherapy; Signal transduction; Cell biology","score_opus":0.019901269408656233,"score_gpt":0.29186653579912675,"score_spread":0.27196526639047053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155136577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9138755,0.043378416,0.02314398,0.01600353,0.0005283544,0.0016850801,0.00049408164,0.000029929268,0.00086109445],"genre_scores_gemma":[0.988616,0.0012199342,0.0006742342,0.0077821026,0.00029197516,0.00074296934,0.000027644,0.00005093084,0.000594223],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987298,0.0001031483,0.00020843599,0.00046477388,0.0001460562,0.0003477609],"domain_scores_gemma":[0.99923325,0.00003751294,0.00007506837,0.00043285755,0.00010559258,0.000115744646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021328958,0.00022321593,0.00018474532,0.0000389808,0.0001354589,0.00004502412,0.00024740395,0.00010612413,0.000013960954],"category_scores_gemma":[0.00003917193,0.0001777693,0.00008353237,0.00012624776,0.00014090378,0.000003920171,0.000080641876,0.00008032876,9.215755e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010592755,0.000039819195,0.0045633814,0.000052973704,0.00021411381,0.000002983797,0.00013710765,0.0005257847,0.9833735,0.002909331,0.0010369796,0.0060847285],"study_design_scores_gemma":[0.001370699,0.000102204605,0.004328608,0.00007236908,0.00012913163,0.0000011245708,0.000045418587,0.00007278336,0.5900581,0.00071597233,0.40272862,0.00037498673],"about_ca_topic_score_codex":0.00013137455,"about_ca_topic_score_gemma":0.001115486,"teacher_disagreement_score":0.40169165,"about_ca_system_score_codex":0.000050630297,"about_ca_system_score_gemma":0.0002120965,"threshold_uncertainty_score":0.7249221},"labels":[],"label_agreement":null},{"id":"W2155321348","doi":"10.1158/1535-7163.mct-05-0099","title":"Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Protein kinase B; Kinase; Integrin-linked kinase; MAPK/ERK pathway; Cancer research; Wortmannin; PI3K/AKT/mTOR pathway; Protein kinase A; Phosphatidylinositol; Chemistry; Biology; Cell biology; Molecular biology; Signal transduction; Cyclin-dependent kinase 2","score_opus":0.0073327816817469645,"score_gpt":0.21447004087722632,"score_spread":0.20713725919547935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155321348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99634194,0.0019153453,0.00033907435,0.00010680193,0.00020238965,0.00089699804,0.000069462956,0.000011786999,0.000116208066],"genre_scores_gemma":[0.99930197,0.00005992671,0.00007508632,0.00022264375,0.00004806989,0.00014555635,0.000040879786,0.000038295948,0.00006759502],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984524,0.00022032241,0.0004057995,0.00041138715,0.00019910591,0.00031098054],"domain_scores_gemma":[0.9992571,0.00002261941,0.00019889434,0.0004107497,0.000069138194,0.00004150959],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001478532,0.0002577038,0.00025334998,0.00008134502,0.00004997713,0.00001892873,0.00015461602,0.00022555375,0.0000015735963],"category_scores_gemma":[0.00001990139,0.00022211634,0.00008032654,0.00030573146,0.00012210866,0.00000592829,0.00009760582,0.000164034,6.9067346e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007510766,0.00022386594,0.001028923,0.00011375178,0.000030472753,0.000052007184,0.000089151785,0.00039312628,0.9958637,0.00030142523,0.00002348758,0.0011290454],"study_design_scores_gemma":[0.0033982224,0.0005497787,0.0034563458,0.00023093923,0.00003241712,0.0000014061654,0.000017695502,0.00022426131,0.9908762,0.00034890155,0.0006133664,0.00025044326],"about_ca_topic_score_codex":0.00040742496,"about_ca_topic_score_gemma":0.00041571204,"teacher_disagreement_score":0.004987444,"about_ca_system_score_codex":0.00005500508,"about_ca_system_score_gemma":0.000116781164,"threshold_uncertainty_score":0.90576416},"labels":[],"label_agreement":null},{"id":"W2155784435","doi":"10.1158/1535-7163.mct-06-0596","title":"Radiation-induced cell signaling: inside-out and outside-in","year":2007,"lang":"en","type":"review","venue":"Molecular Cancer Therapeutics","topic":"Effects of Radiation Exposure","field":"Medicine","cited_by":327,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Cell biology; Paracrine signalling; Signal transduction; Autocrine signalling; Biology; Cell signaling; Kinase; Protein kinase B; Intracellular; Receptor; Biochemistry","score_opus":0.07123259998810326,"score_gpt":0.38355879384918684,"score_spread":0.31232619386108357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155784435","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007705213,0.9959733,0.00026351534,0.0001910503,0.0003692598,0.0015205564,0.000017235527,0.00006164886,0.00083294563],"genre_scores_gemma":[0.004269201,0.99240804,0.00032638616,0.0021554148,0.00025196825,0.0001260629,0.00007536196,0.0001695099,0.000218044],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99766165,0.00020622455,0.00071500137,0.0005538302,0.0004376188,0.00042566165],"domain_scores_gemma":[0.99859625,0.0002250385,0.0003743576,0.0005215856,0.00009625791,0.00018653243],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004123628,0.00053840893,0.0014905146,0.0004982231,0.000043337397,0.00004077927,0.00015650214,0.0006537622,0.00003627879],"category_scores_gemma":[0.000031039915,0.0004911497,0.00040527564,0.00042712502,0.00004741932,0.00004708827,0.000037222686,0.0008010858,0.00003079397],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017615524,0.0000725512,0.00016651044,0.0064222924,0.00038121504,0.00024711015,0.0002652204,0.000007709762,0.00091253786,0.000031181484,0.00003254025,0.9914435],"study_design_scores_gemma":[0.0013165603,0.00019743992,0.000050917253,0.003941604,0.0021549114,0.000037073536,0.00001699624,0.000030881885,0.0024613373,0.000033486012,0.9892251,0.00053369114],"about_ca_topic_score_codex":0.000048280133,"about_ca_topic_score_gemma":0.000025807682,"teacher_disagreement_score":0.9909098,"about_ca_system_score_codex":0.000438103,"about_ca_system_score_gemma":0.00073294947,"threshold_uncertainty_score":0.999754},"labels":[],"label_agreement":null},{"id":"W2155841399","doi":"10.1158/1535-7163.mct-10-0321","title":"PIM Kinase Inhibitors Downregulate STAT3Tyr705 Phosphorylation","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Mechanisms and Therapy","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Natural Science Foundation of China; Prostate Cancer Canada; Ontario Institute for Cancer Research","keywords":"Kinase; Cancer research; Cell growth; Cell culture; STAT5; Cancer cell; Downregulation and upregulation; Phosphorylation; Prostate cancer; Biology; Molecular biology; Chemistry; Cancer; Cell biology; Biochemistry","score_opus":0.013961841674693744,"score_gpt":0.28505471495867224,"score_spread":0.2710928732839785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155841399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842172,0.00392762,0.004905315,0.0037260605,0.0015030672,0.0005822817,0.000026723208,0.00015819153,0.0009534918],"genre_scores_gemma":[0.9915014,0.00049401063,0.0016802509,0.0052094753,0.00034816773,0.00007354707,0.000026675167,0.00008376255,0.000582708],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986621,0.000023192279,0.00025273423,0.00033923035,0.0003781968,0.0003445043],"domain_scores_gemma":[0.9990655,0.000011608284,0.000101659585,0.0005028734,0.00015286058,0.00016548189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013948779,0.00024009231,0.0002616653,0.000095172756,0.00009301101,0.000040808438,0.00010515199,0.0001771784,0.00067714055],"category_scores_gemma":[0.000004042631,0.00021784502,0.00016364991,0.00026158508,0.00008275882,0.000061120074,0.000025601734,0.00041566652,0.000025892341],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021343584,0.000089390625,0.0005396667,0.000021566251,0.00015588503,0.00004527858,0.0002504136,0.00003417836,0.85622174,0.0029311173,0.000089780464,0.13940753],"study_design_scores_gemma":[0.0020081683,0.00022216889,0.0023391063,0.000045217723,0.00019231378,0.00001979424,0.0000383403,0.00060319685,0.8024667,0.0024495935,0.18932046,0.00029493243],"about_ca_topic_score_codex":0.00019418608,"about_ca_topic_score_gemma":0.00012296315,"teacher_disagreement_score":0.18923067,"about_ca_system_score_codex":0.000100274054,"about_ca_system_score_gemma":0.00020476762,"threshold_uncertainty_score":0.88834625},"labels":[],"label_agreement":null},{"id":"W2155927815","doi":"10.1158/1535-7163.mct-14-0751","title":"The IGF-Trap: Novel Inhibitor of Carcinoma Growth and Metastasis","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal; McGill University Health Centre","funders":"Canadian Institutes of Health Research; Ministero dello Sviluppo Economico; Mitacs; McGill University","keywords":"Cancer research; Metastasis; In vivo; Angiogenesis; Receptor; Cancer; Cell growth; Biology; Medicine; Internal medicine; Biochemistry","score_opus":0.04735227450325679,"score_gpt":0.287548949260484,"score_spread":0.24019667475722722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155927815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97381365,0.02140534,0.0008862292,0.0024566546,0.00025213012,0.00032061088,0.00002427189,0.000028487597,0.00081261696],"genre_scores_gemma":[0.9969423,0.0008207179,0.00046935506,0.0015421914,0.00008817578,0.00002900933,0.0000061357596,0.00004237839,0.00005978193],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99867165,0.0000439733,0.00031883232,0.00023195565,0.0004382085,0.0002953731],"domain_scores_gemma":[0.99901235,0.00004906672,0.00011880325,0.00035546147,0.00026462067,0.000199687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020519226,0.00020578969,0.00031691528,0.00007565009,0.00007734646,0.000025513003,0.00013549668,0.00010153525,0.0000034503194],"category_scores_gemma":[0.000038759998,0.00013962414,0.00011830209,0.0002730156,0.00022281612,0.000057031946,0.000060170005,0.00019928836,0.0000018687086],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010893911,0.0003783829,0.07615943,0.00022556596,0.0015052169,0.000060837025,0.0027461376,0.000006398997,0.8792961,0.006863028,0.00066196965,0.031007502],"study_design_scores_gemma":[0.004846105,0.0010135163,0.03289618,0.0000608371,0.0010817496,0.000058292007,0.00077658525,0.0002158641,0.9319364,0.0009394884,0.025802907,0.00037206835],"about_ca_topic_score_codex":0.00021371951,"about_ca_topic_score_gemma":0.00001267901,"teacher_disagreement_score":0.052640267,"about_ca_system_score_codex":0.000056646375,"about_ca_system_score_gemma":0.00027886571,"threshold_uncertainty_score":0.56937075},"labels":[],"label_agreement":null},{"id":"W2156678982","doi":"10.1158/1535-7163.mct-06-0517","title":"Synergism between vitamin D and secreted protein acidic and rich in cysteine–induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Colorectal cancer; Calcitriol receptor; Chemotherapy; Cancer research; Medicine; Apoptosis; Cancer; Vitamin D and neurology; Cancer cell; Internal medicine; Oncology; Biology; Biochemistry","score_opus":0.021886781490850743,"score_gpt":0.3042405412308481,"score_spread":0.2823537597399973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156678982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930654,0.0029277266,0.000059600115,0.00161143,0.000020109563,0.0021764406,0.00008983811,0.000022207718,0.000027248849],"genre_scores_gemma":[0.9970103,0.0020531917,0.0002784133,0.00035764967,0.000037511127,0.00019297798,0.000013227993,0.000045353034,0.000011359066],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99767387,0.00021455906,0.00058190204,0.0005837567,0.00045693762,0.0004889458],"domain_scores_gemma":[0.99906,0.00015532156,0.00014410731,0.00023406057,0.00021325222,0.00019326892],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010932141,0.00031242424,0.0006403897,0.00040201494,0.00005784903,0.000022170812,0.00007481338,0.0002077334,0.0000036200172],"category_scores_gemma":[0.00007751575,0.00027188624,0.000042258955,0.00078798167,0.00030946813,0.00006283545,0.00008392215,0.00032941438,1.5497488e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027086055,0.00012543339,0.06720177,0.00026935383,0.00017635507,0.000028981334,0.0021314977,0.0000015202652,0.9177587,0.000008635691,0.00000276986,0.009586399],"study_design_scores_gemma":[0.0052080685,0.00088410795,0.3540182,0.000376425,0.000035069075,0.0000010677882,0.0002662609,0.000033318338,0.63895416,0.000039370585,0.00001279399,0.0001711277],"about_ca_topic_score_codex":0.0061878273,"about_ca_topic_score_gemma":0.0029802243,"teacher_disagreement_score":0.28681645,"about_ca_system_score_codex":0.00032073673,"about_ca_system_score_gemma":0.00014739692,"threshold_uncertainty_score":0.99997336},"labels":[],"label_agreement":null},{"id":"W2157107922","doi":"10.1158/1535-7163.mct-07-0514","title":"Inhibition of Src family kinases enhances retinoic acid–induced gene expression and myeloid differentiation","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Retinoic acid; Acute promyelocytic leukemia; Myeloid leukemia; Myeloid; Cellular differentiation; Biology; Differentiation therapy; Cancer research; Cell biology; Kinase; Proto-oncogene tyrosine-protein kinase Src; Cell culture; Gene; Biochemistry; Genetics","score_opus":0.015529573131299747,"score_gpt":0.26698234068904575,"score_spread":0.251452767557746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157107922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95712215,0.012605917,0.029517803,0.000032478023,0.00015501096,0.0001705289,0.000010876491,0.000015551534,0.0003696705],"genre_scores_gemma":[0.99519837,0.003013659,0.0009611192,0.0004963366,0.00013879433,0.000022515273,0.00008941926,0.000033852142,0.0000459288],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987761,0.00006304269,0.00030076026,0.00036851576,0.00024121595,0.0002503887],"domain_scores_gemma":[0.9992985,0.000010939029,0.00020153867,0.00027886115,0.00014943116,0.00006072028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018721976,0.00020710997,0.00018041994,0.000059751565,0.00008026626,0.000022626615,0.00011922327,0.00022681526,0.0000068158906],"category_scores_gemma":[0.000015011238,0.00019354647,0.00007706694,0.00011827327,0.00010081567,0.000008240346,0.00007496288,0.00010561429,7.186805e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001364266,0.000047361078,0.00074311835,0.00007267396,0.000053808508,0.0000046831046,0.000106144784,0.000012316664,0.9891329,0.000023750843,0.000011125844,0.009655733],"study_design_scores_gemma":[0.0005409581,0.00022123153,0.0017141314,0.00006740817,0.00006093366,0.0000041182266,0.0001232547,0.000020753663,0.99618113,0.00017090463,0.0006681196,0.00022705008],"about_ca_topic_score_codex":0.000013208927,"about_ca_topic_score_gemma":0.000007447316,"teacher_disagreement_score":0.03807621,"about_ca_system_score_codex":0.000026681128,"about_ca_system_score_gemma":0.00007057943,"threshold_uncertainty_score":0.78925955},"labels":[],"label_agreement":null},{"id":"W2157322564","doi":"10.1158/1535-7163.targ-11-c235","title":"Abstract C235: Interleukin-6 secreted by cancer-associated fibroblasts mediates gemcitabine resistance in pancreatic cancer.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Gemcitabine; Pancreatic cancer; Cancer research; Adenocarcinoma; CA19-9; Cancer; Cancer-Associated Fibroblasts; Internal medicine; Medicine; Tumor microenvironment; Cytokine; Pancreatic tumor; Endocrinology; Oncology; Biology","score_opus":0.022191067881289783,"score_gpt":0.29085276455719167,"score_spread":0.2686616966759019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157322564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9434222,0.054042894,0.00006391978,0.00031778208,0.00019975571,0.00051511894,0.00065931,0.000039360948,0.00073964003],"genre_scores_gemma":[0.98218507,0.014991791,0.00011314832,0.00076950795,0.00008297038,0.000751426,0.00031425245,0.00010506142,0.0006867559],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974786,0.00012303483,0.00043953265,0.0007186067,0.00039852186,0.0008417157],"domain_scores_gemma":[0.9988512,0.000020632791,0.00022357688,0.00051465083,0.00017955423,0.00021038369],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015356095,0.00044645512,0.00041314587,0.000107598484,0.00009207472,0.000041547883,0.0004663639,0.00027441073,0.0003244186],"category_scores_gemma":[0.00002847684,0.00043774128,0.00016167697,0.0003958457,0.00016992376,0.00001660577,0.00011494001,0.00029053754,0.000006971009],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011539075,0.00037427177,0.04398565,0.00011214213,0.0012812034,0.00008695213,0.00058630377,0.000062568986,0.9455597,0.000019766178,0.0015908426,0.0051866905],"study_design_scores_gemma":[0.0045014042,0.0004366107,0.054621443,0.00051579764,0.0002083491,0.0000017225551,0.000098855584,0.0000872678,0.92085224,0.00038223737,0.017370457,0.00092362444],"about_ca_topic_score_codex":0.01231301,"about_ca_topic_score_gemma":0.049516127,"teacher_disagreement_score":0.039051104,"about_ca_system_score_codex":0.0004394539,"about_ca_system_score_gemma":0.00042447154,"threshold_uncertainty_score":0.9998074},"labels":[],"label_agreement":null},{"id":"W2157433648","doi":"10.1158/1535-7163.mct-07-2421","title":"Tumor necrosis factor-α–induced accentuation in cryoinjury: mechanisms <i>in vitro</i> and <i>in vivo</i>","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; National Institutes of Health; University of Minnesota","keywords":"In vivo; LNCaP; Tumor necrosis factor alpha; Cytokine; Apoptosis; Cancer research; In vitro; Cancer; Cancer cell; Medicine; Biology; Chemistry; Pathology; Immunology; Internal medicine; Biochemistry","score_opus":0.02066774793588567,"score_gpt":0.26087438075131864,"score_spread":0.24020663281543297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157433648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947982,0.00154719,0.0028140782,0.0001853852,0.00015255227,0.00037434796,0.0000192839,0.000010081232,0.000098919634],"genre_scores_gemma":[0.99597424,0.0018610978,0.0006269376,0.001287921,0.000032345026,0.000070966635,0.000028429178,0.000040748368,0.00007730729],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99869776,0.00008093594,0.00028616984,0.00043285036,0.00017765808,0.00032462945],"domain_scores_gemma":[0.9995772,0.000006480238,0.00008251371,0.0002450332,0.00003426429,0.00005450921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000114251874,0.00021821717,0.00021526948,0.00013056284,0.000046598016,0.00001974952,0.000120285746,0.00018322814,0.000015863616],"category_scores_gemma":[0.000005159083,0.0002262447,0.00006060715,0.00023242434,0.000034398232,0.000009944506,0.000059700615,0.00013509835,9.592089e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019616674,0.0000750992,0.00093756657,0.000011785436,0.00001498409,0.000028043638,0.00013605157,0.00017700875,0.9928726,0.000086817556,0.0000045451593,0.00545931],"study_design_scores_gemma":[0.0013796334,0.00009622502,0.006797056,0.000023811079,0.000010777142,0.000011690918,0.00003345793,0.0011834953,0.9882903,0.00053060934,0.0013662968,0.00027664067],"about_ca_topic_score_codex":0.00022438416,"about_ca_topic_score_gemma":0.00035721465,"teacher_disagreement_score":0.0058594896,"about_ca_system_score_codex":0.000075199125,"about_ca_system_score_gemma":0.00008844534,"threshold_uncertainty_score":0.9225991},"labels":[],"label_agreement":null},{"id":"W2157901482","doi":"10.1158/1535-7163.mct-08-0562","title":"Nitric oxide initiates progression of human melanoma via a feedback loop mediated by apurinic/apyrimidinic endonuclease-1/redox factor-1, which is inhibited by resveratrol","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Sirtuins and Resveratrol in Medicine","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"Resveratrol; Gene knockdown; Melanoma; Molecular biology; Chemistry; Cancer research; Nitric oxide synthase; AP site; DNA-(apurinic or apyrimidinic site) lyase; DNA damage; Biology; Apoptosis; Biochemistry; Enzyme; DNA","score_opus":0.028085088972556755,"score_gpt":0.30485036226430223,"score_spread":0.2767652732917455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157901482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96530074,0.031217838,0.00020841851,0.0013147603,0.00012992755,0.0009672976,0.0002236436,0.00014526492,0.0004920948],"genre_scores_gemma":[0.9878438,0.005640155,0.0001606946,0.005213248,0.00013124484,0.00009471833,0.00040885902,0.00016439849,0.00034288905],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962286,0.00021314221,0.0009749742,0.0006949606,0.0011737337,0.00071462936],"domain_scores_gemma":[0.9976712,0.00010765594,0.00047767718,0.0007691335,0.00058022304,0.00039414503],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019222312,0.0005927031,0.001002884,0.00030803072,0.0002629069,0.000022599317,0.00032504948,0.00048161196,0.0005511709],"category_scores_gemma":[0.000052501447,0.00047539754,0.00027018157,0.001097252,0.000407549,0.000097215714,0.000091448994,0.0007394183,0.000023782928],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061978266,0.0006958162,0.017671246,0.00016671064,0.0009186933,0.000292239,0.0005569895,0.000003400348,0.96934617,0.0000048403,0.006707293,0.0030168376],"study_design_scores_gemma":[0.010922152,0.0021370011,0.005274664,0.0005955509,0.00082482264,0.00024500611,0.00018545169,0.0008597102,0.968455,0.000048419723,0.009732846,0.0007193388],"about_ca_topic_score_codex":0.00022043833,"about_ca_topic_score_gemma":0.000009258858,"teacher_disagreement_score":0.025577681,"about_ca_system_score_codex":0.0001937622,"about_ca_system_score_gemma":0.00031403892,"threshold_uncertainty_score":0.99976975},"labels":[],"label_agreement":null},{"id":"W2158343538","doi":"10.1158/1535-7163.mct-13-0749","title":"Glioblastoma Cells Containing Mutations in the Cohesin Component <i>STAG2</i> Are Sensitive to PARP Inhibition","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Centre for Drug Research and Development","funders":"National Cancer Institute; Canadian Institutes of Health Research; Canadian Institute for Advanced Research","keywords":"Poly ADP ribose polymerase; Mutant; Biology; Cancer research; Molecular biology; Mutation; DNA repair; DNA damage; PARP inhibitor; Cancer cell; DNA; Cancer; Gene; Genetics; Polymerase","score_opus":0.026576075252569154,"score_gpt":0.3001990841337632,"score_spread":0.27362300888119406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158343538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97249025,0.00047577167,0.005955088,0.018217763,0.00020661869,0.0018075478,0.000057612087,0.00007919456,0.00071014836],"genre_scores_gemma":[0.9438593,0.00009092923,0.00048192873,0.054611273,0.00011704574,0.0007072331,0.000027059856,0.0000543386,0.000050926756],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980334,0.00025153486,0.00040116932,0.00037063158,0.0005170035,0.00042624093],"domain_scores_gemma":[0.99887717,0.00012345909,0.00015916995,0.00041234662,0.00029545132,0.00013239935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022936407,0.00027124703,0.00034257185,0.00018480224,0.00012308528,0.00007703299,0.00011344624,0.0001134364,0.00011964149],"category_scores_gemma":[0.000008852931,0.00022645306,0.00012054556,0.00059195096,0.00012288717,0.000091887174,0.00002782384,0.0003546992,0.00012211785],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042790794,0.00025750182,0.0013144495,0.00004193694,0.00016437338,0.00026116116,0.0057804463,0.0018653873,0.9838523,0.0002942088,0.0010593933,0.004680936],"study_design_scores_gemma":[0.0038997992,0.0007016147,0.0130488705,0.00060800486,0.00017776807,0.00009113106,0.0046019736,0.0011642785,0.9602732,0.0005645787,0.014377666,0.00049110147],"about_ca_topic_score_codex":0.00032523138,"about_ca_topic_score_gemma":0.00015246391,"teacher_disagreement_score":0.036393512,"about_ca_system_score_codex":0.0004148885,"about_ca_system_score_gemma":0.00013356947,"threshold_uncertainty_score":0.9234488},"labels":[],"label_agreement":null},{"id":"W2158453396","doi":"10.1158/1535-7163.mct-05-0066","title":"Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Health and Medical Research Council; Medical Research Council; University of Alberta","keywords":"Gefitinib; Epidermal growth factor receptor; Tumor hypoxia; In vivo; Cancer research; Epidermal growth factor; Hypoxia (environmental); A431 cells; Medicine; Pharmacology; Chemistry; Pathology; Cancer; Internal medicine; Biology; Radiation therapy; Receptor; Cell cycle; Oxygen; Molecular medicine","score_opus":0.020034396896466414,"score_gpt":0.2636662241664722,"score_spread":0.24363182727000576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158453396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97993785,0.012712968,0.0056177066,0.0005625443,0.000591321,0.00032895175,0.00019366178,0.000024655326,0.000030329842],"genre_scores_gemma":[0.9943969,0.0007541634,0.0019377513,0.0012495612,0.0014205518,0.00003330798,0.00008740108,0.000074969656,0.000045356413],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983141,0.0001773718,0.00040354583,0.00042213712,0.00024818536,0.00043465637],"domain_scores_gemma":[0.9990158,0.000015664418,0.00025124836,0.00038234028,0.00024476633,0.00009015923],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016431889,0.0003071103,0.0002591307,0.00004042824,0.00012683116,0.000046264096,0.00028736252,0.00011413281,0.00003673858],"category_scores_gemma":[0.00002549442,0.00026878362,0.00018524686,0.0001749919,0.0001675806,0.000014682209,0.00009144093,0.0002212306,0.0000018481777],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019763241,0.00005275519,0.0005281667,0.000019705818,0.000112659356,8.1873924e-7,0.00011745942,0.00029332354,0.96331,0.00002268108,0.00022712378,0.03511765],"study_design_scores_gemma":[0.0009316758,0.00010702677,0.0017237157,0.000022922468,0.000115211806,0.000026657188,0.000051720268,0.004064142,0.95641,0.000018259,0.036176547,0.00035215367],"about_ca_topic_score_codex":0.00015571783,"about_ca_topic_score_gemma":0.00004851799,"teacher_disagreement_score":0.035949424,"about_ca_system_score_codex":0.00006646889,"about_ca_system_score_gemma":0.00015327673,"threshold_uncertainty_score":0.99997646},"labels":[],"label_agreement":null},{"id":"W2158521269","doi":"10.1158/1535-7163.targ-09-b51","title":"Abstract B51: A phase I dose-escalation study of MGCD265 in patients with advanced malignancies (study 265-102)","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pyrogenesis (Canada)","funders":"","keywords":"Medicine; Cohort; Neutropenia; Toxicity; Internal medicine; Gastroenterology; Surgery","score_opus":0.011750247194241975,"score_gpt":0.2832393718980667,"score_spread":0.2714891247038247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158521269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972842,0.0009913198,0.00022504483,0.000046388905,0.000090925496,0.0012087456,0.00003937804,0.00000974192,0.0001042713],"genre_scores_gemma":[0.99911815,0.00013943363,0.00012930707,0.00040498955,0.000037774655,0.00006958477,0.000055078475,0.000035587353,0.000010079277],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99856687,0.000047072197,0.00038414268,0.00042755977,0.00029328663,0.0002810717],"domain_scores_gemma":[0.9990465,0.000010439092,0.00020213856,0.00049355096,0.00018755547,0.000059793223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000103220256,0.0002566024,0.00028066142,0.000085577965,0.00004778014,0.00002471213,0.00020554147,0.000091614085,0.000009007233],"category_scores_gemma":[0.000011154409,0.00023899077,0.000058485202,0.00022976464,0.00003783128,0.000008157303,0.00004033896,0.00011186792,7.539209e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004734717,0.020545965,0.3649047,0.000035101457,0.00052050553,0.00004453621,0.0023365582,0.012895304,0.4858808,0.00003433463,0.00003251665,0.10803499],"study_design_scores_gemma":[0.01960143,0.013377395,0.9128396,0.000048924278,0.00016878726,5.559446e-7,0.00078031485,0.00006271021,0.051734846,0.00005504825,0.00081919035,0.00051119854],"about_ca_topic_score_codex":0.00010520759,"about_ca_topic_score_gemma":0.00040822194,"teacher_disagreement_score":0.5479349,"about_ca_system_score_codex":0.00005939831,"about_ca_system_score_gemma":0.00011164702,"threshold_uncertainty_score":0.97457606},"labels":[],"label_agreement":null},{"id":"W2158594431","doi":"10.1158/1535-7163.mct-08-0959","title":"Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"RAD51; Imatinib; Cancer research; Clonogenic assay; Gemcitabine; Imatinib mesylate; Mitomycin C; Chemistry; DNA repair; Biology; Molecular biology; Cell; Cancer; Medicine; Internal medicine; DNA; Biochemistry","score_opus":0.026343124940142452,"score_gpt":0.3143477273620954,"score_spread":0.2880046024219529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158594431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98753613,0.0019000703,0.006662755,0.0020687378,0.00016499024,0.0005641723,0.00002435314,0.00008071324,0.000998103],"genre_scores_gemma":[0.98957723,0.00043397088,0.004712672,0.005081138,0.000084272884,0.000014531924,0.000024497635,0.000037036647,0.00003462859],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99818957,0.0001999888,0.00043517555,0.00049005134,0.0002877216,0.00039747581],"domain_scores_gemma":[0.99915475,0.00007000365,0.0002315148,0.00029172903,0.00015635882,0.000095626696],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004988251,0.0002642319,0.00043475785,0.00015486601,0.000090735295,0.00002993292,0.00005443649,0.00013044734,0.0000092802275],"category_scores_gemma":[0.00003698614,0.00028325198,0.0000756047,0.00037194503,0.00009800715,0.000102704995,0.000019385072,0.0003627632,0.0000019626787],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060857227,0.00019944667,0.00018902513,0.000040537772,0.000029426528,0.00020174822,0.0006609938,0.00053146185,0.97453654,0.000026897445,0.000015571073,0.022959758],"study_design_scores_gemma":[0.0057751094,0.00028012838,0.005492164,0.00021569598,0.00007835509,0.00010326738,0.000092340735,0.012360121,0.97430825,0.00076639495,0.00019538234,0.00033277032],"about_ca_topic_score_codex":0.00008046566,"about_ca_topic_score_gemma":0.000008502494,"teacher_disagreement_score":0.022626989,"about_ca_system_score_codex":0.00045377348,"about_ca_system_score_gemma":0.00016413003,"threshold_uncertainty_score":0.999962},"labels":[],"label_agreement":null},{"id":"W2159087758","doi":"10.1158/1535-7163.mct-06-0109","title":"Blockade of transforming growth factor-β signaling in tumor-reactive CD8+ T cells activates the antitumor immune response cycle","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada); inVentiv Health Clinical","funders":"National Cancer Institute; U.S. Department of Defense","keywords":"CD8; Adoptive cell transfer; Cytotoxic T cell; Immune system; Tumor microenvironment; Cancer research; Biology; Transforming growth factor beta; Immunology; T cell; Transforming growth factor; In vitro; Cell biology","score_opus":0.010743989676033659,"score_gpt":0.24567069555011886,"score_spread":0.2349267058740852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159087758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710548,0.027093692,0.000436496,0.000487175,0.00029826784,0.00044122522,0.000054402313,0.000039945724,0.00009400874],"genre_scores_gemma":[0.99893636,0.00036810536,0.000037744107,0.00028121856,0.00001712916,0.000054622575,0.000011483185,0.000054646658,0.00023870348],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977422,0.00076924014,0.00056921854,0.0002952569,0.00009791331,0.00052619306],"domain_scores_gemma":[0.9987829,0.00046508646,0.00026056144,0.0003801911,0.00010121937,0.000010068493],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044069628,0.00032534025,0.00045520632,0.00019940737,0.0001976953,0.00002316681,0.0004365879,0.00018293616,0.00013367302],"category_scores_gemma":[0.00001679007,0.00025091157,0.00023625397,0.0003904173,0.00036267648,0.00011688681,0.000038580543,0.00049804884,0.000012733738],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044786218,0.00020375184,0.00043269328,0.000020672873,0.00032986433,0.000019674939,0.0016077994,0.00029788626,0.9907439,0.00014846357,0.0000030374795,0.001713631],"study_design_scores_gemma":[0.0018028622,0.00018469035,0.007463904,0.00011188125,0.00006984183,0.000022800506,0.00050218997,0.000012400722,0.98515785,0.0002545096,0.004122372,0.00029468504],"about_ca_topic_score_codex":0.0016927974,"about_ca_topic_score_gemma":0.000025049754,"teacher_disagreement_score":0.027881559,"about_ca_system_score_codex":0.00011906228,"about_ca_system_score_gemma":0.00019674662,"threshold_uncertainty_score":0.99999434},"labels":[],"label_agreement":null},{"id":"W2159560706","doi":"10.1158/1535-7163.mct-06-0443","title":"Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy","year":2007,"lang":"en","type":"review","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society","keywords":"XIAP; Apoptosis; Inhibitor of apoptosis; Melanoma; Cancer research; Caspase; Chemotherapy; Immune system; Malignancy; Small molecule; Pharmacology; Chemistry; Medicine; Immunology; Programmed cell death; Biochemistry; Internal medicine","score_opus":0.03438674536190695,"score_gpt":0.32339435661293103,"score_spread":0.2890076112510241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159560706","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007797722,0.9709724,0.024794402,0.000031945336,0.00035683432,0.002844405,0.00017826448,0.000007919617,0.00003405258],"genre_scores_gemma":[0.0049352804,0.9918804,0.0009486494,0.000059236703,0.00033947497,0.00080084155,0.00022574532,0.00012417,0.0006861575],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99817026,0.0001127803,0.0006585424,0.00045804193,0.00026255523,0.0003378214],"domain_scores_gemma":[0.9984371,0.00002954757,0.0006177321,0.0006790037,0.00018509883,0.000051492003],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001693455,0.00049127627,0.00088710967,0.000096630705,0.00008110548,0.000016767515,0.0003204711,0.0005494077,0.000027700491],"category_scores_gemma":[0.000003693669,0.00032002374,0.0010830167,0.00017732328,0.000119748634,0.000002238276,0.000042962605,0.000082222636,0.0000012932946],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011336839,0.00025378406,7.0799604e-7,0.0017579622,0.001596387,0.0000015425555,0.000048390386,0.000039112503,0.12682648,0.0002576853,0.0000064323194,0.8690981],"study_design_scores_gemma":[0.0004759379,0.0016657667,6.556864e-7,0.0006642271,0.0015584735,0.000005735894,0.000015174869,0.000029549825,0.2775699,0.00015021302,0.7175966,0.00026777797],"about_ca_topic_score_codex":0.000041640058,"about_ca_topic_score_gemma":0.0000068620916,"teacher_disagreement_score":0.8688304,"about_ca_system_score_codex":0.00006943213,"about_ca_system_score_gemma":0.00037436327,"threshold_uncertainty_score":0.9999252},"labels":[],"label_agreement":null},{"id":"W2160694221","doi":"10.1158/1535-7163.mct-09-0673","title":"Subcellular Distribution of a Fluorescence-Labeled Combi-Molecule Designed to Block Epidermal Growth Factor Receptor Tyrosine Kinase and Damage DNA with a Green Fluorescent Species","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"National Cancer Institute; McGill University Health Centre","keywords":"Biology; Epidermal growth factor receptor; Molecular biology; DNA damage; Kinase; Tyrosine kinase; Transfection; DNA repair; Phosphorylation; DNA; Cell biology; Biochemistry; Signal transduction; Receptor; Gene","score_opus":0.01278670995869844,"score_gpt":0.23818011937805522,"score_spread":0.2253934094193568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160694221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847427,0.0009907694,0.011925008,0.00094570505,0.00021618669,0.0007184052,0.00040772386,0.000026827145,0.000026670197],"genre_scores_gemma":[0.9956364,0.00046225445,0.0022757514,0.00092884636,0.00013346005,0.00009144255,0.0002323902,0.000086797896,0.00015263948],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980369,0.000095751995,0.00035674442,0.0006220607,0.00037169235,0.0005168067],"domain_scores_gemma":[0.9985544,0.000013614417,0.00018247422,0.0006131585,0.00037689315,0.00025943792],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014843902,0.00042321495,0.00038860497,0.00007576733,0.00012719411,0.00005533975,0.00034364534,0.00023746099,0.000036357385],"category_scores_gemma":[0.000016700387,0.00038454166,0.00012051873,0.00028522624,0.0002269218,0.000009656874,0.0001537663,0.00023668843,0.0000024354113],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071587815,0.00017798958,0.00084153947,0.00006276943,0.00024851025,0.000015049722,0.00016435134,0.000010931622,0.99453896,0.00097232783,0.000053734162,0.0021979439],"study_design_scores_gemma":[0.0017415583,0.0010936528,0.0016145519,0.00005244888,0.00015061161,0.000011932704,0.00004092187,0.0001117369,0.9844901,0.00006057683,0.0101354765,0.0004964136],"about_ca_topic_score_codex":0.00016619629,"about_ca_topic_score_gemma":0.00021288314,"teacher_disagreement_score":0.010893713,"about_ca_system_score_codex":0.000047675756,"about_ca_system_score_gemma":0.00018905119,"threshold_uncertainty_score":0.99986064},"labels":[],"label_agreement":null},{"id":"W2160846997","doi":"10.1158/1535-7163.mct-12-0227","title":"First Evidence of Sphingosine 1-Phosphate Lyase Protein Expression and Activity Downregulation in Human Neoplasm: Implication for Resistance to Therapeutics in Prostate Cancer","year":2012,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Ligue Contre le Cancer; Institut National Du Cancer; Association pour la Recherche sur le Cancer","keywords":"Ceramide; Sphingosine kinase 1; Prostate cancer; Sphingosine; Cancer; Cancer cell; Cancer research; Sphingosine kinase; Sphingosine-1-phosphate; Gene silencing; Apoptosis; Biology; Medicine; Internal medicine; Biochemistry","score_opus":0.028473161347986223,"score_gpt":0.3228567867164746,"score_spread":0.2943836253684884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160846997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9722654,0.019999523,0.005952263,0.00050386705,0.00006351112,0.001176564,0.00002566132,0.0000075248354,0.0000056344156],"genre_scores_gemma":[0.99595696,0.001246181,0.0016109723,0.0002747056,0.00008622533,0.00071843807,0.000011920273,0.000037798884,0.00005679669],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879104,0.00006983797,0.0002957224,0.00034659216,0.00015367511,0.00034311172],"domain_scores_gemma":[0.99931157,0.00002073419,0.00018123389,0.00031281947,0.00010455892,0.00006909394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003765154,0.00019640391,0.00022552983,0.00008672955,0.000071704126,0.000020807482,0.00013725527,0.000117703,0.0000022685042],"category_scores_gemma":[0.000020813146,0.00019456788,0.000047652422,0.00022390495,0.000047620648,0.000030892144,0.00006143067,0.000088983674,1.1957218e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006514629,0.00007943608,0.011279208,0.00018224277,0.000023098126,3.2377326e-7,0.00061388925,0.0015121432,0.98197246,0.0001028553,0.0000026190437,0.0035802943],"study_design_scores_gemma":[0.00092899264,0.000068551555,0.038627073,0.0004383636,0.000032805146,4.4815536e-7,0.000025021305,0.00022995622,0.95619494,0.000108307955,0.0031244238,0.0002211042],"about_ca_topic_score_codex":0.0002217759,"about_ca_topic_score_gemma":0.00058802747,"teacher_disagreement_score":0.027347865,"about_ca_system_score_codex":0.00006297171,"about_ca_system_score_gemma":0.00006678519,"threshold_uncertainty_score":0.7934248},"labels":[],"label_agreement":null},{"id":"W2161336797","doi":"10.1158/1535-7163.mct-11-0421","title":"Digitoxin-Induced Cytotoxicity in Cancer Cells Is Mediated through Distinct Kinase and Interferon Signaling Networks","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ion Transport and Channel Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; University Health Network; Mount Sinai Hospital","funders":"Ontario Institute for Cancer Research","keywords":"Digitoxin; Kinase; Pharmacology; Cancer cell; Biology; Signal transduction; Kinome; Cancer; Cancer research; Chemistry; Biochemistry; Heart failure; Internal medicine; Medicine; Digoxin","score_opus":0.03812928380603275,"score_gpt":0.27108474907897845,"score_spread":0.2329554652729457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161336797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98507196,0.0032224937,0.010962691,0.00009263334,0.00022701218,0.00023255353,0.00003054926,0.000016861432,0.00014324064],"genre_scores_gemma":[0.9971108,0.0011797039,0.00012408337,0.0012591468,0.000117310294,0.00006405828,0.0000616703,0.000045230518,0.000038023627],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99886364,0.000048776765,0.00025366983,0.0003924442,0.0001298987,0.000311591],"domain_scores_gemma":[0.99954957,0.000005675318,0.00009589239,0.00022411959,0.000060343482,0.000064389955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007837345,0.00023717729,0.00019023514,0.000035403493,0.000053042724,0.000019965471,0.00014181339,0.00023574727,0.00005594104],"category_scores_gemma":[0.0000016771423,0.00023014314,0.00007415174,0.0001274325,0.000072279225,0.000009841162,0.000040649065,0.0001492428,0.0000010271663],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023413538,0.000072073155,0.0052823415,0.00002206697,0.00009943386,0.000014018599,0.00070378423,0.00025086498,0.99019736,0.000013436957,0.000012981286,0.003097515],"study_design_scores_gemma":[0.00065738196,0.00017830342,0.0038674935,0.00005447533,0.000053149077,0.000001230397,0.000064521766,0.0013977495,0.99235475,0.00010788206,0.00096083526,0.00030222308],"about_ca_topic_score_codex":0.00039909928,"about_ca_topic_score_gemma":0.00039523063,"teacher_disagreement_score":0.012038808,"about_ca_system_score_codex":0.00004032611,"about_ca_system_score_gemma":0.0000547623,"threshold_uncertainty_score":0.9384965},"labels":[],"label_agreement":null},{"id":"W2161709887","doi":"10.1158/1535-7163.mct-11-0077","title":"Characterization of the Oncogenic Activity of the Novel <i>TRIM59</i> Gene in Mouse Cancer Models","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Queen's University; Sunnybrook Health Science Centre; Lawson Health Research Institute","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Biology; Carcinogenesis; Gene knockdown; Oncogene; Cancer research; Downregulation and upregulation; Cell cycle; Small hairpin RNA; Gene; Transgene; Molecular biology; Cell biology; Genetics","score_opus":0.045084547340752734,"score_gpt":0.26068970851791384,"score_spread":0.2156051611771611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161709887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952687,0.0021693155,0.0014191797,0.00016090945,0.000454177,0.000275703,0.00013159795,0.000007211665,0.00011320632],"genre_scores_gemma":[0.9979735,0.0006246615,0.0000114418635,0.00059454545,0.0000050224385,0.000037966212,0.0000029124978,0.000019623172,0.0007303427],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991796,0.0002126332,0.00023194522,0.00014194635,0.00005127337,0.00018259705],"domain_scores_gemma":[0.9992537,0.000014278235,0.00022967358,0.00041500616,0.000081811835,0.000005553493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000098919874,0.00012977228,0.00020605561,0.000042169446,0.000046130186,0.000002351084,0.000388633,0.00015019934,0.00007109876],"category_scores_gemma":[0.000004371588,0.00008181894,0.00014194369,0.00018225485,0.00020057059,0.000046765374,0.00010636939,0.00020814214,0.00000132586],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042279597,0.00017296213,0.0006211641,0.000012560855,0.00019561689,1.4983266e-7,0.0013161146,0.00006563803,0.99436635,0.00019146188,0.0000015353261,0.0026336715],"study_design_scores_gemma":[0.0006658675,0.000040844974,0.010287071,0.000042236836,0.00006407074,0.0000025687427,0.000019980524,0.00006411174,0.9879155,0.00003541951,0.00077287393,0.000089431676],"about_ca_topic_score_codex":0.0010181259,"about_ca_topic_score_gemma":0.0001527124,"teacher_disagreement_score":0.009665906,"about_ca_system_score_codex":0.00006840862,"about_ca_system_score_gemma":0.00019637698,"threshold_uncertainty_score":0.33364794},"labels":[],"label_agreement":null},{"id":"W2162160107","doi":"10.1158/1535-7163.mct-10-0471","title":"RITA Inhibits Multiple Myeloma Cell Growth through Induction of p53-Mediated Caspase-Dependent Apoptosis and Synergistically Enhances Nutlin-Induced Cytotoxic Responses","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada","keywords":"Downregulation and upregulation; Apoptosis; Mdm2; Cancer research; Cytotoxic T cell; Multiple myeloma; Caspase; Biology; Cell culture; Caspase 8; Programmed cell death; Gene; Immunology; In vitro; Genetics","score_opus":0.023995870911143767,"score_gpt":0.27871922280274636,"score_spread":0.2547233518916026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162160107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920842,0.002186054,0.0024667822,0.0010140084,0.0007345056,0.0009143567,0.00011452527,0.00013959515,0.00034594044],"genre_scores_gemma":[0.9949479,0.0012033638,0.0021907266,0.0010865234,0.00017028407,0.00014578943,0.00004253191,0.00013771885,0.00007516601],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99719304,0.00017524368,0.00064657466,0.0007159773,0.00073754805,0.00053164293],"domain_scores_gemma":[0.9980673,0.00018803161,0.00033201795,0.0006739313,0.0005033568,0.00023531653],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027497843,0.00046118008,0.0006249803,0.00022525575,0.00013205853,0.000040618484,0.00020410494,0.0005404677,0.000063296626],"category_scores_gemma":[0.00025632847,0.00044734872,0.0001790877,0.0005107433,0.00031876104,0.000116904135,0.0001063098,0.00092304527,0.000012594767],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009368311,0.00034007017,0.0003612411,0.00019894796,0.00032354394,0.00006752197,0.0006587621,0.000013012116,0.9945983,0.00015896399,0.000024693152,0.0023180752],"study_design_scores_gemma":[0.003348214,0.0006569995,0.0013197254,0.00017509692,0.0005685075,0.000072326024,0.00017142178,0.00031886023,0.9922437,0.00016867604,0.00051862217,0.00043785805],"about_ca_topic_score_codex":0.0005361032,"about_ca_topic_score_gemma":0.00022209891,"teacher_disagreement_score":0.0028636637,"about_ca_system_score_codex":0.00016381644,"about_ca_system_score_gemma":0.0005255715,"threshold_uncertainty_score":0.9997978},"labels":[],"label_agreement":null},{"id":"W2162351740","doi":"10.1158/1535-7163.mct-04-0310","title":"Strongylophorine-26, a Rho-dependent inhibitor of tumor cell invasion that reduces actin stress fibers and induces nonpolarized lamellipodial extensions","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Silk-based biomaterials and applications","field":"Materials Science","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Lamellipodium; Membrane ruffling; Motility; Stress fiber; Cell biology; Actin; Focal adhesion; Cell migration; Cell; Chemistry; Myofibroblast; Cytoskeleton; Biology; Fibrosis; Medicine; Signal transduction; Biochemistry; Pathology","score_opus":0.026564290346850882,"score_gpt":0.2714589183366407,"score_spread":0.24489462798978984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162351740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962084,0.001688272,0.00015247046,0.000907342,0.00032197847,0.0003928694,0.00022253043,0.00006869904,0.00003742918],"genre_scores_gemma":[0.9962682,0.00040722225,0.0025297701,0.00042386248,0.00018674026,0.0000866207,0.0000122548,0.00004513789,0.000040160954],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984163,0.00010561222,0.0003461158,0.00043898614,0.00037315607,0.0003198476],"domain_scores_gemma":[0.99909025,0.000057972527,0.00028382998,0.00036109248,0.00009504057,0.00011178093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019775495,0.00024540068,0.00030358305,0.00007720548,0.00015652248,0.0001042728,0.000267789,0.000110623725,0.0001538484],"category_scores_gemma":[0.0000063301686,0.00021181286,0.00007091536,0.0001396625,0.00017524273,0.00012385155,0.000121440375,0.00010797623,0.000015300477],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010496912,0.00015742294,0.00015687385,0.000038160964,0.000020480431,0.0000048805546,0.00031135534,0.00014275542,0.99629694,0.000036319034,0.000021470514,0.0027083757],"study_design_scores_gemma":[0.0008130869,0.0000816319,0.00046875878,0.00007225534,0.0000939187,0.0000035386863,0.0002990472,0.00006782502,0.9966795,0.000049953058,0.0011306133,0.00023988576],"about_ca_topic_score_codex":0.00034894716,"about_ca_topic_score_gemma":0.00007185971,"teacher_disagreement_score":0.0024684898,"about_ca_system_score_codex":0.00006903247,"about_ca_system_score_gemma":0.00015864566,"threshold_uncertainty_score":0.8637478},"labels":[],"label_agreement":null},{"id":"W2162579298","doi":"10.1158/1535-7163.mct-13-1086","title":"Monensin Inhibits Epidermal Growth Factor Receptor Trafficking and Activation: Synergistic Cytotoxicity in Combination with EGFR Inhibitors","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Veterinary medicine and infectious diseases","field":"Veterinary","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Canadian Institutes of Health Research; Ottawa Hospital Research Institute","keywords":"Erlotinib; EGFR inhibitors; Epidermal growth factor receptor; Pharmacology; Monensin; Cancer research; Cytotoxicity; Chemistry; Medicine; Internal medicine; Receptor; In vitro; Biochemistry","score_opus":0.03595096515547805,"score_gpt":0.29235425184590286,"score_spread":0.2564032866904248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162579298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99427944,0.0002713532,0.0037456865,0.0007894201,0.00017176203,0.0003445031,0.000009482566,0.0000981013,0.00029026755],"genre_scores_gemma":[0.99805343,0.00008178886,0.00014251363,0.0014234883,0.00015286748,0.00006127983,0.000020453755,0.000052898802,0.000011289925],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985699,0.00022546033,0.0002804269,0.00035972917,0.00027353363,0.00029097305],"domain_scores_gemma":[0.99937886,0.000091549206,0.00013318654,0.0001916573,0.00010834297,0.00009642579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012536702,0.00026110694,0.00027953822,0.00016207393,0.00010710051,0.000043228185,0.00007980006,0.00011017851,0.000043031996],"category_scores_gemma":[0.00004226662,0.00023348028,0.000044718523,0.00028986172,0.00011322502,0.00020442918,0.000036120764,0.00022289451,0.0000052129376],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011009111,0.00053643825,0.028154163,0.00028465636,0.0001937003,0.00011474797,0.0017154024,0.00032534177,0.94677216,0.00086860626,0.000100332756,0.019833572],"study_design_scores_gemma":[0.014562598,0.012954519,0.22111103,0.0023110586,0.00040189794,0.00030461675,0.0007810305,0.017305462,0.71971154,0.0009488065,0.0068553444,0.0027520934],"about_ca_topic_score_codex":0.0002095956,"about_ca_topic_score_gemma":0.000027644073,"teacher_disagreement_score":0.22706059,"about_ca_system_score_codex":0.00016418233,"about_ca_system_score_gemma":0.000057388024,"threshold_uncertainty_score":0.9521049},"labels":[],"label_agreement":null},{"id":"W2164897814","doi":"10.1158/1535-7163.mct-09-0042","title":"Niacin status and treatment-related leukemogenesis","year":2009,"lang":"en","type":"review","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Niacin; Bone marrow; Apoptosis; Cancer research; Biology; DNA damage; Haematopoiesis; Poly ADP ribose polymerase; Leukemia; Chromosomal translocation; Cancer; Chemotherapy; Immunology; Stem cell; Endocrinology; Genetics; DNA","score_opus":0.07197418825721326,"score_gpt":0.3812024341047375,"score_spread":0.30922824584752423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164897814","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028014657,0.99626434,0.000064493586,0.00025968204,0.00027291809,0.0014977808,0.00015056982,0.00015972073,0.0010503236],"genre_scores_gemma":[0.00007298453,0.99571234,0.0002793025,0.0016004745,0.00016959518,0.00036697526,0.00020653343,0.00020598904,0.001385828],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973406,0.00020427453,0.0007132904,0.0007435566,0.00036839448,0.00062988553],"domain_scores_gemma":[0.9984387,0.000056052304,0.00035985743,0.00075540505,0.00009531318,0.0002946638],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009067476,0.0008289817,0.0021713409,0.00030099877,0.000096902106,0.00004990341,0.0001234418,0.00060544716,0.00021686466],"category_scores_gemma":[0.000003749508,0.00066483754,0.00066812546,0.00053124875,0.00015314898,0.000039275827,0.000025244552,0.00038021937,0.000044096694],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051821822,0.00011052918,0.000018959498,0.0013343452,0.002139143,0.00013091475,0.00010567363,0.0000023031698,0.00018073343,0.00008997262,0.000049686827,0.9957859],"study_design_scores_gemma":[0.0023689133,0.00050062087,0.00001697746,0.005121206,0.0060858787,0.00016369193,0.0000083611985,0.000008853038,0.0004250694,0.0001212205,0.98460776,0.00057144533],"about_ca_topic_score_codex":0.00007485789,"about_ca_topic_score_gemma":0.000009985,"teacher_disagreement_score":0.99521446,"about_ca_system_score_codex":0.0016881437,"about_ca_system_score_gemma":0.0013574809,"threshold_uncertainty_score":0.99958026},"labels":[],"label_agreement":null},{"id":"W2165551720","doi":"10.1158/1535-7163.mct-14-0166","title":"Mechanism and Efficacy of Sub–50-nm Tenfibgen Nanocapsules for Cancer Cell–Directed Delivery of Anti-CK2 RNAi to Primary and Metastatic Squamous Cell Carcinoma","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Nanocapsules; Cancer research; RNA interference; Basal cell; Cancer; Cell; Mechanism (biology); Chemistry; Biology; Medicine; Nanotechnology; Biochemistry; Internal medicine; Gene; Materials science; Nanoparticle; Genetics; RNA","score_opus":0.014140979963202276,"score_gpt":0.24905761870376056,"score_spread":0.2349166387405583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165551720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745561,0.018267369,0.0062762033,0.000069920294,0.000114204,0.00047994856,0.00015855682,0.00000942491,0.00006829646],"genre_scores_gemma":[0.99472606,0.002403704,0.0016843323,0.0009071581,0.00004692035,0.00007674842,0.000043030734,0.000049081787,0.00006298379],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99873775,0.000082394414,0.0003195411,0.00042515376,0.00015384537,0.00028129632],"domain_scores_gemma":[0.99911314,0.00003710986,0.00017801607,0.00032974474,0.0002448118,0.00009716289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013646958,0.00025457187,0.0003817893,0.00006210101,0.000056175984,0.000016396245,0.00019364092,0.00012507639,0.000006062647],"category_scores_gemma":[0.000009618745,0.0002418606,0.00011344325,0.00008145677,0.00009526365,0.000006795669,0.00011038102,0.000057573652,3.514361e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023684898,0.00010006095,0.0007543377,0.00028667672,0.000121477635,0.000001231062,0.00019168924,0.00011455739,0.9919157,0.000040330306,0.000068801135,0.0061683147],"study_design_scores_gemma":[0.0014541908,0.00089616876,0.0025472802,0.00003090799,0.00031330052,0.0000031200464,0.00007367844,0.0003976907,0.9924147,0.00008596653,0.0015023872,0.00028056803],"about_ca_topic_score_codex":0.000363748,"about_ca_topic_score_gemma":0.00012804223,"teacher_disagreement_score":0.020169964,"about_ca_system_score_codex":0.000023733248,"about_ca_system_score_gemma":0.00012961632,"threshold_uncertainty_score":0.98627895},"labels":[],"label_agreement":null},{"id":"W2165570750","doi":"10.1158/1535-7163.mct-07-0455","title":"Calcitrol (1α,25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer cells","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Hormonal and reproductive studies","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Université Laval","keywords":"LNCaP; Calcitriol; Prostate cancer; Dihydrotestosterone; Androgen receptor; Calcitriol receptor; Endocrinology; Internal medicine; Androgen; Cancer research; Chemistry; Cancer; Biology; Vitamin D and neurology; Medicine; Hormone","score_opus":0.027047234613975252,"score_gpt":0.2925756800418609,"score_spread":0.2655284454278857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165570750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9744382,0.021550696,0.000080057056,0.0022087062,0.00017233349,0.0007118287,0.000034320557,0.000040406623,0.000763483],"genre_scores_gemma":[0.98975027,0.007046008,0.000121073965,0.0020187253,0.00017572899,0.00023227811,0.000021824959,0.00004300396,0.0005910681],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99835676,0.00007868191,0.00028604537,0.00045640205,0.00043339733,0.0003887056],"domain_scores_gemma":[0.9993872,0.000012917438,0.000086116896,0.00027750753,0.00016209963,0.00007416449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012864145,0.00025067572,0.0003716527,0.00012828254,0.000101208585,0.000010096505,0.0000929478,0.000082207865,0.000031979453],"category_scores_gemma":[0.0000065607696,0.00020491566,0.000103465856,0.0004195536,0.0001474848,0.00006462919,0.00003360811,0.00025683356,0.000017397742],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002606647,0.00047104325,0.02827288,0.0001238934,0.00037853952,0.00058983586,0.0064853956,0.0003475025,0.94833946,0.000068373454,0.00016255409,0.014499876],"study_design_scores_gemma":[0.0027619067,0.00042750387,0.028002784,0.0001360232,0.00024581936,0.0000716591,0.00039015381,0.00025066052,0.9329631,0.00012934268,0.034208834,0.00041221522],"about_ca_topic_score_codex":0.00034715398,"about_ca_topic_score_gemma":0.00009487313,"teacher_disagreement_score":0.03404628,"about_ca_system_score_codex":0.00019704428,"about_ca_system_score_gemma":0.00021080993,"threshold_uncertainty_score":0.83562183},"labels":[],"label_agreement":null},{"id":"W2165769610","doi":"10.1158/1535-7163.1239.3.10","title":"The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Genomics, phytochemicals, and oxidative stress","field":"Biochemistry, Genetics and Molecular Biology","cited_by":153,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Sulforaphane; Apoptosis; Isothiocyanate; Oxidative stress; Cell cycle; Glutathione; Cyclin B1; Pancreatic cancer; Molecular biology; Growth inhibition; Biology; Cyclin-dependent kinase 1; Chemistry; Cancer research; Biochemistry; Cancer","score_opus":0.009102891551533127,"score_gpt":0.23282500371783427,"score_spread":0.22372211216630114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165769610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96509725,0.033886336,0.00006749063,0.00013502939,0.00008312937,0.0004509025,0.0002081918,0.0000053544404,0.00006632562],"genre_scores_gemma":[0.98861694,0.010685978,0.00013133614,0.00034277447,0.000022073596,0.00009528563,0.000055375396,0.00003940493,0.000010813467],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984995,0.000106546904,0.00038731383,0.00046607942,0.0001415306,0.00039901191],"domain_scores_gemma":[0.9993292,0.000024377241,0.00020783195,0.00027156062,0.00010012637,0.00006692297],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014211677,0.00029948904,0.00032589957,0.000067725785,0.00010583849,0.000029863,0.00023590184,0.00012076615,0.0000019212764],"category_scores_gemma":[0.0000071420736,0.00026430367,0.000064999665,0.000162553,0.00030328793,0.000009392385,0.00016048505,0.00020443347,2.1115926e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020329532,0.0001897135,0.0031495763,0.00012361842,0.00009646677,0.0000049592904,0.000727198,0.0010917367,0.994019,0.00007500669,0.000002888345,0.000316543],"study_design_scores_gemma":[0.0021661422,0.00022800345,0.0031995438,0.00014050039,0.000050945506,0.0000012628867,0.00049171067,0.000051177016,0.99218905,0.0011233238,0.000047414862,0.0003109029],"about_ca_topic_score_codex":0.0009626669,"about_ca_topic_score_gemma":0.0007037715,"teacher_disagreement_score":0.023519717,"about_ca_system_score_codex":0.00007048171,"about_ca_system_score_gemma":0.00010880634,"threshold_uncertainty_score":0.9999809},"labels":[],"label_agreement":null},{"id":"W2166435610","doi":"10.1158/1535-7163.mct-13-0032","title":"Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression <i>In Vivo</i>","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Bicalutamide; LNCaP; Prostate cancer; Androgen receptor; Protein kinase B; Antiandrogen; Cancer research; In vivo; PI3K/AKT/mTOR pathway; Medicine; Growth inhibition; Androgen; Internal medicine; Pharmacology; Endocrinology; Cell growth; Cancer; Apoptosis; Chemistry; Biology; Biochemistry","score_opus":0.02192626339959827,"score_gpt":0.3056647247005957,"score_spread":0.28373846130099745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166435610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9653983,0.03087084,0.00007826467,0.0014303819,0.000106348416,0.0016517851,0.00014913289,0.000033020722,0.00028193503],"genre_scores_gemma":[0.9929308,0.0046998924,0.0007717267,0.0002844917,0.000054090488,0.0007427852,0.000041036266,0.000057605448,0.00041755658],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981289,0.000096264645,0.0004336478,0.00041441267,0.00045063984,0.0004761158],"domain_scores_gemma":[0.99907845,0.000041660052,0.0001664013,0.00024204202,0.0003014837,0.00016994453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017355489,0.0002622982,0.0003915486,0.0001250779,0.00008846534,0.000042699365,0.00009604353,0.00012034269,0.00027609983],"category_scores_gemma":[0.000013465471,0.00020007549,0.00007422073,0.0003465416,0.00019477269,0.00009484659,0.000043042073,0.0002167969,0.000003800561],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055032753,0.00016258362,0.014216863,0.0003391755,0.00021033912,0.00006634318,0.00087241776,0.00006437539,0.9550372,0.000041921918,0.00014034401,0.02829814],"study_design_scores_gemma":[0.0027007118,0.0006244005,0.0014518556,0.0006452801,0.00013996144,0.0000034611821,0.00043061312,0.00082212774,0.98887134,0.00013949526,0.003890912,0.00027984814],"about_ca_topic_score_codex":0.0010385856,"about_ca_topic_score_gemma":0.000104171806,"teacher_disagreement_score":0.033834163,"about_ca_system_score_codex":0.00022519325,"about_ca_system_score_gemma":0.00047836974,"threshold_uncertainty_score":0.8158842},"labels":[],"label_agreement":null},{"id":"W2167968468","doi":"10.1158/1535-7163.mct-13-0267","title":"Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Basis Foundation","keywords":"Androgen receptor; Prostate cancer; Enzalutamide; Androgen; LNCaP; Antiandrogen; Androgen Receptor Antagonists; Cancer research; Endocrinology; Medicine; Internal medicine; Pharmacology; Cancer; Hormone","score_opus":0.014741834600917476,"score_gpt":0.29646458112044477,"score_spread":0.2817227465195273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167968468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98918897,0.004633201,0.0016716932,0.0024979915,0.00005218813,0.0018478064,0.000046187648,0.00001938661,0.00004257082],"genre_scores_gemma":[0.9934844,0.0046260175,0.0003537712,0.00035412723,0.000032906344,0.00052294665,0.0001202974,0.00004599878,0.00045953784],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987851,0.00004057594,0.0003047973,0.00026689714,0.00033562118,0.00026702936],"domain_scores_gemma":[0.9991612,0.000006432698,0.00020555321,0.00027258927,0.00026920755,0.000085014326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000054279426,0.00017747984,0.0003321726,0.00012420799,0.000023973174,0.000011923312,0.00009819131,0.000086066335,0.00008234925],"category_scores_gemma":[0.0000010483325,0.00013401436,0.00005900503,0.00043936653,0.00010891928,0.00009954996,0.000019197938,0.00013049625,0.0000031084342],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001126712,0.00014944628,0.03179789,0.00014920211,0.0002371115,0.0000036568633,0.00054867344,0.00010317301,0.829178,0.00002263445,0.0000039193897,0.1366796],"study_design_scores_gemma":[0.004635852,0.00052608503,0.039507493,0.0002472274,0.00016725187,0.000003811983,0.0000962528,0.00095510745,0.9507914,0.000100013465,0.0027974038,0.00017207892],"about_ca_topic_score_codex":0.0008219282,"about_ca_topic_score_gemma":0.000050696235,"teacher_disagreement_score":0.13650753,"about_ca_system_score_codex":0.00016984317,"about_ca_system_score_gemma":0.0005839004,"threshold_uncertainty_score":0.5464947},"labels":[],"label_agreement":null},{"id":"W2168213980","doi":"10.1158/1535-7163.mct-14-0866","title":"Hsp27 Inhibition with OGX-427 Sensitizes Non–Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Erlotinib; A549 cell; Lung cancer; Medicine; Pharmacology; Hsp27; Cancer research; Cancer; Internal medicine; Biology; Epidermal growth factor receptor; Heat shock protein; Hsp70","score_opus":0.01952114444822322,"score_gpt":0.2950278219370564,"score_spread":0.2755066774888332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168213980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97884774,0.0037539839,0.013991059,0.0016231553,0.00010315137,0.001103935,0.000050696173,0.000027152593,0.00049910153],"genre_scores_gemma":[0.9878753,0.0011724948,0.003138356,0.00630928,0.00023721776,0.00030879266,0.000032285898,0.00012642324,0.0007998919],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99815774,0.00011357886,0.00021173645,0.0006037941,0.00036903293,0.0005441424],"domain_scores_gemma":[0.9987594,0.000008275684,0.000066615234,0.0004816623,0.00033239232,0.00035163734],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023552637,0.00032534054,0.0002526681,0.000085382235,0.000087911314,0.00007926755,0.00017165253,0.00021689941,0.000020247493],"category_scores_gemma":[0.0000058513956,0.00029385777,0.00006156116,0.00023469787,0.00010168625,0.000006590614,0.00013063014,0.00020286003,0.0000072385533],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039201553,0.00006306358,0.0011631924,0.00007191446,0.0001465414,0.000030525298,0.0005636839,0.00095611525,0.98981106,0.0000046984446,0.00063975726,0.0061574588],"study_design_scores_gemma":[0.0019057761,0.0005323146,0.00018670977,0.00006492039,0.00005925565,0.000010517919,0.00013083506,0.00057032175,0.96886134,0.000013479452,0.027249832,0.000414675],"about_ca_topic_score_codex":0.00040534942,"about_ca_topic_score_gemma":0.00024687962,"teacher_disagreement_score":0.026610075,"about_ca_system_score_codex":0.000110573936,"about_ca_system_score_gemma":0.00049263233,"threshold_uncertainty_score":0.99995136},"labels":[],"label_agreement":null},{"id":"W2168586185","doi":"10.1158/1535-7163.mct-08-0374","title":"HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Liver physiology and pathology","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"Max Kade Foundation","keywords":"Cancer research; Protein kinase B; Tyrosine kinase; MAPK/ERK pathway; Receptor tyrosine kinase; PI3K/AKT/mTOR pathway; Biology; Kinase; Signal transduction; Chemistry; Cell biology","score_opus":0.035953202806409824,"score_gpt":0.2968964523811407,"score_spread":0.26094324957473086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168586185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99343246,0.0021039601,0.0018582619,0.0013580843,0.00022138252,0.0005991664,0.000081042424,0.0000519119,0.00029372843],"genre_scores_gemma":[0.98511493,0.000917379,0.0011063198,0.011960385,0.00012191819,0.00021174515,0.00009008206,0.000047174854,0.00043007795],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99843216,0.00019969209,0.00030532683,0.0004382862,0.00023991415,0.00038459967],"domain_scores_gemma":[0.9991698,0.000037676225,0.000118922544,0.00034733297,0.00019693967,0.0001292969],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011222628,0.0002521196,0.0003928065,0.0002426069,0.00009014221,0.000006522682,0.000076425225,0.00021488962,0.00019583035],"category_scores_gemma":[0.000013558072,0.000245366,0.00008923005,0.0007164636,0.00013360215,0.00006628112,0.00003234244,0.00030809245,0.000018811972],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011419689,0.00019417013,0.0036672081,0.0000449866,0.0001364374,0.00046510325,0.00070605107,0.00059122546,0.9906343,0.000087176995,0.00042955996,0.0019017785],"study_design_scores_gemma":[0.002575939,0.00039056246,0.025262674,0.000198077,0.000180545,0.000020045825,0.000054760258,0.000038285467,0.96230954,0.00010121996,0.0086011905,0.00026717802],"about_ca_topic_score_codex":0.00027466688,"about_ca_topic_score_gemma":0.00017215699,"teacher_disagreement_score":0.028324813,"about_ca_system_score_codex":0.00035862272,"about_ca_system_score_gemma":0.00032310747,"threshold_uncertainty_score":0.9999999},"labels":[],"label_agreement":null},{"id":"W2169031119","doi":"10.1158/1535-7163.mct-05-0358","title":"Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"CHEK1; G2-M DNA damage checkpoint; DNA repair; DNA damage; Cell cycle checkpoint; Biology; Cell cycle; Cell biology; Cancer research; Cancer cell; Checkpoint Kinase 2; DNA; Molecular biology; Cancer; Genetics","score_opus":0.004450107327435434,"score_gpt":0.24522990227486224,"score_spread":0.24077979494742682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169031119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968572,0.0012513563,0.00052221527,0.00009316002,0.000099393306,0.0005684768,0.000030285148,0.000055361485,0.00052253675],"genre_scores_gemma":[0.99859464,0.00009425643,0.00037260758,0.00040458541,0.00007639064,0.00016745158,0.00013729099,0.000060147555,0.00009264343],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985619,0.00020305227,0.00028190596,0.0004440501,0.00025329096,0.0002557778],"domain_scores_gemma":[0.99929166,0.000011487851,0.00015946967,0.00040982984,0.00007240602,0.00005514758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025761235,0.00026908904,0.00022076795,0.000064264685,0.00005376725,0.000020577734,0.000060428414,0.00023036228,0.000013574076],"category_scores_gemma":[0.0000062174686,0.00024383451,0.0001658498,0.00010640576,0.000099942736,0.000007058581,0.000087049586,0.00011469966,0.0000030282024],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083789363,0.00016792047,0.00048360555,0.00015763221,0.000042322437,0.000027041406,0.000027652693,0.00006624739,0.9962111,0.00006509289,0.000037524245,0.0018759433],"study_design_scores_gemma":[0.0017933381,0.0024507279,0.0009229513,0.00013110672,0.00010004814,0.0000043712053,0.0000069595003,0.0003067238,0.99309355,0.00028736287,0.00064926717,0.00025359247],"about_ca_topic_score_codex":0.000020646437,"about_ca_topic_score_gemma":0.000013086406,"teacher_disagreement_score":0.0031175727,"about_ca_system_score_codex":0.000042003347,"about_ca_system_score_gemma":0.000033777655,"threshold_uncertainty_score":0.99432826},"labels":[],"label_agreement":null},{"id":"W2169157708","doi":"10.1158/1535-7163.mct-05-0362","title":"Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Apoptosis; Caspase 8; Cycloheximide; Cytotoxic T cell; Cancer cell; Cancer research; Caspase; Cell culture; Biology; Chemistry; Molecular biology; Cell biology; Programmed cell death; Cancer; In vitro; Biochemistry; Genetics","score_opus":0.012569205567210723,"score_gpt":0.2612088494725402,"score_spread":0.24863964390532947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169157708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926378,0.003428786,0.002002804,0.0005885833,0.00017287798,0.00048008372,0.00028643425,0.000013211281,0.00038940477],"genre_scores_gemma":[0.99637425,0.00017884422,0.0003616747,0.0016142726,0.00010269683,0.00009921324,0.00017567148,0.0000613825,0.0010320068],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99847865,0.0000770058,0.0003683501,0.00047995642,0.00025318406,0.00034284996],"domain_scores_gemma":[0.99918914,0.000004856823,0.00016099094,0.0004461985,0.000120372475,0.00007842915],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010469392,0.00027511313,0.00028848977,0.00008421904,0.00006365533,0.000028017532,0.00022455082,0.00032844,0.00007973536],"category_scores_gemma":[0.0000018415611,0.00027888422,0.00012760668,0.00024414153,0.0000439336,0.0000054154975,0.000046438196,0.00008893855,9.84291e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017964738,0.000108368884,0.0001658808,0.00003826487,0.000094606905,0.0000032345715,0.00011062499,0.00026904696,0.9964422,0.0002087482,0.0015313124,0.00084808026],"study_design_scores_gemma":[0.0012110862,0.000086128864,0.0012712224,0.00006030254,0.00007232808,5.4860936e-7,0.00002623642,0.00005592907,0.96922725,0.00017734578,0.027481658,0.00032993668],"about_ca_topic_score_codex":0.0023043223,"about_ca_topic_score_gemma":0.0022368396,"teacher_disagreement_score":0.027214907,"about_ca_system_score_codex":0.0000819431,"about_ca_system_score_gemma":0.00011208441,"threshold_uncertainty_score":0.9999663},"labels":[],"label_agreement":null},{"id":"W2169541841","doi":"10.1158/1535-7163.mct-08-0446","title":"Identification and characterization of small-molecule inhibitors of hepsin","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Mechanisms and Therapy","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Serine protease; Chemistry; Small molecule; Cancer research; Cancer; Serine; Metastasis; Prostate cancer; Cancer cell; Tumor progression; Transmembrane protein; Cytotoxicity; Protease; In vitro; Biochemistry; Biology; Enzyme; Gene; Genetics; Receptor","score_opus":0.025046880798219363,"score_gpt":0.2705939419360608,"score_spread":0.24554706113784142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169541841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98990244,0.0018073928,0.0074499324,0.00040385686,0.00011118385,0.00025706648,0.000015814516,0.000014149787,0.0000381613],"genre_scores_gemma":[0.99682605,0.0023464595,0.00017733633,0.00045698832,0.000034516048,0.00001860897,0.000017936038,0.000024337858,0.00009774735],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99930435,0.000022491427,0.00026156104,0.00014761626,0.00016820818,0.00009577588],"domain_scores_gemma":[0.99944335,0.0000042339852,0.00017590018,0.0001959718,0.0001425081,0.000038014347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000060785263,0.00009515998,0.0002090988,0.00007892424,0.000027455008,0.000003380316,0.000041751544,0.000064723135,0.00002776906],"category_scores_gemma":[0.0000014479888,0.00009230942,0.00006055468,0.00017497,0.00008505296,0.000026257916,0.0000125218,0.00005819009,4.539643e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000089032175,0.000060373943,0.001967469,0.000065883214,0.000097779885,0.0000057465136,0.0005076488,0.0000016749283,0.98325896,0.00036001354,0.000001622574,0.013583801],"study_design_scores_gemma":[0.00078733044,0.00015396895,0.015199987,0.000055648317,0.00009079941,0.000014706813,0.000031111053,0.00014742298,0.9826398,0.000075714095,0.0007254299,0.00007809786],"about_ca_topic_score_codex":0.000057435558,"about_ca_topic_score_gemma":0.0000060535313,"teacher_disagreement_score":0.013505703,"about_ca_system_score_codex":0.000028579769,"about_ca_system_score_gemma":0.000096047734,"threshold_uncertainty_score":0.3764269},"labels":[],"label_agreement":null},{"id":"W2170102261","doi":"10.1158/1535-7163.mct-07-2284","title":"Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics","year":2008,"lang":"en","type":"review","venue":"Molecular Cancer Therapeutics","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada); Université de Montréal","funders":"U.S. Food and Drug Administration","keywords":"Histone; Acetylation; Histone deacetylase; Epigenetics; Chromatin; Cancer epigenetics; HDAC11; Biology; Histone deacetylase 5; Histone-modifying enzymes; Cell biology; Chromatin remodeling; Cancer research; Chemistry; Histone methyltransferase; Biochemistry; DNA; Gene","score_opus":0.07793731805207046,"score_gpt":0.39850757749240584,"score_spread":0.32057025944033535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170102261","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035862625,0.9942146,0.0005062059,0.000097279306,0.00018126697,0.0007332468,0.0003464536,0.000012287838,0.00032241264],"genre_scores_gemma":[0.003634947,0.99358946,0.00023488034,0.00005392995,0.0001546733,0.00070457766,0.0001426428,0.0001350468,0.0013498461],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99739486,0.0002912842,0.0007079076,0.0008180934,0.00035594383,0.00043190044],"domain_scores_gemma":[0.9984208,0.000037455975,0.0003286268,0.00080954545,0.00026978087,0.00013380875],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011903757,0.00048731404,0.001018944,0.0003123487,0.00011445476,0.0000142931585,0.0003895089,0.0005966745,0.000033063803],"category_scores_gemma":[0.000035187015,0.00049612805,0.000389397,0.00049351045,0.00073407067,0.0000042923493,0.00015820558,0.0005197055,0.000005109106],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012284995,0.0011218203,0.00007136992,0.004752903,0.001825848,0.000073440926,0.0015691633,0.0004975432,0.0671403,0.00029626754,0.0017341434,0.92079437],"study_design_scores_gemma":[0.00040171697,0.00014817395,0.000016845699,0.000892576,0.0003588599,0.00003812361,0.00010884675,0.000027074962,0.00310673,0.000005871813,0.9943805,0.0005146898],"about_ca_topic_score_codex":0.00043164607,"about_ca_topic_score_gemma":0.0005082449,"teacher_disagreement_score":0.99264634,"about_ca_system_score_codex":0.0005768375,"about_ca_system_score_gemma":0.001980302,"threshold_uncertainty_score":0.99974906},"labels":[],"label_agreement":null},{"id":"W2170220266","doi":"10.1158/1535-7163.mct-07-2117","title":"Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Paclitaxel; Clonogenic assay; In vivo; Ovarian cancer; Chemotherapy; Medicine; Apoptosis; Cancer; Cancer research; Internal medicine; Oncology; Biology","score_opus":0.026150746924365,"score_gpt":0.30451623315443827,"score_spread":0.2783654862300733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170220266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820547,0.014260135,0.00011935503,0.002439324,0.00015017878,0.00083359407,0.000007657487,0.00001718756,0.000117885495],"genre_scores_gemma":[0.98841655,0.007888886,0.00015038485,0.0030789226,0.000053326123,0.00030145652,0.000005766785,0.00003726901,0.000067453686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888796,0.00006553372,0.00028236868,0.00030626435,0.00023913232,0.00021876374],"domain_scores_gemma":[0.99941754,0.000047826208,0.0001280483,0.00025570559,0.00007914289,0.00007175211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000066079134,0.00019824812,0.00036338106,0.00013081745,0.000038749673,0.00000680935,0.000048144866,0.000067253466,0.000024282526],"category_scores_gemma":[0.000009145238,0.00016088483,0.00008884485,0.0002063694,0.000073661446,0.000029558301,0.000016118904,0.0001302601,6.746692e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027723133,0.002132518,0.67288387,0.00056956563,0.0013942113,0.002318347,0.003942305,0.00024043836,0.157705,0.0016586573,0.0000950443,0.15428773],"study_design_scores_gemma":[0.007626223,0.000891673,0.7669569,0.00047705718,0.00016593363,0.000025397523,0.000047350743,0.00018490483,0.22189339,0.00020774674,0.0013336192,0.00018978793],"about_ca_topic_score_codex":0.00097092235,"about_ca_topic_score_gemma":0.00005446817,"teacher_disagreement_score":0.15409794,"about_ca_system_score_codex":0.00029001475,"about_ca_system_score_gemma":0.00015887577,"threshold_uncertainty_score":0.6560693},"labels":[],"label_agreement":null},{"id":"W2170236489","doi":"10.1158/1535-7163.targ-13-a66","title":"Abstract A66: Ablative radiotherapy increases invasion potential in EGFR-wildtype non-small cell lung cancer cells compared to fractionated radiotherapy.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Clonogenic assay; Lung cancer; Radiation therapy; Cancer research; Epidermal growth factor receptor; Medicine; Cancer; Cell growth; Metastasis; Oncology; A549 cell; Cell culture; Internal medicine; Biology; Pathology","score_opus":0.03235643899308948,"score_gpt":0.27934911123444567,"score_spread":0.24699267224135618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170236489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708407,0.020686377,0.0032705867,0.0016418628,0.00032648607,0.0027864315,0.00004089481,0.000088327586,0.00031834698],"genre_scores_gemma":[0.98508364,0.0049687615,0.0031079678,0.005381198,0.00021420248,0.00074082887,0.00007379805,0.00014339027,0.00028623294],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976054,0.00013716432,0.0005187782,0.00064299983,0.00045899296,0.0006366996],"domain_scores_gemma":[0.9986637,0.00006986864,0.00019338101,0.0004771396,0.00026403126,0.0003318651],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014073621,0.0005208688,0.00067657017,0.0003497528,0.00011853022,0.000093926246,0.00022587574,0.0002807436,0.0019194697],"category_scores_gemma":[0.000003436377,0.00047488147,0.0002557705,0.00060801185,0.00006503851,0.0001457101,0.000034018194,0.00041211522,0.00004505164],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005071195,0.00061699294,0.22660723,0.00011330107,0.0007445374,0.00018709825,0.0009570277,0.0015861567,0.75876164,0.0000019752977,0.0006001961,0.00931673],"study_design_scores_gemma":[0.009741782,0.0005340664,0.2252939,0.0005352484,0.00069606333,0.000013468651,0.00021348467,0.051284093,0.70256686,0.000030281428,0.0080092205,0.0010815341],"about_ca_topic_score_codex":0.015030134,"about_ca_topic_score_gemma":0.00033451038,"teacher_disagreement_score":0.056194782,"about_ca_system_score_codex":0.0009147225,"about_ca_system_score_gemma":0.00042256244,"threshold_uncertainty_score":0.9997703},"labels":[],"label_agreement":null},{"id":"W2171131568","doi":"10.1158/1535-7163.1221.3.10","title":"Inhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Kinase; CHEK1; G2-M DNA damage checkpoint; Chemistry; Biochemistry; Protein kinase A; DNA damage; Biology; Cell cycle checkpoint; DNA; Cell cycle; Cell","score_opus":0.011659954915534138,"score_gpt":0.25386121016399404,"score_spread":0.2422012552484599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171131568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807402,0.0031725103,0.013945253,0.0009645424,0.0001864529,0.00037387054,0.00006515262,0.000027696193,0.00052436057],"genre_scores_gemma":[0.9961838,0.00029480638,0.0007979434,0.0022632382,0.00010456898,0.000070145885,0.000098215634,0.00005976367,0.00012749643],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99870867,0.00007418345,0.00030553367,0.00034277045,0.00028023287,0.00028863014],"domain_scores_gemma":[0.999068,0.000005438729,0.00016392449,0.0005905106,0.000111830464,0.000060293845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017708153,0.00023103009,0.00017842009,0.00003382772,0.00007993105,0.000023850153,0.00023453082,0.00018321352,0.000021798867],"category_scores_gemma":[0.000010517496,0.00018921056,0.0001907884,0.00016591598,0.00016257825,0.0000054761394,0.00010549355,0.00013695989,0.0000048929132],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000587983,0.00009036071,0.00004637438,0.000021130754,0.00012551769,0.000004282352,0.00014312885,0.00054422073,0.99662966,0.00036673143,0.00011403858,0.0018557431],"study_design_scores_gemma":[0.0009862056,0.00023616507,0.00007870428,0.000038493763,0.00007589322,0.0000067391366,0.00007324831,0.000050304967,0.9885631,0.0014708445,0.008196315,0.00022395262],"about_ca_topic_score_codex":0.00008100988,"about_ca_topic_score_gemma":0.000043092725,"teacher_disagreement_score":0.015443659,"about_ca_system_score_codex":0.000054159074,"about_ca_system_score_gemma":0.00011705036,"threshold_uncertainty_score":0.7715783},"labels":[],"label_agreement":null},{"id":"W2171369497","doi":"10.1158/1535-7163.mct-14-0208","title":"Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Agilent Technologies","keywords":"Sunitinib; Renal cell carcinoma; Epigenetics; Clear cell renal cell carcinoma; Cancer research; Medicine; Acquired resistance; Oncology; Transient (computer programming); Internal medicine; Pharmacology; Cancer; Biology; Genetics; Gene; Computer science","score_opus":0.025707271109698168,"score_gpt":0.2549107071518875,"score_spread":0.22920343604218935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171369497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98878324,0.0046674255,0.0015543532,0.0009961008,0.000023248876,0.00052904466,0.000021870503,0.0000261953,0.003398504],"genre_scores_gemma":[0.99725825,0.0002755712,0.0007163221,0.0009675397,0.000018194913,0.00007057003,0.000038532544,0.000052889234,0.0006021394],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99859583,0.00014391218,0.00026310585,0.00036985523,0.00033796055,0.00028931786],"domain_scores_gemma":[0.999226,0.00005705039,0.00011228048,0.0003713582,0.0001157276,0.00011760783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012949681,0.00022453739,0.0002895068,0.000117496296,0.00006999812,0.000025296487,0.00007168324,0.000110942194,0.000025505318],"category_scores_gemma":[0.000004264234,0.0001958556,0.000064653716,0.00028548617,0.00008926671,0.00003279122,0.00001160286,0.00019036008,0.000003089299],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024081138,0.0017270076,0.10170598,0.00049105135,0.00039060946,0.00030797286,0.0102440575,0.0015494311,0.87280726,0.000406997,0.00011623991,0.007845264],"study_design_scores_gemma":[0.0066345963,0.0008841153,0.66057533,0.00017578549,0.00063760515,0.0000060482553,0.00013706514,0.0030550791,0.324702,0.00021442144,0.0025902695,0.00038767784],"about_ca_topic_score_codex":0.00011468629,"about_ca_topic_score_gemma":0.00027495594,"teacher_disagreement_score":0.55886936,"about_ca_system_score_codex":0.00025963606,"about_ca_system_score_gemma":0.00011595955,"threshold_uncertainty_score":0.79867595},"labels":[],"label_agreement":null},{"id":"W2171387031","doi":"10.1158/1535-7163.1659.3.12","title":"Camptothecin- and etoposide-induced apoptosis in human leukemia cells is independent of cell death receptor-3 and -4 aggregation but accelerates tumor necrosis factor–related apoptosis-inducing ligand–mediated cell death","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"Institute of Cancer Research; Canadian Institutes of Health Research","keywords":"Camptothecin; TRADD; FADD; Apoptosis; Death domain; Programmed cell death; Biology; Fas receptor; Tumor necrosis factor alpha; Molecular biology; Cell biology; Chemistry; Cancer research; Immunology; Biochemistry; Caspase","score_opus":0.017765968466216912,"score_gpt":0.25370379354166994,"score_spread":0.23593782507545302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171387031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966871,0.0018429988,0.0005492649,0.00006858881,0.00015796887,0.000541074,0.000053733467,0.000020246276,0.00007900214],"genre_scores_gemma":[0.99583375,0.0028221195,0.0006215762,0.00035531458,0.00003894152,0.00004166246,0.0000969508,0.00008027065,0.000109380664],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99801445,0.00008558492,0.00053987204,0.0006734268,0.00028289968,0.00040375767],"domain_scores_gemma":[0.99902016,0.000016216489,0.00034264298,0.0003588688,0.00012904867,0.000133038],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015821861,0.00041002242,0.00038756614,0.00016731379,0.00014642582,0.000073043186,0.000174895,0.00044998445,0.00002001915],"category_scores_gemma":[0.000004752633,0.00040453317,0.000110328576,0.00019959183,0.00005973872,0.00002093403,0.00011226393,0.00025759824,0.0000014488991],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056686145,0.00010065274,0.0024374812,0.00008594376,0.00009081086,0.000002091736,0.00081586494,0.0004886686,0.9946701,0.0000375726,0.000002121196,0.0012120323],"study_design_scores_gemma":[0.0024347112,0.00034450443,0.0021354873,0.000112885224,0.00010542898,0.0000030232811,0.0001750495,0.0002294913,0.9936446,0.00029214314,0.000071951225,0.00045071496],"about_ca_topic_score_codex":0.0011568873,"about_ca_topic_score_gemma":0.00006633208,"teacher_disagreement_score":0.002378025,"about_ca_system_score_codex":0.00019688408,"about_ca_system_score_gemma":0.00020110385,"threshold_uncertainty_score":0.9998407},"labels":[],"label_agreement":null},{"id":"W2172092066","doi":"10.1158/1535-7163.mct-11-0977","title":"O(6)-Methylguanine-DNA Methyltransferase Is a Novel Negative Effector of Invasion in Glioblastoma Multiforme","year":2012,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre; University of Alberta; Montreal Neurological Institute and Hospital","funders":"Alberta Cancer Foundation","keywords":"Glioblastoma; Methyltransferase; O-6-methylguanine-DNA methyltransferase; Temozolomide; Effector; Cancer research; DNA; DNA methyltransferase; Chemistry; Biology; Molecular biology; Genetics; Biochemistry; Methylation","score_opus":0.03053477144979372,"score_gpt":0.31220909533392777,"score_spread":0.28167432388413405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172092066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99283534,0.004407779,0.00089931657,0.0007857908,0.00013596159,0.00075648044,0.00007300613,0.000023132761,0.00008320798],"genre_scores_gemma":[0.99595505,0.0003843324,0.0015028956,0.001871037,0.00004486833,0.00017603952,0.00000738349,0.000049226426,0.000009141989],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99864745,0.00006428988,0.00031818898,0.00023841909,0.00034016516,0.0003914869],"domain_scores_gemma":[0.9992224,0.000113802285,0.000087060216,0.0003195144,0.00010356467,0.00015366025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016869296,0.00025528428,0.00045229544,0.00021132948,0.000027342445,0.000007302371,0.00008139577,0.00012946257,0.0001337796],"category_scores_gemma":[0.000021848386,0.00020516437,0.00019190027,0.00047265436,0.00006791539,0.00007538269,0.000025690562,0.00016407177,0.000015011529],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046296456,0.0013751151,0.047565896,0.00009944465,0.00052638946,0.000028747745,0.0022887103,0.00002240295,0.9373288,0.00009146327,0.00001505484,0.010195009],"study_design_scores_gemma":[0.0055003017,0.00052295,0.036181822,0.00023105557,0.00046527086,0.000012314029,0.00012731671,0.00023558507,0.9556411,0.000025184647,0.0008777457,0.00017938868],"about_ca_topic_score_codex":0.000402616,"about_ca_topic_score_gemma":0.00007741377,"teacher_disagreement_score":0.018312264,"about_ca_system_score_codex":0.00019255775,"about_ca_system_score_gemma":0.00008099496,"threshold_uncertainty_score":0.836636},"labels":[],"label_agreement":null},{"id":"W2172231359","doi":"10.1158/1535-7163.mct-07-2150","title":"Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Neurological Disorders and Stroke; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Protein kinase B; Biology; Kinase; Geldanamycin; Protein kinase A; p38 mitogen-activated protein kinases; PI3K/AKT/mTOR pathway; Synthetic lethality; Signal transduction; Programmed cell death; Molecular biology; Cell biology; Apoptosis; Cancer research; Heat shock protein; Biochemistry; Hsp90; Mutant","score_opus":0.012887109744977344,"score_gpt":0.24512977138803974,"score_spread":0.2322426616430624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172231359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99368507,0.0031140486,0.0026079987,0.00009585783,0.00006326247,0.00022948509,0.000029942985,0.000011354574,0.0001629588],"genre_scores_gemma":[0.99847883,0.00032924805,0.0002676808,0.0005162073,0.00005005387,0.000024480354,0.00004029424,0.000029511737,0.00026372325],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989365,0.000088137895,0.00028860156,0.00030323383,0.000185237,0.00019829773],"domain_scores_gemma":[0.9994755,0.0000056564345,0.00013656817,0.00025213952,0.00007584955,0.000054303036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011815386,0.00017003535,0.00017444184,0.00006285363,0.00007598322,0.0000129442415,0.000121532146,0.00017374552,0.000022174832],"category_scores_gemma":[0.0000059926856,0.00017832282,0.00006471447,0.00014118326,0.00012979799,0.000007186482,0.000050689887,0.00010203568,7.114666e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059173846,0.000066907065,0.00090076163,0.000018657534,0.00003650488,0.0000030235783,0.00009902723,0.00019650585,0.99673027,0.00006871125,0.00014808345,0.0016723548],"study_design_scores_gemma":[0.0006823652,0.0002571198,0.00048086012,0.000027435319,0.000012249075,0.000004247484,0.00001970419,0.00015415071,0.988188,0.000096370626,0.009879931,0.00019755971],"about_ca_topic_score_codex":0.000054362816,"about_ca_topic_score_gemma":0.000034067725,"teacher_disagreement_score":0.009731848,"about_ca_system_score_codex":0.000030879542,"about_ca_system_score_gemma":0.00006210021,"threshold_uncertainty_score":0.72717935},"labels":[],"label_agreement":null},{"id":"W2172727255","doi":"10.1158/1535-7163.mct-15-0679","title":"GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Biotechnology Research Institute","funders":"Ministry of Health and Welfare; Neurosciences Research Foundation","keywords":"Cetuximab; Panitumumab; Epitope; Monoclonal antibody; Antibody; Cancer research; Epidermal growth factor receptor; EGFR inhibitors; Colorectal cancer; Chemistry; Cancer; In vivo; Pharmacology; Receptor; Biology; Medicine; Biochemistry; Immunology; Internal medicine","score_opus":0.02825514190910116,"score_gpt":0.3251876591008646,"score_spread":0.29693251719176345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172727255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99324495,0.001474751,0.00048250062,0.0037935856,0.00015407486,0.0003974405,0.00012222677,0.00007691371,0.00025354995],"genre_scores_gemma":[0.99524015,0.0026577374,0.00024739126,0.0009651871,0.00029028795,0.00003261434,0.000033886194,0.000074559925,0.00045816743],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99790174,0.000109458335,0.0002305456,0.0005673521,0.0005921479,0.0005987832],"domain_scores_gemma":[0.998854,0.00008892067,0.000090442714,0.00044125205,0.0001710277,0.00035439484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023071072,0.00036043455,0.00051016686,0.00014310212,0.00024649565,0.000068843336,0.00017205937,0.00015448214,0.0000690143],"category_scores_gemma":[0.000016407455,0.00021837666,0.000097746524,0.00026652752,0.0004595094,0.00018642834,0.000119713935,0.00033917886,0.0000144849955],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000848933,0.00021023865,0.10510918,0.000104758095,0.0002731674,0.00032680915,0.000159534,0.0000017312706,0.8187978,0.00009763882,0.00001204707,0.074058115],"study_design_scores_gemma":[0.0034412998,0.0013465845,0.21317905,0.0005552665,0.00023168493,0.0000938862,0.00006562025,0.00014983524,0.76906294,0.000051398598,0.011241043,0.0005813712],"about_ca_topic_score_codex":0.0003442977,"about_ca_topic_score_gemma":0.0001144531,"teacher_disagreement_score":0.108069874,"about_ca_system_score_codex":0.00015125776,"about_ca_system_score_gemma":0.00030028386,"threshold_uncertainty_score":0.8905142},"labels":[],"label_agreement":null},{"id":"W2182736412","doi":"10.1158/1535-7163.1525.3.12","title":"Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal General Hospital","funders":"","keywords":"Erythropoietin; Erythropoietin receptor; Cancer research; Cisplatin; Cancer cell; Cell culture; Cancer; Ionizing radiation; Biology; Chemotherapy; Endocrinology; Irradiation; Genetics","score_opus":0.021905567914438085,"score_gpt":0.30706195937927583,"score_spread":0.28515639146483773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2182736412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9333567,0.01900039,0.0015658757,0.043360073,0.00022210921,0.00067695405,0.00003262572,0.0000671951,0.0017180778],"genre_scores_gemma":[0.9769439,0.0032244287,0.008251573,0.010409235,0.00013930033,0.00013582304,0.0000112303205,0.000050071623,0.0008344448],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987576,0.000025876101,0.00023576895,0.00039399447,0.00028227767,0.00030447997],"domain_scores_gemma":[0.9993362,0.000016280897,0.00006873335,0.00026980878,0.00008602208,0.0002229903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000866108,0.0002158782,0.00024324641,0.000062118095,0.0001154013,0.00003731301,0.000069512855,0.00009432459,0.00005485707],"category_scores_gemma":[0.000008490497,0.00019660675,0.000055706514,0.00026109943,0.000041807176,0.000038714017,0.000036056525,0.00012747831,0.000017814564],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071679876,0.00034563628,0.0023886214,0.00022143584,0.00030710245,0.00015333116,0.008016611,0.0018105838,0.9142926,0.00066873705,0.0009814483,0.0700971],"study_design_scores_gemma":[0.004323332,0.00050522,0.0063685244,0.00059935334,0.00033073622,0.000010144188,0.0006780049,0.000014099223,0.90524584,0.00022873929,0.08123971,0.00045631462],"about_ca_topic_score_codex":0.0006311045,"about_ca_topic_score_gemma":0.0005145853,"teacher_disagreement_score":0.08025826,"about_ca_system_score_codex":0.0005550953,"about_ca_system_score_gemma":0.00019427306,"threshold_uncertainty_score":0.8017391},"labels":[],"label_agreement":null},{"id":"W2183162965","doi":"10.1158/1535-7163.mct-04-0137","title":"Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Protein kinase B; PI3K/AKT/mTOR pathway; MAPK/ERK pathway; Cytochrome c; Cell biology; Apoptosis; Kinase; Biology; Signal transduction; Phosphorylation; U937 cell; Jurkat cells; Cancer research; Chemistry; Mitochondrion; Biochemistry; Immunology","score_opus":0.019668314881333755,"score_gpt":0.25963659094923064,"score_spread":0.2399682760678969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2183162965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98207164,0.007584281,0.008724327,0.000975422,0.00006853215,0.00041007975,0.000030897696,0.000017701152,0.00011710301],"genre_scores_gemma":[0.99519193,0.0023490821,0.00027363416,0.0017123519,0.00010774431,0.000060526803,0.00006235314,0.000049442602,0.00019290391],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985736,0.00009891602,0.0002646375,0.00051809556,0.00022738572,0.00031733455],"domain_scores_gemma":[0.99947757,0.000009672607,0.000106962674,0.0002792769,0.000061417326,0.00006513202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016892809,0.0002828028,0.00021091444,0.000038319227,0.00017597311,0.00006520647,0.00015352797,0.00031774412,0.00003671312],"category_scores_gemma":[0.0000017636243,0.0002280927,0.00006811867,0.00014891918,0.00017053718,0.000015413134,0.000041431096,0.00019798352,5.5029625e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000855797,0.000059152997,0.000036544978,0.00003533391,0.00010202354,0.0000017548035,0.000900178,0.0006512065,0.9802316,0.00015376,0.000088772445,0.017654138],"study_design_scores_gemma":[0.0010432182,0.00018225716,0.00014338702,0.000037971415,0.00012638255,0.00001295649,0.00018281347,0.0014803231,0.98706317,0.00069305184,0.008723914,0.00031053176],"about_ca_topic_score_codex":0.00009408955,"about_ca_topic_score_gemma":0.00006221917,"teacher_disagreement_score":0.017343607,"about_ca_system_score_codex":0.00006436169,"about_ca_system_score_gemma":0.00008226249,"threshold_uncertainty_score":0.9301351},"labels":[],"label_agreement":null},{"id":"W2184357820","doi":"10.1158/1535-7163.1343.3.11","title":"Sequence and helicity requirements for the proapoptotic activity of Bax BH3 peptides","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Cytochrome c; Peptide; Apoptosis; Cell biology; Biology; Mitochondrion; Bcl-xL; Programmed cell death; Apoptosome; Bcl-2-associated X protein; Jurkat cells; Bcl-2 family; Biochemistry; Caspase; Caspase 3; Genetics; T cell","score_opus":0.04765989799492853,"score_gpt":0.31908325764797507,"score_spread":0.27142335965304654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2184357820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89011353,0.003606349,0.10519834,0.0004530851,0.00010104816,0.0004748923,0.000020041616,0.0000057316543,0.000026990521],"genre_scores_gemma":[0.9966126,0.0014880856,0.0013115457,0.00036562802,0.000053617576,0.00006612704,0.0000102279155,0.000018118088,0.000074012234],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999406,0.000020379786,0.0001097155,0.00020339656,0.00011303194,0.0001475055],"domain_scores_gemma":[0.9995679,0.000007597765,0.00008414891,0.00023113207,0.000082434526,0.00002673711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011354225,0.00011189409,0.000098154684,0.000014409926,0.00008788131,0.00001377741,0.00010562949,0.00008198123,0.0000020058785],"category_scores_gemma":[0.000006785115,0.00008264137,0.00006703002,0.00005124262,0.000095064664,0.0000037261934,0.00004473721,0.00004153885,1.7452001e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000071569404,0.00003098665,0.0000951359,0.000037139987,0.00010410985,3.4308195e-7,0.000055747336,0.0011403289,0.9758358,0.0006052042,0.0000020415837,0.02202159],"study_design_scores_gemma":[0.0006098858,0.00021194847,0.0009744639,0.00002173015,0.00008573783,0.0000031410432,0.000019607302,0.0005540304,0.99314266,0.0014649141,0.0027988453,0.000113017566],"about_ca_topic_score_codex":0.00007242234,"about_ca_topic_score_gemma":0.000043883963,"teacher_disagreement_score":0.10649911,"about_ca_system_score_codex":0.000018409806,"about_ca_system_score_gemma":0.00007190466,"threshold_uncertainty_score":0.33700174},"labels":[],"label_agreement":null},{"id":"W2187655164","doi":"10.1158/1535-7163.187.4.2","title":"Synergistic antitumor effect of combined use of adenoviral-mediated<i>p53</i>gene transfer and antisense oligodeoxynucleotide targeting<i>clusterin</i>gene in an androgen-independent human prostate cancer model","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"","keywords":"Clusterin; Cancer research; Biology; Genetic enhancement; Prostate cancer; Antisense therapy; Apoptosis; Pharmacology; Cancer; Molecular biology; Oligonucleotide; Gene; Biochemistry","score_opus":0.024208715790543383,"score_gpt":0.3035869524290446,"score_spread":0.2793782366385012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2187655164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921204,0.0048911753,0.0008443478,0.0002315809,0.00009956542,0.0012827914,0.00046905683,0.00005067445,0.000010417986],"genre_scores_gemma":[0.99621516,0.0015626295,0.0008082445,0.0009490134,0.000045984565,0.00014514962,0.00011099336,0.00013029635,0.00003254424],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99729747,0.0002734699,0.00082611915,0.0006079842,0.00046261476,0.00053236086],"domain_scores_gemma":[0.9987396,0.000065270455,0.00018865975,0.0005883979,0.0001864932,0.00023157765],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002912648,0.00045182853,0.0009784803,0.00026443612,0.000056763463,0.000022979955,0.00018021719,0.00019548488,0.000036244863],"category_scores_gemma":[0.000023886272,0.00042914326,0.00015532928,0.000284805,0.0003427043,0.00013749381,0.00010115335,0.00026108947,9.584455e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020232494,0.00039418016,0.060899936,0.00059703604,0.00024604547,0.00033158183,0.00067344063,0.021594016,0.91211456,0.000018647797,0.0000075249063,0.0010997948],"study_design_scores_gemma":[0.008036817,0.0011993651,0.012034824,0.00029843173,0.00082946185,0.000035282665,0.00001896588,0.043191,0.933825,0.000021747474,0.00007506341,0.00043403002],"about_ca_topic_score_codex":0.00027011498,"about_ca_topic_score_gemma":0.00034666478,"teacher_disagreement_score":0.048865113,"about_ca_system_score_codex":0.00016218996,"about_ca_system_score_gemma":0.00018697092,"threshold_uncertainty_score":0.99981606},"labels":[],"label_agreement":null},{"id":"W2202354116","doi":"10.1158/1538-8514.pi3k14-ia05","title":"Abstract IA05: The role of glucose and lipid metabolism in growth and survival of cancer cells","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer cell; Lipid metabolism; Biology; mTORC1; Cancer; Lipogenesis; Cell growth; Carcinogenesis; PI3K/AKT/mTOR pathway; Cancer research; Cell biology; Signal transduction; Biochemistry; Genetics","score_opus":0.014250860325053651,"score_gpt":0.26407760170754646,"score_spread":0.2498267413824928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2202354116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83711785,0.16072723,0.00007668128,0.00018390293,0.0013107386,0.00019270694,0.000074602045,0.0000037330171,0.00031255995],"genre_scores_gemma":[0.96980125,0.028698895,0.000094286384,0.00034614903,0.0009579335,0.000038509945,0.000008950018,0.000031144566,0.00002287808],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989219,0.00008029713,0.00028257907,0.00027622702,0.00020871445,0.00023030111],"domain_scores_gemma":[0.9993187,0.000014983031,0.00015706033,0.00028802163,0.00013467344,0.00008655552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024038876,0.00019101816,0.0003121177,0.000050948962,0.00002423916,0.000013728791,0.00018371179,0.00013495673,0.0000060571992],"category_scores_gemma":[0.000012473572,0.00015210551,0.000071195485,0.00012954988,0.00022897053,0.0000064222677,0.000099696415,0.00012019016,1.7465628e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016622648,0.000046980917,0.003881257,0.000039299353,0.00014807329,1.4489369e-7,0.0004839345,0.00008816924,0.98044693,0.00035940504,0.000043518816,0.014296073],"study_design_scores_gemma":[0.0011302406,0.000052553834,0.01067438,0.000022073815,0.00012033308,0.0000013844634,0.00034309799,0.00003794575,0.85311025,0.00036594164,0.13396186,0.00017990882],"about_ca_topic_score_codex":0.0018625365,"about_ca_topic_score_gemma":0.00074047694,"teacher_disagreement_score":0.13391834,"about_ca_system_score_codex":0.000011632508,"about_ca_system_score_gemma":0.00020600109,"threshold_uncertainty_score":0.6202682},"labels":[],"label_agreement":null},{"id":"W2205644460","doi":"10.1158/1535-7163.mct-15-0409","title":"Translation Inhibition by Rocaglates Is Independent of eIF4E Phosphorylation Status","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Phytochemical compounds biological activities","field":"Biochemistry, Genetics and Molecular Biology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of General Medical Sciences; Canadian Institutes of Health Research","keywords":"EIF4E; Phosphorylation; eIF4A; Protein subunit; Biology; Translation (biology); EIF4G; MAPK/ERK pathway; Initiation factor; Eukaryotic initiation factor; Protein biosynthesis; Cell biology; Eukaryotic translation; Messenger RNA; Cancer research; Molecular biology; Biochemistry; Gene","score_opus":0.034615760157933294,"score_gpt":0.2831360043032137,"score_spread":0.24852024414528037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2205644460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978977,0.010483501,0.009317946,0.00026985412,0.00007457732,0.00018536007,0.000106285646,0.000016400636,0.0005690525],"genre_scores_gemma":[0.99782914,0.0005161365,0.0003588812,0.00089545775,0.000042007923,0.000032576492,0.00026162885,0.000020948664,0.00004324551],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999018,0.00006001957,0.00021335232,0.0002630815,0.00023226216,0.00021329119],"domain_scores_gemma":[0.999458,0.000008596721,0.000118332006,0.00019079274,0.000140805,0.00008348368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000090568625,0.00015761175,0.00015015507,0.00002444873,0.000024979483,0.000014713517,0.000091030226,0.00019366395,0.00001553409],"category_scores_gemma":[0.000009373557,0.00014812249,0.000080605816,0.000100394085,0.00008756011,0.000007778571,0.000036602785,0.000095892865,0.000001868936],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019373934,0.00007938727,0.0012981563,0.000010374907,0.00007990255,5.019802e-7,0.00013610926,0.00009324824,0.98952806,0.000012149631,0.00029260098,0.008275779],"study_design_scores_gemma":[0.00068273104,0.00027729946,0.00018129413,0.000010764027,0.00003355748,0.0000011803045,0.000053845633,0.00019324677,0.97620106,0.001339823,0.020845512,0.00017969978],"about_ca_topic_score_codex":0.00006106751,"about_ca_topic_score_gemma":0.000008100101,"teacher_disagreement_score":0.02055291,"about_ca_system_score_codex":0.000052452422,"about_ca_system_score_gemma":0.000080380036,"threshold_uncertainty_score":0.60402596},"labels":[],"label_agreement":null},{"id":"W2211386458","doi":"","title":"Inhibition of EphA2 receptor tyrosine kinase activity by dasatinib in pancreatic cancer.","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Axon Guidance and Neuronal Signaling","field":"Neuroscience","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Ontario Institute for Cancer Research","funders":"","keywords":"EPH receptor A2; Erythropoietin-producing hepatocellular (Eph) receptor; Dasatinib; Cancer research; Ephrin; Tyrosine kinase; Receptor tyrosine kinase; Pancreatic cancer; Proto-oncogene tyrosine-protein kinase Src; Biology; Autophosphorylation; Cancer; Kinase; Cell biology; Signal transduction; Internal medicine; Medicine; Protein kinase A","score_opus":0.043864998937964986,"score_gpt":0.31923569045112005,"score_spread":0.2753706915131551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2211386458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926967,0.0022031849,0.0037845501,0.00042648884,0.00019886578,0.00030025322,0.0000803009,0.00003564891,0.00027400706],"genre_scores_gemma":[0.99544185,0.0014253093,0.000088865876,0.0028349063,0.0000513174,0.000046135443,0.000003866354,0.0000401209,0.00006761711],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983023,0.00014145204,0.00034546398,0.00040360334,0.00040498702,0.0004022207],"domain_scores_gemma":[0.99927163,0.00014787028,0.00022335364,0.00023540415,0.000048355967,0.00007339278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002636784,0.00020531565,0.0002691993,0.000099949626,0.00006611851,0.000016430933,0.00016333486,0.00009950443,0.00010497438],"category_scores_gemma":[0.000039400322,0.00020721016,0.00007652949,0.00059191114,0.00013370313,0.00012211957,0.00003936008,0.0002463612,0.0000049346927],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024799493,0.00014905306,0.0026255548,0.000036779446,0.000009414588,0.000026195285,0.00018251441,0.00015096072,0.97655606,0.00012343108,0.000040335584,0.019851683],"study_design_scores_gemma":[0.0007266099,0.000091073154,0.0014215225,0.0001306624,0.000026036274,0.0000014472809,0.000020372781,0.00024764054,0.99462,0.0001263175,0.0023804095,0.00020790148],"about_ca_topic_score_codex":0.00045998784,"about_ca_topic_score_gemma":0.00010149369,"teacher_disagreement_score":0.019643782,"about_ca_system_score_codex":0.00017716119,"about_ca_system_score_gemma":0.000093023984,"threshold_uncertainty_score":0.8449786},"labels":[],"label_agreement":null},{"id":"W2216333908","doi":"10.1158/1535-7163.mct-15-0658","title":"Human Leukocyte Antigen–Presented Macrophage Migration Inhibitory Factor Is a Surface Biomarker and Potential Therapeutic Target for Ovarian Cancer","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Macrophage Migration Inhibitory Factor","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Viventia Bio (Canada)","funders":"Stephenson Cancer Center; University of Oklahoma Health Sciences Center; National Institutes of Health; National Institute of Allergy and Infectious Diseases; American Association for Cancer Research","keywords":"Macrophage migration inhibitory factor; Ovarian cancer; Cancer research; Biology; Human leukocyte antigen; Cancer; Immunology; Antigen; Cytokine","score_opus":0.041341736122792065,"score_gpt":0.3067793309965293,"score_spread":0.26543759487373725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2216333908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9387325,0.042823326,0.013184687,0.0016169042,0.0016956645,0.0010935443,0.0006798621,0.00013642645,0.000037086393],"genre_scores_gemma":[0.9944395,0.00035435235,0.0003355739,0.001938206,0.00012366826,0.00017009335,0.00017341465,0.000100962636,0.0023642567],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977774,0.00033242884,0.00048087933,0.00065598043,0.00016178978,0.00059151213],"domain_scores_gemma":[0.9987837,0.000032155844,0.0002665343,0.00043404245,0.00037895917,0.00010459441],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020404409,0.0004608683,0.00042380873,0.00012867317,0.00035251217,0.000103979335,0.0002586055,0.0004602256,0.0005566214],"category_scores_gemma":[0.000008976805,0.00043731552,0.00018893075,0.00020643407,0.00029154154,0.00016112895,0.00008322139,0.00029956765,0.00003029187],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034251396,0.00010087668,0.0033885583,0.000042038362,0.00081302924,0.000010985534,0.0016520548,0.00012657033,0.9869933,0.00007008662,0.0029303154,0.003529636],"study_design_scores_gemma":[0.0039317366,0.00023319027,0.003208681,0.000032630152,0.00019101286,0.000013124544,0.00022300756,0.0006845609,0.8520498,0.00023736652,0.13865598,0.0005388944],"about_ca_topic_score_codex":0.0007771779,"about_ca_topic_score_gemma":0.00017412344,"teacher_disagreement_score":0.13572566,"about_ca_system_score_codex":0.00020969188,"about_ca_system_score_gemma":0.00028683312,"threshold_uncertainty_score":0.99980783},"labels":[],"label_agreement":null},{"id":"W2226081785","doi":"10.1158/1535-7163.mct-15-0282","title":"Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"PARP1; Olaparib; Cancer research; Veliparib; Medicine; In vivo; PARP inhibitor; Poly ADP ribose polymerase; DNA damage; Biology; DNA; Polymerase","score_opus":0.025574440247841997,"score_gpt":0.3001339648040031,"score_spread":0.2745595245561611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2226081785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88615334,0.10536253,0.0008864669,0.005651495,0.000650267,0.00085045607,0.00005482586,0.00019926073,0.00019137037],"genre_scores_gemma":[0.98445326,0.0046498613,0.0011545554,0.007567817,0.0014632117,0.00027824074,0.00004603121,0.00019230833,0.00019472191],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99615777,0.00027818975,0.0007695882,0.0008692767,0.0009686375,0.00095655303],"domain_scores_gemma":[0.99793375,0.00008645508,0.00031470554,0.00078648026,0.00023858945,0.00064002274],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037748567,0.0006726248,0.00083181384,0.000896739,0.00010185324,0.00009556515,0.00029992813,0.0003448438,0.0001242891],"category_scores_gemma":[0.000034176996,0.0006515891,0.00018833674,0.0016917727,0.00017008139,0.00019366718,0.00011903434,0.0007031258,0.000048127342],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017468475,0.0073783216,0.6046704,0.0010521369,0.0021026009,0.008113192,0.0074730576,0.0001990805,0.24684522,0.0034817213,0.0019511435,0.09926465],"study_design_scores_gemma":[0.1710905,0.011942968,0.2196666,0.00046303868,0.0059788725,0.0029789475,0.0012665517,0.0015764964,0.51747733,0.01694399,0.04424937,0.0063653514],"about_ca_topic_score_codex":0.0004535071,"about_ca_topic_score_gemma":0.000044766293,"teacher_disagreement_score":0.3850038,"about_ca_system_score_codex":0.0005493454,"about_ca_system_score_gemma":0.0009011314,"threshold_uncertainty_score":0.99959356},"labels":[],"label_agreement":null},{"id":"W2232682640","doi":"10.1158/1535-7163.813.3.7","title":"Polyamine catabolism in platinum drug action: Interactions between oxaliplatin and the polyamine analogue <i>N</i>1,<i>N</i>11-diethylnorspermine at the level of spermidine/spermine <i>N</i>1-acetyltransferase","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Polyamine Metabolism and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Spermidine; Polyamine; Spermine; Chemistry; Biochemistry; Catabolism; Oxaliplatin; Anticancer drug; Pharmacology; Drug; Enzyme; Biology; Cancer","score_opus":0.047485110370335065,"score_gpt":0.31645435842749275,"score_spread":0.2689692480571577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2232682640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97310024,0.011054539,0.0028276434,0.010869414,0.00021083537,0.00080015016,0.0009381064,0.00001840502,0.00018067776],"genre_scores_gemma":[0.9919344,0.00371025,0.00028433514,0.0019186145,0.0004372349,0.00023168135,0.00041391296,0.00006988365,0.000999654],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977988,0.00018812594,0.00067101984,0.00056091364,0.00031936832,0.00046177412],"domain_scores_gemma":[0.9985146,0.00010542363,0.00024336169,0.00090051314,0.00012178479,0.00011432523],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037915268,0.00043248784,0.0005091583,0.00010851011,0.00026461965,0.000037192334,0.0004931915,0.00014646284,0.000027415506],"category_scores_gemma":[0.000031501237,0.00029988756,0.00021164218,0.00053629,0.00077751937,0.000020009318,0.00022689704,0.00033413264,0.000003795177],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028101538,0.00014552452,0.0041044243,0.000035455934,0.00022898469,0.000005421221,0.0007146558,0.00064168667,0.98611104,0.0012878004,0.00014341343,0.0063005826],"study_design_scores_gemma":[0.0056841886,0.000060458988,0.011389156,0.000049302143,0.00033016346,0.000059379818,0.00028624013,0.000071422655,0.9222119,0.0004037072,0.059009932,0.00044413243],"about_ca_topic_score_codex":0.002719629,"about_ca_topic_score_gemma":0.009239251,"teacher_disagreement_score":0.06389912,"about_ca_system_score_codex":0.00006444462,"about_ca_system_score_gemma":0.00016330868,"threshold_uncertainty_score":0.99994534},"labels":[],"label_agreement":null},{"id":"W2240322070","doi":"10.1158/1538-8514.pi3k14-a46","title":"Abstract A46: Inhibition of PIK3CA with BYL719 can overcome resistance to cetuximab in squamous cell carcinoma of the head and neck (SCCHN)","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cetuximab; Medicine; Oncology; Internal medicine; Epidermal growth factor receptor; EGFR inhibitors; Cancer; Cancer research; Colorectal cancer","score_opus":0.02081037150155034,"score_gpt":0.29531306301326465,"score_spread":0.2745026915117143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240322070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924992,0.0034506244,0.00006282435,0.0017247333,0.000048835635,0.00053339516,0.000067778834,0.0000072346147,0.0016053948],"genre_scores_gemma":[0.9983254,0.000029690267,0.00035351448,0.000983456,0.000014349117,0.000059659134,0.0000075422386,0.000025868347,0.00020049744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913687,0.000025052019,0.00021421375,0.0001831852,0.00027799603,0.00016269053],"domain_scores_gemma":[0.9993472,0.000013579615,0.00011198582,0.00029583796,0.00014649854,0.000084873376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005699503,0.00013292283,0.00023587364,0.00006859586,0.000023595385,0.0000066703983,0.000056616806,0.000051852923,0.000006367551],"category_scores_gemma":[0.00000463587,0.000091752576,0.00004027587,0.00028825522,0.00007299226,0.000028731543,0.000021405505,0.0001010151,3.4476156e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033091593,0.0017284325,0.6453277,0.0011951722,0.00032333154,0.00022452317,0.018790947,0.0018690233,0.32064164,0.0006173013,0.0003858715,0.0055869427],"study_design_scores_gemma":[0.010781318,0.0010242522,0.55927634,0.0005023853,0.0004472653,0.000010152513,0.0007639425,0.00003292406,0.42374983,0.0002576035,0.0029116275,0.00024236146],"about_ca_topic_score_codex":0.0016493172,"about_ca_topic_score_gemma":0.003180767,"teacher_disagreement_score":0.103108205,"about_ca_system_score_codex":0.0002501888,"about_ca_system_score_gemma":0.0004075122,"threshold_uncertainty_score":0.37415615},"labels":[],"label_agreement":null},{"id":"W2241515017","doi":"","title":"Regulation of growth of renal clear cell carcinoma by peroxisome proliferator-activated receptor gamma","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Peroxisome Proliferator-Activated Receptors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Troglitazone; Peroxisome proliferator-activated receptor; Endocrinology; Internal medicine; Receptor; Peroxisome proliferator-activated receptor alpha; Biology; Peroxisome; Chemistry; Biochemistry; Medicine; Nuclear receptor","score_opus":0.010321590877944625,"score_gpt":0.2451649783076107,"score_spread":0.23484338742966607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241515017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99128187,0.002939026,0.00463932,0.000101897276,0.0001805146,0.00040780116,0.000105174004,0.000023932995,0.00032048437],"genre_scores_gemma":[0.9980422,0.00027715514,0.00075149676,0.0003129603,0.00012719883,0.000028409346,0.00018021422,0.000102092235,0.00017823135],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978595,0.00014108229,0.000608,0.0004998679,0.00042802957,0.00046353263],"domain_scores_gemma":[0.9984281,0.000016335725,0.00043823384,0.000500743,0.00047588095,0.00014071858],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031011435,0.0003477707,0.00037133018,0.00013328381,0.000065092776,0.000014137129,0.000337713,0.00042559663,0.00007489983],"category_scores_gemma":[0.000021681673,0.00035130128,0.0001857945,0.00040540876,0.00020786234,0.000013977053,0.00008568279,0.0002210221,0.0000029581956],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001036351,0.00022219564,0.007194739,0.00008976419,0.00019420782,0.000001290993,0.00014563953,0.000058767924,0.98956114,0.00003855652,0.00039845935,0.0010588972],"study_design_scores_gemma":[0.0011588329,0.0006828366,0.0010209313,0.000027615819,0.00006383172,0.0000031073773,0.000060134444,0.000032363976,0.98986256,0.000028980128,0.0067029796,0.00035581997],"about_ca_topic_score_codex":0.000055714838,"about_ca_topic_score_gemma":0.0000054812476,"teacher_disagreement_score":0.0067603923,"about_ca_system_score_codex":0.000092468326,"about_ca_system_score_gemma":0.00020706255,"threshold_uncertainty_score":0.9998939},"labels":[],"label_agreement":null},{"id":"W2242758687","doi":"","title":"Downregulation of XIAP expression induces apoptosis and sensitizes a panel of pediatric tumor cells to cytotoxic agents","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aegera Therapeutics (Canada)","funders":"","keywords":"XIAP; Inhibitor of apoptosis; Cytotoxic T cell; Cancer research; Apoptosis; Programmed cell death; Cancer; Rhabdomyosarcoma; Cancer cell; Biology; Medicine; Immunology; Caspase; Sarcoma; In vitro; Internal medicine; Pathology","score_opus":0.02462555906816942,"score_gpt":0.27633822474735026,"score_spread":0.2517126656791808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242758687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847494,0.0011656653,0.013657212,0.000025429157,0.000099068275,0.0002512941,0.000019740113,0.0000056761983,0.000026515507],"genre_scores_gemma":[0.9973427,0.0004949443,0.0017772111,0.00020163316,0.00009446526,0.000007636119,0.000021731374,0.000022866507,0.000036781978],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991164,0.000029006322,0.00026048068,0.0002373633,0.00018875164,0.00016797539],"domain_scores_gemma":[0.9994414,0.000008756166,0.00016814949,0.00020381201,0.00011262397,0.0000652931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016854476,0.00013766406,0.0001589299,0.000095501295,0.000038634607,0.000007248389,0.000077050834,0.00012132299,0.0000067620153],"category_scores_gemma":[0.00000448429,0.00012690024,0.00006470301,0.00014797838,0.000036334302,0.000003514097,0.000064330285,0.000041134244,3.983564e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010915142,0.000042189287,0.00016803603,0.000049070255,0.00004102729,8.8376584e-7,0.0001648994,0.0006455254,0.99395865,0.000025474004,0.00001323289,0.0047818483],"study_design_scores_gemma":[0.00035268386,0.00016867148,0.0037981735,0.000021925105,0.00007419432,0.0000016378326,0.00007011606,0.00010765459,0.9949034,0.00004551841,0.00031526876,0.0001407563],"about_ca_topic_score_codex":0.000020131096,"about_ca_topic_score_gemma":0.000003930007,"teacher_disagreement_score":0.012593331,"about_ca_system_score_codex":0.0000124255275,"about_ca_system_score_gemma":0.00003270019,"threshold_uncertainty_score":0.5174842},"labels":[],"label_agreement":null},{"id":"W2243992364","doi":"","title":"Functional synergism between IGF-IR tyrosine kinase and NPM-ALK oncogene identifies a novel role of IGF-IR in malignant lymphoma.","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Anaplastic lymphoma kinase; Cancer research; Anaplastic large-cell lymphoma; Lymphoma; Autocrine signalling; Biology; Tyrosine kinase; BCL10; Oncogene; Receptor tyrosine kinase; Cancer; Signal transduction; Cell culture; Internal medicine; Immunology; Medicine; Cell cycle; Lung cancer; Cell biology; Genetics","score_opus":0.01688563241363388,"score_gpt":0.2621212238248602,"score_spread":0.2452355914112263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243992364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9278427,0.06394473,0.0068386267,0.00013896123,0.0005866475,0.00025025095,0.000120916986,0.00001430191,0.000262914],"genre_scores_gemma":[0.993628,0.0037325446,0.00057248265,0.00072036474,0.0007698977,0.000039244525,0.000120385186,0.00006399235,0.000353049],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981373,0.00004816786,0.00048149234,0.0005316303,0.00032814854,0.0004732886],"domain_scores_gemma":[0.99905205,0.000022736465,0.00019010522,0.00043436183,0.00016677377,0.00013400185],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034918636,0.0003162996,0.0003862835,0.00015314909,0.00007379532,0.000030037338,0.00020922105,0.00027539086,0.000018817123],"category_scores_gemma":[0.0000165602,0.0003209266,0.00015778789,0.0002527277,0.0002016304,0.000010179432,0.00014517686,0.00011107864,0.000001839674],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024865428,0.0001403803,0.003046421,0.00003566616,0.00025441265,0.000006688268,0.0001443301,0.00016982343,0.9593747,0.00018574088,0.000066379,0.03632678],"study_design_scores_gemma":[0.0022171312,0.000119194076,0.0373464,0.000051258598,0.00017482704,0.00001694283,0.0001356713,0.0000361249,0.8633479,0.0001831762,0.09601335,0.00035801038],"about_ca_topic_score_codex":0.0005277305,"about_ca_topic_score_gemma":0.00070671167,"teacher_disagreement_score":0.09602681,"about_ca_system_score_codex":0.00007565889,"about_ca_system_score_gemma":0.000286154,"threshold_uncertainty_score":0.9999243},"labels":[],"label_agreement":null},{"id":"W2246998135","doi":"","title":"AZD2171 (Cediranib) is active in first line metastatic renal cell carcinoma (RCC): Interim results of a phase II trial. A trial of the PMH Phase II Consortium.","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Interim analysis; Internal medicine; Phases of clinical research; Renal cell carcinoma; Oncology; Gastroenterology; Neutropenia; Pharmacology; Urology; Surgery; Toxicity; Clinical trial","score_opus":0.06798462123839182,"score_gpt":0.3577161289842715,"score_spread":0.2897315077458797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2246998135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99069726,0.0026293213,0.00052116596,0.0010544333,0.0004208745,0.0033588794,0.00039467102,0.000017169388,0.0009062136],"genre_scores_gemma":[0.9979644,0.00019871694,0.00031589126,0.00076065154,0.00013721442,0.00012307758,0.00004376982,0.00006794143,0.00038838008],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965378,0.00022383942,0.001433485,0.00053118373,0.0007786946,0.00049499766],"domain_scores_gemma":[0.9976105,0.00018461658,0.00083703874,0.0009090086,0.00029732907,0.00016149026],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00066213234,0.00043722196,0.0010190917,0.00027948266,0.00010699359,0.000008735426,0.00030802377,0.00015877717,0.00009034412],"category_scores_gemma":[0.00007730072,0.00031648236,0.00054301077,0.00069064705,0.0002998187,0.000049997027,0.00014820273,0.0004206914,0.0000014222276],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57498807,0.009970502,0.000023301147,0.00014985765,0.0006365476,0.000280615,0.0049818694,0.000030081845,0.392611,0.000012333199,0.00007405263,0.016241794],"study_design_scores_gemma":[0.39003795,0.022847785,0.00005909858,0.00014707465,0.0010766031,0.000011121463,0.00018074365,0.0001634828,0.5830034,0.000031517393,0.0022815603,0.00015965385],"about_ca_topic_score_codex":0.0006830527,"about_ca_topic_score_gemma":0.00028595945,"teacher_disagreement_score":0.19039243,"about_ca_system_score_codex":0.0004226743,"about_ca_system_score_gemma":0.0005822727,"threshold_uncertainty_score":0.9999287},"labels":[],"label_agreement":null},{"id":"W2247744690","doi":"","title":"A monoclonal antibody targeting melanoma-associated chondroitin sulfate proteoglycan demonstrates antitumor activity in human melanoma, ovarian and breast cancer models.","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arius3D (Canada)","funders":"","keywords":"Ovarian cancer; Melanoma; Cancer research; Breast cancer; Chondroitin sulfate proteoglycan; Cancer; Medicine; Metastasis; Immunology; Chondroitin sulfate; Internal medicine; Glycosaminoglycan","score_opus":0.019729038917485755,"score_gpt":0.31578276376009107,"score_spread":0.29605372484260534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247744690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910085,0.002117512,0.004841049,0.0007087005,0.00006441804,0.00069472555,0.00014524673,0.000028191524,0.00039160915],"genre_scores_gemma":[0.9982895,0.0004913477,0.00033640757,0.00032077587,0.00010110998,0.000103080165,0.00013363345,0.00006502518,0.00015911045],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977751,0.00016870277,0.00035830084,0.00062116474,0.00035472788,0.0007220455],"domain_scores_gemma":[0.9991711,0.000012613875,0.00017384543,0.00028333903,0.00019142039,0.00016768665],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006104683,0.00033181187,0.00030542398,0.00016649843,0.00020784872,0.00009003238,0.00024187838,0.00028362684,0.000046792382],"category_scores_gemma":[0.000013191203,0.00033821486,0.00009689989,0.0003500365,0.00016545811,0.00002389977,0.00012629326,0.0003627791,0.0000011269096],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033713385,0.00015011785,0.05270351,0.000032571228,0.00017117603,0.000069362875,0.00008306958,0.0004612895,0.93916684,0.00015966901,0.000009492424,0.006655733],"study_design_scores_gemma":[0.0025436725,0.0002172111,0.14445047,0.00009379487,0.0000507694,0.000032755823,0.00007605018,0.0061596236,0.8445589,0.00038344448,0.0007867101,0.0006466173],"about_ca_topic_score_codex":0.002471729,"about_ca_topic_score_gemma":0.002520958,"teacher_disagreement_score":0.094607994,"about_ca_system_score_codex":0.00012869411,"about_ca_system_score_gemma":0.00024424514,"threshold_uncertainty_score":0.999907},"labels":[],"label_agreement":null},{"id":"W2248318148","doi":"","title":"Response of bladder cancer cells and xenografts to treatment with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and gemcitabine","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Gemcitabine; Apoptosis; Necrosis; Chemistry; Cell culture; Molecular biology; Cytotoxicity; Bladder cancer; Flow cytometry; Medicine; Cancer cell; Cancer; Pharmacology; Cancer research; Pathology; In vitro; Biology; Internal medicine; Biochemistry","score_opus":0.02166410143764098,"score_gpt":0.2942671363975314,"score_spread":0.2726030349598904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248318148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99156976,0.005491788,0.0003199515,0.0012950771,0.00013312795,0.00091671455,0.00012257864,0.00004197713,0.000109042034],"genre_scores_gemma":[0.995288,0.0012157578,0.0006703992,0.0022339888,0.00004199157,0.00009627863,0.0000047445933,0.00008281918,0.00036603448],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99838084,0.000052602398,0.00033392198,0.00047494314,0.00031491087,0.00044278262],"domain_scores_gemma":[0.99904984,0.00006376633,0.00011920426,0.0003245729,0.00013908745,0.00030350412],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013982736,0.0003760432,0.0005159562,0.00018368369,0.00009011516,0.000028885042,0.00006176382,0.0001130465,0.00006456355],"category_scores_gemma":[0.0000034639706,0.00028001203,0.000077924444,0.00036188975,0.0001454967,0.000049632512,0.000029661574,0.00012814818,0.0000018896995],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004924731,0.00023084384,0.015447613,0.000059626793,0.0015130033,0.00006733339,0.003617956,0.000023603845,0.9419995,0.0000057634916,0.000013753309,0.032096274],"study_design_scores_gemma":[0.0053276806,0.0028147432,0.041216604,0.00024469,0.0010170809,0.000027577014,0.0002187816,0.000019659736,0.9452956,0.000010754141,0.0035096416,0.00029721786],"about_ca_topic_score_codex":0.001181058,"about_ca_topic_score_gemma":0.00023205095,"teacher_disagreement_score":0.031799056,"about_ca_system_score_codex":0.0002618974,"about_ca_system_score_gemma":0.0002448494,"threshold_uncertainty_score":0.9999652},"labels":[],"label_agreement":null},{"id":"W2252412663","doi":"","title":"Phase I/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chemokine receptors and signaling","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Juravinski Cancer Centre","funders":"","keywords":"Medicine; CXCR4; Toxicity; CXCR4 antagonist; Metastasis; Internal medicine; Pharmacology; Cancer; Receptor; Oncology; Cancer research; Chemokine","score_opus":0.028047503419849875,"score_gpt":0.3310237124490393,"score_spread":0.3029762090291894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2252412663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99496716,0.0011433875,0.0022355537,0.000091933376,0.00016981231,0.0012083396,0.000020688538,0.000026732898,0.00013640142],"genre_scores_gemma":[0.9983583,0.0001253041,0.00043521848,0.00085919246,0.00004958728,0.00004698686,0.000017306866,0.00007015962,0.00003793558],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979087,0.000022618577,0.00045554503,0.00041255297,0.0007238981,0.00047668826],"domain_scores_gemma":[0.99899846,0.000022038264,0.00023045762,0.00037267184,0.0002388693,0.0001374807],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019962325,0.00030065488,0.0005613012,0.00019180312,0.00006292897,0.000009351875,0.00012239694,0.00009320566,0.00005645767],"category_scores_gemma":[0.0000066379816,0.00024756513,0.000087391265,0.00054855493,0.00007972294,0.000061442675,0.000053434876,0.0002737353,5.4458906e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00913735,0.01728911,0.27947867,0.00024080582,0.001393491,0.000108954235,0.010207008,0.0030971435,0.5233476,0.000019444295,0.000017099861,0.15566328],"study_design_scores_gemma":[0.07631627,0.013568587,0.040231396,0.0008779676,0.00072323385,0.0000043210707,0.001966319,0.0005684135,0.86252874,0.000009354404,0.0024856215,0.0007197653],"about_ca_topic_score_codex":0.00033760018,"about_ca_topic_score_gemma":0.00043649547,"teacher_disagreement_score":0.33918113,"about_ca_system_score_codex":0.00052702875,"about_ca_system_score_gemma":0.0002521229,"threshold_uncertainty_score":0.9999977},"labels":[],"label_agreement":null},{"id":"W2257212963","doi":"","title":"The human cathelicidin, LL-37, kills through activation of the mitochondrial-associated pathway of apoptosis in a caspase-independent manner","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Antimicrobial Peptides and Activities","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of British Columbia","funders":"","keywords":"Jurkat cells; Cathelicidin; Apoptosis; Biology; Cell biology; Caspase; Programmed cell death; DNA fragmentation; Inhibitor of apoptosis domain; Molecular biology; Innate immune system; Immunology; T cell; Immune system; Biochemistry","score_opus":0.018080799101930445,"score_gpt":0.266549425651146,"score_spread":0.24846862654921553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2257212963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964142,0.0014195188,0.00046604918,0.0005117759,0.0004803557,0.00035649838,0.000042227366,0.000012636151,0.0002967286],"genre_scores_gemma":[0.99853075,0.00021280906,0.000024014613,0.0005508091,0.000020038744,0.000016601469,0.000014110529,0.000024956566,0.0006059416],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987751,0.00019407051,0.00041790187,0.0001859465,0.00009167964,0.00033529272],"domain_scores_gemma":[0.9990127,0.00012872895,0.00038896519,0.00034574748,0.00011611478,0.000007756626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025901888,0.00017468906,0.00026413816,0.000038830305,0.00021151117,0.000010506525,0.0003248917,0.00023521036,0.000028458615],"category_scores_gemma":[0.000021200263,0.00011244735,0.00017859881,0.00022806687,0.00031187973,0.000049941533,0.00007949832,0.00029604582,0.0000021294127],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008737528,0.00015780084,0.0010499393,0.00000989135,0.00030205538,6.99235e-7,0.0015474645,0.000075397686,0.99298245,0.0020606644,0.0000789602,0.0016473331],"study_design_scores_gemma":[0.00080503337,0.00006828492,0.003694479,0.00010074495,0.00006254688,0.0000015196403,0.000658077,0.0000011454542,0.9906158,0.00066988205,0.0031938097,0.00012871531],"about_ca_topic_score_codex":0.0022573092,"about_ca_topic_score_gemma":0.0010192087,"teacher_disagreement_score":0.0031148493,"about_ca_system_score_codex":0.00012330218,"about_ca_system_score_gemma":0.00008055542,"threshold_uncertainty_score":0.458547},"labels":[],"label_agreement":null},{"id":"W2263044871","doi":"","title":"Preclinical development of Aneustat (OMN54): a multifunctional multi-targeted natural product derivative with anti-tumor, anti-inflammatory and immuno-modulatory activity","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Click Chemistry and Applications","field":"Chemistry","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Cytotoxic T cell; Immune system; Cancer research; DU145; Cancer; Angiogenesis; Medicine; Immunology; Lung cancer; Cancer cell; Biology; Pharmacology; In vitro; Internal medicine","score_opus":0.026367161400760748,"score_gpt":0.3045943598324489,"score_spread":0.2782271984316882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2263044871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992898,0.0023610399,0.0042214687,0.00007621195,0.000055076034,0.00022110666,0.00003081617,0.000068764,0.00006749965],"genre_scores_gemma":[0.99471515,0.00005337221,0.004807514,0.00011635519,0.00006000577,0.0000664759,0.000038242077,0.000044086697,0.0000987706],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983667,0.000021581549,0.00042380148,0.0005189312,0.00032782127,0.0003411397],"domain_scores_gemma":[0.9988623,0.00009431807,0.00030650917,0.00041669825,0.00022386553,0.00009625832],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020899186,0.00029969373,0.00030935605,0.00003920122,0.0001812502,0.000019116751,0.00018492337,0.00011335258,0.000047032023],"category_scores_gemma":[0.000021392052,0.0002731409,0.000070707596,0.00016989805,0.00031454084,0.000079151454,0.00008137589,0.00042109963,0.0000011930983],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021847988,0.0003168081,0.02790208,0.00019600426,0.0003984734,0.000014669064,0.00046776366,0.000081838305,0.95605415,0.000011982817,0.000002290577,0.014335475],"study_design_scores_gemma":[0.001135664,0.000011974466,0.104141824,0.00007856913,0.00007286327,0.000016958144,0.00012480268,0.00049900566,0.8913445,0.0000064683272,0.0022516032,0.00031576335],"about_ca_topic_score_codex":0.000015597805,"about_ca_topic_score_gemma":0.000024570465,"teacher_disagreement_score":0.07623974,"about_ca_system_score_codex":0.00013226745,"about_ca_system_score_gemma":0.00032317394,"threshold_uncertainty_score":0.9999721},"labels":[],"label_agreement":null},{"id":"W2263916211","doi":"","title":"Role of human CEACAM5 and CEACAM6 in murine lung tumorigenesis","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Carcinogenesis; Carcinoembryonic antigen; Lung; Lung cancer; Cancer research; Genetically modified mouse; Transgene; Biology; Medicine; Internal medicine; Cancer; Immunology; Endocrinology; Gene; Genetics","score_opus":0.022325963629060044,"score_gpt":0.3551653968554965,"score_spread":0.33283943322643644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2263916211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889591,0.00820633,0.00029945213,0.00033199816,0.000013806965,0.00019041328,0.000005433116,0.000017541293,0.0019759554],"genre_scores_gemma":[0.99871194,0.00026261763,0.00024657376,0.0005722455,0.000049987168,0.000019663039,0.000007013807,0.000018474708,0.00011148733],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992699,0.000009819122,0.00022302484,0.00016822114,0.00013862592,0.0001903988],"domain_scores_gemma":[0.9996174,0.000018823222,0.000047199374,0.00018396525,0.000039978346,0.000092624425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012557016,0.00010295125,0.00018106733,0.00004925368,0.000029109997,0.0000038375856,0.00006215132,0.000067935194,0.000042361018],"category_scores_gemma":[0.0000027765457,0.000100221485,0.00004249516,0.00020178087,0.00008771905,0.000014397302,0.000019025323,0.00014852009,5.219541e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052383675,0.00010464613,0.029623292,0.000086291344,0.00005119662,0.000018484721,0.0001210043,0.0000065961435,0.96079624,0.0006001124,0.0000031171242,0.008536628],"study_design_scores_gemma":[0.00079138164,0.000033574535,0.053403474,0.000043296957,0.00012188326,0.0000131413035,0.000112776615,0.00024019959,0.94200325,0.00031817117,0.0028212082,0.00009764363],"about_ca_topic_score_codex":0.000042549855,"about_ca_topic_score_gemma":0.000008047875,"teacher_disagreement_score":0.023780182,"about_ca_system_score_codex":0.00005747034,"about_ca_system_score_gemma":0.000030899857,"threshold_uncertainty_score":0.40869135},"labels":[],"label_agreement":null},{"id":"W2264190290","doi":"","title":"Pharmacokinetics of ARRY-543 from a Phase 1 study in cancer patients","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Pharmacokinetics; Dosing; Medicine; Pharmacology; Animal science; Chemistry; Internal medicine; Biology","score_opus":0.032733211282353625,"score_gpt":0.412456535462635,"score_spread":0.3797233241802814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264190290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932149,0.00403981,0.0006433199,0.0002233949,0.0003019819,0.0010004583,0.00017080871,0.000020760292,0.00038456384],"genre_scores_gemma":[0.9977089,0.00035806984,0.0002297567,0.0013526205,0.00006892904,0.000106222404,0.000055871824,0.000040097446,0.000079523044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987268,0.0000319656,0.00037458714,0.00025835124,0.0003496098,0.00025867886],"domain_scores_gemma":[0.99933785,0.000027344688,0.00012720044,0.00024317372,0.00017238733,0.00009202986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008115506,0.00017940364,0.0003003139,0.00013134954,0.000026598133,0.0000072327816,0.000088660796,0.000059318074,0.00019802642],"category_scores_gemma":[0.000003984046,0.00015783634,0.00007498646,0.0003393838,0.000043751952,0.000031762138,0.000022224729,0.00014170249,0.0000021790654],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093962904,0.008130692,0.78807306,0.000040443905,0.0015282212,0.00014200117,0.005229324,0.0001236751,0.07236354,0.00001333273,0.00004468781,0.12337141],"study_design_scores_gemma":[0.057826135,0.002720356,0.5933349,0.0002864378,0.003913835,0.0000012454556,0.0011346198,0.00036463846,0.3248311,0.00014464908,0.014929721,0.0005123337],"about_ca_topic_score_codex":0.0024158033,"about_ca_topic_score_gemma":0.0006578224,"teacher_disagreement_score":0.25246754,"about_ca_system_score_codex":0.00030741064,"about_ca_system_score_gemma":0.0001859094,"threshold_uncertainty_score":0.6436379},"labels":[],"label_agreement":null},{"id":"W2265903980","doi":"10.1158/1535-7163.223.3.3","title":"Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both<i>in vitro</i>and<i>in vivo</i>","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Hospital and Health Sciences Centre; University of British Columbia","funders":"National Cancer Institute; Canadian Prostate Cancer Research Initiative","keywords":"Clusterin; Cancer research; Paclitaxel; Lung cancer; In vivo; A549 cell; Gene silencing; Apoptosis; Cancer; Small interfering RNA; Biology; Medicine; Molecular biology; Pharmacology; Cell culture; Pathology; Transfection; Internal medicine; Biochemistry","score_opus":0.016024994268128576,"score_gpt":0.28029237430567666,"score_spread":0.26426738003754807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2265903980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854716,0.007621903,0.0019807355,0.0036346451,0.0001872646,0.0007193097,0.000037256406,0.00009147218,0.00025583454],"genre_scores_gemma":[0.98676705,0.00022316384,0.0020402232,0.010570395,0.00009637724,0.00010048926,0.000011215833,0.0001226465,0.000068418936],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99781275,0.00013789322,0.0005028383,0.00060281553,0.00030313156,0.0006405492],"domain_scores_gemma":[0.99914336,0.00005274136,0.00012550276,0.0004723661,0.000057024135,0.00014897926],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023903303,0.00038420202,0.00055144547,0.0002279464,0.00007394754,0.00003249697,0.00016027362,0.00019047922,0.00008192778],"category_scores_gemma":[0.000009213427,0.00036961894,0.00014707129,0.00027604014,0.00022991556,0.000050403065,0.000095615134,0.0003246403,0.0000051202414],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007228353,0.00016820442,0.008935673,0.00019226709,0.00007383744,0.0011403606,0.0007033985,0.00065761793,0.98636335,0.000036466154,0.000012105344,0.0009938815],"study_design_scores_gemma":[0.008626861,0.00012461733,0.0116105825,0.00039400242,0.00015118867,0.000040547904,0.00015794522,0.0008725185,0.9762476,0.00040067683,0.0008884603,0.00048499243],"about_ca_topic_score_codex":0.00016601098,"about_ca_topic_score_gemma":0.00007345094,"teacher_disagreement_score":0.0101157455,"about_ca_system_score_codex":0.00049472856,"about_ca_system_score_gemma":0.00017720376,"threshold_uncertainty_score":0.9998756},"labels":[],"label_agreement":null},{"id":"W2266099825","doi":"","title":"Synthetic Lethal Approaches to the Treatment of Cancers with DNA Repair Defects","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Cancer; Breast cancer; DNA repair; BRCA2 Protein; Biology; Ovarian cancer; Gene; Genetics; Synthetic lethality; Cancer research; Allele; Homologous recombination; Mutation; Prostate cancer; Germline mutation","score_opus":0.08739391783872785,"score_gpt":0.31216636897644845,"score_spread":0.2247724511377206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2266099825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9698834,0.009700249,0.01266639,0.0033716694,0.00022771406,0.0013598026,0.000026705531,0.00011677654,0.002647334],"genre_scores_gemma":[0.993804,0.0005571847,0.0017495271,0.003111938,0.00017359109,0.000266419,0.000006009737,0.000072595074,0.00025877566],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99837136,0.00006183443,0.000291908,0.00038496745,0.00047297784,0.00041696776],"domain_scores_gemma":[0.99880093,0.000069362715,0.00012250502,0.00075641205,0.00009888165,0.00015188355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023241472,0.0002738999,0.00036565706,0.00011007116,0.00008301656,0.0000102565955,0.00012810779,0.00009069512,0.0000532697],"category_scores_gemma":[0.0000034397597,0.00017090277,0.0002137581,0.0004623541,0.00019925556,0.000021844884,0.000011004613,0.00011562793,0.0000073664855],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01659324,0.0028374356,0.037582703,0.0005651118,0.009505501,0.0009775481,0.029077945,0.01770492,0.55014426,0.00528969,0.0005948246,0.32912683],"study_design_scores_gemma":[0.0030751943,0.003216078,0.0040775407,0.00023080023,0.0007438092,0.000088780005,0.00052533124,0.00022889761,0.84586453,0.00007682304,0.1415427,0.00032949998],"about_ca_topic_score_codex":0.00024545295,"about_ca_topic_score_gemma":0.000344685,"teacher_disagreement_score":0.32879734,"about_ca_system_score_codex":0.00090610713,"about_ca_system_score_gemma":0.00035794615,"threshold_uncertainty_score":0.6969213},"labels":[],"label_agreement":null},{"id":"W2266877858","doi":"","title":"Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin.","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Propidium iodide; Melanoma; In vivo; Doxorubicin; In vitro; Apoptosis; Cancer research; Annexin; Pharmacology; MTT assay; Medicine; Chemistry; Chemotherapy; Molecular biology; Biology; Programmed cell death; Biochemistry; Internal medicine","score_opus":0.006366709458148614,"score_gpt":0.2506000983877784,"score_spread":0.2442333889296298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2266877858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763886,0.013810653,0.009219651,0.0000488007,0.0000365571,0.00020272461,0.000033983633,0.0000067635697,0.0002522751],"genre_scores_gemma":[0.9981946,0.00082657597,0.00037764438,0.00042778003,0.00001514368,0.000010610852,0.00004768547,0.000027666356,0.00007230151],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99913126,0.00006194557,0.00022735822,0.00022802579,0.00014854938,0.00020285985],"domain_scores_gemma":[0.99934214,0.000032352207,0.00015946751,0.00025239598,0.00015832324,0.000055319055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001329461,0.00017131442,0.00021684263,0.000059767735,0.000041156713,0.000008065445,0.000111809786,0.0001096821,0.000004423751],"category_scores_gemma":[0.0000074296618,0.0001460321,0.000058219866,0.00013517257,0.00015599169,0.0000043420214,0.00003358771,0.000068230656,2.7921325e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025891053,0.0001505328,0.010774717,0.000050746894,0.00035354786,0.000008214332,0.0001274304,0.00001590247,0.97575027,0.00009764514,0.000020808855,0.012391259],"study_design_scores_gemma":[0.0013893114,0.0009942497,0.005885795,0.000056676527,0.00015484978,0.000010230334,0.00009633676,0.00007042917,0.9904986,0.000056910852,0.0006173369,0.00016925881],"about_ca_topic_score_codex":0.00018097008,"about_ca_topic_score_gemma":0.000057247016,"teacher_disagreement_score":0.021806,"about_ca_system_score_codex":0.000011452735,"about_ca_system_score_gemma":0.0000559081,"threshold_uncertainty_score":0.59550154},"labels":[],"label_agreement":null},{"id":"W2268021342","doi":"","title":"Tissue factor pathway inhibitor (TFPI) interferes with endothelial cell migration via ERK parthway and proteins involved in focal complexes","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Blood Coagulation and Thrombosis Mechanisms","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"Tissue factor pathway inhibitor; Endothelial stem cell; Cell biology; Focal adhesion; Tissue factor; Biology; Angiogenesis; Cell adhesion; Molecular biology; Chemistry; Cell; Phosphorylation; Biochemistry; Coagulation; Cancer research; In vitro; Internal medicine","score_opus":0.029682458290878577,"score_gpt":0.28060840924240793,"score_spread":0.25092595095152936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2268021342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9294178,0.0012585991,0.06754348,0.00054728816,0.00011590381,0.0009020791,0.000022043487,0.000058367008,0.00013443275],"genre_scores_gemma":[0.996267,0.000074359996,0.001962299,0.001398785,0.000102478436,0.00005682115,0.000022588927,0.00004803358,0.000067642206],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99876493,0.000059454946,0.0002885431,0.0003001279,0.00029471685,0.00029220048],"domain_scores_gemma":[0.99946123,0.000023431394,0.00009718259,0.00021223124,0.00008596204,0.000119962206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012077826,0.00022961744,0.00029815428,0.00012945174,0.000052180156,0.000032554883,0.0000631082,0.00013668594,0.000054014497],"category_scores_gemma":[0.0000031167535,0.00018736157,0.000039933242,0.00018176601,0.00008036532,0.000058710473,0.000025874302,0.00021609187,0.0000042942133],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004099353,0.00022098619,0.0047693294,0.00006458374,0.00006532354,0.00004038586,0.001114979,0.0000072566486,0.9617396,0.0003271092,0.0000021966507,0.03123834],"study_design_scores_gemma":[0.0027076686,0.00096481136,0.0059419987,0.00012912128,0.000055511275,0.000008234705,0.00019722518,0.00031042803,0.98341185,0.00023072002,0.0058203144,0.00022210272],"about_ca_topic_score_codex":0.00021254404,"about_ca_topic_score_gemma":0.0030372965,"teacher_disagreement_score":0.06684919,"about_ca_system_score_codex":0.00008230137,"about_ca_system_score_gemma":0.00009451593,"threshold_uncertainty_score":0.7640383},"labels":[],"label_agreement":null},{"id":"W2268487266","doi":"","title":"Classification of anticancer drugs based on tissue penetration using a novel in vitro screening assay","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"3D Printing in Biomedical Research","field":"Engineering","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Spheroid; Penetration (warfare); Drug; Tissue culture; In vivo; Cancer research; In vitro; Pharmacology; Biology; Biochemistry; Genetics","score_opus":0.05429729239070638,"score_gpt":0.3505192375143022,"score_spread":0.2962219451235958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2268487266","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30079833,0.00027474036,0.6977645,0.00012547578,0.00010256278,0.00017240705,0.0000066694224,0.000041769556,0.0007135567],"genre_scores_gemma":[0.97845197,0.00002555778,0.021197263,0.00021759713,0.000041183725,0.0000109037455,0.000008426659,0.000041881958,0.000005197389],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986024,0.000041174648,0.00029051324,0.00017856655,0.000574742,0.00031261562],"domain_scores_gemma":[0.9994355,0.00014070031,0.00005193086,0.00023878721,0.000075838754,0.00005728374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008814295,0.0001270031,0.00014846788,0.00025266354,0.000025034855,0.000018320958,0.00016093938,0.00012377504,0.000026233885],"category_scores_gemma":[0.00003119263,0.00013679735,0.000036440273,0.0005519854,0.000067087916,0.00003758559,0.000014476177,0.0002580255,0.0000014634351],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005434731,0.00003595169,0.0005418098,0.00004687851,0.00002139978,0.0000024510148,0.00008682916,0.041153237,0.8751019,0.00008809788,8.0694457e-7,0.08286629],"study_design_scores_gemma":[0.00030789635,0.000015062979,0.005214872,0.00006699866,0.000009622117,2.2321166e-7,0.000018706554,0.46042407,0.53327054,0.000017014228,0.0005656691,0.00008932982],"about_ca_topic_score_codex":0.00009491935,"about_ca_topic_score_gemma":0.000017554961,"teacher_disagreement_score":0.6776537,"about_ca_system_score_codex":0.00025700053,"about_ca_system_score_gemma":0.00007123017,"threshold_uncertainty_score":0.5578434},"labels":[],"label_agreement":null},{"id":"W2269231033","doi":"","title":"Toxicology and pharmacokinetics of chimeric ARH460-16-2, a therapeutic monoclonal antibody targeting CD44","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arius3D (Canada)","funders":"","keywords":"Monoclonal antibody; Prostate; Cancer; Biology; Antibody; CD44; Medicine; Colorectal cancer; Pathology; Cancer research; Immunology; Internal medicine; In vitro","score_opus":0.02094923130325893,"score_gpt":0.3477244181047692,"score_spread":0.32677518680151024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2269231033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93331003,0.018184276,0.046754286,0.0003402212,0.0001569011,0.00037170466,0.00001949213,0.000016526597,0.0008465411],"genre_scores_gemma":[0.99441355,0.0023217425,0.0012422998,0.0015576178,0.00013278473,0.000020574513,0.00006491685,0.00004828684,0.00019824658],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984248,0.00010185794,0.0003487573,0.00037998438,0.00028402513,0.000460528],"domain_scores_gemma":[0.99924695,0.00002410049,0.00014556068,0.00027683884,0.0001863917,0.000120145036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039868592,0.00022778123,0.00022704032,0.00010942671,0.00008443387,0.00002019192,0.00022155415,0.00018966613,0.00008747179],"category_scores_gemma":[0.000017467346,0.00022152784,0.00009993144,0.00024292375,0.00022546068,0.000004715899,0.00011971693,0.00019405174,0.0000026319276],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026140304,0.000093671624,0.004915567,0.00003670953,0.00023087322,0.0000096462145,0.000069881746,0.00010103234,0.9574148,0.00021149985,0.00003827991,0.036616612],"study_design_scores_gemma":[0.0010576455,0.00036859693,0.0036786895,0.00001221989,0.00006301214,0.000016954478,0.000071946204,0.0004034557,0.9386175,0.00016893596,0.05528245,0.0002585472],"about_ca_topic_score_codex":0.000043061318,"about_ca_topic_score_gemma":0.000023936256,"teacher_disagreement_score":0.061103478,"about_ca_system_score_codex":0.00003115266,"about_ca_system_score_gemma":0.00011269405,"threshold_uncertainty_score":0.9033643},"labels":[],"label_agreement":null},{"id":"W2269888391","doi":"","title":"Intrinsic resistance of prostate cancer to the BH3 mimetic ABT-737 is related to expression of the anti-apoptotic Mcl-1 and additional survival and apoptosis regulating pathways","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Click Chemistry and Applications","field":"Chemistry","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"DU145; LNCaP; Apoptosis; Cytotoxic T cell; Viability assay; Cytotoxicity; Cancer research; Prostate cancer; Pharmacology; Chemistry; Cell culture; Cancer; Biology; In vitro; Medicine; Internal medicine; Biochemistry","score_opus":0.016595383567970697,"score_gpt":0.26639896176410943,"score_spread":0.24980357819613874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2269888391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99460614,0.0013301532,0.00010849205,0.0023622822,0.00004047476,0.0002418141,0.0008200772,0.000019784096,0.0004707981],"genre_scores_gemma":[0.9984731,0.00019837612,0.00035128286,0.00044413254,0.000035414323,0.000097206175,0.000019872983,0.000027752974,0.00035287184],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99874216,0.000026397147,0.00037387232,0.0003140504,0.0003133994,0.00023012502],"domain_scores_gemma":[0.998919,0.00015154504,0.00021513365,0.0004728419,0.00016086835,0.00008057327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017056263,0.00017416033,0.00020728083,0.00002544087,0.00017659995,0.000018358463,0.00023061065,0.00009819032,0.00017698594],"category_scores_gemma":[0.000034001125,0.00012745927,0.00006379801,0.00036843918,0.000158282,0.000024154657,0.00013393993,0.00018059893,5.397978e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006882323,0.000035196597,0.001262007,0.00014072678,0.00006474848,3.2719782e-7,0.0012550587,0.00013747826,0.99289167,0.00023700132,0.00026961352,0.003637324],"study_design_scores_gemma":[0.00030157235,0.000008555396,0.0037290684,0.0004398662,0.00007993575,0.0000013542694,0.00031254502,0.0000382036,0.98716766,0.00038182834,0.0073860483,0.00015334981],"about_ca_topic_score_codex":0.0000427725,"about_ca_topic_score_gemma":0.00003687683,"teacher_disagreement_score":0.0071164346,"about_ca_system_score_codex":0.000056714307,"about_ca_system_score_gemma":0.000065970635,"threshold_uncertainty_score":0.5197638},"labels":[],"label_agreement":null},{"id":"W2270912873","doi":"","title":"Low BRCA1 and ERCC1 mRNA expression correlates with improved survival in ovarian cancer patients","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"ERCC1; Ovarian cancer; Oncology; Chemotherapy; Internal medicine; Stage (stratigraphy); Medicine; Biology; Cisplatin; Cancer; Survival analysis; Cancer research; Nucleotide excision repair; DNA repair; Gene","score_opus":0.012970336250718879,"score_gpt":0.2731652375159512,"score_spread":0.2601949012652323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2270912873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99141526,0.0052830023,0.0008662525,0.0009404404,0.00034279973,0.00071279146,0.000027637983,0.00002914536,0.00038264817],"genre_scores_gemma":[0.99595696,0.0016055618,0.00046076044,0.0016214502,0.00007339399,0.00012157005,0.000021336109,0.000060097464,0.000078844954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985851,0.00003467386,0.00026556605,0.00041495598,0.00029593482,0.00040373913],"domain_scores_gemma":[0.9993071,0.00003969406,0.00010728469,0.00027209954,0.00011757644,0.00015625448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013466831,0.00026323803,0.000339317,0.00010280886,0.000058545873,0.000027493463,0.00006867443,0.00013713482,0.000071781455],"category_scores_gemma":[0.0000039849933,0.0001982703,0.000052388845,0.00024165321,0.00007250514,0.000057231067,0.000033473996,0.00022491776,0.0000017285611],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012517498,0.000810156,0.86421674,0.000092809554,0.00041771313,0.00017347987,0.000783595,0.0000492208,0.07109612,0.00006865558,0.000019230483,0.06102051],"study_design_scores_gemma":[0.012071599,0.0007926026,0.6852244,0.00078796444,0.00039822297,0.0000064653045,0.00011131781,0.00020090964,0.297885,0.00006073023,0.0020710935,0.00038971336],"about_ca_topic_score_codex":0.00079588295,"about_ca_topic_score_gemma":0.0009405267,"teacher_disagreement_score":0.22678886,"about_ca_system_score_codex":0.00033740947,"about_ca_system_score_gemma":0.00016107297,"threshold_uncertainty_score":0.8085228},"labels":[],"label_agreement":null},{"id":"W2271878792","doi":"","title":"Identification and characterization of an antibody to the CD9 tetraspanin: Therapeutic implications for cancer treatment.","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arius3D (Canada)","funders":"","keywords":"Biology; Antibody; Tetraspanin; Cancer research; Cytotoxicity; Pancreatic cancer; Cancer; Epitope; Cancer cell; Molecular biology; Flow cytometry; Monoclonal antibody; In vivo; Cell culture; In vitro; Cell; Immunology; Biochemistry","score_opus":0.04728039646817933,"score_gpt":0.39538664588847505,"score_spread":0.3481062494202957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2271878792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89180297,0.0014560435,0.09681315,0.007975059,0.00007983169,0.0017061868,0.00010782961,0.000026852222,0.00003210313],"genre_scores_gemma":[0.99559945,0.0013736859,0.00031528773,0.0017260958,0.00009242198,0.00034201812,0.00013960681,0.000050315535,0.00036112647],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988762,0.000045613397,0.00029382235,0.00030719498,0.00020908193,0.00026810117],"domain_scores_gemma":[0.9988987,0.000052249332,0.000112804424,0.0004915624,0.00032191374,0.00012277284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002556139,0.00015337481,0.00019891912,0.00013791339,0.00012615643,0.000034146135,0.00013878466,0.000079479956,0.000020979329],"category_scores_gemma":[0.000008046856,0.00011224916,0.000073206305,0.00038237183,0.00007645447,0.0000598576,0.000020152134,0.00007362571,0.0000018752794],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018005025,0.000127262,0.0035434368,0.00003131444,0.00013927443,8.6664164e-7,0.00038674023,0.000011499592,0.81044126,0.00040823786,0.0000016956301,0.18472838],"study_design_scores_gemma":[0.00071895873,0.00044252275,0.25980842,0.000024800884,0.00027334163,0.00000680104,0.000069561655,0.0006577423,0.7194205,0.0001340065,0.018325483,0.00011785943],"about_ca_topic_score_codex":0.00009612155,"about_ca_topic_score_gemma":0.00011545048,"teacher_disagreement_score":0.25626498,"about_ca_system_score_codex":0.00015028914,"about_ca_system_score_gemma":0.00014537614,"threshold_uncertainty_score":0.4577388},"labels":[],"label_agreement":null},{"id":"W2275335512","doi":"10.1158/1538-8514.tumang15-b02","title":"Abstract B02: Ultrasound evaluation of anti-angiogenic therapy on patient-derived renal cell carcinoma xenograft tumors in the chicken embryo model","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"MRI in cancer diagnosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Matrigel; Medicine; Ultrasound; Chorioallantoic membrane; Angiogenesis; In ovo; Pathology; Urology; Embryo; Cancer research; Radiology; Biology","score_opus":0.08660705833989239,"score_gpt":0.3308428850847941,"score_spread":0.24423582674490169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275335512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874768,0.008401998,0.0001332571,0.0012851168,0.00014119243,0.0013234142,0.000044958666,0.00002243406,0.0011707823],"genre_scores_gemma":[0.99510443,0.0009697136,0.00020323676,0.003246069,0.00007051006,0.00028430787,0.0000465596,0.000068112124,0.000007061487],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996965,0.00026769243,0.00048117116,0.00039610598,0.0015128399,0.00037718052],"domain_scores_gemma":[0.99834025,0.00009471504,0.00026931718,0.000765879,0.00041944862,0.0001103657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083296787,0.00030825552,0.0003942779,0.00018351554,0.000046505615,0.000026187568,0.00030308394,0.00014618327,0.000065425666],"category_scores_gemma":[0.000020599859,0.00023154775,0.00022097038,0.00043019888,0.0001160585,0.00005969877,0.000020679743,0.00032108635,0.000006492686],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064689654,0.0010011162,0.014705681,0.00006149949,0.000272514,0.000040364674,0.0116831735,0.06480725,0.89213234,0.00003139713,0.0006507948,0.013967001],"study_design_scores_gemma":[0.0072466843,0.00096440036,0.08527999,0.00016565583,0.00056357915,0.000016174525,0.0008806174,0.010237446,0.89292294,0.00061280356,0.00069575437,0.00041395225],"about_ca_topic_score_codex":0.00043982756,"about_ca_topic_score_gemma":0.00006527287,"teacher_disagreement_score":0.070574306,"about_ca_system_score_codex":0.0003954087,"about_ca_system_score_gemma":0.00085785124,"threshold_uncertainty_score":0.9442243},"labels":[],"label_agreement":null},{"id":"W2275754697","doi":"","title":"High-throughput screening for compounds toxic to human leukemic cells derived from lineage-depleted cord blood cells","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Leukemia; Haematopoiesis; Stem cell; Cancer research; Cancer cell; Biology; Cancer stem cell; Progenitor cell; Population; Cord blood; Cancer; Cell culture; Immunology; Cell biology; Medicine; Genetics","score_opus":0.0304658265468354,"score_gpt":0.29905569904048346,"score_spread":0.2685898724936481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275754697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6428696,0.0018163375,0.35330415,0.0001552661,0.000731812,0.00070698734,0.0003046501,0.00005499538,0.000056206885],"genre_scores_gemma":[0.9582776,0.00032149855,0.02869601,0.01083567,0.00081648206,0.0001409826,0.0004010487,0.00021216576,0.00029857602],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99728155,0.00006396303,0.00055705913,0.0009154966,0.00033433028,0.00084757106],"domain_scores_gemma":[0.99838036,0.00004005877,0.0002276474,0.00084400765,0.00024358646,0.00026435722],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003112213,0.0005189511,0.00045608127,0.00010830277,0.00027378905,0.00009836106,0.00057944003,0.00037979364,0.000035898644],"category_scores_gemma":[0.0000045235265,0.00057219417,0.00030657835,0.00023001108,0.00009242932,0.000007004803,0.00018107002,0.00022427722,0.000007182186],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006177773,0.00012515536,0.000025943355,0.00002061844,0.0007506744,0.000014866705,0.00012933438,0.0005578911,0.9881295,0.00016575833,0.00019766328,0.009264837],"study_design_scores_gemma":[0.0026695859,0.0010383026,0.000093817536,0.00004259488,0.00039342183,0.0000032657426,0.00008286816,0.00012302828,0.9256293,0.00029832224,0.068940766,0.0006847168],"about_ca_topic_score_codex":0.00046496198,"about_ca_topic_score_gemma":0.00052625797,"teacher_disagreement_score":0.32460815,"about_ca_system_score_codex":0.0001076359,"about_ca_system_score_gemma":0.00014653814,"threshold_uncertainty_score":0.99967295},"labels":[],"label_agreement":null},{"id":"W2277059326","doi":"","title":"OB-24, a novel selective and potent HO-1 inhibitor, induces a wide spectrum anti-tumor activity in vitro and in vivo and synergizes with chemotherapy drugs","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Heme Oxygenase-1 and Carbon Monoxide","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Cancer research; In vivo; Cancer; Prostate cancer; Colorectal cancer; Pharmacology; Melanoma; Cancer cell; Growth inhibition; Heme oxygenase; Biology; Medicine; In vitro; Heme; Internal medicine; Enzyme; Biochemistry","score_opus":0.007345860065743424,"score_gpt":0.23728908646897937,"score_spread":0.22994322640323595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2277059326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935121,0.004430564,0.0010058656,0.0005512485,0.00004021203,0.0003367718,0.00001708492,0.000010992688,0.00009517242],"genre_scores_gemma":[0.9961547,0.0015532941,0.00041851655,0.0017070206,0.00005215463,0.000033927863,0.000003530386,0.000049418104,0.000027397306],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985937,0.000053039,0.00019589711,0.000556513,0.00016812477,0.0004327591],"domain_scores_gemma":[0.99954075,0.000021872766,0.00009159441,0.0001995386,0.00003536031,0.000110907706],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024682138,0.00030178612,0.0003001596,0.00012285807,0.000050203053,0.000043904864,0.00008330024,0.00016344372,0.0000012301521],"category_scores_gemma":[0.0000068611776,0.00027556883,0.000034803666,0.00022835097,0.00017447758,0.000012645426,0.00006415742,0.00022467342,7.161166e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009963588,0.00011865002,0.008529625,0.000026936701,0.00010968182,0.000041520325,0.0003741595,0.000018289697,0.98501605,0.000008318927,0.0000033832655,0.0047570113],"study_design_scores_gemma":[0.002401682,0.00023277283,0.025630133,0.000045339846,0.000028371018,0.000029212086,0.00022825219,0.00009498102,0.9699832,0.000042438285,0.00092726044,0.0003563614],"about_ca_topic_score_codex":0.0003733391,"about_ca_topic_score_gemma":0.0008571309,"teacher_disagreement_score":0.01710051,"about_ca_system_score_codex":0.00006478608,"about_ca_system_score_gemma":0.000119803946,"threshold_uncertainty_score":0.99996966},"labels":[],"label_agreement":null},{"id":"W2278657612","doi":"10.1158/1535-7163.mct-15-0581","title":"The Role of HMGB1 in Radioresistance of Bladder Cancer","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced Glycation End Products research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Radioresistance; Gene knockdown; Bladder cancer; Autophagy; Radiation therapy; Cancer research; HMGB1; In vivo; Medicine; Cancer; Radiosensitivity; Biology; Pathology; Cell culture; Internal medicine; Apoptosis; Inflammation","score_opus":0.025624099766628394,"score_gpt":0.33314411984246783,"score_spread":0.30752002007583945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2278657612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85888404,0.13636877,0.0020641661,0.000876335,0.00017081169,0.00037666177,0.000058112182,0.000007314046,0.0011938064],"genre_scores_gemma":[0.994543,0.004349209,0.00044626568,0.00016464444,0.00006011641,0.00007002926,0.000011210645,0.000027082218,0.00032840954],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989483,0.00012103863,0.00022976432,0.00022390063,0.00026325686,0.00021374217],"domain_scores_gemma":[0.99897146,0.0000115613675,0.00011725506,0.00051542686,0.00032602143,0.00005824775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025095625,0.00010633058,0.00012990617,0.000034943136,0.000026399008,0.0000069874627,0.00033461745,0.00007426704,0.000008979814],"category_scores_gemma":[0.000035847945,0.000085501095,0.00004099023,0.00021200099,0.00018914403,0.000005318365,0.000054569595,0.000092881026,6.506595e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002702507,0.00005705146,0.0038324725,0.000011368412,0.000092048955,8.777288e-7,0.00020300549,0.003914207,0.95444953,0.0007425048,0.000045050187,0.036381647],"study_design_scores_gemma":[0.00042648296,0.00011013446,0.0007902329,0.000010994414,0.00001372685,7.60506e-7,0.00023129563,0.00022737753,0.8743602,0.0013846611,0.12234304,0.00010110578],"about_ca_topic_score_codex":0.00016986892,"about_ca_topic_score_gemma":0.00035697495,"teacher_disagreement_score":0.13565901,"about_ca_system_score_codex":0.00003776016,"about_ca_system_score_gemma":0.00035618903,"threshold_uncertainty_score":0.34866333},"labels":[],"label_agreement":null},{"id":"W2278671746","doi":"","title":"Targeted approach towards inhibition of telomere-hnRNP A1 interaction","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA and Nucleic Acid Chemistry","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Biotechnology Research Institute","funders":"","keywords":"Telomere; Telomerase; Small molecule; DNA; Oligonucleotide; Biology; In vitro; Molecular biology; G-quadruplex; Computational biology; Biochemistry; Chemistry; Gene","score_opus":0.016234604581357986,"score_gpt":0.2819143588097175,"score_spread":0.2656797542283595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2278671746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96071774,0.0021163963,0.029944412,0.00008226656,0.00018174763,0.00013144691,0.000020466912,0.000020213838,0.006785329],"genre_scores_gemma":[0.9968647,0.00026671524,0.0016709962,0.0006682032,0.0001603788,0.00001477095,0.00014121714,0.00003982262,0.00017319988],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99893624,0.000026361948,0.00027558042,0.0002985201,0.00020451492,0.00025879862],"domain_scores_gemma":[0.9993243,0.000003858477,0.00014688882,0.00032569974,0.00013285165,0.00006636876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017148776,0.00018428742,0.00016178378,0.000047838246,0.00004006015,0.000011829227,0.00013936801,0.00022041734,0.00003068748],"category_scores_gemma":[0.000009095953,0.00018385466,0.00013239597,0.00015017239,0.000094618226,0.0000050569633,0.00006244156,0.00013608443,0.0000021082478],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016732217,0.00010668122,0.0003649615,0.000045036522,0.00015049435,0.000004257001,0.00007753095,0.00007721265,0.98015153,0.000057497295,0.00010975875,0.018687688],"study_design_scores_gemma":[0.0004724841,0.000099189645,0.0005174292,0.000016890504,0.000055625358,0.000010857586,0.00017497949,0.000079174824,0.98051083,0.00007079178,0.017786546,0.00020517662],"about_ca_topic_score_codex":0.000029621047,"about_ca_topic_score_gemma":0.0000054425395,"teacher_disagreement_score":0.036146976,"about_ca_system_score_codex":0.000042728512,"about_ca_system_score_gemma":0.00006825455,"threshold_uncertainty_score":0.7497375},"labels":[],"label_agreement":null},{"id":"W2279192913","doi":"","title":"Vinorelbine liposomes injection results in greater tumor drug exposure compared to conventional vinorelbine in tumor-bearing nude mice","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Vinorelbine; Pharmacokinetics; Pharmacology; Liposome; Chemistry; Volume of distribution; Internal medicine; Medicine; Chemotherapy; Biochemistry","score_opus":0.026983872306910076,"score_gpt":0.3224996452426178,"score_spread":0.29551577293570774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2279192913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99329334,0.0020844259,0.00013077202,0.0023681668,0.0005263956,0.00080130354,0.000027884333,0.000055312856,0.00071241293],"genre_scores_gemma":[0.9931006,0.00007157784,0.00032650062,0.0053993077,0.00021075025,0.000109875196,0.0000765538,0.00004960946,0.0006552648],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980141,0.00008056829,0.0005876554,0.0004746339,0.00032275863,0.000520282],"domain_scores_gemma":[0.9993143,0.00005261324,0.00012034347,0.00024661052,0.00011157528,0.00015457114],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034628567,0.0002882031,0.00043749824,0.00046974016,0.000047349487,0.000019851925,0.00012763699,0.00007805754,0.00012716312],"category_scores_gemma":[0.000009532198,0.00028221213,0.000111830006,0.00067225494,0.000060113536,0.000058781945,0.000053090378,0.0003565507,0.000020949274],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015622984,0.0013047094,0.47123104,0.00017871174,0.0005379473,0.0022567012,0.004397351,0.0033349968,0.4933022,0.00009961497,0.0006459402,0.0070878053],"study_design_scores_gemma":[0.023115082,0.0010251432,0.6322303,0.00046313007,0.00032982032,0.0001806413,0.00037548578,0.00079563115,0.32483825,0.00012855414,0.015924042,0.0005939654],"about_ca_topic_score_codex":0.0019005644,"about_ca_topic_score_gemma":0.003939634,"teacher_disagreement_score":0.16846396,"about_ca_system_score_codex":0.00078939286,"about_ca_system_score_gemma":0.00016174794,"threshold_uncertainty_score":0.999963},"labels":[],"label_agreement":null},{"id":"W2279288073","doi":"10.1158/1535-7163.targ-09-cn08-01","title":"Abstract CN08-01: 3D-QSAR based design of novel inhibitors of topoisomerase II","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba","funders":"","keywords":"Quantitative structure–activity relationship; Chemistry; Steric effects; Stereochemistry; Ligand (biochemistry); Topoisomerase; Computational biology; Computational chemistry; DNA; Biology; Biochemistry","score_opus":0.02881427801376997,"score_gpt":0.2823049288345023,"score_spread":0.25349065082073235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2279288073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7210731,0.00886236,0.26779753,0.0006298543,0.00043002004,0.0006718832,0.00014821764,0.000027526874,0.00035955396],"genre_scores_gemma":[0.9894114,0.00063577376,0.007077857,0.0026000207,0.00010762815,0.000024952216,0.000038680006,0.00004899298,0.000054661567],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99845207,0.000040788214,0.00046679252,0.00038847447,0.00031041334,0.00034147385],"domain_scores_gemma":[0.99881357,0.000012510512,0.0003052784,0.00058790983,0.00019016747,0.00009057036],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021276771,0.00029801563,0.0003397111,0.00009594331,0.00006966651,0.000011738395,0.00031822085,0.0002342315,0.000045758017],"category_scores_gemma":[0.0000070816272,0.00029921357,0.00022205715,0.00020455949,0.00009732893,0.00000552611,0.000046884088,0.00013121813,6.466667e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035892602,0.0004265864,0.000030724157,0.000032500557,0.00018253709,0.0000029087018,0.00008434087,0.010682926,0.9671259,0.00022701999,0.000032343498,0.020813277],"study_design_scores_gemma":[0.0017535422,0.0010555233,0.00020477216,0.00006235519,0.00012227875,0.0000023066389,0.000028611472,0.0014456974,0.98596686,0.00019544955,0.008838725,0.0003238831],"about_ca_topic_score_codex":0.000046947018,"about_ca_topic_score_gemma":0.00000957071,"teacher_disagreement_score":0.26833838,"about_ca_system_score_codex":0.000039328123,"about_ca_system_score_gemma":0.00030627113,"threshold_uncertainty_score":0.999946},"labels":[],"label_agreement":null},{"id":"W2279294031","doi":"10.1158/1535-7163.mct-15-0714-t","title":"High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Metformin; Medicine; PTEN; Bladder cancer; Cancer; Urothelium; Drug; Cancer research; Urinary system; Pharmacology; PI3K/AKT/mTOR pathway; Internal medicine; Biology; Insulin; Apoptosis","score_opus":0.01740349267522202,"score_gpt":0.259092171826959,"score_spread":0.24168867915173697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2279294031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819282,0.014033482,0.002518323,0.0002617241,0.00015626244,0.0003567502,0.0007160476,0.000010624346,0.000018543593],"genre_scores_gemma":[0.9926994,0.005410085,0.00021453296,0.0012448535,0.000096262476,0.000073598356,0.00003895085,0.000059586135,0.00016271904],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998252,0.0001873744,0.0003696386,0.00044636763,0.00034105917,0.0004036035],"domain_scores_gemma":[0.9990368,0.000014801229,0.00017206278,0.00040344847,0.00026877635,0.00010412362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000285315,0.00028402408,0.00044127053,0.000057523062,0.00003084156,0.000009867452,0.0001738907,0.0001692464,0.000077445475],"category_scores_gemma":[0.000006916681,0.00021942274,0.000115722476,0.00022208955,0.00011693778,0.000019009893,0.00003089652,0.000089498055,4.915735e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004010337,0.00016787497,0.0028709585,0.000023113442,0.00042260453,0.000003255981,0.00041399553,0.004147698,0.96234727,0.000108605,0.000028485085,0.029065084],"study_design_scores_gemma":[0.0019771454,0.00020443487,0.0033677467,0.000083509505,0.00021406078,4.925688e-7,0.000028939274,0.0008911732,0.99156255,0.00009877328,0.0012346369,0.00033654226],"about_ca_topic_score_codex":0.00075136375,"about_ca_topic_score_gemma":0.0046683406,"teacher_disagreement_score":0.029215254,"about_ca_system_score_codex":0.00008391075,"about_ca_system_score_gemma":0.00034923616,"threshold_uncertainty_score":0.89478},"labels":[],"label_agreement":null},{"id":"W2281114779","doi":"10.1158/1535-7163.823.3.7","title":"Role of the transcription factor Ets-1 in cisplatin resistance","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chemotherapy-induced organ toxicity mitigation","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Transcription factor; Cisplatin; Biology; Genetics; Cancer research; Gene","score_opus":0.01929336701741016,"score_gpt":0.2754516404099668,"score_spread":0.25615827339255665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281114779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99187416,0.0023478917,0.00070450956,0.004113873,0.00006921173,0.00040971927,0.000014867779,0.000022494303,0.0004432715],"genre_scores_gemma":[0.99732846,0.0001587138,0.00052601006,0.0018120849,0.000028739052,0.000017314635,0.0000033445942,0.000034765395,0.00009054004],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990594,0.000038910806,0.000243856,0.0001771635,0.00031298245,0.00016770251],"domain_scores_gemma":[0.9994773,0.000009087559,0.00009553221,0.00032100276,0.00006361528,0.00003345873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006267443,0.00012796598,0.00018604421,0.000059032358,0.000028051027,0.000006882518,0.00011390409,0.00011387417,0.0000398392],"category_scores_gemma":[0.000008010394,0.0001041721,0.000103927836,0.0003609406,0.000070821116,0.00003785301,0.00000820827,0.00021556685,0.0000018409454],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009970751,0.00008271876,0.0022438439,0.00004038584,0.00004529093,0.0000024378442,0.0020501202,0.00014490075,0.99047506,0.0004007168,0.0000015151174,0.004413303],"study_design_scores_gemma":[0.0017820603,0.000036965364,0.047845747,0.00020737013,0.000046865414,0.0000026283344,0.000107765554,0.000032616263,0.94637,0.0024053191,0.0010670495,0.00009559687],"about_ca_topic_score_codex":0.0001028699,"about_ca_topic_score_gemma":0.0006003535,"teacher_disagreement_score":0.045601904,"about_ca_system_score_codex":0.00031849626,"about_ca_system_score_gemma":0.00019040778,"threshold_uncertainty_score":0.42480147},"labels":[],"label_agreement":null},{"id":"W2281508145","doi":"","title":"Novel strategy for targeted photodynamic therapy of breast cancer using a chlorin e6 conjugated-aptamer","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced biosensing and bioanalysis techniques","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Aptamer; Systematic evolution of ligands by exponential enrichment; MUC1; Oligonucleotide; Cancer research; Cancer; Breast cancer; Photodynamic therapy; Cancer cell; Biology; Molecular biology; Chemistry; Antigen; Immunology; DNA; Biochemistry; Gene","score_opus":0.031668987847209625,"score_gpt":0.3352866331948813,"score_spread":0.30361764534767166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281508145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.896949,0.0042133033,0.0977162,0.00010094303,0.00011887847,0.0004368019,0.00039386417,0.00003714718,0.000033891924],"genre_scores_gemma":[0.99101585,0.002194298,0.005382305,0.0010056281,0.0001516312,0.000035121648,0.00008699116,0.00007501529,0.000053148564],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99847996,0.000026570564,0.00039407206,0.00045465745,0.00020205822,0.00044269164],"domain_scores_gemma":[0.9988594,0.000011455792,0.00027481501,0.00039032937,0.00038860302,0.00007538177],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022761352,0.00031138147,0.00032330284,0.00009516277,0.00008416448,0.000018767774,0.00021732337,0.00025765653,0.000006261139],"category_scores_gemma":[0.0000041640733,0.00027908664,0.00025685178,0.00026359933,0.0001869149,0.0000059852728,0.00003888963,0.00011557479,1.2978562e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063369976,0.00012585786,0.00021842148,0.000018642346,0.00056479947,0.0000022068994,0.000021189016,0.0006178327,0.9771058,0.000040478863,0.0000090407675,0.020642014],"study_design_scores_gemma":[0.0010379521,0.00021022292,0.00056042685,0.000037670008,0.000119330114,0.000015595311,0.000060175724,0.0012417883,0.9930747,0.00005649137,0.0032193505,0.0003662889],"about_ca_topic_score_codex":0.00035319882,"about_ca_topic_score_gemma":0.00019804855,"teacher_disagreement_score":0.09406689,"about_ca_system_score_codex":0.000071217066,"about_ca_system_score_gemma":0.00018343386,"threshold_uncertainty_score":0.99996614},"labels":[],"label_agreement":null},{"id":"W2282235435","doi":"","title":"A new brain delivery system for therapeutic molecules to treat brain primary or metastatic tumors","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Angiochem (Canada); Université du Québec à Montréal","funders":"","keywords":"Paclitaxel; In vivo; Blood–brain barrier; Pharmacology; Brain tumor; Drug delivery; Medicine; P-glycoprotein; In vitro; Glioma; Cytotoxicity; Monoclonal antibody; Pharmacokinetics; Parenchyma; Cancer research; Cancer; Chemistry; Pathology; Immunology; Antibody; Central nervous system; Drug resistance; Internal medicine; Biology; Multiple drug resistance","score_opus":0.028217966232193838,"score_gpt":0.2905396133293675,"score_spread":0.26232164709717365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2282235435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5972494,0.0034649228,0.3927153,0.0037920042,0.00043565282,0.0017251085,0.00013117035,0.00032438978,0.0001620381],"genre_scores_gemma":[0.9245573,0.000031350937,0.036128014,0.03685576,0.00025867514,0.00038093008,0.000026630369,0.0002612502,0.001500052],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99623656,0.00025488113,0.0007609286,0.0008399186,0.0007319822,0.0011757081],"domain_scores_gemma":[0.9975499,0.0007112037,0.00023745658,0.0008094288,0.00023345332,0.00045857936],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011621339,0.0005489719,0.00064470625,0.00027326524,0.0002147081,0.00019456442,0.00070398604,0.00012147558,0.0001342849],"category_scores_gemma":[0.000042693537,0.00046563052,0.0002545015,0.0007131288,0.00009875321,0.00018430213,0.00011627016,0.00014933212,0.00012871891],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016578779,0.0001043793,0.000023229084,0.00025018826,0.00011991416,0.00021544144,0.0005590502,0.0012974384,0.9483708,0.00091948605,0.0009828974,0.04549929],"study_design_scores_gemma":[0.0024026765,0.0006265562,0.000116587114,0.00018666478,0.0003504927,0.00004903304,0.00038477196,0.00056237576,0.98377335,0.00028149795,0.010593967,0.0006720327],"about_ca_topic_score_codex":0.00034801982,"about_ca_topic_score_gemma":0.00018774028,"teacher_disagreement_score":0.3565873,"about_ca_system_score_codex":0.0007948319,"about_ca_system_score_gemma":0.0008243806,"threshold_uncertainty_score":0.9997795},"labels":[],"label_agreement":null},{"id":"W2282899483","doi":"10.1158/1535-7163.mct-15-0862","title":"<i>In Vitro</i> and <i>In Vivo</i> Studies of a New Class of Anticancer Molecules for Targeted Radiotherapy of Cancer","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Free Radicals and Antioxidants","field":"Chemistry","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of Waterloo","funders":"Canadian Institutes of Health Research; Ontario Ministry of Research and Innovation; Natural Sciences and Engineering Research Council of Canada; Ontario Ministry of Research, Innovation and Science","keywords":"In vivo; Radiation therapy; Cancer; Cancer research; In vitro; Medicine; Ovarian cancer; Cancer cell; Head and neck cancer; Lung cancer; Radiosensitizer; Pharmacology; Oncology; Biology; Internal medicine; Biochemistry; Genetics","score_opus":0.02413943694141593,"score_gpt":0.31119714807880317,"score_spread":0.2870577111373872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2282899483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88465494,0.112246916,0.0011736492,0.0012767765,0.00008589096,0.00018600267,0.0003096595,0.000008300405,0.000057862577],"genre_scores_gemma":[0.9621608,0.035479803,0.0014370596,0.00054936693,0.00005009251,0.00006536264,8.6176937e-7,0.000047819292,0.00020879549],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99860674,0.000026081017,0.0005416561,0.00029256396,0.00023546598,0.00029749423],"domain_scores_gemma":[0.99917203,0.00011895648,0.00028591693,0.00025819155,0.00011286515,0.00005203062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010998925,0.00021540237,0.00065641815,0.00008616729,0.000012989593,0.0000035029088,0.00018844154,0.00012286038,0.000076544886],"category_scores_gemma":[0.000016691563,0.00016322562,0.00012941666,0.00019858513,0.0003226991,0.000050542076,0.000028730969,0.000071476294,4.389111e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063491584,0.00010310494,0.0030305218,0.0004953422,0.0004077411,0.0000043734767,0.00031461398,0.0000668653,0.9763276,0.00021827467,0.00008889135,0.018307732],"study_design_scores_gemma":[0.003362103,0.00005150712,0.00020397062,0.00061967655,0.0000813383,7.167798e-7,0.00006725214,0.0002692677,0.9887974,0.00078909675,0.0055664866,0.0001911557],"about_ca_topic_score_codex":0.00045528513,"about_ca_topic_score_gemma":0.0002387828,"teacher_disagreement_score":0.0775059,"about_ca_system_score_codex":0.00008991922,"about_ca_system_score_gemma":0.00018674119,"threshold_uncertainty_score":0.6656147},"labels":[],"label_agreement":null},{"id":"W2283778444","doi":"","title":"A phase I and pharmacokinetic (PK) study of vinorelbine liposomes injection in patients with advanced solid tumors, non-Hodgkin’s lymphoma, and Hodgkin’s disease","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Vinorelbine; Pharmacokinetics; Medicine; Pharmacology; Lymphoma; Drug; In vivo; Paclitaxel; Internal medicine; Oncology; Cancer; Chemotherapy; Biology","score_opus":0.0105058140867031,"score_gpt":0.3312848075388701,"score_spread":0.320778993452167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2283778444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99389434,0.004250157,0.00009957784,0.00011285139,0.00011438578,0.0014443594,0.000027154189,0.000022007182,0.000035176115],"genre_scores_gemma":[0.9984949,0.00049706304,0.00008671275,0.0006697413,0.000042969245,0.00010598513,0.000026227544,0.000044240693,0.00003215699],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987128,0.000046181405,0.0003188448,0.00036034067,0.0002671528,0.00029470836],"domain_scores_gemma":[0.99934447,0.000028867478,0.00014416689,0.000186873,0.00011161133,0.0001839951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000085573505,0.00025956583,0.00041369573,0.00022831828,0.000045419245,0.000009501456,0.000052460535,0.000047233607,0.000025053965],"category_scores_gemma":[0.000002762832,0.00021729727,0.000034367415,0.00030685458,0.00010408834,0.00006291895,0.0000362007,0.000110766785,2.9476178e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023205683,0.010792258,0.69823974,0.0002004638,0.0007663028,0.00028990424,0.0026816286,0.00015405456,0.040246192,0.0000037759337,0.000009251569,0.22341076],"study_design_scores_gemma":[0.08386487,0.013241177,0.8804952,0.00016591689,0.001398627,0.000010348818,0.00030154205,0.0004256725,0.019383434,0.000019632287,0.00038226772,0.0003113342],"about_ca_topic_score_codex":0.00021087019,"about_ca_topic_score_gemma":0.00019663872,"teacher_disagreement_score":0.22309943,"about_ca_system_score_codex":0.00016537412,"about_ca_system_score_gemma":0.00010765856,"threshold_uncertainty_score":0.8861126},"labels":[],"label_agreement":null},{"id":"W2291176625","doi":"10.1158/1535-7163.mct-15-0730","title":"Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":309,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"Venetoclax; Multiple myeloma; Bortezomib; Cancer research; Bcl-xL; Lenalidomide; Medicine; Pharmacology; Biology; Leukemia; Apoptosis; Immunology; Programmed cell death; Chronic lymphocytic leukemia; Genetics","score_opus":0.05085372977947655,"score_gpt":0.3446252469714147,"score_spread":0.29377151719193817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2291176625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889454,0.0034097044,0.0018963291,0.003294719,0.00007429583,0.0020101673,0.00018308342,0.000038734623,0.00014756432],"genre_scores_gemma":[0.9965779,0.0009420507,0.0006395005,0.0007512691,0.000050893326,0.0006091215,0.000009765876,0.00004224913,0.00037721253],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978141,0.00038962826,0.00031514623,0.0004559638,0.0005171629,0.00050796306],"domain_scores_gemma":[0.9988443,0.00028821427,0.000090864494,0.00036193224,0.00017424824,0.00024038588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003700398,0.00025195372,0.00036277025,0.00014374459,0.000112999856,0.000017837001,0.00019211399,0.00013836344,0.000050207873],"category_scores_gemma":[0.00009257448,0.00013686102,0.00008222678,0.00031724034,0.00019606644,0.000076250784,0.00013153513,0.0002168082,0.000008895876],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013356276,0.00026021167,0.010489531,0.000041299143,0.00025651263,0.00013152395,0.0007045269,0.00017007378,0.93771106,0.000013032439,0.0001872851,0.03667867],"study_design_scores_gemma":[0.010217612,0.0012726269,0.047980227,0.00039113665,0.00013537926,0.000024067427,0.00010053314,0.0065126163,0.9279104,0.00016059815,0.0050722645,0.00022257665],"about_ca_topic_score_codex":0.00011004788,"about_ca_topic_score_gemma":0.00004856081,"teacher_disagreement_score":0.037490696,"about_ca_system_score_codex":0.00044189522,"about_ca_system_score_gemma":0.00041106733,"threshold_uncertainty_score":0.5581031},"labels":[],"label_agreement":null},{"id":"W2291631976","doi":"10.1158/1538-8514.pi3k14-ia10","title":"Abstract IA10: Nuclear PTEN in regulation of genome integrity","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"PTEN; Cowden syndrome; Cancer research; PI3K/AKT/mTOR pathway; Phosphatase; Germline; Cancer; Biology; DNA repair; DNA damage; Medicine; Phosphorylation; Cell biology; Genetics; DNA; Signal transduction; Gene","score_opus":0.04323157160202021,"score_gpt":0.3042399501044616,"score_spread":0.2610083785024414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2291631976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920477,0.0043436363,0.0012972069,0.00029502902,0.00022278269,0.00018965435,0.000031706448,0.000013705535,0.0015585808],"genre_scores_gemma":[0.9980873,0.00018450984,0.0007027652,0.0007220294,0.00012113401,0.000017147328,0.000044975666,0.000049797047,0.00007034051],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987032,0.000080209604,0.00035930527,0.0003314429,0.00028531265,0.00024056899],"domain_scores_gemma":[0.9990348,0.0000066720922,0.00017868905,0.0004931416,0.00020776923,0.00007888505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037176054,0.00018038975,0.00021897911,0.000068331974,0.000019592142,0.000017097476,0.00029919343,0.00023047402,0.0000637193],"category_scores_gemma":[0.000026687969,0.00018263159,0.00010375382,0.00016392105,0.00009841112,0.0000059771037,0.000072736126,0.00019748164,0.000007976106],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019034784,0.00006497043,0.0022898258,0.000021101121,0.0000945478,0.0000046438354,0.00022058014,0.003382596,0.9892171,0.00013955295,0.00011562816,0.0042590788],"study_design_scores_gemma":[0.0027096213,0.00040113335,0.0386654,0.000083119805,0.00007993985,0.000008963784,0.0002071311,0.0011726299,0.8488974,0.0014628182,0.10566934,0.0006425212],"about_ca_topic_score_codex":0.0001746138,"about_ca_topic_score_gemma":0.00006685608,"teacher_disagreement_score":0.14031975,"about_ca_system_score_codex":0.00011856639,"about_ca_system_score_gemma":0.00021852147,"threshold_uncertainty_score":0.74474996},"labels":[],"label_agreement":null},{"id":"W2293000497","doi":"10.1158/1535-7163.mct-15-0003","title":"Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"The Scarborough Hospital; SGS (Canada)","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Pancreatic cancer; STAT3; Cancer research; In vivo; Cancer cell; STAT protein; In vitro; Tumor microenvironment; Kinome; Cancer; Growth inhibition; Chemistry; Medicine; Kinase; Biology; Signal transduction; Cell biology; Internal medicine; Biochemistry; Tumor cells","score_opus":0.03599202423389613,"score_gpt":0.29278891903306714,"score_spread":0.256796894799171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2293000497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769052,0.005772151,0.012251731,0.0030434045,0.0001553057,0.0014146601,0.00009314985,0.000073123054,0.0002912642],"genre_scores_gemma":[0.994923,0.0014243321,0.00049246004,0.0017709096,0.00013358574,0.0008232259,0.0000067767514,0.00010014447,0.0003255895],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99826336,0.00008838549,0.00046484626,0.00042080865,0.00037795433,0.00038462548],"domain_scores_gemma":[0.99906695,0.000052908836,0.00018108217,0.00031610744,0.00022844927,0.00015451493],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001173406,0.00034228188,0.0004689149,0.00014980312,0.00009898377,0.000026726984,0.000115139,0.0001645545,0.00040795677],"category_scores_gemma":[0.000006153856,0.0002482831,0.00022851216,0.00025141006,0.00018306103,0.00009218566,0.000016783504,0.0002551585,0.0000041721855],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004889874,0.00017234046,0.0007022721,0.00017301129,0.0007266618,0.000017243827,0.0006982742,0.000012432833,0.9363592,0.0002371952,0.000008064019,0.0604043],"study_design_scores_gemma":[0.0021521193,0.0004853047,0.00026233905,0.0010312776,0.0007652254,0.000022478558,0.00016539801,0.00015652826,0.9796985,0.0002488317,0.014699196,0.0003128031],"about_ca_topic_score_codex":0.0004278543,"about_ca_topic_score_gemma":0.0000451412,"teacher_disagreement_score":0.060091496,"about_ca_system_score_codex":0.00016308621,"about_ca_system_score_gemma":0.00034813516,"threshold_uncertainty_score":0.99999696},"labels":[],"label_agreement":null},{"id":"W2299417213","doi":"10.1158/1535-7163.mct-15-0843","title":"An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":432,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University College of the North","funders":"","keywords":"Cancer; In vivo; Combination therapy; Cancer cell; Pharmacology; Medicine; Computational biology; Cancer therapy; Drug; Cancer research; Cancer treatment; Biology; Internal medicine; Genetics","score_opus":0.03619010624958395,"score_gpt":0.3574481275927425,"score_spread":0.32125802134315856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2299417213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7615134,0.00039771566,0.23421001,0.002436335,0.00027172198,0.0003532871,0.000062391475,0.000036266993,0.000718889],"genre_scores_gemma":[0.9941135,0.000108502856,0.0013699448,0.0038887367,0.00013479711,0.00006854275,0.00008963313,0.0000365254,0.00018981323],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99889195,0.00009797918,0.00020808096,0.00036074003,0.00019383972,0.0002474025],"domain_scores_gemma":[0.9991863,0.000008816042,0.000088535555,0.00041478992,0.00018147474,0.00012009787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015567121,0.00017268934,0.00013926008,0.00006675508,0.00007781714,0.00006529698,0.0002848188,0.00016985547,0.000041621828],"category_scores_gemma":[0.000011114441,0.00014087603,0.00006543916,0.00012271926,0.00008681051,0.000016503738,0.000053763248,0.000060900482,0.00001710071],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000093907154,0.00013745474,0.00020180171,0.0000035791572,0.00007125629,0.0000032231865,0.000040023737,0.00006266639,0.9744848,0.001530322,0.00022784747,0.023143137],"study_design_scores_gemma":[0.0012624945,0.00065880665,0.0017525513,0.00002024566,0.000027295197,0.0000052148803,0.00008044876,0.00005197941,0.8664481,0.0003502244,0.12909068,0.00025195823],"about_ca_topic_score_codex":0.00006616182,"about_ca_topic_score_gemma":0.00013068486,"teacher_disagreement_score":0.23284006,"about_ca_system_score_codex":0.00008091458,"about_ca_system_score_gemma":0.00021503717,"threshold_uncertainty_score":0.57447577},"labels":[],"label_agreement":null},{"id":"W2304807948","doi":"10.1158/1538-8514.tumang15-b05","title":"Abstract B05: An immune modulatory role for the Fes protein tyrosine kinase","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Cell biology; Signal transduction; Biology; Immune system; Receptor; Tyrosine kinase; Cancer research; Immunology; Biochemistry","score_opus":0.035565328596908204,"score_gpt":0.2956219460281028,"score_spread":0.2600566174311946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2304807948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8511099,0.14268453,0.002322421,0.0013930607,0.0009797759,0.001029121,0.00007134386,0.00010406054,0.00030576868],"genre_scores_gemma":[0.99639,0.0001315178,0.00010529272,0.001075044,0.00005216853,0.00029774755,0.000042700103,0.000050803596,0.0018547422],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989294,0.00014646398,0.00024893717,0.00024185043,0.000057577035,0.00037578825],"domain_scores_gemma":[0.99910676,0.00004628604,0.000105871564,0.0005355589,0.00017572589,0.000029787805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031710477,0.00021933038,0.00021768142,0.000050153718,0.00018669319,0.00003839106,0.00039803924,0.00019246542,0.00012827084],"category_scores_gemma":[0.000021770806,0.00015605187,0.00013724052,0.00007609052,0.00019831231,0.000077156656,0.000053992786,0.00024904904,0.000064815606],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008962335,0.00012399565,0.00002253959,0.000010360592,0.0003325436,0.0000027334686,0.0005507207,0.00007923714,0.96031284,0.000784254,0.00014645506,0.036738068],"study_design_scores_gemma":[0.0012926563,0.00033789928,0.0010065049,0.000026609474,0.00007856728,0.000007784784,0.0004592008,0.00008914586,0.8254777,0.00032087104,0.17070465,0.00019839496],"about_ca_topic_score_codex":0.00027002004,"about_ca_topic_score_gemma":0.0000300019,"teacher_disagreement_score":0.17055818,"about_ca_system_score_codex":0.00008243829,"about_ca_system_score_gemma":0.00019053191,"threshold_uncertainty_score":0.63636106},"labels":[],"label_agreement":null},{"id":"W2305209678","doi":"","title":"Activity of signaling pathways in hypoxic pancreatic and cervical tumor xenografts","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Angiogenesis; In vivo; Metastasis; Hypoxia (environmental); Cancer research; Immunofluorescence; Pancreatic cancer; Tumor hypoxia; Biology; Pathology; Chemistry; Cancer; Antibody; Internal medicine; Immunology; Medicine; Radiation therapy","score_opus":0.019635694739866698,"score_gpt":0.2690314652262114,"score_spread":0.2493957704863447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2305209678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768742,0.019250074,0.0030437207,0.00004925115,0.00032781227,0.0002141354,0.000020891996,0.000010007388,0.00020993773],"genre_scores_gemma":[0.99663424,0.0017153699,0.00050660997,0.00071436807,0.00033470272,0.000021964444,0.000008555773,0.00003780306,0.00002637064],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987554,0.00006823407,0.00027055384,0.0003466543,0.0001915864,0.00036759247],"domain_scores_gemma":[0.99940497,0.000020496702,0.000118777236,0.0002987366,0.00006188243,0.000095165946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030949304,0.00020523641,0.0003018617,0.000086966684,0.0000370256,0.000013390018,0.00014435714,0.00014296445,0.000010031706],"category_scores_gemma":[0.000011624973,0.00020683561,0.00009954432,0.00019311959,0.000121936246,0.0000049077034,0.000073497475,0.00014331307,5.6945515e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022325979,0.00008247116,0.004570589,0.00005340839,0.000085490596,0.000008661623,0.00013634993,0.00007022179,0.96332705,0.00007722052,0.0000058810783,0.03135942],"study_design_scores_gemma":[0.0009912746,0.00014435973,0.021781404,0.000041666295,0.00008809334,0.000013885667,0.00006813524,0.000077123805,0.9648842,0.00018579284,0.011464718,0.00025931443],"about_ca_topic_score_codex":0.00016971462,"about_ca_topic_score_gemma":0.00028196877,"teacher_disagreement_score":0.031100105,"about_ca_system_score_codex":0.000028129893,"about_ca_system_score_gemma":0.000115041665,"threshold_uncertainty_score":0.84345114},"labels":[],"label_agreement":null},{"id":"W2305927988","doi":"10.1158/1538-8514.pi3k14-a20","title":"Abstract A20: Insulin receptor signaling in mammary epithelial cells","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Insulin receptor; Insulin; Signal transduction; Insulin receptor substrate; Hyperinsulinemia; Biology; Cancer research; Endocrinology; Cell biology; Gene knockdown; Internal medicine; Medicine; Cell culture; Insulin resistance; Genetics","score_opus":0.025951007523519722,"score_gpt":0.2727540152847231,"score_spread":0.24680300776120337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2305927988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72424597,0.27230993,0.0015769621,0.00012074046,0.0008632824,0.00023848249,0.00006421229,0.000023667788,0.00055674854],"genre_scores_gemma":[0.9472824,0.046013597,0.0012523362,0.004445738,0.0005913411,0.00009934709,0.000080201935,0.000083309984,0.00015177508],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983735,0.0001049681,0.00032889217,0.0004600299,0.0002871585,0.00044545642],"domain_scores_gemma":[0.9991008,0.000007754258,0.00011660807,0.00047275313,0.0001373125,0.00016478891],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032606805,0.00027183455,0.0002589167,0.000073765776,0.00003483076,0.000048435817,0.00037832878,0.0002570238,0.000060863986],"category_scores_gemma":[0.000013483585,0.0002757187,0.00012493157,0.00018689761,0.00006589852,0.000009474805,0.0000900736,0.00021110378,0.000032426295],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011790665,0.000077067874,0.00016816975,0.000020092377,0.000093571856,0.000011253815,0.00016452887,0.00096970715,0.87559193,0.00006422657,0.00044939146,0.12227217],"study_design_scores_gemma":[0.0009198749,0.0000621147,0.000087053995,0.000017142702,0.000020708028,7.906776e-7,0.000045454784,0.000041149946,0.63899535,0.00024171906,0.35931095,0.00025765452],"about_ca_topic_score_codex":0.00009014333,"about_ca_topic_score_gemma":0.0000485549,"teacher_disagreement_score":0.35886157,"about_ca_system_score_codex":0.000074828975,"about_ca_system_score_gemma":0.000388155,"threshold_uncertainty_score":0.9999695},"labels":[],"label_agreement":null},{"id":"W2307983749","doi":"10.1158/1538-8514.pi3k14-b14","title":"Abstract B14: Targeting amino acid transport to block mTORC1 and cell cycle in prostate cancer","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Amino Acid Enzymes and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Glutamine; mTORC1; Amino acid transporter; Cell growth; Cancer research; Prostate cancer; Cancer cell; LNCaP; Chemistry; Biology; Cancer; Amino acid; Cell biology; Biochemistry; Signal transduction; PI3K/AKT/mTOR pathway; Transporter","score_opus":0.013547124377689556,"score_gpt":0.2641945683393009,"score_spread":0.2506474439616113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2307983749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9655292,0.03239313,0.00044187554,0.00036022984,0.00022422046,0.0003326951,0.000055556506,0.000015989017,0.0006470818],"genre_scores_gemma":[0.9934926,0.0027032152,0.0007926967,0.0023134046,0.00016671754,0.000115222305,0.00003360131,0.000060682203,0.0003218816],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99861133,0.000032633725,0.00026456022,0.00045379755,0.00020046516,0.00043722455],"domain_scores_gemma":[0.99933946,0.0000025695952,0.00007667039,0.00026551663,0.000096821444,0.00021898135],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017198198,0.00025662078,0.00022754999,0.000055397337,0.00004069752,0.00002263685,0.0001745696,0.00013734934,0.00001110438],"category_scores_gemma":[0.000004186025,0.0002517985,0.0000644041,0.00013882748,0.00005353654,0.000007230255,0.000059360133,0.00015104657,0.0000039072165],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012729992,0.000056712666,0.0068779765,0.000033816552,0.000050179362,0.000027277443,0.00078478793,0.0041270396,0.97971433,0.000012531924,0.00017290472,0.008015114],"study_design_scores_gemma":[0.0011820337,0.00010430937,0.0064290757,0.000025787804,0.000052282412,0.0000035366272,0.00023073918,0.00006429349,0.79795825,0.000030095896,0.19352108,0.0003985279],"about_ca_topic_score_codex":0.0004742669,"about_ca_topic_score_gemma":0.00028529193,"teacher_disagreement_score":0.19334817,"about_ca_system_score_codex":0.000043607648,"about_ca_system_score_gemma":0.00018512772,"threshold_uncertainty_score":0.99999344},"labels":[],"label_agreement":null},{"id":"W2310704577","doi":"10.1158/1535-7163.mct-15-0636","title":"Human Neural Stem Cells Overexpressing a Carboxylesterase Inhibit Bladder Tumor Growth","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital","funders":"Korea Research Institute of Bioscience and Biotechnology","keywords":"Bladder cancer; Cancer research; Suicide gene; Cancer stem cell; Cancer; Stem cell; Cancer cell; Medicine; Chemotherapy; Genetic enhancement; Immunotherapy; Biology; Internal medicine; Gene; Cell biology","score_opus":0.023495641485548238,"score_gpt":0.278251621309808,"score_spread":0.2547559798242598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2310704577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893317,0.0073336517,0.00034465853,0.0016734069,0.00030494278,0.0004544628,0.000028721995,0.00012434604,0.00040406347],"genre_scores_gemma":[0.9919391,0.00035993857,0.00006728941,0.005277844,0.00041327343,0.00007673039,0.0000032734172,0.000122018115,0.0017405095],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979451,0.00015398214,0.00039572758,0.0004816008,0.00045834572,0.0005652503],"domain_scores_gemma":[0.9987997,0.000048588627,0.00017570551,0.0006245615,0.00016379023,0.00018764896],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001165145,0.0003780474,0.0004665914,0.00013826467,0.00014451484,0.00006947378,0.00019541701,0.00012250112,0.0001493316],"category_scores_gemma":[0.0000045752154,0.0002758892,0.00026190034,0.00019558179,0.00021122867,0.00011915795,0.000060921117,0.00022655017,0.000020273177],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004940973,0.00011964997,0.0015079,0.00009396743,0.00023537924,0.0003517894,0.00037414918,0.000007797739,0.9765499,0.00006074163,0.00027425136,0.01993035],"study_design_scores_gemma":[0.0038980942,0.0003601437,0.002523547,0.0006695204,0.00042314598,0.00015656595,0.00012429808,0.000108546286,0.9670813,0.000058328682,0.024090828,0.0005056558],"about_ca_topic_score_codex":0.00018130723,"about_ca_topic_score_gemma":0.000017652488,"teacher_disagreement_score":0.023816576,"about_ca_system_score_codex":0.00026247356,"about_ca_system_score_gemma":0.00024641136,"threshold_uncertainty_score":0.9999693},"labels":[],"label_agreement":null},{"id":"W2312543879","doi":"10.1158/1535-7163.targ-13-a154","title":"Abstract A154: Inhibition of eIF4E with Ribavirin suppresses EMT and breast cancer invasiveness.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"EIF4E; Cancer research; Cancer; Metastasis; Oncogene; Carcinogenesis; Breast cancer; Triple-negative breast cancer; Medicine; Ribavirin; Epithelial–mesenchymal transition; Biology; Cell cycle; Immunology; Internal medicine; Translation (biology); Messenger RNA","score_opus":0.022314147813511237,"score_gpt":0.2965809079215373,"score_spread":0.2742667601080261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2312543879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99148005,0.005434989,0.00017916653,0.0017485288,0.00004245316,0.0006315485,0.000058502268,0.000028464907,0.00039630485],"genre_scores_gemma":[0.9959914,0.0024622262,0.0001567,0.00094118336,0.0000645582,0.00020718691,0.00001631585,0.000055274864,0.000105155064],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859655,0.000034406447,0.00023984975,0.00030413005,0.0004888255,0.00033626804],"domain_scores_gemma":[0.99898946,0.0000471453,0.0001071993,0.00035098614,0.0003642362,0.00014099039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007907331,0.00020484564,0.00032174552,0.00009196116,0.00004428187,0.00003549311,0.000088416054,0.000116468655,0.00056911557],"category_scores_gemma":[0.000005427469,0.00015690432,0.00005489836,0.00022088288,0.00029187385,0.00011932569,0.00005642429,0.00019882913,0.000009490052],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065846695,0.00023667363,0.013133006,0.0012142498,0.0007368482,0.00019710725,0.0005306391,0.000350574,0.9401025,0.00012860894,0.00022116386,0.042490132],"study_design_scores_gemma":[0.012741216,0.0002896729,0.10530609,0.0011352693,0.00038458212,0.00028688443,0.00021839573,0.0010998361,0.8762499,0.0002635064,0.0016412048,0.00038342053],"about_ca_topic_score_codex":0.006006106,"about_ca_topic_score_gemma":0.00020366194,"teacher_disagreement_score":0.09217308,"about_ca_system_score_codex":0.0013612596,"about_ca_system_score_gemma":0.00234946,"threshold_uncertainty_score":0.90794754},"labels":[],"label_agreement":null},{"id":"W2316810850","doi":"10.1158/1535-7163.targ-09-a105","title":"Abstract A105: Phase 2 trials of linifanib (ABT-869) in advanced hepatocellular, renal cell and non-small cell lung cancer: Associations of response by CT or DCE-MRI with patient outcome","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Response Evaluation Criteria in Solid Tumors; Hazard ratio; Oncology; Internal medicine; Hepatocellular carcinoma; Progression-free survival; Cancer; Clinical trial; Lung cancer; Phases of clinical research; Sorafenib; Interim analysis; Nuclear medicine; Urology; Overall survival; Confidence interval","score_opus":0.03472244194285886,"score_gpt":0.3741749619326415,"score_spread":0.33945251998978265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2316810850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843575,0.011207364,0.00074921356,0.00089957996,0.00008113099,0.001663762,0.0008335457,0.000019725654,0.00018821316],"genre_scores_gemma":[0.99489105,0.0017805848,0.0018629028,0.0009004301,0.000017835291,0.00016423654,0.00009414875,0.000045998037,0.00024280683],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99775827,0.00015840048,0.001022629,0.0003638561,0.00037638773,0.00032044112],"domain_scores_gemma":[0.9982819,0.00020980244,0.0008126704,0.00034253954,0.00022120163,0.0001318843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041510304,0.00030382804,0.00090819463,0.00017144308,0.000056746147,0.000015503507,0.0000981653,0.0001003355,0.000059046815],"category_scores_gemma":[0.000032427346,0.00022758715,0.00015870317,0.00036956108,0.00006043189,0.00006336944,0.000014627922,0.00021292934,3.887308e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0099012675,0.0028179013,0.070721716,0.00030698424,0.000822171,0.0002348281,0.0030794134,0.0017339719,0.8875824,0.0000071713825,0.00013471006,0.022657467],"study_design_scores_gemma":[0.032592665,0.0042018592,0.033259656,0.0006349202,0.0025013639,0.0000062395516,0.000418839,0.00089179876,0.9214692,0.0000270102,0.0035055792,0.00049083156],"about_ca_topic_score_codex":0.00069373456,"about_ca_topic_score_gemma":0.00018924296,"teacher_disagreement_score":0.037462056,"about_ca_system_score_codex":0.00038215285,"about_ca_system_score_gemma":0.0008163193,"threshold_uncertainty_score":0.92807347},"labels":[],"label_agreement":null},{"id":"W2318057464","doi":"10.1158/1535-7163.targ-09-b160","title":"Abstract B160: ANG1005: New EPiC compound for the treatment of recurrent malignant glioma","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Intrinsik (Canada); Angiochem (Canada)","funders":"","keywords":"Glioma; Medicine; Tolerability; Neutropenia; Adverse effect; Taxane; Internal medicine; Cancer; Oncology; Gastroenterology; Pharmacology; Cancer research; Breast cancer; Toxicity","score_opus":0.053768399153598656,"score_gpt":0.3395313373520377,"score_spread":0.28576293819843906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318057464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89820945,0.0871757,0.0006872295,0.011613304,0.00032137896,0.0016880429,0.00006319743,0.00003578092,0.00020593216],"genre_scores_gemma":[0.99248785,0.0054508434,0.00060795125,0.0010698884,0.00014090484,0.0001265528,0.000026268943,0.00002681109,0.00006294305],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99894124,0.000015540274,0.0002803475,0.0002447609,0.00023929718,0.00027879846],"domain_scores_gemma":[0.9991525,0.00007926004,0.00012874336,0.00044025452,0.00009146361,0.0001078049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000050547093,0.00023259113,0.00035066443,0.00006346316,0.00007251967,0.000020866173,0.000099265344,0.000068919566,0.0000708849],"category_scores_gemma":[0.0000026557034,0.00013901506,0.0003171931,0.00015992828,0.000045017518,0.000017887023,0.000005189746,0.000046289115,0.0000045077404],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077015493,0.0030465014,0.0014376137,0.000048513913,0.0016953637,0.00021979638,0.00072752184,0.00016015643,0.19581245,0.0013506655,0.0006789631,0.7940523],"study_design_scores_gemma":[0.009779409,0.0060092607,0.04887998,0.00023176648,0.0025012365,0.000059324357,0.00009886258,0.00045762057,0.7296879,0.0014801449,0.20049603,0.0003184205],"about_ca_topic_score_codex":0.00016693582,"about_ca_topic_score_gemma":0.000033941255,"teacher_disagreement_score":0.7937339,"about_ca_system_score_codex":0.00021548753,"about_ca_system_score_gemma":0.00014764475,"threshold_uncertainty_score":0.56688696},"labels":[],"label_agreement":null},{"id":"W2319740689","doi":"10.1158/1535-7163.targ-13-c293","title":"Abstract C293: Irinotecan sucrosofate liposome injection, MM-398, demonstrates superior activity and control of hypoxia as measured through longitudinal imaging using [18F]FAZA PET compared to free irinotecan in a colon adenocarcinoma xenograft model.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Irinotecan; Hypoxia (environmental); Tumor hypoxia; Pharmacokinetics; Medicine; Camptothecin; Colorectal cancer; Pharmacology; Nuclear medicine; Internal medicine; Chemistry; Cancer; Radiation therapy; Oxygen","score_opus":0.026230494577792866,"score_gpt":0.2812783448882339,"score_spread":0.255047850310441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2319740689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756223,0.012166526,0.010279816,0.00042504954,0.00032486182,0.000959725,0.00014324333,0.000028447288,0.000050024864],"genre_scores_gemma":[0.9968848,0.00056985335,0.0012729003,0.0007932658,0.0002046715,0.0001551457,0.000015878948,0.000085824046,0.000017610033],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975688,0.00012761667,0.0005071088,0.0007619605,0.0003627756,0.00067175605],"domain_scores_gemma":[0.998515,0.000020245117,0.00023177182,0.0006783115,0.0003561287,0.00019852314],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002031966,0.00048504618,0.00063251803,0.0001566705,0.0001521991,0.00011390597,0.00037976773,0.00016562102,0.000023116563],"category_scores_gemma":[0.000032131844,0.00052073476,0.00018117214,0.00031455903,0.00029646035,0.00005083252,0.00015827885,0.00030319637,0.0000018294786],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051184936,0.00017716005,0.016657,0.00006574301,0.00023044352,0.000011875829,0.00033970168,0.011306543,0.9668314,0.000015071515,0.000019878575,0.0038333545],"study_design_scores_gemma":[0.004310656,0.00046779774,0.10392019,0.0001398396,0.00035859042,0.00016796961,0.00022802473,0.015170799,0.8726126,0.00050063856,0.0011005696,0.0010223456],"about_ca_topic_score_codex":0.009190099,"about_ca_topic_score_gemma":0.0020042686,"teacher_disagreement_score":0.0942188,"about_ca_system_score_codex":0.0001307002,"about_ca_system_score_gemma":0.0004490933,"threshold_uncertainty_score":0.99972445},"labels":[],"label_agreement":null},{"id":"W2320984091","doi":"10.1158/1535-7163.targ-13-c225","title":"Abstract C225: IL1RAP as functionally relevant target for stem-cell directed therapy in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Myeloid leukemia; Medicine; Stem cell; Myelodysplastic syndromes; CD34; Cancer research; Progenitor cell; clone (Java method); Internal medicine; Immunology; Biology; Bone marrow; Genetics","score_opus":0.022164490800552113,"score_gpt":0.28871054114473743,"score_spread":0.2665460503441853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320984091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823254,0.010373617,0.00095309113,0.0025254628,0.00026194332,0.002542041,0.00007708301,0.0001708485,0.00077056524],"genre_scores_gemma":[0.9786838,0.009196555,0.0025167041,0.0038927537,0.00013120915,0.0012032412,0.000116165626,0.00020593114,0.0040536067],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99697953,0.00009890542,0.00058244227,0.00077037635,0.0006880165,0.00088074955],"domain_scores_gemma":[0.99821913,0.00029946014,0.00017724458,0.0005575624,0.00043825092,0.00030837132],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030218644,0.00048760636,0.00068283896,0.00031285046,0.00015170778,0.00014274473,0.00027952372,0.0003547422,0.00058986346],"category_scores_gemma":[0.000023027167,0.00044384107,0.00019262063,0.0004935002,0.00020837542,0.00018423461,0.00008017213,0.0007055786,0.000088725676],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018987816,0.00031421444,0.006340803,0.00039632857,0.0016846186,0.00037828193,0.0005703396,0.0002453563,0.89410913,0.0001026055,0.002006276,0.091953285],"study_design_scores_gemma":[0.055354625,0.008839925,0.2772216,0.0012799734,0.0016310096,0.00092800695,0.0012033919,0.031365138,0.4062245,0.0072255307,0.20463495,0.004091374],"about_ca_topic_score_codex":0.0011436545,"about_ca_topic_score_gemma":0.00007073732,"teacher_disagreement_score":0.4878846,"about_ca_system_score_codex":0.0010545081,"about_ca_system_score_gemma":0.0014006635,"threshold_uncertainty_score":0.99980134},"labels":[],"label_agreement":null},{"id":"W2322809144","doi":"10.1158/1535-7163.targ-09-a51","title":"Abstract A51: Identification of compounds targeting human leukemia stem cells","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Click Chemistry and Applications","field":"Chemistry","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Leukemia; Stem cell; Cancer research; Cancer stem cell; Haematopoiesis; Cancer cell; Etoposide; Cancer; Biology; Population; Cytotoxic T cell; Progenitor cell; Immunology; Medicine; Cell biology; Chemotherapy; Biochemistry; Genetics; In vitro","score_opus":0.026676936184379333,"score_gpt":0.29793394922597594,"score_spread":0.2712570130415966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2322809144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99291253,0.0009338127,0.00063829846,0.00021129967,0.00003204927,0.00006697979,0.000050856757,0.000070496695,0.0050836797],"genre_scores_gemma":[0.99890465,0.000096647214,0.0000838841,0.00021674308,0.00008208859,0.000021608625,0.000055806595,0.000021777529,0.0005167737],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99888945,0.0000073162428,0.00043756815,0.00025779143,0.00021322235,0.00019462964],"domain_scores_gemma":[0.9991045,0.000019829838,0.00029519884,0.0004367998,0.000093644194,0.00005004843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000086831125,0.00015804096,0.00016872029,0.00001959948,0.00011912517,0.000035574805,0.00029401158,0.00012392428,0.00014753708],"category_scores_gemma":[0.0000010802554,0.0001767515,0.00010828352,0.00012296416,0.000058300113,0.000038817605,0.000017906419,0.000189306,0.0000068911127],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000084062585,0.00007604578,0.00008286696,0.000075188946,0.000048934897,0.000001968229,0.00011302552,0.00040247777,0.993122,0.00033978422,0.00012987334,0.005599468],"study_design_scores_gemma":[0.00024094914,0.000005680069,0.00032950562,0.00003630845,0.000059065867,8.3912374e-7,0.00009124239,0.00021189329,0.99108046,0.0004945778,0.007272887,0.00017657068],"about_ca_topic_score_codex":0.000023115235,"about_ca_topic_score_gemma":0.000001340359,"teacher_disagreement_score":0.0071430136,"about_ca_system_score_codex":0.00016131633,"about_ca_system_score_gemma":0.000058776193,"threshold_uncertainty_score":0.72077173},"labels":[],"label_agreement":null},{"id":"W2322879380","doi":"10.1158/1535-7163.targ-09-a142","title":"Abstract A142: Molecular modeling approach to the rational design of promiscuous quinazoline-based EGFR inhibitors","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Quinazolinone synthesis and applications","field":"Chemistry","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Cancer research; Epidermal growth factor receptor; Tyrosine kinase; Quinazoline; Kinase; Biology; Erlotinib; PTEN; Proto-oncogene tyrosine-protein kinase Src; Receptor tyrosine kinase; Biochemistry; Afatinib; Docking (animal); Chemistry; Pharmacology; Signal transduction; Cell biology; PI3K/AKT/mTOR pathway; Receptor; Medicine; Stereochemistry","score_opus":0.039225374973548,"score_gpt":0.2795693104840613,"score_spread":0.2403439355105133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2322879380","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31941935,0.0021328472,0.66912514,0.004809226,0.000047111746,0.0007290982,0.000059020706,0.00010210684,0.0035761206],"genre_scores_gemma":[0.9893244,0.00003726672,0.008550743,0.0015875746,0.00011801945,0.000272191,0.000028631786,0.000048636346,0.00003255254],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99827856,0.00003912861,0.00045295458,0.0004037418,0.0004860766,0.0003395413],"domain_scores_gemma":[0.9988437,0.00004053008,0.00016318337,0.00066920585,0.00018635941,0.00009699332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022902347,0.00027956915,0.00026184594,0.000061091225,0.00013992518,0.000052672123,0.00048515256,0.00014476874,0.00006250856],"category_scores_gemma":[0.000014337937,0.00022362215,0.00018192631,0.0002638564,0.000052875526,0.000036450303,0.000025522279,0.00023387425,0.000009817114],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004626375,0.00022949663,0.000006341313,0.000024792098,0.00005456872,0.0000017142548,0.00011267544,0.40784574,0.5849893,0.00096045743,0.00003011868,0.0056985538],"study_design_scores_gemma":[0.00040931767,0.000031733947,0.000032984626,0.00005740135,0.000112465495,0.00000221063,0.000061075305,0.20418146,0.792497,0.00088990445,0.0014271383,0.00029731524],"about_ca_topic_score_codex":0.00003858327,"about_ca_topic_score_gemma":0.0000016690258,"teacher_disagreement_score":0.66990507,"about_ca_system_score_codex":0.00010796241,"about_ca_system_score_gemma":0.0002667631,"threshold_uncertainty_score":0.91190463},"labels":[],"label_agreement":null},{"id":"W2323767515","doi":"10.1158/1535-7163.targ-09-a188","title":"Abstract A188: Proapoptotic <i>versus</i> prosurvival function of the MAP kinase p38 induced by HDAC inhibitor in hematological malignant cells","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Vorinostat; Histone deacetylase inhibitor; Sodium butyrate; DNA damage; Apoptosis; p38 mitogen-activated protein kinases; Cell cycle; Biology; Cell cycle checkpoint; Histone deacetylase; Cancer research; Cell biology; Kinase; Chemistry; Histone; Cell culture; Protein kinase A; Biochemistry; DNA","score_opus":0.022723297742067893,"score_gpt":0.2864238494424917,"score_spread":0.26370055170042384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323767515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99557877,0.0021447423,0.00013343732,0.0007275852,0.000434619,0.00069176196,0.000031963536,0.000014740111,0.00024236768],"genre_scores_gemma":[0.99884635,0.000104513114,0.00005682998,0.00064142124,0.00009314099,0.00006716165,0.000033407352,0.000036168556,0.000120998615],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99796224,0.00017247781,0.0004222508,0.000495623,0.00048397953,0.00046342128],"domain_scores_gemma":[0.9990209,0.000015028813,0.00017076958,0.000580232,0.00012597494,0.00008709232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025622995,0.0002787905,0.00027047886,0.000058708574,0.00007569404,0.000025496076,0.00037384607,0.00033485488,0.000021258704],"category_scores_gemma":[0.000020916224,0.00021829912,0.00017920976,0.00028702052,0.00014542656,0.000007287122,0.00009450884,0.00035654273,0.0000074758236],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006193688,0.00032676657,0.00012762177,0.0000535114,0.00005576512,0.000009407312,0.000049896214,0.00008173386,0.9957031,0.000052288782,0.0005092014,0.002411337],"study_design_scores_gemma":[0.0014060857,0.0005634112,0.00074053387,0.000065117565,0.000033228946,0.000001810632,0.000043892116,0.000025883533,0.9916199,0.00006472214,0.0051810956,0.00025431794],"about_ca_topic_score_codex":0.000055391272,"about_ca_topic_score_gemma":0.000043535874,"teacher_disagreement_score":0.004671894,"about_ca_system_score_codex":0.00010673244,"about_ca_system_score_gemma":0.0002557499,"threshold_uncertainty_score":0.89019793},"labels":[],"label_agreement":null},{"id":"W2324692647","doi":"10.1158/1535-7163.targ-11-b12","title":"Abstract B12: The effects of Irinophore C™ on the microenvironment and vasculature of a primary orthotopic model of colorectal cancer.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Colorectal cancer; Irinotecan; Medicine; Cancer; Tumor microenvironment; Primary tumor; Pathology; In vivo; Cancer research; Internal medicine; Metastasis; Biology","score_opus":0.01955027477734175,"score_gpt":0.2508242462791802,"score_spread":0.23127397150183845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2324692647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830864,0.015930798,0.000053353408,0.00008676959,0.000036317062,0.0004743641,0.00008056191,0.0000016726842,0.00024975167],"genre_scores_gemma":[0.9908565,0.008579103,0.00008481551,0.0002984984,0.00001181511,0.00011274466,0.000007981069,0.000019507232,0.000029012448],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99922466,0.000048268248,0.00015990894,0.00019289997,0.00020647467,0.00016778968],"domain_scores_gemma":[0.9994329,0.000021264255,0.00013081555,0.00033970724,0.000041082127,0.000034188517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007028254,0.00014499298,0.00017860571,0.000019029692,0.000037889742,0.0000035553503,0.00020046403,0.00008530455,0.000012966631],"category_scores_gemma":[0.0000047304,0.000086552165,0.0001213001,0.000047706533,0.00028324415,0.0000020194868,0.00008263998,0.00010702884,1.7053293e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003561399,0.00014764673,0.0045939228,0.00015975857,0.00066399743,0.0000028055747,0.00029000867,0.00015962588,0.9877592,0.000087622735,0.000017563363,0.00576175],"study_design_scores_gemma":[0.00062422175,0.00038918585,0.03779278,0.00005789664,0.000116616786,0.0000010864073,0.000019170775,0.000054028114,0.96052915,0.00012281189,0.00021432483,0.000078706464],"about_ca_topic_score_codex":0.00036240215,"about_ca_topic_score_gemma":0.00010689823,"teacher_disagreement_score":0.033198856,"about_ca_system_score_codex":0.000030035328,"about_ca_system_score_gemma":0.000113170085,"threshold_uncertainty_score":0.35294947},"labels":[],"label_agreement":null},{"id":"W2328609447","doi":"10.1158/1535-7163.targ-13-b176","title":"Abstract B176: The correlation of clinicopathologic characteristics with oncogenic somatic mutations and Human Papilloma Virus (HPV) in vulvovaginal carcinoma.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; KRAS; Oncology; Cancer; Internal medicine; Carcinoma; Polymerase chain reaction; Somatic cell; Cervical cancer; Biology; Gene","score_opus":0.0405368688106189,"score_gpt":0.34460547801086316,"score_spread":0.30406860920024426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328609447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99557847,0.0017916821,0.00030616185,0.0008004593,0.000037280068,0.00068346225,0.000014967749,0.00001450027,0.0007730344],"genre_scores_gemma":[0.9986534,0.00022908108,0.000116655414,0.00073705975,0.0000400877,0.00013422451,0.000029879095,0.000025579577,0.000033997814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881023,0.00006964784,0.00035738185,0.00020588307,0.00031800894,0.00023885796],"domain_scores_gemma":[0.99923456,0.000083055165,0.00013591877,0.00028605832,0.00018432525,0.00007605783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018877495,0.00014623058,0.00028534222,0.00008829077,0.00007975558,0.000029023186,0.00010265977,0.000087306085,0.00080730434],"category_scores_gemma":[0.00001328523,0.00009619538,0.000050707706,0.00020949933,0.00025352757,0.000051565465,0.00003091243,0.00035067715,0.000010347599],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037223776,0.0004045275,0.6070293,0.00045820535,0.00020389406,0.0001317492,0.0016998254,0.00007888826,0.22424136,0.00051256444,0.000011448405,0.16485599],"study_design_scores_gemma":[0.0014308293,0.00043106265,0.98973554,0.000040199833,0.00016028332,0.000022573035,0.00017784089,0.0010624235,0.006119644,0.00057916035,0.00012564613,0.00011480584],"about_ca_topic_score_codex":0.000821761,"about_ca_topic_score_gemma":0.00020988466,"teacher_disagreement_score":0.38270622,"about_ca_system_score_codex":0.00009165362,"about_ca_system_score_gemma":0.000169386,"threshold_uncertainty_score":0.88394165},"labels":[],"label_agreement":null},{"id":"W2331427771","doi":"10.1158/1535-7163.targ-09-c218","title":"Abstract C218: Antitumor activities of a novel oral formulation of SN38","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Tolerability; Irinotecan; Pharmacology; Pharmacokinetics; In vivo; Active metabolite; Chemistry; Prodrug; Bioavailability; SN-38; Oral administration; Bioequivalence; Medicine; In vitro; Metabolite; Colorectal cancer; Cancer; Biochemistry; Adverse effect; Internal medicine; Biology","score_opus":0.05436867551825783,"score_gpt":0.3722591213640159,"score_spread":0.3178904458457581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2331427771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943987,0.002001047,0.0010462613,0.00062577083,0.00010796542,0.0002573695,0.000030593445,0.000017343153,0.0015149504],"genre_scores_gemma":[0.99754465,0.00030739442,0.00066081155,0.0013108633,0.000040672938,0.000008536378,0.000015579712,0.000012755191,0.00009875372],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993684,0.000008564115,0.00020054754,0.00011370558,0.00016923205,0.00013949878],"domain_scores_gemma":[0.9996013,0.000015117235,0.00013677882,0.00014178519,0.00007169609,0.000033290245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000045857596,0.00011207864,0.00027085055,0.00007713692,0.000016315285,0.0000030848316,0.000048835827,0.000060050574,0.00008695423],"category_scores_gemma":[0.0000013960969,0.00009948503,0.00010868209,0.00012585521,0.000043127642,0.00004501418,0.000006437678,0.00007883413,5.037725e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056933914,0.0005886819,0.0028164722,0.000070464324,0.00028040455,0.000009874264,0.0002496034,0.00014186224,0.96938175,0.00046863215,0.000030799616,0.02539214],"study_design_scores_gemma":[0.0038388642,0.00073568616,0.056239065,0.00008399444,0.0004816128,0.000007182634,0.00003722579,0.00047873138,0.93572056,0.00017129157,0.0020923929,0.00011337028],"about_ca_topic_score_codex":0.00011189715,"about_ca_topic_score_gemma":0.000018733113,"teacher_disagreement_score":0.053422593,"about_ca_system_score_codex":0.000065312524,"about_ca_system_score_gemma":0.00012461943,"threshold_uncertainty_score":0.40568817},"labels":[],"label_agreement":null},{"id":"W2332272456","doi":"10.1158/1535-7163.targ-09-c147","title":"Abstract C147: siRNA targeting TS and TK as an anticancer therapy","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Small interfering RNA; Thymidylate synthase; Biology; Cancer research; Cell growth; Molecular biology; Transfection; Pharmacology; Cancer; Cell culture; Biochemistry","score_opus":0.03276891888321092,"score_gpt":0.3281588253113174,"score_spread":0.2953899064281065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332272456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92482156,0.06632424,0.000052064253,0.00579727,0.00016866898,0.00035753427,0.000007153374,0.00010064929,0.0023708465],"genre_scores_gemma":[0.9680312,0.013192393,0.00038428474,0.017880678,0.00031734593,0.000025362844,0.000012408293,0.000046450514,0.00010986948],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998476,0.00003126861,0.00025368232,0.00045026338,0.0003620686,0.00042669245],"domain_scores_gemma":[0.999222,0.000019360597,0.00008812141,0.000353948,0.00013664908,0.00017991665],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009868451,0.0002992054,0.00037968683,0.00007699997,0.00014836667,0.0000624588,0.00011695933,0.00011509266,0.00011871689],"category_scores_gemma":[0.0000075413645,0.0002541474,0.000116879986,0.00018148075,0.00010906228,0.00010820272,0.000022187702,0.0002687882,0.000007632044],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006727628,0.00028267226,0.034297764,0.000047339654,0.0005278101,0.0002702668,0.0023239257,0.000014126879,0.5199327,0.00036502627,0.00037104567,0.44089457],"study_design_scores_gemma":[0.004709682,0.0012754216,0.8048003,0.00018147794,0.00035975344,0.00006967909,0.0005099802,0.00015734376,0.14250554,0.0021109784,0.042573184,0.00074666063],"about_ca_topic_score_codex":0.00013872134,"about_ca_topic_score_gemma":0.00001462231,"teacher_disagreement_score":0.7705025,"about_ca_system_score_codex":0.00008641882,"about_ca_system_score_gemma":0.00012897594,"threshold_uncertainty_score":0.99999106},"labels":[],"label_agreement":null},{"id":"W2332604050","doi":"10.1158/1535-7163.targ-11-b23","title":"Abstract B23: Real-time dynamic assessment of RAF-signal transduction capacity as a predictive biomarker in patients with advanced neuroendocrine tumor (aNET) treated with sorafenib (S) and metronomic cyclophosphamide (mC): The SORNET study.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Basal (medicine); Pharmacodynamics; Sorafenib; Peripheral blood mononuclear cell; Cyclophosphamide; Oncology; Pharmacology; MAPK/ERK pathway; Internal medicine; Signal transduction; Pharmacokinetics; Chemotherapy; In vitro; Chemistry","score_opus":0.01558948879398097,"score_gpt":0.28739419483359596,"score_spread":0.271804706039615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332604050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963961,0.00023113922,0.000073426236,0.00010398718,0.000025165107,0.0028071508,0.00006297782,0.00005222235,0.00024780235],"genre_scores_gemma":[0.998778,0.00023342296,0.00046180698,0.00009974252,0.0000053850176,0.00027644652,0.000027334405,0.00008790643,0.000029946796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975814,0.00022156187,0.00044068586,0.0006027145,0.0006404495,0.0005131689],"domain_scores_gemma":[0.9988354,0.000062912615,0.0002740637,0.00048573813,0.00019825625,0.00014365047],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012161421,0.00040358852,0.0005742437,0.00021502607,0.00007225497,0.000018378054,0.00019140168,0.00001099481,0.00012051208],"category_scores_gemma":[0.0000075904904,0.00026304804,0.000064539294,0.00047741274,0.00038197052,0.0001764093,0.000039668816,0.00040844304,0.0000011721079],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03438828,0.0042659473,0.8038605,0.00021140456,0.0020936858,0.0028299529,0.0007208488,0.0015085473,0.13785122,0.00001652353,0.0000031624236,0.012249954],"study_design_scores_gemma":[0.009940521,0.007105787,0.95192206,0.00011335266,0.00044142763,0.00011507762,0.00027186648,0.00093520334,0.02885262,0.000028956285,0.000027912127,0.0002452347],"about_ca_topic_score_codex":0.0013599213,"about_ca_topic_score_gemma":0.00034450347,"teacher_disagreement_score":0.14806157,"about_ca_system_score_codex":0.0002619789,"about_ca_system_score_gemma":0.00023146438,"threshold_uncertainty_score":0.9999822},"labels":[],"label_agreement":null},{"id":"W2334087039","doi":"10.1158/1535-7163.targ-11-c143","title":"Abstract C143: Combining siRNAs targeting thymidylate synthase and thymidine kinase 1 or 2 sensitizes human tumor cells to 5FUdR and pemetrexed.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Thymidylate synthase; Thymidine kinase; Cancer research; Gene knockdown; Small interfering RNA; Downregulation and upregulation; Pemetrexed; Cancer cell; Kinase; Cancer; Biology; Chemistry; Pharmacology; Molecular biology; Transfection; Cell culture; Apoptosis; Cell biology; Cisplatin; Biochemistry; Immunology; Chemotherapy; Fluorouracil","score_opus":0.052682980625344725,"score_gpt":0.30001762794600134,"score_spread":0.24733464732065663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334087039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844898,0.012788754,0.000080548685,0.0006817942,0.00019417806,0.000483622,0.000036614416,0.000090998605,0.001153673],"genre_scores_gemma":[0.99333006,0.0008594774,0.0011915957,0.004205504,0.00012494791,0.00004465937,0.000009473471,0.0000801376,0.00015416114],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983445,0.0000417013,0.0003416712,0.0005187279,0.00027469322,0.00047873438],"domain_scores_gemma":[0.99909705,0.000054478165,0.00012119183,0.00031813575,0.0001326296,0.00027650123],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019800056,0.0003700105,0.0005208271,0.00014777928,0.00024941788,0.00005510692,0.000092439404,0.00007881688,0.00011976385],"category_scores_gemma":[0.000021246036,0.0003037252,0.000092271606,0.00021593127,0.00015683797,0.000066248176,0.00014131982,0.0002683779,0.000006094704],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009095824,0.0001841945,0.017630165,0.0003652269,0.00080138276,0.0019739287,0.006925553,0.000006371457,0.95932156,0.000105525774,0.00044441887,0.011332082],"study_design_scores_gemma":[0.004629051,0.0013978041,0.120193824,0.00075208995,0.0012505826,0.00015118644,0.0028855298,0.0001379337,0.8580281,0.00018937576,0.0093223285,0.0010621845],"about_ca_topic_score_codex":0.0005966272,"about_ca_topic_score_gemma":0.00013396361,"teacher_disagreement_score":0.10256366,"about_ca_system_score_codex":0.00007505987,"about_ca_system_score_gemma":0.000069361,"threshold_uncertainty_score":0.99994147},"labels":[],"label_agreement":null},{"id":"W2335421053","doi":"10.1158/1535-7163.targ-11-a95","title":"Abstract A95: The determination of the maximum tolerated dose (MTD) of MGCD265 on an intermittent schedule: Phase I study results (Study 265-102).","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Medicine; Adverse effect; Nausea; Pharmacodynamics; Pharmacokinetics; Tolerability; Internal medicine; Maximum tolerated dose; Pharmacology; Gastroenterology; Oncology","score_opus":0.08630945641426414,"score_gpt":0.38851745837937557,"score_spread":0.30220800196511144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335421053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958599,0.00039575604,0.00003346929,0.00038139863,0.00041063654,0.00207814,0.00004859154,0.000022804643,0.0007692573],"genre_scores_gemma":[0.99876547,0.0000489865,0.00003957298,0.0008014599,0.000056514808,0.0001465717,0.000011249339,0.000035397596,0.00009475667],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983021,0.00025149915,0.0005172616,0.00031712648,0.0003969301,0.00021509518],"domain_scores_gemma":[0.99855864,0.000042982105,0.00035700906,0.0007489188,0.00023024408,0.00006218961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032387173,0.00024194809,0.00034859826,0.00008821722,0.00008581205,0.000010181952,0.00030998644,0.000076458615,0.0001307221],"category_scores_gemma":[0.000010664143,0.00014110327,0.00013772062,0.00030048753,0.00014221131,0.000044654753,0.000055631823,0.0002693164,0.0000025004056],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024766814,0.05532141,0.028362697,0.00011797283,0.00313404,0.00033751767,0.051304907,0.00007665215,0.45718,0.00005382388,0.00007816501,0.379266],"study_design_scores_gemma":[0.03598547,0.020280719,0.30818814,0.00017054944,0.0031934243,0.000015771784,0.005227349,0.0008052404,0.62478477,0.00012958971,0.00086038973,0.0003585819],"about_ca_topic_score_codex":0.0005351818,"about_ca_topic_score_gemma":0.00028493916,"teacher_disagreement_score":0.3789074,"about_ca_system_score_codex":0.00011596819,"about_ca_system_score_gemma":0.00016147282,"threshold_uncertainty_score":0.57540244},"labels":[],"label_agreement":null},{"id":"W2336997490","doi":"10.1158/1535-7163.targ-15-c185","title":"Abstract C185: Targeting PARP and DNA as a novel unimolecular combination model for the enhancement of chemosensitivity","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Olaparib; Synthetic lethality; DNA repair; Poly ADP ribose polymerase; Biology; Cancer research; DNA damage; PARP inhibitor; Programmed cell death; DNA; Polymerase; Genetics; Apoptosis","score_opus":0.07282148049106738,"score_gpt":0.3465300539674201,"score_spread":0.2737085734763527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336997490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6158332,0.004283262,0.3739222,0.0043490543,0.0001686332,0.0010183092,0.000038672286,0.00003186558,0.0003547501],"genre_scores_gemma":[0.99210054,0.00044365923,0.0030849385,0.003958845,0.000055966128,0.00018588346,0.00002652084,0.000048098485,0.00009556151],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998659,0.000034130404,0.00032088495,0.00028249546,0.0004484566,0.00025503195],"domain_scores_gemma":[0.9987988,0.00007746973,0.000214675,0.00031744243,0.0004813334,0.00011026983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006198287,0.00020246427,0.0002906314,0.000051814088,0.00008098835,0.000021123973,0.000093227834,0.00009463487,0.000008765296],"category_scores_gemma":[0.000038583712,0.00016616954,0.00010908763,0.00014840688,0.00016308286,0.000053709133,0.000032470794,0.00016099887,0.0000011835764],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004224037,0.00023313433,0.00006247206,0.000103943436,0.000345019,0.0000042371016,0.0010494338,0.0016094799,0.986151,0.0010685842,0.00012809465,0.008822233],"study_design_scores_gemma":[0.004630536,0.00025315458,0.00025407944,0.000120098535,0.00027501112,0.000009924431,0.00018935336,0.10620579,0.8823849,0.0021068067,0.0033707817,0.00019959245],"about_ca_topic_score_codex":0.0000655559,"about_ca_topic_score_gemma":0.000005590075,"teacher_disagreement_score":0.37626728,"about_ca_system_score_codex":0.00019101067,"about_ca_system_score_gemma":0.00035070186,"threshold_uncertainty_score":0.6776197},"labels":[],"label_agreement":null},{"id":"W2337242297","doi":"10.1158/1538-8514.tumang15-b15","title":"Abstract B15: In vivo analysis of repeated siRNA silencing on protein expression levels","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Gene silencing; In vivo; Small interfering RNA; RNA interference; Survivin; Cancer research; Angiogenesis; Biology; Cell growth; In vitro; Cell; Cancer; Cell culture; RNA; Transfection; Gene; Genetics","score_opus":0.050338421090548015,"score_gpt":0.31234727140875684,"score_spread":0.2620088503182088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337242297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99664885,0.0012259649,0.0010687442,0.000061226354,0.000063059764,0.00018390232,0.00004403452,0.000007975479,0.00069626904],"genre_scores_gemma":[0.9990871,0.00008103457,0.00013205115,0.00043056055,0.000032376094,0.0000359096,0.000025658255,0.000021586797,0.00015370407],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988384,0.00006890107,0.00030564514,0.00033833855,0.00023604334,0.00021266707],"domain_scores_gemma":[0.99919045,0.000005826247,0.00015023023,0.00043690833,0.0001514474,0.000065143504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001911429,0.00017217694,0.00024773317,0.00014192342,0.000018588458,0.00001344405,0.00021265911,0.0001606641,0.000041391377],"category_scores_gemma":[0.000020404477,0.00015762735,0.0001492987,0.00034977222,0.000039897106,0.0000046449086,0.000050940715,0.000108814,0.0000021126386],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022611237,0.000076240525,0.0011073005,0.000010183282,0.00036741092,0.000012373157,0.000188654,0.009954708,0.9859953,0.0000058547425,0.00004315297,0.0020127306],"study_design_scores_gemma":[0.00048775796,0.00023608837,0.0021905836,0.00008342692,0.000117234704,4.2315165e-7,0.00013065779,0.00038885654,0.99542326,0.00003701724,0.00072254176,0.00018214258],"about_ca_topic_score_codex":0.00018433818,"about_ca_topic_score_gemma":0.0001243501,"teacher_disagreement_score":0.009565852,"about_ca_system_score_codex":0.000048550286,"about_ca_system_score_gemma":0.00012338274,"threshold_uncertainty_score":0.64278567},"labels":[],"label_agreement":null},{"id":"W2337430744","doi":"10.1158/1535-7163.mct-15-0695","title":"Strategic Combinations: The Future of Oncolytic Virotherapy with Reovirus","year":2016,"lang":"en","type":"review","venue":"Molecular Cancer Therapeutics","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Guizhou University; National Natural Science Foundation of China","keywords":"Oncolytic virus; Virotherapy; Cancer research; Cancer; Immune system; Radiation therapy; Immunotherapy; Cancer cell; Medicine; Biology; Immunology; Virology; Internal medicine","score_opus":0.05086805946299626,"score_gpt":0.3713914075100794,"score_spread":0.3205233480470831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337430744","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006150658,0.99656045,0.0002776759,0.00034064276,0.00018282337,0.001422342,0.00017678084,0.000017252512,0.00040697845],"genre_scores_gemma":[0.0006655324,0.9967945,0.000054570162,0.0006322867,0.00041337273,0.0005933669,0.00009125643,0.00020818207,0.0005469326],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972526,0.0005798873,0.00052068336,0.000611934,0.00055162475,0.00048330388],"domain_scores_gemma":[0.9976939,0.00004886042,0.00047117818,0.0014434399,0.0002534062,0.00008924177],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003552277,0.0006058223,0.0008935268,0.00012566119,0.0001337047,0.00004987094,0.0010757514,0.0004861167,0.00009006547],"category_scores_gemma":[0.000002735022,0.00033056317,0.00048313083,0.0004342117,0.00040085515,0.0000040186965,0.00009096879,0.0004086789,0.000016192207],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005242775,0.00015228702,0.0000018548458,0.0010330188,0.0020173362,0.000012374976,0.00002888296,0.0000106545285,0.012340402,0.00059859373,0.000076763026,0.98320353],"study_design_scores_gemma":[0.0010226027,0.0022678694,4.5505305e-7,0.0015410774,0.00046398706,0.000022585076,0.000032573775,0.000002740707,0.010771054,0.00029404266,0.9830892,0.0004917883],"about_ca_topic_score_codex":0.000010763865,"about_ca_topic_score_gemma":0.00012789194,"teacher_disagreement_score":0.98301244,"about_ca_system_score_codex":0.00012325592,"about_ca_system_score_gemma":0.0015619629,"threshold_uncertainty_score":0.99991465},"labels":[],"label_agreement":null},{"id":"W2346218376","doi":"10.1158/1538-8514.tumang15-pr06","title":"Abstract PR06: Formation of lymph node metastases is not angiogenesis dependent","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Lymph node; Lymph; Medicine; Angiogenesis; Lymphatic system; Sprouting angiogenesis; Pathology; Cancer; Oncology; Cancer research; Internal medicine; Neovascularization","score_opus":0.04080303947871639,"score_gpt":0.29816431070110855,"score_spread":0.25736127122239216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346218376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97026396,0.019088661,0.0077853054,0.0010491537,0.0002806268,0.00028446302,0.00059085654,0.00002718777,0.0006298098],"genre_scores_gemma":[0.99584615,0.000967269,0.0008083583,0.0020375962,0.000078329474,0.000078910765,0.00009601376,0.000038363578,0.00004897969],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99884725,0.000043580465,0.00026261256,0.00028080217,0.00032008582,0.00024567635],"domain_scores_gemma":[0.9990974,0.000007190062,0.00017324973,0.0003999239,0.00024269537,0.00007951929],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011213918,0.00022610946,0.00022099781,0.00005217753,0.000045775527,0.000016060352,0.00018382263,0.00010380495,0.000016917693],"category_scores_gemma":[0.000008863539,0.00020885766,0.00015643971,0.000108484346,0.00007233596,0.000009017724,0.00008657751,0.00003593441,0.0000074377067],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004921175,0.00024279789,0.005836843,0.000076085125,0.0011924065,0.000012070297,0.0005229107,0.0009463526,0.96168566,0.000057223497,0.00048742272,0.02844814],"study_design_scores_gemma":[0.0012479993,0.0000626399,0.004680831,0.000020915011,0.0002755158,0.000009686762,0.00016527867,0.000031768188,0.9854457,0.000058600188,0.0077802367,0.00022082904],"about_ca_topic_score_codex":0.00024054071,"about_ca_topic_score_gemma":0.00005897813,"teacher_disagreement_score":0.028227312,"about_ca_system_score_codex":0.000089003544,"about_ca_system_score_gemma":0.0001541864,"threshold_uncertainty_score":0.85169685},"labels":[],"label_agreement":null},{"id":"W23699658","doi":"10.1158/1535-7163.mct-12-1249","title":"Ionic and Osmotic Mechanisms Of Insect Chill-Coma And Chilling Injury","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Insect behavior and control techniques","field":"Agricultural and Biological Sciences","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Insect; Coma (optics); Chemistry; Botany; Biology","score_opus":0.01793487351953992,"score_gpt":0.23361546395093455,"score_spread":0.21568059043139462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W23699658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972442,0.0018224911,0.00013722116,0.0003946504,0.00003388963,0.00024779837,0.000009869731,0.000043136515,0.0000667649],"genre_scores_gemma":[0.9983302,0.0005535831,0.00014616633,0.00088804273,0.000021375254,0.000044365213,0.000003424215,0.0000020715495,0.000010820035],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99938303,0.00004025766,0.00013535954,0.00016772017,0.00011048808,0.00016312857],"domain_scores_gemma":[0.9997815,0.000018162542,0.000058639067,0.00005177038,0.000047678746,0.00004227466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006445966,0.00011792014,0.00015263281,0.000012526507,0.000079476245,0.000045703953,0.00009554081,0.00008124354,0.00007721245],"category_scores_gemma":[0.0000017074847,0.000051334304,0.00004331364,0.00009922677,0.00005773134,0.000062881816,0.00004023554,0.000088392495,8.0384234e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000006699146,0.00001661281,0.0012395424,0.0000043747696,0.000016444641,6.758148e-7,0.000038039445,2.4634377e-7,0.85787815,0.0012401994,0.0000012301963,0.1395578],"study_design_scores_gemma":[0.0002708935,0.0007080143,0.30003572,0.00005755189,0.00010940883,0.000011692652,0.0001069239,0.000367415,0.66896796,0.028639559,0.00036869314,0.00035618898],"about_ca_topic_score_codex":0.00062622514,"about_ca_topic_score_gemma":0.00005222612,"teacher_disagreement_score":0.29879618,"about_ca_system_score_codex":0.000010741062,"about_ca_system_score_gemma":0.0000056444896,"threshold_uncertainty_score":0.20933522},"labels":[],"label_agreement":null},{"id":"W2385366530","doi":"10.1158/1538-8514.tumang15-ia22","title":"Abstract IA22: Preclinical modeling of adjuvant and metastatic antiangiogenic therapy: Relevance for better predicting clinical outcomes","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Sunitinib; Metastatic breast cancer; Bevacizumab; Oncology; Internal medicine; Breast cancer; Adjuvant therapy; Primary tumor; Chemotherapy; Pazopanib; Clinical trial; Adjuvant; Metastasis; Cancer","score_opus":0.1294528729338554,"score_gpt":0.3981295523672547,"score_spread":0.26867667943339935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2385366530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9251869,0.04438607,0.029105132,0.00041817196,0.0003289025,0.000430558,0.00008839714,0.000014871605,0.00004101553],"genre_scores_gemma":[0.9862805,0.0057980525,0.0054361774,0.0020361834,0.00021937431,0.00009193081,0.000035771303,0.00006722036,0.000034787074],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99823767,0.00009137075,0.0006539316,0.00048577777,0.0002239285,0.00030731014],"domain_scores_gemma":[0.9988732,0.00008345431,0.0002456153,0.00041110517,0.00025604878,0.00013060865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006895503,0.00024619626,0.00044114288,0.00003500869,0.000050324514,0.000020234218,0.00021646087,0.00018593129,0.000005461715],"category_scores_gemma":[0.00009366842,0.00020707301,0.0003991123,0.00006812089,0.00013696941,0.000008215684,0.000079413716,0.00010995488,7.0302366e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022272249,0.0006227214,0.46216187,0.00022048716,0.0055455347,0.000012627522,0.00041636362,0.009782372,0.2619955,0.00012236797,0.00056711293,0.2563258],"study_design_scores_gemma":[0.04261902,0.008305782,0.09304121,0.0007430359,0.004308701,0.000064854066,0.0012446905,0.16044863,0.49020895,0.006708178,0.18702796,0.0052789836],"about_ca_topic_score_codex":0.000036492394,"about_ca_topic_score_gemma":0.000021777167,"teacher_disagreement_score":0.36912066,"about_ca_system_score_codex":0.000016298942,"about_ca_system_score_gemma":0.00020617466,"threshold_uncertainty_score":0.84441924},"labels":[],"label_agreement":null},{"id":"W2394733107","doi":"10.1158/1535-7163.targ-15-b29","title":"Abstract B29: A multicenter, open-label phase 1/2 study of oral CFG920, in combination with prednisone in adult patients with metastatic castration-resistant prostate cancer","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Adverse effect; Prednisone; Abiraterone acetate; Internal medicine; Hyponatremia; Enzalutamide; Pharmacokinetics; Cancer; Androgen deprivation therapy; Urology; Pharmacology; Androgen receptor","score_opus":0.08138194030855352,"score_gpt":0.39718238655424015,"score_spread":0.31580044624568665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2394733107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937498,0.0008789511,0.000026626969,0.00041682672,0.000044309898,0.004707352,0.00010519269,0.000012703459,0.00005824395],"genre_scores_gemma":[0.9980566,0.0001525631,0.00049120537,0.00016882319,0.000004196249,0.0008989586,0.000109732275,0.000050680275,0.00006726169],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979577,0.00011703925,0.00043392164,0.00038334323,0.0007490314,0.000358944],"domain_scores_gemma":[0.9986539,0.000019165593,0.00017105002,0.00029678462,0.0007210556,0.00013808024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020787962,0.00025843692,0.00046626848,0.00021196798,0.00003538882,0.00005167239,0.00016622072,0.000043212192,0.0000147599785],"category_scores_gemma":[0.000010157652,0.00017943737,0.000017173117,0.00061865564,0.00009392861,0.00021182012,0.000043209107,0.00022836792,8.2105294e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08437713,0.064849466,0.76609135,0.00054480747,0.0018686713,0.00090518844,0.02007076,0.001655768,0.02479316,0.000028835946,0.000022689197,0.03479219],"study_design_scores_gemma":[0.61816716,0.030382395,0.30824265,0.0018415333,0.0010622705,0.0000035285989,0.007530757,0.004014673,0.027799929,0.000054619726,0.00017203156,0.00072847644],"about_ca_topic_score_codex":0.0071308874,"about_ca_topic_score_gemma":0.011401187,"teacher_disagreement_score":0.53379,"about_ca_system_score_codex":0.0005705686,"about_ca_system_score_gemma":0.00080480217,"threshold_uncertainty_score":0.9994807},"labels":[],"label_agreement":null},{"id":"W2394817086","doi":"10.1158/1535-7163.targ-15-b91","title":"Abstract B91: Anti-PD1 blockade increases the activity of tumor infiltrating antigen-specific CD8 T cells induced by a potent peptide vaccine in combination with metronomic cyclophosphamide","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"ELISPOT; Immunogenicity; Immune system; Cytotoxic T cell; CD8; Medicine; Immunology; Tumor microenvironment; Cancer vaccine; Antigen; Cancer research; Tumor antigen; Cancer; Immunotherapy; Pharmacology; Biology; Internal medicine; In vitro","score_opus":0.019080110591711635,"score_gpt":0.2490849723117268,"score_spread":0.23000486172001516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2394817086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9669654,0.0316304,0.00026706373,0.0003131155,0.00020447101,0.00048589244,0.000033890123,0.00003029471,0.00006947021],"genre_scores_gemma":[0.9978219,0.0016569465,0.000055619937,0.00029358605,0.000010404173,0.000049071663,0.000027570144,0.00004503534,0.000039860493],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99837065,0.00040333346,0.00042181727,0.00030044877,0.00010692754,0.0003968253],"domain_scores_gemma":[0.99886227,0.0001560225,0.00039487614,0.0004424313,0.000120560006,0.000023833372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045387584,0.0003039673,0.00044305544,0.0001310206,0.00012141006,0.000029374416,0.00034438036,0.00015137327,0.000044261025],"category_scores_gemma":[0.000013743745,0.0002258857,0.0000959203,0.00032648747,0.00014291941,0.00011914454,0.000049333226,0.00044311,0.0000101802],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015909151,0.00048161892,0.0036493822,0.000011135286,0.0004074155,0.000007910398,0.00050194986,0.00026786007,0.9850652,0.00002184316,0.00006490134,0.007929827],"study_design_scores_gemma":[0.0035988188,0.00038265818,0.073392235,0.00007881034,0.00003855692,0.00001266409,0.00036003854,0.000016750533,0.9154317,0.00002187134,0.0064073503,0.00025855607],"about_ca_topic_score_codex":0.0025282647,"about_ca_topic_score_gemma":0.00008365183,"teacher_disagreement_score":0.06974285,"about_ca_system_score_codex":0.00016953818,"about_ca_system_score_gemma":0.00026222962,"threshold_uncertainty_score":0.9211351},"labels":[],"label_agreement":null},{"id":"W2396978951","doi":"10.1158/1535-7163.targ-15-a159","title":"Abstract A159: Dianhydrogalactitol (VAL-083) enhances activity of platinum drugs in non-small cell lung cancer","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Delmar (Canada)","funders":"","keywords":"Cisplatin; Cytotoxicity; Oxaliplatin; In vivo; Pharmacology; Lung cancer; MTT assay; Medicine; Cancer research; Gemcitabine; Cancer; Oncology; Chemistry; Chemotherapy; Internal medicine; Cell growth; In vitro; Biology; Colorectal cancer; Biochemistry","score_opus":0.021870783041135326,"score_gpt":0.2945530401078155,"score_spread":0.2726822570666802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2396978951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97656745,0.014810186,0.0015857563,0.0006063837,0.0007768045,0.0010906791,0.00006288312,0.00006910755,0.004430737],"genre_scores_gemma":[0.996297,0.001852895,0.0004249279,0.0006253683,0.0001622937,0.0002493292,0.000015869758,0.00013203222,0.00024026168],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99728537,0.00009081235,0.0005607871,0.00062936684,0.00075853535,0.00067513937],"domain_scores_gemma":[0.9982317,0.0000568122,0.00041221638,0.0007183908,0.00027789417,0.00030296968],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032472104,0.00047221262,0.00076056336,0.00027592474,0.00004488686,0.000028735736,0.0002824706,0.00037323713,0.00011495086],"category_scores_gemma":[0.000018675246,0.00047653055,0.00026773202,0.0006636784,0.00014671388,0.00012209879,0.00008457573,0.00075808645,0.000013513909],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068184745,0.00047739348,0.01029482,0.00058836874,0.00042165667,0.00014260394,0.0033085726,0.0031475718,0.96353316,0.000011326165,0.00017228119,0.017220393],"study_design_scores_gemma":[0.0047224937,0.00021313995,0.009014299,0.0007074982,0.0004822569,0.000008436095,0.0002582958,0.0035429827,0.9779774,0.00004820012,0.0025062594,0.00051871757],"about_ca_topic_score_codex":0.003167594,"about_ca_topic_score_gemma":0.00076946756,"teacher_disagreement_score":0.019729558,"about_ca_system_score_codex":0.00091825426,"about_ca_system_score_gemma":0.0014415889,"threshold_uncertainty_score":0.9997686},"labels":[],"label_agreement":null},{"id":"W2397155186","doi":"10.1158/1535-7163.targ-15-a152","title":"Abstract A152: Novel autotaxin inhibitory antibodies block lysophosphatidic acid production in plasma and tumour cell proliferation in vitro","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Burnaby Hospital","funders":"","keywords":"Autotaxin; Lysophosphatidic acid; Lysophosphatidylcholine; Receptor; In vitro; Cell growth; Lipid signaling; Biochemistry; Signal transduction; Biology; Cell culture; Cancer cell; In vivo; Cell biology; Chemistry; Cancer; Phospholipid","score_opus":0.02091265378255236,"score_gpt":0.2574952640580346,"score_spread":0.23658261027548222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397155186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98556805,0.01314287,0.00019405149,0.00032292612,0.00035420133,0.0003164857,0.000012685341,0.000013977101,0.00007473218],"genre_scores_gemma":[0.9976588,0.00077112607,0.00072797097,0.00040055648,0.000263702,0.000058226542,0.000037733036,0.00003666603,0.000045256264],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987556,0.00004675891,0.00029543557,0.0004227409,0.00020100315,0.00027850585],"domain_scores_gemma":[0.9995195,0.000003979253,0.000109490684,0.0002023819,0.00009128078,0.00007334773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031593358,0.00021401783,0.00020503251,0.0001139628,0.000039633425,0.000043426924,0.00010203912,0.00016485176,9.492467e-7],"category_scores_gemma":[0.000028542252,0.0002197713,0.00004113301,0.00016725658,0.000059774677,0.000016450993,0.000050805724,0.00018851167,0.0000010992372],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023775936,0.00011558454,0.0026952326,0.000039216724,0.000021035721,0.000007276171,0.00058351364,0.0016629999,0.9930123,0.0000058941246,0.000017818289,0.0016013446],"study_design_scores_gemma":[0.0014718133,0.000049012066,0.0036599045,0.000034158304,0.000023117856,0.000008456111,0.00015051069,0.000636453,0.99217594,0.000029737108,0.0015140652,0.00024682237],"about_ca_topic_score_codex":0.00010537791,"about_ca_topic_score_gemma":0.000072546005,"teacher_disagreement_score":0.012371743,"about_ca_system_score_codex":0.00005100479,"about_ca_system_score_gemma":0.0002169828,"threshold_uncertainty_score":0.8962014},"labels":[],"label_agreement":null},{"id":"W2397178591","doi":"10.1158/1535-7163.targ-15-a119","title":"Abstract A119: Investigating PIK3CA mutational status on cisplatin and radiation sensitivity in cervical cancer cell lines: Implications for PI3K inhibitor therapy","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SAIT Polytechnic; University of Calgary","funders":"","keywords":"Cisplatin; PI3K/AKT/mTOR pathway; Cancer research; HeLa; Cervical cancer; Medicine; Cancer; Radiation therapy; Mutation; Chemotherapy; Cell culture; Molecular biology; Biology; Internal medicine; Gene; Signal transduction; Genetics","score_opus":0.049310210053979876,"score_gpt":0.3350010664048908,"score_spread":0.2856908563509109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397178591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835621,0.010599058,0.0031311056,0.0014047398,0.000258404,0.00059478043,0.0003059787,0.000021904963,0.00012192985],"genre_scores_gemma":[0.99286896,0.0012726325,0.0012698681,0.0034446982,0.00041635582,0.0004042605,0.00023670845,0.000065449894,0.000021047426],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985099,0.00008785374,0.0003217642,0.0005022541,0.0002093848,0.00036885243],"domain_scores_gemma":[0.9990505,0.000075263204,0.00018484502,0.00027258557,0.00024529404,0.00017149559],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028814084,0.00025940718,0.00020209419,0.0000552346,0.00008604846,0.00005001074,0.000099969024,0.00022415165,0.000008172467],"category_scores_gemma":[0.000045440607,0.0002677679,0.000072627634,0.0001443718,0.00009764597,0.000014494124,0.000034182653,0.00016464423,9.967866e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024004711,0.00011277884,0.020417187,0.000037337562,0.00008474985,0.0000021508883,0.0003830309,0.011256699,0.93645257,0.00012175336,0.00023159689,0.030660113],"study_design_scores_gemma":[0.004207863,0.00054450094,0.06569938,0.00008274235,0.00005617165,0.000004836894,0.00015963445,0.0035923894,0.9073123,0.0012149089,0.016471159,0.0006541585],"about_ca_topic_score_codex":0.00048349888,"about_ca_topic_score_gemma":0.00068647094,"teacher_disagreement_score":0.045282196,"about_ca_system_score_codex":0.00023618467,"about_ca_system_score_gemma":0.0006055423,"threshold_uncertainty_score":0.99997747},"labels":[],"label_agreement":null},{"id":"W2398074214","doi":"10.1158/1535-7163.targ-15-a188","title":"Abstract A188: Diazonamide DZ 2384, a potential therapeutic for pancreatic cancer, binds to tubulin with a unique impact on microtubule dynamics and tubulin curvature","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Vinorelbine; Tubulin; Microtubule; Vinca; Mitosis; Cell biology; Biology; Cancer research; Chemistry; Pharmacology; Genetics","score_opus":0.0129217169998951,"score_gpt":0.28508751888489187,"score_spread":0.2721658018849968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2398074214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9564542,0.012316808,0.027437171,0.0012846125,0.00023335125,0.0015360141,0.00060873275,0.000045244073,0.000083852814],"genre_scores_gemma":[0.9889192,0.0022078888,0.0015934982,0.0054657976,0.00026379037,0.00058283046,0.00038847892,0.00019986344,0.00037863813],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976036,0.00008741108,0.0003744866,0.00085723755,0.000321444,0.000755834],"domain_scores_gemma":[0.99840266,0.00002267821,0.0001882303,0.00069161894,0.0003437017,0.00035109278],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024343659,0.00066778756,0.00051143224,0.00014319742,0.00013927367,0.000127528,0.00040942035,0.00043416582,0.000013346741],"category_scores_gemma":[0.000014036647,0.00054166553,0.00023525167,0.00023516496,0.00013310176,0.000011023464,0.00010438942,0.00033025883,0.000004228191],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042825206,0.00030106062,0.003677293,0.00015627449,0.0018888153,0.000038592985,0.00038679873,0.012507946,0.9389434,0.00029177705,0.0008017075,0.036723837],"study_design_scores_gemma":[0.015396435,0.010221924,0.018918706,0.0009652242,0.002588279,0.0002200566,0.00067046436,0.02465069,0.8690426,0.0017106641,0.050643306,0.0049716467],"about_ca_topic_score_codex":0.00041028575,"about_ca_topic_score_gemma":0.00079640275,"teacher_disagreement_score":0.06990077,"about_ca_system_score_codex":0.00029409982,"about_ca_system_score_gemma":0.0005787105,"threshold_uncertainty_score":0.99970347},"labels":[],"label_agreement":null},{"id":"W2399049874","doi":"10.1158/1535-7163.targ-15-c28","title":"Abstract C28: The combination of Acetazolamide and Sulforophane targets the tumor initiating cells in human bronchial carcinoids","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Queen's University","funders":"","keywords":"Clonogenic assay; Cancer research; Cancer stem cell; Stem cell; Cell culture; Biology; Chemistry; Cell biology","score_opus":0.043283800107408316,"score_gpt":0.34102044359066797,"score_spread":0.2977366434832597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2399049874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918836,0.0046129464,0.0000307275,0.0021223952,0.0000979861,0.00060895144,0.000009515121,0.000015140847,0.000618763],"genre_scores_gemma":[0.99836177,0.00017643206,0.00007210509,0.0012095803,0.000051177587,0.0000484415,0.000005506374,0.00003099872,0.000043983408],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986131,0.00012718215,0.00028040237,0.00018966755,0.0004874648,0.0003021881],"domain_scores_gemma":[0.9992531,0.00008404693,0.00013240159,0.00030026273,0.00015197396,0.000078201265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030948204,0.00014779759,0.00022524764,0.00007376082,0.000074374264,0.000024365578,0.0001833066,0.0000122105375,0.000011079191],"category_scores_gemma":[0.000048607402,0.00009244452,0.000047642927,0.00021032474,0.0002478575,0.00006466811,0.00007864345,0.00037522215,0.0000011560876],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030073046,0.00017971637,0.016621355,0.00015018723,0.00008951481,0.0005639754,0.0011831503,0.0003288487,0.97608256,0.00059336,0.000056892146,0.0038497283],"study_design_scores_gemma":[0.0038585153,0.00069004425,0.055676427,0.000101559366,0.00009573825,0.00010206573,0.00092699326,0.0006838589,0.9336671,0.0018356247,0.002185908,0.00017615707],"about_ca_topic_score_codex":0.0004745901,"about_ca_topic_score_gemma":0.0001931397,"teacher_disagreement_score":0.042415433,"about_ca_system_score_codex":0.00009141455,"about_ca_system_score_gemma":0.00016556545,"threshold_uncertainty_score":0.3769778},"labels":[],"label_agreement":null},{"id":"W2400062612","doi":"10.1158/1535-7163.targ-15-b34","title":"Abstract B34: Coordinated delivery of anticancer drug combinations incorporating molecularly targeted agents provides markedly increased plasma drug exposure, decreased toxicity and increased efficacy in preclinical tumor models","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Celator Pharmaceuticals (Canada)","funders":"","keywords":"Prodrug; Pharmacology; Drug; Chemistry; Pharmacokinetics; Bioavailability; Toxicity; Distribution (mathematics); Tolerability; Drug delivery; Linker; Medicine; Adverse effect","score_opus":0.03979978382547662,"score_gpt":0.29042508235058256,"score_spread":0.25062529852510596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2400062612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99543023,0.0018680166,0.00055588747,0.00026583063,0.00019024659,0.0012626597,0.00019336608,0.00014098546,0.000092761446],"genre_scores_gemma":[0.99623764,0.000045913726,0.002395678,0.0009503304,0.000026608872,0.0001731284,0.000066957175,0.00009449914,0.000009231398],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9952504,0.00095914246,0.0012729374,0.0008673266,0.0009737116,0.0006764592],"domain_scores_gemma":[0.99682987,0.0005699595,0.0007063705,0.00069973915,0.0007083191,0.00048574168],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018335565,0.0005225912,0.0007994845,0.0003058353,0.00013729444,0.00015768969,0.0005836089,0.00016474,0.00004508366],"category_scores_gemma":[0.0003593608,0.0005372144,0.00014967326,0.0007819557,0.00049273943,0.00057272636,0.00022547317,0.0003832371,0.000008841196],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016592373,0.0024344379,0.015318842,0.00014356173,0.00015076195,0.00021020831,0.000703844,0.009833313,0.96805876,0.00020547603,0.000070764,0.0012107891],"study_design_scores_gemma":[0.011422226,0.00022214271,0.016468538,0.00033607794,0.00024711105,0.0000075378907,0.00024285055,0.11635069,0.85255295,0.0014338741,0.00001830483,0.00069770496],"about_ca_topic_score_codex":0.005764855,"about_ca_topic_score_gemma":0.00057681766,"teacher_disagreement_score":0.115505815,"about_ca_system_score_codex":0.00037662993,"about_ca_system_score_gemma":0.0012782082,"threshold_uncertainty_score":0.99970794},"labels":[],"label_agreement":null},{"id":"W2400969352","doi":"10.1158/1535-7163.targ-15-lb-c19","title":"Abstract LB-C19: The investigation of structural determinants that mediate selective inhibition of UBA5, the UFM1 activating enzyme","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Linker; Chemistry; Enzyme; Kinome; Stereochemistry; Active site; Biochemistry; IC50; In vitro; Kinase","score_opus":0.04683034237247323,"score_gpt":0.2934551128160076,"score_spread":0.24662477044353437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2400969352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99634045,0.0023516747,0.00033210503,0.00031863913,0.00012514293,0.0003268183,0.00003911273,0.0000069823377,0.00015910069],"genre_scores_gemma":[0.998954,0.00010414417,0.0001285714,0.000599177,0.000102605634,0.000045361183,0.000027220649,0.000025056994,0.000013855905],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989395,0.00015231519,0.00024075322,0.00019483894,0.00028132478,0.00019127314],"domain_scores_gemma":[0.9990457,0.00003095243,0.00034887658,0.0003066154,0.0002191973,0.000048606085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003253675,0.00016109893,0.00015061135,0.000025618127,0.00007034952,0.000016211025,0.00021101625,0.00012582312,0.0000058159167],"category_scores_gemma":[0.000040203784,0.00010274711,0.00008676232,0.00013532286,0.00022863272,0.000008809948,0.00007029284,0.000154874,6.1539856e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008432929,0.0000074931045,0.0043726047,0.00002624619,0.00009121607,0.000001035418,0.0014097121,0.00020880564,0.9875098,0.000045230336,0.000025144236,0.006218408],"study_design_scores_gemma":[0.0004073241,0.00013455533,0.0082448255,0.000039389008,0.000040474923,0.000004229535,0.00032728066,0.00022297724,0.9888875,0.0010794491,0.000487945,0.00012408454],"about_ca_topic_score_codex":0.0000996984,"about_ca_topic_score_gemma":0.00005984021,"teacher_disagreement_score":0.0060943235,"about_ca_system_score_codex":0.00002999517,"about_ca_system_score_gemma":0.00021862493,"threshold_uncertainty_score":0.41899052},"labels":[],"label_agreement":null},{"id":"W2402002440","doi":"10.1158/1535-7163.targ-15-b173","title":"Abstract B173: Galeterone shows anti-tumor activity in multiple pre-clinical models that express androgen receptor splice variants, supporting correlative patient data seen in ARMOR2","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Enzalutamide; Androgen receptor; Prostate cancer; splice; Cancer research; Androgen; Alternative splicing; Cancer; Biology; Medicine; Internal medicine; Endocrinology; Messenger RNA; Hormone; Gene; Genetics","score_opus":0.22797474971661802,"score_gpt":0.40608981782862924,"score_spread":0.17811506811201122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402002440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913059,0.0041165473,0.001572855,0.00048817872,0.00026778821,0.0015627587,0.00037982024,0.00004091455,0.00026523796],"genre_scores_gemma":[0.9970197,0.0010407263,0.0007875309,0.0005254063,0.000070377624,0.00015284764,0.00025444845,0.00006922721,0.00007971595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970289,0.00027709303,0.00057811965,0.0008033016,0.0006525876,0.0006600158],"domain_scores_gemma":[0.9982241,0.00014843667,0.00027442886,0.0009328373,0.00013024316,0.00028997354],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00082236755,0.00032290412,0.0006311733,0.00013894876,0.000047884372,0.00003456406,0.0003649993,0.00018611105,0.00006780767],"category_scores_gemma":[0.00006509649,0.0002765121,0.000087624,0.0002694032,0.00014635132,0.00031205677,0.00031012477,0.0007264742,0.0000099353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007787335,0.002994804,0.7553848,0.0002789148,0.0010837808,0.0018617462,0.0072317305,0.0037356203,0.13642947,0.000008120608,0.0005717729,0.08263188],"study_design_scores_gemma":[0.04418296,0.0025416687,0.3518977,0.0020055757,0.00070303486,0.000071614886,0.0028798266,0.32460165,0.2607372,0.0004502643,0.007816024,0.002112484],"about_ca_topic_score_codex":0.0012983523,"about_ca_topic_score_gemma":0.00032937605,"teacher_disagreement_score":0.40348715,"about_ca_system_score_codex":0.00045643665,"about_ca_system_score_gemma":0.0006629689,"threshold_uncertainty_score":0.9999687},"labels":[],"label_agreement":null},{"id":"W2402016156","doi":"10.1158/1535-7163.targ-15-b194","title":"Abstract B194: Tivantinib in combination with erlotinib vs erlotinib alone for EGFR mutant NSCLC: Subgroup results from the phase 3 MARQUEE study","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Cancer; Medicine; Oncology; Pharmacology; Internal medicine; Epidermal growth factor receptor","score_opus":0.04897850486155135,"score_gpt":0.3676255073323042,"score_spread":0.31864700247075284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402016156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842637,0.0012951668,0.001618559,0.0064398036,0.00034092128,0.004727358,0.00052150217,0.00007664242,0.00071634486],"genre_scores_gemma":[0.9956507,0.00006652554,0.0007831444,0.0019810325,0.0001352446,0.0006346029,0.0004838177,0.000083075734,0.00018186419],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980027,0.00009705311,0.0004949968,0.0005068568,0.0005221346,0.00037627592],"domain_scores_gemma":[0.9984978,0.00020307556,0.000241893,0.000585317,0.00032977498,0.00014216654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040078175,0.00031114556,0.00042935333,0.000085965185,0.00011552505,0.000064532294,0.00018618301,0.00009674064,0.000021034097],"category_scores_gemma":[0.000043915476,0.00020502754,0.00009179253,0.00034671722,0.00008746585,0.00009311345,0.000026160067,0.00024746745,0.0000073569586],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14835003,0.056814726,0.18825287,0.00031558357,0.01631612,0.0027756016,0.1359509,0.0027630453,0.09458607,0.0017521166,0.0044134436,0.3477095],"study_design_scores_gemma":[0.50028527,0.021848878,0.28084508,0.0013899195,0.0079578785,0.00005753606,0.02038158,0.0038364062,0.057263415,0.0016991277,0.10239849,0.0020364486],"about_ca_topic_score_codex":0.0024704624,"about_ca_topic_score_gemma":0.0016374817,"teacher_disagreement_score":0.3519352,"about_ca_system_score_codex":0.00035717656,"about_ca_system_score_gemma":0.0005531373,"threshold_uncertainty_score":0.83607805},"labels":[],"label_agreement":null},{"id":"W2402074372","doi":"10.1158/1535-7163.mct-15-0849","title":"Pharmacological Inhibition of the Protein Kinase MRK/ZAK Radiosensitizes Medulloblastoma","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Hospital for Sick Children","keywords":"Medulloblastoma; Cancer research; Cell cycle; Radiation therapy; Cell cycle checkpoint; Cancer; Kinase; Radiosensitizer; Medicine; Chemistry; Biology; Cell biology; Internal medicine","score_opus":0.022055733255393846,"score_gpt":0.2898538999910119,"score_spread":0.26779816673561807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402074372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846562,0.0016626752,0.00016203187,0.012476823,0.00011349139,0.00069595495,0.000023556844,0.000030202833,0.00017902123],"genre_scores_gemma":[0.9972686,0.00015768784,0.00016690503,0.0021029036,0.00005514394,0.00015453568,0.0000016921458,0.00002129869,0.000071193615],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990559,0.000087465094,0.00018423394,0.00019096704,0.00028741092,0.00019401593],"domain_scores_gemma":[0.9994775,0.00002730607,0.00009523096,0.00024295996,0.00009080268,0.000066186236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006591678,0.00014528501,0.00020553081,0.000037791997,0.000046058973,0.000005811239,0.00006109218,0.00007581718,0.00012212792],"category_scores_gemma":[0.000010828566,0.00006967168,0.00016890674,0.00015715245,0.00015240777,0.000020608199,0.00003597407,0.00007324797,0.000007668523],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015956021,0.0002948246,0.0016994484,0.000019008003,0.00029276655,0.00012594537,0.000045243345,0.000003896318,0.9716586,0.0003836167,0.00008687013,0.025230262],"study_design_scores_gemma":[0.002789018,0.00023724619,0.0054972116,0.00025628155,0.00038975332,0.000023269922,0.000011832366,0.000016823784,0.9871787,0.00027721914,0.0032321431,0.00009053898],"about_ca_topic_score_codex":0.000018433584,"about_ca_topic_score_gemma":0.000006438214,"teacher_disagreement_score":0.025139723,"about_ca_system_score_codex":0.00013073813,"about_ca_system_score_gemma":0.000081590886,"threshold_uncertainty_score":0.28411287},"labels":[],"label_agreement":null},{"id":"W2403532441","doi":"10.1158/1535-7163.targ-15-c169","title":"Abstract C169: ER maleate is a novel anticancer agent in oral cancer cells: Implications for cancer therapy","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Chemosensitizer; Cancer research; Carboplatin; Syk; Apoptosis; Cancer; In vivo; Cell growth; Cancer cell; Medicine; Biology; Tyrosine kinase; In vitro; Cisplatin; Internal medicine; Cytotoxicity; Chemotherapy; Receptor","score_opus":0.0951377634896796,"score_gpt":0.364094278728318,"score_spread":0.2689565152386384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2403532441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91540706,0.055648997,0.015723776,0.009044545,0.0008567188,0.0015236348,0.0013551424,0.000041353946,0.00039879812],"genre_scores_gemma":[0.96091664,0.023457332,0.0011456498,0.009735901,0.0003395855,0.0033235336,0.000092604314,0.00012965298,0.0008590962],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99797255,0.000036731097,0.000421673,0.00073763327,0.0002348767,0.0005965584],"domain_scores_gemma":[0.9984645,0.000011154965,0.00019829482,0.00072275964,0.0004184584,0.00018482225],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021605514,0.00037759487,0.0003182937,0.000093889306,0.000107198495,0.00007184014,0.0004492318,0.00025297253,0.00011066853],"category_scores_gemma":[0.0000056683575,0.00036047818,0.00020565059,0.00031164015,0.00013146685,0.000015710077,0.00006069424,0.00017251751,0.0000053706344],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027587722,0.00024150271,0.0063165165,0.000026955699,0.0003375381,9.577753e-7,0.00028983722,0.0033986901,0.94335216,0.00016592805,0.0028862974,0.04270771],"study_design_scores_gemma":[0.0028977222,0.00013249074,0.016540507,0.00004851223,0.000096630254,0.0000017064103,0.000087982095,0.00049666024,0.48274764,0.00026366985,0.49607447,0.00061201164],"about_ca_topic_score_codex":0.0013165681,"about_ca_topic_score_gemma":0.0010604025,"teacher_disagreement_score":0.49318817,"about_ca_system_score_codex":0.00027302455,"about_ca_system_score_gemma":0.00080617913,"threshold_uncertainty_score":0.9998847},"labels":[],"label_agreement":null},{"id":"W2404352909","doi":"10.1158/1535-7163.targ-15-b109","title":"Abstract B109: AZD5363, a catalytic pan-Akt inhibitor, in <i>Akt1</i> E17K mutation positive advanced solid tumors","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"AKT1; Cancer; Protein kinase B; Library science; Medicine; Chemistry; Phosphorylation; Biochemistry; Internal medicine; Computer science","score_opus":0.02893861731283678,"score_gpt":0.30944031885153467,"score_spread":0.2805017015386979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2404352909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868372,0.007414456,0.0002707976,0.0012519419,0.0002187825,0.000927322,0.000029148103,0.00007079789,0.002979536],"genre_scores_gemma":[0.9959546,0.00011243364,0.0004518134,0.0027978371,0.00009906624,0.00015931264,0.00012503692,0.00008600881,0.0002139184],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99796563,0.00006406147,0.00045349973,0.00046955765,0.0005756729,0.0004716015],"domain_scores_gemma":[0.9988716,0.00003934338,0.00017211608,0.00043483902,0.00024484104,0.00023725924],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016812602,0.00035035503,0.00047643427,0.00017874128,0.000039295406,0.000032876567,0.00011937553,0.00013541339,0.000016366574],"category_scores_gemma":[0.00002213409,0.0003222664,0.00014608113,0.00038040557,0.000091923444,0.00011851571,0.000039818628,0.0003219705,0.00004852301],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002720209,0.0013038598,0.0073371436,0.00025804344,0.0008424891,0.008944054,0.006439958,0.004145166,0.853446,0.00012690593,0.00023127241,0.114204876],"study_design_scores_gemma":[0.007296177,0.0010850065,0.03722263,0.00043216973,0.0004243899,0.0001992317,0.0006606552,0.0004666864,0.9498274,0.0005217295,0.0013366749,0.0005272976],"about_ca_topic_score_codex":0.0005985774,"about_ca_topic_score_gemma":0.00018076345,"teacher_disagreement_score":0.113677576,"about_ca_system_score_codex":0.0014507575,"about_ca_system_score_gemma":0.00077187066,"threshold_uncertainty_score":0.99992293},"labels":[],"label_agreement":null},{"id":"W2405138885","doi":"10.1158/1535-7163.targ-15-a150","title":"Abstract A150: Anti-BIRC6 antisense oligonucleotide inhibits enzalutamide-resistant castration-resistant prostate cancer growth in patient-derived xenograft model by suppressing multiple signaling pathways","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Occupational Cancer Research Centre; Spinal Cord Injury BC","funders":"","keywords":"Enzalutamide; Prostate cancer; Androgen receptor; Cancer research; Bicalutamide; Survivin; Apoptosis; Medicine; In vivo; Androgen; LNCaP; Cancer; Biology; Internal medicine; Hormone","score_opus":0.0526247472187007,"score_gpt":0.30567236337101195,"score_spread":0.25304761615231125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2405138885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9758565,0.020289822,0.00023948522,0.0010653934,0.00016490005,0.0014484825,0.00066416553,0.000118534976,0.00015271375],"genre_scores_gemma":[0.995038,0.0024450861,0.00087019947,0.00086398755,0.000060454855,0.00029158042,0.00021146829,0.0001636212,0.000055652137],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9961965,0.00014091395,0.00078913016,0.0007866257,0.0010269388,0.0010598629],"domain_scores_gemma":[0.9981679,0.00006231444,0.00029025754,0.00043757918,0.000574768,0.00046718726],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030087735,0.00057042716,0.00067406625,0.0002698801,0.00020082325,0.0001668171,0.00019461864,0.00022399644,0.000026249656],"category_scores_gemma":[0.00003983419,0.0005043585,0.00018470292,0.0005513157,0.00023675214,0.00026954574,0.00008687947,0.00055672525,0.0000061587184],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020743383,0.00043147744,0.006981432,0.00024553924,0.00031924417,0.00084290106,0.0036390333,0.00910304,0.9721549,0.000013367461,0.00012453906,0.0040701893],"study_design_scores_gemma":[0.0066317036,0.00034589192,0.001724465,0.0008010097,0.00020663475,0.000011941888,0.00076616707,0.0118552325,0.9764939,0.00020235167,0.00037776717,0.00058296224],"about_ca_topic_score_codex":0.0018251331,"about_ca_topic_score_gemma":0.0003721869,"teacher_disagreement_score":0.019181447,"about_ca_system_score_codex":0.0009030388,"about_ca_system_score_gemma":0.0013573697,"threshold_uncertainty_score":0.9997408},"labels":[],"label_agreement":null},{"id":"W2405581107","doi":"10.1158/1535-7163.targ-15-c41","title":"Abstract C41: A phase 1 study of OMN54 in patients with advanced malignancies","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Fungal Biology and Applications","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Acuitas Therapeutics (Canada); BC Cancer Agency","funders":"","keywords":"Medicine; Pharmacokinetics; Internal medicine; Dosing; Adverse effect; Gastroenterology; Nausea; Vomiting; Cmax; Toxicity; Cancer; Pharmacology","score_opus":0.03311406230783848,"score_gpt":0.3316198073455244,"score_spread":0.2985057450376859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2405581107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982013,0.00065398467,0.000060281418,0.0001714695,0.000027238868,0.00062253786,0.000014807713,0.000013580788,0.00023476593],"genre_scores_gemma":[0.9991687,0.000014317363,0.00019459998,0.00046938914,0.000007701529,0.00009684031,0.000016332862,0.000013150838,0.000018995692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99939513,0.00001822383,0.00016001053,0.00014830857,0.00015539625,0.00012293847],"domain_scores_gemma":[0.9995028,0.000009711219,0.000070408954,0.00022605466,0.00014104352,0.000050013587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000055220407,0.00009427778,0.00018085666,0.000045869558,0.000014347741,0.00000216366,0.00006193843,0.0000460207,0.0000112185835],"category_scores_gemma":[0.0000049985956,0.0000708403,0.000018840072,0.00017927056,0.000049423346,0.000021416263,0.000011694971,0.00010266523,0.000002493761],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037562693,0.008387006,0.85271555,0.00005126384,0.0003605882,0.000038597263,0.0027187446,0.0003977442,0.10679487,0.00011473276,0.000027267966,0.02463739],"study_design_scores_gemma":[0.041414417,0.008329014,0.8739634,0.00016697159,0.0003297227,0.0000019103966,0.0016595214,0.000046989346,0.07043925,0.00014207468,0.0031844948,0.00032224352],"about_ca_topic_score_codex":0.000036664645,"about_ca_topic_score_gemma":0.000033084085,"teacher_disagreement_score":0.037658148,"about_ca_system_score_codex":0.000044742705,"about_ca_system_score_gemma":0.000093318566,"threshold_uncertainty_score":0.28887838},"labels":[],"label_agreement":null},{"id":"W2405852651","doi":"10.1158/1535-7163.targ-15-lb-a13","title":"Abstract LB-A13: Cellular characterization of the selective inhibition of UBA5 by organometallic, adenosine-based inhibitors","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Endoplasmic reticulum; Unfolded protein response; A549 cell; Cell biology; Cancer cell; Apoptosis; Cell; Cell growth; Cell culture; Cancer; Biology; Chemistry; Cancer research; Biochemistry","score_opus":0.01788890400519245,"score_gpt":0.2401138858856245,"score_spread":0.22222498188043205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2405852651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99380857,0.0017336238,0.0032352202,0.0002732543,0.00016642467,0.00037412706,0.00018024765,0.000010009198,0.00021850424],"genre_scores_gemma":[0.9987746,0.000080781945,0.000072519535,0.00057012297,0.00008243796,0.000038061065,0.0002657132,0.0000408716,0.00007491777],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988885,0.000103753395,0.00030045205,0.00024418996,0.0002806108,0.0001824886],"domain_scores_gemma":[0.9989886,0.0000052435344,0.0003129537,0.00033004564,0.0003031619,0.000059996448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016305412,0.00018213663,0.00018269109,0.000041865285,0.000040786832,0.000011421693,0.00017534297,0.00018023758,0.000020297466],"category_scores_gemma":[0.000017137238,0.00015243108,0.0001266675,0.00025476675,0.00013256978,0.000006276353,0.000051842646,0.00011238142,0.0000022025483],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009524353,0.00011339392,0.000790358,0.00004511372,0.000088166475,7.134179e-7,0.00012799387,0.00010203282,0.997844,0.000029478564,0.00009085733,0.00067265384],"study_design_scores_gemma":[0.0006902638,0.00018390513,0.0007466622,0.0000439403,0.00006096636,7.5045864e-7,0.000026443351,0.00004504634,0.98997486,0.0000576644,0.008001462,0.00016806516],"about_ca_topic_score_codex":0.000037793656,"about_ca_topic_score_gemma":0.000005799882,"teacher_disagreement_score":0.007910605,"about_ca_system_score_codex":0.000042497148,"about_ca_system_score_gemma":0.00027404432,"threshold_uncertainty_score":0.62159586},"labels":[],"label_agreement":null},{"id":"W2410015475","doi":"","title":"AR47A6.4.2, a functional naked monoclonal antibody targeting Trop-2, demonstrates in vivo efficacy in human pancreatic, colon, breast and prostate cancer models","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arius3D (Canada)","funders":"","keywords":"Pancreatic cancer; In vivo; Cancer research; Monoclonal antibody; Cancer; Cytotoxicity; Antibody; Signal transduction; Prostate cancer; Colorectal cancer; Biology; In vitro; Immunology; Medicine; Internal medicine; Cell biology; Biochemistry","score_opus":0.041043055824262084,"score_gpt":0.36784482769629,"score_spread":0.3268017718720279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2410015475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98484975,0.010634826,0.0011228309,0.0014569365,0.00010931541,0.0011503154,0.00007528448,0.000052690637,0.00054803723],"genre_scores_gemma":[0.9959936,0.0018144579,0.0006264129,0.00087069336,0.0001534318,0.00020785182,0.000043124317,0.00009442063,0.000196019],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9969558,0.00013738824,0.0006499093,0.00063361344,0.00070133334,0.00092195603],"domain_scores_gemma":[0.9990167,0.00010566431,0.00013042921,0.0002813674,0.00022766738,0.00023816047],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00079020456,0.0003622435,0.0005523955,0.0003724781,0.00012334311,0.00005850806,0.00014652338,0.00021254338,0.00019673021],"category_scores_gemma":[0.000016125867,0.00034986367,0.000091450565,0.0007199071,0.00028042792,0.00011490849,0.000070517766,0.00071619067,0.0000020066361],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015046021,0.0004550621,0.234239,0.00020471947,0.0002406958,0.00047927906,0.0010386949,0.0034194107,0.7442846,0.00035781623,0.000056462923,0.013719688],"study_design_scores_gemma":[0.028467847,0.0014168425,0.6172762,0.003013006,0.0005962345,0.00038490357,0.0015266697,0.049604267,0.28672168,0.0024423434,0.006471777,0.002078214],"about_ca_topic_score_codex":0.0023903577,"about_ca_topic_score_gemma":0.0013367815,"teacher_disagreement_score":0.4575629,"about_ca_system_score_codex":0.00072542264,"about_ca_system_score_gemma":0.000661239,"threshold_uncertainty_score":0.99989533},"labels":[],"label_agreement":null},{"id":"W2486291976","doi":"10.1158/1535-7163.mct-16-0048","title":"Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Doxorubicin; Osteosarcoma; Pharmacology; Cancer research; Mitochondrion; Medicine; Chemistry; Chemotherapy; Internal medicine; Biochemistry","score_opus":0.023481467536507372,"score_gpt":0.2965816286056582,"score_spread":0.2731001610691508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2486291976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9411893,0.033532158,0.016670147,0.004232537,0.0007556943,0.0011373837,0.00016647701,0.00014164207,0.0021746752],"genre_scores_gemma":[0.9867345,0.0019280382,0.0005644028,0.0032048381,0.0006277209,0.00012654866,0.00007492526,0.0002044611,0.006534569],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962338,0.00031928247,0.0005737215,0.0010321002,0.00074143056,0.0010996198],"domain_scores_gemma":[0.99772847,0.000041554886,0.00020059025,0.0013288542,0.00028476174,0.00041576],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023072962,0.000608651,0.00044279548,0.00017533968,0.00019691393,0.00009332634,0.0007830221,0.00043822275,0.00018060449],"category_scores_gemma":[0.000034744684,0.00046501678,0.00035874508,0.00040436524,0.0003045386,0.000016161659,0.00019007847,0.0002963698,0.00010978891],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005378916,0.00010297087,0.00012395978,0.000020698213,0.00042325543,0.00006319006,0.00008004454,0.000070543436,0.90906864,0.00018535921,0.0020307184,0.08729273],"study_design_scores_gemma":[0.0022241392,0.000568226,0.0002173543,0.000084904284,0.00007933692,0.00001294502,0.00005462375,0.000038149425,0.8287456,0.00024084788,0.16712756,0.0006063129],"about_ca_topic_score_codex":0.00017937864,"about_ca_topic_score_gemma":0.0002881799,"teacher_disagreement_score":0.16509685,"about_ca_system_score_codex":0.00024312915,"about_ca_system_score_gemma":0.00094513496,"threshold_uncertainty_score":0.9997802},"labels":[],"label_agreement":null},{"id":"W2488197870","doi":"10.1158/1535-7163.mct-16-0211","title":"FLIP: A Targetable Mediator of Resistance to Radiation in Non–Small Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Queen's University Belfast; British Lung Foundation; Cancer Research UK; Wellcome Trust; Department of Education and Learning, Northern Ireland","keywords":"Mediator; Lung cancer; Cancer research; Cancer; Flip; Medicine; Oncology; Biology; Immunology; Internal medicine; Genetics; Apoptosis","score_opus":0.009561578925680396,"score_gpt":0.28395312735813805,"score_spread":0.27439154843245767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2488197870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97557545,0.01645355,0.005808404,0.00097781,0.00020652545,0.0005144588,0.000108797474,0.0000083475925,0.00034668727],"genre_scores_gemma":[0.99372417,0.002259749,0.0006036789,0.0006046,0.0001478685,0.00031789314,0.000014191225,0.000059847112,0.002267978],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99844456,0.000099507066,0.00030841725,0.0004304648,0.0002913624,0.00042571983],"domain_scores_gemma":[0.99911684,0.000016936368,0.00010777432,0.00046511355,0.00017098454,0.00012235089],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021741295,0.000192001,0.00022308977,0.0001282715,0.000034543173,0.000010479216,0.00029892253,0.0001697536,0.00005118704],"category_scores_gemma":[0.000027812273,0.00016583552,0.00008855338,0.0003096771,0.00006914646,0.0000055059522,0.00008284284,0.000096908516,0.000006879945],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017586617,0.000058584104,0.0048240838,0.000061357365,0.000054944547,0.0000070312512,0.00020690312,0.0002729942,0.9885985,0.00000980128,0.0011731293,0.004556769],"study_design_scores_gemma":[0.0009946089,0.000071527465,0.0008074897,0.00009553696,0.00002413591,2.872631e-7,0.000018601306,0.00006398609,0.94998807,0.000009962959,0.047704484,0.00022131228],"about_ca_topic_score_codex":0.00016780854,"about_ca_topic_score_gemma":0.00097306253,"teacher_disagreement_score":0.046531357,"about_ca_system_score_codex":0.00021335523,"about_ca_system_score_gemma":0.00039079934,"threshold_uncertainty_score":0.6762576},"labels":[],"label_agreement":null},{"id":"W2499220296","doi":"10.1158/1538-8514.pi3k14-a02","title":"Abstract A02: Biomarkers of drug response to buparlisib: Results of next-generation sequencing in a phase II trial of advanced endometrial carcinoma","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"PTEN; Medicine; Endometrial cancer; PI3K/AKT/mTOR pathway; Oncology; KRAS; Internal medicine; Population; Clinical trial; Cohort; Cancer research; Cancer; Biology; Signal transduction; Colorectal cancer","score_opus":0.06582735248246067,"score_gpt":0.3257918820897812,"score_spread":0.2599645296073205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2499220296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994666,0.0030907525,0.00041303554,0.00017500206,0.00048095966,0.00069964124,0.00037781376,0.00000370554,0.000093084775],"genre_scores_gemma":[0.9980723,0.00032938964,0.0011088216,0.00015422713,0.00014952003,0.000050201335,0.000084416184,0.000033680153,0.000017413711],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981421,0.00014682513,0.0008083208,0.00035683715,0.0003075045,0.000238405],"domain_scores_gemma":[0.9985443,0.000074845615,0.00042570478,0.0005094861,0.00033125613,0.00011441016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089537055,0.0001984634,0.00038872266,0.00024922658,0.000022828644,0.0000104050505,0.00024295782,0.0001384778,0.0000028771847],"category_scores_gemma":[0.0005116088,0.00021279296,0.00014774053,0.00042720494,0.00008556733,0.00000813053,0.00010357818,0.000079755206,2.4959354e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12251624,0.00023548615,0.000046318073,0.000018248234,0.00011837819,0.0000065804734,0.00068614446,0.007082327,0.8606546,0.000010268447,0.000092787304,0.008532649],"study_design_scores_gemma":[0.059880745,0.0034201492,0.000089458284,0.000037102232,0.00006106761,0.0000010281509,0.00027902142,0.0003106655,0.93252945,0.000026184962,0.0031672253,0.00019791079],"about_ca_topic_score_codex":0.0008770229,"about_ca_topic_score_gemma":0.00035759615,"teacher_disagreement_score":0.07187487,"about_ca_system_score_codex":0.0001867138,"about_ca_system_score_gemma":0.0011307227,"threshold_uncertainty_score":0.8677445},"labels":[],"label_agreement":null},{"id":"W2528347464","doi":"10.1158/1535-7163.mct-16-0354","title":"Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia","funders":"National Cancer Institute; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Prostate Cancer Canada; U.S. Department of Defense","keywords":"Enzalutamide; Androgen receptor; Antiandrogens; Prostate cancer; Tetratricopeptide; Cancer research; Small molecule; Chemistry; Pharmacology; Biology; Cell biology; Medicine; Cancer; Internal medicine; Biochemistry","score_opus":0.03141413035605064,"score_gpt":0.3114934926663247,"score_spread":0.2800793623102741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528347464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869387,0.0042400076,0.0010790863,0.006914796,0.0001797671,0.0004472653,0.000026391246,0.000026437216,0.00014754912],"genre_scores_gemma":[0.9957619,0.0029942447,0.00006918149,0.00041377015,0.00006972575,0.000033942793,0.000009622392,0.000026786052,0.000620868],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99927086,0.00004569761,0.00016300024,0.00016370502,0.00021165283,0.00014506262],"domain_scores_gemma":[0.99955463,0.000031143372,0.00008214872,0.00014521147,0.00014171579,0.000045127887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000086996966,0.00010033557,0.00012580036,0.000058479374,0.0001166761,0.000009883855,0.00005461395,0.000051943174,0.00022560768],"category_scores_gemma":[0.000009342153,0.000057075307,0.000050640654,0.00015590488,0.00008321215,0.00007649665,0.0000146704515,0.00009921305,0.000005037142],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029394132,0.000042931613,0.0029493617,0.000032192333,0.00026074034,3.874678e-7,0.00035268546,0.0000037841303,0.95092636,0.00009662001,0.000104291,0.044936676],"study_design_scores_gemma":[0.0018000522,0.00013815548,0.0014091784,0.0003250605,0.00013554933,0.000003654684,0.00019201422,0.00011566586,0.96156526,0.00004010223,0.034177255,0.000098044264],"about_ca_topic_score_codex":0.000011931627,"about_ca_topic_score_gemma":0.0000015871574,"teacher_disagreement_score":0.04483863,"about_ca_system_score_codex":0.0001277043,"about_ca_system_score_gemma":0.0000891177,"threshold_uncertainty_score":0.24702458},"labels":[],"label_agreement":null},{"id":"W2536079445","doi":"10.1158/1535-7163.mct-16-0449","title":"Preclinical Efficacy of an Antibody–Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Public Health Agency of Canada","keywords":"Mesothelin; Antibody-drug conjugate; Monoclonal antibody; Cancer research; Immunohistochemistry; Antibody; In vivo; Pancreatic cancer; Cancer; Mesothelioma; Chemistry; Medicine; Immunology; Pathology; Biology; Internal medicine","score_opus":0.024712442906646,"score_gpt":0.3452394585150638,"score_spread":0.32052701560841784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2536079445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927838,0.004415479,0.0014532201,0.00072824064,0.00006524101,0.0002795094,0.000095032585,0.000032167485,0.00014731736],"genre_scores_gemma":[0.99602294,0.00072090916,0.0020790359,0.00082178396,0.00003297561,0.000015615777,0.000065507345,0.000039604314,0.00020161556],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988838,0.000089542984,0.0002846161,0.00025890776,0.00029772703,0.00018543703],"domain_scores_gemma":[0.99930495,0.00014480307,0.00014430405,0.0002359083,0.000072128794,0.0000978961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012235655,0.00016596999,0.00026352532,0.000036071408,0.00004434881,0.0000071265745,0.00009687408,0.00004999306,0.00020637672],"category_scores_gemma":[0.000022931983,0.000098144075,0.00009382489,0.000081677805,0.00027368133,0.000074579395,0.000026012678,0.00009240961,0.000022540606],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049910555,0.00080356415,0.18917225,0.00006720084,0.0008033852,0.00004824846,0.00035392077,0.00027764335,0.7909651,0.0004939485,0.000019509132,0.012004204],"study_design_scores_gemma":[0.011551818,0.0033013697,0.5025437,0.0014132006,0.0016109623,0.00002257765,0.0003431428,0.0013732985,0.47117838,0.0006017102,0.0053713834,0.0006884811],"about_ca_topic_score_codex":0.000035327423,"about_ca_topic_score_gemma":0.0000043163104,"teacher_disagreement_score":0.3197867,"about_ca_system_score_codex":0.00004762803,"about_ca_system_score_gemma":0.000095495634,"threshold_uncertainty_score":0.40021995},"labels":[],"label_agreement":null},{"id":"W2537108088","doi":"10.1158/1535-7163.mct-16-0325","title":"6α-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Health and Medical Research Council; Griffith University; Prostate Cancer Foundation of Australia; Medical Research Council; Movember Foundation; Australian Government; Prostate Cancer Foundation","keywords":"Microtubule polymerization; LNCaP; Vinblastine; Mitosis; Microtubule; Cancer research; Cancer cell; Biology; Vinca; Prostate cancer; Cell biology; Mitotic catastrophe; Cancer; Pharmacology; Tubulin; Chemotherapy; Genetics","score_opus":0.007828536117142175,"score_gpt":0.2517319151267506,"score_spread":0.2439033790096084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2537108088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890193,0.003109575,0.0054785484,0.00060717354,0.00042718888,0.00048544124,0.0008087918,0.000014746696,0.000049256934],"genre_scores_gemma":[0.9953047,0.0022707197,0.0010816872,0.00063263514,0.00013126238,0.000079615704,0.000058718262,0.00009639702,0.0003442383],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981804,0.00007047812,0.00047354423,0.00055672746,0.00020018146,0.0005186634],"domain_scores_gemma":[0.9989848,0.000012428394,0.0002478709,0.0005227999,0.00014889587,0.00008319549],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010854258,0.00036226807,0.00034720372,0.00009573356,0.00004424513,0.000024365196,0.00033486838,0.00025608955,0.000026543814],"category_scores_gemma":[0.000008601443,0.0002944772,0.00015196015,0.00017633615,0.00016273133,0.000009755655,0.00017856454,0.00016388687,0.0000014783753],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013372352,0.00009627555,0.0065264744,0.00010936686,0.00016821278,0.000007295493,0.000108432345,0.00046469574,0.9818332,0.000054038574,0.00002676892,0.010471515],"study_design_scores_gemma":[0.0016634765,0.00014347336,0.0004367774,0.00021380174,0.0000691944,0.00000860808,0.00007114133,0.0007019626,0.98760134,0.000034156845,0.008629953,0.000426118],"about_ca_topic_score_codex":0.00016501741,"about_ca_topic_score_gemma":0.0020444652,"teacher_disagreement_score":0.010045397,"about_ca_system_score_codex":0.00023170908,"about_ca_system_score_gemma":0.00022384709,"threshold_uncertainty_score":0.9999507},"labels":[],"label_agreement":null},{"id":"W2559479504","doi":"10.1158/1535-7163.mct-16-0416","title":"STAT1 Promotes <i>KRAS</i> Colon Tumor Growth and Susceptibility to Pharmacological Inhibition of Translation Initiation Factor eIF4A","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Cancer Research Society","keywords":"KRAS; Cancer research; Carcinogenesis; Biology; STAT1; Downregulation and upregulation; PI3K/AKT/mTOR pathway; Colorectal cancer; Gene knockdown; Cancer; Signal transduction; Eukaryotic translation; Translation (biology); Messenger RNA; Cell culture; Cell biology; Gene; Genetics","score_opus":0.05675535520054349,"score_gpt":0.33603544510472205,"score_spread":0.2792800899041786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559479504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983063,0.00024505932,0.012570111,0.0031997727,0.00008487719,0.000560743,0.00013722984,0.000037476875,0.00010177438],"genre_scores_gemma":[0.9976719,0.00010607862,0.0005380623,0.0015491078,0.00005053786,0.000047628655,0.000013526994,0.000016238153,0.000006898477],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99917156,0.00006214513,0.0002394198,0.0002112781,0.00017869241,0.00013691674],"domain_scores_gemma":[0.99953306,0.000058834605,0.00008590292,0.00009191242,0.00015206425,0.000078199286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000764064,0.00011556852,0.00017897913,0.000067545385,0.000037766833,0.000009207209,0.000025849125,0.00005290634,0.00014625938],"category_scores_gemma":[0.000024086039,0.000081132115,0.000060284798,0.0001337133,0.000057909776,0.00007516771,0.00001118338,0.00008357061,0.0000020139205],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034067617,0.00013930628,0.0038728325,0.000053815907,0.0000647267,0.000005968952,0.00044903826,0.0000024477802,0.9821938,0.000074556105,0.000009849743,0.012792941],"study_design_scores_gemma":[0.00125463,0.00075971993,0.008571485,0.00012951733,0.00015216421,0.0000063983694,0.0000192682,0.000075762284,0.9879394,0.00021209473,0.0007772368,0.000102316146],"about_ca_topic_score_codex":0.00003931285,"about_ca_topic_score_gemma":0.00002147664,"teacher_disagreement_score":0.014608965,"about_ca_system_score_codex":0.00009215883,"about_ca_system_score_gemma":0.00010211915,"threshold_uncertainty_score":0.33084717},"labels":[],"label_agreement":null},{"id":"W2563098228","doi":"","title":"SFRP1 promoter methylation and its contribution to endometrial tumorigenesis","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"DNA methylation; Carcinogenesis; Endometrial cancer; Microsatellite instability; Epigenetics; Methylation; Biology; Cancer research; Wnt signaling pathway; Bisulfite sequencing; Cancer; Molecular biology; Genetics; Gene; Gene expression; Microsatellite","score_opus":0.021554815787292996,"score_gpt":0.3117308642557196,"score_spread":0.2901760484684266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563098228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8663146,0.011827572,0.1207093,0.00027329056,0.0002717025,0.00046444646,0.000018673636,0.000014394818,0.00010604677],"genre_scores_gemma":[0.9970392,0.0008923205,0.0008861415,0.0006611253,0.0002991218,0.000036115307,0.00005796499,0.00003371255,0.00009431311],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99880517,0.00007339799,0.00025168696,0.00035358392,0.0002130014,0.00030314567],"domain_scores_gemma":[0.9993297,0.000020025289,0.00008671455,0.00020617073,0.00023076235,0.00012661585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000571286,0.00017332235,0.00015025327,0.00011739553,0.00008432244,0.000034480334,0.000099565004,0.00016501539,0.000011414945],"category_scores_gemma":[0.00007177086,0.00017420405,0.00006613028,0.0002469024,0.00002222971,0.000004410026,0.000059764305,0.00006952056,0.0000049547016],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017941363,0.000026104472,0.0012337136,0.0000070738224,0.000078316385,0.0000029939704,0.000048123416,0.000119073586,0.9718167,0.00024640164,0.0000037629197,0.026238307],"study_design_scores_gemma":[0.00071692636,0.00028730472,0.0044481233,0.0000075124485,0.0000586441,0.000001462659,0.000007834971,0.00009793316,0.95005524,0.00021479304,0.043889455,0.00021475187],"about_ca_topic_score_codex":0.000013638749,"about_ca_topic_score_gemma":0.00003236895,"teacher_disagreement_score":0.13072461,"about_ca_system_score_codex":0.000043134973,"about_ca_system_score_gemma":0.000047173944,"threshold_uncertainty_score":0.7103835},"labels":[],"label_agreement":null},{"id":"W2563238632","doi":"","title":"Anticancer activity of a human monoclonal antibody inhibitor of MMP-14","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Matrix metalloproteinase; Immunohistochemistry; Metastasis; Cancer research; Monoclonal antibody; Antibody; Cancer; Tumor progression; Medicine; Phage display; In vitro; Immunology; Pharmacology; Biology; Internal medicine; Biochemistry","score_opus":0.019519780710510498,"score_gpt":0.3232640618103585,"score_spread":0.30374428109984797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563238632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9639987,0.002495165,0.032427825,0.00004855742,0.0001911234,0.00023782528,0.00004544596,0.000009963577,0.00054541265],"genre_scores_gemma":[0.9982634,0.00023508698,0.0008511804,0.0003114278,0.00018853963,0.000012811061,0.000026906522,0.000039397513,0.00007124317],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987303,0.00005011385,0.00031307034,0.000307087,0.00029313794,0.00030626872],"domain_scores_gemma":[0.99907804,0.0000071685145,0.00022925978,0.00041861527,0.00019401412,0.00007292504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027061265,0.00019950703,0.00026317776,0.00006885956,0.00004782961,0.000006550841,0.00021142454,0.00020432062,0.000025718029],"category_scores_gemma":[0.00000829025,0.00019863567,0.00018226115,0.00015406244,0.00015009136,0.000005487875,0.000070091286,0.00012254754,9.0610075e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002249092,0.000141383,0.0010072928,0.000050994633,0.00019467504,0.000006186988,0.00004727083,0.000015466552,0.994032,0.0004004171,0.000022148604,0.0038572387],"study_design_scores_gemma":[0.0006694045,0.0005028625,0.0006378126,0.000046965208,0.000071060684,0.000002271391,0.000018930767,0.00002623979,0.99553967,0.00037293887,0.0018996667,0.00021218607],"about_ca_topic_score_codex":0.00007288681,"about_ca_topic_score_gemma":0.000021560958,"teacher_disagreement_score":0.034264725,"about_ca_system_score_codex":0.00002506735,"about_ca_system_score_gemma":0.00012199725,"threshold_uncertainty_score":0.81001276},"labels":[],"label_agreement":null},{"id":"W2563884867","doi":"10.1158/1535-7163.mct-16-0588","title":"Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Cancer Institute; National Institutes of Health","keywords":"Epigenetics; Epigenetic therapy; Vorinostat; Histone deacetylase; Biology; DNA methylation; Cancer research; Cancer; Decitabine; Pharmacology; Histone; Gene expression; Genetics; Gene","score_opus":0.013206137043269965,"score_gpt":0.29976905953115307,"score_spread":0.2865629224878831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563884867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869784,0.0030153987,0.0054034414,0.0031758668,0.00013445136,0.0008869395,0.000029911875,0.00003269923,0.00034286],"genre_scores_gemma":[0.995364,0.00060886284,0.00086481543,0.00089098635,0.0000984187,0.0009026394,0.000034077424,0.00009241635,0.0011437706],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977028,0.00018897114,0.00034347308,0.0007562268,0.0004358764,0.000572698],"domain_scores_gemma":[0.9987483,0.000019749943,0.0001263819,0.0006637935,0.0002844461,0.00015730473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032020116,0.00027254724,0.0002411292,0.00015378791,0.00011539141,0.000049548908,0.00029185446,0.00018992834,0.000028160763],"category_scores_gemma":[0.000021995364,0.00022325532,0.00008380251,0.00043857782,0.000146442,0.000008800859,0.00010812048,0.00015314149,0.000013721535],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037651233,0.00013270568,0.0015259254,0.000021744407,0.00013307242,0.000017506665,0.0005902345,0.00034507125,0.9542764,0.000044085406,0.00007016155,0.04246659],"study_design_scores_gemma":[0.0018458694,0.0006907868,0.0011159481,0.00017119508,0.000043757685,0.000004749697,0.00009593362,0.000057268433,0.96693045,0.000060906295,0.028558161,0.00042499026],"about_ca_topic_score_codex":0.0004512506,"about_ca_topic_score_gemma":0.00048709958,"teacher_disagreement_score":0.042041596,"about_ca_system_score_codex":0.0003996842,"about_ca_system_score_gemma":0.00034403155,"threshold_uncertainty_score":0.9104088},"labels":[],"label_agreement":null},{"id":"W2565862397","doi":"","title":"Tumor suppressive role of ING3 in human cutaneous melanoma tumorigenesis and its regulation by ubiquitin-proteasome system","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Melanoma; Carcinogenesis; Cancer research; Apoptosis; Ubiquitin ligase; Immunohistochemistry; Suppressor; Proteasome; Ubiquitin; Pathogenesis; Cell; Cancer; Biology; Chemistry; Medicine; Pathology; Cell biology; Internal medicine; Gene; Genetics","score_opus":0.008894793696357222,"score_gpt":0.25984248071814736,"score_spread":0.25094768702179016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565862397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980844,0.017113255,0.0012304374,0.00004608204,0.00004874778,0.00032688418,0.000053394047,0.000011426546,0.00032572335],"genre_scores_gemma":[0.99922603,0.00022435414,0.00010563568,0.00012069061,0.000051768806,0.000065891276,0.000051243424,0.000036316153,0.00011808836],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988947,0.000056775883,0.00031549306,0.00032079793,0.00016571044,0.00024652304],"domain_scores_gemma":[0.99935615,0.0000057634056,0.00018323971,0.00027572736,0.00012134479,0.0000577591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015120584,0.00016644209,0.00018477564,0.00006606252,0.00006446584,0.000015365571,0.00015248948,0.00011553366,0.000009571937],"category_scores_gemma":[0.000003982448,0.00017326201,0.00005151005,0.00011948074,0.00005438866,0.000005111067,0.000045024564,0.00007409833,6.851858e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000078284625,0.000037877886,0.0012892614,0.000049351744,0.00004612394,0.00001112646,0.000091229675,0.00013486488,0.9931836,0.00086158636,0.000010907354,0.004205799],"study_design_scores_gemma":[0.00042311597,0.00012593952,0.001661929,0.000052570027,0.000037820704,0.00004123581,0.00023809812,0.00029918883,0.9928529,0.00008645719,0.0039859326,0.00019477728],"about_ca_topic_score_codex":0.00010841665,"about_ca_topic_score_gemma":0.000053737014,"teacher_disagreement_score":0.018381963,"about_ca_system_score_codex":0.00007928563,"about_ca_system_score_gemma":0.00005415268,"threshold_uncertainty_score":0.706542},"labels":[],"label_agreement":null},{"id":"W2565888311","doi":"","title":"Impaired membrane-type 1 matrix metalloproteinase phosphorylation results in blocking 3D-collagen invasion by tumor cells through cell cycle arrest in G0/G1 phase","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université du Québec à Montréal","funders":"","keywords":"Matrix metalloproteinase; Cell cycle; Molecular biology; Extracellular matrix; Zymography; Flow cytometry; Type I collagen; Cell growth; Cell biology; Biology; Transfection; Cell culture; Type IV collagen; Wild type; Cell; Chemistry; Mutant; Biochemistry; Laminin","score_opus":0.015086422817382634,"score_gpt":0.28585834157452333,"score_spread":0.2707719187571407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565888311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98677653,0.008982262,0.002408105,0.00009741079,0.00035330237,0.0009424223,0.000080100544,0.0000264004,0.00033348997],"genre_scores_gemma":[0.99611455,0.00073254696,0.0015435831,0.0010071868,0.00011247632,0.000062401785,0.00022814145,0.00007500601,0.00012407676],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99773335,0.00013793183,0.0005930349,0.0006449282,0.00031311976,0.0005776062],"domain_scores_gemma":[0.99905425,0.0000150810065,0.00023072597,0.0005107204,0.00008937071,0.000099848025],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006070908,0.00034716135,0.00029092806,0.000101151396,0.00007947275,0.00003974533,0.00027270432,0.00028097373,0.000019874373],"category_scores_gemma":[0.000020604863,0.0003661162,0.00010983421,0.0004584301,0.000049553724,0.000019709722,0.00009475433,0.00019341402,0.00000851217],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013352834,0.00037163025,0.000033615226,0.000042184445,0.000040839383,0.00011143665,0.00022205316,0.0007707391,0.99576604,0.000009151642,0.00008349544,0.0012135524],"study_design_scores_gemma":[0.0043696747,0.0004419579,0.000010409692,0.00007135847,0.000045626257,0.0000029378134,0.00008478725,0.00071413495,0.9851291,0.00014257604,0.008556565,0.00043085686],"about_ca_topic_score_codex":0.00049290695,"about_ca_topic_score_gemma":0.00032449764,"teacher_disagreement_score":0.010636905,"about_ca_system_score_codex":0.00014116647,"about_ca_system_score_gemma":0.00018014693,"threshold_uncertainty_score":0.99987906},"labels":[],"label_agreement":null},{"id":"W2566139700","doi":"","title":"Intramembrane proteolysis of the p75 neurotrophin receptor is required for glioma invasion.","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Ectodomain; Low-affinity nerve growth factor receptor; Biology; Neurite; Cell biology; Proteolysis; Glioma; Receptor; Neurotrophin; Molecular biology; Cancer research; In vitro; Biochemistry","score_opus":0.028463922027722622,"score_gpt":0.3162503988662543,"score_spread":0.28778647683853165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566139700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98806757,0.0038264857,0.005160787,0.0013452705,0.00019401025,0.0011409529,0.00015034643,0.000009791807,0.00010479712],"genre_scores_gemma":[0.9964058,0.0005010594,0.00081711495,0.0015837643,0.00012822739,0.00020814675,0.000034008117,0.000049169474,0.00027273197],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99868524,0.000055255547,0.00025481827,0.00034162213,0.00029015963,0.0003728838],"domain_scores_gemma":[0.99899644,0.000014583194,0.00013422538,0.0005910532,0.00018144854,0.00008223925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018358983,0.00018159176,0.0001722452,0.000050507977,0.00009890892,0.000018917694,0.00036126337,0.0001310122,0.000031049654],"category_scores_gemma":[0.00002989939,0.00013629568,0.00025108582,0.0002669036,0.00014644688,0.000003800934,0.00010717805,0.00009250553,0.0000020306613],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000654235,0.0000933074,0.0005514142,0.000043467353,0.00034446645,0.0000035427543,0.00006727199,0.000023232398,0.97983813,0.000046563848,0.00036669653,0.017967647],"study_design_scores_gemma":[0.001175215,0.00035081687,0.0004036026,0.000023631073,0.00007368311,0.0000043503087,0.000017703453,0.000024069133,0.9537558,0.00017190732,0.04385682,0.0001424129],"about_ca_topic_score_codex":0.00016814847,"about_ca_topic_score_gemma":0.0001317509,"teacher_disagreement_score":0.043490123,"about_ca_system_score_codex":0.000051613468,"about_ca_system_score_gemma":0.00018135087,"threshold_uncertainty_score":0.55579764},"labels":[],"label_agreement":null},{"id":"W2570216110","doi":"","title":"Cell death ELISAs in the phase I clinical evaluation of AEG35156 (XIAP antisense) administered as an intravenous infusion over 7-days, 3-days, and 2-hours.","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Molecular Biology Techniques and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aegera Therapeutics (Canada)","funders":"","keywords":"XIAP; Apoptosis; Programmed cell death; Inhibitor of apoptosis; Pharmacology; Medicine; Cancer; Biology; Caspase; Cancer research; Internal medicine","score_opus":0.05674874129001793,"score_gpt":0.42197239441858936,"score_spread":0.3652236531285714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570216110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864523,0.003739709,0.008228633,0.00012745008,0.00008095409,0.0007387002,0.000031235602,0.000012804642,0.00058824325],"genre_scores_gemma":[0.9942352,0.001927583,0.0011025907,0.0023498645,0.00011318219,0.00006315224,0.0001605099,0.0000341457,0.000013766199],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99797803,0.00045168493,0.0005001306,0.00046668143,0.00031310157,0.00029035704],"domain_scores_gemma":[0.99874765,0.00003060661,0.00022120624,0.00065961387,0.00025788246,0.00008303391],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020676926,0.00021755921,0.00022426921,0.000066849876,0.00007558963,0.000022375045,0.00030037275,0.00034630147,0.000018029146],"category_scores_gemma":[0.000041770716,0.0001814913,0.000106285624,0.00015556798,0.00018350038,0.000005452949,0.0000799164,0.00021278033,9.412321e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024507087,0.00067697867,0.0031447024,0.000012478173,0.00006152248,0.0000104669325,0.00022315541,0.000014349666,0.9138162,0.00035885553,0.00007719506,0.081359014],"study_design_scores_gemma":[0.0035995105,0.0021348714,0.012397492,0.000035233053,0.00032968936,0.000031603366,0.0002397048,0.0008232239,0.9555552,0.0012106214,0.023221212,0.0004216251],"about_ca_topic_score_codex":0.00011735069,"about_ca_topic_score_gemma":0.00011052023,"teacher_disagreement_score":0.080937386,"about_ca_system_score_codex":0.00002605569,"about_ca_system_score_gemma":0.00019000273,"threshold_uncertainty_score":0.7401},"labels":[],"label_agreement":null},{"id":"W2580129211","doi":"10.1158/1535-7163.mct-16-0504","title":"Ras–MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer Cells","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"DNA damage; CHEK1; Cancer research; Biology; Cancer; DNA repair; Cancer cell; G2-M DNA damage checkpoint; Kinase; Signal transduction; Cell biology; DNA; Cell cycle; Cell cycle checkpoint; Genetics","score_opus":0.025533460785314318,"score_gpt":0.3259974071218004,"score_spread":0.3004639463364861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2580129211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905391,0.0045628794,0.0017905849,0.0018044945,0.000700818,0.00031559463,0.00008423075,0.00002959638,0.00017274274],"genre_scores_gemma":[0.9953055,0.00094989035,0.0008218696,0.0021153104,0.00019942984,0.000194791,0.000013581838,0.00009436941,0.00030530326],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99778926,0.0002735703,0.00032228715,0.00064659514,0.00037621782,0.00059206435],"domain_scores_gemma":[0.9984455,0.000047991376,0.00015083548,0.0010749678,0.00012963281,0.00015108123],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00057221926,0.00032883376,0.0002889601,0.00007889205,0.0002118261,0.0001495995,0.0007399281,0.00030181618,0.00010115171],"category_scores_gemma":[0.00012328113,0.0003390532,0.00015312417,0.00006468635,0.0002160478,0.000012994405,0.0002808804,0.00025290795,0.00001248611],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000756109,0.00009886909,0.0005221492,0.000030076102,0.000120362965,0.00014086561,0.00016716824,0.00042062893,0.99577004,0.0001011132,0.00003230556,0.0018403125],"study_design_scores_gemma":[0.0010228973,0.00023447441,0.00079759466,0.00008250148,0.00008131018,0.000004163931,0.000077033525,0.00046627075,0.990568,0.0003488006,0.0058920817,0.00042489357],"about_ca_topic_score_codex":0.00020328721,"about_ca_topic_score_gemma":0.00024511394,"teacher_disagreement_score":0.005859776,"about_ca_system_score_codex":0.0001112337,"about_ca_system_score_gemma":0.0003082874,"threshold_uncertainty_score":0.9999061},"labels":[],"label_agreement":null},{"id":"W2580398445","doi":"10.1158/1535-7163.mct-16-0644","title":"Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; University of Texas at El Paso; University of Toronto; Oregon Health and Science University","keywords":"Metastatic breast cancer; Cancer research; Breast cancer; Cancer; Kinome; Metastasis; Triple-negative breast cancer; Cancer cell; Cytotoxicity; Gene knockdown; In vivo; PLK1; Medicine; Chemistry; Biology; Kinase; In vitro; Internal medicine; Apoptosis; Cell cycle; Cell biology; Biochemistry","score_opus":0.028174877008697374,"score_gpt":0.2928454558962161,"score_spread":0.2646705788875187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2580398445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98819566,0.007464886,0.0006394222,0.0006742774,0.00032707932,0.00044386194,0.0021605948,0.000072980016,0.00002122942],"genre_scores_gemma":[0.9976352,0.00094355195,0.0005307682,0.00052452,0.000035449826,0.000140966,0.000025226971,0.000068349706,0.00009599051],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99771404,0.00011719271,0.00047496753,0.00053488166,0.00052246236,0.00063647394],"domain_scores_gemma":[0.9979938,0.000030749125,0.00046277037,0.001075893,0.00021269062,0.00022408055],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001845617,0.00036379235,0.00048620938,0.000046497116,0.0003544937,0.00018997553,0.0006130724,0.000079460115,0.00049436657],"category_scores_gemma":[0.0000061394207,0.00031379441,0.0001304566,0.00011583759,0.00033212794,0.00048706218,0.00006797174,0.00006827072,0.000029987079],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032227393,0.00077113084,0.0013074623,0.000021261312,0.00020120926,0.000028695058,0.0004009417,0.0005035467,0.9812016,0.000042403703,0.00014466021,0.015054829],"study_design_scores_gemma":[0.0025033627,0.00043032577,0.0008339255,0.00003741484,0.00035141283,0.0000074735262,0.000087534114,0.0030830842,0.99059045,0.00009319535,0.0016055969,0.00037620144],"about_ca_topic_score_codex":0.0044578467,"about_ca_topic_score_gemma":0.0002685832,"teacher_disagreement_score":0.014678628,"about_ca_system_score_codex":0.00034288288,"about_ca_system_score_gemma":0.00022702689,"threshold_uncertainty_score":0.9999314},"labels":[],"label_agreement":null},{"id":"W2581199101","doi":"10.1158/1538-8514.pi3k14-b51","title":"Abstract B51: The tyrphostin, NT157, suppresses insulin receptor substrates and augments therapeutic response of prostate cancer","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"","keywords":"LNCaP; Prostate cancer; IRS1; Cancer research; Protein kinase B; Androgen receptor; PI3K/AKT/mTOR pathway; MAPK/ERK pathway; Insulin-like growth factor 1 receptor; Endocrinology; Internal medicine; Signal transduction; Insulin receptor; Growth factor; Biology; Cancer; Receptor; Medicine; Insulin; Insulin resistance; Cell biology","score_opus":0.03238721274005957,"score_gpt":0.30560673511112435,"score_spread":0.2732195223710648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581199101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9122988,0.0851093,0.00011579425,0.0012774732,0.00042388207,0.00046319162,0.00021360934,0.000023481694,0.000074437114],"genre_scores_gemma":[0.9912981,0.0061289067,0.0001744194,0.0016804688,0.00014735102,0.00021303834,0.000038442653,0.00008714026,0.00023215027],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979742,0.00024268252,0.00041496876,0.00051432726,0.00041602273,0.00043777472],"domain_scores_gemma":[0.99848664,0.000070226146,0.00028748525,0.000616747,0.0003943359,0.00014458844],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005978638,0.00036129088,0.00028975698,0.000056083532,0.0001008875,0.00006346049,0.00045668602,0.00022017209,0.000059666974],"category_scores_gemma":[0.000057344907,0.00028113407,0.00010665337,0.00021743636,0.00039422777,0.000012831922,0.00012599934,0.00022543057,0.0000045284005],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024510352,0.00008393855,0.008901452,0.00005348941,0.00049576093,0.0000054577217,0.0006832622,0.00083578617,0.9757609,0.00002098543,0.00055076584,0.010157181],"study_design_scores_gemma":[0.0013698599,0.00039033275,0.0068738065,0.000086152206,0.00013851718,0.000006001616,0.00025647314,0.000056265246,0.9379053,0.00017477463,0.052373145,0.00036934373],"about_ca_topic_score_codex":0.00028641254,"about_ca_topic_score_gemma":0.000068068264,"teacher_disagreement_score":0.07899926,"about_ca_system_score_codex":0.00008315524,"about_ca_system_score_gemma":0.00063418056,"threshold_uncertainty_score":0.99996406},"labels":[],"label_agreement":null},{"id":"W2585919465","doi":"10.1158/1535-7163.mct-16-0753","title":"Mitogen-Activated Protein Kinases Inhibitors: Potential Therapeutic Agents for Cancer Cachexia","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Kinase; Cancer; Protein kinase A; Cachexia; Mitogen-activated protein kinase; Cancer research; Pharmacology; Medicine; Cancer cachexia; Chemistry; Biochemistry; Internal medicine","score_opus":0.09000478040142562,"score_gpt":0.3960864685893406,"score_spread":0.306081688187915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2585919465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93392885,0.019434487,0.005248266,0.03353835,0.0026569627,0.0042888024,0.00021728387,0.00022818193,0.00045879695],"genre_scores_gemma":[0.9865049,0.00084650354,0.00064143824,0.008531702,0.00068960653,0.0010597843,0.00003851014,0.00010538261,0.0015821606],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982663,0.00005501171,0.00033976452,0.00042404572,0.00037308814,0.0005417831],"domain_scores_gemma":[0.9985355,0.000012049145,0.0002917539,0.0006665898,0.00029596005,0.00019812518],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014070679,0.0002896247,0.00038984176,0.000097160766,0.000605234,0.000121967336,0.00025350536,0.00019046628,0.00018211009],"category_scores_gemma":[0.000015879988,0.00026853083,0.00022212895,0.000085885644,0.00015029039,0.000100156576,0.00004930842,0.00027425095,0.0000074664235],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007881209,0.00020312027,0.0023922208,0.00045655968,0.0004887807,0.00004493124,0.00025099484,0.00001621957,0.9365447,0.0002525799,0.00046031584,0.05810144],"study_design_scores_gemma":[0.00511992,0.00024647152,0.004405526,0.00061437837,0.00043374082,0.000010911108,0.00006543156,0.0006487802,0.78977114,0.0007485069,0.19757003,0.00036519492],"about_ca_topic_score_codex":0.0005657405,"about_ca_topic_score_gemma":0.000056613342,"teacher_disagreement_score":0.1971097,"about_ca_system_score_codex":0.0002642567,"about_ca_system_score_gemma":0.00036291234,"threshold_uncertainty_score":0.9999767},"labels":[],"label_agreement":null},{"id":"W2611439401","doi":"10.1158/1535-7163.mct-16-0819","title":"Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Sirtuins and Resveratrol in Medicine","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Food science; Substrate (aquarium); Chemistry; Biochemistry; Biology; Ecology","score_opus":0.029365483733206646,"score_gpt":0.3017219061666139,"score_spread":0.27235642243340724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611439401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99526024,0.0018152168,0.00073104905,0.0015871745,0.00019669744,0.00020475565,0.000023424835,0.000009775959,0.00017168604],"genre_scores_gemma":[0.9960591,0.0027971903,0.00014469346,0.0006501027,0.00010892935,0.000009200059,0.000013723195,0.000021753507,0.0001952834],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993203,0.000010619491,0.00018300739,0.0001841733,0.00016616432,0.00013573689],"domain_scores_gemma":[0.9993953,0.00000805361,0.00016596654,0.00029500542,0.00007167081,0.00006400107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000090752714,0.00012939135,0.00023762211,0.000045120163,0.00010765351,0.00005902094,0.00005920297,0.00008381723,0.0000047602807],"category_scores_gemma":[0.0000069052353,0.000099639095,0.00003535819,0.000035725123,0.00027406268,0.00010755674,0.000031898424,0.0001187402,2.2566135e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011169316,0.00005581404,0.03152638,0.00008786122,0.00014062993,0.00001926632,0.00018144966,0.0000013523938,0.9611843,0.00020957927,0.0000011278746,0.0064805243],"study_design_scores_gemma":[0.0033780972,0.00025855002,0.49593958,0.00037201325,0.0003741443,0.00004443729,0.000078571895,0.0010097172,0.49760833,0.000046075173,0.0007130048,0.00017745905],"about_ca_topic_score_codex":0.000069002635,"about_ca_topic_score_gemma":0.000011576657,"teacher_disagreement_score":0.4644132,"about_ca_system_score_codex":0.000013726127,"about_ca_system_score_gemma":0.000061012513,"threshold_uncertainty_score":0.40631646},"labels":[],"label_agreement":null},{"id":"W2625910864","doi":"10.1158/1535-7163.mct-17-0009","title":"Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"Pancreatic cancer; MEK inhibitor; Cancer research; MAPK/ERK pathway; Medicine; STAT3; Cancer; Ponatinib; KRAS; Kinase; Selumetinib; Metastasis; Internal medicine; Biology; Signal transduction; Dasatinib; Imatinib","score_opus":0.06310484529008194,"score_gpt":0.36081807515836284,"score_spread":0.2977132298682809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625910864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98621714,0.006971855,0.0008306158,0.002034182,0.00006467389,0.0005130781,0.000023502065,0.0000205715,0.003324372],"genre_scores_gemma":[0.9947232,0.0010919862,0.0026854156,0.00090115156,0.00007684976,0.00006426307,0.000005153071,0.00003765495,0.00041433415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986721,0.00006888583,0.00026483115,0.00030101216,0.00032417872,0.00036896503],"domain_scores_gemma":[0.9987833,0.000069323214,0.00013962123,0.00062753574,0.00016120347,0.00021902815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022907366,0.00018636392,0.00057309127,0.00008687841,0.00021161149,0.00003376046,0.00019021095,0.00010993098,0.00007662517],"category_scores_gemma":[0.000090394096,0.00015727198,0.000081298174,0.00007032402,0.00023524632,0.00005331267,0.00011424568,0.00017507431,0.0000090982485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042465166,0.00009504287,0.6517941,0.00022016797,0.00038027455,0.00028219348,0.0015431581,0.0000019035934,0.33762124,0.00063311064,0.00007401371,0.006930191],"study_design_scores_gemma":[0.00447253,0.0016117069,0.87915,0.00039604708,0.0017985442,0.00016065812,0.0006831474,0.0010338158,0.10756922,0.00097203156,0.0017592522,0.00039307037],"about_ca_topic_score_codex":0.0003852792,"about_ca_topic_score_gemma":0.000021099513,"teacher_disagreement_score":0.23005202,"about_ca_system_score_codex":0.000089542955,"about_ca_system_score_gemma":0.000265311,"threshold_uncertainty_score":0.6413365},"labels":[],"label_agreement":null},{"id":"W2731426244","doi":"10.1158/1535-7163.mct-16-0666","title":"Inactivation of the Kinase Domain of CDK10 Prevents Tumor Growth in a Preclinical Model of Colorectal Cancer, and Is Accompanied by Downregulation of Bcl-2","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Downregulation and upregulation; Colorectal cancer; Cancer research; Cancer; Kinase; Protein kinase domain; Medicine; Chemistry; Biology; Cell biology; Internal medicine; Gene; Genetics","score_opus":0.04300192920630522,"score_gpt":0.3410777621829696,"score_spread":0.2980758329766644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2731426244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99689907,0.0014722713,0.00032289972,0.00035599858,0.000084057254,0.0006515833,0.00014009912,0.0000031701975,0.00007083055],"genre_scores_gemma":[0.998682,0.00029047023,0.0008048829,0.00012186864,0.000009911153,0.000051715982,0.0000037313155,0.000022192577,0.000013230226],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99864787,0.000073209194,0.0005301386,0.00021715944,0.0003933784,0.00013823256],"domain_scores_gemma":[0.9985186,0.000057792924,0.00077490805,0.0003910598,0.00022183041,0.000035814763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000199922,0.00014633138,0.000464442,0.00006160215,0.000031765765,0.0000043164764,0.00023232524,0.00011784745,0.000012636515],"category_scores_gemma":[0.00006434857,0.00011672,0.00010273347,0.00013300752,0.00036371505,0.000046051584,0.00009464797,0.00014555022,2.6549014e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010265952,0.00021851265,0.0815916,0.0002808808,0.00013831696,3.3034897e-7,0.0011934638,0.00041426465,0.9117149,0.00007620661,0.000012154399,0.0033327532],"study_design_scores_gemma":[0.0019377512,0.00018261641,0.22700937,0.00033437752,0.00013633845,7.0032115e-7,0.00003359107,0.0055849757,0.76324606,0.0014490236,0.000008866576,0.00007630939],"about_ca_topic_score_codex":0.00074316503,"about_ca_topic_score_gemma":0.00012919788,"teacher_disagreement_score":0.14846884,"about_ca_system_score_codex":0.00012277365,"about_ca_system_score_gemma":0.00029987714,"threshold_uncertainty_score":0.47597036},"labels":[],"label_agreement":null},{"id":"W2743088462","doi":"10.1158/1535-7163.mct-17-0374","title":"Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Liver physiology and pathology","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; McGill University","funders":"","keywords":"Epitope; Cancer research; Biology; Computational biology; Immunology; Antibody","score_opus":0.01655211928093965,"score_gpt":0.2955177967313981,"score_spread":0.27896567745045847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2743088462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941193,0.0012726467,0.0035131893,0.000209097,0.00018511071,0.00040871528,0.00009375005,0.00003063126,0.00016756906],"genre_scores_gemma":[0.99635774,0.000101479825,0.002078385,0.0012677704,0.00006079889,0.000035943514,0.000023427783,0.000038534632,0.000035907906],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988314,0.00017930203,0.00020017607,0.00036396287,0.0001615096,0.00026368542],"domain_scores_gemma":[0.9989459,0.00026533994,0.0002423194,0.00033852263,0.0001269199,0.000081005586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016021205,0.00022823118,0.00046048086,0.000045618555,0.00021285124,0.000014263182,0.00016584358,0.000102940605,0.00001478768],"category_scores_gemma":[0.00016978329,0.00018779642,0.0000889622,0.000041984884,0.00025527927,0.000038745573,0.00009445756,0.00024995438,0.0000042717434],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004532901,0.0001451038,0.00945051,0.000107185915,0.00034939987,0.00017968143,0.00032914328,0.00006143232,0.98334444,0.0008528149,0.000011750112,0.0047152312],"study_design_scores_gemma":[0.0030890678,0.0014415055,0.005684606,0.00012832636,0.0004714316,0.000025647932,0.000032718646,0.001501592,0.9846084,0.002558001,0.00022873472,0.00022996645],"about_ca_topic_score_codex":0.0001872164,"about_ca_topic_score_gemma":0.000015225194,"teacher_disagreement_score":0.004485265,"about_ca_system_score_codex":0.000037751262,"about_ca_system_score_gemma":0.000042618485,"threshold_uncertainty_score":0.76581156},"labels":[],"label_agreement":null},{"id":"W2744273464","doi":"10.1158/1535-7163.mct-17-0259","title":"Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor–Chromatin Interactions","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Enzalutamide; Androgen receptor; Prostate cancer; LNCaP; Chemistry; Chromatin; DNA-binding domain; Cancer research; Small molecule; Transcription factor; Pharmacology; Mechanism of action; Cancer; Biology; DNA; Biochemistry; Genetics; In vitro; Gene","score_opus":0.04388678794563423,"score_gpt":0.327327484174485,"score_spread":0.28344069622885076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2744273464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9065469,0.034162316,0.021947267,0.028064827,0.00074637984,0.002816191,0.00046534894,0.00018057709,0.005070189],"genre_scores_gemma":[0.9718477,0.0029604838,0.01863237,0.0006121172,0.000061182596,0.00043361163,0.000055588065,0.00011251647,0.005284425],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99828136,0.00007470173,0.0002631295,0.00043041917,0.00049338635,0.00045700755],"domain_scores_gemma":[0.9983396,0.000024435727,0.0003787761,0.00079056836,0.00031461165,0.00015198514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014190502,0.00030411707,0.00044156174,0.000107930544,0.00038669852,0.00011331947,0.0002954293,0.00007539772,0.00020684626],"category_scores_gemma":[0.000009034207,0.00022875123,0.00013078598,0.00013791004,0.000313464,0.000139229,0.00008392734,0.00028692788,0.000004361152],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004169442,0.00048091172,0.02245323,0.00088329957,0.003118628,0.0003389406,0.0032434633,0.00019908261,0.9414623,0.0009991275,0.0007418593,0.021909764],"study_design_scores_gemma":[0.00304925,0.0001570313,0.0014580633,0.0012197183,0.00040074185,0.000009835518,0.00041672972,0.00028082306,0.9752091,0.0010104197,0.016472515,0.00031573972],"about_ca_topic_score_codex":0.00042711128,"about_ca_topic_score_gemma":0.00056838844,"teacher_disagreement_score":0.0653008,"about_ca_system_score_codex":0.0003041189,"about_ca_system_score_gemma":0.000523574,"threshold_uncertainty_score":0.93282044},"labels":[],"label_agreement":null},{"id":"W2747905863","doi":"10.1158/1535-7163.mct-17-0292","title":"Estrogen Receptor β Is a Novel Target in Acute Myeloid Leukemia","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Grand River Hospital; University of Guelph; Regional Municipality of Waterloo; Ontario Institute for Cancer Research; University of Waterloo","funders":"","keywords":"Myeloid leukemia; Estrogen receptor; Leukemia; Cancer research; Haematopoiesis; Gene knockdown; Pharmacology; Biology; Myeloid; Stem cell; Cell culture; Cancer; Immunology; Cell biology; Breast cancer","score_opus":0.013674953197759812,"score_gpt":0.2825024646678262,"score_spread":0.2688275114700664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747905863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861982,0.009490149,0.0015934813,0.0010755867,0.0003549087,0.00030629104,0.000077012526,0.000018945704,0.0008854471],"genre_scores_gemma":[0.9901312,0.0037163266,0.002374068,0.00255931,0.00018607118,0.000090912035,0.00007624321,0.00008391014,0.0007819628],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986517,0.00003922762,0.00021429129,0.0004711812,0.00018698264,0.0004366508],"domain_scores_gemma":[0.99879634,0.0000039214683,0.00015838843,0.0008738653,0.000062681574,0.0001048007],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000121954276,0.000275792,0.0002241695,0.000048249105,0.00018948255,0.00008625544,0.0005694437,0.00036651434,0.000033562843],"category_scores_gemma":[0.000010377817,0.00026422404,0.00017172591,0.00006662793,0.00014194506,0.00000843543,0.00017617826,0.00026245273,0.000025341651],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014955741,0.000059292594,0.004522087,0.000010007591,0.00046720356,0.000020531947,0.00009098095,0.000116723895,0.9897556,0.00013936558,0.00035486143,0.0043138294],"study_design_scores_gemma":[0.0014406119,0.00017495983,0.0012514361,0.000032170108,0.00008755037,0.000012787431,0.000013638424,0.000354047,0.9091887,0.00007987072,0.087006085,0.00035815162],"about_ca_topic_score_codex":0.00011422292,"about_ca_topic_score_gemma":0.0000100604975,"teacher_disagreement_score":0.08665122,"about_ca_system_score_codex":0.00009666027,"about_ca_system_score_gemma":0.00026352383,"threshold_uncertainty_score":0.999981},"labels":[],"label_agreement":null},{"id":"W2749993682","doi":"10.1158/1535-7163.mct-16-0739","title":"PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"S100 Proteins and Annexins","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer","funders":"","keywords":"Triple-negative breast cancer; Breast cancer; Cancer research; Cancer; Annexin A1; Annexin; Predictive marker; Medicine; Biology; Internal medicine; Oncology; Apoptosis","score_opus":0.0220421876638564,"score_gpt":0.31089966051514145,"score_spread":0.28885747285128505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2749993682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949951,0.0010824215,0.002474362,0.00050745753,0.00016104223,0.0005315747,0.00007561721,0.000012819698,0.00015961094],"genre_scores_gemma":[0.9977194,0.00035780342,0.0008278793,0.000624845,0.00012247048,0.00015372717,0.000020977393,0.0000621926,0.00011067111],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99832624,0.00021456486,0.00035523018,0.0004904878,0.00024433783,0.00036915447],"domain_scores_gemma":[0.9985274,0.00001889417,0.00040245926,0.00078320183,0.00018082352,0.00008719988],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037066775,0.00030966903,0.00031463,0.0001071486,0.0001889239,0.000055391352,0.00047435734,0.0002622089,0.00001701376],"category_scores_gemma":[0.00004368577,0.00029490623,0.00015254087,0.00010110026,0.00014545454,0.000020457477,0.00010529182,0.00013283032,8.4131284e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002671276,0.00009931751,0.0031304478,0.000025113626,0.00007811378,0.000024166608,0.00032750375,0.00006874519,0.97685695,0.00002088419,0.000015204164,0.01668229],"study_design_scores_gemma":[0.0029506045,0.00040006364,0.021256609,0.00015450404,0.000023760384,0.000011169055,0.00010183464,0.0002520494,0.9730085,0.00042168424,0.0010945649,0.00032461708],"about_ca_topic_score_codex":0.000631451,"about_ca_topic_score_gemma":0.0005289733,"teacher_disagreement_score":0.018126162,"about_ca_system_score_codex":0.00012360972,"about_ca_system_score_gemma":0.00027452418,"threshold_uncertainty_score":0.9999503},"labels":[],"label_agreement":null},{"id":"W2753735822","doi":"10.1158/1535-7163.mct-17-0397","title":"Death by HDAC Inhibition in Synovial Sarcoma Cells","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; Vancouver Coastal Health Research Institute; Vancouver Coastal Health","funders":"","keywords":"Synovial sarcoma; Cancer research; Apoptosis; Sarcoma; Cancer; Histone deacetylase; Histone deacetylase inhibitor; Transcriptome; Biology; Cancer cell; Medicine; Histone; Pathology; Internal medicine; Gene expression; Biochemistry","score_opus":0.02300530319860789,"score_gpt":0.32064326584401637,"score_spread":0.2976379626454085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753735822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933546,0.002420418,0.0014873671,0.000651402,0.00024209886,0.00028101666,0.000078204175,0.000013113183,0.0014717821],"genre_scores_gemma":[0.9972081,0.0006698254,0.00015956232,0.0008027423,0.00014037124,0.000078063946,0.000077722085,0.000058861133,0.0008047308],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99849194,0.00009969356,0.00022213969,0.00045413658,0.00029670226,0.00043540949],"domain_scores_gemma":[0.9988664,0.000005695291,0.00011540317,0.0008311192,0.00008534725,0.0000960681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019005287,0.00021469149,0.00017682885,0.00006247382,0.00020981426,0.00010040513,0.00031890333,0.00023674595,0.000030883475],"category_scores_gemma":[0.000019334493,0.00023136192,0.00010309634,0.000057687164,0.0001680763,0.000008709654,0.00017448275,0.00022730816,0.000023309403],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000093297494,0.00010547815,0.0011199001,0.000014304559,0.00004625639,0.000060325445,0.000038932318,0.000038922073,0.99398774,0.000041235253,0.0012108241,0.0032427914],"study_design_scores_gemma":[0.00095216976,0.00013948914,0.0004978214,0.000028694192,0.00001449011,0.0000060879647,0.000009007682,0.00009923396,0.93202364,0.00006772757,0.065905124,0.00025649538],"about_ca_topic_score_codex":0.00041277215,"about_ca_topic_score_gemma":0.00021696065,"teacher_disagreement_score":0.0646943,"about_ca_system_score_codex":0.000112134614,"about_ca_system_score_gemma":0.00015318466,"threshold_uncertainty_score":0.94346654},"labels":[],"label_agreement":null},{"id":"W2756647112","doi":"10.1158/1535-7163.mct-17-0456","title":"Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":234,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Phenomenome Discoveries (Canada)","funders":"","keywords":"MAPK/ERK pathway; Medicine; In vivo; Melanoma; Cancer research; Cancer; Pharmacology; Phosphorylation; Potency; MEK inhibitor; Targeted therapy; In vitro; Internal medicine; Biology; Cell biology; Biochemistry","score_opus":0.039443511507001754,"score_gpt":0.3106321426094479,"score_spread":0.2711886311024461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756647112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98812985,0.0022350908,0.005285225,0.0028570355,0.00030020435,0.0007680457,0.000046000496,0.000019128403,0.000359434],"genre_scores_gemma":[0.9971607,0.00018989271,0.00030621633,0.0012695558,0.0005307146,0.00031415035,0.000011766615,0.0000701098,0.00014693967],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980711,0.00019577086,0.00027589378,0.0006116888,0.0003113881,0.00053418975],"domain_scores_gemma":[0.9984624,0.000054297652,0.00039301798,0.0008553367,0.00016185438,0.00007310725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059831736,0.00033509458,0.00028048214,0.000026672724,0.00069137017,0.00017490533,0.0007290062,0.00022909621,0.000010047267],"category_scores_gemma":[0.00006628419,0.00020388006,0.00013124982,0.00011091185,0.0002948581,0.000015943586,0.00022424165,0.00051675824,0.0000016833824],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004083852,0.000107620035,0.0044497196,0.000022449734,0.00023055832,0.000011116064,0.00044131998,0.0010566002,0.982826,0.000040025363,0.00005906405,0.010347147],"study_design_scores_gemma":[0.0012239804,0.00028895235,0.0037834318,0.00009224686,0.000078509154,0.0000071546324,0.00012630998,0.00066508487,0.97420955,0.000038359358,0.019118905,0.00036750254],"about_ca_topic_score_codex":0.0004249576,"about_ca_topic_score_gemma":0.000813902,"teacher_disagreement_score":0.019059842,"about_ca_system_score_codex":0.00007914755,"about_ca_system_score_gemma":0.00048568728,"threshold_uncertainty_score":0.8313987},"labels":[],"label_agreement":null},{"id":"W2756935441","doi":"10.1158/1535-7163.mct-17-0170","title":"Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute","keywords":"Olaparib; PARP inhibitor; Veliparib; Breast cancer; Cancer research; Triple-negative breast cancer; Cancer; Gene signature; Biology; DNA damage; Poly ADP ribose polymerase; Medicine; Molecular biology; Oncology; Internal medicine; Gene expression; Gene; Genetics; DNA","score_opus":0.029570303604162327,"score_gpt":0.32340810719261665,"score_spread":0.2938378035884543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756935441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9727645,0.0016194755,0.0013547093,0.021348862,0.0003610798,0.0015275251,0.0005809863,0.000118173455,0.00032469252],"genre_scores_gemma":[0.98506767,0.0004052284,0.00037611264,0.01234796,0.00019604358,0.0008259833,0.000043861393,0.00013140698,0.00060576433],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971353,0.00035404728,0.0004350841,0.0006881237,0.0007458617,0.000641601],"domain_scores_gemma":[0.99773943,0.00011018576,0.00042166119,0.0009383175,0.00052743463,0.00026298547],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00055609556,0.00045999925,0.0006262002,0.00027240356,0.00030335618,0.00011506139,0.00023191363,0.0003480376,0.00021060799],"category_scores_gemma":[0.00010700204,0.00040704777,0.00014522253,0.00055205735,0.00022495778,0.00018512383,0.000064777596,0.000678447,0.00001239777],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01619626,0.0003698827,0.008917336,0.0000327508,0.00066966016,0.0006826791,0.0019060485,0.0007648615,0.9619322,0.00005676293,0.00024050895,0.008231091],"study_design_scores_gemma":[0.019555602,0.00084572565,0.35495448,0.0014654244,0.0003225893,0.00008153378,0.00020565321,0.00038196926,0.61786604,0.0006369886,0.0027400267,0.0009439539],"about_ca_topic_score_codex":0.0005626223,"about_ca_topic_score_gemma":0.00096077955,"teacher_disagreement_score":0.34603715,"about_ca_system_score_codex":0.0016112147,"about_ca_system_score_gemma":0.001039043,"threshold_uncertainty_score":0.9998381},"labels":[],"label_agreement":null},{"id":"W2765801571","doi":"10.1158/1538-8514.synthleth-pr01","title":"Abstract PR01: A functional variomic chemi-genetic screen in C. elegans identifies new synthetic lethal interactions with PARP inhibition that are conserved from worm to human","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Genetics, Aging, and Longevity in Model Organisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Biology; Caenorhabditis elegans; Synthetic lethality; Genetics; Olaparib; Model organism; Gene; Genetic screen; Mutation; PARP inhibitor; DNA repair; Poly ADP ribose polymerase; Homologous recombination; Polymerase; Mutant","score_opus":0.04231862433460418,"score_gpt":0.28328139181690526,"score_spread":0.24096276748230108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765801571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98418665,0.0007554146,0.012447859,0.0016574773,0.00026554352,0.0003835412,0.000081442544,0.000023974437,0.0001981206],"genre_scores_gemma":[0.99680424,0.000105057865,0.000762153,0.001178729,0.00027838975,0.0000744213,0.00014549823,0.00007730462,0.0005742335],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983306,0.000048774666,0.00029606564,0.0006472722,0.00029090684,0.00038640416],"domain_scores_gemma":[0.9985319,0.000012804276,0.00027348878,0.00091003353,0.0001124944,0.00015927714],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009868984,0.00034120452,0.00027455812,0.0000925019,0.00030440593,0.0002495879,0.00037591235,0.00018749732,0.00013418071],"category_scores_gemma":[0.000013985551,0.0003500695,0.00011359669,0.00006512431,0.00016322888,0.000020091193,0.00014575607,0.00025996493,0.000017740384],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001685793,0.00011237375,0.015167597,0.000020309983,0.00025471917,0.000043589367,0.00051186455,0.0013700959,0.9808372,0.0000115792955,0.00019708043,0.0013049755],"study_design_scores_gemma":[0.0011926276,0.00011257709,0.23940127,0.00017216179,0.00014923046,0.000017223574,0.00019898896,0.00006657908,0.7554858,0.00048715883,0.0022248048,0.0004916402],"about_ca_topic_score_codex":0.005872632,"about_ca_topic_score_gemma":0.01854817,"teacher_disagreement_score":0.22535148,"about_ca_system_score_codex":0.00009432103,"about_ca_system_score_gemma":0.00020043322,"threshold_uncertainty_score":0.99989516},"labels":[],"label_agreement":null},{"id":"W2766480817","doi":"10.1158/1538-8514.synthleth-b04","title":"Abstract B04: RAD51 expression as a biomarker of homologous recombination deficiency in ovarian cancer","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"RAD51; Homologous recombination; DNA repair; Ovarian cancer; Biology; Molecular biology; DNA damage; Cancer research; PARP inhibitor; Cancer; Olaparib; Synthetic lethality; Poly ADP ribose polymerase; DNA; Genetics; Polymerase","score_opus":0.05492772240357369,"score_gpt":0.37437744291218916,"score_spread":0.3194497205086155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766480817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97708726,0.008212792,0.00089408294,0.004183205,0.0007100939,0.00067103724,0.00003887813,0.000040002018,0.008162678],"genre_scores_gemma":[0.9954651,0.0022739503,0.0004199727,0.0012965441,0.000053855314,0.00021486194,0.000012102799,0.000054173826,0.00020941779],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982684,0.00006860406,0.00045908242,0.0004084463,0.000446246,0.00034921916],"domain_scores_gemma":[0.99834394,0.000033104217,0.00046757766,0.00086529454,0.00019942471,0.00009065374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000295015,0.00023992911,0.00039353888,0.00020914889,0.00015561839,0.000040335544,0.00031608826,0.00022402684,0.00065809983],"category_scores_gemma":[0.000031506162,0.00022595086,0.00014242316,0.00018507431,0.00022573944,0.0001396846,0.00005329796,0.00027680345,0.000009949921],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005916812,0.00032060992,0.017263733,0.00012255048,0.00009809949,0.00010182572,0.00044888197,0.00005549418,0.9313696,0.00027435063,0.00011556359,0.04923758],"study_design_scores_gemma":[0.0048520654,0.00016352253,0.23215368,0.0007723055,0.00009381235,0.000023446142,0.00005360087,0.0002049769,0.75646275,0.0025338458,0.0024065396,0.00027943458],"about_ca_topic_score_codex":0.001363239,"about_ca_topic_score_gemma":0.00012465297,"teacher_disagreement_score":0.21488994,"about_ca_system_score_codex":0.00036723525,"about_ca_system_score_gemma":0.00040989227,"threshold_uncertainty_score":0.9214009},"labels":[],"label_agreement":null},{"id":"W2767374855","doi":"10.1158/1538-8514.synthleth-a04","title":"Abstract A04: Cross-species analysis identifies MUS81, a structure-specific endonuclease, as a novel synthetic lethal interaction with PARP","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Biology; Synthetic lethality; Olaparib; PARP inhibitor; Poly ADP ribose polymerase; Homologous recombination; DNA repair; Genetics; Cell biology; DNA damage; Molecular biology; Polymerase; DNA","score_opus":0.0529701463254155,"score_gpt":0.356372261200227,"score_spread":0.3034021148748115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767374855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98346263,0.0024737127,0.0063616564,0.0017534815,0.000657573,0.000545969,0.00022311711,0.0001284659,0.0043933727],"genre_scores_gemma":[0.9955828,0.0008623909,0.0007067801,0.0015065416,0.0003081648,0.00010369555,0.00005503863,0.00010819551,0.00076640205],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973393,0.00006011804,0.0004978634,0.000754658,0.00083948905,0.0005085535],"domain_scores_gemma":[0.9970579,0.00008499375,0.000596917,0.0016518589,0.0004169987,0.00019131869],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021160637,0.000471074,0.000662744,0.0003361565,0.0005455559,0.00069005135,0.00045048838,0.00024120898,0.002117826],"category_scores_gemma":[0.000029850868,0.00040330552,0.00042115443,0.00038332815,0.0006447894,0.00034817948,0.00006763931,0.000631555,0.000039106744],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022747417,0.00028691685,0.009290629,0.00010880758,0.0054915277,0.00032544637,0.0010291281,0.0017318836,0.9705445,0.00059859053,0.00008632917,0.008231506],"study_design_scores_gemma":[0.005534276,0.00032790992,0.18907087,0.0004245059,0.0026116073,0.00025612133,0.00044165613,0.00039103234,0.7443717,0.00063609524,0.055053864,0.00088034326],"about_ca_topic_score_codex":0.00041556932,"about_ca_topic_score_gemma":0.00027608225,"teacher_disagreement_score":0.22617276,"about_ca_system_score_codex":0.00050439156,"about_ca_system_score_gemma":0.00022575323,"threshold_uncertainty_score":0.99984187},"labels":[],"label_agreement":null},{"id":"W2767673199","doi":"10.1158/1538-8514.synthleth-ia06","title":"Abstract IA06: Leveraging genome-wide CRISPR screens and synthetic lethal interactions for novel cancer therapeutics","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CRISPR and Genetic Engineering","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"CRISPR; Frizzled; Biology; Wnt signaling pathway; Cancer; Genome editing; Computational biology; Cas9; Genome; Context (archaeology); Cancer research; Genetics; Gene","score_opus":0.040523857169522455,"score_gpt":0.35626202916618976,"score_spread":0.3157381719966673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767673199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6905946,0.013215831,0.29172003,0.0024110205,0.00074168394,0.00059361063,0.00021026906,0.00003747381,0.00047548593],"genre_scores_gemma":[0.9928766,0.0024716544,0.002068155,0.0016331769,0.00032428227,0.00018584315,0.00003395831,0.0001029548,0.00030340586],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998554,0.000016048867,0.0002647925,0.0005351144,0.00016272589,0.00046733223],"domain_scores_gemma":[0.9987753,0.00003132274,0.00016661047,0.0007606017,0.0001541944,0.00011195403],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001445206,0.00033545986,0.00024667243,0.00005810342,0.00043967573,0.00017049364,0.00039709822,0.00016153329,0.00002059679],"category_scores_gemma":[0.000023789735,0.00034578083,0.00017083333,0.000036429115,0.00015305585,0.000013139368,0.00014297657,0.00020470207,0.0000012864487],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000761785,0.00005615076,0.0018476127,0.00006648081,0.00053220487,0.0000043021278,0.00021532208,0.0022522716,0.97606933,0.000043654192,0.000036861715,0.018799614],"study_design_scores_gemma":[0.0017865616,0.00014794777,0.036740832,0.00012226253,0.00047713047,0.000027884367,0.0002159566,0.0029706005,0.7540295,0.0001402003,0.20243108,0.0009100072],"about_ca_topic_score_codex":0.00021200832,"about_ca_topic_score_gemma":0.00024236547,"teacher_disagreement_score":0.30228198,"about_ca_system_score_codex":0.00005146844,"about_ca_system_score_gemma":0.000106152336,"threshold_uncertainty_score":0.99989945},"labels":[],"label_agreement":null},{"id":"W2768045733","doi":"10.1158/1538-8514.synthleth-a38","title":"Abstract A38: Genome-wide CRISPR-Cas9 screens reveal modulators of temozolomide sensitivity in glioblastoma","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CRISPR and Genetic Engineering","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"Temozolomide; MSH6; CRISPR; Cancer research; Biology; Synthetic lethality; Gene; DNA repair; Medicine; Glioblastoma; Genetics; DNA mismatch repair","score_opus":0.014533477766253739,"score_gpt":0.30992175175134634,"score_spread":0.2953882739850926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768045733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864827,0.002460997,0.009995379,0.0002363661,0.00016424106,0.00022293291,0.000046933506,0.000012362852,0.00037811478],"genre_scores_gemma":[0.9984517,0.0004447757,0.0005258758,0.0003177259,0.00010382513,0.000017244598,0.000011563097,0.00005435854,0.00007293869],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986834,0.00003713717,0.0003140338,0.00039805827,0.00019316458,0.0003742209],"domain_scores_gemma":[0.998694,0.00001234588,0.00017910716,0.0009334902,0.00009575008,0.00008527525],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024880876,0.0002518969,0.00028522447,0.00007539874,0.000098717646,0.00003661019,0.00030229357,0.0002047018,0.000010193342],"category_scores_gemma":[0.000038683476,0.00027226802,0.00015540897,0.0000654013,0.00013754536,0.000006946254,0.00015269259,0.0001749176,0.000002706488],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010700757,0.000051751216,0.029774565,0.000046888195,0.00013689316,0.00004942069,0.000064239095,0.007904271,0.957684,0.000013461253,0.000025575817,0.00414197],"study_design_scores_gemma":[0.0005575363,0.00009855623,0.23501498,0.000037515252,0.00003736438,0.0000075040193,0.000029607063,0.00040285575,0.7607267,0.00004528955,0.0027681603,0.00027397912],"about_ca_topic_score_codex":0.00027770488,"about_ca_topic_score_gemma":0.0007552479,"teacher_disagreement_score":0.2052404,"about_ca_system_score_codex":0.00003890078,"about_ca_system_score_gemma":0.00008318355,"threshold_uncertainty_score":0.99997294},"labels":[],"label_agreement":null},{"id":"W2773439479","doi":"10.1158/1538-8514.synthleth-b18","title":"Abstract B18: Mechanisms of regulation and synthetic lethal strategies against PALB2 and APRIN, two DNA double-strand break repair proteins","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"PALB2; Homologous recombination; DNA repair; Biology; DNA damage; Genetics; Genome instability; Cancer research; Mutation; DNA; Cell biology; Gene; Germline mutation","score_opus":0.019716191837931104,"score_gpt":0.28236122566860666,"score_spread":0.26264503383067556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2773439479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873759,0.0019090527,0.008351625,0.0002367648,0.00012424291,0.00059215346,0.000034815643,0.000039333587,0.0013360792],"genre_scores_gemma":[0.9968099,0.00054874783,0.0022027306,0.00014420741,0.00006273314,0.00006683248,0.000021958513,0.0000556772,0.00008720742],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986049,0.000048694288,0.00029134456,0.0005276076,0.00024051467,0.00028691816],"domain_scores_gemma":[0.9986346,0.000007534933,0.0002958975,0.0008496379,0.00011879238,0.00009355773],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026294315,0.00028445173,0.00026616998,0.000045685054,0.00020697272,0.00012583933,0.00024618593,0.00021871868,0.000010822004],"category_scores_gemma":[0.000010163237,0.00027904805,0.00011719174,0.00003204709,0.0002674497,0.00002237178,0.00014886537,0.00012444645,6.761863e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022713254,0.000049345515,0.00015016501,0.0001124957,0.00022324389,0.000014322798,0.00008281224,0.00010454225,0.98840064,0.0035953822,0.0000048028246,0.0070350976],"study_design_scores_gemma":[0.0017286423,0.00021547597,0.002901718,0.00009179064,0.00011337263,0.000020028969,0.00010081905,0.00036020318,0.98910445,0.0041025006,0.00093436753,0.00032660947],"about_ca_topic_score_codex":0.00012454882,"about_ca_topic_score_gemma":0.00012389632,"teacher_disagreement_score":0.009433973,"about_ca_system_score_codex":0.000019166942,"about_ca_system_score_gemma":0.0001223793,"threshold_uncertainty_score":0.99996614},"labels":[],"label_agreement":null},{"id":"W2785529934","doi":"10.1158/1535-7163.targ-17-b181","title":"Abstract B181: The Chk1 inhibitor, SRA737, demonstrates chemical synthetic lethality with replication stress-inducing agents, including low-dose gemcitabine, in preclinical models of cancer","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada)","funders":"","keywords":"Gemcitabine; Cisplatin; Synthetic lethality; Cancer research; DNA damage; Topoisomerase; Biology; Cancer cell; Mitomycin C; Cancer; DNA replication; DNA repair; CHEK1; Cell cycle; Pharmacology; Cell cycle checkpoint; In vitro; DNA; Biochemistry; Genetics; Chemotherapy","score_opus":0.05506971729150969,"score_gpt":0.3484874899095117,"score_spread":0.29341777261800206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2785529934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937074,0.002520543,0.0022719186,0.00047030265,0.0001316382,0.00051617366,0.00005346501,0.000023610124,0.0003049058],"genre_scores_gemma":[0.9977896,0.00050932675,0.00062305585,0.0005856329,0.00019292459,0.00018454141,0.000033846623,0.00006273054,0.000018293189],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978332,0.00012767191,0.00053203624,0.0007549398,0.00035208592,0.00040009772],"domain_scores_gemma":[0.9982473,0.000038795133,0.00030808765,0.0010911314,0.00023584056,0.00007880798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005040878,0.000294525,0.00029521642,0.00004825072,0.000083690786,0.000031537693,0.00045925373,0.0002794797,0.00002246303],"category_scores_gemma":[0.000043934248,0.0002297233,0.0001222584,0.00023660895,0.00036157048,0.000014476256,0.0001736846,0.0002872348,0.0000013170494],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026717086,0.00018459604,0.004845209,0.000066775516,0.00020417209,0.0000045973734,0.0001957462,0.0016155732,0.9816869,0.00014078405,0.000010848183,0.010777621],"study_design_scores_gemma":[0.0007083041,0.00015624051,0.0028344553,0.0002648589,0.000098685734,0.0000045357124,0.00009078856,0.0040585385,0.9907738,0.00047142277,0.00025347748,0.00028491297],"about_ca_topic_score_codex":0.00055575126,"about_ca_topic_score_gemma":0.00055461685,"teacher_disagreement_score":0.010492708,"about_ca_system_score_codex":0.000097234384,"about_ca_system_score_gemma":0.00033207095,"threshold_uncertainty_score":0.93678445},"labels":[],"label_agreement":null},{"id":"W2786006104","doi":"10.1158/1535-7163.targ-17-a190","title":"Abstract A190: Management of germline findings revealed throughout the course of tumor-normal whole genome sequencing in oncology","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Children's Hospital; BC Cancer Agency","funders":"","keywords":"Germline; Genetic counseling; Context (archaeology); Cancer; Medicine; Penetrance; Oncology; Internal medicine; Bioinformatics; Genetics; Gene; Biology; Phenotype","score_opus":0.026910687958789307,"score_gpt":0.3418710277015232,"score_spread":0.3149603397427339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2786006104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99017984,0.005311754,0.0016696204,0.0005358191,0.00021519887,0.00036633393,0.000087152395,0.0000067547276,0.001627538],"genre_scores_gemma":[0.99628603,0.0006803311,0.0015639281,0.0010996986,0.00011964174,0.00006823446,0.000039811428,0.000038119153,0.00010422786],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986683,0.00007432669,0.0004512827,0.00031092647,0.00019905786,0.00029611014],"domain_scores_gemma":[0.99896497,0.000014175076,0.0002404692,0.0005556933,0.0001932324,0.00003144809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000384914,0.00018582221,0.00024368845,0.00005274132,0.000055989014,0.000008490011,0.00041810639,0.0001271894,0.000047876678],"category_scores_gemma":[0.000004735266,0.00015828307,0.000107851076,0.00025851536,0.00038307192,0.000005473316,0.00013575655,0.00014392908,0.0000032530345],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012557219,0.00006666606,0.001090279,0.0000795163,0.00037777986,0.000015579337,0.0007294956,0.0017963178,0.98958325,0.00011234324,0.0000552811,0.0059679323],"study_design_scores_gemma":[0.0012382047,0.00038151315,0.018849883,0.0000874051,0.00015654824,0.000014976021,0.0009598407,0.00020071823,0.93962765,0.00024396466,0.037966892,0.00027237696],"about_ca_topic_score_codex":0.000087577326,"about_ca_topic_score_gemma":0.00015482843,"teacher_disagreement_score":0.04995556,"about_ca_system_score_codex":0.0002754126,"about_ca_system_score_gemma":0.00048607143,"threshold_uncertainty_score":0.64545965},"labels":[],"label_agreement":null},{"id":"W2786998403","doi":"10.1158/1535-7163.targ-17-b011","title":"Abstract B011: Immunoediting in untreated mismatch repair deficient colorectal cancer","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; Ontario Institute for Cancer Research","funders":"","keywords":"Immunoediting; Microsatellite instability; DNA mismatch repair; Colorectal cancer; Cancer; Exome; Biology; Immune checkpoint; Immune system; Exome sequencing; Cancer research; Medicine; Genetics; Gene; Microsatellite; Immunotherapy; Mutation; Allele","score_opus":0.026547168257235767,"score_gpt":0.3139578065377615,"score_spread":0.28741063828052577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2786998403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98590785,0.008114907,0.000082888204,0.0008287488,0.0011223825,0.000685972,0.000035815883,0.00019284216,0.00302858],"genre_scores_gemma":[0.99538493,0.0006392485,0.000672451,0.0024789807,0.00032186942,0.00024522585,0.00001633576,0.000099245124,0.00014171428],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976411,0.00006135126,0.0004971021,0.00057613215,0.00053953344,0.0006847903],"domain_scores_gemma":[0.9988671,0.0000516251,0.00016028243,0.00044346656,0.00034038353,0.00013716321],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022520893,0.00035956188,0.00044467338,0.000175837,0.000105959545,0.000031259544,0.00019993201,0.00025092956,0.00097392866],"category_scores_gemma":[0.000029916528,0.0003370764,0.0001982346,0.0006510315,0.00028136966,0.000042093114,0.00007398084,0.0004252369,0.000042619293],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009616624,0.0002611238,0.07927338,0.00013009165,0.0004729888,0.00018820484,0.0016679286,0.0003291272,0.8897516,0.000033319666,0.0003189109,0.02661164],"study_design_scores_gemma":[0.0027851975,0.0006801209,0.23526233,0.0005061004,0.00030744958,0.00003919003,0.00028895956,0.0022745572,0.7437743,0.00009899989,0.013408839,0.0005739433],"about_ca_topic_score_codex":0.0018781103,"about_ca_topic_score_gemma":0.0011379861,"teacher_disagreement_score":0.15598895,"about_ca_system_score_codex":0.0009335263,"about_ca_system_score_gemma":0.00057551364,"threshold_uncertainty_score":0.9999393},"labels":[],"label_agreement":null},{"id":"W2787014069","doi":"10.1158/1535-7163.targ-17-b148","title":"Abstract B148: Activity of the TAM kinase-targeting compound, SLC-391, is mediated by the engagement of the immune system in CT-26 syngeneic mouse model","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SignalChem (Canada)","funders":"","keywords":"Immune system; Cancer research; Tumor microenvironment; Kinase; CD8; Biology; Immunology; Cancer; Pharmacology; Medicine; Internal medicine; Biochemistry","score_opus":0.02416915970491095,"score_gpt":0.26254877021169204,"score_spread":0.23837961050678108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787014069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826252,0.015336903,0.00026823988,0.00057470135,0.00040148792,0.0005396656,0.000100207566,0.000021070195,0.00013255511],"genre_scores_gemma":[0.99924743,0.00022136932,0.000009200913,0.0002962561,0.000012039072,0.000041912703,0.000010265583,0.00003389069,0.00012764843],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983787,0.0005061373,0.0004634978,0.00022267771,0.0001365457,0.0002924553],"domain_scores_gemma":[0.9985695,0.000085528554,0.000501483,0.00071015314,0.00012439302,0.00000897143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005535774,0.00021194837,0.0003216429,0.000037350903,0.00027032674,0.000011866317,0.0006369374,0.00012815201,0.000031200856],"category_scores_gemma":[0.000014501855,0.000118745425,0.0001946026,0.00024386037,0.00043771134,0.00004647331,0.00018445023,0.00037319353,0.0000058526743],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008140917,0.0001269546,0.0008185052,0.000048905476,0.00035502083,2.1102744e-7,0.0008325894,0.0006759518,0.9945795,0.0001025348,0.00009751036,0.0022809163],"study_design_scores_gemma":[0.00077784224,0.00003414342,0.006647857,0.00010295155,0.00010828468,0.0000017119678,0.00022870016,0.0023338017,0.98719656,0.000022729568,0.0024177055,0.00012768956],"about_ca_topic_score_codex":0.0006855062,"about_ca_topic_score_gemma":0.0000615181,"teacher_disagreement_score":0.016622247,"about_ca_system_score_codex":0.00016987059,"about_ca_system_score_gemma":0.00012344272,"threshold_uncertainty_score":0.4842298},"labels":[],"label_agreement":null},{"id":"W2787342755","doi":"10.1158/1535-7163.targ-17-a109","title":"Abstract A109: DNA-damaging agent dianhydrogalactitol (VAL-083) targets HR repair pathway and suggests combination therapy with topoisomerase and PARP inhibitors","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Delmar (Canada); University of British Columbia","funders":"","keywords":"DNA damage; DNA repair; Olaparib; Topoisomerase; Poly ADP ribose polymerase; Cancer research; Biology; Cancer cell; Homologous recombination; Topoisomerase inhibitor; Molecular biology; DNA; PARP inhibitor; Chemistry; Cancer; Polymerase; Genetics","score_opus":0.011364562012254002,"score_gpt":0.25349216129835606,"score_spread":0.24212759928610206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787342755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914742,0.0064114095,0.00053920224,0.0004487068,0.00024600612,0.00046123317,0.000017394057,0.00007757544,0.00032426923],"genre_scores_gemma":[0.99552816,0.001778504,0.00065527594,0.0015350357,0.00018046312,0.00007487318,0.000041848543,0.000080571655,0.00012525135],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984104,0.00008913467,0.00023653118,0.00061173085,0.00027043844,0.00038174898],"domain_scores_gemma":[0.9990794,0.000012590664,0.00014831164,0.00045635446,0.00015311092,0.0001502361],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020846642,0.0003377668,0.00021790012,0.000071412964,0.00017852383,0.00007523627,0.00012809712,0.00018247614,0.000022204802],"category_scores_gemma":[0.00000868788,0.00029960638,0.00008064535,0.000121439276,0.00024051822,0.000019062063,0.00008419066,0.00014452692,0.000003845617],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002047857,0.00012722441,0.004703835,0.000031650863,0.0002818429,0.000044551238,0.0003694128,0.000009896128,0.9731847,0.00013907473,0.00006352364,0.020839516],"study_design_scores_gemma":[0.0015777539,0.00085553987,0.005209954,0.000050478062,0.000051296276,0.000029387555,0.00010313993,0.0002130808,0.96165854,0.0002003533,0.029611956,0.00043855037],"about_ca_topic_score_codex":0.00007099961,"about_ca_topic_score_gemma":0.00009711493,"teacher_disagreement_score":0.029548433,"about_ca_system_score_codex":0.000047037487,"about_ca_system_score_gemma":0.0001149589,"threshold_uncertainty_score":0.9999456},"labels":[],"label_agreement":null},{"id":"W2787457224","doi":"10.1158/1535-7163.targ-17-a082","title":"Abstract A082: A phase I study of the MDM2 antagonist RO6839921, a pegylated intravenous prodrug of idasanutlin, in patients with AML","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Neutropenia; Nausea; Pharmacology; Prodrug; Dosing; Vomiting; Internal medicine; Pharmacodynamics; Phases of clinical research; Pharmacokinetics; Gastroenterology; Toxicity","score_opus":0.015465020455442565,"score_gpt":0.2865701823240733,"score_spread":0.2711051618686307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787457224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99599487,0.00069658936,0.00014137526,0.00015708576,0.00019844866,0.0024826275,0.00005707367,0.00003053403,0.00024142604],"genre_scores_gemma":[0.9992591,0.000035788522,0.000091314825,0.00038433116,0.000041311032,0.00006808192,0.000016370672,0.0000871044,0.000016567119],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976671,0.00010637772,0.000642345,0.000433329,0.000769496,0.00038135392],"domain_scores_gemma":[0.99797004,0.00001634615,0.00043999977,0.0009330142,0.00055464724,0.000085963766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017251722,0.00031786168,0.0005613699,0.00017183507,0.00006989541,0.000013822205,0.00029772843,0.00014352363,0.000052674775],"category_scores_gemma":[0.000019254638,0.00022693486,0.000120325145,0.0008940301,0.00033677364,0.000040355466,0.00007329696,0.00042547582,0.0000021288595],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014615049,0.027801052,0.1714508,0.0005410168,0.0033792572,0.00022439507,0.021074345,0.00073263573,0.7067634,0.00004909507,0.000053882282,0.053315118],"study_design_scores_gemma":[0.04670158,0.0134714,0.3441768,0.001080018,0.0014002436,0.000014375085,0.0009769175,0.00043549782,0.59015,0.000051429568,0.00092224934,0.0006195202],"about_ca_topic_score_codex":0.0006863455,"about_ca_topic_score_gemma":0.00056542025,"teacher_disagreement_score":0.172726,"about_ca_system_score_codex":0.00023288926,"about_ca_system_score_gemma":0.00049361296,"threshold_uncertainty_score":0.9254135},"labels":[],"label_agreement":null},{"id":"W2787641076","doi":"10.1158/1535-7163.targ-17-a189","title":"Abstract A189: Identification of antibody-drug conjugate targets using curated public data, in-house glycoproteomics, and a surrogate in vitro ADC assay","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada","funders":"","keywords":"Biology; Cancer research; Population; Cancer; Computational biology; Medicine; Genetics","score_opus":0.06927556907969151,"score_gpt":0.3802044517327276,"score_spread":0.3109288826530361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787641076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923361,0.0048351767,0.00046353543,0.0015071561,0.00011761548,0.0005069638,0.00015167418,0.00002325548,0.000058527166],"genre_scores_gemma":[0.9969987,0.0016327375,0.0006212991,0.000429392,0.00006863605,0.0000109473185,0.0001403662,0.000048309244,0.0000495992],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99811417,0.00013032187,0.0005412713,0.0004255947,0.00038783601,0.0004008366],"domain_scores_gemma":[0.9988702,0.00004817532,0.00019111537,0.00051495683,0.00026788193,0.00010770282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008096192,0.00019228582,0.0003720943,0.000262528,0.00005748144,0.00004742766,0.00025260804,0.000102184415,0.000037981543],"category_scores_gemma":[0.00004790182,0.00017592782,0.00004364974,0.00043273132,0.00033429984,0.00018199607,0.00014500317,0.00030360164,0.000007933783],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000773452,0.00015533071,0.030708086,0.00017996001,0.00012599486,0.00008353478,0.00029923493,0.000012060824,0.961111,0.00004242921,0.0000071456225,0.006501776],"study_design_scores_gemma":[0.0021461856,0.00007861988,0.074474424,0.00022479308,0.00007024239,0.000022813865,0.00009956828,0.030074006,0.8896402,0.00022066294,0.0026804667,0.00026798062],"about_ca_topic_score_codex":0.0023499406,"about_ca_topic_score_gemma":0.000518412,"teacher_disagreement_score":0.07147076,"about_ca_system_score_codex":0.00009887199,"about_ca_system_score_gemma":0.00030716238,"threshold_uncertainty_score":0.7174129},"labels":[],"label_agreement":null},{"id":"W2789873517","doi":"10.1158/1535-7163.mct-17-0552","title":"Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; University of California, San Francisco; National Institutes of Health; Sunnybrook Research Institute","keywords":"Pharmacodynamics; Pharmacology; Biomarker; Medicine; Pharmacokinetics; Drug; Biology","score_opus":0.019470182303289663,"score_gpt":0.3456646254658927,"score_spread":0.32619444316260304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789873517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97151375,0.00234782,0.022202339,0.0008647431,0.00025815386,0.0017912969,0.000030069685,0.0000816559,0.0009101507],"genre_scores_gemma":[0.97742987,0.000076970544,0.017222926,0.0044675297,0.00010055863,0.00055018585,0.000050893268,0.00005912208,0.000041974417],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99831796,0.00006405344,0.0004308518,0.00047270156,0.00033510922,0.00037933196],"domain_scores_gemma":[0.9990089,0.000035006055,0.00015729303,0.00033807973,0.00025846018,0.00020224518],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001654315,0.00032227606,0.0004524179,0.00017060066,0.000112503294,0.00002142472,0.00015015584,0.00009657796,0.00004826169],"category_scores_gemma":[0.000013656395,0.00026168386,0.00012898872,0.0005304308,0.00014934094,0.000028650747,0.00007265313,0.00014623675,0.00002403102],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004482328,0.00036224356,0.001161175,0.00009330433,0.001685856,0.00005814956,0.0022111551,0.001104417,0.9497164,0.001146307,0.00003305004,0.041979734],"study_design_scores_gemma":[0.0031115788,0.00045546363,0.001413839,0.00020209933,0.0008658517,0.000007361842,0.0001241771,0.00033649028,0.98431164,0.00022984951,0.008620222,0.00032145213],"about_ca_topic_score_codex":0.00007719007,"about_ca_topic_score_gemma":0.000017398588,"teacher_disagreement_score":0.041658282,"about_ca_system_score_codex":0.00044905173,"about_ca_system_score_gemma":0.00040076888,"threshold_uncertainty_score":0.99998355},"labels":[],"label_agreement":null},{"id":"W2791467603","doi":"10.1158/1535-7163.mct-17-1091","title":"Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Sunnybrook Hospital; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Canadian Cancer Society; Government of Canada","keywords":"Immune checkpoint; Cancer research; Cisplatin; CD8; Immune system; Biology; In vivo; Cancer; Cytotoxic T cell; Immunology; Immunotherapy; Chemotherapy; Genetics; In vitro","score_opus":0.027543629945367083,"score_gpt":0.33420471881669817,"score_spread":0.3066610888713311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791467603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955179,0.0023510861,0.000034011708,0.0008693771,0.00009552095,0.0005757919,0.000035463985,0.000030939125,0.00048987556],"genre_scores_gemma":[0.99726665,0.00028759163,0.00014387308,0.0019837725,0.00010830534,0.000064226886,0.000024542012,0.000058259586,0.00006278531],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99811345,0.00011050034,0.00054495136,0.0003509646,0.00052506843,0.00035506077],"domain_scores_gemma":[0.998722,0.000056398818,0.0002266246,0.0004902518,0.0004071149,0.00009756527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033048444,0.00030144682,0.0004627734,0.00021825501,0.00003388509,0.0000133915955,0.00017284046,0.000143573,0.00044799584],"category_scores_gemma":[0.000039564395,0.000244146,0.00037035564,0.0005853204,0.00024215775,0.000043918746,0.000026313277,0.0002638287,0.000009888128],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024495738,0.00045951162,0.0024786054,0.000018445731,0.00067050726,0.000068144254,0.00074420066,0.000010585179,0.9328652,0.000025464613,0.000011512118,0.038152073],"study_design_scores_gemma":[0.0074860402,0.0029220774,0.11671976,0.0002556786,0.000053363237,0.000038666043,0.0000449896,0.00017729748,0.8716166,0.00013629129,0.0003059866,0.00024323032],"about_ca_topic_score_codex":0.002639514,"about_ca_topic_score_gemma":0.000024338853,"teacher_disagreement_score":0.11424115,"about_ca_system_score_codex":0.0008251561,"about_ca_system_score_gemma":0.0011531181,"threshold_uncertainty_score":0.99559855},"labels":[],"label_agreement":null},{"id":"W2792862146","doi":"10.1158/1535-7163.mct-17-0559","title":"Anti-<i>hTERT</i> siRNA-Loaded Nanoparticles Block the Growth of Anaplastic Thyroid Cancer Xenograft","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Association for the Study of the Liver","keywords":"Anaplastic thyroid cancer; Telomerase; Telomerase reverse transcriptase; Thyroid cancer; Chemistry; Cancer research; In vivo; Pharmacology; Cancer cell; Cytotoxicity; Poloxamer; Cancer; In vitro; Molecular biology; Medicine; Biology; Biochemistry; Internal medicine","score_opus":0.02168774687493087,"score_gpt":0.2887609737655415,"score_spread":0.26707322689061064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792862146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9638576,0.027568817,0.00010863885,0.0070552924,0.0004121337,0.00056027283,0.000060757437,0.00006183892,0.0003146741],"genre_scores_gemma":[0.9893267,0.0037214896,0.00012541155,0.0061414246,0.00028947173,0.0002303549,0.0000055982487,0.00006711361,0.000092434675],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981652,0.00008000997,0.0003893771,0.00039128025,0.000490532,0.00048363462],"domain_scores_gemma":[0.99867755,0.000064408894,0.00019565813,0.0005833009,0.00034194038,0.00013713105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001059741,0.00031693358,0.00046987776,0.000077711586,0.00015580546,0.000033362627,0.00025216758,0.000103962535,0.00013728398],"category_scores_gemma":[0.000010343914,0.00020906157,0.00021810149,0.0004875111,0.0004492421,0.000047196896,0.000066115324,0.00017761487,0.00001799192],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040172308,0.00046769014,0.02673698,0.00009580732,0.0014443621,0.000046376044,0.00089343445,0.00006192331,0.96160907,0.00044857414,0.0008599459,0.006934115],"study_design_scores_gemma":[0.00234979,0.0010731391,0.022406416,0.00021852805,0.0012345605,0.000020831932,0.00007766131,0.00014578147,0.9633388,0.00017115951,0.008725829,0.00023753861],"about_ca_topic_score_codex":0.00059575954,"about_ca_topic_score_gemma":0.00023249834,"teacher_disagreement_score":0.025469128,"about_ca_system_score_codex":0.0001622926,"about_ca_system_score_gemma":0.00026038606,"threshold_uncertainty_score":0.85252833},"labels":[],"label_agreement":null},{"id":"W2796900308","doi":"10.1158/1535-7163.targ-17-lb-a12","title":"Abstract LB-A12: Results from the phase 3 study ARIEL3: mutations in non-<i>BRCA</i> homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive high-grade ovarian carcinoma","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"PARP inhibitor; Olaparib; Oncology; Medicine; Internal medicine; BRCA mutation; Cancer research; Homologous recombination; Ovarian cancer; Cancer; Genetics; Biology; Gene; Poly ADP ribose polymerase","score_opus":0.023965657891026924,"score_gpt":0.29624467251739556,"score_spread":0.2722790146263686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796900308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880126,0.00015064294,0.0010890369,0.005710451,0.0003209566,0.003988193,0.0005802157,0.000059484744,0.000088406545],"genre_scores_gemma":[0.9954149,0.000037453276,0.00048512526,0.0028740852,0.00019314532,0.00063669716,0.00025649657,0.000071199785,0.000030873653],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970494,0.00046266025,0.0005853594,0.00080253696,0.0005898682,0.00051019836],"domain_scores_gemma":[0.9978108,0.00033722704,0.0003307503,0.0008558032,0.0005481087,0.00011735923],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047178354,0.00046283827,0.000521417,0.00014266111,0.00023466798,0.000057875783,0.00013063417,0.00012788648,0.000015340136],"category_scores_gemma":[0.000025696003,0.00027518946,0.000087189335,0.0006860666,0.00034697808,0.00009366809,0.00003563421,0.00041340914,0.0000075981748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.117948085,0.029160809,0.4868185,0.00006877433,0.005160141,0.003303953,0.16293825,0.0046936595,0.054500315,0.00024424907,0.0013876836,0.13377559],"study_design_scores_gemma":[0.052895885,0.009961769,0.8896772,0.0004670092,0.00046093174,0.000015556308,0.0029627373,0.00096108293,0.040505953,0.000096380885,0.001401775,0.0005937146],"about_ca_topic_score_codex":0.0068757837,"about_ca_topic_score_gemma":0.014517188,"teacher_disagreement_score":0.40285873,"about_ca_system_score_codex":0.0011300504,"about_ca_system_score_gemma":0.0004184958,"threshold_uncertainty_score":0.99997},"labels":[],"label_agreement":null},{"id":"W2801224767","doi":"10.1158/1535-7163.mct-17-1066","title":"Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Sunnybrook Health Science Centre","funders":"National Cancer Institute; National Institutes of Health; Roswell Park Alliance Foundation, Roswell Park Cancer Institute; Roswell Park Cancer Institute; U.S. Department of Defense","keywords":"Tumor microenvironment; Biomarker; Immune system; Angiogenesis; Transcriptome; Biology; Antibody; Cancer research; Cancer; Immune checkpoint; Immunology; Immunotherapy; Medicine; Gene; Gene expression; Genetics","score_opus":0.011340171221078185,"score_gpt":0.2542033933345853,"score_spread":0.2428632221135071,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801224767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769721,0.020509567,0.0007498462,0.0005455899,0.00044269185,0.0002605682,0.000114193,0.000021603599,0.00038384262],"genre_scores_gemma":[0.9943819,0.0019169057,0.0002158319,0.0027826265,0.00039491078,0.000060449802,0.000059881644,0.00007905429,0.00010845509],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985007,0.000050745246,0.00031160717,0.00052457437,0.00021288425,0.00039947173],"domain_scores_gemma":[0.9990643,0.000011935148,0.00014141847,0.0004791078,0.00015904967,0.00014418691],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014607339,0.0003004895,0.00022543344,0.000058803376,0.00014117028,0.00007806251,0.00022996668,0.00018663883,0.000039049508],"category_scores_gemma":[0.00001858604,0.0003096765,0.0001456126,0.00014171435,0.00017977458,0.0000048057627,0.00021418073,0.00010870395,0.000011494212],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000811845,0.00004397925,0.0014706537,0.000012545944,0.00021893097,0.0000064130168,0.00009230575,0.0000029485773,0.99239945,0.00006091926,0.00029822797,0.005312431],"study_design_scores_gemma":[0.0006961229,0.00042356853,0.002151183,0.000019343799,0.00009538568,0.000013235706,0.00007845081,0.000047424353,0.9355118,0.00009284979,0.06046833,0.00040229544],"about_ca_topic_score_codex":0.00023145629,"about_ca_topic_score_gemma":0.00012799326,"teacher_disagreement_score":0.060170103,"about_ca_system_score_codex":0.000062995954,"about_ca_system_score_gemma":0.00016423118,"threshold_uncertainty_score":0.9999355},"labels":[],"label_agreement":null},{"id":"W2885489314","doi":"10.1158/1535-7163.targ-17-a184","title":"Abstract A184: Clinical application of whole genome and transcriptome sequencing in cancer care","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Indel; Transcriptome; Computational biology; Personalized medicine; Cancer; Genome; Whole genome sequencing; Personal genomics; Cancer genome sequencing; Genomics; Ensembl; DNA sequencing; Precision medicine; Biology; Gene; Genetics; Bioinformatics; Gene expression","score_opus":0.029734807867320797,"score_gpt":0.3326298229840574,"score_spread":0.3028950151167366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885489314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718786,0.023967482,0.0030907942,0.0001729974,0.00018347338,0.0002735199,0.00017260884,0.000006526195,0.0002539804],"genre_scores_gemma":[0.99279505,0.005206306,0.0003751214,0.0011692692,0.00027443914,0.00007048784,0.000058604313,0.00003645756,0.00001428396],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988886,0.000031136093,0.00035993473,0.00037868062,0.00011472604,0.0002269237],"domain_scores_gemma":[0.9993044,0.000011796657,0.00012456812,0.0003266197,0.00016493906,0.000067647605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013565918,0.00016070384,0.00021342191,0.000050004415,0.000039197843,0.000015629892,0.00016698512,0.00018226786,0.000010571293],"category_scores_gemma":[0.000007788544,0.000171498,0.0000810125,0.00011657096,0.00021003258,0.0000038278367,0.00004814817,0.00011626955,0.0000016389166],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008271522,0.000026393669,0.01311757,0.00005523773,0.000075803335,0.0000021641686,0.00043347137,0.00037234116,0.9532972,0.00005277822,0.0000092654045,0.03247504],"study_design_scores_gemma":[0.0030234058,0.0008140295,0.09940482,0.00011345926,0.0002200055,0.0000054615584,0.0007903456,0.0008652649,0.6984014,0.00034733498,0.19518144,0.0008330613],"about_ca_topic_score_codex":0.00066107686,"about_ca_topic_score_gemma":0.0015409979,"teacher_disagreement_score":0.25489584,"about_ca_system_score_codex":0.000104393934,"about_ca_system_score_gemma":0.00030235725,"threshold_uncertainty_score":0.69934857},"labels":[],"label_agreement":null},{"id":"W2885983462","doi":"10.1158/1535-7163.targ-17-a152","title":"Abstract A152: Emerging indications for kinase-targeted therapies: screening for new targets","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SignalChem (Canada)","funders":"","keywords":"Kinome; Kinase; Vandetanib; Tyrosine kinase; Receptor tyrosine kinase; Medicine; Pharmacology; Cabozantinib; Cancer research; Sorafenib; Biology; Cancer; Biochemistry; Signal transduction; Internal medicine","score_opus":0.0617206210391006,"score_gpt":0.37740121309189767,"score_spread":0.3156805920527971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885983462","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.112574585,0.026111161,0.8413188,0.013497291,0.00063639984,0.004583737,0.00018035455,0.0002837609,0.00081392546],"genre_scores_gemma":[0.9513563,0.00043089982,0.0398393,0.0051479363,0.0011548685,0.000624475,0.00015168764,0.00017253826,0.0011219766],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99804777,0.000023466657,0.00035338354,0.00045842316,0.0004269148,0.0006900359],"domain_scores_gemma":[0.9984838,0.00015018616,0.00014449457,0.00055654795,0.00043164103,0.00023334868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028155794,0.00025962334,0.00032662097,0.0001720057,0.00027381864,0.000055825545,0.0002695026,0.00017515584,0.00028102478],"category_scores_gemma":[0.000076134456,0.00024073545,0.00024504153,0.00032938545,0.00017373232,0.00007684534,0.000040646923,0.00019841589,0.000015040946],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021883924,0.00028050662,0.0004009753,0.0005511586,0.003041419,0.000030443689,0.004680461,0.00019046078,0.60261834,0.0020527404,0.008333675,0.37563145],"study_design_scores_gemma":[0.023339922,0.0008502636,0.0012465295,0.0003216186,0.0005961679,0.000017871962,0.00039138415,0.02641844,0.3873949,0.0030319714,0.5557922,0.0005987158],"about_ca_topic_score_codex":0.00038510715,"about_ca_topic_score_gemma":0.0000698811,"teacher_disagreement_score":0.8387817,"about_ca_system_score_codex":0.001898953,"about_ca_system_score_gemma":0.00423818,"threshold_uncertainty_score":0.98169065},"labels":[],"label_agreement":null},{"id":"W2886557345","doi":"10.1158/1535-7163.targ-17-a100","title":"Abstract A100: Seamless phase I/II clinical trials in oncology: retrospective analysis of the last 7 years","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; McMaster University","funders":"","keywords":"Medicine; Clinical trial; Internal medicine; Phases of clinical research; Clinical Oncology; Population; Oncology; Food and drug administration; Cancer; Drug development; Sample size determination; Drug; Pharmacology","score_opus":0.06756027576180723,"score_gpt":0.4308483398892855,"score_spread":0.36328806412747827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886557345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956875,0.0014842323,0.0008543182,0.00033350804,0.0005834319,0.00032127346,0.0002098224,0.0000048829315,0.0005210675],"genre_scores_gemma":[0.9961956,0.0012925157,0.00016955195,0.001893502,0.00032184678,0.00003078978,0.000033531716,0.000027515427,0.00003511104],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99794304,0.00038311176,0.0008141869,0.00040657856,0.00019779071,0.0002552984],"domain_scores_gemma":[0.9985106,0.00011379264,0.00048519115,0.0006264431,0.00019735126,0.00006664748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017820005,0.00017188046,0.0006715031,0.000112472124,0.00006276194,0.000016967584,0.00037632883,0.00028038112,0.00005900181],"category_scores_gemma":[0.00029768114,0.00014339844,0.0005696248,0.0006079917,0.0003468498,0.000002523247,0.00018632988,0.00020970237,0.0000017660693],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007783798,0.0012961375,0.09816946,0.00001348464,0.005024466,0.00001709626,0.000493141,0.00081820594,0.80431587,0.0004409403,0.00072559563,0.08790721],"study_design_scores_gemma":[0.0078523625,0.002745372,0.45892578,0.000056678495,0.0032219405,0.0000022875502,0.00017071603,0.00083178526,0.3855716,0.00051169714,0.13948637,0.0006234119],"about_ca_topic_score_codex":0.0001525594,"about_ca_topic_score_gemma":0.0025546532,"teacher_disagreement_score":0.4187443,"about_ca_system_score_codex":0.00011423313,"about_ca_system_score_gemma":0.00043792222,"threshold_uncertainty_score":0.58476186},"labels":[],"label_agreement":null},{"id":"W2887451076","doi":"10.1158/1535-7163.targ-17-b056","title":"Abstract B056: Non-V600 BRAF mutations in melanoma: actionable targets for rational drug combinations","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; McGill University; University of Toronto","funders":"","keywords":"Trametinib; Dabrafenib; Vemurafenib; Melanoma; Cancer research; MAPK/ERK pathway; MEK inhibitor; Medicine; Kinase; Targeted therapy; Mutant; V600E; In vivo; Cell culture; Cell growth; Metastatic melanoma; Cancer; Biology; Internal medicine; Cell biology; Biochemistry; Genetics","score_opus":0.017198359884491442,"score_gpt":0.28795492942818246,"score_spread":0.27075656954369104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887451076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9501817,0.0014404705,0.040091533,0.0018413552,0.0008038828,0.0008618148,0.00024218553,0.00002805042,0.004508991],"genre_scores_gemma":[0.9950894,0.0000643331,0.0016292946,0.0011474288,0.00028700457,0.0003394537,0.0005062874,0.000037949805,0.0008988357],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99897665,0.000028560427,0.00023356278,0.00033118422,0.00014754185,0.00028248478],"domain_scores_gemma":[0.99933785,0.00001809527,0.00008996253,0.0002569456,0.00023735529,0.000059808233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013454996,0.00016864766,0.00013309982,0.00008014123,0.00017386061,0.000034083503,0.00017114368,0.00012887982,0.00007719608],"category_scores_gemma":[0.000016337735,0.00018084387,0.00009724597,0.00013431584,0.00009666762,0.00001051262,0.000033210756,0.00008800197,0.000015586584],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000089699024,0.00025270166,0.0010964659,0.000026562151,0.00013940095,0.000004429519,0.00025371675,0.0004053801,0.990908,0.002149245,0.0017825066,0.0028918912],"study_design_scores_gemma":[0.0023838547,0.0002608385,0.00968022,0.000020807549,0.000055498025,0.0000063966727,0.00012192717,0.0010996995,0.85187846,0.00341306,0.13068937,0.00038987005],"about_ca_topic_score_codex":0.00007044473,"about_ca_topic_score_gemma":0.00050367485,"teacher_disagreement_score":0.13902955,"about_ca_system_score_codex":0.00005541177,"about_ca_system_score_gemma":0.00029239213,"threshold_uncertainty_score":0.7374599},"labels":[],"label_agreement":null},{"id":"W2890293509","doi":"10.1158/1535-7163.mct-18-0348","title":"Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Canadian Centre for Applied Research in Cancer Control; University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung","keywords":"SMARCA4; Biology; EZH2; Cancer research; Histone deacetylase; Histone Acetyltransferases; Acetylation; Histone; Epigenetics; Chromatin remodeling; Genetics; Gene","score_opus":0.01518160534608104,"score_gpt":0.25976281553028563,"score_spread":0.2445812101842046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890293509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996412,0.002133831,0.00047012078,0.00013706865,0.00025653586,0.00033303266,0.000022780761,0.0000072011408,0.00022742494],"genre_scores_gemma":[0.9988377,0.00007978294,0.00036569414,0.00038708097,0.000109125314,0.000021379808,0.000006900941,0.000052369847,0.00013994167],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987398,0.00007710338,0.00029663788,0.00038841166,0.00021164559,0.0002864399],"domain_scores_gemma":[0.99886787,0.000008878757,0.00018436715,0.00064801524,0.00022160675,0.00006925925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013306076,0.0002364635,0.00027549732,0.00007159515,0.00004783764,0.000007665804,0.0003022868,0.00014487101,0.000006847785],"category_scores_gemma":[0.000012096755,0.00018438148,0.000111479516,0.0004266221,0.00024683317,0.000004160919,0.0001384987,0.00014382055,0.0000016779685],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038188847,0.00012817168,0.0054279575,0.00008548877,0.000044217333,0.0000042029906,0.00026129518,0.00095706794,0.9906432,0.0000047196227,0.00007542562,0.001986367],"study_design_scores_gemma":[0.00082613504,0.0005913311,0.0025888556,0.000120030265,0.0000788042,0.0000073303354,0.000054039418,0.0002613482,0.9944691,0.000009263915,0.0007579821,0.00023577029],"about_ca_topic_score_codex":0.000935881,"about_ca_topic_score_gemma":0.0007922979,"teacher_disagreement_score":0.0038259116,"about_ca_system_score_codex":0.000106653155,"about_ca_system_score_gemma":0.00043664497,"threshold_uncertainty_score":0.7518859},"labels":[],"label_agreement":null},{"id":"W2892613404","doi":"10.1158/1535-7163.mct-18-0107","title":"Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"University of British Columbia","keywords":"Gene knockdown; Gene silencing; Cancer research; In vivo; Biology; Apoptosis; Bladder cancer; Cancer; Gene; Biochemistry; Genetics","score_opus":0.014284392125237026,"score_gpt":0.262702458021119,"score_spread":0.248418065895882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892613404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894069,0.0076657278,0.0005497045,0.0004782987,0.0008619967,0.0003204401,0.00015868623,0.0000073835536,0.00055087364],"genre_scores_gemma":[0.993041,0.00424274,0.00009615211,0.0016804414,0.00063833117,0.00007162876,0.00001843937,0.000041546777,0.0001697398],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99880797,0.00008797715,0.00029442104,0.00031818653,0.0002397539,0.00025166932],"domain_scores_gemma":[0.9988384,0.0000072869693,0.00025648565,0.00032932102,0.0005230746,0.00004539443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000932744,0.0002039726,0.00024225881,0.000045404064,0.00006590188,0.000007724684,0.00021894703,0.00015960829,0.00004485457],"category_scores_gemma":[0.000010423504,0.00016130066,0.0002050919,0.00026538607,0.00041554053,0.000007052514,0.00004488613,0.00011450178,7.511801e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018272785,0.000057922054,0.0008360644,0.000039413047,0.00043256851,3.1373736e-7,0.0007119394,0.00002943278,0.99413055,0.00008633521,0.000493096,0.0029996173],"study_design_scores_gemma":[0.0006902289,0.00017037088,0.0046412083,0.00006562739,0.00024163858,0.00000203494,0.000072392075,0.000007221225,0.9818231,0.00025139205,0.011844336,0.00019047596],"about_ca_topic_score_codex":0.00034935042,"about_ca_topic_score_gemma":0.0007148844,"teacher_disagreement_score":0.012307497,"about_ca_system_score_codex":0.000027952965,"about_ca_system_score_gemma":0.0004246137,"threshold_uncertainty_score":0.657765},"labels":[],"label_agreement":null},{"id":"W2894608512","doi":"10.1158/1535-7163.mct-18-0341","title":"Immune Effector Functions of Human IgG2 Antibodies against EGFR","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"KWF Kankerbestrijding","keywords":"Antibody-dependent cell-mediated cytotoxicity; Panitumumab; Effector; Antibody; Immune system; Immunology; Isotype; Biology; Cetuximab; Cancer research; Monoclonal antibody","score_opus":0.03897247107650753,"score_gpt":0.35629938265856026,"score_spread":0.31732691158205273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894608512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825928,0.0066116,0.00034118022,0.001019481,0.00025314043,0.00030014195,0.00006933254,0.00004258957,0.008769711],"genre_scores_gemma":[0.99383354,0.0006954824,0.00020288795,0.0013672282,0.0003087374,0.000025341222,0.00006628398,0.00003822349,0.0034622573],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99869764,0.00006464849,0.00027747397,0.00023098472,0.0003988434,0.00033039565],"domain_scores_gemma":[0.9990948,0.000033176315,0.000081444894,0.00037059071,0.00032194314,0.00009803409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012997861,0.00018277678,0.0003475832,0.000121004676,0.00017277902,0.000013787047,0.00014469412,0.00009046065,0.00037953188],"category_scores_gemma":[0.000009305708,0.00014611824,0.00020675221,0.00025756608,0.00047488135,0.000029331883,0.000073772826,0.0002105772,0.0000985436],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025514452,0.00014205865,0.014749163,0.00015076688,0.00054753886,0.000028011396,0.0002237885,0.000002696582,0.96738327,0.00028093698,0.00031536122,0.015921272],"study_design_scores_gemma":[0.0012815767,0.001135591,0.051560264,0.00024322787,0.00025586018,0.000014339977,0.00008251272,0.0002069469,0.86309075,0.000116725634,0.08176834,0.00024385373],"about_ca_topic_score_codex":0.00028835112,"about_ca_topic_score_gemma":0.0000392375,"teacher_disagreement_score":0.104292504,"about_ca_system_score_codex":0.000059644502,"about_ca_system_score_gemma":0.00011125114,"threshold_uncertainty_score":0.5958529},"labels":[],"label_agreement":null},{"id":"W2898886729","doi":"10.1158/1535-7163.mct-17-1261","title":"TRAF2 Cooperates with Focal Adhesion Signaling to Regulate Cancer Cell Susceptibility to Anoikis","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"NF-κB Signaling Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Fondation du cancer du sein du Québec; Qatar Foundation","keywords":"Anoikis; Focal adhesion; Cancer research; Cancer; Signal transduction; Cell adhesion; Cell biology; Biology; Immunology; Cancer cell; Cell; Genetics","score_opus":0.020287511333151355,"score_gpt":0.2846268657186688,"score_spread":0.2643393543855174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898886729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754441,0.0020082425,0.020790095,0.0006095257,0.00023804787,0.00061794225,0.000073243886,0.00004952523,0.00016932565],"genre_scores_gemma":[0.9879109,0.0001105585,0.0034002569,0.0073831305,0.0004255024,0.0001553592,0.000030963303,0.00011520858,0.00046808776],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977495,0.00012209914,0.00029814878,0.000873542,0.0003413654,0.0006153456],"domain_scores_gemma":[0.9983802,0.000010404977,0.00008607011,0.0007523569,0.0004831368,0.00028785836],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002392118,0.00038886082,0.00028035208,0.000050855662,0.00017751969,0.00006825259,0.00040168726,0.00021195736,0.00014609064],"category_scores_gemma":[0.0000101850555,0.00034379496,0.00010351867,0.00033021974,0.00013955602,0.0000073410724,0.00013507827,0.0001304123,0.000023509987],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007399173,0.000083692335,0.001196477,0.000026399579,0.00012469778,0.000008512264,0.0005351928,0.004786356,0.9873755,0.000009852106,0.00027948458,0.0048338952],"study_design_scores_gemma":[0.000625519,0.0017522887,0.00043262512,0.00007565868,0.000096007105,0.0000035703442,0.000070837275,0.00019791236,0.97126704,0.000016500384,0.024935177,0.0005268397],"about_ca_topic_score_codex":0.0005047487,"about_ca_topic_score_gemma":0.0019784302,"teacher_disagreement_score":0.024655692,"about_ca_system_score_codex":0.00014426246,"about_ca_system_score_gemma":0.00032824004,"threshold_uncertainty_score":0.9999014},"labels":[],"label_agreement":null},{"id":"W2911547717","doi":"10.1158/1535-7163.mct-18-0831","title":"First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Pharmacokinetics; Adverse effect; Pharmacodynamics; Cancer; Phases of clinical research; Lung cancer; Dosing; Internal medicine; Pharmacology; GiST; Gastroenterology; Oncology; Chemotherapy; Stromal cell","score_opus":0.014303057858761273,"score_gpt":0.33164271540461165,"score_spread":0.31733965754585036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911547717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99789613,0.00026234591,0.00006502348,0.000026306569,0.00004235338,0.0016134589,0.000022196195,0.000007999939,0.000064193955],"genre_scores_gemma":[0.99934024,0.000019386778,0.0001544504,0.00013963575,0.000019992978,0.00015638328,0.00006680103,0.00006534386,0.000037761754],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99803615,0.00017878055,0.00037259122,0.0005318025,0.00043444426,0.00044625133],"domain_scores_gemma":[0.99895656,0.000004943834,0.000098361015,0.00069434365,0.00015504102,0.00009076522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018840519,0.0002452542,0.00033881085,0.00015153839,0.00003942795,0.000017538332,0.00033586094,0.0001258948,0.000029725274],"category_scores_gemma":[0.000007581121,0.00022730495,0.00004437548,0.0003093693,0.00006381251,0.000013195453,0.000116151474,0.00022335084,0.0000021829767],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017325814,0.00457426,0.17144197,0.00007143584,0.00013368834,0.00003937998,0.000555725,0.00624121,0.8064893,0.000008362373,0.0000021939154,0.008709912],"study_design_scores_gemma":[0.029582534,0.019476976,0.06422469,0.00015239623,0.00003496981,0.0000012111933,0.00050681503,0.00061628484,0.8833427,0.000030446874,0.001353308,0.00067766255],"about_ca_topic_score_codex":0.00029039133,"about_ca_topic_score_gemma":0.0014104063,"teacher_disagreement_score":0.107217275,"about_ca_system_score_codex":0.00009335718,"about_ca_system_score_gemma":0.00014598775,"threshold_uncertainty_score":0.9269227},"labels":[],"label_agreement":null},{"id":"W2946097255","doi":"10.1158/1535-7163.mct-18-1241","title":"17-Hydroxy Wortmannin Restores TRAIL's Response by Ameliorating Increased Beclin 1 Level and Autophagy Function in TRAIL-Resistant Colon Cancer Cells","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Autophagy in Disease and Therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health","keywords":"Autophagy; Wortmannin; Cancer; Colorectal cancer; Cancer research; Function (biology); Biology; Medicine; Pharmacology; Internal medicine; Cell biology; PI3K/AKT/mTOR pathway; Apoptosis; Biochemistry; Signal transduction","score_opus":0.026037454798142574,"score_gpt":0.3021730784373269,"score_spread":0.2761356236391843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946097255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97159994,0.025662087,0.00026345332,0.0009823861,0.0002461898,0.00085839815,0.00016826202,0.00007897604,0.00014029158],"genre_scores_gemma":[0.98936,0.0010013381,0.00018097955,0.0074285525,0.000072655595,0.0001959282,0.00004204887,0.000093745315,0.0016247507],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977199,0.00031365402,0.00046500078,0.0005774987,0.0004495529,0.00047440222],"domain_scores_gemma":[0.9989695,0.0001190585,0.00019093986,0.0004386493,0.00008996327,0.00019186581],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043963222,0.00036277133,0.00051994435,0.00019672285,0.000089549256,0.000047866877,0.00013659762,0.00025494272,0.00036886925],"category_scores_gemma":[0.000011800409,0.00034697755,0.00012604141,0.0004110837,0.00012364924,0.000097468095,0.00002989242,0.00038968984,0.000011056578],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009563038,0.00020917642,0.003670995,0.00007842351,0.0002991466,0.00012972413,0.0007064066,0.00021271221,0.97498345,0.00003833792,0.00054400513,0.009564573],"study_design_scores_gemma":[0.010886227,0.0013449368,0.11535483,0.00062650524,0.0006027762,0.000009308526,0.0003941158,0.0034082578,0.8106629,0.000227899,0.055659708,0.0008225056],"about_ca_topic_score_codex":0.0011030071,"about_ca_topic_score_gemma":0.00029925696,"teacher_disagreement_score":0.16432053,"about_ca_system_score_codex":0.00034201276,"about_ca_system_score_gemma":0.00047893784,"threshold_uncertainty_score":0.9998982},"labels":[],"label_agreement":null},{"id":"W2953753155","doi":"10.1158/1535-7163.mct-19-0105","title":"Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Hôpital du Sacré-Cœur de Montréal; Centre Hospitalier Universitaire de Sherbrooke; Centre Hospitalier de l’Université de Montréal; McGill University; Institut universitaire de cardiologie et de pneumologie de Québec; IGNIS Innovation (Canada); Jewish General Hospital","funders":"Pfizer Canada; Astex Pharmaceuticals","keywords":"Crizotinib; Anaplastic lymphoma kinase; Fusion gene; Oncology; KRAS; Exome sequencing; Lung cancer; Cancer research; Mutation; Internal medicine; Exome; Biology; Medicine; Gene; Genetics","score_opus":0.024932329947555787,"score_gpt":0.34800049562069807,"score_spread":0.3230681656731423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953753155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99764836,0.0002713866,0.0001350822,0.00050650886,0.00018225546,0.0004783645,0.00008449804,0.000010314079,0.0006832058],"genre_scores_gemma":[0.9978873,0.00004326223,0.000045016946,0.0012634436,0.0000062372296,0.000034649867,0.00008980159,0.00001798944,0.000612274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990638,0.00004630412,0.00031657703,0.00018772917,0.00024892192,0.00013670327],"domain_scores_gemma":[0.9992436,0.00005931463,0.00017914968,0.0003381004,0.0001494478,0.000030383777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008656538,0.00011341515,0.00036282893,0.00012307099,0.00003289948,0.0000122214,0.00009392369,0.00006777222,0.00006311245],"category_scores_gemma":[0.000014346454,0.00006877781,0.0002192612,0.0006532806,0.000049945473,0.000030055528,0.000022413271,0.00011425575,0.0000023891992],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040919032,0.0004246286,0.9898317,0.00000591101,0.00626192,0.000001004879,0.00041517318,0.0012925162,0.0011238554,0.00003536672,0.000008521464,0.0005585232],"study_design_scores_gemma":[0.0030927942,0.00008534301,0.99052644,0.00004739309,0.0048055034,1.2449215e-7,0.00008491584,0.0008359774,0.00021854827,0.0000088850675,0.00021549579,0.000078587254],"about_ca_topic_score_codex":0.00021217525,"about_ca_topic_score_gemma":0.0014205512,"teacher_disagreement_score":0.0030518752,"about_ca_system_score_codex":0.00012406448,"about_ca_system_score_gemma":0.00019728545,"threshold_uncertainty_score":0.28046775},"labels":[],"label_agreement":null},{"id":"W2956215750","doi":"10.1158/1535-7163.mct-18-0873","title":"Co-targeting Bulk Tumor and CSCs in Clinically Translatable TNBC Patient-Derived Xenografts via Combination Nanotherapy","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; Ottawa Hospital; Canadian Nuclear Laboratories; University of Ottawa","funders":"Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; Government of Canada","keywords":"Triple-negative breast cancer; Cancer research; Wnt signaling pathway; Medicine; Cancer stem cell; Breast cancer; Cancer; Carcinogenesis; Paclitaxel; Chemistry; Internal medicine; Signal transduction","score_opus":0.01803710046393301,"score_gpt":0.30022522338139024,"score_spread":0.2821881229174572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956215750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98524386,0.01080529,0.0012781727,0.0009766994,0.0003342596,0.0008553882,0.000019985138,0.000039800325,0.00044652572],"genre_scores_gemma":[0.98936236,0.002307573,0.0012955524,0.006770756,0.00004315334,0.000054023676,0.000036325608,0.00006439712,0.00006588632],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99838775,0.00008446774,0.00046791224,0.00038461073,0.00031718676,0.00035806315],"domain_scores_gemma":[0.9993357,0.00004148061,0.00014906202,0.00027571915,0.000094022456,0.00010399207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024293952,0.0002233683,0.00042439412,0.000108986016,0.000045523684,0.00003491178,0.000081592334,0.00010118817,0.000199854],"category_scores_gemma":[0.0000048999636,0.00021017039,0.0001147269,0.00023107512,0.000067533634,0.000067506495,0.000012625042,0.00025611927,0.000010648613],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057060726,0.00023546729,0.015833521,0.00012794943,0.0001629275,0.00004806678,0.0010610431,0.00006684248,0.8847158,0.00003201941,0.000026006415,0.09711977],"study_design_scores_gemma":[0.013096658,0.001965305,0.005809162,0.00037998596,0.0003433958,0.00003201833,0.00037712723,0.0019453486,0.8421033,0.00032867398,0.13287424,0.0007447608],"about_ca_topic_score_codex":0.00022188644,"about_ca_topic_score_gemma":0.000029978075,"teacher_disagreement_score":0.13284823,"about_ca_system_score_codex":0.000101528545,"about_ca_system_score_gemma":0.00014044558,"threshold_uncertainty_score":0.85705},"labels":[],"label_agreement":null},{"id":"W2963802995","doi":"10.1158/1535-7163.mct-18-1337","title":"GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Ferring; U.S. Department of Defense","keywords":"Prostate cancer; Testosterone (patch); Castration; Internal medicine; Endocrinology; Leuprorelin; Androgen deprivation therapy; LNCaP; Luteinizing hormone; Hormone; Medicine; Androgen; Enzalutamide; Chemistry; Androgen receptor; Cancer; Gonadotropin-releasing hormone","score_opus":0.01493351646129815,"score_gpt":0.30932913083751007,"score_spread":0.2943956143762119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963802995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9725848,0.022730693,0.000023565424,0.0017241669,0.00033477458,0.0016254431,0.00006489934,0.000064436455,0.0008472318],"genre_scores_gemma":[0.99166614,0.0047514276,0.0001065818,0.0012763975,0.00016780538,0.00032820026,0.000060395447,0.000075723576,0.0015673398],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99814594,0.000098767894,0.00024049854,0.0005358871,0.00051105884,0.00046785703],"domain_scores_gemma":[0.99912626,0.000053642732,0.00009858741,0.00038649922,0.0001352385,0.00019975551],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011751489,0.0003274177,0.00039729648,0.00011687781,0.0001243611,0.000058758116,0.00008367391,0.00013012494,0.00008089553],"category_scores_gemma":[0.000004696652,0.00024744423,0.00009055114,0.0001560524,0.00010649111,0.000078481564,0.000052225023,0.00030466565,0.000014903635],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021750939,0.0001465679,0.024872795,0.00046165183,0.00033754887,0.00031395824,0.0005134344,0.000042580614,0.92712855,0.000011391019,0.000102856735,0.043893542],"study_design_scores_gemma":[0.004336148,0.001006522,0.008000308,0.0007201236,0.0001996853,0.000015576055,0.00005235008,0.00024439194,0.9748994,0.000060072027,0.010171467,0.0002939273],"about_ca_topic_score_codex":0.00020895139,"about_ca_topic_score_gemma":0.000054201326,"teacher_disagreement_score":0.047770847,"about_ca_system_score_codex":0.00033953524,"about_ca_system_score_gemma":0.0002740664,"threshold_uncertainty_score":0.9999978},"labels":[],"label_agreement":null},{"id":"W2965511029","doi":"10.1158/1535-7163.mct-19-0132","title":"Serum PD-1 Is Elevated after Pembrolizumab Treatment but Has No Predictive Value","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Pembrolizumab; Immunotherapy; Medicine; Adverse effect; Internal medicine; Oncology; Blockade; Antibody; Multiplex; Immune checkpoint; Toxicity; Immune system; Immunology; Cancer; Receptor; Bioinformatics; Biology","score_opus":0.0194290354595217,"score_gpt":0.27511367244459595,"score_spread":0.25568463698507427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965511029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807024,0.011330118,0.00028542336,0.003165969,0.00072932936,0.0012903592,0.00022669214,0.00012278243,0.0021469004],"genre_scores_gemma":[0.97598314,0.002075885,0.00014308032,0.014020316,0.00016788283,0.0002427313,0.00003196393,0.00009864049,0.0072363857],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981757,0.000070599395,0.00031631073,0.0005137201,0.00043464222,0.0004890671],"domain_scores_gemma":[0.9988579,0.000019523975,0.00011009176,0.00069794024,0.00019049703,0.00012403508],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000074974036,0.000391112,0.00044382655,0.00010263147,0.00007209331,0.00005128566,0.00013507881,0.00021483912,0.0021866078],"category_scores_gemma":[0.0000019061002,0.00031559114,0.00034439043,0.00026013356,0.00013035732,0.000064813015,0.000030402782,0.00018869559,0.00025200503],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033732742,0.00079570536,0.03955435,0.0002247488,0.007456375,0.00027012578,0.003021647,0.00008713541,0.8737724,0.00004686614,0.0005993218,0.040438604],"study_design_scores_gemma":[0.019564938,0.0046414165,0.05019957,0.00036670384,0.0013966167,0.000076793105,0.00017780416,0.002940483,0.5447735,0.00010230719,0.37496153,0.0007983439],"about_ca_topic_score_codex":0.0004990983,"about_ca_topic_score_gemma":0.000016039283,"teacher_disagreement_score":0.3743622,"about_ca_system_score_codex":0.0007880723,"about_ca_system_score_gemma":0.00050552934,"threshold_uncertainty_score":0.9999296},"labels":[],"label_agreement":null},{"id":"W2966417378","doi":"10.1158/1535-7163.mct-18-0864","title":"Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Samuel Waxman Cancer Research Foundation; American Cancer Society","keywords":"Lung cancer; MAPK/ERK pathway; Cancer research; Apoptosis; Kinase; Cancer; Biology; Adenocarcinoma; Tyrosine kinase; Medicine; Signal transduction; Internal medicine; Cell biology; Biochemistry","score_opus":0.0060368601078012556,"score_gpt":0.24139905025273745,"score_spread":0.2353621901449362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966417378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9725181,0.023646073,0.002607971,0.00040493603,0.00019326819,0.0003298673,0.000078185236,0.000022136626,0.00019947503],"genre_scores_gemma":[0.99138814,0.005010583,0.0002977115,0.002365218,0.00007386677,0.00005620283,0.00023953873,0.0000629673,0.0005057512],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987988,0.000041459916,0.00020437196,0.00045298378,0.00014902494,0.00035339678],"domain_scores_gemma":[0.9994205,0.0000057367415,0.00010758453,0.00031461887,0.00007583455,0.00007569603],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008926903,0.00025162476,0.0001874947,0.000044227938,0.00008558088,0.000053400276,0.00011406753,0.00017098288,0.000038347545],"category_scores_gemma":[0.0000035722387,0.00025871384,0.0000805374,0.00011057931,0.000059546543,0.000008499777,0.00010564542,0.00012277016,0.0000040214],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059916474,0.000033637494,0.0025000414,0.0000567745,0.00016763933,0.0000011668338,0.000058454658,0.00014069874,0.9914899,0.000065603,0.00039995057,0.005026215],"study_design_scores_gemma":[0.00088019215,0.00015861682,0.00013300807,0.00005826292,0.000112674614,0.0000041688595,0.000064154716,0.0010318026,0.98226434,0.000023834058,0.014931206,0.00033774995],"about_ca_topic_score_codex":0.00017890453,"about_ca_topic_score_gemma":0.000039024202,"teacher_disagreement_score":0.018870072,"about_ca_system_score_codex":0.00008289748,"about_ca_system_score_gemma":0.000075654665,"threshold_uncertainty_score":0.9999865},"labels":[],"label_agreement":null},{"id":"W2967512896","doi":"10.1158/1535-7163.mct-19-0162","title":"eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Montreal Neurological Institute and Hospital; McGill University Health Centre","funders":"Canadian Institutes of Health Research; National Institute of General Medical Sciences; Government of Canada","keywords":"Palbociclib; Cancer research; Cancer; Cancer cell; Downregulation and upregulation; KRAS; Cell cycle; Cyclin D1; Estrogen receptor; Medicine; Cyclin-dependent kinase 6; Breast cancer; Pharmacology; Biology; Internal medicine; Metastatic breast cancer; Colorectal cancer","score_opus":0.012868211759400505,"score_gpt":0.28810024795350697,"score_spread":0.27523203619410647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967512896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9767664,0.013733928,0.00033990192,0.0070782998,0.00036696158,0.0012063286,0.00006484233,0.00008602164,0.00035728866],"genre_scores_gemma":[0.9888709,0.0005888571,0.0009312698,0.0073371404,0.000114620336,0.00031947027,0.0000108143695,0.0001270438,0.0016998617],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99761254,0.00016768998,0.0004221787,0.00070658466,0.0004885931,0.00060242414],"domain_scores_gemma":[0.9988005,0.00007258775,0.00013879528,0.00060712686,0.00016212498,0.0002188774],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025738103,0.0003850752,0.0005139207,0.0002676874,0.000065198954,0.00004417702,0.00011599959,0.00018956664,0.00018249893],"category_scores_gemma":[0.000012874537,0.0003900717,0.00009574805,0.00064266194,0.00012501309,0.00016792849,0.00009479607,0.0002500204,0.000030493786],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0090152435,0.00013748072,0.008792095,0.00023371662,0.00010205921,0.00010702276,0.0021224595,0.0012984711,0.969517,0.000042822277,0.00007958467,0.008552081],"study_design_scores_gemma":[0.008215709,0.00044493048,0.055355534,0.0013417696,0.00016286272,0.000024939884,0.0006117508,0.00022745677,0.86870587,0.00046610917,0.06360649,0.00083657884],"about_ca_topic_score_codex":0.00021974606,"about_ca_topic_score_gemma":0.0003294465,"teacher_disagreement_score":0.1008111,"about_ca_system_score_codex":0.0006617403,"about_ca_system_score_gemma":0.00026460527,"threshold_uncertainty_score":0.9998551},"labels":[],"label_agreement":null},{"id":"W2970508726","doi":"10.1158/1535-7163.mct-19-0299","title":"Microvesicle-Mediated Delivery of Minicircle DNA Results in Effective Gene-Directed Enzyme Prodrug Cancer Therapy","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Extracellular vesicles in disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"National Center for Advancing Translational Sciences; National Institutes of Health","keywords":"Minicircle; Microvesicle; Prodrug; Genetic enhancement; Gene delivery; Cancer; DNA; Biology; Medicine; Pharmacology; Gene; Cancer research; Biochemistry; Genetics; Microvesicles; microRNA","score_opus":0.009704326669691708,"score_gpt":0.26292250647217813,"score_spread":0.2532181798024864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970508726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96165675,0.03608949,0.000084088,0.00020778169,0.0002715534,0.0011926605,0.0002770059,0.00003653085,0.00018411729],"genre_scores_gemma":[0.9938053,0.00370848,0.00031057105,0.001352691,0.00008859948,0.00021579629,0.0001732594,0.000096537806,0.00024879628],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977402,0.0002905954,0.0005000815,0.00071652746,0.0002890137,0.0004635862],"domain_scores_gemma":[0.9985551,0.00005003037,0.0002730357,0.00079761323,0.00022470119,0.00009949916],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026563587,0.00034011222,0.00036716732,0.00010871966,0.000031619835,0.000018846204,0.00043136626,0.0002723905,0.000033047476],"category_scores_gemma":[0.000028325305,0.00035147968,0.00019387099,0.00036809585,0.00013440257,0.000009701799,0.0001071987,0.0001982634,0.0000124523385],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015966763,0.00028040758,0.0068939626,0.000049079194,0.0003626234,0.000017793578,0.00027803954,0.00067100354,0.97661024,0.000004651596,0.0001184308,0.013117097],"study_design_scores_gemma":[0.0039169136,0.00028077493,0.01249909,0.00007593857,0.00005221928,0.0000023436455,0.000041032617,0.0007047171,0.9750322,0.000029174866,0.0069594975,0.00040610513],"about_ca_topic_score_codex":0.0004027818,"about_ca_topic_score_gemma":0.00020100639,"teacher_disagreement_score":0.03238101,"about_ca_system_score_codex":0.000104134924,"about_ca_system_score_gemma":0.0003306761,"threshold_uncertainty_score":0.9998937},"labels":[],"label_agreement":null},{"id":"W2970593485","doi":"10.1158/1535-7163.mct-18-1215","title":"Inhibition of AKT Sensitizes Cancer Cells to Antineoplastic Drugs by Downregulating Flap Endonuclease 1","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"National Natural Science Foundation of China","keywords":"Protein kinase B; DNA repair; Cancer research; Biology; Cancer cell; DNA damage; Transcription factor; Cell growth; Cancer; Signal transduction; Cell biology; DNA; Gene; Biochemistry; Genetics","score_opus":0.006340465986751245,"score_gpt":0.2394554376583952,"score_spread":0.23311497167164394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970593485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99381715,0.0014814613,0.0031806417,0.00019795037,0.00035995425,0.00044561838,0.0001638178,0.000029366816,0.00032405122],"genre_scores_gemma":[0.9957537,0.00016231189,0.0010826195,0.0022219778,0.000086785054,0.000045371897,0.00006165683,0.00007769988,0.00050786964],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985135,0.00007925176,0.0002907377,0.00047462666,0.00028640195,0.00035547602],"domain_scores_gemma":[0.9991031,0.0000139942795,0.00015873945,0.00045550978,0.00016166152,0.00010698899],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011406862,0.00025728054,0.00025758933,0.00005930286,0.000041350457,0.000022668173,0.00014782755,0.00016192386,0.000090139096],"category_scores_gemma":[0.0000072329944,0.00026875155,0.00013764437,0.00017163754,0.000044194323,0.0000054843867,0.00011976688,0.00009639848,0.000022349255],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012420869,0.000045690253,0.0001808686,0.00006274282,0.0001442574,0.0000032844716,0.00017871027,0.0022997893,0.9920266,0.000040843624,0.0003126209,0.0045803376],"study_design_scores_gemma":[0.00072295754,0.00022105408,0.000037307003,0.00008523783,0.00008085843,0.000002737562,0.00009408071,0.00062759285,0.9903265,0.00003247947,0.00745258,0.0003165847],"about_ca_topic_score_codex":0.00011707427,"about_ca_topic_score_gemma":0.000019448153,"teacher_disagreement_score":0.0071399594,"about_ca_system_score_codex":0.000043377528,"about_ca_system_score_gemma":0.000107974185,"threshold_uncertainty_score":0.99997646},"labels":[],"label_agreement":null},{"id":"W2974766534","doi":"10.1158/1535-7163.mct-18-0986","title":"PD-1/PD-L1 Immune Checkpoint Inhibition with Radiation in Bladder Cancer: <i>In Situ</i> and Abscopal Effects","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Cancer Research Society","keywords":"Abscopal effect; Bladder cancer; Immune system; Cancer research; In situ; Medicine; Cancer; Immune checkpoint; Immunology; Chemistry; Internal medicine; Immunotherapy","score_opus":0.0077958635843792725,"score_gpt":0.2630815545146738,"score_spread":0.2552856909302945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974766534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97795695,0.017940212,0.00013991511,0.0014242749,0.00018133078,0.0012384508,0.000014972951,0.000032590946,0.0010713039],"genre_scores_gemma":[0.9934142,0.0032494888,0.000100850455,0.0026730793,0.0000637587,0.00026201285,0.000024302524,0.000059888374,0.00015240075],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986495,0.00006556276,0.00027008133,0.00038975896,0.00028417262,0.00034095225],"domain_scores_gemma":[0.999493,0.00002295635,0.00009214065,0.0002657771,0.000047772897,0.000078357996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001024195,0.0002625405,0.0003988622,0.00015047415,0.000027759634,0.000024581575,0.000047588797,0.00012972634,0.00007097515],"category_scores_gemma":[0.0000023044151,0.00022273298,0.000060500282,0.00032806135,0.000058558067,0.000092774004,0.000021826825,0.00025967407,0.000010776044],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019188441,0.00033200157,0.11847648,0.0004030141,0.00044502428,0.00023849412,0.0016219612,0.0004997492,0.81629187,0.000074652125,0.000010159606,0.059687734],"study_design_scores_gemma":[0.016097123,0.0009750933,0.29003158,0.00090538006,0.00036581917,0.000029784933,0.000100933226,0.00041980445,0.68906707,0.00017900078,0.0014229964,0.00040538886],"about_ca_topic_score_codex":0.0013530308,"about_ca_topic_score_gemma":0.00075059047,"teacher_disagreement_score":0.17155512,"about_ca_system_score_codex":0.00040106368,"about_ca_system_score_gemma":0.00024406325,"threshold_uncertainty_score":0.90827876},"labels":[],"label_agreement":null},{"id":"W2976358175","doi":"10.1158/1535-7163.mct-19-0386","title":"Inhibition of Autotaxin with GLPG1690 Increases the Efficacy of Radiotherapy and Chemotherapy in a Mouse Model of Breast Cancer","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; Northern Alberta Institute of Technology; University of Alberta Hospital; University of Alberta","funders":"Canadian Cancer Society Research Institute","keywords":"Autotaxin; Breast cancer; Chemotherapy; Radiation therapy; Cancer; Medicine; Internal medicine; Oncology; Cancer research; Pharmacology; Biology; Receptor; Lysophosphatidic acid","score_opus":0.009515745732182383,"score_gpt":0.24897653042427426,"score_spread":0.23946078469209187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2976358175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989845,0.0075924844,0.0019368127,0.0001573652,0.000021129754,0.00032092698,0.00010422901,0.0000038068436,0.00001828487],"genre_scores_gemma":[0.9944492,0.0043566716,0.00047563243,0.00058372464,0.000031938645,0.000024884417,0.000008016309,0.00003591641,0.000034015313],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99912137,0.0000626107,0.00026257508,0.00022131548,0.0001757572,0.0001563667],"domain_scores_gemma":[0.999321,0.000016074242,0.00021037713,0.00031923482,0.000105948304,0.000027368173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014736068,0.00016063852,0.00029222123,0.00005742936,0.000015266563,0.0000057859393,0.00012963534,0.00009654274,0.000013858385],"category_scores_gemma":[0.0000027829446,0.00011541722,0.00007140957,0.00014051712,0.00015529146,0.0000057112807,0.000026427773,0.00007652088,4.4301416e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090000016,0.00012585962,0.014396312,0.00006909983,0.00019064744,2.399381e-7,0.00041456643,0.015030358,0.9656128,0.00010958017,0.000002127236,0.003148359],"study_design_scores_gemma":[0.0032656563,0.00014419311,0.007498842,0.000097519085,0.000053677137,0.0000030725587,0.000075566626,0.004685962,0.9838754,0.000030581945,0.00011694391,0.0001525975],"about_ca_topic_score_codex":0.00062978006,"about_ca_topic_score_gemma":0.00006502007,"teacher_disagreement_score":0.018262537,"about_ca_system_score_codex":0.000016106273,"about_ca_system_score_gemma":0.00015617622,"threshold_uncertainty_score":0.47065777},"labels":[],"label_agreement":null},{"id":"W2990311629","doi":"10.1158/1535-7163.targ-19-b006","title":"Abstract B006: Targeting EZH2 increases therapeutic efficacy of PD-1 blockade in models of prostate cancer","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Prostate cancer; EZH2; Cancer research; Cancer; Interferon; Immunotherapy; Biology; CD8; Medicine; Immunology; Gene expression; Antigen; Internal medicine; Gene","score_opus":0.018336811812654997,"score_gpt":0.29934188399017714,"score_spread":0.28100507217752213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990311629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9641732,0.032118928,0.00182858,0.00015828575,0.00017054955,0.0010129639,0.000113824644,0.000016895949,0.00040677306],"genre_scores_gemma":[0.9933618,0.005450935,0.00028360542,0.00038264217,0.00006353953,0.00013348153,0.00006734006,0.00011914287,0.00013755029],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973125,0.00015848869,0.0006733147,0.00064801035,0.00058507326,0.00062261545],"domain_scores_gemma":[0.9984673,0.000038453843,0.00035493754,0.0007251677,0.00030964473,0.000104456565],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003608138,0.0003756029,0.00050885405,0.00020953474,0.0000363105,0.000020207844,0.00052084733,0.0003298736,0.00013850475],"category_scores_gemma":[0.000021787002,0.0003797751,0.00025944025,0.00045961465,0.00015057351,0.000013829796,0.00018551941,0.00035713907,0.0000041059643],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069972064,0.00027366052,0.0015781485,0.0002007225,0.0004330023,0.000008713861,0.00020047852,0.05850598,0.9295612,0.00013944347,0.000014836968,0.008384093],"study_design_scores_gemma":[0.0025980263,0.00031320163,0.0016324156,0.0002348534,0.00009580069,0.0000028553968,0.0001131267,0.0028907107,0.98946476,0.00037549975,0.001857834,0.00042089453],"about_ca_topic_score_codex":0.001403894,"about_ca_topic_score_gemma":0.00015281732,"teacher_disagreement_score":0.05990358,"about_ca_system_score_codex":0.00011485789,"about_ca_system_score_gemma":0.00061252207,"threshold_uncertainty_score":0.9998654},"labels":[],"label_agreement":null},{"id":"W2992010002","doi":"10.1158/1535-7163.targ-19-b057","title":"Abstract B057: BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Mesothelin; Nivolumab; Medicine; Mesothelioma; Pharmacology; Pharmacokinetics; Antibody-drug conjugate; Ovarian cancer; Cancer; Internal medicine; Monoclonal antibody; Oncology; Antibody; Immunology; Immunotherapy; Pathology","score_opus":0.013724104482352615,"score_gpt":0.33586451875733075,"score_spread":0.32214041427497814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992010002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980525,0.00045526284,0.00011128329,0.000106974214,0.000057793775,0.0010720644,0.000062725194,0.000018194583,0.00006324373],"genre_scores_gemma":[0.9984491,0.00050049264,0.0002533769,0.00030080357,0.000023688055,0.00007696604,0.00026448254,0.00007432918,0.000056780715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977351,0.00020573594,0.00038607937,0.0007193348,0.00038718065,0.0005665831],"domain_scores_gemma":[0.9989433,0.000026335634,0.00021802579,0.00049601076,0.0001801278,0.00013617126],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026337084,0.0003442911,0.00047064258,0.000113231035,0.00005399242,0.00005562348,0.00024758693,0.00015634591,0.000028283868],"category_scores_gemma":[0.000010648855,0.00026741132,0.00006974092,0.00032030328,0.00014903473,0.000042090927,0.00004912428,0.0003379279,0.000006844271],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065555805,0.001554142,0.7443492,0.000046744914,0.00027224387,0.000065628796,0.000051175924,0.0012892986,0.23110008,0.000003387906,0.000003401861,0.014709125],"study_design_scores_gemma":[0.015254888,0.0033538658,0.7539398,0.00016904793,0.00003829017,0.00000310753,0.000040607305,0.00042367878,0.22612472,0.000015035924,0.0001816701,0.00045528234],"about_ca_topic_score_codex":0.0007130422,"about_ca_topic_score_gemma":0.004960143,"teacher_disagreement_score":0.014253843,"about_ca_system_score_codex":0.00012767567,"about_ca_system_score_gemma":0.00058752997,"threshold_uncertainty_score":0.9999778},"labels":[],"label_agreement":null},{"id":"W2992028221","doi":"10.1158/1535-7163.targ-19-b058","title":"Abstract B058: CD73 siRNA therapy regulates glioblastoma immune microenvironment","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Immune system; Tumor microenvironment; Glioma; In vivo; Gene knockdown; Cancer research; Medicine; Small hairpin RNA; Cancer; Brain tumor; In vitro; Pharmacology; Apoptosis; Biology; Immunology; Pathology; Internal medicine","score_opus":0.009754058284271675,"score_gpt":0.24300462953699847,"score_spread":0.2332505712527268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992028221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9406069,0.05754104,0.00035160145,0.00038841728,0.00024320916,0.00030448465,0.000014347105,0.00002403311,0.0005259661],"genre_scores_gemma":[0.9917754,0.0043399646,0.00018884796,0.0022434313,0.00020861275,0.000036338555,0.000047762274,0.00008346214,0.0010762106],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985744,0.000044831733,0.0002835523,0.00046676997,0.00023168091,0.00039877693],"domain_scores_gemma":[0.9991017,0.000008859477,0.00013786987,0.0006317193,0.00004735706,0.00007251726],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001095305,0.0003076108,0.00022788264,0.00004520243,0.00006845874,0.000039732713,0.00032582076,0.00019782942,0.00039226713],"category_scores_gemma":[0.0000018987829,0.0002860088,0.0002041225,0.00009763606,0.00007148329,0.0000057735056,0.000090685586,0.0001553154,0.00006829509],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023737857,0.0000847726,0.0012665733,0.000016357308,0.00031226923,0.000011457755,0.000058911708,0.001300114,0.99004966,0.000028621067,0.00036197208,0.0062719374],"study_design_scores_gemma":[0.0009963894,0.0003078273,0.003489984,0.000028483717,0.000028790124,0.00001055047,0.000039641465,0.00005333093,0.8734195,0.00007121114,0.121205136,0.00034911223],"about_ca_topic_score_codex":0.00004247529,"about_ca_topic_score_gemma":0.000002568777,"teacher_disagreement_score":0.120843165,"about_ca_system_score_codex":0.000037680507,"about_ca_system_score_gemma":0.000063236366,"threshold_uncertainty_score":0.99995923},"labels":[],"label_agreement":null},{"id":"W2992330814","doi":"10.1158/1535-7163.targ-19-cn06-01","title":"Abstract CN06-01: Lineage plasticity and the neuroendocrine phenotype as a resistance mechanism in prostate cancer","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Cancer research; Prostate; Exome sequencing; Adenocarcinoma; Somatic evolution in cancer; DNA methylation; Biology; Cancer; Epigenomics; Copy number analysis; Chromoplexy; Liquid biopsy; Medicine; Phenotype; Copy-number variation; PCA3; Genetics; Gene; Genome","score_opus":0.02010044019727532,"score_gpt":0.3109422800884922,"score_spread":0.29084183989121687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992330814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9677335,0.019827249,0.000028588434,0.008793175,0.00022045014,0.0016929129,0.000042894575,0.000043221098,0.001618008],"genre_scores_gemma":[0.979695,0.012728996,0.00006534903,0.003438992,0.000065168475,0.000299042,0.000010504071,0.000059726015,0.0036371984],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982464,0.00008241412,0.00028080042,0.00044173963,0.00044541009,0.00050325016],"domain_scores_gemma":[0.99925107,0.00010119323,0.00009814715,0.00033555727,0.00010134053,0.00011268913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001547742,0.0002664362,0.00040693342,0.00009453087,0.000078472054,0.00005170756,0.00015104329,0.00004850392,0.00023081782],"category_scores_gemma":[0.000017261555,0.00017279803,0.00008650989,0.00031493045,0.00019883955,0.000063100604,0.00007679997,0.00048303802,0.000024790545],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06808464,0.0012030083,0.050706614,0.0029905478,0.003030406,0.005249921,0.007642454,0.00095247733,0.7936905,0.02427369,0.00043100695,0.04174474],"study_design_scores_gemma":[0.09812719,0.0015518606,0.109363794,0.0026037148,0.0015050735,0.00013181874,0.001065978,0.005984492,0.6792601,0.013075241,0.08541703,0.0019137245],"about_ca_topic_score_codex":0.0006677799,"about_ca_topic_score_gemma":0.0004472563,"teacher_disagreement_score":0.1144304,"about_ca_system_score_codex":0.00019700402,"about_ca_system_score_gemma":0.00033808476,"threshold_uncertainty_score":0.7046499},"labels":[],"label_agreement":null},{"id":"W2992420236","doi":"10.1158/1535-7163.targ-19-c031","title":"Abstract C031: Ras processing by RRSP protease as a strategy to inhibit Ras-driven tumors","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"KRAS; Cancer research; Biology; Epidermal growth factor receptor; Cancer; Cell growth; Cetuximab; Cancer cell; Colorectal cancer; Molecular biology; Genetics","score_opus":0.01686012876723437,"score_gpt":0.31852805887283403,"score_spread":0.30166793010559967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992420236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99003065,0.0058165737,0.00042469412,0.00047422072,0.0000569903,0.0012680878,0.000109640125,0.000030487172,0.0017886476],"genre_scores_gemma":[0.9957493,0.00021100994,0.0001415523,0.002060735,0.00009279359,0.0003456645,0.00014471298,0.00008448358,0.0011697573],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99805003,0.000052013173,0.00024413684,0.0006453132,0.00040721978,0.0006012562],"domain_scores_gemma":[0.99898106,0.000004449141,0.00010300663,0.00048735982,0.00014711019,0.00027700438],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009364339,0.00032455544,0.00023947317,0.00006556258,0.00009252387,0.00011962749,0.0003147477,0.00016231155,0.00021678963],"category_scores_gemma":[0.000009255042,0.00030554077,0.00013071654,0.00020973725,0.0000618689,0.000011570183,0.00011359261,0.00020637053,0.00014710317],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003927357,0.00015940015,0.0017739378,0.00006984859,0.00021651354,0.000045623277,0.000072424584,0.00047551107,0.95696175,0.00001288589,0.00045503734,0.039364323],"study_design_scores_gemma":[0.0017635968,0.0009946949,0.0008468434,0.00010856303,0.000045588848,0.00001272682,0.00007975117,0.00007963728,0.9354687,0.0000980919,0.06003128,0.00047054802],"about_ca_topic_score_codex":0.0005796719,"about_ca_topic_score_gemma":0.00010536047,"teacher_disagreement_score":0.05957624,"about_ca_system_score_codex":0.00012726965,"about_ca_system_score_gemma":0.0005992193,"threshold_uncertainty_score":0.9999397},"labels":[],"label_agreement":null},{"id":"W2992593954","doi":"10.1158/1535-7163.targ-19-b075","title":"Abstract B075: eIF4A regulates ERK activation by controlling the translation of DUSP6","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"ATP Synthase and ATPases Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"DUSP6; MAPK/ERK pathway; Kinase; Neuroblastoma RAS viral oncogene homolog; Molecular biology; Biology; Western blot; Phosphatase; Cancer research; Cell biology; Phosphorylation; KRAS; Protein phosphatase 2; Genetics; Gene; Mutation","score_opus":0.020847619617093815,"score_gpt":0.30224239951864657,"score_spread":0.28139477990155276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992593954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98838955,0.0060105007,0.0037614862,0.0008244378,0.00006254865,0.00035373314,0.000034289307,0.000007949749,0.00055552495],"genre_scores_gemma":[0.9982773,0.00069799286,0.00008129684,0.000540262,0.00006288,0.000025559504,0.00008920857,0.000029383553,0.0001961243],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990836,0.000058718477,0.00019469191,0.00022144712,0.00023858623,0.00020299312],"domain_scores_gemma":[0.99939984,0.000032035376,0.00010742057,0.0003334298,0.00009730335,0.000029971266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015871468,0.0001313613,0.0001348847,0.000023445316,0.000054448235,0.000021179087,0.000192786,0.00013012995,0.000069216105],"category_scores_gemma":[0.000006548632,0.000100398414,0.00011080588,0.000098689474,0.000068188296,0.0000060700722,0.000021014226,0.00011464098,0.000005139706],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016329806,0.000033288157,0.00060818635,0.000022645927,0.00017529727,3.8038223e-7,0.000052583877,0.00072292064,0.97234654,0.00003746462,0.000083692175,0.02575368],"study_design_scores_gemma":[0.00064147596,0.00009484042,0.0007870316,0.000025556501,0.00003094794,3.453765e-7,0.000051530624,0.0006964861,0.9707644,0.00007440703,0.026708845,0.00012413478],"about_ca_topic_score_codex":0.00007307975,"about_ca_topic_score_gemma":0.0000084260855,"teacher_disagreement_score":0.026625153,"about_ca_system_score_codex":0.000015833179,"about_ca_system_score_gemma":0.00007374055,"threshold_uncertainty_score":0.40941283},"labels":[],"label_agreement":null},{"id":"W2993545890","doi":"10.1158/1535-7163.targ-19-c027","title":"Abstract C027: A Phase I, dose finding study of BI 754111, an anti-LAG-3 antibody, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumors: preliminary results from the microsatellite stable (MSS) metastatic colorectal cancer (mCRC) cohort","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); University of Alberta","funders":"","keywords":"Blockade; Medicine; Antibody; Monoclonal antibody; Immune checkpoint; Lung cancer; Cancer; Cancer research; Internal medicine; T cell; Oncology; Immune system; Pharmacology; Immunology; Receptor","score_opus":0.01862583428759236,"score_gpt":0.3292702647812341,"score_spread":0.31064443049364177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993545890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923378,0.0020129918,0.00004130347,0.00013166806,0.00019023717,0.004685355,0.00052838895,0.00004600461,0.00002623276],"genre_scores_gemma":[0.99718463,0.000795862,0.00022713102,0.0003917468,0.000024996476,0.00014996756,0.001085319,0.00012731462,0.000013004592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961252,0.0003213681,0.001026634,0.0009561314,0.0009031228,0.0006675415],"domain_scores_gemma":[0.9978005,0.00012647216,0.00074323436,0.00088361785,0.00032433422,0.00012180566],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006265486,0.00058358826,0.0010640488,0.00033875945,0.00012005717,0.00008673734,0.00040375532,0.00013566099,0.000054776116],"category_scores_gemma":[0.000010740282,0.00041680012,0.000095153155,0.001186082,0.00023845721,0.0004982439,0.00005736296,0.0004910258,0.00000143515],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045904294,0.0060800873,0.5553299,0.000100135876,0.0008728093,0.00013108375,0.0046469998,0.0019123212,0.37737638,0.0000012299956,0.0000013614133,0.0076434086],"study_design_scores_gemma":[0.051084477,0.012788553,0.8585028,0.0012556479,0.00046023368,0.0000055622395,0.0022798753,0.0012910896,0.07171465,0.0000066934676,0.00006319376,0.00054723874],"about_ca_topic_score_codex":0.008262068,"about_ca_topic_score_gemma":0.0025469845,"teacher_disagreement_score":0.30566174,"about_ca_system_score_codex":0.00038566472,"about_ca_system_score_gemma":0.00054403476,"threshold_uncertainty_score":0.9998284},"labels":[],"label_agreement":null},{"id":"W2993613817","doi":"10.1158/1535-7163.targ-19-c048","title":"Abstract C048: Novel master checkpoint Cbl-b siRNA-based adoptive cellular therapy: Superior antitumor efficacy in a syngeneic murine hepatocellular carcinoma Hepa1-6 model following APN401 monotherapy and synergistic effects with anti-PD1","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Cancer research; In vivo; Immune system; Immunotherapy; Medicine; Hepatocellular carcinoma; Cancer; Immunology; Pharmacology; Biology; Internal medicine","score_opus":0.034315951275988264,"score_gpt":0.280333360489796,"score_spread":0.24601740921380774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993613817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977085,0.011516908,0.006587491,0.00048818134,0.00017862582,0.0037849515,0.00002933565,0.0001143028,0.00021522473],"genre_scores_gemma":[0.99468076,0.00064662046,0.0015343679,0.001856966,0.00009529383,0.0003057216,0.000049148148,0.0003941194,0.0004370184],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99544877,0.00016396593,0.00071212323,0.0013027317,0.0011385839,0.0012338206],"domain_scores_gemma":[0.997772,0.0001955934,0.00021484922,0.0012429337,0.0002017714,0.00037288107],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005352499,0.0009477344,0.0013912756,0.0005159363,0.00012662167,0.00014696438,0.0003927959,0.0002983845,0.00024158641],"category_scores_gemma":[0.000014480547,0.0008023823,0.0004592666,0.00073602115,0.00025414527,0.00015347105,0.000085269916,0.00088544784,0.000017817152],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028616928,0.0010021954,0.078839995,0.00053898914,0.0008621238,0.0015662013,0.0006494967,0.005773305,0.90339893,0.000021325546,0.0000011398274,0.0044845804],"study_design_scores_gemma":[0.024068126,0.0014390468,0.031815305,0.00086755183,0.00032693564,0.000033314598,0.00008644194,0.1527539,0.7870445,0.00001879999,0.000514625,0.0010313952],"about_ca_topic_score_codex":0.0004805732,"about_ca_topic_score_gemma":0.000031208514,"teacher_disagreement_score":0.1469806,"about_ca_system_score_codex":0.0004981693,"about_ca_system_score_gemma":0.0007413194,"threshold_uncertainty_score":0.9994427},"labels":[],"label_agreement":null},{"id":"W2993657848","doi":"10.1158/1535-7163.targ-19-a072","title":"Abstract A072: Preliminary results of ASTX660, a novel non-peptidomimetic cIAP1/2 and XIAP antagonist, in 107 patients with solid tumors or lymphoma","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Lymphoma; Internal medicine; Oncology; Adverse effect; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Chemotherapy","score_opus":0.012321276851566318,"score_gpt":0.2545202610382896,"score_spread":0.2421989841867233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993657848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970041,0.00093488686,0.00023001221,0.000057227728,0.00007016768,0.00070073904,0.00019848591,0.000008629293,0.0007957801],"genre_scores_gemma":[0.9982094,0.00018749776,0.00061676087,0.00048139947,0.0000354748,0.000054179254,0.00010488924,0.000059148995,0.00025124283],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99845374,0.0000388433,0.0003988377,0.00050176575,0.0002482713,0.00035856297],"domain_scores_gemma":[0.99906415,0.000019982252,0.00023961354,0.00046868954,0.00012562197,0.000081919774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016831374,0.00028533765,0.0003324412,0.000082460014,0.00003704871,0.000023125993,0.00022220305,0.0001750444,0.00001825501],"category_scores_gemma":[0.000013780526,0.00023326329,0.0000682933,0.00016582913,0.00012211267,0.000008177926,0.00010859376,0.00010810352,0.0000036415029],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008479151,0.00047002707,0.010509365,0.000186409,0.00018984353,0.000015662801,0.00029140912,0.0003613918,0.96891326,0.000011793901,0.000018932837,0.010552772],"study_design_scores_gemma":[0.009249393,0.0026460122,0.07041363,0.00027843777,0.000056361372,0.000011550146,0.000086841894,0.00026952615,0.9145251,0.000020518799,0.002001163,0.00044146378],"about_ca_topic_score_codex":0.00009050445,"about_ca_topic_score_gemma":0.000043781474,"teacher_disagreement_score":0.059904262,"about_ca_system_score_codex":0.000037022295,"about_ca_system_score_gemma":0.00025455895,"threshold_uncertainty_score":0.9512201},"labels":[],"label_agreement":null},{"id":"W2993673395","doi":"10.1158/1535-7163.targ-19-b117","title":"Abstract B117: Treatment of castrated resistant prostate cancer with EPI-7386, a second generation N-terminal domain androgen receptor inhibitor","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Androgen receptor; Prostate cancer; In vivo; Cancer research; Biology; Androgen; Cancer; Chemistry; Pharmacology; Biochemistry; Genetics; Hormone","score_opus":0.031789674954218174,"score_gpt":0.3149602222976824,"score_spread":0.2831705473434642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993673395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829211,0.013595349,0.000010757422,0.0008886629,0.00016762018,0.0017006578,0.0003069107,0.000032363423,0.00037656978],"genre_scores_gemma":[0.9940747,0.0024892578,0.00035351704,0.00019258646,0.00014993703,0.00037546724,0.00017704413,0.00007486657,0.0021126203],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981926,0.00006030403,0.00035363476,0.0004635198,0.00048261468,0.00044733888],"domain_scores_gemma":[0.99895567,0.000012954384,0.00018966725,0.00039898808,0.00028328714,0.00015945379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009104587,0.00033082045,0.0004791653,0.000095122006,0.00007105064,0.00003731839,0.000078590565,0.0001285126,0.0006911352],"category_scores_gemma":[8.855521e-7,0.00022769351,0.00012483376,0.00029491782,0.00012924495,0.000078804434,0.000014230717,0.0001564017,0.000015458401],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048127132,0.00042925004,0.012131524,0.00027768032,0.0011244623,0.00031701158,0.0014016713,0.00007892426,0.9625739,0.000016207492,0.000050923714,0.016785774],"study_design_scores_gemma":[0.009125018,0.003739242,0.00544225,0.00039484922,0.00033129886,0.000030514651,0.00026541314,0.000097894364,0.9580201,0.000017774686,0.022214245,0.00032139345],"about_ca_topic_score_codex":0.00037951386,"about_ca_topic_score_gemma":0.0004625272,"teacher_disagreement_score":0.022163322,"about_ca_system_score_codex":0.0006954766,"about_ca_system_score_gemma":0.0008985742,"threshold_uncertainty_score":0.92850715},"labels":[],"label_agreement":null},{"id":"W2993755223","doi":"10.1158/1535-7163.targ-19-b049","title":"Abstract B049: Hyperprogressive disease after two cycles of immunotherapy in HER-2 positive metastatic gastric cancer","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Pembrolizumab; Medicine; Nivolumab; Cancer; Immunotherapy; Response Evaluation Criteria in Solid Tumors; Internal medicine; Oncology; Regimen; Immunohistochemistry; Stomach; Gastroenterology; Disease; Progressive disease","score_opus":0.009132067387983691,"score_gpt":0.28665847441968845,"score_spread":0.2775264070317048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993755223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9210065,0.07709077,0.00031816424,0.00025341642,0.0002442042,0.00053684326,0.0004040673,0.0000067581545,0.00013926011],"genre_scores_gemma":[0.9866771,0.010637382,0.0003609539,0.0017917574,0.00007908714,0.00025772734,0.00006745336,0.00007520066,0.00005330494],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99849516,0.000062686944,0.00036252933,0.00045952306,0.00023328933,0.00038679174],"domain_scores_gemma":[0.99901706,0.000029384562,0.00020403127,0.00050303305,0.00014274428,0.00010377163],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009789919,0.0002999198,0.00032797334,0.000100202575,0.00002511236,0.00003000669,0.00025793767,0.00008035332,0.0001493995],"category_scores_gemma":[0.0000081762655,0.00029550903,0.00019701151,0.00020295988,0.00010782808,0.0000079426545,0.000077604665,0.00014616565,0.0000074309773],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015991025,0.00032545286,0.10061609,0.000088116605,0.00060566,0.00007348694,0.0002041038,0.006312452,0.8503324,0.00008444296,0.00002253674,0.039736174],"study_design_scores_gemma":[0.007827307,0.0006946702,0.3742016,0.0007240851,0.00045802427,0.00001105421,0.00021407516,0.0006767933,0.6019797,0.0008707798,0.010858232,0.0014836879],"about_ca_topic_score_codex":0.0005044777,"about_ca_topic_score_gemma":0.00026035233,"teacher_disagreement_score":0.2735855,"about_ca_system_score_codex":0.00009734132,"about_ca_system_score_gemma":0.00039236998,"threshold_uncertainty_score":0.9999497},"labels":[],"label_agreement":null},{"id":"W2993844726","doi":"10.1158/1535-7163.targ-19-c128","title":"Abstract C128: Reprogramming transcription factors SOX2 and REST modulates SPINK1 expression in governing cellular plasticity in prostate cancer","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Cancer research; Biology; Reprogramming; Transcription factor; SOX2; Androgen receptor; Cancer; Gene silencing; Androgen deprivation therapy; TMPRSS2; Prostate; Internal medicine; Genetics; Medicine; Cell","score_opus":0.032841490813874503,"score_gpt":0.3118384028705806,"score_spread":0.2789969120567061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993844726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851705,0.0130000515,0.00005765017,0.0004072918,0.00013560393,0.0010483142,0.000028293984,0.00003738792,0.000114909584],"genre_scores_gemma":[0.99512476,0.0041153464,0.0001264703,0.00012438027,0.00003179223,0.0001297325,0.000042255473,0.000054243752,0.00025102528],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99820316,0.000052674113,0.00032268694,0.00052301283,0.0003966084,0.0005018809],"domain_scores_gemma":[0.999484,0.000032976015,0.00009446279,0.00021973935,0.00005757031,0.00011123745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013204089,0.00026352867,0.0003710755,0.00017594383,0.000050814804,0.000047759557,0.000081623,0.0001479864,0.0000950862],"category_scores_gemma":[0.00000794531,0.00021528498,0.00007112308,0.000291354,0.000076186254,0.0001359612,0.00003401133,0.000486463,0.000004831844],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000516639,0.00010088022,0.3224734,0.00024971872,0.00005166603,0.00010357274,0.0014356949,0.0005893514,0.66361326,0.000003675591,0.0000015857265,0.010860537],"study_design_scores_gemma":[0.0043287533,0.00022518312,0.3588706,0.0012714089,0.000067110064,0.0000023606267,0.00043650126,0.002036367,0.6308069,0.000047056288,0.0016051334,0.00030260326],"about_ca_topic_score_codex":0.001464773,"about_ca_topic_score_gemma":0.00029266404,"teacher_disagreement_score":0.036397174,"about_ca_system_score_codex":0.00045603357,"about_ca_system_score_gemma":0.00014336177,"threshold_uncertainty_score":0.8779066},"labels":[],"label_agreement":null},{"id":"W2994334473","doi":"10.1158/1535-7163.targ-19-c077","title":"Abstract C077: Updated results of phase 1 study of ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRA inhibitor, in patients with gastrointestinal stromal tumor (GIST) by line of therapy (NCT02571036)","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research","funders":"","keywords":"GiST; Medicine; PDGFRA; Response Evaluation Criteria in Solid Tumors; Internal medicine; Trabectedin; Phases of clinical research; Dosing; Gastroenterology; Oncology; Surgery; Pharmacology; Stromal cell; Clinical trial","score_opus":0.01661905398869492,"score_gpt":0.3009924335799647,"score_spread":0.2843733795912698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994334473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970728,0.00055431534,0.000033153963,0.00013332494,0.00001966111,0.0017897809,0.00030327018,0.000015165883,0.000078531986],"genre_scores_gemma":[0.99920404,0.00003314077,0.00047168785,0.00005126362,0.000011975834,0.00003114463,0.00012187988,0.00004852273,0.00002635283],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975628,0.00009970173,0.0007279337,0.0004373866,0.0007558026,0.00041636228],"domain_scores_gemma":[0.9985117,0.000058516733,0.0004650737,0.00048025115,0.0003261641,0.00015831922],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002061762,0.00032238936,0.0006851639,0.00019288652,0.000019747271,0.000010444551,0.00014723718,0.000033620436,0.00005884763],"category_scores_gemma":[0.000021110045,0.0002460563,0.00007687764,0.00034788114,0.00018333674,0.000052999578,0.00004887437,0.00032104627,0.000001112537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03890174,0.013125246,0.7151645,0.00018005856,0.00054614275,0.00021447409,0.00048585696,0.00007692939,0.2290287,0.000005408225,0.000021355489,0.002249617],"study_design_scores_gemma":[0.11731435,0.09068783,0.548387,0.0013533096,0.00026917137,0.000057601897,0.0006667622,0.00033110406,0.24051578,0.000020392945,0.000074476535,0.00032223985],"about_ca_topic_score_codex":0.00092599355,"about_ca_topic_score_gemma":0.00006658252,"teacher_disagreement_score":0.16677749,"about_ca_system_score_codex":0.000095440635,"about_ca_system_score_gemma":0.00024781437,"threshold_uncertainty_score":0.99999917},"labels":[],"label_agreement":null},{"id":"W2999172547","doi":"10.1158/1535-7163.targ-19-lb-a06","title":"Abstract LB-A06: A high-throughput functional screen discovered that endogenous DNA damage underlies mechanisms of selected gene susceptibility factors predisposing to lung cancer","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Biology; Candidate gene; Genome-wide association study; Genetics; Carcinogenesis; Gene; Lung cancer; DNA repair; DNA damage; Genome instability; Expression quantitative trait loci; Cancer; Single-nucleotide polymorphism; DNA; Genotype; Medicine; Pathology","score_opus":0.032821973962103755,"score_gpt":0.27215793891343004,"score_spread":0.23933596495132628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999172547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9409778,0.0025260665,0.05422818,0.00019364666,0.00038939875,0.0007478382,0.0008079222,0.00002481288,0.000104331906],"genre_scores_gemma":[0.99732494,0.00044531023,0.00066411437,0.0005115571,0.00010131057,0.00011072844,0.00054690614,0.000078425306,0.00021671543],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980265,0.00007567561,0.00034338803,0.00069778494,0.0004140664,0.00044256845],"domain_scores_gemma":[0.99862117,0.000016857304,0.00021807813,0.00073312485,0.00029529614,0.00011547928],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012389802,0.00035302783,0.00033370926,0.00007368061,0.00012507118,0.000054616747,0.00033257357,0.00022147225,0.00025301386],"category_scores_gemma":[0.000007952288,0.00033163247,0.0001718551,0.0002871988,0.000085381325,0.000018927278,0.00011508932,0.00015374516,0.0000034048342],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024488196,0.00011407275,0.009867534,0.000067171815,0.000565843,0.000001566959,0.00017008944,0.006431832,0.98149824,0.00018858386,0.000051387964,0.000798817],"study_design_scores_gemma":[0.000708218,0.00018339537,0.065819845,0.00004532402,0.00015554829,0.0000018053622,0.00014304447,0.00015635656,0.9317566,0.00015136755,0.00050058693,0.0003778877],"about_ca_topic_score_codex":0.0011714075,"about_ca_topic_score_gemma":0.0005921015,"teacher_disagreement_score":0.056347128,"about_ca_system_score_codex":0.00020870077,"about_ca_system_score_gemma":0.0004576133,"threshold_uncertainty_score":0.9999136},"labels":[],"label_agreement":null},{"id":"W3000670779","doi":"10.1158/1535-7163.targ-19-pl03-01","title":"Abstract PL03-01: Targeting DNA Repair and Defective DNA repair","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Genome instability; DNA repair; DNA damage; Synthetic lethality; Cancer research; Cancer; Immune system; Biology; Medicine; DNA; Immunology; Genetics","score_opus":0.009671563450140181,"score_gpt":0.25208394996784766,"score_spread":0.2424123865177075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000670779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97928405,0.017080517,0.00036078913,0.00020902122,0.00045329428,0.00042806423,0.0000680115,0.00007929277,0.0020369368],"genre_scores_gemma":[0.99225694,0.0032221747,0.0008738535,0.0029370554,0.00026195252,0.000054020496,0.00007165901,0.00008830239,0.00023404909],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99835706,0.000049117705,0.00029480256,0.0006718895,0.00019537575,0.00043174523],"domain_scores_gemma":[0.9990119,0.00003574973,0.00014172083,0.00056815334,0.000118438846,0.00012404192],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020955355,0.00031091855,0.0002612696,0.000049800554,0.00009836512,0.000047221594,0.00017562372,0.00023961837,0.00006594634],"category_scores_gemma":[0.00003370422,0.00032335718,0.00026809002,0.000110771776,0.00009449979,0.0000067440756,0.00016806182,0.00018474695,0.000019320396],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016965414,0.00006891714,0.012385381,0.00007785095,0.00048948993,0.00002093814,0.00015246955,0.00040555323,0.9819165,0.00033035377,0.0009980019,0.002984901],"study_design_scores_gemma":[0.0018282171,0.0005660802,0.017890144,0.0000792725,0.00024132659,0.000018629858,0.00025725094,0.0006377884,0.6256748,0.00048065727,0.3513094,0.0010164499],"about_ca_topic_score_codex":0.00011955908,"about_ca_topic_score_gemma":0.00008022721,"teacher_disagreement_score":0.3562417,"about_ca_system_score_codex":0.0000779975,"about_ca_system_score_gemma":0.00018042319,"threshold_uncertainty_score":0.99992186},"labels":[],"label_agreement":null},{"id":"W3005081400","doi":"10.1158/1535-7163.mct-19-1015","title":"Effect of Modulating FcRn Binding on Direct and Pretargeted Tumor Uptake of Full-length Antibodies","year":2020,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Education and Early Childhood Development","funders":"Genentech","keywords":"Antibody; Chemistry; Molecular biology; Cancer research; Biology; Virology; Immunology","score_opus":0.032291007926630415,"score_gpt":0.32976001119495113,"score_spread":0.2974690032683207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005081400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926215,0.0052228007,0.000061815175,0.00074486155,0.000044542623,0.0003645365,0.000071098126,0.000023286315,0.00084560295],"genre_scores_gemma":[0.99823815,0.0006332843,0.00038763758,0.0005704136,0.000056279576,0.000010834084,0.000015133449,0.000031939442,0.000056325447],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986942,0.00011053129,0.0002906433,0.00025024777,0.00041413796,0.00024028578],"domain_scores_gemma":[0.99939084,0.00013431866,0.00012101154,0.00015470014,0.00008455816,0.00011458138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019003419,0.0001921231,0.000514793,0.0000765594,0.000048287864,0.000007859816,0.00008836727,0.000053654087,0.000037148864],"category_scores_gemma":[0.00005740413,0.00014282078,0.00013432279,0.0002172914,0.00013691901,0.000022009246,0.000058220354,0.00019412984,0.0000021561987],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019143925,0.000040306983,0.014948649,0.0011092669,0.0005123338,0.00005630871,0.0005077475,0.00014511918,0.94361216,0.00007282447,0.000012669137,0.037068225],"study_design_scores_gemma":[0.0012670369,0.0032970815,0.0043962337,0.0003773216,0.00025845793,0.000012649374,0.000038783783,0.010240256,0.97814655,0.000011083114,0.0018006493,0.00015389912],"about_ca_topic_score_codex":0.000045094657,"about_ca_topic_score_gemma":0.0000016897477,"teacher_disagreement_score":0.03691433,"about_ca_system_score_codex":0.000020126767,"about_ca_system_score_gemma":0.000052419917,"threshold_uncertainty_score":0.5824062},"labels":[],"label_agreement":null},{"id":"W3009135015","doi":"10.1158/1535-7163.targ-19-b001","title":"Abstract B001: Safety and efficacy of ZW25, a HER2-targeted bispecific antibody, in combination with chemotherapy in patients with locally advanced and/or metastatic HER2-expressing gastroesophageal cancer","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Capecitabine; Medicine; Trastuzumab; Internal medicine; Oncology; Cancer; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Metastatic breast cancer; Paclitaxel; Breast cancer; Phases of clinical research; Colorectal cancer","score_opus":0.0167205724280495,"score_gpt":0.3281169170133715,"score_spread":0.31139634458532195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009135015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935234,0.0033022806,0.000578951,0.0005156351,0.000045123597,0.0019136104,0.00003214387,0.000021299289,0.000067553374],"genre_scores_gemma":[0.99572366,0.0017781028,0.0017805246,0.00045978252,0.000011170532,0.00006936525,0.000038180013,0.00009689031,0.000042342723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976878,0.00011093715,0.0004686277,0.00053267257,0.00070926646,0.0004906807],"domain_scores_gemma":[0.9989749,0.00008524063,0.00021303286,0.00037195385,0.0002293824,0.00012549736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002572091,0.00032611424,0.00066106,0.0002680604,0.000035338497,0.00003264003,0.00012948374,0.00009280492,0.00013731573],"category_scores_gemma":[0.000009897345,0.00024259149,0.00003667815,0.0006208411,0.00022855174,0.00012527185,0.000033972126,0.0004278423,9.00432e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02440039,0.0011242292,0.7975185,0.00089321804,0.000373813,0.0001196158,0.0013127468,0.0021964845,0.053616807,0.000020951988,0.0000019619074,0.11842131],"study_design_scores_gemma":[0.031411406,0.0021754368,0.9472937,0.002064629,0.00007695855,0.000005086585,0.00015971086,0.0010618988,0.015101232,0.000013032929,0.00035527046,0.00028165974],"about_ca_topic_score_codex":0.0005420914,"about_ca_topic_score_gemma":0.00040767092,"teacher_disagreement_score":0.1497752,"about_ca_system_score_codex":0.00034436843,"about_ca_system_score_gemma":0.00046642162,"threshold_uncertainty_score":0.98925936},"labels":[],"label_agreement":null},{"id":"W3009819010","doi":"10.1158/1535-7163.targ-19-lb-b04","title":"Abstract LB-B04: A multi-omic surfaceome study identifies DLK1 as an epigenetically regulated protein and immunotherapeutic target in neuroblastoma","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; BC Cancer Agency","funders":"","keywords":"Neuroblastoma; Cancer research; Biology; Immunotherapy; Flow cytometry; Cell culture; Molecular biology; Cancer; Genetics","score_opus":0.02274710327787047,"score_gpt":0.3251311079405694,"score_spread":0.3023840046626989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009819010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938422,0.0018224771,0.000029332914,0.0005721098,0.00009178374,0.003471509,0.000014630837,0.000085436564,0.00007053042],"genre_scores_gemma":[0.99766785,0.0001857739,0.0002585338,0.0007913349,0.000015049458,0.00019817943,0.000013813242,0.00012591705,0.0007435385],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9973022,0.00025071463,0.00045090212,0.00075584353,0.00058909063,0.0006512834],"domain_scores_gemma":[0.99873203,0.000037343696,0.00010876746,0.00075305253,0.00013221886,0.0002366051],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023658942,0.00040579497,0.00052023097,0.0002616636,0.00007514164,0.00011006267,0.00022209944,0.00013980128,0.00023734619],"category_scores_gemma":[0.000012794245,0.00036502944,0.000098238146,0.0003698929,0.00013534178,0.00013397881,0.00008805053,0.00045905207,0.000099493984],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015063235,0.002015883,0.03402199,0.000101267295,0.00052761356,0.00086167257,0.00063612405,0.00014702836,0.9561847,0.000011594306,9.4771383e-7,0.003984868],"study_design_scores_gemma":[0.011987508,0.0042906054,0.6592769,0.00021724238,0.00016271975,0.00005795657,0.00028993658,0.001632455,0.32101718,0.000270423,0.00032154878,0.0004755178],"about_ca_topic_score_codex":0.0005056023,"about_ca_topic_score_gemma":0.0002359313,"teacher_disagreement_score":0.6351675,"about_ca_system_score_codex":0.00014816683,"about_ca_system_score_gemma":0.00025399853,"threshold_uncertainty_score":0.9998802},"labels":[],"label_agreement":null},{"id":"W3011044624","doi":"10.1158/1535-7163.mct-19-0745","title":"Decitabine Response in Breast Cancer Requires Efficient Drug Processing and Is Not Limited by Multidrug Resistance","year":2020,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Cancer Centre; Dalhousie University","funders":"Nova Scotia Health Research Foundation; Canadian Institutes of Health Research; Cancer Research Society; Natural Sciences and Engineering Research Council of Canada; Dalhousie Medical Research Foundation","keywords":"Decitabine; Cancer research; DNA methylation; Triple-negative breast cancer; Cancer; Breast cancer; Demethylating agent; Biology; Azacitidine; Medicine; Oncology; Internal medicine; Gene; Genetics; Gene expression","score_opus":0.01684294837552151,"score_gpt":0.28332691116307607,"score_spread":0.26648396278755454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011044624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93327683,0.047714386,0.0021863026,0.016315924,0.000048526086,0.00023800513,0.00017868135,0.000015219525,0.000026144384],"genre_scores_gemma":[0.9881451,0.0041493415,0.00044787853,0.0069352137,0.00006653864,0.000059959355,0.000025173118,0.000052251653,0.000118504475],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99850875,0.00015156684,0.0002821801,0.0005348575,0.00022835401,0.000294285],"domain_scores_gemma":[0.9993904,0.000018252416,0.0001208479,0.00022918654,0.00012095454,0.00012032844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020499362,0.00022865507,0.00019191488,0.00004330149,0.00008012378,0.00005557826,0.00016373079,0.00012774105,0.000010989832],"category_scores_gemma":[0.000022402384,0.0002299049,0.000052855634,0.00024405388,0.00009599946,0.000005424137,0.00008131232,0.00013545496,8.577404e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018329533,0.000044014658,0.0025455568,0.000048046146,0.000041073272,0.0000059381264,0.0008722907,0.0010817655,0.9842715,0.0000029965731,0.00018899134,0.009064819],"study_design_scores_gemma":[0.0012861531,0.00006594901,0.008972608,0.000079373836,0.000045076475,8.9265336e-7,0.000093047754,0.006092373,0.9494934,0.00001675201,0.033482682,0.00037169873],"about_ca_topic_score_codex":0.000059408336,"about_ca_topic_score_gemma":0.000058411857,"teacher_disagreement_score":0.05486833,"about_ca_system_score_codex":0.00004907353,"about_ca_system_score_gemma":0.00013411461,"threshold_uncertainty_score":0.937525},"labels":[],"label_agreement":null},{"id":"W3012015863","doi":"10.1158/1535-7163.targ-19-pl03-03","title":"Abstract PL03-03: Navigating gene-gene and drug-gene interaction landscapes underpinning the DNA damage response","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CRISPR and Genetic Engineering","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Gene; Genome; Computational biology; Genome editing; Biology; Cancer; Drug response; Human genome; CRISPR; DNA; Genetics; Drug; Pharmacology","score_opus":0.011009322859606855,"score_gpt":0.30987547611098887,"score_spread":0.298866153251382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012015863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871757,0.009066933,0.0023875935,0.00067091145,0.00030684864,0.00023148536,0.00001763501,0.000023960529,0.00011894586],"genre_scores_gemma":[0.99719656,0.0009207493,0.00053775124,0.0009240772,0.00015065674,0.000028654536,0.00005090096,0.00005851925,0.00013210635],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988557,0.000086273016,0.00021678608,0.00037610132,0.00016991024,0.00029523027],"domain_scores_gemma":[0.99931186,0.00004040526,0.00009153282,0.00043542587,0.00005857672,0.00006222039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003071671,0.0002330489,0.00015380952,0.000030918523,0.00011566481,0.000076221746,0.00019859256,0.000117110554,0.000020916586],"category_scores_gemma":[0.000012681937,0.00019859157,0.000088154695,0.000100686986,0.00004202572,0.0000072414473,0.00010917729,0.00023630468,0.000008257973],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018547942,0.000013998934,0.00090179435,0.000019120256,0.00015069166,0.000006709068,0.0004946153,0.006792306,0.98614633,0.0000057700518,0.000016775577,0.0052664336],"study_design_scores_gemma":[0.00051006663,0.00007682138,0.0057687173,0.00004388212,0.000054161825,0.000021523027,0.00035279396,0.0011739914,0.9801754,0.00001920068,0.011530848,0.00027260432],"about_ca_topic_score_codex":0.000050325118,"about_ca_topic_score_gemma":0.000038388695,"teacher_disagreement_score":0.011514073,"about_ca_system_score_codex":0.00003182054,"about_ca_system_score_gemma":0.000060474722,"threshold_uncertainty_score":0.80983293},"labels":[],"label_agreement":null},{"id":"W3012106145","doi":"10.1158/1535-7163.mct-19-1117","title":"Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with <i>KRAS</i> -Mutated Colorectal Cancer","year":2020,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ATCO (Canada)","funders":"National Cancer Institute; National Institute on Aging; American Society of Clinical Oncology","keywords":"FOLFIRI; Irinotecan; KRAS; Bevacizumab; Colorectal cancer; Medicine; Oxaliplatin; Cancer research; Cytotoxic T cell; Pharmacodynamics; Internal medicine; Pharmacology; Immunology; Oncology; Cancer; Biology; Pharmacokinetics; Chemotherapy","score_opus":0.021005429558043586,"score_gpt":0.3223750773659806,"score_spread":0.301369647807937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012106145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954622,0.001573723,0.000105048726,0.0009944576,0.00011207767,0.0014404578,0.000112507085,0.000022319295,0.00017725902],"genre_scores_gemma":[0.99765325,0.0005116613,0.00007004211,0.0013324902,0.000037465605,0.00027676453,0.000077564546,0.000035051522,0.000005742743],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99870497,0.00005371628,0.00035936254,0.00030299588,0.0003389199,0.00024001459],"domain_scores_gemma":[0.9995107,0.00001681762,0.00014748321,0.000097878,0.00015265269,0.00007443852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000052044787,0.00021129804,0.0004695671,0.0000920641,0.000023097313,0.000007966522,0.00007038681,0.00006695784,0.00006647158],"category_scores_gemma":[0.000008386819,0.00017125248,0.000069243564,0.0006168772,0.00007206242,0.000051814644,0.000027322312,0.0001904866,6.5125874e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39794642,0.0038731247,0.46690458,0.00023715805,0.001576937,0.0001907685,0.005947162,0.0016806314,0.052877314,0.00002412272,0.000040136423,0.06870167],"study_design_scores_gemma":[0.6734761,0.01753551,0.17299722,0.0004661584,0.0015966863,0.0000020915168,0.0004811263,0.01161813,0.11916316,0.000032818592,0.0018041888,0.00082678633],"about_ca_topic_score_codex":0.00039939207,"about_ca_topic_score_gemma":0.0004843631,"teacher_disagreement_score":0.29390734,"about_ca_system_score_codex":0.0003491812,"about_ca_system_score_gemma":0.000255065,"threshold_uncertainty_score":0.69834733},"labels":[],"label_agreement":null},{"id":"W3021366882","doi":"10.1158/1535-7163.mct-20-0087","title":"Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734","year":2020,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Optometric Education Trust Fund; Paraza Pharma (Canada)","funders":"National Cancer Institute; National Institute of General Medical Sciences; Genentech","keywords":"Bromodomain; Nut; BRD4; Biology; Cancer research; Medicine; Pharmacology; Chemistry; Genetics; Histone; DNA","score_opus":0.011698964360440794,"score_gpt":0.2392130122808768,"score_spread":0.227514047920436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021366882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893061,0.0048467433,0.0013024618,0.003562705,0.00019941291,0.00049381173,0.000082177234,0.000015658405,0.00019093687],"genre_scores_gemma":[0.9950493,0.00015517636,0.00026604926,0.0040870206,0.00016182348,0.000050172384,0.00008926805,0.000048446414,0.00009271655],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983656,0.00023466155,0.0004019782,0.00041369366,0.00027516155,0.00030890826],"domain_scores_gemma":[0.9992751,0.0000124572425,0.00019475693,0.00030254162,0.0001286163,0.00008655096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014586761,0.0002464675,0.0002543125,0.000033099674,0.00007450206,0.00001950948,0.00029791205,0.00019740513,0.00002000115],"category_scores_gemma":[0.000057496207,0.00021364671,0.000155131,0.0003961674,0.00013517604,0.0000067143533,0.00015093433,0.00025577104,0.0000017634229],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019318772,0.000085535,0.006420067,0.00003289686,0.000082938284,0.0000044640005,0.00028819698,0.00013441494,0.9894893,0.00004301867,0.0024205688,0.00080541533],"study_design_scores_gemma":[0.0014663525,0.00032084805,0.0011825471,0.000022059321,0.000033149943,0.0000017137087,0.00009051178,0.0005686347,0.9795942,0.000068523936,0.016402721,0.00024876505],"about_ca_topic_score_codex":0.00013153978,"about_ca_topic_score_gemma":0.000033613695,"teacher_disagreement_score":0.0139821535,"about_ca_system_score_codex":0.000058576672,"about_ca_system_score_gemma":0.00019608214,"threshold_uncertainty_score":0.871226},"labels":[],"label_agreement":null},{"id":"W3033074253","doi":"10.1158/1535-7163.mct-19-0977","title":"NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors","year":2020,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Nuclear Structure and Function","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Breast Cancer Research Alliance; National Cancer Institute; Ovarian Cancer Research Alliance; National Institutes of Health; Cancer Prevention and Research Institute of Texas","keywords":"ERBB3; Neuregulin 1; In vivo; Ovarian cancer; Cancer research; Downregulation and upregulation; Biomarker; Cancer; Sine; Biology; Signal transduction; Medicine; Pharmacology; Gene; Internal medicine; Cell biology; Biochemistry; Genetics","score_opus":0.01907139910147032,"score_gpt":0.25107729773700266,"score_spread":0.23200589863553234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033074253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840256,0.0011388555,0.0066614575,0.0061203297,0.00033748974,0.00029360055,0.000021032947,0.000045530935,0.0013561127],"genre_scores_gemma":[0.9794686,0.0000918932,0.00071568735,0.018848466,0.00053403893,0.000032814085,0.000044794884,0.000052255025,0.00021144278],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989344,0.000052609987,0.00017631624,0.00040661157,0.00020225701,0.00022779834],"domain_scores_gemma":[0.99942774,0.0000036545916,0.00007821977,0.0002722535,0.00009578249,0.00012234806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000049961436,0.00018986156,0.00013553172,0.000030018133,0.00008305727,0.00004028805,0.00018098972,0.00016848672,0.00003197791],"category_scores_gemma":[0.000019324913,0.00018807633,0.0000846302,0.00023209583,0.000034171695,0.000007048095,0.00007063791,0.00008576951,0.00001973343],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025553635,0.000012841955,0.00012582076,0.000016178781,0.000087235094,0.000002782709,0.00027286832,0.00014886013,0.98751855,0.00014206917,0.0015438048,0.009873448],"study_design_scores_gemma":[0.0002411145,0.00014117137,0.00037788102,0.000012470594,0.00001828894,4.863939e-7,0.000052276435,0.000010883073,0.6851424,0.000054182186,0.31377342,0.00017544547],"about_ca_topic_score_codex":0.00001018677,"about_ca_topic_score_gemma":0.000018284922,"teacher_disagreement_score":0.3122296,"about_ca_system_score_codex":0.000032796852,"about_ca_system_score_gemma":0.00009593334,"threshold_uncertainty_score":0.766953},"labels":[],"label_agreement":null},{"id":"W3033597903","doi":"10.1158/1535-7163.mct-20-0094","title":"Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types","year":2020,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Terry Fox Research Institute; University Health Network; Ontario Institute for Cancer Research; BC Cancer Agency; Canada's Michael Smith Genome Sciences Centre; University of British Columbia; Pancreas Centre (Canada)","funders":"Canada Research Chairs; Canadian Institutes of Health Research; Genome British Columbia; Canada Foundation for Innovation","keywords":"Biology; Immunogenicity; Pancreatic cancer; Endogenous retrovirus; Cancer; Cancer research; Epigenetics; Colorectal cancer; Epigenomics; Breast cancer; Molecular mimicry; Immunology; Gene; DNA methylation; Gene expression; Genetics; Antibody; Genome","score_opus":0.061660860817377,"score_gpt":0.2671429476222009,"score_spread":0.20548208680482394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033597903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74756324,0.24976486,0.0003732227,0.0010921359,0.00027557777,0.00048404888,0.0002854876,0.00009549873,0.00006593292],"genre_scores_gemma":[0.9916024,0.0022028238,0.000032185464,0.0055611725,0.000014211621,0.00015628964,0.000037682094,0.0000868606,0.00030632727],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99790674,0.00057872495,0.00038184517,0.00042103985,0.00010852769,0.00060311396],"domain_scores_gemma":[0.9991899,0.0001533175,0.00022200019,0.00029531238,0.00011007009,0.000029387576],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015098561,0.0003896386,0.0005760777,0.00010523755,0.00017138844,0.000031367115,0.00039946407,0.00024937827,0.00064960896],"category_scores_gemma":[0.000044507262,0.00032768282,0.00017235636,0.00048973446,0.0002189892,0.0000867466,0.00002420974,0.0006384549,0.000025144345],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023235106,0.00016083408,0.0019423061,0.000027213275,0.0025654037,0.00009178887,0.0030961207,0.0011637742,0.9832883,0.000017437413,0.00003572533,0.0052876053],"study_design_scores_gemma":[0.0054118,0.00050980016,0.007589681,0.00016077654,0.00038833395,0.0000114429995,0.00035977035,0.00006045226,0.96698904,0.000022505354,0.01796547,0.00053093466],"about_ca_topic_score_codex":0.0005628223,"about_ca_topic_score_gemma":0.00037531563,"teacher_disagreement_score":0.24756204,"about_ca_system_score_codex":0.00017248142,"about_ca_system_score_gemma":0.000282023,"threshold_uncertainty_score":0.9999175},"labels":[],"label_agreement":null},{"id":"W3034998325","doi":"10.1158/1535-7163.mct-19-0993","title":"Patient Selection Strategies to Maximize Therapeutic Index of Antibody–Drug Conjugates: Prior Approaches and Future Directions","year":2020,"lang":"en","type":"review","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Clinical trial; Selection (genetic algorithm); Antibody-drug conjugate; Drug development; Medicine; Biomarker; Drug; Expression (computer science); Computational biology; Computer science; Pharmacology; Antibody; Machine learning; Internal medicine; Monoclonal antibody; Biology; Immunology","score_opus":0.0828555232670809,"score_gpt":0.3865256745269056,"score_spread":0.3036701512598247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034998325","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017952784,0.9934795,0.0011051374,0.0013766563,0.00032891464,0.0028943745,0.00011338656,0.00009731727,0.0004252222],"genre_scores_gemma":[0.0016316441,0.99571395,0.0005537888,0.0007702654,0.00039319228,0.00060773356,0.00005858252,0.00019929564,0.00007156464],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99677134,0.00037061019,0.0007604543,0.00081279455,0.0007743058,0.00051052484],"domain_scores_gemma":[0.9984877,0.00007794551,0.00034197315,0.000528299,0.00026604964,0.00029803163],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020504463,0.00066124526,0.0019070011,0.0003666331,0.00012481761,0.00010671406,0.00024451967,0.00039422556,0.000092395756],"category_scores_gemma":[0.000008944893,0.00054094364,0.00042660002,0.0012801673,0.0001911858,0.000062567255,0.0001240752,0.0010308217,0.00000875759],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001339931,0.0001227655,0.000056366982,0.011709534,0.0017530086,0.000030035204,0.0012299201,0.000012673314,0.00037095882,0.0002051809,0.0000349546,0.9843406],"study_design_scores_gemma":[0.00046812135,0.00048399175,0.00005052098,0.0038602368,0.0020605724,0.00008012027,0.0005480475,0.00013383647,0.00039087268,0.00007070772,0.99139583,0.00045714335],"about_ca_topic_score_codex":0.00016089198,"about_ca_topic_score_gemma":0.000044888042,"teacher_disagreement_score":0.9913609,"about_ca_system_score_codex":0.00044630747,"about_ca_system_score_gemma":0.002146882,"threshold_uncertainty_score":0.9997042},"labels":[],"label_agreement":null},{"id":"W3080241619","doi":"10.1158/1535-7163.mct-19-1031","title":"Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer","year":2020,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Terry Fox Research Institute","keywords":"Bladder cancer; Gene silencing; Biology; Cancer research; Slug; Metastasis; Cancer; Gene; Genetics","score_opus":0.044195244923870614,"score_gpt":0.2920252293583531,"score_spread":0.2478299844344825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080241619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97133434,0.014306166,0.0012857079,0.011008515,0.00020565522,0.00075808086,0.00020045912,0.00007838143,0.0008226683],"genre_scores_gemma":[0.988479,0.0038116483,0.00045289,0.0066159163,0.00018608269,0.00010822618,0.000018503008,0.000074995114,0.0002527021],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985693,0.00006154404,0.00029638343,0.00039693425,0.00040313083,0.00027270414],"domain_scores_gemma":[0.99915844,0.000018934163,0.000120219745,0.00024149282,0.0002528616,0.00020803876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005419698,0.00026623174,0.0004396365,0.000043736767,0.000045713543,0.000020653995,0.00013169862,0.000113730945,0.0006076764],"category_scores_gemma":[0.000011395661,0.00022022586,0.00011037793,0.0001965078,0.00011161998,0.000051661907,0.00006397612,0.00015050588,0.0000070263773],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084629987,0.00016389611,0.031575296,0.0002899709,0.001385442,0.00009388185,0.0014002018,0.000014535055,0.9535502,0.000048595964,0.0001998536,0.010431799],"study_design_scores_gemma":[0.0038518677,0.000647052,0.009654497,0.00013175744,0.00087594,0.000008115366,0.00006216034,0.00019168612,0.97826153,0.00026157076,0.0057735145,0.0002803311],"about_ca_topic_score_codex":0.00046066323,"about_ca_topic_score_gemma":0.000028844788,"teacher_disagreement_score":0.02471128,"about_ca_system_score_codex":0.000051953102,"about_ca_system_score_gemma":0.0002796672,"threshold_uncertainty_score":0.898055},"labels":[],"label_agreement":null},{"id":"W3087748453","doi":"10.1158/1535-7163.mct-20-0227","title":"Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health; Physiotherapy Foundation of Canada; U.S. Department of Defense","keywords":"Prostate cancer; DU145; Cancer research; Microparticle; Metastasis; Prostate; PLGA; In vivo; Cancer; Medicine; Chemistry; Pharmacology; In vitro; Internal medicine; Biology; LNCaP; Biochemistry","score_opus":0.14216629894576716,"score_gpt":0.3733259680806046,"score_spread":0.23115966913483743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087748453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742688,0.021110697,0.00096769433,0.0014273942,0.000019408697,0.0016080668,0.0005870525,0.000007829266,0.0000030376455],"genre_scores_gemma":[0.9911052,0.006423353,0.001703929,0.00031620447,0.000012183529,0.00039828903,0.000014858037,0.000016134385,0.0000098670525],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989602,0.00006483803,0.000490211,0.00018140145,0.00014927167,0.00015410506],"domain_scores_gemma":[0.9992551,0.000099056415,0.00022473818,0.00015410746,0.00023395283,0.00003301181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000098589284,0.00012723287,0.0003906879,0.000030674524,0.000023513367,0.0000027626804,0.000053254917,0.000042780477,0.000010187248],"category_scores_gemma":[0.000035458226,0.00008236652,0.00012093623,0.00019080266,0.00014626782,0.000021259619,0.000012343422,0.00004289615,1.6363242e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019988138,0.0003890336,0.038595278,0.00021460856,0.000556505,0.000003511573,0.0058999313,0.011770557,0.93183166,0.000054239143,0.000005530391,0.008680335],"study_design_scores_gemma":[0.0025597983,0.0020823001,0.02140161,0.000080638485,0.0006763637,2.560528e-7,0.00012963038,0.10218922,0.87041765,0.000082426996,0.00029027686,0.00008981271],"about_ca_topic_score_codex":0.0015191935,"about_ca_topic_score_gemma":0.0012098915,"teacher_disagreement_score":0.09041867,"about_ca_system_score_codex":0.0000741212,"about_ca_system_score_gemma":0.00024678258,"threshold_uncertainty_score":0.3358809},"labels":[],"label_agreement":null},{"id":"W3093982502","doi":"10.1158/1535-7163.mct-20-0333","title":"TACIMA-218: A Novel Pro-Oxidant Agent Exhibiting Selective Antitumoral Activity","year":2020,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Genomics, phytochemicals, and oxidative stress","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université du Québec à Montréal; Centre Hospitalier Universitaire Sainte-Justine; Hôpital Maisonneuve-Rosemont; Université de Montréal; McGill University","funders":"Merck Sharp and Dohme; McGill University Health Centre; Meso Scale Diagnostics; Merck","keywords":"Apoptosis; Oxidative stress; Programmed cell death; Chemistry; Protein kinase B; Cancer cell; Cancer research; Cell culture; Biology; Biochemistry; Cancer; Cell biology; Genetics","score_opus":0.040839858531741394,"score_gpt":0.29106520153573406,"score_spread":0.2502253430039927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093982502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94758075,0.0019952566,0.04774421,0.001275727,0.00018927203,0.00048288167,0.00012354273,0.000041695937,0.0005666538],"genre_scores_gemma":[0.99281716,0.0002520638,0.0020435094,0.0042179907,0.0003812391,0.000085124826,0.000051274452,0.00007458142,0.0000770363],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99825966,0.00007220194,0.0002388391,0.000709383,0.000230668,0.0004892594],"domain_scores_gemma":[0.9991385,0.0000063218845,0.00017617164,0.0003276148,0.00017158713,0.00017982202],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008289628,0.00034756432,0.000297653,0.000028695538,0.00011785179,0.00005372334,0.00031532708,0.00016595668,0.000015481883],"category_scores_gemma":[0.000030823736,0.0003590684,0.00016945483,0.0001823156,0.00013734517,0.000008267218,0.00019379181,0.00026408915,0.000008684027],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024536927,0.00014556867,0.001016264,0.000047539826,0.00028223393,0.000015644899,0.000249628,0.00013833247,0.9937987,0.0000524117,0.00016148815,0.0038468204],"study_design_scores_gemma":[0.0011124985,0.0002828276,0.00081115303,0.000021931357,0.000081552265,0.000009282259,0.00006489836,0.0008777897,0.9839749,0.000050183568,0.012264251,0.0004487787],"about_ca_topic_score_codex":0.000032898388,"about_ca_topic_score_gemma":0.000014613858,"teacher_disagreement_score":0.045700703,"about_ca_system_score_codex":0.00006883157,"about_ca_system_score_gemma":0.0001993144,"threshold_uncertainty_score":0.99988616},"labels":[],"label_agreement":null},{"id":"W3094632508","doi":"10.1158/1535-7163.mct-20-0259","title":"Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition","year":2020,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Occupational Cancer Research Centre; McGill University Health Centre; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Reprogramming; Biology; Epigenetics; Cancer research; Kinase; BET inhibitor; Cancer; MEK inhibitor; Genetics; Bioinformatics; MAPK/ERK pathway; Cell; Gene; Bromodomain","score_opus":0.028912408390285946,"score_gpt":0.2730069190894758,"score_spread":0.24409451069918983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094632508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94280493,0.04969742,0.005965354,0.0011921743,0.00007066327,0.00017860025,0.00003419743,0.00002337448,0.000033268952],"genre_scores_gemma":[0.9887685,0.007479062,0.0015128901,0.001816619,0.0002658005,0.00003187709,0.000060865797,0.000051529252,0.000012859541],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99883574,0.000077108256,0.00028168247,0.0003927786,0.000190908,0.00022178412],"domain_scores_gemma":[0.9993805,0.000010384616,0.0001382792,0.00026621588,0.00009494725,0.00010963723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010595669,0.00020024482,0.0002505742,0.000027203396,0.000050110866,0.000022535247,0.00012073821,0.00013400003,0.00001364749],"category_scores_gemma":[0.000011303837,0.00019232565,0.00010905719,0.000113864146,0.00011408941,0.0000038599046,0.00006857146,0.00009601181,0.0000011904232],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063657644,0.000020269741,0.0009558956,0.00005274983,0.00020996845,0.0000037351144,0.00024303322,0.00034657586,0.91767764,0.000042018048,0.0000275523,0.080356926],"study_design_scores_gemma":[0.000801046,0.00019568746,0.00076631573,0.000032497766,0.0001024488,0.0000012977499,0.000067569206,0.00040261395,0.96586335,0.00021817033,0.03130934,0.00023968954],"about_ca_topic_score_codex":0.00006585476,"about_ca_topic_score_gemma":0.0000070074566,"teacher_disagreement_score":0.08011724,"about_ca_system_score_codex":0.000009945061,"about_ca_system_score_gemma":0.00006731442,"threshold_uncertainty_score":0.78428125},"labels":[],"label_agreement":null},{"id":"W3106906902","doi":"10.1158/1535-7163.mct-20-0130","title":"Disruption of SND1–MTDH Interaction by a High Affinity Peptide Results in SND1 Degradation and Cytotoxicity to Breast Cancer Cells <i>In Vitro</i> and <i>In Vivo</i>","year":2020,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Mechanisms and Therapy","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Hong Kong Polytechnic University; University Grants Committee","keywords":"Chemistry; Cancer research; Breast cancer; Peptide; Cancer cell; Cytotoxicity; In vitro; Biochemistry; Cancer; Internal medicine; Medicine","score_opus":0.018288676461397656,"score_gpt":0.2798321028020886,"score_spread":0.26154342634069094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3106906902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98942465,0.0011385549,0.001012385,0.0071064224,0.00010326056,0.0006562992,0.0005040975,0.000016781862,0.00003756523],"genre_scores_gemma":[0.99111545,0.0027080688,0.00034231597,0.005614147,0.00004948981,0.00009115746,0.00002422432,0.000033808188,0.00002131176],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99857473,0.00008563973,0.0004304821,0.00043176298,0.00023208381,0.00024529433],"domain_scores_gemma":[0.99947476,0.000031024723,0.00014257767,0.00016502605,0.000057944057,0.0001286496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017024518,0.00021270833,0.0004039657,0.00013248036,0.000026437225,0.000021082025,0.000063205465,0.00011250367,0.00002390726],"category_scores_gemma":[0.0000066048538,0.00021408401,0.000043240216,0.00044942313,0.000038600137,0.00010281377,0.000036151152,0.00026020527,5.276021e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005446768,0.00013873534,0.0013169388,0.00009433686,0.00003725281,0.000018252455,0.0013485863,0.0003344122,0.97744876,0.000021790764,0.000046485497,0.013747681],"study_design_scores_gemma":[0.004707185,0.00025639992,0.007690179,0.00027773035,0.00005568636,0.0000070621077,0.00025108326,0.0020634905,0.98298967,0.00006619724,0.0014080361,0.00022726101],"about_ca_topic_score_codex":0.0049498063,"about_ca_topic_score_gemma":0.0026807382,"teacher_disagreement_score":0.01352042,"about_ca_system_score_codex":0.0002719185,"about_ca_system_score_gemma":0.00008676958,"threshold_uncertainty_score":0.87300926},"labels":[],"label_agreement":null},{"id":"W3133986190","doi":"10.1158/1535-7163.mct-20-0510","title":"Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University College of the North","funders":"Janssen Research and Development","keywords":"Prostate cancer; Androgen receptor; Cancer research; Antagonist; Cancer; Internal medicine; Medicine; Receptor; Endocrinology; Pharmacology; Biology","score_opus":0.06884914067294168,"score_gpt":0.3620688245716197,"score_spread":0.29321968389867803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133986190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832801,0.012718369,0.00011132943,0.0025042938,0.00016531932,0.0007978876,0.000346895,0.000014118464,0.00006168341],"genre_scores_gemma":[0.97548,0.021375952,0.0015332894,0.0004691902,0.00005850724,0.00016839764,0.0005256771,0.00004644308,0.00034250086],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99811333,0.00017717462,0.00055416947,0.00044287517,0.00038652346,0.0003258983],"domain_scores_gemma":[0.9989807,0.00007753604,0.00020314481,0.00024930848,0.0003891203,0.00010021462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022119329,0.00022745467,0.00044025684,0.00013973535,0.00012433824,0.000102430764,0.00006232928,0.00008748443,0.00001685021],"category_scores_gemma":[0.000043531167,0.00019459332,0.00008516998,0.0006966843,0.0002022834,0.00020942555,0.00003951746,0.0002493047,0.0000013473103],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013395402,0.0002507559,0.0074948217,0.00016965262,0.00068775093,0.00026580432,0.0019726437,0.00016200215,0.9761092,0.000069515096,0.000014549015,0.011463776],"study_design_scores_gemma":[0.005193828,0.0005764134,0.0028605692,0.000543117,0.00049186684,0.00001615781,0.002072644,0.00078737736,0.98588055,0.00019772766,0.0010807556,0.000298962],"about_ca_topic_score_codex":0.00019494853,"about_ca_topic_score_gemma":0.00063620665,"teacher_disagreement_score":0.011164814,"about_ca_system_score_codex":0.0003475062,"about_ca_system_score_gemma":0.0016801251,"threshold_uncertainty_score":0.79352856},"labels":[],"label_agreement":null},{"id":"W3170601186","doi":"","title":"The synthetic triterpenoid CDDO-Imidazolide suppresses experimental liver metastasis","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"","keywords":"Metastasis; Apoptosis; In vivo; Cancer research; In vitro; Medicine; Cancer; Melanoma; Pathology; Cell culture; Cancer cell; Chemistry; Biology; Internal medicine; Biochemistry","score_opus":0.02368258694422533,"score_gpt":0.3100096398386744,"score_spread":0.2863270528944491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170601186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.843655,0.13853104,0.014278277,0.0005119594,0.001011131,0.0005248077,0.000063349995,0.00005914572,0.0013652765],"genre_scores_gemma":[0.9938722,0.0023066334,0.0006664444,0.002211194,0.00033396707,0.000108704735,0.000024207746,0.00010038141,0.0003762713],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978862,0.00013315612,0.00036272174,0.00053820165,0.000409333,0.00067041715],"domain_scores_gemma":[0.99869746,0.00006743029,0.00014890956,0.0008150425,0.00013959788,0.00013154505],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004760308,0.00035174275,0.00022221112,0.00005274426,0.00029390372,0.000109049746,0.0006363828,0.00019310556,0.000089341294],"category_scores_gemma":[0.000024906716,0.0002837578,0.00024282848,0.00017217653,0.0002909238,0.000007333747,0.00016934153,0.00020014407,0.000016202592],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032506778,0.00008866598,0.0001439794,0.000013053691,0.00042719996,0.000036277048,0.0001457106,0.00016960193,0.97814655,0.00017629273,0.00042013888,0.019907445],"study_design_scores_gemma":[0.0004649531,0.00017221623,0.000088410925,0.000017234957,0.00010829411,0.000022364049,0.00013245916,0.000057850844,0.7777393,0.00004752684,0.22084953,0.0002998692],"about_ca_topic_score_codex":0.000065022905,"about_ca_topic_score_gemma":0.00007864536,"teacher_disagreement_score":0.22042939,"about_ca_system_score_codex":0.00010991902,"about_ca_system_score_gemma":0.00014098124,"threshold_uncertainty_score":0.99996144},"labels":[],"label_agreement":null},{"id":"W3174270804","doi":"10.1158/1535-7163.mct-21-0159","title":"Current Development of Glioblastoma Therapeutic Agents","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Emergent BioSolutions (Canada)","funders":"National Cancer Institute","keywords":"Glioblastoma; Tyrosine kinase; Receptor tyrosine kinase; Targeted therapy; Phenotype; Growth factor receptor; Precision medicine; Drug development; Receptor","score_opus":0.043008722865672325,"score_gpt":0.3326312226341538,"score_spread":0.2896224997684815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174270804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94843996,0.048441794,0.001473327,0.00074773666,0.00029767616,0.00026079777,0.000009597573,0.000032641023,0.00029645287],"genre_scores_gemma":[0.9959399,0.001265164,0.0013794692,0.0011996293,0.000031448868,0.00008780938,0.000018669452,0.00003679492,0.000041121293],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987439,0.00004128343,0.00030753418,0.000268607,0.00039003475,0.00024866886],"domain_scores_gemma":[0.99922806,0.000015280486,0.00009429841,0.00035394478,0.00021064974,0.00009773867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000054928274,0.00018978152,0.0003050879,0.00007415007,0.00005158353,0.000012907398,0.00007550279,0.000060313236,0.00023495023],"category_scores_gemma":[0.000003168723,0.00016322004,0.00015784761,0.0002707478,0.000041090185,0.000018527804,0.00004528831,0.000107111104,0.00001935091],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014170705,0.0017626929,0.023969125,0.00020002502,0.0016910221,0.00031096392,0.00092246017,0.000041862826,0.35901186,0.0005284386,0.00007267435,0.6113472],"study_design_scores_gemma":[0.0017249214,0.00010814432,0.023767192,0.0002045891,0.00042919506,0.000025753827,0.00005837076,0.00010286084,0.86933786,0.00011056298,0.10397529,0.0001552791],"about_ca_topic_score_codex":0.0000041762696,"about_ca_topic_score_gemma":0.000016210679,"teacher_disagreement_score":0.6111919,"about_ca_system_score_codex":0.00014953254,"about_ca_system_score_gemma":0.00047078653,"threshold_uncertainty_score":0.665592},"labels":[],"label_agreement":null},{"id":"W3199957122","doi":"10.1158/1535-7163.mct-20-0144","title":"Targeting the IGF-Axis Potentiates Immunotherapy for Pancreatic Ductal Adenocarcinoma Liver Metastases by Altering the Immunosuppressive Microenvironment","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Cancer Institute; Canadian Institute for Military and Veteran Health Research; Mitacs","keywords":"Cancer research; Immunotherapy; Tumor microenvironment; Medicine; Blockade; Metastasis; Immune system; Pancreatic cancer; Immunology; Biology; Cancer; Internal medicine; Receptor","score_opus":0.024979566459188366,"score_gpt":0.3042864441328752,"score_spread":0.27930687767368684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199957122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7170864,0.2671887,0.008778849,0.005651772,0.00012912058,0.0009908129,0.00009773381,0.000021907135,0.000054730914],"genre_scores_gemma":[0.96562445,0.023966176,0.002217134,0.0061045685,0.00015063798,0.00070150115,0.00013992714,0.0000858471,0.0010097837],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980753,0.00029188217,0.00034951037,0.00037431534,0.00036949202,0.0005394879],"domain_scores_gemma":[0.9987786,0.00027064115,0.00014070142,0.0006104636,0.00014045977,0.000059181057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034167073,0.00027182116,0.0004555049,0.00002911004,0.00045002231,0.000071681956,0.0002935253,0.0000934242,0.00036304444],"category_scores_gemma":[0.000038668586,0.00016266889,0.00026032218,0.00014339265,0.0003215577,0.000044001896,0.000116783354,0.0003119526,0.000010310945],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042414744,0.00020137624,0.015599884,0.000102556914,0.0035252832,0.00018296318,0.0012786286,0.00005705593,0.9715693,0.00006362541,0.0014725132,0.005522678],"study_design_scores_gemma":[0.0073744725,0.0010477959,0.03927331,0.00031533823,0.0058029047,0.00063537585,0.0046176575,0.008860814,0.8248252,0.00047056825,0.10597663,0.0007998911],"about_ca_topic_score_codex":0.00016986336,"about_ca_topic_score_gemma":0.0000059123313,"teacher_disagreement_score":0.24853806,"about_ca_system_score_codex":0.00018274406,"about_ca_system_score_gemma":0.00023198192,"threshold_uncertainty_score":0.6633445},"labels":[],"label_agreement":null},{"id":"W3204325537","doi":"10.1158/1535-7163.mct-21-0368","title":"IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NorQuest College","funders":"National Institute for Occupational Safety and Health; National Institute of Environmental Health Sciences; National Cancer Institute; National Institutes of Health","keywords":"Pancreatic cancer; Medicine; Immunoglobulin E; Immunotherapy; Cancer research; Ovalbumin; Immunology; Cancer; Cancer immunotherapy; Antigen; Antibody; Immune system; Internal medicine","score_opus":0.043125097673283985,"score_gpt":0.3266197887092266,"score_spread":0.2834946910359426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204325537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9479601,0.039783373,0.008444276,0.001378648,0.0018243843,0.00025662893,0.00001253293,0.00003774603,0.00030230873],"genre_scores_gemma":[0.9948225,0.0017068782,0.000059326427,0.0019458269,0.000009602592,0.000104137245,0.00004572281,0.000026393504,0.0012796225],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981348,0.0007642094,0.0004648577,0.00030437726,0.000080331236,0.00025143442],"domain_scores_gemma":[0.9990144,0.00021740739,0.00019892656,0.00031812192,0.00023760962,0.000013536446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031688533,0.00017873086,0.000345791,0.00012757671,0.000060573275,0.000014792449,0.00014218176,0.00020518906,0.0007608833],"category_scores_gemma":[0.000029972703,0.0001737646,0.00013972685,0.00030699646,0.00013159608,0.000096068725,0.000025162199,0.00030562733,0.000018894727],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025136012,0.00040221107,0.001541517,0.00003908099,0.00027800642,0.00000827994,0.00028600704,0.0022986303,0.98667496,0.0004746715,0.000036031353,0.00544699],"study_design_scores_gemma":[0.0022084236,0.00026430498,0.006146064,0.00017654659,0.00014614295,0.000005602046,0.00015543682,0.002368745,0.98127645,0.00044604752,0.006607165,0.00019904386],"about_ca_topic_score_codex":0.00020049592,"about_ca_topic_score_gemma":0.00007627503,"teacher_disagreement_score":0.046862386,"about_ca_system_score_codex":0.00013292681,"about_ca_system_score_gemma":0.00042233142,"threshold_uncertainty_score":0.8331139},"labels":[],"label_agreement":null},{"id":"W3216161881","doi":"10.1158/1535-7163.mct-21-0411","title":"Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Ralaniten Analogs for the Treatment of Androgen Receptor–positive Prostate and Breast Cancers","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre","funders":"National Cancer Institute; National Institutes of Health","keywords":"Palbociclib; Prostate; Androgen receptor; Medicine; Cyclin-dependent kinase 4; Internal medicine; Kinase; Cancer research; Androgen; Oncology; Endocrinology; Prostate cancer; Pharmacology; Breast cancer; Biology; Cancer; Cyclin-dependent kinase 2; Hormone; Cell cycle; Metastatic breast cancer; Biochemistry","score_opus":0.014216953938682468,"score_gpt":0.2829275605301325,"score_spread":0.2687106065914501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216161881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96439373,0.02747552,0.0022384492,0.0037609315,0.00011995878,0.0015901598,0.0003721449,0.000022759985,0.000026316158],"genre_scores_gemma":[0.9924076,0.0050515146,0.0008475496,0.00082546147,0.00005994335,0.00050234154,0.00009767144,0.000056827448,0.0001510676],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988508,0.00006384664,0.00024912233,0.00033497036,0.00023695358,0.0002643063],"domain_scores_gemma":[0.9991388,0.00008333381,0.00014195357,0.00026666198,0.0003016198,0.00006765788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000074914264,0.00022786781,0.00036172586,0.00006668654,0.000068761714,0.000019228786,0.000054269272,0.000068521265,0.000013923838],"category_scores_gemma":[0.0000031644904,0.00015649419,0.00007772942,0.00027634038,0.00017123394,0.00005491212,0.000014248887,0.00009330179,2.8887308e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009864077,0.0011798249,0.063911475,0.00025026282,0.002729218,0.00020040254,0.008954732,0.0014686154,0.29033956,0.00039334162,0.0000079427555,0.62070054],"study_design_scores_gemma":[0.033198215,0.003910451,0.03355457,0.00071196054,0.0013832296,0.00022459951,0.0032050237,0.0013127973,0.9066275,0.00070921547,0.014561742,0.0006007402],"about_ca_topic_score_codex":0.00032827246,"about_ca_topic_score_gemma":0.00056559,"teacher_disagreement_score":0.6200998,"about_ca_system_score_codex":0.0005739084,"about_ca_system_score_gemma":0.0004183214,"threshold_uncertainty_score":0.6381648},"labels":[],"label_agreement":null},{"id":"W4200008328","doi":"10.1158/1535-7163.targ-21-p096","title":"Abstract P096: Using CRISPR-Cas9 screens to identify microRNA involved in aggressive prostate cancer phenotypes","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CRISPR and Genetic Engineering","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"CRISPR; microRNA; DU145; Prostate cancer; Cas9; Biology; Cancer research; In silico; Computational biology; Cancer; Gene knockout; Metastasis; Guide RNA; Phenotype; Gene; Bioinformatics; Genetics; LNCaP","score_opus":0.025782153819473522,"score_gpt":0.36377515183888737,"score_spread":0.33799299801941385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200008328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9500488,0.04013015,0.008458604,0.0005316476,0.00035928073,0.00028626446,0.00008058347,0.000016444086,0.000088239605],"genre_scores_gemma":[0.9926682,0.0027648916,0.0018903216,0.0021879503,0.00017529512,0.000069933696,0.000049871007,0.00007927411,0.000114226736],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99844193,0.000046554702,0.00029889814,0.0005393815,0.00020038178,0.00047285415],"domain_scores_gemma":[0.9991308,0.000007071106,0.00010769224,0.00043073928,0.0002020122,0.000121697165],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009631641,0.0002797024,0.00023818282,0.000078721285,0.00006263183,0.000065619126,0.00020981887,0.00016715682,0.000052415384],"category_scores_gemma":[0.000021331616,0.0003096043,0.000117239106,0.00029358495,0.000042253112,0.0000057935745,0.0001449223,0.00018394474,0.000005172762],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000068710484,0.00004693622,0.0037484113,0.00005372705,0.000175342,0.00012334784,0.00028433444,0.022003047,0.9658729,0.0000073768515,0.00008103465,0.007534845],"study_design_scores_gemma":[0.0006376038,0.00003708002,0.010216455,0.00017163929,0.000071477785,0.000008675947,0.00019846017,0.00035966063,0.9756383,0.000044453787,0.0122001,0.00041611757],"about_ca_topic_score_codex":0.00039683864,"about_ca_topic_score_gemma":0.0013751695,"teacher_disagreement_score":0.04261945,"about_ca_system_score_codex":0.000088897956,"about_ca_system_score_gemma":0.00028033074,"threshold_uncertainty_score":0.9999356},"labels":[],"label_agreement":null},{"id":"W4200026444","doi":"10.1158/1535-7163.targ-21-lba020","title":"Abstract LBA020: Targeting FGFR2c isoform, a novel therapeutic target with FGFR inhibitor in endometrial cancer","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Endometrial cancer; Oncology; Cancer; Medicine; Internal medicine; Gene isoform; Cohort; Clinical trial; Disease; Alternative splicing; Cancer research; Biology; Gene","score_opus":0.02507841938843143,"score_gpt":0.3026499582272994,"score_spread":0.277571538838868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200026444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9676985,0.023754645,0.005870157,0.0009848606,0.00042519922,0.0006047833,0.00015944634,0.000039173276,0.00046323522],"genre_scores_gemma":[0.99400204,0.0013591832,0.0018582577,0.0015269456,0.00044634007,0.00024689126,0.00015812684,0.00015458607,0.00024763518],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969277,0.00012907445,0.0004773909,0.0008620853,0.0006560628,0.00094770774],"domain_scores_gemma":[0.9986706,0.00004740968,0.00017380754,0.00058845704,0.00034693693,0.00017280187],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000319071,0.0004652387,0.00042116063,0.00018383175,0.00011677686,0.0001153611,0.00040827127,0.00033536708,0.00028646045],"category_scores_gemma":[0.000056954435,0.00042342095,0.00019782316,0.0008416442,0.00018123053,0.000018570063,0.00019577533,0.0005499254,0.000009691031],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006608495,0.00024539133,0.012430936,0.000083934916,0.00045017237,0.00008897257,0.0001266755,0.0017416739,0.98001266,0.0000566999,0.00008599262,0.0040160283],"study_design_scores_gemma":[0.0037021188,0.00029893382,0.00605729,0.00011992939,0.000053951946,0.000017006552,0.0001346677,0.00022413433,0.94370073,0.000060190996,0.04501923,0.00061183225],"about_ca_topic_score_codex":0.00028715451,"about_ca_topic_score_gemma":0.00046820717,"teacher_disagreement_score":0.044933237,"about_ca_system_score_codex":0.00020114171,"about_ca_system_score_gemma":0.0011784817,"threshold_uncertainty_score":0.9998218},"labels":[],"label_agreement":null},{"id":"W4200042354","doi":"10.1158/1535-7163.targ-21-cc06-01","title":"Abstract CC06-01: Identifying therapeutic options for patients with advanced prostate cancer through genes in liquid biopsies","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Prostate cancer; Medicine; Androgen deprivation therapy; Androgen receptor; Oncology; Prostatectomy; Internal medicine; Disease; Prostate; Circulating tumor cell; Cancer; Liquid biopsy; Metastasis; Bioinformatics; Biology","score_opus":0.04885802728738338,"score_gpt":0.3650282655748881,"score_spread":0.31617023828750473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200042354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8970764,0.09685142,0.0007457273,0.0028413418,0.00028004037,0.0018161718,0.00018150562,0.00006518363,0.0001421699],"genre_scores_gemma":[0.9606176,0.032483935,0.0024467758,0.0016634887,0.00007606085,0.0017350046,0.00027909927,0.00012428372,0.0005737777],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979875,0.000047476402,0.00033324416,0.00054322334,0.00045978208,0.0006287403],"domain_scores_gemma":[0.9988304,0.000047993402,0.000117254596,0.0003915403,0.00051512674,0.00009771709],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008521275,0.00032230414,0.00041084632,0.00010898554,0.00015944168,0.00006845265,0.00012484445,0.00011814166,0.00012576526],"category_scores_gemma":[0.0000067307474,0.0002513828,0.00014529191,0.0005426399,0.00014141011,0.00019040999,0.000044732333,0.00024909384,0.0000029527237],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01325846,0.002684348,0.13369565,0.0018669562,0.0035998824,0.0004702844,0.0051880903,0.0024712912,0.62583,0.0006816149,0.000057885187,0.21019554],"study_design_scores_gemma":[0.028271168,0.002176151,0.11651467,0.002094935,0.0011544965,0.0000145059075,0.0014246143,0.0002763704,0.785613,0.0012268181,0.059993517,0.0012397479],"about_ca_topic_score_codex":0.00011508303,"about_ca_topic_score_gemma":0.0002726115,"teacher_disagreement_score":0.2089558,"about_ca_system_score_codex":0.0004208183,"about_ca_system_score_gemma":0.0007134526,"threshold_uncertainty_score":0.99999386},"labels":[],"label_agreement":null},{"id":"W4200048265","doi":"10.1158/1535-7163.targ-21-p058","title":"Abstract P058: Anti-tumor activity of ATR inhibitor BAY 1895344 in patient-derived xenograft (PDX) models with DNA damage response (DDR) pathway alterations","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Weyerhauser (Canada)","funders":"","keywords":"In vivo; Medicine; Cancer research; Immunohistochemistry; Cancer; DNA damage; Internal medicine; Oncology; Pathology; Biology; DNA","score_opus":0.021527253508414817,"score_gpt":0.26002207716267794,"score_spread":0.23849482365426314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200048265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99268496,0.0019238197,0.0039276043,0.00036197965,0.00010648765,0.00042751236,0.0002581193,0.000019664842,0.0002898595],"genre_scores_gemma":[0.99767554,0.00020586695,0.0009328636,0.0007994093,0.000060707105,0.000113058275,0.0000956207,0.00006917061,0.000047767462],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980541,0.00033037804,0.00035868413,0.00054780673,0.0003044685,0.00040454674],"domain_scores_gemma":[0.99871325,0.000035406363,0.00021528074,0.0006725563,0.00025625288,0.00010722187],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002186354,0.00031926628,0.00033055677,0.00008682358,0.00009362733,0.00005015035,0.0001985883,0.00018298232,0.000043267777],"category_scores_gemma":[0.000028563041,0.0003092138,0.00014969063,0.00029208278,0.00013851306,0.000021070604,0.00011751033,0.0002451786,0.0000021018236],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091556815,0.00030102037,0.00041819966,0.000059284,0.00015072612,0.00017340344,0.00043535334,0.0024200953,0.992173,0.000045234163,0.0000130508915,0.0028950654],"study_design_scores_gemma":[0.001149834,0.00040670825,0.0019672972,0.00011040677,0.000039098155,0.000018210892,0.00013069136,0.000503031,0.99192965,0.00007671191,0.0032893443,0.00037903662],"about_ca_topic_score_codex":0.000048366175,"about_ca_topic_score_gemma":0.00030318982,"teacher_disagreement_score":0.0049905833,"about_ca_system_score_codex":0.00005444032,"about_ca_system_score_gemma":0.00066392595,"threshold_uncertainty_score":0.999936},"labels":[],"label_agreement":null},{"id":"W4200094785","doi":"10.1158/1535-7163.targ-21-p154","title":"Abstract P154: Genomic profiling and matched therapy for recurrent or metastatic salivary gland neoplasms. Results from the matched cohort of the GEMS-001 clinical trial","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Salivary gland; Cohort; Medicine; Profiling (computer programming); Clinical trial; Oncology; Internal medicine; Pathology; Computer science","score_opus":0.10994641830223084,"score_gpt":0.3807383389832205,"score_spread":0.2707919206809897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200094785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785209,0.012932623,0.00005164384,0.0045235665,0.0007390188,0.0025440885,0.0006244542,0.000020226793,0.000043526226],"genre_scores_gemma":[0.986634,0.008214597,0.0013515801,0.0027554955,0.00028066646,0.00035126472,0.0002822409,0.000055530243,0.00007460139],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978436,0.00024118583,0.00082500983,0.00048490858,0.00033453104,0.00027071717],"domain_scores_gemma":[0.997584,0.0011035353,0.00036176323,0.00070451986,0.00015688574,0.00008928625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059346826,0.00027511342,0.00067723583,0.00002022341,0.00011294671,0.000046296143,0.00017290826,0.00010648443,0.000060850827],"category_scores_gemma":[0.000100282516,0.0001376199,0.0003160593,0.00014567257,0.0001338733,0.000023885901,0.00006188273,0.0002513196,0.0000017245331],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2966658,0.007404199,0.55292946,0.00035195137,0.019593334,0.0005212775,0.0025780133,0.00009981821,0.022870395,0.0002995758,0.0012823842,0.09540381],"study_design_scores_gemma":[0.1818659,0.0023317991,0.72683996,0.00044384899,0.0041275765,0.000055646233,0.0004445949,0.00046442717,0.07307286,0.0011831586,0.008700242,0.00047000436],"about_ca_topic_score_codex":0.00032003288,"about_ca_topic_score_gemma":0.00015523889,"teacher_disagreement_score":0.1739105,"about_ca_system_score_codex":0.000064111446,"about_ca_system_score_gemma":0.00051324436,"threshold_uncertainty_score":0.5611977},"labels":[],"label_agreement":null},{"id":"W4200113851","doi":"10.1158/1535-7163.targ-21-p136","title":"Abstract P136: Response to alpelisib in an adolescent with <i>PIK3CA</i>-mutated metastatic gastrointestinal stromal tumour","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"PDGFRA; SDHB; Stromal tumor; Sunitinib; GiST; Cancer; CD117; Germline; Cancer research; Germline mutation; Pathology; Imatinib; Internal medicine; Biology; Medicine; Oncology; Stromal cell; Mutation; CD34; Genetics; Gene","score_opus":0.0441469780952872,"score_gpt":0.3455051166161648,"score_spread":0.30135813852087756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200113851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99286836,0.0005849009,0.001908603,0.0037249974,0.000023401113,0.0006704611,0.00004685943,0.00006117406,0.00011126763],"genre_scores_gemma":[0.97566223,0.000017020233,0.021940093,0.0020345089,0.000023667719,0.00010617611,0.000059236947,0.00007645717,0.000080621656],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9973536,0.00025310353,0.0003484714,0.0005739012,0.0007058526,0.0007650441],"domain_scores_gemma":[0.9983666,0.000062985106,0.00007662426,0.00048831024,0.00042295098,0.0005825521],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002770921,0.00034633972,0.0004236797,0.00019416875,0.000055812987,0.00007596119,0.00014979372,0.000023347602,0.00013450715],"category_scores_gemma":[0.00007022024,0.00028628128,0.00010043748,0.0006051079,0.00007891402,0.00007271571,0.00005333668,0.00046159723,0.00002382792],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012755923,0.0019000263,0.067051455,0.00010775525,0.00015899683,0.04748841,0.00015315396,0.00075022154,0.86656076,0.00001775365,0.000020475018,0.0030350492],"study_design_scores_gemma":[0.010252884,0.008146069,0.71429145,0.0022741118,0.00036541946,0.0060182177,0.0007904186,0.0009628188,0.25591487,0.000049360544,0.00043186187,0.0005025396],"about_ca_topic_score_codex":0.00018200718,"about_ca_topic_score_gemma":0.00046355798,"teacher_disagreement_score":0.64724,"about_ca_system_score_codex":0.0004205328,"about_ca_system_score_gemma":0.0010815406,"threshold_uncertainty_score":0.99995893},"labels":[],"label_agreement":null},{"id":"W4200167174","doi":"10.1158/1535-7163.targ-21-p081","title":"Abstract P081: <i>In vitro</i> activity and efficacy of novel dual PARP-HDAC inhibitors","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Acuitas Therapeutics (Canada)","funders":"","keywords":"PARP inhibitor; Poly ADP ribose polymerase; DNA repair; Cancer research; Molecular biology; Synthetic lethality; Chemistry; Histone; Biology; Polymerase; DNA; Biochemistry","score_opus":0.03704472708377646,"score_gpt":0.3269870545350563,"score_spread":0.2899423274512798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200167174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881277,0.007198435,0.00056346785,0.0023614592,0.00026943703,0.0003138541,0.000071765535,0.000031622407,0.00106226],"genre_scores_gemma":[0.9950552,0.0013153703,0.00086501124,0.002467921,0.00012607401,0.000043724667,0.000011314885,0.000054857403,0.00006054839],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983302,0.000051201227,0.00036545674,0.0004185499,0.0005089887,0.00032565588],"domain_scores_gemma":[0.999003,0.000088191504,0.00016095102,0.00041547706,0.00021488535,0.00011752168],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019693136,0.00024359314,0.00046805615,0.000105233434,0.000038752034,0.000018752682,0.00006256866,0.00017115385,0.00009106185],"category_scores_gemma":[0.000023269542,0.00024724158,0.0001461549,0.0004002586,0.00017179962,0.00006821992,0.000044606066,0.00035563868,0.0000034543743],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007572045,0.0006516395,0.0008415464,0.00011580898,0.00020872535,0.00013462633,0.00029349182,0.00008952363,0.9652841,0.00006828612,0.000035728182,0.031519286],"study_design_scores_gemma":[0.0067165066,0.000080013895,0.022079384,0.00024162799,0.00011763758,0.000049593236,0.000056156805,0.00013377066,0.9641863,0.000058753798,0.006053272,0.00022699498],"about_ca_topic_score_codex":0.00011889233,"about_ca_topic_score_gemma":0.000031705527,"teacher_disagreement_score":0.031292293,"about_ca_system_score_codex":0.00023015113,"about_ca_system_score_gemma":0.0004988267,"threshold_uncertainty_score":0.999998},"labels":[],"label_agreement":null},{"id":"W4200172388","doi":"10.1158/1535-7163.targ-21-p200","title":"Abstract P200: Pre-clinical development of a dopamine receptor 2, PD-1 and CD47 trispecific antibody for treatment of small cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Biotechnology Research Institute","funders":"","keywords":"Lung cancer; Cancer; Antibody; Immunotherapy; Cancer research; Medicine; CD47; Immune system; Immunology; Receptor; Biology; Oncology; Internal medicine","score_opus":0.06606885790911159,"score_gpt":0.41531484241515276,"score_spread":0.34924598450604116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200172388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9512968,0.04485225,0.0018954282,0.00048745642,0.00018262629,0.0010748907,0.000088093635,0.000018038561,0.00010440267],"genre_scores_gemma":[0.9521342,0.027174348,0.017897073,0.00023591184,0.00013393808,0.00034723344,0.00008361756,0.00009109392,0.001902574],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998141,0.000063165746,0.00067204033,0.00043775683,0.00032376437,0.00036228102],"domain_scores_gemma":[0.9987079,0.00016296231,0.00024104219,0.00036011578,0.0003674015,0.00016056138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000113307084,0.00023733728,0.00065240444,0.00008298614,0.00004308016,0.000011632563,0.00009735022,0.000032873413,0.00014923674],"category_scores_gemma":[0.00002619301,0.00020174574,0.00017712406,0.00019588706,0.00012823442,0.00002757681,0.000041808657,0.00010679548,7.5893155e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013908264,0.0012940699,0.025458993,0.001056132,0.00075012876,0.00019975136,0.00033460252,0.00003894614,0.87507576,0.000008239042,0.0000487073,0.09434386],"study_design_scores_gemma":[0.0052923253,0.0007920248,0.01392576,0.00021016435,0.00030104961,0.000018925368,0.00009147844,0.00018186231,0.91063046,0.000008871305,0.06837444,0.00017262607],"about_ca_topic_score_codex":0.000062801155,"about_ca_topic_score_gemma":0.000098228484,"teacher_disagreement_score":0.09417123,"about_ca_system_score_codex":0.00016386152,"about_ca_system_score_gemma":0.00097603665,"threshold_uncertainty_score":0.82269526},"labels":[],"label_agreement":null},{"id":"W4200262298","doi":"10.1158/1535-7163.targ-21-p035","title":"Abstract P035: A phase 1 pharmacokinetic trial of single agent trametinib a MEK inhibitor in advanced cancer patients with hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study (NCI 9591)","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Trametinib; Medicine; Pharmacokinetics; MEK inhibitor; Internal medicine; Dosing; Cancer; Oncology; Gastroenterology; Pharmacology; Kinase; MAPK/ERK pathway","score_opus":0.03730481211282161,"score_gpt":0.3268553980221237,"score_spread":0.2895505859093021,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200262298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99225307,0.0038464281,0.0001442367,0.00021623682,0.0009670418,0.0023565372,0.00003871449,0.000052625364,0.00012508659],"genre_scores_gemma":[0.9976438,0.0004724226,0.00016229972,0.0005019664,0.00019894955,0.00081203965,0.00007826165,0.000084624495,0.000045633587],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973835,0.0001517053,0.00064879475,0.00065419404,0.00074796844,0.00041383327],"domain_scores_gemma":[0.9987556,0.000047812766,0.0003130613,0.00037294178,0.00037284757,0.00013778511],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014589448,0.00041724223,0.0007265366,0.00015606446,0.00010996721,0.000036721245,0.00008932761,0.00008995143,0.00023328699],"category_scores_gemma":[0.000018115636,0.0003458148,0.00014046296,0.00081230607,0.00008005069,0.00010938452,0.000041255425,0.0002765721,0.0000011113415],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14591555,0.041744404,0.11895213,0.00034132038,0.003592305,0.0006011932,0.007426176,0.00088604016,0.22127078,0.000003844491,0.000016531738,0.4592497],"study_design_scores_gemma":[0.57819873,0.05241011,0.22881405,0.0015766072,0.0061672926,0.000012817059,0.0046467935,0.0004699039,0.121150315,0.000040802704,0.0050980733,0.0014145026],"about_ca_topic_score_codex":0.00042217175,"about_ca_topic_score_gemma":0.0023674907,"teacher_disagreement_score":0.4578352,"about_ca_system_score_codex":0.0007780061,"about_ca_system_score_gemma":0.00034953645,"threshold_uncertainty_score":0.9998994},"labels":[],"label_agreement":null},{"id":"W4200263052","doi":"10.1158/1535-7163.targ-21-p072","title":"Abstract P072: Combining ATR inhibitors with carboplatin in chemoresistant TNBC conditionally reprogrammed cells and patient-derived xenografts","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Carboplatin; Triple-negative breast cancer; Cancer research; Medicine; Chemotherapy; Breast cancer; Cancer; Oncology; Internal medicine; Cisplatin","score_opus":0.00993659552053282,"score_gpt":0.23665763558083086,"score_spread":0.22672104006029803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200263052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949286,0.0038744698,0.00024108977,0.00026164882,0.00014492049,0.0002744388,0.000040874027,0.000024863943,0.00020908726],"genre_scores_gemma":[0.99587435,0.0002797271,0.0022324065,0.0012494255,0.000041906438,0.00008703432,0.00014022163,0.00006144512,0.000033480355],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99846166,0.00006783255,0.00028683356,0.0005703285,0.00026541212,0.00034793792],"domain_scores_gemma":[0.9992176,0.000012582444,0.00013775588,0.00038911714,0.00014338932,0.00009950224],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009174991,0.00025483116,0.00022403721,0.000045784207,0.00006161594,0.000055684493,0.00010299427,0.00017351632,0.000021360527],"category_scores_gemma":[0.0000094936595,0.00025480907,0.00007578607,0.00017375505,0.00010935784,0.0000060226666,0.00009504802,0.00016828354,0.0000011045782],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013634199,0.00010408395,0.00076877075,0.000031965617,0.00017361536,0.00029740328,0.00021480235,0.00016716076,0.9926882,0.000041629406,0.00002834697,0.005347694],"study_design_scores_gemma":[0.0013012324,0.00022594586,0.0020625822,0.00007795247,0.000048103902,0.000022906393,0.0003512846,0.00004479327,0.9911915,0.00009126024,0.0042473227,0.00033513884],"about_ca_topic_score_codex":0.00004913514,"about_ca_topic_score_gemma":0.0002639613,"teacher_disagreement_score":0.005012555,"about_ca_system_score_codex":0.000046345434,"about_ca_system_score_gemma":0.00022873009,"threshold_uncertainty_score":0.9999904},"labels":[],"label_agreement":null},{"id":"W4200284612","doi":"10.1158/1535-7163.targ-21-p054","title":"Abstract P054: RP-3500: A novel, potent and selective ATR inhibitor that is effective in pre-clinical models as a monotherapy and in combination with PARP inhibitors","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Saint-Laurent","funders":"","keywords":"In vivo; DNA damage; Kinase; Pharmacology; Cancer research; Chemistry; Biology; Biochemistry; DNA; Genetics","score_opus":0.01768560921090383,"score_gpt":0.292498156566137,"score_spread":0.27481254735523314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200284612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900555,0.005752155,0.0027288017,0.00046799966,0.0000866622,0.00076188095,0.000016437158,0.000013519161,0.00011703937],"genre_scores_gemma":[0.99551916,0.0017133006,0.000783566,0.0016106464,0.00004296219,0.00019286113,0.000021085352,0.000059055386,0.000057363584],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983151,0.00015083158,0.00029199605,0.0007152452,0.00022902236,0.00029778547],"domain_scores_gemma":[0.9993571,0.000034409713,0.00012566253,0.0002737016,0.00012166063,0.00008746512],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002584904,0.00028637453,0.00031208695,0.000079254285,0.000040899118,0.000051499304,0.00008716529,0.00030420494,0.0000044703665],"category_scores_gemma":[0.000012694982,0.000275,0.000072065566,0.00020616472,0.0001075334,0.000018983379,0.00008380554,0.00027719513,5.675502e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013455547,0.0006316156,0.018304057,0.00005780261,0.00045847413,0.0001146905,0.0013126783,0.0007829095,0.9510142,0.00010495273,0.000016171996,0.025856894],"study_design_scores_gemma":[0.005035399,0.0008663285,0.02702014,0.00014950936,0.000064484746,0.000046169345,0.00015966146,0.0021803752,0.962263,0.0013696428,0.00042493403,0.0004203666],"about_ca_topic_score_codex":0.00019791316,"about_ca_topic_score_gemma":0.00045009702,"teacher_disagreement_score":0.025436528,"about_ca_system_score_codex":0.00008793827,"about_ca_system_score_gemma":0.0002048285,"threshold_uncertainty_score":0.9999702},"labels":[],"label_agreement":null},{"id":"W4200320387","doi":"10.1158/1535-7163.targ-21-p196","title":"Abstract P196: Novel hydrophilic drug linkers enable exatecan-based antibody-drug conjugates with promising physiochemical properties and in vivo activity","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Profound Medical (Canada)","funders":"","keywords":"In vivo; Conjugate; Linker; Pharmacokinetics; Chemistry; Camptothecin; Drug; Potency; Pharmacology; Combinatorial chemistry; Pharmacodynamics; In vitro; Biochemistry; Medicine; Biology","score_opus":0.04894244771709914,"score_gpt":0.32794026793012554,"score_spread":0.2789978202130264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200320387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98801786,0.0062003443,0.00012371782,0.0043509137,0.000055603366,0.0007467279,0.000024874202,0.000059760107,0.00042019266],"genre_scores_gemma":[0.9970359,0.00056679366,0.00043496097,0.0014228902,0.00007935292,0.00012050711,0.000012177566,0.00009811313,0.00022926719],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99779713,0.00007666575,0.00025592328,0.00063870824,0.0006406141,0.00059098325],"domain_scores_gemma":[0.9989396,0.000052155618,0.000088413544,0.0004977505,0.00023786479,0.00018422399],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002298485,0.00032542326,0.00048435258,0.00010974227,0.00009084905,0.000092601906,0.00014051334,0.00012082841,0.0000724924],"category_scores_gemma":[0.000025597396,0.00026813868,0.00007769192,0.00045193272,0.0003951632,0.000088087545,0.00006567536,0.0006642178,0.0000023476007],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083965325,0.0003905725,0.0033148509,0.00086139137,0.00017885641,0.00023498951,0.00046553471,0.0006448909,0.99061334,0.0000041876983,0.000029623749,0.0024220836],"study_design_scores_gemma":[0.0028044041,0.00009494337,0.0015587771,0.001292553,0.00009456316,0.000024466053,0.00017259101,0.0042386265,0.9873518,0.000023832512,0.0020135795,0.0003298949],"about_ca_topic_score_codex":0.0011535619,"about_ca_topic_score_gemma":0.000309692,"teacher_disagreement_score":0.009018072,"about_ca_system_score_codex":0.00036831913,"about_ca_system_score_gemma":0.0015193387,"threshold_uncertainty_score":0.99997705},"labels":[],"label_agreement":null},{"id":"W4200320597","doi":"10.1158/1535-7163.targ-21-p239","title":"Abstract P239: Safety and efficacy of copanlisib in combination with nivolumab: A phase Ib study in patients with advanced solid tumors","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Nivolumab; Internal medicine; Pharmacodynamics; Cancer; Pharmacokinetics; Gastroenterology; Oncology; Adverse effect; Pharmacology; Immunotherapy","score_opus":0.01232018435498204,"score_gpt":0.3024308497985526,"score_spread":0.29011066544357056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200320597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968781,0.0017257113,0.000097738346,0.00017112373,0.00003184873,0.0009900111,0.00001676133,0.000012067982,0.00007666133],"genre_scores_gemma":[0.9991128,0.0002522533,0.00013946963,0.0003721991,0.000005086131,0.00003305058,0.00003564478,0.000034377103,0.000015159778],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987298,0.000059200993,0.00036814058,0.00029833743,0.0003385178,0.00020600721],"domain_scores_gemma":[0.9993358,0.000029274608,0.00015327235,0.0002693622,0.0001671933,0.00004506571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012410838,0.00018296098,0.00040699696,0.00012138147,0.00002731163,0.0000123435775,0.000058137448,0.000050776995,0.000028359133],"category_scores_gemma":[0.0000064465066,0.00014981965,0.000034160767,0.00050325046,0.0000931921,0.00006333239,0.000016711487,0.00017731838,1.8328616e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.071546465,0.011932146,0.60032094,0.00022219206,0.00084522,0.00042867853,0.003988986,0.00050579204,0.07035483,0.000017116687,0.00000167541,0.23983598],"study_design_scores_gemma":[0.07673793,0.0036694019,0.90129083,0.0005081207,0.000114048984,0.0000042213633,0.000560608,0.000080748134,0.016688053,0.000005377483,0.00014964183,0.00019098891],"about_ca_topic_score_codex":0.00021099413,"about_ca_topic_score_gemma":0.00064970116,"teacher_disagreement_score":0.30096993,"about_ca_system_score_codex":0.00019187851,"about_ca_system_score_gemma":0.00027577937,"threshold_uncertainty_score":0.6109468},"labels":[],"label_agreement":null},{"id":"W4200326442","doi":"10.1158/1535-7163.targ-21-lba026","title":"Abstract LBA026: Survivin peptides formulated in the DPX delivery platform rather than standard emulsions, elicit a robust, sustained T cell response to survivin in advanced and recurrent ovarian cancer patients","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dartmouth General Hospital","funders":"","keywords":"Survivin; Immune system; T cell; Medicine; Antigen; Ovarian cancer; ELISPOT; Cancer research; Immunology; Cancer; Internal medicine","score_opus":0.016343360451750596,"score_gpt":0.2675560092356468,"score_spread":0.2512126487838962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200326442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96041995,0.036899574,0.0001056272,0.0010048011,0.0003833783,0.0008801368,0.00018733111,0.00003089592,0.00008831061],"genre_scores_gemma":[0.9923083,0.0052063274,0.000077527926,0.0016240843,0.000010195213,0.00021007085,0.00008450577,0.00006525211,0.0004137272],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968496,0.0010900295,0.00060983346,0.0005362757,0.00017060719,0.00074366154],"domain_scores_gemma":[0.99849194,0.0004948763,0.0001725491,0.000541441,0.00026145854,0.000037704936],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000984225,0.00042539043,0.0005081975,0.000277855,0.00022453767,0.00007525057,0.00037846668,0.00032885614,0.00024352234],"category_scores_gemma":[0.0000897627,0.00034659274,0.00012996537,0.000685588,0.00011862414,0.00015780043,0.00010245299,0.0006492136,0.000011249551],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023066677,0.0005710548,0.010695403,0.000051205945,0.0002811744,0.00006038507,0.007823555,0.0007560864,0.92183715,0.000047165384,0.00007647721,0.034733657],"study_design_scores_gemma":[0.015473975,0.0012967187,0.33820853,0.00067203975,0.0001310818,0.000016764288,0.006348488,0.00004997301,0.5911888,0.00021532468,0.04518914,0.001209208],"about_ca_topic_score_codex":0.0010607305,"about_ca_topic_score_gemma":0.0033169873,"teacher_disagreement_score":0.3306484,"about_ca_system_score_codex":0.0003957178,"about_ca_system_score_gemma":0.00049949705,"threshold_uncertainty_score":0.9998986},"labels":[],"label_agreement":null},{"id":"W4200371948","doi":"10.1158/1535-7163.targ-21-p064","title":"Abstract P064: Novel engineering of therapeutic <i>Fusobacterium nucleatum</i> phage for colorectal cancer treatment","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Bacteriophages and microbial interactions","field":"Environmental Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brantford Energy (Canada)","funders":"","keywords":"Fusobacterium nucleatum; Biology; Computational biology; Genome; Gene; Bacteria; Genetics","score_opus":0.01874106915550633,"score_gpt":0.26708564430504544,"score_spread":0.24834457514953912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200371948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917014,0.0015160685,0.0040992005,0.0006206238,0.00073618174,0.00038382516,0.00037806298,0.00004317862,0.0005214303],"genre_scores_gemma":[0.9964744,0.0006482046,0.0013231497,0.0008603017,0.000065257416,0.00017727599,0.000026268312,0.00006175034,0.00036341508],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989565,0.0000129726595,0.00025039553,0.00032576168,0.00012439494,0.00033000196],"domain_scores_gemma":[0.99951285,0.00003658836,0.000115161514,0.00022722069,0.000040749776,0.00006741227],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000040949944,0.00023620175,0.00025558966,0.000023064782,0.00007178739,0.000039360802,0.00014845679,0.0000929606,0.0014353242],"category_scores_gemma":[0.0000026190337,0.00022434538,0.00022308451,0.00016352178,0.00006337696,0.00009948262,0.000052208765,0.000099676094,0.0000119304605],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051754163,0.00025630306,0.00021692291,0.000024367926,0.00027510387,0.000007479332,0.000314474,0.0017837301,0.9779988,0.00003504561,0.000031946063,0.019004067],"study_design_scores_gemma":[0.0007781542,0.00009867604,0.016285898,0.00003461507,0.00017867771,0.000010393669,0.000037645244,0.00071849464,0.8951146,0.000011884582,0.08649593,0.00023504875],"about_ca_topic_score_codex":0.0005619079,"about_ca_topic_score_gemma":0.00037940132,"teacher_disagreement_score":0.08646398,"about_ca_system_score_codex":0.00048685528,"about_ca_system_score_gemma":0.00007469155,"threshold_uncertainty_score":0.9994775},"labels":[],"label_agreement":null},{"id":"W4200442084","doi":"10.1158/1535-7163.targ-21-lba030","title":"Abstract LBA030: DPX-SurMAGE, a novel dual-targeted immunotherapy for bladder cancer, induces target-specific T cells with a favorable safety profile in preclinical model","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dartmouth General Hospital; Université Laval","funders":"","keywords":"Survivin; Immunotherapy; Immunogenicity; Bladder cancer; Cystectomy; T cell; Cancer immunotherapy; Medicine; Cancer research; Antigen; Immune system; Immunology; Major histocompatibility complex; Cancer; Internal medicine","score_opus":0.04251056014399972,"score_gpt":0.30769736813059273,"score_spread":0.265186807986593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200442084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7153283,0.25184342,0.026120543,0.0015810237,0.0013098043,0.0020632609,0.0011406204,0.00016443759,0.00044863345],"genre_scores_gemma":[0.9555362,0.02515212,0.007240134,0.003922139,0.00008272284,0.0014373853,0.0004558032,0.00029160673,0.005881901],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967889,0.00028433301,0.0008890558,0.00086797425,0.00015638224,0.0010133412],"domain_scores_gemma":[0.9981515,0.0002878255,0.00034592772,0.0007966385,0.00037664906,0.00004146902],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000498552,0.0006040634,0.00084849104,0.00016860127,0.0003233405,0.00008449569,0.00042420617,0.000624592,0.0012289054],"category_scores_gemma":[0.000015162338,0.0005335387,0.00031626498,0.0005179073,0.00033849516,0.0001972113,0.0000683397,0.00085101277,0.000028053355],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006748606,0.00092413864,0.00010287819,0.00005597029,0.0016919592,0.000024584071,0.0012173614,0.0060879886,0.9673815,0.00017312061,0.00028663606,0.015305257],"study_design_scores_gemma":[0.00864005,0.0002996575,0.0012365091,0.000181351,0.000089852554,0.00002195756,0.00027714926,0.0006104939,0.88306576,0.00014050487,0.1047072,0.00072950934],"about_ca_topic_score_codex":0.0002193805,"about_ca_topic_score_gemma":0.00010157027,"teacher_disagreement_score":0.24020793,"about_ca_system_score_codex":0.00023941029,"about_ca_system_score_gemma":0.0014568099,"threshold_uncertainty_score":0.99971163},"labels":[],"label_agreement":null},{"id":"W4200454923","doi":"10.1158/1535-7163.targ-21-p175","title":"Abstract P175: Investigating inositol polyphosphate-4-phosphatase, type II (INPP4B) signaling and role in acute myeloid leukemia","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Gene knockdown; Lysosome; Myeloid leukemia; Biology; Cancer research; Leukemia; Inositol; Cell biology; Gene; Biochemistry; Immunology; Enzyme; Receptor","score_opus":0.01787392291850707,"score_gpt":0.26711645911801035,"score_spread":0.2492425361995033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200454923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94007516,0.058676116,0.000110087705,0.00034567874,0.0001606782,0.00019548423,0.00006116581,0.000021641274,0.0003539802],"genre_scores_gemma":[0.99107677,0.002817501,0.0018311265,0.003725213,0.000118314456,0.000045285935,0.00019262127,0.00005964205,0.00013350252],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984793,0.00007160369,0.00030492974,0.00052326074,0.00019727435,0.00042365308],"domain_scores_gemma":[0.9992566,0.000012636123,0.00011411046,0.0003591445,0.000121806384,0.00013571147],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015821644,0.00027822546,0.00023761757,0.000043547112,0.00015336547,0.000068140725,0.00018901237,0.000248186,0.000059662114],"category_scores_gemma":[0.000023505434,0.0003031766,0.00007411645,0.00026137097,0.00009587007,0.000010738044,0.00021834229,0.0002716338,0.0000043859436],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006217336,0.000035975376,0.0040495414,0.00003768626,0.00017311427,0.000084217645,0.00026494966,0.00024356946,0.98088765,0.00015805091,0.000046613633,0.01395646],"study_design_scores_gemma":[0.00070924405,0.00012402322,0.0017316511,0.0000918178,0.00006447592,0.000023513378,0.00012349534,0.00019800666,0.9806885,0.00033593483,0.015541995,0.00036731866],"about_ca_topic_score_codex":0.00015821168,"about_ca_topic_score_gemma":0.00007918768,"teacher_disagreement_score":0.055858616,"about_ca_system_score_codex":0.00007097827,"about_ca_system_score_gemma":0.00049383414,"threshold_uncertainty_score":0.99994206},"labels":[],"label_agreement":null},{"id":"W4200466845","doi":"10.1158/1535-7163.mct-21-0519","title":"Targeting IKKε in Androgen-Independent Prostate Cancer Causes Phenotypic Senescence and Genomic Instability","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"NF-κB Signaling Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Fonds de Recherche du Québec - Santé; Cancer Research Society","keywords":"Prostate cancer; Prostate; Cancer; Senescence; Cell growth; Cancer cell; Phenotype","score_opus":0.017693203283027186,"score_gpt":0.2687015989948471,"score_spread":0.2510083957118199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200466845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9552179,0.04311774,0.000794229,0.0002691627,0.00018645068,0.0002749857,0.00006892082,0.00001773458,0.000052855114],"genre_scores_gemma":[0.99130076,0.006422629,0.00048391707,0.0014158748,0.00008643665,0.00010039663,0.000049825285,0.000055269767,0.000084862295],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982558,0.00016110924,0.00030076646,0.00066936394,0.00019515192,0.00041779169],"domain_scores_gemma":[0.99925876,0.000010323804,0.00010013451,0.00038995806,0.00015250406,0.00008833308],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020778508,0.00025765973,0.00023331036,0.000038465492,0.00008394601,0.000048697362,0.00015754832,0.00016510919,0.00004270001],"category_scores_gemma":[0.000020978168,0.00027507514,0.000065291235,0.00017319672,0.00010640547,0.000006226491,0.00018619532,0.0001931505,0.0000020209711],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007324767,0.000061098784,0.07073002,0.00006062996,0.00010072902,0.00005885424,0.00031206285,0.0013776266,0.9208571,0.000028578781,0.000006466578,0.006333628],"study_design_scores_gemma":[0.00090551586,0.000055717952,0.0060583455,0.00005185015,0.000055513705,0.00001566458,0.00016649601,0.00038682143,0.9829112,0.00015415518,0.0088435365,0.00039514631],"about_ca_topic_score_codex":0.00022045156,"about_ca_topic_score_gemma":0.0008278206,"teacher_disagreement_score":0.06467167,"about_ca_system_score_codex":0.00011326791,"about_ca_system_score_gemma":0.00048743497,"threshold_uncertainty_score":0.99997014},"labels":[],"label_agreement":null},{"id":"W4200468047","doi":"10.1158/1535-7163.targ-21-cc04-01","title":"Abstract CC04-01: First-in-human biomarker-driven phase I TRESR trial of ataxia telangiectasia and Rad3-related inhibitor (ATRi) RP-3500 in patients (pts) with advanced solid tumors harboring synthetic lethal (SL) genomic alterations","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CRISPR and Genetic Engineering","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Zygosity; Germline; Medicine; Internal medicine; Neutropenia; Biomarker; Cancer research; Oncology; Biology; Genetics; Chemotherapy; Gene","score_opus":0.010232009975896364,"score_gpt":0.30269688500943903,"score_spread":0.2924648750335427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200468047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99521923,0.0034270538,0.0005715316,0.000059167927,0.0001365536,0.00046370577,0.000058331112,0.0000105294475,0.0000538754],"genre_scores_gemma":[0.9989832,0.00036464309,0.0003137328,0.000035039342,0.000041294763,0.00006111917,0.00013193986,0.000053763764,0.000015233123],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985775,0.000053017247,0.00045365997,0.00044177118,0.00016422075,0.00030987913],"domain_scores_gemma":[0.9993803,0.00001427901,0.00012773904,0.00034386726,0.00006247373,0.000071356444],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000084589126,0.000252782,0.0003068326,0.00011543685,0.00005624197,0.000026458167,0.00012555644,0.0001405171,0.000015123902],"category_scores_gemma":[0.000013371167,0.00026017352,0.00008449062,0.0001984716,0.0000706397,0.000008866859,0.0000621891,0.00016071806,4.4848167e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001662736,0.00041990302,0.0030247392,0.00006581814,0.0001710031,0.000059802453,0.0002092764,0.010661619,0.9772184,0.0000071427507,0.0000028685513,0.00649673],"study_design_scores_gemma":[0.043939203,0.0010468344,0.018638415,0.00026745035,0.0001178093,0.000011081816,0.00008539345,0.0013257628,0.9331492,0.00001535555,0.0008773998,0.0005260945],"about_ca_topic_score_codex":0.000046523044,"about_ca_topic_score_gemma":0.0002405665,"teacher_disagreement_score":0.04406916,"about_ca_system_score_codex":0.00006669772,"about_ca_system_score_gemma":0.00011369411,"threshold_uncertainty_score":0.99998504},"labels":[],"label_agreement":null},{"id":"W4200471492","doi":"10.1158/1535-7163.targ-21-lba029","title":"Abstract LBA029: Development of computational tools for evaluating differential protein expression relative to spatial oxygen gradients using imaging mass cytometry","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Metabolomics and Mass Spectrometry Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Hypoxia (environmental); Tumor hypoxia; Biology; Mass cytometry; Flow cytometry; Immunohistochemistry; Pathology; Cancer research; Phenotype; Chemistry; Immunology; Medicine; Radiation therapy; Oxygen; Internal medicine; Gene; Biochemistry","score_opus":0.05323106642199492,"score_gpt":0.34676904839407935,"score_spread":0.2935379819720844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200471492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5453985,0.0008752272,0.45320156,0.000053365562,0.000103851875,0.00029650165,0.000043887765,0.0000038310122,0.000023314644],"genre_scores_gemma":[0.8451092,0.000017552255,0.15437731,0.0001490516,0.00006895483,0.00009292787,0.00012639993,0.000032007014,0.000026574278],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985896,0.000057148107,0.00036989138,0.00040833696,0.0003017953,0.00027326326],"domain_scores_gemma":[0.9991377,0.000022783133,0.00019670943,0.00019271759,0.0003889632,0.00006112649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014825119,0.0002001133,0.00024523566,0.00007874405,0.00015587099,0.00004213734,0.00013445251,0.00007353324,0.000022097927],"category_scores_gemma":[0.000075141565,0.00020164771,0.00012207338,0.00015309214,0.000032991593,0.0000089315645,0.00013901424,0.00007755342,5.1081247e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013527302,0.00006328211,0.00030451355,0.000050626128,0.00031507513,0.0000020842508,0.00016861148,0.0017216032,0.9794137,0.000060542654,0.000003830456,0.017760871],"study_design_scores_gemma":[0.0008508437,0.00006636419,0.004133561,0.000082890394,0.00007027732,0.000001470106,0.0000994228,0.0017460193,0.99119055,0.00047912868,0.0010354371,0.00024405435],"about_ca_topic_score_codex":0.000007347497,"about_ca_topic_score_gemma":0.000006709577,"teacher_disagreement_score":0.29971075,"about_ca_system_score_codex":0.00007170199,"about_ca_system_score_gemma":0.0002848731,"threshold_uncertainty_score":0.8222955},"labels":[],"label_agreement":null},{"id":"W4200494616","doi":"10.1158/1535-7163.targ-21-lba018","title":"Abstract LBA018: Discovery of novel functional TROP2 antibodies for treatment of epithelial cancers","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Biotechnology Research Institute","funders":"","keywords":"Antibody; Antibody-drug conjugate; Cancer research; Medicine; Cancer; Epitope; In vivo; Immunology; Monoclonal antibody; Biology; Internal medicine","score_opus":0.07663870833426535,"score_gpt":0.3582199704934611,"score_spread":0.28158126215919577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200494616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815927,0.009795336,0.004730941,0.0014989263,0.00022441213,0.00036041308,0.0010461402,0.000007987866,0.0007431217],"genre_scores_gemma":[0.99201566,0.0037820837,0.0019123028,0.0005879774,0.00021420309,0.00006315765,0.00017768706,0.000026002805,0.001220925],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879944,0.000019151496,0.0002889097,0.00022681255,0.00042678832,0.00023890089],"domain_scores_gemma":[0.9992198,0.00009099567,0.000104040824,0.00022015975,0.00031478537,0.000050228286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000059013346,0.00016680911,0.00041602078,0.00006556575,0.00004311682,0.000011106647,0.000066910856,0.00007143449,0.000082482744],"category_scores_gemma":[0.000008746035,0.00012903976,0.00035120768,0.00013818445,0.00014071276,0.000039625826,0.000014021953,0.00005303761,8.177466e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00160489,0.00084104383,0.0032553466,0.00038529697,0.001067823,0.00004418134,0.00031653247,0.00021244652,0.9773827,0.0013640696,0.000056979472,0.013468643],"study_design_scores_gemma":[0.003616261,0.0009798646,0.027191928,0.00012716425,0.00039154012,0.00002799978,0.0002233694,0.00026490595,0.93870056,0.00014891684,0.028172107,0.00015538253],"about_ca_topic_score_codex":0.00043178772,"about_ca_topic_score_gemma":0.00006875451,"teacher_disagreement_score":0.038682185,"about_ca_system_score_codex":0.00012934678,"about_ca_system_score_gemma":0.0007328174,"threshold_uncertainty_score":0.5262089},"labels":[],"label_agreement":null},{"id":"W4200501854","doi":"10.1158/1535-7163.targ-21-p230","title":"Abstract P230: A phase 1/2 study of BLU-945, a highly potent and selective inhibitor of epidermal growth factor receptor (EGFR) resistance mutations, in patients with <i>EGFR</i>-mutant non-small cell lung cancer (NSCLC)","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"T790M; Osimertinib; Medicine; Epidermal growth factor receptor; Exon; Cancer research; EGFR inhibitors; Mutant; Lung cancer; Mutation; Gefitinib; Cancer; Oncology; Internal medicine; Erlotinib; Gene; Biology; Genetics","score_opus":0.010582206417046503,"score_gpt":0.289737410597893,"score_spread":0.2791552041808465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200501854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924399,0.0045287684,0.00023634442,0.00035007801,0.0001231472,0.0017241857,0.00046401913,0.0000166764,0.00011683436],"genre_scores_gemma":[0.9980251,0.00041235102,0.00068660796,0.0003290464,0.000032866632,0.00029706644,0.00008090747,0.00006291329,0.00007311724],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980736,0.00008656908,0.00056409545,0.00049700413,0.00046005342,0.00031870263],"domain_scores_gemma":[0.9983577,0.00005719268,0.00036502516,0.00030036873,0.00079639885,0.00012332789],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00006284359,0.0003134492,0.0005753165,0.00015378628,0.00007315182,0.000019500847,0.000081471255,0.00009524463,0.000030236873],"category_scores_gemma":[0.000011115987,0.00026381743,0.000080551414,0.0005737906,0.00008270802,0.00008938388,0.00003199301,0.00022964209,3.459436e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043654353,0.012872229,0.6411853,0.0013681882,0.0035509677,0.00027154453,0.022506693,0.00039841494,0.3062664,0.00002302438,0.00006236457,0.007129463],"study_design_scores_gemma":[0.03919671,0.0021323157,0.47595102,0.0011763354,0.002213709,0.000002384351,0.00224195,0.000117090734,0.47627744,0.000018899267,0.00016903001,0.00050311175],"about_ca_topic_score_codex":0.0010202178,"about_ca_topic_score_gemma":0.0010658094,"teacher_disagreement_score":0.17001104,"about_ca_system_score_codex":0.00050901074,"about_ca_system_score_gemma":0.00097618584,"threshold_uncertainty_score":0.9999814},"labels":[],"label_agreement":null},{"id":"W4200504528","doi":"10.1158/1535-7163.mct-21-0615","title":"RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors","year":2021,"lang":"en","type":"letter","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Saint-Laurent; Telesta Therapeutics (Canada); Aegera Therapeutics (Canada)","funders":"","keywords":"Kinase; Olaparib; Pharmacology; In vivo; DNA damage; PARP inhibitor; PI3K/AKT/mTOR pathway; Cancer research; Chemistry; Biology; Biochemistry; Signal transduction; DNA; Poly ADP ribose polymerase","score_opus":0.04383461660618057,"score_gpt":0.33004020380099386,"score_spread":0.28620558719481326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200504528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5880611,0.03883379,0.0033460413,0.36205402,0.0005297603,0.006372121,0.00019034334,0.0001313403,0.00048146353],"genre_scores_gemma":[0.5149267,0.0075756903,0.0007239834,0.4737989,0.0006095039,0.0016561494,0.00014925198,0.00030798506,0.000251859],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99599147,0.000413838,0.0006679162,0.0014040584,0.00085383316,0.00066887465],"domain_scores_gemma":[0.9983562,0.00027759743,0.0003897884,0.0005396734,0.00029762535,0.00013909127],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00034101613,0.0008206949,0.0012934541,0.000553044,0.00007606114,0.000109395565,0.00013910647,0.001266112,0.000025863761],"category_scores_gemma":[0.000014534016,0.00076759333,0.00017462358,0.0007625483,0.00037454147,0.0002025493,0.000072858435,0.002669179,0.0000019024999],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05595026,0.010254471,0.19154719,0.009518212,0.026592784,0.019801343,0.07007995,0.0034530659,0.23848769,0.0006323247,0.079713084,0.29396963],"study_design_scores_gemma":[0.15246643,0.0122785615,0.021742446,0.025592288,0.0039602877,0.0018147395,0.0013224886,0.014919832,0.49817568,0.016321143,0.2433088,0.008097304],"about_ca_topic_score_codex":0.0005584962,"about_ca_topic_score_gemma":0.0002389486,"teacher_disagreement_score":0.2858723,"about_ca_system_score_codex":0.001018439,"about_ca_system_score_gemma":0.00067172974,"threshold_uncertainty_score":0.9996317},"labels":[],"label_agreement":null},{"id":"W4200516710","doi":"10.1158/1535-7163.targ-21-p061","title":"Abstract P061: <i>De novo</i> design of importin-<i>a</i>-specific NLS sequences for nuclear-targeted therapeutics","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Nuclear Structure and Function","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"NLS; Nuclear localization sequence; Importin; Nuclear transport; In silico; Computational biology; Amino acid; Chemistry; Biology; Biochemistry; Cell biology; Cell nucleus; Gene","score_opus":0.029122613546647753,"score_gpt":0.2737225353320046,"score_spread":0.24459992178535683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200516710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8702986,0.027790602,0.09868013,0.00087366824,0.00085114257,0.00067261944,0.00016442737,0.00006144906,0.00060731504],"genre_scores_gemma":[0.9822074,0.00400981,0.009325743,0.003879527,0.00023191879,0.000028860239,0.00010246868,0.00010527219,0.00010895845],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985894,0.00007476679,0.00035390642,0.00041856163,0.00019542532,0.00036797093],"domain_scores_gemma":[0.9989406,0.000021136928,0.00021334471,0.0004746679,0.00028229062,0.000067970315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017928686,0.00024450757,0.00024849197,0.00003431824,0.00010520326,0.0000450074,0.00023501574,0.00026451336,0.00009101347],"category_scores_gemma":[0.000010107196,0.00024302026,0.0002170788,0.00015759085,0.00011350476,0.000006835694,0.000046027795,0.00013869416,0.000002557707],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003044916,0.000066380926,0.00018814356,0.00004159144,0.00035650525,0.000013698619,0.00013299994,0.0009724541,0.98241234,0.00029482163,0.00025517313,0.014961404],"study_design_scores_gemma":[0.0006595176,0.00022479573,0.00052979984,0.00001953259,0.000117390795,0.000028708859,0.00012601128,0.00016954055,0.82545626,0.000659971,0.17173636,0.00027211284],"about_ca_topic_score_codex":0.000007893709,"about_ca_topic_score_gemma":0.000005374299,"teacher_disagreement_score":0.17148119,"about_ca_system_score_codex":0.00003995588,"about_ca_system_score_gemma":0.00023374688,"threshold_uncertainty_score":0.9910078},"labels":[],"label_agreement":null},{"id":"W4200523372","doi":"10.1158/1535-7163.targ-21-p246","title":"Abstract P246: Discovery and characterization of selective, FGFR1 sparing, inhibitors of FGFR2/3 oncogenic mutations for the treatment of cancers","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Street Contxt (Canada)","funders":"","keywords":"Cancer research; Allosteric regulation; Mutation; Fibroblast growth factor receptor 1; Gene; Cancer; Biology; Drug discovery; Genetics; Bioinformatics; Fibroblast growth factor; Receptor","score_opus":0.02203547535401564,"score_gpt":0.3028328847848733,"score_spread":0.2807974094308577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200523372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991781,0.0042470573,0.003165321,0.00009868978,0.0000740767,0.00035681084,0.00025151207,0.0000022055476,0.000023321274],"genre_scores_gemma":[0.9959972,0.0034814712,0.0001327306,0.000033455366,0.000041751795,0.00008029567,0.00012986116,0.000025024467,0.000078206554],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992302,0.00003610652,0.00023667853,0.0002052874,0.00014431115,0.00014743538],"domain_scores_gemma":[0.9992785,0.000035727484,0.0001768699,0.00023526212,0.0002475031,0.000026138856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000052471245,0.00012022135,0.00017815785,0.000035549227,0.00004116068,0.000010992291,0.00008290442,0.0000799113,0.0000052205137],"category_scores_gemma":[0.000011321743,0.00009808715,0.00012322949,0.0001414056,0.00014757813,0.000006703879,0.000026485672,0.00003938783,5.8503797e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015426605,0.000100092875,0.004805201,0.00009363271,0.0005290704,6.6510165e-7,0.00024666818,0.00040604325,0.9868722,0.00004071983,0.0000028199772,0.006748605],"study_design_scores_gemma":[0.0006216679,0.00042317272,0.021339599,0.00003092856,0.00011448013,0.0000013118002,0.00007457249,0.00013098479,0.9748759,0.000025286234,0.002276715,0.00008532961],"about_ca_topic_score_codex":0.00016050135,"about_ca_topic_score_gemma":0.0001367534,"teacher_disagreement_score":0.0165344,"about_ca_system_score_codex":0.000061619205,"about_ca_system_score_gemma":0.0004003406,"threshold_uncertainty_score":0.3999878},"labels":[],"label_agreement":null},{"id":"W4200525569","doi":"10.1158/1535-7163.targ-21-lba013","title":"Abstract LBA013: Phosphoproteomics reveals active drug targets on pathways of resistance and predicts response to midostaurin plus chemotherapy in FLT3 mutant-positive acute myeloid leukemia","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Drug resistance; Oncology; Midostaurin; Population; Medicine; Cancer; Internal medicine; Cancer research; Biology; Pharmacology; Genetics","score_opus":0.015226976321128209,"score_gpt":0.28659163156104833,"score_spread":0.27136465523992015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200525569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855879,0.0043311617,0.00029343786,0.007050743,0.00009807488,0.0016203438,0.0005012476,0.000056551617,0.00046053017],"genre_scores_gemma":[0.98658574,0.0039193523,0.0023238228,0.005993456,0.00006815469,0.00019622828,0.00004972529,0.00013890308,0.0007246439],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996713,0.00029648584,0.00059499167,0.0008547763,0.0008220636,0.0007186746],"domain_scores_gemma":[0.99787974,0.00028263582,0.0002214631,0.0008168402,0.00048117986,0.00031813557],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00061341946,0.00045995705,0.00083194446,0.0002819542,0.00008810781,0.00003798006,0.00026933866,0.00027705287,0.000054937536],"category_scores_gemma":[0.00013245341,0.00045918758,0.00015692593,0.00082728284,0.00020719554,0.00008948207,0.0001338978,0.00084459176,0.000007812199],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035215147,0.00017475893,0.00028820467,0.00016920682,0.000757695,0.0020410826,0.0057536433,0.00018571292,0.94763553,0.000074493575,0.00023684106,0.0074676936],"study_design_scores_gemma":[0.0067895297,0.00039478904,0.040788904,0.00092628994,0.00014082826,0.00003579519,0.0005915492,0.00021584108,0.9475115,0.0002291526,0.001990504,0.00038530643],"about_ca_topic_score_codex":0.00017186737,"about_ca_topic_score_gemma":0.00013806099,"teacher_disagreement_score":0.040500697,"about_ca_system_score_codex":0.0032181295,"about_ca_system_score_gemma":0.002658689,"threshold_uncertainty_score":0.99978596},"labels":[],"label_agreement":null},{"id":"W4200541805","doi":"10.1158/1535-7163.targ-21-p229","title":"Abstract P229: Pre-clinical evaluation of next-generation inhibitor targeting a wide spectrum of oncogenic BRAF dimers","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Computational Drug Discovery Methods","field":"Computer Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stornoway Diamond (Canada)","funders":"","keywords":"Cancer research; Mutation; Allosteric regulation; Mutant; Oncogene; In vivo; HEK 293 cells; V600E; Biology; Cancer; Chemistry; Computational biology; Cell culture; Gene; Genetics; Cell cycle; Receptor","score_opus":0.12276256465408687,"score_gpt":0.40031708090822754,"score_spread":0.2775545162541407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200541805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7349879,0.004727807,0.25841853,0.0007785385,0.0007297961,0.00020924867,0.00000568016,0.000020597105,0.00012191607],"genre_scores_gemma":[0.96316487,0.00017698747,0.03588019,0.00057062437,0.00013856623,0.000018540959,0.000021039143,0.00001884344,0.00001037181],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99694854,0.00070265564,0.00072712183,0.00043075738,0.0009928176,0.00019807996],"domain_scores_gemma":[0.99818957,0.00027645062,0.00042323058,0.0004625554,0.0005911882,0.00005703407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018750463,0.00015545562,0.000282017,0.00007585133,0.000046201578,0.00006131172,0.0003612026,0.000095065916,0.00005048572],"category_scores_gemma":[0.00019045218,0.00016694322,0.00021858976,0.0004921542,0.000068009045,0.00026687066,0.00014009402,0.00017769716,0.0000022046513],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023870582,0.0002281392,0.00097476505,0.000037376798,0.0003026646,0.000008459565,0.0006112873,0.18367378,0.65265137,0.001529636,0.00005718336,0.15990144],"study_design_scores_gemma":[0.00056351477,0.00005821359,0.0071939477,0.000042210584,0.00011381926,0.000002175281,0.000022158421,0.45532498,0.5323589,0.0038094153,0.00035359207,0.00015706499],"about_ca_topic_score_codex":0.000045835804,"about_ca_topic_score_gemma":0.00003540876,"teacher_disagreement_score":0.2716512,"about_ca_system_score_codex":0.00013681743,"about_ca_system_score_gemma":0.001258882,"threshold_uncertainty_score":0.6807747},"labels":[],"label_agreement":null},{"id":"W4200563501","doi":"10.1158/1535-7163.targ-21-lba021","title":"Abstract LBA021: Immune resistance interrogation study (IRIS): Initial report of next generation sequencing (NGS) results in patients with primary versus acquired resistance to anti-PD1/L1 antibodies","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Antibody; Cancer; Biopsy; Liquid biopsy; Internal medicine; Oncology; Pathology; Immunology","score_opus":0.03779555001429525,"score_gpt":0.29310929680525416,"score_spread":0.2553137467909589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200563501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944992,0.0029343455,0.00072593597,0.0002142097,0.0004229388,0.0005348322,0.00013939016,0.000009951264,0.0005192149],"genre_scores_gemma":[0.99660623,0.00035827133,0.0016543359,0.0003449255,0.00012444881,0.0000523177,0.0007035385,0.00005056834,0.00010536362],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99789643,0.0000916313,0.00070919504,0.0006392923,0.0003704888,0.00029294894],"domain_scores_gemma":[0.9982372,0.000026557165,0.00037565705,0.00073118333,0.0005674231,0.00006195873],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025490872,0.00026148127,0.0003432079,0.000083805106,0.00007792796,0.000064199136,0.00019596881,0.00012862617,0.0000049450277],"category_scores_gemma":[0.00007663615,0.0002799404,0.000079755984,0.00031545418,0.000069837246,0.000019558705,0.000118916876,0.00010455628,7.6063446e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044311676,0.00037243674,0.0085809175,0.000070691036,0.000325331,0.00024438085,0.00083088176,0.0022711891,0.98157364,0.000016281361,0.000109993955,0.0011730922],"study_design_scores_gemma":[0.007254789,0.0007155958,0.16830315,0.0002534238,0.00015923323,0.000002986966,0.00079532136,0.000028551483,0.8177558,0.000014620455,0.0041140383,0.00060245336],"about_ca_topic_score_codex":0.0001266019,"about_ca_topic_score_gemma":0.0037849888,"teacher_disagreement_score":0.16381781,"about_ca_system_score_codex":0.00031380323,"about_ca_system_score_gemma":0.0007514017,"threshold_uncertainty_score":0.99996525},"labels":[],"label_agreement":null},{"id":"W4200592628","doi":"10.1158/1535-7163.targ-21-p062","title":"Abstract P062: The CL2A-SN38 linker-payload system conjugated to trastuzumab results in improved cellular cytotoxicity over time relative to T-DM1","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Linker; Cytotoxicity; Chemistry; Conjugate; Trastuzumab; Conjugated system; Antibody-drug conjugate; Internalization; Prodrug; Endosome; Cancer cell; Biophysics; Combinatorial chemistry; Biochemistry; Monoclonal antibody; Cancer; In vitro; Antibody; Biology; Intracellular; Cell","score_opus":0.03613944612334209,"score_gpt":0.33726379957734026,"score_spread":0.3011243534539982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200592628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97085804,0.003392355,0.0019091427,0.015001409,0.00043299684,0.00338002,0.00038174944,0.00017619657,0.004468105],"genre_scores_gemma":[0.98976445,0.00013099816,0.00049872854,0.00738805,0.00022100846,0.00036107903,0.000060605842,0.00013826959,0.0014368381],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99575293,0.00039886124,0.0008671614,0.000967906,0.0010629378,0.00095019204],"domain_scores_gemma":[0.9972752,0.00022253687,0.00015883101,0.0013374271,0.000558812,0.00044722078],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00083406497,0.00046060665,0.00072018884,0.00020894877,0.00014456184,0.00011473592,0.0004690175,0.000345786,0.00023844665],"category_scores_gemma":[0.00018725355,0.00037516418,0.00023623618,0.001462406,0.000120465455,0.00007480767,0.00020943763,0.0011628036,0.00027423436],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001614352,0.00020244764,0.00036169883,0.00018820797,0.00047361932,0.0010761678,0.0024600194,0.0006396246,0.9871453,0.00010469342,0.0005199067,0.005213941],"study_design_scores_gemma":[0.0056000976,0.00079334684,0.016587993,0.0013282446,0.00027194273,0.00004300064,0.00063811726,0.005520478,0.9278391,0.000059392063,0.040587462,0.00073084806],"about_ca_topic_score_codex":0.001092164,"about_ca_topic_score_gemma":0.00041366986,"teacher_disagreement_score":0.05930624,"about_ca_system_score_codex":0.0020848156,"about_ca_system_score_gemma":0.0013136828,"threshold_uncertainty_score":0.99987},"labels":[],"label_agreement":null},{"id":"W4200594151","doi":"10.1158/1535-7163.targ-21-p251","title":"Abstract P251: Discovery and characterization of RLY-2608: The first allosteric, mutant, and isoform-selective inhibitor of PI3Kα","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Paraza Pharma (Canada)","funders":"","keywords":"Allosteric regulation; PI3K/AKT/mTOR pathway; Mutant; Gene isoform; Kinase; Protein kinase B; P110α; Protein kinase domain; Small molecule; Chemistry; Phosphoinositide 3-kinase; Pharmacology; Biochemistry; Biology; Phosphorylation; Enzyme; Signal transduction; Gene","score_opus":0.01830301609038135,"score_gpt":0.28625230891469156,"score_spread":0.2679492928243102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200594151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99428415,0.0034861153,0.00036730364,0.0012188917,0.00006495824,0.0003304279,0.00004356685,0.00000765322,0.00019692851],"genre_scores_gemma":[0.995927,0.0030647304,0.00004325411,0.0007512737,0.00005317104,0.00002251384,0.000021045795,0.000028625756,0.0000884327],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989504,0.000032940003,0.00026263978,0.0002266525,0.0003289133,0.00019842183],"domain_scores_gemma":[0.9992531,0.000067952904,0.00013367043,0.00028660902,0.00021002942,0.000048634483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011410661,0.00013769537,0.00027975216,0.000046178295,0.00005117825,0.000028035762,0.0000694632,0.000087999215,0.000020516018],"category_scores_gemma":[0.000019426232,0.00010110224,0.00005872191,0.00023435276,0.00023823912,0.000093025184,0.00009076457,0.00014812416,4.606558e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029513787,0.00008601677,0.0020429443,0.00041445464,0.0003443586,0.000051687774,0.0011253465,0.0000052154255,0.9877458,0.00009768742,0.000004856612,0.0077864714],"study_design_scores_gemma":[0.0038504675,0.00019733877,0.04898389,0.00027230603,0.00021031935,0.00009268783,0.0001638187,0.0010302782,0.9431531,0.00008130939,0.0018411295,0.00012338728],"about_ca_topic_score_codex":0.0001550422,"about_ca_topic_score_gemma":0.000053003227,"teacher_disagreement_score":0.046940945,"about_ca_system_score_codex":0.00062737544,"about_ca_system_score_gemma":0.001451195,"threshold_uncertainty_score":0.41228297},"labels":[],"label_agreement":null},{"id":"W4210445101","doi":"10.1158/1535-7163.mct-21-0216","title":"Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype","year":2022,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"National Cancer Institute; National Institutes of Health; Leukemia and Lymphoma Society","keywords":"EZH2; Phenotype; Histone methyltransferase; Chromatin remodeling; Chromatin; Acquired resistance; Drug resistance; Immune system","score_opus":0.025262360970294405,"score_gpt":0.28925851494496996,"score_spread":0.2639961539746756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210445101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875507,0.006778406,0.0041015693,0.00060185546,0.0002965936,0.00042912876,0.00006426902,0.000014194449,0.00016330802],"genre_scores_gemma":[0.997715,0.00016720984,0.00041487123,0.0007765911,0.00017360569,0.00014028515,0.00016922886,0.000049927814,0.0003933104],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985895,0.00021126926,0.00028687873,0.00036253087,0.00032454362,0.00022523254],"domain_scores_gemma":[0.9990552,0.00000858035,0.00018048131,0.00053710304,0.00015809023,0.000060542192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021394223,0.00018367422,0.00015949819,0.000048384645,0.00025301822,0.000031063988,0.00036234775,0.00008062289,0.00003258668],"category_scores_gemma":[0.0000070466563,0.00016214835,0.00009771893,0.00019883137,0.000057026482,0.0000043163677,0.0001717623,0.00008819465,8.644687e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010875756,0.00016835512,0.00079310464,0.000025336774,0.000059503913,8.827103e-7,0.00066009513,0.00091030856,0.99525905,0.00008513907,0.000055438002,0.0018740201],"study_design_scores_gemma":[0.00046707905,0.00052941334,0.001961977,0.000007748143,0.00006989066,1.7789358e-7,0.00014312475,0.0001276434,0.97359025,0.00046508203,0.022421682,0.00021592084],"about_ca_topic_score_codex":0.000039859293,"about_ca_topic_score_gemma":0.0001213895,"teacher_disagreement_score":0.022366244,"about_ca_system_score_codex":0.000039248498,"about_ca_system_score_gemma":0.000080427475,"threshold_uncertainty_score":0.6612218},"labels":[],"label_agreement":null},{"id":"W4220863628","doi":"10.1158/1535-7163.mct-21-0550","title":"Proteolytic pan-RAS Cleavage Leads to Tumor Regression in Patient-derived Pancreatic Cancer Xenografts","year":2022,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"Canadian Institutes of Health Research; Robert H. Lurie Comprehensive Cancer Center; Hospital for Sick Children; National Cancer Institute; Frederick National Laboratory for Cancer Research","keywords":"KRAS; Pancreatic cancer; Cancer research; In vivo; Cancer; MAPK/ERK pathway; Cell growth; Biology; Medicine; Internal medicine; Signal transduction; Colorectal cancer","score_opus":0.03958382700937004,"score_gpt":0.355408717971385,"score_spread":0.315824890962015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220863628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98581564,0.0055915467,0.00020742028,0.004921778,0.00025499443,0.0023764614,0.000040753635,0.00006691529,0.00072447717],"genre_scores_gemma":[0.9847019,0.00043724486,0.00070406974,0.009924749,0.00008614695,0.0034686856,0.000019742316,0.000085492815,0.00057202164],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970141,0.00038275722,0.0004700286,0.0005414515,0.0008454096,0.0007462593],"domain_scores_gemma":[0.9988701,0.00006987978,0.00014089841,0.0005696522,0.000109763896,0.00023974893],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031292724,0.00030984462,0.00071011594,0.00031124716,0.00023177061,0.00002177358,0.00026566462,0.00009142207,0.00069521676],"category_scores_gemma":[0.000043129876,0.0002695002,0.00013021626,0.00084713893,0.00012012444,0.000042016363,0.0002477008,0.00069937744,0.00002559654],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020180556,0.0006757054,0.23043653,0.00022366366,0.00037126022,0.0016773199,0.0037101547,0.00030743988,0.72116566,0.00006272382,0.0007460083,0.03860546],"study_design_scores_gemma":[0.019355496,0.011134825,0.2855109,0.002424828,0.002536447,0.00048933737,0.0048083803,0.0066147707,0.5578402,0.0007082613,0.1062234,0.0023531034],"about_ca_topic_score_codex":0.0011585818,"about_ca_topic_score_gemma":0.00020904724,"teacher_disagreement_score":0.16332541,"about_ca_system_score_codex":0.0010508519,"about_ca_system_score_gemma":0.0008551073,"threshold_uncertainty_score":0.99997574},"labels":[],"label_agreement":null},{"id":"W4225531330","doi":"10.1158/1535-7163.mct-21-0442","title":"Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes","year":2022,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK; Wellcome Trust; National Institute on Handicapped Research","keywords":"Medicine; Drug; KRAS; Combination therapy; Targeted therapy; EGFR inhibitors; Pharmacology; Oncology; Computational biology; Cancer research; Cancer; Internal medicine; Biology; Epidermal growth factor receptor; Colorectal cancer","score_opus":0.04739014557391607,"score_gpt":0.32061531870945986,"score_spread":0.2732251731355438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225531330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98722506,0.00974721,0.001738862,0.00038458055,0.00018683923,0.000403296,0.00030621953,0.0000034437132,0.000004474825],"genre_scores_gemma":[0.99318457,0.005677279,0.00058708165,0.00030580285,0.000026967262,0.00011984559,0.00006835442,0.000020131412,0.000009982639],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99897116,0.00018684963,0.0002915603,0.00021979581,0.00020006797,0.00013056498],"domain_scores_gemma":[0.99944615,0.000037297832,0.00020304113,0.00016349756,0.00013046109,0.000019536594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045182282,0.00012281413,0.00019912333,0.00011509766,0.0000800255,0.000008865462,0.00010978944,0.000051098636,0.000012499955],"category_scores_gemma":[0.000018987468,0.00013430048,0.000047826074,0.00019453862,0.000117083546,0.0000036878491,0.000117026044,0.000084272484,3.7351274e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022835215,0.00012853132,0.0012066787,0.000015896405,0.00036571108,0.0000022951351,0.0011174716,0.0034265956,0.9839098,0.00060802314,0.000006516047,0.0069289734],"study_design_scores_gemma":[0.0008853316,0.00064301776,0.0012664263,0.000019781133,0.00008132185,0.0000037788848,0.00070429617,0.0017986043,0.9915966,0.0024053105,0.00046806742,0.00012750579],"about_ca_topic_score_codex":0.000085438995,"about_ca_topic_score_gemma":0.000045255427,"teacher_disagreement_score":0.0076867724,"about_ca_system_score_codex":0.00008251242,"about_ca_system_score_gemma":0.00020112682,"threshold_uncertainty_score":0.5476615},"labels":[],"label_agreement":null},{"id":"W4232401843","doi":"10.1158/1535-7163.targ-09-a9","title":"Abstract A9: Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Pazopanib; Topotecan; Ovarian cancer; Medicine; Pharmacology; Paclitaxel; Chemotherapy; Ovarian carcinoma; Cancer; Bevacizumab; Oncology; Cancer research; Internal medicine; Sunitinib","score_opus":0.03545390850934368,"score_gpt":0.3495010082494963,"score_spread":0.31404709974015266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232401843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9633308,0.019902276,0.0004578764,0.013490497,0.00015420686,0.0023594634,0.00023031433,0.000020742369,0.000053821823],"genre_scores_gemma":[0.99387217,0.0044121724,0.0002927911,0.0008325763,0.00011310936,0.0003448193,0.000023296176,0.000046990153,0.00006207385],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985054,0.000057349127,0.00043691127,0.000342914,0.00028822065,0.00036921876],"domain_scores_gemma":[0.99849254,0.0001724377,0.00032786428,0.0007310784,0.00017125171,0.00010484469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017264085,0.00033700556,0.0006503973,0.00005904455,0.000095759184,0.000022440488,0.00020995422,0.000083961335,0.00010701013],"category_scores_gemma":[0.0000032780354,0.00016257708,0.00074210035,0.00022606636,0.00017070913,0.00003000218,0.000010967908,0.000109143715,8.7885576e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020900363,0.010294785,0.04999933,0.00018674678,0.031620797,0.00007676674,0.0031680122,0.015521766,0.03857106,0.00071078335,0.00063699577,0.8283126],"study_design_scores_gemma":[0.020688862,0.01335834,0.83312565,0.0002808201,0.007784127,0.000010034085,0.00018939182,0.0015127098,0.1183001,0.00019163512,0.0041420134,0.00041628684],"about_ca_topic_score_codex":0.0022602396,"about_ca_topic_score_gemma":0.00052368344,"teacher_disagreement_score":0.8278963,"about_ca_system_score_codex":0.00062494655,"about_ca_system_score_gemma":0.0007116965,"threshold_uncertainty_score":0.6629701},"labels":[],"label_agreement":null},{"id":"W4282930398","doi":"10.1158/1535-7163.mct-21-0984","title":"Discovery and Characterization of a Novel Aryl Hydrocarbon Receptor Inhibitor, IK-175, and Its Inhibitory Activity on Tumor Immune Suppression","year":2022,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"Immune system; Aryl hydrocarbon receptor; Proinflammatory cytokine; Biology; Tumor microenvironment; Cancer research; Cytokine; Pharmacology; Chemistry; Immunology; Transcription factor; Inflammation; Biochemistry","score_opus":0.0140388904798786,"score_gpt":0.24125740306119572,"score_spread":0.22721851258131712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282930398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98449,0.012865951,0.0001086156,0.0003217751,0.0015476259,0.00038445517,0.00021890567,0.000029227249,0.000033469092],"genre_scores_gemma":[0.9979076,0.0009370378,0.000010404073,0.00055638654,0.000034118093,0.00012831857,0.000097550066,0.00004865303,0.00027998225],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988098,0.00017008322,0.0002663697,0.000383168,0.0001080717,0.00026248617],"domain_scores_gemma":[0.99932945,0.00005790143,0.00027843766,0.00027807988,0.00004044902,0.000015697204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016685332,0.00023768723,0.0003215536,0.000085790394,0.000219083,0.000016667585,0.00014952726,0.00012396785,0.00007952593],"category_scores_gemma":[0.000007979348,0.0002388696,0.00006571558,0.00014860283,0.00015325194,0.00012862669,0.00028231431,0.0005048369,0.0000020104337],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010475246,0.00026513523,0.00022555034,0.00005830827,0.00016675664,0.0000027541296,0.0006207843,0.000027103939,0.9929908,0.00007648352,0.000012302561,0.0045064874],"study_design_scores_gemma":[0.0017755975,0.0003560795,0.003279595,0.00009644605,0.00007305848,0.000015871738,0.00008242729,0.00009414101,0.9860097,0.000008667365,0.007957845,0.00025052746],"about_ca_topic_score_codex":0.000031206557,"about_ca_topic_score_gemma":0.0000013621474,"teacher_disagreement_score":0.013417575,"about_ca_system_score_codex":0.00015071694,"about_ca_system_score_gemma":0.00009974368,"threshold_uncertainty_score":0.974082},"labels":[],"label_agreement":null},{"id":"W4283329314","doi":"10.1158/1535-7163.mct-22-0037","title":"Inhibition of the Translation Initiation Factor eIF4A Enhances Tumor Cell Radiosensitivity","year":2022,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA and protein synthesis mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"National Center for Advancing Translational Sciences; National Institute of General Medical Sciences; National Institutes of Health","keywords":"Radiosensitivity; Radioresistance; Polysome; Initiation factor; Clonogenic assay; Biology; Translational efficiency; Protein biosynthesis; Cancer research; Cell culture; Gene knockdown; eIF4A; Molecular biology; Translation (biology); Cell biology; Messenger RNA; Medicine; RNA; Radiation therapy; Ribosome; Gene; Biochemistry; Genetics; Internal medicine","score_opus":0.021699739588702433,"score_gpt":0.2512214470314223,"score_spread":0.22952170744271985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283329314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868,0.001922751,0.009983129,0.00027157716,0.0002445474,0.00031874215,0.0001067664,0.000008340031,0.0003441354],"genre_scores_gemma":[0.99842715,0.00011416241,0.0002400672,0.0009728715,0.000052050706,0.00008625443,0.000029972349,0.000022959981,0.00005451928],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99894345,0.00029345334,0.00016996643,0.00020300587,0.00025506312,0.00013503539],"domain_scores_gemma":[0.9994987,0.000010790208,0.00016741024,0.00025393255,0.00004934671,0.000019794403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014057817,0.000116925155,0.0001060134,0.000026194464,0.00015477196,0.0000097039665,0.00012668186,0.00004946467,0.000069598354],"category_scores_gemma":[0.00000439109,0.00010337604,0.00012510453,0.00012777645,0.00004107358,0.0000042567476,0.00005191289,0.00009232874,6.6761845e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063307816,0.000047605092,0.00014787422,0.00001622795,0.000031464147,0.0000013047617,0.0001984487,0.00040536938,0.99098444,0.00003492916,0.000008478882,0.008060535],"study_design_scores_gemma":[0.00029761225,0.00012887263,0.0003829451,0.000007397424,0.000037330086,0.000003515822,0.00006472206,0.00008907355,0.99315155,0.00025192558,0.0054576625,0.00012737139],"about_ca_topic_score_codex":0.000020583942,"about_ca_topic_score_gemma":0.000014675336,"teacher_disagreement_score":0.01162713,"about_ca_system_score_codex":0.000029623696,"about_ca_system_score_gemma":0.00009675266,"threshold_uncertainty_score":0.42155528},"labels":[],"label_agreement":null},{"id":"W4289950574","doi":"10.1158/1535-7163.1.4.1","title":"Induction of caspase-dependent, p53-mediated apoptosis by apigenin in human neuroblastoma","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children","funders":"National Cancer Institute; Hospital for Sick Children","keywords":"Apigenin; Apoptosis; Programmed cell death; Neuroblastoma; Caspase; Cancer research; Biology; Caspase 3; Cell culture; Pharmacology; Flavonoid; Chemistry; Molecular biology; Biochemistry; Genetics","score_opus":0.012731329094541836,"score_gpt":0.2625937425773251,"score_spread":0.24986241348278326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289950574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99319905,0.002058781,0.0039862217,0.0002619779,0.000118438336,0.00020286923,0.00002944579,0.000013554714,0.00012965042],"genre_scores_gemma":[0.9981747,0.0005843933,0.00016897699,0.00046934042,0.00009144109,0.000032369528,0.00013971307,0.000041888085,0.00029717665],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989586,0.00007023616,0.0002712804,0.00030111533,0.00018020453,0.00021858202],"domain_scores_gemma":[0.9994958,0.0000034454147,0.00012682992,0.00026387683,0.000063188956,0.000046841087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009816899,0.0001667416,0.00015147383,0.000075289776,0.000042722124,0.000011715306,0.00013571634,0.00020552466,0.000037238664],"category_scores_gemma":[0.0000036352992,0.00017277211,0.00007629945,0.00014898644,0.00004697382,0.0000055079727,0.000043047385,0.000108680004,0.000002457365],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041348587,0.00010134887,0.00016709833,0.000009439518,0.000054103242,0.0000011050709,0.000059790018,0.0012744073,0.9846132,0.000054682914,0.00009959794,0.013523894],"study_design_scores_gemma":[0.00074906996,0.00016899925,0.00034341423,0.000011870002,0.000032469514,0.0000030717333,0.000025707144,0.0004244287,0.98869985,0.000040444458,0.009317622,0.00018306472],"about_ca_topic_score_codex":0.00012131459,"about_ca_topic_score_gemma":0.00016636225,"teacher_disagreement_score":0.01334083,"about_ca_system_score_codex":0.000042848107,"about_ca_system_score_gemma":0.000041712578,"threshold_uncertainty_score":0.7045442},"labels":[],"label_agreement":null},{"id":"W4293022944","doi":"10.1158/1535-7163.23.4.1","title":"(−)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-XL-mediated apoptosis resistance","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institutes of Health; University of Pittsburgh; U.S. Department of Defense","keywords":"Gossypol; Jurkat cells; Apoptosis; Mitochondrion; Transfection; Biology; Bcl-xL; Programmed cell death; Etoposide; Cytochrome c; Cell biology; Molecular biology; Cell culture; Biochemistry; T cell; Immunology","score_opus":0.013904997928625488,"score_gpt":0.2572712026939176,"score_spread":0.24336620476529214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293022944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96428126,0.011807696,0.005315,0.014764021,0.0004815076,0.00094779825,0.00007065538,0.000052443404,0.002279617],"genre_scores_gemma":[0.9835807,0.002463538,0.0010399995,0.009887593,0.0002935438,0.000111519184,0.00003771065,0.000057516798,0.0025278411],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998687,0.000088815876,0.00020157076,0.00044257712,0.00025210984,0.0003278809],"domain_scores_gemma":[0.999185,0.000027198748,0.00008151818,0.00051011663,0.00007903159,0.000117112155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001325155,0.00025059617,0.00016625076,0.000049193703,0.00015751882,0.00006163388,0.00021382915,0.00018105659,0.000040930667],"category_scores_gemma":[0.000021363345,0.00018907618,0.00009044524,0.00017014529,0.000060308525,0.000005008801,0.00007696608,0.00012513198,0.000017423965],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015125443,0.0000448938,0.000034263106,0.000010027328,0.00011282825,0.0000012728985,0.00013631748,0.0002520427,0.98405707,0.00068265764,0.0007705971,0.013746768],"study_design_scores_gemma":[0.00037861452,0.000107468346,0.0004886726,0.0000296357,0.000041627365,0.000001273384,0.000021532469,0.0001577623,0.59179956,0.000109004926,0.40663603,0.00022883834],"about_ca_topic_score_codex":0.000019410392,"about_ca_topic_score_gemma":0.00015033613,"teacher_disagreement_score":0.40586543,"about_ca_system_score_codex":0.00005253407,"about_ca_system_score_gemma":0.000052596813,"threshold_uncertainty_score":0.7710303},"labels":[],"label_agreement":null},{"id":"W4296078948","doi":"10.1158/1535-7163.mct-21-0875","title":"BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors","year":2022,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Antibody-drug conjugate; Cancer research; Pharmacology; Conjugate; Clinical trial; Cancer; Antibody; Oncology; Internal medicine; Immunology; Monoclonal antibody","score_opus":0.03166265876332708,"score_gpt":0.327637395701249,"score_spread":0.2959747369379219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296078948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907168,0.002141791,0.003322859,0.0026655076,0.000053632983,0.00051962846,0.00023334876,0.00004988654,0.00029650543],"genre_scores_gemma":[0.99510574,0.00007559968,0.00061661546,0.003108854,0.00006564564,0.0003072512,0.000076630015,0.00003533166,0.0006083035],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99902594,0.0000523146,0.00027126004,0.00020959532,0.00022219322,0.000218691],"domain_scores_gemma":[0.99949527,0.000026163778,0.00013480862,0.00019433418,0.00008355475,0.00006588164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000093112096,0.00013637458,0.00034162818,0.00010109389,0.00013426098,0.0000060863154,0.000055268993,0.000026921352,0.00038519944],"category_scores_gemma":[0.0000063862494,0.00012570247,0.00028899586,0.00023816095,0.00003831696,0.000013975461,0.000021305153,0.000053291635,0.0000017901864],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003039243,0.0004256836,0.00065082277,0.00004750085,0.000567469,0.000047988724,0.00068888965,0.0015295978,0.9863149,0.00009886157,0.00014175901,0.0091826115],"study_design_scores_gemma":[0.0036301923,0.0014344972,0.00021135029,0.00006687027,0.00056667154,0.000018772562,0.00085864105,0.0083224755,0.9365467,0.00025018418,0.0478849,0.00020878718],"about_ca_topic_score_codex":0.00008936075,"about_ca_topic_score_gemma":0.000008059062,"teacher_disagreement_score":0.04976823,"about_ca_system_score_codex":0.000226332,"about_ca_system_score_gemma":0.00014156885,"threshold_uncertainty_score":0.51259977},"labels":[],"label_agreement":null},{"id":"W4296465570","doi":"10.1158/1535-7163.1207.3.10","title":"Topoisomerase-IIα expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel","year":2004,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Docetaxel; Doxorubicin; Confidence interval; Medicine; Odds ratio; Internal medicine; Breast cancer; Chemotherapy; Cancer; Oncology; Paclitaxel; Population; Topoisomerase; Pharmacology; Chemistry; In vitro","score_opus":0.019418069999127794,"score_gpt":0.3001555046830174,"score_spread":0.28073743468388956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296465570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939775,0.0024538776,0.00016525677,0.0008922627,0.00021333183,0.0018569971,0.00015376367,0.000054527223,0.00023249038],"genre_scores_gemma":[0.99673605,0.00060535053,0.00019413975,0.0013562423,0.00006445635,0.0004955508,0.000116265845,0.00008909245,0.00034285238],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99794745,0.00010456292,0.0005022432,0.0005081253,0.0005029804,0.00043465555],"domain_scores_gemma":[0.9989579,0.00003479987,0.00031843715,0.000294318,0.0002474297,0.00014717084],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00006986235,0.00041687058,0.0006449184,0.00021956326,0.000060095415,0.00001515544,0.000104887935,0.0001594207,0.0003998186],"category_scores_gemma":[0.000005848038,0.00029185982,0.00013776921,0.0005317049,0.00009875077,0.000121652556,0.000032288193,0.0002041249,0.000002812733],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07660706,0.004980081,0.21221253,0.00018101076,0.0011390854,0.00021405914,0.0019727862,0.0047382275,0.67202115,0.000006966478,0.00002533828,0.02590166],"study_design_scores_gemma":[0.08291593,0.006813283,0.28151152,0.0021097336,0.0018276224,0.000051961622,0.00019845058,0.0001696161,0.62237173,0.00008755595,0.0012795319,0.0006630839],"about_ca_topic_score_codex":0.002205747,"about_ca_topic_score_gemma":0.0009463462,"teacher_disagreement_score":0.069298975,"about_ca_system_score_codex":0.0013351002,"about_ca_system_score_gemma":0.0002536693,"threshold_uncertainty_score":0.9999533},"labels":[],"label_agreement":null},{"id":"W4302027542","doi":"10.1158/1535-7163.mct-22-0004","title":"NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition","year":2022,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Oncode Institute; Janet D. Cottrelle Foundation; BC Cancer Foundation; China Scholarship Council; Ovarian Cancer Canada; VGH and UBC Hospital Foundation","keywords":"Trametinib; MEK inhibitor; Cancer research; KRAS; Gene knockdown; Selumetinib; Synthetic lethality; MAPK/ERK pathway; Medicine; Downregulation and upregulation; Ovarian cancer; Serous fluid; Cell culture; Biology; Cancer; Internal medicine; Mutant; Gene; Signal transduction; Genetics; Colorectal cancer","score_opus":0.03380773318638299,"score_gpt":0.30289646492390804,"score_spread":0.26908873173752507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4302027542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9669748,0.0035791406,0.00089364307,0.026924718,0.00036128628,0.0009773071,0.0001266855,0.000040439558,0.00012196068],"genre_scores_gemma":[0.98280734,0.00019209499,0.00042058696,0.015591743,0.00008462465,0.0007052892,0.00001777235,0.00005843678,0.00012209652],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99816996,0.000274267,0.00030720924,0.00034011752,0.000594528,0.00031392573],"domain_scores_gemma":[0.99903643,0.00010416655,0.00013654135,0.0004951389,0.00011548405,0.00011225904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039036834,0.00020563367,0.0002988667,0.00011633999,0.00022176983,0.000020427866,0.00014484374,0.000049603088,0.00024886653],"category_scores_gemma":[0.000011964272,0.00016679012,0.00016442516,0.0006132202,0.000056626046,0.00002439483,0.000069707814,0.0002486124,0.0000043887267],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00447791,0.00048700845,0.0019409267,0.00008980441,0.0011311768,0.0003333817,0.0051817438,0.029596314,0.94081473,0.0005143597,0.00050459424,0.014928062],"study_design_scores_gemma":[0.0037672033,0.0016359984,0.007848971,0.0002359748,0.0008357655,0.00005454577,0.0009994004,0.00046247753,0.9477003,0.00019370217,0.035925854,0.00033976865],"about_ca_topic_score_codex":0.0005864534,"about_ca_topic_score_gemma":0.000061129525,"teacher_disagreement_score":0.03542126,"about_ca_system_score_codex":0.0010548658,"about_ca_system_score_gemma":0.0006485788,"threshold_uncertainty_score":0.6801504},"labels":[],"label_agreement":null},{"id":"W4313857431","doi":"10.1158/1535-7163.mct-22-0159","title":"Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Research Nova Scotia; Canadian Institutes of Health Research; Li Ka Shing Foundation","keywords":"TMPRSS2; Prostate cancer; Erg; Cancer; Prostate; Medicine; Biology; Cancer research; Ophthalmology; Internal medicine; Coronavirus disease 2019 (COVID-19); Retinal; Disease","score_opus":0.03742462221571558,"score_gpt":0.35936550688908914,"score_spread":0.32194088467337356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313857431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94725406,0.00826857,0.00008456783,0.04087819,0.00042277793,0.0020227332,0.00021328162,0.00021228917,0.00064350193],"genre_scores_gemma":[0.97284853,0.009890891,0.000049223458,0.0084522115,0.00020343064,0.0012719443,0.000075666976,0.00010792729,0.007100192],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976349,0.00010779017,0.00025134248,0.0004983527,0.00072044303,0.0007872119],"domain_scores_gemma":[0.99877506,0.000094454066,0.0000735189,0.0005449884,0.00025852764,0.0002534385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020584789,0.00032551578,0.00034439465,0.00018899422,0.0002859145,0.000074058444,0.00025513416,0.00010766539,0.00020509379],"category_scores_gemma":[0.000016161423,0.00020786794,0.00017469127,0.0012785137,0.00014907675,0.00006991121,0.00017461296,0.00037747223,0.0001462931],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027749396,0.00028718825,0.041181836,0.00022198676,0.0027986222,0.0012417235,0.008762604,0.0014390203,0.78221405,0.00037124965,0.005359789,0.153347],"study_design_scores_gemma":[0.004015409,0.00079995533,0.068222195,0.000590082,0.00063497084,0.000028911587,0.00085321715,0.001122148,0.79848105,0.00071843393,0.12383389,0.00069973717],"about_ca_topic_score_codex":0.0007184405,"about_ca_topic_score_gemma":0.00013455101,"teacher_disagreement_score":0.15264727,"about_ca_system_score_codex":0.0003912543,"about_ca_system_score_gemma":0.00054113625,"threshold_uncertainty_score":0.84766084},"labels":[],"label_agreement":null},{"id":"W4318754916","doi":"10.1158/1535-7163.mct-22-0092","title":"Inhibition of the MNK1/2–eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer","year":2022,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont; University of Toronto; University Health Network; McGill University; Jewish General Hospital","funders":"Warren Y. Soper Charitable Trust; Fonds de Recherche du Québec - Santé; Fondation De Famille Alvin Segal; Jewish General Hospital; Canadian Institutes of Health Research; Cancer Research Society; Genome Canada; Faculty of Medicine, McGill University; McGill University","keywords":"Palbociclib; Cancer research; EIF4E; Clonogenic assay; Melanoma; Cancer; Survivin; Medicine; Downregulation and upregulation; Cell cycle; Breast cancer; Pharmacology; Biology; Cell; Translation (biology); Internal medicine; Messenger RNA; Metastatic breast cancer; Biochemistry","score_opus":0.0161072384513956,"score_gpt":0.28223943783779337,"score_spread":0.26613219938639776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318754916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98938763,0.005090491,0.00014116756,0.0039626453,0.00025089202,0.0006408972,0.00041816098,0.000032417232,0.00007570543],"genre_scores_gemma":[0.9962716,0.000523852,0.000057914396,0.0026108902,0.0000452057,0.000326265,0.000012686463,0.000056161854,0.00009542338],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99833226,0.00017284571,0.00027588152,0.00035748494,0.0005300393,0.00033149496],"domain_scores_gemma":[0.9992031,0.000031443153,0.00022397572,0.0003866735,0.00008537856,0.00006944235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015657373,0.00023220025,0.0003718808,0.00012026616,0.00013800731,0.000010400913,0.00014287382,0.000064953696,0.00027786684],"category_scores_gemma":[0.000005053443,0.00019418853,0.00010369093,0.0006329353,0.00019657976,0.00008378643,0.00018102555,0.00041366852,7.746919e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012564949,0.00031697535,0.1730133,0.00012870328,0.00032573933,0.000052560845,0.0010532427,0.0005447749,0.7707724,0.000056973215,0.000010904906,0.05246794],"study_design_scores_gemma":[0.007594282,0.00027509528,0.7422545,0.00031847812,0.00031575424,0.00015678638,0.00048811873,0.0009428002,0.24073619,0.00042697423,0.006033678,0.00045733128],"about_ca_topic_score_codex":0.0008740801,"about_ca_topic_score_gemma":0.00020623808,"teacher_disagreement_score":0.5692412,"about_ca_system_score_codex":0.00053224363,"about_ca_system_score_gemma":0.0002917324,"threshold_uncertainty_score":0.79187787},"labels":[],"label_agreement":null},{"id":"W4320486696","doi":"10.1158/1535-7163.mct-22-0583","title":"A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Cancer Institute, University of Pittsburgh; Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute; University of Texas MD Anderson Cancer Center; Pfizer; Yale Cancer Center; Merck KGaA; Princess Margaret Cancer Foundation; Johns Hopkins University; Dana-Farber/Harvard Cancer Center; AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company; Regeneron Pharmaceuticals; California Space Grant Consortium","keywords":"Olaparib; Medicine; Prostate cancer; Internal medicine; Oncology; Radium-223; Cancer; Adverse effect; Urology; Bone metastasis","score_opus":0.047131900191674674,"score_gpt":0.35707104660009653,"score_spread":0.30993914640842185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320486696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99199307,0.0036998743,0.00030270868,0.0014295783,0.000038161863,0.0022293646,0.00015330498,0.00007125553,0.00008265637],"genre_scores_gemma":[0.9969482,0.0010003697,0.0003400525,0.00041651158,0.000016548864,0.0010095594,0.00006582576,0.00007689388,0.00012608375],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997835,0.00019254943,0.00049228244,0.00044927985,0.0006759643,0.00035491664],"domain_scores_gemma":[0.9989492,0.000062502164,0.00028444943,0.00035765563,0.00023481523,0.00011135317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031005434,0.00031434992,0.00061212137,0.00035332356,0.00008014023,0.000036762565,0.00008225703,0.000044908815,0.000036103986],"category_scores_gemma":[0.0000045742454,0.00024470902,0.000041624382,0.0012208351,0.0001805748,0.0001269743,0.000021247011,0.00022034271,0.0000010757985],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027523374,0.013462672,0.037682947,0.0012565348,0.006427654,0.0024822475,0.029333066,0.005162602,0.8345515,0.00067445484,0.00023118457,0.04121173],"study_design_scores_gemma":[0.34908846,0.038577076,0.058554705,0.0027744356,0.006944751,0.00024564136,0.024437418,0.016215647,0.49555036,0.00094636116,0.0044247694,0.002240392],"about_ca_topic_score_codex":0.0013182816,"about_ca_topic_score_gemma":0.0014761483,"teacher_disagreement_score":0.33900118,"about_ca_system_score_codex":0.00023411441,"about_ca_system_score_gemma":0.00039509404,"threshold_uncertainty_score":0.99789447},"labels":[],"label_agreement":null},{"id":"W4366083752","doi":"10.1158/1535-7163.mct-22-0676","title":"Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Macrophage Migration Inhibitory Factor","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Bundesministerium für Digitalisierung und Wirtschaftsstandort; Bundesministerium für Verkehr, Innovation und Technologie; Österreichische Forschungsförderungsgesellschaft","keywords":"Macrophage migration inhibitory factor; Monoclonal antibody; Macrophage; Cancer research; Inhibitory postsynaptic potential; Pharmacology; Chemistry; Biology; Immunology; Antibody; In vitro; Biochemistry; Cytokine; Neuroscience","score_opus":0.06691227969315192,"score_gpt":0.3560835251783305,"score_spread":0.2891712454851786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366083752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862561,0.007998631,0.0022894365,0.00038169432,0.0015866882,0.0009467057,0.00023586072,0.00025407525,0.000050764735],"genre_scores_gemma":[0.9979209,0.00032220528,0.00019622843,0.00055376504,0.00011425836,0.00021978695,0.00036081465,0.000088919965,0.00022312622],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996994,0.0006987974,0.0007934444,0.00060802675,0.00039006464,0.0005156402],"domain_scores_gemma":[0.99824965,0.00015519426,0.00037810806,0.0005621197,0.00059607445,0.00005886091],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00092697947,0.00038076637,0.00045791865,0.00026276792,0.00016165507,0.0000389754,0.00032755942,0.0004676131,0.0016217093],"category_scores_gemma":[0.00010817677,0.00036432114,0.00022701964,0.0005760359,0.00023553259,0.00017445027,0.00006349575,0.0004059215,0.00017248782],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002502301,0.00022282502,0.0005463936,0.000041319025,0.0004819509,0.0000032339744,0.001686408,0.00094363163,0.98540723,0.00020761565,0.00012319454,0.010085944],"study_design_scores_gemma":[0.003754187,0.0003055758,0.0029522637,0.000055613404,0.00039935284,0.0000052838964,0.00035753628,0.007012032,0.9792707,0.00028174891,0.0051834397,0.00042224786],"about_ca_topic_score_codex":0.0001837605,"about_ca_topic_score_gemma":0.0000766874,"teacher_disagreement_score":0.011664752,"about_ca_system_score_codex":0.00020440455,"about_ca_system_score_gemma":0.00046317192,"threshold_uncertainty_score":0.99988085},"labels":[],"label_agreement":null},{"id":"W4368361249","doi":"10.1158/1535-7163.mct-22-0237","title":"Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Androgen receptor; Transactivation; Prostate cancer; Enzalutamide; Cancer research; Androgen; Chemistry; Transcription factor; Biology; Cell biology; Cancer; Endocrinology; Gene; Genetics; Biochemistry; Hormone","score_opus":0.0386941703284861,"score_gpt":0.33365179603329276,"score_spread":0.29495762570480666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4368361249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816803,0.009467356,0.0003957363,0.0057954057,0.00024980077,0.0018211498,0.0004709498,0.000052498915,0.00006682861],"genre_scores_gemma":[0.9915415,0.0028574842,0.0006608567,0.0006764211,0.00027009536,0.0016015527,0.00024536424,0.0000926823,0.0020540182],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983707,0.00007476814,0.00034388225,0.0003335355,0.00038980713,0.00048728072],"domain_scores_gemma":[0.9991746,0.000069730966,0.0001472331,0.0002898253,0.00024374637,0.0000748541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029719033,0.00022233224,0.0003013603,0.00009860847,0.00018268713,0.0000573596,0.0001527392,0.000084871295,0.000021511341],"category_scores_gemma":[0.00001459077,0.00014692561,0.00020012814,0.00049919536,0.00018540991,0.000062155596,0.000054407956,0.00016701859,0.0000038194344],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018711975,0.00008894777,0.0019902154,0.00035743098,0.0005999216,0.00007911877,0.0014503397,0.000068341375,0.9876775,0.00013664251,0.0006167588,0.005063567],"study_design_scores_gemma":[0.0034453236,0.00060531945,0.0006818479,0.00032193708,0.00034459136,0.000006443259,0.00094487437,0.0005040013,0.97876745,0.00028716962,0.0138452565,0.00024576052],"about_ca_topic_score_codex":0.00017597376,"about_ca_topic_score_gemma":0.00007421999,"teacher_disagreement_score":0.013228498,"about_ca_system_score_codex":0.0002018982,"about_ca_system_score_gemma":0.0006705265,"threshold_uncertainty_score":0.59914523},"labels":[],"label_agreement":null},{"id":"W4381715051","doi":"10.1158/1535-7163.mct-23-0041","title":"A Carbonic Anhydrase IX/SLC1A5 Axis Regulates Glutamine Metabolism Dependent Ferroptosis in Hypoxic Tumor Cells","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Juravinski Cancer Centre; BC Children's Hospital; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Glutamine; GPX4; Lipid peroxidation; Glutathione; Biochemistry; Metabolism; Homeostasis; Chemistry; Cell biology; Glutathione peroxidase; Biology; Enzyme; Amino acid","score_opus":0.014710784035728829,"score_gpt":0.2607522654575003,"score_spread":0.24604148142177146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381715051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.955575,0.040982712,0.00019113248,0.0004379885,0.0017960267,0.0005212225,0.00017061539,0.00008721947,0.00023811372],"genre_scores_gemma":[0.9826345,0.0123494,0.00021771519,0.0021975315,0.00084943516,0.0002928542,0.00014920697,0.00015507721,0.0011543181],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99706125,0.00018444657,0.0004962109,0.00088829506,0.00045457185,0.00091520866],"domain_scores_gemma":[0.9985772,0.000017627748,0.0001668091,0.0009220344,0.00012108393,0.00019527014],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032322126,0.0005085341,0.00053291133,0.0002795043,0.00010423104,0.0000659622,0.00050537824,0.00026927172,0.000048174745],"category_scores_gemma":[0.000020644571,0.0005148325,0.00029963374,0.00079216814,0.00014185914,0.00001121187,0.00024041653,0.00027488687,0.000036709836],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015332906,0.000099255136,0.00032889316,0.00004161226,0.0002637207,0.000042546322,0.00019217386,0.0022464828,0.9873248,0.000046553534,0.00048139595,0.008779253],"study_design_scores_gemma":[0.0016853381,0.00009033777,0.002586089,0.000032087868,0.00020133278,0.000014799592,0.00011724078,0.0005560095,0.8250108,0.00017941966,0.16893238,0.0005942026],"about_ca_topic_score_codex":0.0004951146,"about_ca_topic_score_gemma":0.00066590676,"teacher_disagreement_score":0.16845098,"about_ca_system_score_codex":0.000094391944,"about_ca_system_score_gemma":0.00031607857,"threshold_uncertainty_score":0.99973035},"labels":[],"label_agreement":null},{"id":"W4385196540","doi":"10.1158/1535-7163.mct-23-0196","title":"A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Division of Chemistry; National Cancer Institute; National Science Foundation; National Institutes of Health; School of Medicine, New York University; KU Leuven; New York State Department of Health","keywords":"Enzalutamide; Androgen receptor; Prostate cancer; Cancer research; Chemistry; Cancer; Biology; Cell biology; Genetics","score_opus":0.05644194386507937,"score_gpt":0.3467204731395425,"score_spread":0.2902785292744631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385196540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.967693,0.012276008,0.00008001751,0.016643561,0.0003140189,0.0020671927,0.0005616866,0.00023932052,0.0001252289],"genre_scores_gemma":[0.97376335,0.017718446,0.00013807388,0.0021281296,0.00015008159,0.0014497255,0.00012129726,0.00012440557,0.0044064787],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99739254,0.00011177872,0.0002848665,0.00064502825,0.0007808912,0.0007849111],"domain_scores_gemma":[0.99886405,0.000031784137,0.000075905984,0.000398123,0.0002915409,0.00033862007],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021641083,0.00039073805,0.00044610663,0.00024824933,0.000200912,0.000064634885,0.00016590406,0.00013836741,0.000384637],"category_scores_gemma":[0.000006406534,0.00031007585,0.00023964002,0.00087065157,0.00014425644,0.00009039865,0.000058238234,0.00031082446,0.00010175601],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004497935,0.0002517337,0.0038552945,0.00011658951,0.00094829337,0.00010230076,0.0017425845,0.0004382093,0.9342128,0.000028865892,0.00043171976,0.053373694],"study_design_scores_gemma":[0.005792536,0.0007249111,0.01519942,0.00029049476,0.0001532947,0.000004350311,0.00013491132,0.0009399322,0.87957895,0.00012489443,0.09660816,0.00044811913],"about_ca_topic_score_codex":0.00041365033,"about_ca_topic_score_gemma":0.00006800079,"teacher_disagreement_score":0.09617644,"about_ca_system_score_codex":0.00052408164,"about_ca_system_score_gemma":0.0005267996,"threshold_uncertainty_score":0.99993515},"labels":[],"label_agreement":null},{"id":"W4385217389","doi":"10.1158/1535-7163.mct-23-0065","title":"First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pharmacyclics; EMD Serono; Adaptive Biotechnologies; GlaxoSmithKline; Exelixis; Genentech; AstraZeneca; Taiho Pharmaceutical; Pfizer","keywords":"Medicine; Internal medicine; Nausea; Adverse effect; Anemia; Gastroenterology; Mucositis; Neutropenia; Combination therapy; Refractory (planetary science); Pharmacokinetics; Olaparib; Cancer; Diarrhea; Toxicity; Pharmacology","score_opus":0.012174103357139603,"score_gpt":0.249141873966883,"score_spread":0.2369677706097434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385217389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983287,0.00036078301,0.000052841904,0.00004189926,0.00003412172,0.0011174361,0.00001990287,0.000011688258,0.000032629854],"genre_scores_gemma":[0.9994721,0.00004107964,0.00008545069,0.00007018939,0.0000163418,0.00017537652,0.000039057075,0.0000494161,0.000051033974],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984354,0.00013683148,0.0004662834,0.00040721873,0.00027441845,0.00027989835],"domain_scores_gemma":[0.999226,0.0000068365393,0.00022883521,0.00038150832,0.00010189769,0.00005495155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019234896,0.00022609974,0.00031468985,0.00020876905,0.000041227962,0.000011001282,0.00018087956,0.00012925036,0.0000037129332],"category_scores_gemma":[0.00001485123,0.00020733668,0.000048200407,0.00041240762,0.000109093104,0.0000072560315,0.00011755517,0.000089996014,4.645682e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059807114,0.0014557446,0.09864867,0.00013473397,0.00013926464,0.000034626755,0.00071283156,0.0003211971,0.8962984,0.00003964488,0.000009799211,0.0016070378],"study_design_scores_gemma":[0.008023286,0.0032600635,0.111780405,0.0003032574,0.00003333148,8.9712455e-7,0.00040606956,0.00013404283,0.8754146,0.000051610008,0.00023612542,0.0003562839],"about_ca_topic_score_codex":0.00024094294,"about_ca_topic_score_gemma":0.0006404526,"teacher_disagreement_score":0.020883752,"about_ca_system_score_codex":0.000047539863,"about_ca_system_score_gemma":0.00010133212,"threshold_uncertainty_score":0.84549445},"labels":[],"label_agreement":null},{"id":"W4387475515","doi":"10.1158/1535-7163.mct-23-0158","title":"Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada","keywords":"Tumor microenvironment; Cancer research; Extracellular matrix; Flow cytometry; Biomarker; Chemistry; Pathology; Cancer; Medicine; Immunology; Internal medicine; Biochemistry; Tumor cells","score_opus":0.019380802925599804,"score_gpt":0.2850677300030378,"score_spread":0.265686927077438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387475515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.894975,0.015306469,0.08939411,0.00005865187,0.000058588834,0.00014099559,0.000044778353,0.000015617905,0.0000057762477],"genre_scores_gemma":[0.9967091,0.0011339309,0.0015972521,0.00024200915,0.00004174193,0.000021704944,0.00018320221,0.00004943325,0.00002163692],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99860764,0.000098926175,0.00032435084,0.000439408,0.0002384995,0.00029117413],"domain_scores_gemma":[0.9993626,0.0000071379177,0.00017073801,0.00033080508,0.00007102578,0.000057721412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024742167,0.00021804818,0.0002476124,0.00013019683,0.00013885599,0.000030468555,0.00012556466,0.000090211244,0.000010797594],"category_scores_gemma":[0.000004033282,0.00021792935,0.00019569347,0.00031306257,0.0001056888,0.000009653383,0.00013473166,0.00005711563,6.1090145e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003091303,0.000022721004,0.010339381,0.00004121016,0.0005860482,0.000002517446,0.00022050315,0.014421206,0.963215,0.0000010708712,0.0000138257865,0.011105622],"study_design_scores_gemma":[0.00032841126,0.00001931269,0.0015553363,0.000033539665,0.00045290854,0.000001969536,0.00015051127,0.2605974,0.73485,0.000015894799,0.0017644279,0.00023027054],"about_ca_topic_score_codex":0.00026836898,"about_ca_topic_score_gemma":0.000014094605,"teacher_disagreement_score":0.2461762,"about_ca_system_score_codex":0.00004676241,"about_ca_system_score_gemma":0.000043802167,"threshold_uncertainty_score":0.8886901},"labels":[],"label_agreement":null},{"id":"W4388510152","doi":"10.1158/1535-7163.mct-23-0102","title":"Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Work & Health; University of Toronto","funders":"Merck KGaA","keywords":"Biology; Cancer research; Angiogenesis; Cell growth; Cancer; Clear cell renal cell carcinoma; Renal cell carcinoma; Internal medicine; Biochemistry; Medicine; Genetics","score_opus":0.025521641462663426,"score_gpt":0.26833662115125356,"score_spread":0.24281497968859014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388510152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98740107,0.00045000782,0.007249015,0.0030905143,0.00008443027,0.00061803433,0.00020213802,0.0002003177,0.00070444786],"genre_scores_gemma":[0.9907651,0.00006304633,0.003323438,0.0039952667,0.00023921978,0.0001723537,0.00014625466,0.00014125991,0.0011540514],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99689025,0.00009052393,0.0007101327,0.00069818425,0.0009893939,0.0006214997],"domain_scores_gemma":[0.99800557,0.000054295633,0.00028311842,0.00059577555,0.00063954876,0.00042170184],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029627865,0.00049013813,0.00078062824,0.00073399197,0.0001224144,0.00004148336,0.00020579874,0.00016441598,0.00012719475],"category_scores_gemma":[0.00002344577,0.0004091253,0.00035085317,0.002320731,0.00018920413,0.00013721274,0.00012693317,0.0003949473,0.00006221604],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005328908,0.0003414547,0.00049665925,0.0002676836,0.00028335716,0.00016479706,0.0007677625,0.0023585288,0.9927174,0.00022258952,0.0012010304,0.00064583984],"study_design_scores_gemma":[0.003118889,0.0007897958,0.0003136162,0.0009245128,0.0005006443,0.000023945582,0.00035705703,0.0028129714,0.9893145,0.000061771454,0.0012756663,0.0005066067],"about_ca_topic_score_codex":0.0002839996,"about_ca_topic_score_gemma":0.000041323536,"teacher_disagreement_score":0.003925577,"about_ca_system_score_codex":0.00021755024,"about_ca_system_score_gemma":0.00038936708,"threshold_uncertainty_score":0.9998361},"labels":[],"label_agreement":null},{"id":"W4389081332","doi":"10.1158/1535-7163.mct-23-0460","title":"Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (<i>IDH1/2</i>) Mutant Cholangiocarcinoma","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Trinity College; Princess Margaret Cancer Centre","funders":"","keywords":"Isocitrate dehydrogenase; IDH1; Biomarker; Glioma; Cancer research; Internal medicine; Biology; Chemistry; Mutant; Medicine; Biochemistry; Enzyme; Gene","score_opus":0.045130157489544055,"score_gpt":0.3297217594717431,"score_spread":0.284591601982199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389081332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745759,0.017521635,0.0016725084,0.0032115278,0.0006380766,0.0012416678,0.00015764764,0.00036706874,0.0006139706],"genre_scores_gemma":[0.9907016,0.0010047778,0.00033566667,0.0063894754,0.00035516784,0.0005077942,0.00014573036,0.00016678187,0.00039298524],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971954,0.00007831203,0.00050994987,0.00072337425,0.00054915115,0.0009437939],"domain_scores_gemma":[0.99865985,0.000055655266,0.00018005776,0.00058537006,0.00026741024,0.0002516536],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030852365,0.0004833299,0.00066782587,0.00030993568,0.00031972156,0.000092634145,0.00021813861,0.00019665876,0.00006075436],"category_scores_gemma":[0.00002560241,0.00045174803,0.00067343446,0.001053045,0.00014212947,0.00009585675,0.000108730426,0.00026486343,0.00008581797],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056411244,0.000112293565,0.008219248,0.0002294381,0.0022690631,0.0012406155,0.0011063534,0.00036827166,0.9673699,0.00021832761,0.00029824776,0.018004129],"study_design_scores_gemma":[0.025570916,0.0014155995,0.13618927,0.00063976547,0.007474374,0.0012416509,0.0018050504,0.06841519,0.65103966,0.004420698,0.09853283,0.003255003],"about_ca_topic_score_codex":0.00019209247,"about_ca_topic_score_gemma":0.000019688354,"teacher_disagreement_score":0.31633025,"about_ca_system_score_codex":0.00021010163,"about_ca_system_score_gemma":0.00033509752,"threshold_uncertainty_score":0.9997934},"labels":[],"label_agreement":null},{"id":"W4389227449","doi":"10.1158/1535-7163.targ-23-ia003","title":"Abstract IA003: Refining our understanding of ADCs: Drug development insights from 40 years of data","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Magic bullet; Medicine; Drug; Linker; Pharmacology; Computational biology; Computer science; Bioinformatics; Biology","score_opus":0.2877227097958665,"score_gpt":0.4243710880456244,"score_spread":0.1366483782497579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901151,0.0060378374,0.001004832,0.0010538124,0.00030373674,0.0002818237,0.00015466507,0.00007999422,0.0009681894],"genre_scores_gemma":[0.99611074,0.0010395864,0.0020377047,0.00032662915,0.00006870446,0.000018322968,0.00018003969,0.00006732268,0.00015097561],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978875,0.000056757966,0.0004606581,0.00039372267,0.0008814063,0.0003199467],"domain_scores_gemma":[0.99863225,0.00008544927,0.00016821783,0.00090014224,0.00010894522,0.000105021296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035020342,0.00016000734,0.00038012085,0.00022678205,0.000044500564,0.000014412632,0.00047130464,0.00010224007,0.00006129438],"category_scores_gemma":[0.0000309809,0.0001611246,0.00006273716,0.0006178939,0.000089951915,0.00006886126,0.0002597878,0.00029848222,0.000023588023],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079683185,0.00027693703,0.00760868,0.0010927368,0.0028696163,0.00063340703,0.014717038,0.00056809647,0.7672162,0.00050473225,0.0024973452,0.20121835],"study_design_scores_gemma":[0.0066019096,0.00029489884,0.090419516,0.0050244993,0.00072446954,0.000007740806,0.01782934,0.0032368156,0.67577326,0.0020866033,0.19686203,0.0011389337],"about_ca_topic_score_codex":0.0005395096,"about_ca_topic_score_gemma":0.00021377477,"teacher_disagreement_score":0.20007941,"about_ca_system_score_codex":0.00037884028,"about_ca_system_score_gemma":0.0009457488,"threshold_uncertainty_score":0.65704703},"labels":[],"label_agreement":null},{"id":"W4389227464","doi":"10.1158/1535-7163.targ-23-lb_c11","title":"Abstract LB_C11: Small-molecule bifunctional inhibitors of PARP1/2 and HDAC enzymes","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Olaparib; PARP1; PARP inhibitor; Histone deacetylase; Pharmacology; Cancer research; Vorinostat; DNA repair; Poly ADP ribose polymerase; Synthetic lethality; Biology; Polymerase; Histone; Enzyme; Biochemistry; DNA","score_opus":0.04751386002510425,"score_gpt":0.32016666766537677,"score_spread":0.2726528076402725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790444,0.012965931,0.00052118243,0.003801733,0.0005451713,0.0004824463,0.00008206317,0.00022092147,0.002336202],"genre_scores_gemma":[0.99264586,0.0031482747,0.00028443633,0.0030786952,0.00021456047,0.000118932934,0.00005279587,0.0000776737,0.00037877765],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983774,0.00004231707,0.00040232434,0.00037290255,0.0004558841,0.00034921212],"domain_scores_gemma":[0.99909604,0.00006807457,0.00016158067,0.000352116,0.00018279217,0.00013940119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002049687,0.000249881,0.00035706288,0.00024224816,0.00007695151,0.0000205277,0.000097443015,0.0001615184,0.00024887692],"category_scores_gemma":[0.000013162466,0.0002396492,0.00015943157,0.00059862185,0.0002264282,0.00004701098,0.000045700253,0.00024413964,0.000026871254],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047175953,0.00016412616,0.009820237,0.0003737069,0.0007656203,0.00011728171,0.00050725683,0.00023716014,0.9655184,0.0011131923,0.001976562,0.018934676],"study_design_scores_gemma":[0.00287213,0.00028219813,0.02252742,0.0003107371,0.00022773094,0.00003370326,0.00017238868,0.0003519129,0.9294434,0.0008804642,0.04254176,0.0003561087],"about_ca_topic_score_codex":0.00007114948,"about_ca_topic_score_gemma":0.000011444447,"teacher_disagreement_score":0.0405652,"about_ca_system_score_codex":0.00010447814,"about_ca_system_score_gemma":0.00024832235,"threshold_uncertainty_score":0.9772611},"labels":[],"label_agreement":null},{"id":"W4389227549","doi":"10.1158/1535-7163.targ-23-c163","title":"Abstract C163: KRAS alterations combined with TP53 mutations as novel synthetic lethal genomic lesions for PKMYT1 inhibition","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aegera Therapeutics (Canada)","funders":"","keywords":"KRAS; Cyclin-dependent kinase 1; Cancer research; Biology; Cell cycle; Cell growth; Mutation; Mutant; Kinase; Molecular biology; Cancer; Genetics; Gene","score_opus":0.040011646229417434,"score_gpt":0.30921393146085024,"score_spread":0.2692022852314328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92674136,0.0009095419,0.06011181,0.0074021616,0.00042524133,0.0024923666,0.00040212114,0.00043190652,0.0010834761],"genre_scores_gemma":[0.99332106,0.00017978388,0.002042958,0.00212184,0.00011805213,0.0009466258,0.0007167021,0.00017567666,0.0003773079],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981125,0.000033004188,0.00039988002,0.00052622985,0.00042190394,0.0005065043],"domain_scores_gemma":[0.99870056,0.00010007738,0.00015918483,0.00055017177,0.00030596578,0.00018404974],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001581086,0.00033190497,0.00035303077,0.00030627326,0.00031726956,0.00006787665,0.0001151175,0.00019701124,0.00010344914],"category_scores_gemma":[0.000033169355,0.0003196892,0.00023143677,0.000672358,0.0001596806,0.000074007105,0.000035502708,0.00033782658,0.00010217794],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044359703,0.0002594022,0.00004312875,0.000108328255,0.00057422346,0.00012722454,0.00059589295,0.010010092,0.9819118,0.0022514255,0.00020151529,0.0034733948],"study_design_scores_gemma":[0.019461539,0.0031346527,0.008269174,0.0013554565,0.0039349957,0.0005254133,0.0008636789,0.020667564,0.8998316,0.0034745813,0.03675716,0.0017242132],"about_ca_topic_score_codex":0.00010872532,"about_ca_topic_score_gemma":0.000119253535,"teacher_disagreement_score":0.08208021,"about_ca_system_score_codex":0.0003660095,"about_ca_system_score_gemma":0.00076107285,"threshold_uncertainty_score":0.9999255},"labels":[],"label_agreement":null},{"id":"W4389227554","doi":"10.1158/1535-7163.targ-23-b154","title":"Abstract B154: Safety and preliminary activity of the selective ALK inhibitor NVL-655 in patients with ALK fusion-positive solid tumors","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Anaplastic lymphoma kinase; Tolerability; ALK inhibitor; Crizotinib; Response Evaluation Criteria in Solid Tumors; Adverse effect; Internal medicine; Pharmacodynamics; Lung cancer; Refractory (planetary science); Pharmacokinetics; Oncology; Pharmacology; Clinical trial; Phases of clinical research","score_opus":0.008498528870247834,"score_gpt":0.28725035057182013,"score_spread":0.2787518217015723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969156,0.00032086528,0.00004796583,0.00088779145,0.000086744454,0.0009831453,0.00010943702,0.000024755287,0.00062370923],"genre_scores_gemma":[0.99916375,0.00013854867,0.000040361876,0.0004059058,0.000023298966,0.00006676995,0.00002893422,0.000034014258,0.00009843611],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898887,0.000048945923,0.0001825863,0.00025276744,0.00030585652,0.00022095533],"domain_scores_gemma":[0.99940085,0.0000482578,0.00013091984,0.00021813501,0.00014654949,0.0000553005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006363438,0.00017263199,0.0002604923,0.00008465532,0.00009414466,0.000008712988,0.000060457645,0.00006737513,0.000009667243],"category_scores_gemma":[0.0000074110835,0.00011337671,0.00005939919,0.00046572243,0.00010811694,0.000057548397,0.000050268573,0.00016974464,0.0000011049938],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012710176,0.002212358,0.72188014,0.0003906761,0.0031514594,0.0001821034,0.014209928,0.002404875,0.09106564,0.000107105225,0.00016297387,0.15152258],"study_design_scores_gemma":[0.0033135107,0.000644607,0.9394347,0.00034221727,0.00030992905,0.0000023159462,0.00014319921,0.00014873555,0.0553107,0.00004453898,0.00018187855,0.00012365292],"about_ca_topic_score_codex":0.00027387377,"about_ca_topic_score_gemma":0.00009555698,"teacher_disagreement_score":0.2175546,"about_ca_system_score_codex":0.000253849,"about_ca_system_score_gemma":0.00028811756,"threshold_uncertainty_score":0.4623368},"labels":[],"label_agreement":null},{"id":"W4389227555","doi":"10.1158/1535-7163.targ-23-b045","title":"Abstract B045: Ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in combination with low dose gemcitabine in patients with solid tumors with DNA damage response (DDR) aberrations: Preclinical and Phase 1b results","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Medicine; Gemcitabine; Internal medicine; Response Evaluation Criteria in Solid Tumors; Pharmacology; Oncology; Clinical trial; Cancer; Phases of clinical research; Adverse effect","score_opus":0.010640445084492668,"score_gpt":0.2818753531656338,"score_spread":0.2712349080811411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99735945,0.00091446086,0.000046881672,0.0005619843,0.000046762398,0.00079223304,0.0002325628,0.00002182559,0.000023808077],"genre_scores_gemma":[0.9982861,0.00047893735,0.0001493084,0.000304337,0.00002254751,0.00010035825,0.0005584643,0.00006224057,0.000037697086],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983003,0.000120638164,0.00043484246,0.00057156367,0.0002278607,0.00034480158],"domain_scores_gemma":[0.9990977,0.00008915804,0.00018756746,0.0003783806,0.0001310754,0.00011611611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003428194,0.00028868308,0.0002800823,0.00018681251,0.00007610298,0.00006354641,0.000112868474,0.00017567609,0.0000021877827],"category_scores_gemma":[0.000083360006,0.00024191968,0.000027307004,0.00046466925,0.00019448242,0.000018843954,0.00006928863,0.0002328868,0.0000010933646],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14978082,0.0059531345,0.2939898,0.00033674855,0.0009774194,0.0012871417,0.0029759808,0.010378667,0.5112316,0.000091387206,0.00041708144,0.022580177],"study_design_scores_gemma":[0.058818415,0.0060367244,0.8628885,0.0005378449,0.0001400596,0.000011984365,0.00023149296,0.0016432966,0.067394465,0.00006403373,0.0013611602,0.00087201275],"about_ca_topic_score_codex":0.00014979964,"about_ca_topic_score_gemma":0.0012248335,"teacher_disagreement_score":0.5688987,"about_ca_system_score_codex":0.000075317716,"about_ca_system_score_gemma":0.00033353188,"threshold_uncertainty_score":0.9865198},"labels":[],"label_agreement":null},{"id":"W4389227665","doi":"10.1158/1535-7163.targ-23-pr008","title":"Abstract PR008: MYTHIC: First-in-human (FIH) biomarker-driven phase I trial of PKMYT1 inhibitor lunresertib (lunre) alone and with ATR inhibitor camonsertib (cam) in solid tumors with <i>CCNE1</i> amplification or deleterious alterations in <i>FBXW7</i> or <i>PPP2R1A</i>","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Nausea; Internal medicine; Rash; Oncology; Gastroenterology; Adverse effect; Pharmacology","score_opus":0.028046193371300807,"score_gpt":0.31586548706828144,"score_spread":0.2878192936969806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961936,0.0008699643,0.0003994015,0.0006964075,0.00012883561,0.0014475582,0.00019452319,0.000024099463,0.00004562648],"genre_scores_gemma":[0.9961713,0.0017751266,0.0002937619,0.0006658717,0.00013280116,0.0005117391,0.00028310402,0.0001039488,0.00006237165],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99751943,0.00009599848,0.000798152,0.00072359457,0.00031187062,0.0005509522],"domain_scores_gemma":[0.9987675,0.00007505162,0.00030975664,0.00057315384,0.00014095812,0.00013359587],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026738615,0.00041745836,0.0005335577,0.0002867358,0.00010530807,0.00007996714,0.0002554226,0.00024208552,0.000009441017],"category_scores_gemma":[0.00003612762,0.00034328946,0.000073622265,0.00077765126,0.00023242336,0.000023476568,0.000105652216,0.00024953583,0.0000012911461],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044420328,0.0008774353,0.0063603097,0.0001869164,0.00016902384,0.00028810315,0.0007545863,0.0047719,0.9386413,0.000014247778,0.00020330411,0.003312526],"study_design_scores_gemma":[0.11822737,0.008805136,0.011817852,0.0013153512,0.00024438804,0.00007117826,0.0007029522,0.0028829768,0.8435844,0.00007615017,0.010447216,0.001824984],"about_ca_topic_score_codex":0.0010422933,"about_ca_topic_score_gemma":0.034216434,"teacher_disagreement_score":0.09505688,"about_ca_system_score_codex":0.00013593567,"about_ca_system_score_gemma":0.0005927672,"threshold_uncertainty_score":0.9999019},"labels":[],"label_agreement":null},{"id":"W4389227710","doi":"10.1158/1535-7163.targ-23-a123","title":"Abstract A123: Circulating tumor DNA (ctDNA) genomic and epigenomic profiling (GuardantINFINITY) for diagnosis of DNA damage repair (DDR) loss of function (LOF) and response monitoring in the TRESR and ATTACC trials","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; PALB2; Cancer research; Biology; CHEK2; BRCA2 Protein; Internal medicine; Oncology; Genetics; Medicine; Germline mutation; Mutation; Gene; Poly ADP ribose polymerase","score_opus":0.05445792351080183,"score_gpt":0.3262254619171759,"score_spread":0.2717675384063741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906072,0.007987318,0.00016893099,0.00016147744,0.00014480294,0.0007412928,0.00016653894,0.000011472994,0.000010988481],"genre_scores_gemma":[0.9951395,0.0040446394,0.0002992131,0.00013303455,0.00012542159,0.00018149511,0.000027304035,0.000044452696,0.000004950201],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998462,0.00019553908,0.00056434737,0.00038851445,0.00012541462,0.00026415254],"domain_scores_gemma":[0.9986609,0.0005642759,0.00033525558,0.0003147562,0.00007858617,0.000046197514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016651208,0.00020865657,0.00039425815,0.00013024287,0.000091719856,0.000037344787,0.000117334675,0.00011906099,0.0000012390791],"category_scores_gemma":[0.0002972708,0.0001913197,0.00013081628,0.00017228135,0.00013464731,0.000007464794,0.00010024211,0.00010178964,1.2231651e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009383056,0.00003260498,0.08755988,0.00020146927,0.00017967516,0.0000107961405,0.0003787584,0.00044881084,0.90618527,0.00006294637,0.000006250531,0.0039952407],"study_design_scores_gemma":[0.0019664124,0.00042943668,0.38066748,0.00012681496,0.00027624046,0.0000073806473,0.00068408455,0.00045531825,0.6134091,0.00032375174,0.001358368,0.00029560592],"about_ca_topic_score_codex":0.00008514244,"about_ca_topic_score_gemma":0.000046174875,"teacher_disagreement_score":0.2931076,"about_ca_system_score_codex":0.000031441265,"about_ca_system_score_gemma":0.00014454986,"threshold_uncertainty_score":0.7801791},"labels":[],"label_agreement":null},{"id":"W4389239758","doi":"10.1158/1535-7163.targ-23-b114","title":"Abstract B114: A Phase 1/1b study of KAZ954 alone and in combination with spartalizumab (PDR001) and taminadenant (NIR178) in patients with advanced gastrointestinal malignancies","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Biochemical and Molecular Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pharmacokinetics; Tolerability; Cmax; Pharmacology; Gastroenterology; Internal medicine; Dosing; Adverse effect","score_opus":0.014724666737021675,"score_gpt":0.28811517428666833,"score_spread":0.27339050754964667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389239758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99850637,0.00058142556,0.00014784028,0.00008175614,0.000009052034,0.00063225144,0.000018050929,0.000007827174,0.000015441045],"genre_scores_gemma":[0.9994117,0.00015707375,0.00015973576,0.00006107962,0.0000050128724,0.00009294896,0.000068355985,0.00003073759,0.000013377842],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99875873,0.000051253763,0.00021406438,0.00038840255,0.00027833303,0.00030918382],"domain_scores_gemma":[0.99951905,0.000009475219,0.000084152496,0.00021155378,0.00010975249,0.000066031214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011097892,0.00019165542,0.00021721341,0.00011861857,0.000029726805,0.000017769305,0.00010316629,0.00006077912,0.0000017988872],"category_scores_gemma":[0.000011396762,0.00015366454,0.000017576665,0.00030969508,0.00014631012,0.000007643533,0.0000849847,0.00013462185,2.5880615e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024149928,0.0021186837,0.2083006,0.00010707059,0.00008344284,0.00011477738,0.0002802449,0.00012956951,0.77529144,0.000008316893,0.0000036769761,0.011147164],"study_design_scores_gemma":[0.030429473,0.0073647695,0.64681464,0.0003291803,0.000051622512,0.000014975558,0.00063367747,0.00020353265,0.31354493,0.00003467395,0.00015818905,0.00042035052],"about_ca_topic_score_codex":0.00015055691,"about_ca_topic_score_gemma":0.0005003715,"teacher_disagreement_score":0.46174654,"about_ca_system_score_codex":0.000022857857,"about_ca_system_score_gemma":0.00006187374,"threshold_uncertainty_score":0.62662584},"labels":[],"label_agreement":null},{"id":"W4389239811","doi":"10.1158/1535-7163.targ-23-b020","title":"Abstract B020: <i>SF3B1 </i>hotspot mutations confer sensitivity to PARP inhibition through a defective replication stress response","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Synthetic lethality; Mutant; DNA repair; DNA damage; Cancer research; DNA replication; Transcriptome; Genetics; DNA; Gene; Gene expression","score_opus":0.06120906213030747,"score_gpt":0.3779009795185503,"score_spread":0.3166919173882428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389239811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9622239,0.00043131498,0.015436661,0.018316092,0.00025853657,0.00142394,0.00044487833,0.0005137256,0.00095097366],"genre_scores_gemma":[0.98250437,0.00030776666,0.00062362524,0.015055842,0.00016974875,0.00071995455,0.0002829772,0.0001075474,0.00022819711],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973926,0.00031522778,0.00043124607,0.00077004515,0.0005994079,0.0004914999],"domain_scores_gemma":[0.9978105,0.0003518977,0.00018231585,0.000959633,0.00051087484,0.00018477085],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00070069043,0.00032718352,0.00037570353,0.0002454906,0.00020815872,0.00005834188,0.00007932168,0.00020224118,0.00014047505],"category_scores_gemma":[0.00013702721,0.00034705346,0.00020088306,0.0012196257,0.00014940127,0.00015012955,0.00004494267,0.00035272934,0.00024918246],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002523163,0.0001837042,0.0010334371,0.000074596544,0.0003080404,0.0002603452,0.002796325,0.002431648,0.98330116,0.0004435515,0.0009963837,0.005647615],"study_design_scores_gemma":[0.0026053977,0.00029504884,0.070156746,0.00042029086,0.0002353175,0.000057097892,0.0005402236,0.00047510874,0.89547706,0.0015511431,0.02770414,0.000482443],"about_ca_topic_score_codex":0.00019649955,"about_ca_topic_score_gemma":0.00007405605,"teacher_disagreement_score":0.08782414,"about_ca_system_score_codex":0.0006012739,"about_ca_system_score_gemma":0.00041317745,"threshold_uncertainty_score":0.99989814},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"bench_or_experimental","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W4389239817","doi":"10.1158/1535-7163.targ-23-c053","title":"Abstract C053: BACE1 cleaves EGFR to drive lung adenocarcinoma brain metastasis","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced biosensing and bioanalysis techniques","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Metastasis; Brain metastasis; Cancer research; Adenocarcinoma; Lung cancer; Cancer; In vivo; Medicine; Biology; Internal medicine; Genetics","score_opus":0.021694790002659597,"score_gpt":0.3243851626453038,"score_spread":0.3026903726426442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389239817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98001903,0.0034467303,0.009282688,0.005812553,0.0001837254,0.00043512715,0.00013399764,0.00025327498,0.00043288988],"genre_scores_gemma":[0.9885437,0.0008346669,0.0028534643,0.0066037076,0.00017864193,0.000057188,0.00015001613,0.000082330975,0.00069630233],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998157,0.00008020467,0.0002928896,0.00065128505,0.0002966127,0.00052197266],"domain_scores_gemma":[0.9989122,0.000020238562,0.00010652789,0.0006616105,0.00014717213,0.00015222424],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023887824,0.00032763582,0.00028091657,0.00017141277,0.0001346564,0.000058845813,0.00034041275,0.00021085303,0.000011960317],"category_scores_gemma":[0.000031799624,0.00030764224,0.00026040315,0.00062299013,0.00009482367,0.000005799185,0.00017788245,0.00016102436,0.000028322538],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007040876,0.000031224525,0.0008763391,0.000019808283,0.0004462301,0.00003830465,0.000074821095,0.00023243694,0.97116137,0.00005207389,0.0042460803,0.022750895],"study_design_scores_gemma":[0.00025935096,0.00014801347,0.0040003625,0.000031232034,0.0001477174,0.000006310522,0.00012535954,0.00017295091,0.93392986,0.00014427709,0.060593806,0.00044078272],"about_ca_topic_score_codex":0.000039077317,"about_ca_topic_score_gemma":0.00006372992,"teacher_disagreement_score":0.056347728,"about_ca_system_score_codex":0.00006448245,"about_ca_system_score_gemma":0.00008202336,"threshold_uncertainty_score":0.9999376},"labels":[],"label_agreement":null},{"id":"W4389239845","doi":"10.1158/1535-7163.targ-23-c051","title":"Abstract C051: Alteration of protein translation by eIF4A1 inhibition exquisitely primes lymphoma cells to induction of ferroptosis","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bioinformatics Solutions (Canada)","funders":"","keywords":"Transcriptome; GPX4; Cancer research; Biology; Diffuse large B-cell lymphoma; Cancer cell; Cell biology; Lymphoma; Glutathione; Cancer; Gene expression; Biochemistry; Immunology; Gene; Glutathione peroxidase; Genetics","score_opus":0.02214157215039006,"score_gpt":0.27714127663917787,"score_spread":0.25499970448878784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389239845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98832154,0.0031604688,0.006432061,0.0002692718,0.0010040164,0.0005627647,0.00013741928,0.000023136376,0.00008934427],"genre_scores_gemma":[0.99719447,0.00089062494,0.00044166698,0.0002562389,0.00069716846,0.000111406436,0.00024998013,0.000040696195,0.00011774943],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988427,0.000054063476,0.00034964096,0.0003000767,0.00025365347,0.00019981938],"domain_scores_gemma":[0.9993327,0.000004721134,0.00017744156,0.00026451785,0.00016696079,0.00005360604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015290701,0.00017081706,0.00019979857,0.00011723091,0.000042029224,0.000015277914,0.0000943654,0.00017339656,0.000015286689],"category_scores_gemma":[0.0000052728187,0.00018321154,0.000115467745,0.00033225594,0.00004923402,0.000011347781,0.000023487533,0.000049513557,0.0000037347147],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016746687,0.000066072054,0.00003183432,0.00006998411,0.000082836414,7.260695e-8,0.0002663571,0.0008286282,0.9286461,0.000020996202,0.00073683634,0.069082834],"study_design_scores_gemma":[0.0006593149,0.00015926769,0.0011078048,0.000049876056,0.00005084114,5.5207164e-7,0.000058963797,0.00007833478,0.9369302,0.00004482774,0.060685135,0.00017488356],"about_ca_topic_score_codex":0.00013450028,"about_ca_topic_score_gemma":0.000025733598,"teacher_disagreement_score":0.068907954,"about_ca_system_score_codex":0.000032463806,"about_ca_system_score_gemma":0.00011659526,"threshold_uncertainty_score":0.74711496},"labels":[],"label_agreement":null},{"id":"W4389239940","doi":"10.1158/1535-7163.targ-23-a109","title":"Abstract A109: Targeting pyrimidine biosynthesis as a metabolic vulnerability in brain metastasis","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Biochemical and Molecular Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Pyrimidine metabolism; Dihydroorotate dehydrogenase; Metastasis; Cancer research; Biology; Cancer; Biochemistry; Pyrimidine; Purine; Enzyme; Genetics","score_opus":0.036327890488446965,"score_gpt":0.3446842506897804,"score_spread":0.30835636020133345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389239940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851944,0.009282744,0.00032119884,0.003970687,0.00011077514,0.00039283495,0.000062904066,0.00006741168,0.00059704523],"genre_scores_gemma":[0.9937997,0.002339045,0.00032941982,0.002761977,0.00011740055,0.00019248661,0.00017652079,0.000088082605,0.00019539695],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99735326,0.00022633655,0.00041163655,0.0007788001,0.00044589434,0.00078408996],"domain_scores_gemma":[0.99892634,0.000051691957,0.000090756475,0.0006307031,0.00012448426,0.00017601118],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008422824,0.00034741775,0.00035324175,0.00019054982,0.00009936434,0.000056568017,0.00048144348,0.00024633,0.00014716557],"category_scores_gemma":[0.0002591684,0.0003296346,0.00028059265,0.0008535474,0.00016771456,0.0000071804793,0.00027155946,0.0003418401,0.00006881909],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010846508,0.00010966716,0.0009752608,0.00005032743,0.00025034408,0.00006674933,0.000055267687,0.00017661239,0.9758343,0.00015002197,0.0005124518,0.021710498],"study_design_scores_gemma":[0.0005585624,0.00006210383,0.0020992032,0.000021823062,0.000044784258,0.0000046677073,0.00007283222,0.00012814444,0.9056367,0.00054346304,0.0904587,0.00036896314],"about_ca_topic_score_codex":0.000346254,"about_ca_topic_score_gemma":0.000074645795,"teacher_disagreement_score":0.08994625,"about_ca_system_score_codex":0.00004502908,"about_ca_system_score_gemma":0.00019342873,"threshold_uncertainty_score":0.9999156},"labels":[],"label_agreement":null},{"id":"W4389239942","doi":"10.1158/1535-7163.targ-23-a158","title":"Abstract A158: Rational development of synergistic therapies alongside BMI1 Inhibition for group 3 medulloblastoma","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; McMaster University","funders":"","keywords":"Medulloblastoma; BMI1; Context (archaeology); Biology; CRISPR; Cancer research; PI3K/AKT/mTOR pathway; Cancer; Gene; Signal transduction; Genetics","score_opus":0.022646037020298843,"score_gpt":0.28626446070610195,"score_spread":0.2636184236858031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389239942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94232154,0.0019265788,0.054901544,0.00017814196,0.00014597207,0.00038755997,0.000068416106,0.00003203162,0.000038192393],"genre_scores_gemma":[0.9957568,0.00008654903,0.002621984,0.0002286137,0.000093051945,0.00025384227,0.000855623,0.000047443926,0.000056099514],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99887216,0.00003735891,0.00035192282,0.0002860101,0.0002239708,0.00022857776],"domain_scores_gemma":[0.9993754,0.00001980495,0.00017291598,0.00022485766,0.00016697827,0.000040019706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022146346,0.0001733084,0.0001482803,0.00007775915,0.00009833218,0.000018226532,0.00011196826,0.00012705321,0.00002501412],"category_scores_gemma":[0.000016638543,0.00017808004,0.00011698328,0.00015393946,0.00007426679,0.000005379076,0.000041000058,0.00004196261,0.000005804543],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010455866,0.000052645075,0.00015522983,0.00008851373,0.00026997356,0.0000024684355,0.00013299337,0.00095725455,0.98474115,0.00032095905,0.00015515553,0.013019069],"study_design_scores_gemma":[0.0006655473,0.0000628886,0.015180637,0.000051881445,0.000052148276,0.0000015429787,0.00006010309,0.00032527276,0.9674567,0.0006622469,0.01524927,0.00023175804],"about_ca_topic_score_codex":0.0000052471855,"about_ca_topic_score_gemma":0.000030822455,"teacher_disagreement_score":0.05343523,"about_ca_system_score_codex":0.000046463716,"about_ca_system_score_gemma":0.00020073977,"threshold_uncertainty_score":0.7261893},"labels":[],"label_agreement":null},{"id":"W4389239948","doi":"10.1158/1535-7163.targ-23-a161","title":"Abstract A161: A differentiation based therapeutic approach for KMT2A rearranged leukemia in infants and children","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Leukemia; Cancer research; Biology; Cellular differentiation; Childhood leukemia; Immunology; Medicine; Gene; Genetics","score_opus":0.023317490521837108,"score_gpt":0.27921369683628583,"score_spread":0.2558962063144487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389239948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880866,0.0023316892,0.008672694,0.00012737213,0.00008038613,0.00050404505,0.00006344391,0.000027887745,0.00010587537],"genre_scores_gemma":[0.99684197,0.00084897905,0.00029903324,0.0011154255,0.000078203695,0.00023124405,0.00047384627,0.000044731485,0.000066579545],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99889797,0.000044409873,0.00020439131,0.0004080315,0.00013321839,0.00031200398],"domain_scores_gemma":[0.9995247,0.0000132347495,0.00007269233,0.00028486387,0.00005767915,0.000046833462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015634991,0.00020175304,0.00017318832,0.00011226315,0.00006008981,0.000041540687,0.00016885009,0.00018922861,0.0000067570872],"category_scores_gemma":[0.000007971979,0.00019462881,0.00009332907,0.00017521718,0.000049953564,0.0000058476644,0.000039264287,0.00010638584,0.0000022261936],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028173666,0.00003865058,0.016223207,0.00003896626,0.00018408419,0.000001676864,0.00009367976,0.0020815723,0.95892996,0.00001765575,0.000088336514,0.022020495],"study_design_scores_gemma":[0.0034113273,0.00033740877,0.40970835,0.00006194293,0.00012696281,0.000003662748,0.00008587721,0.026228044,0.55754435,0.00029912882,0.0015307355,0.00066222437],"about_ca_topic_score_codex":0.00008152753,"about_ca_topic_score_gemma":0.00005462866,"teacher_disagreement_score":0.4013856,"about_ca_system_score_codex":0.000050708124,"about_ca_system_score_gemma":0.00012749303,"threshold_uncertainty_score":0.7936732},"labels":[],"label_agreement":null},{"id":"W4389239952","doi":"10.1158/1535-7163.targ-23-a150","title":"Abstract A150: Effects of radioimmunotherapy on human and canine osteosarcoma microenvironment","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Radioimmunotherapy; Medicine; Tumor microenvironment; Osteosarcoma; Cancer research; Cancer; Oncology; Immune system; Internal medicine; Immunology; Antibody; Monoclonal antibody","score_opus":0.014507093166392402,"score_gpt":0.27712896738402265,"score_spread":0.2626218742176302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389239952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96662784,0.032046646,0.00010182208,0.0002147127,0.00050198,0.00032017563,0.000032867396,0.000020968182,0.00013298496],"genre_scores_gemma":[0.9784154,0.019245025,0.00007113037,0.0013328759,0.00031164233,0.000073691524,0.000062371044,0.00006825353,0.00041956792],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99889725,0.00004757556,0.0002119686,0.0003519347,0.00019070283,0.0003005351],"domain_scores_gemma":[0.9993519,0.000013851551,0.00010689463,0.00043526507,0.000025596108,0.0000664697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009968276,0.00023139988,0.00024164173,0.00007262852,0.00007629435,0.000015511232,0.00015797037,0.0001343845,0.000017876515],"category_scores_gemma":[0.000003840826,0.00022650535,0.000115991876,0.00011600895,0.0001333605,0.0000025083243,0.0000568859,0.00010886985,0.0000046153336],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009050205,0.00006174415,0.00033390112,0.00007633097,0.00025243184,0.0000062278577,0.0001256107,0.0001237682,0.9656211,0.00007230487,0.00032301483,0.03291304],"study_design_scores_gemma":[0.0014209074,0.00032639064,0.026309539,0.000047618796,0.00006706773,0.000003795415,0.000020454037,0.0000086824175,0.83104295,0.00006433352,0.14045943,0.00022882005],"about_ca_topic_score_codex":0.00011097812,"about_ca_topic_score_gemma":0.00003264551,"teacher_disagreement_score":0.1401364,"about_ca_system_score_codex":0.000026378762,"about_ca_system_score_gemma":0.00004502341,"threshold_uncertainty_score":0.923662},"labels":[],"label_agreement":null},{"id":"W4389240120","doi":"10.1158/1535-7163.targ-23-b086","title":"Abstract B086: Targeting ATR to overcome Carboplatin resistance in triple-negative breast cancer patient-derived models","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; McGill University","funders":"","keywords":"Carboplatin; Triple-negative breast cancer; DNA damage; Cancer research; Olaparib; Apoptosis; Cancer; Biology; Molecular biology; Breast cancer; Chemotherapy; Cisplatin; Poly ADP ribose polymerase; DNA; Polymerase; Genetics","score_opus":0.01619635138061313,"score_gpt":0.27038447573317664,"score_spread":0.2541881243525635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389240120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926145,0.0035093003,0.0011582328,0.0009471199,0.00030944817,0.0006061954,0.00047836042,0.000047189762,0.00032962463],"genre_scores_gemma":[0.9945093,0.0018430002,0.0006684555,0.002080844,0.000121498015,0.00028875866,0.00011254177,0.00009569226,0.00027994337],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997991,0.00008099603,0.00041337276,0.00063238817,0.00027040247,0.0006118281],"domain_scores_gemma":[0.99913496,0.000017354296,0.00014545958,0.00042412087,0.00015088869,0.00012720755],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014852895,0.00033841515,0.00029387922,0.00013486903,0.0000950605,0.000043117074,0.0002993193,0.00022479639,0.00002961342],"category_scores_gemma":[0.000014893391,0.0003579477,0.00014335476,0.00053978676,0.000054966895,0.00001282696,0.00015716373,0.00021988012,0.000010108672],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002790333,0.000045476507,0.00084611017,0.000040693692,0.00015025015,0.000027117156,0.0009739187,0.016756613,0.9763841,0.000038877533,0.00069473125,0.0037630494],"study_design_scores_gemma":[0.0024507926,0.00014037373,0.01848764,0.0002899952,0.00009366469,0.000004440408,0.0006314191,0.0036062642,0.96007276,0.0009823247,0.011875175,0.0013651841],"about_ca_topic_score_codex":0.00075833476,"about_ca_topic_score_gemma":0.002616288,"teacher_disagreement_score":0.01764153,"about_ca_system_score_codex":0.00016014141,"about_ca_system_score_gemma":0.00020573499,"threshold_uncertainty_score":0.9998872},"labels":[],"label_agreement":null},{"id":"W4389240124","doi":"10.1158/1535-7163.targ-23-c003","title":"Abstract C003: A quantitative mass spectrometry workflow for highly multiplexed measurement of immunomodulatory proteins to support immunotherapy clinical trials","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced Proteomics Techniques and Applications","field":"Chemistry","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"FuelCell Energy (Canada)","funders":"","keywords":"Peptide; Chemistry; Immunotherapy; Mass spectrometry; Selected reaction monitoring; Computational biology; Biomarker; Tandem mass spectrometry; Antibody; Chromatography; Biomarker discovery; Quantitative proteomics; Sample preparation; Immune system; Proteomics; Biology; Biochemistry; Immunology","score_opus":0.16647023828762625,"score_gpt":0.4365019973843337,"score_spread":0.27003175909670746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389240124","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29343984,0.002049528,0.69753957,0.0013363527,0.00023434096,0.0039055636,0.0007316319,0.00045193403,0.0003112627],"genre_scores_gemma":[0.7234048,0.00096852885,0.27133384,0.00043401416,0.00011469173,0.0034249553,0.00006017603,0.0001383589,0.00012059011],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99721277,0.00008897752,0.0012725184,0.0005143897,0.0004730207,0.0004383246],"domain_scores_gemma":[0.99781877,0.00027882884,0.00062675547,0.00077701645,0.0003953941,0.00010322107],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024528867,0.00030723063,0.0007545057,0.00014499927,0.00010460717,0.00003282713,0.00047025018,0.00022942678,0.00012452417],"category_scores_gemma":[0.00017977235,0.00029853117,0.000536284,0.00048094723,0.00009258742,0.00004846193,0.000047777354,0.0002889888,0.000013810456],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065986626,0.00015533432,0.0001521635,0.000096609605,0.00062973116,0.0000028313436,0.00010904881,0.00037950982,0.96100914,0.000977224,0.00009448109,0.035734072],"study_design_scores_gemma":[0.0016619243,0.00028914018,0.00042186593,0.00012401592,0.000094777904,3.3799944e-7,0.000072916584,0.0003692748,0.9739051,0.0057140454,0.01698243,0.00036417815],"about_ca_topic_score_codex":0.000031470758,"about_ca_topic_score_gemma":0.0000068672075,"teacher_disagreement_score":0.429965,"about_ca_system_score_codex":0.000250961,"about_ca_system_score_gemma":0.00027703552,"threshold_uncertainty_score":0.99994665},"labels":[],"label_agreement":null},{"id":"W4389240146","doi":"10.1158/1535-7163.targ-23-a034","title":"Abstract A034: Synthesis and biological activities of a novel series of “combi-molecules” designed to delay metabolic dealkylation prior to crossing the blood brain barrier in the context of optimizing their potency against glioblastoma multiforme","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Gefitinib; Temozolomide; Pharmacology; Context (archaeology); Cancer research; In vivo; Tyrosine kinase; Epidermal growth factor receptor; U87; Potency; Chemistry; Medicine; Cancer; Biology; Internal medicine; In vitro; Signal transduction; Glioma; Biochemistry; Genetics","score_opus":0.034743075980362505,"score_gpt":0.2932496063632243,"score_spread":0.25850653038286175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389240146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99429244,0.0016474496,0.00064500567,0.0024101338,0.00002452061,0.00085571443,0.0000912423,0.00001489655,0.000018596116],"genre_scores_gemma":[0.9968082,0.0003118106,0.0014691425,0.0011632759,0.000009969844,0.00020659676,0.0000035045443,0.000025138082,0.0000023858095],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988005,0.000107030166,0.00038737574,0.0002177951,0.0002435743,0.00024371158],"domain_scores_gemma":[0.99890614,0.00047095676,0.00017356266,0.0002915531,0.00010285065,0.0000549426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004046791,0.00020411002,0.00044814034,0.00019110867,0.0001031151,0.00003161968,0.00014618033,0.00008745655,0.0000039754],"category_scores_gemma":[0.00010944476,0.0001152897,0.0001311329,0.0005386145,0.00019956421,0.000047685953,0.00005416718,0.0000942749,2.8014043e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045901787,0.00031505866,0.0029240784,0.000055674707,0.00041028106,0.000026701782,0.010004891,0.0012361378,0.93699586,0.00019687312,0.0000016796602,0.04737373],"study_design_scores_gemma":[0.0012894709,0.00041221076,0.0649683,0.000274784,0.00021355606,0.000013570363,0.004176442,0.0004572419,0.9279133,0.00002215253,0.00013702194,0.00012196778],"about_ca_topic_score_codex":0.00020196041,"about_ca_topic_score_gemma":0.00013648797,"teacher_disagreement_score":0.062044222,"about_ca_system_score_codex":0.0000286025,"about_ca_system_score_gemma":0.000106408246,"threshold_uncertainty_score":0.47013777},"labels":[],"label_agreement":null},{"id":"W4389240186","doi":"10.1158/1535-7163.targ-23-a045","title":"Abstract A045: EZH2 inhibition re-sensitizes drug resistant triple-negative breast cancer PDX models to Eribulin","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Eribulin; Medicine; Breast cancer; Oncology; Internal medicine; Metastatic breast cancer; Cancer; Drug resistance; Triple-negative breast cancer; Cancer research; Biology","score_opus":0.033048788028452444,"score_gpt":0.29665449180796155,"score_spread":0.2636057037795091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389240186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98240125,0.0031092244,0.0033772662,0.00756453,0.00045131505,0.0007194405,0.0012697801,0.00011071785,0.0009964852],"genre_scores_gemma":[0.9901456,0.0035281705,0.00029700762,0.0035217418,0.00031227348,0.00046803438,0.00020161331,0.00009613607,0.0014293775],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99800724,0.00008429046,0.0003684698,0.00067101733,0.0003606888,0.00050831237],"domain_scores_gemma":[0.9987221,0.00001464897,0.00014859907,0.0006234513,0.0003253224,0.00016592584],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022565115,0.00032763288,0.0002583719,0.00012727937,0.00019733267,0.0000769477,0.0002300006,0.0001832272,0.000096579846],"category_scores_gemma":[0.000008123243,0.0003260143,0.00017595624,0.00056445313,0.00009609168,0.000014508983,0.00010396892,0.00017860667,0.00004115812],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049188995,0.000052419553,0.00003679149,0.000031344713,0.0002274135,0.000020774864,0.00044720457,0.016064834,0.96655923,0.00019009715,0.005650086,0.0102279065],"study_design_scores_gemma":[0.0014466414,0.0001205942,0.0049657566,0.00016372075,0.0001415662,0.0000067693586,0.00070000376,0.0019287192,0.9538514,0.0014842964,0.034335703,0.0008548018],"about_ca_topic_score_codex":0.00076675054,"about_ca_topic_score_gemma":0.00092211313,"teacher_disagreement_score":0.028685618,"about_ca_system_score_codex":0.00015753349,"about_ca_system_score_gemma":0.00029078318,"threshold_uncertainty_score":0.9999192},"labels":[],"label_agreement":null},{"id":"W4389241514","doi":"10.1158/1535-7163.targ-23-b130","title":"Abstract B130: Phase 1 study of Zanidatamab Zovodotin (ZW49): Safety Profile and Recommended Dose (RD) in patients with Human Epidermal Growth Factor 2 (HER2)-positive solid cancers","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada); McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Medicine; Trastuzumab; Pharmacokinetics; Internal medicine; Population; Cancer; Pharmacology; Adverse effect; Antibody-drug conjugate; Oncology; Breast cancer; Antibody; Gastroenterology; Immunology; Monoclonal antibody","score_opus":0.040658240370309094,"score_gpt":0.36794027471688073,"score_spread":0.32728203434657166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389241514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99664503,0.00021281741,0.00000976463,0.00079058815,0.000055376848,0.0014181258,0.00052973215,0.000033155757,0.00030538772],"genre_scores_gemma":[0.99867153,0.00021815315,0.00005798249,0.00044285136,0.000037987367,0.00008511733,0.0003005252,0.00005334856,0.00013250556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979197,0.00012512085,0.00044695492,0.00042796734,0.0005952405,0.0004850335],"domain_scores_gemma":[0.99911755,0.00007525141,0.00015709273,0.00027264576,0.00021904336,0.00015838757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017480637,0.00028173666,0.0005144762,0.00021317936,0.00012114127,0.000020338093,0.00014934427,0.00008663975,0.00021802676],"category_scores_gemma":[0.000011178236,0.00022101765,0.00006221861,0.00046414143,0.00012288518,0.000078549405,0.000103641214,0.0003908048,0.0000055370765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01588282,0.005558936,0.8269795,0.0006856566,0.0024739192,0.0006891883,0.008885251,0.00009082368,0.058159217,0.000076284,0.00026252735,0.08025588],"study_design_scores_gemma":[0.01454113,0.0037452674,0.9594638,0.00018869012,0.0001312299,0.0000025482789,0.000798358,0.00018550933,0.020285238,0.000026943997,0.00033863264,0.00029269975],"about_ca_topic_score_codex":0.002828467,"about_ca_topic_score_gemma":0.00043177482,"teacher_disagreement_score":0.13248426,"about_ca_system_score_codex":0.00020684906,"about_ca_system_score_gemma":0.00019731901,"threshold_uncertainty_score":0.9012838},"labels":[],"label_agreement":null},{"id":"W4389241633","doi":"10.1158/1535-7163.targ-23-c082","title":"Abstract C082: SCD1 is a potent therapeutic target in MYC-amplified group 3 medulloblastoma","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; McMaster University","funders":"","keywords":"Medulloblastoma; In vivo; Biology; Lipid metabolism; Cancer research; Wnt signaling pathway; Transcriptome; Enzyme; In vitro; Chemistry; Biochemistry; Gene; Genetics; Gene expression","score_opus":0.02090510750237412,"score_gpt":0.28368864123222604,"score_spread":0.2627835337298519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389241633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9460786,0.036093622,0.0035972742,0.0027177504,0.008041023,0.0010944175,0.0002545791,0.00019522023,0.0019274884],"genre_scores_gemma":[0.97803366,0.007618742,0.00030942864,0.009485091,0.003032157,0.00030201735,0.00019802853,0.00016270689,0.0008581535],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99742436,0.00009491005,0.00045405098,0.0007746235,0.0004343588,0.0008177007],"domain_scores_gemma":[0.9988216,0.000016689562,0.00014433553,0.0007536493,0.00010383618,0.00015985881],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030933748,0.00043872147,0.0003934279,0.00020739292,0.000107921536,0.000065981876,0.00047396263,0.00034401772,0.00013018839],"category_scores_gemma":[0.000010795432,0.00044066645,0.00029470428,0.0005919781,0.00013104761,0.0000101913,0.00014223083,0.00029340092,0.00006918177],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026350297,0.00013683684,0.0014593023,0.000058587062,0.00035866487,0.000005753601,0.00042356417,0.0005962727,0.9595472,0.00031485574,0.004684416,0.03215102],"study_design_scores_gemma":[0.001983658,0.00017159196,0.021096556,0.000057517376,0.000091574635,0.000009900211,0.00024006126,0.00039580287,0.14689101,0.0012444837,0.8270846,0.0007332354],"about_ca_topic_score_codex":0.00023297832,"about_ca_topic_score_gemma":0.00023975383,"teacher_disagreement_score":0.8224002,"about_ca_system_score_codex":0.00008706878,"about_ca_system_score_gemma":0.00023240031,"threshold_uncertainty_score":0.9998045},"labels":[],"label_agreement":null},{"id":"W4389241646","doi":"10.1158/1535-7163.targ-23-b169","title":"Abstract B169: Retrospective baseline biomarker analyses in a first-in-human Phase 1 trial of the PKMYT1 inhibitor lunresertib (RP-6306) in pts with advanced solid tumors harboring <i>CCNE1</i> amplification and/or deleterious alterations in <i>FBXW7</i> or <i>PPP2R1A</i>","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Internal medicine; Medicine; Oncology; Biomarker; Tolerability; Cyclin E1; Concordance; Fluorescence in situ hybridization; Cancer research; Cancer; Biology; Cyclin D1; Cell cycle; Adverse effect; Gene; Genetics","score_opus":0.03904351749104924,"score_gpt":0.35771871629521995,"score_spread":0.3186751988041707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389241646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99694103,0.0011046287,0.00026374246,0.00042926532,0.00014415475,0.00094694295,0.0001282169,0.0000101155865,0.000031902015],"genre_scores_gemma":[0.99685925,0.0019483896,0.00012839881,0.0004623805,0.000067289984,0.00038228932,0.00008124208,0.000050829636,0.000019938467],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981316,0.00010048714,0.0006510171,0.0005263246,0.00021437641,0.0003762498],"domain_scores_gemma":[0.9990926,0.00006740517,0.0002314144,0.00046522077,0.00008718453,0.000056200697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029969914,0.00026872286,0.0003833524,0.00023097236,0.00007369641,0.000041295454,0.00022335327,0.00012971465,0.00000620583],"category_scores_gemma":[0.00009990815,0.00020847748,0.00007557472,0.00096740515,0.00012442248,0.000016359734,0.000096898715,0.00020213606,3.0312185e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012858816,0.00046119286,0.005009241,0.000059109578,0.00006152866,0.000074128664,0.0003872637,0.009101756,0.96865773,0.000014703099,0.000020352794,0.0032941918],"study_design_scores_gemma":[0.06148804,0.0018311647,0.047936678,0.00078251335,0.000099497076,0.000009215727,0.0004992074,0.0053675147,0.87943274,0.00013892572,0.0015869294,0.0008276046],"about_ca_topic_score_codex":0.0008815977,"about_ca_topic_score_gemma":0.026452633,"teacher_disagreement_score":0.089225,"about_ca_system_score_codex":0.00017991994,"about_ca_system_score_gemma":0.00029799793,"threshold_uncertainty_score":0.9913121},"labels":[],"label_agreement":null},{"id":"W4389241863","doi":"10.1158/1535-7163.targ-23-c028","title":"Abstract C028: A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced or metastatic claudin 18.2+ solid tumors","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Chimeric antigen receptor; Radioimmunotherapy; Cancer research; Leukapheresis; Immunotherapy; Cancer; Monoclonal antibody; Immunology; Pharmacology; Antibody; Stem cell; Internal medicine; Biology; CD34","score_opus":0.056765147181907914,"score_gpt":0.3818371142617724,"score_spread":0.3250719670798645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389241863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950389,0.0011897564,0.00020857646,0.0005798746,0.000048244856,0.0026333237,0.00002757769,0.00007364039,0.00020005192],"genre_scores_gemma":[0.9977384,0.0006279501,0.00032716888,0.00063412986,0.000023280048,0.00016859181,0.000012840377,0.000098560944,0.00036905127],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971676,0.00029835312,0.0006015302,0.0004925821,0.0008082525,0.0006317239],"domain_scores_gemma":[0.9982912,0.0005565865,0.00022190249,0.00059959805,0.00016772164,0.00016298391],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009315265,0.00033092024,0.0007232495,0.00027276922,0.0001137145,0.00004114186,0.00027589194,0.00006817254,0.00019933787],"category_scores_gemma":[0.00009464605,0.00021119056,0.00007550141,0.0016897517,0.0003912298,0.000058257127,0.00010444097,0.00061046286,0.000004061105],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009122101,0.0009025276,0.0028762452,0.00034081176,0.0009308981,0.0015648254,0.005083534,0.007814811,0.8996138,0.000011416295,0.000014446666,0.07172459],"study_design_scores_gemma":[0.07992512,0.014960535,0.09115031,0.0020494056,0.0012622897,0.00018759067,0.012494756,0.021814516,0.7727379,0.00022243182,0.001970478,0.0012246264],"about_ca_topic_score_codex":0.0003972926,"about_ca_topic_score_gemma":0.00062830787,"teacher_disagreement_score":0.12687586,"about_ca_system_score_codex":0.00017000033,"about_ca_system_score_gemma":0.0008191642,"threshold_uncertainty_score":0.8612101},"labels":[],"label_agreement":null},{"id":"W4389241939","doi":"10.1158/1535-7163.targ-23-pr003","title":"Abstract PR003: Repotrectinib in patients with <i>ROS1</i> fusion-positive (<i>ROS1</i>+) non-small cell lung cancer (NSCLC): Update from the pivotal phase 1/2 TRIDENT-1 trial","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; ROS1; Cohort; Clinical endpoint; Lung cancer; Oncology; Cancer; Clinical trial; Adenocarcinoma","score_opus":0.013758122112712929,"score_gpt":0.317288329426474,"score_spread":0.30353020731376107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389241939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98922384,0.0027670565,0.00025220902,0.001823698,0.0010055065,0.003386633,0.0009020937,0.00010477693,0.0005341709],"genre_scores_gemma":[0.9925013,0.0007997597,0.0001227994,0.004077991,0.00030270295,0.0009484241,0.00072459294,0.00012637171,0.00039603657],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99746394,0.00009192005,0.0005394435,0.00067636097,0.00063585496,0.0005924685],"domain_scores_gemma":[0.9985315,0.00013827943,0.00031355117,0.0006135317,0.0002383712,0.00016477509],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015940882,0.00044058432,0.0005010698,0.0001344138,0.00023216766,0.0000937677,0.0002274863,0.00015276035,0.00016256775],"category_scores_gemma":[0.000012028811,0.00030074417,0.0001999826,0.00084749394,0.00009422133,0.00011011794,0.00006615929,0.00045482448,0.000023204353],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16196886,0.012244031,0.5341155,0.00042324368,0.010283691,0.0023713927,0.02045759,0.003695308,0.07527974,0.00004173267,0.0097366115,0.16938227],"study_design_scores_gemma":[0.4743255,0.0033238565,0.4108251,0.0019579849,0.0069398936,0.000006183991,0.000922999,0.0017621673,0.08620693,0.00008414808,0.011934431,0.0017107886],"about_ca_topic_score_codex":0.0026221373,"about_ca_topic_score_gemma":0.0008254388,"teacher_disagreement_score":0.31235665,"about_ca_system_score_codex":0.0005099667,"about_ca_system_score_gemma":0.0008502539,"threshold_uncertainty_score":0.99994445},"labels":[],"label_agreement":null},{"id":"W4389242040","doi":"10.1158/1535-7163.targ-23-b125","title":"Abstract B125: Neutralizing acidosis with L-DOS47 urease immunoconjugate enhances responses to anti-PD1 checkpoint blockade in a preclinical orthotopic model of pancreatic adenocarcinoma","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Helix Biopharma (Canada); University of Calgary","funders":"","keywords":"Cancer research; Medicine; Pancreatic cancer; Tumor microenvironment; Cancer; Immunoconjugate; Pharmacology; Internal medicine; Immunology; Antibody","score_opus":0.04433827230524842,"score_gpt":0.32572716228300996,"score_spread":0.28138888997776157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389242040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841864,0.013600333,0.0007355358,0.00044204565,0.00022783579,0.0005967705,0.00009488292,0.000035325553,0.00008086861],"genre_scores_gemma":[0.98934114,0.008108871,0.00095810305,0.0007578625,0.00019552617,0.00027516228,0.00004008521,0.000075381606,0.00024789147],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978313,0.000117683805,0.00057187,0.00063378736,0.00029777968,0.00054761313],"domain_scores_gemma":[0.9988163,0.000034467594,0.00019507186,0.0006752037,0.00012985313,0.00014910554],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034526398,0.00034626035,0.0005293515,0.00017857533,0.000063130574,0.00003341693,0.00035880812,0.00021749052,0.000013285726],"category_scores_gemma":[0.000041930434,0.00031670826,0.00019899831,0.00049260876,0.00013683616,0.000011008903,0.000118025244,0.0002161204,0.00000527053],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009944193,0.00009866328,0.0075922175,0.0000951325,0.00027604995,0.000014463753,0.00036545008,0.0064018355,0.97932965,0.000016664459,0.000018708526,0.0047967453],"study_design_scores_gemma":[0.0015532398,0.00030122217,0.050321158,0.00018587857,0.00021489785,0.000007884657,0.00012283746,0.0007007686,0.9410827,0.000059719336,0.0049916343,0.00045807147],"about_ca_topic_score_codex":0.0003116869,"about_ca_topic_score_gemma":0.00027989925,"teacher_disagreement_score":0.04272894,"about_ca_system_score_codex":0.000036183912,"about_ca_system_score_gemma":0.00042841936,"threshold_uncertainty_score":0.9999285},"labels":[],"label_agreement":null},{"id":"W4389242080","doi":"10.1158/1535-7163.targ-23-b035","title":"Abstract B035: A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cytokine release syndrome; Adverse effect; Chimeric antigen receptor; Pneumonitis; Internal medicine; T cell; Pharmacokinetics; Leukapheresis; Immunotherapy; Refractory (planetary science); Oncology; Gastroenterology; Pharmacology; Cancer; Immunology; Immune system; Lung; Stem cell","score_opus":0.07208883215688347,"score_gpt":0.3961923356484441,"score_spread":0.3241035034915606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389242080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99553734,0.0012004205,0.000026938344,0.0011293762,0.00016082334,0.0012540789,0.000028394525,0.00011061358,0.0005519982],"genre_scores_gemma":[0.99662226,0.0011010868,0.00019457626,0.00078538933,0.00012902194,0.000075158416,0.000033938664,0.000094959556,0.00096358254],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99753135,0.00016672292,0.00073001557,0.0004459761,0.00058637105,0.0005395694],"domain_scores_gemma":[0.998682,0.00029308564,0.00022620363,0.0004974795,0.000110981055,0.00019022277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074949814,0.0002710909,0.00069476163,0.00034032942,0.00009914411,0.000019134948,0.00017921418,0.00021906686,0.00045030337],"category_scores_gemma":[0.00022977324,0.00023366892,0.00013594766,0.0009479497,0.00030888245,0.000040843875,0.00010506751,0.0006639874,0.0000065039208],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040726554,0.00062844146,0.00021891456,0.00017877246,0.0002958586,0.00053643284,0.0021372298,0.00018509763,0.7938264,0.000024080176,0.00003855026,0.16120365],"study_design_scores_gemma":[0.4675491,0.020061187,0.029140292,0.0022165724,0.00065016403,0.00012714122,0.0015046261,0.012124685,0.42362392,0.00050918193,0.041059125,0.0014340145],"about_ca_topic_score_codex":0.0002461304,"about_ca_topic_score_gemma":0.00007699549,"teacher_disagreement_score":0.42682254,"about_ca_system_score_codex":0.00023822609,"about_ca_system_score_gemma":0.00077050197,"threshold_uncertainty_score":0.9528742},"labels":[],"label_agreement":null},{"id":"W4389242188","doi":"10.1158/1535-7163.targ-23-c097","title":"Abstract C097: Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; McMaster University","funders":"","keywords":"Pyrimidine metabolism; Metabolomics; Transcriptome; Dihydroorotate dehydrogenase; Biology; Medulloblastoma; Cancer research; CRISPR; Pyrimidine; Biochemistry; Computational biology; Genetics; Enzyme; Bioinformatics; Gene; Purine; Gene expression","score_opus":0.023224252692736997,"score_gpt":0.30126416254341226,"score_spread":0.2780399098506753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389242188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9474478,0.047803774,0.0002748893,0.00070238404,0.0020200983,0.00053315423,0.00018063954,0.000100750985,0.00093651796],"genre_scores_gemma":[0.97232026,0.02249802,0.000102461396,0.002008747,0.0011887858,0.00070054334,0.000101134654,0.00012263717,0.0009573891],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99747014,0.00013167792,0.00043377475,0.00076318096,0.00038251322,0.00081868784],"domain_scores_gemma":[0.99887925,0.000029288678,0.00014708767,0.00061456516,0.00018455982,0.00014526377],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003177649,0.00042977583,0.0004726564,0.00022937362,0.00012397078,0.000057289733,0.00041619153,0.00030892578,0.00009017856],"category_scores_gemma":[0.000035743033,0.00044105249,0.0002500494,0.0007755138,0.00017247634,0.000012367379,0.00012780314,0.00033915055,0.000026336958],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002595601,0.00008986157,0.0018979479,0.00005717258,0.0004343901,0.000010329689,0.0006467097,0.003317941,0.9442129,0.00036288743,0.0015274814,0.0471828],"study_design_scores_gemma":[0.0015298125,0.00010074763,0.028268822,0.000046278183,0.00012685283,0.0000057643792,0.00031944877,0.00014306934,0.5309791,0.0006622029,0.43715945,0.00065843813],"about_ca_topic_score_codex":0.0010682178,"about_ca_topic_score_gemma":0.002250376,"teacher_disagreement_score":0.43563196,"about_ca_system_score_codex":0.000093234754,"about_ca_system_score_gemma":0.0005239661,"threshold_uncertainty_score":0.99980414},"labels":[],"label_agreement":null},{"id":"W4390743751","doi":"10.1158/1535-7163.mct-23-0747","title":"PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; CancerCare Manitoba Foundation; Strong; Research Manitoba","keywords":"Cancer; Protein degradation; Proteasome; Ubiquitin; Computational biology; Cancer therapy; Medicine; Bioinformatics; Biology; Cell biology; Genetics","score_opus":0.016959634164403457,"score_gpt":0.32957666936802354,"score_spread":0.3126170352036201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390743751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6215294,0.35044953,0.0106127905,0.012442879,0.0028536206,0.0014024796,0.00007657618,0.0000805218,0.00055219256],"genre_scores_gemma":[0.9726134,0.021480612,0.000143126,0.0027488295,0.0019511993,0.00034716303,0.000070195565,0.00006110653,0.000584392],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99881727,0.000060525017,0.00019559056,0.0004480579,0.00025308933,0.00022548057],"domain_scores_gemma":[0.9994867,0.0000032576788,0.000036309113,0.00024847346,0.000095082665,0.0001301774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010520471,0.00021362882,0.00014666405,0.00007073546,0.00006734642,0.00007019662,0.00014713818,0.00012971375,0.00012322243],"category_scores_gemma":[0.000005285729,0.00017070612,0.00006018281,0.00018032285,0.00006862921,0.000006648766,0.00008089718,0.00016163466,0.000008808102],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007359158,0.000019170398,0.000028274519,0.00005288872,0.000093877636,0.00000858611,0.00010392783,0.000066716486,0.57597274,0.00039126203,0.0018220311,0.42136696],"study_design_scores_gemma":[0.0003893387,0.0004965309,0.00015167156,0.00016447797,0.000076281096,0.000012486445,0.000060833205,0.00032053457,0.26163173,0.0003663669,0.73608786,0.00024189902],"about_ca_topic_score_codex":0.00006698259,"about_ca_topic_score_gemma":0.000027469088,"teacher_disagreement_score":0.7342658,"about_ca_system_score_codex":0.000036152785,"about_ca_system_score_gemma":0.00017116971,"threshold_uncertainty_score":0.6961193},"labels":[],"label_agreement":null},{"id":"W4391805157","doi":"10.1158/1535-7163.mct-23-0822","title":"Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Camptothecin; Drug; Conjugate; Pharmacology; Payload (computing); Antibody; Chemistry; Medicine; Immunology; Biochemistry; Computer science","score_opus":0.12025473286422184,"score_gpt":0.44940770754084514,"score_spread":0.3291529746766233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391805157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.56003726,0.12712605,0.30102885,0.0060066176,0.0005342461,0.00464402,0.00013852392,0.00011286193,0.00037156208],"genre_scores_gemma":[0.99108195,0.0018874584,0.0053944644,0.00080885837,0.000101269936,0.00041282145,0.000024540186,0.00008093925,0.00020768092],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99828565,0.00011667256,0.00025914994,0.00034611352,0.00071226025,0.00028013758],"domain_scores_gemma":[0.9989359,0.00018554584,0.000048689777,0.00028776086,0.0004595486,0.00008258957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013782411,0.000167945,0.00027621366,0.0001409011,0.000043155167,0.000045079512,0.00009573036,0.00008612224,0.00009961308],"category_scores_gemma":[0.00003801166,0.00014257831,0.00008727746,0.00026407995,0.0001347995,0.000040860305,0.000028043154,0.00017012781,0.0000033099188],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025044655,0.00007808248,0.000355349,0.0007118469,0.0005192982,0.000008539226,0.0011269967,0.00053590746,0.89632916,0.00050031324,0.00023672213,0.09934735],"study_design_scores_gemma":[0.0035333028,0.00048713642,0.0004216894,0.0009454735,0.0013587588,0.000027049935,0.0001731471,0.26872447,0.6935044,0.0016707572,0.028873453,0.0002803643],"about_ca_topic_score_codex":0.00013890781,"about_ca_topic_score_gemma":0.000012014919,"teacher_disagreement_score":0.4310447,"about_ca_system_score_codex":0.00020957609,"about_ca_system_score_gemma":0.00088543963,"threshold_uncertainty_score":0.5814175},"labels":[],"label_agreement":null},{"id":"W4392123900","doi":"10.1158/1535-7163.mct-23-0868","title":"Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Victoria; National Research Council Canada","funders":"National Cancer Institute; National Institute of General Medical Sciences; University of Nebraska-Lincoln; National Institutes of Health; American Cancer Society","keywords":"Antibody; Cancer; Pancreatic cancer; Humanized antibody; Medicine; Humanized mouse; Immunology; Cancer research; Pharmacology; Immune system; Internal medicine; Monoclonal antibody","score_opus":0.10186513711662239,"score_gpt":0.38613226941365764,"score_spread":0.28426713229703526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392123900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97792274,0.017475149,0.0014932472,0.0015278233,0.00022591885,0.00071306055,0.0005018156,0.00004049044,0.00009978022],"genre_scores_gemma":[0.9912871,0.0064810123,0.0010098837,0.0003393665,0.00016801979,0.00011280193,0.000075533484,0.000049292677,0.00047697488],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987608,0.000058355556,0.00021698744,0.0003457302,0.00031473459,0.00030337885],"domain_scores_gemma":[0.9993701,0.0001189744,0.00006084102,0.00016280153,0.0001920659,0.000095215604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012438858,0.000209551,0.00040110192,0.00012480059,0.00008662725,0.00003539781,0.0000718934,0.00009735263,0.0002012044],"category_scores_gemma":[0.0000149329835,0.00016347505,0.00017294446,0.00019065157,0.0001474313,0.000064445216,0.000039922266,0.0002053266,0.000002377874],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007829067,0.00006019167,0.0046189968,0.0018239275,0.0010216832,0.000034863435,0.00042783516,0.000044517536,0.86032784,0.00008507571,0.000027873011,0.13074428],"study_design_scores_gemma":[0.0031721964,0.0007950399,0.06855851,0.0022937616,0.0019839567,0.00006460706,0.00015164794,0.055303834,0.8598937,0.0009306096,0.006218348,0.0006338039],"about_ca_topic_score_codex":0.0007878574,"about_ca_topic_score_gemma":0.00005744117,"teacher_disagreement_score":0.13011047,"about_ca_system_score_codex":0.000097390555,"about_ca_system_score_gemma":0.00018124325,"threshold_uncertainty_score":0.6666319},"labels":[],"label_agreement":null},{"id":"W4392243634","doi":"10.1158/1535-7163.mct-23-0876","title":"ATPase Copper Transporting Beta (ATP7B) Is a Novel Target for Improving the Therapeutic Efficacy of Docetaxel by Disulfiram/Copper in Human Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chao Family Comprehensive Cancer Center; National Cancer Institute; National Institutes of Health; National Institute of General Medical Sciences; Canadian Institute for Advanced Research; U.S. Department of Veterans Affairs","keywords":"Disulfiram; Docetaxel; Cancer; Prostate cancer; Copper; Pharmacology; Medicine; Cancer research; Internal medicine; Chemistry","score_opus":0.022507716593409412,"score_gpt":0.30820903045262193,"score_spread":0.28570131385921255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392243634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90344393,0.07254687,0.012054354,0.007750063,0.0004845973,0.0027200442,0.00076635653,0.00012666415,0.00010714086],"genre_scores_gemma":[0.9938767,0.00079344836,0.00054658036,0.0030601842,0.00010974716,0.0005591718,0.00009783796,0.00017744675,0.00077891717],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973854,0.00003369411,0.0007743858,0.00063449476,0.00050550996,0.0006665125],"domain_scores_gemma":[0.99902064,0.000061711464,0.0001848195,0.0004852685,0.0001393232,0.000108252876],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041133745,0.00043373124,0.00061015005,0.00013411685,0.00015129596,0.000058874004,0.0002820116,0.00018998902,0.00007667746],"category_scores_gemma":[0.000003164429,0.00029910298,0.00043090663,0.0005122494,0.00019355972,0.00008587087,0.00001734224,0.0004565497,0.000001200313],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049939146,0.0003462167,0.0038251628,0.0012433799,0.00069701875,0.00003002254,0.0041400488,0.00022444026,0.96843296,0.0006870421,0.000090930356,0.019783411],"study_design_scores_gemma":[0.0077114166,0.00049160706,0.004314959,0.0015136121,0.002206787,0.0000072593834,0.00060502463,0.0031764936,0.9299547,0.0005739038,0.048635893,0.00080834277],"about_ca_topic_score_codex":0.00039003548,"about_ca_topic_score_gemma":0.00017990534,"teacher_disagreement_score":0.090432756,"about_ca_system_score_codex":0.00017954424,"about_ca_system_score_gemma":0.00039026974,"threshold_uncertainty_score":0.9999461},"labels":[],"label_agreement":null},{"id":"W4394750689","doi":"10.1158/1535-7163.mct-23-0761","title":"Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Beetle Biology and Toxicology Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quebec Rehabilitation Research Network; Telesta Therapeutics (Canada)","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; National Institutes of Health; U.S. Department of Defense","keywords":"RNase P; Biology; Leiomyosarcoma; Immunohistochemistry; Copy number analysis; Copy-number variation; Microarray; Molecular biology; Cancer research; Andrology; Gene; Pathology; Medicine; Genetics; Immunology; Gene expression; RNA","score_opus":0.01985373473061958,"score_gpt":0.2875097695471899,"score_spread":0.2676560348165703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394750689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94467175,0.052778207,0.0006475464,0.0006438763,0.0007402976,0.00020939739,0.0001229291,0.000023321885,0.00016267088],"genre_scores_gemma":[0.99679416,0.0017844045,0.000114670846,0.0008395379,0.000075414086,0.00004525248,0.000018084096,0.000026339998,0.00030213484],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988564,0.00015744114,0.00029478502,0.00033017006,0.0001364438,0.0002247471],"domain_scores_gemma":[0.99921536,0.000020856058,0.00010721861,0.0005100251,0.00011952519,0.000027030768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020638609,0.00018458517,0.00021954716,0.00004705419,0.000077019584,0.000007625043,0.00029453848,0.00023094473,0.00001213502],"category_scores_gemma":[0.000016414544,0.00013510117,0.00029938496,0.00020937534,0.00062476844,0.0000026045866,0.00020464437,0.00014070763,0.0000015928782],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007758919,0.000075982614,0.005181289,0.00011671656,0.0008973938,0.000017918914,0.00018420168,0.000060307608,0.99149686,0.0011039736,0.00036019227,0.00042760323],"study_design_scores_gemma":[0.00021986928,0.00015019308,0.0033040545,0.00005173205,0.00018857738,0.00001777644,0.000056993624,0.00004085172,0.96638095,0.0004079791,0.029034415,0.00014658677],"about_ca_topic_score_codex":0.000033348795,"about_ca_topic_score_gemma":0.00009447042,"teacher_disagreement_score":0.05212241,"about_ca_system_score_codex":0.000022621043,"about_ca_system_score_gemma":0.00017842826,"threshold_uncertainty_score":0.5509266},"labels":[],"label_agreement":null},{"id":"W4398256048","doi":"10.1158/1535-7163.mct-23-0681","title":"Radiation and Chemo-Sensitizing Effects of DNA-PK Inhibitors Are Proportional in Tumors and Normal Tissues","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Etoposide; DNA; DNA damage; Cancer research; Sensitization; Chemistry; Biology; Molecular biology; Pharmacology; Pathology; Chemotherapy; Immunology; Medicine; Biochemistry","score_opus":0.006169938039703382,"score_gpt":0.24723507276119552,"score_spread":0.24106513472149213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398256048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.970185,0.028778829,0.00047058353,0.00016981902,0.00013782171,0.00020434675,0.000007355514,0.000014588713,0.000031695432],"genre_scores_gemma":[0.9982337,0.0010770886,0.0002877241,0.00021510181,0.00007651056,0.000026187225,0.000018057652,0.000026949336,0.000038732665],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992753,0.000039011888,0.00015976872,0.00025965908,0.00012371861,0.00014252246],"domain_scores_gemma":[0.9997592,0.000009295968,0.000054535303,0.00010947157,0.000031107567,0.000036389796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009702823,0.00012596989,0.00012966008,0.000063670675,0.00002059642,0.00002186745,0.000038515267,0.00010177317,0.0000018535064],"category_scores_gemma":[0.000010520784,0.00012662286,0.00003510716,0.000092649585,0.00006165212,0.0000061633677,0.00004916865,0.000074362026,3.525801e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023544915,0.000016687387,0.001968555,0.00024327391,0.00006808706,0.000054622564,0.00016819181,0.000028799439,0.97040397,0.00015671576,0.0000103644,0.026857197],"study_design_scores_gemma":[0.00029983677,0.00011527469,0.0035310406,0.00016914107,0.000038834034,0.00002313998,0.00004511094,0.00061768305,0.9931519,0.00018308448,0.001683281,0.0001416628],"about_ca_topic_score_codex":0.000025330824,"about_ca_topic_score_gemma":0.00001964251,"teacher_disagreement_score":0.028048687,"about_ca_system_score_codex":0.000023357341,"about_ca_system_score_gemma":0.00005758993,"threshold_uncertainty_score":0.5163531},"labels":[],"label_agreement":null},{"id":"W4398256251","doi":"10.1158/1535-7163.mct-23-0564","title":"PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Telesta Therapeutics (Canada)","funders":"National Cancer Institute; National Institutes of Health; Susan G. Komen; Golfers Against Cancer; Cancer Prevention and Research Institute of Texas; Breast Cancer Research Foundation; Pfizer; Robert and Janice McNair Foundation; Susan G. Komen for the Cure","keywords":"Palbociclib; Gemcitabine; Breast cancer; Cancer research; Estrogen receptor; Cancer; Tamoxifen; Medicine; Internal medicine; Biology; Oncology; Metastatic breast cancer","score_opus":0.019532345515422503,"score_gpt":0.31857852558174427,"score_spread":0.2990461800663218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398256251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7095473,0.26607382,0.003448389,0.01734625,0.00041367792,0.0018497136,0.0010905114,0.000121329766,0.0001090088],"genre_scores_gemma":[0.98847514,0.003179417,0.0023107121,0.0032876306,0.00015004039,0.0010787648,0.000009754871,0.00015792111,0.0013505999],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979921,0.0001140185,0.0004559137,0.00063768344,0.00029667883,0.00050359697],"domain_scores_gemma":[0.99897057,0.00015948627,0.000109227425,0.00044591812,0.00016878446,0.00014601936],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023940353,0.0004322446,0.0006259494,0.0002709876,0.00005421392,0.000036339286,0.00011622522,0.00016716978,0.00020647177],"category_scores_gemma":[0.0000068505124,0.00036235797,0.00022517858,0.0005127311,0.00023117787,0.00007958041,0.000029304727,0.00019082124,0.0000017769263],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03305874,0.00043168696,0.010328052,0.0015867525,0.0030088087,0.00017412017,0.0076750284,0.00018274681,0.6909646,0.00083690963,0.00010842059,0.25164416],"study_design_scores_gemma":[0.0155347055,0.0021473942,0.04988849,0.004312242,0.0016619244,0.00019061132,0.0006711002,0.004851228,0.2506216,0.008608978,0.6600329,0.0014787897],"about_ca_topic_score_codex":0.00014881812,"about_ca_topic_score_gemma":0.00014101551,"teacher_disagreement_score":0.6599245,"about_ca_system_score_codex":0.0010919565,"about_ca_system_score_gemma":0.0009836067,"threshold_uncertainty_score":0.9998828},"labels":[],"label_agreement":null},{"id":"W4399504358","doi":"10.1158/1538-8514.synthleth24-b009","title":"Abstract B009: Exploring the putative Kras-p53 mutational interface for vulnerability","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"KRAS; Oncogene; Biology; Mutation; Cancer; Cancer research; Gene; Mutant; Carcinogenesis; Genetics; Cell cycle","score_opus":0.08243197940406843,"score_gpt":0.3663281620360799,"score_spread":0.28389618263201144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69124955,0.042652756,0.24326077,0.01510431,0.002972168,0.0026331525,0.0003268765,0.0004331236,0.0013673092],"genre_scores_gemma":[0.9951684,0.00029217123,0.0011542534,0.0018126197,0.00025528294,0.000964378,0.00005114614,0.00011083674,0.00019094747],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99826473,0.00006216982,0.0003489068,0.00051189645,0.0004307854,0.00038153413],"domain_scores_gemma":[0.9989572,0.00023236526,0.000066167886,0.0004159154,0.00022849237,0.0000998648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034786703,0.00028225634,0.00026681757,0.000096627904,0.00014156563,0.00010037394,0.00014498341,0.00010693602,0.0001237084],"category_scores_gemma":[0.000048617592,0.0002149051,0.00031028074,0.00035486452,0.00016803776,0.000106202526,0.0000331831,0.00055135175,0.000024774963],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060911354,0.00017249168,0.00004505762,0.0006484512,0.0023058304,0.0002589443,0.004964144,0.008885033,0.70793617,0.0033777542,0.0005092194,0.27028778],"study_design_scores_gemma":[0.0018774581,0.00041870834,0.0023910857,0.0005999595,0.0010989822,0.00013199457,0.0006543347,0.018183848,0.82024807,0.0052722115,0.14854993,0.00057344267],"about_ca_topic_score_codex":0.00005191827,"about_ca_topic_score_gemma":0.00001915147,"teacher_disagreement_score":0.30391884,"about_ca_system_score_codex":0.0004811711,"about_ca_system_score_gemma":0.0005057072,"threshold_uncertainty_score":0.87635756},"labels":[],"label_agreement":null},{"id":"W4399504365","doi":"10.1158/1538-8514.synthleth24-a013","title":"Abstract A013: NF1 loss is syntetic lethal with Trastuzumab emtansine","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"In vivo; Microtubule; Microtubule polymerization; In vitro; Cancer research; Tubulin; Chemistry; Biophysics; Cell biology; Biology; Biochemistry","score_opus":0.046124812847405355,"score_gpt":0.3743399704367299,"score_spread":0.3282151575893245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83210033,0.08926605,0.010646523,0.05195432,0.001072942,0.0017373088,0.00021064874,0.00062014256,0.012391746],"genre_scores_gemma":[0.99070966,0.0023614434,0.0004797887,0.004365011,0.00030951927,0.00012444145,0.000016903423,0.00019280285,0.0014404136],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972103,0.0000489286,0.00032209873,0.00064598426,0.0010807198,0.00069195597],"domain_scores_gemma":[0.99875027,0.00007746312,0.00004256026,0.00067866675,0.00020407248,0.00024695136],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022328897,0.0003661572,0.00041085345,0.00019380363,0.00007757781,0.00013994938,0.00024460355,0.00017992037,0.0015939737],"category_scores_gemma":[0.000008948334,0.00028756124,0.00018245167,0.00067897304,0.00028634013,0.000073627576,0.00004428048,0.00080739654,0.00017629165],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022128595,0.00083938375,0.0048193852,0.0061905747,0.0061304565,0.037392788,0.0061161155,0.00038920043,0.5286522,0.002017581,0.0099375425,0.3953019],"study_design_scores_gemma":[0.0039246613,0.0021009697,0.008718983,0.004945034,0.0016233958,0.0015849748,0.00043308164,0.0038733354,0.35777217,0.0007272146,0.612893,0.0014031818],"about_ca_topic_score_codex":0.0002524147,"about_ca_topic_score_gemma":0.000050513136,"teacher_disagreement_score":0.60295546,"about_ca_system_score_codex":0.0006441124,"about_ca_system_score_gemma":0.0014231082,"threshold_uncertainty_score":0.9999577},"labels":[],"label_agreement":null},{"id":"W4399504372","doi":"10.1158/1538-8514.synthleth24-a025","title":"Abstract A025: KAT6A/B and Menin-MLL complexes coordinately regulate estrogen receptor-driven gene expression programs in breast cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Estrogen receptor; Breast cancer; Cancer research; Estrogen; Gene; Medicine; Bioinformatics; Biology; Genetics; Internal medicine","score_opus":0.02197417418845879,"score_gpt":0.2782134374509887,"score_spread":0.2562392632625299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9437083,0.053128544,0.00042265025,0.0013292928,0.00043255428,0.0004418446,0.0003884727,0.000043197026,0.0001051521],"genre_scores_gemma":[0.981534,0.016065398,0.0008259891,0.00067335076,0.00028116416,0.0002127632,0.00020052513,0.00010088108,0.00010593227],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982655,0.000047906917,0.00032615234,0.0006858638,0.00020477333,0.0004698116],"domain_scores_gemma":[0.9992916,0.00001655444,0.00008573255,0.00037400954,0.000094219125,0.00013785645],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011873316,0.00034822602,0.00027346757,0.00008820046,0.00007991647,0.00015792412,0.00023911231,0.0002405652,0.00005322689],"category_scores_gemma":[0.0000033754309,0.0003378623,0.000121044555,0.00019925764,0.00015239969,0.000011236146,0.0001694155,0.0002174227,0.0000050255167],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016660594,0.000070873204,0.0060712756,0.00008759898,0.00020906604,0.00005245119,0.0001606892,0.0008836283,0.94338137,0.00013770942,0.0004145601,0.048364174],"study_design_scores_gemma":[0.001251263,0.00019339913,0.009254813,0.00052828965,0.0001471665,0.000045652003,0.00009404593,0.0008972978,0.8704375,0.00036385568,0.11595449,0.0008322526],"about_ca_topic_score_codex":0.00051569554,"about_ca_topic_score_gemma":0.00022647907,"teacher_disagreement_score":0.11553993,"about_ca_system_score_codex":0.00012522512,"about_ca_system_score_gemma":0.0002480554,"threshold_uncertainty_score":0.9999073},"labels":[],"label_agreement":null},{"id":"W4399504382","doi":"10.1158/1538-8514.synthleth24-a006","title":"Abstract A006: Delineating functional drivers of esophageal adenocarcinoma to identify synthetic lethal interactions","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Citation; Cancer; Library science; Esophageal adenocarcinoma; Adenocarcinoma; Medicine; Cancer research; Internal medicine; Computer science","score_opus":0.052669354927098115,"score_gpt":0.38190117296881715,"score_spread":0.329231818041719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.951104,0.034446415,0.008617552,0.0033701528,0.0007264878,0.00061868597,0.00010090268,0.00011585358,0.0008999625],"genre_scores_gemma":[0.99778473,0.00015542933,0.000642394,0.0006394374,0.0001967108,0.00011018472,0.0000313801,0.000050786082,0.00038894473],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99845135,0.000034337347,0.00029188022,0.00036157842,0.0005487266,0.00031210488],"domain_scores_gemma":[0.9992287,0.00007696185,0.00004365004,0.00027723293,0.00017666421,0.00019676096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012297908,0.00019168077,0.00023875081,0.00023709747,0.000069771995,0.000049538507,0.00009850277,0.000061230894,0.0008023884],"category_scores_gemma":[0.00001584519,0.00017074654,0.00021972996,0.00035948385,0.00007103238,0.00007534424,0.00004676363,0.00032925353,0.000092684255],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001486112,0.0008761613,0.049123805,0.0017394206,0.006247388,0.006828213,0.0035789036,0.0044382755,0.6709842,0.002241208,0.0014437564,0.25101256],"study_design_scores_gemma":[0.003191391,0.0013439759,0.40977645,0.002052809,0.0020155993,0.00048171837,0.0007698877,0.0052988674,0.56581175,0.0006632703,0.007907614,0.0006866658],"about_ca_topic_score_codex":0.00022453888,"about_ca_topic_score_gemma":0.000031901895,"teacher_disagreement_score":0.36065266,"about_ca_system_score_codex":0.00039630412,"about_ca_system_score_gemma":0.0003726668,"threshold_uncertainty_score":0.87855905},"labels":[],"label_agreement":null},{"id":"W4399504392","doi":"10.1158/1538-8514.synthleth24-a020","title":"Abstract A020: TP53 mutation and prediction of platinum response in BRCA-mutated ovarian cancer: A prospective case-series analysis","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ovarian cancer; BRCA mutation; Medicine; Olaparib; Oncology; Missense mutation; Internal medicine; Germline mutation; Nonsense mutation; PARP inhibitor; Cancer; Germline; Serous fluid; Mutation; Somatic cell; Cancer research; Genetics; Biology; Gene; Poly ADP ribose polymerase","score_opus":0.020173704639477968,"score_gpt":0.3064825006325342,"score_spread":0.2863087959930562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807271,0.015226858,0.0004852414,0.0022151028,0.00014475969,0.0006261188,0.00036574906,0.00006014846,0.00014896398],"genre_scores_gemma":[0.9975732,0.001525337,0.0002756915,0.00016053447,0.000040375497,0.0003001428,0.0000417896,0.000034896057,0.000048010203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878705,0.00006983776,0.0003410709,0.0003858787,0.00022832667,0.0001878669],"domain_scores_gemma":[0.9994813,0.00005817654,0.00008830024,0.00020480907,0.000103080856,0.00006433331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020086375,0.00019149769,0.00036219365,0.0003693211,0.000042109576,0.000042745134,0.000030709754,0.00010918671,0.00011137458],"category_scores_gemma":[0.000010133209,0.00017094972,0.00011816005,0.0010431706,0.00008051555,0.00008602767,0.00001386427,0.00016826704,0.000001027565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016593011,0.0012240503,0.52732587,0.0015799652,0.026754873,0.044403695,0.027766984,0.013682088,0.15341577,0.0017602978,0.000062051855,0.18543136],"study_design_scores_gemma":[0.0045915465,0.0011837981,0.90369093,0.0008577496,0.008248834,0.0009377836,0.0009164558,0.012770005,0.06455939,0.0005966188,0.0012954215,0.00035143414],"about_ca_topic_score_codex":0.0018517757,"about_ca_topic_score_gemma":0.00096303324,"teacher_disagreement_score":0.3763651,"about_ca_system_score_codex":0.0005050722,"about_ca_system_score_gemma":0.00033314756,"threshold_uncertainty_score":0.6971127},"labels":[],"label_agreement":null},{"id":"W4399504410","doi":"10.1158/1538-8514.synthleth24-b006","title":"Abstract B006: Data-driven discoveries of molecular mechanism and therapeutic vulnerabilities of CDK12 mutant tumors","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Genome instability; Somatic cell; Transcription (linguistics); Genetics; Cancer research; Gene; DNA damage; Cell biology; DNA","score_opus":0.020590134841365283,"score_gpt":0.28168873907034986,"score_spread":0.26109860422898457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93778116,0.051981404,0.00814003,0.00031576867,0.0002687988,0.0002998242,0.0009861146,0.00001896991,0.00020791133],"genre_scores_gemma":[0.9934146,0.0052275765,0.00054876826,0.00044148308,0.000080076876,0.000033233835,0.00014269057,0.00007697794,0.000034608416],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99838907,0.000051941042,0.00044107158,0.00056575896,0.0002632047,0.00028894393],"domain_scores_gemma":[0.99874616,0.0000508963,0.0001410915,0.0008811796,0.00010816669,0.000072510455],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019074262,0.00029447392,0.0003546765,0.000082447164,0.000044178745,0.000058008685,0.00043095538,0.00015380362,0.000033407985],"category_scores_gemma":[0.000021662157,0.00027617216,0.00013341456,0.0001454266,0.00032416167,0.000010744132,0.00030335525,0.0001484213,9.0664565e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000837599,0.00005969642,0.00015581926,0.0003276166,0.0005620038,0.000025037814,0.00025473323,0.00090498675,0.9772957,0.011919826,0.000020576364,0.00839024],"study_design_scores_gemma":[0.00039759398,0.00030932872,0.0003576091,0.00016337729,0.00027805395,0.000015103659,0.00024624806,0.001537116,0.9814807,0.0070252772,0.007819957,0.0003696083],"about_ca_topic_score_codex":0.00019756128,"about_ca_topic_score_gemma":0.00007677489,"teacher_disagreement_score":0.055633407,"about_ca_system_score_codex":0.000030485484,"about_ca_system_score_gemma":0.0003494926,"threshold_uncertainty_score":0.99996907},"labels":[],"label_agreement":null},{"id":"W4399504411","doi":"10.1158/1538-8514.synthleth24-b011","title":"Abstract B011: Detecting pairwise and higher-order antagonistic epistatic effects among somatic cancer genotypes to discover synthetic lethality","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Computational Drug Discovery Methods","field":"Computer Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Epistasis; Synthetic lethality; Cancer; Somatic cell; Pairwise comparison; Genotype; Biology; Lethality; Genotype-phenotype distinction; Genetics; Gene; Computer science; Artificial intelligence","score_opus":0.02178582790011043,"score_gpt":0.3228895334487908,"score_spread":0.3011037055486804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504411","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47094196,0.008631602,0.5170418,0.0016237869,0.0010116895,0.0004301989,0.00001882195,0.00019091816,0.00010921414],"genre_scores_gemma":[0.9816425,0.00013503,0.016373035,0.001393333,0.00009296363,0.0002166316,0.0000021160308,0.00006513328,0.00007930062],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99747705,0.00030539327,0.0003735804,0.0008132851,0.00052932557,0.0005013831],"domain_scores_gemma":[0.9981965,0.0008874426,0.00009540475,0.00054552837,0.00009547777,0.00017967509],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048078064,0.00037340628,0.00034606838,0.00018128443,0.00018059555,0.000673404,0.0005093537,0.000088925925,0.000029879406],"category_scores_gemma":[0.00005690593,0.0003424221,0.000113665075,0.000778351,0.0001307835,0.00035206514,0.00025793767,0.00027003628,0.000016647944],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004701765,0.00015396049,0.0026827252,0.0029380077,0.0010274041,0.00060575287,0.004769967,0.13215998,0.06959428,0.015685992,0.000037837624,0.7702971],"study_design_scores_gemma":[0.0008572156,0.00023820263,0.210836,0.002380251,0.00067611906,0.00003708223,0.00005714839,0.66262686,0.055215176,0.06152803,0.003485542,0.0020623931],"about_ca_topic_score_codex":0.000638555,"about_ca_topic_score_gemma":0.00012569569,"teacher_disagreement_score":0.76823467,"about_ca_system_score_codex":0.0002993042,"about_ca_system_score_gemma":0.00034275276,"threshold_uncertainty_score":0.9999028},"labels":[],"label_agreement":null},{"id":"W4399504413","doi":"10.1158/1538-8514.synthleth24-b015","title":"Abstract B015: Combinatorial genetic screens to map synthetic lethal interactions and identify new cancer drug targets in <i>KRAS</i> mutant cancers","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Computational Drug Discovery Methods","field":"Computer Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; KRAS; Mutant; Cancer drugs; Synthetic lethality; Computational biology; Library science; Biology; Genetics; Computer science; Gene; Colorectal cancer","score_opus":0.024459811909872002,"score_gpt":0.34358106007884665,"score_spread":0.31912124816897464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504413","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46003577,0.030695228,0.47952476,0.017168224,0.011008691,0.00091007585,0.00009798441,0.0002672549,0.00029200956],"genre_scores_gemma":[0.9872809,0.00046318857,0.009763588,0.0018882334,0.0002824276,0.0001352085,0.0000037003904,0.000057722293,0.00012502758],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9976141,0.00016759329,0.00041119993,0.00080145575,0.00052697945,0.0004786796],"domain_scores_gemma":[0.99894845,0.00022287469,0.00007479562,0.0004344703,0.000087989996,0.00023141367],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002868096,0.0003210586,0.00029147952,0.00030511987,0.00009472964,0.00048795325,0.00062859524,0.00007127191,0.000060443057],"category_scores_gemma":[0.000013818225,0.0003360608,0.000114906856,0.00075610954,0.000067116904,0.00033582305,0.00026990054,0.000420037,0.00002378568],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013510966,0.0001873962,0.0006522889,0.0003548409,0.00080864405,0.0011422747,0.011481278,0.36927527,0.13922568,0.023408558,0.002459399,0.45086926],"study_design_scores_gemma":[0.0031389238,0.00023783073,0.034108467,0.0027680115,0.00046624296,0.00016504289,0.00040279466,0.4940191,0.12562211,0.093715936,0.2420736,0.0032819582],"about_ca_topic_score_codex":0.005087546,"about_ca_topic_score_gemma":0.0015787267,"teacher_disagreement_score":0.52724516,"about_ca_system_score_codex":0.00075307925,"about_ca_system_score_gemma":0.0010495308,"threshold_uncertainty_score":0.99990916},"labels":[],"label_agreement":null},{"id":"W4399504416","doi":"10.1158/1538-8514.synthleth24-b014","title":"Abstract B014: Unveiling the future: Exploring cutting-edge technologies for synthetic lethality discovery","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Computational Drug Discovery Methods","field":"Computer Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; Personalized medicine; Precision medicine; Drug discovery; CRISPR; Identification (biology); Cancer; Computer science; Computational biology; Cancer treatment; Data science; Medicine; Bioinformatics; Biology; DNA repair","score_opus":0.06713313725205455,"score_gpt":0.34101817805531315,"score_spread":0.2738850408032586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504416","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06703726,0.027493037,0.8877376,0.014135185,0.0024506454,0.0003957974,0.000022119835,0.0006354767,0.00009293352],"genre_scores_gemma":[0.9780508,0.00075555244,0.019711751,0.00070411706,0.00026548616,0.00043163766,0.0000034693064,0.000046596633,0.000030569274],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99818206,0.00010843057,0.0003005594,0.0006138419,0.00038937057,0.00040574494],"domain_scores_gemma":[0.9983528,0.0006898114,0.00007780491,0.0007678391,0.000082445295,0.000029249835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007666614,0.00025835654,0.00019746477,0.000114561495,0.00022712206,0.00079245935,0.0012052236,0.00008932436,0.0000023702194],"category_scores_gemma":[0.000030165018,0.00019032347,0.0002422291,0.0005671512,0.00012291379,0.00065680593,0.00030445468,0.00035308136,0.0000062548806],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012807205,0.000035440564,0.000022488894,0.00018771699,0.00023613712,0.000029720226,0.0010143126,0.022730518,0.013862051,0.24915873,0.000026155885,0.7126839],"study_design_scores_gemma":[0.00035458,0.00008529242,0.00081513496,0.00041553675,0.00017171673,0.000033053577,0.0011284756,0.35839602,0.18328938,0.3476408,0.10673895,0.0009310414],"about_ca_topic_score_codex":0.000013212754,"about_ca_topic_score_gemma":0.000006000533,"teacher_disagreement_score":0.91101354,"about_ca_system_score_codex":0.00017233161,"about_ca_system_score_gemma":0.0002559002,"threshold_uncertainty_score":0.77611655},"labels":[],"label_agreement":null},{"id":"W4399504421","doi":"10.1158/1538-8514.synthleth24-b018","title":"Abstract B018: Investigating vulnerabilities associated with chromosome arm aneuploidy in cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Aneuploidy; Chromosome; Citation; Cancer research; Medicine; Biology; Library science; Genetics; Oncology; Computer science; Gene","score_opus":0.02352014157130147,"score_gpt":0.28498421393324036,"score_spread":0.2614640723619389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.968629,0.028727168,0.00019660499,0.0010029594,0.00038697812,0.00028405857,0.00018736412,0.000049043592,0.00053684827],"genre_scores_gemma":[0.99350566,0.0028968656,0.00012422742,0.0025822048,0.00025359806,0.00023845729,0.00011387969,0.00010468341,0.00018041559],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983912,0.000049737446,0.0003044473,0.0005608635,0.00023939877,0.00045433885],"domain_scores_gemma":[0.9993276,0.0000546016,0.000080912905,0.00033909673,0.00009762071,0.0001001504],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018186239,0.0003102983,0.00024413965,0.0000906724,0.00007026329,0.00012301745,0.00021820713,0.00020275977,0.00007244065],"category_scores_gemma":[0.00003941123,0.000289821,0.000096999785,0.00031986393,0.00017612867,0.000009286453,0.0000692555,0.00030385156,0.0000036447004],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060882445,0.00016567881,0.010099376,0.00018013158,0.00054741825,0.000116185816,0.0005855623,0.012653798,0.9649433,0.0004009243,0.00030926563,0.009937493],"study_design_scores_gemma":[0.0021332535,0.0009115719,0.017164594,0.0013854668,0.0003293808,0.000021692555,0.00027682644,0.0036177973,0.8951265,0.0017704344,0.07552463,0.0017378032],"about_ca_topic_score_codex":0.00061793503,"about_ca_topic_score_gemma":0.0026580081,"teacher_disagreement_score":0.07521536,"about_ca_system_score_codex":0.00023268546,"about_ca_system_score_gemma":0.00062946544,"threshold_uncertainty_score":0.9999554},"labels":[],"label_agreement":null},{"id":"W4399504446","doi":"10.1158/1538-8514.synthleth24-b016","title":"Abstract B016: Discovering novel synthetic lethal relationships with large-scale cellular simulations","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell Image Analysis Techniques","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; Pairwise comparison; In silico; Computational biology; Computer science; Biology; Artificial intelligence; Gene; Genetics","score_opus":0.019646075350274867,"score_gpt":0.2852439478668929,"score_spread":0.26559787251661804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5620093,0.0062781405,0.42973438,0.0003048076,0.00005368882,0.00023370559,0.00006278297,0.000106452455,0.0012167497],"genre_scores_gemma":[0.9961316,0.00019861876,0.0025376305,0.00027121426,0.00012237282,0.000048993053,0.00017166244,0.00009471821,0.0004232196],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99863386,0.00004343949,0.00023736706,0.0005234859,0.00024302278,0.00031881285],"domain_scores_gemma":[0.99917,0.000025474932,0.000060363298,0.00059119693,0.00008466961,0.000068266396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017734543,0.0002510568,0.00016681245,0.00009961192,0.00014555498,0.00013695736,0.0002060731,0.0001673059,0.000054746266],"category_scores_gemma":[0.000009952048,0.00022606004,0.00016155062,0.00027894106,0.00008710605,0.000015458969,0.000074491465,0.0002877988,0.000010158351],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022947443,0.000079431054,0.0006753565,0.000041861946,0.0003329617,0.000026973892,0.00014413382,0.006393752,0.9911876,0.0001622133,0.00005988621,0.0008729341],"study_design_scores_gemma":[0.00027012915,0.00006773318,0.00055454025,0.000111508714,0.00034593514,0.0000133451595,0.00010159606,0.010166187,0.9240305,0.00013009315,0.06378293,0.00042551509],"about_ca_topic_score_codex":0.000037936607,"about_ca_topic_score_gemma":0.00024347485,"teacher_disagreement_score":0.43412226,"about_ca_system_score_codex":0.000056924466,"about_ca_system_score_gemma":0.00012322857,"threshold_uncertainty_score":0.92184615},"labels":[],"label_agreement":null},{"id":"W4399504454","doi":"10.1158/1538-8514.synthleth24-b026","title":"Abstract B026: Screening non-small cell lung cancer patient-derived organoids with epigenetic probes reveals PRMT5 as an oncogenic target","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Organoid; Cancer research; Matrigel; Epigenetics; Biology; Lung cancer; Cancer; Protein arginine methyltransferase 5; Targeted therapy; Medicine; Bioinformatics; Methyltransferase; Pathology; Cell biology; Gene; Methylation; Genetics; Angiogenesis","score_opus":0.009760627953152426,"score_gpt":0.2628823215821492,"score_spread":0.2531216936289968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92257375,0.05550219,0.019848729,0.00030281517,0.00040143984,0.0009971765,0.000087863504,0.00008650402,0.0001995426],"genre_scores_gemma":[0.9919663,0.0025278998,0.0030967204,0.0008256934,0.0003729019,0.00035744286,0.00025295978,0.00024456874,0.00035548265],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974705,0.00009802827,0.0004323699,0.00097272656,0.00039403458,0.00063235237],"domain_scores_gemma":[0.99867254,0.000011293111,0.00018734987,0.0006856485,0.00024138081,0.00020178496],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014089003,0.000515679,0.00031753702,0.00012069231,0.00015647002,0.00015745718,0.00033759468,0.00038829437,0.0001599601],"category_scores_gemma":[0.000004130445,0.0004829409,0.00018064423,0.000387924,0.00011038428,0.000020670048,0.00009667555,0.0003226718,0.000009425077],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019856682,0.00007631067,0.001404317,0.00021638202,0.0006367419,0.000037095397,0.00052046945,0.020121112,0.9546415,0.000006148271,0.00012351843,0.02201779],"study_design_scores_gemma":[0.00075462344,0.0006138191,0.0018169194,0.00030289686,0.0004084326,0.000019025732,0.00009554727,0.0030145834,0.9809085,0.00006264998,0.011280926,0.0007220388],"about_ca_topic_score_codex":0.00030792804,"about_ca_topic_score_gemma":0.00023177119,"teacher_disagreement_score":0.06939259,"about_ca_system_score_codex":0.0001875609,"about_ca_system_score_gemma":0.0008304222,"threshold_uncertainty_score":0.99976224},"labels":[],"label_agreement":null},{"id":"W4399504457","doi":"10.1158/1538-8514.synthleth24-b025","title":"Abstract B025: A genome-wide CRISPR screen identifies synthetic lethality of double-stranded RNA with BRCA1 loss","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CRISPR and Genetic Engineering","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"RNA silencing; Biology; Interferon; RNA; Programmed cell death; CRISPR; Cell biology; RNA interference; Molecular biology; Genetics; Gene; Apoptosis","score_opus":0.01680530824172085,"score_gpt":0.31105312946064945,"score_spread":0.2942478212189286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89458895,0.025482012,0.07800917,0.00042067547,0.0002235062,0.00031860932,0.000091721806,0.000049896084,0.0008154307],"genre_scores_gemma":[0.99759984,0.0013726527,0.00031264886,0.00022507586,0.0001021985,0.000040811374,0.00005337738,0.00007494641,0.00021846092],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985731,0.000027789458,0.00030674852,0.00047291417,0.00027952043,0.00033987706],"domain_scores_gemma":[0.9991978,0.000017330673,0.000062613195,0.0005295708,0.00010942055,0.00008330455],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001804734,0.00028414867,0.0002497009,0.00007434063,0.000047669273,0.000070760565,0.0002746725,0.00016241454,0.000056538847],"category_scores_gemma":[0.000004435285,0.00025209156,0.00017667659,0.00017718575,0.00015873004,0.0000066087323,0.000060359238,0.00017966735,0.0000049308933],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002094992,0.0000461109,0.00042167614,0.00030861347,0.00073029415,0.00006178933,0.00018589925,0.0046559838,0.9895017,0.00008777276,0.000029407924,0.0037612324],"study_design_scores_gemma":[0.0007204234,0.00013214507,0.0033496793,0.00013824108,0.00022285985,0.000019422023,0.00006567714,0.00011185547,0.97980475,0.00011384232,0.014963438,0.00035766046],"about_ca_topic_score_codex":0.00013253572,"about_ca_topic_score_gemma":0.00010935879,"teacher_disagreement_score":0.103010856,"about_ca_system_score_codex":0.000029559877,"about_ca_system_score_gemma":0.0001459071,"threshold_uncertainty_score":0.99999315},"labels":[],"label_agreement":null},{"id":"W4399504458","doi":"10.1158/1538-8514.synthleth24-b013","title":"Abstract B013: Deep learning-based prediction of synthetic essentialities in <i>CTNNB1</i>-mutated hepatocellular carcinoma","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Bioinformatics and Genomic Networks","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Gene; Hepatocellular carcinoma; Context (archaeology); Computational biology; Biology; Synthetic lethality; Bioinformatics; Genetics; DNA repair","score_opus":0.011712332517158001,"score_gpt":0.2354377841799214,"score_spread":0.2237254516627634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9438048,0.028681923,0.02619663,0.0001591803,0.00039937216,0.00028306138,0.00005721255,0.00003661472,0.00038123273],"genre_scores_gemma":[0.9983039,0.0009123279,0.000118178934,0.00022808983,0.000084055,0.00004476752,0.00018498063,0.00005046732,0.000073270974],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987824,0.000058829464,0.0004002192,0.00028784524,0.0001830212,0.0002876654],"domain_scores_gemma":[0.99949175,0.00001493853,0.00009278508,0.00027950096,0.0000704638,0.00005053837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020283616,0.00021280318,0.00019743263,0.000103987775,0.000039704577,0.00004594177,0.00016701713,0.00022136862,0.000039625997],"category_scores_gemma":[0.000004830136,0.0002120109,0.00015009333,0.00019154583,0.000106654836,0.0000058619603,0.00004070128,0.00023252897,0.000004066268],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016122461,0.00010696112,0.008861959,0.00055684184,0.00035703758,0.000059130954,0.000509176,0.051151447,0.91380537,0.0002617468,0.000068420915,0.024100715],"study_design_scores_gemma":[0.0009020026,0.00027193554,0.0025055495,0.00035323453,0.00016467478,0.000009168782,0.00019174811,0.3074478,0.6678767,0.00043783657,0.019410353,0.00042896453],"about_ca_topic_score_codex":0.00009755777,"about_ca_topic_score_gemma":0.00003598729,"teacher_disagreement_score":0.25629637,"about_ca_system_score_codex":0.00004528219,"about_ca_system_score_gemma":0.00016174371,"threshold_uncertainty_score":0.86455536},"labels":[],"label_agreement":null},{"id":"W4399504463","doi":"10.1158/1538-8514.synthleth24-ia024","title":"Abstract IA024: RNA-modifying enzyme inhibitors as synthetic lethal cancer therapeutics","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"RNA Helicase A; Interferon; RNA; Biology; Helicase; Cell biology; Molecular biology; Chemistry; Biochemistry; Gene; Genetics","score_opus":0.029176071433605323,"score_gpt":0.3177458225239607,"score_spread":0.2885697510903554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71945786,0.26170486,0.006625483,0.0037185787,0.0023495934,0.00062473584,0.00018904483,0.00018497794,0.0051448853],"genre_scores_gemma":[0.97645366,0.017671384,0.00017196096,0.0029089071,0.00076357456,0.0003623793,0.000053402957,0.00017558926,0.0014391467],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99754494,0.00008227691,0.00043950204,0.000864242,0.00044463587,0.00062437146],"domain_scores_gemma":[0.99876684,0.000023336908,0.00011835003,0.0007800184,0.00016416605,0.00014728493],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022351809,0.0004781324,0.0002812808,0.00010520725,0.00018922419,0.00024323529,0.00046082019,0.00037395832,0.00020257465],"category_scores_gemma":[0.000006713869,0.00044860024,0.00033455086,0.00028423787,0.00019775811,0.00001766701,0.00010140712,0.00041302646,0.00005230427],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065331646,0.00007207073,0.0000622655,0.00009916596,0.0006943119,0.00004547471,0.00024374758,0.0013544,0.8970145,0.00075495907,0.00064457126,0.098949194],"study_design_scores_gemma":[0.0002940745,0.00008802549,0.000102923776,0.0001397394,0.00022742603,0.00002053234,0.00008043374,0.00064563775,0.5893525,0.00026682857,0.40827978,0.0005020978],"about_ca_topic_score_codex":0.00044261295,"about_ca_topic_score_gemma":0.00006783549,"teacher_disagreement_score":0.4076352,"about_ca_system_score_codex":0.00018290497,"about_ca_system_score_gemma":0.0005405688,"threshold_uncertainty_score":0.99979657},"labels":[],"label_agreement":null},{"id":"W4399504483","doi":"10.1158/1538-8514.synthleth24-b017","title":"Abstract B017: Loss of UXS1 selectively kills KEAP1 mutant cancer cell lines by depleting pyrimidines and inducing replication stress","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Mutant; Cancer cell; Molecular biology; Cancer research; Cancer; Biochemistry; Chemistry; Gene; Genetics","score_opus":0.01778759834117769,"score_gpt":0.2980180303979056,"score_spread":0.2802304320567279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90538377,0.09073103,0.0025431078,0.00048788093,0.000157748,0.00022267546,0.0002571995,0.00002604576,0.00019055336],"genre_scores_gemma":[0.9794385,0.01943799,0.0001827985,0.00033369233,0.00015906214,0.00013828749,0.000082220955,0.00006042,0.0001670192],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986547,0.000036373844,0.00029699746,0.00058632676,0.0001670625,0.00025853625],"domain_scores_gemma":[0.9991613,0.000016768741,0.00014457159,0.0004267381,0.0001882524,0.000062341875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015302868,0.00021784485,0.00017808455,0.00003976372,0.000083228224,0.00006744504,0.0001740215,0.00016827538,0.000026071006],"category_scores_gemma":[0.000010667362,0.00020581685,0.0000795834,0.00017120143,0.000099026794,0.000013146923,0.000051751926,0.00013015006,7.3315175e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029159995,0.000047522954,0.0016446332,0.00017283535,0.00017402577,0.0000023671264,0.0001911309,0.0003942825,0.96892726,0.000044433622,0.00017077987,0.028201543],"study_design_scores_gemma":[0.00020828517,0.00005718643,0.0014429996,0.00013269551,0.000101359336,0.0000037218826,0.000097030206,0.00058681495,0.97412044,0.000045182558,0.022958187,0.00024610444],"about_ca_topic_score_codex":0.0008031413,"about_ca_topic_score_gemma":0.00015713369,"teacher_disagreement_score":0.074054755,"about_ca_system_score_codex":0.00007066388,"about_ca_system_score_gemma":0.00020046416,"threshold_uncertainty_score":0.8392967},"labels":[],"label_agreement":null},{"id":"W4399504496","doi":"10.1158/1538-8514.synthleth24-a009","title":"Abstract A009: Synthetic lethality in the context of STAG2-mutant Ewing sarcoma","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; Sarcoma; Context (archaeology); Cancer research; Biology; Metastasis; Cancer; CRISPR; Mutant; Genetics; Medicine; Gene; Pathology","score_opus":0.022651395863248824,"score_gpt":0.29375279504041024,"score_spread":0.2711013991771614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95401835,0.04178417,0.0012210243,0.0012566759,0.00037016365,0.00029317752,0.00015889962,0.000011840811,0.00088566984],"genre_scores_gemma":[0.9943543,0.0031168328,0.00006318863,0.0022167193,0.00011629211,0.000047546117,0.000027532376,0.000039495713,0.000018064917],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99876964,0.00007607651,0.00031795847,0.00034103187,0.0002176671,0.00027762356],"domain_scores_gemma":[0.99927187,0.00007339056,0.0000665835,0.0004923892,0.0000580315,0.000037735124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036179688,0.00019264287,0.0001883506,0.000054968437,0.000038345683,0.00006244546,0.00033973463,0.00012869561,0.000025108602],"category_scores_gemma":[0.000020486857,0.00015488887,0.00016079818,0.00017748628,0.00012453855,0.0000036769445,0.00006623143,0.0001934589,0.000003829355],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000069976355,0.000089910565,0.00063409697,0.00012195294,0.00017731567,0.00006514891,0.0007084966,0.00026925208,0.95183474,0.002115391,0.000120127326,0.043793593],"study_design_scores_gemma":[0.0005486373,0.0001879362,0.0025185836,0.00017436226,0.00012381183,0.000020824387,0.0007223768,0.00039460254,0.8183941,0.00081836205,0.17573142,0.00036492935],"about_ca_topic_score_codex":0.000333377,"about_ca_topic_score_gemma":0.00027391454,"teacher_disagreement_score":0.1756113,"about_ca_system_score_codex":0.000055155004,"about_ca_system_score_gemma":0.00024690054,"threshold_uncertainty_score":0.63161844},"labels":[],"label_agreement":null},{"id":"W4399504508","doi":"10.1158/1538-8514.synthleth24-pr011","title":"Abstract PR011: Inhibiting eIF4E phosphorylation sensitizes triple-negative breast cancer to CDK4/6 inhibition","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Triple-negative breast cancer; EIF4E; Cancer research; Cancer; Gene knockdown; Biology; Carcinogenesis; EIF4EBP1; MAPK/ERK pathway; Kinase; Small hairpin RNA; Metastasis; Breast cancer; Translation (biology); Cell biology; Messenger RNA; Cell culture; Genetics; Gene","score_opus":0.01769327595877911,"score_gpt":0.2959992058422084,"score_spread":0.2783059298834293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97093517,0.013509408,0.008904547,0.0028735604,0.0013957823,0.00076911727,0.0006279849,0.00016354858,0.00082087546],"genre_scores_gemma":[0.9930069,0.00088398205,0.0005612838,0.003769059,0.0009253264,0.00027276677,0.000117347845,0.00014489102,0.0003184538],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99772435,0.00008670511,0.0004162807,0.0008175475,0.00042381443,0.00053130346],"domain_scores_gemma":[0.99900895,0.000032264965,0.00012731654,0.000373226,0.000298175,0.00016007666],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002676968,0.0004187023,0.00026717348,0.00013779421,0.00015086163,0.00017387758,0.00016685305,0.00028864213,0.00016454227],"category_scores_gemma":[0.000021682104,0.00043098786,0.00021001538,0.00045481385,0.00010333439,0.000021618798,0.00009999201,0.00031787975,0.000036827467],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022350825,0.00003667835,0.00018038873,0.00009940665,0.00035794388,0.000046726953,0.00040884555,0.0029529193,0.9553859,0.0000876419,0.0011850697,0.039034963],"study_design_scores_gemma":[0.0005992428,0.00012624191,0.0013522401,0.00048801943,0.00014386754,0.000031452666,0.00010625975,0.0007464627,0.9802598,0.00028011718,0.015266143,0.00060020224],"about_ca_topic_score_codex":0.0004126535,"about_ca_topic_score_gemma":0.00018993433,"teacher_disagreement_score":0.038434763,"about_ca_system_score_codex":0.00032757738,"about_ca_system_score_gemma":0.00043444094,"threshold_uncertainty_score":0.9998142},"labels":[],"label_agreement":null},{"id":"W4399504518","doi":"10.1158/1538-8514.synthleth24-pr005","title":"Abstract PR005: CX-5461 sensitizes DNA damage repair-proficient castrate-resistant prostate cancer to PARP inhibition","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Poly ADP ribose polymerase; Cancer research; PARP inhibitor; DNA repair; DNA damage; Medicine; Cancer; In vivo; Internal medicine; Biology; Oncology; Polymerase; DNA; Genetics","score_opus":0.03612750988906618,"score_gpt":0.3464587231508978,"score_spread":0.31033121326183166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9610215,0.023441553,0.00012635955,0.010925413,0.0005761652,0.0017950056,0.00040506606,0.00041936061,0.0012895878],"genre_scores_gemma":[0.9906889,0.0026292852,0.0002742919,0.0024874392,0.0002500832,0.0005814183,0.0001287891,0.00013160624,0.0028281817],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997167,0.000070381786,0.00042046732,0.00077281555,0.0007902058,0.0007791605],"domain_scores_gemma":[0.9987676,0.000035090736,0.00006321609,0.0005051843,0.00029195403,0.00033696604],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028782402,0.0004085265,0.00039555685,0.0002561867,0.00016302023,0.00017241374,0.00009323539,0.00015484134,0.00026287846],"category_scores_gemma":[0.000008024248,0.00032417275,0.00026235654,0.0007155307,0.00015292919,0.00010629353,0.00007074188,0.00044946725,0.000084453284],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013463795,0.00017512396,0.0005473747,0.00087731093,0.00089167256,0.0038308625,0.0017926694,0.00036488796,0.97208786,0.00020924622,0.0016530053,0.01622362],"study_design_scores_gemma":[0.002160603,0.0008428518,0.009421268,0.0021472403,0.0007381613,0.000044546956,0.00059701514,0.0015805921,0.90600026,0.000199622,0.075592004,0.00067586126],"about_ca_topic_score_codex":0.00065909594,"about_ca_topic_score_gemma":0.00022446827,"teacher_disagreement_score":0.073938996,"about_ca_system_score_codex":0.00088644336,"about_ca_system_score_gemma":0.000994325,"threshold_uncertainty_score":0.999921},"labels":[],"label_agreement":null},{"id":"W4399504527","doi":"10.1158/1538-8514.synthleth24-pr014","title":"Abstract PR014: Combinatorial genetic screens to map synthetic lethal interactions and identify new cancer drug targets in <i>KRAS</i> mutant cancers","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CRISPR and Genetic Engineering","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CRISPR; Computational biology; Cas9; Biology; Gene; Synthetic lethality; Genetics; Precision medicine; Personalized medicine; KRAS; Drug discovery; Genetic screen; Mutant; Mutation; Bioinformatics","score_opus":0.011146393027114728,"score_gpt":0.32737120774996303,"score_spread":0.3162248147228483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91931295,0.060848042,0.013466005,0.0021910793,0.0033297043,0.0005423056,0.00010205252,0.00005297858,0.00015487985],"genre_scores_gemma":[0.995402,0.0024594592,0.00045050934,0.0006962895,0.00048591255,0.00013036474,0.000018629024,0.000085951695,0.00027088297],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984122,0.00003602947,0.0003028057,0.0005999604,0.00021366386,0.00043537654],"domain_scores_gemma":[0.9993735,0.000017752543,0.000038587426,0.00032298794,0.000050380146,0.00019679846],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000103752296,0.00030619834,0.00022257463,0.00012968127,0.000057275618,0.000114830844,0.00020742396,0.00012190464,0.0000726045],"category_scores_gemma":[0.00000811058,0.00032341052,0.00010504804,0.0002070594,0.0000537012,0.0000085409365,0.00010569942,0.0002660613,0.000009627252],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006739421,0.000029035302,0.00039659845,0.00011817708,0.00024994533,0.000083781546,0.00062100583,0.012492874,0.9650127,0.000061029827,0.0010527986,0.019814637],"study_design_scores_gemma":[0.0009299931,0.00011775263,0.0049041123,0.00045168266,0.00020178298,0.00003521961,0.00019623114,0.0016538813,0.76679957,0.00032775174,0.22358336,0.0007986755],"about_ca_topic_score_codex":0.002046675,"about_ca_topic_score_gemma":0.0022205296,"teacher_disagreement_score":0.22253056,"about_ca_system_score_codex":0.00016952465,"about_ca_system_score_gemma":0.00034252275,"threshold_uncertainty_score":0.9999218},"labels":[],"label_agreement":null},{"id":"W4399504533","doi":"10.1158/1538-8514.synthleth24-b022","title":"Abstract B022: TEAD inhibition overcomes YAP/TAZ-driven resistance to RAS(ON) inhibitors","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Hippo pathway signaling and YAP/TAZ","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Hippo signaling pathway; KRAS; Biology; Cancer research; Transcription factor; In vivo; CRISPR; Kinase; Cell biology; Mutation; Genetics; Gene","score_opus":0.01731672147573724,"score_gpt":0.2854520544565914,"score_spread":0.2681353329808541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97990084,0.011701575,0.0022295415,0.0020677166,0.00080186944,0.00038116207,0.00015159552,0.0001279852,0.002637696],"genre_scores_gemma":[0.9925168,0.0006872288,0.00036773243,0.0043001343,0.0005500983,0.00011342291,0.00009093272,0.000111522095,0.0012620899],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99802154,0.00007523584,0.00032773815,0.00073026353,0.0003828122,0.00046241048],"domain_scores_gemma":[0.99910784,0.000023673134,0.000063967804,0.0005383541,0.00010108165,0.00016508884],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019241238,0.00036231443,0.00023016903,0.00013798874,0.00012677256,0.00013380892,0.0002215731,0.00026646414,0.000053903186],"category_scores_gemma":[0.000018929852,0.00035075186,0.00023208279,0.00031031444,0.00007716802,0.0000088765,0.000071753326,0.00028717934,0.00014236204],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013166183,0.000060313472,0.00010233357,0.00008002005,0.00019149037,0.00008368777,0.00021255082,0.0010592433,0.98901784,0.00033637325,0.0009907596,0.007733747],"study_design_scores_gemma":[0.0002799019,0.00018044683,0.00022661647,0.0003427858,0.00005102804,0.000004025381,0.00003762775,0.00005153122,0.74635756,0.00021260459,0.25185737,0.00039849977],"about_ca_topic_score_codex":0.000025028814,"about_ca_topic_score_gemma":0.00007672822,"teacher_disagreement_score":0.25086662,"about_ca_system_score_codex":0.00010928388,"about_ca_system_score_gemma":0.00021163619,"threshold_uncertainty_score":0.99989444},"labels":[],"label_agreement":null},{"id":"W4399504538","doi":"10.1158/1538-8514.synthleth24-pr001","title":"Abstract PR001: KIF18A inhibition, via ATX020, leads to mitotic arrest and robust anti-tumor activity through a synthetic lethal interaction with chromosome instability","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Mitosis; Cell cycle checkpoint; Kinesin; Mitotic catastrophe; Cell cycle; Cell biology; Synthetic lethality; Biology; Genome instability; Cell growth; Chromosome instability; DNA damage; Microtubule; Molecular biology; Apoptosis; DNA repair; Genetics; Chromosome; DNA; Gene","score_opus":0.016252035979291327,"score_gpt":0.2701834701455655,"score_spread":0.2539314341662742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9606348,0.002142633,0.035123732,0.00090278086,0.00038333182,0.0005043874,0.00006763221,0.000053005413,0.00018767278],"genre_scores_gemma":[0.99728227,0.00047259548,0.00060556305,0.0011793223,0.00018715125,0.00010460586,0.000048922135,0.00008185819,0.000037708407],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983605,0.00007450483,0.0002366487,0.00075439666,0.00020265621,0.00037128697],"domain_scores_gemma":[0.9992361,0.000018593655,0.00007598488,0.00045695776,0.000103606966,0.00010872148],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012243082,0.0003494208,0.00025789547,0.00006197507,0.00010913686,0.00013120206,0.00012912841,0.00016933886,0.000026543077],"category_scores_gemma":[0.000010026531,0.00031591798,0.0001073045,0.00022062093,0.00016286602,0.000030400915,0.00009172134,0.00029853,0.000010622056],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016786544,0.00014213688,0.0005475578,0.0002251416,0.00021411711,0.00007306399,0.00018818192,0.0016648973,0.99172413,0.000032797234,0.000041827,0.0049782936],"study_design_scores_gemma":[0.00049941713,0.00044498636,0.0030643812,0.00033479245,0.00020693078,0.00016396614,0.000056381687,0.0009786336,0.97557133,0.000069719215,0.017997824,0.00061164313],"about_ca_topic_score_codex":0.0001375554,"about_ca_topic_score_gemma":0.00032046268,"teacher_disagreement_score":0.03664745,"about_ca_system_score_codex":0.00011682847,"about_ca_system_score_gemma":0.00017579671,"threshold_uncertainty_score":0.9999293},"labels":[],"label_agreement":null},{"id":"W4399504543","doi":"10.1158/1538-8514.synthleth24-ia006","title":"Abstract IA006: Synthetic lethalities for SWI/SNF mutant cancers","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"SMARCA4; SWI/SNF; ARID1A; SMARCB1; Cancer research; Biology; Chromatin remodeling; Chromatin; Protein subunit; Cancer; Genetics; Mutation; Gene","score_opus":0.025110584373677736,"score_gpt":0.30821713346379886,"score_spread":0.2831065490901211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85457486,0.10048783,0.038545653,0.0015765419,0.0018266783,0.000650315,0.00041550552,0.00015576741,0.0017668272],"genre_scores_gemma":[0.9934207,0.0027739853,0.0005156725,0.0016311099,0.00046421113,0.0002725597,0.00007513708,0.00010929964,0.00073729083],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99855024,0.000027680528,0.00026784898,0.00052909367,0.00021214395,0.0004129705],"domain_scores_gemma":[0.99932754,0.000024131175,0.000054942,0.0004150611,0.00010046578,0.000077887395],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017171857,0.00027770083,0.0001996396,0.000051381972,0.00009662778,0.000104389175,0.00023501845,0.00019233231,0.00006724842],"category_scores_gemma":[0.000010540317,0.0002606467,0.0002668032,0.000107211235,0.00010535817,0.0000051309753,0.000040911542,0.00014037943,0.000008606204],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008040478,0.00001972286,0.0000150483165,0.0002786081,0.0004410209,0.00001438822,0.00019343643,0.0034490393,0.94903505,0.00047531823,0.0007188059,0.045279168],"study_design_scores_gemma":[0.00037673622,0.0001276608,0.000019246805,0.00019597422,0.00016100943,0.00001776936,0.00014065494,0.0044495333,0.7123534,0.0008655151,0.28087485,0.00041762355],"about_ca_topic_score_codex":0.0001714486,"about_ca_topic_score_gemma":0.00007843492,"teacher_disagreement_score":0.28015605,"about_ca_system_score_codex":0.00015695092,"about_ca_system_score_gemma":0.0004978248,"threshold_uncertainty_score":0.99998456},"labels":[],"label_agreement":null},{"id":"W4399504544","doi":"10.1158/1538-8514.synthleth24-pr016","title":"Abstract PR016: Investigating vulnerabilities associated with chromosome arm aneuploidy in cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Aneuploidy; Chromosome instability; Cancer research; Carcinogenesis; Cancer; Lung cancer; Chromosome; Metastasis; Genetics; Pathology; Gene; Medicine","score_opus":0.02427322320843445,"score_gpt":0.2893144687131825,"score_spread":0.26504124550474806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9454871,0.04938897,0.00016167453,0.0008316644,0.0029807833,0.0003581404,0.00013494767,0.00007633044,0.0005804187],"genre_scores_gemma":[0.99052227,0.0033008123,0.00009930697,0.002179214,0.002774485,0.0003376517,0.000094196905,0.000114435315,0.000577645],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981682,0.000084231535,0.0003264936,0.00061021006,0.00030189744,0.00050899526],"domain_scores_gemma":[0.99931043,0.000027079033,0.00009034709,0.00035822942,0.00010619522,0.00010773387],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022902315,0.0003424961,0.0003028901,0.000101566126,0.00007542755,0.000099752266,0.00022562165,0.0002296637,0.00008846158],"category_scores_gemma":[0.000027420141,0.00030567215,0.000119346165,0.00036268967,0.00020755369,0.000014653712,0.000055574714,0.0003551455,0.0000033726915],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005803919,0.000120528246,0.003446661,0.00018423372,0.00049430766,0.0000064298924,0.0007375368,0.0030132406,0.97977376,0.00018998368,0.00091537,0.0110598905],"study_design_scores_gemma":[0.0020823043,0.00046270184,0.01367848,0.0011265732,0.00033042952,0.000018705985,0.00030097432,0.0010438099,0.46136582,0.00068634754,0.51749617,0.0014076892],"about_ca_topic_score_codex":0.0006532878,"about_ca_topic_score_gemma":0.0024039212,"teacher_disagreement_score":0.51840794,"about_ca_system_score_codex":0.00017537405,"about_ca_system_score_gemma":0.00067578466,"threshold_uncertainty_score":0.99993956},"labels":[],"label_agreement":null},{"id":"W4399504601","doi":"10.1158/1538-8514.synthleth24-a021","title":"Abstract A021: Hunting for synthetic lethal partners in DNA damage response-altered endometrial cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Endometrial cancer; Ovarian cancer; ARID1A; Biology; Cancer; Synthetic lethality; Biomarker; Computational biology; Cancer research; Medicine; Gene; Genetics; DNA repair; Mutation","score_opus":0.04197064345278476,"score_gpt":0.35958159737386725,"score_spread":0.31761095392108246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9723129,0.021151027,0.0036824723,0.0008808266,0.0011183083,0.00046534144,0.00012987446,0.000050524835,0.00020868769],"genre_scores_gemma":[0.9965023,0.0009869927,0.00043237073,0.00066448096,0.0006150003,0.00037562472,0.000047508696,0.000106470914,0.0002692957],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981352,0.000111681155,0.00038972587,0.0006264631,0.00023675359,0.00050014316],"domain_scores_gemma":[0.99926394,0.00010034723,0.00008405663,0.00039673538,0.00007891165,0.00007599583],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005881246,0.0002916806,0.00026588247,0.00015925031,0.000075083706,0.00011262396,0.0002633399,0.00023339954,0.000053848373],"category_scores_gemma":[0.00007046794,0.0002902449,0.00025430383,0.00029377194,0.00008384723,0.00000805029,0.00005908132,0.00021581989,0.0000042521133],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094612053,0.000035795547,0.00015575194,0.00014213065,0.00023177388,0.000023301818,0.00017236924,0.003446653,0.9642854,0.000040444847,0.00017658637,0.03034372],"study_design_scores_gemma":[0.0021282039,0.00021658707,0.0008082124,0.00041825557,0.00016429431,0.000010479172,0.0001220382,0.007116157,0.87886304,0.00021534736,0.10929733,0.0006400463],"about_ca_topic_score_codex":0.00019983282,"about_ca_topic_score_gemma":0.00022200403,"teacher_disagreement_score":0.10912074,"about_ca_system_score_codex":0.00015404203,"about_ca_system_score_gemma":0.00047482987,"threshold_uncertainty_score":0.999955},"labels":[],"label_agreement":null},{"id":"W4399504621","doi":"10.1158/1538-8514.synthleth24-b020","title":"Abstract B020: Novel WRN helicase inhibitors selectively target microsatellite unstable cancer cells","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Helicase; Cancer; Microsatellite instability; Cancer cell; DNA; DNA replication; Biology; DNA damage; In vivo; Molecular biology; Cancer research; Genetics; Microsatellite; Gene","score_opus":0.019242336463347318,"score_gpt":0.28797967615959064,"score_spread":0.2687373396962433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79015934,0.17543808,0.026771443,0.0021838106,0.0019284604,0.00078174856,0.001026434,0.00015454089,0.0015561156],"genre_scores_gemma":[0.98409647,0.010045844,0.0011354921,0.0023315013,0.00053781044,0.00028509813,0.00012075439,0.00013649814,0.0013105425],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99811447,0.00003441285,0.00032930495,0.0007460067,0.00025084763,0.0005249519],"domain_scores_gemma":[0.99909645,0.000013870507,0.000089845635,0.00047948683,0.00018778202,0.0001325337],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014652709,0.00036060906,0.00021675638,0.00008929424,0.00014196515,0.00017768069,0.0002879168,0.00025375086,0.00024263149],"category_scores_gemma":[0.000003984975,0.00034809785,0.00021612935,0.00038656566,0.00012285518,0.000014010801,0.00006883908,0.0002684481,0.000033614004],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057263816,0.000107749045,0.00008752959,0.00008098959,0.00039319176,0.000016566073,0.0001211778,0.0019676297,0.9805314,0.00017052406,0.0020052742,0.014460691],"study_design_scores_gemma":[0.0002322988,0.000050085007,0.0001019803,0.000052055344,0.00006545645,0.0000056396925,0.000024974834,0.000356469,0.62635934,0.000069950016,0.3723808,0.00030094926],"about_ca_topic_score_codex":0.00033815292,"about_ca_topic_score_gemma":0.000078527875,"teacher_disagreement_score":0.3703755,"about_ca_system_score_codex":0.00015969809,"about_ca_system_score_gemma":0.000552219,"threshold_uncertainty_score":0.9998971},"labels":[],"label_agreement":null},{"id":"W4399504630","doi":"10.1158/1538-8514.synthleth24-pr004","title":"Abstract PR004: Computational discovery of paralog dependencies drives target identification in lung cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Bioinformatics and Genomic Networks","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Druggability; Synthetic lethality; Gene duplication; Lung cancer; Biology; Cancer; Gene; Copy-number variation; Computational biology; Crizotinib; Genetics; Genome; Bioinformatics; Cancer research; Medicine; DNA repair; Oncology","score_opus":0.011426439612726784,"score_gpt":0.2841934073314392,"score_spread":0.27276696771871245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8465308,0.059212036,0.09248051,0.0004944726,0.0005173902,0.00030981563,0.00018742925,0.000015954784,0.0002515869],"genre_scores_gemma":[0.996719,0.0018773811,0.0006305947,0.0003073006,0.00008465925,0.000059688333,0.00016008114,0.000024049954,0.00013721758],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990657,0.000022505374,0.0003368448,0.00022720502,0.00016129066,0.00018648153],"domain_scores_gemma":[0.99963135,0.000011928874,0.000093614675,0.0001810172,0.000056803372,0.000025298647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013481376,0.00014317474,0.00013633362,0.00006478644,0.000029044902,0.00006897196,0.00016219416,0.00012410487,0.000018721335],"category_scores_gemma":[0.000002596685,0.00013591185,0.00009405864,0.00013205325,0.000075789736,0.000016031245,0.000045578407,0.00011875506,0.0000014975262],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006984949,0.00007349335,0.007234985,0.00046441468,0.00052686856,0.000011008314,0.0006101143,0.14661011,0.8284276,0.002261273,0.00044634024,0.013263908],"study_design_scores_gemma":[0.0014929516,0.0001588004,0.076780505,0.00077724585,0.0003025012,0.000014574673,0.0003594058,0.23321979,0.65278405,0.015533125,0.017282328,0.0012947132],"about_ca_topic_score_codex":0.00007104344,"about_ca_topic_score_gemma":0.00010320236,"teacher_disagreement_score":0.17564358,"about_ca_system_score_codex":0.000045397443,"about_ca_system_score_gemma":0.00021471024,"threshold_uncertainty_score":0.5542324},"labels":[],"label_agreement":null},{"id":"W4399504642","doi":"10.1158/1538-8514.synthleth24-a011","title":"Abstract A011: Enhancing chaperone-mediated autophagy to impede glioblastoma growth","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Autophagy in Disease and Therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Autophagy; Downregulation and upregulation; Cancer research; Cell growth; Cell; Cell biology; Cancer cell; Gene knockdown; Cell cycle; Lysosome; Glioblastoma; Cell culture; Biology; Cancer; Apoptosis; Biochemistry; Gene; Genetics","score_opus":0.014623750132437874,"score_gpt":0.30705426175059897,"score_spread":0.2924305116181611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95741504,0.032216717,0.0039296914,0.0032159507,0.00080051494,0.00063050067,0.000057241654,0.00057468686,0.0011596697],"genre_scores_gemma":[0.9843173,0.0010297511,0.0002376044,0.013279263,0.00037275447,0.00014655244,0.000024520814,0.00014013203,0.0004521364],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980098,0.000033205575,0.0003609618,0.00054260885,0.00049012585,0.00056330307],"domain_scores_gemma":[0.998987,0.000060804843,0.00004788278,0.00043105293,0.00012082267,0.00035242256],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001463531,0.0003542171,0.0003669614,0.00024605784,0.00008508047,0.00009076548,0.00019115223,0.00017670145,0.000815258],"category_scores_gemma":[0.000016793792,0.00031360524,0.00024412764,0.0006026054,0.00006246972,0.00009474997,0.00004784984,0.00035103504,0.00044007174],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003466074,0.0001260025,0.000091159745,0.00025033852,0.0008596836,0.001224718,0.0011094647,0.000025922407,0.9709714,0.0008872622,0.00027219133,0.02383527],"study_design_scores_gemma":[0.0009892759,0.00049693626,0.004638691,0.00049284456,0.00038581813,0.00005166907,0.000097147604,0.0009814102,0.95834845,0.00051902153,0.032535408,0.00046335175],"about_ca_topic_score_codex":0.00007413147,"about_ca_topic_score_gemma":0.000022807988,"teacher_disagreement_score":0.032263216,"about_ca_system_score_codex":0.0002492017,"about_ca_system_score_gemma":0.00042215994,"threshold_uncertainty_score":0.9999316},"labels":[],"label_agreement":null},{"id":"W4399504645","doi":"10.1158/1538-8514.synthleth24-ia018","title":"Abstract IA018: Vulnerabilities of TP53-mutated AML and therapeutic implications","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CRISPR; Biology; Myeloid leukemia; Cancer research; Mutant; Etoposide; Gene; Genetics; Chemotherapy","score_opus":0.020459853698692798,"score_gpt":0.29845115482399365,"score_spread":0.27799130112530085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9408836,0.05108208,0.004568175,0.0018196012,0.000226276,0.00029056292,0.00009137398,0.00005202292,0.0009863451],"genre_scores_gemma":[0.9968582,0.001634928,0.00020345754,0.00082016096,0.000074301046,0.0000732813,0.00005009634,0.000037736372,0.000247867],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99913806,0.00004159594,0.00022846194,0.00030141018,0.00011548831,0.00017500887],"domain_scores_gemma":[0.999486,0.000015678428,0.000051966024,0.00030621275,0.00008985916,0.000050241662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011069871,0.00015998317,0.00012908569,0.000061318824,0.000054377433,0.000046206584,0.00012825182,0.000121057914,0.000048309317],"category_scores_gemma":[0.000007733702,0.00014528948,0.00008886278,0.00014703699,0.00016331504,0.000005124391,0.000041614407,0.00010922244,0.0000031815414],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020699079,0.000027552836,0.00043320042,0.0000733854,0.00019971712,0.0000013186718,0.00010581032,0.000048966955,0.9531279,0.0022039,0.000093318056,0.04366424],"study_design_scores_gemma":[0.00023891825,0.00009432119,0.00415943,0.000049014994,0.000077678356,0.000008664833,0.00007447682,0.00020769425,0.9339891,0.0020908986,0.05878528,0.00022452713],"about_ca_topic_score_codex":0.000038887014,"about_ca_topic_score_gemma":0.000010553826,"teacher_disagreement_score":0.05869196,"about_ca_system_score_codex":0.000020349478,"about_ca_system_score_gemma":0.00012672339,"threshold_uncertainty_score":0.59247327},"labels":[],"label_agreement":null},{"id":"W4399504649","doi":"10.1158/1538-8514.synthleth24-b030","title":"Abstract B030: Expression patterns of miR181a and miR30d in patients with breast cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SNC-Lavalin (Canada)","funders":"","keywords":"PTEN; microRNA; Breast cancer; PI3K/AKT/mTOR pathway; Gene expression; Protein kinase B; Fold change; Biology; Cancer research; Gene; RNA extraction; Cancer; Signal transduction; Cell biology; Genetics","score_opus":0.009593150931669644,"score_gpt":0.2787001405741748,"score_spread":0.2691069896425052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98414373,0.011192793,0.00343598,0.00026651577,0.00015245644,0.0004132662,0.00031977857,0.000016465456,0.000059026755],"genre_scores_gemma":[0.997227,0.0020146682,0.00011448943,0.00027315633,0.0000535572,0.00010683473,0.000065303415,0.00008193707,0.000063022024],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984606,0.000052588395,0.00024206856,0.00051818404,0.00037514692,0.0003514456],"domain_scores_gemma":[0.99934125,0.000008342744,0.00006477531,0.0003569004,0.0001393997,0.00008934623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010119453,0.00024721478,0.00020500459,0.00013464254,0.000032778913,0.000045868313,0.00018858923,0.00020440639,0.00008494469],"category_scores_gemma":[0.0000028420793,0.00021098428,0.00007209064,0.00020376962,0.00007674439,0.000010190799,0.00011136028,0.0002448278,0.000001288498],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048505721,0.000115252355,0.015307237,0.00024937888,0.00024655482,0.000026531752,0.00011588383,0.0004728693,0.95508397,0.000031579515,0.00003761226,0.027828055],"study_design_scores_gemma":[0.001917676,0.00029283942,0.10031799,0.0008161199,0.0000808339,0.0000073175966,0.000043167594,0.00020546486,0.890865,0.000043436576,0.0049681836,0.0004419262],"about_ca_topic_score_codex":0.0003217067,"about_ca_topic_score_gemma":0.00022611274,"teacher_disagreement_score":0.08501076,"about_ca_system_score_codex":0.000074213516,"about_ca_system_score_gemma":0.00020886054,"threshold_uncertainty_score":0.8603689},"labels":[],"label_agreement":null},{"id":"W4399504653","doi":"10.1158/1538-8514.synthleth24-a019","title":"Abstract A019: Inhibition of nicotinamide adenine dinucleotide (NAD) production is a potent therapeutic strategy to inactivate homologous recombination in cancer cells","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Québec; Centre hospitalier universitaire de Québec","funders":"","keywords":"RAD51; Synthetic lethality; Olaparib; DNA repair; Homologous recombination; Genome instability; Biology; Poly ADP ribose polymerase; PALB2; NAD+ kinase; Cancer cell; DNA damage; Cancer research; PARP inhibitor; Nicotinamide phosphoribosyltransferase; Cancer; Cell biology; DNA; Mutation; Genetics; Biochemistry; Germline mutation; Enzyme; Polymerase; Gene","score_opus":0.03737261863275776,"score_gpt":0.3369266505763999,"score_spread":0.29955403194364216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97206664,0.0113489395,0.0016004753,0.01164327,0.0011688871,0.001499413,0.000090412934,0.00016089596,0.0004210414],"genre_scores_gemma":[0.99147844,0.0038046404,0.00026695995,0.0031727103,0.00019411977,0.0004588689,0.000031037744,0.00012707434,0.0004661393],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972802,0.00011316017,0.0007416332,0.00076479325,0.0006060389,0.0004941788],"domain_scores_gemma":[0.998826,0.000043195367,0.00021236805,0.00047789622,0.00030247399,0.00013801565],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003507728,0.00040048605,0.0005168203,0.00059653365,0.000060189486,0.000057474208,0.0001356109,0.00022802108,0.00037094968],"category_scores_gemma":[0.000009093325,0.00039318769,0.0002025458,0.0012115896,0.00011807774,0.00020449697,0.000034304383,0.000575114,0.000027531694],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005304798,0.00035277594,0.00045857756,0.00044468217,0.00032554823,0.00009566085,0.0010888488,0.0035125723,0.89328694,0.00027310077,0.0003370292,0.099293776],"study_design_scores_gemma":[0.0013769811,0.00066549674,0.007463553,0.0017288373,0.00022407166,0.00003668155,0.00017596784,0.0007907123,0.98198795,0.0023453422,0.0028039885,0.00040044205],"about_ca_topic_score_codex":0.00083111564,"about_ca_topic_score_gemma":0.00014716446,"teacher_disagreement_score":0.09889334,"about_ca_system_score_codex":0.001398995,"about_ca_system_score_gemma":0.0005346751,"threshold_uncertainty_score":0.999852},"labels":[],"label_agreement":null},{"id":"W4399504661","doi":"10.1158/1538-8514.synthleth24-ia002","title":"Abstract IA002: Overcoming the K-Ras inhibitor resistant cell state in PDAC with molecular glues.","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Reprogramming; Cancer research; Cancer cell; Cancer drugs; Chemistry; Cell; Computational biology; Pharmacology; Biology; Biochemistry; Genetics","score_opus":0.010614817586967583,"score_gpt":0.25642293442096986,"score_spread":0.24580811683400228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95897,0.031857837,0.005519447,0.0014098532,0.00030832828,0.0005266801,0.000047571084,0.000049692,0.0013105574],"genre_scores_gemma":[0.9958492,0.0009066525,0.00034862952,0.002109424,0.00012057402,0.00011082803,0.00004051219,0.000090677706,0.0004235169],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982997,0.000095338255,0.00031767559,0.00052779214,0.00034869747,0.00041080196],"domain_scores_gemma":[0.999217,0.000016346034,0.00008039663,0.0005368153,0.00007294767,0.00007651441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002554365,0.00030813194,0.00017732497,0.0000897507,0.00008008656,0.00015854668,0.0003013855,0.0001465236,0.00003247009],"category_scores_gemma":[0.000007795448,0.00022331436,0.00012757577,0.00032815099,0.00013330068,0.000012568077,0.00008530278,0.0003306881,0.000012335579],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001799962,0.00005023334,0.00015082177,0.00007036797,0.00011923497,0.00013214615,0.00017801399,0.00072278833,0.9925119,0.00015775797,0.00030073887,0.0054259948],"study_design_scores_gemma":[0.0005408098,0.00015289034,0.0002844287,0.00013865082,0.000042882493,0.000005992594,0.00008014753,0.00021389594,0.9007182,0.00032379964,0.097160704,0.000337591],"about_ca_topic_score_codex":0.000154846,"about_ca_topic_score_gemma":0.00017703026,"teacher_disagreement_score":0.09685996,"about_ca_system_score_codex":0.00009307129,"about_ca_system_score_gemma":0.00028813528,"threshold_uncertainty_score":0.91064954},"labels":[],"label_agreement":null},{"id":"W4399504666","doi":"10.1158/1538-8514.synthleth24-a004","title":"Abstract A004: Radiotherapy sensitizes preclinical models to DNA damage response agents","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Radiation therapy; In vivo; Cancer research; DNA damage; Pharmacology; Viability assay; Medicine; Cancer; In vitro; Biology; Internal medicine; DNA; Biochemistry","score_opus":0.10184426850061963,"score_gpt":0.40615270182311075,"score_spread":0.30430843332249113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9296116,0.016873933,0.025153227,0.023615016,0.0013411427,0.0011897113,0.00013664429,0.00057084835,0.0015078313],"genre_scores_gemma":[0.9575801,0.0019955274,0.0028907293,0.035499327,0.0005112894,0.00020457782,0.000023598343,0.00021303771,0.0010818461],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971567,0.00021739553,0.0005698269,0.0007693967,0.0007181208,0.0005685812],"domain_scores_gemma":[0.99833196,0.00022978084,0.000072746734,0.00083795656,0.00016688427,0.00036068045],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000674524,0.0004171154,0.00051826175,0.000285837,0.000091929694,0.0001733695,0.00022164155,0.00026468857,0.0006706861],"category_scores_gemma":[0.000016238551,0.0003911634,0.0003638207,0.0005750241,0.00014116373,0.0001740278,0.000042195003,0.0005265581,0.00012350566],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005933381,0.00020488529,0.000060726717,0.00017032435,0.0012900509,0.0011639408,0.0023043635,0.004054113,0.9399519,0.00047678655,0.0042617507,0.040127754],"study_design_scores_gemma":[0.0058362847,0.0012473767,0.0053613684,0.0019050827,0.0006317793,0.00019569717,0.00022483688,0.027961273,0.40861207,0.0030819334,0.5436012,0.0013410756],"about_ca_topic_score_codex":0.000043166925,"about_ca_topic_score_gemma":0.00000837576,"teacher_disagreement_score":0.5393395,"about_ca_system_score_codex":0.0006342915,"about_ca_system_score_gemma":0.00060552306,"threshold_uncertainty_score":0.999854},"labels":[],"label_agreement":null},{"id":"W4399504672","doi":"10.1158/1538-8514.synthleth24-ia017","title":"Abstract IA017: Synthetic dependencies arising during tumor evolution","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Science, Research, and Medicine","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Mechanism (biology); Computational biology; Cancer research; Biology; Medicine; Epistemology; Genetics; Philosophy","score_opus":0.03373505215618335,"score_gpt":0.33982575037990825,"score_spread":0.3060906982237249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95506895,0.036442466,0.0028159537,0.0019691684,0.0006608506,0.00030401623,0.000005961909,0.00017431345,0.0025583433],"genre_scores_gemma":[0.99734634,0.00071086094,0.00015621411,0.00081259664,0.00028304497,0.000033077114,0.000003088702,0.000042252777,0.0006125516],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99809515,0.000026721378,0.00021679774,0.00038149868,0.00076597114,0.00051387167],"domain_scores_gemma":[0.99930316,0.000038884722,0.000032921314,0.00032990615,0.00010330388,0.0001918174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034550673,0.00017418645,0.00021372933,0.00023995932,0.00012468775,0.00007424369,0.00014131147,0.000070814574,0.00020191283],"category_scores_gemma":[0.00003780131,0.00013811201,0.00012211809,0.00046330175,0.00018628522,0.000091222515,0.000037009868,0.000387647,0.000055406595],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008444266,0.00005234458,0.0020274583,0.0004689382,0.0001673937,0.0011571414,0.0007228543,0.00007197502,0.972366,0.00044671603,0.000039542247,0.022395195],"study_design_scores_gemma":[0.0021916633,0.00039899402,0.13787745,0.0038403051,0.00090751535,0.0011409863,0.0020693794,0.009218797,0.81238663,0.0016493737,0.027570076,0.0007488348],"about_ca_topic_score_codex":0.00019316423,"about_ca_topic_score_gemma":0.000026146457,"teacher_disagreement_score":0.15997937,"about_ca_system_score_codex":0.00044757934,"about_ca_system_score_gemma":0.0005611619,"threshold_uncertainty_score":0.5632044},"labels":[],"label_agreement":null},{"id":"W4399504681","doi":"10.1158/1538-8514.synthleth24-pr012","title":"Abstract PR012: KAT6A/B and Menin-MLL complexes coordinately regulate estrogen receptor-driven gene expression programs in breast cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chromatin; Cancer research; Epigenetics; Estrogen receptor; Biology; Breast cancer; Cancer; Histone; Transcription factor; Regulation of gene expression; Cell biology; Gene; Genetics","score_opus":0.024792615467604442,"score_gpt":0.2836719021734467,"score_spread":0.25887928670584226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96772176,0.029143691,0.00044777218,0.001587257,0.00030479956,0.00050162536,0.00013150464,0.00005745219,0.000104109866],"genre_scores_gemma":[0.99390167,0.0039342777,0.0008185581,0.00046670836,0.00019113182,0.00022313379,0.00017859132,0.00006963124,0.00021630999],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985438,0.00006822795,0.00027931537,0.0005483067,0.00020893759,0.000351426],"domain_scores_gemma":[0.99944973,0.0000054931716,0.000076862474,0.00028771473,0.000076630145,0.00010359188],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011636205,0.0002771154,0.00020024418,0.00007902351,0.000070167436,0.00011417932,0.0001858077,0.00021179985,0.0000629169],"category_scores_gemma":[0.0000024200606,0.0002521687,0.00009227922,0.00019293142,0.00012808367,0.00001591612,0.00010590504,0.00019193933,0.0000048935685],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010445146,0.00005220361,0.0030431903,0.00006352213,0.00012726271,0.00002037786,0.00010330278,0.00012820036,0.9491488,0.000076555094,0.00033668874,0.046795458],"study_design_scores_gemma":[0.0005512345,0.00008294135,0.002867629,0.0003006449,0.000039196253,0.000018393299,0.000041393687,0.00033083372,0.9321344,0.00009770409,0.06317375,0.0003619117],"about_ca_topic_score_codex":0.00018767812,"about_ca_topic_score_gemma":0.00005638305,"teacher_disagreement_score":0.062837064,"about_ca_system_score_codex":0.00007490405,"about_ca_system_score_gemma":0.0001452598,"threshold_uncertainty_score":0.999993},"labels":[],"label_agreement":null},{"id":"W4399504696","doi":"10.1158/1538-8514.synthleth24-ia020","title":"Abstract IA020: Functional studies of genetic variation using precision genome editing","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CRISPR and Genetic Engineering","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Genome editing; Genome; Computational biology; Genetics; Indel; Gene; Precision medicine; Genotype; Single-nucleotide polymorphism","score_opus":0.03605868568233169,"score_gpt":0.3466691388137472,"score_spread":0.31061045313141555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68813646,0.0705432,0.24034387,0.000058315778,0.00071412855,0.00011836935,0.0000212174,0.000018465367,0.00004598582],"genre_scores_gemma":[0.9945715,0.0016872754,0.0030248936,0.00010119748,0.0005002682,0.000015355703,0.000022443764,0.00003964396,0.0000373999],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99909973,0.000019857807,0.00024850856,0.00027365203,0.00018690393,0.00017136212],"domain_scores_gemma":[0.9995916,0.000013992594,0.00005336081,0.00019358477,0.00011654929,0.00003089405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012454175,0.00014898436,0.0001302363,0.00006376293,0.00004400335,0.000023954315,0.000086087704,0.000097282005,0.000024156043],"category_scores_gemma":[0.000012764695,0.0001459762,0.00010182046,0.00012674977,0.000040663454,0.000003865497,0.000053764332,0.00008277216,0.000001687459],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014939498,0.000012286937,0.00011733762,0.00011363708,0.0003511789,0.000005084742,0.00015780293,0.068793364,0.9220783,0.00002751822,0.000019083196,0.008309456],"study_design_scores_gemma":[0.0003928179,0.00015250538,0.017391948,0.00021047481,0.00031086133,0.00002586169,0.00016391477,0.01569808,0.9500707,0.0004291196,0.0147443535,0.00040940495],"about_ca_topic_score_codex":0.000012422004,"about_ca_topic_score_gemma":0.0000047397957,"teacher_disagreement_score":0.30643508,"about_ca_system_score_codex":0.000042009124,"about_ca_system_score_gemma":0.00008219209,"threshold_uncertainty_score":0.5952737},"labels":[],"label_agreement":null},{"id":"W4399504765","doi":"10.1158/1538-8514.synthleth24-ia010","title":"Abstract IA010: Targeting genome instability in cancer: Translating synthetic lethal biology into the clinic","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Cancer research; Genome instability; Ovarian cancer; Medicine; Cyclin-dependent kinase 1; Biology; Cell cycle; Synthetic lethality; Chromosome instability; Mitosis; Genome; Genetics; Gene; DNA damage; DNA; DNA repair","score_opus":0.023979100531711532,"score_gpt":0.31970008194537397,"score_spread":0.29572098141366243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8676129,0.12639217,0.0015648892,0.0026738641,0.0007635168,0.000369199,0.00010058983,0.000030292602,0.00049259455],"genre_scores_gemma":[0.9879049,0.009677247,0.00028014075,0.0014017835,0.00038212797,0.0001950686,0.000058455218,0.00007627984,0.000023983603],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99802923,0.00012593275,0.0005156151,0.00068659923,0.00014657923,0.0004960169],"domain_scores_gemma":[0.99918085,0.00009960908,0.00009152616,0.00048668173,0.000068234054,0.000073078314],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005857761,0.00030703688,0.00026432428,0.00007278474,0.00012506242,0.000089909045,0.0004136183,0.0002631397,0.00011455468],"category_scores_gemma":[0.000042695538,0.00025533454,0.00022003267,0.0002723737,0.00019100145,0.000006380594,0.0001131893,0.0004323812,0.000009804452],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007093103,0.000059313334,0.0025524914,0.00011284382,0.00021533002,0.000023596122,0.0011804184,0.002099987,0.89847696,0.00022098148,0.000030761083,0.094956405],"study_design_scores_gemma":[0.0022538714,0.0006948641,0.014153384,0.00045504232,0.0005313532,0.000024685718,0.0016366101,0.004562882,0.3985868,0.0076554026,0.5670971,0.0023479569],"about_ca_topic_score_codex":0.0012783429,"about_ca_topic_score_gemma":0.0012977704,"teacher_disagreement_score":0.5670664,"about_ca_system_score_codex":0.00016198821,"about_ca_system_score_gemma":0.00050161284,"threshold_uncertainty_score":0.99998987},"labels":[],"label_agreement":null},{"id":"W4399504818","doi":"10.1158/1538-8514.synthleth24-ia019","title":"Abstract IA019: Identification of metabolic adaptation mechanisms that confer resistance to glutathione depletion in Ewing sarcoma","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"GCLM; GCLC; Glutathione; Buthionine sulfoximine; Biochemistry; Cancer cell; Chemistry; Cysteine; HT1080; Cystathionine beta synthase; Oxidative stress; Mitochondrion; Cell biology; Biology; Cell; Cancer; Enzyme","score_opus":0.027716169541918974,"score_gpt":0.28916715189581155,"score_spread":0.2614509823538926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6839542,0.07300499,0.23989084,0.0005761331,0.0015692898,0.00055380893,0.000092012444,0.000034567187,0.00032416862],"genre_scores_gemma":[0.9939138,0.003749459,0.0011286401,0.0005082262,0.00020067196,0.00012212359,0.000069514106,0.000050146464,0.00025736095],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985836,0.00006962904,0.00037121357,0.00043930096,0.00028878552,0.00024744245],"domain_scores_gemma":[0.9993627,0.000010072587,0.00010748394,0.0003490359,0.000110617926,0.00006008311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032866985,0.00019220766,0.00021600253,0.0001574117,0.00003996555,0.00005403482,0.00018011332,0.00014880997,0.000018926821],"category_scores_gemma":[0.000013148291,0.00020545578,0.00012320741,0.0003076163,0.000039451326,0.000014270177,0.00003754779,0.00011841673,0.000006961917],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010337774,0.000034593122,0.00004492265,0.00007301962,0.00010813687,0.0000031088518,0.00059334835,0.0010980048,0.96968216,0.005283908,0.00004033484,0.022935065],"study_design_scores_gemma":[0.00037162378,0.000029467048,0.0063038906,0.00009702193,0.00009951521,0.0000027473227,0.00021933799,0.00046752466,0.9103114,0.0012881645,0.080571756,0.00023756477],"about_ca_topic_score_codex":0.0001197277,"about_ca_topic_score_gemma":0.00060530583,"teacher_disagreement_score":0.30995968,"about_ca_system_score_codex":0.00004179066,"about_ca_system_score_gemma":0.00019034898,"threshold_uncertainty_score":0.83782434},"labels":[],"label_agreement":null},{"id":"W4399504870","doi":"10.1158/1538-8514.synthleth24-a008","title":"Abstract A008: Pre-diabetic D-glucose exposure promotes EOC progression and cisplatin resistance: Role of BAD associated pathway and potential therapeutic strategy","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prediabetes; Cisplatin; Cancer research; Insulin resistance; Ex vivo; Glucose uptake; Medicine; Internal medicine; Tumor progression; Cancer; Endocrinology; In vivo; Diabetes mellitus; Type 2 diabetes; Biology; Oncology; Insulin; Chemotherapy; Biotechnology","score_opus":0.00846297219287443,"score_gpt":0.26245784418486523,"score_spread":0.2539948719919908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6934092,0.30528447,0.00022911838,0.000106106025,0.0002929044,0.00037840332,0.00010290108,0.000031728454,0.00016513161],"genre_scores_gemma":[0.9881608,0.010799192,0.00014907587,0.00014890675,0.00026780515,0.00008871392,0.00007199831,0.00007764109,0.00023586232],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99825525,0.000112766895,0.00035643944,0.00057918386,0.00031097585,0.00038538338],"domain_scores_gemma":[0.99926126,0.000018197483,0.00015178086,0.0003303503,0.00012925525,0.000109161396],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024859628,0.00033309203,0.00032470826,0.00007463797,0.00009617467,0.00011275411,0.00015671393,0.00032863824,0.000021347918],"category_scores_gemma":[0.000011750205,0.00029891616,0.00012430294,0.00016925512,0.00020009145,0.000015295112,0.00007972515,0.00023237157,5.7960796e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015687727,0.000082932274,0.00030740385,0.00017095782,0.0003683332,0.0000070666392,0.0002594621,0.000041311025,0.8379905,0.00014530243,0.000025531945,0.16044432],"study_design_scores_gemma":[0.0012709665,0.0004916207,0.015545603,0.00036559763,0.0003907579,0.000013358721,0.00013001735,0.00052440766,0.945351,0.0016536143,0.033700652,0.00056241424],"about_ca_topic_score_codex":0.000021598722,"about_ca_topic_score_gemma":0.00007359405,"teacher_disagreement_score":0.29475158,"about_ca_system_score_codex":0.00002552461,"about_ca_system_score_gemma":0.0002602478,"threshold_uncertainty_score":0.9999463},"labels":[],"label_agreement":null},{"id":"W4399504875","doi":"10.1158/1538-8514.synthleth24-b001","title":"Abstract B001: Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal cancers","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytidine; Cancer; Diacylglycerol kinase; Cancer cell; Cancer research; Biology; Biochemistry; Chemistry; Enzyme; Genetics; Protein kinase C","score_opus":0.013493765148433163,"score_gpt":0.28116485368334937,"score_spread":0.2676710885349162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77122986,0.20764345,0.0025549321,0.0021879103,0.012937966,0.00078057597,0.00052296603,0.00011363257,0.0020287184],"genre_scores_gemma":[0.9824136,0.0101013845,0.00024343198,0.002526333,0.003542813,0.00026943468,0.000074575626,0.00014493038,0.00068351603],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99740446,0.00008004755,0.00045552687,0.00091644295,0.00038905835,0.00075446017],"domain_scores_gemma":[0.99896014,0.000025066345,0.000090195455,0.00065326534,0.00008395769,0.00018736869],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027875323,0.00048378843,0.0004180066,0.00015799666,0.00007952965,0.00011819535,0.00038462377,0.00030913323,0.00034004878],"category_scores_gemma":[0.000018920498,0.0004751669,0.00032933732,0.00037811787,0.000179194,0.000016997577,0.000108196815,0.00038340726,0.00003090318],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003660737,0.00011117857,0.00053676765,0.00021478374,0.00061277725,0.000040343533,0.00064193085,0.00230604,0.9575901,0.00025322562,0.0052163308,0.03211047],"study_design_scores_gemma":[0.00084509153,0.00010683739,0.00058453466,0.00016982485,0.00014339779,0.000022872342,0.00007969643,0.0010394935,0.32603833,0.00019945113,0.6701768,0.0005936916],"about_ca_topic_score_codex":0.0009864332,"about_ca_topic_score_gemma":0.00029440617,"teacher_disagreement_score":0.66496044,"about_ca_system_score_codex":0.00023865988,"about_ca_system_score_gemma":0.0007547017,"threshold_uncertainty_score":0.99977},"labels":[],"label_agreement":null},{"id":"W4399504877","doi":"10.1158/1538-8514.synthleth24-b021","title":"Abstract B021: CFLAR targeting selectively exploits extrinsic apoptosis signaling in triple-negative breast cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Necroptosis; Cancer; Cancer research; Programmed cell death; Cancer cell; Apoptosis; Triple-negative breast cancer; Downregulation and upregulation; Medicine; Breast cancer; Biology; Internal medicine; Biochemistry","score_opus":0.022100990123752995,"score_gpt":0.288813788610542,"score_spread":0.266712798486789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9151642,0.08088292,0.0005158755,0.0010012743,0.0014571263,0.00039403842,0.00014077061,0.00015419388,0.00028963108],"genre_scores_gemma":[0.99569803,0.0024071967,0.00005038727,0.0007604639,0.000065387474,0.00019861943,0.000022132688,0.00007884843,0.00071890117],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99801654,0.00031983657,0.00043487127,0.0005187437,0.00008662841,0.00062337215],"domain_scores_gemma":[0.9993794,0.0001704038,0.00009767548,0.0001929396,0.00013231287,0.000027271459],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002973087,0.0003592889,0.00038574132,0.00029337272,0.00013761585,0.000075450385,0.00026352177,0.00028339188,0.0011582596],"category_scores_gemma":[0.000019779713,0.00032899875,0.00019388739,0.0005382728,0.00013649157,0.00016390836,0.00006232407,0.00075049006,0.0001266018],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058128085,0.00007799517,0.00032206986,0.000066346845,0.0008066537,0.000029356335,0.0020868543,0.0001587755,0.95920044,0.00017138667,0.00022244964,0.036276363],"study_design_scores_gemma":[0.0010220826,0.00007902408,0.0031247768,0.00047155932,0.00011765601,0.000021899095,0.00069111295,0.00006298977,0.98459375,0.00012562798,0.00926973,0.00041981164],"about_ca_topic_score_codex":0.0010261198,"about_ca_topic_score_gemma":0.000087595065,"teacher_disagreement_score":0.08053389,"about_ca_system_score_codex":0.00039318364,"about_ca_system_score_gemma":0.00035088204,"threshold_uncertainty_score":0.9999162},"labels":[],"label_agreement":null},{"id":"W4399504893","doi":"10.1158/1538-8514.synthleth24-ia015","title":"Abstract IA015: Identifying and targeting synthetic lethalities of aneuploid (cancer) cells","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Aneuploidy; Biology; Cancer cell; Cancer; Cancer research; Gene silencing; Chromosome instability; Genetics; Cell biology; Gene; Chromosome","score_opus":0.020122958474689347,"score_gpt":0.28696961743507254,"score_spread":0.2668466589603832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83358175,0.16276628,0.001919221,0.00032828795,0.0006563575,0.00017683857,0.00019561594,0.000025427387,0.00035020866],"genre_scores_gemma":[0.96947217,0.02908069,0.00037271623,0.000595909,0.00022763023,0.000046568744,0.000026049249,0.00006909609,0.000109168235],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879074,0.00002978073,0.00029736094,0.00041915933,0.00017479944,0.00028816392],"domain_scores_gemma":[0.9994532,0.000038909828,0.000088122215,0.00026626233,0.00008339056,0.000070152615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016185125,0.00022350467,0.00020899216,0.00006756292,0.00006128519,0.00009712913,0.000170066,0.00014029242,0.00004738958],"category_scores_gemma":[0.000010967087,0.0002283476,0.00012667417,0.00010986509,0.00014987787,0.0000066212174,0.000110213485,0.00013961914,0.0000026235507],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030561914,0.000022047161,0.0001778736,0.00035845803,0.00024254803,0.000022203489,0.00025829935,0.0005564172,0.9837825,0.00041392125,0.00028468855,0.013850531],"study_design_scores_gemma":[0.00020372379,0.00007159981,0.00018635824,0.0001957326,0.00014511422,0.0000075212415,0.00017129646,0.00030837665,0.9492302,0.00050641317,0.048682414,0.00029125542],"about_ca_topic_score_codex":0.00019326297,"about_ca_topic_score_gemma":0.000033762044,"teacher_disagreement_score":0.13589041,"about_ca_system_score_codex":0.000037477323,"about_ca_system_score_gemma":0.00017057086,"threshold_uncertainty_score":0.93117446},"labels":[],"label_agreement":null},{"id":"W4399504903","doi":"10.1158/1538-8514.synthleth24-a003","title":"Abstract A003: Unwinding the complexities of helicases as compelling drug targets in oncology","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Science, Research, and Medicine","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Helicase; Computational biology; Biology; Drug discovery; Drug; Cancer; Genetics; Bioinformatics; Pharmacology; Gene; RNA","score_opus":0.08729093644661247,"score_gpt":0.4190637755425328,"score_spread":0.33177283909592037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9109123,0.066433184,0.00053409446,0.01194301,0.0005300656,0.0004763782,0.000012286208,0.000047665624,0.00911101],"genre_scores_gemma":[0.99347776,0.002686528,0.00014273533,0.0031904567,0.00015469422,0.000024699702,0.0000068855425,0.000022779988,0.00029346303],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859893,0.00006535965,0.0002833616,0.00022725493,0.0004883012,0.0003367816],"domain_scores_gemma":[0.9992877,0.00025938617,0.00004752591,0.00023271247,0.00008810147,0.00008453673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058065547,0.00013110161,0.00029431796,0.00020214243,0.00005947355,0.000021644013,0.00018689095,0.00005927745,0.00022392691],"category_scores_gemma":[0.000027858345,0.000084909334,0.0000901828,0.00047844913,0.00042580205,0.000035474986,0.00003869794,0.00039218419,0.000014792239],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047200095,0.000362743,0.005038161,0.0011084119,0.0005942717,0.0022464285,0.022314062,0.00079175225,0.79946554,0.014305824,0.00071377517,0.15258703],"study_design_scores_gemma":[0.003248033,0.0009804784,0.016815603,0.0030692779,0.0004536143,0.000297349,0.016180659,0.011870284,0.5681616,0.0070209564,0.3713915,0.0005106536],"about_ca_topic_score_codex":0.00082325295,"about_ca_topic_score_gemma":0.00016800845,"teacher_disagreement_score":0.37067774,"about_ca_system_score_codex":0.00017518306,"about_ca_system_score_gemma":0.0005682832,"threshold_uncertainty_score":0.34625024},"labels":[],"label_agreement":null},{"id":"W4399504914","doi":"10.1158/1538-8514.synthleth24-a002","title":"Abstract A002: Understanding mechanisms of resistance to WRN small molecule inhibitors","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Genetics; Helicase; Mutation; Cancer research; Cancer; Computational biology; Gene","score_opus":0.05844738360686748,"score_gpt":0.30760596226002596,"score_spread":0.2491585786531585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83054525,0.026153974,0.12307742,0.0064736297,0.002357559,0.0015023891,0.00008887355,0.0003088118,0.009492126],"genre_scores_gemma":[0.9946432,0.00022727702,0.0025521154,0.0019213478,0.00008820574,0.00007120685,0.000005735447,0.00010489182,0.0003860093],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982727,0.000029465084,0.00036294604,0.0004568071,0.0004978285,0.00038025895],"domain_scores_gemma":[0.99920213,0.00004444142,0.00006600189,0.00041637328,0.00010612382,0.00016492564],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017121498,0.0002649947,0.0003324219,0.00020925532,0.000044001266,0.000042572912,0.00016926217,0.00015834636,0.00022590521],"category_scores_gemma":[0.000011154104,0.00025116347,0.00018958317,0.0005964434,0.0000767736,0.000026438282,0.00005856458,0.00027817467,0.000023087794],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001931126,0.00004239447,0.00010131682,0.00046284118,0.00037676023,0.00014850346,0.0006661483,0.0001411902,0.98891467,0.0047475556,0.0003870808,0.0038184086],"study_design_scores_gemma":[0.00042911957,0.0002554685,0.00032974224,0.000772222,0.00026548363,0.000007903978,0.00038848992,0.0000961365,0.98447853,0.0054007038,0.007287092,0.0002891339],"about_ca_topic_score_codex":0.000054038417,"about_ca_topic_score_gemma":0.00017942878,"teacher_disagreement_score":0.164098,"about_ca_system_score_codex":0.000698775,"about_ca_system_score_gemma":0.0003988049,"threshold_uncertainty_score":0.99999404},"labels":[],"label_agreement":null},{"id":"W4399504926","doi":"10.1158/1538-8514.synthleth24-a018","title":"Abstract A018: STRIDE as a technology platform for accurate measurement of DNA breaks and breaks-associated repair proteins","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"DNA repair; DNA damage; DNA; Synthetic lethality; Computational biology; Biology; Genetics","score_opus":0.05037764949518274,"score_gpt":0.3367402551636608,"score_spread":0.28636260566847804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94408596,0.03858323,0.0047385357,0.006859121,0.00046498634,0.0031829544,0.00030499394,0.00072811404,0.0010521295],"genre_scores_gemma":[0.99603164,0.0011791799,0.00069472875,0.001117821,0.00007888493,0.0006741089,0.000023073098,0.00009212514,0.00010841385],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99810547,0.000021645317,0.0004936824,0.00044776674,0.0005419295,0.0003895207],"domain_scores_gemma":[0.99883604,0.000048419977,0.00017813157,0.00040174922,0.00043945602,0.00009617843],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004301911,0.00028615794,0.0004480427,0.00026583642,0.00007435112,0.000032593227,0.000120792596,0.0002998026,0.00006137344],"category_scores_gemma":[0.00004355779,0.00026132376,0.00022404408,0.0004775079,0.00017740706,0.00007802397,0.000033638706,0.00031772902,0.0000045716397],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006180497,0.00020059674,0.0002495759,0.0006708643,0.0021427458,0.00007398556,0.00034535045,0.000023655775,0.94928676,0.001805245,0.00028367635,0.044299513],"study_design_scores_gemma":[0.004068531,0.0009614646,0.0014747782,0.0018045575,0.00069043605,0.000070641865,0.00016952776,0.0008685212,0.9278569,0.0059647635,0.055675864,0.00039397783],"about_ca_topic_score_codex":0.0001209386,"about_ca_topic_score_gemma":0.00007144824,"teacher_disagreement_score":0.055392187,"about_ca_system_score_codex":0.0005421587,"about_ca_system_score_gemma":0.0007036353,"threshold_uncertainty_score":0.9999839},"labels":[],"label_agreement":null},{"id":"W4399505041","doi":"10.1158/1538-8514.synthleth24-a016","title":"Abstract A016: Companion Diagnostics (CDx) to identify hallmarks of Alternative Lengthening of Telomeres (ALT)","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Telomere; Telomerase; Cancer; Cancer research; Biomarker; Biology; Computational biology; Molecular biology; Medicine; DNA; Genetics; Gene","score_opus":0.023445458253527066,"score_gpt":0.3276595688487436,"score_spread":0.3042141105952165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95899504,0.026523732,0.01199264,0.00031891948,0.00082191447,0.00032737086,0.0003445523,0.000016928227,0.0006589291],"genre_scores_gemma":[0.9895736,0.008687906,0.0007523112,0.00055168674,0.00022233174,0.000038464383,0.00006210443,0.00006829676,0.000043291948],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99855524,0.000037922626,0.0004532259,0.0004021507,0.00027315776,0.0002783178],"domain_scores_gemma":[0.9990271,0.000098571836,0.00014947496,0.00041546515,0.0002150769,0.00009436318],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016781127,0.00024147704,0.00029808827,0.00012932674,0.000036414862,0.000043695112,0.00033148148,0.00014133465,0.00003985274],"category_scores_gemma":[0.00005825399,0.0002460366,0.00019646423,0.0002053156,0.0001086279,0.0000058361043,0.00016159796,0.00014656226,0.000005871438],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000097696044,0.00008054838,0.0007456536,0.00019941787,0.00051012175,0.00001966898,0.00040219942,0.004989105,0.9706423,0.0009645963,0.0005070187,0.02084166],"study_design_scores_gemma":[0.0003844517,0.00025346747,0.0037786453,0.00030731797,0.00015656177,0.0000042206716,0.000108460714,0.0004747623,0.9530202,0.00043626688,0.04076357,0.00031207417],"about_ca_topic_score_codex":0.00029957798,"about_ca_topic_score_gemma":0.000094175215,"teacher_disagreement_score":0.040256552,"about_ca_system_score_codex":0.00005563398,"about_ca_system_score_gemma":0.00020987765,"threshold_uncertainty_score":0.99999917},"labels":[],"label_agreement":null},{"id":"W4399505066","doi":"10.1158/1538-8514.synthleth24-b028","title":"Abstract B028: Expression of NOTCH1 in head and neck tumours at selected hospitals in Ghana","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Immunohistochemistry; Head and neck; Paranasal sinuses; Head and neck cancer; Pathology; Cancer; Internal medicine; Surgery","score_opus":0.013765133537670424,"score_gpt":0.3027731964715795,"score_spread":0.28900806293390907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9607888,0.036554597,0.0014569681,0.00036289333,0.00013800735,0.00041005062,0.00003646282,0.000018437904,0.00023376763],"genre_scores_gemma":[0.9966663,0.0024427192,0.00031131384,0.00021494713,0.000042773583,0.00008651465,0.00005355336,0.00007638261,0.00010547665],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982253,0.000087923676,0.00035230425,0.0005801673,0.00031137522,0.00044293204],"domain_scores_gemma":[0.99938637,0.000016440585,0.00006200458,0.0003566017,0.00009107947,0.00008748682],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020089584,0.0002526118,0.0002612182,0.0002304207,0.000029862995,0.000035030116,0.00020969915,0.0002973571,0.000043941865],"category_scores_gemma":[0.000021746111,0.00025891367,0.00008678181,0.00054273347,0.00009011167,0.000008200282,0.00017332,0.00031453455,0.0000034180725],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020174946,0.000057273683,0.0007614081,0.00013601015,0.000058410573,0.00009955314,0.0001862339,0.0006777967,0.99280816,0.000041715943,0.000058975987,0.0049127126],"study_design_scores_gemma":[0.00089818187,0.00021553323,0.0062084226,0.00040297193,0.000021981346,0.000010913878,0.000047732123,0.00063487916,0.98959106,0.0000972021,0.0015886407,0.0002825009],"about_ca_topic_score_codex":0.00023375545,"about_ca_topic_score_gemma":0.0005491166,"teacher_disagreement_score":0.035877507,"about_ca_system_score_codex":0.00016333211,"about_ca_system_score_gemma":0.00026475743,"threshold_uncertainty_score":0.9999863},"labels":[],"label_agreement":null},{"id":"W4399505067","doi":"10.1158/1538-8514.synthleth24-a017","title":"Abstract A017: Characterizing intratumoral heterogeneity of <i>CCNE1</i> amplification in ovarian cancer using digital pathology","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Aegera Therapeutics (Canada)","funders":"","keywords":"Ovarian cancer; Biology; Cancer research; Synthetic lethality; Cancer; Gene; Genetics; DNA repair","score_opus":0.028236156593509535,"score_gpt":0.302029070117898,"score_spread":0.27379291352438845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764349,0.017483393,0.0045385202,0.000297304,0.00056563516,0.00020903486,0.00036517504,0.000012935796,0.00009309386],"genre_scores_gemma":[0.9952066,0.00335676,0.00023713385,0.000745169,0.0002153848,0.00004968489,0.00012339011,0.000057059664,0.000008849811],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99873346,0.00002858173,0.00036152705,0.0004413903,0.00012964343,0.00030540317],"domain_scores_gemma":[0.99940383,0.000014200376,0.000112262256,0.00033543803,0.00007631111,0.000057951234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011733173,0.00021145,0.00022169089,0.000086206914,0.00003335852,0.00009285653,0.00019030322,0.00017880464,0.000014377858],"category_scores_gemma":[0.000010233333,0.00023145186,0.00012342114,0.00019181636,0.000095970616,0.000013109971,0.00007833418,0.00016194186,0.0000018166761],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000071166076,0.000056183697,0.0054028034,0.000079698206,0.00011144871,0.000042742235,0.00009385685,0.0009254857,0.9768501,0.00018310362,0.00001383172,0.016169567],"study_design_scores_gemma":[0.0004882156,0.00009373624,0.011512489,0.00018174465,0.00008037047,0.000024801073,0.00003180029,0.0011072293,0.9729976,0.00025429294,0.0128357345,0.00039196011],"about_ca_topic_score_codex":0.0001995179,"about_ca_topic_score_gemma":0.0001537946,"teacher_disagreement_score":0.01877166,"about_ca_system_score_codex":0.000105503896,"about_ca_system_score_gemma":0.00032888056,"threshold_uncertainty_score":0.94383335},"labels":[],"label_agreement":null},{"id":"W4399505079","doi":"10.1158/1538-8514.synthleth24-b023","title":"Abstract B023: Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA-mutated cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; Cancer; Cancer research; Medicine; Biology; Genetics; Gene; DNA repair","score_opus":0.0453209368628729,"score_gpt":0.36038447832171006,"score_spread":0.31506354145883714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92635924,0.0517683,0.0011527896,0.018567536,0.00045843355,0.0008697001,0.00008965772,0.00008481851,0.0006495069],"genre_scores_gemma":[0.9901328,0.0033317353,0.00013138028,0.0058322693,0.000114704104,0.0003087557,0.000006116644,0.00007272393,0.00006952557],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980606,0.00011262103,0.00050409755,0.0004822645,0.00042973174,0.00041069902],"domain_scores_gemma":[0.999103,0.00012825718,0.000094316914,0.00043034455,0.000115037285,0.00012906025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044954356,0.00028411005,0.0004408932,0.00020078114,0.00005851374,0.000046362915,0.00017007382,0.00015095511,0.00020585654],"category_scores_gemma":[0.000017107317,0.0002221606,0.00012498604,0.00070321216,0.0001977686,0.00006380782,0.00003977743,0.000492339,0.000006577251],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032824845,0.00011440692,0.0025927587,0.00053053343,0.0006221793,0.00015627092,0.004491612,0.0010218318,0.91380674,0.00041890208,0.00021375049,0.075702764],"study_design_scores_gemma":[0.0019973707,0.00019420365,0.045258705,0.0029517019,0.00041174208,0.00005832378,0.0005212409,0.0013182808,0.8973489,0.0017496159,0.04760543,0.000584485],"about_ca_topic_score_codex":0.0010722685,"about_ca_topic_score_gemma":0.00022634814,"teacher_disagreement_score":0.07511828,"about_ca_system_score_codex":0.00032941677,"about_ca_system_score_gemma":0.0004039035,"threshold_uncertainty_score":0.90594465},"labels":[],"label_agreement":null},{"id":"W4399505093","doi":"10.1158/1538-8514.synthleth24-a005","title":"Abstract A005: A live cell PRMT5 NanoBRET™ target engagement assay querying competitive and uncompetitive modes of inhibition","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Protein arginine methyltransferase 5; Uncompetitive inhibitor; Methylation; Methyltransferase; Chemistry; Biochemistry; Non-competitive inhibition; Enzyme; Cell biology; Biology; DNA","score_opus":0.013766816945919797,"score_gpt":0.26511029169682343,"score_spread":0.25134347475090363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.911265,0.060458962,0.023484625,0.00048711014,0.00035647504,0.0006232595,0.00022328137,0.000051643303,0.0030496195],"genre_scores_gemma":[0.9953869,0.0027912995,0.0010922507,0.00019906684,0.00013379408,0.000047150163,0.0001571171,0.00005622229,0.00013621706],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986951,0.0001256693,0.00027138507,0.00044684554,0.00022744293,0.00023357761],"domain_scores_gemma":[0.9994394,0.000025952815,0.00011432157,0.00021626364,0.00014755216,0.000056467587],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024549593,0.00023796789,0.00019436998,0.000086474654,0.00006980367,0.000045938876,0.00007953169,0.00018629247,0.000059312435],"category_scores_gemma":[0.0000064172755,0.000245792,0.00011584752,0.0001396166,0.00013431405,0.0000114678005,0.00008332476,0.00019114523,0.0000040476116],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077565535,0.00005054863,0.000113313574,0.00020229376,0.0003100037,0.000011108794,0.00044097748,0.004554737,0.9868303,0.0011437035,0.00007375596,0.0061917193],"study_design_scores_gemma":[0.0004493578,0.00019433396,0.0003742001,0.00028955648,0.00012832577,0.0000058029445,0.0003522421,0.0023425412,0.9722319,0.00036092798,0.022983287,0.00028747448],"about_ca_topic_score_codex":0.00007824438,"about_ca_topic_score_gemma":0.000046989175,"teacher_disagreement_score":0.08412186,"about_ca_system_score_codex":0.00009921915,"about_ca_system_score_gemma":0.00019220573,"threshold_uncertainty_score":0.9999994},"labels":[],"label_agreement":null},{"id":"W4399505096","doi":"10.1158/1538-8514.synthleth24-b007","title":"Abstract B007: Unexpected synthetic lethality mechanisms in eIF4A-targeted therapy","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer research; Gene knockdown; Targeted therapy; In vivo; Medicine; Tumor microenvironment; Biology; Cancer; Cell culture; Internal medicine; Tumor cells; Genetics","score_opus":0.04855124951664799,"score_gpt":0.35807060044628053,"score_spread":0.30951935092963256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9225903,0.060706083,0.0014919563,0.010466745,0.0005156482,0.00071597163,0.00006205704,0.00020690789,0.0032443337],"genre_scores_gemma":[0.991222,0.0045928285,0.0003900077,0.0026452923,0.0001152036,0.00009502506,0.00003721797,0.000072129005,0.00083028525],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99794495,0.00009980663,0.00034355914,0.0004765662,0.00061217893,0.00052294706],"domain_scores_gemma":[0.9992723,0.00009012685,0.000035028097,0.0003619573,0.00009434569,0.00014626459],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029490647,0.00028133087,0.0003650902,0.00022565841,0.00005755229,0.00006647284,0.00018384006,0.00017467976,0.00095602096],"category_scores_gemma":[0.0000106982,0.00021958142,0.000226614,0.0005753,0.000113333415,0.000050753566,0.00004185568,0.0006069959,0.00008240873],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006411715,0.00024920242,0.00093478075,0.00025784588,0.00057436153,0.0013673372,0.00058098324,0.00005453125,0.9187616,0.0043084226,0.00009673713,0.072172984],"study_design_scores_gemma":[0.002938755,0.0006928397,0.06241138,0.0011363445,0.00020431033,0.00014612131,0.00022182864,0.00715857,0.7657079,0.013639754,0.14474736,0.0009948022],"about_ca_topic_score_codex":0.00094637193,"about_ca_topic_score_gemma":0.000077208846,"teacher_disagreement_score":0.1530537,"about_ca_system_score_codex":0.00018788199,"about_ca_system_score_gemma":0.00032705916,"threshold_uncertainty_score":0.99995726},"labels":[],"label_agreement":null},{"id":"W4399505132","doi":"10.1158/1538-8514.synthleth24-pr002","title":"Abstract PR002: Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA-mutated cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"PARP1; Synthetic lethality; Olaparib; Cancer research; DNA damage; Biology; DNA ligase; DNA repair; Cancer; Chemistry; Poly ADP ribose polymerase; DNA; Genetics","score_opus":0.04460359950510362,"score_gpt":0.3589815907362381,"score_spread":0.31437799123113447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9264865,0.052172106,0.0011048461,0.018038139,0.0004297995,0.0009403805,0.00008779372,0.000084705855,0.00065573276],"genre_scores_gemma":[0.99075186,0.0031448312,0.0001371634,0.0053666565,0.00011259408,0.00033665268,0.0000059375857,0.0000722917,0.0000720393],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998059,0.000113972776,0.00050464727,0.00048312722,0.0004307186,0.0004085377],"domain_scores_gemma":[0.99910593,0.00012521325,0.0000965259,0.0004278223,0.00011670876,0.00012782132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044782096,0.00028384794,0.0004378603,0.00019700966,0.00005776532,0.00004676708,0.00016836953,0.00015003968,0.00020343199],"category_scores_gemma":[0.000017669832,0.00022108894,0.00012201644,0.0006917209,0.00019635967,0.000065033455,0.00003944735,0.00048996555,0.0000061512774],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003310679,0.00012116555,0.0024641748,0.0005692418,0.00062598963,0.00014864813,0.00473036,0.0009771772,0.90343297,0.00041472912,0.00020713478,0.08597736],"study_design_scores_gemma":[0.0019650157,0.00019966466,0.04860349,0.0030434078,0.00041202072,0.000058634585,0.00048309128,0.0013239946,0.89565253,0.0016044155,0.04608066,0.0005730976],"about_ca_topic_score_codex":0.0009321861,"about_ca_topic_score_gemma":0.00020692346,"teacher_disagreement_score":0.08540426,"about_ca_system_score_codex":0.0003281597,"about_ca_system_score_gemma":0.00036778126,"threshold_uncertainty_score":0.90157455},"labels":[],"label_agreement":null},{"id":"W4399505141","doi":"10.1158/1538-8514.synthleth24-a022","title":"Abstract A022: Synthetic lethality of <i>ERBB2</i> and <i>CCND1</i> in breast cancer at scale","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"National Research Council Institute for Biodiagnostics","funders":"","keywords":"Synthetic lethality; Cyclin D1; Cancer research; Biology; Breast cancer; Cancer; Gene; Gene expression; Invasive lobular carcinoma; Oncology; Medicine; Genetics; Invasive ductal carcinoma; DNA repair; Cell cycle","score_opus":0.013207778565682265,"score_gpt":0.29053109331859234,"score_spread":0.27732331475291006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.928679,0.06736075,0.000338419,0.0019724832,0.00039642656,0.00022666562,0.00040319096,0.000021144268,0.0006019451],"genre_scores_gemma":[0.99032384,0.0077750976,0.00017924063,0.001232576,0.000111552865,0.00012775656,0.000023384144,0.00006257238,0.00016395046],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859697,0.00005631743,0.00030951665,0.0005273522,0.00021481208,0.00029501825],"domain_scores_gemma":[0.9993589,0.000019109,0.000072992785,0.00040361763,0.00008119398,0.00006422031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019218419,0.00023034724,0.00021902336,0.0000739741,0.000045110053,0.000031486346,0.00018625609,0.00018700167,0.00010010731],"category_scores_gemma":[0.0000031868422,0.00022972515,0.000106694286,0.00023683277,0.00023306858,0.0000071914556,0.00012866149,0.00016125113,0.0000036427537],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000081108825,0.000049479997,0.0070325285,0.0002133993,0.00019863501,0.000013946028,0.00022585553,0.0007609691,0.95896256,0.000048083908,0.00034511893,0.032068327],"study_design_scores_gemma":[0.0006022658,0.000050450166,0.021584386,0.00028145284,0.00015193112,0.00005645969,0.00007201175,0.00033681645,0.90202254,0.00027623872,0.074110426,0.00045500233],"about_ca_topic_score_codex":0.00035821777,"about_ca_topic_score_gemma":0.00058497617,"teacher_disagreement_score":0.07376531,"about_ca_system_score_codex":0.00021175016,"about_ca_system_score_gemma":0.00030523282,"threshold_uncertainty_score":0.93679196},"labels":[],"label_agreement":null},{"id":"W4399505148","doi":"10.1158/1538-8514.synthleth24-ia022","title":"Abstract IA022: Mechanisms of splicing dysregulation and dependency in cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA Research and Splicing","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"RNA splicing; Biology; Alternative splicing; Splicing factor; RNA-binding protein; Exonic splicing enhancer; Genetics; RNA; Gene; Computational biology; Messenger RNA","score_opus":0.021667386956810735,"score_gpt":0.3223889909467752,"score_spread":0.30072160398996445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733444,0.018574903,0.0073365783,0.00030754125,0.000100615085,0.00016172799,0.000015887596,0.000009640778,0.00014873133],"genre_scores_gemma":[0.9965187,0.0027039344,0.00026864326,0.00020745315,0.000044635242,0.00003848053,0.000011290104,0.00002931502,0.00017755032],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991293,0.000027596274,0.00017890579,0.00027264588,0.00017368376,0.00021785598],"domain_scores_gemma":[0.99969983,0.000008903174,0.000034226425,0.00016862476,0.000043357497,0.000045030436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015859625,0.00012041103,0.00012051701,0.000087463275,0.000025535024,0.000029524512,0.00009826465,0.000109370914,0.000026114318],"category_scores_gemma":[0.000005081829,0.00011441826,0.00005021477,0.00014426801,0.000039640985,0.0000062482573,0.00004877491,0.000118084965,7.855255e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003478317,0.000014679337,0.0011120432,0.00010193072,0.00007769023,0.000013659398,0.000064656095,0.0005104835,0.94151706,0.00071906927,0.0000062596937,0.05582772],"study_design_scores_gemma":[0.00030978158,0.00010875446,0.007374361,0.00017330612,0.000028250923,0.0000046477267,0.000058550348,0.0037565473,0.9854142,0.001802193,0.00080177264,0.00016763674],"about_ca_topic_score_codex":0.0005424714,"about_ca_topic_score_gemma":0.00046592936,"teacher_disagreement_score":0.055660084,"about_ca_system_score_codex":0.000036471112,"about_ca_system_score_gemma":0.00012542366,"threshold_uncertainty_score":0.46658412},"labels":[],"label_agreement":null},{"id":"W4399505149","doi":"10.1158/1538-8514.synthleth24-a024","title":"Abstract A024: SOX11: An <i>Achilles heel</i> of mantle cell lymphoma enhancing sensitivity to DNA damaging agents by impairing DNA repair","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chromatin; DNA damage; Homologous recombination; Transcription factor; Cell biology; DNA repair; Biology; Histone; DNA-binding domain; Molecular biology; Cancer research; Chemistry; DNA; Genetics; Gene","score_opus":0.017109744278648097,"score_gpt":0.2964902886175709,"score_spread":0.2793805443389228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878945,0.008818675,0.0007205859,0.0006883901,0.00029153153,0.0004538899,0.000092839255,0.0002222615,0.00081736577],"genre_scores_gemma":[0.99576163,0.00049135665,0.0005703544,0.0027740465,0.00009802676,0.00004952662,0.000050753984,0.00009512937,0.00010916398],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99810815,0.00007858433,0.00037709938,0.00056245754,0.00043294323,0.0004407587],"domain_scores_gemma":[0.9989981,0.000064144275,0.000081526596,0.0005435375,0.00008107819,0.0002316236],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002822273,0.00033429085,0.0004246141,0.00013094685,0.00008835906,0.00007313684,0.00009138331,0.00010603745,0.000046437293],"category_scores_gemma":[0.0000055293863,0.00029978377,0.00028422681,0.0002630145,0.0000481394,0.00012202678,0.000069777096,0.000102526414,0.000025388887],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000860981,0.00080781727,0.0038070385,0.00041693109,0.00065101736,0.0009811554,0.0013277518,0.00011962513,0.95355797,0.000032241358,0.0006146808,0.03759769],"study_design_scores_gemma":[0.0013629175,0.00025623362,0.016347598,0.00063615467,0.00056230545,0.000050972863,0.00028301825,0.0016657489,0.9645076,0.000019891531,0.013982635,0.00032495867],"about_ca_topic_score_codex":0.00058072776,"about_ca_topic_score_gemma":0.00011089113,"teacher_disagreement_score":0.037272733,"about_ca_system_score_codex":0.00046779047,"about_ca_system_score_gemma":0.00023802863,"threshold_uncertainty_score":0.9999454},"labels":[],"label_agreement":null},{"id":"W4399505153","doi":"10.1158/1538-8514.synthleth24-pr013","title":"Abstract PR013: Detecting pairwise and higher-order antagonistic epistatic effects among somatic cancer genotypes to discover synthetic lethality","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Epistasis; Biology; Mutation rate; Cancer; Pairwise comparison; Genetics; Genotype; Selection (genetic algorithm); Computational biology; Germline mutation; Mutation; Gene; Computer science; Machine learning; Statistics; Mathematics","score_opus":0.011308736983207541,"score_gpt":0.28094719466838086,"score_spread":0.2696384576851733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9498371,0.037713382,0.009716053,0.0007196029,0.0009795666,0.0006413264,0.00013918115,0.000055479824,0.00019831874],"genre_scores_gemma":[0.99434584,0.0023802852,0.0005887407,0.0017459755,0.00029762677,0.00031016176,0.000024232548,0.00012331025,0.00018384584],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981056,0.000077247736,0.0003342257,0.00073139585,0.00024150158,0.00051003625],"domain_scores_gemma":[0.9990111,0.0001322248,0.00008572697,0.00048129397,0.00009090614,0.00019874788],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018953037,0.0003960837,0.00031055528,0.00008746793,0.00014363286,0.0002519421,0.00021345826,0.0001801228,0.000045274075],"category_scores_gemma":[0.00006207262,0.00037695735,0.0001252173,0.00024958243,0.00016419217,0.000011047661,0.00015246298,0.00019189979,0.000009798102],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011811713,0.00009315806,0.007228587,0.0013277336,0.0008489347,0.0001440932,0.00051576796,0.004012948,0.90007347,0.0002884498,0.00016899103,0.085179776],"study_design_scores_gemma":[0.0019009449,0.00089550647,0.13694501,0.0021470955,0.0019129878,0.000039056235,0.00014537429,0.0043335254,0.7905874,0.0028842743,0.0552545,0.0029542723],"about_ca_topic_score_codex":0.000827372,"about_ca_topic_score_gemma":0.0006795972,"teacher_disagreement_score":0.12971643,"about_ca_system_score_codex":0.00014252114,"about_ca_system_score_gemma":0.00029618805,"threshold_uncertainty_score":0.9998682},"labels":[],"label_agreement":null},{"id":"W4399505156","doi":"10.1158/1538-8514.synthleth24-ia011","title":"Abstract IA011: Towards mapping the landscape of cancer vulnerabilities","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Computational Drug Discovery Methods","field":"Computer Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Resource (disambiguation); Dependency (UML); Citation; Computational biology; Cancer research; Biology; Computer science; Library science; Genetics; Artificial intelligence","score_opus":0.057324274623232245,"score_gpt":0.3432844338601982,"score_spread":0.28596015923696594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505156","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24187908,0.06986261,0.6710596,0.012125494,0.0019938021,0.00031134972,0.000049214803,0.00020996649,0.002508876],"genre_scores_gemma":[0.99222165,0.00059880584,0.0055504707,0.0012962146,0.00012088833,0.00008283367,0.000001933728,0.00002346498,0.00010373677],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9985744,0.00012940519,0.00027178947,0.00033385362,0.00045202664,0.00023854588],"domain_scores_gemma":[0.9990785,0.00023891767,0.000067809415,0.00046306435,0.0001155362,0.00003617411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004556778,0.0001686658,0.00017393,0.00010484188,0.000076472075,0.00020873132,0.0007759034,0.000052311338,0.0000776298],"category_scores_gemma":[0.000010141896,0.00012012712,0.00015583301,0.0005942505,0.000094161434,0.00018604829,0.00016649337,0.00022625574,0.000005203109],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010602647,0.000041215168,0.00039338687,0.00027376128,0.0005178704,0.0000289997,0.0050969888,0.098359145,0.022000054,0.06915896,0.00024850463,0.8038705],"study_design_scores_gemma":[0.00042933525,0.000084857194,0.02647328,0.00051510805,0.00014066041,0.000015230892,0.00041600692,0.6996656,0.09622257,0.07510032,0.100187,0.0007500421],"about_ca_topic_score_codex":0.0003488035,"about_ca_topic_score_gemma":0.000032036845,"teacher_disagreement_score":0.8031205,"about_ca_system_score_codex":0.00008717547,"about_ca_system_score_gemma":0.0005072208,"threshold_uncertainty_score":0.48986417},"labels":[],"label_agreement":null},{"id":"W4399505157","doi":"10.1158/1538-8514.synthleth24-pr015","title":"Abstract PR015: Discovery of LY4050784 (FHD-909), a selective BRM (SMARCA2) ATPase inhibitor for the treatment of BRG1(SMARCA4) mutant cancers","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"SMARCA4; Chromatin remodeling; Cancer research; Mutant; Synthetic lethality; Cancer; Cell growth; Chemistry; Gene; Chromatin; Biology; Molecular biology; Genetics; Biochemistry","score_opus":0.019402608017725084,"score_gpt":0.300713497200709,"score_spread":0.2813108891829839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91215444,0.073748715,0.011366786,0.0003644847,0.0006014373,0.00090145983,0.0006731089,0.000024119143,0.00016548033],"genre_scores_gemma":[0.98862624,0.009817386,0.0002944048,0.00021049491,0.00033528716,0.00031160816,0.00006658799,0.000067555375,0.00027044275],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985342,0.000036708083,0.00039674906,0.0004502257,0.00026279085,0.00031931393],"domain_scores_gemma":[0.999086,0.000053469903,0.00015675268,0.00046326537,0.00019135856,0.00004915179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013695737,0.00029590528,0.00030552223,0.00005190346,0.00007420144,0.00004082578,0.00021267458,0.00016917878,0.000010812497],"category_scores_gemma":[0.000009687828,0.00021168013,0.00041389608,0.00018833019,0.00017903952,0.000008283229,0.00003069716,0.00009626402,6.937072e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037795058,0.00015301422,0.000075708114,0.00022840974,0.001263762,0.000006530229,0.00063047645,0.0042155995,0.94268984,0.00011501192,0.00018921914,0.050054487],"study_design_scores_gemma":[0.0009611635,0.0008786478,0.00016454773,0.00013821582,0.00040372636,0.000006170386,0.00016511079,0.004159965,0.9482155,0.0001583901,0.04449088,0.00025769946],"about_ca_topic_score_codex":0.0005965412,"about_ca_topic_score_gemma":0.00031462382,"teacher_disagreement_score":0.07647182,"about_ca_system_score_codex":0.00027829743,"about_ca_system_score_gemma":0.0008196741,"threshold_uncertainty_score":0.8632065},"labels":[],"label_agreement":null},{"id":"W4399505159","doi":"10.1158/1538-8514.synthleth24-a015","title":"Abstract A015: Exploiting endogenous replication stress with a novel targeted therapy in Ewing sarcoma","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer research; Biology; DNA replication factor CDT1; FLI1; Pediatric cancer; Mitosis; FOXM1; Targeted therapy; Medicine; Chromatin remodeling; Cell cycle; Cancer; Bioinformatics; Transcription factor; Genetics; Gene","score_opus":0.04317926041654674,"score_gpt":0.2878575235038117,"score_spread":0.24467826308726498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9686253,0.020036146,0.009554477,0.0005128891,0.00014003275,0.00044323786,0.000055887616,0.00006471299,0.00056730525],"genre_scores_gemma":[0.9967176,0.0011877469,0.00062720163,0.0008787741,0.00014194647,0.0001798657,0.00014589344,0.00006653982,0.000054475884],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99874437,0.00003416706,0.00023272274,0.000513546,0.00019747518,0.0002777425],"domain_scores_gemma":[0.9993462,0.0000092469645,0.000065891465,0.00046035065,0.00006930302,0.000049039172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015726924,0.00020514178,0.00012918538,0.000087657645,0.0000578482,0.000083278785,0.00017983484,0.00012499868,0.000019347868],"category_scores_gemma":[0.0000079231795,0.00018062147,0.00007174626,0.00024966834,0.00004663994,0.000011951101,0.00003138834,0.00017249346,0.0000024296412],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007744018,0.000072247996,0.00068699697,0.000029379944,0.00011720154,0.000022316686,0.00019504363,0.00029109127,0.9468155,0.00012267396,0.000013274421,0.05155682],"study_design_scores_gemma":[0.00063030043,0.00016042977,0.00096788135,0.00012421931,0.000013777388,0.000016016304,0.00010215949,0.0004254545,0.97760427,0.000035428307,0.019664088,0.0002560019],"about_ca_topic_score_codex":0.000111357964,"about_ca_topic_score_gemma":0.000054433607,"teacher_disagreement_score":0.051300816,"about_ca_system_score_codex":0.000060430757,"about_ca_system_score_gemma":0.00016197572,"threshold_uncertainty_score":0.736553},"labels":[],"label_agreement":null},{"id":"W4399505160","doi":"10.1158/1538-8514.synthleth24-ia005","title":"Abstract IA005: Therapeutic vulnerabilities of cohesin-mutant myeloid malignancies","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA Research and Splicing","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myeloid leukemia; Cancer research; Cohesin; Biology; DNA repair; RNA splicing; Genetics; Gene; Chromatin; RNA","score_opus":0.023480445135015973,"score_gpt":0.30302701060462456,"score_spread":0.2795465654696086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9391083,0.05571494,0.0032885193,0.0006239737,0.000257857,0.00024330529,0.00006559703,0.00004046167,0.00065705297],"genre_scores_gemma":[0.9947733,0.0030213445,0.00016773901,0.00071149017,0.00013983717,0.00006216445,0.00002696262,0.00006788875,0.0010292477],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99840325,0.00007463568,0.00031497568,0.0004141545,0.0003548811,0.00043811748],"domain_scores_gemma":[0.9992169,0.000033791697,0.000058391866,0.00046383752,0.00014176748,0.000085272695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027729257,0.00024832264,0.00023264621,0.00009156025,0.0000729596,0.00007943207,0.0003023231,0.00016025994,0.00009581776],"category_scores_gemma":[0.000014321658,0.00021371094,0.00021784558,0.00019976318,0.0002271468,0.000008331109,0.00007477104,0.00019876884,0.000010305466],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008389734,0.000040544524,0.00040072636,0.00020440246,0.00039533235,0.00002708135,0.00013357216,0.00022982873,0.9719314,0.0010429046,0.00006661512,0.025443675],"study_design_scores_gemma":[0.00024009547,0.00021460239,0.0010762053,0.00012070094,0.00006243173,0.000012688557,0.00017156426,0.0004216411,0.9575133,0.00052994647,0.03936899,0.00026788007],"about_ca_topic_score_codex":0.00011694344,"about_ca_topic_score_gemma":0.000040243296,"teacher_disagreement_score":0.05566503,"about_ca_system_score_codex":0.00004806779,"about_ca_system_score_gemma":0.00033758188,"threshold_uncertainty_score":0.8714879},"labels":[],"label_agreement":null},{"id":"W4399505170","doi":"10.1158/1538-8514.synthleth24-pr010","title":"Abstract PR010: <i>CDK12</i> loss promotes prostate cancer development while exposing vulnerabilities to paralog-based synthetic lethality","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"PTEN; Prostate cancer; Synthetic lethality; Cancer research; Prostate; Biology; Cancer; Context (archaeology); Medicine; DNA repair; PI3K/AKT/mTOR pathway; Signal transduction; Cell biology; Genetics; Gene","score_opus":0.048963146014998474,"score_gpt":0.34636403839556645,"score_spread":0.297400892380568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9306507,0.04821765,0.0012162885,0.016026126,0.0005728908,0.0022898023,0.00015747536,0.000331238,0.00053780555],"genre_scores_gemma":[0.99227583,0.00089102756,0.0013258538,0.0025537815,0.00013849683,0.0016651467,0.0000658008,0.00012643248,0.0009576057],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99716645,0.00007862553,0.000451644,0.0007627855,0.0007372775,0.00080322806],"domain_scores_gemma":[0.9988224,0.00008997331,0.000058669168,0.0004922469,0.00024430602,0.0002924256],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003826677,0.00043471484,0.00044374357,0.00019679705,0.00020542409,0.00019542573,0.00018843272,0.00014504687,0.00031227383],"category_scores_gemma":[0.000013575917,0.000339216,0.00017317057,0.0005008214,0.00021107946,0.00009791071,0.00006330777,0.00045831798,0.000049910508],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020263088,0.0009706634,0.017100483,0.005681739,0.0024833824,0.0017265847,0.0122093,0.0023919542,0.5538167,0.00022047765,0.00061527477,0.40075716],"study_design_scores_gemma":[0.0014330541,0.00034773603,0.0040778387,0.002849122,0.00033049035,0.00001862354,0.00017912898,0.0006149091,0.88738513,0.00023444099,0.10189866,0.00063088053],"about_ca_topic_score_codex":0.00036603629,"about_ca_topic_score_gemma":0.000110372115,"teacher_disagreement_score":0.40012628,"about_ca_system_score_codex":0.0010453368,"about_ca_system_score_gemma":0.00203901,"threshold_uncertainty_score":0.999906},"labels":[],"label_agreement":null},{"id":"W4399505172","doi":"10.1158/1538-8514.synthleth24-pr007","title":"Abstract PR007: Delineating functional drivers of esophageal adenocarcinoma to identify synthetic lethal interactions","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CRISPR; Carcinogenesis; Biology; Synthetic lethality; Computational biology; Gene knockdown; Cancer research; Transcriptome; Gene; Genetics; DNA repair; Gene expression","score_opus":0.05331619994262055,"score_gpt":0.38327893890016274,"score_spread":0.3299627389575422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94262654,0.04226143,0.008718183,0.003575963,0.0008019541,0.0007848238,0.000103286664,0.00012582807,0.0010019991],"genre_scores_gemma":[0.9977309,0.00019864656,0.0006607166,0.0005951588,0.00020445633,0.00013043481,0.000029801846,0.000050816976,0.00039907885],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984319,0.000035759243,0.000298868,0.0003684354,0.0005532871,0.00031172403],"domain_scores_gemma":[0.9992218,0.000078191675,0.000045658322,0.00028092533,0.00017656192,0.00019686007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013241943,0.00019134473,0.0002396258,0.00023489846,0.00006860837,0.000049582395,0.00009799907,0.00006117115,0.0006853998],"category_scores_gemma":[0.000017751441,0.00016946596,0.00021993248,0.00035622105,0.000070523754,0.000075107535,0.00004691645,0.0003301152,0.000081441525],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017072489,0.0009163965,0.053955566,0.0022306948,0.0066321297,0.006846196,0.0037378587,0.0044021625,0.63614786,0.00239375,0.0013067572,0.27972338],"study_design_scores_gemma":[0.0033609716,0.0014428018,0.40806547,0.002392493,0.0019921274,0.0004696102,0.0006798485,0.0053063896,0.56588703,0.00054804195,0.00918887,0.0006663594],"about_ca_topic_score_codex":0.00017384024,"about_ca_topic_score_gemma":0.000029384784,"teacher_disagreement_score":0.3541099,"about_ca_system_score_codex":0.0003999081,"about_ca_system_score_gemma":0.0003948046,"threshold_uncertainty_score":0.7504647},"labels":[],"label_agreement":null},{"id":"W4399505173","doi":"10.1158/1538-8514.synthleth24-ia009","title":"Abstract IA009: Single strand DNA GAP accumulation as a functional biomarker for DNA Repair Inhibitors","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; DNA repair; Cancer research; Homologous recombination; PARP1; Biology; Genome instability; DNA damage; Olaparib; Polymerase; Poly ADP ribose polymerase; Genetics; Gene; DNA","score_opus":0.11938644281047917,"score_gpt":0.37918037371034874,"score_spread":0.2597939308998696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9298529,0.02424855,0.024066746,0.008930087,0.0036402508,0.0022617376,0.0002540589,0.0011275032,0.00561814],"genre_scores_gemma":[0.9923831,0.00028357212,0.0006745366,0.0044875136,0.00074357947,0.00035898585,0.00018305785,0.00013999912,0.00074564666],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979337,0.000040766605,0.00047212528,0.00058832543,0.0005613831,0.0004037419],"domain_scores_gemma":[0.9990139,0.000119568875,0.000100756675,0.00038477354,0.0002299362,0.0001510613],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027087994,0.00032968813,0.00030560495,0.00022886494,0.00012430172,0.00010565895,0.00007964621,0.00024473976,0.00077446876],"category_scores_gemma":[0.000017111279,0.00031295046,0.00047481744,0.00041341726,0.000117319716,0.00016342408,0.000016530941,0.00024170418,0.00006688136],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012144923,0.0002159618,0.0003882908,0.0003873625,0.0011425487,0.00007239824,0.00029609524,0.00024648666,0.9597186,0.00086569006,0.0038317111,0.0316204],"study_design_scores_gemma":[0.004332571,0.0005665971,0.005932539,0.00091782433,0.00071993243,0.00009247352,0.00009919598,0.0042550764,0.5746275,0.0048105605,0.4030192,0.0006265597],"about_ca_topic_score_codex":0.00003099241,"about_ca_topic_score_gemma":0.000011808128,"teacher_disagreement_score":0.39918748,"about_ca_system_score_codex":0.0005462262,"about_ca_system_score_gemma":0.00048736468,"threshold_uncertainty_score":0.9999322},"labels":[],"label_agreement":null},{"id":"W4399505192","doi":"10.1158/1538-8514.synthleth24-b019","title":"Abstract B019: Stearoyl-CoA desaturase is a synthetic lethal target in SMAD4-deficient cancers","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; Cancer research; Biology; Mutant; Carcinogenesis; Fatty acid synthesis; CRISPR; In vivo; Cancer; Gene; Genetics","score_opus":0.01588855896612284,"score_gpt":0.28248608657922153,"score_spread":0.2665975276130987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8247839,0.15751682,0.0018907415,0.0013453362,0.011611083,0.0006406251,0.00035472657,0.00008610668,0.0017706327],"genre_scores_gemma":[0.98682374,0.0061732563,0.00026390425,0.0026037826,0.0028797216,0.00017849583,0.00007126074,0.00012060683,0.0008852388],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978043,0.00007287087,0.0003666682,0.00079773256,0.00031816814,0.0006402567],"domain_scores_gemma":[0.99909586,0.000017312217,0.000070676135,0.00059698423,0.000073340925,0.00014582223],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002066904,0.0004066422,0.0003309778,0.00015428392,0.000070595954,0.00011298574,0.000304562,0.00028010094,0.00017812948],"category_scores_gemma":[0.000010117703,0.00038585314,0.0002880722,0.00032390084,0.0001482965,0.000009431685,0.00007151234,0.0002971769,0.000026871005],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001812651,0.00008996487,0.00028816884,0.00013267016,0.00032958438,0.000017197284,0.00086917775,0.0029321155,0.9547368,0.00020628447,0.0031138337,0.037102908],"study_design_scores_gemma":[0.0005898032,0.000110529014,0.00040084,0.000108042885,0.00009204068,0.000018042832,0.00013108237,0.0007113119,0.222098,0.00011962543,0.7751639,0.00045679623],"about_ca_topic_score_codex":0.0009812581,"about_ca_topic_score_gemma":0.00043845334,"teacher_disagreement_score":0.7720501,"about_ca_system_score_codex":0.00031036435,"about_ca_system_score_gemma":0.0008709833,"threshold_uncertainty_score":0.99985933},"labels":[],"label_agreement":null},{"id":"W4399505200","doi":"10.1158/1538-8514.synthleth24-b012","title":"Abstract B012: Predicting targetable paralog synthetic lethalities and functional redundancies in cancer genomes","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CRISPR and Genetic Engineering","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Concordia University","funders":"","keywords":"Synthetic lethality; Biology; Breast cancer; Cancer; Genome; Gene; Cancer cell; Genetics; Context (archaeology); Computational biology; Triple-negative breast cancer; Gene duplication; CRISPR; Cancer research; DNA repair","score_opus":0.019180244438083548,"score_gpt":0.3024860092635994,"score_spread":0.2833057648255159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7411842,0.25449073,0.0029262505,0.00040562588,0.00046353476,0.0001285671,0.000046722966,0.000031526848,0.00032286285],"genre_scores_gemma":[0.9892583,0.009392525,0.00017389125,0.00030851763,0.0002137202,0.000106587504,0.000025300604,0.000044974622,0.0004762032],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99900305,0.000020662304,0.0001880375,0.0003534407,0.00013603336,0.0002987803],"domain_scores_gemma":[0.99971133,0.000015556625,0.000023833963,0.00016790944,0.000031582204,0.00004979116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012719588,0.00018814916,0.000140645,0.00006888495,0.00005209594,0.00006961398,0.000076348595,0.00011717439,0.000060324495],"category_scores_gemma":[0.000005674477,0.00018593813,0.00006407019,0.00010709081,0.00007911694,0.0000068434815,0.00004966677,0.000152483,0.0000017095706],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032035092,0.000021188604,0.00648297,0.0002220078,0.00023450707,0.000020669795,0.0003648072,0.019094257,0.9590091,0.00016275414,0.000112872054,0.0142427925],"study_design_scores_gemma":[0.000614682,0.00012471991,0.025729492,0.0003655003,0.00016908589,0.000041924213,0.00044211978,0.006536844,0.8051897,0.00069360976,0.15931292,0.0007793692],"about_ca_topic_score_codex":0.00017718326,"about_ca_topic_score_gemma":0.00015742071,"teacher_disagreement_score":0.24807411,"about_ca_system_score_codex":0.000043191358,"about_ca_system_score_gemma":0.0001243031,"threshold_uncertainty_score":0.7582337},"labels":[],"label_agreement":null},{"id":"W4399505234","doi":"10.1158/1538-8514.synthleth24-ia023","title":"Abstract IA023: Targeting epigenetic complexes in leukemia","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Epigenetics; Myeloid leukemia; Chromatin; Leukemia; Cancer research; Cancer; NPM1; Biology; Computational biology; Medicine; Bioinformatics; Genetics; Gene","score_opus":0.01900543605627948,"score_gpt":0.29165553551237583,"score_spread":0.27265009945609636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9381013,0.054411996,0.0045964653,0.0007356757,0.00053275685,0.0002757758,0.000026155281,0.000056021207,0.0012638613],"genre_scores_gemma":[0.9961503,0.0016125484,0.0004436966,0.0011291323,0.00022591281,0.00005743708,0.00008196799,0.000049599097,0.0002494067],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989019,0.00004370466,0.0002481143,0.000365879,0.00016022578,0.00028014957],"domain_scores_gemma":[0.9996334,0.000008243711,0.000037148362,0.00023174362,0.000037194037,0.00005232183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015051782,0.00018131589,0.00012436631,0.00007755959,0.000042528332,0.00007024351,0.00017834043,0.00013997729,0.0000747313],"category_scores_gemma":[0.000010022014,0.0001772199,0.00009957777,0.00018573471,0.000060784998,0.000005243907,0.000053850825,0.00017074682,0.000022875474],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017678793,0.000017765064,0.00044850828,0.000045846227,0.000062910374,0.000024422086,0.000059920585,0.000629921,0.97899276,0.00027416027,0.00062678935,0.018799318],"study_design_scores_gemma":[0.00022697765,0.000047165573,0.001241474,0.00007032044,0.000015790612,0.000003065537,0.000032386884,0.0008316545,0.78287035,0.0002836035,0.21413724,0.00023994784],"about_ca_topic_score_codex":0.00008724748,"about_ca_topic_score_gemma":0.000061008253,"teacher_disagreement_score":0.21351045,"about_ca_system_score_codex":0.00009121821,"about_ca_system_score_gemma":0.00020791024,"threshold_uncertainty_score":0.72268176},"labels":[],"label_agreement":null},{"id":"W4399505248","doi":"10.1158/1538-8514.synthleth24-pr008","title":"Abstract PR008: Targeting mechanisms of dosage compensation to selectively kill aneuploid cancer cells","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA regulation and disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Aneuploidy; Cancer cell; Gene dosage; Cellular stress response; RNA-binding protein; Stress granule; Cancer; RNA; Dosage compensation; Genetics; Cell biology; Gene; Gene expression; Cancer research; Translation (biology); Molecular biology; Chromosome; Messenger RNA; Fight-or-flight response","score_opus":0.014409730613178021,"score_gpt":0.2850744484675493,"score_spread":0.2706647178543713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9277783,0.008455251,0.061425265,0.00069678534,0.0004945567,0.00048516534,0.00016608919,0.000055338962,0.00044322954],"genre_scores_gemma":[0.99657613,0.00035053433,0.0010004784,0.0015895381,0.0001118367,0.000068101515,0.00005827295,0.00005283338,0.00019229823],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988914,0.00004323795,0.00023755728,0.00037105053,0.00022608042,0.0002306779],"domain_scores_gemma":[0.9994642,0.000008681456,0.00007340248,0.00020938527,0.00013856257,0.00010572812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011167326,0.00018745028,0.00014891553,0.0000735238,0.000049023223,0.000044076467,0.00014749983,0.000117067975,0.00011503035],"category_scores_gemma":[0.0000052039404,0.00018400536,0.0001226447,0.00021952727,0.000034131535,0.000006519384,0.000044279008,0.00008389141,0.000009783385],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008208747,0.000040193176,0.000121879886,0.00008198513,0.00016220193,0.000007637029,0.00013485903,0.005165298,0.9882611,0.0005491364,0.00031247977,0.0050811316],"study_design_scores_gemma":[0.0002431827,0.00008542664,0.0015908015,0.000056272816,0.00007408738,0.0000010383433,0.000043597407,0.001087001,0.9844975,0.00041320163,0.011675894,0.00023198227],"about_ca_topic_score_codex":0.00006919243,"about_ca_topic_score_gemma":0.000020984133,"teacher_disagreement_score":0.06879779,"about_ca_system_score_codex":0.000055362245,"about_ca_system_score_gemma":0.00020954682,"threshold_uncertainty_score":0.750352},"labels":[],"label_agreement":null},{"id":"W4399505261","doi":"10.1158/1538-8514.synthleth24-ia008","title":"Abstract IA008: Exploiting tumor selective vulnerabilities with structure based drug design","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"DNA repair; Homologous recombination; Biology; DNA damage; Base excision repair; DNA replication; Genome instability; Cell biology; PARP1; Genetics; DNA; Poly ADP ribose polymerase; Polymerase","score_opus":0.032613292186137746,"score_gpt":0.3090953129435718,"score_spread":0.27648202075743405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8124334,0.025729632,0.14726292,0.007502759,0.0008036105,0.002328132,0.0002630679,0.0011914871,0.0024849826],"genre_scores_gemma":[0.985653,0.00008105074,0.0062126066,0.0070723593,0.00030041265,0.00028655154,0.000025218766,0.00016732706,0.00020146549],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979262,0.00011880556,0.00031378944,0.0005820942,0.00058626843,0.00047288425],"domain_scores_gemma":[0.9989632,0.00018185414,0.000088822875,0.00041277116,0.00021782989,0.00013553382],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020463979,0.00039472175,0.00037595443,0.00018562717,0.00013457911,0.00012309621,0.00013460875,0.000096409225,0.00058979297],"category_scores_gemma":[0.0000093159,0.00031585284,0.00014657805,0.0005353647,0.00019132109,0.00012988002,0.000012865272,0.0006418233,0.000012316309],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022999074,0.0001951896,0.0016126051,0.0013101213,0.002021624,0.0013309685,0.0047946405,0.021638198,0.9378329,0.0009104612,0.0017083058,0.024345063],"study_design_scores_gemma":[0.0022277264,0.0003807707,0.00077977177,0.0015747729,0.0003791797,0.00012012317,0.00049595546,0.0065269847,0.97122365,0.0019890673,0.013712645,0.0005893375],"about_ca_topic_score_codex":0.000077991754,"about_ca_topic_score_gemma":0.00002235882,"teacher_disagreement_score":0.17321959,"about_ca_system_score_codex":0.00060112495,"about_ca_system_score_gemma":0.00095584145,"threshold_uncertainty_score":0.99992937},"labels":[],"label_agreement":null},{"id":"W4399505265","doi":"10.1158/1538-8514.synthleth24-ia012","title":"Abstract IA012: Generation and Mining of a Pediatric-focused Cancer Cell Line Atlas to Define Druggable Genetic Interactions in Childhood Malignancies","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Druggability; Pediatric cancer; Cancer; Medicine; Computational biology; Bioinformatics; Cancer cell lines; CRISPR; Cancer research; Biology; Cancer cell; Genetics; Gene; Internal medicine","score_opus":0.038638325271009515,"score_gpt":0.3261852411758328,"score_spread":0.2875469159048233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97028595,0.027869357,0.00020697321,0.00084239244,0.00014816837,0.00041340484,0.000046837653,0.00002654238,0.00016038738],"genre_scores_gemma":[0.9926389,0.0051979586,0.0011931091,0.00038069102,0.00015892422,0.0001526377,0.000012011362,0.00004271993,0.00022306497],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99894917,0.000025656092,0.00024754566,0.00029046254,0.00023259108,0.00025459394],"domain_scores_gemma":[0.9995709,0.000035437453,0.000040831965,0.00016625547,0.00007408392,0.00011251384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000051464525,0.00015953026,0.00020419079,0.00018621117,0.000033350985,0.000037003232,0.000051884646,0.00003944674,0.00009772075],"category_scores_gemma":[0.00000682889,0.00014116944,0.000058571106,0.00034973814,0.000020150228,0.000059634916,0.000033532742,0.00014243044,0.0000063044204],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014528751,0.00042323812,0.012671823,0.0003679231,0.00027441702,0.0003495233,0.0016073969,0.0020872976,0.94342136,0.0000139747435,0.00019245142,0.038445294],"study_design_scores_gemma":[0.003402032,0.0009043659,0.11338391,0.00059715373,0.0007559551,0.00003863861,0.0001337305,0.0063271187,0.8699242,0.000050119554,0.0040722336,0.0004105724],"about_ca_topic_score_codex":0.00069984904,"about_ca_topic_score_gemma":0.0011622261,"teacher_disagreement_score":0.10071209,"about_ca_system_score_codex":0.00014817117,"about_ca_system_score_gemma":0.0002644826,"threshold_uncertainty_score":0.57567227},"labels":[],"label_agreement":null},{"id":"W4399505282","doi":"10.1158/1538-8514.synthleth24-pr009","title":"Abstract PR009: Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal cancers","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; Cancer; Cancer research; Cytidine; Biology; Cancer cell; Cell culture; Molecular biology; Gene; Genetics; Biochemistry; DNA repair; Enzyme","score_opus":0.013188119822859976,"score_gpt":0.2813339167505841,"score_spread":0.2681457969277241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7693207,0.2097027,0.0025680445,0.0023085321,0.012607849,0.00086679513,0.0005232229,0.00011715486,0.0019850049],"genre_scores_gemma":[0.98316765,0.009441269,0.0002538695,0.0024549798,0.0034778614,0.0002917397,0.000072973766,0.00014443567,0.0006952164],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99740624,0.00008079875,0.00045621407,0.00091751944,0.00039118022,0.0007480434],"domain_scores_gemma":[0.9989637,0.000024404175,0.000092120776,0.00064850703,0.00008510782,0.00018612816],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027948953,0.00048231301,0.00041505648,0.00015590513,0.00007850612,0.00011860407,0.00038106996,0.0003073343,0.0003123726],"category_scores_gemma":[0.000019671106,0.00047198567,0.00032348235,0.00037537003,0.00017671245,0.000017286364,0.000107978,0.00038062467,0.000028849596],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037467445,0.000116314244,0.0005536397,0.00023294277,0.00061667676,0.00003845705,0.00068308297,0.0022888223,0.9577603,0.00025760286,0.005178104,0.03189942],"study_design_scores_gemma":[0.00082708814,0.00011238424,0.0006077334,0.00017784013,0.0001428587,0.000022674634,0.000076684744,0.0010213373,0.33375287,0.00019508979,0.6624748,0.0005886101],"about_ca_topic_score_codex":0.00088152935,"about_ca_topic_score_gemma":0.0002773024,"teacher_disagreement_score":0.6572967,"about_ca_system_score_codex":0.00023683447,"about_ca_system_score_gemma":0.00079623837,"threshold_uncertainty_score":0.9997732},"labels":[],"label_agreement":null},{"id":"W4399505293","doi":"10.1158/1538-8514.synthleth24-a026","title":"Abstract A026: Single-cell landscape deciphering cancer Single-cell landscape deciphering cancer cell-of-origin and cellular heterogeneity in malignant transformation of 13 major tissues","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Carcinogenesis; Cancer stem cell; Cancer; Malignant transformation; Tumor microenvironment; Cancer research; Stem cell; Cancer cell; Cell; Tumor progression; Immunology; Cell biology; Genetics","score_opus":0.024759803609713,"score_gpt":0.2682939568048664,"score_spread":0.2435341531951534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6855331,0.310968,0.0009145315,0.00007611855,0.0010986837,0.00037114997,0.000104021456,0.000054711112,0.000879696],"genre_scores_gemma":[0.98319626,0.015829906,0.0002226663,0.0001346933,0.000059225153,0.00013922078,0.00005217402,0.00012371299,0.00024212763],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974812,0.00014320984,0.000895275,0.0006129698,0.00018183315,0.0006854634],"domain_scores_gemma":[0.99897045,0.000112380396,0.00030515663,0.00044199673,0.000120351935,0.000049638264],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029059243,0.0005187129,0.0006979381,0.00018271821,0.000091496884,0.00005867619,0.00037397008,0.0004626887,0.00080287986],"category_scores_gemma":[0.0000027569672,0.00050424825,0.00021045843,0.00036425423,0.00019127,0.0002187767,0.00009194031,0.00046615987,0.000011564372],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022421103,0.00025716584,0.004769896,0.0011377743,0.00033661426,0.000031380496,0.0031131082,0.0033595103,0.96777815,0.000012686052,0.00004375869,0.01893575],"study_design_scores_gemma":[0.0018688311,0.00016916824,0.0004922144,0.00076785457,0.00028715536,0.0000074734694,0.00045205987,0.00045539535,0.97692436,0.000027830252,0.01801626,0.00053139793],"about_ca_topic_score_codex":0.0025154438,"about_ca_topic_score_gemma":0.0020157709,"teacher_disagreement_score":0.29766318,"about_ca_system_score_codex":0.00033165643,"about_ca_system_score_gemma":0.00025112828,"threshold_uncertainty_score":0.9997409},"labels":[],"label_agreement":null},{"id":"W4399505299","doi":"10.1158/1538-8514.synthleth24-a010","title":"Abstract A010: Proteasome inhibitors induce a BAX and BAK independent, non-canonical apoptosis","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Apoptosome; Cytochrome c; Proteasome; Apoptosis; Programmed cell death; Caspase; Biology; Intrinsic apoptosis; Cell biology; Cancer cell; Molecular biology; Biochemistry; Cancer; Genetics","score_opus":0.014131911110175468,"score_gpt":0.2729970201583335,"score_spread":0.258865109048158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807927,0.013023247,0.0038414458,0.000596171,0.0006101085,0.000468364,0.000023168213,0.000038283124,0.00060652255],"genre_scores_gemma":[0.99649024,0.0017581724,0.00027200315,0.0005076376,0.00033334107,0.0000991701,0.00004465265,0.00006337676,0.00043141536],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99872816,0.000030430854,0.00022045682,0.0005049586,0.000231233,0.0002847692],"domain_scores_gemma":[0.9995192,0.000006750733,0.000050323928,0.00026658628,0.00005260446,0.000104496656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014847952,0.00023550428,0.00015476876,0.00007003266,0.0000786286,0.00011832984,0.00012996342,0.00032029196,0.0000401718],"category_scores_gemma":[0.000004129936,0.00021172722,0.00011956404,0.00014061396,0.000068993235,0.000008490044,0.00010052771,0.00022031018,0.000008052882],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003256323,0.000037493228,0.000113750975,0.00008281258,0.00018348396,0.000011326246,0.000072664676,0.000056168534,0.96234924,0.0002619348,0.000090806156,0.03670777],"study_design_scores_gemma":[0.00041384881,0.00017087309,0.0014993085,0.00011136552,0.000101477315,0.000017656883,0.000034231278,0.00055380363,0.941765,0.0003975071,0.05457326,0.00036163346],"about_ca_topic_score_codex":0.000061205275,"about_ca_topic_score_gemma":0.000023407774,"teacher_disagreement_score":0.054482453,"about_ca_system_score_codex":0.000041845895,"about_ca_system_score_gemma":0.00017960451,"threshold_uncertainty_score":0.86339855},"labels":[],"label_agreement":null},{"id":"W4399505308","doi":"10.1158/1538-8514.synthleth24-b010","title":"Abstract B010: Drug tolerant persister cancer cells escape therapy-induced senescence","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ferroptosis and cancer prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill Genome Centre; McGill University Health Centre; Université de Montréal; Institute for Research in Immunology and Cancer; McGill University","funders":"","keywords":"Autophagy; Medicine; Cancer; Cancer research; Senescence; Breast cancer; Cancer cell; Drug resistance; Chemotherapy; Oncology; Pharmacology; Internal medicine; Biology; Apoptosis","score_opus":0.043022519505777325,"score_gpt":0.3139448282089302,"score_spread":0.27092230870315287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89116365,0.09411754,0.00022887158,0.0103519475,0.0018586239,0.00076163,0.00005500864,0.00026991943,0.0011928091],"genre_scores_gemma":[0.9736369,0.01378623,0.00015806315,0.010704087,0.00045469336,0.000333726,0.0000110882875,0.00015127426,0.00076393335],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975558,0.000055280692,0.00039623596,0.0007391625,0.00064574694,0.0006077715],"domain_scores_gemma":[0.99893755,0.000033018478,0.000080357444,0.0005636157,0.00017770389,0.00020773824],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000178468,0.00045895056,0.00047770425,0.00014289177,0.00011633774,0.0001788799,0.00024937527,0.00018675395,0.0014305806],"category_scores_gemma":[0.0000014924317,0.00037193898,0.00044024189,0.0004632913,0.000093825794,0.00011680651,0.0000447276,0.0005295722,0.00007486952],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020071678,0.00015458922,0.0007229371,0.00030797158,0.0008107477,0.00016851258,0.0013978871,0.000115097915,0.8259692,0.00004066231,0.001009142,0.1691025],"study_design_scores_gemma":[0.0011375161,0.00016501176,0.0026581176,0.0009198644,0.00051281817,0.00001782883,0.000245526,0.002564953,0.87693095,0.000030650826,0.11423231,0.00058443676],"about_ca_topic_score_codex":0.0006443168,"about_ca_topic_score_gemma":0.000058551403,"teacher_disagreement_score":0.16851807,"about_ca_system_score_codex":0.0003459754,"about_ca_system_score_gemma":0.000549425,"threshold_uncertainty_score":0.9998733},"labels":[],"label_agreement":null},{"id":"W4399505311","doi":"10.1158/1538-8514.synthleth24-ia003","title":"Abstract IA003: Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Helicase; Allosteric regulation; Biology; DNA repair; DNA; Molecular biology; Cell biology; Enzyme; Cancer research; Genetics; Biochemistry; RNA; Gene","score_opus":0.0202534664455088,"score_gpt":0.2925839687847679,"score_spread":0.2723305023392591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.963092,0.029293455,0.0064073056,0.00028265634,0.0002434463,0.0002501359,0.00016132391,0.000011645263,0.0002579951],"genre_scores_gemma":[0.9961001,0.0027293125,0.000307265,0.0002779549,0.00011712128,0.00008210305,0.00004527527,0.0000429183,0.0002979086],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989895,0.000024294723,0.00031268716,0.00031202278,0.00018447918,0.00017700464],"domain_scores_gemma":[0.99931604,0.000006334033,0.00010738341,0.00043953117,0.00009368998,0.000037047193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000097987926,0.00016660267,0.0001827793,0.000055611137,0.000021795524,0.000029105422,0.00018441137,0.000118611184,0.00003125046],"category_scores_gemma":[0.000004270534,0.00015199871,0.00018820832,0.00016278726,0.00011739943,0.000007759578,0.000058381946,0.00009114248,0.000003225822],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008751797,0.00007646635,0.000108782195,0.00022464701,0.00025614692,0.0000065511217,0.000066836,0.00015728938,0.98603314,0.00016762114,0.00011866905,0.012696304],"study_design_scores_gemma":[0.00027476862,0.00013146551,0.0005629182,0.00011716303,0.00008438684,0.0000061459077,0.000035053654,0.00012447487,0.97981495,0.00007901308,0.018601352,0.00016833971],"about_ca_topic_score_codex":0.000054176897,"about_ca_topic_score_gemma":0.000009597322,"teacher_disagreement_score":0.033008106,"about_ca_system_score_codex":0.000035305453,"about_ca_system_score_gemma":0.00022958728,"threshold_uncertainty_score":0.61983275},"labels":[],"label_agreement":null},{"id":"W4399505312","doi":"10.1158/1538-8514.synthleth24-b002","title":"Abstract B002: POLB knockout is synthetic lethal with PARP inhibition leading to complete and durable responses in BRCA-mutant tumor xenografts","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; Cancer; Mutant; Cancer research; Poly ADP ribose polymerase; Homologous recombination; PARP1; Mutation; Biology; Polymerase; Genetics; DNA; Gene","score_opus":0.04220035080186927,"score_gpt":0.3308149417042294,"score_spread":0.28861459090236014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974553,0.010408608,0.0014925832,0.011311189,0.00023761702,0.0007999936,0.00015080748,0.00015928964,0.00088693906],"genre_scores_gemma":[0.98854977,0.00055456423,0.00064816675,0.009541401,0.00013521803,0.00021042963,0.000012145088,0.0001187681,0.0002295472],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99779636,0.00009190649,0.00041711572,0.00065908063,0.0004979936,0.0005375468],"domain_scores_gemma":[0.99911326,0.00011412847,0.00007579488,0.00039586003,0.00009877199,0.00020217575],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002984608,0.00036262427,0.00045589742,0.00042469605,0.00009958547,0.00013479765,0.00008944223,0.00010821501,0.00023002457],"category_scores_gemma":[0.00001135867,0.00032050352,0.00009505128,0.0006788451,0.00017653254,0.000119375574,0.000034100325,0.00044677762,0.00005405747],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015809127,0.000095878735,0.0011032826,0.00037203848,0.00027275534,0.0017300742,0.0023596243,0.00015903753,0.978822,0.00028311432,0.00019475444,0.01302654],"study_design_scores_gemma":[0.0035665382,0.0009233857,0.0075415145,0.0058548716,0.00033605561,0.0010214949,0.00043545655,0.00077618874,0.8943854,0.00063648645,0.083644345,0.00087824184],"about_ca_topic_score_codex":0.00018260498,"about_ca_topic_score_gemma":0.000094773226,"teacher_disagreement_score":0.084436566,"about_ca_system_score_codex":0.0004764107,"about_ca_system_score_gemma":0.00033302236,"threshold_uncertainty_score":0.9999247},"labels":[],"label_agreement":null},{"id":"W4399505326","doi":"10.1158/1538-8514.synthleth24-a007","title":"Abstract A007: Assessment of metabolic vulnerabilities of breast cancer brain metastasis","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Cancer; Brain metastasis; Metastasis; Medicine; Oncology; Internal medicine","score_opus":0.023367633508795116,"score_gpt":0.3419840851669647,"score_spread":0.3186164516581696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8644061,0.12063246,0.009525677,0.0023162882,0.0004701265,0.0003135794,0.0012820923,0.00002201282,0.001031636],"genre_scores_gemma":[0.9910944,0.0071908454,0.00054843415,0.00046910506,0.00012513324,0.00016445966,0.00004204467,0.000046228728,0.0003193198],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986897,0.00007492893,0.0003812502,0.00035912276,0.00027083312,0.00022418187],"domain_scores_gemma":[0.9991025,0.000020792193,0.0001296882,0.0004871689,0.00020815934,0.00005171931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024710788,0.0002065802,0.00028934542,0.00008814346,0.00003824122,0.000028693163,0.00024186222,0.000115237744,0.00029182798],"category_scores_gemma":[0.0000044300173,0.00018299241,0.0002513367,0.00024292213,0.00016908853,0.000008108882,0.000050508166,0.00012853679,0.0000010261292],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031326086,0.00007872913,0.0009849877,0.00019314575,0.0010084185,0.0000018797625,0.00009054324,0.0015971329,0.93778116,0.004219578,0.00026926197,0.05374383],"study_design_scores_gemma":[0.0004213245,0.00008651173,0.026160318,0.00012389413,0.00041504402,0.0000072817547,0.00015037486,0.0006266436,0.8502487,0.00034646297,0.12107334,0.0003401371],"about_ca_topic_score_codex":0.00039494582,"about_ca_topic_score_gemma":0.00006696607,"teacher_disagreement_score":0.1266883,"about_ca_system_score_codex":0.000033170345,"about_ca_system_score_gemma":0.0005040114,"threshold_uncertainty_score":0.7462214},"labels":[],"label_agreement":null},{"id":"W4399505334","doi":"10.1158/1538-8514.synthleth24-ia001","title":"Abstract IA001: Exploiting pathway activation as a new form of synthetic lethality","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; KRAS; Cancer; Cancer research; Context (archaeology); Biology; Genetic screen; Neuroblastoma RAS viral oncogene homolog; Gene knockout; MAPK/ERK pathway; PTEN; Genetics; DNA repair; Gene; Phenotype; Kinase; PI3K/AKT/mTOR pathway; Signal transduction; Colorectal cancer","score_opus":0.02420162346289654,"score_gpt":0.2950557847781103,"score_spread":0.2708541613152137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9674047,0.008414787,0.021247124,0.0011938452,0.00037383783,0.00028914967,0.000022006187,0.000050324183,0.0010042158],"genre_scores_gemma":[0.99809146,0.0005612893,0.00022525353,0.00038809408,0.00027103722,0.00003361926,0.00006881583,0.00006242782,0.00029799106],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987932,0.00003541719,0.00029636134,0.0003841625,0.00025362702,0.00023723212],"domain_scores_gemma":[0.9993216,0.000016750611,0.00011672842,0.0003721413,0.00008895298,0.0000838229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015108976,0.00019845612,0.00015836286,0.00006961973,0.000043336906,0.000040390532,0.00014724938,0.00021828727,0.000072347575],"category_scores_gemma":[0.00002509784,0.00020290597,0.0001720177,0.00020166066,0.00005546427,0.000011641229,0.00004581005,0.0001451832,0.000008518979],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000624846,0.000022233738,0.000040926094,0.00008389641,0.00021844759,0.0000029264745,0.00022943052,0.0008991312,0.8791886,0.00045836967,0.000100393925,0.11869318],"study_design_scores_gemma":[0.00026321132,0.0000993737,0.0003158673,0.0001884455,0.0000679555,0.000008472523,0.00005438985,0.0004784596,0.9620867,0.0023013947,0.033915248,0.00022047649],"about_ca_topic_score_codex":0.00018021355,"about_ca_topic_score_gemma":0.000030344736,"teacher_disagreement_score":0.1184727,"about_ca_system_score_codex":0.0001005715,"about_ca_system_score_gemma":0.00057518453,"threshold_uncertainty_score":0.8274265},"labels":[],"label_agreement":null},{"id":"W4399505344","doi":"10.1158/1538-8514.synthleth24-a001","title":"Abstract A001: KIF18A inhibition, via ATX020, leads to mitotic arrest and robust anti-tumor activity through a synthetic lethal interaction with chromosome instability","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Mitosis; Chromosome; Cancer cell lines; Cancer research; Cancer cell; Medicine; Biology; Genetics; Gene","score_opus":0.016284862487596755,"score_gpt":0.2701334875232295,"score_spread":0.25384862503563277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9597047,0.002304704,0.035912853,0.00090278644,0.00039985674,0.0004638545,0.00006890313,0.00005239865,0.00018993708],"genre_scores_gemma":[0.9972111,0.0005086662,0.0005807718,0.0012460944,0.00019189798,0.000095367854,0.000047867696,0.000081786755,0.00003643016],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983641,0.000073819654,0.00023607936,0.0007525701,0.00020149641,0.00037195827],"domain_scores_gemma":[0.9992357,0.000018818495,0.00007445338,0.00045928414,0.00010216049,0.00010960182],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012176352,0.00035021265,0.00025987858,0.00006272971,0.00011034159,0.00013019209,0.00012937606,0.00017023992,0.000028242113],"category_scores_gemma":[0.000009775204,0.00031778731,0.00011029688,0.0002213438,0.00016314567,0.00002996622,0.0000936479,0.00030049417,0.0000112916705],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016437155,0.00013589983,0.00045428434,0.0002096424,0.00021120784,0.000074623524,0.00018042901,0.0017004639,0.99050933,0.000031926094,0.00004342383,0.006284394],"study_design_scores_gemma":[0.00050598546,0.0004258148,0.003482719,0.00032475404,0.00020922814,0.00016325501,0.000058995614,0.0009743166,0.97547495,0.00007231254,0.017687293,0.0006203924],"about_ca_topic_score_codex":0.00019078891,"about_ca_topic_score_gemma":0.00037342665,"teacher_disagreement_score":0.03750641,"about_ca_system_score_codex":0.00011548872,"about_ca_system_score_gemma":0.00016865038,"threshold_uncertainty_score":0.9999274},"labels":[],"label_agreement":null},{"id":"W4399505345","doi":"10.1158/1538-8514.synthleth24-a012","title":"Abstract A012: Targeting proteasome vulnerabilities for the treatment of monosomy 7 associated blood disorders","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Haploinsufficiency; Biology; Gene dosage; Proteasome inhibitor; Cancer research; Gene expression profiling; Monosomy; Genetics; Proteasome; Gene expression; Gene; Phenotype; Chromosome; Karyotype","score_opus":0.016507640641385664,"score_gpt":0.28274371844658425,"score_spread":0.2662360778051986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8796954,0.10488042,0.010553307,0.002038735,0.00058856106,0.0017834092,0.00019975493,0.00005586475,0.0002045606],"genre_scores_gemma":[0.9935782,0.004705041,0.0002176321,0.00017822161,0.00015718826,0.00065038656,0.00009134085,0.000042417778,0.0003795972],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99915415,0.000040127412,0.00021790269,0.00025301697,0.00012842452,0.00020635636],"domain_scores_gemma":[0.9995613,0.00004181807,0.00006924694,0.0002294032,0.00006979668,0.000028439428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012115127,0.00017072211,0.00013148495,0.000028222466,0.00009354093,0.00004091809,0.00013209734,0.000109617984,0.000019795472],"category_scores_gemma":[0.000022787615,0.0001199153,0.00021964048,0.00009429789,0.00008721564,0.000004552723,0.000014531838,0.000058164438,8.356008e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005842583,0.00023528618,0.0002859213,0.00007970831,0.001045994,9.4374354e-7,0.0003140363,0.00049241626,0.9464325,0.0002762568,0.00017331053,0.050605252],"study_design_scores_gemma":[0.00051541853,0.0004346642,0.00014038969,0.000031810992,0.00016240377,3.685099e-7,0.00009692142,0.0005919054,0.7931598,0.000378902,0.20433484,0.00015261333],"about_ca_topic_score_codex":0.000079230485,"about_ca_topic_score_gemma":0.00004579568,"teacher_disagreement_score":0.20416154,"about_ca_system_score_codex":0.00003965899,"about_ca_system_score_gemma":0.00011412893,"threshold_uncertainty_score":0.48900038},"labels":[],"label_agreement":null},{"id":"W4399505349","doi":"10.1158/1538-8514.synthleth24-b008","title":"Abstract B008: Utilizing pathway incompatibility for synthetic lethality: A therapeutic strategy for B-cell lymphoma","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; MAPK/ERK pathway; Cancer research; Lymphoma; Diffuse large B-cell lymphoma; Biology; STAT5; Cancer; Signal transduction; Genetics; Medicine; Immunology; Gene; DNA repair","score_opus":0.04477044937500035,"score_gpt":0.3176650040480756,"score_spread":0.2728945546730753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75256675,0.068951964,0.1700331,0.0013548317,0.0013356588,0.0032069336,0.00068211585,0.00020420285,0.0016644206],"genre_scores_gemma":[0.9957954,0.0003838668,0.00086759817,0.0013827488,0.00026717738,0.00068585534,0.00018552391,0.000106470885,0.00032531365],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981603,0.00007320623,0.00039397617,0.0007143386,0.00020586532,0.0004523312],"domain_scores_gemma":[0.999034,0.00006229966,0.000099475,0.0005448304,0.000163561,0.000095831674],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004121878,0.00033786587,0.00025016346,0.0000684115,0.00014361164,0.00015171056,0.0002877503,0.0002658022,0.000024239682],"category_scores_gemma":[0.000019020357,0.00031627875,0.0003710837,0.00013961026,0.00010944181,0.000012030969,0.0000477607,0.000103463884,0.000005172907],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018175917,0.00019453697,0.000037510606,0.00042164337,0.00023881643,0.0000031598345,0.00007438761,0.00010420676,0.83341575,0.0014946747,0.00015555405,0.16367799],"study_design_scores_gemma":[0.0010478268,0.00032606715,0.000098253746,0.000074068026,0.0000984215,0.0000037689115,0.00009156621,0.0023728048,0.79763466,0.0022412308,0.19563219,0.000379131],"about_ca_topic_score_codex":0.00003435596,"about_ca_topic_score_gemma":0.000032648182,"teacher_disagreement_score":0.24322866,"about_ca_system_score_codex":0.000093074246,"about_ca_system_score_gemma":0.00045373628,"threshold_uncertainty_score":0.99992895},"labels":[],"label_agreement":null},{"id":"W4399505351","doi":"10.1158/1538-8514.synthleth24-b027","title":"Abstract B027: A pathway-informed framework to infer synthetic lethal relationships in pediatric cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Bioinformatics and Genomic Networks","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; Epistasis; Gene; Indel; Biology; Mutation; Computational biology; Genetics; Cancer; Lethality; Lethal allele; Mutant; Genotype","score_opus":0.025665711285766956,"score_gpt":0.2951549860997575,"score_spread":0.26948927481399054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9262194,0.038667317,0.027976409,0.002447867,0.001307395,0.00072051096,0.000112833724,0.000070822345,0.002477443],"genre_scores_gemma":[0.9927138,0.0031180256,0.0011845613,0.0020368814,0.00044434753,0.00021525209,0.000037350364,0.00006548638,0.00018428473],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984863,0.000042372343,0.00041668568,0.0003762894,0.00021607264,0.00046231796],"domain_scores_gemma":[0.9992646,0.0000522076,0.00006589676,0.00042344027,0.00006014827,0.00013373558],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026642543,0.00027424807,0.0001947352,0.00016131854,0.00007659687,0.000113667826,0.00026900606,0.00038828,0.00007149047],"category_scores_gemma":[0.000031982636,0.00026311036,0.00013592366,0.00044318175,0.000041342973,0.000010428035,0.00010138718,0.000526099,0.000051064],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092707353,0.00054548326,0.052962076,0.0027587048,0.0020693755,0.0004213668,0.012017273,0.10616296,0.3042641,0.02179604,0.0078046783,0.48827088],"study_design_scores_gemma":[0.0024493516,0.0007423696,0.06578857,0.002141503,0.0007196454,0.00006932895,0.0007064571,0.01402675,0.100059435,0.017904133,0.7907957,0.0045967656],"about_ca_topic_score_codex":0.00006630175,"about_ca_topic_score_gemma":0.00031673626,"teacher_disagreement_score":0.782991,"about_ca_system_score_codex":0.0001177781,"about_ca_system_score_gemma":0.0005122881,"threshold_uncertainty_score":0.9999821},"labels":[],"label_agreement":null},{"id":"W4399505359","doi":"10.1158/1538-8514.synthleth24-a014","title":"Abstract A014: Inhibiting eIF4E phosphorylation sensitizes triple-negative breast cancer to CDK4/6 inhibition","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Cancer; Phosphorylation; Breast cancer; Triple-negative breast cancer; Cancer research; Citation; Medicine; Library science; Internal medicine; Chemistry; Biochemistry; Computer science","score_opus":0.020628025765530616,"score_gpt":0.3142404357098953,"score_spread":0.29361240994436466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93502444,0.021148527,0.01715074,0.020807466,0.0014567398,0.001814815,0.00061564386,0.00080213015,0.001179499],"genre_scores_gemma":[0.98833,0.00067879196,0.0015157486,0.007794549,0.0007255871,0.0003328041,0.000050545645,0.00018957391,0.00038238996],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974227,0.00005876785,0.0005015363,0.0007503812,0.00065258343,0.0006140284],"domain_scores_gemma":[0.9987901,0.000081883925,0.00013317748,0.0003626198,0.0003865399,0.00024566564],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020997728,0.0004808651,0.00048101234,0.0002944673,0.0001574558,0.0001331043,0.00009097143,0.00019509126,0.0004828192],"category_scores_gemma":[0.000015415799,0.0004571843,0.00023900815,0.00088413694,0.00013291553,0.0002668196,0.000055381646,0.0005317724,0.00008607652],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008174363,0.00007051115,0.0003204238,0.00028803892,0.00061869755,0.00028452833,0.0020723564,0.0013887782,0.67169094,0.0003589346,0.00013083707,0.3219585],"study_design_scores_gemma":[0.0030046,0.00021094973,0.018310893,0.0035952923,0.00070962013,0.00032542803,0.0008154526,0.0022835727,0.949187,0.0019883069,0.018530054,0.0010388425],"about_ca_topic_score_codex":0.00058252877,"about_ca_topic_score_gemma":0.00011841089,"teacher_disagreement_score":0.32091966,"about_ca_system_score_codex":0.0010630592,"about_ca_system_score_gemma":0.00047188648,"threshold_uncertainty_score":0.999788},"labels":[],"label_agreement":null},{"id":"W4399505367","doi":"10.1158/1538-8514.synthleth24-a023","title":"Abstract A023: Determining genetic interaction from double knockout CRISPR screening","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Bioinformatics and Genomic Networks","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CRISPR; Computational biology; Genetics; HeLa; Gene; Biology; Genetic analysis; Gene knockout; Cell","score_opus":0.028155571502357132,"score_gpt":0.30483762212633536,"score_spread":0.2766820506239782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7885056,0.029829126,0.17770845,0.00030778392,0.0014345574,0.00027500564,0.0000624913,0.00008075381,0.0017962402],"genre_scores_gemma":[0.9929606,0.0010678595,0.0035634947,0.0013673421,0.00058716314,0.00004413704,0.00012912165,0.00007267569,0.00020761148],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99877614,0.00002083871,0.0003225451,0.0003868331,0.00016324861,0.0003304115],"domain_scores_gemma":[0.9993922,0.000014116556,0.00008152524,0.0003789882,0.000049776914,0.000083401756],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009096048,0.00025018715,0.0001607312,0.000058644808,0.000088108376,0.00020319257,0.00023068592,0.00021644862,0.00011430146],"category_scores_gemma":[0.000001884184,0.00024633,0.00016493977,0.00010304534,0.00004660047,0.000011208438,0.000101904996,0.00025087124,0.000037697922],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012118675,0.000021525988,0.0003227923,0.00005364311,0.0005659839,0.000039440172,0.00028190628,0.004260283,0.6327698,0.00004263056,0.00066617347,0.3608546],"study_design_scores_gemma":[0.0013245044,0.00020498026,0.0032786962,0.00041042003,0.0003482518,0.000038670987,0.00025988376,0.041494288,0.5338079,0.00065283955,0.41715518,0.0010243909],"about_ca_topic_score_codex":0.00013312223,"about_ca_topic_score_gemma":0.00006809898,"teacher_disagreement_score":0.416489,"about_ca_system_score_codex":0.00003776704,"about_ca_system_score_gemma":0.00009118169,"threshold_uncertainty_score":0.99999887},"labels":[],"label_agreement":null},{"id":"W4399505369","doi":"10.1158/1538-8514.synthleth24-b003","title":"Abstract B003: Identification of novel genes that regulate aneuploidy tolerance by attenuating aneuploidy-induced stresses","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Aneuploidy; Biology; Genetics; Chromosome instability; Gene; Chromosome","score_opus":0.029410639860997394,"score_gpt":0.29462235743129006,"score_spread":0.26521171757029266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9504665,0.041656468,0.0060383547,0.00035385948,0.00061575026,0.0002774772,0.0004402746,0.00003610575,0.000115210256],"genre_scores_gemma":[0.99334043,0.0051456303,0.0002584831,0.0005173374,0.00021049274,0.00006564248,0.00020380919,0.00009117074,0.00016702023],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983663,0.000025053017,0.00043343572,0.00057357515,0.00028199592,0.00031966495],"domain_scores_gemma":[0.9989875,0.00003311687,0.00020731773,0.00054644165,0.00015217847,0.00007345356],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016314702,0.0002849241,0.0002342138,0.000065847795,0.00007618721,0.00010560441,0.00031068965,0.00019777192,0.000016432112],"category_scores_gemma":[0.000015732956,0.0002985366,0.00015668277,0.00019480778,0.000087707645,0.000012298798,0.00007955332,0.00014353346,0.000004231894],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036851045,0.00008907065,0.00071773917,0.00018645513,0.0002105339,0.0000069279454,0.00008563658,0.00213177,0.97464746,0.000097566495,0.0003045593,0.02148545],"study_design_scores_gemma":[0.00038852743,0.000087206514,0.0016989837,0.00010063831,0.000111974725,0.000007325484,0.000042913987,0.0019110797,0.9772163,0.000050934643,0.018045317,0.0003387923],"about_ca_topic_score_codex":0.00012223687,"about_ca_topic_score_gemma":0.000052387848,"teacher_disagreement_score":0.04287391,"about_ca_system_score_codex":0.0000519364,"about_ca_system_score_gemma":0.00018802968,"threshold_uncertainty_score":0.99994665},"labels":[],"label_agreement":null},{"id":"W4399505374","doi":"10.1158/1538-8514.synthleth24-b005","title":"Abstract B005: Regulation of replication-induced PARP1/PARP2 activation by base excision repair: Implications for PARP and PARG inhibitor resistance","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"XRCC1; PARP1; Base excision repair; PARP inhibitor; Poly ADP ribose polymerase; Cancer research; DNA repair; DNA damage; Molecular biology; Polymerase; Biology; Chemistry; DNA; Genetics","score_opus":0.05036201442551773,"score_gpt":0.3601647727333316,"score_spread":0.30980275830781384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88418335,0.021654353,0.060508817,0.028403558,0.00039083578,0.0031020958,0.00046874053,0.00055164867,0.0007365766],"genre_scores_gemma":[0.9926844,0.0012853461,0.0029657993,0.001310906,0.00018752365,0.0008680295,0.00024959655,0.00008308617,0.0003652704],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99812436,0.000047657886,0.0005885663,0.0006950972,0.00030101626,0.00024328078],"domain_scores_gemma":[0.9982379,0.00019493475,0.00023761562,0.0008697048,0.00035322027,0.00010661698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037717883,0.00023849795,0.00030668726,0.00014738078,0.00012343946,0.000043097894,0.00008841957,0.00019592732,0.00004952825],"category_scores_gemma":[0.00004945243,0.00023600832,0.00018497532,0.00042201445,0.000095858435,0.00017266301,0.000016981541,0.00017964243,0.0000026460104],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044144638,0.0000947529,0.00051632937,0.00040255676,0.00021886322,8.777617e-7,0.0002007648,0.000017187358,0.9667247,0.0026926757,0.0052972212,0.023392629],"study_design_scores_gemma":[0.001410218,0.0001625463,0.014200033,0.0007741136,0.00024012594,0.0000047971794,0.000037392103,0.0008412437,0.8834471,0.0055236435,0.09308414,0.00027461545],"about_ca_topic_score_codex":0.000026499276,"about_ca_topic_score_gemma":0.00000837839,"teacher_disagreement_score":0.10850107,"about_ca_system_score_codex":0.00030789358,"about_ca_system_score_gemma":0.00026060862,"threshold_uncertainty_score":0.96241397},"labels":[],"label_agreement":null},{"id":"W4399505390","doi":"10.1158/1538-8514.synthleth24-ia021","title":"Abstract IA021: Environmental challenge rewires functional connections among human genes","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Bioinformatics and Genomic Networks","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Adaptability; Gene; Epigenetics; Genetic architecture; Context (archaeology); Computational biology; Cancer; Genetics; Ecology; Phenotype","score_opus":0.02020761552575187,"score_gpt":0.25562605260560906,"score_spread":0.23541843707985718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93363184,0.05416203,0.0077309497,0.0005122533,0.00085797714,0.00024638482,0.00009674301,0.000059040085,0.0027028057],"genre_scores_gemma":[0.9949793,0.0030103456,0.000076510536,0.00052205485,0.00049190334,0.000062021536,0.00023448312,0.000049347593,0.0005740203],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990412,0.000019420611,0.00022128511,0.00030775223,0.00015266526,0.00025768048],"domain_scores_gemma":[0.9995707,0.0000056203244,0.000048577258,0.00028918398,0.000015708683,0.00007016927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000903496,0.00020209124,0.000113444774,0.000046015444,0.00015880371,0.0000795026,0.00013512773,0.00019280317,0.0002188718],"category_scores_gemma":[7.6600674e-7,0.00019681863,0.00015579436,0.000055906734,0.00012738763,0.0000074620207,0.00006851228,0.00017334023,0.000024296609],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025958216,0.00007607625,0.00090874673,0.000060676506,0.0007015331,0.000019434907,0.00013829925,0.0014162769,0.9561149,0.0015121051,0.0012387299,0.03778725],"study_design_scores_gemma":[0.0010056089,0.00041346365,0.012446293,0.00013739309,0.00033229665,0.000044067907,0.00036554728,0.0054761725,0.19855985,0.0027235297,0.77723205,0.0012637407],"about_ca_topic_score_codex":0.000024710353,"about_ca_topic_score_gemma":0.000065511565,"teacher_disagreement_score":0.7759933,"about_ca_system_score_codex":0.000046808265,"about_ca_system_score_gemma":0.000054449814,"threshold_uncertainty_score":0.80260307},"labels":[],"label_agreement":null},{"id":"W4399505409","doi":"10.1158/1538-8514.synthleth24-pr006","title":"Abstract PR006: DNA repair inhibition via targeting ATR activates cGAS/STING signaling, promotes anti-tumor immunity, and is a synthetic lethal strategy to augment immunotherapy response in preclinical models and clinical samples of small cell lung cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer research; Blockade; Immunotherapy; Immune checkpoint; Tumor microenvironment; Biology; Immune system; Immunology; Medicine; Receptor","score_opus":0.08230421986962153,"score_gpt":0.4102955688589184,"score_spread":0.3279913489892968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9405562,0.05482363,0.0012543916,0.0016456508,0.000098190445,0.0014406968,0.00006707167,0.00009308617,0.000021066591],"genre_scores_gemma":[0.9920438,0.0052585686,0.0017425634,0.0005124824,0.00009298538,0.00022208775,0.000006929548,0.000095243755,0.000025331989],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967875,0.00048023922,0.0009811708,0.0007437653,0.00047381513,0.00053352094],"domain_scores_gemma":[0.9981341,0.0009260354,0.00020550202,0.0003617036,0.00020936636,0.000163297],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002211318,0.00037185752,0.0007335773,0.00024128299,0.00011717484,0.00008394298,0.00012765072,0.00017435577,0.000039780807],"category_scores_gemma":[0.00013132575,0.00032490585,0.00020802359,0.0003541196,0.0002891864,0.00012139256,0.00019073478,0.0007721049,5.470339e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035380179,0.00037420428,0.024226172,0.0020721548,0.0011094708,0.00020063853,0.0040244255,0.0011605044,0.9484078,0.000011192633,0.000024800891,0.014850574],"study_design_scores_gemma":[0.0048165717,0.0036595867,0.06268258,0.009789327,0.0009603772,0.0000452075,0.0012800886,0.06390379,0.85065156,0.0008011381,0.00039621073,0.0010135635],"about_ca_topic_score_codex":0.0014899599,"about_ca_topic_score_gemma":0.00008322308,"teacher_disagreement_score":0.09775629,"about_ca_system_score_codex":0.0003325206,"about_ca_system_score_gemma":0.0006475765,"threshold_uncertainty_score":0.9999203},"labels":[],"label_agreement":null},{"id":"W4399505421","doi":"10.1158/1538-8514.synthleth24-b004","title":"Abstract B004: An isogenic CRISPR screen identifies novel MYC-driven vulnerabilities","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced biosensing and bioanalysis techniques","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"CRISPR; Synthetic lethality; Biology; Computational biology; Context (archaeology); Cancer; Gene; Cancer research; Breast cancer; Cancer cell; Drug discovery; Genetics; Bioinformatics; DNA repair","score_opus":0.026187002403998665,"score_gpt":0.33083445030912395,"score_spread":0.30464744790512527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94009435,0.017052691,0.039926134,0.000869888,0.00040486388,0.0003123143,0.00038150046,0.00032714548,0.0006311372],"genre_scores_gemma":[0.99280345,0.0015479231,0.0031244,0.0012399718,0.00033320556,0.000031414605,0.0002713114,0.000083316314,0.00056502514],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99830407,0.000056307472,0.00031134285,0.00068169646,0.0002698473,0.00037671544],"domain_scores_gemma":[0.9990147,0.000013104457,0.00006908581,0.00065298995,0.00015135936,0.000098780874],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018788519,0.00032596054,0.0002334921,0.00010750973,0.000130445,0.00018672782,0.0003182387,0.00025918518,0.000019084508],"category_scores_gemma":[0.000011501332,0.00029138578,0.0002778,0.00021485092,0.00020892183,0.000018138684,0.00009276585,0.00023458777,0.000009015346],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041088217,0.000070450646,0.00008835283,0.000039428753,0.00042120172,0.000017448096,0.00007643309,0.00018981229,0.9870782,0.0002016183,0.00026392515,0.011512066],"study_design_scores_gemma":[0.00017256374,0.00016134935,0.00035560655,0.00006494186,0.00019698235,0.000016352069,0.00011255819,0.0008670351,0.9593998,0.00049087685,0.03771461,0.00044728976],"about_ca_topic_score_codex":0.00016620368,"about_ca_topic_score_gemma":0.0002505897,"teacher_disagreement_score":0.052709106,"about_ca_system_score_codex":0.00005406863,"about_ca_system_score_gemma":0.00013010982,"threshold_uncertainty_score":0.9999538},"labels":[],"label_agreement":null},{"id":"W4399505433","doi":"10.1158/1538-8514.synthleth24-b024","title":"Abstract B024: Leveraging synthetic lethality across EP300-mutant solid cancers through selective CBP degradation","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Synthetic lethality; CREB-binding protein; Cancer research; Mutant; Genetics; Transcription factor; Gene; CREB","score_opus":0.034946920178070745,"score_gpt":0.347682932035319,"score_spread":0.3127360118572483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89483106,0.0357505,0.0664959,0.0006752973,0.0007899188,0.00033924152,0.00011675043,0.00007055522,0.0009307403],"genre_scores_gemma":[0.9938531,0.004167572,0.00056186103,0.000698554,0.0002619434,0.00008586454,0.00011430929,0.000090924834,0.00016588716],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980056,0.00009789499,0.00034827908,0.00070980826,0.00032242434,0.00051597285],"domain_scores_gemma":[0.999173,0.000027224629,0.00010742769,0.00044686528,0.00016752732,0.00007794305],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032024473,0.0003280321,0.00022662317,0.000040057155,0.00018810909,0.00016496191,0.00022649871,0.00025025848,0.00003149496],"category_scores_gemma":[0.000019178775,0.00032497197,0.00019366336,0.00026440868,0.00012116091,0.000016584843,0.000076687094,0.0002737547,0.000012044989],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000502806,0.000031118576,0.00034934253,0.000075759985,0.00037458426,0.000020374377,0.00064748566,0.004487117,0.9638615,0.0001634918,0.000038092272,0.0299008],"study_design_scores_gemma":[0.0002707289,0.000103526276,0.0009757591,0.00008835098,0.000105638326,0.0000061507,0.0001588302,0.0014129508,0.95466506,0.0011562809,0.040635988,0.00042071028],"about_ca_topic_score_codex":0.00047187513,"about_ca_topic_score_gemma":0.00021293337,"teacher_disagreement_score":0.09902199,"about_ca_system_score_codex":0.00027824228,"about_ca_system_score_gemma":0.00038982433,"threshold_uncertainty_score":0.99992025},"labels":[],"label_agreement":null},{"id":"W4399505443","doi":"10.1158/1538-8514.synthleth24-b029","title":"Abstract B029: Assessing gene expression and methylation of KMT2D and IGF2 genes in patients with non-small cell lung cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Methylation; DNA methylation; Epigenetics; Carcinogenesis; Biology; Gene; CpG site; Bisulfite sequencing; Gene expression; Genomic imprinting; Promoter; Molecular biology; Lung cancer; Cancer; Cancer research; Genetics; Pathology; Medicine","score_opus":0.012648116511731849,"score_gpt":0.27961275147079473,"score_spread":0.26696463495906286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9282857,0.06505362,0.006209397,0.000054825836,0.000071360264,0.0002103271,0.000028466082,0.0000056308154,0.00008065521],"genre_scores_gemma":[0.9935848,0.004942406,0.0011768609,0.00009075732,0.000038721737,0.00006527187,0.000034761833,0.00003357445,0.000032819553],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992212,0.00002636305,0.0001710448,0.00031898066,0.00011673562,0.00014566405],"domain_scores_gemma":[0.9996228,0.0000070052374,0.000074209354,0.00018021368,0.00007816476,0.0000375951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007773956,0.00014659521,0.00012782402,0.00006231382,0.000039434533,0.00005209839,0.00006606251,0.00010698478,0.0000069743996],"category_scores_gemma":[0.0000010516051,0.00012353422,0.00002738913,0.00010897574,0.000052242554,0.000012410345,0.000035998364,0.00008251503,9.1136776e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041002986,0.00003460392,0.055175442,0.0001512687,0.000058130667,0.0000015134468,0.00013284288,0.00070900307,0.91673946,0.0000066400166,0.00000517552,0.026944928],"study_design_scores_gemma":[0.0006512221,0.000058611586,0.11447925,0.0001685444,0.000080779566,4.0559357e-7,0.000036222413,0.00090077054,0.88256985,0.000019581597,0.0008473378,0.00018740965],"about_ca_topic_score_codex":0.000107506276,"about_ca_topic_score_gemma":0.000039974522,"teacher_disagreement_score":0.06529911,"about_ca_system_score_codex":0.000032051983,"about_ca_system_score_gemma":0.00011732652,"threshold_uncertainty_score":0.50375795},"labels":[],"label_agreement":null},{"id":"W4399505656","doi":"10.1158/1538-8514.synthleth24-pr003","title":"Abstract PR003: Mechanisms of therapeutic vulnerability of mismatch repair defective cancers to RNA polymerase I inhibitors","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Synthetic lethality; Genetics; Cancer research; DNA repair; Molecular biology; Gene","score_opus":0.023950450692404004,"score_gpt":0.3160822818356816,"score_spread":0.2921318311432776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9698372,0.019434085,0.0053752614,0.0010064074,0.0016147743,0.0013278727,0.000122748,0.0001873451,0.001094341],"genre_scores_gemma":[0.9960132,0.00025200495,0.0016316295,0.0015842007,0.00011429147,0.00019417638,0.000006758127,0.00011151092,0.000092226976],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973914,0.00010428067,0.00066763896,0.0006444965,0.000751126,0.00044105315],"domain_scores_gemma":[0.9984678,0.00013147312,0.00015532448,0.0007139995,0.00032700217,0.00020439642],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037066286,0.00038609022,0.0006496948,0.0002452227,0.00004478756,0.000017247861,0.00020316549,0.00022876439,0.00034389278],"category_scores_gemma":[0.00003201792,0.00034279918,0.0004897119,0.00084425835,0.00020062277,0.000046743124,0.00006664537,0.00040451728,0.0000094763345],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005741898,0.0001426038,0.0008806401,0.0008513231,0.0012008171,0.000030834308,0.0015546782,0.00080935354,0.9628141,0.0005091196,0.00011114472,0.030521218],"study_design_scores_gemma":[0.0006059277,0.00090466253,0.0037411056,0.00059936795,0.00063335267,0.000010867309,0.00025408147,0.00047627598,0.98856646,0.0019896382,0.0018982172,0.00032005383],"about_ca_topic_score_codex":0.001122143,"about_ca_topic_score_gemma":0.00012740427,"teacher_disagreement_score":0.030201163,"about_ca_system_score_codex":0.0008253107,"about_ca_system_score_gemma":0.0011579851,"threshold_uncertainty_score":0.9999024},"labels":[],"label_agreement":null},{"id":"W4399901966","doi":"10.1158/1535-7163.mct-23-0393","title":"Anti-Claudin-2 Antibody–Drug Conjugates for the Treatment of Colorectal Cancer Liver Metastasis","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; McGill University","funders":"Institute of Cancer Research","keywords":"Metastasis; Colorectal cancer; Claudin; Cancer; Cancer research; Monoclonal antibody; Antibody; In vivo; Antibody-drug conjugate; Medicine; Liver cancer; Immunology; Biology; Internal medicine; Tight junction","score_opus":0.06740540409596586,"score_gpt":0.41211183557284087,"score_spread":0.344706431476875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399901966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5420891,0.44204894,0.002443314,0.009104317,0.00093939074,0.0023719117,0.0006777824,0.000101707745,0.00022351141],"genre_scores_gemma":[0.8906509,0.1059026,0.00046860546,0.00087964797,0.0002576707,0.00092275685,0.00003199258,0.00010998397,0.0007758111],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99817145,0.00007811734,0.0003217245,0.00043216354,0.0005203002,0.00047622807],"domain_scores_gemma":[0.99883574,0.00031108406,0.00006889264,0.00039869637,0.00027872695,0.000106841115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023337359,0.00029118411,0.0005128777,0.0001283509,0.00010991216,0.00006347671,0.00020739547,0.000090417656,0.00045904735],"category_scores_gemma":[0.000009645069,0.00018444384,0.00040981107,0.00045600763,0.00029706047,0.000040168576,0.00002997343,0.00017823934,0.000012503267],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007557618,0.00048551906,0.0042675133,0.001176994,0.0075111673,0.00022651358,0.0030106057,0.0004209065,0.6871908,0.00083857874,0.0016682339,0.29244745],"study_design_scores_gemma":[0.0011495162,0.00070351746,0.0009741515,0.00029135426,0.0018003859,0.000016085334,0.00012562884,0.009329237,0.62769306,0.00007864441,0.3576507,0.00018775479],"about_ca_topic_score_codex":0.0013807875,"about_ca_topic_score_gemma":0.00022167097,"teacher_disagreement_score":0.35598245,"about_ca_system_score_codex":0.00048555224,"about_ca_system_score_gemma":0.00079371367,"threshold_uncertainty_score":0.75214016},"labels":[],"label_agreement":null},{"id":"W4400926625","doi":"10.1158/1535-7163.mct-23-0314","title":"Targeting Ovarian Cancer Stem Cells by Dual Inhibition of the Long Noncoding RNA HOTAIR and Lysine Methyltransferase EZH2","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Congressionally Directed Medical Research Programs; School of Medicine, Indiana University; York University; National Cancer Institute; School of Medicine, New York University; National Institutes of Health; Ovarian Cancer Alliance of Greater Cincinnati; Van Andel Research Institute; GlaxoSmithKline; Stand Up To Cancer; U.S. Department of Defense","keywords":"HOTAIR; Cancer research; Cancer stem cell; Biology; EZH2; Ovarian cancer; Epigenetics; Long non-coding RNA; Cancer; Genetics; RNA; Gene","score_opus":0.01459618961777851,"score_gpt":0.2807979107888266,"score_spread":0.26620172117104807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400926625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7367345,0.10486929,0.15392287,0.0020375135,0.00093641074,0.0008893882,0.00042849968,0.000052606636,0.0001289354],"genre_scores_gemma":[0.9913798,0.0069226124,0.00017315778,0.0007780637,0.00017292704,0.00010874127,0.00004290685,0.000105112995,0.0003166662],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979627,0.00020870502,0.0003499827,0.00059635803,0.00044756554,0.0004346626],"domain_scores_gemma":[0.9992455,0.00001839931,0.00008481073,0.00039752037,0.0001520372,0.00010168567],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031481803,0.00030436306,0.00024479165,0.000083413186,0.00013892345,0.00009234967,0.00020230265,0.00026580197,0.000050212628],"category_scores_gemma":[0.0000054916686,0.0002591903,0.00018710872,0.00041943375,0.00020327135,0.000011731975,0.00016011,0.00037479482,0.0000014037283],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007444276,0.000031553915,0.00001733046,0.00018510912,0.00046631493,0.000025818223,0.0001611328,0.0015121734,0.9768703,0.00011619047,0.0004081307,0.020131528],"study_design_scores_gemma":[0.00057471433,0.00011396806,0.000011126627,0.00018213352,0.00022412535,0.000009569606,0.000066464876,0.002218751,0.9855288,0.00006035288,0.010717328,0.00029266844],"about_ca_topic_score_codex":0.00022524392,"about_ca_topic_score_gemma":0.00007734283,"teacher_disagreement_score":0.25464532,"about_ca_system_score_codex":0.00011715872,"about_ca_system_score_gemma":0.00032306346,"threshold_uncertainty_score":0.99998605},"labels":[],"label_agreement":null},{"id":"W4403250299","doi":"10.1158/1535-7163.mct-24-0307","title":"Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NAEJA-RGM Pharmaceuticals (Canada); Princess Margaret Cancer Centre; University of Toronto; University Health Network; University of Alberta","funders":"Leukemia and Lymphoma Society of Canada; Alberta Cancer Foundation; Cancer Research Institute","keywords":"MCL1; Myeloid leukemia; Myristoylation; Cancer research; Leukemia; Biology; Endoplasmic reticulum; Proto-oncogene tyrosine-protein kinase Src; Programmed cell death; Apoptosis; Cell culture; Phosphorylation; Cell biology; Immunology; Downregulation and upregulation; Biochemistry; Genetics","score_opus":0.01172884225734684,"score_gpt":0.2648238642681726,"score_spread":0.2530950220108258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403250299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8699387,0.041640736,0.087113835,0.00023608365,0.0003434797,0.00033318833,0.00012096633,0.0000626114,0.00021042406],"genre_scores_gemma":[0.9870887,0.008140798,0.0017451434,0.0021286053,0.0001981441,0.000097548655,0.00012549378,0.000110645764,0.00036494678],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99806046,0.000078230645,0.000337948,0.00078263634,0.00030098986,0.00043970515],"domain_scores_gemma":[0.99925035,0.000031895303,0.000052236468,0.00033185433,0.00016162828,0.00017203965],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016715053,0.00040080416,0.00025707344,0.000097354685,0.00017283637,0.00018897543,0.00023217026,0.0002269421,0.00001959028],"category_scores_gemma":[0.000008511905,0.00038955404,0.00013688851,0.00033128756,0.00013312497,0.000016753065,0.000093519135,0.00024444293,0.000015029617],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011087232,0.000019500845,0.000086409265,0.00012465268,0.0003786905,0.000060817583,0.00061104546,0.0017102766,0.9833665,0.00009079305,0.00015863098,0.013281797],"study_design_scores_gemma":[0.00033238428,0.00023612684,0.00002463274,0.00015835967,0.00024792005,0.000013059696,0.00021609846,0.0006681843,0.9515933,0.00021751654,0.045792885,0.0004995625],"about_ca_topic_score_codex":0.00004821237,"about_ca_topic_score_gemma":0.000009862558,"teacher_disagreement_score":0.11715,"about_ca_system_score_codex":0.00014772017,"about_ca_system_score_gemma":0.0003977417,"threshold_uncertainty_score":0.99985564},"labels":[],"label_agreement":null},{"id":"W4404349036","doi":"10.1158/1538-8514.rnadrivers24-pr002","title":"Abstract PR002: Hypoxia-induced epigenetic changes coordinate transcription start site selection and translational control through remodeling of 5’UTRs","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; University of Alberta; McGill University; Queen's University","funders":"","keywords":"Epigenetics; Transcription (linguistics); Biology; Hypoxia (environmental); Transcription factor; Cell biology; Genetics; Computational biology; Bioinformatics; Chemistry; Gene","score_opus":0.03261615726080063,"score_gpt":0.2898283294451097,"score_spread":0.2572121721843091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404349036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8824696,0.030767731,0.08486226,0.0012124954,0.0001739978,0.00029149558,0.00009940198,0.000023925604,0.00009912417],"genre_scores_gemma":[0.9947305,0.00402865,0.0004870908,0.00039987377,0.00012036813,0.00007316707,0.00006088535,0.000041612777,0.00005790743],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99901056,0.000045688914,0.00022275445,0.00035815584,0.00016922249,0.00019361361],"domain_scores_gemma":[0.999604,0.000009015394,0.00006136481,0.00016318998,0.0001246672,0.000037752303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012737926,0.0001755961,0.0001539097,0.000054471515,0.00007172094,0.00004006883,0.00007561576,0.00015249796,0.000022730432],"category_scores_gemma":[0.000002088192,0.0001751758,0.00008810483,0.00014470534,0.000049418064,0.00001130417,0.0000064063183,0.00011472022,0.0000011308362],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009245781,0.000026326192,0.00013747164,0.00008546123,0.00020076879,0.0000010222116,0.0003136045,0.0030807643,0.9622394,0.00020481851,0.000010162095,0.03360776],"study_design_scores_gemma":[0.00083955616,0.00022195447,0.0025283876,0.000093633775,0.0002415803,0.000008377475,0.00006058246,0.016192727,0.9590932,0.00061796774,0.019796664,0.00030537584],"about_ca_topic_score_codex":0.00011569662,"about_ca_topic_score_gemma":0.00018961633,"teacher_disagreement_score":0.11226088,"about_ca_system_score_codex":0.000021274891,"about_ca_system_score_gemma":0.0001167118,"threshold_uncertainty_score":0.7143462},"labels":[],"label_agreement":null},{"id":"W4404349215","doi":"10.1158/1538-8514.rnadrivers24-pr003","title":"Abstract PR003: Preventing and treating HPV-related Cancer with mRNA Therapy Expressing A DC-targeting Antigen","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"iProgen Biotech (Canada)","funders":"","keywords":"Medicine; Cancer; Antigen; Cancer research; Immunology; Messenger RNA; Virology; Biology; Internal medicine; Gene; Genetics","score_opus":0.018570002721795736,"score_gpt":0.2936979135475358,"score_spread":0.27512791082574006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404349215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8353747,0.1607924,0.002298898,0.00036319892,0.00014985442,0.00027640117,0.0000227389,0.000055771106,0.000666022],"genre_scores_gemma":[0.9804518,0.01747315,0.00082862144,0.00038296913,0.00018412255,0.00017650127,0.000039237886,0.000098910765,0.00036466756],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985268,0.000055136315,0.00027976738,0.0005759042,0.00019523394,0.00036713167],"domain_scores_gemma":[0.9994151,0.000012988034,0.00012054017,0.0002885971,0.00009031473,0.00007248585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017840927,0.00028446136,0.00018580227,0.0000604207,0.00020659695,0.00020486212,0.00015507397,0.00015441456,0.00007811274],"category_scores_gemma":[0.000004199356,0.00023399902,0.00009234818,0.0002086687,0.000102415506,0.000018029927,0.000044369666,0.00019623157,0.0000015665328],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004656075,0.000027066135,0.0023336525,0.000057551617,0.0004549685,0.000016228832,0.00041626435,0.00091841375,0.82310706,0.000036320893,0.000050726747,0.17253518],"study_design_scores_gemma":[0.0010271242,0.00016090447,0.004672872,0.0005168742,0.0001518774,0.000025184856,0.0002807972,0.0030573048,0.91463256,0.00011981181,0.07463374,0.00072092615],"about_ca_topic_score_codex":0.00016407845,"about_ca_topic_score_gemma":0.000029627592,"teacher_disagreement_score":0.17181425,"about_ca_system_score_codex":0.00004635217,"about_ca_system_score_gemma":0.00022028148,"threshold_uncertainty_score":0.9542203},"labels":[],"label_agreement":null},{"id":"W4404349232","doi":"10.1158/1538-8514.rnadrivers24-a008","title":"Abstract A008: Identification of EYA2 as a promising biomarker for DICER1-related tumor predisposition","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Congenital Diaphragmatic Hernia Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; University of British Columbia; Vancouver Coastal Health","funders":"","keywords":"Identification (biology); Biomarker; Biology; Cancer; Genetic predisposition; Medicine; Computational biology; Cancer research; Genetics; Gene","score_opus":0.026915283655905786,"score_gpt":0.3376645662852509,"score_spread":0.3107492826293451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404349232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742138,0.017041296,0.00393675,0.0018340317,0.00039565205,0.0013559592,0.000092935814,0.00012008471,0.0010094992],"genre_scores_gemma":[0.9986777,0.00016004834,0.00022141941,0.0002855744,0.000038440732,0.00019001872,0.00004619938,0.00005454791,0.00032607376],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987974,0.000021893287,0.0004570754,0.00026442503,0.00027225603,0.00018695189],"domain_scores_gemma":[0.9993583,0.000068936,0.00011210719,0.00022711835,0.00018434053,0.000049230584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021519374,0.00015761725,0.00023880415,0.00012602254,0.000044958688,0.000041092073,0.0000659704,0.00007488904,0.00007609486],"category_scores_gemma":[0.00003807862,0.00014128626,0.0001778218,0.0002675439,0.00007809316,0.000065003216,0.000018984609,0.00010343148,0.000022895945],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017913719,0.00009304108,0.00023781731,0.0011236393,0.0012286925,0.00003816563,0.0009807675,0.000012064558,0.91957426,0.00032137617,0.00005954313,0.07615152],"study_design_scores_gemma":[0.0031981599,0.0004751493,0.08246141,0.0028040954,0.0043265834,0.00010050747,0.0005152792,0.030581633,0.8551053,0.0062878965,0.013495532,0.0006484455],"about_ca_topic_score_codex":0.000033731074,"about_ca_topic_score_gemma":0.0000055435285,"teacher_disagreement_score":0.082223594,"about_ca_system_score_codex":0.00013504986,"about_ca_system_score_gemma":0.00018093496,"threshold_uncertainty_score":0.5761487},"labels":[],"label_agreement":null},{"id":"W4405170886","doi":"10.1158/1538-8514.cancerchem24-a003","title":"Abstract A003: In vitro anticancer activities of some organoplatinum (IV) derivatives","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Metal complexes synthesis and properties","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"In vitro; Chemistry; Pharmacology; Combinatorial chemistry; Stereochemistry; Biology; Biochemistry","score_opus":0.04939737418752027,"score_gpt":0.31224513293350126,"score_spread":0.262847758745981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405170886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9533745,0.043439295,0.0002454352,0.0010872171,0.00021293371,0.00022380817,0.000026990076,0.0000471144,0.0013426876],"genre_scores_gemma":[0.9967542,0.0014389438,0.0005190184,0.00088303303,0.000080078484,0.000033189095,0.0000053526865,0.00004963958,0.0002365021],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989246,0.000045127996,0.00028726904,0.0002337265,0.00027966272,0.00022957788],"domain_scores_gemma":[0.9995588,0.000076361655,0.00005379579,0.00023128612,0.00003952762,0.000040225983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013245446,0.0001805929,0.0003810384,0.00014490295,0.00002358535,0.000030975298,0.00009188045,0.00007389634,0.000267713],"category_scores_gemma":[0.000011916653,0.00013976108,0.00011775742,0.0002413038,0.0001361254,0.00010608307,0.00002977917,0.00020909666,0.0000064081096],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025330667,0.00005676936,0.00045341047,0.0004059594,0.00027895972,0.000037895647,0.00091579155,0.000014596074,0.96126544,0.0005796695,0.000012300604,0.03572589],"study_design_scores_gemma":[0.0002828118,0.00007038094,0.0040492704,0.00042002506,0.00011058456,0.0000057212437,0.00019663412,0.000501199,0.9871742,0.00069543096,0.006337348,0.0001563552],"about_ca_topic_score_codex":0.000095158386,"about_ca_topic_score_gemma":0.000008313346,"teacher_disagreement_score":0.043379724,"about_ca_system_score_codex":0.00008035728,"about_ca_system_score_gemma":0.00020219419,"threshold_uncertainty_score":0.5699291},"labels":[],"label_agreement":null},{"id":"W4405170902","doi":"10.1158/1538-8514.cancerchem24-a022","title":"Abstract A022: Discovery of conformationally constrained ALK2 inhibitors for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG)","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Glioma; Medicine; Drug discovery; Chemistry; Cancer research; Biochemistry","score_opus":0.021783403526060348,"score_gpt":0.29722597304466636,"score_spread":0.275442569518606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405170902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96673137,0.027495097,0.0009965836,0.0028734216,0.00031305544,0.0010690931,0.00034323827,0.000026954858,0.00015117507],"genre_scores_gemma":[0.9969366,0.0022403079,0.00020045452,0.00023256526,0.00008614171,0.00016359403,0.00007002621,0.000029645898,0.00004064711],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989992,0.000011569928,0.00039382325,0.00016508404,0.00025800965,0.00017231592],"domain_scores_gemma":[0.9992245,0.0002176112,0.000120855824,0.00026356423,0.00013210521,0.000041360996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000067459456,0.00019129974,0.0003184138,0.00011329119,0.000036595044,0.000032540043,0.000066161985,0.000063034284,0.000031062427],"category_scores_gemma":[0.0000066074854,0.00011403879,0.00032384082,0.00019365868,0.00013801239,0.00005618896,0.0000099491435,0.0000480331,0.00000163344],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008766144,0.0024314467,0.0017419214,0.00065951364,0.0071485266,0.00020052523,0.0018336002,0.00021050133,0.61239433,0.0075358697,0.00019425766,0.36477292],"study_design_scores_gemma":[0.006746436,0.0015779919,0.008773878,0.0004312214,0.002109147,0.00003708154,0.00024705555,0.0013224736,0.94942087,0.0003439584,0.02879543,0.00019446737],"about_ca_topic_score_codex":0.00014019465,"about_ca_topic_score_gemma":0.000023525323,"teacher_disagreement_score":0.36457846,"about_ca_system_score_codex":0.00012257803,"about_ca_system_score_gemma":0.00022334701,"threshold_uncertainty_score":0.4650367},"labels":[],"label_agreement":null},{"id":"W4405170903","doi":"10.1158/1538-8514.cancerchem24-ia014","title":"Abstract IA014: Mechanistic insights for the advancement of PPARG inverse agonists in muscle invasive urothelial cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Peroxisome Proliferator-Activated Receptors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Peroxisome proliferator-activated receptor gamma; Urothelial cancer; Cancer; Cancer research; Computational biology; Medicine; Pharmacology; Biology; Bioinformatics; Chemistry; Internal medicine; Receptor; Bladder cancer; Peroxisome","score_opus":0.023572853075600766,"score_gpt":0.301992560166491,"score_spread":0.27841970709089026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405170903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9297119,0.051127184,0.014763797,0.0012481789,0.0014166662,0.0013321267,0.00027654265,0.000032578915,0.00009103482],"genre_scores_gemma":[0.9842998,0.013238912,0.00022537641,0.0010869215,0.0002033702,0.0007220012,0.000041230247,0.00007341379,0.00010898943],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998641,0.000050677343,0.0003208357,0.00044400542,0.00021715749,0.00032630767],"domain_scores_gemma":[0.9993123,0.00005148269,0.000101132464,0.0003599861,0.00011745933,0.00005764288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012869669,0.00026185825,0.00021732364,0.000080726415,0.00007309829,0.000039618404,0.00030436544,0.00017776553,0.00005625111],"category_scores_gemma":[0.000022883927,0.00020498257,0.00015820118,0.00021688319,0.00011963284,0.00000930573,0.00007507629,0.00016815844,0.0000033652104],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016274286,0.00006540356,0.000056647543,0.000165989,0.00037547838,0.000008153817,0.00031227383,0.0022288507,0.97793037,0.00048593298,0.00007107073,0.018137107],"study_design_scores_gemma":[0.00059386913,0.00013755138,0.00010058936,0.00012094984,0.00009058807,0.0000011410042,0.00009947033,0.00073951477,0.8730699,0.00030467278,0.12451179,0.00022995753],"about_ca_topic_score_codex":0.00015980343,"about_ca_topic_score_gemma":0.0007077418,"teacher_disagreement_score":0.12444072,"about_ca_system_score_codex":0.00013433155,"about_ca_system_score_gemma":0.0005391295,"threshold_uncertainty_score":0.83589464},"labels":[],"label_agreement":null},{"id":"W4405170909","doi":"10.1158/1538-8514.cancerchem24-ia011","title":"Abstract IA011: Strategies to close the translational gap for nanoscale drug delivery systems","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug delivery; Drug; Medicine; Pharmacology; Nanotechnology; Materials science","score_opus":0.029552377155361534,"score_gpt":0.29235890923163527,"score_spread":0.26280653207627375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405170909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9570599,0.022110017,0.013287689,0.003877235,0.00188571,0.0009879982,0.0003600419,0.00019993007,0.00023148554],"genre_scores_gemma":[0.99715626,0.000097369324,0.0004774073,0.0013790042,0.0002430422,0.00041919085,0.000011410983,0.000059953883,0.00015635298],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982302,0.00008567454,0.0003348562,0.0004293714,0.0004532438,0.00046665137],"domain_scores_gemma":[0.9991218,0.00021606057,0.000050514922,0.00036957508,0.00014558756,0.00009650016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049450115,0.00022863483,0.0001879995,0.00007073145,0.00018124604,0.0005761515,0.0003908558,0.000071774826,0.00011462113],"category_scores_gemma":[0.000003988082,0.00017079871,0.00014813084,0.00024734272,0.00009322376,0.00022586419,0.000029940531,0.00012639622,0.00014129574],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010106109,0.00003876326,0.000011207759,0.00014388876,0.00007773932,0.000020820016,0.0011107393,0.01437671,0.97346485,0.006414117,0.0008656483,0.0033744802],"study_design_scores_gemma":[0.00047950557,0.000081054895,0.0001357256,0.00020955731,0.00021954333,0.0000075307435,0.00076466537,0.009443112,0.9144538,0.004017724,0.06972818,0.00045961756],"about_ca_topic_score_codex":0.00023819388,"about_ca_topic_score_gemma":0.000129794,"teacher_disagreement_score":0.068862535,"about_ca_system_score_codex":0.00011125822,"about_ca_system_score_gemma":0.0004552316,"threshold_uncertainty_score":0.6964969},"labels":[],"label_agreement":null},{"id":"W4405181185","doi":"10.1158/1538-8514.cancerchem24-a014","title":"Abstract A014: OICR41103: a chemical probe for investigating DCAF1 function and therapeutic potential","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Structural Genomics Consortium; Ontario Institute for Cancer Research","funders":"","keywords":"Function (biology); Cancer; Chemistry; Computational biology; Biology; Cell biology; Genetics","score_opus":0.019119935887306844,"score_gpt":0.27659563995872405,"score_spread":0.2574757040714172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8325384,0.042989813,0.12028423,0.0020778778,0.0008209638,0.000902831,0.000055825687,0.000116856645,0.00021320439],"genre_scores_gemma":[0.99555343,0.00030382507,0.0011710916,0.002073906,0.00041222112,0.00020682345,0.00009162799,0.000059688915,0.00012736888],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989557,0.000027344677,0.00020590576,0.00041564534,0.00014792668,0.00024743617],"domain_scores_gemma":[0.9995973,0.00000944723,0.000051490395,0.00019488425,0.00007037342,0.00007651044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013444744,0.00020140735,0.00012161017,0.000045889705,0.000081157166,0.00011508434,0.000104045386,0.00019015188,0.000017384917],"category_scores_gemma":[0.000010952561,0.00018789811,0.00011609703,0.00009637017,0.00010230536,0.0000074307522,0.000044627734,0.00013901465,0.0000032954163],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053376723,0.000020335794,0.0000511166,0.000101701706,0.00018672897,0.0000016463106,0.000031877822,0.00002546896,0.94107044,0.00091289135,0.00017804609,0.057366397],"study_design_scores_gemma":[0.00053408195,0.00020844283,0.00021351715,0.00006863425,0.00013577144,0.000011160818,0.000028916553,0.0017765809,0.91976815,0.0034037996,0.07354835,0.00030260865],"about_ca_topic_score_codex":0.000009553305,"about_ca_topic_score_gemma":0.0000029658963,"teacher_disagreement_score":0.16301505,"about_ca_system_score_codex":0.000027043872,"about_ca_system_score_gemma":0.00012637672,"threshold_uncertainty_score":0.7662263},"labels":[],"label_agreement":null},{"id":"W4405181189","doi":"10.1158/1538-8514.cancerchem24-a001","title":"Abstract A001: Navigating the future of therapeutic development: innovations in safety and efficacy through advanced research methodologies and nanotechnology","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacogenomics; Risk analysis (engineering); SAFER; Drug delivery; Computer science; Medicine; Nanotechnology; Pharmacology","score_opus":0.10169475308274675,"score_gpt":0.42888031368134283,"score_spread":0.32718556059859605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5367224,0.43080854,0.006585363,0.024557559,0.00047875728,0.0005317384,0.000023298626,0.00008152736,0.00021076071],"genre_scores_gemma":[0.97602564,0.012144174,0.010691396,0.0010039677,0.000018149487,0.00003595849,0.0000059691574,0.000023102133,0.00005161776],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984966,0.00041848648,0.00036392556,0.0003241561,0.000068027184,0.00032878475],"domain_scores_gemma":[0.9987376,0.0008771258,0.000059508602,0.00022364587,0.0000936799,0.000008484093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013005829,0.0001611977,0.00027081202,0.0000965303,0.00018486663,0.000025690693,0.00020547197,0.00035677562,0.000030767333],"category_scores_gemma":[0.00005066108,0.000104411454,0.000035912228,0.00075894035,0.00082804955,0.000048934337,0.00013818947,0.001138819,0.000001338903],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007520642,0.000018654215,0.00009446761,0.00005293475,0.00020315852,0.000004049065,0.0010602128,0.0000056148897,0.3704331,0.015822284,0.000004773778,0.6122256],"study_design_scores_gemma":[0.0010306062,0.00015936796,0.013665456,0.00039409415,0.00009479468,0.0000306571,0.0022113852,0.000038524453,0.6588185,0.022427572,0.3008163,0.00031275794],"about_ca_topic_score_codex":0.000039269424,"about_ca_topic_score_gemma":0.000048153608,"teacher_disagreement_score":0.6119128,"about_ca_system_score_codex":0.000044768185,"about_ca_system_score_gemma":0.00011980856,"threshold_uncertainty_score":0.4947665},"labels":[],"label_agreement":null},{"id":"W4405181191","doi":"10.1158/1538-8514.cancerchem24-ia013","title":"Abstract IA013: Discovery of the dual A2A/A2B receptor antagonist MK-1088 for the treatment of solid tumors","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Receptor; Adenosine receptor; Antagonist; Adenosine A2A receptor; Pharmacology; Chemistry; Medicine; Internal medicine; Agonist","score_opus":0.021162784562571205,"score_gpt":0.30132039662547233,"score_spread":0.28015761206290113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9129973,0.07930358,0.0046649436,0.0011644138,0.0006520196,0.0005444503,0.0005558346,0.0000108211925,0.000106658095],"genre_scores_gemma":[0.9947529,0.003718838,0.0000863569,0.00027555195,0.00032931493,0.00008606754,0.000043045082,0.000042051084,0.00066588086],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99909914,0.00003035142,0.000271182,0.00024272212,0.00015678463,0.00019984199],"domain_scores_gemma":[0.99935627,0.000045471967,0.00011110038,0.0004021559,0.00006261847,0.000022402173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000083991006,0.00018572107,0.000185203,0.000020273947,0.00008215959,0.000029157967,0.00021390092,0.00009192087,0.000017410552],"category_scores_gemma":[0.000004835535,0.000105808824,0.00033174586,0.00010152702,0.00016122442,0.0000044237177,0.000036644404,0.00006193782,7.5360424e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014146866,0.00010190588,0.000166558,0.000077021774,0.0006805328,0.0000030329215,0.00022235463,0.000996866,0.99120164,0.00023853127,0.00093404524,0.005236069],"study_design_scores_gemma":[0.0003430848,0.0003047773,0.0002865815,0.00005772769,0.00020135415,0.000004106304,0.000103803985,0.0001871368,0.88089824,0.00008308544,0.117405795,0.0001243348],"about_ca_topic_score_codex":0.00009632589,"about_ca_topic_score_gemma":0.000015410787,"teacher_disagreement_score":0.11647175,"about_ca_system_score_codex":0.00003227764,"about_ca_system_score_gemma":0.00020647737,"threshold_uncertainty_score":0.43147585},"labels":[],"label_agreement":null},{"id":"W4405181193","doi":"10.1158/1538-8514.cancerchem24-a018","title":"Abstract A018: Somatic mutations in the <i>PIK3CA</i> gene and its prognostic implications among Ethiopian Breast cancer patients","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Mutation; Medicine; TaqMan; Oncology; Immunohistochemistry; Internal medicine; Cancer; Proportional hazards model; Somatic cell; Cancer research; Gene; Biology; Genetics; Polymerase chain reaction","score_opus":0.013527528709464463,"score_gpt":0.27751536784514025,"score_spread":0.2639878391356758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97573215,0.019534096,0.00027714943,0.0028188704,0.00023514769,0.0006308685,0.00058562553,0.000019377954,0.0001667087],"genre_scores_gemma":[0.99223036,0.0045726798,0.00005097594,0.0022246877,0.00014625122,0.0005283623,0.00017101128,0.000050829876,0.000024834288],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988233,0.000049113914,0.00026630814,0.00039854948,0.00016458296,0.00029815026],"domain_scores_gemma":[0.9994129,0.00005720639,0.000066023946,0.00029307167,0.000101029735,0.00006977743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012118936,0.00021617881,0.00013386572,0.000066896515,0.000116061856,0.00014829363,0.0002404154,0.00013946187,0.000018199813],"category_scores_gemma":[0.000015374593,0.00018162264,0.000078790974,0.00022263861,0.000089749425,0.000010358153,0.00006379084,0.00019742436,0.0000052370915],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000690017,0.00057632994,0.18865925,0.00048385136,0.00077095674,0.000047395122,0.0025332088,0.0025703933,0.745572,0.002245133,0.0007271583,0.055745356],"study_design_scores_gemma":[0.001009754,0.00014663502,0.93553555,0.00022741337,0.00041966225,0.000028481354,0.00014705464,0.001236709,0.046714675,0.0013514962,0.012477502,0.0007050579],"about_ca_topic_score_codex":0.00016778913,"about_ca_topic_score_gemma":0.0005718571,"teacher_disagreement_score":0.7468763,"about_ca_system_score_codex":0.00006190755,"about_ca_system_score_gemma":0.00022944479,"threshold_uncertainty_score":0.74063563},"labels":[],"label_agreement":null},{"id":"W4405181201","doi":"10.1158/1538-8514.cancerchem24-a015","title":"Abstract A015: Design and deciphering of precision peptide inhibitors for cancer stemness using generative deep learning and molecular dynamics simulations","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Machine Learning in Bioinformatics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Concordia University","funders":"","keywords":"Computational biology; Peptide; Molecular dynamics; Notch signaling pathway; Molecular mechanics; Amino acid; Biology; Deep learning; Chemistry; Artificial intelligence; Biochemistry; Computer science; Receptor","score_opus":0.020815070898189177,"score_gpt":0.32440934917473274,"score_spread":0.30359427827654356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5031623,0.012453738,0.4838155,0.00006165666,0.000106639505,0.00033852254,0.000027575914,0.000015656493,0.000018398398],"genre_scores_gemma":[0.9599445,0.0010321053,0.03861128,0.00012188662,0.000070677685,0.000049700655,0.000048949358,0.00007761383,0.00004330598],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99879915,0.000082592924,0.0003487404,0.000343389,0.00017971382,0.00024641282],"domain_scores_gemma":[0.9993804,0.00008283096,0.00014811024,0.00016680078,0.00015551264,0.00006633213],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002323978,0.0002521532,0.00022249084,0.00008420611,0.0001336119,0.00009472901,0.000100278645,0.00018614548,0.000007289771],"category_scores_gemma":[0.00003987951,0.00024923033,0.000081620536,0.00013990026,0.00010293866,0.000016232763,0.00009818631,0.00019044714,1.3170919e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005388627,0.000010777228,0.0008124106,0.00022546425,0.00023637888,0.0000026045632,0.0004267264,0.3544144,0.6125041,0.000112145935,0.0000017319882,0.031199384],"study_design_scores_gemma":[0.00035348636,0.00013669129,0.00015361121,0.00019800596,0.00016727603,0.0000069088255,0.00012387443,0.7858411,0.20980583,0.00018496557,0.0027477783,0.00028046005],"about_ca_topic_score_codex":0.000044040942,"about_ca_topic_score_gemma":0.000056559664,"teacher_disagreement_score":0.45678216,"about_ca_system_score_codex":0.00007482694,"about_ca_system_score_gemma":0.00015683136,"threshold_uncertainty_score":0.999996},"labels":[],"label_agreement":null},{"id":"W4405181202","doi":"10.1158/1538-8514.cancerchem24-a012","title":"Abstract A012: Discovery and characterization of Casdatifan (AB521), a clinical-stage, potent, and selective Hypoxia-Inducible Factor (HIF)-2α inhibitor","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer research; Hypoxia-inducible factors; Small molecule; Pharmacology; Angiogenesis; Hypoxia (environmental); Pharmacophore; Drug discovery; Biology; Chemistry; Biochemistry; Gene","score_opus":0.027973633052217086,"score_gpt":0.3158958127372145,"score_spread":0.28792217968499745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96795523,0.02685368,0.002809071,0.00020974307,0.001220573,0.00035013066,0.00045727903,0.000023224335,0.00012106075],"genre_scores_gemma":[0.9762859,0.021413313,0.00012010848,0.0005807709,0.0007895315,0.00003922239,0.00012469277,0.000065292465,0.00058118935],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99843776,0.00007771133,0.0004064946,0.00061464985,0.00018751327,0.00027584084],"domain_scores_gemma":[0.99928904,0.0000214584,0.00014837089,0.00032480812,0.000107913285,0.00010843083],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017338654,0.00027176505,0.0003228441,0.00008473107,0.00006942414,0.00011678058,0.00011351391,0.00025721942,0.000012181885],"category_scores_gemma":[0.000015996198,0.00025417568,0.0001375403,0.00018525064,0.0001722245,0.000031496253,0.000097047305,0.00021990776,0.0000012150617],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000107372085,0.000055553624,0.000961309,0.000141251,0.00035447642,0.0000040173436,0.00016373255,0.0000054257093,0.92167115,0.00008103329,0.00004643339,0.07640825],"study_design_scores_gemma":[0.00079873076,0.00023904261,0.053655155,0.000110631365,0.0002025725,0.000010804605,0.000051201867,0.0001106015,0.792971,0.00006893863,0.1513793,0.00040199474],"about_ca_topic_score_codex":0.00009206005,"about_ca_topic_score_gemma":0.000053108783,"teacher_disagreement_score":0.15133287,"about_ca_system_score_codex":0.00002634384,"about_ca_system_score_gemma":0.00025072723,"threshold_uncertainty_score":0.99999106},"labels":[],"label_agreement":null},{"id":"W4405181206","doi":"10.1158/1538-8514.cancerchem24-ia004","title":"Abstract IA004: Overcoming traditional design limitations with AI-based discovery","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Computational Drug Discovery Methods","field":"Computer Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tolerability; Drug discovery; Cancer; Clinical trial; Medicine; Drug; Adverse effect; Cancer therapy; Computational biology; Computer science; Pharmacology; Bioinformatics; Biology; Internal medicine","score_opus":0.11281916508748142,"score_gpt":0.3286391155321317,"score_spread":0.2158199504446503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181206","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0060498146,0.0022097807,0.9845642,0.005848631,0.00045212696,0.00023121419,0.00003301291,0.00021490059,0.00039632682],"genre_scores_gemma":[0.8271459,0.00003461023,0.16817334,0.0043656835,0.00008181253,0.00010268313,0.000017486453,0.000039153903,0.000039345097],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9982758,0.00014931551,0.00021980243,0.0004914067,0.00058162055,0.0002820494],"domain_scores_gemma":[0.9986097,0.0008094354,0.00005161123,0.0003623407,0.00009542788,0.00007144265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028334497,0.00022850157,0.00015355632,0.0001819832,0.00012325814,0.00079845014,0.00048163722,0.000058395035,0.000016594924],"category_scores_gemma":[0.000010140289,0.00020221068,0.00012813359,0.000641042,0.000079593665,0.0008771154,0.0000397557,0.00026603116,0.000014506282],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033337816,0.00009751021,0.000025516068,0.000049733066,0.00023371575,0.0001596935,0.0002995986,0.77517134,0.010334383,0.14805816,0.00012066986,0.06541631],"study_design_scores_gemma":[0.0003967775,0.00011686492,0.0019312007,0.00020613724,0.000077455734,0.000019561012,0.000012592032,0.91036266,0.022509659,0.058691975,0.005240858,0.00043427016],"about_ca_topic_score_codex":0.000014766946,"about_ca_topic_score_gemma":0.0000076620745,"teacher_disagreement_score":0.82109606,"about_ca_system_score_codex":0.00021011036,"about_ca_system_score_gemma":0.0010790467,"threshold_uncertainty_score":0.8245912},"labels":[],"label_agreement":null},{"id":"W4405181241","doi":"10.1158/1538-8514.cancerchem24-a016","title":"Abstract A016: Targeting calpain-1 and calpain-2 for prevention of breast cancer metastasis: In vivo insights and drug discovery approaches","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Calpain Protease Function and Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University of British Columbia; Queen's University","funders":"","keywords":"Calpain; In silico; Proteases; Cancer research; Metastasis; Small molecule; Peptide; Biology; Cancer cell; Cancer; In vivo; Chemistry; Biochemistry; Enzyme; Genetics; Gene","score_opus":0.02110762181405774,"score_gpt":0.2726137891838403,"score_spread":0.2515061673697826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92234516,0.059692346,0.01632117,0.00069395645,0.00018146091,0.00056414277,0.00015186699,0.0000145657905,0.000035332654],"genre_scores_gemma":[0.99668485,0.002180909,0.00031501488,0.00017239983,0.00011140859,0.00018477131,0.000048563285,0.000033765034,0.00026830158],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990469,0.000068297515,0.00024413307,0.00036349928,0.00011384018,0.00016330219],"domain_scores_gemma":[0.99969727,0.000019960067,0.000073432435,0.00012301566,0.00004380278,0.000042528856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002234008,0.0001672726,0.00016815656,0.000080454665,0.000048119164,0.000052656877,0.00005203647,0.00011299484,0.000008626781],"category_scores_gemma":[0.0000060992315,0.00014448691,0.00009148624,0.000102975566,0.00008908823,0.00001754911,0.000038517723,0.00008352933,8.0205105e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021750975,0.00006435375,0.00068705855,0.0005678094,0.00032597914,0.0000027452725,0.0003248843,0.0007650248,0.9525262,0.00051302946,0.00013730905,0.043868106],"study_design_scores_gemma":[0.001606419,0.00014808084,0.005621674,0.0005237691,0.000365208,0.000014218345,0.0006683436,0.009337071,0.9391781,0.0016347156,0.04030294,0.0005994495],"about_ca_topic_score_codex":0.000117382864,"about_ca_topic_score_gemma":0.00021019229,"teacher_disagreement_score":0.07433971,"about_ca_system_score_codex":0.00003476749,"about_ca_system_score_gemma":0.00009446866,"threshold_uncertainty_score":0.58920056},"labels":[],"label_agreement":null},{"id":"W4405181306","doi":"10.1158/1538-8514.cancerchem24-a004","title":"Abstract A004: Broad and synergistic anti-tumor effects of small-molecule inhibitors of hypoxia inducible factors when paired with immune checkpoint blockade","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer research; Immune checkpoint; Immune system; Tumor microenvironment; Cancer; Metastasis; Immunotherapy; Angiogenesis; Blockade; Tumor progression; Medicine; Hypoxia (environmental); Tolerability; Cancer cell; Pharmacology; Immunology; Chemistry; Receptor; Internal medicine; Adverse effect","score_opus":0.012570323182186401,"score_gpt":0.23839274607863178,"score_spread":0.22582242289644539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9058445,0.09166176,0.0011328196,0.00007753598,0.0007113029,0.00041260067,0.000053094962,0.000029440174,0.000076942924],"genre_scores_gemma":[0.9968466,0.002253052,0.00026888153,0.00011048215,0.00024712645,0.0000529821,0.00003957173,0.00010008296,0.00008122978],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99821854,0.000066054345,0.00047147702,0.0005758907,0.00028138576,0.00038667946],"domain_scores_gemma":[0.99895895,0.00003102044,0.00022040457,0.0005380451,0.00013269388,0.000118910306],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001495222,0.00039887664,0.00051443005,0.00013645137,0.000051261042,0.000040988045,0.00023041738,0.00020623216,0.000014372025],"category_scores_gemma":[0.000020321997,0.0003390243,0.00022412276,0.00023690557,0.00027922398,0.000008997656,0.000105759864,0.00022048687,7.2243233e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008281014,0.00009505792,0.00054416526,0.00076724833,0.00075308135,0.000021325435,0.00035295388,0.00008869923,0.9906166,0.000038624792,0.000027555145,0.0066118822],"study_design_scores_gemma":[0.00093103957,0.00032805908,0.006786118,0.000360104,0.0004403355,0.0000115149305,0.000105477564,0.000043408836,0.9836772,0.00005245994,0.0068736603,0.00039060463],"about_ca_topic_score_codex":0.0005893965,"about_ca_topic_score_gemma":0.00007246447,"teacher_disagreement_score":0.091002084,"about_ca_system_score_codex":0.000030946783,"about_ca_system_score_gemma":0.00036258568,"threshold_uncertainty_score":0.9999062},"labels":[],"label_agreement":null},{"id":"W4405181440","doi":"10.1158/1538-8514.cancerchem24-pr003","title":"Abstract PR003: Structure-guided design and optimization of small molecule CD73 inhibitors with excellent drug-like properties: discovery of quemliclustat","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Small molecule; Cancer; Pancreatic cancer; Drug; Medicine; Pharmacology; Drug discovery; Cancer research; Adenosine; Chemistry; Biochemistry; Internal medicine","score_opus":0.020507422312418623,"score_gpt":0.2466415928509153,"score_spread":0.2261341705384967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.745469,0.04374017,0.21013403,0.00012358655,0.000099031895,0.00036025204,0.000025557358,0.000013897611,0.00003449238],"genre_scores_gemma":[0.9929224,0.0017098432,0.004865997,0.00019409234,0.000059982907,0.000024048639,0.000035632696,0.00005859626,0.0001294106],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989388,0.000059012433,0.00029474247,0.00033678993,0.00018384705,0.0001867878],"domain_scores_gemma":[0.9994638,0.000012058133,0.00011823843,0.00024179432,0.00012236109,0.000041746676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000096608805,0.0002207594,0.00019973812,0.00006529331,0.000033336477,0.000040223513,0.00012283683,0.00010774334,0.000009554255],"category_scores_gemma":[0.000004210199,0.00016971744,0.00006709905,0.00014771389,0.0001293098,0.0000110313,0.0000571766,0.000095857926,1.1025055e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015787763,0.000031589716,0.00007590258,0.00027089237,0.00027711014,0.000010247888,0.00028935092,0.23838794,0.75981647,0.000023892098,0.00014890158,0.0005098068],"study_design_scores_gemma":[0.00042651503,0.00020885817,0.000017242752,0.00027758913,0.00014490042,0.000011416765,0.00010763066,0.008567112,0.989262,0.00002738679,0.000718891,0.00023046731],"about_ca_topic_score_codex":0.0001114163,"about_ca_topic_score_gemma":0.000008583349,"teacher_disagreement_score":0.24745342,"about_ca_system_score_codex":0.000021264139,"about_ca_system_score_gemma":0.00023029889,"threshold_uncertainty_score":0.69208765},"labels":[],"label_agreement":null},{"id":"W4405181441","doi":"10.1158/1538-8514.cancerchem24-ia017","title":"Abstract IA017: Transferrin receptor targeting chimeras (TransTACs) for targeted degradation of membrane and extracellular proteins in cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Transferrin receptor; Epidermal growth factor receptor; Cancer cell; Cancer; Cancer research; Targeted therapy; Extracellular; Receptor; Biology; Chemistry; Medicine; Cell biology; Biochemistry; Internal medicine","score_opus":0.04099871369861158,"score_gpt":0.3359801257257002,"score_spread":0.2949814120270886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9100767,0.078445435,0.005893273,0.0026942429,0.00020849134,0.002361409,0.00013122827,0.00006662888,0.00012260476],"genre_scores_gemma":[0.9881216,0.008167126,0.0017143748,0.00020581814,0.00012092138,0.0006335698,0.000086960186,0.00012554949,0.0008240755],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981568,0.000064137195,0.00047325282,0.00045655746,0.0004286867,0.00042057212],"domain_scores_gemma":[0.99940836,0.00007480417,0.000052229952,0.00022501528,0.00013395508,0.000105612315],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00046671843,0.00025937895,0.00041481399,0.00024941016,0.00004786771,0.00004065572,0.00011229879,0.00018173584,0.0010125767],"category_scores_gemma":[0.000011763745,0.0002417866,0.00017103985,0.000440803,0.000091901056,0.00009123356,0.000010558639,0.0003996026,0.0000014643031],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068959227,0.00011818375,0.00040741803,0.0014281454,0.00038773098,0.000027050854,0.0008820697,0.0001744447,0.8908954,0.00016150027,0.000015002963,0.10481346],"study_design_scores_gemma":[0.0019298355,0.00024223315,0.00057754555,0.000594956,0.0001773451,0.000003955536,0.000110899346,0.0037053418,0.96205103,0.00008838152,0.030276667,0.0002418158],"about_ca_topic_score_codex":0.00072311616,"about_ca_topic_score_gemma":0.00020104059,"teacher_disagreement_score":0.10457164,"about_ca_system_score_codex":0.00020529173,"about_ca_system_score_gemma":0.00038807903,"threshold_uncertainty_score":0.99990064},"labels":[],"label_agreement":null},{"id":"W4405181476","doi":"10.1158/1538-8514.cancerchem24-ia020","title":"Abstract IA020: Discovery of brain-penetrant inhibitors for the treatment of BRAF mutant tumors","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Penetrant (biochemical); Cancer research; Mutant; Cancer; Kinase; Neuroblastoma RAS viral oncogene homolog; Medicine; Pharmacology; Biology; Gene; Genetics; Internal medicine","score_opus":0.020412385785389217,"score_gpt":0.28341883247375693,"score_spread":0.2630064466883677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9553143,0.03540132,0.007321075,0.00054518087,0.000443918,0.00053061306,0.00030630175,0.000010910319,0.00012637473],"genre_scores_gemma":[0.9966494,0.0024270378,0.00009936038,0.00024987568,0.00019018483,0.000105347564,0.000050495626,0.000043465792,0.00018484035],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990495,0.000023108578,0.0002918594,0.0002759285,0.00014982747,0.00020981082],"domain_scores_gemma":[0.9994082,0.000049655486,0.00008938858,0.00036504678,0.000055567623,0.000032181586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009789804,0.00019285968,0.0002041647,0.000038236045,0.00003937809,0.00002603023,0.00016832688,0.00009499924,0.000009991339],"category_scores_gemma":[0.000005752707,0.00012748696,0.0003126795,0.00009546967,0.00011209881,0.000004206321,0.000019466472,0.000044960667,7.492696e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000107965716,0.00011165964,0.0000852297,0.00012461554,0.0005203118,0.000011583008,0.00022408899,0.00023666471,0.968996,0.00058588275,0.00009074886,0.028905263],"study_design_scores_gemma":[0.00045377715,0.0008191154,0.000467475,0.000063050895,0.00014755694,0.0000059076397,0.000073919604,0.00019782202,0.92958874,0.00014936978,0.067891054,0.00014219011],"about_ca_topic_score_codex":0.000087037515,"about_ca_topic_score_gemma":0.000051589508,"teacher_disagreement_score":0.067800306,"about_ca_system_score_codex":0.000029895295,"about_ca_system_score_gemma":0.00020694618,"threshold_uncertainty_score":0.5198767},"labels":[],"label_agreement":null},{"id":"W4405181481","doi":"10.1158/1538-8514.cancerchem24-ia010","title":"Abstract IA010: Bioengineering cell-based therapeutics","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Medicine; Immunotherapy; Immune system; Cancer immunotherapy; Clinical trial; Immunology; Cancer research; Internal medicine","score_opus":0.02177684781242973,"score_gpt":0.3098515751553033,"score_spread":0.2880747273428736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7689035,0.184302,0.038991403,0.0020765392,0.0011711515,0.00080846634,0.000377424,0.00027479406,0.0030947211],"genre_scores_gemma":[0.9950062,0.0023932618,0.00038830144,0.001385698,0.00019922334,0.000118190444,0.00013593628,0.000104974046,0.00026821558],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985719,0.000028128447,0.00018243869,0.00046071183,0.00028844154,0.0004684179],"domain_scores_gemma":[0.99933773,0.000012810691,0.000029680332,0.0004412017,0.000063717605,0.0001148504],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000091307294,0.0002823473,0.00014552833,0.00009578766,0.000069561414,0.00013665092,0.00024825367,0.00015808898,0.00008068451],"category_scores_gemma":[0.0000018833381,0.0002602352,0.00020367559,0.00021814142,0.00007179387,0.0000056800664,0.00004974476,0.0002020424,0.00003779173],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007915805,0.00008929183,0.0003489036,0.00012827171,0.0004887389,0.00009667258,0.000039580038,0.0022695526,0.9686323,0.000045734036,0.00025356672,0.027528226],"study_design_scores_gemma":[0.00055561913,0.00017556628,0.0002942902,0.000053489533,0.000097506985,0.000004608025,0.000014611508,0.0017948992,0.7612674,0.000063318235,0.23537391,0.00030476987],"about_ca_topic_score_codex":0.000104841994,"about_ca_topic_score_gemma":0.000040976345,"teacher_disagreement_score":0.23512034,"about_ca_system_score_codex":0.000092464754,"about_ca_system_score_gemma":0.00033199164,"threshold_uncertainty_score":0.999985},"labels":[],"label_agreement":null},{"id":"W4405181517","doi":"10.1158/1538-8514.cancerchem24-a002","title":"Abstract A002: Computational identification for missense mutations of bladder cancer candidate genes using TCGA datasets","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Missense mutation; Genetics; Biology; Gene; Bladder cancer; Cancer; Mutation; Genome; Cancer research","score_opus":0.05754441736755274,"score_gpt":0.38405656591091075,"score_spread":0.326512148543358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.838026,0.0646744,0.07703799,0.0034352278,0.0014186237,0.0021637913,0.012978041,0.0001468412,0.00011912636],"genre_scores_gemma":[0.99493605,0.0006526173,0.0019471669,0.00077170756,0.00014223429,0.0001748694,0.0012106005,0.000062042,0.000102727645],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988511,0.000019823208,0.0003344094,0.00031473077,0.0002785016,0.00020139366],"domain_scores_gemma":[0.9993319,0.00004762337,0.00009734607,0.00022974882,0.00022189268,0.00007147367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007127698,0.00017954307,0.0002206654,0.0001210791,0.00008289713,0.000048273603,0.0000743085,0.000075796925,0.00021859292],"category_scores_gemma":[0.0000043055697,0.00016582047,0.00013461019,0.00022520317,0.00008089954,0.00008107823,0.000012590052,0.000087640736,0.000005610113],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004522907,0.0003294146,0.001649004,0.0013780486,0.0043864925,0.00012516236,0.0010153943,0.028074274,0.885729,0.0005344456,0.00091525784,0.0754112],"study_design_scores_gemma":[0.005643387,0.00031441535,0.022483012,0.0013633925,0.0080970805,0.00011211747,0.00029710485,0.1121259,0.7898617,0.0044109225,0.054350223,0.000940747],"about_ca_topic_score_codex":0.0008698946,"about_ca_topic_score_gemma":0.00006839213,"teacher_disagreement_score":0.15691008,"about_ca_system_score_codex":0.00019768783,"about_ca_system_score_gemma":0.0005169876,"threshold_uncertainty_score":0.6761963},"labels":[],"label_agreement":null},{"id":"W4405181528","doi":"10.1158/1538-8514.cancerchem24-a020","title":"Abstract A020: Liposomal topotecan with low-intensity focused ultrasound utilization to improve drug penetration with brain parenchyma in pediatric brain tumors","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Topotecan; Liposome; Medicine; Pharmacology; Drug; Blood–brain barrier; Drug delivery; In vivo; Brain tumor; Chemotherapy; Chemistry; Internal medicine; Pathology; Biology; Central nervous system","score_opus":0.01306792124204388,"score_gpt":0.25162254319628446,"score_spread":0.2385546219542406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98917073,0.0008114925,0.0059624854,0.0027132872,0.0002812048,0.0007578825,0.000053410397,0.0001881496,0.0000613602],"genre_scores_gemma":[0.9965062,0.000031150415,0.0006527014,0.0023901428,0.00014426089,0.000116372685,0.000020878586,0.00007760335,0.000060685696],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976226,0.00011679322,0.00038838133,0.00073255936,0.000595015,0.0005446143],"domain_scores_gemma":[0.9989497,0.00016565995,0.00010937864,0.00043341462,0.00018587099,0.00015596849],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000436365,0.00033187785,0.00028346028,0.0002298488,0.00009310029,0.00032858475,0.0002666276,0.000090187736,0.000096721255],"category_scores_gemma":[0.000034334033,0.00028211245,0.000053809108,0.0009883383,0.00008704916,0.00030260623,0.00003692548,0.00024121552,0.000050323033],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043956254,0.0001090073,0.0033933362,0.00013687981,0.000028619957,0.00023231299,0.001297088,0.0073053627,0.98325324,0.00011477913,0.00010100451,0.0035887884],"study_design_scores_gemma":[0.00094429165,0.00043666942,0.020127099,0.00020900142,0.00009771468,0.000019328116,0.00016013115,0.0021036149,0.97493625,0.00017490447,0.00024009762,0.0005509224],"about_ca_topic_score_codex":0.0006713979,"about_ca_topic_score_gemma":0.0023429764,"teacher_disagreement_score":0.016733764,"about_ca_system_score_codex":0.00034761304,"about_ca_system_score_gemma":0.00057358213,"threshold_uncertainty_score":0.9999631},"labels":[],"label_agreement":null},{"id":"W4405181578","doi":"10.1158/1538-8514.cancerchem24-ia022","title":"Abstract IA022: DYP688, a first-in-class PMEL17-targeted antibody drug conjugate delivering a Gq/11-specific inhibitor for the treatment of metastatic uveal melanoma","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"GNAQ; Cancer research; Melanoma; Antibody-drug conjugate; Cancer; In vivo; Medicine; Antibody; Biology; Monoclonal antibody; Internal medicine; Immunology; Mutation","score_opus":0.04368181140493892,"score_gpt":0.34694866315720063,"score_spread":0.3032668517522617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89404684,0.09798036,0.0006388148,0.0052061984,0.00040715063,0.0013143505,0.00022072496,0.000041055508,0.00014449989],"genre_scores_gemma":[0.9799925,0.018092938,0.0004571906,0.0003383951,0.00019755139,0.0002698792,0.00007077448,0.00006917122,0.0005115906],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99813473,0.00004832342,0.0004675772,0.00039795387,0.00045518478,0.0004962053],"domain_scores_gemma":[0.99897456,0.00038276022,0.00007469977,0.00032768372,0.00013032093,0.000110000095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020309296,0.00030881847,0.0004888789,0.0001729599,0.00011236091,0.000056947796,0.0001688398,0.00006636369,0.00015490927],"category_scores_gemma":[0.0000055238434,0.00019849908,0.00036627334,0.00033199321,0.00016932953,0.00004625059,0.000030543793,0.00019273556,0.000014265668],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004177708,0.0015307917,0.007956596,0.0028323445,0.005575379,0.0020230226,0.009312254,0.0014189791,0.8155148,0.0022044287,0.0006931,0.14676058],"study_design_scores_gemma":[0.004154207,0.0013348503,0.011905055,0.0008031339,0.0007944024,0.00005101276,0.00051906804,0.02419051,0.26369408,0.00030502607,0.6917839,0.00046473343],"about_ca_topic_score_codex":0.0010208501,"about_ca_topic_score_gemma":0.00051119877,"teacher_disagreement_score":0.6910908,"about_ca_system_score_codex":0.00026051744,"about_ca_system_score_gemma":0.00023304294,"threshold_uncertainty_score":0.80945575},"labels":[],"label_agreement":null},{"id":"W4405181590","doi":"10.1158/1538-8514.cancerchem24-a007","title":"Abstract A007: Anti-cancer activity of (Z)-endoxifen-related compounds in ERα+ breast cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Estrogen receptor; Estrogen; Tamoxifen; Estrogen receptor alpha; Chemistry; Cancer research; Cancer; Breast cancer; Cell culture; Cell growth; Pharmacology; Cancer cell; Internal medicine; Endocrinology; Biology; Medicine; Biochemistry; Genetics","score_opus":0.011732084392369386,"score_gpt":0.28999987400331206,"score_spread":0.2782677896109427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93412167,0.06324871,0.00011091903,0.0007824395,0.0006407478,0.0002986102,0.00021089992,0.00004097246,0.00054500735],"genre_scores_gemma":[0.98481256,0.014325557,0.000026400176,0.0002926618,0.00012037137,0.00009565369,0.000037597354,0.00008628074,0.00020293599],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983286,0.000094430325,0.00034150883,0.0005369369,0.000261658,0.00043683947],"domain_scores_gemma":[0.99930966,0.000018870132,0.00011938687,0.00037373567,0.00008775154,0.00009057242],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017328028,0.0003365613,0.0003537539,0.00013100173,0.000049536608,0.000042778254,0.00026370588,0.00042143764,0.000094258095],"category_scores_gemma":[0.0000028483842,0.00030639934,0.00024594745,0.0004142825,0.00016627139,0.000012934253,0.000083138264,0.00046090144,0.0000069087837],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017138981,0.00015519929,0.004211289,0.00016152774,0.00088269735,0.000047792877,0.000094402516,0.0018039544,0.96516776,0.00007870687,0.00015262845,0.02707267],"study_design_scores_gemma":[0.0010582006,0.000096774274,0.017057225,0.00033169804,0.00018431286,0.000024246634,0.000017245517,0.001178154,0.9738043,0.000059514394,0.0057443185,0.00044403493],"about_ca_topic_score_codex":0.00063394586,"about_ca_topic_score_gemma":0.00008992899,"teacher_disagreement_score":0.05069085,"about_ca_system_score_codex":0.000111473724,"about_ca_system_score_gemma":0.00036939865,"threshold_uncertainty_score":0.9999388},"labels":[],"label_agreement":null},{"id":"W4405181601","doi":"10.1158/1538-8514.cancerchem24-pr004","title":"Abstract PR004: Brain penetrant allosteric EGFR inhibitors for NSCLC","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Erlotinib; T790M; Osimertinib; Gefitinib; Cancer research; Pharmacology; Epidermal growth factor receptor; EGFR inhibitors; In vivo; Kinome; Mutant; Medicine; Chemistry; Allosteric regulation; Kinase; Cancer; Biology; Internal medicine; Receptor; Biochemistry; Gene; Genetics","score_opus":0.026207182971794737,"score_gpt":0.35854694130504794,"score_spread":0.3323397583332532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71602833,0.14505854,0.026565587,0.091168806,0.0043584257,0.005375678,0.0005498531,0.00078753056,0.010107271],"genre_scores_gemma":[0.9902189,0.00038124766,0.0008157105,0.00621955,0.0002796032,0.00038117912,0.0000919392,0.000086978056,0.0015248983],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989594,0.00001204085,0.00021336938,0.00031912717,0.00021590872,0.0002801073],"domain_scores_gemma":[0.99951494,0.000052690448,0.000034483477,0.00022619618,0.000075801836,0.000095866206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007371015,0.0001957594,0.00019769218,0.00009409958,0.00006636452,0.0000711329,0.000066638015,0.00009080942,0.0001261724],"category_scores_gemma":[0.0000046979562,0.00015842612,0.00020737463,0.00019996558,0.000042756954,0.00005795686,0.000012025987,0.00012768542,0.000021478469],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003221907,0.0003253291,0.00065215304,0.0010553162,0.0034392616,0.0003956962,0.0024879181,0.00015673235,0.5513841,0.0018696774,0.00620839,0.4317032],"study_design_scores_gemma":[0.003550632,0.0006868606,0.0045257634,0.0009109594,0.0021984223,0.000057073543,0.000229831,0.0011898589,0.104456365,0.0009784721,0.880703,0.0005127944],"about_ca_topic_score_codex":0.00008600699,"about_ca_topic_score_gemma":0.000027578655,"teacher_disagreement_score":0.87449455,"about_ca_system_score_codex":0.0002868677,"about_ca_system_score_gemma":0.00040042368,"threshold_uncertainty_score":0.64604294},"labels":[],"label_agreement":null},{"id":"W4405181612","doi":"10.1158/1538-8514.cancerchem24-a013","title":"Abstract A013: Prioritization of Eleven-Nineteen-Leukemia (ENL) inhibitors as orally available drug candidates for acute myeloid leukemia","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myeloid leukemia; Leukemia; In vivo; Medicine; Cancer; Pharmacology; Drug; Cancer research; Acute leukemia; Potency; Immunology; In vitro; Biology; Internal medicine; Biochemistry","score_opus":0.010768484327422797,"score_gpt":0.2777045741678547,"score_spread":0.26693608984043193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95856756,0.029484011,0.006748064,0.00075451116,0.0011696588,0.0012009196,0.00037295252,0.000113766284,0.0015885473],"genre_scores_gemma":[0.9872173,0.0041369237,0.0013068927,0.0010232679,0.00045550644,0.0002050603,0.0006810731,0.000119358025,0.0048546065],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983451,0.00004087833,0.00044642214,0.00052599784,0.00028183765,0.00035979884],"domain_scores_gemma":[0.9991079,0.000018579478,0.00015478999,0.00039508296,0.00022877978,0.000094883326],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020277272,0.00030408954,0.00025418744,0.000108544315,0.00008884024,0.00009333572,0.00026369462,0.000244869,0.00010326358],"category_scores_gemma":[0.00002259146,0.00029778382,0.00021305522,0.0002546775,0.00010062657,0.00002155268,0.00006898983,0.00016619115,0.000027207072],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014660948,0.000024248642,0.00011996606,0.00015134782,0.00048910873,0.000008597221,0.0000870869,0.00024515606,0.9765256,0.00034135746,0.011717956,0.010142982],"study_design_scores_gemma":[0.00050383346,0.00016027529,0.000045326975,0.00011217593,0.00014815209,0.0000055284195,0.000021000318,0.00069817516,0.76504153,0.00027606633,0.23270743,0.00028051063],"about_ca_topic_score_codex":0.00020114025,"about_ca_topic_score_gemma":0.00006209184,"teacher_disagreement_score":0.22098948,"about_ca_system_score_codex":0.0002349309,"about_ca_system_score_gemma":0.0011484026,"threshold_uncertainty_score":0.9999474},"labels":[],"label_agreement":null},{"id":"W4405181643","doi":"10.1158/1538-8514.cancerchem24-pr001","title":"Abstract PR001: Discovery of Etrumadenant, a first-in-class dual A2a and A2b adenosine receptor antagonist for cancer immunotherapy","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Adenosine; Medicine; Adenosine receptor; Pharmacology; Adenosine A2A receptor; Receptor; Immunology; Internal medicine; Agonist","score_opus":0.016733300270360376,"score_gpt":0.29198112175010776,"score_spread":0.2752478214797474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.793966,0.20026198,0.002735581,0.0018045235,0.00044295882,0.00041818517,0.00028414902,0.000026207652,0.000060409846],"genre_scores_gemma":[0.97724456,0.020837685,0.0002623509,0.0006273827,0.00031912627,0.00018054328,0.000077228455,0.000106621745,0.0003444843],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986751,0.000027010616,0.00034452038,0.00045709446,0.00016070224,0.0003355485],"domain_scores_gemma":[0.9995016,0.000035891477,0.00009577843,0.000259536,0.0000630927,0.000044088818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013810024,0.00026613817,0.0002745735,0.00008386363,0.000055001754,0.00008200487,0.00015461276,0.00019618918,0.00002577954],"category_scores_gemma":[0.0000062048575,0.00023917775,0.00014890183,0.0001579505,0.00012351955,0.000015240411,0.000049567218,0.00014648018,5.9101166e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042333783,0.00007372337,0.0014086295,0.00032151424,0.0004556064,0.000016077456,0.00021739864,0.00038925104,0.9881343,0.00032003116,0.0011702459,0.0070698326],"study_design_scores_gemma":[0.0012897466,0.00030021783,0.0012284153,0.00035183015,0.000098814424,0.000011159524,0.00008680049,0.0004588838,0.74069905,0.00018056614,0.25486633,0.00042817846],"about_ca_topic_score_codex":0.00026113284,"about_ca_topic_score_gemma":0.00011366687,"teacher_disagreement_score":0.25369608,"about_ca_system_score_codex":0.000050599498,"about_ca_system_score_gemma":0.00020667948,"threshold_uncertainty_score":0.9753385},"labels":[],"label_agreement":null},{"id":"W4405181656","doi":"10.1158/1538-8514.cancerchem24-ia006","title":"Abstract IA006: Progress, pitfalls and promise: the journey to effective and well tolerated DNA damage response inhibitor combinations in the clinic","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"PARP inhibitor; Tolerability; Medicine; Cancer; DNA damage; Poly ADP ribose polymerase; Pharmacology; Cancer research; Polymerase; DNA; Adverse effect; Internal medicine; Chemistry; Biochemistry","score_opus":0.032133666429144336,"score_gpt":0.368427072439368,"score_spread":0.33629340601022367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.932503,0.01778202,0.00009131256,0.046454795,0.00026037585,0.0024311128,0.000030396737,0.00006738253,0.00037959512],"genre_scores_gemma":[0.988748,0.000844093,0.00007687358,0.009151316,0.00011893489,0.00080721057,0.000008315569,0.000055398174,0.00018983586],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99813163,0.00046046864,0.00034265735,0.00039799506,0.00037079022,0.00029644652],"domain_scores_gemma":[0.9988636,0.00046204563,0.00006946004,0.00038698578,0.00011496326,0.00010294092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012384612,0.00024729443,0.00025992547,0.00015968668,0.00015807389,0.00022983926,0.00015422428,0.00012395182,0.00006888986],"category_scores_gemma":[0.00003649045,0.00015471931,0.00007244474,0.00063867663,0.00030007266,0.0000835856,0.000043382195,0.00059502025,0.000020974967],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01344434,0.0018365853,0.009361027,0.0011700316,0.0022368808,0.001892948,0.057218183,0.00011076162,0.79131985,0.0031523525,0.011134782,0.107122235],"study_design_scores_gemma":[0.014641554,0.0032031015,0.45088953,0.0038586033,0.000977629,0.00035307716,0.0027327193,0.0019819355,0.15029967,0.003875708,0.36595666,0.0012298168],"about_ca_topic_score_codex":0.000022841052,"about_ca_topic_score_gemma":0.000030687,"teacher_disagreement_score":0.6410202,"about_ca_system_score_codex":0.00018228711,"about_ca_system_score_gemma":0.00026557085,"threshold_uncertainty_score":0.630927},"labels":[],"label_agreement":null},{"id":"W4405181739","doi":"10.1158/1538-8514.cancerchem24-ia007","title":"Abstract IA007: Preclinical Approaches to Discovery and Development of Novel Combination Therapies","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Computational Drug Discovery Methods","field":"Computer Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Identification (biology); Drug discovery; Computational biology; Combination therapy; Disease; Medicine; Computer science; Bioinformatics; Biology; Pharmacology","score_opus":0.19982647271638201,"score_gpt":0.37102503845031026,"score_spread":0.17119856573392825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181739","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22234598,0.003470061,0.7718515,0.0017256032,0.0002680846,0.00018057718,0.000006170592,0.000048898466,0.000103126666],"genre_scores_gemma":[0.822756,0.0000409655,0.17669609,0.00040488888,0.000020520793,0.000040457446,0.0000032761245,0.000015344207,0.000022438906],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9987738,0.000053204396,0.00030695484,0.0003732127,0.00033742865,0.00015539365],"domain_scores_gemma":[0.999394,0.00022613168,0.000055129472,0.00023383465,0.000042524964,0.000048373287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045851432,0.00014454249,0.00016414734,0.00011636851,0.0000475752,0.0002343077,0.0003353317,0.000051725194,0.000002470648],"category_scores_gemma":[0.000009556717,0.00012909129,0.000053620563,0.00028878133,0.000051216535,0.00030302256,0.00017934266,0.00011477451,0.0000020899254],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027677117,0.0003113154,0.00017529377,0.0001821652,0.00039793472,0.0000054409566,0.00763602,0.014665099,0.030738426,0.15613078,0.000010679432,0.78971916],"study_design_scores_gemma":[0.0019934848,0.00038152977,0.08178118,0.00081064657,0.00012166736,0.000020122305,0.00035661642,0.60407853,0.23092419,0.04021129,0.03778356,0.0015371693],"about_ca_topic_score_codex":0.0000072064586,"about_ca_topic_score_gemma":0.000005555911,"teacher_disagreement_score":0.788182,"about_ca_system_score_codex":0.00006519305,"about_ca_system_score_gemma":0.0003196195,"threshold_uncertainty_score":0.526419},"labels":[],"label_agreement":null},{"id":"W4405181913","doi":"10.1158/1538-8514.cancerchem24-ia009","title":"Abstract IA009: An integrative approach to nanomedicine: Leveraging new tools to advance drug delivery","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nanomedicine; Drug delivery; Context (archaeology); Medicine; Personalized medicine; Cancer; Nanotechnology; Computer science; Bioinformatics; Biology; Nanoparticle; Internal medicine","score_opus":0.028127996443314887,"score_gpt":0.2954347089554965,"score_spread":0.26730671251218163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9281683,0.006924211,0.06001728,0.0019946094,0.0011367569,0.0007067297,0.000070888,0.0003370692,0.00064416206],"genre_scores_gemma":[0.97680146,0.00010422276,0.012797331,0.009306812,0.00031898654,0.00014862939,0.000015169299,0.00010004937,0.00040734257],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99721956,0.00010807778,0.00041655503,0.0009183433,0.00061346206,0.0007239804],"domain_scores_gemma":[0.99852455,0.00009620657,0.000060766564,0.0006698777,0.00013692302,0.0005117058],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044455368,0.0004029925,0.0003587051,0.00021354189,0.00011824093,0.00042810137,0.00063039875,0.00007713219,0.0002010418],"category_scores_gemma":[0.000017917848,0.00034995098,0.00010851226,0.00070475694,0.00007280221,0.0005537378,0.0001257147,0.00027813416,0.00035330144],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010873259,0.00008557238,0.000013964418,0.000048662296,0.000048870323,0.000070539856,0.006776213,0.008568383,0.9069452,0.00035659096,0.00077097677,0.07620627],"study_design_scores_gemma":[0.00037640624,0.00012377168,0.00013842847,0.00037643942,0.00009207782,0.000008763485,0.0010693489,0.0020231137,0.9650091,0.00043454155,0.02977442,0.00057356525],"about_ca_topic_score_codex":0.0006368357,"about_ca_topic_score_gemma":0.000089911984,"teacher_disagreement_score":0.07563271,"about_ca_system_score_codex":0.00047777547,"about_ca_system_score_gemma":0.0005859053,"threshold_uncertainty_score":0.9998953},"labels":[],"label_agreement":null},{"id":"W4405181965","doi":"10.1158/1538-8514.cancerchem24-ia003","title":"Abstract IA003: Synthetic lethality: Pathways to therapeutic discovery","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CRISPR and Genetic Engineering","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Synthetic lethality; Computational biology; Cancer; Context (archaeology); Drug discovery; Genome; Chromatin; Biology; CRISPR; DNA repair; Bioinformatics; DNA; Genetics; Gene","score_opus":0.02024564830007196,"score_gpt":0.3161788515262899,"score_spread":0.2959332032262179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.645938,0.055937923,0.29220238,0.0023066194,0.0014302855,0.00063799793,0.00011630354,0.00014618713,0.0012843403],"genre_scores_gemma":[0.9950315,0.0009195415,0.0003442858,0.0027156668,0.0003309576,0.00014512266,0.000031145588,0.000108773325,0.000373043],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984294,0.00003760653,0.00026007116,0.0005789094,0.00025898305,0.0004349851],"domain_scores_gemma":[0.9991868,0.000017345215,0.00002705262,0.0005988279,0.00004920313,0.00012078694],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000195361,0.0003073886,0.00019258718,0.00008560653,0.00005938065,0.00018452696,0.00028714907,0.00016533936,0.000041870557],"category_scores_gemma":[0.000009320044,0.00028905508,0.0002062284,0.00021683308,0.00005112729,0.0000075592457,0.00009875464,0.00018188526,0.000041147454],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034002136,0.000030624848,0.00006236281,0.00009190976,0.00030411725,0.000042666812,0.00020024057,0.00267,0.94168067,0.0010409851,0.00014837174,0.05369404],"study_design_scores_gemma":[0.00018589532,0.0001494895,0.0010123538,0.00013145861,0.00012212942,0.000025591362,0.000063774045,0.00045005462,0.82571876,0.0006711504,0.17093258,0.00053675304],"about_ca_topic_score_codex":0.0000321991,"about_ca_topic_score_gemma":0.000022979684,"teacher_disagreement_score":0.3490935,"about_ca_system_score_codex":0.000050094768,"about_ca_system_score_gemma":0.00015406852,"threshold_uncertainty_score":0.99995613},"labels":[],"label_agreement":null},{"id":"W4405181970","doi":"10.1158/1538-8514.cancerchem24-ia018","title":"Abstract IA018: Pan-RAF-MEK molecular glue NST-628 is a potent and brain-penetrant inhibitor of the RAS-MAPK pathway","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"MAPK/ERK pathway; Cancer research; MEK inhibitor; Tolerability; Phosphorylation; Medicine; Kinase; Cancer; Chemistry; Pharmacology; Internal medicine; Biochemistry; Adverse effect","score_opus":0.012600471978043988,"score_gpt":0.2521511944222847,"score_spread":0.2395507224442407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9525502,0.04017178,0.0026831029,0.0022462318,0.00079090864,0.0005250596,0.00022690624,0.000034922185,0.0007708955],"genre_scores_gemma":[0.9935346,0.0010606381,0.00019912087,0.004520199,0.00017868698,0.000066080494,0.000034189394,0.0000916178,0.00031487193],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99799395,0.00009980087,0.00041401433,0.0006597024,0.00039058886,0.00044192307],"domain_scores_gemma":[0.99888617,0.000026403548,0.0001234024,0.0007331789,0.00011235913,0.00011847933],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021551049,0.00039235165,0.00029833603,0.00006960738,0.00009813076,0.000083187384,0.00038324486,0.00028602642,0.00003503491],"category_scores_gemma":[0.000017582031,0.00030168088,0.00033708112,0.0002252557,0.00021099877,0.000008326458,0.00019441856,0.000273467,0.000007154067],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000061755665,0.000061725266,0.0001774327,0.00019061085,0.0004011415,0.00007353142,0.0002953182,0.000046814534,0.97265506,0.0007092805,0.000518777,0.024808573],"study_design_scores_gemma":[0.000526691,0.00019881473,0.001206879,0.00016403846,0.000121341065,0.00003602271,0.00006568212,0.00013356464,0.8968619,0.0004248778,0.09990467,0.00035549828],"about_ca_topic_score_codex":0.00008671653,"about_ca_topic_score_gemma":0.00003347755,"teacher_disagreement_score":0.09938589,"about_ca_system_score_codex":0.000039758266,"about_ca_system_score_gemma":0.00034749188,"threshold_uncertainty_score":0.99994355},"labels":[],"label_agreement":null},{"id":"W4405181977","doi":"10.1158/1538-8514.cancerchem24-ia002","title":"Abstract IA002: Leveraging synthetic lethality for the development of novel cancer therapies","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; Genetic screen; Cancer; Lethal allele; Biology; RNA interference; Cancer cell; Gene; Population; Mutant; Cancer research; Computational biology; Genetics; Medicine","score_opus":0.04465749761615503,"score_gpt":0.3207776675550195,"score_spread":0.2761201699388645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6656773,0.10773626,0.22235428,0.0021948048,0.0010545156,0.0007252519,0.000110134126,0.000041510775,0.00010594287],"genre_scores_gemma":[0.99572676,0.0013599793,0.0017334586,0.00033683536,0.00022766314,0.0003397136,0.000032163916,0.00006890038,0.00017453534],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99873835,0.000023704928,0.00034020483,0.00039146168,0.00023235232,0.0002739523],"domain_scores_gemma":[0.999291,0.000047873287,0.000106579,0.00038085348,0.0001389932,0.000034714518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030134336,0.00022461591,0.00016794383,0.000047752965,0.00013088381,0.000048842507,0.0002508482,0.00015311777,0.000035866626],"category_scores_gemma":[0.000007374254,0.00017544345,0.0001845246,0.00015271665,0.00011323221,0.0000056138992,0.000052699932,0.00012236585,0.0000010511934],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006945801,0.000036080433,0.00007137586,0.00013366064,0.0009045702,3.3488317e-7,0.0007486514,0.0067151366,0.85139096,0.00012301373,0.00006897344,0.1397378],"study_design_scores_gemma":[0.00043959034,0.00003381897,0.001546937,0.0001657128,0.00018981389,0.0000027637116,0.00013542926,0.003708315,0.8343313,0.00009287696,0.1590802,0.00027326724],"about_ca_topic_score_codex":0.00006970797,"about_ca_topic_score_gemma":0.00015596217,"teacher_disagreement_score":0.33004946,"about_ca_system_score_codex":0.00010661252,"about_ca_system_score_gemma":0.00050596526,"threshold_uncertainty_score":0.7154376},"labels":[],"label_agreement":null},{"id":"W4405182084","doi":"10.1158/1538-8514.cancerchem24-a008","title":"Abstract A008: Evaluation of natural and synthetic compounds on epithelial to mesenchymal transition in triple negative breast cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Tannin, Tannase and Anticancer Activities","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Epithelial–mesenchymal transition; Vimentin; Triple-negative breast cancer; Cancer research; Mesenchymal stem cell; Cancer; Cancer cell; Metastasis; Chemistry; Breast cancer; Biology; Cell biology; Immunology; Immunohistochemistry","score_opus":0.022583135608798644,"score_gpt":0.3084671364835852,"score_spread":0.28588400087478655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405182084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98115176,0.014801785,0.00007350529,0.0021946854,0.00078461505,0.0003700607,0.00040291043,0.000027813769,0.00019283633],"genre_scores_gemma":[0.99875516,0.00047461648,0.000010484988,0.00052313757,0.000039891922,0.00010003858,0.00001589066,0.000022334887,0.00005845561],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989734,0.00015917579,0.00021489305,0.00029435716,0.0001267872,0.0002313617],"domain_scores_gemma":[0.99963635,0.0000759432,0.00004548306,0.00012619792,0.000098219956,0.000017812343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024507326,0.0001781688,0.00024306458,0.00017362465,0.000055968543,0.000023178422,0.000080917016,0.00011570924,0.0001707589],"category_scores_gemma":[0.0000054049933,0.00015555264,0.00007145957,0.00021802778,0.00014737547,0.00008056365,0.000013642092,0.00026582685,0.000007828313],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005297448,0.000080735306,0.000094864714,0.00006355776,0.00033008686,0.0000086678665,0.0035586553,0.0006704354,0.9070806,0.00033854,0.0000399397,0.0872042],"study_design_scores_gemma":[0.0021852728,0.00020791945,0.031576686,0.00093655253,0.00041598987,0.000031745385,0.00079060846,0.0016612754,0.9597416,0.0008789336,0.0011888101,0.00038461195],"about_ca_topic_score_codex":0.00082615914,"about_ca_topic_score_gemma":0.00030779355,"teacher_disagreement_score":0.08681959,"about_ca_system_score_codex":0.00016123711,"about_ca_system_score_gemma":0.00019143742,"threshold_uncertainty_score":0.63432527},"labels":[],"label_agreement":null},{"id":"W4405182115","doi":"10.1158/1538-8514.cancerchem24-a009","title":"Abstract A009: Genetic disruption of CAPNS1 impedes triple-negative breast cancer metastasis: A case for selective calpain-1/2 inhibitors","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Calpain Protease Function and Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Calpain; Cancer research; Biology; Metastasis; Cancer; Cell biology; Genetics","score_opus":0.016128409611007265,"score_gpt":0.30366891695897996,"score_spread":0.2875405073479727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405182115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9383626,0.027409462,0.029342065,0.00089818676,0.00095585966,0.00155711,0.0013328659,0.000063659296,0.00007819566],"genre_scores_gemma":[0.996899,0.00094442617,0.00055201445,0.0003293627,0.00038284317,0.0005504994,0.00007957973,0.000072043294,0.00019021372],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985618,0.0000931655,0.00036310233,0.0004935216,0.00020087794,0.00028755135],"domain_scores_gemma":[0.9991875,0.000032269072,0.0001418469,0.00024222021,0.0003068538,0.00008926105],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019040123,0.000276164,0.00023318068,0.00011714028,0.00010946373,0.000049769536,0.00009216345,0.00021340506,0.000045413082],"category_scores_gemma":[0.000016967015,0.00024597495,0.00030070232,0.00028479827,0.00012448376,0.000011059906,0.000032662905,0.00013446317,0.0000018390307],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050777907,0.00008806743,0.00018086564,0.000297195,0.001173781,0.00005610867,0.00037479994,0.0014326392,0.9121584,0.000076699864,0.0006438738,0.083009735],"study_design_scores_gemma":[0.0012695357,0.00030464065,0.0017099627,0.00016884723,0.00067318033,0.00032096417,0.00036427632,0.0032114116,0.9769836,0.00043515,0.014065249,0.00049318816],"about_ca_topic_score_codex":0.00045878073,"about_ca_topic_score_gemma":0.0003617654,"teacher_disagreement_score":0.08251654,"about_ca_system_score_codex":0.00012513732,"about_ca_system_score_gemma":0.00033317442,"threshold_uncertainty_score":0.9999992},"labels":[],"label_agreement":null},{"id":"W4405182172","doi":"10.1158/1538-8514.cancerchem24-a011","title":"Abstract A011: Discovery and characterization of the first highly potent and selective AXL receptor tyrosine kinase inhibitor AB801","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"GAS6; Kinome; MERTK; Cancer research; Receptor tyrosine kinase; Cancer; Cancer cell; AXL receptor tyrosine kinase; Tyrosine kinase; Kinase; Tumor microenvironment; Pharmacology; Tyrosine-kinase inhibitor; Immune checkpoint; Immune system; Biology; Signal transduction; Chemistry; Immunotherapy; Cell biology; Immunology; JAK-STAT signaling pathway","score_opus":0.009851442890421419,"score_gpt":0.2301417661797985,"score_spread":0.2202903232893771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405182172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9703464,0.026839083,0.00029158776,0.0015141603,0.00064341736,0.00022351608,0.00009223092,0.000021692136,0.000027948538],"genre_scores_gemma":[0.9973482,0.0020204314,0.000006472625,0.00029024584,0.000031839325,0.000020942733,0.00005061632,0.000020465293,0.0002108247],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993939,0.00004489004,0.0001817466,0.00020284379,0.00004102818,0.00013562129],"domain_scores_gemma":[0.9997048,0.000020868603,0.000079449725,0.00014114058,0.00004511128,0.000008626306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006759786,0.00013328307,0.00014921004,0.000045012635,0.00010505363,0.000044402415,0.000065782915,0.00012215153,0.0000151024915],"category_scores_gemma":[0.0000029252196,0.00009463417,0.000055236076,0.0001357358,0.00014750307,0.0001306358,0.000050139584,0.00014216284,0.0000028714906],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006844515,0.000036077083,0.00073538086,0.00006684572,0.0002066485,6.5566803e-7,0.00036924143,0.0000034091945,0.97950923,0.00046516833,0.000037027097,0.01850186],"study_design_scores_gemma":[0.00033797324,0.00006110104,0.10648153,0.00017557791,0.000092436276,0.0000055170176,0.000016663911,0.000032300406,0.8731598,0.00007183792,0.019456819,0.00010844514],"about_ca_topic_score_codex":0.000049588027,"about_ca_topic_score_gemma":0.000009636395,"teacher_disagreement_score":0.10634944,"about_ca_system_score_codex":0.000053491865,"about_ca_system_score_gemma":0.000050809194,"threshold_uncertainty_score":0.38590693},"labels":[],"label_agreement":null},{"id":"W4405182221","doi":"10.1158/1538-8514.cancerchem24-pr002","title":"Abstract PR002: EP300 loss of function is a pan-cancer sensitizer to BET inhibition","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Google (Canada)","funders":"","keywords":"Synthetic lethality; Cancer; Cancer research; Biology; Loss function; Regulator; DNA replication; Cancer cell; Gene; Genetics; Phenotype; DNA repair","score_opus":0.017115491448581287,"score_gpt":0.28770267258928095,"score_spread":0.2705871811406997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405182221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9670516,0.01259196,0.015344093,0.0030135217,0.00073313783,0.00045235507,0.0001953703,0.00004853825,0.0005694146],"genre_scores_gemma":[0.99238443,0.0010483031,0.00020724563,0.0052913004,0.00030865066,0.00010502178,0.00008024723,0.000052009356,0.0005227778],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998825,0.000036336936,0.0002666684,0.0003989183,0.00024719868,0.0002258632],"domain_scores_gemma":[0.99940157,0.0000055946207,0.00006848078,0.00030118568,0.00015244538,0.000070718714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001168493,0.00019911127,0.00015457408,0.00008894072,0.000043266205,0.00004578193,0.00008529929,0.0001799928,0.00016788435],"category_scores_gemma":[0.0000058009628,0.00019172882,0.00015113536,0.00024410643,0.000059147995,0.000009310958,0.000050527648,0.00012425109,0.000027415836],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011417859,0.000035663896,0.0001333499,0.00009118197,0.00022821616,0.000009032129,0.00011389465,0.000102368685,0.96463645,0.0001527158,0.0031283072,0.031254668],"study_design_scores_gemma":[0.0002293615,0.0001348134,0.0006570835,0.00013060556,0.00007356808,0.0000035078235,0.000023345274,0.000076664954,0.8210679,0.00015634461,0.17724548,0.00020131448],"about_ca_topic_score_codex":0.00006808386,"about_ca_topic_score_gemma":0.000025851024,"teacher_disagreement_score":0.17411718,"about_ca_system_score_codex":0.00005003653,"about_ca_system_score_gemma":0.00014899208,"threshold_uncertainty_score":0.7818474},"labels":[],"label_agreement":null},{"id":"W4405182229","doi":"10.1158/1538-8514.cancerchem24-a017","title":"Abstract A017: The FES tyrosine kinase as an emerging target for cancer immunotherapy","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Cancer immunotherapy; Cytotoxic T cell; Innate immune system; Immunotherapy; Immune system; Immunology; Cancer research; Cancer; Biology; Acquired immune system","score_opus":0.024937751555463322,"score_gpt":0.32578274876147373,"score_spread":0.30084499720601043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405182229","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42472187,0.5622417,0.002958996,0.00549455,0.003101985,0.0007922246,0.00016659449,0.0003699574,0.00015218761],"genre_scores_gemma":[0.971435,0.01850155,0.00015677155,0.0054958784,0.00017986904,0.00077210873,0.000105744846,0.00023697765,0.0031160817],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981491,0.0002217136,0.00039795265,0.0004871235,0.00009244357,0.0006516698],"domain_scores_gemma":[0.998911,0.00019244655,0.00011035094,0.0006374504,0.0001255601,0.000023171147],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041832132,0.00041321028,0.00034318992,0.00012642497,0.0004447693,0.00017082212,0.00057918654,0.00028166483,0.0011717993],"category_scores_gemma":[0.000010357444,0.00029512128,0.00032913298,0.00027757807,0.00029262787,0.00018382815,0.000038313603,0.00047280185,0.00006619896],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010023382,0.00009281929,0.000035047193,0.00004702895,0.0014111224,0.00001151788,0.0014609417,0.00010296221,0.80625516,0.0018091094,0.00047443146,0.18729752],"study_design_scores_gemma":[0.0007521502,0.00022127833,0.00043809437,0.000094698065,0.000096225594,0.000015223848,0.00017153584,0.000065085565,0.4486911,0.000821625,0.5483538,0.00027916254],"about_ca_topic_score_codex":0.0007289493,"about_ca_topic_score_gemma":0.000044905755,"teacher_disagreement_score":0.5478794,"about_ca_system_score_codex":0.00012731501,"about_ca_system_score_gemma":0.00037962614,"threshold_uncertainty_score":0.9999501},"labels":[],"label_agreement":null},{"id":"W4405182261","doi":"10.1158/1538-8514.cancerchem24-a019","title":"Abstract A019: Discovery of a potent and brain-penetrable tubulin inhibitor SB-216 that shows efficacy in primary tumor growth and brain metastasis","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Taxane; Medicine; Brain metastasis; Prostate cancer; Cancer; Breast cancer; Cancer research; Metastasis; Ovarian cancer; Pharmacology; Metastatic breast cancer; Internal medicine","score_opus":0.024585093130380844,"score_gpt":0.3082285957801095,"score_spread":0.2836435026497287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405182261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92651814,0.062483404,0.000103166305,0.009407098,0.00023146412,0.0006326097,0.00010647327,0.00003547128,0.00048214992],"genre_scores_gemma":[0.9906483,0.0029467945,0.00017648134,0.0057148566,0.00009044866,0.00006777164,0.0000318778,0.000055466146,0.00026797372],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986388,0.00006801676,0.00029820873,0.0004316606,0.00025488442,0.0003084001],"domain_scores_gemma":[0.9994046,0.00021847639,0.00006837814,0.00017914208,0.000026877218,0.00010250636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001918122,0.00027049103,0.0004755574,0.00019798633,0.000032145093,0.000057617875,0.00006994868,0.00008533524,0.000054232773],"category_scores_gemma":[0.000009517095,0.0002272362,0.00012122714,0.00024790427,0.00014564791,0.0001253957,0.00005757051,0.00027847555,0.0000013792541],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011173015,0.0006187191,0.0074503105,0.0013963241,0.0013201704,0.001002151,0.00094994775,0.00003073824,0.92998177,0.00024079008,0.0007284359,0.055163354],"study_design_scores_gemma":[0.0106568765,0.001280039,0.12551771,0.0011828342,0.001898837,0.00021337907,0.00019531228,0.00035180192,0.8400949,0.0005438122,0.017361527,0.00070292776],"about_ca_topic_score_codex":0.00034941497,"about_ca_topic_score_gemma":0.000085873835,"teacher_disagreement_score":0.1180674,"about_ca_system_score_codex":0.00017288857,"about_ca_system_score_gemma":0.00029152367,"threshold_uncertainty_score":0.92664236},"labels":[],"label_agreement":null},{"id":"W4405182393","doi":"10.1158/1538-8514.cancerchem24-ia023","title":"Abstract IA023: Dual-drug ADC platform for effective and safe cancer treatment","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Antibody-drug conjugate; Tolerability; Drug; Cancer; Pharmacology; Cancer research; Drug resistance; Internal medicine; Antibody; Immunology; Biology; Adverse effect; Monoclonal antibody","score_opus":0.05581262807661499,"score_gpt":0.4060311569159849,"score_spread":0.35021852883936994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405182393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7961105,0.18154296,0.0011045547,0.011572611,0.0012563753,0.0049927104,0.0006077225,0.00025503602,0.0025575403],"genre_scores_gemma":[0.9783249,0.013543864,0.00040499822,0.0018439587,0.00051904155,0.0029708592,0.000038519538,0.00015509753,0.0021987455],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99819744,0.000027353171,0.00025392984,0.00056232844,0.00041471966,0.0005442151],"domain_scores_gemma":[0.99906844,0.00019630657,0.000042065618,0.00034307383,0.00014097292,0.00020912898],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021347452,0.00033054128,0.00040393567,0.00014481964,0.0001056158,0.00009841808,0.00008305277,0.0001429308,0.00023589117],"category_scores_gemma":[0.000010633833,0.00025783354,0.00019843671,0.00025072528,0.00013345719,0.00006978819,0.000035625835,0.00029340343,0.000020585267],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007756874,0.00014886042,0.0012165796,0.0012959033,0.0020877083,0.00034561838,0.0020800945,0.000089639725,0.0990864,0.0006211677,0.0012794764,0.89097285],"study_design_scores_gemma":[0.0037425747,0.0010528433,0.0059613627,0.001124566,0.0010213074,0.000052639076,0.00018827569,0.0034539937,0.24768175,0.0008332671,0.73437893,0.00050845457],"about_ca_topic_score_codex":0.0010855129,"about_ca_topic_score_gemma":0.00039451726,"teacher_disagreement_score":0.8904644,"about_ca_system_score_codex":0.0012385576,"about_ca_system_score_gemma":0.00069278764,"threshold_uncertainty_score":0.99998736},"labels":[],"label_agreement":null},{"id":"W4405182420","doi":"10.1158/1538-8514.cancerchem24-ia008","title":"Abstract IA008: Leveraging conformational dynamics for improved selectivity","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Mutant; Selectivity; Oncogene; Fibroblast growth factor receptor; Cancer research; Gene; Kinase; Small molecule; Computational biology; Chemistry; Biology; Biochemistry; Receptor; Fibroblast growth factor; Cell cycle","score_opus":0.02282076174909704,"score_gpt":0.31750582159659335,"score_spread":0.2946850598474963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405182420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6956634,0.0062320023,0.29236308,0.0022223024,0.0006809111,0.0010068667,0.0005862072,0.00011719344,0.0011280677],"genre_scores_gemma":[0.9974841,0.00013750976,0.0007443054,0.0005967072,0.00017753568,0.0001440033,0.00034492122,0.0000677951,0.00030312935],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988696,0.000025252999,0.0001876606,0.00035976773,0.00017536838,0.00038238056],"domain_scores_gemma":[0.99945927,0.000029410237,0.00003844852,0.00024690578,0.00015658993,0.00006936746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019289776,0.00019554512,0.00012628574,0.00007155296,0.00009318859,0.00013032832,0.00020455456,0.00015742015,0.000030420733],"category_scores_gemma":[0.000015399331,0.00019495716,0.00015717077,0.00013842012,0.00006605635,0.000011645477,0.00006423569,0.00019105387,0.000007041421],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010303512,0.00002521226,0.00013898712,0.00016138695,0.00033140168,0.0000025540762,0.00005541461,0.00028996493,0.968684,0.00077784347,0.00034987,0.029080333],"study_design_scores_gemma":[0.00070859544,0.00023072338,0.0010611538,0.000065042776,0.00006063595,0.000014678013,0.00003600191,0.08169921,0.79086137,0.0009410596,0.12383643,0.00048513568],"about_ca_topic_score_codex":0.000029511086,"about_ca_topic_score_gemma":0.000057622692,"teacher_disagreement_score":0.30182073,"about_ca_system_score_codex":0.00014022736,"about_ca_system_score_gemma":0.00037494063,"threshold_uncertainty_score":0.79501224},"labels":[],"label_agreement":null},{"id":"W4405182464","doi":"10.1158/1538-8514.cancerchem24-pr005","title":"Abstract PR005: Helping academic investigators develop small molecules for the clinic: The NCI Developmental Therapeutics Program and Stepping-Stones","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug development; Drug discovery; Computer science; Medicine; Business; Pharmacology; Bioinformatics; Drug; Biology","score_opus":0.1834990704941047,"score_gpt":0.43125011165171767,"score_spread":0.24775104115761298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405182464","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39545873,0.4584692,0.007660293,0.12931943,0.0015154897,0.005743951,0.00007859185,0.0005200394,0.0012342649],"genre_scores_gemma":[0.88396466,0.062000874,0.007108559,0.044493474,0.00049326505,0.0013736464,0.000022024513,0.00017125347,0.0003722646],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99808466,0.000084796484,0.00047333693,0.00045157035,0.00035894706,0.00054670323],"domain_scores_gemma":[0.9984087,0.00094770914,0.00012727219,0.00022384628,0.00015233587,0.0001401347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007532564,0.00036611065,0.00031169908,0.00005260404,0.00049930916,0.0001904161,0.0002947211,0.00019490118,0.00003453099],"category_scores_gemma":[0.00007507695,0.00020474422,0.00014672776,0.00035088952,0.00047286056,0.00008552005,0.00014624615,0.00091582036,0.000011378171],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036515328,0.0000938505,0.002192968,0.0006542118,0.00392892,0.00005330943,0.0035767977,0.000020286576,0.035916302,0.00074238505,0.00039750178,0.9520583],"study_design_scores_gemma":[0.0008067115,0.00018096436,0.0064988937,0.00039789948,0.0016573373,0.00009191687,0.0013619694,0.0060205623,0.014818356,0.00065420946,0.9671176,0.00039359962],"about_ca_topic_score_codex":0.000039478684,"about_ca_topic_score_gemma":0.000034692894,"teacher_disagreement_score":0.9667201,"about_ca_system_score_codex":0.00013833542,"about_ca_system_score_gemma":0.0005340027,"threshold_uncertainty_score":0.8349227},"labels":[],"label_agreement":null},{"id":"W4405318800","doi":"10.1158/1535-7163.mct-23-0872","title":"CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Institute for Health and Care Research; Royal College of Surgeons of England; Wellcome Trust","keywords":"Fibrosis; Cancer research; Biology; Stromal cell; CD8; Immune system; Downregulation and upregulation; Flow cytometry; Pathology; Immunology; Medicine; Gene","score_opus":0.03499067173412827,"score_gpt":0.33885979000763966,"score_spread":0.3038691182735114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405318800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72681665,0.2661028,0.00003471643,0.0057349843,0.00054482854,0.00053615274,0.000025349873,0.00009610209,0.00010844949],"genre_scores_gemma":[0.95426655,0.04140191,0.00022014246,0.0032937827,0.00021067272,0.00038968524,0.000057395173,0.000080836646,0.00007903511],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99845237,0.000068762085,0.0003400639,0.00046464172,0.00031463735,0.0003595531],"domain_scores_gemma":[0.9993695,0.000039781757,0.000055983535,0.00037098778,0.000058449208,0.00010530436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116111456,0.00026930345,0.00036564135,0.00021585623,0.000060524915,0.00007020996,0.00009676288,0.00013291286,0.00018908219],"category_scores_gemma":[0.0000027710416,0.00023443202,0.00017441751,0.00048882957,0.000038846283,0.000071685936,0.000017394092,0.00022358773,0.000024963296],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005844333,0.0003886466,0.004660947,0.000092930306,0.0010400371,0.00021916155,0.0016069795,0.00010607086,0.5328079,0.00013139307,0.00017727782,0.4581842],"study_design_scores_gemma":[0.0028749467,0.0011004143,0.03460937,0.00033762062,0.00019807735,0.00001733376,0.00006950397,0.00066457555,0.8806535,0.00017077872,0.07895336,0.0003505444],"about_ca_topic_score_codex":0.00087406544,"about_ca_topic_score_gemma":0.000052593816,"teacher_disagreement_score":0.45783368,"about_ca_system_score_codex":0.0006713479,"about_ca_system_score_gemma":0.000491676,"threshold_uncertainty_score":0.955986},"labels":[],"label_agreement":null},{"id":"W4408296465","doi":"10.1158/1535-7163.mct-24-0906","title":"Specific Genetic Mutations Impact Chemotherapy Resistance and Therapeutic Efficacy of Oncolytic Viruses in Ovarian Cancer","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Guelph; University of Saskatchewan; Ottawa Hospital; University of Ottawa","funders":"Canadian Institutes of Health Research; Ovarian Cancer Canada","keywords":"Carboplatin; Oncolytic virus; Ovarian cancer; Cancer research; KRAS; PTEN; Tumor microenvironment; Biology; Medicine; Immunotherapy; Cancer; Immunology; Chemotherapy; Immune system; Internal medicine; PI3K/AKT/mTOR pathway; Colorectal cancer; Cisplatin; Apoptosis","score_opus":0.027853922752414526,"score_gpt":0.3608405036014598,"score_spread":0.33298658084904526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408296465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.918318,0.0781967,0.0016096635,0.0007498326,0.00010644666,0.00066124403,0.000056319386,0.000013529489,0.0002882825],"genre_scores_gemma":[0.9858708,0.011170453,0.00036241082,0.0019732348,0.000065034954,0.0001733445,0.000013953141,0.000070488975,0.0003003077],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980259,0.00021756854,0.000439103,0.00057323184,0.00027381262,0.00047036848],"domain_scores_gemma":[0.99889857,0.00005308205,0.00013729498,0.00067065156,0.00015766882,0.00008271464],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021985684,0.0003336435,0.00036736453,0.00024709437,0.00008565775,0.000043281078,0.00038227625,0.00020672742,0.00008171742],"category_scores_gemma":[0.000010847741,0.0003247587,0.00016203082,0.00067693583,0.00030081533,0.000005415063,0.00006696093,0.00021447582,0.0000015179972],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027404055,0.00019439153,0.010717359,0.00005392906,0.0005685277,0.000007837917,0.00022150885,0.002156926,0.948524,0.00009377543,0.00005550319,0.03466583],"study_design_scores_gemma":[0.004354559,0.0006365951,0.062233333,0.00014949433,0.00009492762,0.0000022236113,0.000052388095,0.0002137658,0.9213706,0.00085632893,0.009616484,0.00041925142],"about_ca_topic_score_codex":0.00018812878,"about_ca_topic_score_gemma":0.0009490616,"teacher_disagreement_score":0.06755279,"about_ca_system_score_codex":0.00016977235,"about_ca_system_score_gemma":0.0006392656,"threshold_uncertainty_score":0.9999204},"labels":[],"label_agreement":null},{"id":"W4408296594","doi":"10.1158/1535-7163.mct-24-0656","title":"5′- <i>S</i> -(3-Aminophenyl)-5′-thioadenosine, a Novel Chemoprotective Agent for Reducing Toxic Side Effects of Fluorouracil in Treatment of MTAP-Deficient Cancers","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Biochemical and Molecular Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; BC Cancer Agency; Ontario Institute for Cancer Research; Vancouver Coastal Health Research Institute; University of British Columbia","funders":"National Cancer Institute; Canadian Institutes of Health Research; Terry Fox Research Institute; Lotte and John Hecht Memorial Foundation; U.S. Department of Defense","keywords":"Toxicity; Pharmacology; Cytotoxicity; Chemistry; Cancer cell; Cancer research; Cancer; Biochemistry; Medicine; In vitro; Internal medicine","score_opus":0.019357844538171295,"score_gpt":0.3081458575001949,"score_spread":0.2887880129620236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408296594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94534206,0.026074776,0.02585733,0.00034506695,0.00018543226,0.0016353177,0.00007683647,0.0000089621135,0.0004742282],"genre_scores_gemma":[0.9960364,0.0011961043,0.0012575921,0.0004923942,0.000035016597,0.00066977844,0.000039070692,0.00003643755,0.00023718827],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99841064,0.00005832079,0.00038468052,0.00051494536,0.00022610933,0.000405277],"domain_scores_gemma":[0.9990882,0.000039531915,0.00014598624,0.0004616671,0.00021123848,0.000053377713],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000111705915,0.00027321352,0.00039727727,0.00012520807,0.000040949453,0.000010319613,0.00024440378,0.00022768822,0.0000020651237],"category_scores_gemma":[0.000048086717,0.00025598714,0.00026031077,0.0003537415,0.00015710705,0.0000028971835,0.00008721517,0.00009844494,2.3820786e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044628652,0.0004979519,0.00010546161,0.00046688566,0.00040839793,0.0000044736257,0.00017159563,0.000885221,0.9783906,0.00010818303,0.000023136621,0.018491816],"study_design_scores_gemma":[0.0027455457,0.0008114994,0.00030381244,0.00023645851,0.0001300415,0.0000015561614,0.000064776104,0.00031809424,0.9906528,0.00010005448,0.0044201426,0.00021523435],"about_ca_topic_score_codex":0.00059539196,"about_ca_topic_score_gemma":0.000075374206,"teacher_disagreement_score":0.05069437,"about_ca_system_score_codex":0.0003100938,"about_ca_system_score_gemma":0.00047125365,"threshold_uncertainty_score":0.9999892},"labels":[],"label_agreement":null},{"id":"W4409890102","doi":"10.1158/1535-7163.mct-24-0998","title":"A Novel Squaramide Derivative, HR-19011, Induces the Integrated Stress Response via the HRI–eIF2α–ATF4 Pathway, Effectively Inhibiting Hematologic Malignancies","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Endoplasmic Reticulum Stress and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada)","funders":"Ministry of Science and ICT, South Korea; Korea Drug Development Fund; National Research Foundation","keywords":"Integrated stress response; ATF4; mTORC1; Cancer research; eIF2; Biology; Cell cycle; Cell growth; P70-S6 Kinase 1; Phosphorylation; Signal transduction; Unfolded protein response; Cell biology; Apoptosis; Translation (biology); PI3K/AKT/mTOR pathway; Endoplasmic reticulum; Biochemistry; Gene; Messenger RNA","score_opus":0.015758981806903605,"score_gpt":0.2766060427206724,"score_spread":0.2608470609137688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409890102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9651429,0.009563547,0.021379407,0.0025239051,0.00022846925,0.0006806889,0.0001444475,0.000042290707,0.00029433984],"genre_scores_gemma":[0.99348396,0.00030095325,0.00016906226,0.0053092614,0.000051119307,0.00040145614,0.00005018732,0.000041935262,0.00019207517],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99777776,0.00053861574,0.00036837196,0.00055591273,0.00027084726,0.00048846926],"domain_scores_gemma":[0.99859303,0.00021044728,0.00021333138,0.0006583851,0.00025523728,0.00006958996],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003956375,0.000413277,0.0002919924,0.000067484594,0.00041159723,0.00012890193,0.00060460763,0.00022731301,0.000011048027],"category_scores_gemma":[0.00019944235,0.00024977056,0.00022832103,0.0004345491,0.00045967894,0.000008802021,0.00026612415,0.0003282522,0.0000029274183],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000694719,0.00014888361,0.0010546134,0.000056777073,0.00037884925,0.000023069844,0.00027919514,0.0005630082,0.9930261,0.00080284494,0.000115957286,0.0028559898],"study_design_scores_gemma":[0.00095593976,0.00015792523,0.0030012357,0.00020657195,0.00014194185,0.000018195058,0.0010154609,0.00042957335,0.9873159,0.0003213567,0.0060954215,0.00034047995],"about_ca_topic_score_codex":0.00019976209,"about_ca_topic_score_gemma":0.00010750789,"teacher_disagreement_score":0.028341044,"about_ca_system_score_codex":0.00007317381,"about_ca_system_score_gemma":0.00041902825,"threshold_uncertainty_score":0.99999547},"labels":[],"label_agreement":null},{"id":"W4412110327","doi":"10.1158/1535-7163.mct-24-0995","title":"KRAS Codon-Specific Mutations Differentially Toggle PI3K Pathway Signaling and Alter Sensitivity to Inavolisib (GDC-0077)","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"Broad Institute","keywords":"KRAS; MAPK/ERK pathway; PI3K/AKT/mTOR pathway; Colorectal cancer; Cancer research; In vivo; Biology; Signal transduction; Mutation; Cancer; Genetics; Gene","score_opus":0.025798403816910124,"score_gpt":0.30644119302712286,"score_spread":0.28064278921021274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412110327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9629363,0.0099339085,0.019765334,0.004651152,0.00035506565,0.0006913531,0.000060505943,0.00006699396,0.0015393848],"genre_scores_gemma":[0.9929516,0.0008981898,0.00075376814,0.004602327,0.00007735701,0.00011867597,0.000019364306,0.000028446646,0.00055029686],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998861,0.000058022546,0.00020981253,0.0003710373,0.00021634648,0.0002837729],"domain_scores_gemma":[0.99937785,0.00006826551,0.00004424248,0.00024206845,0.00017054676,0.00009704898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008355861,0.00023348095,0.00035934412,0.000119161545,0.00018929386,0.000054988795,0.000045809917,0.00007161677,0.000042123913],"category_scores_gemma":[0.00000653116,0.00020074897,0.00009819804,0.00028453936,0.00008437959,0.000030298135,0.00006487985,0.00014616203,0.0000048495062],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080342346,0.00037356728,0.009534292,0.0001380903,0.0017404323,0.00027834278,0.0030606533,0.00018432978,0.774468,0.0029105286,0.00029172128,0.20621659],"study_design_scores_gemma":[0.006723349,0.0013718681,0.09629692,0.00081585115,0.0016815835,0.000039558436,0.0010606557,0.00082384655,0.746536,0.0025490501,0.14109129,0.0010099994],"about_ca_topic_score_codex":0.00014132669,"about_ca_topic_score_gemma":0.00029492856,"teacher_disagreement_score":0.20520659,"about_ca_system_score_codex":0.00020197818,"about_ca_system_score_gemma":0.0001493888,"threshold_uncertainty_score":0.8186305},"labels":[],"label_agreement":null},{"id":"W4412956201","doi":"10.1158/1535-7163.mct-24-1176","title":"Preclinical Pharmacokinetic, Pharmacodynamic, and Safety Profile of OBI-992: A Novel TROP2-Targeted Antibody–Drug Conjugate","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"FSD Pharma (Canada)","funders":"National Applied Research Laboratories","keywords":"Pharmacology; Medicine; Pharmacokinetics; In vivo; Toxicity; Pharmacodynamics; Drug; Antibody; Cancer research; Cell culture; Immunology; Internal medicine; Biology","score_opus":0.03920731020912873,"score_gpt":0.42594948924018755,"score_spread":0.38674217903105884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412956201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90547234,0.041219514,0.01803895,0.016969817,0.0009716292,0.0042980798,0.0007683085,0.00019834447,0.012062996],"genre_scores_gemma":[0.98102367,0.0076046996,0.0023087966,0.0075839325,0.000110941255,0.00016058396,0.000093649374,0.00007058016,0.0010431454],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99727166,0.00022564329,0.00068793254,0.00058027153,0.00069182436,0.00054266234],"domain_scores_gemma":[0.99863464,0.00016021887,0.00015610372,0.00051695155,0.00035317164,0.0001789168],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059166056,0.00032862322,0.0006503995,0.00022691854,0.00007875745,0.00003000837,0.0003283532,0.00014958241,0.0004046004],"category_scores_gemma":[0.00003921828,0.00030260716,0.00019470428,0.0005987763,0.0003657597,0.00004986006,0.00012489097,0.0006576249,0.0000070024284],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018350561,0.00053440465,0.0056396895,0.0009433854,0.00095726684,0.000072354305,0.00035513443,0.000044616663,0.951355,0.00048318197,0.00047633008,0.037303593],"study_design_scores_gemma":[0.017473415,0.00063225144,0.015114496,0.0010062307,0.0019327648,0.00005045443,0.00016329886,0.022525577,0.8083454,0.00030007196,0.13182706,0.000628984],"about_ca_topic_score_codex":0.00013995192,"about_ca_topic_score_gemma":0.000010422094,"teacher_disagreement_score":0.14300959,"about_ca_system_score_codex":0.00016589763,"about_ca_system_score_gemma":0.00075204764,"threshold_uncertainty_score":0.9999426},"labels":[],"label_agreement":null},{"id":"W4413956624","doi":"10.1158/1535-7163.mct-24-0861","title":"CRISPR Screen Identifies HDAC3 as a Novel Radiosensitizing Target in Small Cell Lung Cancer","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Terry Fox Research Institute; Canada Foundation for Innovation; Deutsche Forschungsgemeinschaft; Clinical and Translational Science Center, Weill Cornell Medical College; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Radioresistance; Cancer research; Clonogenic assay; DNA repair; Olaparib; HDAC3; Gene knockdown; DNA damage; Radiosensitivity; Synthetic lethality; Biology; Radiosensitizer; Cell; Chemistry; Cell culture; Poly ADP ribose polymerase; Radiation therapy; Medicine; Histone; Genetics; DNA; Histone deacetylase; Internal medicine","score_opus":0.02859787776326449,"score_gpt":0.36494875402170607,"score_spread":0.33635087625844157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413956624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77558506,0.17957541,0.012144604,0.01716427,0.00095654506,0.0023079505,0.00010678789,0.00019127001,0.011968109],"genre_scores_gemma":[0.9735224,0.0070616654,0.0014339858,0.012355104,0.00016836342,0.00042888816,0.000018160155,0.000090059984,0.0049213227],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99772453,0.00008830943,0.0004044494,0.00058779813,0.0004586523,0.00073624327],"domain_scores_gemma":[0.99886477,0.000077674726,0.0000930847,0.00054112985,0.0003000538,0.00012327307],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028797885,0.00034933077,0.0005767051,0.00038971004,0.00013976492,0.00007548201,0.00025973772,0.00015475567,0.00008759341],"category_scores_gemma":[0.000040887793,0.00033402513,0.00018470443,0.0008454734,0.00016829,0.000069473404,0.00020288579,0.000573719,0.0000072567173],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078501506,0.00037782794,0.06747078,0.0015981941,0.0021666072,0.0006704618,0.002727058,0.001180516,0.9129815,0.000756947,0.0026667234,0.006618366],"study_design_scores_gemma":[0.009421165,0.0002012253,0.026148034,0.0025637003,0.0013886875,0.000022684331,0.0012270432,0.007682278,0.9040809,0.0008709808,0.045467436,0.0009258211],"about_ca_topic_score_codex":0.0057964376,"about_ca_topic_score_gemma":0.0014033274,"teacher_disagreement_score":0.1979374,"about_ca_system_score_codex":0.0010060619,"about_ca_system_score_gemma":0.001038148,"threshold_uncertainty_score":0.9999112},"labels":[],"label_agreement":null},{"id":"W4414011186","doi":"10.1158/1535-7163.mct-25-0428","title":"Advancing Preclinical Biology for Ewing Sarcoma: An International Effort","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"National Institutes of Health; Alan B. Slifka Foundation; National Cancer Institute; Sarcoma UK","keywords":"Sarcoma; Biology; Preclinical testing; Ewing's sarcoma; Preclinical research; Cancer research; Medicine; Computational biology; Virology; Bioinformatics; Pathology","score_opus":0.022380694008475602,"score_gpt":0.3632700260581574,"score_spread":0.3408893320496818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414011186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77199274,0.0049522934,0.21694796,0.0014262524,0.0024232809,0.00051860756,0.0001731914,0.00003077968,0.0015348814],"genre_scores_gemma":[0.98199314,0.0014267846,0.007433745,0.007836991,0.00061151024,0.00016889427,0.0002851308,0.000038967115,0.00020486282],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99891406,0.00002874747,0.00025857068,0.00043934412,0.0000657617,0.00029351766],"domain_scores_gemma":[0.9992622,0.000034634675,0.000073410876,0.00039205173,0.00018297209,0.000054695425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001854722,0.0001644235,0.00016084699,0.00005675935,0.000086941836,0.000038240898,0.00035803934,0.00018063874,0.000012360185],"category_scores_gemma":[0.000060291142,0.00017501571,0.00013392267,0.000077604,0.00008931523,0.0000046897753,0.00012468643,0.000079661,0.0000011958643],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042052031,0.0001518509,0.01629085,0.000025851146,0.00053746585,0.0000019514332,0.000041855452,0.0004918424,0.9071381,0.004794651,0.0006570644,0.06944797],"study_design_scores_gemma":[0.0013477086,0.00043453157,0.0011635437,0.00002568082,0.00010977463,0.0000020249408,0.000025994255,0.0018955152,0.39062196,0.0029350165,0.6011718,0.00026644015],"about_ca_topic_score_codex":0.00002452944,"about_ca_topic_score_gemma":0.000093140974,"teacher_disagreement_score":0.60051477,"about_ca_system_score_codex":0.000059740632,"about_ca_system_score_gemma":0.00024002316,"threshold_uncertainty_score":0.7136933},"labels":[],"label_agreement":null},{"id":"W4415444204","doi":"10.1158/1535-7163.targ-25-c122","title":"Abstract C122: Effects of standard-of-care therapies on tumor growth, tumor-induced bone loss and bone pain in preclinical models of breast and prostate cancer bone metastasis and multiple myeloma bone disease","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Prostate cancer; Breast cancer; Multiple myeloma; Bone metastasis; Bone marrow; Bone pain; Bortezomib; Bone disease; Zoledronic acid","score_opus":0.02186134890478176,"score_gpt":0.32442425017968674,"score_spread":0.302562901274905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8966033,0.100109525,0.0000466977,0.0012252951,0.000055278524,0.0014348057,0.0004955314,0.00001746377,0.000012133101],"genre_scores_gemma":[0.99201787,0.0065531963,0.00033831265,0.0008286248,0.000010438748,0.00017341567,0.000019379715,0.00004848588,0.00001025357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978372,0.00019719407,0.0007216472,0.00048932503,0.00038941912,0.0003652007],"domain_scores_gemma":[0.9985528,0.00029160434,0.00033173244,0.0003421368,0.00024189927,0.00023984649],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036585468,0.00035347132,0.001109307,0.00023244596,0.000056492736,0.000012884227,0.000050661798,0.000099196885,0.000004003608],"category_scores_gemma":[0.00006845597,0.0002961089,0.00011247341,0.0002809426,0.00028438956,0.000071055576,0.000055747372,0.00025506422,7.175161e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038461093,0.0019765017,0.45879352,0.02061674,0.0021944488,0.0011736552,0.0038594918,0.000104585364,0.09649193,0.00040703503,0.000010852673,0.37591013],"study_design_scores_gemma":[0.032572184,0.003668288,0.77379674,0.008312792,0.002303028,0.000044494092,0.00055122195,0.0016885517,0.1741578,0.0021273901,0.00012785927,0.0006496465],"about_ca_topic_score_codex":0.000959012,"about_ca_topic_score_gemma":0.00027720083,"teacher_disagreement_score":0.3752605,"about_ca_system_score_codex":0.0001178586,"about_ca_system_score_gemma":0.00045684678,"threshold_uncertainty_score":0.9999491},"labels":[],"label_agreement":null},{"id":"W4415444241","doi":"10.1158/1535-7163.targ-25-c073","title":"Abstract C073: Heritable resistance and phenotypic stochasticity are likely drivers of irreproducibility in experimental determination of <i>in vitro</i> potency of anticancer agents","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Phenotype; Potency; In vitro; Cell; Offspring; Cell culture; Variation (astronomy); Resistance (ecology)","score_opus":0.018460214615827534,"score_gpt":0.29679045021619954,"score_spread":0.278330235600372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98893666,0.0068779355,0.003169815,0.0001706525,0.00009778576,0.00043397458,0.000029533068,0.000006355466,0.0002772704],"genre_scores_gemma":[0.99800104,0.00026618637,0.0014956391,0.00012418433,0.000004916502,0.000020503678,0.000004444294,0.000012832969,0.0000702816],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998763,0.00002955756,0.00044972493,0.00033399503,0.00025238103,0.00017128943],"domain_scores_gemma":[0.9993159,0.000019273493,0.00019845815,0.0003251138,0.0001126889,0.000028529608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002170536,0.00013793811,0.00044920022,0.00013275161,0.000015388265,0.0000024444676,0.000086698565,0.000086120934,0.000013577713],"category_scores_gemma":[0.0000112643065,0.0001364695,0.000069311434,0.00031833723,0.00016181149,0.000043680615,0.000017200127,0.000120107616,5.6771874e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001173202,0.00046644462,0.027927414,0.00086161745,0.000050540733,0.000015609845,0.00072113273,0.000072643525,0.96522504,0.00012298698,7.046248e-7,0.0033626663],"study_design_scores_gemma":[0.0015129119,0.000041630596,0.1925756,0.00065308536,0.00007313442,1.9933161e-7,0.0003858333,0.00018936966,0.80413073,0.00032890297,0.00002633033,0.000082237435],"about_ca_topic_score_codex":0.00019652474,"about_ca_topic_score_gemma":0.00028494373,"teacher_disagreement_score":0.16464819,"about_ca_system_score_codex":0.000121814315,"about_ca_system_score_gemma":0.00013837565,"threshold_uncertainty_score":0.5565065},"labels":[],"label_agreement":null},{"id":"W4415444243","doi":"10.1158/1535-7163.targ-25-c072","title":"Abstract C072: Comparing and combining existing radiological criteria for hyperprogressive disease in patients receiving immune-oncology therapy: Building towards a sensitive and conservative method to assess the presence of hyperprogressive disease","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Queen's University; Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre","funders":"","keywords":"Radiological weapon; Disease; Incidence (geometry); Cancer; Lung cancer; Colorectal cancer","score_opus":0.08760377124632727,"score_gpt":0.41821971517671414,"score_spread":0.33061594393038685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97320765,0.016546166,0.005717284,0.0023017253,0.00017290456,0.0019089967,0.000055342898,0.000021760461,0.00006814419],"genre_scores_gemma":[0.9897471,0.00082774414,0.0066242195,0.0023492987,0.000024989155,0.00037824333,0.00001505672,0.000026282909,0.000007037976],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981421,0.00038263758,0.00047334784,0.0004660205,0.00019784164,0.00033804093],"domain_scores_gemma":[0.99825335,0.0007947812,0.00026106043,0.00025151123,0.0003088732,0.00013041116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006919931,0.00027175507,0.00062831753,0.0001250127,0.00017376512,0.000052067608,0.00014667037,0.00009777168,0.0000031258837],"category_scores_gemma":[0.00024320316,0.00019811392,0.00011437804,0.00031049785,0.00036703356,0.00006436008,0.00012667921,0.00022657978,3.730758e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029609168,0.00044397137,0.33658114,0.00053578033,0.0012900103,0.00010312117,0.0047742287,0.0001538642,0.19834058,0.0003544815,0.000015216489,0.42779842],"study_design_scores_gemma":[0.006493025,0.00055499293,0.9627966,0.0022158986,0.000346604,0.0000045014276,0.00096637884,0.0059011886,0.019073538,0.00036553762,0.0009739789,0.00030774888],"about_ca_topic_score_codex":0.00013819791,"about_ca_topic_score_gemma":0.000009308193,"teacher_disagreement_score":0.62621546,"about_ca_system_score_codex":0.0001766194,"about_ca_system_score_gemma":0.00037384377,"threshold_uncertainty_score":0.80788517},"labels":[],"label_agreement":null},{"id":"W4415444339","doi":"10.1158/1535-7163.targ-25-a055","title":"Abstract A055: Treatment and tumor heterogeneity – Effects of competition, variable response to treatment, and finite resources","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Competition (biology); Population; Genotype; Phenotype; Tumor progression; Genetic heterogeneity; Immune system","score_opus":0.015398708554844598,"score_gpt":0.29802094633967297,"score_spread":0.28262223778482837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97889197,0.017163606,0.00035221732,0.0022639139,0.00009444713,0.00085594394,0.00007828273,0.000026866013,0.00027276084],"genre_scores_gemma":[0.9941713,0.0025266653,0.0006924302,0.0020358288,0.000023952676,0.0003026709,0.000009184564,0.000023633173,0.00021431706],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990403,0.000084038766,0.00021416064,0.0003557749,0.000098580684,0.00020716473],"domain_scores_gemma":[0.99915016,0.00025843273,0.00006932057,0.0003320126,0.00006523445,0.00012485849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007949691,0.00024432532,0.00042206145,0.000130634,0.00007787919,0.000028661736,0.000039106966,0.000060690385,0.000020000298],"category_scores_gemma":[0.000014174239,0.00019159957,0.00007734502,0.00019738225,0.00007435454,0.000021039523,0.00002573037,0.000043629236,0.0000015121806],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010844066,0.0038503339,0.14382735,0.0013009369,0.008296473,0.0005260204,0.0030108418,0.00052957644,0.6900039,0.001808963,0.00006728315,0.13593428],"study_design_scores_gemma":[0.0104105845,0.004337683,0.2657197,0.0009415097,0.002114061,0.000017397659,0.00006771319,0.00008266817,0.6117785,0.0002437338,0.10399776,0.00028867577],"about_ca_topic_score_codex":0.000469403,"about_ca_topic_score_gemma":0.000059761554,"teacher_disagreement_score":0.1356456,"about_ca_system_score_codex":0.0003237681,"about_ca_system_score_gemma":0.0001710659,"threshold_uncertainty_score":0.7813204},"labels":[],"label_agreement":null},{"id":"W4415444344","doi":"10.1158/1535-7163.targ-25-a038","title":"Abstract A038: Lomitapide enhances cytotoxic effects of temozolomide in chemo-resistant glioblastoma","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"Temozolomide; Glioma; Cytotoxic T cell; Drug; Cytotoxicity; Mevalonate pathway; Cancer; Glioblastoma; Prodrug","score_opus":0.0066340411992944544,"score_gpt":0.26711669047576625,"score_spread":0.2604826492764718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9417097,0.054555267,0.0010497726,0.0002009426,0.0011106543,0.00045229736,0.000023359817,0.000017801756,0.0008801951],"genre_scores_gemma":[0.991747,0.005867488,0.0002297582,0.001347121,0.00024433338,0.00013999606,0.0000127910835,0.000041737596,0.00036974717],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983421,0.0000769976,0.00044421465,0.0004941254,0.00021546433,0.00042709135],"domain_scores_gemma":[0.99905807,0.000038091395,0.00017511121,0.0005587017,0.00010396189,0.000066089655],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017615192,0.00030809006,0.00043000985,0.00016021529,0.000046395435,0.000022049397,0.00036234604,0.00025575372,0.000015494887],"category_scores_gemma":[0.000043497676,0.00031056194,0.00021709225,0.0003548937,0.00015647872,0.0000065254826,0.00010000683,0.00018392474,0.0000028031518],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052236015,0.0001301153,0.0003094451,0.00027720127,0.00026339586,0.000008136468,0.00006954339,0.0001426918,0.9816693,0.00014083784,0.0002730004,0.01619399],"study_design_scores_gemma":[0.0014715008,0.00015104734,0.005802795,0.00018583289,0.00009957752,0.0000014475576,0.000037311656,0.000020727504,0.93383616,0.00025186743,0.057866663,0.00027507337],"about_ca_topic_score_codex":0.00017304267,"about_ca_topic_score_gemma":0.000582322,"teacher_disagreement_score":0.057593662,"about_ca_system_score_codex":0.00007245127,"about_ca_system_score_gemma":0.00034256687,"threshold_uncertainty_score":0.9999347},"labels":[],"label_agreement":null},{"id":"W4415444393","doi":"10.1158/1535-7163.targ-25-b142","title":"Abstract B142: EO3001: A novel agent for ARID1A mutant cancers","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"ARID1A; Oxidative stress; Cancer; Cell culture; Ex vivo; Chromatin remodeling; Mitochondrion; In vivo; Cell; Cell growth","score_opus":0.02569021721449196,"score_gpt":0.3146437236870415,"score_spread":0.2889535064725496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6356864,0.025242986,0.33165008,0.0017269922,0.001539686,0.0010310498,0.00032174392,0.0000745561,0.002726522],"genre_scores_gemma":[0.98736423,0.0017415803,0.0016233544,0.0077702412,0.00020196979,0.00034353073,0.000085161,0.000058513288,0.00081143517],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998632,0.000015425603,0.00029259865,0.0004929807,0.00016772361,0.0003992355],"domain_scores_gemma":[0.99916726,0.000012758875,0.00010707916,0.0004923806,0.00016262686,0.000057887646],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001331291,0.00026437946,0.00021789325,0.000055319404,0.00012368243,0.000046016736,0.00029069546,0.00020002702,0.000022496768],"category_scores_gemma":[0.0000142298595,0.0002626834,0.00023357678,0.00014736499,0.00007625778,0.000002929832,0.00006274635,0.000121403384,0.0000021185785],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001791133,0.00006388325,0.000093648196,0.000108267595,0.00047036476,0.0000023060911,0.000051163126,0.008625718,0.9664207,0.00026415806,0.0009288775,0.022791762],"study_design_scores_gemma":[0.0016559412,0.00010187615,0.000216218,0.00011362639,0.0001695036,0.0000032917435,0.00006769101,0.0041299355,0.6865189,0.00031960188,0.30632603,0.000377353],"about_ca_topic_score_codex":0.00021311555,"about_ca_topic_score_gemma":0.00018255475,"teacher_disagreement_score":0.35167783,"about_ca_system_score_codex":0.00019357953,"about_ca_system_score_gemma":0.0006636697,"threshold_uncertainty_score":0.99998254},"labels":[],"label_agreement":null},{"id":"W4415444529","doi":"10.1158/1535-7163.targ-25-c108","title":"Abstract C108: The therapeutic candidate antibody PODO447 recognizes a glycopeptide on podocalyxin-expressing tumor cells that have undergone a partial epithelial-mesenchymal transition","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Epitope; Monoclonal antibody; Antibody; Transmembrane protein; Phenotype; Glycopeptide; Cell sorting; MUC1; Cell","score_opus":0.037539001050955666,"score_gpt":0.34695113606352124,"score_spread":0.3094121350125656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.957431,0.006353653,0.005437515,0.02424123,0.00061463885,0.0012667273,0.0002378853,0.000112523274,0.004304804],"genre_scores_gemma":[0.976922,0.0019582484,0.00018978638,0.018673996,0.00026629967,0.00009931532,0.000094020405,0.00007303975,0.0017232978],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970021,0.00026170994,0.00046316595,0.0006222328,0.000837238,0.0008135022],"domain_scores_gemma":[0.99864346,0.00023117845,0.000152694,0.00062283716,0.0001712582,0.00017855938],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038047635,0.0004827405,0.0005536168,0.00020170619,0.00044529026,0.00015198886,0.00035384358,0.00017053809,0.00031550098],"category_scores_gemma":[0.00001191149,0.00032516257,0.00038893943,0.00036101567,0.000384576,0.000087933724,0.00007014941,0.0008136571,0.00005527021],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034575958,0.0003727021,0.00067617703,0.0002216109,0.0011239556,0.00039381048,0.0006772243,0.0004880923,0.95099545,0.00043036067,0.00021646348,0.04094656],"study_design_scores_gemma":[0.0026609665,0.0004208641,0.008008552,0.0009232098,0.00062019523,0.000043023287,0.00044429227,0.004315232,0.93321,0.00088120945,0.047988065,0.00048436018],"about_ca_topic_score_codex":0.0010774938,"about_ca_topic_score_gemma":0.00009968212,"teacher_disagreement_score":0.0477716,"about_ca_system_score_codex":0.00019901965,"about_ca_system_score_gemma":0.0005387425,"threshold_uncertainty_score":0.99992007},"labels":[],"label_agreement":null},{"id":"W4415444549","doi":"10.1158/1535-7163.targ-25-b102","title":"Abstract B102: Using subclonal dynamics to detect and quantify fitness advantages of resistant subclones in tumors under treatment","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Selection (genetic algorithm); Population; Genetic drift; Dynamics (music); Mutation Accumulation; Evolutionary dynamics; Distribution (mathematics); Cancer","score_opus":0.038737620427158496,"score_gpt":0.36027169737587644,"score_spread":0.32153407694871794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9751777,0.017041445,0.0060601104,0.0011113647,0.00018857731,0.00023229267,0.00008711158,0.00001288917,0.00008852546],"genre_scores_gemma":[0.99667823,0.0006228092,0.0019468887,0.0006071098,0.0000041862704,0.00001231637,0.0000066958005,0.000014428839,0.000107320855],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99897444,0.00012172628,0.00030890686,0.00028463517,0.000040163926,0.00027011908],"domain_scores_gemma":[0.9995424,0.00010866199,0.00007205541,0.00020594761,0.000049799917,0.000021099704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016103582,0.00019326177,0.0003686683,0.00016125059,0.000056675133,0.000011809878,0.00011571319,0.00018898344,0.000030719755],"category_scores_gemma":[0.00000879862,0.00015747469,0.00008114256,0.00028008517,0.00017974214,0.000018625795,0.00004970823,0.00013760035,6.0709453e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005633188,0.00008343039,0.008282116,0.00006467262,0.00045083486,0.000019805957,0.00007047464,0.00023782667,0.9596615,0.0021056675,0.0000020638613,0.028458335],"study_design_scores_gemma":[0.001502298,0.000303368,0.09843532,0.00027111743,0.0003017599,0.0000076040765,0.00031812614,0.00028821494,0.8942176,0.0025913643,0.0014466529,0.00031655788],"about_ca_topic_score_codex":0.0005529023,"about_ca_topic_score_gemma":0.000977645,"teacher_disagreement_score":0.0901532,"about_ca_system_score_codex":0.0001870939,"about_ca_system_score_gemma":0.00011792068,"threshold_uncertainty_score":0.64216316},"labels":[],"label_agreement":null},{"id":"W4415444599","doi":"10.1158/1535-7163.targ-25-b101","title":"Abstract B101: Subclonal drift predicts tumor response to treatment","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Population; Genetic drift; Dominance (genetics); Cancer; Population mean; Fixation (population genetics); Genetic model; Survival analysis","score_opus":0.022892048329930383,"score_gpt":0.3198704918538981,"score_spread":0.29697844352396774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977866,0.00512797,0.00017827725,0.014031666,0.00026749916,0.00083845225,0.00005720249,0.000081926046,0.001550996],"genre_scores_gemma":[0.9885078,0.00023653344,0.00045968426,0.009574019,0.000051402858,0.00044222787,0.000017895403,0.000035721245,0.0006746886],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987034,0.000050035593,0.00024691012,0.0003711832,0.0002822299,0.00034621748],"domain_scores_gemma":[0.999119,0.00007293219,0.00004835882,0.00047612767,0.00010196462,0.00018165064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010177306,0.00026338157,0.00032264547,0.00018933322,0.000079144054,0.00003430562,0.000095125484,0.000073824966,0.00013819672],"category_scores_gemma":[0.000014988094,0.0002093741,0.00018663613,0.00032839787,0.00003977852,0.000020138757,0.00002995569,0.000092480994,0.000051308543],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00738574,0.0027264978,0.04950498,0.000090299385,0.0030223525,0.002923196,0.0006754389,0.00046416576,0.8352649,0.0007236395,0.0013652314,0.09585355],"study_design_scores_gemma":[0.0052237413,0.0010674833,0.2447724,0.0002686416,0.00082940893,0.000023570024,0.000055697335,0.00008871292,0.4745731,0.00013162328,0.27273005,0.00023557905],"about_ca_topic_score_codex":0.00016769647,"about_ca_topic_score_gemma":0.000048849153,"teacher_disagreement_score":0.36069182,"about_ca_system_score_codex":0.00056407525,"about_ca_system_score_gemma":0.00044807643,"threshold_uncertainty_score":0.8538028},"labels":[],"label_agreement":null},{"id":"W4415444620","doi":"10.1158/1535-7163.targ-25-c116","title":"Abstract C116: Novel ATR inhibitors with CNS penetrance developed by artificial intelligence","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ovarian Cancer Canada","funders":"","keywords":"Drug discovery; Penetrance; Kinase; Cancer; Synthetic biology; DNA damage; Drug; DNA repair","score_opus":0.026453306694786675,"score_gpt":0.29194081987832765,"score_spread":0.26548751318354097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8615228,0.041106768,0.08781708,0.0031995,0.0019383588,0.000621563,0.000112958405,0.00017319036,0.003507767],"genre_scores_gemma":[0.9943893,0.00039078845,0.00018541374,0.0023038657,0.000014044955,0.000050096158,0.00003826441,0.000029608169,0.0025986242],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987895,0.00006604957,0.00033678775,0.00034365704,0.00005848589,0.0004055101],"domain_scores_gemma":[0.99940455,0.00005887818,0.000095964926,0.00030316872,0.0001204094,0.00001701597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000117391755,0.00026297144,0.00025215474,0.00010402993,0.00016149403,0.00003845701,0.00032181543,0.0002247472,0.00025914778],"category_scores_gemma":[0.00001031795,0.00022285701,0.000083429884,0.00029057753,0.00026894335,0.00005195976,0.00004988962,0.00037519608,0.00008826388],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008319978,0.00013746708,0.00011904732,0.000020247846,0.00046566856,0.0000049070945,0.00021213085,0.000048393336,0.9333978,0.0012365689,0.00046955838,0.06305616],"study_design_scores_gemma":[0.00036148384,0.00010463078,0.00066062075,0.00010905911,0.00006642424,0.0000071257964,0.00016338576,0.000008581422,0.8566272,0.00010257198,0.14154226,0.00024661384],"about_ca_topic_score_codex":0.00017890579,"about_ca_topic_score_gemma":0.00011138238,"teacher_disagreement_score":0.1410727,"about_ca_system_score_codex":0.00009926001,"about_ca_system_score_gemma":0.00028627846,"threshold_uncertainty_score":0.9087845},"labels":[],"label_agreement":null},{"id":"W4415444727","doi":"10.1158/1535-7163.targ-25-a042","title":"Abstract A042: Evolution of resistance in brain tumors: Effects of the blood brain barrier","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ferroptosis and cancer prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Blood–brain barrier; Drug; Pharmacokinetics; Drug resistance; Penetration (warfare); Population; Brain tumor","score_opus":0.008232857330306542,"score_gpt":0.27139404634458325,"score_spread":0.2631611890142767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96652275,0.024339193,0.0003200462,0.0065924046,0.00017841384,0.00063647766,0.000014671009,0.000014470742,0.0013815468],"genre_scores_gemma":[0.9959466,0.00018596687,0.00010572221,0.0031942818,0.000021283484,0.00009128045,0.0000014403647,0.0000218464,0.0004315774],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987515,0.00009805356,0.00038428212,0.00023384459,0.00031527583,0.00021700149],"domain_scores_gemma":[0.9990843,0.000116994335,0.00016694888,0.00047902283,0.0001191703,0.0000335635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021007341,0.00015782434,0.00035542346,0.0001200808,0.000031429092,0.0000060566895,0.00019481295,0.00011115666,0.000023416536],"category_scores_gemma":[0.00008589467,0.0001223633,0.00018430695,0.00067946425,0.0001455188,0.000027295986,0.00004330137,0.00021934767,3.6840646e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028737588,0.0003282862,0.04961175,0.0015727313,0.00039857504,0.000014088521,0.00044145543,0.00007664558,0.9391756,0.0035914388,0.00034566995,0.004156359],"study_design_scores_gemma":[0.002028916,0.000090913374,0.27708256,0.0022836819,0.0002703849,7.307931e-7,0.00006245485,0.000042864,0.71401453,0.0010084555,0.0030044792,0.00011003964],"about_ca_topic_score_codex":0.00023577161,"about_ca_topic_score_gemma":0.0002799707,"teacher_disagreement_score":0.2274708,"about_ca_system_score_codex":0.00018605085,"about_ca_system_score_gemma":0.0004598901,"threshold_uncertainty_score":0.49898306},"labels":[],"label_agreement":null},{"id":"W4415444744","doi":"10.1158/1535-7163.targ-25-a085","title":"Abstract A085: OBP-004, a novel small-molecule dual inhibitor of CDK9/13, reduces bone, brain, lung and lymph node metastases in vivo, with highest potency on bone metastases","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Bioluminescence imaging; Lymph node; Prostate cancer; Bone marrow; Cancer; Breast cancer; Spleen; Metastatic breast cancer; Bone metastasis","score_opus":0.022776783337146733,"score_gpt":0.31268964073595384,"score_spread":0.2899128573988071,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9646842,0.026339423,0.0002141103,0.0063978243,0.00021437577,0.00073335774,0.0003446335,0.00004833038,0.0010237279],"genre_scores_gemma":[0.9913221,0.0012490918,0.00074947806,0.0058612972,0.00007450283,0.00016787858,0.00005046071,0.000060512575,0.00046470657],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998061,0.00008257714,0.0005096193,0.00056098204,0.0003401662,0.00044566853],"domain_scores_gemma":[0.9989998,0.0001567227,0.00022142188,0.0003472109,0.00014849589,0.00012635234],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001869548,0.000435845,0.00076864986,0.00039850632,0.00007349168,0.000029989646,0.00009991761,0.00013979196,0.00011061347],"category_scores_gemma":[0.00001833697,0.0003605622,0.00014651059,0.00056859193,0.00024410429,0.000062895386,0.000056872865,0.0002516382,0.000001064398],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034022655,0.0017835273,0.003870231,0.00044742614,0.0019790716,0.0007608981,0.00033663388,0.00032334402,0.9795388,0.0003205496,0.00075254275,0.0064847344],"study_design_scores_gemma":[0.013479919,0.0008621121,0.01375383,0.0009147933,0.0025252327,0.00008230564,0.00020294984,0.00016755608,0.95976245,0.000052802417,0.007712672,0.0004833493],"about_ca_topic_score_codex":0.0013369969,"about_ca_topic_score_gemma":0.0004326106,"teacher_disagreement_score":0.026637854,"about_ca_system_score_codex":0.00024123657,"about_ca_system_score_gemma":0.00056691037,"threshold_uncertainty_score":0.9998846},"labels":[],"label_agreement":null},{"id":"W4415444785","doi":"10.1158/1535-7163.targ-25-c006","title":"Abstract C006: Fitness landscape modeling indicates decreased effectiveness of microtubule assembly targeting drugs in tumors demonstrating chromosomal instability (CIN)","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Aneuploidy; Chromosome instability; Chromosome; Fluorescence in situ hybridization; Chromosome segregation; Karyotype","score_opus":0.008318810987489468,"score_gpt":0.26700331271438726,"score_spread":0.2586845017268978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852493,0.00545411,0.008200335,0.000044756238,0.00010224067,0.0004847482,0.00003907105,0.000018806293,0.00040667216],"genre_scores_gemma":[0.99869895,0.00022781787,0.00057995936,0.000169344,0.000031261698,0.000099438126,0.00014491515,0.000041023555,0.000007304771],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99809754,0.00021989501,0.0005497205,0.00055013696,0.00016767664,0.00041501064],"domain_scores_gemma":[0.9991956,0.000058590635,0.00018059734,0.00037148758,0.00013379117,0.0000599753],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006093253,0.00031015062,0.00040133132,0.00013377666,0.00008850356,0.00003354337,0.00033654578,0.00027843576,0.000010121504],"category_scores_gemma":[0.000046190034,0.00032465762,0.000170602,0.00033501422,0.00009742338,0.000010969476,0.00012929676,0.0002555581,7.6796516e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002454877,0.00018011255,0.05320116,0.00042708896,0.00016491544,0.0000048478573,0.00008090242,0.011181641,0.932898,0.00007161045,0.0000022228128,0.0015420042],"study_design_scores_gemma":[0.0015945634,0.00006613181,0.009287262,0.0004536915,0.000068256406,0.0000019521747,0.00019420692,0.015758108,0.9719624,0.0002259027,0.00005263772,0.00033492094],"about_ca_topic_score_codex":0.00040382543,"about_ca_topic_score_gemma":0.00012475466,"teacher_disagreement_score":0.043913897,"about_ca_system_score_codex":0.00007670762,"about_ca_system_score_gemma":0.0004770162,"threshold_uncertainty_score":0.99992055},"labels":[],"label_agreement":null},{"id":"W7116690571","doi":"10.1158/1535-7163.mct-25-0298","title":"Development of a SIN1 Targeting Inhibitor as a Novel Therapeutic Approach for the Treatment of Malignancies","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; U.S. Department of Veterans Affairs","keywords":"mTORC2; mTORC1; PI3K/AKT/mTOR pathway; MAPK/ERK pathway; Cancer; Carcinogenesis; Cell growth; Targeted therapy","score_opus":0.031107782075481927,"score_gpt":0.303339722933979,"score_spread":0.27223194085849706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116690571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47575417,0.066287115,0.4555028,0.0002731554,0.0004158041,0.001308629,0.000086436885,0.000018277848,0.00035362097],"genre_scores_gemma":[0.97324985,0.00095117826,0.023845598,0.00077377073,0.000099768054,0.0006562163,0.000048041107,0.000046459583,0.0003291027],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986967,0.000034941506,0.00042836106,0.00035166155,0.00020026747,0.00028809783],"domain_scores_gemma":[0.9990458,0.00004279231,0.00021468819,0.00042727005,0.00024091743,0.000028517721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018504405,0.000255751,0.0002864547,0.000055659773,0.00011730502,0.000015526532,0.00030723313,0.00015071347,0.0000053282715],"category_scores_gemma":[0.000011583863,0.00018940835,0.00022269349,0.00019612515,0.00016036644,0.0000025908914,0.000047989655,0.00005062961,2.3616403e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002838313,0.00034475361,0.00019217553,0.00010988707,0.0011754944,2.2993038e-7,0.0006990999,0.0013257544,0.96736646,0.00043364288,0.000030220264,0.028038425],"study_design_scores_gemma":[0.0011033459,0.00032576735,0.00006576082,0.000042798307,0.00022384949,7.9915844e-7,0.0002806571,0.0006246342,0.87775064,0.000067246394,0.119343996,0.00017052173],"about_ca_topic_score_codex":0.000029576513,"about_ca_topic_score_gemma":0.000011423203,"teacher_disagreement_score":0.4974957,"about_ca_system_score_codex":0.00010008328,"about_ca_system_score_gemma":0.00062621955,"threshold_uncertainty_score":0.7723848},"labels":[],"label_agreement":null},{"id":"W7116791432","doi":"10.1158/1535-7163.mct-25-0667","title":"Lipophilic Statins Deplete GPX4 to Promote Ferroptosis and Sensitize Cancer Cells to Immune Checkpoint Blockade","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Fonds de Recherche du Québec - Santé; American Cancer Society; Canadian Institutes of Health Research; Melanoma Research Alliance; National Heart, Lung, and Blood Institute; American Skin Association; Dermatology Foundation","keywords":"Mevalonate pathway; Programmed cell death; Simvastatin; GPX4; Cancer cell; Statin; Cancer; Apoptosis; In vivo","score_opus":0.011335501226152279,"score_gpt":0.2773822437731999,"score_spread":0.26604674254704763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116791432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9620445,0.020274835,0.006493807,0.0058926186,0.0038393831,0.0009945065,0.00018612544,0.000044521035,0.00022970373],"genre_scores_gemma":[0.9640533,0.008860619,0.0033544297,0.017271543,0.0027894157,0.0005935896,0.000041819087,0.00014129974,0.0028939885],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979685,0.00008231642,0.00038829347,0.000749297,0.00023139114,0.0005802084],"domain_scores_gemma":[0.9987963,0.00000819243,0.0000900229,0.0006684753,0.00020104666,0.00023596318],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016396772,0.00039331813,0.0004059319,0.00013535097,0.0001414863,0.0000736853,0.0002754225,0.00019921656,0.000025538595],"category_scores_gemma":[0.000017101585,0.0004034795,0.000164981,0.00038521437,0.00007821585,0.0000047166664,0.00027614908,0.00017836572,0.0000073456886],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020011952,0.00004597024,0.000115750096,0.000052358733,0.00036451538,8.63777e-7,0.0004188103,0.0007018493,0.95731694,0.000025803243,0.00082014204,0.039936908],"study_design_scores_gemma":[0.00053727714,0.000102530736,0.00065893866,0.000058523394,0.0001430551,0.0000021620833,0.000051478386,0.000059907827,0.5911017,0.00003785605,0.4069502,0.00029637647],"about_ca_topic_score_codex":0.00078955974,"about_ca_topic_score_gemma":0.00072035415,"teacher_disagreement_score":0.40613008,"about_ca_system_score_codex":0.000098657605,"about_ca_system_score_gemma":0.00032650703,"threshold_uncertainty_score":0.9998417},"labels":[],"label_agreement":null}]}